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Abstract
These guidelines are a consensus work of a considerable number of members of the
immunology and flow cytometry community. They provide the theory and key practi-
cal aspects of flow cytometry enabling immunologists to avoid the common errors that
often undermine immunological data. Notably, there are comprehensive sections of all
major immune cell types with helpful Tables detailing phenotypes in murine and human
cells. The latest flow cytometry techniques and applications are also described, featuring
examples of the data that can be generated and, importantly, how the data can be anal-
ysed. Furthermore, there are sections detailing tips, tricks and pitfalls to avoid, all writ-
ten and peer-reviewed by leading experts in the field, making this an essential research
companion.
 Additional supporting information may be found online in the Supporting Informationsection at the end of the article.
Note: In order to make the guidelines as beneficial as possible to the scientific
community, if you wish to refer to a specific section when referring to these
guidelines, please ensure to use the Chapter and Section information. For exam-
ple: . . . as noted in section VII.11 of [1] . . .
1. Cossarizza, A., Chang, H. D., Radbruch, A., Acs, A., Adam, A., Adam-Klages,
S., Agace, W. et al., Guidelines for the use of flow cytometry and cell sorting in
immunological studies Eur. J. Immunol. 2019. 49: 1457–1973.
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Introduction
Continuing my theme of the marriage between immunology and
cytometry noted in my Introduction to the previous version of
these Guidelines [1], long relationships always have periods in
which the partners have contrasting feelings for each other, and
may eventually divorce; however, this does not seem to be the case
for immunology and cytometry, disciplines that continue with a
very stable and incredibly productive marriage, as witnessed by
the enormous number of publications in almost all areas of the
immunology discipline that we all love. It is indeed almost impos-
sible to count the original papers, reviews, abstracts, and meeting
communications, and talks in which an immunologist, from under-
graduate students to Nobel laureates, has measured a parameter
of interest at the single cell, organelle, or even molecular level
using one of the sophisticated cytometric technologies that we are
discussing here.
Unfortunately, measuring what happens in a biological system,
starting from the single cell level (that is, ‘cyto’ for cell, ‘metry’ for
measure) is not as simple as it seems, and can lead to results that
are not always optimal. In most cases, flow cytometry is relatively
easy to use, and often even a brief training—if not the simple read-
ing of a bench manual or a rapid glance over a protocol—enables
a researcher to use a flow cytometer and start producing data. As
we have already pointed out in ref. [1], paradoxically, this is a
main weakness of cytometry. Indeed, a well-trained cytometrist
can often identify in published papers experimental aspects or
data that must be improved, if not fully redone. The importance
of adequate controls, correct compensation, clean and well mon-
itored sorting strategies, correct data analysis, presentation, and
interpretation, and the description of the methods used cannot be
stressed enough.
It is for these reasons, a few years ago, following enthusias-
tic discussions at the European Congress of Immunology held in
Vienna, September 2015, and under the guidance of Professor
Andreas Radbruch (at that time Chair of the Executive Commit-
tee of the European Journal of Immunology (EJI) and currently
EFIS President), that the Editorial Team of the European Journal
of Immunology felt that it was worthwhile to offer our community
guidelines for the correct use of cytometric techniques in the field
of immunology. For this, we were able to put together a large team
of renowned experts who prepared a first collection of protocols
of interest for our community.
In the previous version of the guidelines, which was authored
by 236 scientists from 194 institutions spread across the world, we
focused on core aspects including advice and best practice regard-
ing how to study complex cell phenotypes, the type or amount
of molecules produced or secreted after stimulation by the cell
population of interest, signaling processes, differentiation, prolif-
eration, cell death, cytotoxic activities, cell–cell interactions, the
functionality of organelles such as mitochondria, the different
types of response induced against tumours, transcription factor
activity, quantification of soluble molecules, drug uptake, and rare
events, not forgetting the parts related to the choice of reagents,
the preparation and/or storage of the cells under analysis, the
overall experimental plan, and last but not least, the analysis of
data.
But a good scientist knows that all efforts, including those col-
lected in extensive guidelines like ours, can andmust be improved.
Accordingly, we asked for feedback on the published guidelines
and received critical comments, new ideas, and suggestions for
this new version, and here we are! In this updated version, we
have tried to ameliorate and update several parts and the reader
will find more standardized sections that should make it easier
to navigate throughout the text that now features novel tips and
pitfalls to avoid. Importantly the phenotyping sections are clearly
divided into human and murine sections, again to help the reader
find the section most relevant to their work.
There are also several new or expanded sections, with the phe-
notyping section covering all the major cell types including, for
example, dendritic cells and their subsets, unconventional T cells,
such as gamma delta, NKT or MAIT cells, B cells, and beyond, as
well as sections covering the functional aspects of regulatory T
cells and recently described assays on antigen specific cells. There
is also the identification and characterization of bone marrow and
cord blood neutrophils, plus liver cells and brain/neural cells are
actors that play a crucial role in the economy of the immune system
and can now be analyzed by cytometric assays. Soluble molecules
have received particular attention with cytokine-producing cell
sorting with secretion assays, as well as the quantification of sol-
uble cytokines with cytometric bead arrays, are now described.
A discussion regarding single cell genomics and cytometry is
also present, along with novel cytometric views on the micro-
biota, methods to detect inflammasome assembly and activation
in immune cells, and assays related to multidrug resistance.
The importance of the optimal organization of a laboratory
is self-evident, and clearly highlighted in the new sections that
describe how to perform flow cytometry under GLP/GMP condi-
tions, how to set up and maintain a core facility, including house-
keeping/shared resource lab management, as well as covering
the importance of sample banking and high-throughput screening
methods.
There is no need to underline how fundamental and complex
data analysis is, especially when we are coping with polychro-
matic and high dimensional flow cytometry, and are able to detect
dozens of antigens in a cell—not to mention mass cytometry. As
an aside, who will be the first to measure 100 parameters in a sin-
gle cell by using a cytometric assay? Thus, new sections are now
present that discuss neuronal networks, dimensionality reduction,
methods for clustering and creating trajectories, and integration
of cytometric data into multi-omics analysis among others. We
would like to stress once again that today the limit for asking crit-
ical questions is our creativity, and certainly not the instruments,
the technology, or the bioinformatics approach that we can use in
our experiments.
The following three points have already been flagged in the
previous version of the Guidelines but we would nonetheless like
to remind our readers that, first, “FACS” (fluorescence activated
cell sorting) should only be used for Becton Dickinson (BD) tech-
nologies as it is a BD trademark (FACSTM); the more general term
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“flow cytometry” (for the pure analysis of the cells of interest) or
“flow cytometry cell sorting” (obviously, if one sorts cells) should
be used to be company agnostic and correct. Second, CD mAbs
and not anti-CD mAbs (in other words, CD1 mAb and not anti-
CD1 mAb for example) should be used. This is because the CD
nomenclature is primarily a system to cluster/characterize mAbs
and it was only later accepted to use this system to also describe
the respective CD molecules. Third, although the Guidelines are
as comprehensive as possible, there are naturally limitations, e.g.,
only a subset of antibodies and antigens are shown and, at times,
only certain reagents/companies are used as examples, and others
work in the same excellent manner.
In conclusion, we would like to thank the people who played
a major role in ensuring that Andreas Radbruch’s and Andrea
Cossarizza’s vision became a reality. These are Hyun-Dong Chang
and Ute Hoffman, both at the DRFZ (Berlin), and Karen Chu, for-
mer Associate Editor, who were instrumental in getting the first
version of the guidelines in place. For the revision, Nadja Bako-
cevic (Associate Editor), Sylvia Heider (Editorial Assistant), Cate
Livingstone (Managing Editor), and Laura Soto-Vazquez (Asso-
ciate Editor) of the European Journal of Immunology, together with
Hyun-Dong Chang and Ute Hoffman, worked tirelessly together
with the authors and those providing feedback to ensure that this
revised version is a significant improvement. It is a job that is
never done as, due to time limits, some suggestions could not be
incorporated but we feel that this version will continue to provide
invaluable advice for the immunology community.
I Cytometry equipment
1 Fluidic system of a flow cytometer
1.1 Purposes of the fluidic system of a flow cytometer
To accurately measure optical properties of cells with a flow
cytometer, cells have to pass through the uniformly bright cen-
ter of focused laser beams. Light collection optics is focused on
the intersection point of cells with the laser beams to pick up flu-
orescence and scattered light from cells. This is the sensing zone
of a flow cytometer, here, the measurements of cell parameters
are taken. In stream-in-air cell sorters, the sensing zone is located
around 0.3 mm under the nozzle tip, in other cytometers it is
located inside a cuvette.
One purpose of the fluidic system is to move the cells one by
one precisely through the sensing region in a liquid stream in such
a way that each cell is illuminated by the same amount of light
from the lasers.
In cytometers with sort capabilities or cell sorters, the fluidic
system has to establish a stable break off from the liquid stream
in small uniform droplets. Droplets containing the cells of interest
can be charged and deflected in an electric field for sorting.
This kind of cell sorting technique was invented by Mack
J. Fulwyler in 1965 at Los Alamos National Laboratory [2].
Figure 1. Sample core after hydrodynamic focussing by laminar sheath
flow in a flow chamber.
Mack Fulwyler needed a machine for testing the performance
of Coulter counters, so the first particle separator was used
for sorting of particles with different Coulter volumes. Len
Herzenberg was interested in a machine that could sort living
cells on the basis of fluorescence, he got the design plans of
the particle separator from Mack Fulwyler and found a little
group at Stanford University to build the first FACS in the late
1960s (see the video Inventing the Cell Sorter, Herzenberg Lab,
https://www.youtube.com/watch?v=Ro8P3w9BPhg).
1.2 Hydrodynamic focusing
For precise positioning of cells in a liquid jet, the hydrodynamic
focusing technique is used in most cytometers and cell counters
[3].
The cells in suspension are injected by a thin tubing in a laminar
flow of a sheath fluid that enters from a wide tubing into a narrow
tubing or small orifice. The sheath flow speeds up when it enters
the narrow tubing and the diameter of sheath and sample flow
(sample core) is decreased (Fig. 1). Crosland-Taylor described
this technique first in Nature 1953 [4] and used it in a device for
counting small particles suspended in a fluid. Some years before in
1947, F.T. Gucker used a similar technique for detecting bacteria
in a laminar sheath stream of air [5].
The hydrodynamic focusing takes place in the so-called flow
chamber or flow cell of a cytometer. A detailed description of an
optimized flow chamber for a stream-in-air cell sorter can be found
in the patent applications from Gerrit van den Engh [6, 7]) and
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Figure 2. Intensity profile of a focus spot of a gaussian laser beam. Note: if a cell is out of the center of the laser focus by 10 µm (20 µm sample
core), laser intensity goes down about 5% with a 60 µm diameter laser focus.
a flow chamber of a cuvette system is found in another patent
application from BD [8].
In addition to flow chambers for laser based cytometers, flow
chambers with hydrodynamic focusing for cytometers with an arc
lamp light source were developed. These early cytometers were
based on a standard fluorescence microscope with epi- fluores-
cence setup. Here, the same microscope lens is used to bring exci-
tation light to the cells and take fluorescence emission from the
cells. Excitation and emission light is separated by a dichroic mir-
ror and special filters. With an immersion microscope lens of high
numerical aperture, a stabilized arc lamp and optimized staining
protocol, and DNA histograms with coefficient of variations (CVs)
lower than 1% (0.50–0.7%) were achieved [9, 10].
With the hydrodynamic focusing technique, cells can be aligned
to a precision of one micrometer. With high sample flow rates the
sample core is increased, however, and cells in the sample core
can move out of the focus center of the laser. Thus, not all cells
get the same amount of laser illumination. This means that the
accuracy of measurements is lost.
To avoid loss of measurement precision when the sample core
increases and to maintain laser intensity, cytometers use elliptical
laser focus spots. Typical sizes of focus spot are 60–150 µm hori-
zontally and 5–20 µm vertically. Recently, beam shaping optics for
flat top focused laser beams were introduced in flow cytometers by
the manufacturer. The intensity profile of a Gaussian laser beam
with 60, 100, and 150 µm focus diameters is shown in Fig. 2.
An approximation of the sample core diameter d in microme-
ters is given in ref. [11] as follows:
d = 1.13 ∗ 1000 ∗ 2√u/nv with u = particle measurement rate
in particle per second, n =particle concentration in particle/mL,
and v = jet velocity in m/s.
An approximation of the jet velocity is given by
v = 3,7 ∗ 2
√
delta P
with v in m/s and delta P, the sheath pressure drop at the nozzle
in psi (in practice around the pressure on the sheath container
minus 1 to 3 psi pressure drop on tubings and sterile filter).
The approximation of the sample core diameter calculation
shows that for a ten times lower sample concentration a more
than three times bigger sample core diameter is necessary to keep
the particle measurement rate.
For the sheath fluid, PBS (phosphate buffered saline) fil-
tered through a 0.22 or 0.1 µm filter is often used. The sheath
fluid should be compatible with cells or species that have to be
sorted.
1.3 Acoustic focusing of particles in a liquid stream
An acoustic focusing technology was developed by Gregory
Kaduchak and co-workers at the Los Alamos National Laboratory
in 2001 and introduced to flow cytometry [12, 13]. Recently,
the acoustic focusing technique was implemented into a flow
cytometer to support hydrodynamic focusing. This technique helps
to increase measurement precision in particular if wide sample
cores are used. According to the manufacturer, cytometers with
acoustic-assisted hydrodynamic focusing can run samples with low
concentrations of cells up to ten times faster as compared with
cytometers without and still maintain the precision of the mea-
surements. The fundamentals of acoustic cytometry are given in
ref. [14].
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Figure 3. Liquid stream of a jet in air sensing cell sorter. Depending
of abort settings of the cell sorter, cells that are too close together are
aborted from sorting. Reproduced with permission from ref. [16].
1.4 Droplet generation of a cell sorter
Based on the invention from Richard Sweet [15], droplet forma-
tion of the liquid jet of a cell sorter is stabilized by vibrations of
an ultrasonic transducer.
Little disturbances on the surface of the liquid jet at the exit
of the nozzle orifice are generated by the transducer. The dis-
turbances grow exponentially and lead to break up of the jet in
little droplets [3, 11]. A cell of interest that should be sorted is
measured at the sensing zone and moves down the stream to the
breakoff point. During the separation of the droplet with the cell
in it from the intact liquid jet, a voltage pulse is given to the liquid
jet. So electrons are caught with the cell in a droplet and cannot go
back when the droplet is separated from the liquid stream and the
voltage pulse is shut off. The droplet with the cell is charged and
can be deflected in a static electric field of two deflection plates
for sorting (Fig. 3).
It is important for the sorting process that the cell of interest is
at the right place when a voltage pulse is given to the liquid jet to
charge a droplet. The delay from the measurements of cell param-
eters to the charging pulse is determined by the cell sorter operator
or by the cell sorter electronics. This is done with the help of flu-
orescent beads and a laser beam under the deflection plates. The
laser beam illuminates the streams of deflected and undeflected
droplets. The fluorescent beads are sorted all in one direction, and
with a camera, the fluorescence in the droplet streams is observed
on a monitor. During observation of the fluorescent spots the drop
delay is changed so that the brightness of the fluorescence of the
deflected droplet stream is maximized and the brightness of the
fluorescence of the un-deflected droplet stream is minimized. The
distance from the sensing zone to the break off point is controlled
by a microscope and held constant.
The delay setting is fixed during sorting and in general the
break off distance is kept constant by the operator. If the velocity
of the liquid jet is constant during sorting the sorting works fine,
but in practice this is not always the case. Small changes of sheath
pressure, for example, due to partial clogging of the sheath filter
can alter jet velocity during sorting. Petersen and van den Engh
have examined the problem and showed how little variations of
sheath pressure can disturb the sorting process and how the oper-
ator can handle it [17]. Toralf Kaiser examined how temperature
changes of sheath fluid alters sorting performance and gives a
solution for stabilizing sheath fluid temperature [18]).
A schematic of a typical fluid system of a cell stream-in-air
sorter is shown in Fig. 4.
2 Optics and electronics
2.1 Introduction
From a technical point of view, a flow cytometer is a light detection
device capable of detecting photons of different wavelengths over
a high dynamic range. In order to achieve a high dynamic range,
the optics, signal detection, and processing units must be carefully
designed.
2.2 Optics
2.2.1 Lenses. In flow cytometers, lenses are used to collect light
emitted from the cell of interest, i.e., due to their spatial resolu-
tion they collect light only from the point of interest. Furthermore,
they are used to make the collected light parallel in order to direct
it through the optical bench to the detectors. A flow cytometer
employs collection and collimation lenses. Collection lenses (con-
vex lenses) are used to focus the light from the interrogation point
either to the end of an optical fiber or directly to a collimation lens
(e.g., aspheric condenser lenses). Some instruments use optical
fibers to route the detected light to detectors, which are installed
in an octagon. In this case, a collimation lens is installed at the
other end of the fiber to ensure that all light is routed parallel
through the octagon. Inside the octagon another collimation lens
is placed in front of each detector to focus the parallel light onto
the photocathode. In instruments without fiber optics the parallel
light is routed through the optical bench and then focused onto
the photocathode by a collimation lens.
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Figure 4. Schematics of fluidics of a jet in
air sensing cell sorter.
2.2.2 Optical filter. The photodetectors used in flow cytometers
are spectrally broadband and therefore unable to generate a signal
exclusively from specific wavelengths and thus specific markers.
To add specificity, optical filters and dichroic mirrors are used in
a well defined manner to route the light to the detectors. Optical
filters are designed as band pass (BP), long pass (LP), or short
pass (SP) filters, and are mostly installed in front of the light
detectors. The common property of the filters is that they transmit
light only within a spectral range. An LP filter transmits light
below a certain wavelength. For example, a LP of 660 nm will
transmit all light above 660 nm. In contrast, SP filters will pass
short wavelengths and block longer ones. A BP filter transmits light
in a certain wavelength range. For example, if the BP is named as
660/20, this means that light between 650 and 670 nm will pass
through the filter. Dichroic mirrors are also used to allocate light
to a specific detector based on wavelength. Like optical filters,
dichroic mirrors are separated in LP and SP versions. To achieve
maximum sensitivity, dichroic LPs are installed closer to the light
source (flow cell) to first direct long-wave photons onto the light
detector. Due to aging, quality of coating, and contamination,
the actual parameter of an optical filter or dichroic mirror can
differ from the technical description. Therefore, it is recommended
to check the transmission spectra of new filters provided by the
manufacturer and always keep filters dust free. Sometimes mirrors
(usually silver mirrors) are used in the optical bench of a flow
cytometer in order to deflect light for geometrical or constructive
reasons. These filters are >99% reflective over a wide range of
wavelengths.
2.2.3 Dispersing elements. Recently, commercial cytometers
have become available which use spatially dispersing elements
instead of or in combination with optical filters in order to deflect
light wavelength specific to a detector array. The rationale behind
this is the measurement of the entire emission spectra of a cell (see
section I.3 Flow cytometry, including flow cytometry cell sorting).
A dispersing element can be a dispersive prism or a grating. Prisms
have a higher light efficiency over gratings and they are not sen-
sitive for polarized light. This maybe the reason why they are
employed in the spectral flow cytometer from Sony. A dispersing
element is installed between the interrogation point and a detector
array.
2.2.4 Laser. Lasers employed for flow cytometers are mainly
solid-state, continuous wave lasers. Such lasers have a small foot-
print and a typical output power range from 20 to 100 mW. Lasers
are coherent light sources that allow a high photon density at the
illumination point, and therefore an efficient energy transfer to
the fluorochrome.
2.3 Electronics
As a flow cytometer measures the biological information of a par-
ticle (e.g., a cell) via photons, this light needs to be converted to
electrons and processed by an amplifier, filter, analog to digital
converter (ADC), and baseline restorer in order to visualize and
store the biological information of the cells or other particles. In
this section, the main components of cytometer electronics are
briefly described.
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Figure 5. Typical electronic signal processing of a flow cytometer. The
signal coming from a PMT or photo diode is amplified by a preamp and
a main amp. The analogue signals are then digitized by an ADC board.
A personal computer (PC) is used for further data processing and HV
controlling.
2.3.1 Detectors. From a technical point of view, the detection
of cell related light is difficult due to (i) the low light level, (ii)
the high analysis rate, and (iii) the high dynamic range of the
light level. Photomultiplier tubes (PMTs) meet these requirements
and are therefore employed in almost all flow cytometers. PMTs
are vacuum tubes containing a photocathode, electron focusing
electrodes, and a series of dynodes for electron multiplication.
The photocathode converts photons to photoelectrons that are
then multiplied by a series of dynodes driven by a high voltage
(Fig. 5). Photocathodes of PMTs employed in flow cytometers are
made from bialkali material that determines the spectral quantum
efficiency η of the PMT, which is the ratio of emitted electrons to
incident photons. The quantum efficiency of the photocathode is
always 0 < η < 1 and is a function of the light quantum energy
(h × f). A typical PMT (R9220, Hamamatsu) of a cytometer
has a quantum efficiency η = 0.2 at 500 nm and η = 0.09 at
700 nm, which is a reduction in sensitivity of about 7 dB. This
means that the detection of PE-Cy7 is always less sensitive as the
detection of FITC, for example. In many applications, PMTs are
increasingly being replaced, e.g., by avalanche photodiodes due to
their higher quantum efficiency. However, in flow cytometry, only
one commercial instrument (CytoFlex, Beckman Coulter, Aurora
and Norther lights, Cytek) employs APDs in order to improve the
sensitivity for wavelengths > 700 nm [19].
2.3.2 Amplifier and signal processing. Amplifiers in a flow
cytometer can be grouped as pre- and main amplifiers. Pre-
amplifiers are either voltage (VA) or transimpedance (TIA) ampli-
fiers that are used to amplify the voltage amplitude of a PMT (VA)
or to convert a signal current of a photodiode to a voltage (TIA).
Furthermore, pre-amplifiers perform operations, such as:
 impedance matching,
 filtering and pulse shaping,
 and bandwidth limiting.
All amplifiers in a cytometer are analogue hardware devices
which must be very well designed for optimal signal to noise ratios
(SNRs). In a typical cytometer such amplifiers have an SNR of>86
dB. Once the signals are processed by the pre-amplifiers, the main
amplifier moves the signal level to a suitable range for the ADC
(Fig. 5).
In modern cytometers, the conversion of the continuous ana-
log voltage signal into discrete digital values is done by ADCs
that are defined by their sampling frequency and sample reso-
lution. The required dynamic detection range (DNR) of a flow
cytometer can be defined as the intensity range of stained and
unstained cells, for example. A stained cell can be 10 000 times
brighter than an unstained cell that gives a DNR of 4 log or 80
dB (DNR[dB]=20log(104)). The DNR of an ideal ADC is given by:
DNR = 6.02*N + 1.76 dB [20].
This means that in theory, an ADC with N = 14 bit will have
a DNR of 86.04 dB. In practice, the effective number of bits of an
ADC is, due to noise and distortion of the circuit, some decibels
below the theoretical value (e.g., the ADC AD9240AS of the BD
Diva electronic has 78.5 dB [21]). This limits the dynamic range to
less than 4 decades and, more importantly, shrinks the resolution
of dim signals.
The sampling frequency of the AD9240AS is 10 MHz that
results in 30 samples per measured pulse of a high speed cell
sorter (pulse length = 3 µs). This results in a peak detection error
of 1–2% [22]. Modern ADCs have a resolution of 16 bit and a
sampling frequency of 250 MHz which allows the design of flow
cytometers with dynamic range of >4 decades and a peak detec-
tion error of <0.1%.
In the digital domain, the signals are processed by filters, base-
line restorer, pulse height, pulse width algorithms, and trigger
(see Section I.3). Filtering is done to smooth the raw PMT signal
in order to improve the SNR. The resulting signal consists of an
unwanted DC part due to laser scatter light and electronic noise
(among others) and a specific AC part. Hence, the DC part is sub-
tracted by baseline restorers to increase the SNR and the DNR of
the cytometer. The baseline restorer attempts to keep the baseline
at zero. In practice, however, baseline restoring is not perfect and
can lead to negative values on the histogram axis or introduce a
slight distortion of low signals and therefore to an increased CV of
dim signals. After baseline restoring, the pulse parameters (height,
width, and area) are extracted and converted into a *.fcs file.
Taken together, the analogue and digital components of a flow
cytometer in combination with the baseline and pulse shaping
algorithms need to be well adjusted in order to maximize SNR
and DNR.
3 Flow cytometry, including flow cytometry cell
sorting
3.1 Convention, or fluorescence-activated flow cytometry
and sorting
Since the invention of the first prototype of a Fluorescence Acti-
vated Cell Sorter in 1968 at Stanford University, the technol-
ogy has become a powerful tool to analyze and sort individual
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cells based on their functional status. Moreover, flow cytometry
provides a robust statistic of thousands of individual cells and can
detect rare events at a frequency below 10–4 cells. The sample
uptake by the instrument can be done from tubes or multi-well
plates at an acquisition rate of thousands of cells/s. In a typi-
cal cytometer, the sensitivity decreases with increasing flow rate
due to the increasing diameter of the cell stream within the flow
cell. Alternatively, the AttuneNXT (ThermoFisher) uses acoustic-
assisted hydrodynamic focusing, which helps keeping the core
stream tight and therefore gives accurate results even at a much
higher sample throughput. Furthermore, the serial acquisition of
multiple cell samples can be automated by using high-throughput
platforms (HyperCyt R©).
Today, instruments are available designed to detect up to 27
different bio-markers on an individual cell. Typically thesemarkers
are fluorescently tagged antibodies, molecular sensors, as well as
genetically encoded reporters. For instance, the FACSymphonyTM
(Becton Dickinson) is technically capable of detecting up to 50
parameters of an individual cell. In practice, this high number of
parameters is not achievable because at the moment the range of
appropriate fluorescent dyes is limited.
Technical limitations regarding the maximum number of
detectable markers are also given by the overlap of the emission
spectra of the different fluorescent tags, since each fluorescence
detection channel is correlated to a biological marker. To over-
come this, fluorescent tags became available that have different
excitation wavelengths. Currently, up to seven lasers with emis-
sion wavelengths from 325 to 808 nm are used in order to achieve
a high flexibility in the choice of the fluorescent tags. Furthermore,
tunable lasers are used for special applications like fluorescent life
time measurements (FLIMs).
Flow cytometers use either PMTs or avalanche diodes to con-
vert the emitted or scattered light into amplified electrical pulses
that are processed by appropriate electronics to extract informa-
tion like pulse height, area, length, and time. The electronics
of the cytometer consist basically of a preamp circuit, baseline
restoration circuit, and an ADC. In most modern cytometers, the
data post-processing (i.e., pulse integration, compensation, log-
transformation) and data analysis is done in a computer by soft-
ware. All components together must have a low noise level (i.e.,
a high SNR) to achieve high instrument sensitivity (Q) and low
background (B) detection.
Avalanche diodes have better detection efficiency in long wave-
lengths and thus a better SNR in that range over PMTs. Further-
more, they open new possibilities for the application of fluorescent
tags with long-wave emission spectra. Avalanche diodes are imple-
mented in the CytoFLEX (Beckman Coulter) cytometer.Within this
instrument, the emitted fluorescence light is divided by a wave-
length division multiplexer (WDM) through a series of band pass
filters and integrated optics, onto an array of avalanche diodes
that enables a high sensitivity in the detection of, e.g., PE-Cy7.
Avalanche diodes or PMTs itself are light detectors that are
unsuitable for wavelength detection, hence, the fluorescent light
needs to be filtered by optical filters andmirrors. These filters must
be carefully chosen because a multiparameter experiment, i.e., an
experiment in which multiple parameters (markers) are analyzed,
requires that multiple fluorophores are used simultaneously; a
consequence of this is spectral overlap or spillover (see Section
II.1 Compensation).
Conventional flow cytometers circumvent this problem by com-
pensation (see Section II.1 Compensation) in order to accurately
correlate the physical light properties with the biological proper-
ties of the cell. Following this, the data are analyzed in a multi-
variate fashion in combination with a hierarchical gating strategy
(see Section VII.1 Data analysis).
It is essential to adapt the combination of fluorescent tags to
the given optical, laser, and electronic setup of the instrument to
minimize spillover, increase Q, and lower B signals. For instance,
by choosing the right concentration of a certain reagent (see Sec-
tion III.2 Titration: Determining optimal reagent concentration),
the fluorochrome related B can be optimized such that it con-
tributes ideally nothing to the B given by the instrument. This can
help to increase the separation (the distance between the means)
between a blank and a fluorescent population that is a function of
Q and B. Thus, it requires the characterization of Q and B of the
used instrument.
Mostly polystyrene particles (beads) are used for this purpose
in combination with software based protocols implemented in the
instruments, e.g., MACS R©Quant, Fortessa, Yeti, Cytoflex to name
just a few. Beads are small particles and so to say “cell dummies” of
well-defined fluorescent intensity and sizes that also can be used
for PMT voltage optimization, compensation setup, cell counting,
scale calibration, and so on.
Scale calibration is an especially useful approach to mea-
sure absolute values (e.g., number of binding antibodies, amount
of fluorescent molecules or photoelectrons) instead of relative
mean fluorescent intensities (MFIs), which leads to quantitative
flow cytometry (see Section VII). Beside beads, scale calibration
can also be achieved by using LED light pulses. Recently, the
quantiFlashTM (APE) tool has become available that provides ultra
stable LED light pulses. Furthermore, by using this tool, instru-
ments can be compared within or between labs regarding their Q
and B values.
Up to this point, analytical cytometers have been described but
cells can, in addition, be sorted based on specific marker expres-
sion for downstream analysis (molecular biology, sequencing, etc.)
or cell culture (see Section II).
3.2 Spectral flow cytometry: Principles and evolution
For spectral flow cytometry, the “one detector, one marker”
paradigm is changed. After excitation (Fig. 6A), the complete
emitted light of a marker (Fig. 6B) is spectrally dispersed
either by refraction within a prism or by diffraction within a
grating (Fig. 6C) over a highly sensitive photo detector array
(Fig. 6D). Gratings are susceptible for polarized light. As polar-
ization occurs frequently in flow cytometry [23], the total effi-
ciency of a grating may be reduced. In fact, prisms are better
suited for spectral light dispersion because they have a better
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Figure 6. Principle of a spectral flow cytometer. (A) Excitation light
source (laser), (B) labeled cell, (C) dispersing element, (D) multichannel
light detector (CCD or multichannel PMT).
light transmission and are also stable for polarized light. Unfortu-
nately, the dispersion of a prism is not linear with regard to the
wavelength, which makes it difficult to use linear detector arrays
such as multianode PMTs [24].
As mentioned above, multianode PMTs or charge-coupled
devices (CCDs) can be used as detector arrays. CCDs have a high
quantum efficiency of 80–90% in the visible range (500–800 nm)
and a relative long readout time that limits the acquisition rate. On
the other hand, this in combination with high spectral resolution
allows the spectral detection of Raman scattering, which is a char-
acteristic spectrum of molecular vibrations, much narrower than
fluorescence spectra. This allows the application of new biological
markers, such as surface enhanced Raman scattering tags or near
infrared fluorescent dyes [25, 26].
Spectral flow cytometry was introduced in 1979 [27], when
the cytometric measurement of FITC- and PI-labeled mouse cells
was demonstrated using a video camera tube as a detector. More
recently, Robinson et al. developed a single cell spectral flow
cytometer based on a grating and PMT array [28–31]. This instru-
ment created single cell spectra and demonstrated a spectral flow
cytometer based on a 32-channel PMT array detector using a holo-
graphic grating and showed the detection and analysis of labeled
lymphocytes and microspheres in hyperspectral space. Goddard
et al. [32] employed a grating spectrograph attached to an intensi-
fied CCD for measuring microspheres and cells. This spectrograph
was implemented in the optical pathway of a conventional flow
cytometer and was able to take spectra of single cells and micro-
spheres as well as to discriminate free versus bound propidium
iodide.
The first commercially available spectral flow cytometer, the
SP6800, was developed by Sony [33]. This instrument employs a
prism array to disperse the collected light over a 32-channel mul-
tianode PMT. Moreover, the instrument is equipped with three
lasers (405, 488, and 638 nm), which allow for full spectral detec-
tion of the resulting emission spectra. The measured spectra from
single cells are subsequently unmixed by using reference spectra
of all used dyes and the autofluorescence spectrum. Least Square
Fitting algorithms are used to calculate the most accurate fit for all
reference spectra, leading to an accurate determination of which
dyes are present on each cell and at which intensity. Using this
method, a complete fluorescence emission is used instead of only
a small portion of emitted light entering a dedicated detector
through a specific set of mirrors and optical filters. This is a major
advantage over conventional flow cytometry, in which light that
is lost outside of the optical filters also contaminates other chan-
nels with unwanted light that has to be corrected by a subtractive
method (see Section II.1 Compensation). Since dyes frequently
used in flow cytometry have rather broad emission spectra and
large spectral overlaps, spectral unmixing can help mitigate this
problem. Therefore, applications for spectral flow cytometry are
similar to those performed on conventional flow cytometers with
the additional benefit of spectral unmixing, which allows spec-
trally overlapping dyes to bemeasured, and auto-fluorescence sub-
traction to be included. Moreover, control of reagents (especially
tandem dyes) is paramount with the increased need for standard-
ization. Given that spectral flow cytometry shows full spectrum
unbiased data, quality control is more or less integrated.
In this fashion, spectral flow cytometers are designed to mea-
sure the biological information across multiple detection chan-
nels, where the optical configuration can be fixed for all exper-
iments, giving the added benefit of instrument stability, sensi-
tivity [34], and easier standardization across instruments, aided
by the lack of individual PMTs and individual optical filters and
mirrors.
II Setup—Instrument setup and quality
control
1 Compensation
1.1 Introduction
In flow cytometry, fluorescence spillover (i.e., which can be over-
come by compensation) is probably the single greatest source of
frustration for the scientist and cause of bad data. Correctly com-
pensating for spillover is critical to accurately identify populations
in multicolor flow experiments. Errors in compensation for one
fluorochrome can be propagated into other detectors resulting
in erroneous “virtual” positive populations or errors in popula-
tion percentages due to incorrect gating. Mastering fluorescence
spillover is much like chess, the rules are simple, but becoming a
skilled practitioner can take some effort. Here, the basic concepts
of fluorescence spillover are reviewed and some simple principles
to follow in order to maximize data quality are provided, while
debunking some of the myths that surround this field. For further
information on this subject, readers are referred to the following
references: [35–38]. In addition, a guide as to the Minimum Infor-
mation about a Flow Cytometry experiment has been developed
and vetted by the International Society for the Advancement of
Cytometry (ISAC) [39]. This includes recommendations for ways
to document compensation of complex panels.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 Setup—Instrument setup and quality control 1485
Figure 7. Spillover and compensation: (A) the emission spectra of PerCP-Cy5.5 and PE-Cy7. (B) Peripheral blood lymphocytes stained with PerCP-
Cy5.5 CD4 mAb. The MdFI is shown for the PerCP-Cy5.5 and PE-Cy7 detectors without (left) and with (right) compensation.
1.2 Principle of spillover and compensation
Fluorescence spillover is the amount of signal, measured inmedian
fluorescence intensity (MdFI), that a fluorochrome emits in a sec-
ondary detector specific for a different fluorochrome (Fig. 7A
shows the fluorochrome PerCP-Cy5.5 is spilling into the PE-Cy7
detector [dark red]). This is equivalent to a background in that
detector. We can calculate a spillover value (SOV) of PerCP-Cy5.5
into PE-Cy7 as Y/X × 100% (Fig. 7B, left). Compensation is the
mathematical process used in all flow cytometers and software in
which these SOVs are used to determine a compensation matrix
that effectively subtracts/corrects background due to spillover in
all detectors (Fig. 7B, right).
The accuracy of this correction is totally dependent upon the
accuracy of the SOVs determined from the appropriate single-color
compensation controls. In Fig. 7B, the spillover is correct when the
MdFI [PE-Cy7] of the PerCP-Cy5.5 positive (+) population is equal
to the MdFI [PE-Cy7] of the PerCP-Cy5.5 negative (–) population.
With a few exceptions, the mathematical calculation of SOVs is the
same for all cytometers and flow cytometry software packages.
1.3 Measuring SOVs/compensation controls
On all cytometers, SOVs should be determined using single-color
compensation controls. Most errors in calculating SOVs are due
to the use of inappropriate compensation controls. A compensa-
tion control should consist of a positively stained population and a
negative or unstained population. The positive and negative pop-
ulations do not need to be run in the same tube. Cytometer and
software protocols will specify what combinations can be used. It
is never good practice to try to run two controls in the same tube,
for example, using FITC CD4 mAb and PE CD19 mAb. This makes
the assumption that there is absolutely no antibody bound to the
“negative” cells, which is typically not the case.
Many software packages from flow cytometer manufactures
and third party companies have an “auto-compensation” feature.
While these can be very powerful, they are based on automated
gating algorithms in which the software identifies the positive and
negative populations. These gates may not always be appropriate.
It is recommended that for new controls the user confirm that the
software is providing correct gates and results.
In general, correct SOVs can be obtained by following four
simple principles for single-color compensation controls:
1. The fluorescence spectrum of the compensation control
fluorochrome-conjugated reagent should be identical to the
reagent used in the experiment. More specifically, the fluo-
rochrome should be identical not similar. For example, even
though Alexa Fluor R© 488 and FITC are spectrally very similar,
an Alexa Fluor R© 488 compensation control cannot be used for
a FITC reagent or vice versa. Other examples are allophyco-
cyanin (APC)/Alexa Fluor R© 647 and APC-Cy7/ APC-H7.
This principle is especially critical for tandem reagents (e.g.,
PE-Cy7, APC-Cy7) where there can be significant spectral dif-
ferences from lot to lot, which can lead to differences in the
SOV [40]. In such cases, it is recommended that users run
individual single-color, lot-specific compensation controls.
2. The autofluoresence of the positive and negative populations
must be equivalent. The spillover calculation assumes that any
difference in the MdFI of the spillover detector (e.g., Y in
Fig. 7A, left) is due to the presence of the fluorochrome mea-
sured by the primary detector. If the autofluoresence differs,
then part of the MdFI in the spillover detector will be due to the
difference in autofluoresence and not the fluorochrome itself.
An example is shown in Table 1. In measuring the SOV of FITC
into PE when similarly autofluorescent positive and negative
cells are used, the calculated SOV is 27%; however, incorrectly
using beads for the negative population results in an SOV of
22%, a 5% error.
This also applies to cell types. Cell lines and untransformed
lymphocytes should not be used for the same control. If a
stained cell line is used as a positive control, the same unstained
cell line should be used as a negative control. It is similar
with cell subsets, for example, if lymphocytes are analyzed,
lymphocytes, and not monocytes, should be used as both the
positive and negative control. Some software programs allow
a universal negative population (e.g., unstained lymphocytes);
however, this is acceptable only as long as all analyzed samples
are exclusively lymphocytes.
Myth: the SOV depends upon the type and autofluores-
ence of the cells you are analyzing. False. The SOV is only
a function of the fluorochrome. When correctly measured,
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1486 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
the SOV is independent of the cell type(s) in the biological
sample.
3. The positive population should be as bright as possible.
As noted earlier, the SOV is equal to the slope of the MdFI
of the two detectors (Fig. 8, dashed line). The actual SOV is
not a function of the brightness of the positive population but
is the same all across the dynamic range. A truly correct SOV
will provide correct compensation whether it is derived from a
bright or dim positive population (Fig. 8, Correct SOV). When
calculating a slope, the most accurate measurement (i.e., SOV)
is obtained when the two data points obtained are apart as far
as possible. This is especially important for low spillover values
such as PE-Cy7 into PE.
However, we rarely get “perfect” SOVs, and the impact of any
errors in the SOV are magnified as the MdFI of the primary
detector increases as shown in Fig. 8. In this example, if there
is a 1% under compensation error in the SOV (Fig. 8; red line),
it would have a minimal impact on a dim population. In this
example, in an MdFI of 103 in FL1, the error would be 10 MdFI
in FL2, not noticeable. However, if the FL1 MdFI is 105, the
MdFI error in FL2 would be 1000 and this would incorrectly
look like a new positive population.
Myth: For spillover to be correct, it is required that the com-
pensation control positive population needs to be as bright as
your sample. Partly False.
To restate the message here, you want to get the most accurate
slope/SOV possible. Therefore as noted in the title, it is good
practice to have the positive control population as bright as
possible, preferably close to your sample MdFI (static or acti-
vated). However, for spillover to be correct, it is not required
that the compensation control positive population needs to be
as bright as your sample. In some cases, the positive popu-
lation of compensation beads may not be as bright as your
sample. This does not mean it is not a valid compensation
control. In general, if the positive population is approximately
equivalent to CD4, you will get good results. There is onemajor
caveat to this statement. For all measurements, it is critical that
the positive population is in the linear range of the detector.
Outside of this range, the corrected data will be inaccurate.
Most cytometer manufacturers provide linearity information
for their instruments.
4. Collect enough events to obtain meaningful accurate SOVs.
As a rule of thumb, collect at least 5000 events for both your
negative and positive population. Again this is to ensure the
accuracy of the measurements, especially for low SOVs.
1.4 Compensation controls
Compensation controls typically fall into two categories: (i)
stained cells; (ii) beads, these are seen as either (i) directly
fluorochrome-coated or (ii) anti-Ig capture beads and are available
from a number of sources. Each of these controls has advantages
and disadvantages. In a given multicolor experiment, compensa-
tion controls can be mixed and matched including all three types.
Figure 8. Brightness of positive population.
Table 1. The consequences of using positive and negative
populations with differing autofluoresence: Lymphocytes were
stained with diluted FITC CD4 mAb. The MdFI of the CD4+ [Cells (+),
unstained [Cells (–)] cells and unstained beads [Beads (–)] were
measured in the FITC and PE detectors. SOVs were calculated using
positive and negative cells or positive cells and negative beads
Fluorescence (MdFI)
FITC PE SOV
Cells (+) 3 135 903 n/a
Cells (–) 95 78 27%
Beads (–) 107 228 22%
That is beads (positive and negative) can be used to compensate
Fluorochrome A, and cells (positive and negative) to compensate
Fluorochrome B. The key is to follow the second principle and not
mix and match different control types within the same single color
fluorescent control.
1.4.1 Stained cells. The advantage of using stained cells is that
these controls most closely replicate what is happening in the
assay tube. The disadvantage is that you may have to use precious
biological material. In particular, if you need a tandem, lot-specific
control for a specific CD marker, splitting the sample to generate
such a control decreases the number of cells available for analysis.
This may therefore require the use of even more of the biological
sample at the outset.
1.4.2 Beads. The advantage of beads is that no biological mate-
rial is required and they are easy to prepare and use. Following
the manufacturer’s protocols, for many fluorochromes, beads pro-
vide sufficiently accurate SOVs. The disadvantage is that these
beads are a surrogate for cells and may not in all cases provide
a perfect match to cells. This can result in discernible and repro-
ducible differences in the SOVs obtained from the exact same
reagent measured on beads versus cells. Where different SOVs are
obtained, the cells must be considered the biologically relevant
gold standard.
Compensation controls using fluorochrome-coated and anti-Ig
capture beads are available from a variety of sources. Some are
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Figure 9. Accuracy for SOV: The figure shows two different assays in which lysed whole blood was stained with the same fluorochromes:
BD HorizonTM Brilliant Violet 510 (BV510) and BD HorizonTM Brilliant Violet 605 (BV605). Both assays used the same BV605 reagent. In the top
panels, the BV510 positive population was dim while in the bottom panels the BV510 positive population is very bright. For each assay, the
SOVs were determined and the correct spillover was applied (Middle panels). For the left panels, the BV510→BV605 SOV was increased by
1% (overcompensated) and compensation applied. For the right panels, the BV510→BV605 SOV was decreased by 2% (undercompensated) and
compensation applied.
used as stand-alone controls, some are integrated into software
packages. However, when used for 10–18 color instruments, dif-
ferences in SOVs can be seen in all of these beads when comparing
the SOVs obtained with the beads to the SOVs obtained with the
gold standard of cells. These differences can vary from manufac-
turer to manufacturer. For example, the beads from Manufacturer
A may be more accurate than the beads from Manufacturer B
when calculating the SOV of Fluorochrome X into Y, while the
beads from Manufacturer B may be better for calculating the SOV
of Fluorochrome Y into Z. SOV differences between beads and
cells can be as large as 5–10%.
Compensation beads are a powerful tool for making the pro-
cess of determining SOVs fast and easy and should be used where
appropriate. However, it is important to use them with reasonable
caution. The best laboratory practice to ensure accurate compen-
sation when using beads is to pretest any new reagent on both
beads and cells to ensure that they are providing you with SOVs
equivalent to your stained assay samples. For example, if you are
using a new fluorochrome or a new lot of a tandem, run a quick
test staining both cells and beads; calculate the SOVs from both.
If the SOVs are effectively equivalent then you can be comfortable
using the beads as controls for all future assays. However, if there
are significant differences, you may need to use cells as your con-
trols or try a different bead. Finally, in such a test, you may want
to treat the cells and beads as you would in your assay, e.g., if
your assay includes a fix/perm step, you can include this in your
control staining. Fix/Perm buffers can sometimes, but not always,
alter the SOV of your fluorochromes.
1.5 What are “good” SOVs?
This is really a question that cannot be definitively answered.
There is great deal of misunderstanding regarding what SOVs
actually mean in terms of a multicolor flow cytometer and the
experiments run on them. First and foremost, SOVs are empirically
determined mathematical values that are used by flow cytometry
software to correct for the background due to fluorescence. While
these values are related to fluorescence spillover, they are not
direct absolute measurements of the fluorescence spillover of one
fluorochrome into another detector. SOVs are based upon median
fluorescence measurements, which are gain (i.e., PMT voltage)
dependent. That means that when you change the PMT voltage
on a detector, the SOVs associated with that detector will change.
However, the actual spillover of fluorescence from one detector
into another is unchanged. So you cannot ask “Why is the SOV on
my instrument different than the lab next door?” without knowing
the PMT voltages. The single most important fact to remember is
“Changing the PMT voltage on an instrument will change the SOVs
but it has absolutely no impact on the actual florescence spillover
and its associated spread and does not affect the quality of the
data.”
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1488 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
1.6 What is “good enough” accuracy for SOVs?
Using the right compensation controls under the right conditions
will maximize the accuracy of your spillover values. Still, nomatter
which controls are used, it is likely that there will be some error in
some of the SOV measurements you make. This brings up the final
question of what SOV accuracy is good enough to provide you
quality data. The honest answer is that “it depends.” It depends
upon the design of your assay, the fluorochromes used, and the
density of the antigens being analyzed. Any error in the final data
is directly proportional to both the error in the SOV measurement
and the brightness (MdFI) of the population being analyzed. This is
demonstrated in Fig. 9. In the assay represented in the top panels,
the Brilliant VioletTM (BV) 510 positive population is somewhat
duller (MdFI 6000). In this situation, small (±2%) errors in the
BV510 into BV605 detector do not significantly affect the error in
the MdFI in the BV605 detector (±100).
The situation in the assay shown in the bottom panels is quite
different. The BV510 positive population is quite bright (MdFI
68000). Identical errors (i.e., ±2%) in the BV510 → BV605
SOV results in truly BV605 negative populations appearing to be
positive (BV605 MdFI errors of ±1300). The MdFI error in the
spillover detector (here BV605) = the MdFI of the population in
the primary detector (BV510) × the %error in the SOV. Therefore,
an “acceptable” error in the SOV for one assay (e.g., the top panels)
may be quite unacceptable for another (the bottom panels). This
is again why it is important to pretest your compensation controls
to better understand and manage any potential errors that can
impact the quality of the final assay.
In conclusion, with an understanding of the concepts of com-
pensation/fluorescence spillover and following a simple set of
principles when using compensation controls, it should be rel-
atively easy to obtain and present high quality multicolor flow
cytometry data.
2 Maintenance
Flow cytometric experiments produce relative data and they are
strictly dependent on the actual context of measurement (e.g.,
sample quality, reagent quality, or instrument performance). To
get comparable results over time, each single step of a flow cytome-
try experiment needs to be controlled. This section focuses on the
instrument side and discusses important (preventive as well as
some reactive) steps in maintaining flow cytometric instruments
to ensure a constant quality level of measurement. Even if several
tips and tricks are mentioned, this section can only offer a basic
selection of possibilities and options. For some maintenance steps,
you need to have additional experience. In case of doubt, consult
the technical support of the respective company.
2.1 Introduction
The signals generated by flow cytometric instruments are deter-
mined by many different factors, such as optical layout (laser and
laser power, optical filter), sheath fluid, room climate, and so on.
It is therefore a prerequisite to “know” the performance of the
respective system at a certain time point. By using appropriate
controls and standards, it is possible to define the original status
of instrument performance and track it over time. This can be
performed in different ways and depends upon the type of instru-
ment (analyzer, cell sorter), the instrumental layout (number of
lasers, high-throughput system (HTS)) and the type of measure-
ment one wants to conduct (e.g., screening, diagnostic, qualitative
vs. quantitative or volumetric tests). Due to an increasing diversity
of available flow cytometers on the market, there is no common
routine of conducting maintenance and also the time frames and
maintenance intervals may vary from one instrument type to the
other. While most of the manufacturers offer service contracts for
their systems, the experienced user can do several things to pre-
vent potential damage and maintain or restore the instrument’s
original level of performance. Be aware that for some steps during
maintenance (e.g., laser alignment) additional precautions (e.g.,
wearing laser safety goggles) are necessary to accommodate for an
altered hazardous potential (optical (high energy laser), biologi-
cal, or electrical (high voltage)) compared to normal instrument
operation. Those interventions should only be done by service
engineers or specially trained users with the necessary risk assess-
ment and personal protection equipment in place.
Maintaining a flow cytometer means retrieving information
about the actual status of an instrument and comparing it to the
original (ideal) situation. It should be ensured that the data have
been collected under comparable conditions such as comparable
laser warm up time (between 15 and 30 min), fluidic setup (using
a primed system and choosing the same flow speed: low, medium,
high), and event-rate. If the performance check fails, one needs
to know how to bring it back to the original level (if possible).
Below several options detailing how to check the performance of
a flow cytometric instrument and what can be done as preventive
mainentance procedures are described (summarized in Table 2).
2.2 Maintaining optical devices
Maintenance starts with cleaning the instrument. To prevent dan-
ger from laser radiation or electrical hazards, this can be done
without switching on the cytometer. For example, it is necessary
to remove dust from the ventilation systems to allow effective air-
cooling of lasers and power supplies as well as from optical filters
(BP, SP, and LP), (dichroic) mirrors, and prisms of the optical
path. Dust will impair the laser-alignment and sensitivity of flu-
orescence signals by generating additional background and loss
of fluorescence signals. These parts can be cleaned with unsoiled
pressurized air (e.g., as used for electronic parts or computers)
and more resistant dust can be carefully removed with cotton
swaps or dust free paper wipes (moistened with a drop of pure
methanol (e.g., those used in microscopy) as methanol will evapo-
rate without leaving residues on the optics). How often these types
of preventive maintenance have to be performed strictly depends
on the environmental conditions and are sometimes included in
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Table 3. Summary of some critical parameters defining the optical
performance of a flow cytometer
Parameter A measure for . . . Recommended
Value
SDEN . . . electronical noise as low as possible
%rCV . . . Laser alignment as low as possible
Qr . . . Detector efficiency as high as possible
Br . . . the channel
background
as low as possible
Signal to
Noise ratio
. . . sensitivity of
Detector
as high as possible
maintenance contracts of the vendors. Many flow cytometers’
lasers are directed via glass fibers to the detection site and,
therefore, are relative stable over time in their alignment. Other
machines are equipped with fixed optical benches, making repeti-
tive laser- and filter-alignment nearly obsolete. But in any case, it
is important to check (or “know”) the instrument status prior to
the measurement.
The Cytometer Setup and Tracking (CS&T) module from Bec-
ton Dickinson (BD), available since software version DIVA 6.0,
is an example, how instrument performance can be monitored
over time (BD Cytometer Setup and Tracking Application Guide
V3.0, [41]). The combination of software and the use of stan-
dardized beads make possible to retrieve critical parameters in
one run. After installation through a service engineer or exchange
of components (e.g., lasers, filters, or PMTs), the status of the
instrument is documented in a so-called “baseline.” A lot of infor-
mation (not all of it is listed here) about the linear range of each
PMT (important for proper measurement and compensation (see
Chapter II Section 1.3 Measuring SOVs/compensation controls),
electronic noise and background (Br, SDEN), detector efficiency
(Qr), as well as sensitivity (Peak ratio between negative and pos-
itive population) and quality of laser alignment (%rCV) is stored
in this file. All the introduced values are summarized in Table 3
with a very brief explanation and are described in much greater
detail elsewhere [42–51].
In a second step, the instrument performance can be tracked
and compared to the baseline values by running the same lot of
standard-beads at different time points. The software module is
then reporting every observed change. In Fig. 10A, a typical result
of a CS&T performance check is shown. A wrong BP filter in front
of the PMT-detector resulted in a lower signal. As a consequence,
the system needed a higher PMT-voltage (V) to reach the
defined target value for this particular channel. The change in V
was larger than the accepted range (which is as default value in
CS&T  50 V) and instrument performance failed with notice to
the user (red cross). On flow cytometers without a CS&T-option,
a similar result can be achieved by using nearly any kind of
standardized particles (e.g., Rainbow Beads, 6- or 8-Peak Beads,
Calibrite R©, CS&T Beads [41] or other fluorescent-labeled Beads).
Instead of a “baseline,” one has to generate a system-specific
calibration containing all the fluorescent channels and parameters
including a fluorescence channel of each available laser versus
time. At already suggested time-points, one is measuring the
beads under defined settings and save this result as a (instrument
specific) “standard.” Future measurements with the same kind of
beads (consider and document potential lot to lot variations over
time) and the same instrument settings (see Chapter IV, Section
2.1) will allow a comparison to the first “standard” measurement
and monitors changes in instrument performance. In Fig. 10B, a
result for the same situation as described for the CS&T-option is
shown. With the correct BP filter (510/50), the beads are falling
inside the target values (positive peak of the blue curve is inside
the brackets), whereas with a wrong BP filter (610/20), the
instrument performance fails (red curve).
Having this kind of information for all parameters at vari-
ous timepoints (every day or week) will give a good overview
of the performance of the system. Tracking at least one fluo-
rescent channel per laser over time gives additional information
about the stream stability and indicates if air bubbles inside the
system are causing problems. Displaying these plots during an
experiment may help to reveal problems with sticky or unfiltered
samples.
Beside the target channels, also the shape and width of the
peaks are of importance and can indicate for instance a laser
misalignment. As shown in Fig. 11A, the peak of the positive
beads is still inside the defined target area, but the width (%rCV)
is twice as big as the corresponding measurement during the
standard performance (Fig. 11B). After realigning the laser, the
shape of the peak and the %rCV value are again in the expected
range.
The selected examples illustrate, that tracking an instrument
performance is possible in different ways (8-Peak Beads, CS&T
or fluorescent labeled beads, etc.) as long as one knows where
to look at and to what instrument specific “standard” an actual
result has to be compared to. As noted earlier, there are several
additional parameters, which can be tracked (e.g., laser delay and
area scaling factors), but with a correct standard setup, most of
them can be accessed via appropriate bead measurements.
2.3 Maintaining the fluidic system
2.3.1 Sheath filters. The fluidic system of most flow cytometers
is assembled with parts that need to be maintained on a regular
basis. One has to ensure that the fluidic lines and filters are free
of air bubbles. Entrapped air compresses differently than sheath
fluid and can cause unstable (“dancing”) fluorescence signals due
to incorrect time calculation of the incoming signals. The more
lasers a machine has, the less tolerant the system is against air
bubbles or unstable compressed air supply. Sheath or saline fil-
ters therefore have to be vented on a daily basis and replaced
every 6 months (most commonly suggested time interval by man-
ufacturers). In machines without extra sheath supply (e.g., Guava
EasyCyte, Partec/ Sysmex, Accuri etc.), air in the systemwill cause
false values for volumetric cell counting or will lead to empty fcs-
files without any measured event.
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Figure 10. Examples for performance tracking with and without a CS&T module [130]. (A) A Levey-Jennings chart of a weekly measured perfor-
mance for one parameter (out of 10) is shown. The cross in red indicates a failure in the performance check (a higher PMT-Voltage is needed to
reach the target values of the beads, which corresponds to a loss of sensitivity). After checking and changing the band-pass filter in front of the
corresponding PMT, the performance is measured again and is compared to the previous situation (blue dots). With the correct band-pass filter
installed, the performance of the PMT is back to the previous level. The graph is taken from a CS&T-Cytometer Performance Report of a BD FAC-
SCanto II equipped with 3 lasers. (B) The histogram of channel A of the violet 405 nm laser shows the corresponding measurement to the situation
described above in (a) and is taken from a self-defined, instrument-specific calibration worksheet. The blue population represents the “standard”
setup (with a 510/50 band-pass filter in front of the PMT of channel A, where the beads are reaching the respective target values (brackets). The
red curve shows a measurement with a 610/20 nm band-pass filter instead. The beads are clearly outside the target values and the positive and
negative populations are barely separated from each other. This is an example, how one can easily track basic instrument performance without
having a separate software module available.
2.3.2 Sheath tanks. Sheath tanks, especially when they are pres-
surized, have to be refilled and checked for leakiness on a frequent
basis. Bal seals have to be replaced before they lose integrity. The
consequences are similar to those described above for entrapped
air bubbles. An additional consequence in cell sorters is an unsta-
ble droplet breakoff point, which is critically dependent on a con-
stant and stable pressure (especially for nozzle sizes above 85 µm,
see also Chapter I Section 1.4 Droplet generation of a cell sorter).
Degasing Sheath tanks before usage can therefore improve the
stability of the droplet formation in cell sorters.
To ensure sterile cell sorting, one has to clean/autoclave the
sheath tanks on a regular basis. This goes in line with cleaning the
sample injection port (SIP) and the sample tubing (see Table 2,
Fluidics). Some machines offer semi-automated start-up and shut-
down protocols, as well as cleaning routines one can run after a
defined period of time or on demand [52]. In general, there are at
least four basic protocols to maintain a fluidic system, depending
on the intention of the cleaning:
- sterilization/decontamination,
- avoid crystallization for long-term storage (e.g., overnight),
- unclogging,
- and bleaching (get rid of cross-contaminating dyes).
2.3.3 Fluidic lines, SIP, and HTS. For long-term storage, such as
an overnight shutdown or prior to maintenance through a service
engineer, most labs run a decontamination protocol followed by a
wash cycle before they switch off the instrument (or hand it over
to a service technician). The most commonly used solutions to
decontaminate a flow cytometer are 1% sodium hypochlorite or
70–80% Ethanol. But freshly prepared 1% hydrogen peroxide can
also be used. Distilled or deionized water is ideal for washing out
the cleaning solution. To keep a machine in a “dormant”/unused
state for a longer period of time (weeks/month), one could dry
the tanks and system tubing completely after the cleaning process
or flush all lines and tanks with distilled or deionized water (con-
taining some preserving agents to prevent bacterial and fungal
Figure 11. How one can detect suboptimal
alignment of lasers. Both histograms display a
negative and positive bead population in the
450/50 channel of the UV-Laser of a BD FAC-
SAria SORP cell sorter. Although the positive
peak in (A) still falls into the defined target
area (brackets = P2), the shape and %CV of the
peak suggest a suboptimal alignment of theUV-
Laser. After realignment the shape of the posi-
tive peak becomenarrowerwith only the half of
the %CV. (B) Laser-alignment is optimal, when
the lowest %CV values are reached.
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contamination). When possible, a sample tube containing water
can be left at the SIP. All this is to ensure that no salt crystal for-
mation occurs, which could subsequently cause clogging, even if
the SIP or tubing were to dry out.
Sticky or clumpy cells, which are either not properly filtered
or used at too high a cell concentration, could block the orifice of
an instrument. In some (mostly pump driven) instruments (e.g.,
BD Accuri, Merck/Millipore Guava EasyCyte) one can reverse the
direction of the fluidics to push the blockage backwards out of
the tubing. Running a (prewarmed) detergent (e.g., FACSRinse)
through the system for several minutes, followed by filtered deion-
ized water or PBS, can help to release the obstraction in clogged
SIP and/or sample lines. In machines where one can easily access
and remove the SIP, sonication (in clean water) of the tubing is
also an option (e.g., Guava EasyCyte). As a last option, one could
use thin wires to clean the SIP, working like a sweeper cleaning a
chimney. If an optional HTS or Carousel Module is available, the
washing steps are even more important and fluidic parts and tub-
ing should be changed like recommended from the vendor. The
usage of fluorescent dyes such as PI, DAPI, or Acridine Orange
(AO), which are used to stain nucleic acids (e.g., live/dead, cell
cycle, or RNA–DNA ratio) makes an additional cleaning step nec-
essary (because the use of AO can cause a lot of trouble, there
are different alternatives available for many applications in which
AO is used [e.g., lysotracker, Syto R© dyes, and Pyronin Y]). These
dyes are often stained in excess to ensure a good staining profile.
Due to their planar structure, they are sticky and can also adhere
to the tubing. Therefore, a high likelihood of cross-contaminating
samples between different users exists. Running a bleaching solu-
tion (e.g., 1% sodium hypochlorite) for 5–10 min will prevent this.
To check for efficient cleaning, run an unstained cell sample and
observe in a bivariate plot (fluorescence channel of the dye (e.g.,
PI) versus time) if background of these cells is increasing over
time. In that case additional cleaning is necessary.
In all situations, one has to be careful with the use of aggres-
sive/corrosive solutions and make sure that they are washed
out/replaced by the respective sheath fluid or distilled water and
are not left inside the flow cell for an extended period of time (e.g.,
overnight) [53], as this could damage the tubing and sealing and
end up in leakiness of the system.
Some flow cytometers (e.g., Accuri C6, Guava Easycyte, Attune
Nxt, MACS R©Quant, and CyFlow) allow volumetric measurement,
which enables counting and direct calculating of the cell number
and concentration of a sample. A prerequisite for accurate cell
counting is also an air bubble and particle free (filtered) sheath
fluid and intact sample lines. Mechanical stress makes it necessary
to replace the tubing at appropriate intervals (e.g., a bimonthly
change of the peristaltic pump tubing is recommended for the BD
Accuri C6 system [54]).
2.3.4 Flow Cell/Cuvette. The flow cell is part of the fluidic and
optical system of a flow cytometer and is therefore included when
performing a cleaning as described above. Nevertheless, some
instruments (e.g., BD FACSAria cell sorter, BD FACSCanto II)
provide separate automated cleaning procedures to improve per-
formance. For most instruments (e.g., FACSCalibur, LSRII, and
Fortessa), there are also manual cleaning options, which will
require separate training.
2.4 Computer and software
Beside the above-described maintenance steps to ensure proper
function of a flow cytometer, the computer and software need
some attention. Defragmentation of the computer’s hard drive and
backups of the FCS-files should be scheduled in a frequent way
(weekly/monthly, depending on the usage). Where the FCS-files
are organized in databases, one should take care that the size of the
database does not exceed recommended size limits (e.g.,45% of
available disk space for the BD FACSDiva Software [55]). This will
impair and slow down at a certain time point the performance of
the entire system. Using the implemented Data Manager software
on BD instruments (at least once per month) reduces the size of
the database log file and is improving the overall performance and
stability of the DIVA software.
Although most flow cytometers on the market are very robust
and reliable, there are still many things that need to be con-
trolled. Table 2 summarizes many common steps to consider dur-
ing instrument maintenance. As already mentioned, it depends on
the instrument and environmental setup which steps have to be
done in which frequency and the focus might vary from labora-
tory to laboratory. Therefore, it is an overview and a suggestion of
procedures, which should help to get the best results out of your
flow data. In any case of doubt, contact the reference guidelines
and/or service engineers of your vendor to prevent damage from
your system and to keep it in a good condition.
3 PMT voltage optimization
Correctly setting PMT voltage gains is essential to optimize signals
and improve the resolution of dim populations. The aim is to
bring signal out of the low end of the scale, which is dominated
by electronic noise that will obscure dim events, without pushing
bright events off the top of the scale.
Historically, many cytometry users set voltages by eye, often
by placing an unstained population in the first decades of a log
scale. However, this method is potentially problematic, particu-
larly in channels with inherently low autofluorescence, such as
those in the red spectrum. Alternatively, while it is possible to set
voltages using stained cells on a per experiment basis this is time-
consuming, uses valuable samples and lacks reproducibility. As a
result, standardized methods to optimize voltages are required.
Due to their ability to provide consistent signals, fluorescent
bead-based methods are an important step in PMT setup. Several
approaches can be used. On BD instruments Cytometer setup and
tracking (CS&T), an automated bead-based method is available
[41]. In this case, CS&T beads are used in an automated fashion to
obtain an initial baseline voltage optimization based on setting the
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Figure 12. Voltage walk displaying rCV and rSD of the second peak of
sperotech 8 peak rainbow calibration particles. The arrow indicates the
point of minimal PMT voltage.
MdFI of dim beads to 10 times the robust standard deviation of the
electronic noise (rSDen), essentially ensuring that electronic noise
only contributes 10% or less of the signal. This allows setting of
reproducible voltages in reference to a bead standard, but does not
guarantee that the voltages are optimal for the biological samples
being used in a particular experiment.
An alternative is a voltage walk approach in which a
range of voltages are applied to beads to determine the
point at which separation of an unstained and dim bead
population is maximal, while also ensuring that the separation
of highly stained bead populations is not altered. The level of sep-
aration can be determined via ratios such as M2 (separation of
dimmest peak = MFI of the lowest positive peak/90th percentile
of the negative bead) and M5 (separation of brightest peak) [48]
or via calculation of the stain index [56]. A variant of this approach
is the peak 2 method which also applies a voltage walk to a bead
set containing a dim population [57]. This is used to find the point
at which the robust CV (rCV) of the second peak, the dimmest pos-
itive population, is not reduced by further voltage increases. The
rCV of dim particles directly corresponds to the resolution sensi-
tivity [58]. This point also coincides with the point at which the
standard deviation begins to increase (Figure 12). A disadvantage
here is that the exact point to choose is subjective and differing
bead sets may have differing levels of separation of the peak 2
beads, affecting sensitivity.
While bead-based methods are effective at determining mini-
mal voltage requirements and tracking reproducibility, some fur-
ther optimization may be required to determine optimal settings
for particular biological samples. In some cases, it may be found
that the minimum voltage determined by beads causes highly
stained cells to be off scale or above the linear maximum. In this
case, it is essential to reduce the voltage in order to obtain reli-
able results from these cells since data outside the linear range
will result in compensation errors. If this occurs regularly, switch-
ing to a dimmer fluorochrome for the highly stained marker or
adjusting staining protocols may be a better solution to preserve
resolution of dim populations for this channel. Another source of
variation in optimal PMT voltages is the difference in the level of
autofluorescence in a cell population and the calibration beads.
One method to deal with this is to use the BD application set-
tings [59]. To ensure that electronic noise does not have a major
influence on the resolution of dim populations, unstained cells
can be run and the PMT gain adjusted until the population has
an rSDen of 2.5 times baseline. This will effectively balance the
autofluorescence of the population on the outer edge of the elec-
tronic noise meaning that dim signals should be resolvable and
define the minimal acceptable voltage. BD application settings
are able to save these cell population optimized values in refer-
ence to CS&T baseline values so that they can be automatically
adjusted in reference to any PMT between CS&T baseline and
CS&T daily performance checks. On non-BD instruments, it is also
possible to carry out these daily adjustments if the electronic noise
of the instrument has been determined by the user or by using
a voltage walk approach to define optimal separation distances
of measured populations and then saving these values in refer-
ence to a corresponding MdFI of a bead population at the same
voltage [48].
In summary, the goal of PMT voltage optimization is to initially
determine the settings with optimal sensitivity and then reproduce
them on a daily basis. It is important to note that the aim is not
to reuse the same voltage value but rather to optimize the voltage
each time to ensure the same signal. While multiple methods are
available, most conform to a similar basic structure: 1) initial setup
using a control population (normally a bead control) to determine
reproducible minimum voltage requirements; 2) validation and
if needed, further optimization of settings for relevant biological
samples, to be saved in reference to the bead control; and 3) a
daily check of the beads controls in order obtain the desired ref-
erence values and thus the optimal voltage. Importantly, while
steps 1 and 2 may be initially time-consuming, baseline settings
determined in this way should be robust for an instrument as
long as it does not undergo significant configuration changes.
Once this baseline is set, a relatively brief daily performance
check can be used to ensure reproducibility and maintain optimal
performance.
III Before you start: Reagent and sample
preparation, experimental design
1 Controls: Determining positivity by eliminating
false positives
1.1 Introduction
For antibodies, the desired way of binding is the specific binding
of the antibody, i.e., via its antigen-binding site, to its antigen.
However, antibodies can bind in another manner to cells, also
deemed as “specific,” by interaction with that cell’s endogenous
Fc receptors. A third possible interaction between antibodies and
antigens is “nonspecific,” and occurs through ionic and hydropho-
bic interactions between the two molecules (“stickiness”). It is of
critical importance to exclude the latter two to be able to reliably
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quantify antigen expression by immunofluorescence. Therefore,
proper controls are essential in flow cytometry to determine back-
ground fluorescence and/or background staining, to distinguish
false positivity from true staining and to quantitate “true” positiv-
ity as such. Antibodies, the most widely used staining reagents in
flow cytometry, can bind a cell in many different manners.
1.2 Fluorescence spreading into the channel of interest:
Fluorescence minus one controls
The first step in establishing what a positive signal should
look like is to obtain a reference for the natural or back-
ground levels, autofluorescence, in that particular detection chan-
nel. For this purpose, a sample without the staining of inter-
est should be acquired. In the case of multiparameter staining,
this should be the fluorescence minus one (FMO) control. In
the FMO control, all antibody conjugates in the experiment are
included except the one that is controlled for. The FMO con-
trol provides a measure of the spread of fluorescence from the
other staining parameters into the channel of interest, and is
required to accurately determine the threshold for positive stain-
ing [60]. It does not, however, provide any measure of nonspecific
binding.
1.3 Specificity of reagent for staining target: Biological
controls
There are several methods to control for the specificity of antibody-
mediated immunofluorescent staining, each of which confers vary-
ing degree of confidence. The most reliable, but often also the
most difficult to obtain, control is a negative control consisting of
cells that do not express the marker of interest. The negative con-
trol should be as similar as possible to the experimental sample
to exclude differences due to autofluorescence, size, “stickiness,”
and so on. Such a negative control could be represented by using
cell lines that do not usually express the marker of interest, and
comparing these against cell lines engineered for ectopic overex-
pression of the marker, or by comparison to cells genetically defi-
cient for the marker of interest, both of which provide excellent
controls for establishing staining protocols and for testing staining
specificity. Depending on the nature of the marker of interest, the
comparison to activated versus non-activated cells may be suit-
able if markers dependent on activation are analyzed, although
one has to consider that activation may also change properties of
the cell, such as its size and shape, which may also increase the
inherent autofluorescence or unspecific staining. The use of inter-
nal controls, by staining additional markers to identify cells not
expressing the marker of interest within the same sample, e.g.,
using CD8+ T cells as a negative control for CD4+ T-cell-specific
markers, or CD19+ B cells when examining CD3+ T cell-specific
markers, should also be considered.
1.4 Specificity of reagent for staining target: Blocking and
isotype controls
In cases where biological negative controls are not available or
difficult to come by, blocking controls can also provide an excel-
lent measure of unspecific binding. Specific binding is blockable,
i.e., loss of staining by the fluorescently labeled antibody after
the addition of either excess soluble antigen or unlabeled anti-
body, both of which block the specific interaction of the staining
antibody with its cognate antigen. Unlabeled blocking antibody
must recognize the same antigenic epitope with comparable affin-
ity of the labeled antibody whose specificity has to be verified.
Ideally the same antibody clone should be used. Any positive sig-
nals still detected despite the use of blocking controls indicate that
unspecific binding due to ionic and hydrophobic interactions of the
antibody or the fluorochrome has occurred. When using these con-
trols, however, one has to be aware that blocking controls do not
exclude cross-reactivity of the staining antibody to other antigens.
Normal human serum (10% in PBS with an optional addition of
0.5% BSA) can be used to block the binding of labeled antibodies
to FcγR when human cells (particularly B cells or myeloid cells,
i.e., monocytes, dendritic cells, and macrophages) are analyzed.
Probably the most widely used staining control, the isotype
control, is of limited use in determining the threshold of positiv-
ity/level of background fluorescence due to unspecific binding.
The rationale behind using isotype controls is the assumption that
unspecific staining is due to the isotype of the antibody. As a
matter of fact, positive staining with isotype controls may be an
indication that antibodies bind via Fc receptors to the cell. In that
case, Fc receptor blocking reagents should be used to prevent such
an interaction [61]. However, isotype controls are by nature dif-
ferent reagents than the staining antibody, with a different amino
acid composition in the variable region, different numbers of flu-
orochromes bound to the antibody, and different concentrations,
and, thus, have different “unspecific” binding properties. There-
fore, a negative staining with the isotype control does not infer
that the staining one observes with the experimental antibody is
specific.
2 Titration: Determining optimal reagent
concentration
Before any experiment, it is good practice to validate and optimize
the reagents used. In flow cytometry, these reagents are generally
specific antibodies used to detect and quantify proteins on sin-
gle cells. Using too much or too little of the staining reagent will
result in increased unspecific staining, decreased SNR, decreased
sensitivity, lack of linearity between level of expression and stain-
ing intensity, and increased experimental costs. Thus, it cannot
be stressed enough that determining the optimal concentration
of antibodies for your experiment is of utmost importance. The
optimal concentration or “titer” of an antibody or any other stain-
ing reagent has to be determined empirically for target and your
staining condition (i.e., staining time and temperature), and for
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Figure 13. Titration of a CD4 mAb (clone GK1.5) conjugated to FITC and titrated on murine splenocytes. The antibody was titrated in 1:2 dilution
steps starting from a 1:100 dilution (5.4 µg/mL) up to 1:12 800 (0.04 µg/mL). (A) Histograms of the stained samples are shown. (B) MFI of the positive
and negative populations (left axis) and SNR between the positive and negative populations (right axis) are plotted. Best separating titer for this
particular antibody was determined to be 0.7 µg/mL (1:800 dilution).
every new batch of staining reagent for that matter. Live cells
may have a different staining optimum than fixed cells, proteins
stained on the cell surface different than the same protein stained
intracellularly. As it is very improbable that commercial reagents
have been tested on your particular experimental conditions, they
should also always be titrated rather than being used at the man-
ufacturer’s recommended titer or concentration.
To determine the optimal titer for the staining antibody it is
recommended to make a serial dilution of the antibody. If it is not
known from which concentration to start from, a generic starting
point is 10 µg/mL of antibody, which is then serially diluted 1:2 for
six to eight dilution steps. The number of cells used for the titration
should be orientated toward the number of cells being stained
in the actual experiment. However, while the number of cells
affects the staining quality, staining tends to be quite robust within
quite a large density range, e.g., 105–5 × 106 cells. Once titrated,
an antibody concentration generally gives comparable staining
quality within a ten- to 50-fold range of cell concentrations. If
cell concentrations are increased by more than that, it is usually
sufficient to increase antibody concentrations by two- to threefold,
or to make a quick two to three step titration.
Once a titration series has been made, there are several ways
to evaluate the data to determine the optimal titer. The simplest
method is to calculate the ratio of the MFI of the positive pop-
ulation (stained by the CD4 mAb) to the MFI of the negative
population, i.e., the SNR (Fig. 13A and B). It should be taken into
consideration that the applied gates for the negative and positive
population will have to be adjusted for each sample in the titration
series. The titer for the best separation will be the one with the
highest SNR (Fig. 13B), i.e., in this case 0.68 µg/mL or a 1:800
dilution of the original antibody stock.
One can also consider the lowest antibody concentration that
gives near maximum signal. This will be the concentration at
which staining is saturating andmost robust toward changes in cell
number, staining time, and temperature. Other methods to assess
optimal staining by determining the staining index are described
here [62]:
Additional aspects to consider are
1. When using antibodies, it is the concentration of the anti-
body which is the critical parameter, i.e., when upscaling an
experiment to stain in a bigger volume, increase the amount
of antibody correspondingly to keep the concentration the
same.
2. When titrating an antibody, make sure you have a population
that does not express the antigen of interest; this helps to
correctly assess background staining. If there are no “negative”
cells in the population, consider spiking in cells.
3. Once an optimal titer has been determined, indicate the con-
centration of the staining antibody for optimal staining, and
not the dilution factor, when it comes to publishing your
results.
4. If possible, use counterstains to identify subsets of cells that
coexpress or do not coexpress the marker you are titrating for.
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This will help determine/confirm the specificity of the titrated
antibody.
3 Preparation of single-cell suspensions
3.1 Introduction
The fluidic nature of counting in flow cytometry requires single-
cell suspensions. If cells from either solid tissue or an adherent
cell culture have to be analyzed, a disintegration of the tissue or
the cell layer into single cells is an absolute prerequisite for any
flow analysis.
Techniques for the disaggregation of tissue into single cells are
very old with most of the basic protocols being from the 1980s
or 1990s. Since flow cytometry was first developed, it has always
been of great importance to measure cells not only from a sus-
pension culture but also from adherent cell cultures or from solid
tissue. In particular, in tumor research, disaggregation of the tis-
sue has to be done carefully for the application of flow cytometry.
Nonetheless, despite all the protocols and even some automatic
disaggregation systems, disaggregation is still a process that has
to be optimized specifically for each tissue in order to get the best
possible results. A high degree of standardization can be main-
tained in the cytometric laboratory using automatic processing
machines from industrial companies. For non-automated proto-
cols, companies provide a large variety of special enzymes and
protocols for enzymatic digestion.
The protocol for cell preparation depends strongly on the cel-
lular properties that are under study. These staining targets could
either be markers on the cell surface, in the cell plasma, or in
the nucleus. Alternatively, it could be DNA or RNA extracted from
each cell after cell sorting.
With similar techniques, subcellular components such as
nuclei, chromosomes, and mitochondria can be extracted either
directly from the tissue or after disintegration.
The twomain principles for dissociation of a tissue or an adher-
ent cell culture into single cells are mechanical or enzymatic dis-
sociation; however, the effect of the enzymes on each protein of
interest needs to be determined, e.g., some cell surface proteins are
cleaved by collagenase. Also note, just as a reminder, if unknown
clinical material is to be analyzed, biological safety regulations
have to be maintained.
3.2 Mechanical disintegration
From a tissue (e.g., solid tumors), a sufficient number of cells
have to be extracted by applying mechanical forces. The tissue
is generally placed into a Petri dish containing some growth
medium and held by forceps. Using a scalpel, the tissue is then
scraped and minced, as long as it takes until cells are released.
The solution is then filtered to remove large tissue pieces and very
gently centrifuged. The resulting pellet is resuspended in growth
medium afterward.
3.3 Enzymatic digestion
For enzymatic digestion, very often trypsin and collagenase Type
II are used. In addition, other commonly used enzymes include
papain, elastase, pronase, hyaluronidase, and Dispase R©. If the
degree of ploidy has to be determined, as in the case of tissue
from solid tumors, DNase I should be added to the cocktail to
remove DNA from non-intact cells. The tissue is incubated in the
enzyme solution, usually at 37°C for some time. This is followed
by removing the enzymatic cocktail by centrifugation and resus-
pending the cells in medium.
It is advised after dissociation by either mechanical or enzy-
matic methods to determine the number of cells and their viability.
An easy way of determining viability is to use a dye exclusion test
with the classical Trypan blue test in a hemocytometer by visual
microscopic inspection being the “gold standard.” Use of either this
test, or other dye exclusion tests with fluorescing dyes that can be
assessed by flow cytometry are helpful to perform. Further infor-
mation on establishing/controlling for viability is covered later in
this article (Section III.4 Dead cell exclusion, cell viability, and
sample freezing). After viability has been established, the cell sus-
pension can be used directly for flow cytometric analysis or stored
after fixation or freezing for later measurement.
In many published protocols, both mechanical and enzymatic
methods of generating single-cell suspensions from original mate-
rial are commonly combined and modified appropriately to give
the best results in term of cell yield, cell viability, and integrity
of aneuploid populations. A good representation of all kinds of
cells in the sample after tissue dissociation is always aimed for;
however, it can never be taken for granted that it is 100% and that
the proportion of different cell types in the final sample resembles
exactly their proportions in the tissue. Furthermore, the physiolog-
ical state of the generated cell suspension may be different from
that in the starting material.
3.4 Special disaggregation techniques
Two special disaggregation techniques deserve a mention and
these are nuclei from paraffin-embedded tissue and nuclei and
chromosome isolation.
3.4.1 Nuclei from paraffin-embedded tissue. The preparation of
samples from paraffin-embedded sections for flow cytometry
requires a different protocol from those described above. In clini-
cal research, the flow cytometric analysis of cells from a paraffin-
embedded section can be required, especially if backward screen-
ing of patients needs to be performed. Preparations of cell nuclei
from paraffin sections are possible. In principle, a section cut from
the paraffin block has to be dewaxed using a solvent such as
xylene, followed by treatment with ethanol and water for rehydra-
tion. However, this can be a very lengthy procedure. Thereafter,
DNA staining of the isolated nuclei with intercalating dyes can
give reasonably good DNA histograms.
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3.4.2 Nuclei and chromosome isolation. Pure cell nuclei and/or
micronuclei can be isolated directly from most tissues and the
protocols used for nuclei preparation for cells in suspension can be
adopted. Excellent results from adherent cell cultures are possible
even without using trypsination. The tissue is first treated with
salt solutions containing a detergent and RNase. This is followed
by treatment with an acidic sucrose solution. In this way, the
cytoplasm is destroyed and nuclei are released [63]. In a very
similar way, whole chromosomes can be isolated from metaphase
cells and their DNA content can be measured with high precision.
Even single chromosomes can be sorted based on their difference
in DNA content.
3.5 Ensuring a single-cell suspension/removing oversized
aggregates after extraction
For all disaggregation methods described, it is essential to ensure
a single-cell suspension and to remove oversized aggregates after
extraction. To do so, the suspensions should be filtered through a
simple mesh (30 to 50 µm) or a cell strainer to remove larger
aggregates, which otherwise can clog the flow cytometer’s nozzle
or channel.
3.6 General comments
Once a protocol for a certain cell type and experiment has been
developed, it is strongly recommended to always proceed in a
highly standardized way. Automatic systems with high repro-
ducibility provide mechanical as well as enzymatic tissue disag-
gregation in a more or less automatic process and may be advan-
tageous in the routine cytometric laboratory. For a typical solid
tissue, the cell yield is about 107 cells/mg material and it should
be possible to achieve >50% viability in the isolated cells. What
should not be underestimated, however, is the probability of per-
turbing cell surface structures and epitopes or disrupting the cell,
which could occur in solid tissue disaggregation. In some cases,
cell clumping, dramatically reducing the cellular yield, can be a
big obstacle for a productive flow analysis.
Many protocols for tissue dissociation and cell isolation use
a combination of the above procedures as one technique on its
own may not deliver a high cell yield and cell viability. Alternative
methods such as aspiration may also be used [64]. A successful
protocol depends in general on the personal experience in the
laboratory. It is also highly dependent on the amount of available
tissue(s), the nature of the tissue, and the planned use of the
material.
4 Dead cell exclusion, cell viability, and sample
freezing
4.1 Exclude dead cells
The cell type and the isolation procedure from dissociated tis-
sues or liquid samples will influence cellular integrity and via-
bility. In principle, dead cells will increase background signals
either caused by a general increase in autofluorescence or by
an increased behavior to bind antibodies in a low-affinity and
unspecific manner. Therefore, dead cells should be labeled by
high affinity DNA stains such as PI, DAPI, or 7- ADD (7-amino-
actinomycin D), so that they can be excluded by appropriate gat-
ing from further analysis (see live/dead discrimination see Sec-
tion III.4 and Section V.2). In general, fluorochromes for discrim-
ination of living and dead cells can be differentiated between
those that passively integrate in the DNA of plasma membrane-
permeable dead cells or those that were actively transported into
living cells only. However, these probes are not applicable for
intracellular analyses, since all cells have to be fixed and per-
meabilized before staining. For these purposes, fixable dead cell
stains are available that bind to amines of proteins. These probes
are available in a wide range of different fluorescence colors, and
samples are to be stained first before applying the fixation and
permeabilization protocol. An extensive overview of life/dead
cell discrimination based on dye exclusion can be found in
ref. [65].
4.2 DNA-binding dyes
The principle of identifying dead cells using DNA binding dyes
is based on the concept that these dyes are impermeable to the
plasma membrane and so cannot enter viable cells having intact
membranes. Viable cells will exclude these dyes and therefore
exhibit little to no fluorescence. Cell viability can therefore be
assessed by incubating samples with a DNA dye such as PI or 7-
AAD; dead cells will stain positively for either of these two nuclear
dyes. It is important to be aware that dyes such as PI and 7-AAD
can be taken up into viable cells over time, and so these stains
should be added immediately (10min) prior to analysis, and the
staining protocol should be standardized across the experiments.
It is also important to note that DNA binding dyes cannot be used
on fixed or permeabilized cells such as those that would be used
in studies interrogating the expression of intracellular “targets”
using intracellular flow cytometry.
For the analysis, a data acquisition region is placed around the
positively stained cells, and color-eventing or “back gating” on the
PI+ or 7-AAD+ cells present is used to identify most, but not all,
dead cells as exhibiting lower FSC and higher SSC than viable cells.
Although it is possible to gate around the viable cell population on
the basis of their light scatter profile and use this for all subsequent
samples, even if these samples do not include a viability indicator,
by far the best method for excluding dead cells from data analysis
is to use a vital DNA dye in all samples. Although common dyes
used in multicolor analyses include PI, 7-AAD, TOPRO-3, pyronin
Y(G) (PY(G)), and SYTOX, a plethora of options are now avail-
able from a range of commercial suppliers. A note of caution is
that the broad emission spectrum of 7-AAD (600–750 nm at 20%
normalized emission maximum) can result in a significant level
of spectral overlap into other detectors and exclude its use in the
context of other fluorochromes such as PE-Cy5, PerCP, and PerCP-
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Cy5.5 in large multi-parameter panels. Furthermore, it is quite a
“dim” (low quantum efficiency) fluorescent molecule when com-
pared to PI, which is very “bright.” However, the minimal spectral
overlap between 7-AAD emission and that of fluorochromes such
as FITC and PE can be useful in some instances. One will also need
a compensation control for these dyes, and this could be generated
by staining cells that have been heat treated (70°C, 30 min), or by
leaving cells in isotonic saline without nutrition overnight.
Although these approaches use one of the fluorescent detec-
tion channels and thereby reduce the number of other parameters
that can be interrogated, the issue of viability is an important one
and the integrity of the experimental data and their interpreta-
tion should not be compromised by not including a viability stain
in all experiments. The far-red viability dye DRAQ7TM (Biostatus
Ltd., UK) is another viability dye that can be used in similar set-
tings to PI and 7-AAD and allows the identification or exclusion of
apoptotic, damaged, or dead cells. A particularly useful feature of
DRAQ7TM is that its dual excitation using blue (488 nm) and red
(633/638 nm) lasers and its emission at 650–800 nm allowsmulti-
beam excitation and the exclusion of dead (DRAQ7+) cells with-
out “consuming” what could be a vital, and much needed, addi-
tional fluorescent channel [66, 67]. The advantages of the classical
DNA-binding dyes are that this is a well-established approach that
involves a short incubation at the end of the staining procedure,
and that the reagents are of low cost. However, they are limited in
their spectral (excitation, emission) characteristics and a signifi-
cant disadvantage is that they are not suitable for experiments that
are interrogating intracellular expression of relevant antigens that
require fixation and permeabilization. A typical staining protocol
involves the following:
1. Add 500 µL of cell suspension (1–2 × 106 cells—unfixed) to a
12 × 75 mm polystyrene tube.
2. Add nuclear staining compound dissolved in PBS [PI: 5 µL,
200 µg/mL, 7-AAD: 4 µL, 250 µg/mL, TO-PRO-3: 4 µL,
250 µg/mL, or PY(G): 5 µL, 200 µg/mL] to tube.
3. Incubate cells on ice for at least 5 min.
4. Analyze cells by flow cytometry.
4.3 Protein-binding dyes
In some instances, the aim of the analysis will be to determine
and compare the expression of intracellular molecules/proteins,
in which case cells must be fixed and permeabilized in order to
allow the probes and antibodies to enter the cells. The use of
DNA binding dyes is inappropriate in these circumstances. In these
instances, the use of dyes binding to the amine groups of proteins
(amine-binding dyes), not DNA, is recommended.
The identification of nonviable cells under such circumstances
can be achieved using products having varied fluorescence spec-
tral properties such as the LIVE/DEADR fixable range of prod-
ucts from Life Technologies, the eFluorTM fixable dyes from eBio-
science, BioLegend’s Zombie range of fixable dyes, Tonbo bio-
sciences’ Ghost DyesTM, and the Fixation and Dead Cell Discrimi-
nation Kit from Miltenyi Biotec. These dyes covalently react with
protein so that the discrimination is completely preserved follow-
ing fixation of the sample. It should be noted that these dyes are
membrane impermeable and so will be internalized only by non-
viable cells. However, the level of fluorescence emitted by viable
cells (with which the dye has had access to only a few amines
on the cell surface), and nonviable cells (in which the dye has
had access to many more amines intracellularly) will be clearly
distinguishable. A word of caution: it is crucial to ensure that
staining protocols are performed in the absence of proteins in the
staining buffer, to which the dye will bind. Experiments can be
compensated using commercial amine-reactive beads or labeled
and unlabeled cells.
4.4 Vital dyes
A third category of reagent that can be used for determining cell
viability and cell death are the vital dyes. These dyes indicate via-
bility by emitting fluorescence in response to metabolic activity
in cells. Cellular esterases cleave the acetomethoxy group to yield
calcein inside metabolically active cells. “Free” calcein binds intra-
cellular calcium and fluoresces brightly green. Calcein AM dyes
can be passively loaded into adherent and non-adherent cells.
These cell-permeable esterase substrates serve as viability probes
that measure both enzymatic activity, which is required to activate
their fluorescence, and cell membrane integrity, which is required
for intracellular retention of their fluorescent products. Available
with blue, violet, and green fluorescence, these dyes are ideal for
short-term staining (signals can be measured within 5 min, but
once the AM group is cleaved, it can be actively transported out of
the cell within a few hours) of live cells and can be used in multi-
plexed flow cytometry experiments. However, as the fluorescence
generated by these dyes is driven by the presence of metabolic
activity, it is not easy to include them in staining protocols that
require fixation and permeabilization.
4.5 Dye-free approaches
As a sub-optimal alternative to the use of fluorescent stains, the
light scatter properties of dying cells and cells undergoing apop-
tosis change and these can be detected by flow cytometry based
on forward and side light scatter (FSc, SSc) properties. However,
the nature of these changes and their detection will depend on the
cells and the optical design of the instrument being used. Apop-
totic or dying cells can therefore be identified without any staining
by FSC and SSC parameters only. Reardon et al. [68] have exten-
sively compared the use of light scatter- and fluorescence-based
approaches for monitoring viability after freezing. Cells can also be
stained for apoptotic markers (e.g., cleaved caspase-3 or cleaved-
PARP). This works well for cells that are directly collected from
growth culture or in vivo, as cells in these situations commonly
die by apoptosis. These markers will not work for cells that die by
necrosis, but such cells are more likely to have abnormal scatter.
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4.6 Freezing cell samples
The freezing of cell samples offers the advantage of being able
to monitor responses over a prolonged period and to man-
age longitudinal studies involving many patients and/or healthy
donors/controls. Freezing of cells is also used when including sam-
ples taken at multiple sites and having them analyzed at a central
laboratory. Freezing, therefore, facilitates the logistics of measure-
ment, such as when only a few samples per day are to be analyzed
and the simultaneous analysis of samples that have been collected
at different times reduces the potential impact of experimental
and analytical variabilities that can be introduced. Of course, all
of these should be minimized by establishing standard operating
procedures for the experimental set up and flow cytometric anal-
yses and undertaking robust and regular quality control processes
for the instrument.
However, even if precautions are taken, freezing cells
inevitably influences cellular biology and key parameters that are
likely to be a key element of the study such as viability, immuno-
logical capacity and responsiveness, and ability to be expanded in
vitro. The properties of thawed cells might be significantly differ-
ent to their freshly isolated counterparts. These potential issues
and limitations therefore need to be taken into consideration.
Whenever possible, one should determine the effect of freezing
and thawing on the key biological and immunological readouts
before embarking on an experimental program that stores frozen
samples.
Maintaining the highest level of viability requires cells to be
frozen in a cryoprotective solution. DMSO is a commonly used
solution that, when used at a concentration between 5 and 10%
v/v in an appropriate medium, retains a high level of viability
after storage. One technical point to consider is that the best
recovery is achieved with a gradual freezing process, i.e., low-
ering the temperature of the cells by 1 to 2°C/min. This pro-
cedure is intentionally slow in order to prevent the formation
of ice crystals and cell rupture. Higher concentrations of DMSO
(up to 10% v/v) allows faster freezing and has been shown to
deliver 85% post-thaw viability, with some variability between
different types of leukemia. Automatic freezing techniques using
temperature-controlled setups have been developed for the rou-
tine cytometry laboratory. In these systems, the cell samples are
slowly moved down a tank of liquid nitrogen by a motor-driven
spindle. Commercially available cell freezers are the most suitable
appliances for this process. However, manual methods have been
widely reported to give adequate results.
The thawing process is as important as the freezing one and
must be done very rapidly, with active thawing being prefer-
ential to a passive one. Active thawing and other steps in the
thawing process have been evaluated for leukocytes by Hønge
et al. [69]. It should be appreciated that different cell types
respond differently to thawing, and this needs to be taken into
consideration during experimental design. As an example, Alsayed
et al. [70] reported that myeloid leukemia cells recovered better
than lymphoid leukemia cells. Immunophenotyping is an impor-
tant and frequently used method in risk assessment and post-
therapy follow-up in the clinical laboratory that requires a high
degree of standardization and post-thaw viability tests in order to
ensure that results are accurate and robust.
It is also possible to fix live cells and then freeze them. This is
not appropriate for any setting where the cells need to be analyzed
for function after thawing, if the main issue is one of logistics,
fixing, and then freezing works well. One can use the Smart Tube
System (Smart Tube Inc), or the fixing protocol published by Chow
et al. [71].
5 Cell fixation and permeabilization for flow
cytometric analyses
5.1 Introduction
The analysis of intracellular targets using flow cytometry (intra-
cellular cytometry) presents a number of technical challenges that
are not generally encountered in the measurement of cell sur-
face epitopes, or in the measurement of dye uptake/processing
(e.g., Calcein AM) in viable cells. In general, cells (in suspension)
must be first “fixed” to preserve and maintain both the structure
and location of target epitopes, then “permeabilized” to allow
probe (e.g., antibodies) access—ideally to all cellular compart-
ments (cytoplasm, mitochondria, ribosomes, nucleus, etc.).
In general, cell fixation is accomplished by the use of either
crosslinking fixatives (e.g., formaldehyde, glutaraldehyde), or low
molecular weight alcohols (methanol, ethanol), which generally
act to “coagulate” proteins. Formaldehyde has the advantage of
generally maintaining the overall conformation of the native pro-
tein. However, since formaldehyde generates multiple reactive
sites on peptides, polysaccharides, and lipids, crosslinking can hide
or sequester epitopes such that they are not freely accessible to
antibody probes after fixation. An additional benefit of formalde-
hyde fixation in the study of posttranslational protein modifica-
tions (e.g., phosphorylation, methylation, acetylation, ubiquitina-
tion, etc.) is that formaldehyde appears to both “fix” the modi-
fication of target amino acids (serine, threonine, tyrosine), and
also inhibits the degradation of these targets in living cells (e.g.,
phosphatase removal of phosphorylations, demethylase removal
of methylations, and so on). In contrast, alcohol fixation generally
results in poor detection of some (phospho-, and potentially other
protein) modifications.
5.2 Fixation of whole blood specimens
Studies in the field of immunology frequently utilize peripheral
blood, lymph node, or bone marrow cells, often with a prelim-
inary purification step (Ficoll–Hypaque, hypotonic lysis, ammo-
nium chloride) to remove red blood cells. In addition, preliminary
purification techniques can remove potential target cell popula-
tions (e.g., loss of blasts using Ficoll–Hypaque). In this section,
we will first cover fixation and permeabilization techniques for
samples containing red blood cells, and subsequently cover fixa-
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tion and permeabilization techniques for isolated cell populations
(tissue culture cells, isolated lymphocytes, monocytes, etc.)
Following fixation, cell permeabilization is performed in order
to gain access to the cell interior. This can be accomplished using
either detergents (e.g., Triton X-100, NP-40) or saponifiers (e.g.,
Saponin), or with low molecular weight alcohols (methanol or
ethanol). A complete discussion of the advantages and disadvan-
tages of different approaches/reagents is beyond the scope of this
guideline, but also see Chapter V section 15. Here, we focus on
a fixation and permeabilization technique developed for use with
clinical samples (whole blood, bone marrow) [71]. We set out to
develop a technique that would allow the direct addition of fixa-
tive to clinical samples (to immediately “fix” phospho-epitopes and
prevent dissociation of signaling inhibitors out of cells, which can
result in rapid reversal of their inhibition). However, the addition
of fixative directly to whole blood presented the problem of how
to remove RBCs after fixation. We discovered that the addition of
Triton X-100 at the appropriate concentration and time directly
to the sample (still containing formaldehyde) achieved RBC lysis
andWBC fixation without any significant loss of WBC populations.
As a cautionary note, it is important that the incubation times are
strictly followed.
As shown in Fig. 14, whole blood from a healthy human
fixed using the formaldehyde/Triton X-100 technique shows three
major populations using FSC versus SSC (lower panel). Here, the
location of the monocyte population (blue) is determined using
CD14. The separation of lymphocytes from monocytes by light
scatter alone is sufficient to identify both populations; and as
shown in the figure, the use of CD14 provides a good resolu-
tion of these cell types. The resolution of lymphocytes from cel-
lular debris using light scatter alone, however, is problematic.
The lysis of RBCs generates a significant amount of debris that
overlaps with lymphocytes in light scatter measurement. How-
ever, as shown in Fig. 14 (top panel), staining the sample with
CD45 allows clear resolution of CD45-positive/negative lympho-
cytes from CD45-positive/negative debris. The data shown here
were generated after a single wash following the RBC lysis step.
Use of additional washes at this point reduces debris significantly
for most samples.
5.3 Materials
5.3.1 Staining whole human blood.
1. Fresh human whole blood (5–10 mL) collected in anticoagu-
lant (K2EDTA or sodium heparin).
2. Formaldehyde, 10% (methanol-free). Store at room tempera-
ture in the dark. Use within 6 months.
3. Triton X-100 detergent (e.g., Surfact-AmpsTM X-100, Thermo
Fisher). Prepareworking solution by diluting 116 µL 10%aque-
ous Triton X-100 solution with 10 mL 1× PBS. Store stock and
working solutions at room temperature. Working solution is
stable for 1 month.
4. PBS, calcium- and magnesium-free, pH 7.4.
Figure 14. Human whole blood fixed with formaldehyde and perme-
abilizedwith TX-100.White blood cell populationswere identified using
CD14-PE-Cy7 and CD45-Krome Orange. Debris (red) is identified using
CD45 versus SS (top panel—region C). Identification of peripheral blood
monocytes (shown in blue in both panels) was accomplished using CD-
14-PE-Cy7 (not shown).
5. Wash buffer—PBS/5% BSA (preferably protease-free BSA if
also using for antibody dilutions).
6. Methanol—100% reagent grade, dilute to 50 or 80%with NaCl
(final concentration 0.9%), store at –20°C; use at 4°C).
5.3.2 Procedure: Whole blood fixation and permeabilization.
1. Place anti-coagulated whole blood sample at 37°C and allow
temperature to equilibrate.
2. For 100 µL whole blood sample, add 65 µL 10% formalde-
hyde, and immediately vortex. Incubate at room temperature
(24°C) for exactly 10 min.
3. After exactly 10 min of incubation in formaldehyde at room
temperature, add 1 mL of room temperature Triton working
solution, vortex, and place in 37°C bath and set timer for 15
min.
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4. Add 1 mL of cold (4°C) wash buffer and vortex. Centrifuge at
500 × g for 4 min.
5. Inspect tube for complete RBC lysis (rust red pellet, clear red
supernatant—not turbid). If RBC lysis is incomplete, resus-
pend pellet in 1 mL Triton working solution at 37°C for an
additional 15 min.
6. Remove supernatant, and wash pellet thrice using cold wash
buffer (centrifuge at 500 × g).
7. For methanol treatment, slowly add 1 mL 4°C methanol solu-
tion (50 or 80% depending on target epitope) to the washed
cell pellet while vortexing pellet. Incubate in ice for 10 min.
8. Centrifuge (500 × g) and wash pellet twice using 2 mL cold
wash buffer.
9. After final centrifugation, carefully remove as much super-
natant fluid as possible. Resuspend pellet by vortexing. Add
antibody cocktail, incubate and wash twice with cold wash
buffer.
10. Resuspend cell pellet in 0.5 mL wash buffer and analyze
immediately on flow cytometer. For intracellular epitopes that
degrade, or for samples that need to be analyzed more than
6 h after resuspension, resuspend in 0.1% paraformaldehyde
in PBS. Store at 4°C in the dark until analysis.
5.4 Effect of methanol on epitope staining
Some intracellular or intranuclear epitopes remain poorly acces-
sible to antibody probes after fixation and permeabilization using
the formaldehyde–Triton technique described above. This is likely
a limitation of all similar aldehyde–detergent (only) fixation and
permeabilization techniques. In our experience, phospho-STAT
proteins are largely undetected after this type of processing. How-
ever, treatment of the fixed and permeabilized cells with cold
(4°C) methanol for 5–10 min “unmasks” these epitopes [71],
although care must be taken to validate the effects of methanol
treatment particularly when used post-staining and when using
tandem dyes as described below. As shown in Fig. 15, treatment
of fixed and permeabilized whole blood (activated using GM-CSF)
with up to 50% cold methanol has minimal impact on the qual-
ity of P-STAT5 staining (same signal intensity for 50% methanol
or untreated sample indicating almost no P-STAT5 staining, not
shown). However, treatment with 80% cold methanol produces
a significantly stronger P-STAT5 signal. The impact of treatment
with methanol at both 50% (top) and 80% (bottom) concentra-
tions on P-ERK and P-S6 staining (ribosomal S6 protein) is also
shown in Fig. 15. Here, methanol treatment has minimal effect on
the P-ERK signal intensity and reduces the P-S6 signal by about
20%. It is therefore important, when first developing and optimiz-
ing fixation and permeabilization for new cytoplasmic epitopes, to
determine the impact of methanol treatment on all target epitopes
that will be measured in the assay.
While methanol “unmasking” is important for the evaluation
of some phospho-epitopes, it also has the effect of decreasing
(or eliminating) the immunoreactivity of other important epitopes
used to detect specific cell populations. In our experience, this is of
Figure 15. Impact of methanol concentration on P-STAT5 immunore-
activity in peripheral bloodmonocytes activated in vitro using GM-CSF.
Whole blood from a normal donor was treated with GM-CSF for up to 20
min in vitro at 37°C. One part of the fixed and permeabilized samples
was treated with 50% methanol (A) and the other with 80% methanol
(B) at 4°C. After washing, all samples were stained with (  ) P-STAT5,
(  ) P-ERK, and (  ) P-S6.
particular importance in the analysis of some myeloid–monocyte
markers in human blood or bone marrow (CD14, CD33, CD64),
and of less importance for stem-cell or progenitor cell markers
(CD34, CD117). See ref. [72, 73] for details regarding cell surface
CD markers that we have tested, which are effected by methanol
treatment.
In the example illustrated in Fig. 16, we have compared the sig-
nal strength obtained when staining whole blood CD14-positive
monocytes using either 50 or 80% cold methanol. In addition,
in this study, cell surface CD14 was stained with a tandem dye
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Figure 16. Effect of methanol treatment on CD14 stain-
ing of human peripheral blood monocytes. Whole blood
samples from one individual were stained with CD-14-PE-
Cy7 before (left panels) or after (right panels) fixation and
permeabilization. Samples were treated with either 50%
(top panels) or 80% (lower panels) methanol. See text for
details.
(PE-Cy7) either before fixation and permeabilization (and prior to
cold methanol treatment), or after fixation, permeabilization, and
cold methanol treatment. Looking at the impact of 50% methanol
treatment (upper panels), comparing the CD14 fluorescence inten-
sity for monocytes labeled before or after fix-perm and methanol,
the MFIs are very similar for cells labeled before or after fixa-
tion and subsequent treatment. In contrast, when considering the
impact of pre- or post-fixation staining as shown in the lower
panels, cells labeled with CD14 after fix-perm and 80% methanol
(lower right panel) show a significant reduction in CD14 stain-
ing intensity (compared with that of cells stained after 50% cold
methanol, top right). While cells stained with CD14 mAb before
fix-perm and 80% cold methanol treatment (bottom left) show
a fourfold higher MFI than cells stained after, they still show a
50–60% loss in CD14 staining intensity (relative to unfixed whole
blood). Together, these data support the concept that the CD14
epitope detected by the antibody used here (BCI clone RMO52) is
not affected significantly by treatment with 50% cold methanol,
but is affected following 80% cold methanol. In addition, these
data show that the antibody-conjugate is also impacted by 80%
cold methanol (MFI is lower for cells stained following fix-perm
and 80% methanol treatment). These data should reinforce the
concept that all of the details of fixation–permeabilization and
methanol treatment need to be validated for the complete set of
antibody conjugates used for a new experiment. For more infor-
mation regarding the use of pre- or post-staining peripheral blood
in relation to intracellular and CD epitopes, see ref. [74]. This
technique [74] has been utilized to stain both cell surface and
intracellular epitopes for the analysis of MAP Kinase, STAT, and
ribosomal S6 signal transduction pathways in human bone mar-
row samples [72, 73].
5.5 Fixation and permeabilization for non-adherent tissue
culture cell preparations
Routine fixation and permeabilization of tissue culture cells
(anchorage-independent cell lines) is accomplished using
formaldehyde fixation followed by permeabilization of cytoplas-
mic and nuclear membranes using absolute methanol. Although
we routinely stain both cell surface and cytoplasmic or nuclear
epitopes simultaneously, it is also possible to stain cell surface
epitopes with some antibody conjugates prior to fixation and per-
meabilization [74]. This approach is particularly useful for cell
surface markers that are altered (e.g., CD19) or destroyed (e.g.
CD14, CD15, CD64) by fixation using alcohol treatment alone.
5.5.1 Determining optimal formaldehyde fixative concentration.
Optimal detection of phospho-epitopes appears to be influenced
by the formaldehyde concentration used to fix different types
of cells. As shown in Fig. 17, P-STAT5 in K562 cells is opti-
mally detected following treatment with 0.05 to0.4% formalde-
hyde (37°C for 10 min). Since the degree of potential epitope
cross-linking/fixation is proportional to the formaldehyde
concentration, incubation time, and temperature, all three of these
variables should be controlled and performed identically each
time. As shown in Fig. 17 at higher final formaldehyde concen-
trations, the P-STAT5 signal decreases, likely from overfixation,
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Figure 17. Effect of formaldehyde concentration on P-STAT5
immunoreactivity in K562 cells (reproduced from ref. [75] with per-
mission). Cells were fixed at 37°C for 10 min using increasing final con-
centrations of formaldehyde, permeabilized, and stained with anti-P-
STAT5-PE as described.
and limitation of phospho-epitope accessibility by antibody con-
jugates [75]. As also shown in Fig. 17, treatment with absolute
methanol alone (no formaldehyde: first data point) results in a
background level of signal.
5.5.2 Routine fixation, permeabilization, and antibody staining for
non-adherent cultured cell preparations. For fixation and perme-
abilization of non-adherent tissue culture cells, we add the optimal
formaldehyde concentration directly to sub-confluent cells (ideally
re-fed 12–24 h prior to harvest) in tissue culture media (routinely
containing 15–20% FBS), and return cells to the 37°C tissue cul-
ture incubator for 10 min. Cells are then centrifuged (400 × g
for 10 min), and resuspended using a vortex mixer (note: cells
are clumped at this point and require vigorous treatment with
vortex to achieve resuspension of all cells). While vortexing, abso-
lute methanol (stored at –20°C) is added with 1 mL absolute
methanol per 107 cells being added. At this point, the cells can
be stored in a well-sealed container at –20°C for several weeks
with no significant decrease in the detection of phospho-epitopes
(epitopes tested thus far).
For staining of intracellular epitopes, place 3–5 × 106 cells
into each tube (we routinely perform staining of tissue culture
cells in 1.2 mL microfuge tubes). Centrifuge tubes (for refriger-
ated microfuge, use 10 000 rpm for 12 s), carefully aspirate off
supernatant, and resuspend the cell pellet in 1 mL cold (4°C) wash
buffer (Dulbecco’s PBS/5% FCS or Dulbecco’s PBS/5% protease-
free BSA) while vortexing. Place tube on ice for 5 min to allow
buffer to equilibrate and remove residual alcohol. Centrifuge as
above. Repeat and wash twice with cold wash buffer.
Carefully remove supernatant following the last centrifugation
step, and resuspend cells in 100 µL of antibody conjugate (or
antibody conjugate mixture). It is important that each antibody
used is titrated to ensure optimal SNR. Incubate cells with antibody
(or antibodies) on ice (4°C) in the dark (if using photosensitive
conjugates) for 30 min.
Resuspend cells in 0.5 mL cold wash buffer for flow cytometry
analysis (if cells are to be analyzed within 1–2 h). If cells will not
be analyzed within 1–2 h, centrifuge the washed cells, and resus-
pend the cell pellet in cold PBS/0.1% paraformaldehyde. Cells
post-fixed in 0.1% paraformaldehyde and stored at 4°C (dark)
are stable (light scatter and phospho-epitope detection) for at
least 24 h. It should be noted that the signal intensity of some
phospho-epitopes start to decrease significantly within minutes of
the final resuspension in cold wash buffer (e.g., P-S6). For these
epitopes, it is strongly recommended to immediately place the cells
in PBS/0.1% formaldehyde, which significantly decreases the rate
of signal loss.
6 Variable lymphocyte receptor antibodies
6.1 Overview
Variable lymphocyte receptor antibodies of the evolutionarily dis-
tant jawless sea lamprey are structurally distinct from Igs of jawed
vertebrates. They recognize antigens with a high degree of speci-
ficity and can be utilized in various biomedical research appli-
cations in which their unique antigen recognition characteristics
complement conventional antibody panels. In this section, we pro-
vide a protocol for the use of these novel reagents in multicolor
flow cytometry applications.
6.2 Introduction
The recently identified variable lymphocyte receptor (VLR) anti-
gen receptors of jawless vertebrates have contributed greatly to
our understanding of the evolution of the adaptive immune sys-
tem [76]. Three VLR genes (VLRA, VLRB, and VLRC) have been
described that are assembled by a gene conversion-like mecha-
nism, and are expressed by cells reminiscent of αβ T cells, B cells,
and γδ T cells, respectively, with VLRB being secreted in the form
of disulfide-linked decameric complexes. Conventional antibodies
utilize the Ig domain as the basic structural unit and are gen-
erated by recombination of the variable (V), diversity (D), and
joining (J) gene segments for the antibody heavy chain and the
V and J gene segments of the antibody light chain. As illustrated
in Fig. 18, the resulting antibody consists of an F(ab)/F(ab’)2
domain that engages the antigen primarily via interactions medi-
ated by residues located in the complementarity determining
regions (CDR) 1, 2, and 3 whereas the Fc domain allows for the
communication with various cells of the immune system to elicit
biological responses. The ability of antibodies to recognize their
antigens with a very high degree of specificity and to label these
reagents with fluorescent dyes makes antibodies the key compo-
nent of most flow cytometric applications. Unlike conventional
antibodies, VLR antibodies utilize the leucine-rich repeat (LRR) as
a basic structural unit [77]; the resulting gene product assumes
a solenoid shape (Fig. 19A), wherein the corresponding antigen
interacts with residues located at the inner concave surface, and
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Figure 18. Structural characteristics of Igs. Rib-
bon diagram of a mouse monoclonal IgG anti-
body consisting of two identical heavy and light
chain proteins, respectively. Antibody heavy
chain residues are indicated in blue and light
chain residues in green. Amino acid residues
encoding the CDR1, 2, and 3 regions are shown
in red. (Image was generated using the Swiss
PDB viewer and PDB accession number 1IGT).
with a variable loop structure protruding from the capping C-
terminal LRR unit [78, 79]. VLR antibodies have become a novel
class of highly specific biomedical research tools, by virtue of the
vast VLR antibody repertoire. Interestingly, VLR antibodies appear
to be particularly suited for the specific recognition of posttransla-
tional protein modifications. Several monoclonal VLR antibodies
recognizing carbohydrate moieties were described [80, 81] and
recently our group reported the isolation of a monoclonal VLR
antibody recognizing the HLA-I antigen in a tyrosine sulfation-
dependent manner specifically on human memory B cells and
plasma cells, a binding pattern distinct from those of any described
conventional antibody [82]. The distinctive antigen recognition
characteristics of these VLR antibodies indicate that the unique
origins and protein architecture of VLR antibodies may permit
binding to antigens that conventional antibodies may not readily
recognize because of tolerogenic and/or structural constraints. An
established protocol harnesses the expansive repertoire to gener-
ate antigen-specific monoclonal VLR antibodies with ready appli-
cability in standard laboratory techniques such as flow cytometry
and ELISAs [83].
Several research groups have used monoclonal VLR antibod-
ies, either unmodified or engineered as Fc fusion proteins for
purification using protein A/G columns and detection with a vari-
ety of commercially available reagents recognizing the IgG Fc
domain. Alternatively, purification is also readily performed using
Ni-columns targeting an engineered 6xHis epitope tag followed by
detection of the VLR antibody with reagents specific for the incor-
porated HA-epitope tag (Fig. 19B). Here, we describe a protocol
for use of VLR antibodies in multicolor flow cytometry analyses of
human PBMCs in combination with conventional, directly labeled
monoclonal antibodies. Depending on the type of VLR antibody
used and the expression levels of the targeted antigen, a two-
layer or three-layer staining approach can be used (see below for
protocol). The use of monoclonal VLR antibodies with engineered
epitope tags or VLR-Fc fusion proteins permit a more efficient two-
layer staining approach. The use of unmodified monoclonal VLR
antibodies or experiments targeting antigens expressed at low lev-
els require a three-layer staining approach since the established
anti-VLRB monoclonal antibody 4C4 cannot be readily modified
with common labeling systems that target primary amines. Several
positive and negative control reagents for VLR-based experiments
have been described [83, 85].
6.3 Experimental workflow and acquisition
6.3.1 Reagents.
* Fluorescently labeled anti-epitope tag or Fc-specific reagents
are available from several commercial sources.
* Monoclonal mouse anti-VLRB clone 4C4 [86]. Note that this
antibody is reactive with an epitope in the stalk region
of all VLRB molecules, and it displays impaired antigen-
binding characteristics following modification with amine-
reactive dyes.
* Negative control monoclonal VLR4 antibody (specific for the
BclA antigen of the exosporium of B. anthracis [83]).
* Positive control VLR32 antibody (specific for human CD5) [87]
or VLRB MM3 antibody (specific for human CD38 on plasma
cells) [85]. Suitable cell lines for testing of positive controls are
the Jurkat T-cell leukemia and the Daudi Burkitt’s lymphoma,
respectively.
6.3.2 Two-layer staining approach.
* Incubate PBMCwith monoclonal VLR antibody in PBS/0.5 BSA
for 25 min on ice (v = 40 µL).
Figure 19. Structural characteristics of VLR antibodies. (A) Ribbon diagram of the antigen-binding units of a monoclonal VLR antibody. Parallel
β-sheets lining the concave antigen-binding surface are shown in blue and a variable loop structure involved in antigen binding is depicted in red.
The invariant stalk region necessary for multimerization of the secreted VLR antibody was omitted (Model was generated using the Protein Model
Portal Algorithm [84]). (B) Structural characteristics of VLR antibodies. Individual VLRB units consist of a signal peptide, N-terminal LRR (LRR-NT),
LRR-1, up to nine variable LRRv units, a connecting peptide, C-terminal capping LRR (LRR-CT) and the invariable stalk region and can be modified
by inclusion of engineered 6xHis and HA-epitope tags or Fc-fusion sequences.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 Before you start: Reagent and sample preparation, experimental design 1505
* Wash with PBS/0.5% BSA.
* Resuspend cells in antibody cocktail containing fluorescently
labeled lineage-specific conventional monoclonal antibodies
and fluorescently labeled anti-epitope tag antibodies (or anti-
Fc antibodies if VLR-Fc fusion proteins are used), incubate for
15 min on ice.
* Wash twice with PBS/0.5% BSA.
* Resuspend in PBS/0.5% BSA/1 µg/mL PI and analyze by flow
cytometry.
6.3.3 Three-layer staining approach.
* Incubate PBMC with monoclonal VLR antibody in PBS/0.5%
BSA for 25 min on ice (v = 40 µL).
* Wash with PBS/0.5% BSA.
* Resuspend cells in PBS/0.5% BSA, add anti-VLRB clone 4C4
at a concentration of 1 µg/mL and incubate for 15 min on ice
(v = 40 µL).
* Wash with PBS/0.5% BSA.
* Resuspend cells in PBS/0.5% BSA, add fluorescently labeled
goat anti-mouse reagent (typically at a 1:300 dilution), incu-
bate for 15 min on ice (v = 40 µL).
* Wash with PBS/0.5% BSA.
* Resuspend cells in PBS/0.5% BSA/5% normal mouse serum,
incubate for 10 min on ice. (Blocking step, see “Pitfalls” below)
* Add antibody cocktail containing fluorescently labeled lineage-
specific conventional mAbs, continue incubation for 15 min on
ice.
* Wash twice with PBS/0.5% BSA.
* Resuspend in PBS/0.5% BSA/1 µg/mL PI and analyze by flow
cytometry.
As is the case with all conventional antibodies, monoclonal VLR
reagents must be titrated prior to use and 2 µg/mL serves well as a
starting point. While background signals with the negative control
VLR4 are not typically observed, negative control stains lacking
any VLR antibody, in addition to negative controls or the various
conventional antibodies, should be routinely included.
6.4 Pitfalls
Potential omission of blocking step in three-layer staining
approach. This blocking step is important to prevent binding of
directly labeled antibodies from the next incubation step to poten-
tially unoccupied binding sites of the goat anti-mouse reagent from
the previous step.
7 New antibody reagents
As discussed earlier in this chapter, the determination of specific
binding of antibodies to antigens and Fcγ receptors as well as
nonspecific antibody binding to cells can be difficult. Furthermore,
the critical role of antibodies and their limitations are known and
published [88]. Therefore, to improve the data reliability in these
respects, further advanced technologies are desirable and various
antibody products with improved characteristics are available. A
few of them are discussed here.
Miltenyi Biotec developed the REAfinity antibodies. These are
recombinant antibodies, which are engineered by cloning of the
antibody-binding region of mouse or rat mAbs with the human
IgG1 Fc region. The construct is expressed in a mammalian cell
line under standardized conditions. To eliminate any binding of
the recombinant antibodies to the Fcγ receptors, the Fc region of
the antibody is mutated suggesting that no blocking of the Fcγ
receptor binding sites on the target cell surface is necessary. Since
all recombinant antibodies are derived fromhuman IgG1, the same
isotype control antibody can be used to prove that there is no bind-
ing of any REAfinity antibody to the Fcγ receptors on target cells.
Additional advantages are proposed to be a very high antibody
purity and a very good lot-to-lot consistency due to the standard-
ized antibody expression by the used cell lines. Other compa-
nies, such as Enzo Lifesciences, provide recombinant antibodies
as well.
Another type of antibodies without any reactivity to mam-
malian Fcγ receptors is the chicken IgY [89], making it an alter-
native to be considered for improving data accuracy. One more
possibility to reduce error sources, when analyzing cells with high
multiparameter panels, is the use of the Duraclone system pro-
vided by Beckman Coulter. These are pre-formulated antibody
panels, which are unitized and dry, allowing an easy work flow,
since no pipetting and antibody mixing is necessary. To perform
the staining, the cell suspension (e.g., a sample of whole blood)
needs to be added to the lyophilized antibody mixture. Due to that
standardization, a reduced staining variability can be expected.
Additionally, the panel does not need to be developed, in contrast
leading to a reduced flexibility, although drop-in markers are pro-
vided. Solutions to stain samples for compensation are included
in the available kits.
Another technology to be mentioned here, because it allows a
huge flexibility (especially if a primary conjugated antibody flu-
orochrome combination is not available) is the Zenon labeling
system by Thermo Fisher Scientific. It consists of Fab fragments
conjugated with fluorochromes, which target the Fc region of pri-
mary, non-conjugated antibodies. The creation of that complex
can be performed with very small amounts and it is very fast. It
needs only some minutes, although remaining unbound Fab frag-
ments should be captured afterward by addition of nonspecific
IgG. Also, the ratio between the Fab fragments and the primary
antibody needs to be titrated to obtain the desired degree of bind-
ing and therefore the staining intensity. After staining the cells,
a fixation based on aldehydes might be beneficial to preserve the
staining and to prevent the transfer of Zenon labels from one
antibody to another one. Since the Zenon labeled antibodies are
significant bigger than directly labeled primary antibodies, there
might be limitations when using them especially for intracellular
staining.
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It should be noted that this section should not be understood
as an advertisement to specific products. Rather it is an incom-
plete selection of some materials on the market to get an overview
about different systems. Other related or comparable products,
which are not discussed here, are offered by various compa-
nies. Nevertheless, the discussed materials might help improving
the data quality. However, irrespectively which of the discussed
techniques are used, the researcher needs to gain an impres-
sion if the used material will indeed help to create more accu-
rate results. Furthermore, the same controls, as stated above,
should be considered to ensure the reliability of the obtained
data.
IV Cell sorting
1 Pre-enrichment of low abundant cell populations
prior to acquisition/cell sorting
1.1 Introduction
One of the major advantages of flow cytometry is the capability to
measure multiple parameters per cell with a speed of several thou-
sand cells per second. This allows the measurement and detection
of rare cell populations with frequencies below one in one million
cells (1/1 × 106). But even with this relatively high number of
cells analyzed per second, a lot of time is required to acquire a
significant number of rare cells for statistical analysis. Assuming
a frequency of one cell of interest per 1 × 106 cells in a given
sample, one would need to acquire a minimum of 1 × 109 cells
to have at least 103 cells of interest at the end of acquisition. The
average acquisition speed of many flow cytometric analyzers, at
which they will detect and acquire all incoming signals without
significant loss due to coincident or electronic aborts, is around
104 cells/s. It would therefore take more than 24 h to acquire
enough of the described sample in order to reach the 1000 cells
of interest.
While this time calculation is basically true for many available
flow cytometric analyzers, for cell sorting, the time calculation is
different. Here, additional parameters come into focus. In common
flow cytometers that hydrodynamically focus the cells in front of
the laser intersection point (point of fluorescence detection, see
Chapter I Section 1.2 Hydrodynamic focusing), the speed of the
carrier stream is given by the system and only the volume of
sample running through per time can be adjusted by the user.
In contrast, the fluidic of most cell sorters is more variable and
allows adjustments of speed and flow-through volumes at various
steps (both on the sample and instrument side). In many cell sort-
ing experiments, there is a demand to maximize both the yield
and purity of the sorted cells and minimize the time you need
to run your cells through a machine. Yield and purity influence
each other and are both dependent on the speed (cells running
through a sorter per second) and the frequency of cells of interest
(see Chapter IV, Section 2.1). Unfortunately, they cannot be max-
Figure 20. In cell sorting experiments one often needs to find a com-
promise between purity, yield, and time, which cannot be optimized all
at the same time.
imized both at the same time. The less abundant a cell population
is, the lower the speed of sorting has to be, in order to ensure
a high yield with an acceptable purity (>95%). If you speed up
(increase the number of cells running through the machine per
time), your yield will drop significantly (up to 50% in some cases)
or alternatively, the purity is sacrificed for a higher yield obtained
in a shorter period of time (see Fig. 20). Therefore, sorting 1000
rare cells with high purity could last twice as long as the acqui-
sition only (the relation between speed, frequency of cells, yield,
and purity are discussed in more detail in Chapter IV, Section
2.1). This crude calculation only accounts for the time needed
for acquisition and cell sorting; not counted is the time already
invested in preparing and staining the cells (see, e.g., Chapter III,
Section 3).
Given that flow cytometry as a method allows the identifica-
tion and quantification of individual cells within a given popula-
tion and given that in cell sorting this decision takes even more
time, thereby slowing down the process, it is obvious that enumer-
ation/evaluation of every single event especially of samples with
large cell numbers prior to sorting is not a practicable way to go
about analysis and sorting of rare cell populations. How then can
we achieve acceptable work times and make it possible to analyze
those rare cell populations?
We need a reduction in workload, meaning a reduction of
the amount of cells that need to be measured in the flow
cytometer. One way to overcome this situation is to get rid of
as many “unwanted” cells as possible prior to acquisition, in
the form of pre-enrichment. Cells can be separated from each
other in many different ways and some methods of pre-enriching
rare cells before flow cytometric analysis are discussed below.
Because same pre-enriching techniques can be used as stand-
alone bulk sorting approaches, the following section comple-
ments the subsequent chapter about parallel cell sorting. Require-
ments and pitfalls analysing rare cells are discussed in Chapter V,
Section 1.
In general, we can distinguish methods based on physical prop-
erties (such as density and size) or using immunological features
(antibodies coated to beads or magnetic particles) as discussed in
the following two sections.
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1.2 Pre-enrichment by physical properties
Physical properties of cells may be exploited to enrich them. For
instance, monocytes, macrophages, and dendritic cells within a
mixed cellular population adhere to plastic and are in general
adherent within the first 2 h of being incubated on a Petri dish.
Cells other than macrophages and dendritic cells can be removed
and washed off with the supernatant. After longer incubation peri-
ods (20 h), dendritic cells start detaching from the plastic again.
With this method, an enrichment of up to 70% could be reached
for dendritic cells. This method is used in the process of generating
and isolating dendritic cells out of monocytes and macrophages
derived from blood or bone marrow [90, 91].
Another simple method to eliminate unwanted events is the
lysis of red blood cells (see also Chapter IV, Section 2.5 and
Fig. 22B), which are a common “contaminating element” in tis-
sue preparations. In contrast to nucleated cells, erythrocytes burst
upon brief exposure (<60 s) to a hypotonic medium (e.g., erythro-
cyte lysis buffer: 155 mMNH4Cl; 10 mM KHCO3; 100 mM EDTA).
Remember that human and mouse erythrocytes differ in size and
ability to resist hypotonic shock over time. Various buffers and
protocols are available, which differ in temperature and exposure
time, affecting lysis outcome. It is therefore necessary to adapt
the lysing protocol to the experimental conditions ([92–94] and
Chapter IV, Section 2.5).
Peripheral PBMCs can be enriched by density gradient centrifu-
gation using Ficoll R©. This biological inert polysaccharide allows
the separation of PBMCs from plasma, granulocytes, and erythro-
cytes based on their cellular density (Fig. 21) (see also Section
IV.2: Parallel cell sorting: 1.3.1 Ficoll-PaqueTM, LymphoprepTM).
While many users report a lower recovery (up to 10–15%)
in the absolute numbers of target cells after density gradi-
ent centrifugation, they profit from faster operational times in
downstream assays and lowered costs, because fewer (staining)
reagents in less buffer are needed for the significantly reduced
total cell numbers. In functional assays, e.g., antigen presenta-
tion or proliferation assays and transplantation (e.g., hematopoi-
etic stem cell transplantation to reconstitute bone marrow and
blood formation in irradiated mice), a higher cell viability and
reconstitution frequency is reported when Ficoll-enriched cells
were used, as compared to preparations without preenrichment
via density gradients.
Elutriation [95–97] is another method of separating cells based
on their size, which uses centrifugal forces. The technique is also
called counter flow centrifugation and makes use of a modified
elutriator rotor containing a separation chamber with which one
can gently separate a large variety of cells from different tissues
and specimens. The cells are separated in this chamber mainly
based on their different sizes by the opposing action of the cen-
trifugal field generated by the rotation of the rotor and the liquid
flow inside the chamber (Fig. 21; centripetal, means in direction
to the rotor axis (counter flow)). Because the separation is not
dependent on a specific density gradient, this method is com-
patible with a wide set of media. Another big advantage is high
viability and low activation of the cells, making it an interesting
tool in a clinical environment [98].
1.3 Pre-enrichment by immunological properties
Although pre-enrichment methods based on physical properties
(such as size, density, etc.) are straightforward, they do not allow
for functional or biological discrimination of sub-populations, e.g.
discrimination between T and B lymphocytes. To do so, immuno-
logical separation methods, which make use of antibodies to
reach the specificity and cell population of interest, could be
used.
One of the first methods established (in the early 1970s) is
antibody-mediated complement lysis of unwanted cells. The cells
(e.g. erythrocytes or T cells in a mixed lymphocyte pool) that you
want to eliminate are detected and opsonized with specific anti-
bodies (at the beginning serum from immunized animals were
used, nowadays one can also use mAbs against the antigen of
interest). Soluble parts from the complement C system are added
to the cell suspension, bind to the antibody-tagged cells, and lyse
them [99, 100]. There are more “classical” methods to enrich dif-
ferent immune cell subpopulations, some of which are still in use.
These methods are summarized elsewhere [101] and are only
mentioned to complete the overview. In the meantime, a vari-
ety of easier and more efficient techniques have become avail-
able. These techniques combine the advantages of beads and
antibodies.
To enrich or deplete subpopulations out of a heterogeneous
cell population, one can use beads coupled with mAbs against
antigens expressed on the cells of interest that bind to the anti-
gens forming larger aggregates. These cell-bead aggregates can
now be easily separated from the unbound cells in the solution by
passing the bead/cell-mixture over a mesh (Fig. 21). Cells that are
bound to beads would not pass through the mesh, and are thus
enriched on the mesh surface, whereas all other cells are smaller
than the mesh-size and flow through. After filtration through the
mesh, the antibody-coupled beads can be detached from the cells
to allow the cells to be further analyzed. Using varying sizes of
mesh and beads make sequential separations possible. For exam-
ple, the pluriBead R© technology allows cell enrichment as well as
depletion of specific subpopulations [102]. Advantages and dis-
advantages of that technology are further discussed in Chapter IV
Section 2.2.1.1.
The most commonly used methods for pre-enrichment of sub-
populations are based on beads passing a magnetic field. A variety
of companies offer different solutions for enrichment or depletion
of cell populations. One system of immunological pre-enrichment
employing magnetic fields is the MACS R© Bead-Technology
[103].
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Figure 21. This figure shows a summary of discussed enrichment methods. (A) The separation of different cell types with a Ficoll R© density
gradient is shown. (B) Once one applies a centrifugal force in an elutriation chamber, cells will stop passing through and start separating along a
density gradient built inside the chamber. The equilibrium formed depends on the speed of the cellular flow, the amount of applied centrifugal
force, and the viscosity of the medium used. This is the reason why elutriation is compatible with a wide range of cell types and carrier media.
(C) Target cells (black) can form aggregates with antibody-labeled beads and If you add beads that are coated with specific antibodies against your
target cells (black) to the cell suspension, the target cells will form aggregates with the beads. These aggregates are held back on the top of the
mesh while the rest of the cell suspension is passing through. With this method one can either deplete or enrich for a specific cell population.
Combining different mesh and bead sizes is allowing for a serial enrichment of target cells.
1.4 Magnetic pre-enrichment for high-resolution detection
and analysis of rare cell populations
For the detection and analysis of cell subsets that are detectable
only in very low frequencies (<0.1%), appropriate pre-enrichment
strategies, as detailed in the sections “Pre-enrichment by physical
properties” and “Pre-enrichment by immunological properties,”
may help improve gating resolution for the cell population of inter-
est. Typical applications are the detection of hematopoietic stem
cells [104], CTCs [105], dendritic cells [106], or lymphocyte sub-
sets, such as antigen-specific T cells [107]. As one of the most com-
monly used pre-enrichment technologies immunomagnetic posi-
tive and negative selection strategies have been established (this
has been exemplified in the context of detecting antigen-specific T
cells (Chapter V Section17.5.3, Fig. 67). Magnetic pre-enrichment
is a unique tool to improve resolution of cell populations, e.g., via
isolation of weakly labeled cells to achieve separation of “overlap-
ping” populations, depletion of irrelevant cells, or enrichment of
rare cells (Fig. 24). As described above for mesh-filtration based
enrichment, the concept is based on the attachment of small, inert,
supra-magnetic particles to mAbs specific for antigens on the tar-
get cell population.
Cells labeled to these antibody–bead conjugates are then sep-
arated via a column containing a ferromagnetic matrix. By apply-
ing a magnetic field to the matrix, the beads stick to the matrix
inside the column and the bead-carrying cells are held back from
passing through (Fig. 22C). Unlabeled cells can pass through the
matrix and are collected in the flow-through (Fig. 22D). To elute
the trapped cells from the column, the magnetic field is sim-
ply removed. The MACS R© technology therefore enables different
strategies for positive enrichment or depletion of cells. MACS R©
beads are comparable small and offer the advantage of not inter-
fering (too much) with downstream assays (see also Chapter V,
Section 18.5). In contrast to cell sorting, up-scaling the cell num-
bers does not significantly increase processing times. For some
cell types (e.g., CD4+ T cells or B cells), a high enough purity
can be achieved such that further enrichment is not necessary
(of course this is dependent on the quality needed for the down-
stream assay, e.g., RNA/DNA purification). Solutions using mag-
netic beads other than MACS R© beads are also available for cell
separation (e.g., Dynal R© Beads [108] or BD iMagTM [109]). The
beads in these kits are generally larger than the MACS R© beads and
do not require a separate matrix to retain the cells in the magnetic
field. The disadvantage of using these systems is that, for many
downstream assays, it is necessary to detach the beads from the
cells to avoid interference with the system.
To pre-enrich your cells, you can choose a protocol from a
variety of different techniques, which separate your cells based on
their physical and/or immunological properties. Pre-enrichment
could be useful to cut down the processing time of your experi-
ment, increase the quality of downstream assays, or to reduce the
amount of reagents needed.
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Figure 22. Enrichment of human B cells out of whole blood stained for CD45 BV421 and CD19 APC. (A) Staining prior enrichment. (B) Staining after
lysis of erythrocytes with Lysing-buffer. (C) Staining after CD19+ MACS R© enrichment. (D) Staining of the CD19− fraction (MACS R© flow through).
2 Parallel cell sorting
2.1 Introduction and general considerations
Parallel or bulk cell sorting is generally used to isolate a large
number of cells in a batch mode, often as a pre-enrichment step
before a single-cell sort (see Section IV.1 “Pre-enrichment of low
abundant cell populations prior to acquisition/cell sorting”). Par-
allel sorting uses parameters such as cell size, density, magnetic,
or electrical properties. Affinity binding reagents (e.g., antibodies)
for specific cell subsets can be used to change specific properties,
e.g., magnetism or density to achieve an antigen-specific bulk sort.
General considerations: Bulk cell sorting from a cell mixture
can be done by many methods, each one having different advan-
tages and challenges. The main variable parameters to be con-
sidered are specificity, yield, purity, viability, and functionality.
Moreover, speed, cost, and consumables for equipment must be
also taken into account. The importance of the different functional
parameters will depend on the specific experimental goals, e.g.,
very high purity may be essential inmany cases, while yieldmay be
less important, because sufficient material is available. Instrumen-
tation features depend on the specific needs and the experience of
the user(s). Figure 23 illustrates the various parameters needed
in deciding on a sorting strategy or method. Not always can all
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Figure 23. Check-list: Parameters for select-
ing a sorting method. The parameters that
affect cell sorting and therefore must be pri-
oritized when choosing a sorting strategy are
shown. Starting from the available material
(amount, fragility), they range from the mun-
dane cost aspect to practical and methodologi-
cal concerns such as the available time, to the
important experimental approaches regarding
what yield, purity, or versatility is needed for
down-stream applications. Optimization of one
parameter may downgrade another parameter,
e.g., a high purity may be at the expense of a
high yield or speed, or unchanged functional-
ity of the cells may not allow direct positive
selection.
parameters be set at optimal levels simultaneously. For cell iso-
lations, where multiparameter sorting is not needed, but where
speed is of essence, e.g., because high numbers of cells must be
sorted, bulk cell sorting is preferred.
Flow cytometry cell sorting, where cells are sorted one-by-one,
is the gold standard for multiparameter cell sorting. This proce-
dure yields very high specificity according to one or several surface
markers, which are made visible by fluorescence-labeled antibod-
ies. The limitation is mainly the number of cells that can be sorted
during a work-day. Pre-enrichment for subsequent flow cytometry
cell sorting is another important application of bulk sorting and
should always be considered, especially when the wanted cells
are comparatively rare. First, because it reduces time of the cell
sort, and second because it helps to improve gating quality by
eliminating potential fluorescence overlap between stained and
unstained cells (Fig. 24). An overview of cell sorting technologies
and applications can be found in ref. [110]
Bulk cell sorting can either use any cell surface marker for
distinction, or use distinct physical properties of cells, such as
density differences (FicollTM isolation), size, plastic adherence,
phagocytic capacity (macrophage enrichment), or sensitivity to
hypotonicity (erythrocyte lysis). Keeping track of cell numbers,
viability, and analyzing the sorted cells before, during, and after
any separation is good routine in order to determine cell yield and
cell purity, and to detect any unreasonable cell losses or damages.
Cell “yield” is the fraction of wanted cells in the original mixture
that could be recovered alive after the sorting procedure.
To quantitatively evaluate sorting performance, several calcu-
lations can be performed. The purity, i.e., fraction of positive cells
in the sorted fraction, can be expressed as the ratio of positive
cells and the sum of positive and negative cells. Then, using the
measured purity and yield, the yield for nontarget particles, the
negYieldFraction (Fraction = Percentage/100), in the target sam-
ple after sorting can be calculated. This provides a helpful metric
when optimizing a sorting technology. Ideally this number will
be zero, when 100% purity is achieved in the separation. The
negYieldFraction, a measure for how many unwanted cells are
found in the sorted sample, can be calculated by re-arranging the
equation:
Purity Fraction = posFraction ∗ posYieldFraction
posFraction ∗ posYieldFraction + negFraction ∗ negYieldFraction
to obtain
negYieldFraction = posFraction ∗ posYieldFraction ∗ (1.0/PurityFraction − 1.0)
1.0 − posFraction .
Another approach for the evaluation of bulk sorting perfor-
mance is described in ref. [111], where it only uses fractions of
cells in the original and positive fraction and does not need infor-
mation about the yield of the positive (wanted) population. The
enrichment factor Fe in ref. [111] is the inverse of the negYield-
Fraction, if the yield of positive cells is 100%. At lower yields,
there are small differences between the two metrics. Table 4 pro-
vides an example showing that final purity values alone are not a
good measure for sorting performance (rows 4 and 5 in Table 4),
even though it may be the important measure for biological
activity.
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Figure 24. Improvement of population discrimina-
tion after pre-enrichment. Cytometer histograms of
unwanted (gray lines) and wanted (solid green) pop-
ulations. (A) A large excess of an unwanted popula-
tion may create substantial overlap with the target
population, making it impossible to achieve a good
single cell sort. (B) After a pre-enrichment bulk sort,
which removes most of the unwanted population a
good discrimination between the two populations can
be achieved.
Table 4. Example of sort performance metrics. The values for purity,
yield, and the fraction of positive cells in the original sample are
measured and the negative logarithm of negYieldFraction, –log(Y–)
(the underlying equations are detailed in the text (IV.2.1) and the
logarithm of Fe [111] are calculated
Purity (%) Yield (%) Orig (%) -log(Y-) Log(Fe)
95 100 50 1.28 1.28
95 90 50 1.32 1.28
95 10 50 2.28 1.28
99 90 1 4.04 3.99
95.6 90 0.1 4.38 4.34
2.2 Antibody based bulk cell sorting
Physical properties of cells can be changed by the reaction with
specially tagged affinity reagents like antibody conjugates with
magnetic particles. In this way, specific subsets can be isolated
with bulk sorting methods.
2.2.1 Magnetic beads coupled to antibodies. This technique uses
the force of magnetism to sort out cells according to specific
cell surface markers. Several commercial systems are available,
which use either inorganic superparamagnetic or ferromagnetic
materials embedded in polystyrene beads or in a matrix such as
dextran, or coatedwith graphene [112]. Beads in sizes from tens of
nanometers up to several times the size of a typicalmammalian cell
are available for bulk cell sorting. The bead-size is not disclosed by
all companies. Cells are incubated with the beads and then drawn
to a magnet of appropriate strength either in a column, tube, or
96-well plate. Nanometer sized beads require high field strength
and field gradients, generally achieved in columns or microflu-
idic channels with optimized ferromagnetic structures. Unwanted
cells are poured off or eluted. In negative selection strategies, all
unwanted cells are labeled, leaving the wanted ones untouched for
downstream applications or a second round of selection by another
surface marker. Several bead or affinity reagent chemistries allow
the detachment from the cells if needed. The bulk sorting method
hinges on the quality of the antibodies used, and the density of
the surface markers on the cells. Cells with a low density sur-
face marker expression may be more difficult to sort. Rare cell
sorting is possible, albeit it may require several rounds of sorting
and intensive washing to remove nonmagnetic cells. Bulk sort-
ing with beads, especially with large beads, cannot distinguish
between high and low expression of a given antigen on the cells.
Selection of a good antibody is crucial for successful sorting, as
is the concentration of beads in the labeling step. Nonspecific
binding associated with antibodies clustered on beads has to be
addressed with some reagents and cell types. Nowadays, many
kits for sorting a range of cell types in various species are com-
mercially available. Custom-made beads may be a choice as well,
and are offered by some companies. Conjugation of antibodies to
magnetic beads in your own laboratory or the use of avidin beads
with second-step labeling with biotinylated antibodies is another
option.
Advantages: Fast, high cell numbers, specific, positive, and neg-
ative selection possible.
Pitfalls: No distinction of antigen density in sorting with larger
beads (some nanometer-sized colloidal beads show some differ-
ences in magnetic retention in some systems [113]); activation
of cells by bead attachment is possible (must be excluded for
individual downstream applications). Temperature and duration
for binding must be considered (in the context of phagocytosis,
decreasing possibility of nonspecific binding, capping, or efficient
binding kinetics). Note: the sort quality must always be analyzed
to detect possible cell losses and impurities. Also the cell viability
can be influenced by buffers or bead sizes.
Selected manufacturers: miltenyibiotec.com, Sepmag.eu, stem-
cell.com, thermofisher.com, turbobeads.com, cd-bioparticles.com,
biolegend.com
2.2.1.1 Nonmagnetic beads coupled to antibodies. Nonmag-
netic beads coupled to antibodies (pluribeads R©) use strainers to
fish out cells, attached to large polystyrene beads. The method
is based on the size-enlargement of cells as the beads are larger
than cells. Specificity is achieved by the antibodies and, again, the
quality of the antibodies is important. As beads vary in size, sev-
eral cell subsets can be sorted out of a mixture by using different
sized beads for different antibodies. A potential advantage is that
the size of the beads may prevent phagocytic uptake. Beads can
be detached by a special buffer, and sequential sorting is possible.
Advantages: Fast, high cell numbers, specific, positive, and neg-
ative selection possible.
Pitfalls: Generally no distinction of antigen density in sort-
ing; activation of cells by bead attachment/detachment proce-
dure is possible (must be excluded for individual downstream
applications); nonspecific binding (the sort quality must be ana-
lyzed to detect possible cell losses and impurities). Temperature
and duration for binding must be considered (in the context of
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phagocytosis, decreasing possibility of nonspecific binding, cap-
ping, or efficient binding kinetics).
Selected manufacturer: pluriselect.com
2.3 Methods based on density differences
Cells, organelles, parasites, and so on have different densities, and
their density differences can be used for cell separation [114, 115].
2.3.1 Ficoll-PaqueTM, LymphoprepTM. Ficoll-PaqueTM contains
FicollTM, a highly branched polysaccharide, and metrizoate.
LymphoPrepTM replaces the latter with sodiumdiatrizoate. Sideby-
side comparisons of the gradient media have previously been
done [116]. They have low viscosity, are nontoxic, and can be pre-
pared for different densities. Ready-made solutions are also com-
mercially available. Ficoll-PaqueTM gradients are frequently used
to separate peripheral PBMCs versus granulocytes/erythrocytes
from whole blood. Efficient removal of dead cells from a mixture
is possible as well (note of caution: this procedure is stressful for
the living cells). When separating blood, the upper fraction con-
tains both lymphocytes and other mononuclear cells. Addition of
iohexol, a nonionic X-ray contrast agent, to the gradient medium
can remove monocytes as well [116]. NycoprepTM and OptiPrepTM
are gradient solutions without FicollTM, based on a tri-iodinated
derivative of benzoic acid with three aliphatic, highly hydrophilic
side chains or on iodixanol, respectively. They thus are not based
on a polysaccharide net [117]. From the granulocyte/erythrocyte
mix, neutrophil granulocytes can be isolated further by dextran
sedimentation [118, 119], and erythrocytes lysed by hypotonic
shock (see Chapter IV, section 2.5).
Advantage: Easy to use, little equipment needed.
Pitfalls: Density for similar cells between species can differ
(e.g., for mouse, horse, and human lymphocytes [120]); erythro-
cytes and granulocytes can become captured in the upper layer,
if the gradient is overloaded or the blood was frozen. Centrifuga-
tion must be done at room temperature and with the centrifuge
brakes turned off. The step of overlayering blood on the gradient
is time consuming and must be done with care. Various commer-
cially available systems such as SepMateTM exist to aid in this,
including prepared Ficoll-gradients in containers to draw blood.
Loss of cells and recontamination when harvesting them from the
gradient surface is possible. Cell activation can be an issue, e.g.,
when isolating neutrophils [118].
Selected manufacturers: gelifesciences.com, http://www.
stemcell.com/en/Products/Popular-Product-Lines/SepMate.aspx
Percoll: A second density separation medium is Percoll,
made from colloidal nanosized silica particles coated with
polyvinylpyrrolidone [121]. Percoll is nontoxic and has a low vis-
cosity, so cells can be centrifuged at low centrifugal forces. Iso-
osmotic gradients of densities between 1.0 and 1.3 g/mL can be
formed by layering solutions of different percentages of Percoll
in a tube. Cells of differing densities collect at the different inter-
faces and can be taken off. Colored density marker beads made
of SephadexTM are helpful to visualize the density borders in the
gradients.
Advantage: Versatile, as several cell types separate in the dif-
ferent layers in one tube.
Pitfalls: See Ficoll-PaqueTM; cell activation can be an issue and
must be considered.
2.4 Methods based on cell size
Size differences of cells of interest, e.g., erythrocytes, platelets,
leukocytes, or circulating tumor cells (CTCs) in blood, can also be
used for separation.
2.4.1 Filters. Membrane filters are applied in sample de-bulking
as they can separate particles or molecules based on size. The
pore size enables larger cells to be retained on the membrane
and smaller cells to pass through. For example, leukocytes (mean
diameter 8–10 µm) can be isolated from erythrocytes (6–8 µm
but disc shaped) by flowing whole blood through a membrane
filter; back flushing will recover the captured white blood cells.
However, classical filter membranes do not have homogeneous
and precisely controlled pore sizes, so the resolving power of this
separation is limited and, due to the material of the filter, the
recovery of white blood cells may be inefficient.
Another separation method based on cell size that targets red
blood cells and platelets specifically uses microfibrated silicon
chips. These feature homogeneously etched slots of a certain size
designed to let erythrocytes pass through under a certain pressure
while retaining leukocytes on the surface of the chip. The leuko-
cytes can then be recovered by elution. Early evaluation of this
technology has demonstrated 98.6 ± 4.4% recovery of leukocytes
without bias to any leukocyte subpopulation and 99% removal
of erythrocytes. The enriched leukocytes have over 95% viabil-
ity [122].
Mesh-size based catching of cells from adipose tissue directly in
culture has been demonstrated using various filtermaterials [123].
Advantages: Easy to use and little equipment is needed.
Pitfalls: Throughput of the filters is limited by surface area and
overload may result in reduced purity and recovery of leukocytes.
So far the commercial devices can only handle up to 2 mL of whole
blood, which is sufficient for some cell analysis assays but not
enough for blood transplantation and cell therapy applications.
The recovery of leukocytes is sensitive to the pressure applied—
pushing with higher pressure and higher flow rate may result in
decreased recovery.
Selected manufacturer: avivabio.com (for microchip devices)
2.4.2 Deterministic lateral displacement. A method of bulk sort-
ing currently under development is based on cell size. There are
several publications reporting a microfluidic device that separates
particles and cells with high resolution [124] and is able to not
only fractionate whole blood components by their sizes [125]
but to also isolate CTCs from whole blood [126]. Recent work
describes improvements for the routine use of the technology for
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rare cell enrichment [127], for the isolation of leukocytes from
whole blood [128], and for cell washing for cellular therapy appli-
cations [129]. The micro-fabricated silicon device consists of a
matrix of obstacles, and the gap and the size of the obstacles are
precisely controlled. When the particle mixture is introduced to
the device, the laminar flow goes through the arrays of obstacles
and the smaller particles will follow the streamlines and the larger
particles will be “bumped” by the obstacles and deflected into a
different flow stream. Multiple sections of an obstacle matrix with
varying gap sizes can be built in one device so that multiple sized
particles can be isolated because each sized particle will follow its
own determined path flowing through the device. In theory, there
should be no throughput limitation of the technology as it is a
continuous flow system; however, some surface treatment of the
device may be needed to avoid cell adhesion. The device has little
tolerance to clogging, air bubbles, or cell aggregates, as changes
in the fluid flow profile alter the particle travel path and deflect
the flow streams possibly resulting in decreased purity and/or
recovery.
Advantages: High resolution, continuous separation, and hav-
ing the potential to be high throughput, high resolution size
discrimination with high purity of cell populations with non-
overlapping sizes.
Pitfalls: Clogging with samples with cell aggregates.
Manufacturer: Contact gpbscientific.com for quote for custom
fabrication.
2.4.3 Acoustic particle sorting. Particles exposed to an acoustic
field are known to move in response to an applied acoustic radi-
ation force. Numerous researchers have investigated the effect of
acoustic waves on cells and particles in aqueous solution. The
force exerted on a particle by an acoustic field can be described by
the following equation:
F x ∼ r3Ksin(2πx/λ)
where r is particle radius, K is a constant proportional to density
of medium and particle, ϕ is the acoustic contrast factor (propor-
tional to density and compressibility), and x is the distance from
the pressure node in the direction of the wave [130]. Thus, acous-
tic focusing can be used to separate and position particles based on
size, density, and deformability. The ultrasonic standing wave is
generated by a piezoelectric transducer and resonance vibration
of the microfluidic device made in silicon or glass. The channel
width is designed to match half a wave length resonance of 2 MHz
in order to have larger cells “focused” in the middle of the chan-
nel. [131]) demonstrated the removal of platelets from peripheral
blood progenitor cell product on a microfluidic device in which
an acoustic standing wave is generated in the fluidic channel. The
acoustic pressure pushes leukocytes to the pressure node located
at the center of the channel and leaves platelets at the side stream
going to a waste outlet. Size is a dominant parameter for acoustic
cell sorting but not the only parameter as shown in the equation
above. For example, separation of leukocytes from erythrocytes in
whole blood is not easily done on an acoustic device as erythro-
cytes, although having a smaller diameter, move to the acoustic
energy node along with leukocytes as the erythrocytes have a
higher density. Recently, optimization of the technology has been
achieved and the preparation of mononuclear cells from diluted
peripheral blood has been reported [132].
Advantages: Continuous flow—no throughput limitation, label
free.
Pitfalls: The cell moving trajectory in the flow channel is deter-
mined by both the acoustic pressure and the shear pressure so
the flow rate and channel configuration need to be well controlled
otherwise the separation efficiencywill suffer. Due to the heteroge-
neous nature of cells in biological sample and the multiparameter
physics of acoustic separation, separations have to be optimized
for specific samples.
Manufacturer: acousort.com
2.5 Erythrocyte lysis
Enucleated erythrocytes are more susceptible to hypotonic shock
than nucleated cells (see also Chapter IV, Section 1.2). Either a
low isotonic Tris/NH4Cl buffer for several minutes at room tem-
perature or 37°C, or pure water for several seconds will lyse ery-
throcytes in cell mixtures. The latter method is particularly useful
for blood, which contains approximately 1000 times more ery-
throcytes than leukocytes. Several other cell lysis solutions are
available commercially as well [92, 93].
2.6 A historical note
Themethods described in Chapter IV, Sections 2.2–2.5 have super-
seded older methods to specifically isolate cells, such as panning
on antibody-coated plastic dishes [133], nylon–wool based iso-
lation of T cells, or sheep red blood cell rosetting followed by a
Ficoll gradient [134, 135]. The latter is still commercially available
under the name RosetteSepTM for specific uses, in particular for
the removal of unwanted cells from blood and can be considered
a protocol still in use. These older methods are not discussed here,
but they are summarized in ref. [101].
3 Serial cell sorting
3.1 Cell sorting by flow cytometry
Successful cell sorting by flow cytometry often requires that more
attention be paid to sample preparation than is typically done
when preparing samples for analysis only.When sorting, the often-
challenging objective is to not only separate some sample fraction
in a timely manner such that the sorted output is a pure viable
fraction, but also that the sorted cells be functionally capable,
that they expand well in culture or perhaps be competent to per-
form in some other subsequent assay (e.g., produce cytokines or
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some other vital cellular function). Another requisite for good
cell sorting is to have a proper single-cell suspension, ensuring a
desirable sample behavior in flow where good doublet discrimi-
nation can be performed with minimal conflict aborts during the
sort. How to best achieve good sample behavior and maximize
performance?
3.1.1 Choice of buffers. The most commonly used media/buffers
for processing mammalian cells were designed to work at 1 atmo-
sphere pressure either on a laboratory bench or within a CO2
incubator, yet inside the sample chamber of most cell sorters the
pressure can often exceed 2 to 4 atmospheres depending on the
conditions and nozzle size chosen for the sort. Sample buffers that
historically tend to perform well for sorting such as Dulbecco’s
PBS or HBSS (minus Ca++ and Mg++), both with 10 to 25 mM
HEPES and protein (usually 1 to 2% heat inactivated serum or
BSA), and more recently BD FACSTM Pre-Sort Buffer plus from 0.2
to 2% protein (application dependent) are recommended. Bicar-
bonate media buffers such as Roswell Park Memorial Institute
(RPMI) or DMEM usually do not make the best candidates for
sample sort buffers or sort collection buffers since they (i) are a
different buffer type than the cytometer’s sheath buffer (bicarbon-
ate vs. phosphate), and (ii) by design require 5% CO2 to main-
tain physiological pH, and (iii) usually contain divalent cations
(Ca2+ and Mg2+) plus phenol (very fluorescent). If a bicarbonate
media is used, one should be wary and use either Ca++ or Mg++
minus formulas without phenol or mitigate the undesirable diva-
lent cation side effects for sorting (making the cells “sticky”) by
adding 1 mM EDTA in addition to 25 mM HEPES and protein.
HEPES buffered bicarbonate media has been reported to be light
sensitive [136].
3.1.2 Considerations for adherent cells and cells isolated from solid
tissues. In preparing adherent cell lines for sorting a common
pitfall is often within the protocol to remove the cells from a
dish using trypsin or trypsin-EDTA and subsequently inactivate
the trypsin by adding back culture media containing a significant
amount of serum. This step is designed to stop the proteolytic
activity of the trypsin and make the cells “sticky” to easily adhere
to a plastic dish when passaging the cells. The opposite is desired
for cell sorting by flow cytometry, the sample should not be “sticky”
with a tendency to adhere to plastic. As a result, good flow cytom-
etry cell sorting protocols for adherent cells will typically either
inactivate the trypsin with soybean trypsin inhibitor or use one of
the many available nonenzymatic cell disassociation buffers (e.g.,
AccutaseTM); in either case, if the cells grow in media with serum,
the culture should be gently rinsed twice with Dulbecco’s PBS
before disassociating and removing the cells from their substrate.
Some cell types, when disassociated with nonenzymatic disasso-
ciation buffers that rely on chelating agents, may show decreased
viability as compared to trypsin disassociation [137]. If there is any
doubt, a few simple pilot experiments designed to determine the
best preparation method for the specific cells in question is often a
very good investment toward successful sorting, since things like
EDTA can affect certain cell types [138].
Similarly, isolating cells from any primary tissue for flow
cytometry cell sorting can be very challenging, care should be
taken to ensure the chosen protocol is optimized and tested to not
only provide the intended cells (e.g., regarding isolated dendritic
cells from spleen different protocols can enrich for different phe-
notypes) but helps coerce the cells into a well-behaved single-cell
suspension. The highest quality reagents should be used, especially
when using proteolytic enzymes such as collagenase, pronase, dis-
pase, or trypsin since small amounts of contaminants can have
serious undesirable effects resulting in poor sample performance.
Collagenase is dependent on calcium for activation, for example,
and other divalent cations may be activators (Zn++) or inhibitors
(Mg++) [139], and care should be taken to ensure any additive
endotoxin levels are as low as possible.
3.1.3 Stickiness to plastic: A menace of cell sorting. When per-
forming bulk sorts and collecting a sorted fraction into a plastic
tube, it is usually best to precoat the tube with serum leaving some
at the bottom, or if desired, additionally seed the tube with a small
volume of the sample buffer containing 2 to 10% serum. Adding
unbuffered bicarbonate media to the collection tube and sorting
on top of it runs the risk of high pH conditions causing undesirable
salts to formwhile the phosphate and bicarbonate buffers mix with
the cells present, thereby reducing cell viability. When performing
single-cell sorts into a microtiter plate, any media pre-added to
the wells should be HEPES buffered and conditioned beforehand
if possible. Additionally, when sorting onto/into small targets such
as microtiter plate wells extra care should be taken to ensure the
accuracy of the deflected drops during the sort by choosing an
appropriate nozzle size to minimize the effects of cells on drop
breakoff [140] (choose a nozzle at least five to six times the cell
diameter as verified under a microscope).
3.1.4 Cell concentrations and sorting rates. Once prepared, the
sample should have a final cell concentration that allows the
desired event rate to be achieved with only a modest differen-
tial pressure on the sample. Increasing the sample rate signifi-
cantly by simply forcing more through the system is not recom-
mended. The sample should be filtered just prior to being loaded
onto the sorter to help ensure no clumps are present and fur-
ther disperse any weakly adhered cells. After filtering the sample
through a Nitex nylon monofilament mesh with an appropriate
pore size (30–50 µm depending on cell size), any samples that
tend to dynamically re-aggregate during a sort are best dealt with
by installing an in-line nylon sample filter of the same pore size
to help prevent clogs. Generally, since the theoretical sorting effi-
ciency of a single cell preparation is that of a homogeneous Pois-
son process [141], the operational efficiency of the sorter may be
estimated by
E f f iciency = e−
(
rate ×(1.0− f raction) × drop packetf requency
)
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where rate is total events/s, fraction is percent being sorted, drop
packet is the number of drops including any additional temporal
purity mask, and frequency is the drop rate in drops/s. Normaliz-
ing to sorter drop frequency, this means when sorting a fraction
that is 10% of the total at an event rate of one cell to every four
to five drops, it can be expected to sort with an efficiency of 80 to
85% when using a single drop sort.
3.1.5 Purity and doublets. If, after optimizing the sorter during
setup, suddenly the application sorting efficiency is low (higher
than expected conflict abort rate), it is indicative that the sample
is not a monodisperse cell suspension, that cells are likely “sticky,”
adhering to one another during entrainment and not arriving into
the sensing zone as a homogeneous Poisson process. This is a very
common scenario withmany cell preparations, especially adherent
and primary cells, and often the sorter performance is blamed
for what is a behavior intrinsic to the sample. Much of the time
this can be significantly mitigated by reexamination of the sample
preparation protocol to discover what might be improved to help
coerce the cells into a well-behaved single-cell suspension. This
often involves the addition of EDTA or DNase etc. to the sample
sort buffer.
Whenever a sorted sample using a purity sort mode (where
system-defined spatial-temporal drop zones in the stream are
examined logically for potential contaminants for each sort event)
is not as highly sorted as desired, the most common reasons are
that either the classification scheme for single cells is not robust
enough and hidden passenger cells are occasionally sorted, or that
there are particles in the stream that are disturbing the droplet
breakoff stability and, as a result, thewrong dropswill occasionally
appear in the collection tube, or a combination of the two. Sorters
certainly cannot read the operator’s mind and will attempt to do
exactly what they are set up to do so, if a positive selection from the
sorter suffers from disappointing purity, one simple performance
check is enough to sort a completely negative cell fraction for
comparison. If that sorted negative fraction is 99% pure or higher,
yet the positive fraction is only 80 to 95% pure, then the likely
cause is undetected “doublets” due to an insufficiently constrained
single-cell gating strategy. In many flow systems, doublets tend to
align with the doublet figure’s major axis in line with the partially
developed laminar flow and the pulse width becomes a very useful
parameter to help distinguish singlets from doublets. Other sys-
tems, such as the BD FACSAriaTM family that use fully developed
laminar flow in their fluidics design can have those same doublet
figures rotate off axis after entrainment in flow such that forward
scatter (FSC) pulse width alone will not detect enough doublets,
and in such cases using both FSC and side scatter (SSC) look-
ing at plots of Height versus Width (or Height versus Area—but
that usually leaves less screen real estate for drawing gates) will
help reveal many more doublets, boosting the purity to a more
acceptable level with careful gating. Figure 25 (reproduced with
permission from ref. [142]) is an example of such a strategy where
pulse geometry gates on both FSC and SSC detect an additional
9% of doublets that would pass through a standard scatter gate.
Matching nozzle size to particle size is key, and the general rule of
thumb is that the nozzle should be four to five times that of the par-
ticles for bulk sorting and five to six times that of the particles for
plate deposition where accuracy is more critical. Ensure that the
actual cell size is what you expect it to be when choosing a nozzle,
and whenever there is doubt it is very useful to quickly compare to
known bead size standards by simply putting small drops of each
on a microscope slide and checking, not only the size(s) within
the sample but also the quality as the amount of debris should
be low, the number of single cells high, and clumps/aggregates
should be the rare exception rather than the rule. Electrostatic
cell sorters tend to perform very well with monodisperse sam-
ples and struggle with poorly dispersed ones so, as with many
other applications, sample preparation can be the limiting or
enabling step. The International Society for the Advancement of
Cytometry (ISAC) Cell Sorter Biosafety Standards were published
in 2014 by the ISAC Biosafety Committee [143], and related
information is readily available and is a highly recommended
reading before embarking on any series of cell sorting experiments
including:
1. The ISAC web site (http://isac-net.org) Resources for
Cytometrists → Biosafety
2. CYTO University (ISAC’s on-line portal for cytometry edu-
cation) http://cytou.peachnewmedia.com → Course: Flow
Cytometry Biosafety
3.1.6 Gating Strategies. Most real-world sort samples are a com-
plex mixture of cells in various states and contain varying amounts
of debris and dead cells; identifying and sorting the cells of interest
while excluding unwanted populations and debris is done by “gat-
ing” the sample using selected features and some number of graph-
ical gate regions combined with Boolean logic. This can become
complex in high dimensional experiments where it is now possi-
ble to sort cells based on over 30 dimensions on some instruments
(such as BD FACSymphonyTM). Any classical gating strategies used
to phenotypically identify the cells may not be the most effective
or even possible to use for the purposes of sorting, especially if
the number of gates is high or the population of interest is iden-
tified through a variety of clustering methods or a dimensionality
reduction technique such as tSNE [144] or UMAP [145]. Algo-
rithms such as GateFinder [146], Hypergate [147], and Hyper-
Finder [148] tackle this problem where analytical methods or
data projections are unavailable in the cell sorter by treating the
identified population of interest as a training set, and computa-
tionally determine an optimal feature set and gating strategy by
using data dimensions that do exist in hardware to sort the pop-
ulation. These algorithms objectively optimize feature selection
and gate efficacy by means of an F1 measure, the harmonic mean
of precision (purity) and recall (yield) at each gate step. Since
the real-time sort decisions within the sorter are done extremely
rapidly within onboard electronics, it is always desirable to find a
gating strategy that is efficient and uses as few gates as possible.
When population analysis and identification is by computational
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Figure 25. PBMC Sort. A PBMC sort on a BD
FACSAriaTMwhere by adding both FSC and SSC
Height versus Width plots and carefully gating
on singlets an additional 9% of likely doublets
are removed (reproducedwith permission from
ref. [142]).
methods, then creating a set of optimal sort gates by means of an
appropriate optimizing algorithm becomes necessary.
3.1.7 Prevention of cell sedimentation. Long-term sorting often
leads to sedimentation of the cells. The sedimentation rate of cells
in a fluid depends on their physical properties such as density,
cell size, cell shape, viscosity of the surrounding medium, and
gravity [149]. In addition, the effective density of a cell is also
affected by its water content, and thus the sedimentation rate is
not a constant property for an individual cell type [149, 150].
Sedimentation of cells can be avoided by shaking or rotat-
ing the sample tube, or stirring with the sample line inside the
cell sorter (BD FACS [151]). Rotating unidirectionally is not very
effective since the sedimentation is delayed but not prevented. For
example, the threshold rate of human leukocytes decreases to 80%
after 30 min of cell sorting and then to 50% after an additional
15 min. Moreover, the constant rotation of the tube, especially
if cells stick between the lower end of the sample line and the
tube bottom, acts like a “cell crasher.” A more effective and gentle
treatment is achieved by shaking or pipetting the cell suspension.
Another possibility is the use of Surface Acoustic Waves (SAW)
to keep the cells in a homogeneous suspension. SAWs are gener-
ated on the surface of a piezoelectric crystal by applying a high-
frequency electrical signal to specially formed pairs of electrodes
deposited on the crystal [152]. By use of a coupling fluid (e.g.,
water) between the crystal and the sample tube, the SAWs are con-
ducted to the sample via the tube bottom. This allows amechanical
and gentle resuspending of the sample by acoustic streaming. This
approach is specific in that it uses low amplitudes and high fre-
quencies and is therefore not detrimental for living cells and can
be implemented in a cell sorter (e.g., BD FACSAriaTM) [153].
Furthermore, the sedimentation of cells can be controlled by
using isopycnic (i.e., equal or constant density) media [154]. This
can be achieved by using various reagents, e.g., Percoll R©, Ficoll R©,
HBSS, Nychodenz R©, Xanthan Gum [149, 154, 155]. For exam-
ple, a 60% Percoll solution results in a media density of 1.07
g/cm³, which is equal to the density of human lymphocytes but
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Figure 26. The threshold value defines a signal intensity, in one or more parameters, above which the cytometer starts to recognize an event.
All other events will be invisible to the instrument’s electronics. A particle passing the laser beam emits a certain amount of light over time. The
threshold is set on the height of the signal that is emitted by each particle. On the left-hand side a dotplot with the forward scatter as the trigger
parameter is shown. Only particles with a signal higher than this threshold value are recognized by the software as an event and shown in the
dotplot (black and orange dots). The dots in on the left side of the threshold value (grey and blue dots) are not included in the data file.
different from that of human erythrocytes (1.10 g/cm³). However,
in practice the sedimentation rate of both cell types is decreased
or stopped and therefore sedimentation is drastically minimized.
The toxicity of the final buffer should be tested by leaving cells in
the buffer overnight at 4°C and the resultant cell viability should
not be below 80%.
3.1.8 Trigger and threshold. To facilitate the discrimination of
particles of interest from background events, it is useful to define
a minimal signal value, the threshold value, which a particle pass-
ing the optics of a flow cytometer must reach to be actually recog-
nized as an event. The threshold value defines the signal intensity
above which the cytometer starts to recognize an event and there-
fore limits the number of events coming from background signal
(Fig. 26). Every event showing a lower signal than the thresh-
old defined will not be processed by the cytometer electronic and
will not be represented in the data file. Therefore, it is advisable
to look for a leading parameter (i.e., a parameter with a clear
discriminator for the population of interest) as the trigger param-
eter, and predefine a threshold value. This fact is important to
consider when it comes to cell sorting. Because the instrument
ignores events below the threshold, they are not being included
in the process of the sort decision. Consequently, sorted fractions
can get contaminated due to the fact that these “invisible” particles
are in fact still part of the sample. When the droplets are formed
these particles can end up inside or in the neighboring drop of a
target cell because the settings of the sorting mask are ignored,
resulting in a contamination of the sorted fractions. It is therefore
recommendable to use the minimal threshold value possible for
identifying the required population.
The default setting of the trigger parameter on most instru-
ments is set to forward light scatter. Alternatively, a fluorescence
parameter can be used for triggering. The discrimination of small
particles, e.g., platelets, erythrocytes, or extracellular vesicles, is
often more specific when the threshold can be set on a fluores-
cent signal (e.g., a common surface marker or even autofluores-
cence that clearly defines the target population) as background
discrimination in FSC and SSC is often difficult. A combination of
several threshold parameters can also be used to set the thresh-
old more strictly. In this case, the event must meet the value of
multiple thresholds to be processed by the flow cytometer. Such
a threshold combination is often used when the expected signal
of a particle is quite close to the background noise of the trigger
channel. As threshold levels are applied to pulse height (H), it is
advisable to set threshold values while viewing pulse height [24],
especially if the trigger parameter might be a fluorescence param-
eter where signal levels are low and the main contributor to area is
pulse width (W). For many cytometers, pulse height and width are
not collected by default and have to be chosen in the instrument
setting beforehand.
3.2 Microfluidic
Recently, microfluidic devices have entered the arena of flow
cytometry and, in particular, cell sorting devices [156–159]. As
these devices also utilize sequential sorting and similar fluores-
cence detection technologies to identify the cells of interest, best
practices for microfluidic devices have a lot in common with
those applicable to droplet sorters. This is especially true for con-
siderations regarding sample preparation, such as choosing the
right marker panel or appropriate buffer selection as discussed
above (See Chapter IV Cell sorting). While sequential sorting
technologies have a lot in common, there are also some major
differences and knowing and understanding these differences is
key to successful application. One of the biggest differences is
that droplet sorters are typically operated in resonance [160],
whereas many microfluidic sorters are operated purely on demand
[158, 161, 162]. To explain further, operated in resonance means
that the drop generating nozzle is running in resonant mode, sta-
bly generating a constant stream of drops. This way, drop vol-
ume and spacing is fixed and cells are randomly “positioned”
inside the drops. This contrasts with many microfluidic sorters,
where the displaced volume can be fine-tuned in size (volume)
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and time/space (centering the target cells). Although the enabling
principles vary, the sorting effect is mainly generated by displac-
ing a certain volume [161, 163]. Given that the sort-timing is
precise and correct, this volume defines expected purities and
yields of target cells. In an ideal system, target cells and nontarget
cells are totally uncorrelated and thus follow a Poisson distri-
bution [164]. In the case of a “yield sort,” where all target cell
candidates are to be sorted independently of the nontarget cells
nearby, the expected yield is 100% by definition. The expected
purity can be calculated as follows: Let λT be the average number
of target cells per displaced volume, then the relative number of
sort-actuations is defined by NλT = e−λT. For each displaced vol-
ume, there is a chance to catch a nontarget cell, defined by λN,
the average number of nontarget cells per displaced volume. With
this, the expected purity P can be calculated to be
P = 1
1 + λN e−λT .
On the other hand, in case of a “purity sort,” every time a second
cell is in close proximity to a target cell, the potential displacement
will be inhibited. Thus, the theoretical purity is 100%, whereas
the expected yield decreases. In this case, the yield calculation is
simply the likelihood of having a single cell within the displaced
volume:
Y = (λN + λT )
1
(λN + λT ) 1! e
(−λN−λT ) = e(−λN−λT )
Besides the obvious close formal relationship between the two
formulas, it is worth noting that the expected yield in a purity sort
is solely determined by the total cell frequency (λN + λT) and not
by the target/nontarget ratio, whereas the expected purity in yield
sorts is strongly dependent on the target cell frequency. In order
to give a practical example, these two figures are here calculated
for a virtual sorting device assuming that the microfluidic sorter:
1. has a sample flow rate of 4 mL/h and does not require a sheath
to be operated.
2. is able to redirect 100% of the sample stream into the target
cell reservoir for 50 µs and then instantly return the flow back
to the nonsorted fraction.
Table 5. Expected purities, yields and processing times for different
starting cell concentrations
Total cells/mL 106 107 108
Purity in Yield Sort [%] 96 69 18
Yield in Purity Sort [%] 96 64 11
Time to process 109cells 309 31 3:05
3. uses a sample with 106 total cells/mL with 0.1% target cells.
This translates to a flow of 1.1 µL/s and cell detection frequency
of 1.1× 103 total cells/s. Since in this example 0.1% of all cells are
target cells, the target cell frequency is 1/s; resulting in an average
time of 1 000 000 µs between target cells and 900 µs between any
two cells. Given that the sorting volume displacement is done in
50 µs, λT and λN can be calculated as:
λT = 50 μs1.000.000 μs = 0.00005
λN = 50 μs900 μs = 0.056
Thus, the expected purity in a yield sort would be
P = 100%
1 + 0.056 e−0,00005 = 96%
Similarly, the expected yield in a purity sort would be
Y = 100% · e(−0.05605) = 96%
Using the same calculation for 1 × 107 total cells/mL and 1 ×
108 total cells/mL, generates the data presented in Table 5. The
key observation here is that, even though the resulting purity in
the above yield sort example is limited, especially when process-
ing input material with a concentration of 1 × 108 total cells/mL
(Table 5), the enrichment from 0.1 to 18% purity is still 180-fold.
This opens up the opportunity to utilize a sequential sorting strat-
egy, where a fast yield sort is followed by a purity sort. When
starting the experiment with the higher frequency yield sort from
the above example, the first pass would have theoretically yielded
an 18% pure target cell fraction being processed with a rate of
Figure 27. Staining pattern and gating strategy for a CD34+ enrichment. The cells are stained with CD34-Pe and CD45-APC. For analysis purposes
only, PI was added for post analysis only.
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Figure 28. Result of a sequential sorting process. 109 total cells have been processed sequentially in 5 h to a final purity greater than 99%.
Overall 280 000 target cells have been harvested from 800 000 target cells starting material, resulting in an overall yield of approximately
35%.
roughly 100 000 cells/s. If re-suspended again in the original vol-
ume, the second pass is processed with a total cell count very close
to the one in the first example and would have yielded the target
cells in a greater than 99% pure fraction. The above is demon-
strated with a microfluidic sorter using a MEMS sorting chip in a
completely closed cartridge performing a CD34+ cell enrichment
from a nonmobilized donor. As seen in Fig. 27, the staining pattern
and gating strategy is straightforward. The target cell frequency
was determined to be 0.08% and the total concentration was cho-
sen so that the 109 total cells were suspended in 10 mL solution.
From there, a yield sort was carried out, with a flow rate of 4
mL/h. The resulting cell processing rate was 110 000 total cells/s.
With a target frequency of 0.08%, approximately 90 sorting actu-
ations per second were expected. The enriched cells were then
re-suspended in 10 mL solution and processed a second time for
purity. The results are shown in Fig. 28. As a result of this sequen-
tial sorting strategy, with an overall sorting time investment of
only 5 h, a result was achieved equaling a typical 20 h single-pass
sort.
Since microchip sorting devices are particularly powerful in
sorting cells gently due to the absence of high shear forces or elec-
trostatic charges, they are ideally suited to follow such a sequen-
tial sorting approach. The rarer the target cell population or the
higher the total cell count, the more advantageous this method
becomes.
4 Collecting cells
4.1 Introduction
Even if a cell sorter is well adjusted, i.e., the instrument is able to
deflect the right drop with the cell of interest at the right moment,
it is still possible that the drop does not hit the collection vessel,
due to issues regarding the relationship between cell size, nozzle
size, sheath fluid temperature, and pressure stability. This results
in a low sort yield and sometimes low purity. Optimal collec-
tion efficiency therefore depends on the setup of the cell sorter
as well as the position and properties of the sample collection
tubes.
4.2 Cell sorter-specific parameters
For a cell sort with high purity and yield an optimal gating strat-
egy and detector setup is mandatory. Often, the discrimination
between stained and unstained cell populations is problematic
if they have a high overlap. In “dim” populations (i.e., low sig-
nal intensity, e.g., due to low marker expression or weak fluo-
rochrome) the distribution of the cell events is dominated by the
photon counting statistic of the PMTs and the background light
and electronic noise of the detection channel. In other words,
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1520 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
when the light intensity emitted from a single cell is measured
by a PMT, the specific signal has an additive part of a constant
amount of nonspecific signal (coming from the background light,
electronic noise, etc.). Thus, when a specific cell signal decreases,
the nonspecific part remains stable and more and more dominates
the entire signal and hence the distribution of the population. Con-
sequently, the relative position of a cell inside a dim population
is dominated by the background signal. This can lead to low cell
recovery if gates are not well adjusted. Proper staining controls
such as FMO [165] controls instead of unstained/single stained
cells are very helpful to find the real boundaries of cell populations
(see Section III.1: Controls: Determining positivity be eliminating
false negatives). Furthermore, an optimal SNR by choosing the
required PMT gain is essential for good population discrimination
and optimal cell recovery [48].
Modern cell sorters can sort up to six cell populations simulta-
neously in collection devices equipped with tubes (e.g., Falcon R©
5–50 mL round buttom tubes, 1–2 mL microcentrifuge tubes).
Depositions of single cells in multi-well culture plates or onto
slides, are also possible. Droplet sorters allow drops to be charged
on different charge levels either positively or negatively, which
allows drops to be deflected either to the left, far left or to
right, far right. Deflection streams containing populations with
the highest number of events to be sorted should be placed close
to the center stream (i.e., left or right), since the focusing of the
deflection streams is often better if their deflection is low. This
minimizes the risk of cross contamination between the collection
tubes.
Furthermore, the position of the deflection stream should be
monitored during the sort process. This can be achieved by using
the AccuDropTM technology (BD FACSAria user’s guide [151]) that
consists of a red diode laser for side stream illumination, a filter
block, and a camera mounted in the back of the sort chamber. The
camera provides an image of the deflection streams with the inter-
cept points of the laser beam. This allows the user the monitoring
of the deflection stream quality in terms of position, focusing, and
stability. Some sorters allow the monitoring of the break-off point
using a camera and control the amplitude of the drop drive fre-
quency depending on the camera image. This keeps the break-off
point in a stable position by increasing or decreasing the amount
of drop drive energy to the stream. This is a useful approach as
long as the viscosity, density, and pressure of the sheath fluid is
stable. If not, the cell recovery decreases even if the position of
the break-off point is stable. Rapid temperature fluctuations of
the sheath fluid of 1–2 K inside or next to the nozzle can become
critical for cell recovery as well as for the side stream focusing.
Therefore, good air conditioning or a sheath cooling [18] a device
is highly recommended.
The side stream position for cells sorting in multi-well plates
is essential and needs to be verified by test sorting of the target
cells because the final drop positioning is often slightly different
for beads or other cells. For single-cell sorting of 384-well plates,
a plate cooling device is recommended to avoid evaporation of the
cell media.
4.3 Sample collection tubes
The collection tubes can differ in terms of material as well as
size. Polypropylene tubes are preferable over polystyrene tubes
because the cells adhere less to the tube wall. Polystyrene tubes
may build up the charge of the deflected drops on their surface.
This can generate cross-contamination between collection tubes
due to “jumping drops” caused by repulsion of incoming drops
but can be prevented by using a grounded wire connected to a
bent injection needle hung over the side of tube, such that the
needle is in the fluid [154]. Different tubes sizes can be combined
in a specific tube holder depending on the flexibility of the cell
sorter. Moreover, a custom made tube holder became available
recently as 3D print file [166].
The size of the collection vessel should fit to the expected vol-
ume of the sorted cell suspension and is correlated to the drop size
and therefore to size of the nozzle. For example, 4 × 106 cells fill
approximately a 5 mL Falcon R© tube (12 × 75 mm), when using
a 70 µm nozzle. The same amount of cells would require five 5
mL tubes when a 100 µm nozzle is used. Especially for long-term
sorts, these correlations should be concerned, in order to prepare
enough collection tubes beforehand. On the other hand, there is a
high risk that cells may not be recovered in the collection tube if
the tube size is much higher than the expected sample volume.
Collection tubes should be coated with proteins to avoid that
the sorted cells stick to the tube wall as this results in reduced
recovery and viability. This can be done by filling the tubes with
10% FCS 30 min before sorting or incubated overnight at 4°C with
10% BSA. As a general rule, the collection tubes should be prefilled
with a small volume of media optimized for the cells of interest.
This prevents the dehydration of the sorted cells and keeps the
cells under optimal conditions to ensure their viability [167].
5 Flow-Cytometric Cell Sorting under GMP Conditions
5.1 Introduction
Flow cytometric cell sorting is a versatile and well-established
research tool to isolate cells in high purity and speed. Multipa-
rameter sorting permits the identification and isolation of spe-
cific cell subpopulations based on qualitative and/or quantitative
antigen expression as well as on positive and negative selection
criteria within a single selection procedure. With the advent of
numerous cell therapy approaches for clinical applications, mainly
driven by the success of chimeric-antigen-receptor-modified (CAR)
T cells [168], interest in the clinical use of flow cytometric sorting
is rising. Yet, cytometry-based cell sorting under good manufac-
turing practice (GMP) conditions is not yet available in a ready-
to-use format and custom-made solutions pose a major challenge
as stringent rules and regulations must be obeyed. The authors of
this section established GMP-compliant and approved flow-sorting
technologies and protocols adhering to European guidelines and
regulations for the isolation of regulatory T cell subpopulations to
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generate homogeneous cell products for the treatment of patients
with graft-versus-host disease [169] within clinical trials. Based
on their experience, a “list to consider” for researchers envisag-
ing the implementation of flow sorting for medicinal products
is provided, but not an “easy to use recipe,” as manufacturing
rules are complex and vary for each product depending on cell
source, applied reagents, manufacturing process, cell specifica-
tions, (inter-) national and regional regulations, and various other
issues pinpointed in this section. Thus, the first issue to clarify
when flow-sorting is envisaged for the production of medicines is
the clinical need and benefit as compared to established and/or
approved alternative cell enrichment technologies, taking into
account the efforts and implementation costs for GMP-compatible
flow cytometric sorting.
5.2 GMP: Regulatory Requirements and Product
Classification
When cellular products are supposed to be administered to
patients, strict requirements have to be obeyed including inter-
national, national, and regional laws, rules, and regulations. For
pharmaceutical manufacturing, GMP principles have highest pri-
ority and adherence to these guidelines is inspected by regulatory
agencies during the manufacturing authorization process and reg-
ularly thereafter. GMP rules shall ensure high quality and batch to
batch consistency for pharmaceutical products to prevent harm of
patients caused by deviations during drug manufacturing. In con-
trast to the United States, full GMP-adherence is required within
the European Union (EU) even for phase-I clinical trials [170],
including cell therapy studies. Main areas covered by these GMP-
regulations include detailed prerequisites concerning (i) quality
management system, (ii) personnel, (iii) facility and equipment,
(iv) documentation, (v) manufacturing, (vi) quality control, (vii)
external suppliers, (viii) complaints and callbacks, and (ix) self-
inspections.
The regulatory landscape in Europe is complex and became
even more so since the category “advanced therapy medicinal
products” (ATMP) was introduced by the European Commission
(EC) in 2008 to discriminate unmanipulated blood products and
tissues from gene therapy-, somatic cell therapy-, and tissue engi-
neered medicinal products. ATMPs are medicinal products “con-
taining cells or tissues that have been subject to substantial manipula-
tion so that biological characteristics [ . . . ] have been altered”. They
“have properties [ . . . ] to treat, prevent or diagnose a disease through
the pharmacological, immunological or metabolic action of its cells
or tissues” [171–173]. “Substantial manipulation” in this context
is defined in Annex I to regulation (EC) No 1394/2007 [174]
where those manipulations are listed that are not considered
substantial (e.g., cutting, grinding, centrifugation) and thus do
not result in classification of a product as ATMP (then regulated as
conventional blood, tissue, or cell products). Thus, flow cytomet-
ric cell sorting itself does not lead to classification as ATMP, unless
additional cell manipulations before (e.g., gene transduction) or
after cytometric sorting (e.g., in vitro stimulation or expansion)
are performed. In such cases, ATMP-specific GMP rules installed
in 05/2018 by the European Commission must be obeyed [171].
5.3 Facility and Equipment
GMP rules concerning facility and equipment focus on controlled
manufacturing conditions to ensure final product quality with a
particular focus on the prevention of (cross-) contaminations (e.g.,
by particles or microbial agents). Thus, the facility and equipment
must be qualified for the intended purpose and environmental
conditions during manufacturing must be tightly monitored (e.g.,
controlled air flow and pressure, temperature, humidity, environ-
mental particles, sterility, and so on). Based on thorough risk
analyses and embedded in a detailed quality management system,
qualification of the facility and all equipment (such as a flow-
cytometric cell sorter) is performed in a stepwise fashion with
particular attention on the intended performance and the inher-
ent risks of a manufacturing process:
Design qualification (DQ): Documented verification that the
proposed design of the facilities, systems, and equipment is suit-
able for the intended purpose. Thus, an upfront description of the
intended use and definition of quality criteria for a manufacturing
equipment (and/or the whole facility) is required and defined in
“user requirement specification” (URS) documents.
Installation qualification (IQ): Documented proof that the URS
are met by the equipment after its installation at the manufactur-
ing site.
Operation qualification (OQ): Documented proof that the
equipment is suited for the intended purpose and meets all prede-
fined quality criteria when in operation.
Process qualification (PQ): Documented proof that the equip-
ment is suited for the intended purpose within the whole manu-
facturing process of a pharmacologic agent.
During cell sorting with a stream in air cytometer the cells are
exposed to the environment. Even instruments using cuvette flow
cells contain open handling steps where the cells are exposed to
the environment, therefore both techniques require clean room
conditions class A (laminar air flow hood) in a class B room.
The classification of clean room conditions in Europe is based on
the maximal permitted airborne particle numbers as described in
Annex 1 to part I of the European GMP guidelines (Table 6).
As no commercially available cell sorter is designed to meet
these criteria, we cooperated with a cytometer manufacturer and a
laminar air flow provider specialized in manufacturing equipment
for the pharmaceutical industry and installed the cell separation
chamber of the sorter in a custom-made laminar air flow bench
qualified to meet class A clean room conditions while all auxiliary
equipment potentially emitting particles (due to their air cooling
systems) are contained in a separate air-filtered (in- and outlet)
cabinet (Figure 29).
For cell therapy medicinal products batch to batch cross-
contamination by cells, infectious agents or subcellular compo-
nents (e.g., RNA or DNA) must be omitted and aseptic conditions
are required. With conventional flow-cytometric cell sorters vali-
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1522 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
Table 6. Maximum permitted airborne particle concentration for each cleanroom grade (modified after EU GMP Guidelines Annex 1). Annex 1 to
the EU GMP Guidelines defines the maximum permitted number of particles equal to or greater than 5.0 µm/m3 as 20, corresponding to an ISO
classification of 4.8. ISO class 5 would permit 29 particles equal to or greater than 5.0 µm per m3. ISO = EN ISO 14644. Other clean room
definitions apply to the US and other non-EU countries
Maximum permitted number of particles/m3 equal to or greater than the tabulated size
Clean room grade At rest Clean room grade In operation
Annex 1 ISO 0.5 µm 5.0 µm Annex 1 ISO 0.5 µm 5.0 µm
A 5/4.8 3520 20 A 5/4.8 3520 20
B 5 3520 29 B 7 352 000 2900
C 7 352 000 2900 C 8 3 520 000 29 000
D 8 3 520 000 29,000 D – Not defined Not defined
dation of line clearance is almost impossible as it must be proven
for each potential microbial contaminant (bacteria, fungi, viruses,
endotoxins) and the test systems themselves for sterility testing
have to be validated. To circumvent these problems, we use a
sorter permitting the exchange of the whole fluidics system after
production of each batch that is then replaced with a new ster-
ile (γ-irradiated) single-use kit. Some providers currently develop
new sorters that use mechanical valves or air pulses in closed sys-
tems for fluorescence-based cell separation that may significantly
facilitate GMP-compatible flow sorting in the future.
5.4 Raw Materials
For themanufacturing of cell-basedmedicinal products a variety of
rawmaterials are required. Hardly any of these rawmaterials, e.g.,
fluorescence-labeled antibodies for sorting, are covered by a phar-
macopoeia or have ever been used for production of a medicinal
product before. Since they come into direct contact with the cells,
they are classified as critical for the safety, purity and potency of
the final product. Therefore, in-house specifications, considering
all potential risks, have to be provided if no reference to phar-
macopoeial monographs can be made. Minimal requirements for
quality control of critical raw materials are identity, biological
activity/potency, toxicity, content, purity, sterility and microbial
safety (including mycoplasma where applicable), viral safety, risk
of transmissible spongiform encephalopathies (where applicable),
and stability. As these quality criteria reach back at least two gen-
erations (thus, definition of environment, equipment, and quality
standards during the production of the respective materials), it
is pivotal to ensure their highest possible quality for cell manu-
facturing. Since hardly any GMP-compliant (fluorescent-labeled)
antibodies for flow-sorting are currently commercially available,
they have to be custom-made by a qualified manufacturer.
5.5 Process validation, quality control, and product release
Process validation usually has to be performed prospectively with
production of at least three batches. However, it is accepted by
most authorities that process validation of investigational medici-
nal products (IMP; for clinical trials) cannot be as complete as for
authorized (marketed) medicinal products. Guidance on process
validation is provided by the European Medicines Agency (Guide-
line [175]) and the U.S. Food and Drug Administration (Guid-
ance for Industry [176]). During process validation not only pre-
defined final release criteria have to be examined, but also process-
related impurities. These may originate from the cells (e.g., pro-
teins, DNA), cell culture media (e.g., antibiotics, media supple-
ments), or downstream processing equipment (e.g., columns).
Most often they originate from raw materials for cell process-
ing, e.g., cytokines, antibodies, serum, culture media, chemicals,
Figure 29. Custom-madeGMP-compliant flow cyto-
metric cell sorter (A) with auxiliary equipment cabi-
net (left) and laminar air flowhood (right) containing
the sort chamber and (B) the sort unit in operation
(safety-cabinet-enclosed sort unit seen between the
two operators).
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enzymes, and nucleic acids for genetic modifications. Since at least
some of these substances (e.g., cytokines and stimulatory or sort-
antibodies) may have an influence on the therapeutic cell product
and/or may put a patient at risk even if administered in residual
amounts (e.g., immunogenicity of antibodies, in vivo activity of
cytokines), their presence in the final cell product has to be eval-
uated (ICH Q6B) [177]. Based on the potential risk, strategies for
the determination of impurities may be arithmetical (calculation
of residual amounts based on starting concentration and dilution
factors or washing efficacy) or analytical (quantitative or limit
test for impurities in the final product). While the arithmetical
approach may be suited and accepted for impurities with low risk
profile, evaluation of a particular impurity may be necessary or
requested by the authorities for every batch if substances are sus-
pected to bear a significant risk for the recipient (e.g., biologically
active antibodies, toxic fluorochromes). Since standardized meth-
ods for the analysis of impurities are usually not available, respec-
tive test systems have to be designed and validated individually in
advance (proving the appropriateness of an assay with respect to
sensitivity, specificity, accuracy, precision, detection limit, range
and limits of quantitation, robustness, and repeatability) [178],
which is at least laborious and time consuming.
A successfully validated manufacturing process is a prerequi-
site to receive a manufacturing license by the respective author-
ities for cell therapy medicinal products that are either applied
within clinical trials (separate clinical trial approval required) or
as authorized medicinal products. In Europe, each cellular prod-
uct for clinical use must be released by a qualified person who is
responsible for the GMP-compliant manufacturing and final qual-
ity of the product. Predefined quality and release criteria typically
include parameters such as volume, cell numbers, cell concen-
tration, viability, identity, purity, potency, cellular contaminants,
sterility, endotoxins, mycoplasma negativity, visual control, and
eventually impurities (e.g., for sort-antibodies). Almost all assay
systems for these quality controls (including flow cytometry-based
tests) have to be developed individually and specifically for a given
cell product and require validation (same criteria as described
above) during the development of the manufacturing process to
ensure their adequacy.
5.6 Final Remarks
The huge advantages of multi-parameter flow cytometric cell sort-
ing with its speed and flexibility in a research environment thus
far do not apply to GMP-compatible sorting. The high demands
on the quality of auxiliary and raw materials and on the envi-
ronmental conditions as well as stringent quality assurance mea-
sures and controls require a precisely structured and long-term
preparation phase for each cell manufacturing process that cannot
easily be changed once established. Thus, product characteristics
and manufacturing tools and methods for an envisaged clinical
cell product must be defined in detail in preclinical testing and
be robust enough to justify the implementation of an expensive
and strenuous manufacturing process involving flow cytometry.
Most importantly, the clinical benefit and advancement has to be
considered in comparison to established and comparably “easy
to use” cell enrichment technologies. Yet, once established it is
satisfying to witness that cell purities easily exceeding 95% are
regularly achieved with GMP-compatible flow sorting, which may
be relevant in certain clinical situations such as GvHD therapy.
The increasing interest of clinicians in cell therapy may moti-
vate equipment and reagent manufactures to invest in financial
and intellectual resources for the development of GMP-compatible
flow sorting equipment and to provide a broader range of suited
sort reagents in the near future.
V Biological applications
1 Rare cells: General rules
1.1 Introduction
Rare cell populations are of growing importance in several fields,
from basic research to translational medicine and diagnostics. In
several clinical settings, rare cell counts provide valuable infor-
mation on the status and stage of the patient’s disease. Some
examples are rare CTCs in the peripheral blood, tumor stem cells,
circulating endothelial cells, hematopoietic progenitor cells and
their subpopulations, and fetal cells in maternal circulation. Inter-
esting applications of rare cell analysis include the detection of
metastatic breast cancer cells [179] or neuroblastoma cells infil-
trating the bone marrow [180], monitoring of minimal residual
disease [181, 182], detection of stem cells and rare HIV-infected
cells in peripheral blood [183], antigen specific T cells, invariant
natural killer T (iNKT) cells, and analysis of mutation frequencies
in genetic toxicology [184]. Moreover, polyfunctional assays, such
as the Ag-induced production of different cytokines by T lympho-
cytes, are often performed, and these raise the problem of finding
rare cells within these T-cell populations aswell. In this section, the
main issues of this topic will be discussed, including the amount of
biological material required, the use of pre-enriched populations,
the number of markers to use and cells to acquire, the importance
of excluding doublets and the use of a DUMP channel.
1.2 Optimization
Studying rare cells requires attention, optimal methodologies in
all phases, including collection of biological samples, well-defined
controls, and adequate use of software and hardware [185]. The
term “rare” generally refers to events with a frequency of 0.01% or
less, although the record claimed in the literature has long stood
at one cell in 10 million for tumor cells spiked in the peripheral
blood [186, 187]. For this, the acquisition of a large number of
events (see Section V.1.2.3: Number of acquired events) and a
high SNR (see Section V.1.2.5: Thresholds, gating, and DUMP
channel) are the most relevant aspects.
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1.2.1 The quantity of the biological material. On the basis of the
estimated frequency of the rare cells under investigation, it is cru-
cial to calculate how much biological material is required. For
example, if the endpoint of the experiment is to enumerate rare
cell populations present in the cerebrospinal fluid (CSF), consid-
ering that only a few milliliter can be obtained from a patient, it
is logical that all the CSF has to be used. If blood is the biologi-
cal matrix of interest, the rare cell population of interest and the
pathology of the patient should be considered in depth. Should
the endpoint of the study be the evaluation of cytokine production
after in vitro stimulation by cells such as iNKT cells in patients
with HIV infection, some pre-analytical considerations should be
taken into account. For example, iNKT cells are extremely rare
among peripheral PBMCs (0.01–1%), and in order to define this
population several markers must be used, including those for rec-
ognizing CD3, CD4, CD8, invariant TCR, as well as those for cell
viability and several cytokines such as TNF-α, IFN-γ, IL-4, and IL-
17 could be of interest, meaning that nine markers are required.
HIV+ patients who do not take antiretroviral therapy are obviously
severely immunocompromised, and have a low number of CD3+ T
lymphocytes. Thus, the amount of blood required to detect a rea-
sonable number of rare cells (according to Poisson statistics) can
be as much as 50 mL of blood, since either resting or stimulated
cells have to be analyzed [188].
1.2.2 Enrichment and choice of markers. On the basis of the
experimental endpoint(s) (e.g., phenotyping, functional assays),
the rare population may be enriched or not, and the number of
markers that are needed to unambiguously identify a rare cell pop-
ulation needs to be defined. For example, the accurate quantifica-
tion of circulating endothelial cells and their progenitors, shown in
Fig. 30, is a matter of debate. Several studies have been published,
but no consensus has thus far been reached on either the markers
that should be used to identify these cells, or on the necessity of a
pre-analytical enrichment (by density gradient, buffy coat, and/or
magnetic enrichment). The enrichment, however, can have nega-
tive effects if rare cells are lost, or these effects may be positive,
if unwanted cells are removed [189–193]. Unfortunately, quite
often, the lack of well standardized methods influences the deci-
sion regarding the number of markers, which are necessary for
the identification of the population of interest. Depending on the
technical characteristics of the flow cytometers, which have a vary-
ing number of fluorescence channels and the speed of acquisition,
the most important marker allowing the identification and char-
acterization of such populations should be decided. For example,
in the case of iNKT cells, the Vα24Jα18 invariant TCR allows the
unique identification of these cells. Having done that, the marker
panel has to be built following a general rule that the brightest
fluorochrome has to be used for the weakest expressed marker.
Finally, attention should be paid to compensation, and acquisition
of FMO controls, which is covered in more detail in Section II.1:
Compensation and Section III.1: Controls: Determining positivity
by eliminating false positives.
1.2.3 Number of acquired events. Concerning the number of
events that need to be acquired, it is recommended to use Poisson
statistics, which defines the probability that a given number of
events will occur in a fixed interval of time/space, assuming these
events would occur with a known average rate and independently
of the time elapsed from the previous event [194]. Therefore, Pois-
son statistics are applied to count randomly distributed cells in a
certain volume. Let us consider a general case of enumerating a
total of N events, of which Rmeet a certain criterion (i.e., they are
positive, P). In this case, a proportion of P events is defined as P =
R/N. The probability of any single event to be positive is obviously
0  P 1, and this is related to the random manner in which
cells are selected for analysis. As with all statistical distributions,
the variance, Var, is a fundamental parameter, and is defined as:
Var(R)= NP(1 – P). The SD is the square root of the variance,
and the CV is the SD equal to 1/square root of Var [195]. These
equations can be used to examine some practical situations. Let
us consider a phenotype analysis of human PBMCs stained with a
mAb for detection of B cells (e.g., CD19 mAb). In healthy individ-
uals, 10% of the cells can be positive, so that: P = 0.1 and P(1 –
P) = 0.09. Good experimental practice suggests to keep CV below
5%; thus, acquiring even 5000 events could be sufficient, because
the CV is 0.047 (i.e., in percentage, 4.71%). Using a number of
cells such as 10 000, the CV becomes 3.33%. However, should pos-
itive events be less frequent, a higher number of events must be
acquired. Table 7 reports an example for events whose frequency
is 0.01%, as often occurs studying antigen-specific T cells.
This is clearly the ideal methodology. However, real life is
different from theory, and very often the final number of events
cannot be high enough to satisfy this golden rule. For example, we
can consider the case in which one million peripheral T cells are
stimulated with an antigen that activates less than 0.1% of them,
namely 100 cells in one million. Nowadays, by polychromatic flow
cytometry, T-cell activation can be analyzed by evaluating the
polyfunctionality of these cells, and protocols have been devel-
oped that can identify in a relatively easy manner four or even
five functions per cell. Thus, among responding cells, up to 32
populations can exist, likely with a different frequency, and each
subpopulation contains a few cells that are completely absent in
the control, unstimulated sample. Can we consider such cells pos-
itive, even if their number is much lower than that indicated by a
strict statistical approach? A pivotal paper by Mario Roederer, an
opinion leader in this field, gives us very useful and clear sugges-
tions [196]. Indeed, if alternative explanations for the presence of
such positive events can be excluded (i.e., if there is no noise due
to dead cells or fragments, and if cell activation is really due to the
antigen used in vitro and not to a pre-activation in vivo of T cells),
the events can be considered positive, irrespective of their number.
Thus, there is no reason to fix a threshold for the number of events
below which any frequency must be considered “negative” [196].
In this case, “positivity” can be determined after comparison of
the measurement against a set of control samples, among which
the adequate negative controls, using standard statistical tools to
compare the frequencies. For example, assuming that from the
technical point of view the experiment is well performed, if T
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Figure 30. An example of a gating
stategy for rare cells. Gating stategy
used to identify circulating endothelial
cells (CECs) and their precursors (EPCs)
among peripheral blood leukocytes. (A)
Debris and aggregates were eliminated
using FSC-Area versus FSC-Height, (B)
possible clogs were removed using the
parameter Time versus SSC. (C) A DUMP
channel was used to remove CD45+
cells and dead cells from the analy-
sis. (D) Nucleated cells were identified
based on Syto16 positivity. (E) Stem cells
were identified according to CD34 pos-
itivity, (F) EPCs (CD133+, CD31+) and
CECs (CD133–, CD31+) were identified.
The expression of CD276, also named B7-
H3 (G, I), and CD309 (H, J), also named
VEGFR-2 or KDR, was evaluated in each
subpopulation. In this example, more
than 10 million events were initially
acquired in order to enumerate a pop-
ulation that, according to the literature,
is always represented less than 0.1%.
cells from “n” unvaccinated controls show no activation after the
stimulation with the adequate peptides, while T cells from “n”
vaccinated individuals do, even extremely low frequencies can
be taken as positive. The same logics can be applied in thou-
sands of other cases, assuming that the relative controls are well
chosen.
1.2.4 Sample concentration and flow rate. Because it is crucial
to acquire a high(er) numbers of events for detection of rare
cell population, sample concentration and flow rate are critical
parameters, which can typically shorten acquisition time. How-
ever, care must be taken that increasing the flow rate results in an
increase of coincidence, and thus higher CV, if flow cytometers use
Table 7. Example to calculate the number of acquired events for a rare cell population representing 0.01%
Acquired events(N) 10 000 500 000 1 000 000 4 010 000 10 000 000 20 000 000
Positive (R) 1 50 100 401 1000 2000
Proportion (P) 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
Variance (Var) 0.9 49.99 100.0 400.1 999.9 1999.80
Standard deviation (SD) 0.9 7.07 10.00 20.02 31.62 44.72
Coefficient of Variation (CV) 100.00 14.14 10.00 4.99 3.16 2.24
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hydrodynamic focusing (which is the system used at present in
most commercially available flow cytometers).
1.2.5 Thresholds, gating, and DUMP channel. A threshold should
be fixed in order to distinguish the signal (using fluorescence or
scatter) required to define the population of interest from the
noise/background (see Section V.2: Trigger, thresholds, and live
gating). Hence, maximizing the SNR of the cells of interest is
mandatory. Gates should be drawn to exclude dead cells, identi-
fied by viability marker, doublets/aggregates/debris, and all the
unwanted cell populations from the analysis, and a “DUMP” chan-
nel containing antibodies that identify cells of no interest is highly
recommended. Moreover, using a dot plot with the parameter
“time” versus that of interest allows to remove the event bursts
caused by clogs or other transient problems during the acquisi-
tion. The instrument should be kept clean, and it is essential to
wash the instrument between acquisitions of different samples in
order to minimize sample contamination, which could cause the
detection of false positive events.
1.3 Data analysis
Finally, data analysis requires adequate software and powerful
hardware (more than 8 GB RAM or higher), because acquired
data file tend to be huge, depending on how many events and
parameters have been acquired (e.g., ten colors and two scatters
in 10 million events are indeed a good test for your computer). To
minimize the file size, parameters that are not really needed can
be unselected, and a fluorescence/scatter threshold trigger can be
used. Data analysis will be covered in greater detail in Sections
VII.1–2: Data analysis: An overview, Data analysis—Automated
analysis: Automated flow cytometry cell population identification
and visualization, and Statistics for flow cytometry. In conclusion,
flow cytometry is at present the most potent technology to address
rare cell analysis, and the so called “next generation” instruments
with very high speed and sensitivity are already allowing an easy
detection and analysis of such cells.
2 Organisms, cells, organelles, chromosomes, and
extracellular vesicles
2.1 Overview
Flow cytometry allows information about the structural and chem-
ical characteristics of particles to be measured. Although the
most common applications of flow cytometry use single mam-
malian cells, it is also applicable to studies of bacteria, yeast,
and viruses as well as whole organisms such as nematodes and
Drosophila. Conversely, parts of cells such as isolated nuclei,
chromosomes, organelles, or extracellular vesicles may also be
examined.
2.2 Organisms
Model systems are used to study molecular biology, developmen-
tal biology, and neurology and an example of this is the use of
Caenorhabditis elegans (C. elegans). These organisms are around
1 mm in length, can be cultivated in large numbers, and have a
short life cycle that makes them ideal for studying many areas of
developmental biology. Particles of this size are not able to pass
through the injection port and flow cell of most cytometers so
specifically designed analyzers and sorters are available to identify
and separate these organisms [197]. These large particle sorters
can also be used for analyzing and sorting groups of cells such as
imaginal discs, pancreatic islets, or embryoid bodies [198, 199].
2.3 Cells
Flow cytometry is perfectly suited for cells that are naturally in
suspension, e.g., blood but any multicellular system (cell lines,
tissue samples, whole organisms) may be made into single cell
suspensions using a variety of mechanical and enzymatic tech-
niques. In all cases, there is a balance between creating a good
single cell suspension and keeping cell viability high. It is always
important to make sure that measurement exclude dead cells as
these will show increased autofluorescence and may bind anti-
bodies and probes non-specifically. Exclusion of dead cells may
be achieved by adding a viability dye—either a DNA binding dye
such as DAPI or Propidium Iodide or an amine-reactive dye, which
will bind to proteins [200, 201]. Any part of a cell may be labeled
with a fluorescent probe but it is important to remember that flow
cytometry gives whole cell information, there is no localization of
the fluorescence nor any idea about its distribution within the cell.
To determine the location of fluorescence, an imaging technique
is needed, e.g., fluorescence or confocal microscopy or imaging
flow cytometry [202].
2.4 Nuclei
Sometimes only the DNA or a nuclear protein is of interest and
in these cases, cell nuclei can be produced that often will have
less nonspecific binding and therefore a cleaner background. Pro-
duction of nuclei from cells can be achieved in unfixed samples
by treating cells with a detergent, e.g., 0.1% Triton-X100, which
will lyse cells and release nuclei [203]. Or in fixed samples, cells
may be treated with an enzyme such as pepsin that will digest
the cytoplasm and again release nuclei [204]. Isolated nuclei will
often give a better CV (coefficient of variation, a measure of data
spread) than whole cells, making it easier to discern cell cycle
phases.
2.5 Cell organelles
Cell organelles within whole cells can be specifically iden-
tified by staining them with fluorescent dyes. These dyes
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may be fluorochrome-labeled antibodies or fluorescent probes.
Autophagosomes may be identified by staining with LC3 anti-
body [205], whereas mitochondria can be stained with Mito-
Tracker dyes [206]; lysosomes, endoplasmic reticulum, and Golgi
can also be identified [207]. Care must be taken with many dyes
that are organelle-specific as the staining time and concentration
will be very cell-type dependent and these factors may need to be
determined empirically. Also important when analyzing organelles
are controls; not just a negative control to assess background flu-
orescence but also a positive control to ensure that staining is
successful as the majority of these assays involve unfixed samples.
Also important is building in a kinetic element to experiments, i.e.,
looking at time points following treatment or stimulation.
Cell signaling events are often studied in immunological cells
and a common way to do this is to monitor changes in calcium
levels that result from the binding of antibodies to surface recep-
tors. There are several fluorescent dyes available that can monitor
calcium levels such as Indo-1, Fluo-4, and Fura Red [208]. Indo-1
is a UV-excited dye that precludes its use in many common flow
cytometers but it does have the advantage that it uses a ratio of the
bound to unbound calcium signal and is therefore independent of
cell size and variability in dye loading.
If cell organelles are to be analyzed, in some cases it is better
to digest the organelle from the cell. It is possible to isolate mito-
chondria, endocytic vesicles, and endoplasmic reticulum by sev-
eral methods generally using tissue homogenization [209]. Such
treatment will inevitably lead to some cell loss and a sample that
will have a considerable amount of debris. However, the selec-
tion of dyes combined with light scatter characteristics can allow
specific organelles to be identified. Although isolated organelles
can often result in cleaner staining, the smaller the particle the
more problems there will be with co-incident events, i.e., when
more than one event is being measured in the flow cell of the
cytometer. Both in analysis and sorting, the use of light scatter
and fluorescence is needed to delineate true particles from back-
ground.
2.6 Chromosomes
Although interphase chromosomes cannot be delineated by stan-
dard flow cytometry, chromosomes at metaphase may be identi-
fied and isolated and this is important in genomic analysis in many
animal and plant species [210]. Cell division is blocked during
metaphase using a drug such as colcemid, chromosomes are iso-
lated following rupture of the cells in a detergent solution and are
stained with two DNA binding dyes that have different base-pair
specificities [211]. In this way, chromosomes may be separated
on size and base-pair ratio, Chromomycin A3 (G-C binding) and
Hoechst 33258 (A-T binding) is the preferred pair of DNA dyes.
This is an extremely powerful technique but is not widespread as
the dyes used require nonstandard excitation wavelengths (355
and 457 nm) and high-powered lasers that are not widely avail-
able. However, chromosome analysis and sorting is also possi-
ble using standard benchtop analyzers or sorters [212]. Sample
preparation, staining buffer, and cytometer setup are all critical in
chromosome analysis.
2.7 Extracellular vesicles
A growth area in cytometric analysis in recent years has been the
detection of small particles that encompass exosomes, micropar-
ticles, microvesicles, and cell-derived microparticles (including
platelets, endothelial, and leukocyte microparticles). Microvesi-
cles are defined as being 100–1000 nm in size [213] compared
with exosomes, which are <100 nm [214], which can lead to
challenges with detecting them using a flow cytometer. Most mod-
ern cytometers will have a detection limit in terms of the size of
the particle that will be governed by the optical configuration of
the cytometer. Light scatter is traditionally generated by using a
488 nm laser but it can be detected from any laser wavelength
given the correct optical filters [215]. In general, microvesicles
will be identified and detected by a combination of light scatter
(side scatter, or right angle light scatter is preferred to forward
scatter) and fluorescence. Vesicles mostly consist of a lipid mem-
brane plus cytosolic contents that may include cellular organelles,
therefore, labeling the lipids, specific membrane proteins, or spe-
cific organelles is the best approach. This can be an amine reactive
dye such as carboxyfluorescein succinimidyl ester [216], a spe-
cific lipid binding protein such as fluorescently-labeled annexin
V [217] or mitochondria-binding dyes such as MitoTracker [218].
As the size of the particles is smaller than the diameter of the lasers
used in the flow cytometer, there are the same considerations of
co-incidence as with isolated organelles. As well as in conventional
flow cytometry, exosomes and microvesicles can also be studied
using other cytometric technologies such as imaging flow cytom-
etry [219]. See Chapter V Section 2.7 Extracellular vesicles for
more detailed information.
3 Mitochondria
Mitochondria are essential mediators of cell metabolism, being
producers and targets of reactive oxygen species (ROS), regu-
lators of ATP levels and calcium homeostasis, and hubs of the
biosynthetic pathways involved in the synthesis of amino acids,
lipids, and nucleotides [220]. Mitochondria are present in all cells,
including those that rely mostly on glycolysis rather than on oxida-
tive phosphorylation for ATP synthesis. They are very heteroge-
neous in size, shape, and number, depending on the metabolic
requirement of the cells, the underlying tissue, and several other
factors. Given their crucial role in cellular and organismal func-
tions, it is not surprising that mitochondrial (mt) dysfunctions
have been observed in a number of genetic and nongenetic dis-
eases, as well as in cancer and aging [221]. In the vast majority
of cases, distinctive features of mt dysfunction include changes in
mtmP, mt mass, and redox potential.
Flow cytometry allows the rapid monitoring of all these param-
eters in intact cells, avoiding artifacts associated with mt isolation
and/or permeabilization, and offering the benefits to work in a
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Table 8. Main fluorescent probes used to stain mitochondria in intact, living cells
Full name Short name Abs (nm) Em (nm) Fixable
Mitochondrial membrane potential
3,3’-Dihexyloxacarbocyanine iodide DiOC6 484 501 No
Rhodamine 123 Rh123 507 529 No
5,5’,6,6’-Tetrachloro-1,1’,3,3’-tetraethyl-benzimidazolcarbocyanine JC-1 514 529/590 No
3,3’-Dimethyl-αlpha-naphthox-acarbocyanine iodide JC-9 522 535/635 No
Tetramethylrhodamine ethyl ester TMRE 549 574 No
Tetramethylrhodamine methyl ester TMRM 548 573 No
MitoTracker Red CMXRos 578 599 Yes
Mitochondrial mass
Nonyl Acridine Orange NAO 495 519 No
Mito ID Red 558 690 Yes
Mitotraker Green FM 489 517 No
Mitotraker Deep Red 633 644 665 Yes
MitoTracker Red 580 581 644 No
Mitochondrial reactive oxygen species
MitoSOX Red mitochondrial superoxide indicator MitoSOX 510 580
Mitochondria Peroxy Yellow-1 MitoPY-1 510 528/540
Abs, absorbance; nm, nanometers.
preserved cellular environment [222]. A number of mt-specific
fluorescent probes have been developed, which can be used to
measure mtmP, mt mass, and intra-mt ROS (Table 8) [223].
mtmP is the main component of the proton-motive force, which
is established by protons pumped from the mt matrix to the inter-
membrane space, and combines the mtmP to the mt pH gradient.
This potential varies according to the status of mitochondria, it is
related to their capacity to synthetize ATP, and is a common indi-
cator of cell health. According to the Nernst equation [224], the
mt matrix is negative, thus indicating that hyperpolarized or depo-
larized mitochondria present a more or less negative mt matrix,
respectively. Dyes for measuring mtmP are typically lipophilic
cationic compounds, i.e., positively charged molecules that can
cross membranes without binding them, and accumulate in the mt
matrix in direct proportion tomtmP. Hyperpolarizedmitochondria
accumulatemore dye, whereas depolarizedmitochondria accumu-
late less dye. WhenmtmP is assessed by flow cytometry, twomajor
recommendations have to be taken into account. First, dye concen-
tration should be carefully titrated. High dye concentrations lead
to fluorescence quenching, which generates artifacts and mislead-
ing results. Even if quenching threshold varies depending on the
dye, concentrations in the range 1–30 nM should be low enough to
avoid unwanted quenching phenomena [225]. Second, functional
controls must be used to ensure that changes in the dye signal are
interpreted properly and are not caused by other parallel changes,
including those in mt mass. Appropriate controls are represented
by:
1. carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
(FCCP), carbonyl cyanide m chlorophenyl hydrazine (CCCP),
and valinomycin, which are uncouplers;
2. oligomycin, an ATP synthase inhibitor;
3. and nigericin, a K+/H+ ionophore.
While FCCP, CCCP, valinomycin, and oligomycin induce depo-
larization, nigericin induces hyperpolarization.
A list of the main fluorochromes used to assay mtmP
in living cells is shown in Table 8. Among them, 3,3′-
dihexyloxacarbocyanine iodide (DiOC6) has been extensively used
in flow cytometric studies [226]. However, DiOC6 activity as
NADH inhibitor, together with its toxicity toward mt respira-
tion, strongly limits the use of this probe [227, 2258]. Similarly
to DiOC6, rhodamine 123 (Rh123) was initially used in several
studies [228]. However, Rh123 enters easily into the cells and
rapidly equilibrates, but is not well retained. In addition, in cer-
tain conditions, Rh123 binding to mitochondria can be indepen-
dent of mitochondrial energy status, and this further restricts its
use [229, 2258]. Conversely, tetramethylrhodamine ethyl ester
(TMRE) and tetramethylrhodamine methyl ester (TMRM) are
widely used to probe mtmP by flow cytometry [230, 231]. These
dyes are nontoxic, specifically stain polarized mitochondria, and
do not display quenching effects [231]. They should be used at
relatively low concentrations, and the analysis can be performed
immediately after staining, even in the absence of wash steps.
Upon excitation at 488 nm, TMRE and TMRM emits at 574 nm.
As monochromatic dyes, the MdFI relative to the proper channel
should be measured for TMRE and TMRM. Typically, an unstained
sample (also known as “blank”) should be prepared, in order to
set the levels of background fluorescence, and subtract this back-
ground fluorescence to fluorescence of the stained sample. When
assayed by TMRE or TMRM, changes in mtmP are thus evaluated
as changes in MdFI of a given sample (Fig. 31).
Carbocyanine dyes, especially 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethyl-benzimidazol-carbocyanine (JC-1), are considered the
most reliable probes for the detection of mtmP. JC-1 has poly-
chromatic fluorescence emission spectra, and allows a ratiometric
semi-quantitative assessment of mt polarization [232, 233]. In the
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Figure 31. TMRM and JC-1 staining of CD4+ T cells.
The K+ ionophore valinomycin depolarizes mito-
chondria of CD4+ T cells, as revealed by the decrease
in TMRM fluorescence, and by the decreased fluo-
rescence of JC-1 aggregates and increased fluores-
cence of JC-1 monomers. Untreated cells (CTRL) are
shown in left panels. For TMRM, unstained sam-
ple is also shown in right panel. Dot plot combining
untreated sample and valinomycin-treated sample
is also reported (lower right panel).
monomeric state, it emits a green fluorescence (529 nm), whereas
in the aggregate state, which is highly dependent upon mtmP,
it emits an orange-red fluorescence (>590 nm), well detectable
in healthy cells. In the presence of compounds that cause a col-
lapse in mtmP, JC-1 becomes monomer. This means that while in
healthy cells both green and orange-red fluorescence are expected,
cells with depolarized mitochondria display only green fluores-
cence [234]. Considering the shift in fluorescence due to mtmP
changes, the best way to display results is that of indicating the
percentage of cells with high or low mtmP, rather than the ratio
between green and orange-red fluorescence. Since 1993, JC-1
has been reported as a reliable membrane potential indicator for
several cell types and assay conditions [232, 235, 236], and its
compatibility with other fluorescent probes has also been demon-
strated in the design of multicolor panels [237, 238]. However,
the sensitivity of JC-1 toward hydrogen peroxide, its photosensi-
tivity, and the slow rate of equilibration between monomers and
aggregates, could partially limit its use. Other dyes, similar to JC-
1, are also available but are scarcely used. JC-9 is characterized by
polychromatic fluorescence emission, with excitation at 522 nm,
and emission at 535 or 635 nm, in the monomeric or aggregate
forms, respectively. The green fluorescence of JC-9, characterized
by a different chemical structure respect to JC-1, is essentially
invariant with membrane potential, whereas the red fluorescence
is significantly increased at hyperpolarized membrane potentials.
JC-10 is excited at 490 nm, and emits at 520 nm (monomeric
form) or 590 nm (aggregated form). Compared to JC-1, JC-10 is
characterized by higher water solubility and diffuses out of mito-
chondria in apoptotic and necrotic cells.
Mitochondrial mass can be monitored by using dyes able to
bind specific mt components regardless of mt polarization status.
For this reason, the amount of fluorescence is directly proportional
to mt content. Mito ID and nonyl acridine orange (NAO) bind to
cardiolipin in the inner mt membrane, whereas MitoTracker dyes
react with the thiol groups of cysteine residues present in mt pro-
teins [239, 240]. Some of these dyes, including MitoTracker deep
red 633, also form covalent bonds with mt proteins, thus allow-
ing fixation after cell staining. As described for TMRE and TMRM,
the MdFI relative to the proper channel should be measured for
MitoTracker dyes, and the MdFI of the unstained sample should
be subtracted to the MdFI of the stained one (Fig. 32).
Regarding mt ROS, two fluorescent probes, i.e., MitoSOX red
mitochondrial superoxide indicator (MitoSOX) and mitochondria
peroxy yellow-1 (mitoPY1), have been recently developed to stain
specifically anion superoxide and hydrogen peroxide in mito-
chondria, respectively [241–243]. MitoSOX is the mitochondria-
targeted form of hydroethidine. It accumulates into mitochondria
depending on mtmP, and it emits fluorescence upon oxidation
and binding to mitochondrial DNA [244]. As already reported for
other probes, when using MitoSOX and mitoPY1, preparing ade-
quate positive and negative controls is crucial to fully validate
the presence of mt H2O2 in biological systems. Antimycin A or
doxorubicin are best-suited positive controls for MitoSOX stain-
ing, whereas exogenous H2O2 or other molecules that increase
the fluorescence signal of the probe represent proper positive
controls for mitoPY1. Negative controls for MitoSOX staining are
cell-permeable superoxide dismutase mimetics or mt uncouplers,
depending on the cell type. Additional controls can be represented
by antioxidants, such as N-acetylcysteine, or other specific scav-
engers that highly reduce free radical production [245]. MitoSOX
and mitoPY1 have been tested by flow cytometry for selective
quantification of mt anion superoxide and mt hydrogen peroxide
in keratinocytes, endothelial cells, fibroblasts, several cancer cell
lines, among others [246–249]. The possible simultaneous use of
MitoSOX and mitoPY1 in the same panel for the analysis of mt
ROS in living cells has also been reported (Fig. 33; [246]).
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Figure 32. MitoTracker Green staining of
different subsets of CD8+ T cells. Differ-
ent CD8+ T-cell subsets, i.e., central mem-
ory (CM), naı¨ve (N), effector memory (EM),
and terminally differentiated effector mem-
ory (EMRA) were identified according to the
expression of CD45RA and CD197. Among
them, the use of MitoTracker Green (MT
Green) allows to determine mt mass, which
is clearly different among cell subsets.
Flow cytometry is undoubtedly a useful tool to assay mt func-
tions in biological samples. Protocols to assay mt parameters can
be applied to several cell models, and are relatively fast, as the
time required to complete staining and data analysis (even in the
case of multicolor panels) rarely exceeds 3 h. In addition, the anal-
ysis of several thousands of cells in a few minutes allows accurate
measurements. Nevertheless, as a general rule, the use of more
than one probe, as well as the use of complementary methods to
assess changes in mt membrane potential or mt mass, is strongly
recommended.
4 Extracellular vesicles
4.1 Overview
Body fluids contain cell-derived extracellular vesicles (EVs), which
can suppress and enhance the immune system and contribute
to the development of systemic autoimmune disease. To inves-
tigate the role of EVs in immunology, flow cytometry (FCM) is
the technology of choice for determining the concentration of EVs
expressing certain antigens. However, because EVs are substan-
tially smaller and dimmer than cells, EV detection and data inter-
pretation are challenging, leading to misconceptions. For exam-
ple, on the one hand, it is often overlooked that FCM does not
detect the entire size range of EVs. On the other hand, it is
often incorrectly thought that FCM is incapable of detecting EVs
smaller than the wavelength of light. The aim of this section is
to briefly address some common misconceptions of EV FCM and
to provide recommendations to prevent potential artifacts aris-
ing from sample preparation, staining, assay protocol, and data
analysis.
4.2 Introduction
Blood and other body fluids contain cell-derived extracellular vesi-
cles (EVs), which is the umbrella term for all types of cell-derived
vesicles includingmicrovesicles and exosomes. Figure 34A shows a
transmission electron microscopy (TEM) image of EVs, which can
be seen as subcellular cargo containers transporting biomolecules,
such as transmembrane receptors and genetic information, to tar-
get cells. From an immunological perspective, EVs are interesting
because EVs transport ligands that can suppress the immune sys-
tem, enhance the immune response by antigen presentation, and
contribute to the development of systemic autoimmune disease
[250]. See also Chapter V Section 2 Organisms, cells, organelles,
chromosomes, and extracellular vesicles.
4.3 EV analyses by flow cytometry
EV FCM is particularly useful to determine the number concen-
tration of certain EV types in (body) fluids. However, the small
size of EVs complicates FCM analyses. Figure 34B shows a size
distribution of EVs from human urine based on TEM and resistive
pulse sensing. General properties of an EV size distribution are a
smallest diameter of 50 nm, a peak below 400 nm, and a decreas-
ing concentration with increasing diameter for EVs larger than the
peak diameter [251, 255–257]. Thus, most EVs are smaller than
the illumination wavelength (λ) typically used in FCM. A general
misconception is that EVs smaller than the illumination wave-
length cannot be detected by FCM. According to the Rayleigh cri-
terion, EVs smaller than roughly half the illumination wavelength
cannot be distinguished by classical light microscopy [258]. How-
ever, even the smallest EVs do scatter light of longer wavelengths
and can be detected by FCM, provided that single EVs are illu-
minated and the flow cytometer has nanoparticle sensitivity. In
practice, most flow cytometers do not have nanoparticle sensi-
tivity: a recent standardization study showed that only six of 46
tested flow cytometers in the field were able to detect EVs as small
as 300 nm [259].
To explain how the size of EVs affect their light scattering
intensity, Fig. 34C shows the FSC measured by FCM (A60-Micro,
Apogee Flow Systems, UK) versus the diameter of platelet-derived
EVs and platelets exposing integrin β3 (CD61) from human plasma
and, for comparison, of polystyrene particles. The diameters of
EVs, platelets, and polystyrene particles were obtained from the
FCM scatter ratio [253], literature values [254], and specifications
of the manufacturer, respectively. Please notice that the scattering
intensity of EVs rapidly decreases for small diameters [251, 258,
260, 261] and is substantially lower compared to platelets and
similar-sized polystyrene particles [260, 261]. The low scattering
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Figure 33. MitoSOX Mitochondrial Red super-
oxide indicator and Mitochondria Peroxy
Yellow-1 staining of different subsets of CD8+ T
cells. Doubletswere excluded from the analysis
of PBMCs by using FCS-A and FSC-H (upper left
panel); viable cells were selected according to
negativity for annexin-V (ANX-V) Pacific Blue
conjugate and TO-PRO-3 iodide (upper right
panel). Then, CD4+ or CD8+ T lymphocytes
were selected on the basis of positivity for a
CD4−APC-H7 mAb or a CD8-PO mAb respec-
tively. Among these, fluorescence intensity of
MitoSOXMitochondrial Red Superoxide Indica-
tor (MitoSOX) andMitochondria PeroxyYellow-
1 (mitoPY) was analyzed.
efficiency of EVs implies that a flow cytometer cannot detect EVs
as small as the smallest detectable polystyrene beads.
The small size of EVs also results in low fluorescence intensities.
Figure 34D shows the fluorescence intensity versus diameter of
EVs and platelets labeled with APC CD61 mAb. The parabolic
curve indicates that EVs and platelets have a similar surface density
of CD61. However, because the surface area scales quadratically
with the particle diameter, EVs have much less antigens available
to bind APC CD61 mAb than platelets and therefore emit less
fluorescence. The complex size distribution combined with low
scatter and fluorescence intensities imply that signals from EVs are
close to and/or below the detection limit of FCM. Hence, a flow
cytometer with the dynamic range to detect all EVs in biological
samples does currently not exist.
The difficulty of EV FCM is recognized by the EV Flow Cytom-
etry Working Group (evflowcytometry.org), which consists of
experts from the International Society for Extracellular Vesi-
cles (ISEV), International Society for Advancement of Cytometry
(ISAC), and International Society on Thrombosis and Haemosta-
sis (ISTH). At present, the working group is compiling a series
of consensus manuscripts, which will become a framework that
is consistent with the MIFlowCyt guidelines [39]. A preliminary
outcome is that a general step-by-step protocol for EV FCM does
not exist yet, because the optimal procedures depend on the
research question, the sample studied, and the flow cytometer
used. The steps below are therefore recommendations for EV
FCM experiments with references to articles with detailed pro-
tocols and examples. This section does not cover imaging FCM,
flow sorters, or mass cytometry. Based on new insights and
reaching consensus in the rapidly evolving EV research field,
however, current recommendations will likely become subject to
change.
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Figure 34. Flow cytometry (FCM) detection of extracellular vesicles (EVs). (A) Transmission electron microscopy (TEM) image of EVs from human
urine after one freeze–thaw cycle [251]. (B) Size distribution of EVs from human urine by TEM [251]. Please note that all graphs have logarithmically
scaled vertical axes. The size distribution has a maximum and follows a power-law distribution for larger EVs. For comparison, λ1 and λ2 (dashed
lines) indicate illumination wavelengths typically used in FCM. (C) Forward scatter (FSC) versus diameter for EVs and platelets exposing integrin
β3 (CD61+) from human blood plasma and polystyrene particles measured (symbols) by FCM (A60-Micro, Apogee Flow Systems, UK) and calculated
(lines) with Mie theory (Rosetta Calibration, Exometry, the Netherlands) [252]. The diameters of EVs, platelets, and polystyrene particles were
obtained from the FCM scatter ratio [253], literature values [254], and specifications of the manufacturer, respectively. Polystyrene particles were
modeled as solid spheres with a refractive index (RI) of 1.633, whereas EVs and platelets were modeled as concentric spheres having a shell with
a thickness of 4 nm and an RI of 1.48 and a core with an RI of 1.38. FSC increases with increasing diameter and refractive index and scatter of
polystyrene particles cannot be directly related to the scatter and diameter of EVs. (D) CD61-APC versus diameter for EVs and platelets exposing
CD61+. The parabolic fit describes CD61-APC expression of EVs and platelets (R2 = 0.59), meaning that EVs and platelets have a similar density
of CD61. In (C) and (D), the EV diameter was determined by the FCM scatter ratio [253], whereas the platelet diameter was obtained from the
literature [254].
4.4 Step-by-step sample preparation
4.4.1 Collection, isolation, and storage. Because cells may still
release EVs after collection of a (body) fluid, unprocessed fluids
are unstable EV samples [262, 263]. To obtain stable EV samples, it
is common practice to collect the fluid, remove cells, and freeze EV-
containing aliquots. However, each pre-analytical step will impact
the concentration and composition of EVs. The optimal proto-
col depends on the research question, the type of (body) fluid,
the type of the EVs of interest, and the used flow cytometer. To
limit the scope and emphasize differences between pre-analytical
variables involved in cell and EV FCM, we will summarize consid-
erations involved in collection and isolation of EVs from human
blood for characterization by FCM. The considerations are based
on ISEV guidelines [264], ISTH guidelines [265], and method-
ological guidelines to study EVs [262]. Considerations for other
fluids, such as urine [266] and saliva [267] can be found in the
literature [263].
4.4.2 Collection. Collect blood from overnight fasting subjects
with a 21-gauge needle and avoid prolonged use of a tourni-
quet [268–271]. Collect blood in plastic tubes at room temperature
and discard the first 2–3 mL of collected blood [272, 273]. Omit
hemolyzed blood samples or interpret results with care [264]. The
recommended anticoagulant for FCM analyses is citrate (0.109
mol/L final concentration) [265]. During transport, minimize
vibrations and keep the tubes in a vertical position. Minimize and
standardize the time interval between collection and removal of
cells.
4.4.3 Isolation. When preparing serum, EVs are released during
the clot formation [262]. Therefore, plasma is usually preferred
over serum and serum that is used as culture medium should be
EV-free. To prepare plasma from blood, current guidelines recom-
mend to apply two subsequent centrifugation steps of 2500× g for
15 min at room temperature [265]. Use the lowest or no deceler-
ation, and do not collect the 5 mm of plasma above the buffy coat.
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Quantify the number of residual platelets in the platelet-depleted
plasma. To improve reproducibility, report centrifugation condi-
tions, including deceleration, rotor type, speed, temperature, time,
tube type, and volumes in the tubes [274].
A misconception about EV FCM is the use of additional high-
speed and ultracentrifugation steps to isolate and concentrate EVs
of different size (e.g., microvesicles and exosomes). Separating
EVs of different sizes is unnecessary because the size of EVs can be
determined by FCM based on scatter or fluorescence signals [252,
253, 275]. Concentrating EVs is unnecessary for all EV samples
that require dilution upon FCM analysis. A centrifugation washing
step or size exclusion chromatography, however, may be useful to
decrease the concentration of lipoprotein particles, which overlap
in size with EVs, soluble proteins, and unbound reagents [276].
The presence of these non-EV particles may cause artifacts, which
will be discussed in the next sections about staining and swarm
detection.
4.4.4 Storage. Although the stability of EVs during a freeze–
thaw cycle and storage warrants further investigation [263], freez-
ing is the most common method to store EVs. Use vials with
a rubber ring and screw lid to minimize cryo-precipitation and
to prevent formation of ice crystals. Snap-freeze aliquots in liq-
uid nitrogen [277], store aliquots at or below −80°C, and thaw
aliquots at 37°C [278–280].
4.5 Staining
EVs can be stained with labels available for cells, such as antibod-
ies (Abs; Chapter III, Section 1.1 Controls: Determining positivity
by eliminating false positives), membrane dyes, and fluorescent
dyes that are used to stain nucleic acids (see V.6 DNA synthe-
sis, cell cycle, and proliferation). EV staining, however, involves
different problems and choices and requires more controls than
cell staining. For example, if a flow cytometer detects smaller and
thus more EVs with fluorescence triggering compared to scatter
triggering, EVs are preferably stained with a generic EV marker,
such as lactadherin. However, generic EV markers that specifically
detect all and exclusively EVs do not exist [281].
When designing experiments for polychromatic FCM, Ab-
conjugated fluorochromes should be carefully selected. Preferably,
use fluorochromes that (i) are readily conjugated to Abs, (ii) have
high associated fluorescence intensities (“bright”), and (iii) exhibit
little spectral overlap with other fluorochromes [282, 283]. The
use of bright fluorophores increases the SNR of EVs with low
antigen exposure (Fig. 34D), whereas spectral overlap should be
reduced because compensation of spectral spill-over is compli-
cated by low signal levels and unstable autofluorescence levels.
The aforementioned restrictions on fluorochromes limit the num-
ber of Abs that can be simultaneously measured in typical EV FCM
experiments. To increase specificity, phallotoxin can be used to
differentiate between intact EVs and nonspecific binding of mAb
conjugates to damaged membrane fragments [284].
Similar to cell analysis, it is good practice to titrate reagents to
find the optimal Ab concentration (see III.2 Titration: Determining
optimal reagent concentration). To prevent that Ab-aggregates are
artifactually counted as EVs, remove Ab-aggregates by centrifuga-
tion at 19 000 × g for 5 minutes before staining. After staining,
reduce the concentration of unbound reagents by washing, size
exclusion chromatography, or dilution to reduce sample related
noise and thus increase the SNR.
4.6 Assay protocol
4.6.1 Swarm detection. Before optimizing the acquisition set-
tings, it is important to realize that in most FCM measurements,
only a part of the EVs exceed the detection limit [251, 260].
Due to the complex size distribution of EVs (Fig. 34B), how-
ever, the fraction of EVs below the detection limit may outnumber
EVs exceeding the detection limit. Consequently, EVs below the
detection limit may contribute to the measured signal or even
exceed the trigger threshold (see Chapter IV, Section Cell sort-
ing). This special form of coincidence detection is named swarm
detection [260, 285]. Serial dilutions can be used to find the opti-
mal dilution and minimize the effect of swarm detection. The
measured number concentration versus dilution should give a lin-
ear decrease and a consistent median fluorescence and scatter
intensity.
4.6.2 Acquisition settings. The optimal acquisition settings differ
between flow cytometers. Select settings that lead to the highest
sensitivity, and thus detection of the dimmest EVs, while avoiding
background noise and swarm detection. In general, use the high-
est illumination power, use the shortest illumination wavelength
for scatter detection, select the lowest flow rate, and optimize
detector voltages and thresholds (See Chapter IV, Section Cell
sorting) [57]. The choice whether to trigger on scatter or fluores-
cence depends on the flow cytometer [281, 286–288]. Regarding
scatter, SSC is generally more sensitive than FSC, particularly for
instruments equipped with a photodiode at FSC [260, 289].
4.6.3 Controls. To verify what events are truly EVs, controls are
needed, such as buffer only control, reagents in buffer control,
unstained sample control, blocking and isotype control alone or
in addition to the related FMO control, serial dilutions, detergent
treatment, and sample analyses by techniques complementary to
FCM [57].
The buffer only control involves periodic measurements of
buffer to address sources of noise and monitor the stability of
background counts. The reagents in buffer control involves the
addition of reagents to the buffer at the same concentration as
used in the experiment, and to confirm the absence of events
caused by the reagents [216, 281, 290]. The unstained sample
control (see also Chapter V, Section 3 Mitochondria) involves a
measurement of unstained EVs and may assist in determining aut-
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ofluorescence levels and setting gates. Blocking and isotype con-
trols can be used to differentiate between specific and nonspecific
binding of Abs (Chapter III, Section 1.4 Specificity of reagent for
staining target: Blocking and isotype controls), but not to set gates
or to correct counts for nonspecificity. Isotype controls should be
used from the same manufacturer and at the same concentration
as the respective Ab [291]. In an FMO control, which is used for
experiments with multiple Abs, one reagent is left out or added
to the isotype control to determine the fluorescent gate for that
reagent (Chapter III, Section 1.2 Fluorescence spreading into the
channel of interest: FMO controls).
Serial dilutions can minimize the effect of swarm detection,
as discussed before. Detergent treatment involves the lysis of EVs
by addition of detergent to check whether events that are sup-
posed to be EVs disappear. Results of detergent treatment should
be interpreted with care, because other particles than EVs may
lyse as well [292] and change in scattering properties due to a
refractive index change of the medium [293]. For FCM, data from
complementary techniques are useful for experimental design.
For example, the size distribution and concentration measured
by resistive pulse sensing may be used to determine the optimal
dilution and prevent swarm detection, whereas surface plasmon
resonance imaging or a western blot may be used to confirm the
presence of certain antigens.
4.6.4 Calibrations. FCM provides data in arbitrary units. To
improve data interpretation and enable data comparison, fluores-
cence signals can be calibrated in units of molecules of equivalent
soluble fluorophore (MESF) or equivalent reference fluorophore
(ERF) [294–296] and scatter signals can be calibrated in units
of nm2 [252, 259, 260, 297]. Do not use the scatter intensity
of two sizes of polystyrene particles to set gates for two reasons.
First, polystyrene particles scatter light much more efficiently than
similar-sized EVs (Fig. 34C), which may lead to data misinterpre-
tation. For example, an earlier proposed gating strategy based on
the scatter intensities of 500 nm and 900 nm polystyrene par-
ticles [298, 299] leads to the inclusion of platelets, membrane
fragments, and perhaps erythrocyte ghosts [255] instead of the
envisioned EVs [260]. Second, a gate based on two polystyrene
particles selects different EV sizes at different flow cytometers and
therefore is not suitable for the purpose of data comparison [259].
Statements about the number concentration of EVs also require
calibration of the flow rate, especially because the actual flow rate
may be 50% lower or 100% higher than the set flow rate [259].
The flow rate can be estimated using commercial reference par-
ticles with a specified concentration, by mass discharge measure-
ments [259], or by a calibrated flow rate sensor.
4.7 Materials
Materials required for collection, isolation, storage, and staining
depend on the experiment. Generally, use a clean, filtered buffer
and measure the buffer to confirm cleanness. Preferably, the flow
cytometer is able to detect the scatter intensity of at least 200 nm
polystyrene particles and a fluorescence intensity of at least 1000
MESF (see also Fig. 34C and D). For comparison, one of the most
sensitive flow instruments for EV detection today can detect single
20 nm polystyrene particles and a single PE molecule [300].
4.8 Data analysis
Most data analyses steps can be done with software capable of
reading FCMdata, creating histograms and scatter plots and apply-
ing gates. Preferably, start with the aforementioned calibrations
of the scatter and fluorescence detectors to obtain data with units
that are understandable and comparable. Use the aforementioned
controls to exclude swarm detection and define gates. Count the
number of EVs within the gate during a measurement and use
the calibrated flow rate to relate counts to number concentration.
Because only a part of the EVs can be detected [251, 260], the
reported number concentration should be accompanied with the
range wherein the EVs are detected. For example, in Fig. 34D we
measured a concentration of 4.4 × 108 CD61+ EVs/mL with an
APC intensity between 5.0 × 102 and 11.7 × 103 MESF.
Because the size, scatter intensity, and fluorescence intensity
distributions of EVs are often asymmetrical, the use of statisti-
cal parameters such as mean, median, and SD should be used
with care. To describe the shape of an EV distribution, it is gener-
ally more appropriate to use a mathematical function. For exam-
ple, EV size distributions can often be described with a power-
law function (Fig. 34B), log-normal function, or exponential
decay.
New, sophisticated procedures exist to derive the diameter of
EVs from scatter or fluorescence signals. For example, Exometry
offers a commercial kit and the National Institute of Health offers
free software [301] to determine the EV diameter from a single
scatter detector. The information from two scatter detectors can
be combined to determine the refractive index, which can be used
for label-free differentiation between EVs and lipoprotein particles
[253].
To ensure reproducibility, all details involved in sample col-
lection, isolation, storage, staining, data acquisition, controls, cal-
ibrations, and data analyses such as gating (Chapter VII, Section
3 Analysis presentation and publication (MIFlowCyt)) should be
reported. Graphs should have clear axes labels and calibrated
scales and reported values of the fluorescence intensity and scat-
tering intensity preferably have comparable units. Data sharing
via public repositories is highly recommended (See Chapter VII,
Section 4 Data repositories: Sharing your data).
4.9 Pitfalls
 Detecting artifacts, such as swarm detection and background
noise, instead of single EVs.
 Using the scatter intensity of two sizes of polystyrene particles
to gate EVs.
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 Providing the concentration of EVs without reporting the
dynamic range of the detector(s) in standardized, comparable
units.
 Using high-speed and ultracentrifugation steps to isolate and
concentrate EVs of different size (e.g., microvesicles and exo-
somes) upon FCM analyses.
4.10 Top tricks
 Realize that FCM measures only a part of all EVs in the sample.
 Quantify which EVs the flow cytometer can measure and map
out related artifacts.
 Use controls to verify detection of the envisioned, single EVs.
 Report (1) the research question and hypotheses, (2) all details
of the protocol required to reproduce the data, and (3) data
values in standardized, comparable units.
5 Surface parameters
5.1 Overview
This section focuses on the handling of suspension cells and cells
obtained enzymatically from tissue samples for the detection of
cell surface molecules. Although this is the most commonly used
application in flow and mass cytometry, some pitfalls during sam-
ple handling, staining, and data analysis can occur, which will be
discussed here.
5.2 Introduction
Surface molecules comprise membrane proteins, such as recep-
tors, enzymes, ion channels, adhesion, and transporter molecules,
lipids, or polysaccharides but also external ligands, either specif-
ically loaded onto their specific receptors, e.g., cytokines or Abs
or nonspecifically attached to the cell surface (reviewed in ref.
[302]). These molecules are easily accessible by FCM and do
not typically require special preparation of cells, such as fixa-
tion or permeabilization. Most surface markers, in particular those
known as lineage markers, are also expressed at reasonable den-
sity allowing clear-cut discrimination between positively and neg-
atively stained cells.
In principle, surface molecules can be detected with different
types of labels in a range of affinities, such as Abs, receptor ligands,
lectins for the detection of glycan structures, annexin V for the
detection of phosphatidylserine at the outer membrane of apop-
totic cells (see Chapter V Section 7: Measuring cell death mecha-
nisms) and complex multivalent reagents, e.g., for increased bind-
ing avidity, e.g., MHC/peptide-tetramers (see Chapter V Sections
17.3-17.5: Antigen-specific T-cell cytometry), which in general are
chemically conjugated to fluorescent reporter molecules.
5.3 Minimize artifacts by minimal cell manipulation
If possible, surface molecules should be stained on live cells to
avoid any kind of antigen denaturation possibly introduced by
pre-treatment steps, such as cell fixation or cell permeabilization,
to clearly differentiate between intra- and extracellular localiza-
tion. For combined intracellular (see also Chapter V Section 14
Intracellular parameters) and surface staining, surface markers
should be stained first, followed by fixation and permeabilization
before staining for intracellular antigens. Defined reagents such
as recombinant Abs [303] with reduced “nonspecific” interactions
should be used whenever possible (see also Chapter III Section
1, Controls: Determining positivity by eliminating false positives)
especially when cells do express high or low affinity Ig Fc receptors,
such as CD64 or CD32. Unspecific, Fc receptor-mediated binding
of immunoglobulins can be suppressed by incubating cells in the
presence of blocking reagents, such as purified Igs.
In contrast to blood cells or cells from liquid exudates, primary
cells located in tissues often require an enzymatic pretreatment for
tissue dissociation to finally obtain cells in suspension (see Chap-
ter III Section 3). But during this procedure antigenicity of surface
proteins can be also affected. Therefore, depending from the tis-
sue type and cells of interest, conditions for enzymatic digestions
have to be carefully established. In general, there are a variety
of enzymes available, such as elastase, hyaluronidase, dispase,
and different types of collagenases. They differ in their digestive
characteristics and, therefore, incubation time, temperature, and
concentration of enzymes have to be optimized with respect to cell
viability, cell yield, and preservation of antigens that will be inves-
tigated by FCM. In the case of very sensitive antigens, which are
destroyed during tissue digestion, isolated cells may be cultured
over night to allow re-expression of affected cell surface proteins.
Principally, cells obtained after enzymatically tissue digestion are
much more stressed than suspension cells and therefore, require
the identification of dead cells and their exclusion from the analy-
sis as described in Chapter III, Section 4: Dead cell exclusion, cell
viability, and sample freezing. As described there, dead cells will
increase background signals due to a general increase in autoflu-
orescence or due to the increased unspecific binding of staining
reagents.
A very detailed protocol to isolate thymic epithelial cells is
given by Jain and Gray [304] and for human skin mast cells by
Gru¨tzkau et al. [305]. Moreover, The tissue dissociation guide from
Worthington summarizes all aspects of tissue dissociation in a
very comprehensive way (Worthington Biochemical Corporation
Tissue Dissociation Guide [306]).
Although flow cytometric analyses should ideally be performed
with fresh samples, there are several possibilities to stabilize cells
or blood samples before preparation for FCM (see also Chapter
III, Section 3: Preparation of single-cell suspensions; Section 4:
Dead cell exclusion, cell viability, and sample freezing; and Sec-
tion 5: Cell fixation and permeabilization for flow cytometry).
Short-term preservation of blood for up to 24 h by Ficoll 70 kDa
is mainly aiming at inhibiting blood settling-induced stress that
is caused by RBC aggregation [307]. For long-term storage, the
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cryopreservation of PBMCs is another option. But it should to
be kept in mind that some surface molecules, like CD62L or
chemokine receptors in general, can be negatively affected by this
procedure. In addition, some cell types may be more sensitive to
this type of treatment, which has to be determined individually
for each cell population of interest.
In addition, there are several commercial reagents available,
that can be used for long-term storage of blood samples, such
as TransFix (CYTOMARK, Caltag Medsystems, Buckingham, UK),
Cyto-Chex BCT (Streck, Omaha, US) and Smart Tube (Smart Tube,
San Carlos, CA) [308]. The latter one even allows analyzing frozen
blood samples after appropriate treatment without losing granu-
locytes.
But for all these stabilizing protocols, it is strongly recom-
mended that they have thoroughly been validated for the surface
markers of interest.
Live cells may be sensitive to prolonged in vitro handling proce-
dures or may actively internalize surface molecules or shed them
from the surface, e.g., after labeling with Abs. This can be avoided
by gentle treatment, e.g., careful pipetting, short handling time,
low temperature (on ice), or addition of sodium azide to the stain-
ing buffers, which blocks active shedding/internalization. After
staining, cells should be immediately analyzed or strictly be kept
on ice and in the dark to avoid photobleaching.
For the detection and analysis of cell subsets that are detectable
only in very low frequencies (<0.1%), appropriate pre-enrichment
strategies may help to improve gating resolution for the cell popu-
lation of interest (see Chapter IV Section 1: Pre-enrichment of low
abundant cell populations prior to acquisition/cell sorting).
5.4 Transient surface markers
Some markers are only transiently expressed on the cell sur-
face and thus may escape detection. This can be caused by
different mechanisms, such as ectodomain shedding [309] or
rapid internalization and subsequent endocytic recycling [310].
Cytokine receptors especially behave in a very sensitive manner
during sample preparation and thus different results may be
obtained by analyzing whole blood after hypoosmotic lysis of
erythrocytes or enrichment of PBMCs after Ficoll density gradient
centrifugation [311]. Moreover, incubation temperature and time
for Ab staining have to be carefully adjusted for each particular
Ab. For instance, chemokine receptors are often stained rather
at room temperature than at 4°C to ensure highest sensitivity of
receptor detection [310]. Another example is the identification of
antigen-specific T cells by the detection of CD154 (CD40-ligand),
which is transported to the cell surface only upon T-cell activation
and is then rapidly internalized after binding to its receptor (see
Chapter V Section 17.3: Antigen-specific T-cell cytometry). A final
example is the rapid downregulation of the CD3/TCR complex
upon TCR/CD3-ligation [312]. In principle, depending on the
marker investigated internalization can be prevented by pharma-
cological or Ab blockade as shown for the chemokine receptor
CCR5 by Mu¨ller et al. [313] or alternatively the antigen has to
be continuously stained during culture or by intra-cytoplasmic
staining.
5.5 Genuine membrane molecules versus membrane
adsorption
Not all molecules detected on the cell surface are genuine sur-
face molecules but may have been passively adsorbed to the
cell surface or exchanged by an intercellular transfer of mem-
brane patches. This might lead to significant artifacts and is par-
ticularly relevant for cells from cell cultures and for cells get-
ting in close contact with each other, e.g., within cell pellets
following centrifugation. On the other hand, it can be caused
by alternative peptide/protein transfer mechanisms, such as tro-
gocytosis, extracellular vesicle-mediated transfer between cells
(i.e., through exosomes or microvesicles, see also Chapter V
Section 2 Organisms, cells, organelles, chromosomes and extra-
cellular vesicles) or tunneling nanotubes, which may allow an
intercellular transfer of preformed MHC class I and class II
molecules in the immunological synapse [314]. Principally, unspe-
cific adsorption may be reduced by short processing times and
low temperature, addition of Ca2+ chelators (EDTA) or neutral
“blocking” proteins such as BSA to all staining buffers and by
repetitive washing steps, or even short treatment with high salt or
low pH. Passive adsorption can also be tested for by incubation
with the relevant molecule, block of transport to the cell surface
(e.g., brefeldin A for activation-induced molecules) or by the use
of purified cell populations to prevent cross-feeding. However, if
the results remain insensitive to these treatments, they have to
be confirmed by alternative analysis methods, e.g., fluorescence
microscopy (to determine spatial distribution on the cell surface),
RNA-analysis, transgenic expression of the molecule of interest in
cell lines, and so on.
Adsorption of molecules to the cell surface can also actively be
exploited for staining of surface receptors with the specific ligands,
such as chemokines [315], cytokines, soluble ligands/Fc-fusion
proteins, if suitable Abs are not available.
5.6 Quantitative considerations
Quantification of surface marker expression on particular cell
types can be principally done in two ways: (i) calculation of rel-
ative frequencies as percent positive cells expressing a particular
surface protein or a combination of several ones according to a
threshold determined by an isotope or FMO control; (ii) quan-
tification of absolute cell numbers per sample volume; and (iii)
calculation of the strength of protein expression on a particular
cell type considering fluorescence intensity as given by the mean,
geometric mean, or median value of fluorescence intensity (see
Chapter III Section 1: Controls determining positivity by eliminat-
ing false positives; and Chapter VII Section 2: Statistics for flow
cytometry). The decision whether to calculate relative frequencies,
absolute cell numbers for a given sample volume or both depends
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 Biological applications 1537
on the scientific question, e.g., to discriminate between an appar-
ent decrease of a particular cell population probably caused by
an increase of other cell populations or by a real decline probably
caused by an increased rate of cell death. Principally, frequen-
cies are useful when asking for a percentage of activated cells
within a given population (e.g., percentage of CD69-positive CD4
cells) while reporting data in absolute cell counts (i.e., 1x106 CD4
cells/µL blood) will be essential in many settings, e.g., to address
questions of emigration or immigration of immune cells from or
in the peripheral blood circulation.
To analyze the activation of cells not only the percentage of
activated cells is of interest but also the magnitude of activation
marker expression, e.g., CD69, CD25, or HLA-DR, is important
and can be given by the fluorescence intensity. In quantitative
FCM, fluorescence-labeled beads are used, which are commer-
cially available from several vendors, such as Calibrites from BD
or calibration beads from BioCytex or QuantumTM MESF kits from
Bangs laboratories. These beads not only allow a standardized
detection of fluorescence intensity units as needed for diagnostic
applications butmay be also used to assess the detection threshold,
resolution, and linearity of the relevant detector. For quantitative
comparison of surface marker expression, it should be kept in
mind that the surface increases with the square of the cell diame-
ter, i.e., the same marker density results in much brighter signals.
Thus, changes in cell size, e.g., upon cellular activation, have to
be considered for selection of the proper controls.
6 DNA synthesis, cell cycle, and proliferation
Cell cycle analysis was one of the very first applications for which
FCMwas used, and has since been used in a large range of different
settings such as interrogating the biology of cancer, drug devel-
opment, and toxicology studies [316]. In mammals, non-dividing
cells in the G0 phase enter the G1 phase when they are preparing
for division. The G1 phase does not result in an increase in DNA,
but does involve the synthesis of proteins that are required for
subsequent progression. DNA synthesis occurs when cells enter
the synthetic (S) phase of the cell cycle, in which they will remain
until the DNA content has doubled, at which time they will enter
the G2 phase and undergo mitosis. Cells in G0 and G1 therefore
contain the same amount of DNA andwill exhibit the same fluores-
cent properties when stained with a DNA-binding dye. In contrast,
the fluorescent intensity of cells moving through S Phase will pro-
gressively increase as their DNA content increases until they have
twice the amount of DNA than cells in G0 when they reach the G2
and M Phases.
6.1 DNA synthesis and cell cycle analysis
The determination of DNA synthesis and cell cycle analysis
involves the use of fluorescent dyes that bind to DNA, of which
there are many (e.g., PI, Hoechst stains, TO-PRO-3, SYTOX, acri-
dine orange, pyronin Y, 7-AAD, DAPI, DRAQ5TM, and DRAQ7TM).
The selection of the dye to be used will be dependent on the
instrument that is available and the spectral parameters that it can
detect. One should also be aware of the binding characteristics of
the dyes and their preference for base pairs. The compatibility of
an instrument for a dye will be dictated by the wavelength of the
lasers that are available, and the optical characteristics of the fil-
ters with which each laser is associated. This highlights the issue
of understanding your instrument and its capabilities, as without
this understanding it will not be possible to design and deliver
valid experimental data. The investigator should consult the man-
ufacturer’s instruction manual for specific information regarding
the operation and capabilities of their FCM platform. Online FCM
resources (see Useful resources below) provide a repository of key
information and tools for informing and facilitating good experi-
mental design, and for improving FCM practice.
Another consideration relates to whether there is a need to
analyze viable or fixed cells, and whether to only fix or fix and
permeabilize samples. Given that permeabilization can remove
intracellular components, this approach can give more definite
peaks on the fluorescent histograms. Crosslinking agents such as
formaldehyde lower dye binding because of chromatin crosslink-
ing. Although dehydrating fixatives such as methanol and ethanol
can also be used, at high concentrations, these can cause cell
clumping due to protein coagulation. Dehydrating fixatives can
also negatively impact on fluorescent dyes if DNA is being stained
in association with surface marker staining for the expression
of antigenic determinants, as many protein-based fluorescent
molecules are sensitive to the dehydrating effects of the alco-
hols. One should also be aware that signals from Green Fluores-
cent Protein, mCherry, and Cerulean can be destroyed by alcohol
treatment. The addition of permeabilizing detergents to disrupt
the plasma membrane such as Triton, NP-40, and saponin can
improve access of the DNA dye. Another issue to consider is that
the concentration of the DNA dye must be sufficient so that it
binds in proportion to the amount of the DNA in the cell. It is
therefore essential to determine the DNA profiles that are gener-
ated at different concentrations and incubation times for a defined
cell number and identify the approach, which generates the lowest
CV, but in the absence of any cytotoxic effect (i.e., check the via-
bility of cell populations and the influence of the dye thereupon).
One should also remember that some dyes (PI, for example) will
bind to both DNA and RNA. In such instances, it is necessary to
include a ribonuclease (RNAse) in the staining buffer, otherwise
the fluorescence histograms that are generated will be sub-optimal
as they will include a signal from the RNA. A typical experimental
protocol using PI for staining and generating a typical staining
profile (Fig. 35) will involve the following:
1. Fix cells that have been harvested and washed in PBS in 70%
v/v ethanol. Adding the ethanol dropwise to the cell pellet
while vortexing will ensure that all cells are fixed and will
minimize clumping.
2. Fix cells for 30 min at 4°C, after which wash cells twice in PBS
(850 × g). Be careful to avoid cell loss when discarding the
supernatants.
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Figure 35. Representative DNA fluorescence histogram of PI-stained
cells. Isolated cells are fixed and stained as described above, and their
fluorescence determined on a linear fluorescence scale. The presence of
a sub-G1 peak can be used to indicate the presence of cells undergoing
apoptosis (See Apoptosis: Measurement of apoptosis).
3. Treat cells with RNAse (50 µL, 100 µg/mL) in order to ensure
that only DNA is stained.
4. Add PI (200 µL PI, 50 µg/mL stock solution) immediately
before analyzing.
The “quality” of the DNA histogram that is generated is typ-
ically indicated by the appearance and CV (data spread) of the
G0/G1 peak, which must be as low as possible (Fig. 35). Factors
that can influence this element of the data acquisition include the
flow rate (which must be low) and laser alignment and hydrody-
namic focusing (both of which should always be optimized as part
of the routine maintenance and quality control procedures that
are stipulated by the instrument and calibration bead manufac-
turers). It is essential to maximize the electronic signal intensity
and minimize variability of the measurement of the beads in order
to achieve accurate DNA measurements. The precise definition of
“low,” “medium,” and “high” flow rate will depend on the instru-
ment and its configuration. It is better to run a more concentrated
sample at a slower flow rate, than a diluted sample at a higher
flow rate.
Although it would appear obvious, it is crucial that the pres-
ence of cell aggregates or doublets is minimized, and that these
are excluded from the analysis. Doublets or cells going through
the cytometer together can mimic cells in the G2/M phase. Such
problems can be avoided by employing good experimental tech-
niques for the preparation of samples and filtering samples before
the analysis [316] (see Chapter III, Section 3: Preparation of single
cell suspensions). The analysis gate can be set to acquire data on
singlet cells by acquiring data using a “Pulse/Cell Width” versus
“Pulse/Cell Area” plot or “Pulse/Cell Height” versus “Pulse/Cell
Area,” which can be set using the instrument software (Fig. 36).
This approach allows doublets and aggregates to be easily iden-
tified and excluded from the analysis. As with all experiments,
controls should be included. Chicken and trout erythrocytes have
been proposed as internal standards for analysis of DNA content by
cytometry in order to control andmaintain consistency in the stain-
ing and measurement approaches. However, it should be noted
that the ploidy of DNA in fish can also vary, and so it is important
to be aware of ploidy when using cells as a standard [317].
It is also crucial to exclude nonviable cells from any analy-
sis, as the presence of these can introduce heterogeneity into the
datasets that are generated. Although DNA analysis, by its nature,
requires that cells are fixed and therefore nonviable, it is possible
to stain cells using nonfixable dyes (protein-binding dyes) prior
to their fixation for DNA staining. Details on these approaches
are provided in the relevant section (see Chapter III Section 4.2:
DNA-binding dyes).
A typical instrument setup and sample acquisition could use the
following sequential series of plots, and 10 000–20 000 relevant
(NOT total) events should be collected:
 FSC versus SSC plot to identify relevant cell population(s)
 “Pulse Width” versus “Pulse Area” plot or “Pulse Height” versus
“Pulse Area” plots (to exclude doublets)
 Live/Dead versus FSC (to exclude dead cells)
 DNA stain (e.g., PI) versus FSC (to monitor instrument perfor-
mance)
 DNA histogram (using a linear scale)
A typical analysis could use the following sequential series of
plots:
 “Pulse Width” versus “Pulse Area” plot, or “Pulse Height” versus
“Pulse Area” plots (to exclude doublets)
 Live/dead versus PI (to exclude dead cells)
 FSC versus SSC plot (to exclude unusual-looking populations)
 DNA histogram (using a linear scale)
The placement of markers on the G1, S, and G2 peaks for
the analysis of cell cycle profiles can be subjective, as a con-
sequence of which the analysis and interpretation of cell cycle
analysis data now involve a number of mathematical models, all
of which attempt to deconvolute the peaks and provide a more
objective approach. Specialized programs such as ModFit LTTM
from Verity Software House (http://www.vsh.com/products/
mflt/mfFeatures.asp) andMulticycle AVTM fromPhoenix Flow Sys-
tems (http://www.phnxflow.com/MultiCycle.stand.alone.html)
have been designed for this purpose.
Although cell cycle analysis is a powerful tool, it requires a great
deal of optimization for the data to be robust, interpretable, and
meaningful. Furthermore, although cell cycle analysis provides
information on the proliferation of cells, other approaches must
be used if you are wanting to quantify how many times cells have
replicated (see part 7.2 Proliferation).
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Figure 36. Identification of single cell popula-
tions for analysis using FCM. Cultured tumor
cells were harvested, washed, and stained
[316]. (A) Tumor cells are identified on an FSC
versus SSC plot and gated to exclude debris,
which is found in the lower left corner. (B)
Single cells can be separated from cell aggre-
gates by analyzing cell height and area (upper
right)—single cells will show as a correlated
line, with any clumped cells below. (C) Viable
cell populations can be identified using via-
bility stains such as the LIVE/DEAD R© fixable
range of products from Life Technologies, the
eFluor R© fixable dyes from eBioscience, BioLe-
gend’s Zombie range of fixable dyes, Tonbo
biosciences’ Ghost DyesTM, and the Fixation
and Dead Cell Discrimination Kit from Mil-
tenyi Biotec, as described in Chapter III Section
4 Dead cell exclusion, cell viability, and sam-
ple freezing. Reproduced with permission from
ref. [316].
6.2 Proliferation
The analysis of cell proliferation is at the core of many biolog-
ical studies and is typically used for cell growth and differenti-
ation studies, and for the evaluation of toxicity and therapeutic
responses to stimulators and inhibitors in a variety of settings.
Cell proliferation can be determined on the basis of direct cell
counting, on the basis of DNA synthesis (using an approach that
typically involves measuring the uptake of 3H-thymidine), or by
measuring metabolic activity such as mt dehydrogenase activity
using colorimetric assays such as the MTT (3-(4,5-dimethythiazol-
2-yl)-2,5-diphenyl tetrazolium bromide) assay. For the latter, cells
are incubated with MTT, and the yellow MTT is converted into
an insoluble purple formazan product by mt succinate dehy-
drogenase. The product is solubilized and level of proliferation
determined by measuring the absorbance of the medium with
a spectrophotometer. An alternative colorimetric approach uses
the [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium] tetrazolium salt that results in a
soluble, rather than an insoluble, formazan product. Although
these approaches are effective, their common disadvantage is that
they provide a measure of proliferation in the bulk population,
and do not provide insight into the proliferative responses of cell
subpopulations. The multiparameter capabilities of FCM offers a
number of options for studying cellular proliferation in complex
settings, and the majority of the approaches involve the measure-
ment of nucleotide incorporation or dye dilution. The approach
that needs to be used will very much depend on the experimental
setting (Table 9)
6.3 DNA synthesis—Nucleotide incorporation
Analogous to the measurement of proliferation based on 3H-
thymidine incorporation, cell division can be monitored by FCM
using 5-bromo-2’-deoxyuridine (BrdU), a synthetic nucleoside
Figure 37. Schematic representation of fluorescent
dot plot for the flow cytometric analysis of cell prolif-
eration based on BrDU incorporation. Human PBMCs
have been labeledwith BrDUand aphenotypicmarker,
with unlabeled cells acting as the control. The total
viable cell population was used for the analysis.
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Table 9. Approaches for determining cell proliferation
Nucleotide incorporation/
dye dilution
Determination
of cell divisions
BrdU 1–2
BrdU/Hoechst/PI
(quenching) technique
3–4
Dye dilution >4
BrdU, 5-Bromo-2′-deoxyuridine
analogue of thymidine. For this, BrdU is incorporated into the
newly synthesized DNA of replicating cells (during the S phase
of the cell cycle), and its incorporation detected using conjugated
Abs specific for BrdU, which are widely available from a number
of commercial sources. Binding of the Ab requires denaturation
of the DNA, usually by exposing the cells to acid or heat. The
measurement of BrdU is typically undertaken in conjunction with
viability dyes and/or DNA stains for cell cycle analysis.
Although appearing to be a straightforward assay, sample
preparation and DNA denaturation for BrdU-based measurements
of cell division must be performed carefully, as too little treatment
will result in a low signal and too much treatment will influence
the DNA and the signal that is generated. Samples need to be
washed well (at least three times), as any residual acid will dena-
ture the detecting Ab. Furthermore, BrdU is labile even at 4°C and
so must be used fresh. A typical experimental protocol producing
a typical staining profile (Fig. 37) involves the following:
1. Incubate cells with BrdU (10 µM) for 30–60 min
2. Fix harvested and pelleted cells by suspending in ice-cold 70%
v/v ethanol at 4°C for at least 30 min (samples can be left for
up to 7 days).
3. Pellet cells, wash in PBS and incubate for 30 min at room
temperature (RT) (with occasional mixing) in freshly prepared
2 M HCl.
4. Wash cells twice in PBS, and then in PBS-Tween (PBS contain-
ing 0.1% w/v BSA and 0.2% v/v Tween 20, pH 7.4).
5. Add an appropriate amount of anti-BrdU mAb (conju-
gated/unconjugated), as determined by titration experiments,
to the cell pellet and incubate samples at RT for 20 min in the
dark (BrdU is photo-unstable).
6. Wash samples twice in PBS-Tween and, if an unconjugated
mAb has been used, incubate samples with an appropriate
secondary Ab at RT for 20–30 minutes.
7. After washing in PBS, incubate cell pellets with RNAse (50 µL,
100 mg/ml) for 15 min at RT or 37°C.
8. Add an appropriate volume of the required viability stain (e.g.,
PI, 200 µL, 50 mg/mL).
9. Analyze the viable cell populations(s) by FCM, collecting a
minimum of 10 000 relevant events per sample.
An alternative to BrdU is the modified nucleoside, EdU (5-
ethynyl-2′-deoxyuridine). Assays such as the Molecular ProbesTM
Click-iTTM EdU cell proliferation assay are based on the labeling of
proliferating cells with a bright, photostable Alexa Fluor R© dye in a
Figure 38. Schematic fluorescence histogram depicting a progressive
decline in the fluorescent intensity of proliferating cells stained with
CFSE. For the assays, 106 isolated cells (e.g., human PBMCs) are incu-
bated with CFSE (5 mM final concentration) at room temperature for
8 min, at which time the reaction is blocked by the addition of FBS (2%
v/v final concentration). Cells are washed in PBS containing 2% v/v FBS,
after which they are stimulated. The fluorescence of the stimulated
cells is then measured at appropriate time-points using FCM. (A) The
bright/strong, undiluted fluorescent signal of nonproliferating/arrested
cells. (B) The (serially) diluted fluorescence intensity of cell populations
from successive generations of proliferated cells.
fast, highly specific click reaction. Unlike BrdU assays, EdU assays
are not Ab -based and therefore do not require DNA denaturation
for the detection of the incorporated nucleoside. Click-iTTM EdU
can also easily be multiplexed with fluorescent proteins like R-
PE, R-PE tandems, and green fluorescent protein. Only a mild
fixation and detergent permeabilization is sufficient for the small
molecule-based Click-iTTM EdU detection reagent to gain access
to the DNA. A typical experimental protocol producing a typical
staining profile and improved DNA histograms has previously been
reported [318, 319].
6.4 Dye dilution
The essence of dye dilution approaches is that cells are labeledwith
fluorescent dyes that intercalate into the cells such that the dye is
approximately equally distributed between the two daughter cells
following division. As the cell divides, the dye is diluted out and
by counting the peaks (or modeling the pattern) the number of
original dividing cells can be calculated (Fig. 38).
As originally described in 1994 by Lyons and Parish [320],
cells were stained with the protein-binding, amino-reactive dye
carboxyfluorescein succinimidyl ester (CFSE). One limitation of
CFSE is that there is a proliferation-independent loss of fluores-
cence in the first 24–36 h, and therefore, this must be consid-
ered during the analysis and interpretation of the data. Although
alternatives for which there is no loss of signaling after labeling
include membrane-labeling lipophilic dyes that include the PKH2
(green), PKH67 (green), PKH26 (orange), and CellVueTM claret
(far red) dyes from Sigma–Aldrich, these are more suitable for
cell tracking experiments. More suitable for dye dilution stud-
ies are protein-binding dyes such as the CellTraceTM range from
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Molecular Probes R©, the eFluor R© Cell Proliferation dyes from eBio-
science, the BDHorizonTM dyes from BD Biosciences and the Tag-it
VioletTM Proliferation and Cell Tracking Dye from BioLegend. If
cells require fixing, then it is important to avoid organic solvents
when using membrane dyes. It is also important to use the correct
dilution of dyes, as they can have adverse effects on cell viability
and function. Use the highest concentration that does not induce
such negative effects for a given cell number. Protocols for the
staining and analysis approaches can be accessed from the many
suppliers of the reagents that are being used.
As with all experiments, it is essential to include the relevant
negative and positive controls. Moreover, once the instrument set-
tings have been optimized, it is important to place unstimulated
cells at the highest decade on the fluorescence plot. Nonviable
cells should be excluded, as they lose the dye as they enter apop-
tosis. Doublets should be excluded as a doublet of two cells in
the G0/G1 phase would exhibit the same fluorescence intensity on
a DNA stain as a single cell in the G2/M phase. G0/G1 doublets
would therefore create false positive results for G2/M cells [321].
Furthermore, a doublet formed between a positive and negative
cell would be seen as being positive during a cell sort, as a con-
sequence of which the sort would be contaminated with negative
cells. The presence of doublets would also cause problems for
DNA content/ploidy analyses and could lead to misinterpretation
of double positives during immunophenotyping studies, in that
a double positive cell could in fact be a mixed doublet of two
individually positive cells.
Useful Resources
 BitesizeBio Flow Cytometry Channel (http://bitesizebio.com/
category/technical-channels/flow-cytometry)
 Chromocyte Limited: Resource for FCM and cell-based assays
(www.chromocyte.com)
 European Society for Clinical Cell Analysis (ESCCA,
www.escca.eu)
 Expert Cytometry: Flow cytometry training (www.expert
cytometry.com)
 International Society for Advancement of Cytometry (ISAC,
http://isac-net.org)
 Purdue University Cytometry Laboratories (www.cyto.
purdue.edu)
7 Measuring cell death mechanisms
7.1 Apoptosis: Measurement of apoptosis
The above approaches for identifying the induction and presence
of cell death are based on the loss or maintenance of membrane
integrity, and thereby reflect cellular necrosis. They provide little
insight into the nature of that cell death. In instances where the
induction of cell death is a primary endpoint of the experiment,
interrogating changes in the plasmamembrane provides an oppor-
tunity to generate insight into the mechanisms that are involved.
By far the most common approach is to determine the induction
of apoptosis (programmed cell death). Apoptosis is a tightly con-
trolled and programmed pattern of cell death that is required for
the maintenance of normal cell growth and development. Defec-
tive apoptosis can result in abnormal development and patho-
genesis. Understanding cell death mechanism(s) is important, as
the mode of cell death (necrosis vs. apoptosis) can influence the
pro- and anti-inflammatory responses that cell death can induce.
The importance of this area was recognized by the award of the
2002 Nobel Prize in Physiology or Medicine to Sydney Brenner, H.
Robert Horvitz, and John E. Sulston “for their discoveries concern-
ing genetic regulation of organ development and programmed cell
death.”
During early apoptosis, phosphatidylserine (PS) is translocated
from the cytosolic side of the intact plasmamembrane to the extra-
cellular surface. Early apoptotic cells cannot therefore be reliably
identified using approaches that are based on membrane perme-
ability. Annexin V belongs to a family of proteins consisting of
over 160 members, and has high affinity, specificity, and sensi-
tivity for PS. Thus, the binding of annexin V to cells can be used
as a marker of early apoptosis [322]. In order to rule out “leaky”
necrotic cells, annexin V staining must always be used in con-
junction with reagents that determine the integrity of the cell
membrane, such as PI or 7-AAD. Of course, such assays cannot be
performed using fixed cells.
Although the protocols for such assays are relatively straight-
forward, they should be undertaken according to the instructions
provided by the supplier of the reagents. This is especially impor-
tant in the case of Annexin V binding, as all Annexin family mem-
bers share the same characteristics of Ca2+-dependent binding to
negatively charged phospholipid surfaces. It is essential that the
correct staining buffers are used, as changing or variations in Ca2+
ion concentrations can have dramatic effects on the staining pro-
files. Furthermore, the binding of Annexin V to PS is reversible,
and so samples must be analyzed as soon as possible (typically 1–3
h after labeling), using a consistent and reproducible protocol. A
typical experimental protocol producing a typical staining profile
(Fig. 39; [323, 324]) involves the following:
1. Wash cells (1 × 105) in Annexin V Binding Buffer (PBS con-
taining 10% v/v FCS, 1.0 mM MgCl2, and 2.5 mM CaCl2);
2. Pellet cells (5 min, 400 × g), remove the supernatant, either by
decanting or vacuum aspiration and resuspend cells in 100 µL
of Annexin V Binding Buffer;
3. Incubate cells with an appropriate volume (e.g., 5 µL) of
fluorescently-conjugated Annexin V (e.g., Alexa FluorTM647-
Annexin V, Biolegend), vortex mix in order to ensure even dis-
tribution of the stain) for 15 min at room temperature while
protected from light;
4. Wash cells in Annexin V Binding Buffer and resuspend cells in
250 µL fresh buffer;
5. Transfer cells to 12× 75mm polypropylene tubes, stored on ice
protected from light before being analyzed by flow cytometry;
6. Immediately prior to analysis, add DNA-binding dye (PI: 5 µL,
200 µg/mL, 7-AAD: 4 µL, 250 µg/mL] to allow identification,
and exclusion, of any nonviable cells.
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Figure 39. Identifying healthy and apoptotic cells based on Annexin V
staining. The human prostate cancer cell line LNCap was seeded into
six-well plates and allowed to adhere overnight. The following day,
cells were left untreated (A) or incubated for 6 h with 4 µg/mL human
recombinant granzyme B [323, 324] (B). After the incubation period, cells
were harvested and processed as described above, with 105 cells being
stainedwithAlexa-Fluor R© 647AnnexinV (following themanufacturer’s
instructions) and PI (final concentration 1 µg/mL). Cells were analyzed
on a Beckman Coulter GalliosTM flow cytometer. Plotting Annexin V
binding on the x-axis of a 2Ddot/density plot and PI/7-AADon the y-axis
enables the identification of healthy (Annexin VnegativePI/7-AADnegative,
bottom left quadrant), apoptotic (Annexin VpositivePI/7-AADnegative, bot-
tom right quadrant) and late apoptotic/dead (Annexin VpositivePI/7-
AADpositive, top right quadrant) cells. The cells incubated in the pres-
ence of granzyme B showed induction of apoptosis and increased cell
death.
Although Annexin V staining is probably the most commonly
used approach used for determining apoptosis, others can be used.
For instance, the terminal deoxynucleotidyltransferase (TdT)-
mediated dUTP nick end labeling (TUNEL) method involves label-
ing the ends of DNA breaks with dUTP using TdT. These labeled
breaks can then be detected using an anti-BrdU antibody. In
this case, fixation is required. However, given that this approach
depends on DNA damage rather than staining actual components
of the apoptotic pathway, it can be insensitive. Another alternative
to the Annexin V assay is the Violet Ratiometric Membrane Asym-
metry Probe, F2N12S from ThermoFisher. This probe is excitable
at 405 nm and detects variations in surface charge associated with
PS flipping. Viable cells produce an orange emission that shifts to
green with apoptosis, resulting in a decreased orange/green emis-
sion ratio.
The later stages of apoptosis involve chromatin condensation
and DNA fragmentation, a consequence of which is that the nuclei
of apoptotic cells become smaller than those of viable cells and
display higher fluorescence when labeled with dyes such as UV
excited Hoechst 33342 (which is available from a number of sup-
pliers and is also excited at 405 nm) or 405 nm-excited VybrantTM
DyeCycleTM Violet stains (ThermoFisher). When paired with an
impermeable dead cell stain, it is possible to distinguish live, apop-
totic, and necrotic cell populations using such chromatin conden-
sation assays.
The loss of mitochondrial membrane potential is another hall-
mark of early apoptosis [325]. In cells undergoing apoptosis, the
mitochondria will release cytochrome C and the apoptosis induc-
ing factor—both of which are necessary for caspase activation (yet
another critical step in apoptosis). It is also possible to assess apop-
tosis based onmitochondrial membrane polarization using fluores-
cent dyes such as JC-1 (5,5 ,6,6 -tetrachloro- 1,1 ,3,3 -tetraethyl-
benzimidazol-carbocyanine) or JC-10 that can be obtained from
a number of different suppliers. As the mitochondrial potential
is lost during apoptosis, the emission shifts from red to green,
thereby resulting in a decreased red/green fluorescence ratio. The
principle of this approach is that the dye accumulates in healthy
mitochondria, in which it is present as amultimer. Upon disruption
of the mitochondrial membrane, the dye is released, and changes
color due to it transforming into a monomer in the cytoplasm.
DiIC1(5) (1,1 3,3,3 3 -hexamethylindocarbocynanine iodide)
is another positively charged dye that accumulates in active mito-
chondria. It is excited at 635 nm and is read in the APC channel
(peak emission 658 nm). The fluorescence intensity of DiIC1(5)
decreases as membrane potential is lost. MitoTracker Red CMXRos
is another useful mitochondrial probe that is optimally excited at
561 nm, and to a lesser extent 488 nm, and read in the phycoery-
thrin (PE) channel (peak emission 599 nm). CMXRos also shows
a decrease of fluorescence as membrane potential is lost.
A key issue to be aware of is that the sample preparation
process can all lead to preferential loss of apoptotic cells during
sample preparation (i.e., prolonged trypsinization, mechanical or
enzymatic disaggregation from tissues, centrifugation steps). It is
therefore important to collect cells that have been released into the
media when experimenting with adherent cell cultures. Density
gradient separation of cells can also selectively deplete apoptotic
cells due to differing relative densities.
7.2 Apoptosis: Caspase activation
A distinctive feature of the early stages of apoptosis is the acti-
vation of caspase enzymes. The caspases constitute a family of
aspartate-specific cysteine proteases that cleave protein substrates
at specific amino acid residues. This triggers a sequence of cleav-
age events, including the cleavage of other caspases, and generates
a caspase signaling cascade that leads to apoptosis. In mammals,
the “initiator” caspases-2, -8, -9, -10, and -12 are closely coupled
to upstream, pro-apoptotic signals, and cleave and activate down-
stream effector or “executioner” caspases-3, -6, and -7 that modify
the proteins that ultimately drive apoptosis [326, 327]. In most
cases, caspase activation is one of the earliest measurable mark-
ers of the apoptotic cascade, and precedes the induction of cell
permeability, DNA fragmentation, cytoskeletal collapse, and the
“flipping” of PS. The pivotal and early involvement of mitochon-
dria and caspases in cell death events has prompted the develop-
ment of several assays that can be applied alone, or in conjunc-
tion with assays for detecting other aspects of the cell death pro-
cess [325, 328]. Several commercial suppliers provide validated
assays for the detection of apoptosis based on caspase activation.
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Figure 40. Identifying healthy and apoptotic cells based on the expres-
sion of activated caspase-3. Thehumanbreast cancer cell lineMDA-MB-
231 was seeded into six-well plates and allowed to adhere overnight.
The next day, cells were left untreated or incubated for 24 h with the
topoisomerase I inhibitor camptothecin (4 µg/mL, induces apoptosis).
After the incubation period, cells were harvested and stained using
the FITC active caspase-3 apoptosis kit (BD Biosciences) following the
manufacturer’s instructions and analyzed on a BD Biosciences LSRII
flow cytometer. Cells were identified using FSc and SSc measurements
(A) and the expression of active caspase-3 determined on the basis of
FITC fluorescence (B; control sample shown on open histogram and
camptothecin treated shown on grey histogram).The cells incubated in
the presence of camptothecin showed activation of caspase-3
Caspase activation assays can involve the intracellular stain-
ing of cell populations using mAbs that are specific for the acti-
vated forms of the relevant caspase (Fig. 40), or can employ small
inhibitor peptides conjugated to a fluorophore that specifically
target the active site of the chosen caspase.
As an example, the CellEventTM Caspase-3/7 Green Detection
Reagent from ThermoFisher is a cell-permeable reagent consist-
ing of a four-amino acid peptide (DEVD) conjugated to a nucleic
acid-binding dye. The activation of caspase-3 and caspase-7 pro-
teins enables them to cleave the caspase 3/7 recognition sequence,
which is encoded in the DEVD peptide. Cleavage of the recognition
sequence and binding of DNA by the reagent labels the apoptotic
cells with a bright, fluorogenic signal that has absorption/emission
maxima of 511/533 nm. When used together with the SYTOXTM
AADvancedTM Dead Cell Stain, apoptotic cells can be easily dis-
criminated from live and necrotic cells.
Caspase activity can also be determined using the PhiPhiLuxTM
system, which employs a nonfluorescent substrate for the enzyme
that yields a fluorescent product if the enzyme is active. The
PhiPhiLuxTM caspase substrates are cell permeable, demonstrate
relatively good caspase specificity, possess high SNRs between
their uncleaved and cleaved forms, and have fluorescence spectral
properties that are compatible with other fluorescent probes. Apo-
Stat (R&D Systems) identifies and quantifies caspase activity in
apoptotic cells by irreversibly labeling cells with a cell permeable,
FITC-conjugated pan-caspase inhibitor (ApoStat). Any unbound
reagent diffuses out of the cell and is washed away, with an
increased fluorescence being indicative of caspase activity. The
CaspGLOWTM staining system detects active caspase-9 in mam-
malian cells using FITC-conjugated LEHD-fluoromethyl ketone, a
specific inhibitor of caspase-9, which is cell permeable and irre-
versibly binds to the active enzyme.
Another approach involves the use of a fluorescently labeled
inhibitor peptide that binds to the active site of the caspase or
FLICATM—Fluorescent-Labeled Inhibitor Caspase. FLICATM probe
based assays, which are available from a number of suppliers,
are composed of an affinity peptide inhibitor sequence, a fluo-
romethyl ketone moiety that facilitates an irreversible binding
event with the activated caspase enzyme, and a fluorescent tag
reporter. The FLICATM are therefore retained in apoptotic cells,
but not in non-apoptotic cells following washing. Necrotic and late
apoptotic cells can be concurrently identified in green FLICATM-
labeled cells using red fluorescent dyes such as PI or 7-AAD, or the
far red dye DRAQ7TM. The ability to measure three apoptotic phe-
notypes in a single assay provides a powerful and comprehensive
view of the apoptotic process, applicable to both suspension cells
by traditional flow cytometry.
The approach selected for measuring cell viability, cell death,
and apoptosis will very much depend on the experimental ques-
tion, the supplier of the reagents, and the analysis of the strengths
and weaknesses for each assay. Conventional internet searches
will readily identify the plethora of kits and approaches that can
be used for measuring caspase activation.
Useful resources.
See the “Useful resources” in DNA synthesis, cell cycle, and
proliferation
7.3 Necroptosis
7.3.1 Overview. Necroptosis is a form of cell death defined by
phosphorylation of the proteins mixed-lineage kinase domain-like
(MLKL) and receptor-interacting serine/threonine protein kinase
3 (RIPK3), induction of the RIPK3/MLKL complex, oligomeriza-
tion of MLKL, and membrane translocation of MLKL. Currently,
none of these biomarkers can be directly and unequivocally deter-
mined by FCM, which may make a section on necroptosis in these
guidelines seem foolhardy; however, once necroptosis has been
validated by, e.g., Western blot identification of the necroptosis-
specific biomarkers, FCM can be used for analysis of cells treated
under the same necroptosis-inducing conditions. Here, we discuss
current and future options to detect necroptosis by FCM. We also
present an easy and straightforward example protocol using dif-
ferences in DNA fragmentation to discriminate necroptosis from
apoptosis as a potential application of FCM to cell death assess-
ment, although it should be noted that this method still requires
that necroptosis be validated by alternative methods.
7.3.2 Introduction. By definition of the Nomenclature Commit-
tee on Cell Death, necroptosis is “a type of regulated cell death
triggered by perturbations of extracellular or intracellular home-
ostasis that critically depends on MLKL, RIPK3, and (at least in
some settings) on the kinase activity of RIPK1” [329]. In con-
trast to apoptosis, necroptosis culminates in the rupture of the
cell membrane and is associated with the release of intracellu-
lar danger-associated molecular patterns (DAMPs) and a strong
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inflammatory phenotype. As a consequence, necroptotic cell death
has been linked to diseases such as kidney and cardiac injury,
Alzheimer’s disease, atherosclerosis, rheumatoid arthritis, sepsis,
stroke, and cancer [330, 331]. Physiologically, necroptosis con-
tributes to immunosurveillance through the stimulation of innate
and adaptive immune responses that target malignant and infec-
tious threats [330, 332]. Furthermore, necroptosis ensures the
elimination of potentially defective organisms before parturition,
thereby contributing to developmental safeguard programs, and
is involved in the maintenance of adult T-cell homeostasis [333].
At the molecular level, all triggers of necroptosis (such as death
receptors, pathogen recognition receptors, or the receptor for type
I IFNs) invariably induce the activation of RIPK3. This is accom-
plished via proteins that contain an RIP homotypic interaction
motif (RHIM), i.e., RIPK1, TRIF, or DAI. The RHIM-mediated inter-
action of RIPK1, TRIF, or DAI with RIPK3 causes oligomerization,
activation, and phosphorylation of RIPK3 at S227 (in humans) or
S232 (in mice). Phosphorylated RIPK3 subsequently binds to the
second essential core protein of necroptosis, MLKL, and phospho-
rylates MLKL at T357/S358 (in humans) or S345 (in mice). This
results in oligomerization, translocation, and probably insertion
of MLKL into the plasma membrane where it elicits rupture of the
plasmamembrane [332]. Inhibitors of necroptosis can prevent this
process, e.g., necrostatin-1s (RIPK1 inhibitor), GSK’840, GSK’843,
GSK’872 (RIPK3 inhibitors), or necrosulfonamide (targets human,
but not mouse MLKL) [334], and sometimes can even switch
necroptotic cell death back to apoptosis, although this switch
mainly applies to the RIPK3 inhibitors [335]. Of note, caspase-8
has been identified as a physiologic negative regulator of necrop-
tosis, supposedly by cleaving and inactivating RIPK1 [336], RIPK3
[337], and the deubiquitinase CYLD [338]. As a consequence,
interference with the enzymatic activity of caspase-8, e.g., by
the broad-spectrum caspase inhibitors benzyloxycarbonyl-Val-Ala-
Asp(OMe)-fluoromethylketone (zVAD-fmk), Q-VD-OPh, or Emric-
asan, will not only inhibit apoptosis, but concurrently also enhance
necroptosis [331]. As a side note, although mitochondria and ROS
have been implicated in necroptosis [339], they are not essential
components [340] and a failure to detect ROS by FCM does not
necessarily rule out necroptosis. Therefore, we do not further dis-
cuss the flow cytometric measurement of mitochondrially derived
ROS and mitochondrial dysfunction here.
At present, the only factors common and specific for all triggers
of necroptosis are phosphorylation of MLKL and RIPK3, forma-
tion of the RIPK3/MLKL complex, oligomerization of MLKL, and
membrane translocation of MLKL [341]. Therefore, any FCM pro-
tocol aiming to deliver definite proof of necroptosis would have
to unequivocally demonstrate the appearance of one or more of
these biomarkers. Unfortunately, none of currently available pro-
tocols fulfills this requirement. To detect phosphorylation of MLKL
and RIPK3, the current method of choice is Western blot with Abs
that recognize phospho-T357/S358 or phospho-S345 in humans
or mouse MLKL and phospho-S227 or phospho-S232 in humans
or mouse RIPK3 [342]. The direct analysis of RIPK3 and MLKL
phosphorylation status by FCM may become an option in the
future, e.g., by adaptation of the BD PhosflowTM protocol. This
will, however, require appropriate Abs for detection of pMLKL and
pRIPK3 under near-native conditions (i.e., intracellular staining,
see Chapter III: “Before you start: Reagent and sample prepara-
tion, experimental design”, Section 5: “Cell fixation and permeabi-
lization for flow cytometric analyses”), which, to the best of our
knowledge, are currently not available. Likewise, formation of the
RIPK3/MLKL complex is generally determined by immunoprecip-
itation analyses, proof of MLKL oligomerization requires separa-
tion of the oligomers on nonreducing gels followed by Western
blot analyses, and evidence for membrane translocation of MLKL
is best obtained by immunostaining analyses or cell fractionation
followed by Western blots [341] rather than by flow cytometric
assays.
Nevertheless, once it has been established by one ormore of the
above assays that a particular treatment indeed induces necrop-
tosis in a specific cell system, FCM can serve as an easy and fast
method to detect and quantify the death of cells subjected to
the same treatment. Today, FCM is routinely used by hundreds
of laboratories worldwide to assess loss of membrane integrity
after treatment with necroptotic stimuli. The protocol is usually
identical to that used to detect apoptotic cells (see Chapter V:
“Biological Applications,” Section 7.1 “Apoptosis: Measurement of
apoptosis”), except that the cells are treated under conditions that
prevent apoptosis, e.g., in the presence of zVAD-fmk. Notably, by
inhibiting caspase-8, zVAD-fmk will not only block apoptosis but
concurrently enhance necroptosis. Furthermore, parallel staining
for PS externalization can be omitted since studies have recently
demonstrated that PS externalization can no longer be regarded as
a reliable marker to differentiate between apoptosis and necropto-
sis because PS is also externalized in necroptotic cells prior to loss
of membrane integrity [343, 344]. Instead, parallel measurements
of samples additionally treated with inhibitors of necroptosis (e.g.,
necrostatin-1s, GSK’840, GSK’843, GSK’872, or necrosulfonamide)
or flow cytometric exclusion of apoptotic caspase-3 activity (e.g.,
via the BD FITC Active Caspase-3 Apoptosis Kit) can ensure that
cells positive for stains such as PI, 7-AAD, or DRAQ7 (i.e., showing
loss of membrane integrity) are indeed necroptotic.
In addition to this straightforward approach, further proto-
cols have been developed to assess necroptosis by FCM but they,
like those noted above, have caveats. Lee and co-workers have
recently described the simultaneous flow cytometric immunophe-
notyping of necroptosis, apoptosis, and RIPK1-dependent apop-
tosis, employing fluorescently tagged Abs that target RIPK3 and
active caspase-3 in combinationwith a fixable live dead fluorescent
dye [345]. This assay scores cells that show upregulation of RIPK3
as necroptotic; however, Moriwaki et al. have recently shown that
RIPK3 has necroptosis- and kinase-independent functions in pro-
moting reparative cytokine expression in tissue repair [346] and,
therefore, detecting upregulation of RIPK3 by itself is not unequiv-
ocal evidence for necroptosis. Pietkiewicz et al. [347] have devel-
oped an approach that uses a combination of imaging flow cytome-
try with classical Annexin V/PI staining. Their protocol uses image-
based analysis of nuclear morphology to differentiate between sec-
ondary necrotic/late apoptotic and necroptotic cells, a distinction
that cannot be achieved by mere flow cytometric measurement
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Figure 41. (A) BxPC-3 pancreatic adenocarcinoma cells were left untreated (top) or stimulated to elicit apoptosis (middle) or necroptosis (bottom).
The left panels show dot plots of cell size (FSC-H) versus granularity (SSC-H) (relevant cell populations gated as gate A). The middle panels show
dot plots of Pulse Width versus Pulse Area of the PI fluorescence channel to gate for singlets (gate B). The right panels depict the respective cell
cycle profiles, with percentages of hypodiploid (sub-G1) cells indicated. (B) BxPC-3 cells were treated as in A and analyzed for loss of membrane
integrity by PI staining. The percentages of PI-negative and PI-positive cells are indicated in the lower and upper right corners of the dot plots.
of PS exposure and loss of membrane integrity [343, 347]. The
comparison of the morphology of ANX-V/PI double positive cells
using imaging flow cytometry [347] or the difference in kinetics
of ANX-V exposure using live microscopy [343] could be used in
the future to differentiate apoptosis and necroptosis. However, not
every laboratory has access to an imaging flow cytometer limiting
the applicability of this approach.
We detail below an easy and straightforward protocol to detect
necroptosis by conventional FCM, although this still needs the val-
idation step of an alternative method for necroptosis confirmation.
This protocol takes advantage of the fact that the DNA fragmenta-
tion caused by caspase activation in apoptotic cells does not occur
in necroptotic cells [348]. Therefore, necroptosis and apoptosis
can be discriminated via simple cell cycle analysis (i.e., detection
of the fraction of hypodiploid (sub-G1) cells, see also Chapter
V: “Biological Applications,” Section 6.1: “DNA synthesis and cell
cycle analysis”). Necroptotic, in contrast to apoptotic, cells do not
show DNA fragmentation as detected in the cell cycle profile as
sub-G1 cells (Fig. 41A). In parallel, PI staining can be used to ver-
ify loss of membrane integrity (Fig. 41B). We want to stress that
although the protocol below is given for a specific setting ((TNF-
related apoptosis-inducing ligand (TRAIL)-induced necroptosis in
human BxPC-3 pancreatic adenocarcinoma cells), it can easily be
adapted to any cell line/type and treatment that elicits necropto-
sis.
The protocol for cell cycle staining described here is an alter-
native protocol that we have applied successfully for other cell
types revealing a satisfactory resolution of the cell cycle pro-
file [349–351]. However, we point out that an incubation of at
least 24 h at –20°C after the addition of 100% v/v ethanol or
using a final concentration of 70% v/v instead of 50% v/v ethanol
may improve the resolution of the cell cycle profiles if required.
7.3.3 Step-by-step sample preparation and assay protocol.
1. Seed 1× 105 BxPC-3 cells in 12-well plates in 1mLRPMI 1640
medium supplemented with 10% v/v FBS, 2 mM L-glutamine,
1 mM sodium pyruvate, and 50 µg/mL each of streptomycin
and penicillin. Prepare two wells for each condition that you
want to analyze. Prepare an additional well per condition for
conventional analysis of loss of membrane integrity (step 20).
2. Let the cells grow for 24 h at 37°C in a humidified incubator
containing 5% v/v CO2.
3. Remove the old medium.
4. For induction of necroptosis, pre-incubate the cells for 30 min
at 37°C in 1 mL of fresh medium that contains 20 µM zVAD-
fmk and 0.5 µMhomoharringtonine (a patient-approved drug
that sensitizes cancer cells for necroptosis [352]). Cyclohex-
imide can be used instead. Optimal concentrations must be
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determined for each cell system. For induction of apoptosis,
omit zVAD-fmk.
5. Add 100 ng/mL KillerTRAILTM and incubate the cells for 16
h at 37°C.
6. Transfer the medium together with any detached cells into
Falcon R© 5 mL polystyrene round bottom test tubes that are
placed on ice. Pool the two wells that you have set up for the
same condition in step 1.
7. Wash the wells with 300 µL PBS, pool into the same 5 mL
tube.
8. Add 300 µL StemProTM AccutaseTM Cell Dissociation Reagent
to each well, incubate for 10–15 min at 37°C to detach all
remaining cells and pool everything into the same 5 mL tube.
9. Repeat step 7.
10. Collect the cells by centrifugation at 4°C (5 min, 400 x g),
wash twice with cold PBS.
11. Resuspend the cells in 500 µL cold PBS/5 mM EDTA.
12. Fix the cells by dropwise addition of 500 µL 100% v/v ethanol
while vortexing.
13. Incubate at room temperature for 30 min (or >24 h at –20°C
to get the best resolution if required).
14. Collect the cells by centrifugation at 4°C (5 min, 560 x g). Be
careful to avoid cell loss.
15. Resuspend the cells in 200 µl cold PBS/5 mM EDTA.
16. Add RNase A to a final concentration of 40 µg/mL.
17. Incubate for 30 min at room temperature.
18. Add 200 µL PI (50 µg/mL in PBS/5 mM EDTA stock solution)
and stain for 30 min at 4°C.
19. Measure your cells in a suitable flow cytometer, such as the
BD FACSCaliburTM.
20. To additionally verify that loss of membrane integrity, i.e.,
necroptotic or apoptotic cell death has occurred, process the
third well from step 1 as outlined above for steps 2–10. After
step 10, resuspend the cells in 100 µL cold PBS/5 mM EDTA,
add 100 µL PI (4 µg/mL in PBS/5 mM EDTA stock solu-
tion) and immediately measure your cells in a suitable flow
cytometer, such as the BD FACSCaliburTM.
7.3.4 Materials.
 BxPC-3 pancreatic adenocarcinoma cell line: ATCC R© CRL-
1687TM, American Type Culture Collection, Manassas, VA, USA.
 Twelve-well plates: CELLSTAR R© Cell Culture Multiwell Plates,
catalog no. 665180, Greiner Bio-One, Frickenhausen, Germany.
 RPMI 1640 medium: catalog no. 52400, ThermoFisher Scien-
tific, Dreieich, Germany.
 Fetal bovine serum: catalog no. 10270, ThermoFisher Scientific,
Dreieich, Germany
 L-Glutamine: catalog no. K 0202, Merck, Berlin, Germany
 Sodium pyruvate: catalog no. 11360, ThermoFisher Scientific,
Dreieich, Germany
 Penicillin/streptomycin: catalog no. A 2212, Merck, Berlin, Ger-
many
 zVAD-fmk: catalog no. 4026865, Bachem, Weil am Rhein, Ger-
many
 Homoharringtonine: catalog no. sc-202652, Santa Cruz, Hei-
delberg, Germany
 KillerTRAILTM: catalog no. ALX-201-123, Enzo, Lo¨rrach, Ger-
many
 Falcon R© 12 x 75mm, 5mL polystyrene round bottom test tubes:
catalog no. 352054, Corning, Wiesbaden, Germany
 StemProTM AccutaseTM Cell Dissociation Reagent: catalog no.
A1110501, ThermoFisher Scientific, Dreieich, Germany
 RNase A: catalog no. 19101, Qiagen, Hilden, Germany
 PI: catalog no. P4170, Merck, Darmstadt, Germany
 BD FACSCaliburTM Flow Cytometer: BD Biosciences, Heidel-
berg, Germany
 BD CellQuestTM Pro software: BD Biosciences, Heidelberg, Ger-
many
7.3.5 Data analysis. The data can be acquired using the acqui-
sition software provided with the flow cytometer, e.g., the BD
CellQuestTM Pro software. Analysis can be done with either the
software used for data acquisition or with any suitable FCM data
analysis software.
Data acquisition for cell cycle analysis is described in detail in
Chapter V: “Biological Applications,” Section 6.1: “DNA synthesis
and cell cycle analysis.” Briefly, PI as DNA-binding dye is excited
at 488 nm (blue laser) and emits at a maximum wavelength of
617 nm. Thus, PI fluorescence can either be detected using a BP
filter 585/42 (FL2 channel of the FACSCalibur flow cytometer)
or using a 670 nm LP filter (FL3 channel of the FACSCalibur flow
cytometer) or a 695/40 BP filter. Instrument settings have to be set
for the PI fluorescence channel on linear fluorescence scale and the
threshold should be set on the same channel with a low value such
as 20. For sample acquisition and analysis, three sequential plots
are needed: dot plot 1: FSC-H versus SSC-H to gate for relevant cell
population(s) (gate A); dot plot 2: Pulse Width versus Pulse Area
of the PI fluorescence channel set on gate A to exclude doublets
and to gate singlets as gate B; histogram 1: Pulse Area of the PI
fluorescence channel gated on gate B. In total, 10 000–20 000
events in gate B should be collected. A typical result is shown in
Fig. 41A. Dot plots 1 are depicted at the left, dot plots 2 in the
middle, the respective histograms are shown at the right. In the
histograms, a marker is placed on sub-G1 cells displaying lower
staining intensity than the cell cycle profile, indicating apoptotic
cells with fragmented and therefore lost DNA. In the dot plots, you
can see a shift of the cell population to smaller and less granular
cells as typical sign for cell death in both apoptotic as well as
necroptotic cells.
Using DNA-binding dyes for quantification of dead cells is
described in Chapter III: “Before you start: reagent and sam-
ple preparation, experimental design,” Section 4.2: “DNA-binding
dyes.” For data acquisition using PI as the DNA-binding dye, instru-
ment settings have to be set for the used PI fluorescence channel
on logarithmic scale and the threshold should be set on FSC to
exclude debris and small cell fragments. For sample acquisition
and analysis, two sequential plots are needed; dot plot 1: FSC-
H versus SSC-H to gate for relevant cell population(s) (gate A),
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thereby excluding debris and small cellular fragments; dot plot
2: FSC-H versus the respective PI channel set on gate A. In total,
10 000–20 000 events in gate A should be collected. A typical result
is shown in Fig. 41B using the same cells and stimulations as used
for Fig. 41A. The percentages of PI-negative and PI-positive cells
are indicated in the respective dot plot 2. A similar increase in
the amount of PI-positive cells is detected in apoptotic as well as
necroptotic samples. In summary, the two cell death modes, apop-
tosis and necroptosis, can be distinguished by cell cycle analysis,
while quantification of cell death can be achieved by the simple
method of PI staining.
7.3.6 Pitfalls/Top tricks. Please see Chapter V: “Biological Appli-
cations,” Section 7.4: “Pyroptosis.”
7.4 Pyroptosis
7.4.1 Overview. Cell death by pyroptosis critically depends on
cleavage of gasdermin proteins by inflammatory caspases, fol-
lowed by oligomerization and membrane translocation of the gas-
derminN-terminal fragment. At present, FCM cannot directly track
these events and the only definitive proof of pyroptosis is, e.g.,
by Western blot to detect cleavage of the protein gasdermin D
(GSDMD). Yet, pyroptotic cells can be detected indirectly by FCM
once pyroptosis has been confirmed. In this section, we present
the currently available options to assess pyroptosis by FCM. In
addition, we provide an example protocol to detect activation of
inflammatory caspases as an indirect indicator for pyroptosis, not-
ing that this method still requires that pyroptosis be validated by
alternative methods but its inclusion in these guidelines is to indi-
cate the potential application of FCM to a variety of cell death
mechanisms.
7.4.2 Introduction. The Nomenclature Committee on Cell Death
defines pyroptosis “as a form of regulated cell death that critically
depends on the formation of plasma membrane pores by mem-
bers of the gasdermin protein family, often (but not always) as
a consequence of inflammatory caspase activation” [329]. Pyrop-
tosis is a variant of regulated cell death that combines features
of both apoptosis and necroptosis. Similar to apoptosis, pyrop-
totic cell death depends on caspase activation. On the other
hand, rupture of the cell membrane and the release of DAMPs
are features shared with necroptosis, classifying pyroptosis as an
intensely inflammatory from of regulated cell death [353]. Pyrop-
tosis occurs in response to microbial infection and has a critical
role in immunity against intracellular pathogens [354]. Pyroptosis
disrupts infected cells and thereby causes the release of intracel-
lular pathogens, making them accessible to killing and phago-
cytosis by neutrophils. The concurrent release of DAMPs and of
the inflammatory cytokines IL-1β and IL-18 recruits additional
immune cells, ensuring a robust inflammatory response of both
the innate and the adaptive immune system [353, 355]. However,
pyroptosis can also drive pathogenic inflammation, i.e., in lethal
septic shock [353, 356]. Pyroptosis is mostly observed in profes-
sional phagocytes, but can also occur in other cell types [357].
Triggers of pyroptosis encompass bacteria and viruses as well as
their products, i.e., LPS and viral DNA [358].
The key molecular event in pyroptosis is caspase-mediated
cleavage of GSDMD. Different from apoptosis, the relevant cas-
pases belong to the inflammatory, not the apoptotic subtype
(i.e., caspases-1, -4, and -5 in humans, and caspases-1 and -
11 in mice) [354, 357]. As an exception, the apoptotic cas-
pase caspase-3 can also induce pyroptosis by cleavage of the
GSDMD-related protein gasdermin E [332]. GSDMD-dependent
pyroptosis can be triggered by two pathways, the canonical
or the noncanonical pathway. In the canonical pathway, cel-
lular stressors such as bacterial or viral pathogen signatures
are recognized by pattern-recognition receptors. Together with
the adapter protein ASC, these pattern-recognition receptors
form complexes (“inflammasomes”), which recruit and activate
caspase-1. In the noncanonical pathway, human caspases-4 and
-5 or mouse caspase-11 are directly activated by cytosolic LPS
from Gram-negative bacteria [332, 354]. In both pathways, cas-
pase activation results in cleavage of GSDMD and release of its
N-terminal domain (GSDMD-N). GSDMD-N then inserts into the
plasma membrane of the cell (or into the bacterial plasma mem-
brane) and causes membrane rupture and pyroptotic cell death
[332, 354].
Given that cleavage of GSDMD as well as membrane translo-
cation and oligomerization of GSDMD-N are the only definitive
biomarkers for pyroptosis, the options for direct flow cytometric
detection of pyroptosis are as equally limited as for necroptosis
(see Chapter V: “Biological Applications,” Section 7.3 “Necropto-
sis”). At present, the bestmethod to detect cleavage of GSDMD into
the 31-kDa GSDMD-N fragment is Western blot using GSDMD-
N-specific Abs. Membrane translocation of GSDMD-N can be
shown via cell fractionation with subsequent Western blot or via
immunostaining, and oligomerization of GSDMD-N can be con-
firmed by nonreducing gel electrophoresis and Western blot.
Although direct flow cytometric detection of these biomark-
ers is not possible at present, the above assays can be performed
to initially ensure that pyroptosis is induced by a specific treat-
ment condition. Subsequently, FCM can be utilized to routinely
detect pyroptotic loss of membrane integrity in identically stim-
ulated cells (PI staining, see also Chapter III: “Before you start:
reagent and sample preparation, experimental design,” Section
4.2: “DNA-binding dyes.” and Chapter V: “Biological Applications,”
Section 7.3 “Necroptosis”). As a further limitation, parallel con-
trol measurements of samples additionally treated with pyrop-
tosis inhibitors are not possible because inhibitors that directly
and specifically target GSDMD-N are currently not commercially
available. As a workaround, cells can be treated with VX-765, an
inhibitor of caspase-1, or with MCC950, an inhibitor of NLRP3
inflammasome activation, although inhibition of caspase-1 or the
inflammasome may elicit cellular responses beyond inhibition of
pyroptosis.
Alternatively, it is possible to employ FCM to detect inflamma-
some formation as an indirect indicator for canonical pyroptosis
induction. Normally, the inflammasome component ASC is dif-
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fusely distributed within the cell, but relocates to a dense speck in
the cytosol within minutes of inflammasome activation. Sester and
colleagues have employed FCM to monitor ASC redistribution in
primary macrophages and monocytes, detecting changes in fluo-
rescence peak height and width of immunostained or fluorescently
tagged ASC as detailed in ref. [359].
A separate approach to assess pyroptosis by FCM exploits
the fact that pyroptosis depends on the activation of inflamma-
tory caspases. Upon addition of a green, cell permeant FLICATM
reagent such as fluorescein-6-carbonyl-Tyr-Val-Ala-DL-Asp(OMe)-
fluoromethylketone (FAM-YVAD-fmk), activated caspases-1, -4,
and -5 covalently and irreversible bind to FAM-YVAD-fmk and
become accessible to quantification by FCM as an indirect mea-
sure for the initiation of pyroptosis. Below, we outline a protocol
to quantify the activation of caspases-1, -4, and -5 in nigericin-
treated pyroptotic human BxPC3 pancreatic adenocarcinoma cells
(a cell line for which pyroptosis has been demonstrated [360]) by
conventional FCM (Fig. 42A), or to simultaneously confirm loss of
membrane integrity by PI staining (Fig. 42B). Although represent-
ing a specific example, the protocol can easily be modified for any
treatment that triggers pyroptosis in a particular cell line. It should
be re-stated that this method needs to be used in conjunction with
alternative validation of pyroptosis.
7.4.3 Step-by-step sample preparation and assay protocol.
1. Seed 1 x 105 BxPC3 pancreatic adenocarcinoma cells in 12-
well plates in 1 mL RPMI 1640 medium supplemented with
10% v/v FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, and
50 µg/mL each of streptomycin and penicillin. Prepare three
wells for each condition that you want to analyze.
2. Let the cells grow for 24 h at 37°C in a humidified incubator
containing 5% v/v CO2.
3. Reconstitute the lyophilized nigericin contained in the
Pyroptosis/Caspase-1 Assay Kit with 100 µL DMSO, yield-
ing a 5 mM stock solution. The stock solution can be stored
at –20°C for 1 year, provided that it is protected from light
and thawed maximally two times.
4. Dilute the nigericin stock solution with sterile ultrapure water
to a working concentration of 500 µM immediately before
use.
5. Remove the old medium from the cells.
6. To initiate pyroptosis, preincubate the cells for 1 h at 37°C in
300 µL of fresh medium that contains 20 µM nigericin (opti-
mal concentrations must be determined for each cell system).
7. Reconstitute a vial with lyophilized FLICATM contained in the
Pyroptosis/Caspase-1 Assay Kit with 50 µL DMSO, yielding a
150–300× stock solution. The stock solution can be stored at
–20°C for 6 months, provided that it is protected from light
and thawed maximally two times.
8. Dilute the FLICATM stock solution 1:5 with sterile PBS to a
30–60× working solution and immediately add the working
solution to the cells in two wells of each condition at a final
concentration of 1–2×.
9. Incubate the cells for 48 h at 37°C, protected from light.
10. Dilute 10× Cellular Wash Buffer contained in the
Pyroptosis/Caspase-1 Assay Kit to 1× with ultrapure water.
11. Transfer the medium together with any detached cells into
Falcon R© 5 mL polystyrene round bottom test tubes that are
placed on ice.
12. Add 300 µL 1x Cellular Wash Buffer to each well, incubate for
10 min at 37°C (this allows any unbound FLICATM to diffuse
out of the cells). Remove the Wash Buffer and transfer into
the 5 mL tube from step 11.
13. Repeat step 12 twice.
14. Add 300 µL StemProTM AccutaseTM Cell Dissociation Reagent
to each well, incubate for 10–15 min at 37°C to detach all
remaining cells and transfer everything into new Falcon R© 5
mL polystyrene round bottom test tubes.
15. Wash the wells with 300 µL 1× Cellular Wash Buffer, transfer
everything into the 5 mL tubes from step 14.
16. Centrifuge the 5 mL tubes from step 13 and from step 15 at
4°C (5 min, 400 × g) to collect all cells.
17. Discard the supernatants and wash the cells twice with cold
1× Cellular Wash Buffer. Be careful to avoid cell loss.
18. Resuspend and combine the cells from the two corresponding
tubes from steps 13 and 15 in a total of 300 µL cold 1×
Cellular Wash Buffer and place on ice.
19. For single-color analysis or for a single-color compensation
control (caspase-1 activity), measure the cells (from the first
well treated with FLICATM) by FCM within 4 h or fix for
analysis within 16 h by adding Fixative contained in the
Pyroptosis/Caspase-1 Assay Kit at a v/v ratio of 1:5. Store
your samples protected from light and at 4°C. For dual-color
analyses (caspase-1 activity and loss of membrane integrity),
add 2 µg/mL PI to the cells from the second well treated with
FLICATM and analyze immediately as such assays cannot be
performed using fixed cells. For a single-color compensation
control (loss of membrane integrity), use the cells from the
third well (not treated with FLICATM), add 2 µg/mL PI and
analyze immediately.
20. Measure your cells in a suitable flow cytometer, such as the
BD FACSCaliburTM.
7.4.4 Materials.
 BxPC-3 pancreatic adenocarcinoma cell line: ATCC R© CRL-
1687
TM
, American Type Culture Collection, Manassas, VA, USA.
 Twelve-well plates: CELLSTAR R© Cell Culture Multiwell Plates,
catalog no. 665180, Greiner Bio-One, Frickenhausen, Germany.
 RPMI 1640 medium: catalog no. 52400, ThermoFisher Scien-
tific, Dreieich, Germany.
 FBS: catalog no. 10270, ThermoFisher Scientific, Dreieich, Ger-
many.
 L-Glutamine: catalog no. K 0202, Merck, Berlin, Germany.
 Sodium pyruvate: catalog no. 11360, ThermoFisher Scientific,
Dreieich, Germany.
 Penicillin/streptomycin: catalog no. A 2212, Merck, Berlin, Ger-
many.
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Figure 42. (A) Single-parameter analysis of BxPC-3 cells left untreated or treated with nigericin for 48 h and analyzed for caspase-1 activity by
FAM-FLICA staining (48 h were determined in previous experiments as optimal to achieve the best separation between the FAM-FLICA-positive
and the FAM-FLICA-negative population). FSC-H versus SSC-H dot plot is depicted on top, the respective histogram is presented at the bottom.
The percentages of FAM-FLICA-positive cells in untreated and nigericin-stimulated cells are indicated in the upper right corner of the histogram.
(B) Dual parameter analysis of BxPC-3 pancreatic adenocarcinoma cells either untreated for 48 h or stimulated with nigericin for 48 h to induce
pyroptosis (cells are from the same experiment as shown in (A) but from a parallel stimulation). For each sample (untreated and treated cells)
FSC-H versus SSC-H dot plots are shown on the left and PI versus FAM-FLICA on the right. The compensation gating is not shown. This flow
cytometric analysis also needs pyroptosis to be validated by methods such as Western blot.
 Pyroptosis/Caspase-1 Assay Kit containing nigericin, FAM-
YVAD-fmk, CellularWash Buffer and Fixative, catalog no. 9146,
ImmunoChemistry Technologies, Bloomington, MN, USA.
 Falcon R© 12 × 75mm, 5 mL polystyrene round bottom test
tubes: catalog no. 352054, Corning, Wiesbaden, Germany.
 StemProTM AccutaseTM Cell Dissociation Reagent: catalog no.
A1110501, ThermoFisher Scientific, Dreieich, Germany.
 PI: catalog no. P4170, Merck, Darmstadt, Germany.
 BD FACSCaliburTM Flow Cytometer: BD Biosciences, Heidel-
berg, Germany.
 BD CellQuestTM Pro software: BD Biosciences, Heidelberg, Ger-
many.
7.4.5 Data analysis. Data can be acquired using the acquisition
software provided with the flow cytometer, for example, the BD
CellQuestTM Pro software. Analysis can be done with either the
software used for data acquisition or with any suitable FCM data
analysis software. For data analysis, follow the manual provided
with the Pyroptosis/Caspase-1 Assay Kit. The FAM-FLICA reagent
is excited at 488 nm (blue laser) and has a peak emission at
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515–535 nm. Thus, FAM-FLICA fluorescence can be detected using
a BP filter 530/30 (FL1 channel of the FACSCalibur flow cytome-
ter). For single-staining, instrument settings have to be set for
the FAM-FLICA fluorescence channel on logarithmic fluorescence
scale and the threshold should be set on FSC to exclude small cel-
lular fragments and debris. For sample acquisition and analysis,
two sequential plots are needed: an FSC-H versus SSC-H dot plot
to gate on the population of interest (gate A) and a histogram
plot with the log FAM-FLICA fluorescence on the x-axis versus the
number of cells on the y-axis set on gate A. Adjust the voltage
of the FAM-FLICA fluorescence channel, if necessary, to ensure
that fluorescence is on scale and caspase-negative (FAM-FLICA-)
cells appear within the lower log fluorescence output decades of
the x-axis. Caspase-positive (FAM-FLICA+) cells will appear as a
shoulder or as a separate peak shifted to the right side of the neg-
ative peak. A typical result demonstrating a histogram overlay of
negative and positive cells is shown in Fig. 42A. The gate is set on
FAM-FLICA-positive cells and their percentages in untreated and
nigericin-stimulated cells are indicated in the upper right corner
of the histogram.
For dual-color analyses using additionally PI as DNA-binding
dye, first run each single-color untreated control. PI is excited at
488 nm (blue laser) and emits at a maximum wavelength of 617
nm. Thus, PI fluorescence can either be detected using a BP fil-
ter 585/42 (FL2 channel of the FACSCalibur flow cytometer) or
using a 670 nm LP filter (FL3 channel of the FACSCalibur flow
cytometer) or a 695/40 BP filter. To determine the correct instru-
ment settings, use the single-color untreated cells and analyze two
dot plots, FAM-FLICA-fluorescence versus FSC-H and PI fluores-
cence versus FSC-H (use a logarithmic fluorescence scale for both
channels) set on gate A. Adjust the voltages for both fluorescence
channels so that PI- or FAM-FLICA-negative cells appear in the
lower log fluorescence output decades. For compensation, use the
single-color nigericin-treated cells as compensation controls (see
Chapter II: “Setup: Instrument setup and quality control,” Section
1: “Compensation”).
For sample acquisition and analysis, the following gating steps
are required. First, FSC-H versus SSC-H to gate for the relevant cell
population(s) (gate A). Second, FAM-FLICA-fluorescence versus
PI fluorescence set on gate A is used to quantify double-negative
cells (healthy), single-FAM-FLICA-positive cells (containing acti-
vated caspase-1 without signs of pyroptosis), single-PI-positive
cells (undergoing cell death independently of caspase-1) and
double-positive cells (undergoing pyroptosis). In total, 10 000–
20 000 events in gate A should be collected. A typical result is
shown in Fig. 42B.
7.4.6 Pitfalls/Top tricks. When studying necroptosis, to obtain
credible results, it is imperative that your cells are mycoplasma-
negative because mycoplasma express large amounts of nucle-
ases [361], and you will detect false-positive DNA fragmentation
in necroptotic cells if cells are contaminated. Also, using NIH3T3
cells may be problematic as various sublines exist that differ in
their disposition to undergo necroptosis with or without caspase
inhibition [362], thus possibly leading to mixed cell death mech-
anisms. However, in our proposed protocol, cell cycle staining
showing fragmented DNA as sub-G1 cells would clearly reveal such
a mixed cell death mechanism by demonstrating more PI-positive
cells (general cell death) than sub-G1 cells (purely apoptosis).
When studying pyroptosis, protect samples containing FAM-
YVAD-FMK from light. Also, the optimal time-point to achieve the
best separation between the FAM-FLICA-positive and the FAM-
FLICA negative population has to be determined individually for
each cell line. In dual-color analyses for pyroptosis, more PI-
positive cells may be detected than in single-color PI analyses due
to the more extensive washing and handling of the cells. As an
additional point to take note of, binding of FLICA reagents to their
target sequence is generally not as caspase-specific as originally
thought because of the FMK group reactivity with thiol groups of
intracellular proteins that become available upon caspase cleav-
age [363]. Nevertheless, and despite this apparent lack of absolute
specificity, FLICA probes have consistently shown themselves to
be highly reliable reporters of caspase activation [364] and the
assay presented here has been successfully used to detect caspase-
1 activation in recent studies [365, 366].
It is recommended to consult Chapter III: “Before you start:
Reagent and sample preparation, experimental design,” Section
4.2: “DNA-binding dyes,” Chapter V: “Biological Applications,”
Sections 6.1: “DNA synthesis and cell cycle analysis,” Section
7.1: “Apoptosis: Measurement of apoptosis,” and Section 7.2:
“Apoptosis: Caspase activation” as well as the manual of the
Pyroptosis/Caspase-1 Assay Kit for additional information regard-
ing cell death measurement.
As a general pitfall, it has to be pointed out that the protocols
described to analyze either necroptosis or pyroptosis by FCM are
not specific for the mode of cell death. The lack of DNA fragmen-
tation as detected by cell cycle analysis merely excludes apop-
tosis but does not discriminate between different modes of cell
death leading to membrane rupture without caspase activation.
Therefore, the occurrence of necroptosis or pyroptosis has to be
validated by alternative methods, i.e., when analyzing a new cell
system, you will have to make sure that your treatment indeed
induces the cell death mode under investigation, either necrop-
tosis, e.g., by Western blot for phosphorylation of RIPK3 and/or
MLKL [352, 367], or pyroptosis by Western blot to detect cleav-
age of GSDMD. Western blot analysis, however, is at best semi-
quantitative, because all cells are analyzed as a single population.
In contrast, FCM yields a quantitative result as it analyses each cell
within the sample separately and therefore provides additional
information.
A reasonable way to enhance the specificity of the flow cyto-
metric assays described here would be the use of inhibitors
while stimulating the cells that are specific for necroptosis
(necrostatin-1s, GSK’840, GSK’843, GSK’872, or necrosulfon-
amide) or pyroptosis (VX-765 and MCC950), although the pyrop-
tosis inhibitors may affect other cell processes and complicate the
interpretation.
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8 Phagocytosis
8.1 Overview
Phagocytes are essential components of the first defensive line of
the innate immune system. Professional phagocytes include neu-
trophilic and eosinopilic granulocytes, monocytes, dendritic cells,
tissue-resident macrophages (e.g, alveolar macrophages, marginal
zone and metallophilic splenic macrophages, Kupffer cells of the
liver, intestinal macrophages, osteoclasts, and microglia of the
brain) and macrophages derived from monocytes during inflam-
matory processes [368]. Phagocytosis is, indeed, one of the most
ancient and evolutionarily conserved functions of immunity [369].
Ingesting and killing of microorganisms involves intrinsic func-
tions of phagocytes as well as complex interactions between
phagocytes, pathogens, and plasma factors such as opsonins. Defi-
ciencies in these functions or interactions are associated with
increased susceptibility to infection. Phagocytosis as part of the
antimicrobial immune defense involves sequentially chemotac-
tic migration of the phagocytes, recognition of pathogen deter-
minants, ingestion of microorganisms, and finally, destruction
by oxygen-dependent (e.g., “oxidative burst” of the phagocyte
NADPH oxidase [Phox], NO production by the type 2 or inducible
nitric oxide synthase [NOS2, iNOS]) and oxygen-independent
mechanisms (e.g., acidification and protease activities, antimicro-
bial peptides) [368].
It is important to note that the interaction with extracellu-
lar or intracellular pathogens may lead to the apoptotic death of
phagocytes [370]. On the other hand, phagocyte recognition of
apoptotic cells helps clearance of senescent, stressed, damaged,
or altered cells of the body from tissues. Phagocytosis of apoptotic
cells prevents the release of cell components that might otherwise
trigger inflammatory response [371]. Phagoptosis is a form of cell
death caused by primary phagocytosis and destruction of viable
cells. Phagoptosis mediates turnover of erythrocytes, neutrophils
and other cells, and thus is one of the main forms of cell death
in the body. Phagoptosis is triggered by exposure of “eat-me” sig-
nals (such as phosphatidylserine or calreticulin) and/or loss of
“don’t-eat-me” signals (such as CD47) on the plasma membrane
of viable cells, causing their phagocytosis by phagocytes. Live cells
may modify the expression of such signals as a result of cell stress,
damage, activation, or senescence [372].
Also of interest is the study of phagocytic ingestion of syn-
thetic nanoparticles in the range of 1–100 nm. These particles are
increasingly used in industrial and commercial products [373].
8.2 Flow cytometric assays of phagocytosis: Fundamentals
and general applications
FCM has been used for many years to study phagocytosis
[374–380]. Although frequent applications include the clinical
study of human immunodeficiencies and septic conditions [381],
phagocytosis assays also serve veterinary [382] and environmental
settings [383] as well as a growing multiplicity of other experi-
mental settings.
In classical FCM phagocytosis assays, phagocytes are incubated
at 37°C with fluorescent target particles pre-opsonized with an
appropriate dilution of serum. Phagocytosis is measured as the
mean fluorescence of effector cells and/or the percentages of
fluorochrome-positive phagocytes, or serum dilutions at which a
defined endpoint value is calculated. These techniques have intrin-
sic drawbacks, such as quenching of fluorescence upon internaliza-
tion, the difficulty to distinguish between adherent and internal-
ized bacteria in most cases, or a failure to determine Ab-mediated
phagocytosis [374–380].
Phagocytosis studies benefit from the unique integration of
functional and phenotypic information provided by FCM and the
large availability of phagocytic cell types and targets (both natu-
ral and synthetic) that are suitable for the technical capabilities
of FCM [374–380]. In many cases, FCM assays of phagocytosis
are available as commercial kits, and may include simultaneous
assessment of other functional aspects or consequences of phago-
cytosis, typically the oxidative burst [381] or apoptosis [381, 384].
8.3 Critical points in the pre-analytical and analytical
phases of assays
8.3.1 Phagocytic cell types and sample preparation. FCM assays
of phagocytosis and other phagocytic-related functions can be per-
formed on a large variety of primary phagocytic cells, including
but not restricted to peripheral blood monocytes and neutrophils
from humans (Fig. 43) [381], rats [385], dogs [386], cats [387],
cows [388], or cetaceans (Fig. 44) [383], human dendritic cells
[389], human peritoneal [390] or monocyte-derivedmacrophages
[391], peritoneal- or bone-marrow murine macrophages [392],
and coelomocytes from earthworms [393]. In addition, several
established cell lines with phagocytic capacity can be used for
experimental studies, typically the human monocytic cell lines
U937 and THP-1, or the murine macrophage cell lines J774A.1
and RAW 264.7 [394].
When usingwhole blood samples, heparin is often the anticoag-
ulant of choice, as both EDTA and citrate bind divalent cations and
thereby can interfere with phagocytosis processes and oxidative
burst (e.g., see ref. [395–397]). All classical anticoagulants nega-
tively affect complement activity and opsonophagocytosis [398].
Anticoagulated blood samples should be processed within 4 h
of collection. Prolonged storage may lead to abnormal results.
Specimens should typically be maintained at 18–22°C, and tem-
peratures below 10°C and above 30°C must be avoided if possible
when using whole blood. If cryo-preserved blood cells are used for
assay, it is essential to thaw and use the cells rapidly. Neutrophils
are particularly fragile. Myeloid cells can be activated by endo-
toxins, excessive agitation, or repeated centrifugations, resulting
in cell death. Endotoxin-free polypropylene tubes should be used.
Cell clumping after standing at room temperature can be avoided
by using the cells promptly or by adding DNase to the cell suspen-
sion [377].
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Figure 43. Representative examples of strategies to differentiate between attached and internalized fluorescent bacteria in whole-blood phago-
cytosis assays by conventional flow cytometry (A–C) and imaging flow cytometry (D–F). In both assays, whole-blood samples anticoagulated with
heparin were stained with CD45-APC (A) or CD45-PE (D) Ab and incubated for 30 min at 37°C (B) or at 4°C (C) with a suspension of Escherichia coli
(ATCC 11775) transformed by electroporation with a plasmid containing the GFP gene (pMEK91 GFP). The ratio of bacteria to leukocytes was 1:4.
Then, samples were lysed with BD FACS Lysing Solution, put on ice and analyzed immediately in a BD Accuri C6 conventional flow cytometer (A–C)
or in an Amnis ImageStream 100 multispectral imaging flow cytometer (D–F), both using a 488 nm blue laser. Graphs B and C show the intensity of
GFP fluorescence emission in granulocytes distinguished by higher granularity (SSC) and lower CD45 expression (purple-colored events in graph
A) after incubation of whole blood with GFP-expressing E. coli at 37°C (graph B) or at 4°C (graph C). Comparison of B and C shows the difference
between granulocytes with adherent and/or internalized bacteria (74.5% of the population after incubation at 37°C) and granulocytes with only
adherent bacteria (3.8% of the population after incubation at 4°C). Graph (D) shows the features of the main leukocyte populations identified on an
imaging flow cytometer by their light scatter under darkfield illumination (intensity SSC) and the expression CD45 (intensity CD45-PE). Composite
graphs (E) and (F) show the intracellular localization of GFP bacteria in single cells of the granulocyte subpopulation (gated on NEUTRO, graph
D) after incubation of whole blood with GFP-expressing E. coli at 37°C. Merged images (BF/GFP) from the brightfield illumination channel (BF) and
the green fluorescence channel (GFP) allow distinguishing cells with external bacteria (graph E) from cells with internalized bacteria (graph F).
Numbers on the BF image in (E) and (F) composites indicate the sequential number of the event in the sample run.
Human PBMCs and neutrophils can be isolated by using dif-
ferent classical procedures, with dextran sedimentation prefer-
able for neutrophil purification and gradient centrifugation by
Histopaque 1077 for monocyte enrichment [399]. In addition,
magnetic separation can be used successfully to isolate functional
primary phagocytic cells based upon immunophenotypic myeloid
cell determinants [91]. Human monocytes are often cultured in
serum-free or serum-supplemented media to create macrophages
or dendritic cells [91].
8.3.2 Phagocytosis targets. A multiplicity of fluorescent biologi-
cal and synthetic micro- or nanoparticles can be used as suitable
targets for phagocytosis with FCM assays, reflecting, on the one
hand, the different roles and clinical failures of phagocytosis, and
on the other hand, the diversity of plasma membrane receptors
that mediate phagocytic recognition of microbes, apoptotic cells,
or synthetic particles [368].
The best biological targets are live microorganisms, includ-
ing pathogenic and nonpathogenic bacteria and yeast. Because of
their hazardous nature, pathogens can be inactivated by different
means. However, inactivation by heat killing (e.g., boiling) may
result in loss of cell wall components, which are extremely impor-
tant for phagocyte recognition, thus potentially reducing phago-
cytosis [400]. Inactivation by fixation with 4% paraformalde-
hyde may preserve some pathogen-associated determinants and
improves recognition [401]. Another typical target for phagocy-
tosis assays are zymosan particles, prepared from the cell wall of
Saccharomyces cerevisiae and consisting of protein-carbohydrate
complexes [376–378, 402]. FCM assays of phagocytosis can use
fluorescent microbeads of different optical properties, chemical
composition, and diameter that may be, in addition, coupled
with components relevant for receptor-mediated particle recog-
nition [377].
Since physiological phagocytosis occurs mainly after binding
of opsonized particles to receptors of the constant fragment of
immunoglobulins (Fc) or complement receptors expressed on
phagocytes, it may be essential to ensure opsonization of phagocy-
tosis targets. Engagement of phagocyte Fc receptors is achieved by
pre-incubation of targets with appropriate sera or IgG solutions,
as well as by coating of fluorescent beads with IgG Abs. In this
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Figure 44. A representative example of
flow cytometric assay of phagocytosis
in whole blood of Bottlenose dolphin
(Tursiops truncatus) using pHrodo Red
E. coli BioParticles. The assay was per-
formed following the protocol described
in the text. Data were obtained in a
CytoFlex flow cytometer (BeckmanCoul-
ter). Graph (A): Doublet exclusion based
on FSC-A versus FSC-H features. Graph
(B): Selection of live cells based on exclu-
sion of DAPI dye. Graph (C): Identifi-
cation of leukocytes based on staining
with CD11a-PECy5 Ab. Graph (D): Mor-
phological features of live blood cells,
showing the populations of phagocytic
cells (monocytes and polymorphomu-
clear neutrophils) where ingestion of
pHrodo Red E. coli BioParticles should be
expected. Graph (E): Fluorescence inten-
sity of pHrodo Red E. coli BioParticles in
the negative control tube, showing the
low level of E. coli ingestion in the sample
treated with Cytochalasin A. Graph (F):
Fluorescence intensity of pHrodo Red E.
coli BioParticles in the assay tube, show-
ing the high level of E. coli BioParticles
ingestion by phagocytic cells from the
blood of a healthy dolphin.
aspect, whole-blood assays of phagocytosis have the advantage of
not requiring additional steps of target opsonization.
As rates of phagocytosis are highly dependent on the target-to-
cell ratio, accurate counting of targets and effector phagocytes and
the use of a suitable ratio is important [402]. Target: effector ratios
ranging from 1:1 [402] to 260:1 [403] have been applied in dif-
ferent assay settings. Similarly, the determination of the duration
of the assay must take into account the difference of phagocytosis
kinetics between synthetic and natural targets, as well as among
different types of biological targets. One-hour incubation is usu-
ally sufficient and typically, phagocytosis assays require incubation
times of 15–30 min [404].
8.3.3 Fluorescent labeling of targets. There are several conve-
nient commercial sources of fluorescently conjugated biological
and synthetic particles [379]. In some cases, such particles are
components of assay kits that can be used in conventional FCM
using a suitable laser. For custom labeling of targets, themost com-
mon fluorescent labels are incorporated as N-hydroxysuccinimide
esters, which react covalently with –NH2 groups [379]. Fluo-
rescein derivatives (e.g., fluorescein, dicarboxyfluorescein, Ore-
gon Green, dihydrodichlorofluorescein) have been popular, but
their fluorescence is quenched in the acidic compartments of
phagocytes and, moreover, their emission wavelength overlaps
markedly with green autofluorescence, which is especially present
in macrophages and monocytes [405]. Other fluorophores such
as Alexa Fluor, BODIPY FL, tetramethylrhodamine, and Texas
Red have stable, intense emission over a broad pH range (pH
4–9). Most interestingly, pHrodo, a new series of probes with
green or red fluorescence emission increasing with decreas-
ing pH has been recently developed [379, 406]. Fluorescent
protein-expressing E. coli strains are also suitable for FCM assays
[407–409].
8.3.4 Identification of live subpopulations of phagocytic cells by light
scatter and surface immunophenotype. The nucleated phagocytes
in whole blood assays may be distinguished from debris and from
smaller targets (microorganisms and fluorescent beads) by gat-
ing on the granulocyte and monocyte populations using FSC and
SSC properties [377, 379]. As phagocytosis may lead to degranu-
lation and even apoptosis of phagocytes, especially neutrophils,
it is recommended to include at least a viability marker and
eventually appropriate immunophenotypic markers (for human
cells, e.g., CD45, CD14, CD13, CD15, CD16, CD11b) [410]. It
is worth mentioning that the lymphocyte population in whole
blood assays may often serve as an internal negative control of
nonphagocytic cells. In FCM assays using homogeneous phago-
cytic populations (e.g., U937, TPH-1, RAW264.7 cell lines) and
small targets, it is recommended to include viability markers,
in order to exclude nonspecific attachment of targets to dead or
dying phagocytic cells. In those specialized assays, in which tar-
get cells (e.g., apoptotic cells, infected erythrocytes) may have
similar size as phagocyte effectors, it is recommended to sepa-
rately label effectors and/or targets with appropriate tracking dyes
[403, 411].
In all cases, phagocytosis assays involving immunophenotyping
with multicolor cytometry should include the appropriate controls
for fluorescence compensation (single-stained tubes) and gating
(FMO controls). This is further discussed in Chapter II, Section 1,
Compensation.
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8.3.5 Distinguishing non-internalized from internalized particles.
In order to accurately assess the phagocytosis process, it is
mandatory to demonstrate that the particles are in fact ingested as
opposed to coincident with the phagocyte in the laser-illuminated
volume or adherent to the cell surface.
While coincidence of phagocytes and targets can be minimized
by running diluted samples at slower flow rates, quantification
of internalized particles as opposed to surface adherent particles
may be approached by different strategies:
1. Comparing the cell-associated fluorescence intensity in condi-
tions avoiding (negative controls) or allowing particle internal-
ization. Negative controls of this type should include cells incu-
bated without fluorescent targets (which allows for the detec-
tion of autofluorescence) and cells and targets co-incubated at
4°C (Fig. 43) or in the presence of inhibitors of cytoskeleton
rearrangement, such as the most commonly used cytochalasins
(Fig. 44), or other inhibitors of phagocyte function, such as N-
ethylmaleimide [404].
2. Using targets labeled with a dye that is sensitive to quench-
ing agents. FITC or Calcofluor White can be quenched by try-
pan blue and crystal violet [377–379], while Sytox Green is
quenched by PI [400]. In this approach, extra washing steps
are necessary to remove the quenching dye, thus increasing
assay time and making the assay prone to artifacts and cell
loss.
3. Using fluorescent targets emitting fluorescence at different
wavelengths at neutral or acidic pH. Probes of this type
include the pHRodo series, and the Eos-FP fluorescent pro-
tein. pHRodo dye can be used for the labeling of targets, as
it reacts with the primary amino groups on the particle to
yield a covalently linked pH probe, which increases fluores-
cence emission as the pH of its environment becomes more
acidic. Due to the low pH of the phagolysosome, phagocytized
targets can be quantified without interference of adherent par-
ticles [379, 406, 412, 413]. The optimal absorption and flu-
orescence emission maxima of the pHrodo Green dye and its
conjugates are approximately 509 nm and 533 nm, respec-
tively, while pHrodo Red excites at 560 nm and emits at 585
nm. Both pHrodo Green and pHrodo Red can also be excited
with the 488 nm argon-ion laser installed onmost flow cytome-
ters (Fig. 44).
Eos-FP can be transfected into infectious microorganisms.
After UV-irradiation of bacteria, peptide cleavage in Eos-FP
occurs and the transfected bacteria emit green (516 nm)
and orange (581 nm) fluorescent light at 488 nm excitation.
Orange fluorescence is sensitive to acidic pH, and the phagocy-
tosed bacteria stop emitting orange fluorescent light as soon as
the phagosomes fuse with lysosomes. The green fluorescence is
maintained in the phagolysosome until bacterial degradation
is completed [408].
4. Applying imaging FCM. This novel technique of cytometry
combines the statistical power and fluorescence sensitivity of
standard FCM with the spatial resolution and quantitative
morphology of digital microscopy, as it is based on the cap-
ture of images of particles in flow and subsequent pixel-based
image analysis of objects [413]. Imaging FCM allows defining
the intracellular localization of fluorescent targets in phago-
cytes, thus ruling out the need of quenching or blocking steps
(Fig. 43) [414–416].
8.3.6 Assessing or quantifying phagocytosis kinetics and capacity.
The simplest calculation is the proportion of phagocytosing cells
within the evaluated population, defined as the percentage of
gated cells with target fluorescence, present in the appropriate
gate(s), established by morphological, viability, and immunophe-
notypic criteria [377], as seen in Fig. 44.
Regarding the quantification of ingested fluorescent targets,
calculation may be relatively straightforward if pH-independent
fluorescent particles (biological or synthetic) are used. The mean
number of particles ingested per effector cell can be calculated
by dividing the MFI of the cell population by the fluorescence of
a single, extracellular target [417]. When using targets labeled
with pH-dependent dyes, however, this calculation is inaccurate
and must be modified by subtracting the number of free targets
per phagocyte from the initial number of targets per phagocyte
[377, 378].
An interesting parameter to quantify phagocytosis capacity is
the phagocytosis product (PP) parameter [377]. PP is defined as
the percentage of phagocytosing cells multiplied by the number
of targets per phagocytosing cell. PP reflects that the total elimi-
nation of targets from a given assay preparation depends both of
the percentage of phagocytosing cells and the number of targets
ingested by each effector cell [377].
8.4 A general protocol for assesing phagocytosis in
whole-blood samples using pHrodo Red E.coli
BioParticles
8.4.1 Overview. This assay is suitable to determine phagocytic
activity in whole blood samples based on the use of pHrodo E.
coli Red BioParticles, which undergo a strong increase in fluores-
cence when the surrounding pH becomes more acidic during the
ingestion phase of phagocytosis process. Labeling of whole blood
samples with appropriate pan-leukocytic markers, such as CD45
or CD11a (Fig. 44), easily allows excluding easily erythrocytes
and platelets. Using species-specific phagocyte markers allows to
evaluate phagocytosis of pHrodo BioParticles by granulocytes in
multiple species [418]. By adding a suitable fluorogenic substrate
of ROS such as Dihydrorhodamine 123 (DHR123), this protocol
allows the simultaneous examination of phagocytosis and oxida-
tive burst.
CD11a clone HI111 reacts with human, rhesus, cynomolgus, or
baboon monkey, dog, and rabbit. Moreover, it has been shown in
our laboratory to crossreact with some cetaceans and pinnipedes.
Thus, in addition to human studies, this protocol has been success-
fully applied to evaluate ingestion of E. coli and respiratory burst
in whole-blood samples of dolphins (Fig. 44), Beluga whales, and
walruses.
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8.4.2 Step-by-step sample preparation and assay protocol.
1. Prepare three tubes and label appropriately for:
- autofluorescence control
- cytochalasin A (negative control)
- pHrodo Red E.coli BioParticles
2. Dispense 50 µL heparinized whole blood into each tube.
3. Dispense 10 µL CD11a PE-Cy5 antibody into each tube and
incubate at room temperature for 15 min in the dark.
4. Place all the tubes on ice for 10 min.
5. Dispense 2 µL 400 µM cytochalasin A into the cytochalasin A
negative control tube and incubate 30 min at 37°C in a CO2
incubator.
6. After that, dispense into:
- negative control tube: 10 µL PBS.
- cytochalasin A negative control tube: 10 µL pHrodo Red
E. coli BioParticles stock solution.
- pHrodo Red E.coli BioParticles tube: 10 µL pHrodo Red
E. coli BioParticles stock solution.
7. Incubate the tubes at 37°C for 15 min in a CO2 incubator.
8. Place the tubes on ice for 5 min.
9. Add 500 µL of lysing solution into all tubes, vortex 1 s, and
incubate for 10–20 min at room temperature and in the dark.
10. Centrifuge the tubes at 200 × g for 5 min.
11. Remove the supernatant and wash all the tubes with 3 mL
PBS.
12. Centrifuge the tubes at 200 × g for 5 min.
13. Remove the supernatant and resuspend the pellet in 300 µL
RPMI 1640 Medium.
14. Add 1 µL of DAPI stock solution previously to flow cytometry
acquisition.
15. Analyze samples in a flow cytometer having blue (488 nm)
and violet (405 nm) laser lines.
8.4.3 Materials.
 Fresh whole blood (1 mL) collected in heparinized tubes.
 Versalyse lysing solution: Store between 18 and 25°C (Beckman
Coulter, Ref: A09777).
 PBS pH 7.4: store between 15 and 30°C (Gibco, Thermofisher
Scientific, Ref: 10010015).
 RPMI 1640 medium (1×) + GlutaMAX (Gibco, Ref: 61870-
010), supplemented with 10% of FBS (Gibco, Ref: 26140-079)
and 1% penicillin/streptomycin (Gibco, Ref: 15140-122). Store
between 2 and 8°C.
 Cytochalasin A: 10 mM in DMSO. Aliquoted and store at –20°C
(ENZO, Ref: ALX-380-057-M001).
 CD11a-PE-Cy5 mouse anti-human mAb, Clone HI111. Store
between 2 and 8°C (BD Biosciences, Ref: 551131).
 pHrodo Red E. coli BioParticles conjugate for phagocytosis: 1
mg/mL in PBS. Aliquote and store at -20°C (ThermoFisher Sci-
entific, Ref: P 35361).
 DAPI: 1 mg/mL in demineralized water. Aliquote and store at
-20°C (Sigma, Ref: D9542).
9 Autophagy
9.1 Overview
Autophagy is a cellular catabolic pathway tightly regulated for
homeostasis maintenance and remodeling. During autophagy, cel-
lular debris and other cargo is delivered by autophagosomes to
lysosomes for degradation and recycling. LC3-II, which localizes
to autophagosomes, is a widely used autophagy marker. In this
section, quantitative measurement of autophagy focusing on FCM
staining of LC3-II will be discussed.
9.2 Introduction
Autophagy is a lysosome-based catabolic pathway for the degra-
dation and turnover of cytoplasmic constituents. Stressors, such
as nutrient starvation and hypoxia, are potent autophagy induc-
ers. To maintain cellular homeostasis, cellular debris is removed
by constitutive (basal) autophagy. Autophagy generates metabo-
lites, which are reused as sources of energy or synthesis of new
macromolecules. It is known to be an important player in the reg-
ulation of proliferation, cell growth, remodeling, and differentia-
tion in a number of systems [419]. There are three main types of
autophagy in mammalian cells: chaperone-mediated autophagy
[420], microautophagy [421], and macroautophagy [419]. The
techniques described in this section detect macroautophagy that
hereafter will be referred to as autophagy.
Autophagy is tightly regulated by complex signaling pathways
including mTORC1, AMPK, class I PI3K complex, AKT, ULK1 com-
plex, and class III PI3K complex. Close to 40 core autophagy genes
have been identified that mediate the completion of a double-
membrane autophagosome, which engulfs unwanted cytosolic
material such as aged and damaged organelles, protein aggre-
gates, or pathogens. Subsequent fusion of the autophagosome
to the lysosome enables degradation of the cargo (Fig. 45).
Autophagy related genes (ATGs) were originally identified in
yeast, but most of these are evolutionarily conserved in higher
organisms such as mammals [422]. A key player often used to
quantify autophagy is the ATG8-family memberMAP1LC3B (LC3).
During autophagosome elongation, the cytosolic protein LC3-I is
lipidated by conjugation to phosphatidylethanolamine to become
LC3-II, and thereby inserted into the membrane of the growing
autophagosome.
Autophagic flux (i.e., flow through the autophagy pathway)
is used to measure autophagic activity. One such approach is to
measure the rate of protein breakdown by autophagy by arresting
the autophagic degradation at a given point and recording the
time-dependent accumulation of representative autophagic car-
goes. The most common way to induce this block is to inhibit
lysosomal proteolysis, thus, increasing levels of autophagosomes
and the autophagosome marker LC3-II, which can be measured.
Many compounds are known to block the autophagic flux [424]
such as chloroquine, which primarily inhibits autophagosome–
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Figure 45. Autophagy pathway (modified and reproduced with permission from ref. [423]). In the first step of autophagy, a double-membraned
vesicle is formed, which elongates to form an autophagosome (left). During the elongation step, the cytosolic protein LC3-I is lipidated to become
LC3-II, which is inserted into the membrane of the growing autophagosome. The autophagosome closes, engulfing bulk cytoplasmic material to
be degraded (middle). The autophagosome then fuses with a lysosome to breakdown the autophagy vesicle and its contents (right). Autophagy
inducers are shown in RED, and autophagic flux inhibitors are shown in BLUE.
lysosome fusion [425], and bafilomycin A1 (BafA), which inhibits
both lysosomal acidification (thus inhibits lysosomal hydrolase
activity) and autophagosome–lysosome fusion [426]. Both are
common inhibitors used to measure autophagic flux (Fig. 45).
9.3 Flow cytometry autophagy assays
In recent years, autophagy has been successfully measured with
commonly used techniques such as Western blot and microscopy
[427]. However, these assays have their limitations since a certain
number of cells are needed or cell sorting is required to measure
autophagy in a specific cell type within a mixed cell population.
More recently, novel techniques for FCM and imaging FCM have
opened up new possibilities in the field of autophagy. Not only can
primary cells be analyzed, these techniques also allow a higher
throughput and the possibility to measure multiple parameters
simultaneously. As the available Abs to LC3 do not discriminate
between its lipidated and non-lipidated forms, these techniques
rely on detecting punctate LC3 visible by imaging or removing the
non-lipidated form prior to staining [428].
Detection of fused autophagosomes also relies on the identi-
fication of lysosomes, as required for the Amnis R© ImageStream
autophagy assay described later. Lysosomes are acidic organelles
that can be identified by pH sensors. One example of such reagents
are the LysoTracker probes (ThermoFisher Scientific), which are
selective for acidic organelles. They must be used at low concen-
trations (usually 50 nM) and incubation time should be restricted
to 1–5 min before imaging, otherwise they induce an increase in
lysosomal pH. They can, however, be fixed with aldehydes, but
the autofluorescence or non-specific staining as mentioned by the
manufacturer, means their specificity for quantifying lysosomes by
FCM will depend on the cell type. However, Lysotracker has had
some success in flow assays with cells showing an increase in signal
after treatment with chloroquine [429]. LysoSensor pH indicators
(ThermoFisher Scientific) are similar, but exhibit a pH-dependent
increase in fluorescence intensity upon acidification. They have
the same issue of increasing lysosomal pH with longer incubation
times and nonspecific staining when used for FCM. Lyso-ID (Enzo)
is another acidic organelle-selective dye but does not increase lyso-
somal pH over time lending itself to short- and long-term track-
ing of lysosomes. An alternative are lysosome-specific Abs, such
as against the LAMP family members. Anti-LAMP1 staining was
shown to give the same results when compared to Lyso-ID in
the autophagy imaging FCM assay discussed later in this guide-
line [430].
Autophagy FCM assays include:
1. Amnis R© ImageStream autophagy assay. Imaging FCM allows
quantification of endogenous LC3 puncta while detecting sur-
face markers. To detect autolysosomes, the co-localization
between LC3 and lysosomes using a bright detail similarity
analysis feature can be used [430–432] (See Chapter VIII, Sec-
tion Imaging FCM for general introduction to ImageStream).
2. Cyto-ID R© Autophagy detection kit (Enzo)
This is a proprietary dye that stains autophagic vesicles. Ver-
sion 2.0 of the kit has been developed in 2015 with better per-
formance in signal intensity and photostability compared to the
old version. Both versions seem to stain autophagic vesicles in
a pH-dependent manner, as blocking lysosomal acidification by
bafilomycin A1 significantly compromises the staining signal.
In contrast, chloroquine that blocks autophagosome–lysosome
fusion is compatible with the kit as shown by themanufacturer.
The staining is simple and direct (see protocol provided by the
manufacturer). However, the data is difficult to interpret as
the manufacturer does not state the mechanism on which the
staining is based.
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3. FlowCellect Autophagy LC3 kit (Merck Millipore). Selective
cell membrane permeabilization with mild detergents allows
discrimination between cytosolic non-lipidated LC3-I from
membrane bound LC3-II by washing out the soluble cytosolic
form. This is our first choice to measure autophagy in primary
cells. Selective detection of endogenous LC3-II by FCM pro-
vides many advantages to investigate autophagy in primary
cells including lower cell numbers, detection of surface mark-
ers, and other parameters at the same time and it is signif-
icantly quicker than the ImageStream autophagy assay. This
assay was first reported by Eng et al. [428], and can also be
performed with common laboratory chemicals and anti-LC3
Abs. Optimization might be required for different conditions
and primary cells.
9.4 Step-by-step sample preparation (FlowCellect
Autophagy LC3 kit, adapted from the manufacturer’s
protocol)
1. Collect tissues and homogenize into single cell suspension.
2. Culture cells at 37°C in appropriate medium (RPMI 1640 with
10% FBS for human or murine hematopoietic cells) contain-
ing autophagic flux inhibitors (e.g., 10 nM bafilomycin A1)
or vehicle for 2 h. Treatment time and doses may need to be
titrated for different cell types.
3. Transfer the cells to tubes or plates for staining.
4. Stain cells with fixable Live/Dead staining (e.g., Ther-
moFisher, BioLegend) and Fc block in PBS in dark at 4°C
for 20 min. Wash cells by topping up with PBS-0.1% BSA and
spin down.
5. Stain cells with surface markers in PBS-0.1% BSA in the dark
at 4°C for 20 min. Wash by topping up with 1× Assay Buffer
(provided with kit) and spin down.
Note: Usually (4) and (5) can be combined together for
one-step surface marker staining in PBS without significantly
compromising the staining quality. Wash by topping up with
1× Assay Buffer.
6. Add 1× Autophagy Reagent B (provided with kit) to the cell
pellet, resuspend by pipetting up and down, and immediately
spin down. This step washes away cytosolic LC3-I.
7. Stain cells with FITC-conjugated anti-LC3 antibody (20×,
dilute in 1× Assay Buffer) in the dark at 4°C for 30 min.
Wash by topping up with 1× Assay Buffer and spin down.
8. Wash once more with 1× Assay Buffer to remove the remain-
ing unbound antibody.
9. Fix cells with 2% paraformaldehyde dissolved in PBS in the
dark at room temperature for 10 min. Wash by topping up
with PBS and spin down.
10. Resuspend cells in PBS and analyze by FCM.
9.5 Materials
FlowCellect Autophagy LC3 Antibody-based Assay Kit (Merck Mil-
lipore), PBS, cell culture medium, autophagic flux inhibitor (e.g.,
bafilomycin A1 or chloroquine), Live/Dead fixable dead cell stains,
Fc Block, Abs for cell surface staining, BSA, and paraformaldehyde.
9.6 Data analysis
A rough idea of autophagic flux can be directly obtained from
LC3-II histograms (Fig. 46A and B). After compensation and gat-
ing on the cell population of interest, the geometric mean of LC3-II
fluorescence intensity can be determined. Autophagy is a complex
cellular process and more accurate assessment requires quantifica-
tion and calculation. Therefore, different aspects of the autophagic
flux are determined by the following calculations:
1. Basal LC3-II levels alone are a direct measurement of the num-
ber of autophagosomes (Fig. 46C). Their increase indicates
either increased autophagosome formation or blocked lysoso-
mal degradation, or both.
2. BafA minus basal LC3-II calculates the amount of LC3-II being
degraded during the period of BafA treatment, which is the net
autophagic flux (Fig. 46D).
3. (BafA minus basal)/ basal LC3-II is a modified version of
autophagic flux measurement, which normalizes the net
autophagic flux to basal LC3-II levels, eliminating variation in
basal LC3-II (including tissue-specific variation and cell size)
and thereby quantifying the efficiency of autophagy (Fig. 46E).
The combination of these different ways of quantification will
gain a comprehensive analysis of autophagy occurring within the
cell. To confirm autophagy levels found by LC3-II, we recommend
to also measure other autophagy-related processes such as lysoso-
mal function andmass, degradation of autophagy adaptor proteins
(e.g., p62), other proteins expressed on autophagosomes (e.g.,
WIPI2), and signaling molecules (e.g., phosphorylation status of
mTOR and ULK1) by FCM, microscopy, and Western blot.
9.7 Pitfalls
The autophagy levels in different types of primary cells under
different conditions vary a lot. Often, only small changes after
autophagy inducing or inhibiting treatments are being observed in
comparison to cell lines. Many commonly used autophagy induc-
ers such as rapamycin, torin 1, or starvation do not cause large
differences in autophagy levels in na¨ıve immune cells according to
our unpublished data. Typically in immune cells, cell-specific stim-
ulations such as through the TCR, BCR, TLR, or cytokine receptors
are the strongest and the most reliable (Table 10) [433]. Gener-
ally, it is wise to test a wide panel of inducers and inhibitors in
a time course to find the best read out. Notably, when using any
compounds to induce autophagy, the vehicle needs to be consid-
ered. For example, DMSO is known to induce autophagy [434] and
therefore should be avoided if possible or used at minimum con-
centrations for a short period. As usual, it is necessary to include
vehicle-treated controls in all experiments as any mild stress might
induce autophagy.
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Figure 46. An example of autophagy induction and flux measurement with the FlowCellect LC3 kit in murine B cells. (A) Unstimulated murine
splenocytes were cultured with 10 nM Bafilomycin A1 (BafA) or Vehicle (Basal) for 2 h. LC3-II expression was quantified by FCM. (B) Purified
murine B cells were stimulated with 10 µg/mL LPS for 3 days and treated with BafA as in (A) during the last 2 h before harvest. LC3-II expression
was measured by FCM. (C–E) The quantification of basal LC3-II levels (MFI Basal LC3-II) (C), net autophagic flux (MFI (BafA-Basal) LC3-II) (D), and
normalized autophagic flux (MFI (BafA-Basal)/Basal LC3-II) (E) are shown. Data are represented asmean ± SEM. Student’s t-test. *P 0.05, **P 0.01,
****P  0.0001.
Table 10. Autophagy inducers for human primary immune cells.
Treatments that successfully induce autophagy after 24 ha)
Primary cell type Autophagy inducer
T cells αCD3/CD28 (highest after 4 days)
B cells IgM, megaCD40L
Monocytes LPS, IFN-γ
Macrophages LPS, IFN-γ
a)This is not an exhaustive list and kinetic experiments have not been
performed.
One also needs to be aware of off-target effects of compounds
used to modulate autophagy. Some may require specific concen-
trations or incubation times [424]. For example, 3-MA (inhibiting
class III PI3K Vps34 in autophagy pathway) is of low potency,
requiring it to be used at10 mM to block autophagosome forma-
tion. At this concentration, it can also affect other kinases including
class I PI3K, p38MAPK, or c-Jun kinase, therefore affecting many
cellular processes [435]. For this reason, 3-MA is not our primary
choice to inhibit autophagy. Bafilomycin A1 is widely used inmany
laboratories but in primary cells, we recommend to use at a low
concentrations for <4 h, otherwise it is toxic. It also needs to be
noted that bafilomycin A may inhibit the proteasome, endocytic
trafficking, and other cellular processes [436].
There are several drawbacks of the FlowCellect Autophagy LC3
kit. The LC3-II staining is incompatible with other intracellular
staining because it requires the wash-out of cytosolic proteins.
As permeabilization and fixation are required for the assay, live-
cell sorting cannot be performed. Moreover, autophagy induction
involves conversion of LC3-I to LC3-II, and thereby the ratio of
LC3-II to LC3-I is another way to quantify autophagy induction.
Yet the current protocol of LC3 kit cannot be used to measure LC3-
I. Generally speaking, every technique has its own advantages
and limitations. It is important to choose the best one for the
experimental question, and ideally combine several techniques.
9.8 Top tricks
Being a stress response, autophagy can be nonspecifically induced
by many insults. Therefore first keeping live cells at low
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temperatures during sample preparation at all times (except for
the cell culture step) helps to minimize these unwanted effects on
autophagy. Second, for adherent cells, care must be taken when
preparing single cell suspensions. The detachment requires dis-
ruption and injury of the plasma membrane, which can induce
autophagy. For some cells, we found Accutase R© induced less
autophagy when compared to scraping or trypsinization.
Finally, the LC3 kit assay involves multiple washing steps.
Accumulative cell loss during each centrifugation may eventually
lead to a very low yield of cells. To maximize the sample recov-
ery, 96-well V-bottom plates are recommended over U-bottom
plates.
10 Reactive oxygen species production with minimal
sample perturbation
10.1 Overview
FCM enables the detection of ROS in live cells. However, RBC
lysis and sample manipulation can result in incomplete lysis of
erythrocytes or in unwanted damage to leukocytes. This sample
manipulation can cause both cellular depletion and artifactual
activation and may result in inaccurate measurements of ROS,
especially in those cases where target cells are the minority. No-
lyse no-wash protocols reduce sample handling, are simple and
fast, and perhaps most importantly, they can minimize sample
preparation and consequent artifacts relevant to the biology of
increasingly important assays that target fragile cell subsets and
or combine live cell function with cell phenotype. In order to
mimic physiological conditions, this method takes advantage of
classic methods that are widely used in FCM and is applicable
for both murine and to human cord blood, peripheral blood, and
bone marrow specimens. Examples provided in this section are
from human PBMCs.
10.2 Introduction
ROS have been shown to be associated with oxidative stress [437].
Toxic, oxygen free radicals contribute to aging [438], apoptosis
[439, 440], and pathological processes [441] in many clinical dis-
orders, such as cardiac dysfunction andmyocyte injury [442, 443].
More recently, ROS have also been shown to be involved in sig-
naling processes [444–450], having a role as signaling molecules
that generate specificity in ROS homeostasis.
ROS are generated during mitochondrial oxidative phospho-
rylation or after interaction of myeloid immune cells with xeno-
biotic compounds [447], and their rate of production increases
under hypoxia or after inhibition of mitochondrial respiration
[451, 452]. The term ROS includes superoxide anion (O2−),
hydrogen peroxide (H2O2), hydroxyl anion (OH−), hypohalous
acid anions (e.g. OCl−, OBr−), ozone, singlet oxygen, and so
on [447]. ROS are formed by the incomplete reduction of oxy-
gen. ROS are mainly free radicals that many times are not very
reactive and have a short half-life [446]. Oxygen-derived free rad-
icals are molecular species with unpaired electrons [453] and are
the product of multiple biological oxidation and reduction path-
ways [447].
Although ROS are generated during normal mitochondrial
oxidative metabolism, they are also generated in cellular response
to exogenous compounds, cytokines, and bacterial invasion [450,
454, 455]. ROS, including all highly reactive molecules that con-
tain oxygen, are members of important mechanisms of protection
against infections [456]. The family of NADPH oxidases (NOX),
notably the phagocyte NADPH oxidase (NOX2), are a key source of
ROS and are critical for the defense against infections with viral,
bacterial, fungal, and parasitic pathogens [456–459]. However,
as well as protecting against infection, ROS generation can result
in cell and tissue damage, as a result of the interaction with cell
membranes, nucleic acids, proteins, and enzymes [446, 460, 461].
Oxidative stress is a consequence of the excessive production of
oxygen reactive species or a decrease in the antioxidant defense
[462]. Oxidative stress causes cytotoxicity through structural and
functional alterations, that result in the disruption of cell home-
ostasis [463].
One of the main sources of anion superoxide (O2·-) during
homeostatic conditions is the electron transport system of mito-
chondria. Anion superoxide is the first ROS to be produced after
oxygen enters living cells and this radicalmay generatemany other
ROS of different reactivity. Superoxide is produced by one electron
reduction of molecular oxygen, has a short half-life, low reactiv-
ity, and does not normally result in oxidative attack of polyun-
saturated lipids and DNA. However, defects in superoxide dismu-
tase (SOD), a powerful enzyme that catalyzes the dismutation of
superoxide into O2 and H2O2, can cause membrane damage due to
spontaneous dismutation of O2− into H2O2, resulting in elevated
levels of superoxide, which can lead to cell membrane damage
because of the accumulation of this oxygen reactive species [464].
Its instability is related to the rapid O2 ·- dismutation reaction to
hydrogen peroxide (H2O2) catalyzed by SOD [465].
Hydrogen peroxide is not a free radical but it can give rise
to other ROS. Most ROS are free radicals that cause little dam-
age due to their short half-life, but they are always reactive.
H2O2 is much more stable and less reactive than superoxide
anion. However, it can cause cell damage at lower concentra-
tions when compared with O2− damage [466]. H2O2 is hydrosol-
uble and can diffuse across cells and reach distant targets to
cause damage a long distance from its site of formation [466].
Hydrogen peroxide is formed by O2·- dismutation, catalyzed by
SOD, and an unstable intermediate, hydroperoxyl radical [467].
However, dismutation can also be spontaneous or can be formed
through direct oxygen reduction with participation of two elec-
trons. Hydrogen peroxide can generate other ROS with enhanced
reactivity, such as the hydroxyl radical (OH•) or the hypohalous
acid anions [450, 466, 468]. The direct activity of H2O2 can dam-
age cells by crosslinking sulfhydryl groups and oxidizing ketoacids,
causing inactivation of enzymes and mutation of DNA and lipids
[466]. Hydroxyl radical is highly reactive and toxic. With a rel-
atively short half-life, hydroxyl radical can also react with many
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biomolecules, including DNA, proteins, lipids, aminoacids, sugars,
and metals [466].
Production of ROS by human monocytes was originally
described using the NBT salt assay [469] or luminol-dependent
chemiluminescence [470]. FCM is progressively replacing these
assays [471] and has several advantages: it is rapid, sensitive,
and multiparametric, and allows cell subpopulations to be stud-
ied [472]. However, in many of these cytofluorometric assays,
samples are subjected to manipulation in the form of centrifuga-
tion, washing steps, erythrocyte lysis, and in some cases, fixation
of cells or enrichment of the target cells by means of density gradi-
ents [473, 474]. This sample manipulation can cause both cellular
depletion and artifactual activation and may result in inaccurate
measurements, especially in those cases where target cells are the
minority.
10.3 Step-by-step sample preparation and assay protocol
Ideally, cytofluorometric functional studies on oxidative burst
should be performed in whole bloodwithminimal samplemanipu-
lation (stain, no-lyse, and no-wash) in order tomimic physiological
conditions. We have tested different probes to detect ROS (V.9.4.
Materials) in leukocyte cells (lymphocytes, monocytes and granu-
locytes) using no-lyse no-wash approaches (Figs. 47 and 48) and
have developed different protocols and recommendations accord-
ing to the reagent used (See also Chapter V Section 16: Assessing
lymphocyte metabolism through functional dyes).
We have developed two no-lyse no-wash strategies for iden-
tifying leukocytes in whole human blood that can be used to
analyze ROS production using FCM. Approach A (Fig. 47) uses
a nucleic acid stain to label and discriminate nucleated cells from
non-nucleated cells, avoiding anucleate mature RBCs. A fluores-
cence threshold is applied to the nucleic acid stain detector to
eliminate the non-nucleated cells from detection by the cytome-
ter during acquisition. Approach B uses a light scatter threshold
(Fig. 48) and exploits the difference in light-absorbing proper-
ties between RBCs and leukocytes. RBCs contain hemoglobin, a
molecule that readily absorbs violet laser (405 nm) light, whereas
leukocytes and platelets/debris do not. This results in an unusual
scatter pattern when analyzing human whole blood with both blue
(488 nm) and violet (405 nm) SSC, which can be used to discrimi-
nate leukocytes from red blood cells by light scatter. Alternatively,
red and violet SSC can also be used (Fig. 48).
The general step-by-step sample preparation is as follows:
1. Dilute 20–50 µL of EDTA anticoagulated fresh blood in 1 mL
HBSS. Adjust the leukocyte concentration to approximately
5 × 105 cells/mL.
2. Prepare positive and negative controls. For positive controls,
use tert-Butyl hydroperoxide 200 µM or PMA 1.63 µM. For
negative controls, prepare a tube in the absence of any ROS
inducing agent.
3. Add the desired ROS staining reagent:
- Dihydrorhodamine 123 50nM
- Total ROS Assay kit 1X
- Cell ROXTM Deep Red/ Green/ Orange 500 nM
4. Add a nucleated cell staining reagent (e.g., VybrantTM
DyeCycleTM Violet (DCV) Stain 1 µM) to each tube if you want
to perform approach A. To perform the approach B, this step
is not required.
5. Incubate samples for 30min, in a dedicatedwater bath at 37oC,
and invert tube samples gently every 5–10 min.
6. Mini-centrifuges are ideal for quick and easy spin down. Cen-
trifuge the tubes shortly (10 s 16.1uf) and conserve the super-
natant. Add 1.5 µg/mL 100 µL final volume of the desired Abs
and incubate 20 min at room temperature.
7. Add the conserved supernatant and the viability dye (e.g.,
DRAQ7TM 3 µM) to discriminate necrotic cells. Incubate 10
min at room temperature.
8. Immediately analyze the samples in the flow cytometer. Run
your isotype controls and adjust compensation properly prior
to analyzing the stained sample (Section II.1: Compensation).
10.4 Materials
10.4.1 Reagents.
1. Hanks’ Balanced Salt Solution (1×) (HBSS), w/o Ca &Mg, w/o
Phenol Red (Capricorn Scientific GmbH, catalog no. HBSS-2A)
2. ROS reagents: Dihydrorhodamine 123 (DHR) (Thermo Fisher
Scientific, catalog no. D23806), Total ROS Assay Kit 520nm
(Thermo Fisher Scientific, catalog no. 88-5930-74), CellROXTM
Deep Red Reagent (Thermo Fisher Scientific, catalog no.
C10422), CellROXTM Orange Reagent (Thermo Fisher Scien-
tific, catalog no. C10443), CellROXTM Green Reagent (Thermo
Fisher Scientific, catalog no. C10444).
3. Induction reagents: PMA (Sigma–Aldrich R© catalog no. P8139-
1MG), tert-Butyl hydroperoxide solution, 70% solution in
water (Thermo Fisher Scientific, catalog no. C10491).
4. Viability dye: DRAQ7TM (BioStatus, catalog no. DR70250)
5. Total nucleated cells dye: VybrantTM DyeCycleTM Violet (DCV)
Stain (Thermo Fisher Scientific, catalog no. V35003)
6. Abs: CyFlowTM CD3 APC-Cy7 (Sysmex, catalog no. AU20
8254), CyFlowTM CD11b PE-Cy7 (Sysmex, catalog no.
CB652124), CyFlowTM CD14 PE (Sysmex, catalog no.
BR806060), CyFlowTM CD33 APC (Sysmex, cat. no.
AW821754)
10.4.2 Equipment.
1. InvitrogenTM AttuneTM NxT flow cytometer (Thermo Fisher
Scientific, catalog. no. A24858)
2. InvitrogenTM AttuneTM No-Wash No-Lyse Filter Kit (Thermo
Fisher Scientific, catalog no. 100022776)
3. Water bath set at 37oC
4. Eppendorf R© Microcentrifuge 5415D, with rotor F 45-25-11
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Figure 47. Identification of leukocytes in human whole blood using violet laser and Vybrant DyeCycle Violet stain on the Attune NxT Flow
Cytometer. Leukocytes are outnumbered by red blood cells 700-fold in whole blood and generally require enrichment by RBC lysis or gradient
centrifugation prior to analysis. This strategy exploits the use of Vybrant DyeCycle Violet stain (DCV), a low cytotoxicity permeable DNA-specific
dye that can be used for DNA content cell cycle analysis and stem cell side population by FCM. DCV threshold levels were set empirically to exclude
the large amounts of red blood cells that are found in unlysed whole blood. A proper threshold is shown in a SSC-H versus DCV-H dotplot (left).
DCV can be excited with violet lasers and can be used for simultaneous staining with Abs. This protocol is ideally suited to study the numbers of
nucleated cells in unlysed whole blood. Using a gate in this figure as the parent gate (R1), the three main leukocyte cell populations (R2) in human
blood are identified using classic forward and side scatter plots (right).
10.5 Data analysis
Install the Attune NxT No-Wash No-Lyse Filter Kit (catalog no.
100022776) in the optical bench of the instrument. To use the
filter kit, remove the 440/50 BP filter in VL1 slot 1 and place the
405/10 BP filter that is placed in the VL1 slot 1 in slot 1. Remove
the 495 Dichroic LP (DLP) filter in a lot A the 415DLP. The Blank
filter in slot 1A is switched with the 417LP filter in slot 0. SSC
was detected using both blue laser (488/10 BP) and violet laser
(405/10 BP filters) (Fig. 49).
Labeled and diluted blood samples were run on the cytometer
with a sample input rate of 100 µL/min. DCV fluorescent threshold
levels were set empirically using a V-SSC versus DCV dual parame-
ter plot to eliminate from detection the large amounts of red blood
cells that are found in unlysed whole blood. A proper threshold is
shown in Fig. 47A. In this example, the DCV threshold values on
the Attune NxT are set at 0.3× 1000, and this setting also excludes
from analysis non-nucleated cells and debris. This value is adjusted
while acquiring data and observing the position of the DCV+ cells
on the bivariate dot plots such that all the nucleated blood cells
are on scale with the least amount of debris appearing in these
plots. Other specimens, such as marrow or cord blood may appear
with different scatter properties and minor variations in fluores-
cence intensities. A rectangular gate R1 was drawn to enclose the
DCV-positive cells, and subsequent bivariate plots were generated
based on this gate.
10.6 Pitfalls
At higher sample concentrations/sample input rates, erythrocytes
are frequently coincident with leukocytes, but leukocytes are very
rarely coincident with each other. Height parameters are more
accurate than area due to contributions to the area from these
erythrocytes, when no-lyse no-wash methods are used. Relation-
ships between extinction pulse widths, peak heights, and inte-
grals, tend to be different for symmetric and asymmetric cells,
and for single particles and doublets or multiplets, making the
Figure 48. Identification of leukocytes in human
whole blood using violet side scatter on the flow
cytometer. Resolution of leukocytes from red blood
cells in whole blood is improved by incorporat-
ing violet 405 nm side scatter. Using both violet
and blue side scatter (left) or both violet and red
side scatter (right), allows identification of leuko-
cytes in whole blood. Using a gate in this fig-
ure as the parent gate, the three main leukocyte
cell populations in human blood can be identi-
fied using classic forward and side scatter plots
(PLTs, platelets; Ly,: lymphocytes; Mo, monocytes;
Gr, granulocytes; RBCs, red blood cells).
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Figure 49. Use of the AttuneNxTNo-WashNo-
Lyse Filter Kit. The standard configuration for
the 405 nm violet laser optical filter block is
shown in (A) and the same optical filter block
using the No-Wash No-Lyse Filter Kit shown in
(B), with changes outlined in red. To use the fil-
ter kit, remove the 440/50 BP filter in VL1 slot 1
and place the 405/10 BP filter that is placed in
the VL1 slot 1in slot 1. Remove the 495 Dichroic
Longpass (DLP) filter in a lot A the 415DLP. The
Blank filter in slot 1A is switchedwith the 417LP
filter in slot 0.
discrimination of pathological large cells from doublets and/or
aggregates difficult. The more conventional way of dealing with
doublets is based on scatter signals. However, fluorescent trigger-
ing using DNA viable stains may increase single-cell discrimina-
tion. Moreover, fluorescence thresholding is typically required at
higher sample concentrations needed for large numbers of cells
per sample. Specific DNA fluorescent labeling can be used to rise
above RBC background through fluorescence thresholding, even
using lyse no-wash methods. Scatter for fluorescence parameters
chosen for thresholds in a no-lyse no-wash assay should produce
the highest separation possible from the background.
Important note: The influence of different blood anticoagulants
on ROS production should not be ignored. Please take into account
which anticoagulants can be used in combination with your kits
and reagents. Dihydrorhodamine 123 flow cytometric method can
be used either with EDTA or heparin, without the usual necessity
of a preliminary search for artifacts.
10.7 Top tricks
In this approach, non-nucleated cells are detected by the instru-
ment during acquisition, but excluded by gating during analysis.
Care must be taken when using the method to keep event rates
below instrument limitations for Poisson coincidence. RBC con-
centration in whole blood is on the order of 5 million cells/µL so
whole blood must be properly diluted (1/100 or greater) to avoid
instrument saturation.
Dead cells often give false positive results, as they tend to bind
nonspecifically to many reagents. Therefore, removing dead cells
from your FCM data is a critical step to help ensure accurate results
and analysis. Different manufacturers market nonfixable cell via-
bility assays for FCM to distinguish live and dead cell populations
withmore accuracy than FSC and SSC data. For more detail on this
control aspect, see Section III.4: Dead cell exclusion, cell viability,
and sample freezing. For ROS production studies, different dyes
can be used on a flow cytometer based on auto-oxidation, photo-
chemical reactions, mitochondrial respiration, cytochrome P450,
NADPH oxidase, and other enzymes. Most of these reagents are
photostable fluorogenic probes that can also be detected by con-
ventional fluorescence microscopy or high content imaging and
screening. One of the most common cytofluorometric assays uses
dihydrorhodamine 123, an uncharged and nonfluorescent ROS
indicator that can passively diffuse across membranes where it is
oxidized to cationic rhodamine 123, which then localizes in the
mitochondria and exhibits green fluorescence [475].
As shown in Fig. 50, ROS production can be easily distinguished
using these markers with a multi-laser FCM protocol using no
color compensation. This simplicity makes these no-lyse no-wash
strategies even more attractive as a better choice for phenotypic
and functional measurements using freshly drawn blood samples
[476].
10.8 Compensation guidelines
Single color compensation controls should be used with all mul-
ticolor experiments in FCM (See Chapter II Section 1: Compen-
sation). Compensation controls need to be at least as bright as
the sample they apply to. Ab capture beads are ideally suited for
this. Background fluorescence should be the same for the posi-
tive and negative control populations for any given parameter.
The compensation color must be matched to the experimental
color. Match fluorophores by brightness (values from the stain
index) to density of the antigens—try to match brightest fluo-
rophores with lowest-expressed antigens (APC-CD33), and least
bright fluorophores with highest-expressed antigens (PE-CD14).
If multiple lasers (spatially separated) are present, spread fluo-
rophores across the lasers to minimize spillover. Know your instru-
ment configuration-pick fluorophores that work with your instru-
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Figure 50. Reactive oxygen species production. Representative experiment of activated leukocytes in unlysed whole blood. Cells were stained
with Vybrant DyeCycle Violet stain to discriminate nucleated cells from erythrocytes (excitation/emission (nm): 405/437), in combination with
dihydrorhodamine (DHR) 123 or Total ROS 520 nm (excitation/emission (nm): 488/530) PE-CD14 (excitation/emission (nm): 561/578), APC-CD33
(Excitation/Emission (nm): 637/660), and 7-ADD (Excitation/Emission (nm): 488/647). A polygonal gate was drawn to enclose the DCV-positive cells,
and subsequent bivariate plots were generated based on this gate. Cells were stimulated with PMA dissolved with DMSO and incubated in presence
of DHR (upper row) or Total ROS (lower row) for 30 min at 37°C. Subsequently, cells were stained with DCV and PE-CD14, PECy7-CD11b, APC-CD33,
and APCCy7-CD3 Abs for 20 min at room temperature. Following incubation, blood was diluted in HBSS and immediately analyzed on the flow
cytometer. DRAQ7TM was added to discriminate necrotic cells (data not shown).
ment’s optical configuration and design panels to maximize use of
multilaser instruments. In order to have a statistically significant
count of the target cells, a minimum of 50 000 DCV+ should be
counted.
Despite limitations, no-lyse no-wash assays are simple and fast
and perhaps most importantly, they can minimize sample manipu-
lations and consequent artifacts relevant to the biology of increas-
ingly important assays that target fragile cell subsets and or com-
bine live cell function with cell phenotype. For more than 15 years,
we have used these no-lyse no-wash methods for ROS production,
but also for the detection of rare cells, as well as for cell sort-
ing experiments [477]. ROS production should be studied using
this simple and fast methodology, but also for rare cell detec-
tion (Chapter V Section 1: Rare cells—general rules), minimal
residual disease studies or human hematopoetic progenitor cell
counting.
11 Intracellular Ca2+ mobilization by means of Indo-1
AM
11.1 Overview
Ca2+ ions play an essential role as an intracellular messenger in
nearly all cellular systems and regulate a multiplicity of cellular
functions [478]. In this section, we focus on antigen receptor-
mediated Ca2+ mobilization in na¨ıve B-cells by means of Indo-
1 AM. However, this method can be adapted to any other cell
population, lymphocyte subpopulation, or cell line that can be
triggered via any surface receptor that induces Ca2+ flux.
11.2 Introduction
In the immune system, Ca2+ mobilization induces many direct pro-
cesses such as activation of platelets, degranulation of mast cells,
or the killing of target cells by cytolytic T cells. It is also an essential
component of the signaling cascades downstream of several recep-
tors, including the B- and T-cell receptors, activating Fc receptors,
and chemokine receptors, and has been shown to regulate the
transcription of target genes and subsequently driving processes
such as proliferation, and differentiation [479–482], suggesting
that Ca2+ mobilization should be a consideration in many aspects
of immunological research. In brief, in the case of antigen recep-
tors, binding of the antigen initiates a signaling cascade leading
to the generation of the second messenger IP3. This binds to its
receptor in the ER membrane after which Ca2+ is released from
the ER into the cytoplasm. This release is the very transient inter-
nal store release (ISR) [483, 484]. Reduced Ca2+ levels in the ER
are sensed by STIM1/2, leading to the opening of the Ca2+ release
activated Ca2+ (CRAC) channels such as ORAI1 in the plasma cell
membrane causing a more sustained store operated Ca2+ entry
(SOCE) from the extracellular space into the cytoplasm (Feske
et al.; [484]). Based on patch clamp methods, Ca2+ currents can
be measured very precisely at the single cell level [485, 486].
Because this method is not feasible for many laboratories,
determination of Ca2+ mobilization by means of the widely avail-
able FCM may represent an easy alternative, providing relative
values of Ca2+ mobilization at the single cell level.
Indo-1 acetoxymethyl ester (AM) is a cell-permeant ratiometric
Ca2+ indicator, used to determine intracellular Ca2+ mobilization
at the single cell level [487]. The dye is excited at 355 nm and
therefore requires a true UV laser. The Indo-1 AM emission peak
at 475 nm in the absence of Ca2+ shifts to 400 nm upon binding of
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Figure 51. Measuring intracellular
Ca2+ mobilization in human B cells in
response to anti-IgM stimulation after
labeling with Indo-1 AM. (A) The shift
in Indo-1 bound to Indo-1 unbound at
low intracellular Ca2+ concentrations
(grey) and high intracellular Ca2+
concentrations (black). Ca2+ increase
was induced in Indo-1-labeled PBMCs
by addition of iono. (B) Setting of
Indo-1 AM bound versus Indo-1
AM unbound on x-axis and y-axis,
respectively. The PMTs should be
adjusted so that unstimulated cells
occur on a line about 45° to the y-axis.
(C) Gating strategy for the analysis of
Ca2+ mobilization in naı¨ve (na), IgM
memory (M Mem), and switched (sw)
memory B cells after stimulation with
anti-IgM. PBMCs were labeled with
Indo-1 AM and stained with CD27,
CD19, IgG, and IgA After gating on
living Indo-1 bound cells, lymphocytes
were determined. Gating of CD19+
B cells is followed by differentiation
of IgG/IgA-/CD27- naıve (na) B cells,
IgG/IgA-/CD27+ IgM Memory B cells
(M Mem), and IgG/IgA+/CD27+ class
switched memory B cells (sw). Dot
plots of time versus ratio of Indo-1
bound/unbound (middle panels) and
kinetics (lower panels) are shown
for the three subpopulations. After
baseline acquisition anti-IgM (arrow)
was added inducing a shift of Indo-1
AM bound/unbound in IgM-expressing
naıve and IgMMemory B cells whereas
this ratio is at baseline levels in IgM-
negative class switched memory B
cells. After addition of iono the ratio of
Indo-1 AM bound/unbound is rapidly
increasing in all subsets. Data were
acquired with a BD LSR FortessaTM and
analyzed by FlowJoTM.
Ca2+ to cytosolic de-esterified Indo-1. Therefore, changes in the
ratio of Ca2+-bound Indo-1 signal at 475 nm to Ca2+-unbound
Indo-1 AM signal at 400 nm allow the immediate detection of
alterations in intracellular Ca2+ concentration (Fig. 51A).
Alternative methods for detecting Ca2+ by FCM include meth-
ods involving the use of Fluo-3 or Fluo-4 [488, 489], either alone
or in combination with Fura Red, taking advantage of excita-
tion with a standard 488 nm laser [208, 490]. This avoids the
necessity of the more costly UV laser required for excitation of
Indo-1. Furthermore, Fura Red can also be used on its own tak-
ing advantage of differential excitation from the violet (405 nm)
and green (561 nm) lasers, enabling ratiometric measurements
as for Indo-1 [491]. Ratiometric measurements have the added
advantage of controlling internally for cell size and dye uptake.
An excellent overview of the different dyes that can be used for
Ca2+ analysis can be found at https://www.thermofisher.com/us/
en/home/references/molecular-probes-the-handbook.html.
11.3 Step-by-step sample preparation
Isolation of peripheral blood mononuclear cells (PBMCs)
1. See Chapter III. Before you start: Reagent and sample prepa-
ration, experimental design; Section 4. Pre-enrichment of low
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abundant cell populations prior to acquisition/cell sorting; Sec-
tion 4.2 Pre-enrichment by physical properties
All steps of cell isolation should be performed at room temper-
ature with buffers and media also at room temperature. If this is
not possible, the cells should be allowed to equilibrate to room
temperature for 30 min.
Loading:
1. Per measurement of Ca2+ mobilization in B cells 2 × 106
PBMCs are needed. Cells are adjusted to 10 × 106 PBMCs/mL
RPMI/10% FCS. The respective amount of cells is loaded with
4.5 µM Indo-1 AM in the presence of 0.045% of the deter-
gent Pluronic F-127 for 45 min at room temperature in the
dark [492].
2. Mix the cell suspension during the loading procedure by drag-
ging the sample tubes over a tube rack every 15 min.
Washing:
1. Wash twice with 5 mL RPMI/3% FCS (300 × g, 5 min, at room
temperature), remove supernatant.
Cell surface staining:
1. Add fluorescence-conjugated Abs (CD27, IgG, IgA, CD19).
2. Incubate for 15 min at room temperature in the dark.
Washing:
1. Wash with 4 mL RPMI/3% FCS, remove supernatant. Resus-
pend cells in 300 µL RPMI 10% FCS.
The sample measurement should be performed within the next
1–2 h.
Flow cytometer settings:
1. Display Indo-1 bound (FL12 405/10) and Indo-1 unbound
(FL13 520/35, 445 LP) on a linear scale.
2. View Indo-1 unbound on the y-axis and Indo-1 bound on
the x-axis. Adjust the PMT voltage so that the signals from
unstimulated cells are located on a line about 45° to the y-axis
(Fig. 51B).
3. A dot plot showing time on the x-axis versus the ratio of Indo-
1 bound/unbound on the y-axis displays the kinetics of Ca2+
mobilization. Ensure that the baseline and the maximal peak
upon stimulation (iono) are within the displayed range. If this
is not the case, the PMTs must be adjusted.
Data acquisition:
Do not change the velocity of data acquisition during the mea-
surement
1. Acquire the baseline for 30 s.
2. Remove the tube and add 10 µg/mL anti-IgM (do not stop data
acquisition).
3. Acquire for an additional 4 min.
4. Add 1 µg/mL iono as a loading control (do not stop data acqui-
sition). In the presence of Ca2+ in the medium and proper
labeling of the cells with Indo-1 AM, all cells have to show a
maximal increase in the intracellular Ca2+ concentration. Stop
acquisition after an additional 90 s.
5. Wash the flow cytometer thoroughly before the next tube is
loaded. Run fresh tubes of PBS twice for 1 min each (residual
iono can directly induce Ca2+ mobilization in the subsequent
sample).
To allow for comparison of different data sets the rate of
sample flow, the time of baseline acquisition, time point of BCR
stimulation and addition of iono must be kept constant between
samples.
11.4 Materials
RPMI 1640 PAN Biotech
FCS Biochrome
Indo-1 AM Life Technologies
DMSO Sigma
Pluronic F-127 Life Technologies
Ionomycin Sigma
Fortessa BD equipped with a UV laser BD Biosciences
Antibodies:
CD19 PE-Cy7 Beckman Coulter
CD27 PerCp-Cy5.5 Biolegend
IgG PE BD Biosciences
IgA PE Southern Biotech
anti-IgM UNLB Southern Biotech
11.5 Data analysis
Depending on the required resolution of the information, data
analysis can be performed by using standard acquisition software
such as BD FACSDIVATM (BD Biosciences, San Jose, CA) or sim-
ilar. In addition, the analysis software programs FCS ExpressTM
from De Novo Software (Glendale, CA), FlowlogicTM from Inivai
Technologies (Victoria, Australia) and FlowJoTM (Treestar Inc.,
Ashland, OR) each offer a “kinetics” tool to analyze the acquired
Ca2+ mobilization data. An example for anti-IgM-induced Ca2+
mobilization in human B-cell subpopulations when analyzed by
FlowjoTM is shown in Fig. 51C. Prior to further gating, Indo-1 AM-
negative cells must be excluded. Thereafter, the commonly used
gating strategy including FSC/SSC, exclusion of doublets, and gat-
ing on the specifically stained subpopulations is performed. Look-
ing at the respective B-cell subpopulations in a dot plot showing
the ratio of Indo-1 AM bound/unbound versus time gives a bet-
ter impression than merely looking at the kinetics function, since
Ca2+ kinetics provide multiple read-out parameters. For exam-
ple, the mean peak intensity and the time to peak, imply the
early phases of Ca2+ mobilization, which in B cells is essential for
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the induction of NF-κB and JNK [493]. In contrast, the decline
represents the later phase, which is important for the activation
of NFAT [479, 493]. Of note, the response of lymphocyte subpop-
ulations is usually less homogeneous than, for example, those of
cell lines. The percentages of responding cells can differ, and the
non-responding population will strongly influence the read out,
especially with regard to the mean values. We therefore advise
you to perform an additional analysis of the parameters men-
tioned above, referring to the responding cells only, by setting the
baseline as the threshold and excluding non-responding cells from
further analysis.
11.6 Pitfalls
As with all functional assays, control samples that have ideally
undergone the same pre-analytical steps as the test samples are
required for Ca2+ mobilization studies. This is especially impor-
tant when samples were shipped or previously frozen. The optimal
temperature for the investigation of Ca2+ mobilization, as for all
signaling studies, is 37°C. However, standard instruments are usu-
ally not equipped with a heatable acquisition chamber to maintain
the samples at a constant temperature of 37°C during themeasure-
ment. Strong fluctuations in temperature during cell preparation
and between the different experiments should be avoided, since
this may influence the Ca2+ flux. Although most cell types are
capable of inducing Ca2+ mobilization at room temperature (e.g.,
human lymphocyte subpopulations), some cell types are more sen-
sitive and may require 37°C to run the assay. In most cases, pre-
warming of the samples to 37°C improves Ca2+ mobilization, but
subsequent cooling during the measurement may lead to changes
of the Ca2+ baseline levels in some subpopulations and may thus
render the analysis inaccurate. Therefore, we perform the entire
process of loading, staining, washing, and measuring the cells at
room temperature. Of note, during cell isolation or preparation
(e.g., isolating PBMCs through Ficoll), labeling, and staining, the
use of cold PBS and other media should also be avoided. Further-
more, mechanical force may induce Ca2+ flux. Therefore, carefully
dragging the sample tubes over a tube rack to mix them during
the entire procedure is better than vigorous shaking or vortexing
of the cells.
It is important to make sure that the Abs used for cell surface
staining do not themselves induce Ca2+ mobilization. This can be
tested by adding the staining Ab to Indo-1 AM loaded cells and
detecting the resulting Ca2+ levels. Since kinetics may vary, the
period of acquisition for these tests should be for at least 10–15
min. If the Ca2+ baseline shifts in response to the staining Ab,
that Ab should not be used. To test whether one of the staining
Abs interferes with binding of the Ab used for stimulation, the
measurement should be compared in the presence and absence of
the respective cell surface Ab.
If datasets from different days have to be compared, it is rec-
ommended that you keep the times between loading, staining, and
data acquisition constant for all of the samples.
The UV laser should be turned on at least 15 min beforehand
to allow it to stabilize prior to use, since it is highly sensitive
and more prone to fluctuation than other lasers. To ensure data
reproducibility, it is also useful to wait a few seconds after loading
the tube before recording the events. This will provide a better
definition of the baseline. The flow rate should be kept constant
throughout the measurement at low or intermediate rates. How-
ever, if the population of interest represents only a very small
percentage of the acquired cells, it will be necessary to measure at
higher speed in order to be able to record enough events/second
for your analysis.
It is important to note that extracellular concentrations of Ca2+
will affect Ca2+ entry, with higher concentrations leading to higher
entry, and other ions (e.g., Cl-, Na+, K+) may also have an effect.
The presence of serum may influence the availability of ions and
other factors. The phosphate present in PBS may precipitate Ca2+,
also affecting extracellular Ca2+ levels. Depending on your exper-
imental question, cell type and other conditions, RPMI with serum
and/or PBS may not be optimal to use as the final buffer. Because
of this, it may be helpful to make your own buffer, in which the
concentrations of all ions are known. For washing your samples
and the final measurement on the cytometer, it may help you to
use HBSS solution without Ca2+ (Hanks solution), preferably self-
made, and to supplement a portion of this with 2 mM Ca2+ on the
day of the experiment.
11.7 Top tricks
11.7.1 Measuring different cell types and various subpopulations.
The protocol described above is in general applicable for the
determination of Ca2+ mobilization in B cells, T cells, NK cells,
granulocytes, monocytes, and also different cell lines. By adding
surface markers to the Ab staining, a high resolution of the dif-
ferent subpopulations from peripheral blood as well as from lym-
phoid organs can be achieved. The stimuli have to be adjusted,
according to the Ca2+ flux-inducing receptor. In primary human
T cells CD3 mAb must be crosslinked. To analyze class switched
B-cell populations in parallel, anti-Ig instead of anti-IgM should
be used for antigen receptor stimulation. While Ca2+ levels are
relatively similar in T and B cells, different cell types have differ-
ent intracellular Ca2+ levels. The appropriate PMT settings for B
cells would not necessarily fit those for granulocytes or cell lines,
therefore PMTs should be reset accordingly.
For cell lines, it might be necessary to serum starve the cells
prior to Ca2+ determination, therefore both loading and washing
steps could occur in the absence of FCS, or in the presence of lower
concentrations of FCS. Alternatively, lower concentrations of Indo-
1 AM, shorter incubation times, and the omission of Pluronic F-
127 can be tested, depending on the cell type and the precise
application, leading to changes in the fluorescence intensity of the
Indo-1.
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11.7.2 Distinction between ISR and SOCE. Cell culture medium
usually contains Ca2+. To differentiate between ISR, from the ER
into the cytoplasm, and SOCE, from the extracellular space into
the cell, Ca2+-containing medium has to be removed by washing
and resuspending the cells in Ca2+-free PBS or other Ca2+-free
buffers. Alternatively, EGTA, a chelator that is related to EDTA
but preferentially binds Ca2+ ions, can be used. The transient ISR
is detected after the appropriate stimulation, while subsequent
addition of CaCl2 during the measurement reveals the sustained
SOCE.
12 mRNA
12.1 Overview
The quantification of transcripts (mRNA) is key to understanding
the immediate response of cells to changes. Furthermore, measur-
ing transcripts is a useful alternative when Abs for protein detec-
tion are not available. Several techniques have been traditionally
developed to quantify mRNA, such as quantitative RT-PCR, North-
ern blot analysis, nuclease protection assays and fluorescence in
situ hybridization but none of these methods allow complex high-
throughput single-cell analysis. This section will introduce a novel
FCM technique that enables simultaneous quantification of tran-
scripts as wells as intracellular and surface proteins on a single-cell
level [494–496].
12.2 Introduction
The immune system comprises many different cell types, each of
them bearing specialized functions. The response of any cell can be
detected first at the transcriptional level (mRNA) and subsequently
at the level of proteins translated from the mRNAs. Until recently,
the simultaneous detection of specific nucleic acid sequences in
combination with proteins on a single-cell basis was restricted
to microscopy, limiting the analysis to a few hundred cells. Flu-
orescence in situ hybridization is an example of such a method,
although high-throughput acquisition is not applicable. Flow cyto-
metric analysis of nucleic acids, especially RNA species, including
mRNA, miRNA, long noncoding RNA (lncRNA), and viral RNA
targets, allows the high-throughput acquisition of several million
cells on a single-cell basis.
The PrimeFlowTM RNA Assay (Invitrogen, ThermoFisher) uses
branched DNA technology (bDNA) to quantify up to four RNA tar-
gets of interest by FCM. bDNA technology amplifies the reporter
signal instead of the target; the latter is the case, for example,
for RT-PCR. By building a tree-like structure for reporter sig-
nal amplification, the specificity and SNR of bDNA technology
increases.
In principle, RNA sequence-specific probe sets consist of
oligonucleotide pairs (20-40 per target) that hybridize to the
target RNA sequence. The preamplifier, which forms the trunk
of the tree, directly hybridizes to adjacent oligonucleotide
pairs. Subsequently, multiple amplifier molecules hybridize to
a single preamplifier molecule, like the branches of the tree.
Finally, multiple fluorescently-labeled probes bind to an ampli-
fier molecule mimicking the leaves of the tree (Fig. 52). Accord-
ing to the manufacturer’s instructions, an 8000–16 000-fold
amplification of the transcript is achieved after optimal assay
performance.
Currently, four fluorescent dyes that are detectable in differ-
ent channels are available: Type 1/AF647, type 10/AF568, type
4/AF488, and type 6/AF750. Of those types, AF647 and AF568
give the strongest signal, and we recommend using those to detect
RNAs with low or unknown expression. AF488 (medium-intensity
signal) and AF750 (low-intensity signal) should be used for highly
expressed RNA targets.
A main advantage of the PrimeFlowTM RNA Assay is that pro-
teins, such as lineage markers, intracellular proteins of interest,
and mRNAs can be detected simultaneously. This will allow for
the quantification of transcripts and protein in defined cell types
on a single-cell level.
12.3 Step-by-step protocol
The PrimeFlowTM RNA Assay can be performed in a conventional
laboratory equipped with a CO2 incubator, capable of stably main-
taining 40°C, a refrigerated swinging bucket centrifuge, and a flow
cytometer supplied with three lasers: blue (488 nm), yellow-green
(561 nm), and red (633 nm or similar).
The assay can be performed in 1.5-mL Eppendorf tubes pro-
vided in the kit, or in 96-well V- or U-bottom plates. The step-by-
step protocol in this version is based on using 96-well V-bottom
plates. When using 1.5-mL Eppendorf tubes, the volumes have to
be adjusted.
It is important that after all centrifugation and discarding steps,
the residual volume in each well does not exceed 10 µL.
12.3.1 Single cell suspension preparation. For reliable results, it
is crucial that the assay is performed with vital cells.
12.3.1.1 Cultured cells. Collect cells by centrifugation (sus-
pension cells) or trypsinization (adherent cells). For cell lines, it
is recommended using cells in the exponential growth phase.
12.3.1.2 Blood. It is recommended that blood is collected
in a solution preventing coagulation and stored at room tem-
perature to ensure best physiological conditions and high qual-
ity sample preparation. RBCs can be removed using a Ficoll- or
Percoll-gradient purification step according to standard operating
procedures (human), or by lysis as described below for tissues
(mouse).
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Figure 52. Schematic workflow for the quantification of transcripts by FCM using the PrimeFlowTM RNA Assay. Step 1: Single-cell suspensions
are stained for surface and intracellular proteins according to standard protocols for FCM followed by a second fixation step. Step 2: Cells are
incubated with mRNA-specific probe sets. Step 3: The signal of the mRNA-specific probes is amplified using different sets of amplifiers and probes.
Step 4: The fluorescence of stained cells is measured using a flow cytometer and analyzed by suitable software after gating on live singlets. The
example shows the expression of intracellular gagpol mRNA and surface p24 Gag protein of J89 cells that were latently infected with HIV-1 and
activated with hTNF-α (10 ng/mL) for 40 h [495]. Steps 1–3 reproduced with permission from ThermoFisher Scientific C© 2019.
12.3.1.3 Tissues (procedure is validated for murine tumors, lung,
and liver). Collect resected tissues in RPMI supplemented with
10% FCS and cut into small pieces. Digest with 1 mg/mL collage-
nase IV (Bioconcept) at 37°C on a rotating device. After 45 min,
add 2.6 µg/mL DNAseI (ThermoFisher) and continue digestion for
additional 15 min at 37°C. Wash cells with 0.01 M EDTA in PBS
by centrifugation at 350 × g for 5 min. Lyse RBCs using RBC lysis
buffer (17 mM Tris pH 7.2, 144 mM NH4Cl) for 2 min. Wash cells
with PBS and filter the cell suspension through a 70-µm filter to
remove debris.
Be aware that collagenase treatment may affect the expres-
sion of certain cell surface antigens [497] and may be replaced
by other methods for single-cell preparation from tissue include
mechanical hashing and serial filtering [498]. Moreover, manip-
ulation of tissues ex vivo may influence both the stability and
composition of mRNA in the sample [499]. Because the influ-
ence of the tissue-processing method on the quality and quan-
tity of individual proteins and transcripts cannot be predicted,
we recommend including test runs or validation steps wherever
possible.
12.3.1.4 Cell surface, intracellular staining, and target probe
hybridization. The method described below is based on the man-
ufacturer’s protocol. All buffers included in the PrimeFlowTM RNA
Assay kit are marked with an asterix (*). The notes are added by
the authors based on their experience.
The following protocol is adapted for the use of 96-well U- or
V-well plates. Please refer to the manufacturer’s protocol for 1.5
mL tube protocol.
The washing buffer should be brought to room temperature
before usage.
1. Prepare 2–5 × 106 cells in 100 µL of FCM buffer (PBS, 2%
FCS) per well of a 96-well plate. Centrifuge at 500 × g for
4 min at 4°C. Discard the supernatant by inverting the plate
over the sink and blotting it on a paper towel.
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Note 1: Please be aware that due to the high number of washing
steps, approximately double the initial amount of cells in comparison
to regular antibody staining should be used.
Note 2: Please note that target expression levels should be taken
into consideration for defining the amount of starting material. The
authors recommend to start with higher amounts of cells if the target
mRNA, the target antigen, or target cell type are present in low
frequency.
Note 3: The authors recommend a final concentration of 20 mM
EDTA at pH 8.0 in the FCM buffer for tissue samples to ensure proper
single cell disaggregation.
2 Surface stain cells with appropriate fluorophore-labeled Abs
diluted in 100 µL FCM buffer for 30 min at 4°C.
Note: Include a fixable viability dye to exclude dead cells from the
analysis. If a fixable viability dye is used, usually an FCS-free buffer
for washing and staining must be used.
3 Centrifuge at 500 × g for 4 min at 4°C and discard the super-
natant. Wash with 200 µL FCM buffer. Discard supernatant
by careful aspiration or inverting and blotting.
4 Prepare Fixation Buffer 1*: Mix equal parts of Fixation Buffer
1A* and Fixation Buffer 1B* (by gently inverting 4 times). A
total volume of 200 µL/sample is required.
Note: Prepare fresh. Avoid vortexing and shaking.
5 Centrifuge at 1000 × g for 4 min at 4°C, discard the super-
natant, and resuspend cells in residual volume by pipetting
(vortexing when using 1.5 mL tubes).
6 Add 200 µL of Fixation Buffer 1* to each well and mix gently
by pipetting. Incubate for 30 min at 4°C.
7 Centrifuge at 1000 × g for 4 min at 4°C, discard the super-
natant and suspend cells in residual volume by pipetting.
8 Prepare Permeabilization Buffer with RNase inhibitors*:
Dilute Permeabilization Buffer* tenfold with RNAse-free
water. Add RNase-inhibitor* at 1/100 ratio. The needed total
volume throughout the assay per sample is 700 µL.
Note: Prepare fresh. Avoid vortexing and shaking. We recommend
to prepare 10% more of the permeabilization buffer to account for
the buffer foaminess and pipetting errors.
9 Add 200 µL of permeabilization buffer with RNase inhibitors*
to each well and mix gently. Centrifuge at 1000 × g for 4 min
at 4°C, discard the supernatant and resuspend cells in residual
volume.
10 Repeat step 9.
11 (Optional) Stain cells intracellularly with the appropriate
fluorophore-labeled Abs in 100 µL permeabilization buffer
with RNase inhibitors* for 30 min at 4°C.
12 (Optional) Centrifuge at 1000 × g for 4 min at 4°C, discard
the supernatant, and suspend cells in residual volume.
13 Repeat step 12.
14 Prepare Fixation Buffer 2*: Dilute Fixation Buffer 2* eight-
fold in Wash Buffer*. Volume per sample: 200 µL. Mix by
inverting.
15 Add 200 µL Fixation Buffer 2* to each well and incubate for
1 h at room temperature in the dark.
Note: The protocol can be stopped at this step after adding Fix-
ation Buffer 2*. The cells can be incubated overnight in the dark at
4°C.
16 Centrifuge at 1000× g for 4min at room temperature, discard
the supernatant, and resuspend cells in residual volume.
17 Wash with 200 µL Wash Buffer*. Centrifuge at 1000 × g
for 4 min at room temperature, discard the supernatant, and
resuspend cells in residual volume.
18 Repeat step 16.
Note: The protocol can be stopped at this step. The cells can be
stored in Wash Buffer* with RNAse inhibitors* (1/100) overnight at
4°C in the dark.
19 Thaw target probe sets at room temperature and pre-warm
Target Probe Diluent* to 40°C in the incubator.
20 Prepare target probes: Dilute target probes 20-fold in Target
Probe Diluent*. Volume per sample is 100 µL.Mix the solution
by pipetting up and down.
Note 1: If you combine more than one target probe in a sample,
make sure that the final volume is 100 µL.
Note 2: For detecting low-expressed mRNA targets, tenfold or
fivefold dilutions of target probe dilutions might be helpful. Be aware
to use the appropriate scrambled probes at the same concentration
to control for unspecific binding.
21 Add 100 µL Wash Buffer* to each well. Add 100 µL of target
probes to the cell suspension and mix by pipetting. Incubate
the plate for 2 h at 40°C.
Note 1: A lid can be used instead of the plastic seal.
Note 2: To increase the signal, the incubation time can be pro-
longed to 3 h.
22 Centrifuge at 1000× g for 4min at room temperature, discard
the supernatant, and suspend cells in residual volume.
23 Wash with 200 µL Wash Buffer*. Centrifuge at 1000 × g
for 4 min at room temperature, discard the supernatant and
suspend cells in residual volume.
24 Repeat step 22.
25 Prepare Wash Buffer* with 1/100 RNase-inhibitor*. Mix by
inverting. Volume per sample: 100 µL.
Note: Prepare fresh. Avoid vortexing and shaking.
26 Add 100 µL Wash Buffer with RNase-inhibitors* to each well
and mix by pipetting.
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Note: For the manageability of the whole procedure, the manu-
facturer recommends to interrupt the procedure at this step and to
keep the cells overnight in the dark at 4°C.
12.3.2 Signal amplification.
27 Pre-warm PreAmp Mix*, Amp Mix* and Label Probe Diluent*
at 40°C (in the incubator).
28 Pre-warm samples and Wash Buffer* at room temperature in
the dark.
29 Thaw Label Probes* on ice in the dark.
30 Add 100 µL of pre-warmed PreAmp Mix* directly into the cell
suspension and pipet to mix. Incubate plate with lid for 1.5 h
at 40°C.
Note: To increase the signal, up to 2 h incubation time can be
performed.
31 Centrifuge at 1000× g for 4min at room temperature, discard
the supernatant, and suspend cells in residual volume.
32 Wash with 200 µL Wash Buffer*. Centrifuge at 1000 × g
for 4 min at room temperature, discard the supernatant, and
suspend cells in residual volume.
33 Repeat step 31.
34 Add 100 µL Wash Buffer* to each well. Add 100 µL of Amp
Mix* directly to the cell suspension and mix by pipetting.
Incubate the plate with lid for 1.5 h at 40°C.
Note: To increase the signal, the incubation time can be prolonged
to 2 h.
35 Centrifuge at 1000× g for 4min at room temperature, discard
the supernatant, and suspend cells in residual volume.
36 Wash with 200 µL Wash Buffer*. Centrifuge at 1000 × g
for 4 min at room temperature, discard the supernatant, and
suspend cells in residual volume.
37 Repeat step 35.
38 Prepare Label Probes*: Dilute Label Probes* 100-fold in Label
Probe Diluent*. Volume needed per sample is 100 µL.
39 Add 100 µL of Wash Buffer* to each well. Add 100 µL of Label
Probes* directly to the cell suspension and mix by pipetting.
Incubate plate with lid for 1 h at 40°C.
Note: To increase the signal, the incubation time can be prolonged
to 2 h.
40 Centrifuge at 1000× g for 4min at room temperature, discard
the supernatant, and suspend cells in residual volume.
41 Wash with 200 µL Wash Buffer*. Centrifuge at 1000 × g
for 4 min at room temperature, discard the supernatant, and
suspend cells in residual volume.
42 Repeat step 40.
43 Resuspend cells in 100 µL Storage Buffer* or FCM buffer.
Transfer each sample to a polystyrene FCM tube and measure
samples in a flow cytometer.
Note 1: You may keep the samples at 4°C for 3 days before
analyzing. The manufacturer recommends storing the cells in IC
Fixation Buffer* at a ratio of 1/1 with the cell suspension.
Note 2: For compensation of fluorophore-labeled Abs for surface
staining, intracellular staining, and viability staining, we recom-
mend using the provided UltraComp beads*. For compensation of the
fluorophore-labeled probes, the manufacturer recommends using the
Compensation Kit* together with the UltraComp beads*. It is not rec-
ommended replacing the Compensation Kit* with other fluorophore-
labeled Abs that are detected in the same BP filters. Alternatively,
samples can be single-stained with house-keeping gene probes labeled
in all four types and used as positive controls for compensation.
12.4 Materials
The PrimeFlowTM RNA Assay kit (ThermoFisher, 88-18005-210)
contains the following material: PrimeFlowTM RNA Fixation
Buffer 1A (00-18100), PrimeFlowTM RNA Fixation Buffer 1B (00-
18200), PrimeFlowTM RNA Permeabilization Buffer (10×) (00-
18300), PrimeFlowTM RNA Fixation Buffer 2 (8×) (00-18400),
PrimeFlowTM RNA Wash Buffer (00-19180), PrimeFlowTM RNA
Target Probe Diluent (00-18185), PrimeFlowTM RNA PreAmp
Mix (00-16000), PrimeFlowTM RNA Amp Mix (00-16001),
PrimeFlowTM RNA Label Probe Diluent (00-19183), PrimeFlowTM
RNA Storage Buffer (00-19178), PrimeFlowTM RNase Inhibitor
(100×) (00-16002), PrimeFlowTM RNA Label Probes (100×) (00-
16003), PrimeFlowTM Compensation Kit (88-17009), IC Fixation
Buffer (00-8222), PrimeFlowTM RNA tubes (1.5-mL microcen-
trifuge tubes) (19197), and UltraComp eBeadsTM Compensation
Beads (Invitrogen, ThermoFisher 01-2222-42).
The following material is required, but not included in the kit:
RNA detection Content
Target Probe Sets Target mRNA of interest in preferred
fluorophore, ThermoFisher
Media Content
RPMI + FCS RPMI, 10% FCS
RNAse-free water
Buffer Content
FCM buffer PBS, 2% FCS
RBC lysis buffer Cat. Number: 00-4300
(ThermoFisher)
Abs
Surface staining
Abs
Fluorophore-labeled Abs for surface
antigens
Intracellular
staining Abs
Fluorophore-labeled Abs for
intracellular antigens
Viability dyes Fixable viability dyes
Other material
96-well plate 96-well V- or U-bottom polystyrene
plate
FCM tube Polystyrene FCM tube
Instruments
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Incubator Incubator validated to maintain 40 ±
1°C
Centrifuge Swinging bucket centrifuge,
refrigeration to 4°C
Flow cytometer Flow cytometer containing three
lasers: blue (488 nm), yellow-green
(561 nm) and red (633 nm).
Excitation/ Emission maximum of
probe sets:
Type 1/AF647: Exmax: 650 nm,
Emmax: 655 nm, bandpass filter:
660/20 nm;
type 10/AF568 (Exmax: 578 nm,
Emmax: 603 nm), bandpass filter:
610/20 nm;
type 4/AF488 (Exmax: 490 nm,
Emmax: 525 nm), bandpass filter:
530/30 nm
type 6/AF750 (Exmax: 749 nm,
Emmax: 775 nm), bandpass filter:
780/60 nm.
12.5 Controls and data analysis
It is recommended to include two negative controls to allow dis-
crimination of false positive results: (i) a sample stained with the
full Ab panel but without the probe (similar to a classical FMO
control) and (ii) a scrambled probe (similar to an isotype con-
trol). Additionally, cells known to not express the target mRNA
serve as a biological control. Background signals can be dimin-
ished by additional washing steps between different incubations,
however this might lead to cell loss.
To control for correct performance of procedure, include a sam-
ple stained with the full Ab panel plus a probe for a housekeeping
transcript.
If the target RNA is expressed at low level, increasing the sig-
nal may be desired. This can be achieved by longer incubation
times of target probes, PreAmp Mix, Amp Mix, and label probe.
In addition, increasing the amount of target probes during 3 h
of incubation significantly increases the signal of the target RNA
detection without increasing the background.
Acquired data can be analyzed with any software compatible
with FCM files.
12.6 Pitfalls
Although the stability and the number of applications have
improved, the technique still harbors some limitations. First, low
expression of mRNA targets is the major pitfall, as rare expression
events may not be detectable with this assay. Second, mutations as
well as splicing variants of the target mRNA might result in signal
reduction or even signal loss. Third, this protocol increases the aut-
ofluorescence of cells, which mostly affects FITC and PE channels.
Fourth, several available fluorochromes are not compatible with
this assay. This mainly affects temperature-sensitive and tandem
dyes such as PerCP, PerCP-Cyanine5.5, and PerCP-eFluor710. This
restriction may hamper the design of large multicolor panels. It is
recommended testing each Ab throughout the whole procedure to
determine its suitability beforehand. Finally, phospho-specific Abs
for intracellular staining that require a methanol-based fixation
are not compatible with the PrimeFlowTM RNA Assay.
12.7 Top tricks
The top tricks to clearly obtain a reliable signal or to increase the
signal for the target mRNAs are:
1. Careful design of the target probes: (i) Use a high number
of target probes pro target mRNA, (ii) Use bright fluorescent
target probes for mRNA with unknown or low-expression.
2. Increase the signal: (i) Increase incubation times of target
probes, PreAmp, Amp, and Label Probes, (ii) Increase con-
centration of target probes.
3. Use a stable incubator and do not open the door during incuba-
tion times at 40°C. If available, monitor the temperature with
a NIST calibrated thermometer.
4. Use all controls suggested and perform a meticulous compen-
sation following the instructions above.
5. Use the RNA inhibitors included in the kit and work in a clean
environment.
6. Contact the manufacturer in advance for panel design.
12.8 Conclusion
In conclusion, the PrimeFlowTM RNA Assay opens up new options
for studying complex cellular interactions, short-term responses
to stimuli, or expression of a certain marker on single-cell level,
when specific Abs for the target proteins are not commercially
available [494–496, 500, 501] Moreover, the simultaneous quan-
tification of mRNA and protein allows the detailed study of cel-
lular dynamics upon certain culture conditions. This assay also
offers the possibility of high-throughput screening on a single-cell
basis.
13 Transcription factors
13.1 Introduction
Cell functionality and differentiation are all controlled by tran-
scription factors within cells that regulate gene expression. As
these factors are generally proteins, they may be detected using
an Ab directed against some specific epitope within the protein. In
this way, detection of transcription factors is in essence no differ-
ent from detecting proteins on the surface of the cell. However, as
the proteins of interest will be located within the cell, either in the
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cytoplasm, within a cellular sub-compartment or in the nucleus,
cells must be permeable to allow access of the Ab to its binding
site. As the factors need to be preserved in their sub-cellular loca-
tion and in their physiological condition at the time of sampling,
any fixation must be very rapid and pervasive.
Detection of transcription factors by FCM thus requires careful
planning, with attention paid to several specific questions that will
dictate the best protocols to follow. The most important of these
questions is, “Will surface staining (i.e., phenotyping) be necessary
to identify the cells of interest?”
The answer to this question is critical, as it will dictate the
best way to prepare the cells, allowing the antigens access to the
intracellular compartment and their target. It will also impact the
choice of fluorochromes used because different fixation methods
can have dramatic impact on the fluorescent molecules [502]. The
two most common fixation reagents are alcohols and aldehydes,
each having their strengths and drawbacks.
Alcohols, such as ethanol and methanol, or acetone, are dehy-
drating fixatives that both coagulate proteins (fixation) and cre-
ate holes in the lipid membrane (permeabilization). Many of the
cyclins and phospho-specific proteins are readily detectable post-
alcohol fixation [503]. Unfortunately, alcohol fixation adversely
affects fluorescent proteins such as GFP, which will be affected by
alcohol fixation in such a way that it will no longer be fluores-
cent after conformational changes or may even leach out of the
cell [504].
Alcohol fixation will also adversely affect commonly used flu-
orochromes including PE, PerCP, and APC, making these fluo-
rochromes a poor choice for surface staining. Small cyclic ring
fluors such as FITC, the Alexa Fluor R©, and the cyanine dyes are
more resistant to alcohol fixation. Surface markers may also be
stained post-fixation if the protein structure, or at least the spe-
cific recognized sequence is unaltered by the chemical process of
fixation. If no evidence is available, this may have to be determined
empirically.
Aldehyde fixation is performed usually with formaldehyde in
the range 1–4% [505]. Aldehydes are cross-linking fixatives so
they lock protein structure in place by forming crosslinks between
lysine residues, forming methylene bridges. This generally means
Abs will still recognize their epitope. However, formaldehyde on
its own is not a good permeabilizing agent and it would normally
be combined with a detergent—this is the basis of many Fix and
Perm kits that are on the market (although the exact composi-
tion of commercial kits is often not common knowledge due to
Intellectual Property policies). A range of detergents is available
such as Triton X-100, lysolecithin, Nonidet-P40, and saponin. The
choice may depend on localization of the protein. Transcription
factors tend to be nuclear and the use of a stronger detergent
such as Triton X-100 (generally around 0.1%) is a good choice as
it can permeabilize both the plasma and the nuclear membrane.
Saponin on the other hand is not a good permeabilizing agent for
nuclear factors due to its more “gentle” and reversible nature and
has often seen more use in cytokine staining. However, it should
also be noted that cytokine staining is also compatible with deter-
gents such as NP-40 (see also Chapter III Section 5: Cell fixation
and permeabilization for flow cytometric analyses) [506].
It is important to note, as with any FCM protocol, the exclu-
sion of dead cells is critical for analysis. Commonly used viability
dyes such as PI or 7AAD rely on an intact membrane for differen-
tiation of live versus dead cells (see Chapter III Section 4: Dead
cell exclusion, cell viability, and sample freezing). When targeting
intracellular markers by flow, the use of fixable amine-reactive
dyes must be used (see also Chapter II Section 5: Cell fixation and
permeabilization for flow cytometric analyses) [201]. These dyes
still allow for the discrimination of dead and live cells from live
even after the fixation and permeabilization processes.
As fixation chemically alters the cells, it will also change to
some extent the autofluorescence of the cell. Changes in morphol-
ogy may be seen as alterations in light scatter patterns in a flow
cytometer. Again, alcohols will have a more dramatic effect. Con-
versely, alcohols do not cause, in general, a change in levels of
background autofluorescence that may be important if a low level
specific signal is expected. If an aldehyde is used, fixation should
be brief and cells should be stored in a phosphate buffer prior
to staining as aldehydes, especially glutaraldehyde, will cause an
increase in autofluorescent background.
Reagent manufacturers each sell specific buffers and kits for
staining of specific transcription factors, often with proprietary
reagents, but these buffers have been designed to allow detection
of nuclear antigens without comprising surface antigen detection.
Some of these kits will have separate fixation and permeabilization
steps, while others will be in a single solution. The choice of which
kit or reagents to use is often dictated by the intracellular target,
so reading of the technical specification of the given Ab is critical.
The location of the target may also influence the fluorochrome
used to label the Ab. Fluorochromes such as PE, APC, and PerCP
and their tandems are large proteins that add considerably to the
molecular weight and size of the Ab. This means that to detect a
nuclear protein, a harsher permeabilization/fixation regime may
be needed, which may also lead to selective loss of small molecules
from the cell. But it may also mean that the comparatively larger
fluorochrome will restrict access of the Ab to the nucleus alto-
gether.
In conclusion, there is not a universal protocol applicable to all
transcription factors, which can be expressed in different cellular
locations (see Table 11); the type of fixation, the length of fixation,
the type of permeabilization, the choice of fluorochromes, and the
staining protocol, including incubation times of Ab staining, must
all be optimized. The principle advantage of FCM in this area is the
ability tomultiplex an assay, and by usingmultiple analytes be able
to very specifically define subsets of interest—this will only be lim-
ited by the cytometer available. One downside of FCM is the lack
of morphological information and inability to specifically localize
the fluorescence within the cell. If this is important then imag-
ing using either fluorescence microscopy, confocal microscopy, or
imaging FCM should be considered.
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Table 11. Most common transcription factors measured by FCM. For more information about them http://www.uniprot.org/uniprot/
Transcription factors Cell type Cellular location
AHR Liver, Treg, and Th17 cells Cytoplasm
Aiolos B, T, and NK cells Nucleus
AIRE Dendritic cells, lymph node, lymphoid stromal cells,
and monocytes
Perinuclear region (??)
BATF B and T cells Nucleus
Bcl-6 B cells and CD4+ T follicular helper cells and memory
T cells
Nucleus
β Catenin Several non-immune tissues, B, T, and hematopoietic
stem cells
Cytoplasm/nucleus
Blimp1 B, T, dendritic, and some NK cells Cytoplasm
c-Maf Neural, ocular, and hematopoietic systems Nucleus
c-Rel Treg, mature T cells Cytoplasm/nucleus
E4BP4 NK, NKT, and dendritic cells Nucleus
Egr1 B, T and myeloid cells Cytoplasm/nucleus
Egr2 (B), T and NKT cells Cytoplasm/nucleus
Eomesodermin/TBR2 NK and T cells Nucleus
Eos T cells and nervous system Transmembrane
FoxJ1 Ciliated epithelial cells, naive B, and T cells Nucleus
FoxP3 CD4+CD25+ regulatory T cells (Treg cells), and
CD4+CD25− cells
Cytoplasm/nucleus
Gata-3 Central nervous system, kidney, mammary glands,
skin, and T cells
Nucleus
Helios/IKZF2 T and hematopoietic stem cells Nucleus
IκB-zeta Macrophages, monocytes, B and T cells Nucleus
IRF4 Macrophages, B and T cells Cytoplasm/nucleus
Nanog Blastocyst, embryonic stem cells, and embryonic germ
cells
Nucleus
NFkB Almost all cell types Cytoplasm/nucleus
NFAT T cells Cytoplasm/nucleus/
transmembrane
Notch1 Thymocytes, bone marrow hematopoietic stem cells, T
and NK cells
Cytoplasm/Golgi/nucleus/
transmembrane
Notch2 Activated peripheral T cells, bone marrow and
thymocytes,
Cytoplasm/Golgi/nucleus/
transmembrane
Notch3 CNS, some thymocyte subsets, vascular smooth
muscle, and T cells
Cytoplasm/Golgi/nucleus/
transmembrane
Notch4 CD8+ splenic dendritic cells, endothelial cells, and
macrophages
Cytoplasm/Golgi/nucleus/
transmembrane
Nurr77 Thymocytes and T cell Cytoplasm/nucleus
OCT3/4 Embryonic stem and induced pluripotent stem (iPS)
cells
Nucleus
Pax5 Hematopoietic cells, B cells Nucleus
PLZF CD4 and CD8+ T cells, gamma delta T cells and NK. Cytoplasm/nucleus
RORγ Heart, kidney, liver, lung, muscle, and CD4+CD8+
thymoycte cells
Nucleus
Runx1/AML1 Hematopoietic, myeloid, B and T cells Cytoplasm/nucleus
Sox2 Embryonic stem cells and neural cells Cytoplasm/nucleus
T-bet B cells and CD4+ T-cell lineage Nucleus
ThPOK Hematopoietic cells, skin, heart, smooth muscle, and
liver, invariant natural killer T (iNKT) cells and
gamma delta T cells
Nucleus
TOX Thymocytes, T lymphocytes, NK cells, and lymphoid
tissue-inducer (LTi) cells
Nucleus
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13.2 Example of a generic protocol for an intranuclear
antigen—pH3
13.2.1 Staining protocol (adapted from ref. [507]). Staining is
done in a 96-well U- or V-bottom plate.
1. Count cells from culture/primary sample and resuspend at
10 million cells/mL, aliquot 100 µL/well (106 viable cells
per sample for staining). Spin down plate at 350 × g for a
minimum of 3 min at room temperature. Flick SN and vortex
plate to re-suspend. These will be the conditions for all wash
steps.
2. Optional: Stain for Live/dead and surface markers prior to fix-
ation. Follow manufacturer’s recommendations for live/dead
staining. Make up Ab cocktail in staining buffer at optimized
dilutions. Add 100 µL per well per million cells and incubate
for optimized time (1 h minimum).
3. Add 100 µL of Staining buffer per well and spin down as in
step 2. Add 200 µL of fresh Staining buffer and spin down
again.
4. Resuspend cells in 100 µL of PBS only and pipette up and
down to ensure cells are fully in suspension. Then add 100 µL
of 4% fixation buffer to final concentration of 2%. The pre-
suspension in PBS minimizes the formation of cell clumps
during the fixation process. Leave at room temperature for a
minimum of 60 min.
5. Spin down cells and treat as in step 1.
6. Resuspend pellet in 100 µL of PERM buffer using a P200
pipette. Incubate tubes at room temperature for exactly 5
min (stagger addition of PERM buffer if needed).
7. Add 100 µL of Staining buffer to each well in staggered fash-
ion to end permeabilization step. Spin down and process as
in step 2.
8. Add 100 µL of primary Ab cocktail and mix in PBS + 2% FCS.
Incubate at room temperature for optimized time (usually
1–2 h).
9. Add 100 µL of Staining buffer and spin down and process as
in step 2. Repeat this wash step with 200 µL fresh Staining
buffer.
10. If necessary, incubate cells with secondary Ab cocktail mix for
the optimized time (usually a minimum of 30 min) at room
temperature in the dark.
11. Wash the cells, as outlined in step 2, twice in fresh Staining
buffer.
Final resuspend volume should be 200–400 µL of Staining
buffer.
14 Intracellular parameters
FCM is a powerful tool to measure expression levels of pro-
teins that can be found inside cells such as transcription fac-
tors, cytoskeletal components, and apoptosis regulators, or those
that are usually secreted like cytokines and chemokines. However,
whereas proteins from the former category are normally expressed
constitutively, cytokine expression usually requires restimulation
of the cell, as is the case for T cells, which express cytokines 2–
24 h after T-cell receptor engagement [508, 509]. However, some
cell types, such as innate lymphoid cells, also express cytokines
constitutively [510, 511]. To enable the intracellular detection of
otherwise secreted proteins, secretion can be blocked by Brefeldin
A or Monensin that block transport of vesicles from the ER to the
Golgi or within the Golgi apparatus, respectively.
To activate cytokine expression, T cells can be stimulated in
two ways: while cytokine expression in some memory T-cell sub-
sets can be induced by cytokine signaling, such as IFN-γ which
can be induced by IL-12 and IL-18 [512, 513], most T cells have
to receive a T-cell receptor signal and a costimulatory stimulus.
This can be achieved in a polyclonal way by agonistic Abs against
CD3ε and CD28, coated to the surface of a culture vessel or in an
antigen-dependent manner by the incubation with peptide-pulsed
APCs. Alternatively, cells can be exposed to the chemicals phorbol
12-myristate 13-acetate (PMA) and ionomycin that mimic TCR sig-
naling by activating protein kinase C/NFκB and calcineurin/NFAT
pathways, respectively. The restimulation conditions have a strong
impact on the cytokine expression results and should thus be cho-
sen carefully:
1. PMA/iono is usually a stronger inducer of cytokine expression
compared to CD3/CD28 stimulation. While it might be argued
that this trigger is not physiological, it is very well suited to
reveal the maximal cytokine expression potential of the T cells
rather than their actual cytokine expression, e.g., in vivo at the
time point of analysis.
2. For PMA/iono, the Ca2+ concentration of the medium can be
critical: maximal cytokine expression requires 1.5 mM of Ca2+
as present for example in Iscove’s modified Dulbecco’s medium,
but not in the routinely used medium RPMI 1640 (Fig. 53A)
[514].
3. The cell concentration should not be too high as this will
reduce cytokine expression. For PMA/iono stimulation, we
have noticed decreased cytokine expression when using 1–5
× 107 cells/mL compared to 2 × 106 cells/mL (Fig. 53B).
4. Expression kinetics can be important. Using PMA/iono, maxi-
mal cytokine expression is achieved as early as 4 h following
stimulation (Fig. 53C) [515].
For the detection of intracellular antigens, cells have to be
fixed and permeabilized. Numerous protocols and reagent kits
are available for fixation and permebilization, each optimized for
the detection of certain antigens, such as cytokines, transcrip-
tion factors, and so on. For cytokine detection, cells can be fixed
after surface Ab staining with 1–4% formaldehyde [516], although
in our experience the use of commercially available fixation kits
can be beneficial for the integrity of the surface staining. Cells
are then permeabilized with a mild detergent, e.g., saponin that
builds complexes with cholesterol and hence forms holes in the
cholesterol-rich plasma membrane but not in the cholesterol-poor
nuclear membrane [517, 518]. It should be noted that restimu-
lation of Th cells leads to internalization of CD3/TCR and CD4
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 Biological applications 1575
Figure 53. An example of intracellular cytokine detection. Shown are viable, single, CD3+CD4+ C57BL/6 WT Th cells from the inflamed colon
of T-cell transfer-induced colitis. (A) Cells were restimulated for 4 h with PMA/iono (and Brefeldin A added after 1 h) in RPMI, IMDM, or CaCl2-
supplemented RPMI and stained for intracellular cytokine expression. (B) Frequency of IL-17+ cells among colonic Th cells restimulated with
PMA/iono at the indicated densities for n = 7 mice. (C) Frequency of IL-17+ cells among colonic Th cells restimulated with PMA/iono for the
indicated amount of time for n = 4 mice per group. *p < 0.05, **p < 0.01, and ***p < 0.001 by one-way ANOVA for repeatedmeasurements and Tukey’s
post hoc test. Reproduced with permission from ref. [514].
proteins from the surface of the cell [519, 520]. It can thus be
beneficial to stain these antigens following fixation and permeabi-
lization to also detect the internalized molecules. To control for
true positive cytokine staining, unstimulated cells, cells that have
not been permeabilized, or endogenous negative control cells can
be used.
Transcription factors can usually be stained directly, i.e., with-
out prior acute restimulation, as they are normally expressed con-
stitutively. Nevertheless, the expression levels of certain transcrip-
tion factors might also change depending on the activation status
of the cell (Fig. 54A). Following surface staining, cells are com-
monly fixed and permeabilized with commercially available kits
for transcription factor staining, as saponin-mediated permeabi-
lization is too weak to enable nuclear penetration of Abs. The
optimal fixation time and condition may vary for each different
transcription factor and among different cell types and should
thus be established for the specific setting of interest (Fig. 54B).
Using T cells from the inflamed gut of T-cell transfer colitis, we
have observed that overnight fixation impaired staining of the
transcription factor eomesodermin, which was clearly detectable
when fixing for only 1 h. In contrast, ROR-γt staining in these cells
was comparable between the two fixation regimens. In contrast,
for splenic T cells from the samemodel, overnight fixation resulted
in an even better ROR-γt staining compared with fixation for 1 h.
The topic of transcription factor staining is covered in more detail
in Chapter V Section 13 Transcription factors.
As for any FCM application, optimal titration of Abs is instru-
mental for obtaining high quality results. Intracellular stainings
tend to have a higher background due to the abundance of biolog-
ically active molecules inside of the cell. As transcription factors
are rather rare proteins, they should be stained with bright flu-
orochromes when designing a panel. Most cytokines accumulate
to high density within a cell during reactivation in the presence
of secretion blockers and can hence be detected with less-bright
fluorochromes. There are, however, also cytokines expressed
at low levels and, thus, the panel design should be adjusted
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Figure 54. An example of intranuclear transcription factor detection. (A–D) Shown are viable, single, CD3+CD4+ C57BL/6 WT Th cells from the
inflamed colon or the spleen of T cell transfer-induced colitis. (A) Transcription factor expression can depend on activation state of the cell:
Interferon regulatory factor 4 (Irf4) and T-box expressed in T cells (T-bet) were stained directly ex vivo (grey shaded) or after 4 h restimulation
with PMA/iono (black line). (B) Fixation time can positively or negatively influence staining quality of transcription factors: Eomesodermin (Eomes)
and retinoic acid receptor-related orphan receptor gamma t (ROR-γt) were stained after 1 h or after overnight (o/n) fixation with the eBioscience
Foxp3/transcription factor staining buffer set. (C–F) Transcription factor staining can be combined with cytokine staining or fluorescent reporter
genes. (C and D) ROR-γt, T-bet, IFN-γ, and IL-17 were stained simultaneously with the eBioscience Foxp3 staining buffer set. (D) Black indicates
the full staining and grey the FMO control for the T-bet antibody (ab). (E and F) Depicted are viable, single, CD45+B220−CD11b−F4/80−Gr-1−CD90+,
TCRβ+, TCRγδ− cells from the small intestine of C57BL/6 RorcGFP/+ reporter mice. (E) IL-22 was stained after 4 h of restimulation with PMA/iono
and 5 µg/mL IL-23 with the Miltenyi Biotec inside stain kit. (F) ROR-γt stained directly ex vivo with the Miltenyi inside stain kit is depicted for
ROR-γt−GFP− (grey shaded) and ROR-γt−GFP+ cells (black line).
according to the expected results. Any intracellular staining panel
should include a fixable viability dye to discriminate dead cells.
This is especially important when analyzing cytokine expression,
as the restimulation can induce apoptosis in a significant fraction
of the cells while maintaining their FSC/SSC profile, thus making
their distinction based on scatter parameters impossible. Fixable
viability dyes are now broadly available and are commonly based
on the unspecific binding of fluorochromes with an active chem-
ical group, e.g., succinimidyl esters, to amino groups of cellular
proteins. Thus, viable cells are poorly labeled through their sur-
face proteins while dead cells with a permeable plasma membrane
are labeled brightly through the binding to intracellular proteins.
For certain questions, a co-staining of transcription factors and
cytokines can be required. While transcription factors are poorly
detected following saponin-mediated permeabilization, several
cytokines can be detected with the same protocol as transcrip-
tion factors, i.e. with commercially available transcription factor
staining kits. We were able to stain IFN-γ, IL-17A, T-bet, and ROR-
γt with a commercial transcription factor staining kit (Fig. 54C
and D). However, other cytokines, such as IL-22, can hardly be
detected using a transcription factor staining kit. In this case, iter-
ative staining and fixation steps of first surface antigens, then
cytokines, and ultimately transcription factors might provide a
solution.
Many researchers want to stain intracellular antigens while
maintaining the fluorescence of endogenous fluorescent proteins
such as GFP. Using commercially available staining kits, GFP fluo-
rescence is often lost, most likely due to the passive leakage of the
protein outside of the cell. This can be prevented by a pre-fixation
step with 0.5–2% formaldehyde prior to fixation/permeabilization
with commercial kits [521, 522]. We have obtained good results
for GFP/cytokine staining and for GFP/transcription factor stain-
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ing using a commercial intracellular staining kit (Fig. 54E and
F).
15 Measurement of signal transduction pathways
by flow cytometry
15.1 Introduction
The large majority of proteins involved in the regulation of cell
signaling, survival, and growth regulation are intracellular. This
section covers the technical aspects of intracellular antigen stain-
ing for FCM, using activation and simultaneous monitoring of
multiple pathways in human peripheral blood monocytes as a
practical example. The approaches we use for cell fixation and
permeabilization that optimize intracellular labeling while pre-
serving light scatter and phenotypic markers are presented in the
section on cell fixation and permeabilization (Chapter III Section
5: Cell fixation and premeabilization for flow cytometric analyses).
Although more demanding than cell surface staining, mastery of
intracellular cytometry enables the study of fundamental regula-
tory mechanisms of normal and abnormal cell biology, many of
which remain underexplored.
Signaling pathways typically relay instructions from outside
the cell to the nucleus, where an appropriate genetic program
such as DNA synthesis or enhanced cell survival is executed in
response to inputs from growth factors, cell–cell contacts, or ECM
interactions. The biochemical basis of signal transduction involves
the addition (by kinases) and removal (by phosphatases) of phos-
phate groups from the amino acids serine, threonine, and tyrosine
that contain –OH side chains. Phosphorylation alters the charge
distribution, hence the conformation, of proteins. Typically this
activates the catalytic site of an enzyme, although some phos-
phorylations are inhibitory, inactivating the kinase function of the
protein. Individual proteins involved in signal transduction are
arranged in pathways, where an incoming phosphorylation acti-
vates the kinase activity, allowing it to pass the phosphorylation
signal on to the next signaling element. There are other key cel-
lular pathways that similarly result in different types of posttrans-
lational protein modifications, including methylation, hydroxyla-
tion, acetylation, ubiquitination, and so on, and the basic fixation
and permeabilizkation technique described in Chapter III Section
5: Cell fixation and permeabilization for flow cytometric analyses,
has been used to study some of these [523].
Signal transduction is clearly a complex area of biology.
Although it is likely that the major signaling pathways in mam-
malian cells have now been identified, basic research into how
these are regulated and interconnected continues at a rapid pace.
The complexity of signal transduction pathways allows for multi-
ple activating and inhibitory inputs, and for networking between
pathways. Considering that signal transduction is essential for the
survival of multicellular organisms, this is to be expected.
Derangements in signal transduction are extremely common in
human cancers, and appear to play a major role in the develop-
ment and progression of both solid and hematological malignan-
cies. Similarly, signal transduction pathways play a pivotal role in
multiple aspects in both the development of the immune system,
and in regulating responses to antigenic challenges.
15.2 Sample preparation for signal transduction analysis
The analysis of phospho-epitope expression in clinical samples
(whole blood, bone marrow, body fluids) is complicated by the
need to lyse RBCs, while at the same time preserving surface
immunophenotypic markers as well as light scatter. For this, we
have developed a technique that starts with fixation of the entire
cell suspension, ensuring that phospho-epitopes are stabilized as
soon as possible, followed by red cell lysis using Triton X-100
(Chapter III Section 5: Cell fixation and permeabilization for flow
cytometric analyses). As discussed there, some epitopes (e.g.,
phosphorylated-STAT proteins) require an additional methanol
“unmasking” step for optimization of their expression [75]. We
have also used this technique for the analysis of signaling in bone
marrow samples [72, 73].
15.3 Activation of signal transduction pathways regulating
acute inflammatory responses
Like most signaling pathways, the MAPK pathways are arranged
in cascades in which one member becomes catalytically active
following phosphorylation by its upstream activating kinase. The
activated upstream kinase is able to pass on the signal by phospho-
rylating its downstream substrate. This complexity allows multi-
ple levels of feedback regulation, and interconnections involving
pathways that are critical to the normal maintenance of tissues.
There are three MAPK pathways that in mammals have very dis-
tinct functions, although they are highly conserved in evolution.
The ERK pathway, often simply called the “MAPK pathway” is
involved in growth factor stimulation, whereas the SAPK/JNK
(Stress-Activated Protein Kinase/c-JUN N-terminal Kinase) and
p38 MAPK pathways are more sensitive to other environmental
cues including osmotic stress and heat shock.
In the innate immune response, the bacterial endotoxin LPS
induces the activation of multiple signaling pathways (“pan-
kinase” activation), which leads to an inflammatory response in
monocytes.
As shown in Fig. 55, LPS activation of signaling pathways
in peripheral blood monocytes is somewhat unique, in that it
results in the activation of multiple signaling pathways, including
all three major MAPKs, PI3K >AKT, and NFκB pathways. NFκB
and MAPK activation induces the production of inflammatory and
other cytokines. These pathways have widespread effects on cell
function, which together coordinate the host response to acute
bacterial infection.
Although the original canonical signaling maps indicated that
LPS activates ERK in monocytes via the “classical” Ras>Raf path-
way [524], in monocytes one pathway for LPS activation of ERK
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Figure 55. “Canonical” pathways for LPS activation of multiple signaling pathways in peripheral blood monocytes via TLR-4 (adapted from Guha
and Mackman [524] and reproduced with permission). Inhibition of PI3K (right) by Ly294002 or GDC-0941) or of MEK 1/2 (left) by U0126 is also
illustrated here. Also shown, in monocytes, activation of the ribosomal S6 protein is predominantly through activated ERK.
is via TPL-2, a MAPKKK, which is sequestered in one of the forms
of IκB, is phosphorylated/activated by IKK, and released from the
complex by proteasomal degradation of IκB. Phosphorylated TPL-
2 subsequently phosphorylates/activates its downstream target,
MEK 1/2, which then activates/phosphorylates ERK 1/2 [525].
Signaling pathways are complex, and a specific pattern or path-
way seen in one type of cell does not predict the same pattern
or pathway in all cells. Therefore, it may be important to study
a broad set of specific signaling proteins/modifications for com-
prehensive understanding of signaling pathways in a specific cell
type.
15.4 Kinetics
In studying the activation (and inactivation) of signaling path-
ways, it is critical to include multiple time-points within the exper-
iment. For example, the phosphorylation of ERK in human bone
marrow CD34+ cells (at 37°C incubation) reaches a peak and
returns to unstimulated cell levels in less than 10 min [72], indi-
cating that the dephosphorylation of P-ERK occurs rapidly in this
cell population.
15.5 Kinase and phosphatase inhibitors
Specific (or relatively specific) kinase inhibitors are very useful
when analyzing pathways downstream from a signaling “node.”
For example, U0126 binds to MEK1/2 and prevents it from
phosphorylating (activating) its downstream partner ERK1/2 (see
Fig. 55). Adding U0126 to a whole blood sample will block activa-
tion of ERK1/2 and activation of any downstream target such as
ribosomal S6 protein (in monocytes). In addition, by comparing
the level of a target phospho-epitope expressed in cells exposed
to an inhibitor with that of untreated cells, it is possible to reveal
background or constitutive levels of activation of a specific kinase
and its downstream partners. In Fig. 56, whole blood was treated
(here for 4 min) at 37°C with LPS alone, or with UO126 (MEK
inhibitor) or with Ly294002 (PI3K inhibitor). In the presence of
UO126, activation of both ERK 1/2 and the downstream S6 ribo-
somal protein are inhibited. Also shown here, the PI3K inhibitor
Ly294002 (we have also used the more specific PI3K inhibitor
GDC-0941 with similar results) likewise inhibits activation of both
ERK 1/2 and S6 at this time point. Neither inhibitor changes the
responses for p38 or SAPK/JNK, although PI3K inhibition does
prevent AKT activation (see below). These results are consistent
with a model in which ERK 1/2 can be activated (in human mono-
cytes) via PI3k>AKT. However, a better understanding of the
responses and inhibitions of specific pathways requires monitoring
the responses to different stimuli over time.
As shown in Fig. 56, after appropriate inhibitor and LPS
treatment, cells were fixed and permeabilized using formalde-
hyde/Triton X-100, and subsequently stained using antibodies to
phospho-ERK 1/2 (p44/42MAPK), phospho-S6 ribosomal protein,
plus CD14 and CD45 to identify monocytes (not shown in figure)
and eliminate debris from the analysis. Figure 56 demonstrates
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Figure 56. LPS activation of the ERK pathway in
human peripheral bloodmonocytes. Samples were
pre-incubated with the indicated inhibitors for 60
min at 37oC before the addition of LPS to all sam-
ples. After 4 min incubation with LPS, all samples
were fixed using formaldehyde and permeabilized
using Triton X-100 (see Chapter III Section 5: Cell
fixation and permeabilization for flow cytometric
analyses, for details on fixation and permeabiliza-
tion steps). Only monocyte responses are shown
here, based on CD45 and CD14 gating (not shown
here).
Figure 57. Simultaneous measurement of four different signaling tar-
gets. Human peripheral blood was incubated with LPS for 10 min at
37oC. Here, each of the measured phospho-epitopes is shown versus
SSC, with the CD-14pos monocytes in red.
several key points mentioned above. LPS activates the ERK path-
way rapidly, and only the monocytes showing maximal levels of
ERK phosphorylation also show phosphorylation of S6 (top left).
U0126 inhibition of ERK activation (top right) inhibits the activa-
tion of both ERK and S6. It should be noted that the “canonical”
pathway usually shown in signaling documents indicates that S6 is
activated by PI3K>AKT [526]. The data shown in Fig. 56 are con-
sistent with the concept that activation of ribosomal S6 protein is
via the ERK pathway in human peripheral blood monocytes, high-
lighting the need to carefully investigate the appropriate upstream
activation pathways. Finally, both the activation of ERK and S6 are
inhibited (at this time point) by the PI3 kinase inhibitor Ly294002,
consistent with the concept that ERK activation in human periph-
eral blood monocytes can also be via AKT (not the “canonical”
RAS>RAF pathway, bottom left) [524]. At first, these data seem
inconsistent with the comment above that ERK activation inmono-
cytes is via TPL-2 [525]. However, as shown below (Figure 58),
there are two separate signaling pathways activating ERK, one
through PI3K (early ERK activation), the other through NF-κB.
Signaling pathways (particularly phosphorylation/
dephosphorylation) in normal cells are frequently activated
and then rapidly inactivated. Inactivation of a kinase involves
dephosphorylation of the target phosphorylated amino acid(s)
by a phosphatase. One of the predictions of this model is that
inactivation of a phosphatase should result in maintaining the
effects of an activated kinase for longer time periods [527].
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Figure 58. Kinetics of LPS activation of the AKT
and ERK pathways in peripheral blood mono-
cytes. Whole blood samples were pretreated
with the PI3K inhibitor GDC-0941 (right panel),
or vehicle controls (left panel), followed by acti-
vation with LPS for 0 to 15 min at 37oC. P-AKT
(orange, lower line in both panels) and P-ERK
(red, upper line in both panels). Note that in
the GDC-0941 treated sample (right), the P-ERK
peak seen in the untreated sample is missing
(arrow, right panel).
15.6 Simultaneous monitoring of multiple signaling
pathways in the context of response kinetics
The results shown above in Fig. 56 can be interpreted to indi-
cate that both ERK and AKT pathways are activated by LPS. While
this conclusion is correct, the use of different pathway inhibitors
in conjunction with detailed kinetic analyses reveals important
details of the specific pathways that are activated in human periph-
eral blood monocytes by LPS.
Using the same logic that is commonly used to understand
complex biological systems (e.g., hematopoietic cell differentia-
tion and lineage reconstruction in bone marrow), for simultane-
ous measurement of multiple signaling targets, we routinely mea-
sure multiple signaling targets in each sample. As in all complex
immunophenotyping experiments, attention to details is essential
in the design and execution of these types of experiments. For
example, large fluorophores such as PE or APC should only be
used for nuclear localizing target phospho-epitopes after running
preliminary experiments to ensure the Ab-conjugate can get to the
target. Similarly, tandem dyes (PE-Cy5) should be used with cau-
tion, with appropriate controls to ensure integrity of the tandem
at the time of the assay.
As an illustration of simultaneous measurement of four dif-
ferent signaling targets, Fig. 57 demonstrates the whole blood
analysis of LPS-stimulated human peripheral blood using CD14-
PE-Cy7 to detect monocytes, plus P-p38 (MAPK)-Alexa Fluor R©
488, P-AKT-PE, P-ERK- Alexa Fluor R© 647, and P-S6-PacBlue.
These results demonstrate that the majority of monocytes
(shown in red) are positive for all four phospho-epitopes at 10
min incubation with LPS. As also shown in Fig. 57, the analysis
of each phospho-epitope response includes an evaluation using
SSC, demonstrating that in this donor, only the monocytes show
significant activation of these phospho-epitopes (in many donors,
the granulocytes also show a positive P-p38 population following
LPS activation, not seen here). However, the details of the indi-
vidual signaling pathway responses can only be appreciated using
both multiple time points for LPS activation and the simultaneous
use of specific pathway inhibitors. As shown in Fig. 58, looking at
the kinetics of both P-ERK and P-AKT activation simultaneously
over a 15 min period of LPS activation shows two different peaks
of P-ERK expression (upper response in red in both panels): one
extremely rapid, peaking at 2–4 min (left panel), the second
peaking at 8–10 min (at 37°C incubation). In most (though not
all) normal human donors, we see both peaks, while in a minority
of donors we only see the “later” P-ERK. In a sample pretreated
with the PI3K inhibitor (here GDC-0941, right panel), only the
“early” (2–4 min) P-ERK response is inhibited. In contrast, pre-
treatment with U0126 (as shown in Fig. 56) inhibits both the
early and the late P-ERK peak, indicating that the first peak goes
through PI3K, but requires P-MEK. The second peak of activation
of P-ERK actually goes through IKK>IκB>TPL-2 [525]. Consistent
with this concept, we have demonstrated that the “second” P-ERK
peak is inhibited by proteasome inhibitors, such as MG-132 (inhi-
bition of proteasomal destruction of IκB prevents the release of
TPL-2, preventing it from activating MEK).
The kinetics of AKT activation (Fig. 58) demonstrate a peak at
4–8 min (left panel, lower response in orange) with a sustained
response for the time period measured here. As shown in the
right panel of Fig. 58, GDC-0941 causes complete inhibition of
AKT activation, a useful internal control that strengthens the con-
cept that the “early” ERK activation is through PI3K>AKT. These
data also suggest that there is a constitutive activation of AKT in
peripheral blood monocytes, which is inhibited by PI3K inhibitors
(GDC-0941).
15.7 Sample protocol for LPS activation of human whole
blood
This same approach can be used to study the impact of spe-
cific signaling pathway inhibitors to determine which down-
stream signaling pathways are affected. Overall, monitoring signal
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transduction pathways in stimulated whole blood (and other sim-
ilar types of samples) offers a unique way to test and validate
Abs, specific agonists, or antagonists, using a relevant biolog-
ical system. In addition, this approach can be used to mon-
itor the activity of targeted therapies (inhibitors) in vivo, or
to monitor the prior exposure of individuals to LPS/endotoxin
[528].
15.8 Materials
1. 4.0–5.0 mL human whole blood collected into K2EDTA or
sodium heparin, stored at room temperature until tested. The
blood sample must be used as soon as possible in order to pre-
serve appropriate signaling capabilities. Sample testing should
(ideally) begin within 1–4 h of collection.
2. Directly conjugated Abs to phospho-epitopes (e.g., Cell Signal-
ing Technology, Danvers, MA) and cell surface-specific conju-
gates are necessary. We generally use multiple (generally 4)
phospho-epitope specific Abs in each tube, using lower molecu-
lar weight fluorophores (e.g., Alexa Fluor R© 488, or 647, Pacific
Blue) for staining nuclear or ribosomal targets, and PE or APC
for cytoplasmic targets. The same guidelines must be used here
for the selection of fluorophore–Ab pairs for phospho as for
other targets (e.g., use “bright” conjugates for non-abundant
targets and “dim” conjugates with abundant targets).
(a) CD14-PC7
(b) CD45-KrO
(c) P-ERK-Alexa Fluor R© 647 [T202/Y204], also known as P-
p44/42 MAPKP
(d) P-S6-Pacific Blue [Ser235/236]
(e) P-AKT-PE [Ser 473]
(f) P-p38 MAPK-Alexa Fluor R© 488
15.9 Reagents
1. LPS from E. coli 0127:B8; dilute to 50 µg/mL in PBS; store this
working dilution at 4°C; stable for up to 6 months.
2. Triton X-100, 10% aqueous solution; prepare working solution
by diluting 116 µL stock with 10 mL PBS; store stock and work-
ing solution at room temperature; working dilution is stable for
1 month.
3. Appropriate pathway inhibitors (e.g., U0126 MEK>ERK, GDC-
0941 PI3K>AKT, bortezomib for proteasome inhibitor), as nec-
essary.
4. Formaldehyde, 10% (methanol-free); store at room tempera-
ture in the dark.
5. Albumin solution from bovine serum; store at 4°C.
6. PBS (calcium- and magnesium-free).
7. Wash Buffer: 4% BSA in PBS; filtered through 0.22 µm sterile
filter.
8. Deionized water (for Triton X-100 dilution)
15.10 Procedure: Whole blood fixation and permeabilization
protocol for kinetics and use of inhibitors
Before starting this procedure, prepare an experiment worksheet
to aid in the critical timing steps (see sample Worksheet presented
in Table 12). The experiment described below is for time points of
up to 10 min of LPS activation. LPS is added to the tube(s) with
the longest incubation time first (here, 10 min), followed by stag-
gered LPS addition for shorter incubation times. For experiments
adding specific signaling pathway inhibitors (not outlined here),
whole blood samples are incubated at 37°Cwith inhibitor(s) for an
appropriate time (generally 30–60 min, depending on the specific
inhibitor) before the addition of LPS.
1. Label the appropriate number of 75 mm polypropylene test
tubes for the experiment. There will be one control tube for
each cell surface Ab-conjugate, and appropriate control tubes
for each phospho-epitope (remember that the compensation
control for each phospho-epitope target should express max-
imal levels of each target).
For phospho-epitopes requiring methanol treatment, have
a 50%methanol solution ready for use in the freezer and right
before use, remove from freezer and place into an ice bucket.
See Chapter III Section 5: Cell fixation and permeabilization
for flow cytometric analyses, for details.
2. Just before use, mix blood by inverting vacutainer tube sev-
eral times, then transfer blood into a 50 mL conical tube. Mix
blood while aliquoting samples into 75 mm tubes from Step
1.
3. Pipette 100 µL of blood sample into the bottom of each
appropriately labeled tube. Use a cotton-tipped applicator to
remove any blood from the side of the tube.
4. Add 100 ng LPS (2 µL of working dilution) to the first of the
designated stimulation tubes and mix by shaking tube. Place
that tube into the water bath and start a stopwatch. At the
appropriate time interval, add LPS to the next tube, vortex
and place it into the water bath. Continue for all tubes in the
stimulation part of the experiment.
5. Continue to use the staggered start to place the 37°C “no LPS”
control tube and the CD14-only tube into the water bath (last
tubes to be placed into the 37°C water bath.
6. At the 10 min mark, remove the first tube in the timed
sequence from thewater bath and add 65 µL of 10% formalde-
hyde to the tube. Immediately mix well by shaking tube and
place it into a tube rack. Continue adding 65 µL of formalde-
hyde to each tube in the timed sequence, mixing between
each one. Note: This is a critical step. Formaldehyde stops
the LPS activation and fixes the cell.
7. Incubate each tube for a total of 10 min at room temperature.
8. After exactly 10 min of incubation in formaldehyde at room
temperature, pipette 1 mL of Triton X-100 solution into each
tube at the appropriate time interval, vortex well, and return
tube to rack. After Triton is added to the last tube, vor-
tex all tubes, place into the 37°C bath, and set timer for
15 min.
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Table 12. Worksheet for timed addition of reagents for 15 min (max) LPS activation of whole blood
Time of addition
Time of
addition
Time of
addition
Tube number Tube label LPS Formaldehyde Triton X-100
1 LPS 15′ 0:00 15:00 25:00
2 LPS 10′ 5:10 15:10 25:10
3 LPS 8′ 7:20 15:20 25:20
4 LPS 6′ 9:30 15:30 25:30
5 LPS 4′ 11:40 15:40 25:40
6 LPS 2′ 13:50 15:50 25:50
7 Unstimulated control 16:00 26:00
8 CD14-PC7/CD45-KrO only 16:10 26:10
Unstimulated control: Vortex and put into 37°C water bath at 14:00
CD14-PC7/CD45-KrO only: Vortex and put into 37°C water bath at 14:10
Blood samples: 100 µL
Addition of LPS: 2 µL of 50 µg/mL PBS; final concentration 100
ng per 100 µL blood
Addition of formaldehyde: 65 µL of 10% solution: final concentration 4%
Addition of 0.1% Triton X-100: 1 mL of 0.1% Triton X-100/PBS
 After 15 min, inspect tubes for complete RBC lysis (clear
nonturbid red color). If lysis is incomplete, continue incu-
bation for a maximum of 15 additional min.
 If lysis is still incomplete, centrifuge, decant supernatant,
loosen pellet by vortexing, resuspend with 1 mL of Triton
working solution, and incubate in 37°C bath for up to 30
min to obtain maximal RBC lysis.
9. Remove tubes from the water bath, dab on paper towel to
remove water from the bottom of the tubes and place in rack.
Add 1 mL of cold (4°C) wash buffer (4% BSA/PBS) to each
of the tubes, and then vortex all tubes well.
10. Centrifuge all tubes at 500 × g for 4 min. Remove super-
natant. Vortex each tube to loosen pellet.
11. Resuspend pellet by adding 1 mL of cold (4°C) wash buffer
(4% BSA/PBS) to each of the tubes, and then vortex all tubes
well.
12. Centrifuge all tubes at 500 × g for 4 min. Remove super-
natant. Vortex each tube well to loosen pellet
◦ For phospho-epitopes that require 80% methanol treat-
ment to “unmask” (e.g. P-STATs)
 Add 1mL of cold (4°C) 80%methanol while vortexing.
NOTE: This is critical to reduce cell aggregation. Place
the tube on ice.
 After the last tube, set timer and incubate for 10 min.
 At the end of the incubation, centrifuge all tubes at
500 × g for 4 min. Remove supernatant. Vortex each
tube well to loosen up the pellet. Pipette 2 mL of cold
(4°C) wash buffer (4% BSA/PBS) to each tube.
 Centrifuge all tubes at 500 × g for 4 min.
 Remove supernatant. Note: not necessary to loosen up
the pellet before the addition of antibody cocktail
13. Add antibodies (concentrations and volumes previously
defined) and cold wash buffer to a final volume of 100 µL.
(Prepare a cocktail containing all desired Abs. This ensures
that the Ab concentration for each tube is “identical.”) All Abs
should be diluted in PBS/4% BSA (protease free).
14. Incubate all tubes at room temperature for 30min in the dark.
15. At the end of the incubation, add 2 mL of cold (4°C) wash
buffer (4% BSA/PBS) to each tube.
16. Centrifuge all tubes at 500 × g for 4 min. Remove as much
of the supernatant as possible, exercising care to preserve the
cell pellet. Vortex each tube well to loosen up the pellet.
17. Resuspend the cells in 350 µL of 0.5% paraformaldehyde
in PBS, and store at 4°C in the dark, until sample can be
analyzed. Samples in 0.5% paraformaldehyde are stable for
24 h.
16 Assessing lymphocyte metabolism through
functional dyes
16.1 Overview
The aim of this chapter is to provide rapid and simple protocols
to measure lymphocyte metabolism by FCM. We briefly layout
general pathways and the relevance of some selected pathways for
lymphocyte biology before going into methodological detail. The
focus is on measuring glucose and fatty acid uptake, mt membrane
potential, mt mass, and ROS.
16.2 Introduction
Lymphocytes upregulate glycolysis and mt oxidative phospho-
rylation (OxPhos) during their activation [529]. Metabolic
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reprogramming differs between B cells and T cells, and also within
regulatory T-cell subsets [529]. For instance, na¨ıve murine splenic
CD4+ T cells upregulate glycolysis as well as glucose uptake
and reveal a strongly enhanced ratio of glycolysis versus OxPhos
upon CD3/CD28 mAb stimulation. In contrast, B cells upregu-
late both glycolysis and OxPhos upon lipopolysaccharide or anti-
B-cell receptor stimulation, and therefore maintain the glycoly-
sis/OxPhos ratio of resting B cells [530]. Although OxPhos ensures
efficient ATP production under aerobic conditions, mitochondria
also contribute cytosolic biosynthetic precursors such as acetyl-
CoA and pyrimidines. Moreover, mitochondria are responsible for
the production of ROS and cell death by the intrinsic apoptosis
pathway [220]. Glycolysis also takes place under aerobic condi-
tions and can be actively induced tomeet the cells’ energy demand,
for instance in cancer cells [531], and also in certain lymphocyte
subtypes, such as activated T cells [529]. However, regulatory T
cells or resting B cells preferentially rely on fatty acid (FA) oxi-
dation by the mt respiratory chain [530, 532] and regulatory T
cells obtain fatty acids exogenously [533]. During hypoxia, which
is encountered by lymphocytes in the bone marrow and the thy-
mus [534, 535], ROS production by complex III of the respiratory
chain has been observed [536]. The three cellular ROS species
are superoxide anions (·O2–) that are the precursors of hydro-
gen peroxide (H2O2), and hydroxyl radicals (·OH). ROS at high
levels can cause oxidative stress to cells by either directly induc-
ing single- and double-stranded DNA breaks or by oxidizing amino
acids in proteins, fatty acids, or enzymatic co-factors [537]. At low
levels and under normoxic conditions, ROS represent important
cellular signaling molecules; i.e., in stem cells, ROS act as second
messenger to ensure cycling of the cells [537]. The ROS species
involved in intracellular signaling is H2O2 as it has a long half-life
and diffuses easily [537]. Numerous proteins are redox sensors.
For instance, the oxidation of cysteine inactivates PTEN or Akt,
which are critically involved in B cell development [537]. Bach2,
a transcription factor involved in Ab class switch recombination,
is also redox-sensitive [538]. Thus, metabolism may reflect the
activation status and predict the fate of an immune cell. In fact,
anergic B cells are metabolically less active than na¨ıve B cells, and
even less than hyperactive B cells from “B-cell activating factor of
the TNF family (BAFF)”- transgenic mice [530]. These selective
examples show that immune cell metabolism comprises glycoly-
sis, mt activity and ROS, which intersect with signaling pathways.
The gold standard to measure glycolytic and mt activities in real
time is via extracellular flux analysis using a SeahorseTM device.
However, this experimental setup requires rapid access to such a
device and a substantial number of cells (up to 2 x 106 per sin-
gle experiment), which (i) might be difficult to achieve, especially
when looking at rare lymphocyte subsets and (ii) may require
time-consuming cell sorting beforehand. In addition, cell sorting
over hours may alter metabolic phenotypes. To perform a quick
first screen or to analyze complex and rare cell populations, such
as bone marrow lymphocytes, without enrichment and purifica-
tion, rapid flow cytometric techniques can provide first clues of
whether a given treatment, genetic deletion or a cytokine alters
glucose uptake, mt activity or generation of ROS.
16.3 Experimental Design
We describe here the use of cell permeable functional dyes to
measure basic parameters such as: (i) glucose uptake (2- or
6-NBDG; 2- or 6-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-
2-Deoxyglucose), (ii) fatty acid (FA) uptake (BoDipy-FA), (iii)
mt mass (MitoTracker Green/Deep Red FM), (iv) mt mem-
brane potential (mtmP) (TMRE; Tetramethylrhodamine), (v) ROS
(DCFDA; 2’-7’-Dichlorodihydrofluorescein diacetate and CellROX)
and mt ROS (MitoSOX). Our focus is on murine B cell analysis but
all protocols can easily be adapted to the investigation of other cell
types, for instance human cells. We found it feasible to choose one
color for all dyes (for instance, FL1/green emission; 2- or 6-NBDG;
MitoTracker Green FM, DCFDA) to analyze complex cell popula-
tions, such as bone marrow lymphocytes. Information on stock
and working concentrations, solvents and commercial distrubu-
tors for all dyes can be found in Table 13. This has the advantage
that one single, titrated cocktail of fluorochrome-coupled Abs can
be combined with each functional dye to analyze glucose uptake,
mt mass, and ROS. Of course, the same strategy can be applied to
use dyes with a different emission wavelength (MitoTracker Deep
Red FM, TMRE, CellRox, MitoSOX). To separate functionally dis-
tinct B cell fractions in vitro, different MitoTracker dyes can be
combined [538].
16.3.1 Measurement of glucose uptake. The direct uptake of glu-
cose into living cells can be monitored in vitro and in vivo by
the fluorescent glucose analogs 2-NBDG or 6-NBDG. 6-NBDG is
supposed to specifically reflect glucose uptake via the glucose
transporter GLUT-1 [539], while 2-NBDG gets imported by all
GLUT-family members [540]. The in vitro incubation of cultured
cells or ex vivo prepared single cell suspensions with 2- or 6-NBDG
requires glucose free medium and results in the uptake of NBDG
instead of glucose. Thus, the increase in 6-NBDG fluorescence mir-
rors GLUT-1 activity. Freshly isolated murine splenic B cells show
a higher uptake of 2- versus 6-NBDG (Fig. 59), likely reflecting
the activity of glucose transporters other than only GLUT-1. By
injecting 2- or 6-NBDG intravenously into mice, this glucose ana-
logue can even be tracked under physiological conditions, reflect-
ing more precisely natural glucose uptake activity of different cell
populations, for instance plasma cells [541] (please consider this
reference for a procedure). Both glucose analogues are detected
in the same emission channel as GFP, what limits their use in com-
bination with a wide range of GFP-reporter mice. However, this
issue can be circumvented by using a spectral fluorescence ana-
lyzer. It has to be noted that this assay does not directly measure
glycolysis, i.e., pyruvate or lactate production, as it is restricted to
measuring specifically glucose up-take only.
16.3.2 Measurement of FA uptake. The direct uptake of FA into
living cells can be monitored in vitro and in vivo by fluores-
cently labeled FA, such as BoDipy-FA [542]. BoDipy-FA analogues
undergo native-like transport and metabolism in cells making it
effective as a tracer for lipid trafficking [543]. Increased sensitiv-
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Table 13. Reagents (*some chemicals such as DCFDA can also be obtained from other suppliers)
Reagents
Dye/Ab Supplier* Solvent (Stock) Working concentration Storage Staining medium
6-NBGD (Life Technologies,
#N23106)
dH2O (100 mM) 300 µM –20°C glucose-free
DMEM
2-NBDG Abcam (#ab146200) dH2O (1mg/ml) 25µg/ml –20°C glucose-free
DMEM
Bodipy-labeled FA Thermo Fisher
Palmitate (#D3821),
C12 (#D3822, D3835)
MeOH (2.5mM) 6-10 µM –20°C PBS containing
20 µM FA-free
BSA
DCFDA Thermo Fisher (#D399) DMSO (100 mM) 1 µM –20°C Optimem or
RPMI1640
MitoTracker
Green FM
Cell signalling (#9074S) DMSO (1mM) 5-10 nM –20°C Optimem or
RPMI1640
MitoTracker Red
FM
Thermo Fisher
(#M22425)
DMSO (1mM) 50-100 nM –20°C Optimem or
RPMI1640
TMRE Life Technologies
(#T668)
MeOH or DMSO (20 µM) 20nM –20°C Optimem or
RPMI1640
CellROX Deep Red Thermo Fisher
(#C10422)
DMSO (2.5 mM) 5-50µM –20°C Optimem or
RPMI1640
MitoSOX Red Thermo Fisher
(#M36008)
DMSO (5mM) 5µM –20°C (HBSS/Ca2+/Mg2+)
Anti B220
PerCP/Cy5.5
eBioscience, clone
RA3-6B2, #45045282
– 1:100 4°C FCM buffer
Anti B220 Brilliant
Violet 421
BioLegend, clone
RA3-6B2, #103420
– 1:100 4°C FCM buffer
Anti CD19
APC-Fire 750
BioLegend, clone 6D5,
#115557
– 1:200 4°C FCM buffer
Anti CD138
Brilliant Violet
421
BioLegend, clone 281-2,
#142508
– 1:100 4°C FCM buffer
Anti CD138
PE/Cy7
BioLegend, clone 281-2,
#142514
– 1:1600 4°C FCM buffer
Anti TACI/CD267
APC
eBioscience, eBio8F10-3,
#17-5942-82
– 1:100 4°C FCM buffer
ity can be reached by coupling FA to quantum dots [544]. The in
vitro incubation of cultured cells or ex vivo prepared single cell
suspensions with labeled FA requires FA-free medium.
16.3.3 Measurement of mt mass and activity. MitoTracker Green
FM labels mt proteins via mildly thiol-reactive chloromethyl- moi-
eties within the dye. MitoTracker Green FM diffuses through the
plasma membrane and is supposed to be taken up by active mito-
chondria irrespective of their mtmP. In contrast, uptake of Mito
Tracker Deep Red FM appears to be influenced by the mtmP of
the cells [545]. However, there are also reports on a sensitivity
of MitoTracker Green FM toward mtmP [545]. Once inside, Mito-
Trackers cannot be removed from the cells again. Like other cell
permeable dyes MitoTrackers are used to semi-quantify mt mass
using standardized conditions for cell numbers, dye concentration,
and incubation time. IncreasedMitoTracker FM staining can either
signify more or larger mitochondria or even more structured mito-
chondria, i.e., increased protein content providing more reaction
targets for the dye, and henceforth, refers to the total mt mass of
a cell. Like MitoTracker Deep Red FM, the lipophilic and cationic
fluorescent dye TMRE specifically accumulates in mitochondria in
relation to their mtmP at low concentrations. It has to be noted
that loss of mtmP is a marker for early apoptotic cells [546].
Thus, care has to be taken to gate on viable cells if alterations of
mtmP that are not related to apoptosis are to be analyzed by Mito-
Tracker Deep Red FM or TMRE. Of course, loss of TMRE staining
is useful to define early apoptotic cells. We provide an example of
MitoTracker staining of bone marrow lymphocytes, revealing that
there are two populations of plasma cells identified byMitoTracker
fluorescence (Fig. 60). Gating on the MitoTrackerhigh cells reveals
that those plasma cells (red dots) have a higher SSC compared
to the MitoTrackerlow cells (grey dots), whereas B cells exhibit-
ing strong MitoTracker fluorescence do not (black dots vs. green
dots). The physiological significance of this finding remains to be
determined.
16.3.4 Measurement of ROS. In lymphocytes, the major sources
of ROS are the two respiratory chain complexes I and III. The
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Figure 59. Glucose uptake activity of
murine splenocytes. Splenic single cell
suspensions from naı¨ve C57BL/6-mice
were incubated with or without (con-
trol) the glucose-derivates 2-NBDG or 6-
NBDG in glucose-free RPMI1640 medium
for 45 min (37°C, 5% CO2). Then, cells
were stained with fluorochrome-coupled
antibodies directed against CD138 (Bril-
liant violet 421), B220 (PerCP/Cy5.5), and
CD19 (APCFire) (in the dark; 20 min, 4°C).
Viable cells were defined by FSC/SSC. B
cells were defined as CD138-B220+CD19+
cells. Numbers indicate percentage gated
cells, numbers in brackets indicate MFI.
The red line indicates the main peak of
the unstained, NBDG, negative fraction.
fluorogenic dye DCFDA or CM-H2DCFDA, a derivative with more
effective cellular retention, detects cellular ROS. Inside a cell,
DCFDA is first deacetylated but does not emit fluorescence until
oxidized into DCF (2’,7’-dichlorofluorescein) by ROS. Of note,
DCFDA is not specific for a particular ROS species [548] but
exhibits a broad reactivity, particularly in the presence of other
oxidizing enzymes and factors like Fe2+ [549, 550]. Alternatively,
the CellROX Deep Red Reagent can be used for intracellular ROS
measurement with the advantage that it is retained even after
formaldehyde-based fixation methods [551]. To selectively detect
mt superoxide the dye MitoSOX Red can be used. MitoSOX Red
is selectively targeted to the mitochondria of viable cells and can
only be oxidized by the short-lived superoxide (·O2-), but not by
other ROS species [552].
Taken together, the results obtained with the methods
described here can provide first indications of the very basal
metabolic and oxidative status of a given cell population. They
may nevertheless be helpful to decipher complex mechanisms,
such as Ab class switch recombination [538].
16.3.5 Step-by-step sample preparation. Cells and buffers
1. Desired single cell preparation.
2. Staining medium (in the case of lymphocytes): Opti-
MEM/RPMI1640 without any additives or glucose-free DMEM
or Hankʼs balanced salt solution with Ca2+ and Mg2+
(HBSS/Ca2+/Mg2+), or PBS containing 20 µM FA-free BSA.
3. FCM buffer (2% fetal calf serum in PBS, 0.02% NaN3; for
measurement of mtmP, NaN3 should be omitted).
4. Abs for staining of surface antigens (Abs indicated in the table
have been used to stain murine B- and plasma cells, Figs. 59
and 60).
16.3.6 Acquisition and analysis.
16.3.6.1 Glucose uptake: 2- or 6-NBDG.
1. Wash desired single cell suspension once with glucose-free
DMEM/RPMI1640 and resuspend samples in the same glucose-
free medium supplemented with 300 µM 6-NBDG or 25 µg/mL
2-NBDG for 30–45 min at 37°C, 7.5% CO2/5% CO2 (1–3 ×
106/mL) in a reaction tube/dish.
2. Pellet cells and discard the supernatant.
3. Wash cells with 250–500 µL FCM buffer, if required stain for
surface antigens with fluorochrome-coupled Abs on 4°C for
15–20 min in the dark.
4. Resuspend cells in 150–250 µL FCM buffer and analyze by FCM
(Figure 59).
16.3.7 FA uptake: BoDipy-FA.
1. Wash desired single cell suspension with PBS and stain surface
antigens with fluorochrome-coupled Abs in PBS/2% FA-free
BSA.
2. Wash cells twice with PBS.
3. Resuspend cells in 6 µM BoDipy-FA (in PBS with 20 µM FA-
free BSA) for 3 min at room temperature. Quench BoDipy-FA
uptake by adding 4× volume of ice-cold PBS with 2% FBS and
two washes.
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Figure 60. MitoTracker FM-staining of plasma cells in different media and buffers. Single cell bone marrow suspensions from femur and tibia of
naı¨ve C57BL/6 mice were prepared and incubated in serum-free medium with MitoTracker Green FM or MitoTracker Deep Red FM (37°C, 30 min,
5% CO2). Suspensions were then stained with fluorochrome-coupled Abs against the surface markers CD138 (PE/Cy7), TACI (APC), B220 (Brilliant
Violet 421), and CD19 (APCFire) [547] in the dark (20 min, 4°C) after incubation with MitoTracker FM. Viable cells were defined by FSC/SSC. Plasma
cells were defined as CD138+TACI+-cells and B cells as B220+CD19+CD138-TACI- [547]. (A) Influence of medium (OPTIMEM or RPMI1640) on plasma
cell staining. (B) Analysis of MitoTracker Green FM and MitoTracker Deep Red FM uptake in bone marrow plasma cells and B cells. Cells were
re-gated on FSc and SSc. Plasma cells and B cells exhibiting a high MFI for MitoTracker Green FM or MitoTracker DeepRed FM are depicted in red
or black whereas plasma cells and B cells exhibiting a low MFI for MitoTracker Green FM or MitoTracker DeepRed FM are depicted in grey or green,
respectively. Numbers indicate percentage gated cells, numbers in brackets indicate MFI.
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4. Optionally: block BoDipy-FA uptake by pre-incubation with
100 µM palmitic acid (Sigma–Aldrich) for 10 min at 37°C prior
to BoDipy-FA addition.
5. Resuspend cells in 150–250 µL FCM buffer and analyze by FCM
(Figure 59).
16.3.8 Mitotracker, ROS, and mtmP.
1. Resuspend cells at 1–3 × 106/mL in 100–300 µL medium
without supplements (serum will cause unspecific MitoTracker
staining); use RPMI1640 especially for analysis of NBDG
uptake in plasma cells because OPTIMEM does not allow
the optimal definition of CD138/TACI+ plasma cells and
CD19/B220+ B cells (Fig. 60A).
2. Incubate the cell suspensions (working concentrations see
17.3) with MitoTracker Green FM (10–100 nM), MitoTracker
DeepRed FM (1 nM), DCFDA (1 µM), TMRM (20 nM), Cell-
ROX (5–50 µM), or MitoSOX (5 µM) in the same serum-free
medium for 10-45 min (needs to be empirically determined for
each cell type) in the respective incubator
3. Wash cells once in the same medium
4. Stain for surface antigens with fluorochrome-coupled Abs in
serum-free medium for 20 min at 4°C in the dark
5. Wash cells with 250-–00 µL FCM buffer or resuspend in 250 µL
of the same buffer and analyze by FCM.
6. To adjust the mt activity to the volume of the cells, normalize
data to the cubic value of FSC pulse width (that is, [FSC pulse
width]3) of the different samples. Important note: In certain
cytometric software, recording FSC pulse width may have to
be activated before acquisition
16.4 Pitfalls
Care has to be taken in the choice of the right medium. For
instance, RPMI1640 is a suitable medium to stain plasma cells
(see Fig. 60). Another problem is, especially when measuring
the organelle content of a cell, such as mitochondria, that flu-
orescence intensity correlates with cell size, which also concerns
plasma cells. Therefore, we recommend to choose the MdFI (more
robust against outliers) over MFI. Some conditions may require
normalization of MdFI to cell volume by adjusting MdFI to FSC
pulse width, which is the preferable parameter to evaluate cell size
rather than the height or area of FSc or SSc [553]. For instance,
large pre B cells that consume more glucose stain 40% brighter
with 6-NBDG but are also significantly larger than small pre B
cells [554]. Normalization of 6-NBDG fluorescence to cell size
within these very related cell populations ruled out staining arti-
facts [554].
Other critical issues are dye concentrations and incubation
times. The specificity of dyes mirroring mtmP (TMRE, MitoTracker
Deep Red FM, Mitotracker Green FM) can easily be verified by
adding nano- to micromolar concentrations of the protonophore
Carbonyl cyanide 3-chloro phenyl hydrazine (CCCP). By titrat-
ing CCCP, this assay can be used to test the stability of mtmP of
different cell types or under different environmental or genetic
conditions [555]. The highest possible signal for the mtmP can be
obtained by adding oligomycin, which is an ATP-synthase inhibitor
and leads to hyperpolarization of the mt membrane. Thus, CCCP
and oligomycin can define the dynamic range of TMRE stain-
ing. As mentioned above, care has to be taken to gate on viable
cells. Moreover, MitoTracker FM staining can be confounded
by mtmP.
16.5 Top tricks
To validate the desired specificity and working concentration
of dyes for ROS measurements, positive controls and negative
controls can be included. For instance, we used the radical
starter ammonium peroxodisulfate (APS; 0.001–0.1%) to assess
the dynamic range of DCFDA. The oxidation of DCFDA can vice
versa be blocked by the addition of vitamin C (mM Range) to the
assay. For further reading on this issue we recommend ref. [548].
The specificity of FA uptake can be assessed by pre-incubation of
the cells with unlabeled FA, such as palmitic acid [542].
17 T cell assays
17.1 Measurement of signal transduction pathways in
human T cells
17.1.1 Overview. In this section, we describe how to investigate,
in human T cells, the phosphorylation status of S6 ribosomal pro-
tein (pS6Ribo) as an indicator of PI3K-Akt-mTOR signaling path-
way activation following TCR stimulation [556]. However, this
protocol can be applied to other signaling pathways in T cells, for
example, cytokine stimulation or costimulatory molecules trigger-
ing [557].
17.1.2 Introduction. T cell activation requires TCR engagement
by peptide-MHC complex together with additional costimuli such
as CD28 triggering by CD80/86 molecules expressed on APCs,
as well as cytokine stimulation. Surface receptor stimulation is
followed by intracellular events that rely mainly on the phos-
phorylation or de-phosphorilation of molecules involved in the
signaling cascade. This is important to amplify and transmit the
information originated by receptor stimulation. Signaling cascades
are usually connected downstream of different surface receptors,
thus leading to an intracellular integration of distinct signaling
events. The final outcome is the activation or inhibition of spe-
cific transcription factors, and then the expression of a specific
gene signature. The investigation of the phosphorylation status
of intracellular mediators is a useful tool to understand step-
by-step how the extracellular information is propagated inside
the cell. By this way it is also possible to understand if any
alteration is present in a given signaling pathway. (See also
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Chapter V Section 15 – Measurement of signal transduction path-
ways by FCM).
17.1.3 Step-by-step sample preparation.
17.1.3.1 Mononuclear cells’ recovery.
1. Collect whole blood in a tube coated with an anticoagulant.
2. Gently stratify 9 mL blood onto 6 mL Ficoll in a 15 mL tube.
3. Centrifuge at room temperature, 1500 × g without break for
20 min.
4. Collect the ring between the phases, containing mononuclear
cells, and transfer in a new 15 mL tube. Fill up the tube with
PBS 7.2 and centrifuge 300 × g for 7 min.
5. Discard the supernatant and resuspend cells in 15 mL PBS 7.2.
Repeat the centrifugation step.
6. Resuspend cells in complete medium (RPMI+10% FBS) and
count. At least 200 000 cells for each experimental condition
are needed.
17.1.3.2 Cell stimulation.
1. Stain cells with mouse anti-human CD3 Ab (clone HIT3a,
IgG2a, 5 µg/mL) and mouse anti-human CD28 antibody
(clone CD28.2, IgG1, 5 µg/mL) in 50 µL of complete medium
in a 1.5 mL Eppendorf tube. Incubate at 4°C for 5 min.
2. Cap primary Abs by adding 50 µL complete medium contain-
ing anti-mouse IgG1 and anti-mouse IgG2a. Final concentra-
tion of anti-mouse IgG1 and anti-mouse IgG-2a is 5 µg/mL.
Incubate at 37°C for the kinetics experiment. We recommend
the following kinetics: 0’ (no stimulation), 10’, 20’, and 30’.
3. At each time point of the kinetics experiment, fill up the appro-
priate tube with cold PBS 7.2 and centrifuge at 300 × g for 7
min at 4°C.
4. Discard the supernatant and resuspend cells in 250 µL of PBS
7.2. Add an equal amount (250 µL) of pre-warmed (37°C)
BD Cytofix and incubate for 10’ at 37°C.
5. Fill up the tube with 1 mL wash buffer (PBS 7.2 +BSA 0.5%)
and centrifuge at 300 × g for 7 min.
6. Resuspend cells in 500 µL wash buffer.
7. Centrifuge the tubes at 300 × g for 7 min.
8. Discard the supernatant and resuspend cells in 500 µL pre-
cooled (–20°C) BD Perm Buffer III. Incubate for 30’ on ice.
9. Fill up the tubes with wash buffer and centrifuge 300 × g for
7 min.
10. Discard the supernatant and stain cells with anti-human CD3-
PB, anti-human CD4-PECy7, anti-human CD8-APCCy7, anti-
human pS6Ribo (Ser235/236)-Alexa Fluor 488 for 20’ at
room temperature.
11. Fill up the tubes with wash buffer and centrifuge at 300 × g
for 7 min to remove unconjugated antibodies.
12. Discard the supernatant and resuspend in 500 µL wash buffer
for FCM analysis
17.1.4 Materials.
1. Complete medium: RPMI+10% heat inactivated FBS
2. Wash buffer: PBS 7.2+0.5%BSA
3. PBS 7.2
4. Fixation buffer: BD Cytofix
5. Permeabilization buffer: BD Perm Buffer III
6. mouse anti-human CD3 Ab (BD, clone HIT3a, IgG2a)
7. mouse anti-human CD28 Ab (clone CD28.2 IgG1, 5µg/ml)
8. Goat anti-mouse IgG1
9. Goat anti-mouse IgG2a
10. anti-human CD3-PB (BD, clone UCHT1)
11. anti-human CD4-PECy7 (BD, clone SK3)
12. anti-human CD8-APCCy7 (BD, clone SK1)
13. anti-human pS6Ribo (Ser235/236)-Alexa Fluor 488 (Cell Sig-
naling, clone 2F9)
17.1.5 Data analysis. Data analysis can be performed via the
identification of the percentage of cells that display the phosphory-
lated protein of interest (as in the Figure 61). However, sometimes
two clear cell subsets (phosphorylated versus unphosphorylated)
cannot be identified. In those cases, it is very useful to evaluate
the MFI of the protein of interest.
17.1.6 Pitfalls. In case of TCR signaling study, staining of surface
CD3 requires the usage of an Ab clone distinct from that used for
cell stimulation. The two Abs should not compete for the same
epitope.
17.1.7 Top Tricks. PI3K-Akt-mTOR activity lasts only several
minutes following stimulation. Alterations of the signaling path-
way can be observed either as a delayed/shorter kinetic of phos-
phorylation or as a reduced/increased magnitude of phosphoryla-
tion. For these reasons, we recommend to perform kinetics experi-
ments rather than a single time point observation. The same can be
applied either to STAT protein phosphorylation or other signaling
cascades.
17.2 Measuring antigen specific T cell responses
17.2.1 Introduction. T cells recognize their cognate antigen in
the context of MHC molecules. Over 20 years ago, Davis and col-
leagues developed the technique to mimic the interaction between
the T-cell receptor and the peptide (p)MHC complex in the labora-
tory [558]. Using fluorescently labeled pMHCmultimers and FCM,
antigen-specific T cells could be visualized and this has become a
crucial tool in the analysis of antigen-specific T cell immunity in
mouse and human.
The classical approach with pMHC multimer detection of anti-
gen specific T cell populations is to have a specific pMHC com-
plex coupled to a single fluorescent dye. The major drawback of
this approach is the limited number of epitopes to which T cell
reactivity can be detected in parallel. This limitation is given by
the limited number of fluorochromes and detectors available for
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Figure 61. pS6ribo evaluation on PBMNC following TCR stimulation. Lymphocytes were gated based on physical parameters, then T cells were
identified as CD3+CD14–. T helper cells were gated as CD4+. pS6ribo was evaluated either on unstimulated cells or upon CD3 mAb and CD28 mAb
stimulation for 10, 20, or 30 min. As a positive control of the procedure PBMNC were stimulated with PMA and Iono for 20 min. In this experiment
CD3 mAb and CD28 mAb capping was performed by the addition of PE-conjugated anti-isotype mAbs (anti-mouse IgG1 and anti-mouse IgG2a).
Thus, cells with an efficient crosslink can be detected as PE-positive.
the detection as well as limitations in the availability of patient
material. Multiplexing strategies have been developed that greatly
increase the number of T cell reactivities that can be detected in a
single sample [559, 560].
The multiplexing strategy we employ is based on the genera-
tion of pMHC complexes with dual fluorochrome codes. Using this
labeling approach, the number of unique codes that can be gener-
ated can be calculated using factorial operations. As an example,
ten distinct fluorochromes yield 45 possible unique dual codes: (10
× 9)/(1 × 2) = 45. Additional approaches have been published
including work from Newell et al., which uses all possible fluo-
rochrome combinations instead of limiting to dual fluorochrome
combinations [559].
An alternative method to identify antigen-specific T cells is
through the use of isotope-labeled pMHC multimers, and time-of-
flight cytometry [561]. However, this method destroys the cog-
nate cells and does not allow further analysis. In the last couple
of years, other high-throughput methods have made their debut,
which are based on adding barcoded DNA oligos to pMHC multi-
mers followed by sequencing to detect antigen-specific T cells.
The cell mixture can be sequenced as a whole, or to reduce
sequencing costs, if the pMHC multimers are labeled with fluo-
rochromes, antigen-specific T cells can be isolated using FCM or
anti-fluorochrome magnetic bead-conjugated Abs before sequenc-
ing. Using next generation sequencing, the cognate peptide is
identified based on the DNA barcode, unique to the peptide
[562–564]. According to the same principle, barcoded DNA oligos
can also be attached to Abs, to detect and quantify surface pro-
tein expression. In the end, proper use of DNA barcoded reagents
allows simultaneous identification of the TCR sequence, tran-
scriptome, surface protein expression, and peptide-specificity of
T cells.
Besides the major benefit of increasing the number of specifici-
ties that can be screened for in a single sample, the other advan-
tage of using multiplexing is the fact that the background signal
is significantly reduced when using dual fluorochrome codes. This
is due to the fact that the vast majority of background signal is
detected in either one or more than two channels detecting fluo-
rescent signal. As the false positive signal decreases, the sensitivity
of the assay increases. This increase in sensitivity is accomplished
using Boolean gating strategies including signal that is only dual
fluorochrome positive. Using this gating strategy, we are currently
working with a cutoff of 0.005% of total CD8+ T cells and a
minimum of ten recorded events. A triple fluorochrome labeling
approach following the same principles, can in theory maintain
the sensitivity of detectable T cell reactivities and further enhance
complexity.
17.2.2 UV light-mediated peptide exchange. Peptide MHC com-
plexes can be generated in vitro by placing the heavy- and β2m
chain of the MHC allele together with the peptide of interest
in optimized conditions allowing correct formation of the pMHC
complex. As refolding the pMHC complexes is a time consuming
and laborious process this approach is not optimal for generation
of large numbers of different pMHC complexes.
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To overcome this limitation, we developed a UV light-mediated
peptide exchange method [565]. With this technology, the MHC
complex is refolded using a peptide that includes a UV light-
sensitive amino acid. Exposure to UV light results in degrada-
tion of the UV-sensitive peptide leading to the dissolution of the
MHC complex. However, when this process takes place in the
presence of a rescue peptide, this peptide can bind and stabi-
lize the MHC complex, thereby giving rise to pMHC complexes
with the peptides of choice. This UV-mediated exchange can be
performed in a multi-well format, allowing the generation of thou-
sands of unique pMHC complexes in parallel. Alternative methods
for the high-throughput refolding of MHCmolecules with peptides
of choice include the use of temperature-labile peptides, periodate-
cleavable peptides, azobenzene-containing peptides that may be
cleaved by sodium dithionite, or the use of certain di-peptides that
bind specifically to the F pocket of MHC class I molecules, catalyz-
ing rapid exchange with peptides in the environment [566–569].
Multiple factors can influence the ligand exchange reaction.
In case UV-cleavable peptides are used, it is crucial to keep the
pMHC complexes in the dark as much as possible as they are
light sensitive and as cool as possible as the pMHC complexes can
be unstable at temperatures above 4°C. Furthermore, it is impor-
tant that these protein-containing reactions are performed using
polypropylene material. This is to avoid loss of protein through
sticking to the plates/tubes. As the solubility of the peptide influ-
ences the ligand exchange, it is possible to add ligands that have a
poor solubility in water from stocks in DMSO. It has been shown
that the ligand exchange reactions proceed normally in conditions
up to 10% DMSO [565].
After the peptide exchange, (biotinylated) pMHC complexes
are multimerized by binding them to streptavidin-conjugated flu-
orochromes. For each peptide, a combination of two differently flu-
orescently labeled pMHC tetramers are produced using a stairway
panel as illustrated in Fig. 62. For example, in one plate, pMHC
tetramers are labeled according to the horizontal fluorochromes
(Fig. 62, top) while in the other plate pMHC tetramers are labeled
according to the vertical fluorochromes (Fig. 62, bottom). All flu-
orescently labeled pMHC multimers are then pooled together and
added to the T cells of interest. Cognate T cells will be double-
positive for the two fluorochromes to which the cognate pMHC
complexes were added.
When selecting what fluorochromes are better suited to include
in the making of the multimers, the main determinant is the
configuration of the flow cytometer that will be used. Next is a
consideration of brightness. In case the goal of using the tech-
nology is to detect viral responses, the brightness is of less con-
cern compared to detecting T-cell responses against self-antigens.
Nevertheless, it is advisable to select bright fluorochromes, and
when using less bright fluorochromes to only combine them in
the dual-codes with the fluorochromes that give a bright signal to
ensure the antigen-specific T cell population is separated from the
background.
Titrations of the pMHC complex:streptavidin-fluorochrome are
crucial to ensure optimal SNR. After multimer formation, addi-
tion of D-biotin ensures any remaining free binding sites on the
streptavidin-conjugated fluorochromes are blocked, thereby pre-
venting the binding of unconjugated pMHC complexes to other
fluorochromes when collecting the pMHC multimer collections
prior to staining.
17.2.2.1 Staining and FCM. Following the multimer forma-
tion, multimers are collected, pooled together, and centrifuged to
remove any aggregates before adding them to the T cells. Aggre-
gates can easily be formed when using multiple multimers in a
single staining, and can cause background issues in the staining.
This is especially true when using rescue peptides that may not
be able to bind sufficiently to stabilize the MHC complex. The
addition of a 1% skim milk solution (in PBS) to the multimers
after adding the streptavidin-conjugated fluorochrome can help
to reduce the level of aggregates.
After centrifugation of the pooledmultimers, T cells are stained
with non-aggregated multimers for a maximum of 15 min at 37°C
if the goal is to solely measure T cell responses, or for a max-
imum of 30 min at 4°C if the goal is to also sort out the cells
for downstream transcriptional analyses. Staining at 37°C results
in improved binding of the pMHC complexes due to pMHC–TCR
dissociation being significantly delayed at this temperature [570].
After the pMHC staining, fluorochrome-conjugated Abs are used
to stain (surface) proteins of choice. It is advised to pick and
choose a certain fluorochrome, ideally with the same emission
spectrum as the live/dead-marker, that is conjugated to Abs tar-
geting cell surface markers unique to unwanted cells to act as
a “dump-channel.” These unwanted cell surface markers include
CD4, CD14, CD16, and CD19, specific for (among others) T helper
cells, monocytes, NK cells, macrophages, and B cells. The cells can
be washed following standard FCM protocol after which they are
ready for analysis.
To ensure that the T cell reactivities detected are indeed real,
a confirmation is required in an independent experiment. For this
purpose, it is recommended tomake new reagents for the potential
hits, change the fluorochrome code and to stain the other half
of the sample tested. We have previously demonstrated that the
reproducibility between these independent experiments is high
(R2=0.9638) [571].
On the basis of the high sensitivity and robustness, this is a
highly suitable tool for the analysis of T cell responses in patient
material. We have previously demonstrated the value of the tech-
nology to map T cell responses against shared antigens in large
patient cohorts as well as T cell responses against mutated anti-
gens on a patient-specific basis [571–574].
17.2.2.2 Example: Detection of neoantigen-specific T cell
responses in an advanced melanoma patient. Based on DNA
sequencing of resected tumor material and healthy PBMCs, tumor-
specific variants were identified using exome sequencing. Based
on the data, 2058 non-synonymous variants were detected. Candi-
date tumor-specific neo-epitopes were determined and annotated
using an in-house epitope prediction pipeline that predicts which
neo-epitopes are most likely expressed on the surface of tumor
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Figure 62. An example of a combinatorial staircase giving 28 unique dual fluorochrome codes to 28 different peptides, allowing the detection of
28 different T cell responses in parallel.
cells based on the RNA expression level of the antigen, proteaso-
mal processing, and binding of the peptide to the MHC. The pre-
diction pipeline led to 1071 unique peptides of which 497 were
used to generate pMHC complexes with the UV light-mediated
peptide exchange method. pMHC complexes were formed with
HLA-A*02:01, B*27:05 and B*40:01 monomers. Using 14 dif-
ferent streptavidin-conjugated fluorochromes for multimer for-
mation, 75 dual color combinations were used in parallel per
tube. This also included peptides predicted to bind more than
one MHC. Using this setup, screening the PBMCs from this patient
for 498 predicted neo-epitopes was possible in eight tubes with
approximately one million cells per tube (20% CD8+ T cells).
The extra eighth tube was included to avoid mixing peptides that
were potentially cross-reactive for multiple TCRs. The analysis of
the PBMCs revealed three confirmed neoantigen-specific T cell
responses against neoantigens (Fig. 63).
17.3 Antigen-specific T-cell cytometry
17.3.1 Introduction. Antigen-specific T cells play a pivotal role
in immune protection toward infection and cancer and are the cel-
lular basis for specific immunotherapy. Antigen-specific T cells are
also crucially involved in the pathophysiology of chronic inflam-
matory diseases, such as allergies, inflammatory bowel disease, or
autoimmune diseases. Therefore, the direct visualization, quan-
tification, and characterization of these cells have important diag-
nostic and therapeutic implications. pMHCmolecules present anti-
genic peptide (epitopes) to T cells, which are recognized by specific
binding of a suitable T-cell receptor (TCR), which is expressed in
multiple identical copies (usually>1 x 105 molecules) on the T-cell
surface. CD8+ T cells recognize peptides presented byMHC class I,
while CD4+ T cells recognize antigen via MHC class II molecules.
Two main experimental approaches have been developed for the
detection of antigen-specific T cells: function-independent meth-
ods such as staining with soluble MHC multimers, and function-
based assays (such as intracellular cytokine staining, ELISPOT, or
cytokine capture technology). Their advantages and limitations
are described below along with other aspects of antigen-specific
T-cell cytometry.
17.4 MHC multimers
Function-independent antigen-specific T cell identification has the
advantage that it can be applied directly to a sample ex vivo and
does not rely on in vitro T cell activation, in contrast to many
function-based assays. Compared to the broadly applied detec-
tion of antigens by mAbs, detection of TCR-ligand (=pMHC)-
binding antigen-specific T cells has turned out to be challeng-
ing. This is mainly due to the relatively low binding affinity of
TCR–pMHC monomer interactions, which does not allow using
soluble (monomeric) pMHC for stable T cell staining. Altman and
Davis addressed this problem by the development of so-called
“MHC tetramers” [558]. The principle behind this approach is the
multimerization of the natural TCR ligand, e.g., to tetrameric com-
plexes, thereby increasing the binding avidity to surface-expressed
TCRs. Dimerization of pMHC via immune globulin fusion proteins
can be sufficient to detect antigen-specific T cells [575], but such
pMHC dimers often fail to identify all antigen-reactive T cells
present in a polyclonal population [576]. However, also pMHC
tetramers might not label all epitope-reactive T cells, which could
be due to very low affinity TCRs [577] or TCR/co-receptor down-
regulation or variable surface distribution [578].
Reagents with different degrees of multimerization have been
developed, asmultimerization seemed to be relevant for stable and
antigen-specific binding. Surprisingly, a direct comparison of MHC
tetramers, pentamers, dextramers, octamers, and higher polymer-
ization reagents has failed to show significantly improving bind-
ing properties with increasing degrees of multimerization [579].
It seems that an avidity gain with MHC trimers represents the cru-
cial threshold to result in stable MHC multimer staining for most
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Figure 63. FCM analysis of PBMCs from a patient suffering from advanced melanoma. Dot plots show the gating strategy (A) used to identify
live single CD8+, PE+, and BV421+ cells. Fluorochrome+ dot plots are made for all fluorochromes used, however to reduce the image size only
gating for PE+ and BV421+ CD8+ cells is shown here. The “Dump channel” consists of CD4+, CD14+, CD16+, CD19+ and dead cells. Dual (AND)
boolean gating of fluorochrome+ channels, combined with all the NOT gates of the other channels to get rid of the background, is done to identify
neoantigen-specific CD8 T cell populations (B). The neoantigen-specific T cells are positioned in the diagonal of the upper right corner of the plot
as they are positive for the two fluorochromes. The gating strategy shown in the upper panel is the one performed for the identification of the
CMTR2 neoantigen-specific T cell population in the lower panel.
TCRs. This interpretation was based on the finding that also in
conventional PE-conjugated MHC “tetramers,” three of the four
MHC molecules simultaneously take part in binding to surface-
expressed TCRs, although they stain polyclonal T cell populations
effectively with high staining intensity [580].
MHC tetramers are based on multimerization with biotiny-
lated ligands and avidin/streptavidin (Fig. 64C, “non-reversible
pMHC”). Conjugation with fluorochromes allows usage in FCM-
based applications and conjugation with paramagnetic particles
promotes combination with magnetic purification technologies
[581, 582]. However, binding of TCR ligands can lead to T
cell stimulation/activation and labeling-reagent internalization,
as well as apoptosis and cell death [583–585]. Therefore, the
reversible MHC Streptamer technology was developed, allowing
removal of staining reagents from the cell surface after their
application (Fig. 64C, “reversible pMHC”) [586, 587]. This is
achieved by targeted disruption of multimer complexes, leaving
only MHC monomers that rapidly dissociate from the cell sur-
face. With directly fluorochrome-labeled MHC molecules, the dis-
sociation can be precisely measured and serves as an important
parameter for TCR avidity (Fig. 64C, “dye-conjugated reversible
pMHC”) [588, 589]. Reversible staining has been further trans-
ferred to low affinity Ab-derived Fab fragments (Fab Streptamer),
extending the applicability of this labeling technology to virtually
any surface antigen [590].
A large spectrum of MHC reagents is commercially available
for the analysis of antigen-specific CD8+ T cells. Assembly of
pMHC monomers requires folding of MHC heavy chain and β2
microglobulin in the presence of the antigenic peptide (Fig. 64A).
For downstream biotinylation or fluorophore-conjugation, pMHC
monomers need to carry a functionalization site. An Avi-tag, for
example, enables BirA-mediated biotinylation for pMHC multi-
merization on a streptavidin backbone (as is the case for classical
tetramers) [558]. Furthermore, solvent exposed cysteine residues
have been used for fluorophore conjugation using maleimid chem-
istry [588, 591]. Reversibility of Streptamers (Fig. 64C, “reversible
pMHC”) is achieved through a Strep-tag, which allows stable mul-
timerization on a streptactin (rather than streptavidin) backbone
in a biotin-free manner [586]. Due to the higher binding affin-
ity of d-biotin to the strep-tag, this multimeric complex can be
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Figure 64. Production and usage of pMHCmultimers. (A) pMHCmonomer generation through folding and functionalization; (B) Epitope exchange
technologies enable high-throughput generation of pMHC complexes for different antigen-specificities; (C) Different usage of nonreversible,
reversible, and dye-conjugated reversible pMHC multimers.
disrupted through addition of D-biotin. As the affinity of
monomeric pMHC complexes to the TCR is not high enough for
stable binding, pMHCmonomers consequently dissociate from the
TCR (Fig. 64C, “reversible pMHC” and “dye-conjugated reversible
pMHC”).
In the past, therefore different pMHC production strategies
were necessary depending on the pMHC reagent (reversible/non
reversible; probe-conjugated/unconjugated) desired for a specific
application. In order to streamline and standardize the produc-
tion process, we have recently developed the so-called “FLEXamer
technology,” which allows flexible generation of pMHC reagents
from a single precursor pMHC protein [592]. These FLEXamers
possess a dual-tag consisting of a Strep-tag for reversibility and a
Tub-tag for versatile functionalization with biotin, fluorophores,
or other probes such as DNA oligos [562] (Fig. 64A).
In order to enable versatility also on the epitope level, a tech-
nology based on UV light-cleavable surrogate peptides has been
developed (for more information also see Chapter V Section 17.2.2
UV light-mediated peptide exchange method) [565], but also
dipeptides can be used for this purpose [569] (Fig. 64B). Further-
more, multiplexed staining of samples with different fluorescence-
conjugated MHC multimers is possible and promotes simultane-
ous analysis or sorting for multiple epitope specificities (for more
information also see Chapter V Section 17.5 Functional read-
outs) [559, 560]. Combinatorial MHC multimer staining can also
be used not only to combine and distinguish large numbers of
different MHC molecules within the same sample, but also to
increase staining sensitivity for the detection of rare cell popula-
tions. Cell incubation with two MHCmultimers, which are specific
for the same antigen but are conjugated to different fluorophores,
results in double-staining of antigen-specific T-cell populations.
This approach significantly reduces background staining (for more
information also see Chapter V Section 17.5 Functional read-outs),
which is fundamentally important to identify rare cell populations.
The pMHC multimer stainings shown in Fig. 65 summarize
many of the above-introduced aspects. Figure 65 shows enhanced
specificity through the use of two pMHCmultimers, with the same
pMHC but backbones with different fluorophores. The antigen-
specific T cell population in Fig. 65 was stained with a non-
reversible pMHC multimerized with streptavidin-PE and a
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Figure 65. Versatile analysis of a murine H2-kb/SIINFEKL-specific T cell population. Double staining with nonreversible pMHC multimerized with
streptavidin-PE (“Tetramer”) and reversible pMHC multimerized with streptactin-APC (“Streptamer”) before (red) and after (blue) addition of D-
biotin; dissociation of Alexa488-conjugated monomeric SIINFEKL-pMHCmolecules over time after addition of D-biotin (outside red box); pregating
on lymphocytes, singlets, living CD19-, CD8+ CD45-color coded T cells; gate of SIINFEKL-MHC-A488 additionally pregated on streptavidin-PE+ T
cells; CD45 color coding enables simultaneous analysis of multiple samples.
reversible (“Streptamer”) pMHCmultimerized on streptactin-APC.
After the addition of D-biotin only the biotinylated pMHCmultimer
staining prevails (Fig. 65), demonstrating reversibility of Strep-
tamer stainings. The breakup of Streptamer pMHC complexes is
followed by dissociation of pMHC monomer from the TCR. Flu-
orophore conjugation of pMHC monomers thereby allows track-
ing of dissociation kinetics, and quantification of TCR-pMHC koff-
rates (Fig. 65). Continuous tracking of the dissociating pMHC
monomers can still be linked to the antigen-specific population
through gating on the population positive for the nonreversible
pMHC. This emphasizes that not only the versatile nature of the
different pMHC constructs themselves, but also their combinato-
rial usage, have made them become indispensable tools for in-
depth T cell characterization.
Co-receptor (CD8 or CD4) interaction is often required for sta-
ble binding of MHCmultimers. Therefore, parallel surface staining
for CD8 or CD4 has to be controlled carefully to avoid artifacts by
blocking (or sometimes even enhancement) of co-receptor bind-
ing. In order to control this problem, most staining protocols are
based on an incubation period with MHC multimers alone before
Ab reagents for co-receptors are added. An initial incubation with
MHC multimer reagent alone for 25 min, followed by the addition
of co-staining mAbs for further 20 min, has proven to be applica-
ble to most MHC multimers in practice. In particular, when using
PE-conjugated MHC multimers, background staining—especially
coming from B cells and dead cells—can complicate the analysis.
Therefore, implementation of a CD19 dump channel and live/dead
discrimination has become standard formostMHCmultimer stain-
ing protocols. By using covalently linkable DNA staining probes
(such as ethidium monoazide bromide (EMA)), it is also possible
to combine live/dead discrimination with cell fixation [593].
Optimal MHC multimer concentrations have to be determined
for each batch by using positive and negative controls, as done for
all other cellular labels used in FCM. Besides reagent concentra-
tion, the duration of incubation time and staining temperature are
crucial parameters for MHC multimer labeling. Since this technol-
ogy relies on binding of the natural TCR ligand to the cell surface,
at higher temperatures (above 10–15°C), signaling events and
potential cell changes (e.g., up- or downregulation of cell sur-
face markers, activation-induced cell death) can occur. Therefore,
whenever possible, MHC class I multimer staining should be per-
formed at low temperatures, i.e., 4°C. For reversible MHC multi-
mer staining, cell labeling/sorting at low temperatures is essential,
as reagent internalization would negatively interfere with its sub-
sequent removal. In contrast, for most of the currently available
MHC class II multimers, successful antigen-specific cell labeling is
only possible at higher temperatures (usually at 37°C for 1 h),
since signal accumulation by reagent internalization seems to be
required in this case [594, 595].
In addition to conventional experimental controls (single
color-, compensation-, and FMO-controls), biological controls for
MHCmultimer staining are recommended to determine the degree
of background staining (e.g., by MHC mismatch controls). Gen-
eral considerations regarding minimal numbers of positive events
that have to be acquired and optimal gating strategy (FSC/SSC,
singlets, live/dead discrimination, co receptor/multimer, etc.)
are important to achieve meaningful and highly reproducible
results. A detailed protocol for MHC multimer staining includ-
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ing some examples for staining artifacts is described in Cellular
Diagnostics—Karger 2009 [596].
For more information, including instructions for the develop-
ment ofMHC class I reagents, please visit our website http://www.
mikrobio.med.tum.de/node/51.
17.5 Functional read-outs
As antigen-specific T-cells are rare, a major goal in antigen-specific
cytometry is to analyze as much parameters as possible from
each single antigen-specific T-cell. Recent advances in multicolor
FCM have increased the number of markers that can be analyzed,
but have also complicated the design and optimization of multi-
color Ab panels, as well as the multidimensional analysis of such
experiments. These important topics have been reviewed else-
where [597–601] and are also discussed in Chapter IV. Section
9 - Key Concepts for the Design and Testing of Multicolor Pan-
els and Chapter VI. Section 1–3 Evaluation/Data handling. In this
section, we will focus on use of flow cytometric methods for the
detection of antigen-specific T-cells following stimulation with an
antigen.
Direct labeling of specific T-cells can be achieved by
peptide/MHC(pMHC)-multimers (see Chapter V Section 17.4—
MHC multimers). However, pMHC-multimers can only be gen-
erated for a limited number of predefined pMHC combinations,
in particular for MHC class I peptides and CD8+ T-cell analysis.
In contrast, MHC class II multimers for identification of antigen-
specific CD4+ T-cells are still less well established. In addition,
tetramer use is limited for complex antigens or antigens not fully
characterized, e.g., microbes, tumors or autoantigens, and for the
heterogeneous MHC background in humans. As an alternative,
functional tests provide more flexibility, since they rely on T-cell
stimulation by autologous APCs, which can process and present
all types of antigens, peptides, proteins, or crude cellular extracts
in the context of the physiological MHC background. Following
in vitro antigen-stimulation, the antigen-induced T-cell response
is analyzed as an indirect read-out indicating specific T cells, i.e.,
proliferation, activation-induced surface, or secreted molecules or
cytotoxicity [602] (Figure 66).
17.5.1 Selection of the right parameter: Minimal manipulation.
Functional assays require stimulation, which may affect T-cell
frequency, function, and phenotype [602]. Cellular proliferation
as a result and readout of stimulation requires usually several
days (typically 3–5 days) of stimulation (see also Chapter V Sec-
tion 6—DNA synthesis, cell cycle, and proliferation) and intro-
duces an unpredictable bias due to significant in vitro selection
and “bystander” proliferation. Therefore, it is difficult to extrap-
olate from frequency and phenotype of cells after proliferation
to the original sample, and proliferation-based assays should be
used with caution for quantitative or qualitative T-cell analy-
ses. Therefore, short stimulation times should be preferred; for
instance, cytokines and rapid activation markers (e.g., CD154,
CD137, CD69) typically require only 5–12 h of stimulation before
their levels are measurable intracellularly, on cell surfaces or in
culture supernatants, ensuring minimal manipulation [602]. Fur-
thermore, β2-integrin activation on activated T cells occurs even
within minutes [603].
For antigen-specific stimulation experiments, it should also be
considered that the source of material (whole blood; PBMCs; dif-
ferent tissues sources), as well as the treatment of the cell source
(fresh or frozen material; resting periods before stimulation; cul-
ture medium), might have a profound influence on T-cell marker
expression and the detection of antigen-specific T cell responses
[514, 604–607]. In our hands, overnight resting (<16 h) at 37°C in
the incubator of freshly isolated PBMCs has been proven to reduce
background expression of activation markers and cytokines, while
retaining responsiveness of antigen-specific CD4+ Tcon and Treg,
leading to an increased SNR for antigen-specific T-cell analyses
(unpublished). However, in multicenter trials, cryopreservation of
PBMCs is often unavoidable. Therefore, standardized procedures
are needed to compare antigen-specific T-cell data from different
laboratories [608, 609]. When analyzing and comparing antigen-
specific T-cell responses from blood and tissue, also the presence
of functional APCs with comparable processing and presenting
capacity should be considered.
17.5.2 Selection of the right parameter—Integrate all T-cell subsets.
T cells are heterogeneous and cover a wide range of different
phenotypical and functional subsets. Information about the fre-
quency, differentiation stage (e.g., naive, memory), phenotype,
and functional properties of antigen-specific T-cells is essential to
gain a comprehensive picture about the immune response against
a certain antigen and the immune status of an individual. As CD4+
and CD8+ T cells provide different functions, also different read-
outs apply for the detection of antigen-specific CD4+ and CD8+ T
cells (see Table 14).
In particular, CD4+ T cells can acquire a highly diverse set of
functional properties. Therefore, antigen-induced cytokine secre-
tion is widely used as functional read-out for CD4+ T cells.
Cytokines can be detected on the cell surface by retention of the
secreted cytokine on the surface of the secreting cells via a cap-
ture matrix [620, 621] or intracellular when cytokine secretion
is inhibited by addition of secretion inhibitors like Brefeldin A
or Monensin [622] (see also chapter V Section 14—Intracellular
parameters, Chapter V Section 17.6 Live cytokine-producing cell
sorting with secretion assay). Differences may apply with usage
of different secretion inhibitors [608], for example, Monensin has
been shown to only insufficiently inhibit TNF-α secretion [623].
Due to the heterogeneity of CD4+ T-cells, ideally, the functional
read-out should encompass all relevant T-cell types to obtain a
complete picture of the immune status, i.e., all conventional T
(Tcon) cells, i.e., na¨ıve, all memory subsets as well as Foxp3+ reg-
ulatory T (Treg) cells, which typically comprise 5–10% of all CD4+
T-cells and are essential for tolerance. An alternative to individ-
ual cytokines, such as IFN-γ, which are often only expressed by a
minor fraction of all antigen-specific CD4+ T-cells [613, 614, 624],
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Figure 66. Principal of antigen-specific stimulation assays. (A) PBMCs or single cell suspensions from tissues are incubated with the antigen
of interest or without antigen as negative control to determine background levels of the assay. If whole proteins are used for stimulation, the
antigen has to be taken up by the autologous APCs of the cell source, processed and presented on MHC molecules. Peptides of a certain length
can bind externally to MHC molecules. (B) The antigen-specific T-cells will start to secrete cytokines and/or cytotoxic molecules (5–12 h), express
activation markers (5–16 h) and at later time points start to proliferate (3–5 days). For the different functions of T-cells, such as cytokine release,
cytotoxicity, expression of activation markers, and proliferation single-cell flow-cytometric assays are available and for most technologies also
selection markers on the cell surface are available allowing additional isolation of the specific cells.
and thus may ignore a significant fraction of specific T cells, are
so called activation markers, that are upregulated on the T-cell
surface upon specific T-cell receptor triggering. In contrast, the
combination of the activation markers CD154 (CD40L; which
is expressed on all Tcon subsets) and CD137 (4-1BB; which is
expressed on Treg) following short-term (6 h) stimulation allows
in parallel detection of naive and memory Tcon and Tregs reacting
against the same antigen [615, 616, 624, 625].
For CD8+ T-cells, cytokines like TNF-α and IFN-γ are widely
used, which are expressed by the majority of the antigen-activated
CD8+ population. The activation marker CD137 is also expressed
by CD8+ T-cells following stimulation for >12 h [618, 619, 626],
but may also be induced due to bystander activation. Furthermore,
for CD8+ T-cells detection of cytotoxic activity by staining for cyto-
toxic effector molecules (e.g., granzyme or perforin) can be used.
In contrast to most other mediators, these molecules are found
preformed in the cells and can be immediately released following
antigen stimulation. An alternative approach for measuring cyto-
toxicity is the detection of CD107a, which is only present on the
cell surface transiently following degranulation [627, 628] (see
also Chapter V Section 17.8 Cytotoxicity).
A common drawback of these techniques is that they all rely on
upregulation or de novo synthesis of the read-out markers, e.g.,
activation markers or cytokines, and therefore, require at least
several hours of stimulation. Recently, a new approach for rapid
identification of activated CD8+ T cells has been introduced, based
on immediate changes of surface integrins that occur within min-
utes following antigen stimulation [603]. The authors made use
of the fact that resting antigen-experienced T cells express high
levels of membrane-bound β2-integrins [629, 630]. TCR activa-
tion leads to clustering of the membrane-bound integrins within
seconds following stimulation, which can be detected by intercel-
lular adhesion molecule 1 (ICAM-1)-multimers, that specifically
bind to activated β2-integrins [603]. An advantage of the assay is
the short stimulation time of only several minutes that allows the
detection of functional (producing cytokines and/or expressing
CD107a) CD8+ T cells. However, comparison with peptide MHC
multimers showed that only a fraction of the peptide MHC multi-
mer positive T cells stained positive for ICAM-1. Further analyses
revealed that activated β2-integrins mark T cells with immedi-
ate, strong effector function, but, for example, miss nonfunctional
antigen-specific cells. In addition, the protocol requires stimula-
tion of low cell numbers in relatively high volumes (7.6 × 105
PBMCs in 380 µL test), which limits the detection limit and makes
it difficult to scale-up the assay for the detection of low-frequent
antigen-specific T cells.
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Table 14. Methods for the detection of antigen-specific T cells
Detection
Method Duration
Commonly used
markers Cell Type Disadvantages
Proliferation 3–5 days CD4+ and CD8+ Bystander proliferation may occur
Selective outgrowth of single clones
No direct quantification of specific cells
Phenotypical and functional changes
during long-term in vitro culture
Cytokine
secretion
5–12 h (different
cytokines may have
different kinetics)
TNF-α CD4+ and CD8+ Restricted to preselected cytokine
producers;
Non-cytokine producing Tcells (e.g.
naive, Treg) are neglected
IFN-γ CD4+ and CD8+
IL-2 CD4+ and CD8+
IL-4, IL-5, IL-9, IL-10,
IL-13, IL-17A, IL-17F,
IL-21, IL-22, GM-CSF,
etc.
Mainly CD4+
GARP/LAP/TGF-β Treg
Activation
marker
5 h to several days
(different activation
markers have
different kinetics)
CD69 (3 till 24
hours) [610]
CD4+ and CD8+ Sensitive to bystander activation
CD25 (24 till <72 h) [610] CD4+ and CD8+ Sensitive to bystander activation; late
up-regulation; constitutively
expressed by Treg
HLA-DR (24 till <72
h) [610]
CD4+ and CD8+ Late up-regulation
CD134 (OX-40) (48 till
72 h) [611, 612]
CD4+ and CD8+ Late up-regulation
CD154 (CD40L) (6 till 16
hours) [613, 614]
Mainly CD4+ Restricted to CD4+ T cells; not
expressed on Treg
CD137 (4-1BB) (6 till 24
hours)
Treg (6h) [615–617]
later also on
CD4+Tcon and
CD8+ [618, 619]
Detection Treg requires co-staining
with CD154; On CD4+ and CD8+ Tcon
sensitive to bystander activation
Cytotoxicity 1–6 h Perforin Mainly CD8+ Restricted to preselected cytotoxic
marker; non-cytotoxic T cells are
neglected
Granzyme A Mainly CD8+
Granzyme B Mainly CD8+
CD107a Mainly CD8+
Activated
integrins
4–120 min (ICAM)-1 multimers that
specifically bind to
activated
β2-integrins [603]
So far described for
CD8+
Restricted to a subset of cytokine
secreting /cytotoxic memory T cells;
non-functional antigen-specific T
cells and naı¨ve cells are neglected
17.5.3 Combination with magnetic enrichment of rare cells.
Antigen-specific T-cells typically comprise <1% and often <0.1%
of the total T-cell population [602]. Therefore, magnetic pres-
election of rare antigen-specific T-cells from large cell samples
is frequently used to decrease background and improve optical
resolution. Preselection increases the sensitivity for the detec-
tion of antigen-specific T-cells, i.e., frequencies down to 1 cell
within 10–5–10–6 and thus even detection of specific T cells within
the na¨ıve repertoire is possible [620, 624, 631–634]. Enrichment
allows the collection of sufficient target cells for subsequent mul-
tiparameter analysis and resolution of small cell subsets. Magnetic
enrichment may employ surface markers, e.g., tetramers, CD154,
CD137, ICAM-1-multimers, or secreted cytokines [602, 603, 620,
624, 631–634] (Figure 67).
17.5.4 Type of antigen. As for the functional read-out, there are
differences between the antigens used for stimulation of CD4+ and
CD8+ T-cells. CD4+ T-cells recognize antigens that are presented
via the exogenous pathway of antigen presentation on class II MHC
molecules [636]. Accordingly, for CD4+ T-cells, peptides, proteins,
and even cellular extracts can be used for stimulation. Presentation
of peptides fromwhole proteins depends on the processing activity
of the available APCs, whichmay vary between cell sources (blood,
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Figure 67. Enrichment of antigen-specific T-cells increases sensitivity for the detection of rare cells. (A) CD154 and TNF-α expression was analyzed
on human CD4+ T-cells without addition of an antigen and following stimulation wit the neo-antigen keyhole limpet hemocyanin (KLH). Cells
are gated on CD4+ T-cells and percentage and absolute numbers of CD154+ cells after acquiring 5 × 105 PBMCs (upper plots) or obtained from
1 × 108 PBMCs after enrichment of CD154+ cells (lower plots). (B) Phenotypic characterization of the enriched CD154+CD4+ T-cells to discriminated
between CD45RO+ memory cells and CD45RO–CCR7+ naive T-cells, following stimulation with a peptide pool of C. albicansMP65 as recall antigen or
KLH as neoantigen. (C) Parallel detection of antigen-specific Tcons (CD154+) and Tregs (CD137+) following stimulation with birch pollen lysate and
magnetic enrichment for CD154+ and CD137+ cells from 2 × 107 stimulated PBMC. Upper plots: cells are gated on CD4+ T-cells and absolute cell
counts of CD154+ and CD137+ cells with and without stimulation are indicated. Lower plots: Overlayed flow-cytometric analysis of birch-specific
CD154+ and CD137+ cells. Numbers indicate percentages among CD137+CD154– CD4+ T-cells and absolute numbers of CD137+CD25+FOXP3+
Treg. (D) To describe the precision of flow cytometry data, the CV can be calculated from the variance and the SD) For rare cell analysis, the
approximations SD = r and CV [%] = 100/r can be used, where r is the number of positive events [635]. From CV [%] = 100/r follows r =
[100/CV]2. Using this approximation the number of total required events is illustrated depending on the frequency of target cells for different CVs.
(lymphoid-) organs) and donors. Antigen preparations containing
potential innate immune signals (pathogen-associated molecular
patterns) may cause bystander activation and specificity of the
antigen-reactive T-cells has to be confirmed for each antigen (see
also Section 17.5.5 Controls and statistical analyses).
In contrast, stimulation of CD8+ T-cells with whole proteins is
difficult, since MHC class I epitopes are not easily generated from
endocytosed proteins that depends on cross presenting capacity of
the APCs. Therefore, short synthetic peptides are preferable. The
use of peptides as antigen stimulants is advantageous as peptides
are instantly presented by all APCs expressing MHC molecules,
including B cells or other nonclassical APCs. Peptides can be used
individually or in pools, such pools being able to cover complete
protein amino acid sequences (protein spanning peptide pools).
The use of peptides of 15 amino acids length and 11 overlaps
has proven very successful for both CD4+ and CD8+ T-cells [637,
638]. The use of 15mers is in conflict with the concept that the
binding groove of class I MHC molecules can only accommodate
a peptide of nine amino acids in length. Since approaches using
15mer peptides are successful, it is assumed that mechanisms exist
that shorten these peptides in the extra cellular space (clipping or
trimming) [639, 640].
17.5.5 Controls and statistical analyses. Standard controls for
flow-cytometric multicolor analyses that apply here (single color,
compensation, FMO-controls, exclusion of doublets and dead cells,
as well as a dump channel) are described in Chapter III. Sec-
tion 1. Controls—Determining positivity by eliminating false posi-
tives. However, special emphasis has to be given to elimination of
background due to the low frequencies of antigen-specific T-cells,
as noted above. A nonstimulated sample processed under iden-
tical conditions is absolutely required to determine background.
Specificity should be verified for each pMHC-multimer and anti-
gen, especially for preparations containing pathogen-associated
molecular patterns, as well as for different cell sources (blood, tis-
sue). Specificity can be determined, for example, by MHC blocking
Abs, the use of fixed APCs (for processing dependent antigens) or
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expansion of cell lines and single cell clones for confirmation of
specificity by antigen re-stimulation [624].
Also, a positive control for the assay should be included, to
determine functionality of the T-cells and APCs. Polyclonal stim-
ulation can be achieved by, e.g., agonistic Abs against CD3 and
CD28 or by stimulation with the chemicals PMA and Iono. How-
ever, these controls only apply for the T-cells and are indepen-
dent of the presence of functional APCs. Alternatively, super-
antigens like Staphylococcus enterotoxin B (SEB) can be used,
which crosslinks MHC molecules and specific Vβ regions of T-
cell receptors. Thus, usage of SEB might be limited in samples
with restricted Vβ repertoires. Since polyclonal stimuli are usually
very strong, an antigen-specific control might represent a more
physiological control, e.g., an antigen derived from an ubiquitous
pathogen like Candida albicans, or standard vaccine like tetanus,
to which typically all donors react [624].
When frequencies of antigen-specific T-cell are calculated,
background values have to be subtracted from that of the anti-
gen sample. Regarding statistical significance of rare event anal-
yses, considerations have to be applied to determine the minimal
number of events that have to be acquired for statistically rele-
vant analyses. To describe the precision of flow-cytometry data,
the CV can be calculated from the variance and the SD [635].
For example, for a CV of 5% at least 400 antigen-specific T-cells
have to be acquired. If the antigen-specific cells occur with a fre-
quency of 0.1%, at least 400 000 total events should be acquired.
If the frequency of specific cells is just 0.01%, at least 4 000 000
have to be acquired, and so on. This illustrates that for many
antigens, magnetic preselection of the rare antigen-specific T-cells
from large cell samples is necessary to increase the sensitivity of
the assay and obtain sufficient target cells for statistically rele-
vant analyses (see also Chapter VII Section 2 Statistics for Flow
cytometry).
For methods employing enrichment, the absolute count of tar-
get cells obtained from a certain input cell number has to be
determined to calculate frequencies in the original sample. The
frequency of positive cells after enrichment is not relevant for
quantification. A minimal SNR and minimal number of events
per input cell number has to be determined for each test system
independently (see also Chapter V Section 1 Rare cells (general
rules)).
17.5.6 Interpretation of results. Originally, specific T-cell anal-
ysis relied on the idea that antigen-specific memory-type T-cells
can only be detected in antigen-experienced individuals. However,
recent advances, in particular in the enrichment of rare cells, has
allowed detection of rare specific T-cells even within the na¨ıve
repertoire [624, 633, 634, 641–644] (Fig. 67B). These analyses
also showed that the memory compartment contains a signifi-
cant fraction of specific T-cells against bona fide “neo-antigens,”
i.e., antigens not previously encountered by the immune system.
This may result from specific (structurally related epitopes) or
from statistical cross-reactivity, i.e., recognition of a neo-epitope
by TCRs from a polyclonal repertoire [624, 642, 644]. Thus, the
presence of memory-type T-cells does not per se imply that this
results from a genuine antigen-specific immune response. There-
fore, additional biological parameters have to be considered to
determine the actual immune status: overall ratio between spe-
cific memory to naive and Treg cells, ratio of memory T-cells in the
antigen-specific population versus the total T-cell population (is
expected to be >1 in genuine memory responses), clonal compo-
sition of TCRs (deep sequencing), and affinity or functional avid-
ity that can be estimated be restimulation of expanded antigen-
specific clones or cell lines with decreasing antigen concentrations
or via reversible MHC-multimers [589].
Taken together, antigen-specific cytometry allows combination
with multiparametric single cell analysis tools for full resolution
of the antigen-specific immune response.
17.6 Live cytokine-producing cell sorting with Cytokine
Secretion AssayTM
17.6.1 Overview. The aim of this section is to illustrate how to
recover live human T cells depending on their capacity to produce
specific cytokines. This technique can be applied to both identifi-
cation and sorting of antigen specific cells, as well as polyclonal T
cells with a common cytokine production profile.
17.6.2 Introduction. Following antigen recognition, T cells
acquire effector properties that guarantee pathogen clearance.
Cytokine secretion is one of the most effective properties of acti-
vated T cells as it orchestrates a functional immune response
involving both cells of adaptive and innate immunity. Different
pathogens evoke different cytokine responses; thus T cells can be
functionally distinguished based on their cytokine profile. Indeed,
there are at least three major types of cell-dependent immunity,
classically defined as types 1–3 responses (see also Chapter VI Sec-
tion 1.11 Human CD4 and CD8 T cells). Type 1 immunity defends
from intracellular bacteria and viruses, involves Th1 and CTL T
(Tc)1 cells and is orchestrated by the transcription factor Tbet
with the production of IFN-γ. Type 2 immunity fights extracellu-
lar parasites and is mediated by Th2 and Tc2 cells, which express
the transcription factor GATA3 and produce IL-4, IL-5, and IL-13.
Finally, RORgt+IL-17+ Th17 and Tc17 cells mediate type 3 immu-
nity, which protects from extracellular bacteria and fungi [645].
Despite these distinctions, it has been described more recently
that distinct effector programs can coexist within the same cell.
Indeed, cells simultaneously producing IFN-γ and IL-17 (Th1/17),
IL-4, and IL-17 (Th2/17) and IFN-γ and IL-4 (Th1/2) have been
identified [646–648]. Moreover, it has been demonstrated that
a single pathogen can evoke functionally heterogeneous T cell
responses [649]. In this complex scenario, the Cytokine Secretion
AssayTM (Miltenyi Biotec) is a versatile tool that allows the identi-
fication and recovery of live antigen specific T cells based on their
cytokine production profile. First, cells are shortly stimulated with
antigen (see also Chapter V Section 17.5 Functional read-outs)
or with polyclonal stimuli. Then, cells are labeled with the Catch
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Reagent specific for the cytokine of interest. Catch Reagent is made
up of two Abs linked for their Fc regions. One Ab is specific for the
pan-leukocyte marker CD45 and allows binding to the leukocyte
surface. The other Ab is specific for the cytokine of interest. Cells
are then incubated again at 37°C to favor cytokine production. If a
cell secretes the specific cytokine, it will bind to the catch reagent
on the cell surface. The addition of a secondary fluorochrome-
linked Ab, recognizing a distinct epitope of the cytokine from
that of the catch reagent allows the detection of cytokine produc-
ing cells. The Cytokine Secretion AssayTM can be applied either
on whole blood, PBMNC, or even directly on T cells when using
polyclonal stimulation. Staining with lineage specific Abs allows
the identification of a specific cell subset that is producing the
cytokine, when working on whole blood or PBMNC [650] or on
cells from biological fluids [651]. Live cytokine producing cells can
then be recovered either by immunomagnetic or flow cytometric
sorting (See also Chapter IV Section 1.4 Magnetic pre-enrichment
for high-resolution detection and analysis of rare cell populations
and Chapter IV Cell sorting).
17.6.3 Step-by-step sample preparation.
17.6.3.1 Starting material. The protocol can be applied
either on whole blood, PBMNC, or isolated T cells. Whole blood
must be collected with anticoagulant sodium heparin. Since cal-
cium is critical for lymphocyte activation, chelating anticoagulants
cannot be used for blood collection. When working with PBMNC,
fresh cells are preferred but cryopreserved cells can be also used.
17.6.3.2 Cell stimulation.
1. Wash cells at 300 × g for 7 min.
2. Resuspend cells in RPMI 1640 supplemented with 5% human
serum. Final cell concentration must be 10 × 106/mL.
3. Add the specific peptide/protein at the desired concentration.
Always include a positive control (SEB, PMA/Ionomycin) and
a negative control (no stimulus). The optimal positive control
must be chosen based on the cytokine of interest. Incubation
period ranges from 3 h in case of polyclonal stimuli to 6–16 h
for proteins. Incubation must be performed at 37°C with 5%
CO2.
4. Following incubation, collect cells in a 15 mL polypropylene
tube.
17.6.3.3 Cytokine Secretion Assay.
1. Prepare 100 mL cold buffer; 100 µL cold medium; 10 mL
warm medium. Volumes are adjusted for up to 10 × 106
cells. Scale up for larger numbers. Do not reduce volumes if
working with less than 10 × 106 cells.
2. Wash cells from previous step 4 with 10 mL cold buffer and
spin down at 300 × g for 7 min.
3. Resuspend up to 10 × 106 cells with 80 µL cold medium, then
add 20 µL of catch reagent. Mix and incubate 5 min on ice.
4. Add warm (37°C) medium and dilute cells depending on the
expected amount of cytokine-producing cells. Proper dilution
is critical to prevent unspecific binding of secreted cytokines
to close cells. If less than 5% cytokine producing cells are
expected, add 10 mL of warm medium to achieve a final
concentration of 106 cells/ml. If more than 5% cytokine pro-
ducing cells are expected, add 100 mL of warm medium to
a final concentration of 105 cells/mL. Further dilution is
required for expected frequencies of cytokine producing cells
>20%.
5. Incubate cells 45 min at 37°C 5% CO2 to allow cytokine secre-
tion and binding to catch reagent. During this incubation
period rotate tubes every 5 min or use MACSMixTM rotator to
avoid cell to settle, thus leading to cytokine unspecific bind-
ing.
6. Following incubation put the tubes on ice. Spin down cells in
a precooled centrifuge at 300 × g for 7 min.
7. Wash cells with cold buffer to block cytokine secretion and
repeat the centrifugation step.
8. Resuspend cells up to 10 × 106 cells with 80 µL cold
medium, then add 20 µL of cytokine detection fluorochrome-
conjugated Ab. Additional Abs can be added at this step to
allow simultaneous detection of other markers. Mix and incu-
bate 10 min on ice.
9. Wash cells with cold buffer and centrifuge at 300 × g for 7
min.
10. Cells are now ready for FCM analysis or sorting. Always add
PI to exclude dead cells from the analysis.
17.6.4 Materials.
 Buffer: PBS, pH 7.2, supplemented with 0.5% BSA and 2mM
EDTA
 Medium: RPMI 1640 supplemented with 5% human serum. Do
not use fetal cow serum or bovine serum to avoid unspecific
stimulation.
 Peptide/Protein of interest
 PMA and Iono; Staphylococcal Enterotoxin B (SEB) for poly-
clonal stimulation
 PI for flow cytometric exclusion of dead cells
17.6.5 Data analysis. Data analysis requires the exclusion of
doublets and dead cells using a live-dead marker. This is espe-
cially true if using cryopreserved cells instead of freshly isolated.
As in Fig. 68, lineage markers allow the identification of the popu-
lation of interest for the identification of cytokine producing cells.
17.6.6 Pitfalls. Dilution steps and continuous rotation during
the incubation period are critical to avoid cytokine binding to
nonproducing cells.
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Figure 68. Cytokine secretion assay per-
formedonPBMNC for the detection of IFN-
ɣ and IL-17 producing T helper cells. Cells
were stimulated with PMA/Iono. Lym-
phocytes were gated based on physical
parameters, then doublets removed using
FSC Height and Area (FSC-H and FSC-A,
respectively). Dead cells were excluded as
PerCP-positive and PE-positive following
PI addition. T helper cells were then iden-
tified as CD3+ positive, CD4+, CD8–. IFN-ɣ
and IL-17 expression were subsequently
analyzed.
17.6.7 Top tricks. Secretion of two distinct cytokines can be eval-
uated simultaneously via combining cell staining with two distinct
catch reagents and detection Abs. The only requirement is that
detection Abs must be conjugated to distinct fluorochromes. Dilu-
tion factor during the incubation period must be calculated based
on the expected higher percentage of cytokine producing cells.
17.7 Quantification of soluble cytokines with cytometric
bead array
17.7.1 Overview. Cytokines are the main soluble proteins
secreted by various cells of the immune system. These soluble
factors play different roles in regulation of immune responses,
since they influence migration, activation, and proliferation of
various cell types, including tissue resident cells. Cytokines show
commonly pleitropic features, exhibit redundant, and overlap-
ping properties; they also mediate production or regulate func-
tion of other cytokines. The final effect on a specific cell type
depends on the balance among multiple cytokines that again
depends on their activity or concentration. Thus, an evaluation
of an extended number of cytokines in biological fluids, rather
than a single cytokine, may be an optimal strategy to better inves-
tigate various physiological and/or pathological settings. In this
context, multiplex bead-based array described in this section is
a valuable tool that allows simultaneous flow cytometry analy-
sis of several analytes from a single sample using a small sample
volume [556, 2218, 2249, 2251, 2253, 2255].
17.7.2 Introduction. Different methods have been developed to
define cytokine concentration in biological fluids, and these are
mainly based on competitive or sandwich principles. In these sys-
tems, antigens or Abs are labeled with an enzyme or a fluorescent,
luminescent, or radioactive molecule. Historically, the classical
method that belongs to this family is the ELISA, in which the
targeted cytokine is sandwiched by two Abs specific for differ-
ent epitopes of the same cytokine. In this method, the first Ab is
linked to a plastic plate support and is defined as the “capture” Ab;
instead, the second Ab is conjugated with the detection molecule
and is defined as the “detector” Ab. ELISA is characterized by high
specificity and sensitivity; however, it only allows detection of a
single analyte and requires the use of a higher sample volume for
each measurement.
The introduction of multiplex beads-based immunoassays sig-
nificantly changed the approach for the quantification of cytokines
and other soluble factors in biological fluids or culture super-
natants. The principle of this method is the use of a specific Ab
coated on microbeads that serve as a “solid” support as in the
version of the ELISA technique. Microbeads can be detected by
FCM instruments, based on their fluorescence. During the incuba-
tion with the sample, the analyte of interest will bind to the Ab–
microbead complex. The addition of a fluorochrome-conjugated
secondary Ab allows the detection of the analyte-microbead com-
plex. Quantification is performed via referring to a standard curve,
prepared with known scalar doses of protein concentration.
The combination of beads with different size and/or beads with
different florescence intensity, represents the flexibility and the
power of this method allowing to evaluate simultaneously up to
100 analytes in the same sample. Several kits for multiplex beads-
based assay are available from different commercial vendors, each
with specific properties, i.e., sample volume (generally ranging
between 50 and 15 µL), assay duration (on average only a few
hours, depending on the period of incubation and washing steps),
the possibility to customize the combination of primary beads,
and sensitivity of the test, which also depends on the range of the
standard curve.
17.7.3 Step-by-step sample preparation. Here, we provide the
detailed protocol of Cytometric Beads ArrayTM (CBA) from BDBio-
science as an example. Specific protocols from other vendors must
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Figure 69. Flow cytometer setup for
multiplex-bead based array. (A) FSC–SSC
plot for the identification of beads based
on their physical parameters. Histogram
plots of APC-Cy7 (B) and ACP (C) chan-
nels showing that PMT voltages are opti-
mally set to the highest visibleMFI. By this
way, it is possible to properly distinguish
different types of beads used. Panel (D)
represents histogram plot of PE channel
(the fluorochrome bound to the secondary
antibody) measured on unstained beads.
be followed according to the manufacturer’s instructions. The
BD CBA kit can detect: human, mouse, and rat soluble proteins,
immunoglobulins, as well as cell signaling factors. BD CBA solu-
tions are available in two formats to meet diverse needs. BD CBA
Kits are preconfigured with routine panels, while BD CBA Flex
Sets provide an open and configurable method of detection, so
that researchers can design their own multiplex kit. Beads are
coated with an Ab specific to the protein of interest; each bead
in the array has a unique red fluorescence intensity so that differ-
ent beads can be mixed and run simultaneously in a single tube.
These beads are incubated with a small sample volume and then
further incubated in the presence of a capture Ab tagged with the
fluorochrome PE. At the same time, a curve of standard samples
ranging from 10 to 2500 pg/mL, is performed to enable protein
quantification.
1 Standard preparation
1.1. Prepare the highest concentration of the standard curve
for all analytes by pooling all the lyophilized standard
spheres in a single 15 mL polypropylene tube. Add the
appropriate amount of assay diluent following manufac-
turer’s instructions.
1.2. Mix well and wait 15 min at room temperature;
1.3. Perform 1:2 serial dilutions in flow cytometric tubes
adding the appropriate volume of assay diluent. Usually
ten standard points are recommended including the 0
(zero) tube that contains only assay diluent.
2 Beads and sample preparation
2.1. Calculate the number of total tubes of the experiment
(including both standards and samples). For each tube,
you need 1 µL of beads for each analyte. Prepare a suf-
ficient volume of beads for all the tubes. Mix all beads
specific for all analytes in a single tube.
2.2. Add 500 µL of Wash Buffer from the kit.
2.3. Centrifuge at 200 × g for 5 min.
2.4. Aspirate supernatant and resuspend in appropriate vol-
ume of Capture Beads Diluent to reach a final volume of
50 µL per tube of the experiment.
Use appropriate Capture Beads Diluent depending on the
type of sample (serum, plasma, or culture supernatants)
2.5. Optional. Depending on the type of experiment and
expected protein concentration, perform appropriate sam-
ple dilution using assay diluent;
2.6. Dispense 50 µL of standard or sample (or its appropriate
dilution) in a tube;
2.7. Add 50 µL of bead mix in each tube of standard or sample;
2.8. Incubate 1 h at room temperature;
2.9. Prepare the total mix of PE reagent containing the sec-
ondary Ab specific for each analyte included in the exper-
iment, based on the number of total tubes to acquire
(including both standards and samples), as reported in
point 2.1;
2.10. Add 50 µL of PE reagent in each tube of standard or sam-
ple;
2.11. Incubate 2 h at room temperature;
2.12. Wash each tube with 1 mL of Wash Buffer, centrifuge at
200 × g for 5 min.
2.13. Remove supernatants, then resuspend beads in 300 µL
wash buffer and vortex before FCM acquisition.
3 Instrument setup
It is necessary to setup the instrument to correctly define the
optimal voltage for different channels. First of all it necessary
to set the FSC and SSC parameters to identify the bead popu-
lation as singlets while excluding doublets (Fig. 69A). Subse-
quently, use compensation beads provided by the kit to set up
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Figure 70. Quantification of human soluble
cytokines with cytometric bead array (CBA) (A)
Representative flow cytometry analysis of an
experimental setting for evaluation of four dif-
ferent cytokines from culture supernatants of
polyclonally stimulated human CD4+ T cells.
The FSC/SSC plot allows identification of the
total beads population; the APC-APC-Cy7 plot
allows the identification of each bead corre-
sponding to a specific analyte. Single beads are
clustered based on the conjugation with differ-
ent quantities of two different flurochromes.
(B) Representative flow cytometric plots of
an experiment for evaluation of six differ-
ent cytokines from culture supernatants of
polyclonally stimulated human CD4+ T cells.
The FSC/SSC plot allows identification of the
total bead population; the APC-APCCy7 plot
allows identification of each bead correspond-
ing to a specific analyte. Single beads are clus-
tered based on their fluorescence intensity;
in this case each bead population is conju-
gated with the same quantity of two differ-
ent flurochromes used for its identification. (C
and D) Representative flow cytometric plots of
a standard curve from an experiment for mea-
surement of six different cytokines, as reported
in panel B: the “zero” tube in panel C (0 pg/mL)
and the “top” tube in panel D (2500 pg/mL).
Beads clusters are identified in APC (or APC-
Cy7) channel and the different quantities of
each analyte are defined by PE MFI.
the APC and APC-Cy7 voltages to reach the highest MFI (see
Fig. 69B and C). This is of importance for proper identification
of different beads, since they have different APC and APC-Cy7
emissions (Fig. 70A and B). Use the provided unstained beads
to set up the minimum voltage of the PE channel (Fig. 69D).
4 Sample acquisition
4.1. Apply the final instrument setup obtained in the previous
step to all samples within the same experiment;
4.2. Acquire the standard tubes from the lowest to the high-
est concentration (this sequence is important as the data
analysis with the FCAP software will be easier, see below
in section “data analysis”);
4.3. Acquire each sample tube. In both standard and sample
tubes it is important to record at least 300 events for each
of the beads included in the mix.
17.7.4 Materials not included in the kit.
- Classic tubes for FCM
- 15 mL polypropylene tubes for preparation of standards solu-
tions
- vortex, centrifuge, pipets, and tips
17.7.5 Data analysis. Data analysis is performed with FCAP
Array software (available for Windows or MAC). Data generated
for each acquired sample (including the standards) are exported
from the acquisition software as .fcs files and then imported in
the FCAP Array software. In the first step, it is necessary to select
in the software menu the fluorescence of the beads (APC-APC
Cy7 in this example) and that of the secondary Ab (PE in the
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example) used in the experiment. Subsequently, the .fcs file of the
first tube of the standard curve is imported into the software. Using
this first .fcs file, the name of the specific target analyte to each
bead cluster is assigned in the software. Next, the remaining .fcs
files (both standards and samples) are imported, and the beads-
recognition setting as set for the first imported file is applied to
all fcs files. Standards should be distinguished from samples in a
specific grid. For each sample it is possible to include the dilution
factor, if applied (step 2.5). Using the MFI of the fluorochrome
on the detector Ab (PE in this example) the software calculates
the standard curve from .fcs files of the standard tubes. A specific
standard curve is generated for each analyte. Unknown protein
concentrations in sample .fcs files are then calculated by the soft-
ware comparing the MFI of each bead cluster to the corresponding
standard curve.
17.7.6 Pitfalls.
- Fluidic alteration during the acquisition of different samples
can induce a wrong bead clusterization impairing the analysis
by the FCAP software.
- Different dilution factors may be required to study different
cytokines in the same sample. In case of preconfigured com-
mercial kits, it is necessary to repeat the experiment with
both diluted and undiluted samples. Instead, in case of cus-
tomized experiments, it is possible to have separate kits so that
cytokines with the same dilution factor are analyzed in the
same experiment and separated from cytokines that require a
distinct dilution.
17.7.7 Top tricks.
- Appropriate resuspension of standards, samples, and their dilu-
tions are important to define the correct final concentration of
the cytokines.
- Usually serum and plasma need higher dilution than culture
supernatants but this depends on the type of analyzed cytokine
as well as culture conditions of in vitro supernatants.
- Gently mix standards and tubes prior to acquisition, by pipet-
ting. Do not use vortex. Use vortex only to resuspend beads
before beads preparation (steps 2.1 and 2.5).
- Samples can be stored –30°C before evaluation; in this case, it
is important to completely defrost samples and mix well before
their dilution and/or usage.
17.8 Cytotoxicity
17.8.1 Overview. Priming of naive pathogen- or tumor-reactive
CD8+ T lymphocytes (TN) occurs in secondary lymphoid organs
(SLOs), where they undergo clonal expansion and differentiate
into effector CD8+ T (TE) lymphocytes (see also Chapter VI Sec-
tion 1.1 Murine CD4 and CD8 T cells). In the course of their func-
tional maturation, CD8+ TE acquire the ability to leave SLOs, enter
non-lymphoid organs (NLOs), produce inflammatory cytokines
and lyse target cells displaying cognate MHC class I-peptide com-
plexes [652, 653]. Besides TE, immune activation also leads to the
generation of long-lived memory T lymphocytes (TM), see also
Chapter VI Section 1.4 Murine tissue resident memory T cells).
CD8+ TM can be found in SLOs and NLOs where they exert imme-
diate effector functions upon secondary Ag contact [654, 655].
Peptide-specific target cell lysis is a cardinal feature of cytotoxic
CD8+ TE/TM (CTLs) [655, 656] and its quantification is a valuable
means to track CD8+ T cell responses. Here, we review methods
to quantify cytotoxic function in vivo and ex vivo and present
exemplary data using these assays to monitor cytotoxic activity of
murine influenza-specific CTLs.
17.8.2 Introduction. Traditionally, in vitro CTL assays relied on
the detection of compounds released from dying target cells. For
example, target cells loaded with radioactive sodium chromate
lose their radioactive label as a result of CTL-mediated lysis.
Hence, the amount of radioactivity in the supernatant of effec-
tor (CTL)/target cell co-cultures directly correlates with the lytic
activity of the respective CTL population [657]. To achieve suitable
effector-to-target cell (E:T) ratios of at least 50:1, high numbers
of CTLs are required for this type of assay. This usually requires
antigen-dependent CTL expansion in vitro, a process thatmay alter
the composition and/or function of the starting CTL population.
In order to replace radioactive CTL assays, several FCM-based
techniques were established in the past years. Their major aim is
to visualize the biochemical processes involved in CTL-mediated
target cell lysis.
CTLs induce target cell apoptosis via the Fas/Fas ligand path-
way [658] or the release of cytotoxic granules containing perforin
and granzymes [659]. Either pathway results in the activation
of caspase-dependent target cell apoptosis. To visualize this pro-
cess, cell-permeable fluorogenic caspase substrates were devel-
oped [660]. They consist of two fluorophores, which are linked by
a caspase-sensitive peptide. Only upon caspase-dependent cleav-
age these substrates become activated and can be detected by
FCM. Alternatively, target cell apoptosis can be visualized with
the help of fluorochrome-labeled inhibitors of caspase (FLICA),
which bind specifically to active caspases [661, 662]. Hence, in
both cases fluorescence intensities correlate with CTL-dependent
target cell destruction. However, similar to the chromium release
assay, relatively high E:T ratios are required for these experimen-
tal approaches.
A more sensitive assay relies on the co-incubation of CTLs with
a mixture of target cells consisting of at least two different popula-
tions. For this so-called fluorometric assessment of T lymphocyte
antigen-specific lysis (FATAL) assay [663], the first target cell pop-
ulation is loaded with the MHC I-restricted peptide of interest and
stained with one dye (e.g., PKH-26). The second population is
loaded with an irrelevant peptide, stained with a different dye
(e.g., CFSE) and serves as negative control [663]. Different con-
centrations of the same dye can be used to stain both target cell
populations, which are discriminated based on their differential
fluorescence intensities. Alternatively, amine-reactive dyes such
as Cell Tracer Violet can be used, which are less prone to dye
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transfer between cells observed with lipophilic dyes. The extent
of CTL activity is determined by the relative numeric decrease of
labeled target cells loaded with the desired peptide over nonspe-
cific target cells after a period of time, usually 5 h. Significant
advantages of this assay are its high sensitivity and favorable SNR
due to negligible amounts of spontaneous tracer release, a com-
mon side effect of the chromium release assay. Due to these advan-
tages, the FATAL assay is often well suited to directly measure CTL
function ex vivo without prior expansion and at comparably low
E:T ratios.
Target cells may be immune (e.g., splenocytes) or somatic cells
(e.g., epithelial cells or fibroblasts) to more closely resemble the
physiological CTL targets. CTLs can be purified from any organ
of interest, either lymphoid or non-lymphoid. Depending on the
research question, purification of total CD8+ T cells, or antigen-
specific CD8+ T cells may be required. In the former case, the
frequency of antigen-specific CTLs can be determined in parallel
by MHC/peptide multimer staining to adjust E:T ratios for dif-
ferent tissue samples. Figure 71 shows an example of ex vivo
cytotoxicity by influenza-specific CTLs isolated from the broncho-
alveolar space of infected mice without the need of a prior sort for
influenza-specific CTLs.
However, if the frequency of antigen-specific CD8+ T cells is
very low, it may be necessary to enrich them prior to the cytotox-
icity assay. In this case, it is not advisable to sort antigen-specific
CD8+ T cells by means of TCR labeling (e.g., by MHC/peptide
multimers) since this may alter their lytic function. If available,
the use of congenically-marked TCR-transgenic (TCRtg) CD8 T
cells might be useful to circumvent this problem. This allows their
marker-based, TCR-independent enrichment prior to the ex vivo
CTL assay. Hence, direct ex vivo CTL assays have several advan-
tages: (i) they are very sensitive, (ii) CTLs may be isolated from
any organ, (iii) the type of target cell may be adapted to the nature
of the experiment, and (iv) E:T ratios can be adjusted to compare
different samples. However, it is important to note that the tis-
sue microenvironment affects CTL activity [664]. Hence, the lytic
potential of tissue-resident CTLs may differ from those purified for
ex vivo CTL assays.
To circumvent this problem CTL activity can be measured in
vivo [656, 665, 666]. Again, at least two target cell populations are
required. One is labeledwith the peptide of interest and e.g., a high
concentration of a suitable dye such as CFSE (CFSEhi population).
The control population is loaded with an irrelevant peptide and a
tenfold lower concentration of CFSE (CFSElo population). Equal
numbers of CFSEhi and CFSElo cells are co-injected into effector
mice. After 4–18 h, SLO can be isolated to analyze single cell
suspensions by FCM. Similar to the direct ex vivo assay described
above, the relative loss of CFSEhi target cells over CFSElo cells
indicate the extent of CTL-mediated lysis. This method provides
the most sensitive and physiological assessment of CTL activity.
Figure 72 shows an example of influenza-specific CTL activity in
lung-draining mediastinal LNs and nondraining distal LNs in mice
undergoing flu infection.
In vivo CTL assays can also be used to determine the lytic poten-
tial of multiple CTL populations with different specificities at the
same time. This requires the simultaneous use of more than two
target cell populations. A simple method to achieve this goal is the
use of splenocytes from homozygous CD45.1+/1+ and heterozy-
gous CD45.1+/2+ congenic mice as target cells in CD45.2+/2+
effector mice. Using mAbs against CD45.1 and CD45.2, mixed
CD45.1+ target cells can be discriminated from host cells. Further-
more, the different target cell types can be distinguished based on
their differential CD45.1/.2 expression and varying CFSE intensi-
ties.
17.8.3 Preparation of target cells. For in vivo CTL cytotoxicity
assays, cell suspensions from the spleen are commonly used as tar-
get cells. For the experimental results shown in Fig. 72, a spleen
cell suspension from naive mice was split in two equal groups.
One group was labeled with 1 µM of the immunodominant IFV
peptide NP366-374 and the other group with an irrelevant peptide
for 30 min at room temperature. Time and concentration may be
changed depending on the affinity of the peptide for MHC class
I. An equal volume of 0.2 µM Cell Proliferation Dye eFluor 670
(CPD-eF670) in protein-free RPMI was then added to the sam-
ple with the irrelevant peptide and immediately mixed. The other
sample was labeled with a tenfold higher concentration of CPD-
eF670. Samples were further incubated in the dark for 15 min at
room temperature. Beyond this point, samples were maintained at
4oC at all times to prevent decay of H-2Db/ NP366-374 complexes.
Samples were extensively washed in PBS containing 10% FCS
to remove excess peptide and dye and counted in independent
triplicates. An equal number of cells was mixed 1:1 and finally
resuspended in PBS. The final concentration of cells to be injected
into mice depends on several factors such as (i) the organ of final
analysis (target cells migrate in higher numbers into the spleen
compared to the lymph nodes); (ii) the amount of target organ
available for analysis; (iii) the desired (expected) effector to target
ratio. Typically, 2 × 106 or 5 × 106 of each target population is
sufficient to analyze kill activity in spleen or lymph nodes, respec-
tively. In the literature killing of 5–10 × 106 of each target cell
population is typically monitored.
For in vitro or ex vivo cytoxicity assays, a wider range of target
cell typesmay be used since effectors and target cells are incubated
in vitro. Independently of this, however, the treatment and label-
ing of target cells is performed in a similar manner as described
above.
17.8.4 Materials.
Product Company
PBS Gibco
RPMI Gibco
FCS Gibco
Peptides Xaia peptides
Cell Proliferation Dye eFluor670 Thermofisher
Hoechst33258 Thermofisher
Propidium iodide Sigma
BD FACSCantoII BD Biosciences
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Figure 71. Quantification of ex vivo cytotoxic-
ity by influenza-specific CTLs. Seven days after
pulmonary infectionwith influenza A/WSN/33,
untouched flu-specific murine CTLs in unfrac-
tionated bronchoalveolar lavage (Effectors, E)
were incubated in vitro with a titrated num-
ber of target cells (T). Targets consisted of
an equal mixture of spleen cells loaded with
the MHC-I-binding influenza peptide NP366-374
(flu) or an irrelevant MHC-I ligand (control).
Flu peptide-loaded spleen cells were labeled
with a higher concentration of Cell Prolifera-
tion Dye eFluor 670 than their control counter-
parts. Five hours later, the relative frequency
of the remaining target cells was quantified by
FCM. The exact frequency of flu-specific CTLs
can be determined in parallel by staining with
the corresponding MHC-I multimer. (A) Flow
cytometric gating strategy to identify target
cells. Shown are results for the Effector:Target
ratio of 2. (B) Histograms showing the percent-
age for each target cell population at the end
of the assay. (C) Quantification of technical
duplicates shown in (B). The percentage of flu-
specific kill was calculated as: 100 – [100 × (Tflu
/ Tcontrol)with E / (Tflu / Tcontrol)without E].
17.8.5 Data analysis. Samples are processed for standard flow
cytometric analysis. Specially, for in vivo cytotoxicity assays, it is
necessary to acquire a relatively large number of events since the
proportion of target cells among the total acquired population is
very low, typically below 1–2%. The gating strategy for quanti-
fying antigen-specific cytotoxic activity is illustrated in Figs. 71A
and 72A for ex vivo and in vivo cytotoxicity assay, respectively. It
is recommended that an “empty channel” is used to gate out aut-
ofluorescent cells. The degree of cytotoxic activity is determined
by the relative decrease in the number of target cells displaying
the specific epitope over those displaying an irrelevant epitope at
the end of the assay time. To calculate the percentage of specific
killing, the following formula can be used:
Ratio = (% control targets/% specific targets)
% specific lysis = 1 − (ratio negative control/ratio test group) ×
100
17.8.6 Pitfalls. Although in vivo CTL assays offer obvious advan-
tages, they are not suitable for all experimental systems. For
example, the choice of target cells is limited. Most somatic cells,
which are often the primary “natural” targets of viral infections,
are trapped within the lung and liver vasculature soon after i.v.
injection into mice. Thus, they are of limited use as target cells
in vivo. The use of naive splenocytes as target cells may help to
circumvent this problem. However, naive splenocytes usually do
not enter NLOs effectively. Hence, the appropriate tissue tropism
of the desired target cell type is a prerequisite for the success-
ful application of the FCM-based in vivo kill assay. A disadvan-
tage of in vivo CTL assays is the fact that E:T ratios cannot be
adjusted. Hence, differences in lytic activity may result from dif-
ferences in CTL numbers and/or the lytic potential of individual
cells. The quantification of specific CTLs by MHC/peptide mul-
timers in the respective target organs may be useful to judge
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Figure 72. Quantification of in vivo cytotoxic-
ity by influenza-specific CTLs. Seven days after
pulmonary infection with influenza A/WSN/33,
infected and naivemice received target cells intra-
venously. Targets consisted of an equal mixture
of spleen cells loaded with an MHC-I-binding
influenza peptide (flu) or an irrelevant MHC-I
ligand (control). Flu peptide-loaded spleen cells
were labeled with a higher concentration of Cell
Proliferation Dye eFluor 670 than their control
counterparts. Four hours later, target cells in
lung-draining mediastinal LNs and non-draining
inguinal (distal) LNs were quantified by flow
cytometry. (A) Flow cytometric gating strategy to
identify target cells in the indicated organs. (B)
Representative histograms indicating the percent-
age of eqch target cell population at the end of the
assay in the indicated organs.
whether differences in target cell lysis rely on differences in CTL
number and/or function.
All assays described so far are suitable to quantify the lytic
action of CTL populations. However, the lytic potential of individ-
ual CTLs cannot be judged. To approach this problem, Abs directed
against, e.g., CD107a can be used. This molecule is present on
the membrane of cytotoxic granules and becomes detectable on
the cell surface of degranulating CTLs. CD107a levels correlate
closely with the lytic potential of CTLs [627]. However, they can
also be differentially regulated [667]. Precise imaging of the accu-
mulation of CD107a, granzyme, and other molecules in the cyto-
toxic immune synapse between T cells and target cells can be
performed by imaging FCM [668] (see also the section on Imag-
ing FCM). mAbs directed against CD107a can be combined with
FATAL assays, MHC/peptide multimers, or cytokine-specific Abs
to determine multiple effector functions of individual antigen-
specific CTLs by FCM [669, 670]. This method might be helpful to
complement the ex vivo and in vivo CTL assays described above.
However, it should be noted that, contrary to the degree of target
cell lysis, the level of CD107a upregulation is most pronounced at
low E:T ratios [669].
17.9 Treg suppression assays
17.9.1 Overview. Regulatory T (Treg) cells are critical for the
maintenance of immune homeostasis. However, since many of
their markers are shared by activated T-cells, accurately defining
Treg cells can be difficult by phenotype alone. One defining feature
of Treg cells is that they are capable of suppressing the prolifer-
ation and activation of other cells both in vitro and in vivo. As
a result, measurement of their in vitro suppressive capacity is an
important part of defining and characterizing a putative Treg cell
population. This chapter details several methods for the assess-
ment of the suppressive function of polyclonal or antigen specific
regulatory T-cells in mice or humans.
17.9.2 Introduction. The ability to measure the capacity of Treg
cells to prevent the proliferation of conventional CD4 and CD8 T-
cells is an important factor in understanding their function. Tregs
have been described to use a range of suppressive mechanisms
with CTLA-4 dependent depletion of the co-stimulatory molecules
CD80 and CD86 from the surface of antigen presenting cells known
to have a critical role [671]. Several methods for the assessment
of cellular proliferation by incorporation of radioactive isotopes
or cells counting have been used to measure cellular proliferation
and suppressive function. However, these assays have difficulty in
determining which cells are proliferating and cannot give detailed
information on the number of divisions undertaken by individual
cells. More recently cytometry-based assays relying on staining
a responder population with an amine-reactive fluorescent dyes
such as CFSE and cell trace violet (CTV) that are diluted in a
predictable manner during cell division has proven an effective
method to measure cell proliferation. Utilizing this system, it is
possible to add Treg cells to culture and observe the effects of
varied ratios of Tregs on the proliferation of the responder pop-
ulation [672]. In addition to assays utilizing polyclonal stimuli
such as CD3 mAb, the measurement of the suppression of human
antigen-specific T cells in vitro provides information closer to the
physiology. However, suppression assays using antigen-specific T
cells is made difficult by the low frequency of T cells specific to a
single antigen in the T cell repertoire in vivo. In addition, highly
functional CD8+ T effector cells, in contrast to their na¨ıve coun-
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Table 15. Materials for murine suppression assay
Reagent Fluorochrome Clone Company Catalog
LIVE/DEADTM Fixable Near-IR Dead Cell Stain Kit Near-IR dye N/A Invitrogen L10119
CD4+ T Cell Isolation Kit, mouse – N/A Miltenyi 130-104-454
Cell TraceTM CFSE Cell Proliferation Kit CFSE N/A Invitrogen C34554
Anti-B220* APC-Cy7 RA3-6B2 BD 552094
Anti-CD11c APC-Cy7 N418 Biolegend 117323
Anti-CD11b APC-Cy7 M1/70 Biolegend 101225
Anti-GITR PE-CY7 DTA-1 BD 558140
Anti-CD25 APC PC65.5 eBioscience 17-0251-82
Anti-CD4 V500 RM4-5 BD 560782
Anti-CD3 AF700 14-A2 Biolegend 100216
Anti-CD3 N/A 145-2C11 BD 553057
terparts, can resist Treg cell suppression in vitro, and can display
multiple molecular strategies (including cell cytotoxicity targeting
Tregs) to counteract excessive Treg cell suppression [673, 674]. In
doing so, they can preserve their effector functions, which can pro-
duce protective or detrimental effects depending on the context
(e.g., infection recovery vs. autoimmunity). As a result, measure-
ment of their in vitro killing capacity is important to discriminate
the highly functional CD8+ T effector cells that are not susceptible
to Treg cell suppression, from those dysfunctional that have lost
the capacity to resist Treg cells, because they become exhausted
in tumor or chronic infection settings. Here, we describe protocols
allowing the measurement of human and murine Treg suppres-
sive function in both a polyclonal manner and using a low number
of antigen-specific CD8+ T cells, by selectively gating the latter
with multimers of MHC class I molecules complexed with relevant
antigenic peptides.
17.9.3 Polyclonal suppression assays.
17.9.3.1 Murine polyclonal suppression assay. Step-by-step
sample preparation (see Table 15 for reagents)
Single cell suspensions of lymph nodes or spleen of a Foxp3-
GFP reporter mouse are subjected to negative selection of CD4
T-cells by magnetic beads (CD4+ T Cell Isolation Kit, Miltenyi
Biotec).
Cells are then stained for 30 min at 4°C with Abs for CD3,
CD4, CD25, and B220 and sorted on a BD Aria-II. Tregs are sorted
as CD3+CD4+B220-Foxp3+CD25+ and confirmed to have a post
sort purity of 90%+ (Fig. 73A). Conventional T (Tconv) cells are
sorted as CD3+CD4+B220-Foxp3-CD25-. When a Foxp3 reporter
mouse is not available CD25 and GITR can be used in its place
(Fig. 73B).
CD4 Tconv are then stained with 1 µM CFSE for 10 min
in serum free media at room temperature. Excess CFSE is then
quenched by addition of media+10%FCS before washing three
times.
A total of 1 × 104 Tconv cells per well are cultured with
or without Treg cells at varied ratios (0:1, 1:1, 1:2, 1:4, 1:8
Treg:Tconv) for 3 days in the presence of 1×105 γ-irradiated
CD4 depleted APCs (18.5Gy irradiated CD4 depleted splenocytes
obtained by magnetic separation in step 1) and 1 µg/mL solu-
ble CD3 mAb (Clone: 145-2C11) in 96-well U-bottomed plates,
in RPMI media containing 10% FCS, 2-ME, L-glutamine and Peni-
cillin/streptomycin with a final volume of 200 µL. In all cases the
number of Tconv is fixed while the number of Tregs is changed to
obtain the intended ratios.
At the end of the 3 day culture period, cells are then stained
with CD4 mAb, CD25 mAb, and IR Live/Dead dye and data col-
lected on a BD LSR Fortessa.
17.9.3.2 Human polyclonal suppression assay. Step-by-step
sample preparation (see Table 16 for reagents)
Initially PBMCs are isolated from fresh blood via Ficol–Paque
centrifugation in Leucosep tubes. CD4 T-cells are enriched by neg-
ative selection of CD4 cells with magnetic beads (Miltenyi). Cells
are stained with Abs for CD4, CD45RA, CD127, and CD25 for 30
min at 4°C.
Bulk Treg cells can be sorted as CD3+CD4+CD127loCD25+
(Fig. 73C). If finer fractionation of Treg cells is required,
CD127loCD25+ cells can then be further separated into fraction
I Na¨ıve Tregs, fraction II effector Tregs and fraction III non-
suppressive cells (Fig. 73C) [675]. It should be noted that while
fraction III as a whole is mostly made up of Foxp3 expressing non-
Treg cells it may contain 20–30% CXCR5+ effector Tfr, which are
functionally suppressive Treg cells [676].
Na¨ıve responder Tconv cells are sorted as
CD25−CD45RA+CD4+CD3+ and then stained with 1 µM
CFSE. A total of 1 × 104 Tconv cells are co-cultured with various
ratios of Tregs cells (0:1, 1:1, 1:2, 1:4, 1:8 Treg:Tconv) and
1 × 105 γ-irradiated APC (18.5Gy irradiated CD4 depleted PBMCs
obtained by magnetic separation in Step 1) and stimulated with
1 µg/mL soluble CD3 mAb (Clone: OKT3) for 4–5 days in 96-well
round-bottom plates in RPMI medium containing 10% AB serum,
2-ME, L-glutamine, HEPES, and penicillin/streptomycin in a final
volume of 200 µL. In all cases the number of Tconv and APC is
fixed while the number of Tregs is changed to obtain the intended
ratios.
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Figure 73. (A) Gating example of murine CD3+CD4+B220-CD25+Foxp3-GFP+ Treg cells. (B) Alternative strategy if Foxp3 reporter is not available.
(C) Gating example of human CD4+CD25+CD127loFOXP3+ cells and further sub gating into fractions I (Naı¨ve Tregs), II (effector Tregs), and III
(Non-Tregs/Tfr). In this example, CD4 APC-Cy7 was used to avoid clash with CXCR5 BV421 but we would recommend CD4 V500 and IR live/dead
when this is not the case.
After a culture period of 4–5 days cells were then stained with
CD4, CD25 and IR Live/Dead dye and data collected on a BD LSR
Fortessa.
17.9.4 Suppression assays and antigen-specific T cells.
17.9.4.1 Human suppression assay of antigen-specific T cells.
Step-by-step sample preparation
1. PBMCs are isolated from fresh heparinized blood by density
gradient centrifugation with Lympholyte (Cedarlane, Burling-
ton, Canada).
2. CD8+ T cells are pre-enriched from PBMCs with the corre-
sponding CD8+ T Cell Isolation Kit (Miltenyi Biotec, Bergisch
Gladbach, Germany) and then highly purified CD8+ T na¨ıve
(TN; CCR7+CD45RA+) cells are enriched from CD8+ T cells by
magnetic bead-separation with the Na¨ıve CD8+ T Cell Isolation
Kit (Miltenyi Biotec). The combination of highly purified CD8+
T effector memory (EM; CCR7–CD45RA–) and effector mem-
ory RA+ (EMRA; CCR7–CD45RA+) cell population is obtained
by using the positive fraction after enrichment of TN cells. Treg
cells are isolated from PBMCswith the CD4+CD25+ Regulatory
T Cell Isolation Kit (Miltenyi Biotec) (Fig. 74). Each purified
cell subset is used in the various experiments only when the
Table 16. Materials for human suppression assay
Reagent Fluorochrome Clone Company Catalog
LIVE/DEADTM Fixable Near-IR Dead Cell Stain Kit Near-IR dye N/A Invitrogen L10119
Ficoll-Paque PLUS N/A N/A GE healthcare 17144003
CD4+ T-cell isolation kit, human N/A N/A Miltenyi 130-096-533
LeucosepTM Centrifuge Tubes N/A N/A Greiner Bio-One 227290
Anti-CD4 V500 RPA-T4 BD 560768
Anti-CD127 AF647 HIL-7R-M21 BD 558598
Anti-CD45RA BV711 HI100 Biolegend 304138
Anti-CD25 PE M-A251 BD 555432
Cell TraceTM CFSE Cell Proliferation Kit CFSE N/A Invitrogen C34554
Anti-CD3 N/A OKT3 BioLegend 317302
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Figure 74. Flow chart illustrating steps of cell subsets isolation. A por-
tion of PBMCs is used for enrichment of CD8+ T cells, another por-
tion is used for enrichment of Tregs. The enriched CD8+ T cells frac-
tion (untouched) is used for isolation of Naı¨ve (negative fraction) and
EM+EMRA (positive fraction) CD8+ T cells, with Naı¨ve CD8+ T cell iso-
lation kit.
purity of the corresponding cells is >96% and 90% for T cell
populations and Treg cells, respectively (Fig. 75A and B).
3. Highly purified autologous CD8+ T cell subpopulations (iso-
lated as described above) are labeled with 10 µM of CFSE
(Thermo Fisher Scientific, Massachusetts, USA) for 15 min at
37°C in RPMI complete medium containing 10% FBS (up to
10 × 106 cells/mL). To quench the reaction, an isovolume of
cold FBS is added and cells are washed twice.
4. Then, they (500 000–1 × 106/well) are co-cultured with both
autologous γ-irradiated (70Gy) PBMCs as APCs (at a 1:1 ratio),
which had previously been pulsed or not with 20 µg/mL of
antigen or peptide(s) plus 1 µg/mL of CD28 mAb, and highly
purified Treg cells, which had previously been stained with
5 µM of CellTrace Violet (Cell Proliferation Kit, Thermo Fisher
Scientific) at different CD8+ T cell:Treg cell ratios (100:1, 10:1,
4:1, and 1:0), in RPMI completemedium containing 5%human
serum AB, in 48-well plate (0.5–1 mL/well). The number of
CD8+ T cells is changed while the number of Tregs is fixed.
Cells are cultured for 7 days, and half of themedium is replaced
with fresh medium containing 20 IU/mL of IL-2 at day 4.
5. Cells are stainedwith Fixable Viability Dye eFluor780 for exclu-
sion of dead cells in PBS 30 min at room temperature. After
washing, cells are incubated with the pool of APC-labeled-
multimers of MHC class I molecules complexed with the rele-
vant peptides, in PBS containing 2% FBS at room temperature
for 10 min. Surface staining are performed incubating cells
with labeled mAbs to CD8, CD4, CCR7, CD45RA, and with a
cocktail of labeled mAbs to CD14, CD16, CD56, CD19, (dump
channel was included for the exclusion of monocytes, NK cells,
and B cells, respectively) for 20 min at 4°C. After washing, cells
are fixed and permeabilized using the FOXP3/Transcription
Factor Staining Buffer Set (eBioscience, MA, USA) at 4°C
for 30 min, washed, and then stained with mAbs to FOXP3
for 30 min at room temperature (Ab details reported in
Table 17) (Fig. 76A and B). All the incubations are per-
formed in the dark. In the representative experiments shown
in Fig. 76, as multimers of MHC class I molecules, we used
APC-labeled-HLA-A*0201 dextramers complexed with self-
peptides (MYH9478-486, MYH9741-749, VIME78-87, VIME225-233,
ACTB266-274) (Immudex, Copenhagen, Denmark) to detect
autoreactive CD8+ T cells in various forms of autoimmune
diseases [673]. The percentage of Treg-mediated suppression
is calculated using the following formula: %Treg suppression
= (MFI CFSE-stained dextramer+ CD8+ T cells with Treg cells
– MFI CFSE-stained dextramer+ CD8+ T cells without Treg
cells)/(MFI CFSE-stained dextramer+ CD8+ T cells unstimu-
lated − MFI CFSE-stained dextramer+ CD8+ T cells without
Treg cells) × 100 (Figure 76C).
17.9.4.2 Human killing assay of Treg cells by antigen-specific
CD8+ T effector cells. Step-by-step sample preparation
1. Highly purified CD8+ T, TEM+EMRA (effectors), or TN cells
are stained with 10 µM of CFSE and co-cultured with autol-
ogous γ-irradiated (70Gy)-PBMCs (1:1 ratio), which had pre-
viously been pulsed (or not) with 20 µg/mL of antigen or
peptide(s) plus 1 µg/mL of CD28 mAb, and highly purified
autologous or allogeneic target cells (purified T cells, Treg
cells, or others), which had previously been stained with 5 µM
of CellTrace Violet (CellTrace Cell Proliferation Kit).
2. CD8+ T cells and target cells are co-cultured (or not) at a ratio
of 10:1 for 7 days in complete RPMI medium containing 5%
human serum AB, as previously described; at day 3, half of
the medium is replaced with fresh medium plus 20 IU/mL of
IL-2.
3. To investigate the granzyme B (GZMB)-mediated killing effect
of CD8+ TEM+EMRA on targets, the assays are performed in
the presence of GZMB inhibitor (Santa Cruz Biotechnology,
Dallas, TX) or NKG2D neutralizing Ab (R&D Systems, Min-
neapolis, MN). Specifically, target cells are treated (or not)
with 20 µM of GZMB inhibitor for 1 h at 37°C, and CD8+
TEM+EMRA cells are treated with 1 µg/1 × 106 of NKG2D
neutralizing Ab for 15 min at room temperature. Cells are
stained with Fixable Viability Dye eFluor780, APC-labelled-
HLA-A*0201 multimers complexed with the relevant peptides
(previously described), labeled mAbs to CD8, CD4, CCR7,
CD45RA and with a cocktail of labeled mAbs to CD14, CD16,
CD56, CD19 (dump channel was included for the exclusion
of monocytes, NK cells, and B cells, respectively) for 20 min
at 4°C. After washing, cells are fixed and permeabilized for
the subsequent intranuclear staining with mAb to FOXP3,
as previously described (Ab details reported in Table 17;
Fig. 77).
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Table 17. Materials for human suppression assay of antigen-specific T cells
Reagent Fluorochrome Clone Company Catalog
Lympholyte N/A N/A Cedarlane CL5010
CD8+ T Cell Isolation Kit N/A N/A Miltenyi 130-096-495
Naı¨ve CD8+ T Cell Isolation Kit N/A N/A Miltenyi 130-093-244
CD4+CD25+ Regulatory T Cell Isolation Kit N/A N/A Milteny 130-091-301
CellTraceTM CFSE Cell Proliferation Kit CFSE N/A Thermo Fisher C34554
CellTraceTM Violet Cell Proliferation Kit Violet N/A Thermo Fisher C34571
FOXP3/Transcription Factor Staining Buffer Set N/A N/A eBioscience 00-5523-00
Viability dye eFluor780 – eBioscience 65-0865-18
Anti-CD8 Vio-Green BW135/80 Fab Miltenyi BW-1 35/80
Anti-CD8 Alexa-Fluor488 SK1 Biolegend 344716
Anti-CD8 BV-510 SK1 Biolegend 344732
Anti-CD45RA BV-605 HI100 Biolegend 304133
Anti-CCR7 PerCP-Cy5.5 G043H7 Biolegend 353220
Anti-GZMB Bv510 GB11 BD Biosciences 563388
Anti-NKG2D PECF594 1D11 BD Biosciences 562498
Anti-FOXP3 PerCP-Cy5.5 PCH101 eBioscience 45-4776-42
Anti-CD14 APC-eFluor780 61D3 eBioscience 47-0149-42
Anti-CD16 APC-eFluor780 CB16 eBioscience 47-0168-42
Anti-CD56 APC-eFluor780 CMSSB eBioscience 47-0567-42
Anti-CD19 APC-eFluor780 HIB19 eBioscience 47-0199-42
Anti-CD3 PE-Cy7 SK7 BioLegend 344816
Anti-CD3 APC SK7 BioLegend 344812
Anti-CD40L BV-421 24-31 BioLegend 310823
Annexin V FITC BioLegend 640906
PI BioLegend 421301
Anti-CD4 Alexa-Fluor488 OKT4 eBioscience 53-0048-42
PI: Propidium Iodide
17.9.4.3 Materials.
17.9.5 Data Analysis. There are several possible approaches to
analyzing proliferation data. A common approach is to place a
gate based on the nondivided peak measuring the percentage of
cells that have divided at least once. This method has the benefit
of simplicity and is commonly used. However, this method is also
insensitive as it fails to take into account the number of divisions
undertaken by the dividing cells. For example, if two populations
have 75% that have divided at least once but the first has most
cells in the second peak and the second has most cells in the fourth
peak, then this method will report the same result despite their
being a clearly observable difference in proliferation.
Modeling of the peaks to calculate the total number of cell in
each peak allows the use of more sensitive measurements such as
division index (the average number of divisions by each cell) or
proliferation index (the average number of divisions undertaken
by each dividing cell) [677]. It should be noted that different
software uses the terms division index and proliferation index
with differing definitions, so they should always be clearly defined
when used, the division index used here was calculated by FlowJo
software. When both percentage divided and division index are
used to measure proliferation in the same population, it may be
seen that while the results are broadly similar, division index is
able tomeasure appreciable suppression at low Treg ratios that are
less clearly different when using percentage divided (Fig. 78). In
the assay calculating the percentage suppression of antigen-driven
T cells (Fig. 76), the resulting T cell proliferation can be detectable
by using the MFI of CFSE-stained T cells better than by using
percentage of divided T cells or the division index. Indeed, because
of the tiny number of T cells specific to a given epitope, they are
less synchronous as compared with polyclonal T cells stimulated
with CD3/CD28 mAb, in which the high number of proliferating
cells allow to define peaks and to distinguish their generations
(see Fig. 78) [677]. Furthermore, the different antigen-specific cell
subsets (e.g., na¨ıve or effector T cells) display a striking difference
in their baseline proliferation (without Treg) (Figs. 76 and 79).
Figure 79 shows the difference between percentage suppression
calculated using percentage divided T cells (A), and percentage
of suppression calculated using MFI CFSE (B) (as reported above
and in Fig. 76C).
17.9.6 Pitfalls. Care must be taken with the timing of the assay
to ensure that the cells do not proliferate to the extent that they
completely lose the proliferation dye. This will both make it impos-
sible to resolve any proliferation past this point but also riskmixing
up the responder and suppressor populations that are often sepa-
rated on the basis of the proliferation dye. To an extend inclusion
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Figure 75. (A) Representative flow-cytometry (FC) analysis of the gating strategy applied for the identification of CD8+ and CD4+ T cells. Briefly,
lymphocytes were first gated by the physical parameter Forward and Side scatter area (FSC-A and SSC-A) and doublets and debris were eliminated
by plotting the width against the area of FSC and SSC parameters (FSC-W and SSC-W). Dead cells were excluded using viability dye (VD), and gating
into live cells we identified CD8+ and CD4+ T cells. (B) Representative FC analysis of pre- and post-enrichment of naı¨ve (N) or effector memory plus
effector memory RA+ (EM+EMRA) CD8+ T cells, gated on (dextamer+)-CD8+ T cells (upper) or (dextramer–)-CD8+ T cells (lower). (C) Representative
FC analysis of pre- and post-enrichment of Treg cells with magnetic beads.
of further stains such as CD25 and Foxp3 may help resolve popu-
lations but these may also be upregulated by proliferating Tconv
cells. If this proves a problem for mice, this can be resolved by
using congenic markers such as CD45.1 Tconv and CD45.2 Treg.
CD8 T-cells can also be used as responders.
It should be remembered that suppressive function is not totally
Treg exclusive. Activated non-Treg cells are capable of showing
some CTLA-4 dependent suppressive function, although this is rel-
atively weak in comparison to Treg cells. As a result, in some cases
inclusion of known highly suppressive and non/lo-suppressive
cells as control groups to allows placement of the cell population
of interest on this scale.
To a large extent the APC dependent suppression assay mea-
sures CTLA-4 dependent suppressive function. However, this is
context dependent, na¨ıve CTLA-4 deficient Treg lack detectable
suppressive function, while highly activated CTLA-4 deficient
Tregs are suppressive due to upregulation of other suppressive
molecules post-activation [671]. Another common variant of this
assay is to use CD3 mAb and CD28 mAb beads in place of APCs,
this APC independent assay largely measures CTLA-4 independent
suppressive function.
The use of CD3 in the sorting strategy (Fig. 73) runs the risk
of causing pre-activation of the T-cells. We have not found this to
be a problem, but if this is a concern CD3 can be omitted without
a major change in the purity of the sorted cells.
As regards the killing assay of Treg cells by antigen-specific
CD8+ T effector cells, care must be taken to ensure that Treg
cells do not display cytotoxicity activity, as suggested in older
reports [678]. This risk can be ruled out by the evidence showing
that: (i) highly purified peripheral Treg cells, as well as Treg cells
infiltrating inflamed tissues, completely lack GZMs, in contrast to
CD8+ T effector cells; (ii) highly purified Treg cells are unable to
kill antigen-specific CD8+ T effector cells in cytotoxicity assays in
vitro (see [673]). S. Koristka et al. proposed that the discrepancy
with older reports [678] is due to the purity of Treg cells used in
the assays [679].
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Figure 76. Representative histograms of purified CFSE-stained CD8+ T (N) cells (A) or effectormemory plus effectormemory RA+ (EM+EMRA) CD8+
T cells (B) stimulated with autologous (a)APCs pulsed (or not) with 20 µg/mL of peptides (aAPCs + peptides) and co-cultured (or not) with Treg cells
at a CD8:Treg ratio of 10:1 for 7 days. Histograms indicate the percentage of cell proliferation (as detected by CFSE dilution) and differentiation (as
detected by CD45RA downregulation) in (dextramer+)-CD8+ T cells. (C) Mean values of four independent suppression assays at different CD8:Treg
ratios. %Treg suppression = (MFI CFSE-stained dextramer+ CD8+ T cells with Treg cells – MFI CFSE-stained dextramer+ CD8+ T cells without Treg
cells) / (MFI CFSE-stained dextramer+ CD8+ T cells unstimulated − MFI CFSE-stained dextramer+ CD8+ T cells without Treg cells) × 100. *P < 0.05
one-way ANOVA with Tukey’s multiple comparison test.
17.9.7 Top tricks. CFSE and CTV dyes can both be used and
we have not observed clear differences in results between them.
When a Foxp3-GFP reporter mouse is used, CTV may be the opti-
mal choice to avoid mixing up signal from GFP and CFSE. How-
ever, when this is not the case and blue, yellow–green, and violet
lasers are all available, we find that CFSE frees up the bright flu-
orochrome BV421 while the blue and Yellow–green lasers allow
better separation of CFSE and PE than would be possible with just
a blue laser. In some cases, high doses of CFSE can be toxic, and
the effect in a particular setting should be defined empirically.
Choice of APCs: With optimization it is possible to use various
cells as APCs. In the murine system, we have successfully used
CD11c+ DCs, B220+ B-cells, and T-cell depleted splenocytes as
APCs. For the human suppression assay, monocytes-derived DCs
and T-cell depleted PBMCs have all proven effective. There is not
necessarily one correct choice but some consideration should be
given to which cell type is appropriate according to experiment in
question.
Since dead cells are often nonrecoverable or excluded from
analysis, counting the total number of recovered Tconv cells can
also be useful to understand the dynamics of the suppression sys-
tem. Cytometric counting beads can be used in order to accurately
count the cells while collecting proliferation data.
Addition of exogenous IL-2: Particularly for humans some
donors Tconv may proliferate poorly even in the absence of Tregs.
In this case, addition of a low dose of exogenous IL-2 in the range
of 10-20 IU/mL may aid proliferation while also allowing clear
suppression. Careful titration is needed as higher doses of IL-2
overwhelm Treg suppressive function.
The use of a pre-enrichment bead sorting is not essential but
improves the purity of the sorted populations. This is more impor-
tant when rare populations such as fraction I na¨ıve Tregs are
sorted.
18 Adoptive T and B cell transfer as a read-out for
antigen-specific immune responses in mice
18.1 Overview
For over three decades now, adoptive transfer of TCR-transgenic
(TCRtg) and BCR-transgenic (BCRtg) cells, followed by challenge
with cognate antigen in various experimental settings such as
immunization, infection, autoimmunity, and tumors, has proven
to be an elegant tool to study antigen-specific immune responses in
vivo. These experiments have generated a wealth of information
on the activation requirements, kinetics, magnitude, and effec-
tor as well as memory responses of T and B cells. Importantly,
adoptive transfer experiments continue fueling research in these
areas. Here, we describe critical parameters for performing adop-
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Figure 77. Representative FC analysis of dead Tregs, as detected by the percentage of VD+ cells in Tregs, alone (0:1) or co-cultured with purified
CD8+ TEM + EMRA cells (10:1) and aAPCs stimulated or not with peptides in the presence or absence of iNKG2D.
tive transfer experiments with TCRtg and BCRtg cells and discuss
advantages and disadvantages of these approaches in regards to
study design and data interpretation.
18.2 Introduction
Experimental immunization or infection of mice is frequently
used to study immune responses in vivo. Using various activa-
tion marker combinations, polyclonal T and B cell responses can
be easily analyzed by FCM. Activated T cells can be identified in
mice by staining for activation markers such as CD69 or CD44 (see
Chapter V, Section 17.5). However, this generally does not provide
information on the differentiation history or the antigen specificity
of these cells. For the detection of antigen-specific CD8+ or CD4+
T cells in bulk cell populations, MHC multimers may be used in
humans and mice (see Chapter V, Section 17.4). While each mul-
timer covers one antigenic specificity, thereby allowing quantifica-
tion of antigen-specific cells, functional and fate-mapping assays
are rather limited. Complementary to this approach, TCRtg T
cells have been widely used for studying antigen-specific T cell
responses in many in vivo settings. The advantage of using TCRtg
cells is the known specificity of these cells and their suitability for
adoptive transfer experiments. Various TCRtg mouse lines have
been described in the literature. Prominent examples for CD8+
T cells include P14, which are specific for LCMV GP33-41 pep-
tide [680] or OT-I, which are specific for OVA257-264 peptide [681].
Examples for CD4+ T cells include SMARTA, which are specific
for LCMV GP61-80 peptide [682], and OT-II, which are specific
for OVA323-339 peptide [683]. All these lines are on the C57BL/6
background. DO11.10mice, which are on the BALB/c background,
carry a TCRtg that also recognizes OVA323-339 peptide [684]. For
this mouse strain, a clonotypic Ab has been generated that allows
detecting DO11.10 TCRtg cells without the need of additional
markers such as congenes or fluorescent reporter alleles. TCRtg
mice can also be used for inducing autoimmunity. For example,
adoptively transferred P14 TCRtg cells can kill genetically engi-
neered LCMV GP-expressing beta cells in the pancreas, thus caus-
ing diabetes [685]. Another example are 2D2 mice, in which 95%
of CD4+ T cells carry a TCR specific for MOG35-55 peptide [686].
These cells can be used to track autoantigen-specific T helper cell
responses in the CNS after MOG/CFA/PTX-induced active EAE.
2D2 cells can also be activated and transferred into secondary
hosts, where they are sufficient to induce full-blown disease (pas-
sive EAE). While TCRtg mice usually harbor only very few Treg
cells, if any, polyclonal Foxp3 reporter mice such as Foxp3-GFP
may be used instead for isolation of GFP+ polyclonal Treg and Tfr
cells with unknown specificity for adoptive transfer experiments.
Similar to T cells, B cell responses can also be studied in detail
using FCM. For example, activated B cells that differentiate into
germinal center B cells downregulate surface IgD expression and
instead express GL-7 and FAS or can be stained with the lectin
PNA (see Chapter VI, Section 2.2). In addition, class-switched Ab
isotypes can be measured by FCM. Since B cells recognize their
cognate antigen directly through their BCR, antigen-fluorophore
complexes can be used to identify antigen-specific B cells by FCM,
e.g., 4-Hydroxy-3-nitrophenylacetyl (NP) hapten-specific B cells
with NP-PE after NP-KLH immunization or hen egg lysozyme
(HEL)-APC after HEL immunization. However, it is often advanta-
geous to be able to track the fate of antigen-specific na¨ıve B cells
during the entire immune response following activation of these
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Figure 78. (A) Gating strategy for identification of responder cells in human polyclonal suppression assay. (B) Proliferation histograms of human
Tconv cells culturedwith various ratios of Treg cells, irradiated CD4- splenocytes, and CD3mAb for 3 days. (C) Summary data comparing percentage
divided and division index of Tconv cells performed in duplicate. Division index is the average number of divisions by each cell as calculated in
Flowjo Software.
cells. BCRtg B cells that can be used in adoptive transfer exper-
iments are ideally suited for this purpose. Several BCRtg mouse
lines have been described in the literature. Among them, HEL-
specific MD4 [687], SWHEL [688], and Hy10 [689] mice as well
as NP-specific B1-8 [690] mice have been used in various studies
to dissect the contribution and kinetics of antigen-specific B cell
responses in vivo.
To limit the precursor frequencies of antigen-specific TCRtg
and BCRtg cells as much as possible to physiological levels, low
numbers of purified na¨ıve TCRtg or BCRtg cells should be trans-
ferred into wild-type recipients. For functional questions, these
donor cells can be derived from control or knock-out backgrounds
and are then being compared in separate or competitive adop-
tive transfers into wild-type mice. Alternatively, for examination
of extrinsic factors important for T and B cell biology, TCRtg or
BCRtg B cells can be transferred into hosts that lack certain genes
(i.e., knock-out mice). In order to distinguish the transferred cells
from host lymphocytes, it is advisable to intercross the TCRtg and
BCRtg lines to different congenic alleles. Since wild-type C57BL/6
mice are CD45.2, TCRtg, and BCRtg cells that carry one or two
alleles of the congene CD45.1 can be easily identified by FCM
or immunofluorescence microscopy by staining with fluorescence-
labeled Abs against CD45.1 and CD45.2. Using combinations of
CD45.1 and CD45.1/2, it is even possible to perform competitive
co-transfers into CD45.2 wild-type C57BL/6 mice, e.g., compar-
ing control and knockout TCRtg or BCRtg cells within the same
host. For T cells, combinations of the congenic markers Thy1.2
(CD90.2, expressed by wild-type C57BL/6 mouse T cells) and
Thy1.1 (CD90.1) have been regularly used as an alternative to the
CD45.2/CD45.1 system. While CD45 is expressed by B cells, Thy1
is not. Alternatively, some BCRtg mice carry different Ig heavy
chain (Igh) allotypes that can be used for identification instead.
For example, MD4 and Hy10 BCRtg B cells are Igha, which is dif-
ferent as compared to the Ighb background of wild-type C57BL/6
mice. This does not only allow for the identification of these cells
by surface or intracellular staining of various Ig isotypes of Igha,
but also secreted Abs derived from these cells, which are also of
the Igha allotype and can be measured by ELISA. Another possibil-
ity is to cross TCRtg or BCRtg mouse lines to fluorescent reporter
alleles, e.g., GFP, which can also be used for intravital two-photon
microscopy studies. For short-term assays or for the assessment of
cell proliferation in vivo for up to 3 to 4 days, na¨ıve TCRtg or BCRtg
cells can be labeled with CFSE, CTV or similar fluorescent dyes
prior to adoptive transfer (see Chapter V, Section 18). BCRtg cells
can also be co-transferred together with antigen-specific TCRtg
cells to study the cooperation between antigen-specific B and T
cells [691]. Examples include co-transfer of OVA-specific OT-II
cells and NP-specific B1-8hi cells, followed by immunization with
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Figure 79. Comparison between different meth-
ods to analyze proliferation in suppression assay of
antigen-specific T cells (as described in Figure 76);
mean values of four independent experiments are
reported. (A) Left panel shows % divided of N or
EM+EMRA (dextramer+)-CD8+ T cells, at different
CD8:Treg ratio. Right panel shows %Treg suppres-
sion calculated using % divided T cells (see for-
mula reported in Fig. 76C). (B) Left panel showsMFI
of CFSE of N or EM+EMRA (dextramer+)-CD8+ T
cells, at different CD8:Treg ratio. Right panel shows
%Treg suppression calculated using MFI of CFSE
(see formula reported in Figure 76 C). *P < 0.05
one-way ANOVA with Tukey’s multiple compari-
son test.
NP-OVA in adjuvants, e.g., alum. If 2D2 TCRtg mice are crossed to
the BCRtg mouse line Th [692], in which approximately 20% of
peripheral B cells are specific for MOG, these compound animals
can be used as a model for spontaneous EAE development [693].
The following protocol provides a framework for adoptive
transfer experiments with CD4+ and CD8+ TCRtg T cells as well as
BCRtg B cells. The protocol can be easily modified and tailored to
the specific question of interest. An example of how this protocol
can be used for the assessment of CD4+ T cell proliferation in vivo
is shown in Figure 80.
18.3 Step-by-step sample preparation
1. Prepare single-cell suspensions from pooled spleen and lymph
nodes of TCRtg or BCRtg donor mice of interest (see Chapter
III, Section 3).
2. Enrich na¨ıve T or B cells with magnetic beads (preferentially by
negative selection) (see Chapter IV, Sections 1 and 2) and/or
by cell sorting (see Chapter IV, Section 3). If the scope of the
study is to analyze the fate of already differentiated cells (in
vivo or in vitro generated), these cells may also be used for
adoptive transfer experiments.
3. To track proliferation and expression kinetics of transferred
cells, they can be optionally labeled with a cell proliferation
dye (e.g., CFSE or CTV) prior to adoptive transfer (see Chapter
V, Section 18).
4. Inject TCRtg or BCRtg cells into host mice (e.g., wild-type
C57BL/6), usually per i.v. route. Keeping in mind to aim for
the lowest feasible number of cells to be injected, adjust the
required cell number to the characteristics of the specific TCRtg
or BCRtg, to the immunization or infection model used, and
to the intended readout (e.g., short term vs. long-term) as
the number of endogenous and transferred cells can strongly
influence the outcome of the experiment [694, 695]. While
typical cell numbers will range from hundreds to hundreds of
thousands, even as few as one or ten transferred cells may be
sufficient for certain experimental settings [634, 696]
5. Before challenging the transferred cells in the new host with
the cognate antigen, allow the transferred cells to equilibrate
in the host for a few hours to days.
6. Immunize or infect the recipientmice with the cognate antigen.
For protein and peptide immunizations, it is usually required
to mix the antigen with an adjuvant to elicit a strong response.
7. Analyze the adoptively transferred cells by FCM. To this end,
prepare single cell suspensions of secondary lymphoid tissues
or other tissues of interest (see Chapter III, Section 3) and
stain the cells with appropriate combinations of fluorescence-
labeled Abs for subsequent acquisition on a flow cytometer or
cell sorter.
18.4 Pitfalls
While adoptive transfer experiments with TCRtg and BCRtg cells
represent an elegant and powerful approach to study T and B cell
responses in vivo, several important points need to be considered
for generating valid and reproducible results:
Purity of adoptively transferred cells. Most often, na¨ıve
TCRtg or BCRtg cells are being used for adoptive transfer exper-
iments. To purify na¨ıve T cells from recipients, it is advisable
to enrich na¨ıve CD4+ or CD8+ T cells with magnetic bead-
coupled Abs, preferentially using negative enrichment that yields
untouched cells for downstream applications (see Chapter IV).
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Figure 80. Gating strategy for the identification of CTV-labeled, Thy1.1+ OT-II cells by FCM. Wild-type C57BL/6 mice were injected i.v. with
5x105 naı¨ve OT-II TCRtg CD4+ T cells. In this setting, such high numbers of naı¨ve OT-II TCRtg CD4+ T cells (in contrast to classical adoptive
transfer experiments with typically less than 1–5 × 104 naı¨ve OT-II cells per mouse) are required for recovering enough events for proper cell
division analyses. One day later, recipient mice were immunized with 5 µg OVA and 2 µg LPS in the hock. Three and a half days later, draining
popliteal lymph nodes were dissected, single-cell suspensions were prepared and the cell surface was stained with appropriate combinations of
fluorescently labeled mAbs. Thereafter, samples were fixed and stained with the Foxp3 transcription factor staining set and samples were then
acquired on a BD LSRFortessa. Single lymphocytes were first gated based on FSC/SSC characteristics. CD4+ T cells were further gated to exclude
dead cells and B cells, and finally with the congenic marker Thy1.1 and CTV to differentiate transferred OT-II cells from endogenous (Thy1.1–) T
cells of the recipient. The CTV profile of the identified OT-II cells is shown in the histogram. To reduce the overall size of the acquisition data file,
50 000 lymphocytes were acquired first and then only TCRtg Thy1.1+ CD4+ T cells were appended to the file.
Alternatively, or in addition, na¨ıve cells can be further purified
using cell sorting. In the case of T cells, na¨ıve CD4+ or CD8+
T cells can be sorted as CD44int/lowCD62Lhi cells. CD25 can be
included as well to exclude activated T cells and Treg cells among
CD4+ cells. The TCR should not be stained directly (e.g., CD3ε),
as this may crosslink the TCR and activate the cells. Untouched
resting B cells can be efficiently enriched using CD43 magnetic
beads.
Precursor frequency. It is highly advisable to transfer as few
TCRtg or BCRtg cells as possible. Endogenous antigen-specific pre-
cursor frequencies are usually very low (in the range of tenth to
hundreds of T cells per mouse) [694]. Since TCRtg or BCRtg mice
harbor millions of cells specific for the same antigen, it is tempt-
ing to also transfer hundreds of thousands or millions of these
cells. However, since all these cells would compete with each
other in the new host for the specific antigen after infection or
immunization, such high precursor frequencies are unphysiologi-
cal and results of these experiments need to be interpreted with
care [634]. In addition, while most transferred TCRtg cells will die
and disappear during the transfer procedure, only a small percent-
age (often less than 10%) of transferred cells will be eventually
“parked” in the host. Nevertheless, under certain conditions, it
can be required to transfer higher cell numbers in order to recover
enough cells for analyses, e.g., in the case of proliferation experi-
ments using CFSE or CTV, in which it is often difficult to recover
enough cells that are within the first cell division(s) [697].
High affinity TCRs and BCRs. TCRtg and BCRtg cells often
carry antigen receptors with very high affinities for the specific
antigen, which may confound the conclusions derived from adop-
tive transfer experiments utilizing these cells. For example, the
HEL-specific BCRs of MD4, SWHEL, and Hy10 BCRtg mouse lines
bind HEL with extremely high affinity. To adapt for this prob-
lem, mutated HEL proteins and peptide sequences have been engi-
neered that exhibit much lower binding affinities to these BCRs,
thus providing a more physiological setting [698]. Alternatively,
the HEL-related duck egg lysozyme, which exhibits lower binding
affinity to these BCRs, has been used as well [689].
Rejection of transferred cells. Congenic markers or fluores-
cent proteins expressed by adoptively transferred cells can poten-
tially facilitate rejection. While this may not be such a big issue
for short-term experiments, long-term experiments require more
careful planning and interpretation by taking this potential caveat
into account. As an example, when transferred into CD45.2 hosts,
heterozygous CD45.1/2 cells might be less prone to rejection than
CD45.1 homozygous cells. The use of CD45.1/2 heterozygous
hosts could provide an elegant solution to this problem, as CD45.1
and CD45.2 homozygous cells would be much less likely rejected
in these mice. In addition, for critical issues, allelic marker combi-
nations of CD45.1 and CD45.2 (or similar) may also be switched in
complementary adoptive transfer experiments to test whether the
same conclusions are reached. To further decrease the possibility
of rejection, TCRtg and BCRtg mice should be bred on and/or
regularly back-crossed to the same background strain of the host
mice used in the adoptive transfer experiments. Another strategy
for reducing the risk of GFP+ cells being rejected after adoptive
transfer is the use of host mice that express GFP under an endoge-
nous promotor, thus rendering these hosts tolerant towards GFP.
Exclusion of dead and contaminating cells. It is imperative
to carefully exclude dead cells as well as “sticky” cells. To exclude
dead cells, which often show autofluorescence and unspecific bind-
ing of fluorescently labeled antibodies, a viability dye should be
incorporated in the FCM staining panel (see Chapter III, Section
4). Similarly, it is advantageous to block unspecific binding by
preincubation with rat or mouse serum (according to the pri-
mary antibodies used for FCM) and Fc receptor blocking reagents.
Finally, a dump channel may be incorporated to exclude cells that
are “sticky” and/or may share marker expression with the cell type
of interest. Typical target antigens that could be used in a dump
channel are CD11c, CD19 (if T cells are the cells of interest) or
CD3 (if B cells are the cells of interest) and other lineage-defining
markers [699]. It is of importance to ensure that the antigen used
in a dump channel is not expressed by the cells of interest though.
TCRtg and BCRtgmice are often “leaky.” This means that not
all T and B cells are monoclonal and some polyclonal T cells have
expanded that do not express the antigen-specific tg. The degree
of T and B cells not carrying the TCRtg and BCRtg, respectively,
varies considerably between the individual mouse lines. One pos-
sibility to generate true monoclonal TCRtg and BCRtg mice is to
cross these mice onto Rag1- or Rag2-deficient backgrounds. This
is particularly important if TCRtg T cells will be transferred into
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lymphopenic hosts, e.g., Rag1, Rag2, TCRαβ or CD3ε knockout
mice, as na¨ıve polyclonal T cells will undergo considerable home-
ostatic proliferation and may even cause disease, such as IBD after
transfer of na¨ıve CD4+ T cells into Rag1 knockout mice.
18.5 Top tricks
Pre-enrichment of target populations: Low numbers of transferred
cells and/or poor expansion of these cells in the host may limit
recovered cell numbers that can be analysed by FCM. To accommo-
date for this problem, pre-enrichment of the adoptively transferred
cells may be used before acquisition on a flow cytometer/sorter.
Similar to the techniques described in the “Purity of adoptively
transferred cells” section above, congenic TCRtg and BCRtg cells
can be pre-enriched from whole host spleen or lymph node tis-
sues by labeling with magnetic beads coupled to monoclonal Abs
against the respective congenic marker (e.g., CD45.1 or Thy1.1).
Small bead sizes (e.g., Miltenyi MACS R© or Stemcell Technologies)
should be preferred over big bead sizes (Thermo Dynabeads) for
this positive selection approach.
VI Flow cytometric phenotyping of cells
across species and tissues
1 T cells and their subsets
1.1 Murine CD4 and CD8 T cells
1.1.1 Differences in flow cytometric analysis of murine and human
T cells. FCM and cell sorting have been instrumental to under-
standing the fundamental principles of T cell differentiation. The
analysis of human samples alongside complementary experimen-
tal animal models has given us great insights into thymic T cell
selection, induction of T cell effector responses and the generation
of long-lived T cell memory (See Chapter VI Section 1.11 Human
CD4 and CD8 T cells). Mice are the primary animal model used to
investigate T cell biology and, while many of the samemechanisms
apply to the differentiation of T cells in humans and mice, there
are some fundamental differences in the flow cytometric analysis
of human and murine T cells.
One key difference is in the infection status of humans as com-
pared to mice. The human immune system is challenged by a daily
onslaught of microorganisms, pathogens, and foreign substances
from the environment. This includes a vast and diverse range
of potential antigen exposures, including non-persistent and per-
sistent latent viruses, bacteria, vaccinations, neoplastically trans-
formed cells, as well as the flora of our individual microbiota.
These agents constantly trigger and shape the human immune
system and, given that the average human lifespan is currently
over 70 years in many countries, these exposures can perturb the
immune system from its original na¨ıve state over a substantial
period of time. In contrast, most laboratory mice are used at 8–12
weeks after birth and are bred and maintained in clean facilities
under specific pathogen-free (SPF) conditions, with reduced expo-
sure to foreign antigens and pathogens. Consequently, immune
composition and immune cell phenotypes from adult SPF mice are
more similar to that of neonatal, rather than adult, humans [700].
The use ofmurinemodels has enabled researchers to selectively
induce disease states and study the T cell response longitudinally
at defined synchronized time points. To amore limited degree, this
is also possible in human clinical studies, for example, those that
monitor the immune response following vaccination [701, 702]
or primary infection after organ transplantation [703]. However,
the tendency to study T cell responses longitudinally in mice has
driven development of terminology that is distinct from those used
in human T cell biology. For example, murine effector T cells are
generally defined as transiently expanding T cells in the effector
phase of an immune response, while in humans, effector T cells
are generally present at any snapshot of analysis.
Finally, different immune compartments are generally more
accessible in mice than in humans. Analysis of human T cells is
largely confined to blood, whereas T cell analyses in murine mod-
els can access blood in addition to bone marrow and secondary
lymphoid organs, including the thymus, lymph nodes, and spleen.
Tissues, such as skin, intestine, and bone marrow, are also more
readily available for analysis in mice and, accordingly, have given
us distinct and unique insights into T cell biology.
1.2 Murine Conventional αβ CD4 T cells
1.2.1 Overview. CD4 T cells are central effector cells that
crosstalk with many other components of the adaptive and innate
immune system. Primed by signals they receive during devel-
opment in the thymus and in the periphery, MHCII-restricted
CD4 T cells specialize functionally. Tregs can suppress immune
responses and balance between immune activation and toler-
ance (See also Chapter VI Section 1.6 Murine Foxp3+ regulatory
T cells). Conventional nonregulatory CD4 T cells contribute to the
efficiency of many vaccines and are vital for the protection against
many infections with bacteria, parasites, and fungi, but they can
also mediate autoimmune diseases. This section focuses on con-
ventional nonregulatory T cells and gives an overview of surface
markers used to identify the diverse CD4 T cells subsets. Fur-
thermore, we provide examples for the detection of transcription
factors and effector functions of conventional CD4 T cells.
1.2.2 Conventional αβ CD4 T cells: Identification and surface mark-
ers. Conventional TCRαβCD4+ T cells can be identified by gating
on time, scatter parameters and exclusion of duplicates and dead
cells to identify viable lymphocytes and gating on CD3ε+ or TCRβ+
cells and CD4+CD8α– cells (Fig. 81). The use of CD3ε or TCRβ as
selection markers is critical for the analysis of CD4 T cells to avoid
inclusion of myeloid cell subsets that express low levels of CD4.
Additional markers may be required in specific tissues to differen-
tiate conventional CD4 T cells from other nonconventional T cell
subsets, such as from CD4+ NKT cells in the liver (See also Chap-
ter VI Section 1.4 Murine tissue resident memory T cells). These
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Figure 81. Murine CD4 and CD8 T cells. Sample gating tree for the identification of CD4 and CD8 T cell subsets from the spleen. Conventional CD4
and CD8 T cells can be identified by gating on time, lymphocytes according to FSC and SSC (R1, R2), exclusion of doublets (R3) and dead cells (R4)
and gating on CD3ε+ or TCRβ+ cells (R4) and CD4+CD8α– cells (R5).
Figure 82. Schematic of murine CD4 T cell differentiation. An array of
CD4 helper T cell subsets differentiate fromCD4 Tn cells, including Th1,
Th2, Th9, Th17, Th22, Tfh, Treg, and cytotoxic CD4 T cells. Molecules
under each CD4 helper T cell subsets heading indicate the key effec-
tor cytokine/molecules, key transcription factor/s, and key chemokine
receptors.
markers can be used in a “dump” gate to exclude myeloid lineages
and nonconventional T cells.
CD4 T cell differentiation state is often defined by the expres-
sion of surface markers that correlate with the location of cells
within the body. Mature CD4 na¨ıve T (Tn) cells are CD44loCD62Lhi
and enriched in the lymphoid tissues (Fig. 81). The L-selectin
CD62L mediates attachment to endothelia and access to lymph
nodes. Upon activation, CD4 T cells acquire CD44, which binds
hyaluronan to promote access to peripheral tissues, and lose
CD62L to become CD4 effector T (Teff) cells. Antigen-activated
Teff populations expand and mediate pathogen clearance, then
contract after pathogen resolution and form CD4 memory T
(Tmem) populations. Two main circulating memory populations
are central memory T (Tcm) cells, which are CD44hiCD62Lhi and
reside predominantly in the lymphoid tissue, and effector mem-
ory T (Tem) cells, which are CD44hiCD62Llo and circulate more
through peripheral tissues (Fig. 81). Additionally, noncirculating
tissue-resident T cells (Trm) are primarily present in barrier tissues
(See also Chapter VI Section 1.4 Murine tissue resident memory
T cells).
Pathogen-specific CD4 Teff (and Tmem) cells can be classi-
fied according to their phenotype and function into multiple T
“helper” (Th) subsets; Th1, Th2, Th9, Th17, Th22, and T follicu-
lar helper (Tfh) cells (Fig. 82). These subsets are each equipped
with a unique set of transcription factors, chemokine receptors,
and effector molecules. However, recent research suggests that
CD4 Th cell subsets are not separate lineages but a continuum of
mixed functional capacities [704]. Alongside these conventional
CD4 Th cell subsets, natural and induced T regulatory (Treg) cells
have a predominant immunomodulatory phenotype with the abil-
ity to suppress autoreactive immune responses and promote res-
olution of active immune responses, by a variety of mechanisms
(for more details See also Chapter VI Section 1.4 Murine tissue
resident memory T cells).
CD4 Th cell subsets participate in a range of diverse and over-
lapping adaptive immune responses [705, 706]. Th1 cells are vital
in the defense against intracellular infections, such as Mycobac-
terium tuberculosis and protozoa. Th2 cells protect against par-
asitic infections, including helminths, but also mediate much of
the pathology associated with allergic reactions and correlate
with asthma severity. Th17 cells, originally described in mice
as being pathogenic in murine models of autoimmune disease
[707, 708], have more recently been shown to protect against cer-
tain pathogens, including fungal infections [709]. Th9 and Th22
cells are relatively newly described subsets, which share some
functional and developmental features with Th2 and Th17 cells,
respectively. Tfh cells crosstalk with B cells to stimulate the pro-
duction of high affinity Abs in germinal center reactions. Intrigu-
ingly, in certain infections such as influenza, unique populations
of CD4 T cells can exhibit cytolytic capacity [710].
In CD4 Th cells, the expression of chemokine receptors is
associated with skewing toward specific effector functions and
migratory behavior. Rapid upregulation of CXCR3 facilitates the
migration of Th1 cells to inflamed tissue sites along gradients of
chemokines, such as CXCL9, CXCL10, and CXCL11 (Figs. 82 and
83) [711]. The specific interaction of CCR4 on Th2 cells with
CCL17 and CCL22 is critical for movement of Tmem into the
skin [712]. Th17 preferentially utilize CCR6, also expressed by
Treg cells, for migration to mucosal tissues that are enriched for
CCL20 [713]. Tfh cells express the chemokine receptor CXCR5,
which is vital in the migration of Tfh cells from the T cell zone
into B cell follicles within the spleen [714] (Figs. 82 and 83) and
also express high levels of PD-1 and ICOS to facilitate B cell inter-
actions (Figure 83).
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Figure 83. Chemokine receptors for identification
of murine CD4 subsets. Subsets of CD4 T cells
can be identified based on the expression of
chemokine receptors. CD4 T cells were gated on
lymphocytes according to scatter parameters, live
cells, dump negative (CD25, NKT tetramer, B220),
and CD3+/ CD4+. Examples shown include Th1
cells that express the chemokine receptor CXCR3
and CD4+ Tfh cells that express PD1 and CXCR5.
1.2.3 CD4 T cells: transcription factors. The differentiation of
specific CD4 Th cell lineages is induced by specific cytokine stim-
ulation and is guided by master transcription factors (Figs. 82
and 84), which control the expression of downstream effector
molecules. Priming of Th1 cells by IL-12 [715] and IFN-γ [716]
results in expression of their master transcription factor T-bet
[717] (Fig. 84), Th2 cell priming by IL-4 [718, 719] leads to
expression of GATA-3 [720] and priming by IL-23, IL-6, and
TGF-β drives RORγt expression in Th17 cells [721] (Fig. 84).
Th22 cells are regulated by expression of the transcription fac-
tor Ahr [722, 723], while Th9 cells do not appear to be regulated
by an individual transcription factor but rather a combination of
factors, including IRF4 and PU.1 [722, 723]. Tfh cells are con-
trolled by the transcription factor Bcl6 [724] (Figure 84) and the
development of cytotoxic CD4 T cells can be mediated by the
transcription of Eomes.
Transcription factors are mainly located intranuclearly and,
to assess these by FCM, staining buffers are used that efficiently
permeabilize the nucleus and enable intranuclear access of Abs.
When no reliable Abs are available, reporter mice are a valuable
tool for the flow cytometric analysis of transcription factor expres-
sion [725]. Additionally, the use of reporter constructs can also
enable functional assays based on transcription factor expression
that are not possible with fixed and permeabilized cells.
1.2.3.1 Step-by-step sample preparation protocol for staining of
the transcription factor Bcl-6 and Tfh surface markers in CD4 T cells.
 Prepare single-cell suspensions of draining lymph nodes (LNs)
and non-draining LNs inHBSS (or PBS) by standard procedures.
 Add 1–2 × 106 cells in 100 µL for each sample into 5 mL FCM
tubes.
 Add 100 µL of 1:1000-diluted eFluor780 Fixable Viability Dye
(eBioscience) in HBSS (or PBS) (no serum/protein, no azide).
◦ Incubate for 10 min on ice.
 Wash cells with 2000 µL FCM buffer (2% FCS in PBS) and pellet
cells at 500 × g for 5 min at 4˚C and remove supernatant.
 Add 200 µL of blocking solution (1 µg/mL CD16/32 mAb, 2%
normal mouse/rat serum in FCM buffer).
◦ Incubate for 5 min on ice.
 Critical step: On top of the blocking solution, add 200 µL of
2×-diluted anti-CXCR5-biotin (clone 2G8, BD Biosciences, 1:50
final dilution).
◦ Incubate for 30 min at 37˚C, gently rolling at room tem-
perature.
Figure 84. Transcription factors for identification of murine CD4 subsets. Subsets of CD4 T cells can be identified based on their expression of
master transcription factors (TFs). Examples shown include Th1 cells identified by expression of T-bet, Th17 cells by RORγt, and CD4+ Tfh cells by
Bcl6 expression. Live CD3+ cells are displayed for Th1 and Th17 cells both gated as shown in Fig. 81. For analysis of Bcl2 expression, within live
CD3+/ CD4+ cells Tfh cells (CXCR5+/CD44 high) and naı¨ve T cells (TN CXCR5–/CD44 low) are displayed.
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 Wash cells with 2000 µL FCM buffer (2% FCS in PBS) and pellet
cells at 500 × g for 5 min at 4˚C and remove supernatant.
 Transfer cells in 40 µL of primary Ab mix containing CD4-
Pe mAb (clone RM4-5, BD Biosciences), anti-ICOS-APC (clone
C398.4A, Biolegend), and anti-PD-1-PeCy7 (clone RMP1-30,
Biolegend) to a 96-well round bottom plate.
◦ Incubate for 20 min at 4˚C
 Wash cells with 200 µL FCM buffer (2% FCS in PBS) and pellet
cells at 500 × g for 5 min at 4˚C and remove supernatant.
 Add 40 µL Streptavidin-PerCP (1:1000 final dilution) per well:
◦ Incubate for 15 min on ice.
 Wash cells with 200 µL FCM buffer (2% FCS in PBS) and pellet
cells at 500 × g for 5 min at 4˚C and remove supernatant.
 Add 100 µL Fixation/Permeabilization buffer from the eBio-
science FoxP3 staining buffer set per well:
◦ Incubate for 15 min at room temperature.
 Add 100 µL Permeabilization buffer from the eBioscience FoxP3
staining set per well and pellet cells at 500 × g for 5 min at 4˚C
and remove supernatant.
 Wash 1× with 200 µL Permeabilization buffer and pellet cells
at 500 × g for 5 min at 4˚C and remove supernatant.
 Add 20 µL of blocking solution (1 µg/mL CD16/32 mAb, 2%
normal mouse/rat serum in Permeabilization buffer).
◦ Incubate for 5 min at room temperature.
 On top of the blocking solution, add 20 µL of 2×-diluted anti-
Bcl6-PE (clone K112-91, BD Biosciences, 1:50 final dilution).
◦ Incubate for 45 min at room temperature.
 Wash thrice with Permeabilization buffer and pellet cells at 500
× g for 5 min at 4˚C.
 Resuspend cells in FCM buffer and analyze on a flow cytometer.
1.2.3.2 Materials.
 Single cell suspension containing T cells
 FCM buffer: PBS with 2% FCS
 Hank’s Balanced Salt Solution (Gibco, catalog no. 14025092)
 FoxP3 staining set (eBioscience, catalog no. 00-5523-00)
1.2.3.3 Antibodies.
 anti-mouse CD16/32 (clone 2.4G2)
 anti-mouse CXCR5-biotin (BD Biosciences, catalog no. 551960,
clone 2G8)
 anti-mouse CD4-Pe (BD Biosciences, catalog no. 553930, clone
RM4-5)
 anti-human/mouse/rat ICOS-APC (Biolegend, catalog
no.313510, clone C398.4A)
 anti-mouse PD-1-PeCy7 (Biolegend, catalog no. 109110, clone
RMP1-30)
 Streptavidin-PerCP (1:1000 final dilution)
 anti-Bcl6-PE (BD Biosciences, catalog no. 561522, clone K112-
91).
 eFluor780 Fixable Viability Dye (eBiosciences, 65-0865-18)
1.2.4 CD4 T cells: effector functions and antigen-specificity. Most
memory CD4 T cells are quiescent in steady state. Consequently,
analysis of CD4 Th cell functional capacity by FCM usually involves
in vitro restimulation and subsequent effector protein profiling
by intracellular staining. The hallmark cytokines for CD4 Th cell
subsets are as follows; Th1 cells express IFN-γ [726], Th2 cells
express IL-4, IL-5, and/or IL-13, Th17 cells express IL-17 [727],
Th9 cells express IL-9, Th22 cells express IL-22, and Tfh cells
express IL-21 (Fig. 85). Although yet to be fully characterized,
cytotoxic CD4 T cells have been identified through the expression
of cytolytic molecules such as perforin [710]. CD4 T cells also
upregulate the expression of the co-stimulatory molecule CD40L
after activation [614], which is crucial for their T helper functions
[691, 728].
To unleash and detect their effector function CD4 T cells can be
stimulated polyclonally using CD3ε mAb to drive TCR signaling or
using the phorbol ester PMA together with Iono to bypass TCR sig-
naling and activate protein kinase C. CD4 T cells can be stimulated
in an antigen-specificmanner with their cognate peptide presented
by MHCII. Antigen can be provided in in vitro stimulation either
as a purified short peptide containing the relevant epitope, or as
more complex antigens; live or killed pathogens, pathogen lysates,
full-length proteins, or long peptides, which are then processed
into short peptides and directly presented on MHCII by profes-
sional APCs. Restimulation with more complex antigen therefore
requires the presence of APCs and, as a result, whole splenocyte
preparations or sorted CD4 T cells with addition of peptide-pulsed
APCs should be used to assess responses to complex antigen. Addi-
tionally, synthetic MHCII dimers loaded with peptide can be gen-
erated and covalently linked to beads or coated onto plates for in
vitro restimulation assays. After activation, T cells start to produce
and/or secrete effector molecules including co-stimulatory surface
molecules, cytokines, and chemokines (see also Chapter V Section
17.5 Functional Read-outs).
To identify cytokine production on single cell level and increase
the signal, cells are treated with protein transport inhibitors such
as brefeldin A (BrefA) or monensin during the stimulation to
allow accumulation of cytokines and activation-associated sur-
face molecules in responding T cells. Of note, when CD4 T cells
are stimulated with complex antigen, protein transport inhibitors
should be added after a delay (2 h) to permit sufficient process-
ing of peptide, loading onto MHCII and surface export of pep-
tide/MHCII complexes. In addition, as extended exposure of cells
to these inhibitors can be toxic, it is optimal to limit exposure. The
stimulation time depends on the kinetic of the detected cytokine,
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Figure 85. Effector molecules produced by murine CD4 T cells. CD4 helper T cell subsets produce distinct sets of cytokines. To analyze production
of cytokines, in vitro generated Th-subsets were restimulated with PMA and Iono in the presence of BrefA. Examples shown include Th1 cells that
produce IFN-γ, Th2 cells that produce IL-4 and Th17 cells that produce IL-17. All dot plots are gated on live CD4+ T cells as shown in Fig. 81.
but 4–6 h is usually sufficient to detect cytokines including IFN-
γ and TNF by intracellular cytokine staining. Administration of
monensin or BrefA to mice during an active immune response and
analysis shortly after administration can be used to assess cytokine
production directly ex vivo [729] (see also Chapter V Section 17.5
Functional Read-outs).
The detection of effector functions by FCM can be used to gain
information about the properties of specific T cell subsets, but
it is also utilized to enumerate antigen-specific CD4 T cells. To
evaluate the total magnitude of an antigen-specific response using
functional measures, an effector response should be selected that
will be present in the majority of antigen-specific CD4 T cells
following restimulation. A particularly useful marker for assess-
ing total response magnitude for CD4 T cells is CD40L, as this
marker is rapidly expressed on CD4 T cells after activation [730].
Unfortunately, it can be difficult to stain for CD40L, as it is tran-
siently expressed on the cell surface and then rapidly secreted or
internalized and degraded after interaction with its ligand, CD40.
To circumvent this issue, cells can be either stained intracellu-
larly for CD40L in the presence of BrefA or stimulated in vitro in
the presence of both fluorescently labeled Ab against CD40L and
blocking CD40 Ab [730]. Staining for CD40L in this way thereby
permits evaluation of the majority of the antigen-specific CD4
T cell response.
The simultaneous detection of multiple activation markers or
cytokines can aid the detection of low frequency responses, due to
the decreased background. For the identification of live CD4 T cells
producing a certain cytokine, a cytokine secretion assay can be
used (see also Chapter V Section 17.6 Live cytokine-producing cell
sorting with Cytokine Secretion Assay). In Chapter V Section 17.5
Functional Read-outs, additional information on antigen-specific
T cell stimulation can be found.
Antigen-specific CD4 T cells can be detected indirectly using
in vitro restimulation with defined antigens, but antigen-specific
CD4 T cells can also be directly identified, analyzed, and tracked
in mice using a number of methods. First, CD4 T cells specific for a
given antigen can be detected by MHCII tetramers/multimers (see
also Chapter V Section 17.4 MHC Multimers). Of note, tetramer
staining can exhibit nonspecific binding and high background. To
improve identification of low frequency tetramer+ T cells, stain-
ing with the same MHCII tetramer labeled with two different flu-
orophores can be used (see also Chapter V Section 17.4 MHC
Multimers). Another strategy to track antigen-specific responses
in vivo is to transfer congenically labeled or fluorescently labeled
TCR transgenic T cells. Different transgenic mouse strains express-
ing TCRs specific for a number of antigens and derived from CD4
T cells have been developed, including ovalbumin (OT-II), LCMV
glycoprotein (SMARTA), and malarial antigen (pBT-II). Allelic
variants of the cell surface molecules CD90 (Thy-1) and CD45
(Ly-5) can be distinguished with selective Abs and allow tracking
of adoptively transferred T cells in congenically distinct recipients.
T cells can also be genetically modified to stably express fluores-
cent proteins, such as Green Fluorescent Protein (GFP), yellow
(Y)FP, and red (R)FP, to track transferred cells or act as reporters
for deletion or expression of genes in genetically modified mice.
Fluorescent dyes, such as carboxyfluorescein succinimidyl ester
(CFSE) and cell trace/tracker violet (CTV) (see Chapter V Section
18 Adoptive T cell transfers as a readout for Ag-specific immune
responses), can be used to label cells, which are then transferred
into hosts to track migration or cell division in vivo, although the
fluorescent signal from these dyes is lost with protein turnover
and so they can only be detected for a finite period. Functional
indicators of antigen-specificity can also be used. Activated T cells
that are actively dividing, can be identified in vivo or in vitro by
uptake of Bromodeoxyuridine (BrdU) or by intranuclear staining
with the proliferation-associated marker Ki-67.
1.3 Murine Conventional αβ CD8 T cells
1.3.1 Overview. MHCI-restricted CD8 T cells are one of the cen-
tral effector cell populations of the adaptive immune system and
contribute to protection against viruses, intracellular bacteria, and
malignant cells. In this section, we provide examples how to iden-
tify conventional CD8 T cells and use surface markers to determine
functionally distinct populations of CD8 T cells in steady state and
during an immune response. Furthermore, we give an overview
of methods that can be used to analyze transcription factors, track
antigen-specific CD8 T cell responses, and measure CD8 T cell
effector function.
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Figure 86. Discriminating murine CD8 T cell subsets. The expression of CD44, CD62L, and CD69 can be used to identify CD8 T cell populations
in the different phases of the immune response. CD8 T cells displayed in the top row were gated as shown in Fig. 81. Naive mice mainly contain
naı¨ve CD8 T cells. Pathogen-specific T cells can be identified using tetramer staining, here GP33-specific CD8 T cells after LCMV infection. During
the effector phase (d8 post infection), the majority of LCMV-specific CD8 T cells upregulate CD44 and downregulate CD62L. In the memory phase
(day 30+ post infection), T cells retain high expression of CD44 and can be divided in Tcm, Tem, and Trm using expression of CD62L and CD69,
with distinct contribution of Tcm, Tem, and Trm in different tissues.
1.3.2 Conventional αβ CD8 T cells: Identification and surface mark-
ers. Conventional TCRαβ CD8+ T cells can be identified by gat-
ing according to time, FSC and SSC, exclusion of doublets and
dead cells, gating on CD3ε+ or TCRβ+ cells and finally gating on
CD4–CD8α+ cells (Fig. 81). Gating on CD3ε+ or TCRβ+ T cells
is useful to exclude myeloid cells or NK cells that express CD8α.
Of note, this gating strategy can lead to the inclusion of uncon-
ventional T cells, such as intraepithelial lymphocytes (IELs), γδ
T cells, NK T cells, and MAIT cells (see also Chapter VI Sections
1.7–1.10), as some of these cells express a CD8αα homodimer.
These unconventional T cell populations can together comprise up
to 50% of the CD8 T cell populations in some peripheral tissues,
such as the small intestine. To avoid this misclassification, CD8β
Abs should be included in gating strategies to exclude unconven-
tional T cells that do not express this marker. The use of CD8β Abs
can, however, reduce binding of MHCI tetramers and thereby limit
the identification of antigen-specific CD8 T cells [731]. These fac-
tors should therefore be taken into consideration when identifying
antigen-specific populations in tissues that are rich in unconven-
tional T cells populations.
The differentiation state of CD8 T cells is defined by CD44
and CD62L expression (Figs. 81 and 86). Na¨ıve CD8 T cells (Tn)
are CD44loCD62Lhi. After infection or immunization, antigen-
activated CD8 T cells upregulate expression of CD44 and lose
CD62L during differentiation into CD8 Teff cells (CD44hiCD62Llo)
(Fig. 86). The expression of additional surface markers during
activation and expansion can be indicative of cellular fate in
developing CD8 Teff cells. Two such markers are CD127, which
is the IL-7 receptor α chain that promotes T cell survival in the
periphery, and KLRG1, which is upregulated with strong or sus-
tained antigen encounter and regarded as a marker of terminal
differentiation (Figure 87). Antigen-specific CD8 T cells derived
from the effector phase of a response can express various com-
binations of CD127 and KLRG1, which define either short-lived
effector cells (SLEC; CD127–KLRG1+), which are lost during the
contraction phase of the immune response, or memory precursor
effector cells (MPEC; CD127+KLRG1–), which are more likely to
persist and contribute to memory populations [732, 733]. Of note,
repeated antigenic stimulation, such as during live or prime boost
vaccination, can drive accumulation of a CD127+KLRG1+ popula-
tion [734], although their functionality and memory potential is
not well defined.
After resolution of infection, the CD8 Teff cell population
contracts and memory populations begin to form. Similar to
CD4 T cells, CD8 Tmem cells are often defined as Tcm cells
(CD44hiCD62Lhi) and Tem cells (CD44hiCD62Llo), as well as tissue
resident memory cells (Trm; CD44hiCD62LloCD69hi; see Chapter
VI Section 1.4 Murine tissue resident memory T cells) (Figure 86).
Additionally, the differential expression of the fractalkine receptor
CX3CR1 can been used to identify CX3CR1int peripheral memory
T cells (Tpm), which have direct access to peripheral tissues for
surveillance [735].
Of note, cytokine stimulation in the absence of antigen stim-
ulation can upregulate memory markers in antigen-na¨ıve CD8
T cells. These virtual memory CD8 T cells (Tvm; CD44hi CD49dlo)
acquire CD44 expression in the periphery in response to IL-15
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Figure 87. Delineating murine SLEC and MPEC
populations. The expression of KLRG1 and
CD127 can be used to differentiate SLECs
(KLRG1+CD127–) from MPECs (KLRG1–CD127+).
Plots are gated on CD8α+ T cells as in Fig. 81
(total CD8 T cells, top two rows) and addition-
ally on tetramer+ cells as in Fig. 86 (bottom
row). Cells are derived from peripheral blood
at the peak (day 27, left) or memory timepoint
(day 230, right) post-vaccination with recombi-
nant adenoviral vector expressing SIV-Gag as a
target antigen.
stimulation but do not upregulate CD49d, a subunit of very-late
activation antigen (VLA)-4 [736]. Other Tvm cell markers include
high expression of Eomes, Bcl-2, CD122, and CD127. While Tvm
cells are antigen-na¨ıve, they are functionally distinct from CD8
Tn cells [737]. Crucially, Tvm cells are also CD62Lhi. As a result,
CD44hiCD62LhiCD49dlo Tvm cells are often included in gates for
CD44hiCD62LhiCD49dhi Tcm cells (Figure 88), when CD49d is not
included in gating strategies or when a marker to identify antigen-
specific Tcm cells, such as tetramer staining, is not used. Given the
unique functional profile of Tvm cells, this has led to misattribu-
tion of Tvm cell qualities to the Tcm cell compartment [738]. Care
should be taken to properly identify Tcm cells versus Tvm cells,
especially during aging when virtual memory cells become more
dominant (see also Chapter VI Section 1.5).
1.3.3 CD8 T cells: Transcription factors. The differentiation of
CD8 T cells from Tn into Teff, Tcm, Tem, and Trm cells is co-
ordinated by a network of transcription factors. Tn cells exhibit
high expression of Bach2, which maintains naivety and multipo-
tency [740]. After activation, some transcription factors favor Teff
cell differentiation, such as Tbet, Id2, Blimp1, while others favor
Tcm or Tem cell differentiation, such as Eomes, Bcl6, and Id3.
Eomes in particular has been correlated with Tcm cell develop-
ment [741] but it is also crucial in Tvm cell development [736].
Additionally, Blimp and Hobit (homolog of Blimp1 in T cells)
mediate Trm generation [742]. To assess transcription factors by
FCM, intranuclear staining is used (see also Chapter V Section 13
Transcription factors).
1.3.4 CD8 T cells: Effector functions and antigen specificity. Dur-
ing activation, CD8 Tn cells start to express surface molecules
and produce and secrete proteins that are necessary for their
effector function. Directed killing of infected or malignant cells
is the main effector function of activated CD8 Teff cells. This
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Figure 88. Discriminating murine Tcm cells
from Tvm cells. The expression of CD44,
CD62L, and CD49d can be used to differ-
entiate antigen-experienced Tcm cells from
antigen-inexperienced Tvm cells. Tcm cells
are CD44hiCD62LhiCD49dhi while Tvm cells are
CD44hiCD62LhiCD49dlo. Shown are splenocytes
from 3-month-old naive or flu-infected (day
60 post-infection) C57BL/6 mice. Cells in con-
tour plots are gated on singlets, lymphocytes,
live, dump (B220, NK1.1, CD4, CD11c, CD11b,
F4/80)-, CD8α+ T cells as given in Quinn et al.
[739].
cytotoxicity is typically mediated by secretion of cytokines, such
as IFN-γ and TNF, the release of cytotoxic granules contain-
ing granzymes and perforin, and/or surface expression of FasL,
which can induce apoptosis of Fas expressing cells. Similar to
CD4 T cells, different subsets of CD8 cytotoxic T (Tc) cells have
been described, including Tc1, Tc2, Tc9, and Tc17 cells [743],
and a subset of CD8 T cells has been observed that can mediate
help via CD40L [744]. Some effector functions, such as constitu-
tive Granzyme B expression, can be directly analyzed in resting
Tmem, while most cytokines are only produced after reactivation.
To assess cytokine production quantitatively and qualitatively,
intracellular cytokine staining is commonly used. Like CD4 T cells
(See Chapter VI Section 1.2.4. CD4 T cells: effector functions and
antigen-specificity), cytokine production in CD8 T cells is gener-
ally analyzed after in vitro restimulation, either polyclonally using
PMA/Ionomycin or CD3/28 mAb, or in an antigen-specific man-
ner using protein (i.e., purified protein, pathogen lysate, or live
pathogen) or peptide. Of note, antigen-specific restimulation of
CD8 T cells involves stimulating the cells with their cognate anti-
gen presented on MHCI. While complex protein antigen can be
used to efficiently stimulate CD4 T cells, cross-presentation of
exogenous complex protein antigen on MHCI by APCs is a rela-
tively inefficient process in vitro and is generally less suitable for
restimulation of CD8 T cells. In contrast, short peptides are very
efficiently loaded onto MHCI (and II) and restimulation with pep-
tides that contain known epitopes is therefore an effective way to
induce and assess CD8 T cell responses. Alternatively, cells directly
infected with bacteria/virus or cell lines expressing MHCI-peptide
conjugates, such as SAMBOK (MEC.B7.SigOVA) [745] or RMA-S,
can be used to stimulate CD8 T cells, as these cells exhibit efficient
presentation of peptide on MHCI.
During stimulation, cells will start to express cytokines and
other effector molecules. To drive the accumulation of these
molecules within the cell and increase the detection of secreted
effector molecules, protein inhibitors like BrefA or monensin are
used during the activation. These protein transport inhibitors are
toxic; thus, it is optimal to limit the time of cell exposure. Typ-
ically, 4–6 h are used to accumulate cytokines like IFN-γ, IL-2,
and TNF for detection by staining (Fig. 89a). In addition, BrefA or
monensin can be administered to mice during an active immune
response, with mice euthanized shortly after administration and
immediate analysis of cytokine production directly ex vivo [729].
The advantage of this approach is that it allows measurement of
cytokine production with in situ antigen presentation, which is
more relevant to understanding immune priming in the lymph
node and site of infection.
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Figure 89. Effector molecules produced by murine CD8 T cells (A) Splenocytes of virus-immune mice were stimulated with peptide for 6 h in the
presence of BrefA to identify virus-specific CD8 T cells based on their cytokine expression and degranulation using CD107a (gated on live CD8α+
T cells). (B) Virus-specific CD8 T cells from different tissues were stained Granzyme B (gated on CD8α+ T cells as in Figure 81, with identification
of transferred OT1 CD8 T cells using congenic markers CD45.1 /CD45.2).
T cells can engage multiple effector mechanisms after activa-
tion. The simultaneous detection of multiple activation markers
or cytokines can aid the detection of low frequency responses,
due to decreased background (Fig. 89A), but it also permits the
assessment of a characteristic known as poly- or multifunction-
ality. Multifunctionality refers to T cells that express more than
one effector molecule or cytokine simultaneously upon stimula-
tion and can be assessed through Boolean gating, processed with
software called Pestle and visualized with software called SPICE.
Alternatively, newer FlowJo plugins such as SPADE analysis and
Cytobank, can facilitate analysis of multiparametric data.
Cytotoxic potential can be assessed directly ex vivo by intra-
cellular staining for cytotoxic proteins such as granzyme B and
perforin. CD8 Teff and some Tmem cells contain vesicles of pre-
formed cytotoxic granules, including granzymes and perforin, that
are detected via intracellular staining directly ex vivo without the
need for stimulation (see protocol, Fig. 89B). This approach is
optimal, as stimulation can cause CD8 T cell degranulation, which
can lead to a reduction in the amount of granzyme B or perforin
per cell and a loss of fluorescence intensity and staining resolution.
Cytotoxic capacity can be directly assessed using in vitro or in vivo
killing assays (see also Chapter V Section 17.8 Cytotoxicity). In
these assays, fluorescently labeled target cells loaded with a target
peptide are mixed at a 1:1 ratio with fluorescently labeled control
cells loaded with an irrelevant peptide. The target/control mix is
either co-incubated in vitro with antigen-specific CD8 T cells at
varying ratios or administered intravenously to immune animals.
A reduction in the relative frequency of target versus control cells
acts as a measure of antigen-specific CD8 Teff cell cytotoxic capac-
ity. Finally, degranulation capacity can also be assessed. When a
CD8 T cell is stimulated, cytotoxic granules can be released at the
cell surface and lysosomal markers such as CD107a and -b become
transiently accessible at the cell surface before being recycled. To
stain these markers as a measure of degranulation, fluorescently
labeled Abs for CD107a and -b are included during restimulation
and monensin should be used to neutralize lysosomal pH and
prevent protein degradation (Fig. 89A).
To identify, analyze, and track antigen-specific CD8 T cells in
mice, a number of methods previously described in the section
on CD4 Teff cell functions, can be used (see also Chapter VI Sec-
tion 1.2.4 CD4 T cells: effector functions and antigen specificity).
Briefly, antigen-specific CD8 T cells can be identified directly ex
vivo using MHCI tetramers/multimers. CD8 Teff cells can be res-
timulated with cognate antigen and proliferation or cytokine pro-
duction can be used to indirectly identify antigen-specific CD8
T cells. Antigen-specific CD8 T cell responses can also be tracked
using transfer of congenically marked or fluorescently labeled TCR
transgenic CD8 T cells from mouse strains such as OT-I, p14, and
gBT-I and subsequent challengewith their cognate antigen. During
an ongoing immune response, activation markers such as CD11a
and CD49d [746], as well as markers of proliferation (BrdU or
Ki67) can be used to directly identify antigen-experienced CD8
cells ex vivo.
1.3.5 Step-by-step sample preparation for detection of GrB inmurine
CD8 T cells.
 Transfer 1–5 × 106 cells per sample to a 96-well V-bottom plate
 Pellet cells at 500 × g for 5 min at 4˚C and remove supernatant.
 Resuspend cells in 50 µL surface stain Ab mix (in FCM buffer).
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 Incubate at 4°C for 15–30 min.
 Wash with 150 µL of FCM buffer, and centrifuge for 5 min at
500 × g at 4˚C and remove supernatant.
 Resuspend cells in 50 µL of freshly prepared Foxp3 Fixa-
tion/Permeabilization working solution prepared according to
manufacturer’s instructions.
 Incubate at 4°C for 30 min.
 Optional: wash in 150 µL FCM buffer, and pellet cells at 500
× g for 5 min at 4˚C, remove supernatant, resuspend in 50 µL
FCM buffer, and store overnight in fridge at 4°C.
 Add 150 µL 1× Foxp3 Perm/wash solution (prepared according
to manufacturer’s instructions), pellet cells at 500 × g for 5 min
at 4˚C and remove supernatant.
 Add intracellular Ab stain mix (in Foxp3 Perm/wash solution)
 Incubate at 4°C for 30 min.
 Add 150 µL 1× Foxp3 Perm/wash solution, and centrifuge at
500 × g for 5 min at 4˚C and remove supernatant.
 Resuspend in FCM buffer for analysis on a flow cytometer.
1.3.6 Materials.
 Single cell suspension containing T cells (here material from
LCMV immune mouse)
 eBioscienceTM Foxp3 / Transcription Factor Staining Buffer Set
(Thermo Fischer, Cat# 00-5523-00)
 FCM buffer: PBS with 2% FCS
1.3.7 Surface stain mix.
 Anti-murine CD8α BUV395 (BD, catalog no. 563786, clone 53–
6.7, dilution 1:200)
 Anti-murine CD45.1 FITC (eBioscience, catalog no. 11-0453-
82, clone A20, 1:200)
 Anti-murine CD45.2 eF450 (eBioscience, catalog no. 48-0454-
82, clone 104, 1:200)
 Anti-murine CD62L BV510 (Biolegend, catalog no. 104441,
clone MEL-14, 1:400)
 LIVE/DEADTM Fixable Near-IR Dead Cell Stain Kit (Thermo
Fischer, catalog no. L10119, 1:1000)
 Diluted in FCM buffer
1.3.8 Intracellular stain mix.
 Anti-human granzyme B AF700 (BD, catalog no. 561016, clone
GB11, dilution 1:200) (this Ab is crossreactive with murine
granzyme B)
1.3.9 Summary Table (Table 18).
Table 18. Molecules that discriminate subpopulations of conventional CD8αβ T cells (identified by expression of CD3 or TCRαβ, lack of TCRγδ and
CD4, expression of CD8a and CD8b)
TN TEFF (SLEC) TEFF (MPEC) TVM TCM TEM TRM
Surface markers
CD44 lo hi Hi hi hi hi hi
CD62L hi lo Lo hi hi lo lo
CD69 lo int Int hi or lo lo lo hi
CD103 hi or lo hi or lo hi or lo lo lo hi or lo
CD25 lo hi hi lo lo lo
CXCR3 lo hi hi hi hi hi hi
CXCR6 lo int int int int hi
CD127 hi lo hi
KLRG1 lo hi lo lo
CD49d int hi hi lo hi hi hi
CD122 lo lo lo hi int lo
CD49a lo hi or lo hi or lo hi or lo int hi
Intracellular markers to be stained ex vivo
Granzyme B lo hi hi int lo lo int
Perforin lo hi hi int lo lo int
Markers to be stained after restimulation
IFN-g lo hi hi hi hi hi Hi
TNF lo hi hi hi hi hi hi
IL-2 lo hi hi lo hi int int
Intranuclear markers and transcription factors
Bach2 hi int int int lo lo lo
Tbet lo hi hi hi int int int
Bcl-2 lo lo lo hi int int
Eomes lo lo lo hi int int int or lo
Hobit lo lo lo hi
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1628 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
Figure 90. Unconventional and conventional murine T cells can have overlapping phenotypes. Splenocytes were gated on scatter parameters (see
Figure 81), live, CD3+/CD4+ T cells. Staining with CD1d PBS-57 tetramer identifies NKT cells that mainly express CD69.
1.4 Murine tissue resident memory T cells
1.4.1 Overview. Tissue-resident memory T cells (Trm) cells are
noncirculating T cells that form the first line of defense against
reinfection in tissues [747, 748]. They are enriched in barrier tis-
sues, such as the lung, skin, and intestine, but they are also present
in internal organs, such as brain, liver, bone marrow, white adi-
pose tissue, and lymphoid organs. The tissue residency phenotype
was initially described for CD8 T cells, but analogous tissue resi-
dency programs for CD4 T cells and other lymphocyte populations
are currently being defined [749].
1.4.2 Methods to identify and analyze tissue resident T cells. Most
tissue resident T cells are located within a dense network of
parenchymal cells and extracellular matrix. This cellular network
needs to be dissociated to analyze the lymphocytes in a single-cell
suspension by FCM. It is important to note that the isolation pro-
cedure of murine T cells from tissues can have a significant impact
on cell viability and detected phenotype. Enzymes like collagenase
and dispase, which are used to enzymatically dissociate tissue, can
cleave off lineage-defining markers such as CD4 and CD8 [750].
Additionally, tissue dissociation not only causes sheer stress and
destruction, but signals released during the dissociation of tissue
can influence the phenotype, function, and viability of CD4 and
CD8 T cells. For example, activation of the danger receptor P2RX7
by extracellular NAD or ATP, released by dying cells during pro-
cessing, can lead to shedding of surface molecules such as CD62L
and CD27, the masking of CD8β and the induction of cell death in
susceptible cells like Treg, NKT, and Trm cells [751–753]. This is
especially important when T cells are used in functional assays. As
a result, the method of tissue dissociation should be carefully cho-
sen and viability of cell preparations used in FCM should always
be assessed.
In many peripheral tissues, unconventional T cells are
increased and can even dominate (see also Chapter VI Sections
1.7-10), which is important to consider when identifying Trm cell
populations. These unconventional T cells can have overlapping
expression patterns with conventional TCRαβ CD4 and CD8 T cells
for basic surface markers. For example, in liver and spleen, the
CD3+ CD4+ gate is composed of both conventional TCRαβ CD4
T cells and a population of NKT cells with a tissue resident pheno-
type (Fig. 90). Similarly, in the small intestine, the CD3+ CD8α+
gate for intraepithelial lymphocytes (IELs) can include conven-
tional TCRαβ CD8αβ T cells and CD8αα IELs and γδ T cells. There-
fore, careful selection of the surface markers is key for the correct
identification of target cells, particularly across tissues.
Their location and signals of the local microenvironment deter-
mine the expression profile of T cells. Accordingly, the physiologi-
cally quite diverse parenchyma of tissues can drive a tissue-specific
phenotype Trm and expression of surface molecules might differ
per organ [747]. CD69 is constitutively expressed by many Trm
cells, it is functionally important for their residency and it is there-
fore a commonly used marker for Trm identification (Figs. 86
and 91). The chemokine receptor CXCR6 (Fig. 91), immunoglob-
ulin CD101 and CD49a, the α-chain of the α1β1 integrin (VLA-1),
are also highly expressed on Trm cells in many tissues. CD8 Trm
cells in epithelial and neuronal tissues can also express CD103
(Fig. 91), which is the α-chain of the αEβ7 integrin [747]. CD103
is also expressed by a subset of CD8 Tn cells, which makes the
use of CD44 or CD62L essential to discriminate between CD8 Trm
and Tn cells. While the majority of Trm cells throughout different
tissues constitutively express CD69, parabiosis and in vivo label-
ing experiments have highlighted that there are CD69– cells that
reside long-term in tissues [754].
In vivo labeling offers an alternative way of Trm identifi-
cation by providing information about the location of T cells.
During in vivo labeling, fluorescently labeled Abs directed
against CD4, CD8 or pan-T cell markers, such as CD90 and
CD45, are injected intravenously shortly before tissue har-
vest [755]. This brief exposure labels leukocytes in circulation,
which can be used to distinguish between the labeled cells
in the vasculature of a tissue and unlabeled T cells located
within the tissue itself. These unlabeled T cells are therefore
enriched for Trm cells and this approach can be particularly
important when working with highly vascularized tissue such as
the lung.
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Figure 91. Identifying Trm cells. Expression of CD69, CD103, and CXCR6 can be used to identify Trm. Lymphocytes from different tissues of
LCMV-immune mice (d30+ post infection) were isolated and LCMV-specific memory T cells identified as live, CD8α+, tetramer+ (see Figs. 81
and 84).
1.4.3 Step-by-step sample preparation for the analysis of Trm from
the small intestine and the liver.
1.4.3.1 Isolation of intraepithelial lymphocytes from the small
intestine.
 Remove small intestine and store in cold HBSS with 2% FCS
(wash buffer)
 Cut intestine into three pieces and store in HBSS with wash
buffer
 Clean each piece of intestine on a wet tissue soaked with wash
buffer from fat, remove peyers patches, cut longitudinal and
remove feces, keep intestine wet during the whole time
 Wash two times with 5 mL wash buffer (e.g., six-well plate)
 Cut into pieces of 1 cm and transfer to 10 mL wash buffer,
vortex 10 s, pour over cell strainer, and collect tissue pieces,
repeat twice
 Transfer tissue pieces to 20mL EDTA solution (HBSS, 10% FCS,
5 mM EDTA, 1 mM DTT)
 Incubate 30 min at 37°C in water bath, vortexing every 10 min
 Filter over cell strainer and collect the flow through containing
intraepithelial lymphocytes
 Remaining tissue pieces and be used for the isolation of lamina
propria lymphocytes
1.4.3.2 Isolation of lymphocytes from the liver.
 Remove liver and store in cold PBS with 0.5% FCS
 Remove gall bladder and other connective tissue attached
 Mash liver over cell strainer with PBS with 0.5% FCS using the
plunger of a 3 mL syringe
1.4.3.3 Enrichment of lymphocytes by gradient centrifugation.
 Pellet cells (500 × g, 5 min, 4°C)
 Resuspend cells in 5 mL 40% isotonic percoll and overlay to
3 mL 60% isotonic percoll in a 15 mL falcon
 Centrifuge 20 min at 800 × g, acceleration 5, deceleration 0
(no break)
 Remove top layer of fat and tissue cells
 Collect lymphocytes from the interphase
 Wash with PBS with 0.5% FCS
1.4.3.4 Staining of lymphocytes.
 Transfer up to 4 × 106 cells to FCM tubes or 96-well V-bottom
plate
 Pellet cells (500 × g, 5 min, 4°C)
 Resuspend in 50 µl staining mix, incubate 30 min at 4°C
 Wash cells with PBS with 0.5% FCS and analyze by FCM
1.4.4 Materials.
 Wash Medium: HBSS/ 2% FCS
 EDTA Medium: HBSS 10% FCS mix, 5 mM EDTA, 1 mM DTT
 PBS
 Percoll (GE, 17-0891-01, density 1,13 g/ml, prepare isotonic
90% Percoll by mixing with 10x or 20x PBS, dilute with PBS to
60% and 40%)
 Surface stain mix (in PBS with 0,5% FCS):
◦ Anti-murine CD8α BUV395 (BD, cat # 563786, 53–6.7,
1:200)
◦ Tetramer (Db GP33 PE, R. Arens, LUMC)
◦ Anti-murine CD69 PeCy7 (eBioscience, cat # 25-0691-82,
H1.2F3, 1:200)
◦ Anti-murine CD62L BV510 (Biolegend, cat # 104441,
MEL-14, 1:400)
◦ Anti-murine CD103 PerCpCy5.5 (BD, cat # 563637, M290,
1:200)
◦ LIVE/DEADTM Fixable Near-IR Dead Cell Stain Kit (Thermo
Fischer, cat # L10119, 1:1000)
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1.4.5 Pitfalls and Top tricks.
 Know the cells you study: Correct selection of markers for iden-
tification and exclusion of other cell populations is key to avoid
misclassification.
 Sample processing can affect detection of your markers, cell
viability, and the outcomes of functional assays.
1.5 Immune senescence (aging) in murine T cells
1.5.1 Overview. Aging leads to loss of immune functionality with
a well-documented impact on adaptive immunity, and in particu-
lar the T cell lineage [756]. Such changes have shown similarities
in humans and mice. Therefore, this chapter will focus on the
phenotyping of T cells in models of aging in mice.
1.5.2 Introduction. To study immune aging in mouse models,
we need to consider the overlaps and the differences between the
aging process in mice and humans. Such differences may be reflec-
tions of intrinsic differences between the two species (e.g., in lifes-
pan, body mass, telomere length, or telomerase activity [757]), or
of the fact that humans are observed in the context of environmen-
tal exposures of the real world, whereas mice are typically studied
in controlled and sterile environments of SPF facilities. Therefore,
long-term exposure of mice to ubiquitous environmental microor-
ganismsmay reflect natural aging processes better than theirmain-
tenance in sterile environments [758, 759]. When working with
mice, 18 months of age or older is considered truly aged [760],
as many mouse strains survive longer than 600 days in standard
SPF housing [761]. While 3-month-old young mice have high fre-
quencies of na¨ıve T cells in blood and lymphoid tissue, the relative
frequency (Fig. 92) and absolute counts of na¨ıve T cells decline
substantially with age as the thymus involutes. In contrast, the
frequency (Fig. 92) and counts of memory T cell subsets, partic-
ularly more differentiated populations, increase with age as the
collective history of antigenic encounters makes a mark on the
aging host.
Phenotyping of na¨ıve and memory T cell subsets by FCM
relies on a combination of markers that are acquired or lost
during T cell differentiation, from na¨ıve and memory to termi-
nally differentiated T cells [762]. Some markers that are used
to identify na¨ıve and memory T cell subsets in humans such as
CD45RA [762] are not suitable for phenotyping murine T cell
subsets, mainly because they do not allow reasonable sepa-
ration in discrete positive and negative fractions. As a result,
markers such as CD44 and CD62L or CCR7 are used in mice
to identify na¨ıve (TN), central memory (TCM), and effector
memory (TEM)/effector (TEFF) subsets, as well as KLRG1 and
CD127, which are used to identify memory precursor effector
cells (MPEC) and the short-lived effector cells (SLEC) popula-
tions, as described previously (See Chapter VI Section 1.1 Murine
CD4 and CD8 T cells, Section 1.4 Murine tissue resident memory
T cells).
In addition to these classical T cell subsets, we can assess senes-
cence markers in T cells. Some surface markers used in humans
such as CD57, the lack of CD28 and the re-emergence of CD45RA
expression, do not translate into mice. Telomere length is also
commonly assessed in humans as an indicator of cellular age and
replicative senescence, sometimes by flow cytometric methods,
but this approach is limited in mice as telomeres are relatively
long, meaning that telomere erosion may not be a major driver
of immune ageing [757]. However, senescent T cells in mice do
exhibit increased expression of NK cell related markers, such as
KLRG1, and the loss of CD27, allowing us to robustly separate
memory subsets and more terminally differentiated populations in
mice (Fig. 93). Senescent T cells in mice and humans both exhibit
an increase in phosphorylated γH2Ax subunits in the cytosol as an
indicator of increased ATM kinase activity, increased DNA dam-
age, and a DNA-damage senescence phenotype [739, 763].
Accordingly, for analysis of ageing phenotypes in mice, one
should profile the differentiation status of the overall T cell
population and assess senescence markers in these subsets, but
the exact method of T cell phenotyping may differ depend-
ing on the experimental context and infection history of the
mice.
1.5.3 Step-by-step sample preparation.
1.5.3.1 Sample collection and RBC lysis.
1. Collect a defined volume of blood (up to 75 µL) using
a heparinized hematocrit capillary and dispense it into
an Eppendorf tube containing 300 µL of HBSS-EDTA
buffer.
2. Remove 75 µL for absolute blood cell counting and process
as indicated in Section 12.1.3.2.
Proceed with the remaining blood in HBSS as indicated
below.
3. Centrifuge for 5 min at 700 × g at 4°C.
4. Aspirate supernatant and resuspend pellet in 600 µL of dis-
tilled water. Immediately thereafter (max 5–10 s), add 200 µL
of 4× PBS and briefly mix by pulse vortexing.
5. Centrifuge for 5 min at 700 × g at 4°C.
6. Aspirate most of the supernatant (leave approximately
100 µL), resuspend cells in the remaining volume and transfer
into a 96-well plate.
7. Centrifuge for 3 min at 700 × g at 4°C.
8. Flick off the supernatant and resuspend pellet in 150 µL of dis-
tilled water using a multichannel pipette. Immediately there-
after (max 5–10 s), add 50 µL of 4× PBS with a multichannel
pipette andmix thoroughly by pipetting. Discard tips between
rows to avoid carryover cell contaminations.
9. Centrifuge for 3 min at 700 × g at 4°C
10. Flick off supernatant and proceed with antibody staining as
described in previous chapters (see Chapter IV Section 2.5.
Erythrocyte lysis).
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Figure 92. Gating strategy used to define TN, TVM, TCM, and TEM CD8 T cell subsets in naı¨ve mice, using splenocytes from naı¨ve SPF 3 month
old and 18 month old C57BL/6J mice. (A) Gating strategy, where cells are gated on singlets, lymphocytes, live, dump-, CD8+ T cells, and then (B)
CD44 versus CD62L then CD49d or (C) CD44 versus CD49d to define the populations indicated in the key. Frequencies indicate the frequency of
indicated subsets within the CD8 T cell population.
1.5.3.2 Absolute cell counts. Lymphocyte counts per volume
of blood can be obtained using automated hematology analyzers
according to manufacturer’s guidelines. For measurements using
VETSCAN HM5 (Abaxis), a minimum of 75 µL of HBSS-EDTA
diluted blood (see 12.1.2.1) is transferred to an Eppendorf tube
and acquired. Absolute values are calculated in relation to the
volume of blood and HBSS-EDTA:
Cr = Co (VT /VB) ,
where Cr is the real count of blood cells, Co is the count observed in
the analyzer, VB is the volume of the blood in the acquired sample,
and VT is the total volume of the blood with HBSS-EDTA at the
time of acquisition. Alternatively, absolute number of cells in a
stained sample can be determined using FCM counting beads (e.g.,
Precision Count Beads, BioLegend) according to manufacturer’s
protocol.
1.5.4 Materials. Media and buffers: HBSS-EDTA: HBSS 5mM
EDTA; Staining buffer: Phosphate buffered saline (PBS) 2% (v/v)
FBS;
Antibodies for uninfected mice: Dump-FITC (anti-B220 (clone
RA3-6B2), CD11c mAb (clone HL3), CD11b mAb (clone M1/70),
anti-F4/80 (clone BM8), anti-NK1.1 (clone PK136)), Brilliant
Ultraviolet 395 CD8a mAb (clone 53–6.7), Alexa Fluor 647
CD49d mAb (clone R1-2), PE-Cy7 CD44 mAb (clone IM7),
Brilliant Violet 605 CD62L mAb (clone MEL-14); Cell Viability
Stain: LIVE/DEAD Fixable Near-IR Dead Cell Stain (Molecular
Probes)
Antibodies for infected mice: FITC CD11a mAb (clone M17/4),
PE CD122 mAb (clone TM-β1), APC CD27 mAb (clone LG.3A10),
APC-eFluor 780 CD3e mAb (clone 17A2), Pacific Blue CD62L
mAb (clone MEL-14), anti-KLRG1-Brilliant Violet 510 (clone
2F1/KLRG1), Brilliant Violet 650 CD4mAb (clone GK1.5), Bril-
liant Violet 785 mAb CD44 mAb (clone IM7), Brilliant Ultraviolet
395 CD8a mAb (clone 53–6.7); Cell Viability Stain: 7-AAD
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1632 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
Figure 93. Gating strategy used to define naı¨ve, memory and TTDE CD8 T cell subsets in aged chronically infected mice (applies also to
Figs. 95 and94). FCM analysis of the peripheral blood of 8-month-old C57BL/6J mouse experimentally infected for 6 months with 106 PFU of a
chronically persistent β-herpesvirus, murine cytomegalovirus (MCMV).
Flow cytometer: Experiments were performed on an LSR
Fortessa (BD Bioscience) equipped with laser excitation lines of
360, 405, 488, 561, and 640 nm and the following filter config-
uration: 386/23(365) for BUV395; 450/50(405) for Pacific Blue;
525/50(405) for BV510, 655/40(405) for BV650; 785/60(405)
for BV785; 525/50(488) for FITC; 685/35(488) for 7-AAD;
585/15(561) for PE; 780/60(561) for PE-Cy7; 670/14(640) for
APC; 710/40(640) for Alexa700; and 780/60(640) for APC-
eF780.
1.5.5 Data analysis.
1.5.5.1 Identification of T cell subsets in aged, uninfected mice.
Na¨ıve aged mice that are held in a Specific Pathogen Free (SPF)
facility will have had limited antigenic exposure. Using the clas-
sical markers, CD44 and CD62L, for defining na¨ıve and memory
subsets in peripheral blood and lymphoid tissue, na¨ıvemice exhibit
a clear shift with age in T cell subset frequencies, with a decrease
in the na¨ıve subset and an increase in memory subsets. Of note,
this shift in frequency with age is driven by a marked decrease
in na¨ıve T cell numbers, particularly CD8 T cells, while memory
cell numbers increase more modestly, consistent with their limited
antigenic exposure.
As described previously (See Chapter VI Section 1.1 Murine
T cells), TN cells are CD44−CD62L+ and TEM (and TEFF) cells
are CD44hiCD62L− cells but, for CD8 T cells, the CD44hiCD62L+
population contains both TCM and virtual memory (TVM) cells
(Fig. 92 and Table 19). Cells must be stained with CD49d to dif-
ferentiate between TCM and TVM cells, with CD49dhi denoting
antigen-experienced TCM cells and CD49dlo denoting antigen-
inexperienced but cytokine-exposed TVM cells. This distinction
becomes important in ageing research as the proportion of CD8
T cells that are TVM cells increases markedly with age (Table 19)
and these cells have been misclassified in the past as TCM cells
[738]. In addition, TVM cells express high levels of CD122 and
NK cell markers, both of which increase with age and would oth-
erwise be misattributed to TCM cells [739, 764]. An additional
feature of aging in mice is that the expression level of CD44 on TN
cells increases, not to become CD44hi, but TN cells become pre-
dominantly CD44int (Fig. 92). This may indicate that the average
post-thymic age of aged TN cells is increased or that aged TN cells
are exposed to the inflamed aged environment, which is driving
modest activation and increased CD44 expression.
1.5.5.2 Identification of T cell subsets in aged chronically
infected mice. Upon infection, particularly infection with persis-
tent pathogens, T cell populations progress more rapidly toward
an aged phenotype, with more terminally differentiated subsets
and increased expression of senescencemarkers (Fig. 95 and refer-
ence [758]). Therefore, a shorthand for the progression of immune
aging phenotypes is given by the frequency and absolute counts of
KLRG1+CD27− Terminally Differentiated Effector T cells (TTDE).
A common strategy to define na¨ıve cells is to combine CD44 and
CD62L staining, where CD44− CD62L+ cells are considered na¨ıve.
Some commonly used mouse strains (e.g., BALB/c) show a poor
separation of na¨ıve from memory cells based on the CD44 marker
so an improved separation of na¨ıve CD8 T cells may be achieved
by combining CD44 and CD11a labeling, where CD44−CD11alo
correspond to na¨ıve cells, although neither of these markers alone
robustly separates na¨ıve from primed cells (Fig. 93). In addition,
CD122, which is expressed on TVM and TCM cells, but not on TN
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Figure 94. FCM analysis of CD122 and CD62L expression in naı¨ve,
memory, and TTDE CD8 T cell subsets (pre-gated according to the gat-
ing strategy shown in Fig. 93) in the peripheral blood of 8 month old
C57BL/6J mouse experimentally infected for 6 months with 106 PFU of
MCMV.
cells, can be used in combination with CD62L to more efficiently
separate na¨ıve cells from other subsets (Fig. 94).
Table 19. Summary table of aged CD8 T cell subpopulations in naı¨ve mice
Percentage of CD8 T cells
Subset of CD8 T cells Phenotype In young mice In aged mice
Naive CD44lo CD62L+ (CD49dlo/int) 70–85% 30–40%
Virtual memory, TVM CD44hi CD62L+ CD49dlo 10–15% 20–40%
Central memory, TCM CD44hi CD62L+ CD49dhi 5–10% 10–15%
Effector memory, TEM (and effector, TEFF) CD44hi CD62Llo (CD49dhi) 2–5% 20–30%
Table 20. Summary table of aged CD8 T cell subpopulations in chronically infected mice
Subset of CD8 T cells Phenotype
Naive CD11alo CD44lo CD27+ KLRG1- CD62L+ CD122-
Central memory, TCM, and virtual memory, TVM CD11ahi CD44hi CD27+ KLRG1- CD62L+ CD122+
Effector memory, TEM CD11ahi CD44hi CD27+ KLRG1- CD62L- CD122−/lo
Terminally Differentiated Effector, TTDE CD11ahi CD44hi CD27- KLRG1+ CD62L- CD122-
It is important to emphasize that phenotyping for immune
aging will necessarily require concurrent measurements of abso-
lute lymphocyte counts per milliliter of blood. Namely, lowered
percentages, but not absolute counts of na¨ıve cells may also be
observed due to expansions of TTDE population in persistent her-
pes viral infections [758], but this does not impair immune pro-
tection against infections [765]. In conclusion, a combination of
six markers (CD11a, CD44, CD27, KLRG1, CD62L, and CD122)
allows the distinction between TN, TCM/TVM, TEM, and TTDE
T cell populations in chronically infected mice (Table 20), with a
robust identification of age-related losses of na¨ıve cell populations
and increases in terminally differentiated CD8 T cells, matching
functional changes in aging humans.
1.5.6 Pitfalls and Top Tricks. When working with aged mouse
models, consider that mice will be housed in SPF conditions, which
is quite different to humans, where pathogen exposure accumu-
lates over the lifespan.
Aged mice can accumulate age-related abnormalities, such as
tumors, or they can overgroom, which can lead to skin abrasions
and infections. This can lead to immune activation in aged mice,
so many researchers exclude mice with overt abnormalities from
analyses.
TVM cells are selectively retained with increasing age and are
often misidentified as TCM cells. Including CD49d in staining pan-
els enables identification of TCM cells as distinct from TVM cells.
Aged leukocytes can be more sensitive to physical manipu-
lation, especially RBC lysis, so make sure to time this reaction
carefully.
1.5.7 Summary tables.
1.6 Murine Foxp3+ regulatory T cells
1.6.1 Overview. Tregs are a subset of CD4+ T cells that have
fundamental functions in the maintenance of immune homeosta-
sis and peripheral tolerance, among others. Treg cells can be found
in almost any tissue including primary lymphoid organs (thymus,
bone marrow), secondary lymphoid organs (spleen, lymph nodes,
Peyer’s patches) as well as various non-lymphoid tissues (e.g.
intestine, skin, lung, liver, fat). Importantly, the Treg cell popula-
tion is extremely heterogeneous and consists of numerous, highly
specialized subsets that vary tremendously between the different
organs and tissues. In this section, guidelines for widely accepted
FCM-based phenotyping strategies for murine Treg cells in both
lymphoid organs and selected non-lymphoid tissues will be pro-
vided, and particular emphasis will be laid on markers for the
identification of Treg cell subsets.
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Figure 95. FCM analysis of KLRG1 and CD27 expression on total
CD44hiCD11ahi CD8 T cells (pregated according to the gating strategy
shown in Fig. 93) in the peripheral blood of 15-month-old (BALB/c ×
DBA/2) F1 mice experimentally infected for 9 months with 106 PFU of
a nonpersistent virus, Western Reserve vaccinia virus (VACV), or 105
PFU of a chronically persistent β-herpesvirus, murine cytomegalovirus
(MCMV) compared to uninfected littermate mice (MOCK).
1.6.2 Introduction. Treg cells were originally described as CD4+
suppressor T cells constitutively expressing CD25, the α-chain of
the IL-2 receptor complex [766]. Yet, precise identification of
Treg cells by CD25 expression turned out to be difficult as CD25
is also induced on many effector T cell subsets upon activation.
Thus, the discovery of the transcription factor Forkhead box pro-
tein 3 (Foxp3) as the lineage-defining factor for Treg cells was
a breakthrough in Treg cell-based research [767, 768]. Impor-
tantly, Foxp3 does not only serve as a marker for the more pre-
cise identification of Treg cells, but it was also shown to support
Treg cell function [767, 768] through the maintenance of Treg-
cell-specific gene expression signatures [769]. The physiological
importance of Foxp3 can be further emphasized by mutations in
the Foxp3 gene, resulting in the development of fatal autoimmune
diseases like the lymphoproliferative scurfy phenotype in mice or
the IPEX-syndrome (immune dysregulation, polyendocrinopathy,
enteropathy, and X-linked inheritance) in humans [770–772].
The Foxp3+ Treg cell population can be roughly catego-
rized into two subpopulations based on the site of their devel-
opment: Some Foxp3+ Treg cells are already generated within
the thymus and thus named thymus-derived Treg cells (tTreg
cells) [773]. These tTreg cells are complemented by peripher-
ally induced Treg cells (pTreg cells), which convert from naive
Foxp3− CD4+ T cells preferentially at mucosal sites [774]. A
number of proteins like Helios, Neuropilin-1 (Nrp-1), or RAR-
related orphan receptor gamma (RORγt) were suggested to dis-
tinguish between tTreg and pTreg cells [775–778], yet their usabil-
ity particularly under inflammatory conditions has been ques-
tioned [779–781]. Importantly, accumulating evidence suggests
that the Foxp3+ Treg cell population is not homogeneous and
that co-expression of additional transcription factors, such as T-
box transcription factor TBX21 (T-bet), GATA binding protein 3
(Gata-3), RORγt, or IFN regulatory factor 4 (Irf4), is required
for the acquisition of unique functional properties within highly
specialized Treg cell subsets [782]. The frequency of murine
Foxp3+ Treg cells in both lymphoid organs and non-lymphoid
tissues fluctuates considerably between individual mice and is
influenced by multiple factors including genetic background, age,
gender, microbiota composition, nutrition, inflammation, and
infection.
1.6.3 Treg cells in murine lymphoid organs.
1.6.3.1 Treg cells in the murine thymus. After CD4 lineage
decision, some CD4 single-positive (SP) thymocytes, upon TCR
stimulation, can develop into CD25+Foxp3+ tTreg cells through
two distinct developmental programs involving CD25+Foxp3−
and CD25-Foxp3+ Treg cell precursors (Fig. 96) [773]. Recent
data suggest that the two distinct developmental programs are
both required for the generation of a comprehensive Treg cell
repertoire [783]. CD25+Foxp3+ tTreg cells can be further subdi-
vided into subsets with different maturity based on CD69 and also
CD24 expression (Fig. 96), which is known to correlate inversely
to the maturity of CD4SP and CD8SP thymocytes [784].
Step-by-step sample preparation of Treg cells from the thymus
Protocol: Isolation and analysis
 Sacrifice 6–10 weeks old animals.
 Expose thorax.
 Remove thymus completely with forceps.
 Place thymus on a 100 µm strainer.
 Use a syringe plunger to dissociate thymus in the presence of
FCM buffer.
 Centrifuge cell suspension for 5 min with 300 × g at 4°C.
 Aspirate supernatant and resuspend cellular pellet with FCM
buffer.
 Filter cell suspension with a 30 µm strainer and count cell
number.
Surface and intracellular staining
 Transfer 2 × 106 cells to a 5 mL FCM tube.
 Centrifuge cell suspension for 5 min with 300 × g at 4°C.
 Aspirate supernatant and resuspend cellular pellet with 100 µL
Live/Dead fixable buffer (1:1000 diluted), keep cell suspension
in the dark at 4°C for 30 min.
 Add 500 µL FCM buffer and centrifuge cell suspension for 5 min
with 300 × g at 4°C.
 Aspirate supernatant and resuspend cellular pellet with 100 µL
FCM buffer with diluted surface Abs, anti-mouse CD16/CD32,
and rat IgG, keep cell suspension in the dark at 4°C for 30 min.
 Add 500 µL FCM buffer and centrifuge cell suspension for 5 min
with 300 × g at 4°C.
 Aspirate supernatant and resuspend cellular pellet with 100 µL
Fixation/Permeabilization working solution, keep cell suspen-
sion in the dark at 4°C for 30 min.
 Add 500 µL 1× Permeabilization buffer and centrifuge cell sus-
pension for 5 min with 300 × g at 4°C.
 Aspirate supernatant and repeat the above step.
 Aspirate supernatant and resuspend cellular pellet with 100 µL
1× Permeabilization buffer with intracellular Abs, anti-mouse
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 Flow cytometric phenotyping of cells across species and tissues 1635
Figure 96. Phenotyping of Treg cells from the murine thymus. Gating strategy to identify Treg cells in the thymus. From all events, lymphocytes
can be distinguished by their FSC/SSC properties (gate G0). After lymphocyte gating, doublets are excluded twice (gates G1 and G2), followed
by exclusion of dead or autofluorescent cells (gate G3). From G3, CD4SP thymocytes (gate G4) are gated, from which two Treg cell precursors
(G5 and G6) and thymic Treg cells (G7) can be identified. Thymic Treg cells (G7) and CD4SP thymocytes (G4) can be subdivided into two subsets
of CD24highCD69+ immature (G8 and G10) and CD24dim/lowCD69− (G9 and G11) mature cells. Figures are based on thymocyte isolations from
Foxp3EGFPCreERT2ROSA26YFP mice.
CD16/CD32 and rat IgG, keep cell suspension in the dark at
4°C for 30 min.
 Add 500 µL 1× Permeabilization Buffer and centrifuge cell
suspension for 5 min with 300 × g at 4°C.
 Aspirate supernatant and repeat the above step.
 Resuspend cellular pellet with 200 µL 1× Permeabilization
Buffer, and cell suspension can be used for immediate anal-
ysis.
Materials: See 1.6.3.3: Isolation and analysis of Treg cells from
murine lymphoid organs
Pitfalls: Isolation and analysis of Treg cells from thymus
 The CD4SP gating is critical. On the one hand, CD4SP gating
needs to be strict; otherwise, contamination from CD4−CD8−
double-negative (DN) cells could substantially increase the fre-
quency of CD25+Foxp3− Treg cell precursors. Yet, the CD25
expression level within DN thymocytes is much higher than
within CD25+Foxp3− Treg precursors. On the other hand,
Treg cells have lower CD4 expression compared to their
CD4+Foxp3− Tcon counterpart. Thus, too strict gating can neg-
atively influence the frequency of Treg cells among CD4SP cells
(Figure 96).
 Mediastinal lymph nodes are located in proximity to the thymus
and can swell under inflammatory conditions. When removing
thymi from mice with local inflammation, particular caution
has to be paid to avoid “contamination” of the thymus material
with mediastinal lymph nodes.
Top tricks: Isolation and analysis of Treg cells from thymus
 A substantial portion of Treg cells found within the thymus
are Treg cells recirculating from the periphery [785]. These
recirculating cells can be identified as CCR6+CCR7− cells [786],
or more easily when using RAGGFP reporter mice. Only recently
developed tTreg cells are RAGGFP positive, while recirculating
Treg cells are RAGGFP negative.
 Not only αβ+ T cells but also γδ+ T cells and NKT cells develop
within the thymus. An extra dump panel for NK1.1+ and
TCRγ/δ+ cells results in higher specificity.
 Thymi will shrink upon aging. 6–10 weeks mice are most com-
monly used to study thymocytes. Younger or older mice may
result in lower numbers of Treg cells for analysis or sorting.
 Sacrificing mice with cervical dislocation can result in bleed-
ing into the thoracic cavity. Washing the blood-stained thymus
with PBS containing 30 µM EDTA removes the “contaminating”
blood.
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Summary Table
Treg cells in the murine thymus
T cell population Phenotype/subphenotype
G4: CD4SP thymocytes CD4+CD8−
G5: CD25+Foxp3− Treg cell
precursors
CD4+CD8−CD25+Foxp3−
G6: CD25−Foxp3+ Treg cell
precursors
CD4+CD8−CD25−Foxp3+
G7: Thymic Treg cells CD4+CD8−CD25+Foxp3+
G8: Immature thymic Treg
cells
CD4+CD8−CD25+Foxp3+
CD69+CD24high
G9: Mature thymic Treg cells CD4+CD8−CD25+Foxp3+
CD69−CD24dim/low
G10: Immature thymic CD4+
T cells
CD4+CD8−CD69+CD24high
G11: Mature thymic CD4+
T cells
CD4+CD8−CD69−CD24dim/low
1.6.3.2 Treg cells in murine spleen and lymph nodes. The fre-
quency of murine Foxp3+ Treg cells among CD4+ T cells usually
ranges from 10% to 20% in secondary lymphoid organs such as
spleen, skin-draining lymph nodes, and mesenteric lymph nodes
(Fig. 97). The Treg cell population in any secondary lymphoid
organ is a mixture of tTreg and pTreg cells, and Helios staining
is most frequently used to discriminate tTreg (Foxp3+Helios+)
and pTreg (Foxp3+Helios−) cells (Fig. 97). On a functional
basis, murine Treg cells in secondary lymphoid organs can be
subdivided into CD62L+CD44− naive-like and CD62L−CD44+
effector/memory-like Treg cells. In comparison to Foxp3− conven-
tional CD4+ T cells (Tcon cells), Treg cells in secondary lymphoid
organs display a higher frequency of cells with a CD62L−CD44+
effector/memory phenotype (Fig. 97).
Step-by-step sample preparation of Treg cells from spleen and
lymph nodes
 Sacrifice animals.
 Expose abdominal cavity.
 Remove spleen, skin-draining lymph nodes (axillary, brachial,
and inguinal lymph nodes), and mesenteric lymph nodes with
forceps.
 Place spleen, skin-draining lymph nodes, and mesenteric lymph
nodes on a 100 µm strainer separately.
 Use a syringe plunger to dissociate spleen and lymph nodes in
the presence of FCM buffer.
 Centrifuge cell suspension for 5 min with 300 × g at 4°C.
 Step for spleen only: Aspirate supernatant and resuspend
splenocytes pellet with 1 mL 37°C prewarmed erythrocyte lysis
buffer and incubate for 3 min at room temperature (RT). Add
9 mL FCM buffer and centrifuge cell suspension for 5 min with
300 × g at 4°C.
 Aspirate supernatant and resuspend cellular pellet with FCM
buffer.
 Filter cell suspension with a 30 µm strainer and count cell
numbers.
Protocol: Surface and intracellular staining
 Same as described in Treg cells in thymus section.
Materials: See 1.6.3.3: Isolation and analysis of Treg cells from
murine lymphoid organs
Pitfalls: Isolation and analysis of Treg cells from spleen and
lymph nodes
 Properly collecting lymph nodes requires practice. Taking out
fat instead of lymph nodes is one common mistake. Thus, for
practicing it is easier to use young mice with lower body fat
content.
 Erythrocyte lysis of spleen samples before staining is mandatory
to avoid high background staining or clogging of the cytometer.
Top tricks: Isolation and analysis of Treg cells from spleen and
lymph nodes
 Inspect collected lymph nodes in FCM buffer before dissociating
them. Lymph nodes should sink, while fat pads float.
 Besides Helios, Nrp-1 is a commonly used maker to distinguish
tTreg and pTreg cells. As Helios−Nrp-1− Treg cells in mesen-
teric lymph nodes are mainly RORγt+, this marker was also
claimed as a good tool to identify pTreg cells within the intesti-
nal system.
 For the sorting of intact Foxp3+ Treg cells for the collection
of RNA, various Foxp3 reporter mouse lines can be used to
avoid the fixation and permeabilization during the intracellular
staining.
 Stimulation of CD4+ T cells before staining will result in down-
regulation of CD3ε and CD4, which could complicate the gat-
ing (Fig. 97). Alternatively, CD90 instead of CD3ε can be
used.
Summary Table:
T cells in spleen and lymph nodes
T cell population Phenotype/subphenotype
G4: CD4+ T cells CD4+CD3ε+
G5: Tcon cells CD4+CD3ε+Foxp3−
G6: Treg cells CD4+CD3ε+Foxp3+
G7: tTreg cells CD4+CD3ε+Foxp3+Helios+
G8: pTreg cells CD4+CD3ε+Foxp3+Helios−
G9: effector/memory
Treg cells
CD4+CD3ε+Foxp3+CD44+CD62L−
G9: effector/memory
Tcon cells
CD4+CD3ε+Foxp3−CD44+CD62L−
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Figure 97. Phenotyping of Treg cells from
murine spleen and lymph nodes. (A) Gat-
ing strategy to identify Treg cells in the
spleen. From all events, lymphocytes can
be distinguished by their FSC/SSC prop-
erties (gate G0). Based on G0, doublets
are excluded twice (gates G1 and G2)
followed by exclusion of dead or aut-
ofluorescent cells (gate G3). From G3,
CD4+CD3ε+ T cells (gate G4) are gated,
from which Foxp3+ Treg cells (gate G6)
and Foxp3− Tcon cells (gate G5) can
be further identified. From G6, Helios+
tTreg (gate G7) and Helios− pTreg cells
(gate G8) are gated. Finally, a staining
for CD62L and CD44 on Treg cells (gate
G6, blue) and Tcon cells (gate G5, orange)
are shown together, with CD62L−CD44+
effector/memory cells being gated (gate
G9). (B and C) Gating strategy to identify
Treg cells in skin-draining lymph nodes
(B) andmesenteric lymphnodes (C). Gates
as described in panel A. Figures are based
on spleen and lymphnode isolations from
wild type mice.
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1.6.3.3 Materials. Isolation and analysis of Treg cells from
murine lymphoid organs
FCM buffer:
 1× PBS (Gibco, #10010-056)
 0.2% Albumin from bovine serum (Sigma–Aldrich, #SI A3912-
100G)
Erythrocyte lysis buffer:
 0.01 M KHCO3, 0.155 M NH4Cl, 0.1 mM EDTA
LIVE/DEADTM Fixable Blue Dead Cell Stain Kit, for UV excita-
tion (Thermo Fisher, #L23105)
Foxp3 Fix/Perm Buffer Set (Thermo Fisher eBiosciences, #00-
5523-00)
100 µm strainer (Greiner Bio, #542070)
30 µm strainer (Partec, #04-0042-2316)
Antibodies
Dilution Antibody Manufacturer
1:100 CD3ε APC-Cy7 (145-2C11) BioLegend
1:1000 CD4 HV500 (RM4-5) BD
1:1000 CD8α APC-Cy7 (53-6.7) BioLegend
1:200 CD25 BV711 (PC61.5) BioLegend
1:1000 CD44 PE-Cy7 (IM7) BioLegend
1:1000 CD62L FITC (MEL-14) eBioscience
1:1000 CD69 PE-Cy5 (H1.2F3) BioLegend
1:400 Foxp3 eFluor660 (FJK-16S) eBioscience
1:100 Helios PacificBlue (22F6) BioLegend
1:400 Rat IgG (11.5 mg/ml) JacksonImmuno
Research
1:400 Anti-mouse
CD16/CD32(1mg/ml)
Bioxcell
Mice
Foxp3EGFPCreERT2ROSA26YFP mice (C57BL/6 background) and
wild-type (WT) mice (BALB/c background) were bred under SPF
conditions in isolated, ventilated cages (Helmholtz Centre for
Infection Research, Braunschweig, Germany).
Cytometer
BD LSR FortessaTM 5-laser cytometer (UV, Violet, Blue, Yellow-
Green, Red)
Analysis
FlowJo Version 10.5.3 (Windows 10)
1.6.4 Treg cells in murine non-lymphoid tissues. Apart from their
fundamental immune regulatory function, Treg cells perform
highly specialized functions in non-lymphoid tissues [787]. They
have been shown to support tissue homeostasis and regenera-
tion, ranging from regulating metabolic parameters in the adi-
pose tissue [788–790] to potentiating tissue repair, e.g. in skeletal
muscles [791] or lung tissue [792]. In addition, Treg cells in non-
lymphoid tissues can manipulate tissue precursor cells to maintain
tissue homeostasis. For example, Treg cells can promote oligo-
dendrocyte progenitor cell differentiation and, thereby, myelin
regeneration in the central nervous system [793]. In the skin,
Treg cells promote hair follicle regeneration by augmenting hair
follicle stem cell proliferation and differentiation [794]. Several
publications identified the epidermal growth factor receptor lig-
and amphiregulin as a key factor of tissue Treg cells to maintain
homeostasis or induce tissue regeneration in a diverse set of tis-
sues, including lung, muscle, and brain [791, 792]. All data show
that these noncanonical Treg cell functions to directly or indirectly
promote organ homeostasis and tissue repair warrant a new def-
inition of Treg cells: Treg cells are not only regulatory as their
historic name implies, but subpopulations of Treg cells residing
in non-lymphoid tissues are tissue-supporting and have ability to
promote tissue regeneration. Recently, Treg cells residing in non-
lymphoid tissues were studied on an epigenetic and transcriptional
level, and a subset of Treg cells expressing the marker KLRG1 and
the IL-33 receptor ST2 was identified [795]. This subset of tissue-
resident Treg cells expressing ST2 was termed tisTregST2. This
population can be found in every organ and tissue analyzed so
far, vigorously increases in number upon IL-33 treatment in vivo,
and is dependent on the transcription factor Batf [795, 796].
TisTregST2 cells are strongly Th2-like biased (among others, high
expression of Gata-3) compared to other Treg cell populations
or Tcon cells found in the same tissue, and express the epider-
mal growth factor receptor ligand amphiregulin in high amounts
[795].
In the following, we describe the isolation and characterization
of these tisTregST2 cells from different murine organs, including
liver, skin, adipose tissue, lung, and colon.
1.6.4.1 Treg cells in murine liver. Step-by-step sample prepa-
ration: Isolation and analysis of Treg cells from liver
 Sacrifice animals.
 Expose thorax as well as abdominal cavity.
 Open inferior vena cava and inject PBS-filled syringe into
left ventricle of heart and flush with >10 mL PBS to clear
body circulation; liver should change from red color to
pale.
 Remove whole organ including right, left, caudate, and
quadrate lobes.
 Place pieces on metal strainers, add 5 mL liver digestion buffer
and cut liver lobes into small pieces as shown in Fig. 98A. A
syringe plunger is used to mash liver, and the metal strainer and
Petri dish can be flushed with additional 5 mL of liver digestion
buffer to collect all remaining cells and fragments.
 Digest sample for 25–40 min on a rotating shaker in incubator
(37°C) or in horizontal-shaking water bath preheated to 37°C.
 Add 50 mM EDTA-PBS to a final concentration of 2 mmol/L
and incubate for 2 min.
 Centrifuge for 5 min with 300 × g at RT.
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 Remove supernatant and resuspend cellular pellet in 10 ml of
40% Percoll-PBS solution; use a 5mL pipette to dissociate pellet
completely.
 Use pipetting aids to slowly and carefully place 10 mL of 80%
Percoll-PBS beneath cell suspension to establish a two-phase
system as shown in Fig. 98B. It is helpful to turn off the electric
force in the pipet aid to slowly release the 80% Percoll-PBS.
 Centrifuge for 20 min with 2000 × g at 4°C, acceleration off,
deceleration off. If successful, hepatocytes will float on top of
gradient and can be removed via aspiration. The middle phase
contains immune cells and should be collected in a separate
tube, while the pellet contains RBCs and other cell types and
can be discarded (Fig. 98B).
 Dilute middle phase with PBS to a volume of 50 mL.
 Centrifuge for 5 min with 300 × g at 4°C. Cellular pellet con-
tains lymphocyte fraction and, following RBC lysis, can be used
for immediate analysis or sorting.
Materials: See 1.6.5: Isolation and analysis of Treg cells from
murine non-lymphoid organs
Pitfalls: Isolation and analysis of Treg cells from liver
 Incomplete perfusion of the animal will result in RBC contam-
ination. Fast experimental protocols and fast animal handling
are required. Do not forget to open the vena cava prior to flush-
ing the circulation with PBS.
 Poor recovery after mashing step with large livers: add more
digestion buffer to completely wash filter mesh. Do not use
medium or PBS to wash filter mash since collagenase levels will
be diluted.
 Gradient setup fails and poor lymphocyte recovery after gra-
dient centrifugation: Slowly add 80% Percoll to solution and
use a pipetting aid without acceleration/deceleration to avoid
mixing 40% and 80% solutions. Handle tubes carefully to avoid
mixing both phases. Carefully balance the centrifuge to avoid
imbalance or rotor damage.
 Low CD4+ T cell content (<0.5%) in final preparation: Avoid
collecting cellular pellet after gradient centrifugation since it
contains unwanted cells. Completely remove top layer contain-
ing hepatocytes.
Top tricks: Isolation and analysis of Treg cells from liver
 If you analyze animals <12 days of age, the liver can be mea-
sured without the need of gradient centrifugation.
 Even after complete perfusion, an RBC contamination can
occur. Perform RBC lysis to deplete red blood cells.
 If you are unsure about the phases after gradient centrifugation
(top: hepatocytes; middle phase: lymphocytes and other cells;
pellet: other cells), harvest each phase and perform a T-cell
staining to calculate your yield.
 Stain for CD45 to discriminate bone marrow-derived cells such
as T or B cells from other cell types.
Summary Table
Treg cells in murine liver and murine spleen
T cell population Phenotype/subphenotype
G5: Liver Tcon cells CD8−CD19−MHCII−CD4+CD3ε+
CD25−Foxp3−
G6: Liver Treg cells CD8−CD19−MHCII−CD4+CD3ε+
CD25+Foxp3+
G7: Liver tisTregST2 cells CD8−CD19−MHCII−CD4+CD3ε+
CD25+Foxp3+Klrg1+ST2+
Gata-3+
G5: Spleen Tcon cells CD8−CD19−MHCII−CD4+TCRβ+
CD25−Foxp3−
G6: Spleen Treg cells CD8−CD19−MHCII−CD4+TCRβ+
CD25+Foxp3+
G7: Spleen tisTregST2 cells CD8−CD19−MHCII−CD4+TCRβ+
CD25+Foxp3+Klrg1+ST2+
Gata-3+
1.6.4.2 Treg cells in murine skin. Step-by-step sample prepa-
ration: Isolation of Treg cells from skin with or without
GentleMACS R©
 Sacrifice animals.
 Animals older than 10 days require hair removal via a small
animal electric shaver.
 Treat shaved skin with commercially available hair removal
creme and incubate for 3 min at RT.
 Wash off hair removal creme with tap water and try to remove
any remaining patches of hair.
 Separate hair-free skin from dorsal surface tissue and place in
10 mL skin digestion buffer.
 Cut into small pieces either in a 50 mL tube or directly in the
GentleMACS R© C tube as shown in Figure 99A.
 When using the GentleMACS R©, the sample can be incubated
using the program “37 C Multi H” for 90 min.
 When digesting manually, the sample is digested for 60 min on
a rotating shaker in the incubator (37°C) or in a shaking water
bath preheated to 37°C.
 Place sample on a metal strainer located in a petri dish and
use a syringe plunger to dissociate remaining tissue pieces (see
Fig. 99B).
 Filter sample via a 100 µm filter unit (Fig. 99C).
 Centrifuge for 5 min with 300 × g at RT.
 Filter sample via a 70 µm filter unit.
 Centrifuge for 5 min with 300 × g at RT.
 Filter sample via a 40 µm filter unit.
 Centrifuge for 5 min with 300 × g at RT.
 Stain sample for analysis or cell sorting.
Materials: See 1.6.5: Isolation and analysis of Treg cells from
murine non-lymphoid organs
Pitfalls: Isolation and analysis of Treg cells from skin
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 Filter clogged during filtration: Remove hair completely, either
by shaving or hair removal cream. Repeat hair removal if
patches of hair remain.
 Filter clogged during filtration: Filter samples sequentially as
listed in Fig. 99C.
 In case of abnormally high lymphocyte content/low Treg cell
percentage (<15%): Possible lymph node contamination. Avoid
collecting inguinal lymph nodes during separation of skin tissue
from dorsal surface tissue. A typically-sized patch of skin from
the back of a >100 day old animal contains not more than
5000–10 000 Foxp3+ Treg cells when applying the proposed
method, and Foxp3+ Treg cell frequency of CD4+ T cells is
usually above 40%.
 GentleMACS R© mechanical failure or tube squeaking sounds:
Cut skin into very small pieces using sharp scissors. When using
thick skin patches or large (>2 g) amounts of skin, recut skin
tissues during incubation on the GentleMACS R© machine. Use
more skin digestion buffer or distribute skin among more C
tubes if required.
 Being unable to find lymphocytes: It is sometimes tricky to
identify lymphocytes during flow cytometric analysis of skin.
Use gating strategy provided in Fig. 99D to identify T cells. If in
doubt, use additional T-cell markers (other than CD4) to clearly
identify the T-cell population, such as TCR-β, CD45, or CD90.
Be aware that CD4 staining is weak if you use the protocol
described above. It is helpful to use an autofluorescence-free
channel with high staining index (such as PE or APC) for CD4
staining.
 Poor sort purity or contamination with skin keratinocytes after
sorting: Use a double-sort approach (yield and four-way-purity)
to avoid contaminating sample with skin-resident cells. See top
tricks for more details.
 Machine clogging or no events: Wash machine and filter sample
again and re-acquire. Keep sample cool at 4°C and continuous
rotation (300 rpm).
Top tricks: Isolation and analysis of Treg cells from skin
 We were unable to perform pre-enrichment using magnetic
beads for murine skin-based samples. Still, because of the very
low frequency of Foxp3+ Treg cells as well as the high viscosity
of the resulting cell mixture in murine skin samples, enrichment
would be beneficial to decrease sorting and measurement time.
 Sorting bulk skin Treg cells can lead to poor recovery of cells
(low “sort efficiency”) and, based on the parameters of the sort-
ing instrument, also to contamination with skin keratinocytes
(aggregates with immune cells). Therefore, we propose a two-
step sorting protocol: first, a pre-enrich sort (sort strategy:
“yield”) where target cells are sorted into FCM buffer. Second,
the sample is re-acquired and sorted again with high purity
(sort strategy: “purity” or “4-way-purity”). Using this strategy,
skin samples can be sorted at high speed without losing many
target cells.
 For flow cytometric analysis, samples should be filtered again
immediately before acquisition. If acquisition takes more than
5 min, the sample should be filtered again to avoid a clogging
of the instrument. Samples should be cooled at 4°C to avoid
clogging.
 Fixing samples will generally increase the sample flow through
cytometers. Be careful when setting your FCS/SSC voltages to
include your target cells. Include a positive staining control
(e.g., splenocytes) to validate the panel and antibody staining
before acquiring skin cells.
Summary Table: T cells in murine skin
T cell population Phenotype/subphenotype
G5: Skin Tcon cells CD8−CD19−MHCII−CD4lowTCRβ+
CD25−Foxp3−
G7: Skin tisTregST2
cells
CD8−CD19−MHCII−CD4lowTCRβ+
CD25+Foxp3+Klrg1+ST2+Gata-3+
1.6.4.3 Treg cells in murine fat tissue. Step-by-step sample
preparation: Isolation of Treg cells from fat
 Sacrifice animals.
 Excise abdominal/epididymal fat pads (male mice) and move
into 10 ml fat digestion buffer in a 50 ml tube. Avoid collecting
the gonads.
 Cut fat pads into small pieces with scissors and digest for 40–45
min on a rotating shaker in the incubator (37°C) or in a shaking
water bath preheated to 37°C.
 Add EDTA-PBS to a final concentration of 2 mmol/L and incu-
bate for 2 min.
 Centrifuge for 5 min with 300 × g at RT.
 Remove supernatant containing fat cells and lipids and perform
erythrocyte lysis as described in spleen section.
 Stain sample for FCM or cell sorting (Fig. 100A).
Materials: See 1.6.5: Isolation and analysis of Treg cells from
murine non-lymphoid organs
Pitfalls: Isolation and analysis of Treg cells from fat
 Little abdominal/epididymal fat depots in abdominal cavity:
Animals might be too young (<10–12 weeks), sick, or fasting.
Gonadal fat depots increase with age, and so does the lym-
phocyte recovery. Gender also influences fat, with male mice
having larger depots.
 Abnormally low Treg cell frequency: Animals might be too
young. Frequency and total number change with age and/or
disease. In general, older animals have more Treg cells in their
abdominal/epididymal fat depots.
 Filter clogged and abnormal big pellet after digestion: Be care-
ful not to include gonads in your digestion. When using old
animals with large gonadal fat depots, use 20 mL of fat diges-
tion buffer per animal.
Top tricks: Isolation and analysis of Treg cells from fat
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 Older animals harbor bigger fat depot, and, in general, a higher
frequency and total number of Treg cells can be expected. Use
retired breeding animals for fat isolation.
 Treg cells from gonadal fat express Gata-3, while Tcon cells
express T-bet. This can serve as a quality control to detect con-
taminations.
Summary Table
T cells in fat
T cell population Phenotype/subphenotype
G5: Fat Tcon cells CD8−CD19−MHCII−CD4+TCRβ+CD25−
Foxp3−
G6: Fat Treg cells CD8−CD19−MHCII−CD4+TCRβ+CD25+
Foxp3+
G7: Fat tisTregST2
cells
CD8−CD19−MHCII−CD4+TCRβ+CD25+
Foxp3+Klrg1+ST2+Gata-3+
1.6.4.4 Treg cells in murine lung tissue. Step-by-step sample
preparation: Isolation and analysis of Treg cells from lung
 Sacrifice animals.
 Expose thorax as well as abdominal cavity.
 Open inferior vena cava and inject PBS-filled syringe into right
ventricle of heart and flush with >10 mL PBS to clear the lung
circulation; lung should change from reddish to colorless.
 Excise lungs and move into 10 mL lung digestion buffer using
a 50 ml tube.
 Cut lungs into small pieces with scissors and digest for 30–45
min on a rotating shaker in the incubator (37°C) or in a shaking
water bath preheated to 37°C.
 Filter lungs via a 100 µm filter unit into a new 50 mL tube.
Add PBS or DMEM to wash filter and use a syringe plunger to
dissociate all tissue pieces.
 Centrifuge for 5 min with 300 × g at RT.
 The cellular pellet contains lymphocyte fraction and can be
resuspended buffer in 500 µL MACS R© buffer following filtra-
tion.
 Add 20 µL Fc-blocking reagent (e.g., Miltenyi #130-092-575)
and incubate for 5 min at 4°C
 Add 5 µL CD25 mAb (e.g., Biolegend clone PC61) or CD4 mAb
(e.g., Biolegend clone RM4-5) and incubate for 10 min at 4°C.
 Add 500 µL MACS R© buffer (when using 1.5 mL tube) or 10 mL
MACS R© buffer (when using 15 mL tube).
 Centrifuge for 4 min with 800 × g at 4°C.
 Add 50 µL of magnetic-labeled beads in 500 µL MACS R© buffer
and incubate for 10 min at 4°C.
 Add 500 µL MACS R© buffer (when using 1.5 mL tube) or 10 mL
MACS R© buffer (when using 1 mL tube).
 Centrifuge for 4 min with 800 × g at 4°C.
 Filter sample and load onto primed magnetic column.
 Collect eluted cells and stain for sorting or analysis (Fig. 100B).
Materials: See 1.6.5: Isolation and analysis of Treg cells from
murine non-lymphoid organs
Pitfalls: Isolation and analysis of Treg cells from lungs
 Incomplete perfusion of the animal will result in RBC contam-
ination. Fast experimental protocols and fast animal handling
are required. Do not forget to open the vena cava prior to flush-
ing the circulation with PBS.
 Blood in the thoracic cavity: Do not use cervical dislocation to
avoid bleeding into the thoracic cavity. Rupture of the thoracic
vessels will make the perfusion more difficult.
 High CD25 or CD4-negative fraction following column-based
enrichment: Use Fc-blocking reagents and perform the proce-
dure at 4°C to avoid unspecific binding to beads and columns.
Top tricks: Isolation and analysis of Treg cells from lungs
 Be aware of the thymus. The thymus is located in the apex of the
heart and in relatively close proximity to the lung tissue; avoid
rupturing the thymus to avoid thymocyte contamination. If in
doubt, use CD4 and CD8 staining in separate channels to iden-
tify CD4+CD8+ thymocytes. There are almost no CD4+CD8+
cells in lung tissue, but they are the majority of cells in the
thymus.
 Be aware of the mediastinal lymph nodes. Lymph node contam-
ination can be identified by a strong decrease in the proportion
of lung tisTregST2 cells (lymph node: <1 %; lung: >10 %) and
a general increase in total T and B cell numbers.
Summary Table: T cells in the murine lung
T cell population Phenotype/subphenotype
G5: Lung Tcon cells CD8−CD19−MHCII−CD4+TCRβ+CD25−
Foxp3−
G6: Lung Treg cells CD8−CD19−MHCII−CD4+TCRβ+CD25+
Foxp3+
G7: Lung
tisTregST2 cells
CD8−CD19−MHCII−CD4+TCRβ+CD25+
Foxp3+Klrg1+ST2+Gata-3+
1.6.4.5 Treg cells in the murine colon tissue. Step-by-step sam-
ple preparation: Isolation and analysis of Treg cells from colon
with lamina propria dissociation kit and GentleMACS R©
 Sacrifice animals.
 Expose abdominal cavity and excise colon from appendix to
rectum; it is usually filled with feces (Fig. 101A).
 Remove feces and open colon longitudinally (Fig. 101B).
 Cut colon into 1 cm pieces (Fig. 101B) and wash three times
with predigestion buffer as described in the methods section
of the Miltenyi lamina propria dissociation kit (Miltenyi #130-
097-410).
 Digest samples in a GentleMACS R© C tube with respective col-
lagenase mixture for 25 min.
 Filter sample on a 100 µm filtration unit and mash using a
syringe plumber.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1642 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
 Use more PBS to flush the filter and the C tube.
 Centrifuge for 5 min with 300 × g at RT.
 Filter and transfer cells to 1.5 mL tube and in 500 µL MACS R©
buffer.
 Add 20 µL Fc-blocking reagent (e.g., Miltenyi #130-092-575)
and incubate for 5 min at 4°C
 Add 5 µL CD4 mAb (e.g., Biolegend clone RM4-5) and incubate
for 10 min at 4°C.
 Add 500 µL MACS R© buffer (when using 1.5 mL tube) or 10 mL
MACS R© buffer (when using 15 mL tube)
 Centrifuge for 4 min with 800 × g at 4°C.
 Add 50 µL of magnetic-labeled beads in 500 µL MACS R© buffer
and incubate for 10 min at 4°C.
 Add 500 µL MACS R© buffer (when using 1.5 mL tube) or 10 mL
MACS R© buffer (when using 15 mL tube).
 Centrifuge for 4 min with 800 × g at 4°C.
 Filter sample and load onto primed magnetic column.
 Collect eluted cells and stain for sorting or analysis
Materials: See 1.6.5: Isolation and analysis of Treg cells from
murine non-lymphoid organs
Pitfalls: Isolation and analysis of Treg cells from colon
 Few T cells in colon of young animals: T cell seeding starts
from day 10–15 after birth. Younger animals have no detectable
Foxp3+ Treg cell population in the colon.
 Column is clogged: use a large column (LS) for positive selec-
tion of T cells from colon.
 Poor CD25 staining: Use a tested clone for this protocol (e.g.,
Miltenyi clone REA568) or stain for Foxp3 intracellularly to
identify Treg cells.
Top tricks: Isolation and analysis of Treg cells from colon
 Feces can be removed from the intact colon by carefully squeez-
ing the colon with forceps.
 After each 20-min-digestion step in the incubator, the sam-
ple is vortexed. Filters can be reused until they are fully
clogged.
Summary Table
T cells in colon
T cell population Phenotype/subphenotype
G5: Colon Tcon cells CD8−CD19−MHCII−CD4+TCRβ+CD25−
Foxp3−
G6: Colon Treg cells CD8−CD19−MHCII−CD4+TCRβ+CD25+
Foxp3+
G7: Colon tisTregST2
cells
CD8−CD19−MHCII−CD4+TCRβ+CD25+
Foxp3+Klrg1+ST2+Gata-3+
As a reference, the tissue staining panels (Figs. 98–101)
were applied also on a spleen sample (Fig. 98D) from
the same animal. The population in gate G7 (tisTregST2:
CD8−CD19−MHCII−CD4+TCRβ+CD25+Foxp3+Klrg1+ST2+Gata-
3+) comprises less than 2% of all Treg cells found in lymphatic
organs. Non-lymphoid tissues showed a clear enrichment for
the tisTregST2 population, with organ to organ variation (liver:
26.4%, skin: 95.3%, abdominal/epididymal fat: 48.4%, lung:
11.5%, colon: 17.2% of all Foxp3+ Treg cells isolated from the
individual tissues) (Figs. 98–101). The frequency and number
of tisTregST2 cells is dependent on the age of the analyzed
animals. For example, the frequency of tisTregST2 cells in
abdominal/epididymal fat tissue can vary depending on the age
of the animals, with older animals showing higher frequencies.
In 20–30 weeks old male mice, the frequency of tisTregST2 cells
among all Treg cells isolated from the abdominal/epididymal fat
depot can be up to 95%.
1.6.5 Materials: Isolation and analysis of Treg cells from murine
non-lymphoid tissues.
FCM staining buffer
 Base medium 1× PBS
 1% FBS
MACS R© isolation buffer
 Base medium 1X PBS
 1% w/v BSA (Sigma–Aldrich #A4503)
 1 mM EDTA (Roth #X986.2)
EDTA-PBS 50 mM
 Base medium 1× PBS
 50 mM EDTA (Roth #X986.2)
Liver digestion buffer (10 mL per digestion)
 Base medium DMEM (Gibco #41965)
 1 mg/mL collagenase type IV (Sigma–Aldrich #C5138)
 20 µg/mL DNAse I (Roche #11284932001)
 5 mg/mL BSA (Sigma–Aldrich #A4503)
40% Percoll solution
 Base medium DI water
 40% Percoll (GE Healthcare #17-0891-01)
 1% PBS (from 10× PBS Gibco #14200-067)
80% Percoll solution
 Base medium DI water
 80% Percoll (GE Healthcare #17-0891-01)
 1% PBS (from 10X PBS Gibco #14200-067)
Skin digestion buffer (10 mL per digestion)
 Base medium DMEM (Gibco #41965)
 4 mg/mL collagenase type IV (Sigma–Aldrich #C5138)
 10 µg/mL DNAse I (Roche #11284932001)
 2% FBS
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Figure 98. Isolation and analysis of
Treg cells frommurine liver and spleen.
(A) Image of liver tissue pre-cut (left)
and after cutting (right) in a metal
sieve. After cutting, a syringe plunger
can be used to disseminate the tis-
sue. (B) Image of the preparation of a
liver suspension in the Percoll gradi-
ent (left). The bottom phase consists
of 80 % Percoll-PBS, the top phase of
40 % Percoll-PBS and the digested liver
cells. On the right, a representative
image of a sample after centrifugation
is shown. Three layers can be discrim-
inated: a top layer consisting mainly
of hepatocytes, the middle layer with
target cells, and a bottom layer with
unwanted cells. (C) Gating strategy to
identify tisTregST2 cells in liver. From
all events, a CD4-gate to identify T cells
can be drawn (gate G0). In the plot,
the smaller color-coded plots indicate
expression of CD3ε in the same SSC-A vs
CD4 plot. Presence of CD3ε+ cells in the
G0 gate can be appreciated. Based onG0,
lymphocytes can be identified by their
FSC/SSC properties (gate G1). Next, dou-
blets are excluded (gate G2) as well as
unwanted, dead or autofluorescent cells
(gate G3). From G3, CD4+CD3ε+ T cells
(gate G4) are gated, from which Treg
cells (gate G6) and Tcon cells (gate G5)
can be identified. Finally, Klrg1+ST2+
tisTregST2 (gate G7) are gated from Treg
cells (gate G6). A staining of Gata-3,
shown in the histogram, exemplifies
the expression of this marker in liver
Tcon cells (gate G5, orange, dotted line),
liver Klrg1+ST2+ tisTregST2 cells (gate
G7, red), and liver Klrg1−ST2− Treg cells
(gate G8, blue). In (D), the same gat-
ing strategy as described for liver is
applied to a spleen sample. In both tis-
sues, CD4+Foxp3+Klrg1+ST2+Gata-3high
tisTregST2 cells can be identified with
the proposed gating strategy. CD3ε or
TCRβ antibodies can beused. Figures are
based on liver digestions and spleen iso-
lations from Foxp3DTR, GFP animals.
Fat digestion buffer (10 mL per digestion)
 Base medium DMEM (Gibco #41965)
 1 mg/mL collagenase type II (Sigma-Aldrich #C6885)
 20 µg/mL DNAse I (Roche #11284932001)
 20 mg/mL BSA (e.g., Sigma A4503)
Lung digestion buffer (10 mL per digestion)
 Base medium DMEM (Gibco #41965)
 1 mg/mL collagenase type IV (Sigma-Aldrich #C5138)
 20 µg/mL DNAse I (Roche #11284932001)
 5 mg/mL BSA (e.g., Sigma A4503)
 GentleMACS R© C tube (Miltenyi #130-096-334)
 Lamina Propria Dissociation Kit (Miltenyi #130-097-410)
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Figure 99. Isolation and analysis of Treg cells from murine skin. (A) Representative image of skin tissue in digestion buffer after cutting with
scissors. Cutting can be performed directly in the GentleMACS R© C tube. (B) Image of the skin tissue after digestion. The sample is poured onto a
metal mesh and can be dissociated manually using a syringe plunger. (C) Sequential filtration workflow for skin samples. (D) Gating strategy to
identify tisTregST2 cells in skin tissue. From all events, a CD4-gate to identify T cells can be drawn (gate G0). In the plot, the smaller color-coded
plots indicate expression of Foxp3 in the same SSC-A vs CD4 plot. Presence of Foxp3+ cells in the G0 gate can be appreciated. Based on G0,
lymphocytes can be identified by their FSC/SSC properties (gate G1). Smaller plot shows FCS/SSC of all events without CD4 pre-gating. Next,
doublets are excluded (gate G2) as well as unwanted, dead or autofluorescent cells (gate G3). From G3, CD4+TCRβ+ T cells (gate G4) are gated, from
which Treg cells (gate G6) and Tcon cells (gate G5) can be identified. Finally, Klrg1+ST2+ tisTregST2 (gate G7) are gated from Treg cells (gate G6).
A staining of Gata-3, shown in the histogram, exemplifies the expression of this marker in skin Tcon cells (gate G5, orange, dotted line) and skin
Klrg1+ST2+ tisTregST2 cells (gate G7, red). Figures are based on skin digestions from Foxp3DTR, GFP animals.
 MACS R© separation columns, size L (Miltenyi #130-042-401)
 Anti-biotin ultrapure magnetic beads (Miltenyi #130-105-637)
 Anti-PE ultrapure magnetic beads (Miltenyi #130-105-639)
 Anti-APC magnetic beads (Miltenyi #130-090-855)
Antibodies
 1:100 CD8 APC-Cy7 (53-6.7)
 1:100 CD19 APC-Cy7 (6D5)
 1:200 MHCII APC-Cy7 (M5/114.15.2)
 1:500 Life/dead e780 (Thermo Fisher eBiosciences #65-0866-
14)
 1:100 CD4-PerCP-Cy5.5 or BUV-395 (RM4-5)
 1:100 TCRβ-BV 510 (H57-597)
 1:100 CD25 APC (PC61 for all tissues except colon)
 1:20 CD25 APC (REA568 for colon samples)
 1:100 IL-33R/ST2 BV 421 (DIH9)
 1:100 Klrg1 BV 711 (2F1)
 1:100 Foxp3 AF488 (FJK-16S)
 1:100 Gata-3 PE (16E10A23)
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 Flow cytometric phenotyping of cells across species and tissues 1645
Figure 100. Isolation and analysis of T cells from the murine fat and lung tissue. Gating strategy to identify Treg cells in fat (A) and lung (B) tissue.
From all events, a CD4-gate to identify T cells can be drawn (gate G0). Based on G0, lymphocytes can be identified by their FSC/SSC properties
(gate G1). Next, doublets are excluded (gate G2) as well as unwanted, dead or autofluorescent cells (gate G3). From G3, CD4+TCRβ+ T cells (gate G4)
are gated, from which Treg cells (gate G6) and Tcon cells (gate G5) can be identified. Finally, Klrg1+ST2+ tisTregST2 (gate G7) are gated from Treg
cells (gate G6). A staining of Gata-3, shown in the histogram, exemplifies the expression of this marker in Tcon cells (gate G5, orange, dotted line),
Klrg1+ST2+ tisTregST2 cells (gate G7, red), and Klrg1−ST2− Treg cells (gate G8, blue). Figures are based on lung and fat digestions from Foxp3DTR, GFP
animals.
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Figure 101. Isolation and analysis of Treg cells from themurine colon tissue. (A) Image of colon tissue after excision. The appendix is still attached
(left image) and should be removed (right image). (B) Image of the colon tissue after cleanup (left). Feces have been removed and the colon has been
cut longitudinally. The colon is then cut into 1 cm pieces (right) and can be washed. (C) Gating strategy to identify Treg cells in colon tissue. From
all events, a CD4-gate to identify T cells can be drawn (gate G0). Based on G0, lymphocytes can be identified by their FSC/SSC properties (gate G1).
Next, doublets are excluded (gate G2) as well as unwanted, dead or autofluorescent cells (gate G3). From G3, CD4+TCRβ+ T cells (gate G4) are gated,
from which Treg cells (gate G6) and Tcon cells (gate G5) can be identified. Finally, Klrg1+ST2+ tisTregST2 (gate G7) are gated from Treg cells (gate
G6). A staining of Gata-3, shown in the histogram, exemplifies the expression of this marker in Tcon cells (gate G5, orange, dotted line), Klrg1+ST2+
tisTregST2 cells (gate G7, red), and Klrg1−ST2− Treg cells (gate G8, blue). Figures are based on colon digestions from Foxp3DTR, GFP animals.
Foxp3 Fix/Perm Buffer Set (Thermo Fisher eBiosciences #00-
5523-00)
Mice
Foxp3GFP,DTR mice (C57BL/6 background) were bred in the
animal facility of the Regensburg University Hospital.
Cytometer
BD LSR FortessaTM 5-laser cytometer (UV, Violet, Blue, Yellow-
Green, Red)
BD LSRIITM 3-laser cytometer (blue-red-violet)
Analysis
BD FlowjoTM Version X (10.5.3 Mac OS)
1.7 Murine γδ T cells
1.7.1 Overview. In this section, we discuss the specific require-
ments to analyze γδ T cells by FCM. This includes general recom-
mendations, an overview of the specific tools available to study γδ
T cells by FCM, a detailed protocol to stain for a specific subset of
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γδ T cells, and a point-by-point protocol to isolate and analyze γδ
T cells from mouse ear skin. Protocols to isolate γδ T cells (and αβ
T cells) from the mouse intestine are given in a subsequent related
section.
1.7.2 Introduction. γδ T cells develop in the thymus together
with αβ T cells but rearrange a different T-cell receptor (TCR)
consisting of a TCR-γ and TCR-δ chain (see also Chapter VI Section
1.15 Human γδ T cells). These TCRγδ are not MHC restricted,
thus their antigen recognition does not rely on CD4 or CD8 co-
receptors, although themajority of mouse intestinal intraepithelial
γδ T lymphocytes (γδ iIELs) express the CD8αα dimer. Mouse γδ
T-cells comprise significantly different populations, and these γδ
T-cell subsets are typically grouped by the variable γ-chain (Vγ)
segments employed by their TCRγδ [797]. Alternatively, γδ T-cell
subsets may also be grouped according to γδ T-cell tissue location
or with respect to γδ T-cell function [798, 799].
1.7.3 γδ T cells in peripheral lymph nodes. FCM of γδ T cells is
technically not different to FCM of αβ T cells. However, γδ T cells
are up to 100-fold less frequent than αβ T cells in blood and
secondary lymphoid organs and therefore their detection faces
the usual challenges connected to identifying rare cell types, i.e.,
make sure to include all real γδ T cells but avoid false positive
events due to autofluorescence and unspecific staining. On the
other hand, γδ T cells can make up the majority of lymphocytes in
tissues such as the skin and the small intestinal epithelium.
1.7.3.1 Step-by-step sample preparation. A dedicated step-by-
step sample preparation protocol to obtain single cell suspensions
from peripheral lymphoid organs is described in the murine Treg
section (Chapter VI Section 1.6Murine Foxp3+ regulatory T cells).
Briefly, lymph nodes are collected and mashed through a cell
strainer or similar and filtered through or a piece of gaze (pore
size 70–100 µm) before adding FcBlock and staining with specific
mAbs.
1.7.3.2 Materials/ Specific tools for FCM of γδ T cells. There
are a number of mAb clones available for detection of γδ TCR
using specific Vγ and Vδ segments. Below is a list of commercially
available mAb clones (Table 21). However, be aware that several
conflicting nomenclatures exist for mouse (and human) Vγ and
Vδ segments, which can be misleading even for insiders to the
field. Please check online resources such as the IMGT website
(http://www.imgt.org) for further explanation. Here, we use the
so-called Heilig/Tonegawa nomenclature [800], while suppliers
like BD Bioscience or BioLegend utilize the Garman nomenclature
[801].
Two additional important, but not currently commercially
available mAb clones are F2.67 directed against Vγ7 by Pablo
Pereira (Institute Pasteur, Paris, France) [802], and the clone
17D1 directed against Vγ5 from Bob Tigelaar (Yale University,
New Haven, USA) [803]. Later, Christina Roark and colleagues
found that 17D1 was cross-reactive to Vγ6 under certain condi-
tions, see below [804].
1.7.3.3 Data analysis. Practically, faithful detection of γδ
T cells is warranted by gating on the lymphocyte area in the FSA
versus SSA plot, gating out doublets, exclusion of dead and auto-
fluorescent cells, followed by a positive gate according to the two
parameters expression of γδ TCR, best clone is GL3 [805] and
CD3ε in the same plot (Fig. 102A). If the experimental design and
equipment allow further parameters, it is advisable to gate out αβ
T cells (clone H-57) and eventually B cells (CD19 mAb) prior to
the GL3 versus CD3ε gate (Fig. 102B).
1.7.3.4 Pitfalls/top tricks. Furthermore, the Tcrd-H2BeGFP
reporter mouse [806], JAX Stock No. 016941, can serve to detect
γδ T cells independent of TCR expression on the cell surface
(e.g., after TCR downregulation following strong TCR activation
in vitro). Note that for visualizing γδ T cells in secondary lymphoid
organs or other tissues containing a large excess of αβ T cells over
γδ T cells in microscopy applications, the use of F1 heterozygotes
from Tcrd-H2BEGFP mice and Tcra–/– (B6.129S2-Tcratm1Mom/J,
JAX Stock No. 002116) will genetically exclude highly fluorescent
false-positive cells. In FCM applications it is sufficient to counter-
stain for TCRβ (Figure 103).
Notably, these Tcrd-H2BeGFP reporter mice were used to
demonstrate that in vivo application of the mAb clones GL3 and
UC7-13D5 does not lead to a depletion of γδ T cells, but rather
renders them invisible for flow cytometric detection due to TCR
downregulation [807]. However, a new genetic knock-in model
for diphtheria toxin-mediated conditional γδ T cell depletion will
circumvent these problems [808].
1.7.4 Intracellular cytokine staining for IL-17-versus IFN-γ-
producing γδ T cells.
1.7.4.1 Introduction. Recent studies suggested that discrete
subsets of γδ T cells; namely IFN-γ- and IL-17-producing γδ T cells,
develop and act as pre-activated effector cells. In particular, a
combination of the the surfacemarkers CD27, CD44, and Ly6C can
be used to indirectly discriminate between those subsets without
intracellular cytokine staining [809–811].
1.7.4.2 Step-by-step sample preparation. For Intracellular
cytokine staining, isolated cells are first stimulated ex vivo with
PMA (50 ng/mL, Calbiochem) and Iono (2 µg/mL, Invitrogen)
together with Brefeldin A (1 µg/mL, Sigma) for 3 h at 37°C.,
Next, stimulated cells are stained against extracellular surface
molecules. After fixation with BD Cytofix/Cytoperm solution for
20 min on ice and permeabilization with BD Perm/Wash buffer
for 10 min on ice according to the manufacturer’s protocol (BD
Fixation/Permeabilization Solution Kit), cells are stained for intra-
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Table 21. List of commercially available mAb clones directed against mouse Vγ and Vδ segments
Target
Garman nomenclature
(used by BD/Biolegend)
Heilig/Tonegawa
nomenclature Clone
Non-exclusicve list of
Supplierer(s)
pan γδ TCR GL3 many sources
pan γδ TCR UC7-13D5 BD Biosciences, Biolegend
pan γδ TCR REA633 (recombinant GL3) Miltenyi
Vγ3 Vγ5 536 Biolegend and BD Biosciences
Vγ1.1/Cr4 Vγ1 2.11 Biolegend, BD Biosciences
Vγ1.1/Vγ1.2 Vγ1/ Vγ2 4B2.9 Biolegend
Vγ2 Vγ4 UC3-10A6 Biolegend, BD Biosciences
Vδ1 TS8.2 Abcam
Vδ6.3 C504.17C Biolegend
Vδ6.3/2 8F4H7B7 BD biosciences
Vδ4 GL2 Biolegend and BD Biosciences
Vδ4 REA372 (recombinant GL2?) Miltenyi
cellular cytokines for 45 min on ice, washed once with PBS, and
analyzed.
1.7.4.3 Data analysis. Surface staining against CD27, CD44,
and Ly6C serves to discriminate activated γδ T cells with
an IL-17-producing effector phenotype (CD44high+CD27–) or
with an IFN-γ-producing effector phenotype (CD44high/intCD27+)
(Fig. 104).
1.7.5 Isolation of lymphocytes from mouse ear skin.
1.7.5.1 Introduction. The skin as well as several mucosal tis-
sues such as the intestine harbor strong and thick walls on their
surface, which are composed of different layers. Hence, isola-
tion of lymphocytes from these tissues warrants elaborated pro-
tocols. The skin consists of two primary layers, the keratinized
epidermis on the surface and the beneath dermis. In mice, lym-
phocytes of both, epidermal and dermal layers, can be prefer-
ably isolated from ear skin according to the following protocol
(Figure 105).
1.7.5.2 Step-by-step sample preparation and Materials.
- Separate dorsal and ventral sites of the ears
- Remove the cartilage from the ventral sites
Figure 102. Representative gating strategy for γδ T cells among live peripheral lymph node cells. (A) Representative contour plot for direct gating
of γδ T cells. (B) Representative contour plots for exclusion of αβ T cells before gating γδ T cells.
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Figure 103. Representative gating strategy for the identification of genuine γδ T cells in pLN based on the H2BeGFP fluorescence in Tcrd-H2BeGFP
mice and counterstaining with anti-TCRβ.
- Place the tissue (4 separated halves) in one 2 mL Eppendorf
tube containing 1900 µL digestionmedium and cut it into small
pieces
- Digest medium: RPMI (1810 µL)+ 2 mg/mL Col IV (Wor-
thington) (40 µL of 100 mg/mL) + 187.5 µg/mL DNAseI
(Roche)(150 µL of 2.5 mg/ml)
- Incubate at 37°C, 1400 rpm, 75 min in an Eppendorf Ther-
moMixer
- Add EDTA, final concentration approx. 37.5 mM (+150 µL 0.5
M EDTA)
- Incubate for additional 15 min at 37°C, 1400 rpm (Ther-
moMixer)
- Dissociate the remaining tissue by sucking up and down the
sample through an approximately 1–2 cm long 19G syringe
needle
- Filter the sample through a Cellstainer (70 µm) and separate
lymphocytes by density gradient centrifugation using Percoll-
gradients (40% and 70% Percoll solutions)
1.7.5.3 Data analysis. The skin harbors a high amount of
lymphocytes. While αβ T cells are barely present in the mouse
skin, the vast majority of lymphocytes are γδ T cells. γδ T cells
localized in the epidermis (dendritic epidermal T cells (DETC))
can be easily distinguished from γδ T cells present in the dermis
Figure 104. Dot plots show strategies to identify IL-17- versus IFN-γ-producing γδ T cells. γδ T cells from pLN of Tcrd-H2BeGFPmice were gated as in
Fig. 103 above. (A and B) Intracellular cytokine staining in correlation to CD44 (A) and CD27 (B) surface marker expression. (C and D) Representative
analyses of γδ T cells from pLN of Tcrd-H2BeGFP mice correlate CD27, CD44, and Ly6C surface staining to expression of Vγ4 and Vγ6.
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Figure 105. Preparation of ear skin. Schematic illustration of prepar-
ing ear skin for subsequent isolation of lymphocytes after enzymatic
digestion of the tissue.
due to their high TCR expression levels as detected by GL3 and
CD3 staining in (Figure 106).
1.7.6 The auxiliary Ab-assisted direct staining of Vγ6+ γδ T cells.
1.7.6.1 Introduction. Vγ6+ γδ T cells solely develop in embry-
onic thymus before birth, and later persist as long-lived self-
renewing lymphocytes in the skin dermis and in many mucosal
tissues such as the uterus or the tongue [812]. Vγ6+ γδ T cells
recently sparked a lot of interest because they rapidly produce
IL-17 and thus contribute to bacterial homeostasis and clear-
ance, but also enhance autoimmunity and inflammatory diseases
[813, 814]. The detection of Vγ6+ γδ T cells requires a combined
staining of GL3 together with the unconjugated rabbit 17D1 IgM
Ab followed by a secondary staining with labeled anti-rabbit IgM.
A validated staining protocol for the identification of Vγ6+ γδ
T cells works as follows.
1.7.6.2 Step-by-step sample preparation and Materials.
Prepare single cell suspension
Block cells with 5% Fc receptor block 5 min on ice
Stain cells in antibody mix with extracellular
surface markers and GL3 diluted in PBS
containing 3% FCS and 4mM EDTA, hre
called FCM buffer
15 min on ice
Add unconjugated 17D1 (final dilution 1:25)
and mix thoroughly (for example: add 4µl
of 17D1 to 100µl cell suspension)
30 min on ice
Wash cells with flow cytometry buffer
Stain cells with labeled secondary anti-IgM
Antibody
diluted in FCM buffer 30 min on ice
Wash cells with flow cytometry buffer
1.7.6.3 Data analysis. Importantly, in skin, clone17D1 not
only stains Vγ6+ γδ T cells in combination with GL3, but also
Figure 106. Representative gating strategy of murine ear skin lymphocytes stained with DAPI, anti- CD45, TCRαβ (H57), γδ TCR (GL3), and CD3 to
detect dermal γδ T cells (CD3+ and GL3+) and epidermal γδ T cells (DETC, CD3hi, and GL3hi).
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Figure 107. Representative gating
strategies of Vγ4+ (red) and Vγ6+
(green) γδ T cells in peripheral lymph
nodes (pLN) (A) as well as epidermal
Vγ5+ γδ T cells (red) and dermal Vγ4+
and Vγ6+ γδ T cells (blue) in ear skin (B)
GL3+CD3+ γδ T cells among TCRß– cells
were separated into different γδ subsets
by staining with anti-Vγ4 as well as
17D1 followed by conjugated anti-IgM
to detect Vγ6+/Vγ5+ γδ T cells.
recognizes the Vγ5 gene segment expressed in dendritic epidermal
T cells (DETC). However, dermal Vγ6+ γδ T cells and epidermal
Vγ5+ γδ T cells can be easily distinguished because of the very
high TCR levels levels in Vγ5+ γδ T cells leading to bright GL3 and
CD3 staining. The epidermis solely contains Vγ5+ γδ T cells, while
the dermal compartment comprises high frequencies of Vγ4+ and
Vγ6+ γδ T cells (Fig. 107).
It follows that an additional counterstaining of 17D1+ skin
T cells with a specific anti-Vγ5mAb clone 536, see Table 21, would
further help to discriminate between dermal and and TCRhigh epi-
dermal T cells (Fig. 107B and not shown). In contrast, peripheral
lymph nodes lack Vγ5+ γδ T cells. While Vγ6+ γδ T cells only
represent a small population in peripheral lymph nodes, a large
proportion of γδ T cells are Vγ4+ γδ T cells and Vγ6–Vγ4– γδ T cells
(mainly Vγ1+ T cells).
1.8 Murine NKT cells
1.8.1 Overview. Murine natural killer T (NKT) cells were orig-
inally defined by their co-expression of surface markers charac-
teristic for T cells (i.e., the TCR) and NK cells (e.g., NK1.1 in
C57BL/6 mice) [815, 816]. This chapter focuses on the pheno-
typic characterization of so-called murine invariant iNKT cells,
which express an invariant Vα14Jα18 TCRα chain and a lim-
ited set of TCRβ chains with a preference for Vβ8, Vβ7, and
Vβ2 [817, 818]. iNKT cells recognize lipids, such as α-galactosyl
ceramide (αGalCer), in the context of the nonclassical MHC
molecule CD1d [819]. As a consequence, iNKT cells can be unam-
biguously identified by surface staining using CD1d tetramers
loaded with αGalCer or its derivatives, such as PBS-57 [820, 821]
(Fig. 108). Subphenotyping of developmental stages in the thy-
mus and effector subsets based on surrogate surface markers and
key transcription factors is described.
1.8.2 Introduction. Development of iNKT cells diverges at the
CD4+CD8+ double-positive stage of T-cell development. Selection
of iNKT cells is mediated by cortical thymocytes rather than epithe-
lial cells. Similar to other unconventional T cells, iNKT cells are
selected by strong TCR signals in a process referred to as agonist
selection [822]. iNKT cells, with the notable exception of some
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Figure 108. (A) Basic gating strategy formurine
thymic iNKT cells. (B) Basic gating strategy
for thymic iNKT cells following magnetic-bead
enrichment. Sample was additionally stained
with Zombie Aqua viability dye and Abs against
lineage markers. Numbers adjacent to gates
indicate frequency of parent population.
tissue-resident subsets, express and are dependent on the proto-
typical transcription factor for innate-like T cells, PLZF (encoded
by Zbtb16) [823, 824]. Intrathymic development of iNKT cells
has originally been described to progress through four pheno-
typically distinct stages (stage 0–3), characterized by differen-
tial expression of the surface markers CD24, CD44, and NK1.1
(in C57BL/6 mice) as well as cell size [825–827] (Fig. 109A).
More recent studies showed that stage 3 iNKT cells represent
long-term resident cells in the thymus [828, 829]. The thymus of
young adult C57BL/6 mice contains around 3–6 × 105 iNKT cells,
corresponding to an overall frequency of 0.3–0.5% of all
thymocytes.
More recently, iNKT cells have been categorized into functional
subsets based on expression of type 1, 2, or 17 cytokines [830]
(Fig. 109B). Like their conventional T-cell counterparts, NKT1
cells are characterized by expression of the transcription factor
Figure 109. Murine thymic iNKT cell
populations. (A) Magnetic-bead
enriched iNKT cells from C57BL/6 mice
were additionally stained with anti-
bodies against CD44, NK1.1, and CD24.
The upstream gating strategy is shown
in Fig. 108. (B) Magnetic-bead enriched
iNKT cells from C57BL/6 mice were
additionally stained intracellulary with
Abs against PLZF, T-bet, and RORγt.
The upstream gating strategy is shown
in Fig. 108. (C) Magnetic-bead enriched
iNKT cells from C57BL/6 mice were
additionally stained with antibodies
against CD122 and CD4. Numbers
adjacent to gates indicate frequency
of parent population. The upstream
gating strategy is shown in Fig. 108.
Boldface S0, S1, S0/1, S2, S3 adjacent to
gates indicate developmental stages.
Boldface p, 1, 2, and 17 adjacent to
gates indicate NKTp, NKT1, NKT2, and
NKT17 subsets, respectively.
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Figure 110. Murine peripheral iNKT cell populations. (A) Magnetic-bead enriched iNKT cells from C57BL/6 mice were additionally stained intra-
cellulary with Abs against PLZF, T-bet, and RORγt. The upstream gating strategy is analogous to that shown in Fig. 108. (B) Magnetic-bead enriched
iNKT cells from C57BL/6 mice were additionally stained with Abs against CXCR3 and CD4. Numbers adjacent to gates indicate frequency of parent
population. The upstream gating strategy is analogous to that shown in Fig. 108. Boldface 1, 2, and 17 adjacent to gates indicate NKT1, NKT2, and
NKT17 subsets, respectively.
T-bet, NKT17 cells express RORγt, whereas NKT2 cells are most
frequently characterized by absence of expression of both tran-
scription factors while simultaneously expressing very high levels
of PLZF (See Chapter VI Section 1.1 Murine T cells). The proto-
typic type 2 transcription factor GATA-3 is variably expressed in
all iNKT cells and cannot be employed for discrimination of NKT2
cells. As a consequence, in the thymus PLZFhi NKT cells contain
both, precursors (NKTp) and NKT2 cells. These cells can be further
distinguished by differential expression of CCR7 (NKTp) and PD-1
(NKT2) [828]. Notably, relative proportions of the three NKT sub-
sets vary widely betweenmouse strains with BALB/cmice showing
a strong bias towards NKT2 cells in the thymus, whereas thymi
in C57BL/6 mice predominantly contain NKT1 cells [830]. To cir-
cumvent intracellular staining for transcription factors, discrimi-
nation of NKT-cell subsets can also be achieved by analysis of sur-
face expression of CD4 and CD122 (thymus) (Fig. 109C) or CXCR3
(periphery) (Fig. 110C).
Outside the thymus, iNKT cells can be found in lymphoid and
as tissue-resident cells in non-lymphoid organs with distinct sub-
set composition for each organ (for review [831, 832]). In mice
(but not humans) up to 40% of all mononuclear cells in liver
constitute iNKT cells [815, 821]. The vast majority of these cells
are of the NKT1 type. Upon stimulation iNKT cells rapidly produce
large amounts of cytokines essentially according to their transcrip-
tion factor profile with the notable exception of IL-4, which can
be produced by NKT1 and NKT2 cells. Similar to other uncon-
ventional T cells, iNKT cells are considered innate-like, because
they can be stimulated both by cognate ligand via the TCR and
in a non-cognate manner through LPS or cytokines like IL-12 and
IL-18 [833, 834]. Whereas stimulation through the TCR results
in rapid release of multiple cytokines, non-cognate stimulation
results mostly in production of IFN-γ.
NKT cells serve a vast variety of functions shaped by their
distinct tissue distribution (reviewed in ref. [831, 835]. Thus,
NKT cells may protect from infection in lung and liver, but may
exacerbate inflammatory conditions and asthma. Although being
comparatively rare in intestinal tissues, NKT cells contribute to
tissue homeostasis and to shaping the intestinal microbiota. Other
roles in tissue homeostasis comprise regulation of T-cell develop-
ment and egress from the thymus through IL-4 as well as pro-
tective functions in type 1 diabetes and graft-versus-host disease
[836].
1.8.3 Step-by-step sample preparation. Cell isolation: Single-cell
suspensions of whole lymphoid organs (thymus, spleen, lymph
nodes) are generated by crushing organs through a 70 µm fil-
ter. RBCs are lysed (spleen only) using Qiagen RBC Lysis Solu-
tion according to the manufacturer’s instructions. For lympho-
cyte isolation from the lung and liver, mice are euthanized and
liver/lungs are immediately perfused with PBS. Lymphocytes
are then isolated using standard procedures for solid organs or
using commercially available kits, for instance as described in
ref. [837].
Surface staining: Following incubation with Fc block (anti
mouse CD16/32, clone 2.4G2) cells are stained using APC-
conjugated CD1d-PBS-57 or CD1d-unloaded (background control)
tetramers for 30 min at room temperature in FCM buffer [838].
Cells are washed once in FCM buffer followed by Ab staining for
surface markers for 10 min at 4°C. In order to minimize back-
ground, it is pivotal to perform lineage exclusion by staining for
the following markers: B220, CD19, CD11b, CD11c. Dead cells
are excluded using the Zombie Aqua Fixable Viability kit as per
manufacturer’s instructions (Biolegend).
Magnetic-bead enrichment: Following CD1d-PBS57-APC
tetramer staining, iNKT cells may be enriched using anti-APC
magnetic microbeads following the manufacturer’s instructions
(Miltenyi Biotec). See also Chapter IV Section 1.4 Magnetic pre-
enrichment for high-resolution detection and analysis of rare cell
populations.
Intracellular staining: To analyze transcription factor expres-
sion, magnetic-bead-enriched CD1d-PBS-57 tetramer+ cells from
lymphoid organs are stained for surface markers and viability
as described above. Samples are then fixed and permeabilized
using the Foxp3/Transcription Factor Staining Buffer Set (eBio-
science) as per the manufacturer’s instructions, following which,
cells are stained for intracellular transcription factors for 30 min
or overnight.
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1.8.4 Materials.
FCM buffer: PBS, 3% FCS
RBC lysis buffer (Qiagen)
Zombie Aqua Fixable Viability kit (Biolegend)
anti-APC magnetic microbeads (Miltenyi Biotec)
Foxp3/Transcription Factor Staining Buffer Set (eBioscience)
Tetramers: Mouse CD1d-PBS-57-APC (NIH tetramer core
facility, Atlanta, USA)
Unloaded mouse CD1d-APC (NIH tetramer core
facility, Atlanta, USA)
Antibodies: CD16/32 mAb (clone 2.4G2)
CD19 mAb (clone 6D5)
Anti-B220 (clone RA3-6B2)
CD11b mAb (clone M1/70)
CD11c mAb (clone N418)
Anti-TCRβ (clone H57-597)
CD4 mAb (clone GK1.5)
Anti-NK1.1 (clone PK136)
CD44 mAb (clone IM7)
CD24 mAb (clone M1/69)
Anti-PLZF (clone Mags.21F7)
Anti-T-bet (clone O4-46)
Anti-RORγt (clone Q31-378)
Anti-CXCR3 (CD183, clone CXCR3-173)
CD122 mAb (clone TM-b1)
1.8.5 Pitfalls. Simultaneous staining of cells with tetramer and
anti-TCRβ is possible. However, due to distinct staining conditions,
it may result in different staining intensities. CD24 Ab staining is
sensitive to EDTA. Distribution of iNKT cell subsets varies between
organs and also between mouse strains. For instance, in liver
iNKT1 cells constitute the predominant iNKT cell subset, whereas
mesenteric lymph nodes predominantly contain iNKT2 cells [839].
Furthermore, BALB/c mice display a strong bias towards iNKT2
cells when compared to C57BL/6 mice [830].
1.8.6 Top tricks. iNKT cells are a rare population of T cells.
Therefore, for some downstream analyses it is advisable to per-
form enrichment using magnetic beads (see also Chapter IV Sec-
tion 1.4 Magnetic pre-enrichment for high-resolution detection
and analysis of rare cell populations). We and others have found
that differences in frequencies of iNKT cells in mouse strains with
iNKT cell deficiency, such as miR-181a/b-1-deficient mice, com-
pared to wild-type mice are essentially retained upon enrichment
via tetramers [840]. The underlying reason remains elusive but
may be attributed to lower affinity of tetramers when compared
to Ab–antigen interaction. We and others have employed Rag-GFP
reporter mice to delineate developmental progression of iNKT cells
in the thymus. Such a mouse model may help to further resolve
NKT cell precursors and mature NKT cell populations in the thy-
mus [828, 841].
1.8.7 Summary table.
Murine NKT cell
population
(TCRβ+CD1d-PBS-
57/αGalCer
tetramer+)
Phenotype/subphenotype
Thymus
Stage 0 CD44–NK1.1–CD24hiFSChi
Stage 1 CD44–NK1.1–CD24loFSClo
Stage 2 CD44+ NK1.1–
Stage 3 CD44+NK1.1+
NKT1 CD122+PLZFloT-bet+RORγt–
NKT2 CD122–CD4+PLZFhiT-
bet–RORγt–PD-1+CCR7–
NKT17 CD122–CD4–PLZFintT-bet–RORγt+
Periphery
NKT1 CXCR3+PLZFloT-bet+RORγt–
NKT2 CXCR3–CD4+PLZFhiT-bet–RORγt–
NKT17 CXCR3–CD4–PLZFintT-bet–RORγt+
1.9 Murine mucosal-associated invariant T (MAIT) cells
1.9.1 Overview. Murine mucosal-associated invariant T cells
(MAIT) share many features with iNKT cells. They express a semi-
invariant TCR comprised of an invariant Vα19Jα33 TCRα chain,
preferentially paired with Vβ6 and Vβ8. MAIT cells recognize
vitamin B metabolites, such as 5-(2-oxopropylideneamino)-6-D-
ribityl-aminouracil (5-OP-RU), in the context of the nonclassical
MHCmoleculeMHC class I-related protein 1 (MR1) [842]. Despite
their virtually simultaneous discovery with NKT cells, understand-
ing of MAIT cell biology is substantially more limited for two main
reasons [843, 844]: (i) MAIT cells are rare in mice and (ii) MR1-
tetramer reagents have only recently been developed [845, 846]
(Fig. 111). This section describes the characterization of MAIT cell
subsets based on MR1-tetramers, surface markers, and key tran-
scription factors. In addition, magnetic-bead based enrichment of
MAIT cells is described.
1.9.2 Introduction. The study of MAIT cells in mice is of
profound interest, mostly because MAIT cells constitute a very
abundant population in various human tissues, comprising
almost 10% of all blood T cells and 20–40% of all liver T cells
(See also Chapter VI Section 1.17 Human mucosal-associated
invariant T (MAIT) cells). In contrast, in C57BL/6 mice, thymus
contains only around 5000 MAIT cells, corresponding to 0.002%
of all thymocytes. Comparably low frequencies are also found in
peripheral lymphoid organs.
Intrathymic development of MAIT cells shares some similar-
ities with that of NKT cells: MAIT cells are selected on cortical
CD4+CD8+ double-positive thymocytes. They progress through
phenotypically distinct precursor stages (stages 1–3) characterized
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Figure 111. A) Basic gating strategy for
thymicMAIT cells. B) Basic gating strategy
for thymicMAIT cells followingmagnetic-
bead enrichment. Numbers adjacent to
gates indicate frequency of parent popula-
tion. Stainingswith control tetramerMR1-
6-FP-APC are displayed as well.
by differential expression of CD24 and CD44 [847] (Fig. 112A).
Development of MAIT cells depends on the transcription factor
PLZF and miRNA, in particular miR-181a/b-1 [840, 841, 847].
These similarities are further underscored by characterization of
T-bet+RORγtlo MAIT1 and T-bet–RORγthi MAIT17 cell transcrip-
tomes, which within matching tissues are virtually identical to
those of NKT1 and NKT17 cells, respectively [832]. MAIT cells
also display a large degree of tissue residency in non-lymphoid
organs [832] (Fig. 112B). In addition to these similarities between
MAIT cells and iNKT cells, there are a number of critical differ-
ences. MAIT cell development is characterized by a later onset
of PLZF expression at developmental stage 3 only, whereas at
Figure 112. Thymic MAIT cell populations. A) Magnetic-bead enriched MAIT cells from C57BL/6 mice were additionally stained with antibodies
against CD44 and CD24. Upstream gating was performed as shown in Fig. 111. B) Magnetic-bead enriched MAIT cells from C57BL/6 mice were
additionally stained intracellulary with antibodies against PLZF, T-bet and RORγt. Numbers adjacent to gates indicate frequency of parent popu-
lation. Upstream gating was performed as shown in Fig. 111. Boldface S1, S2, S3 adjacent to gates indicate developmental stages. Boldface 1 and
17 adjacent to gates indicate MAIT1 and MAIT17 subsets, respectively.
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least some NKTp already express high levels of PLZF [828, 847].
Furthermore, no MAIT2 cells have been described and the ratio
between MAIT1 and MAIT17 cells is geared toward the latter,
whereas NKT1 cells are more abundant than NKT17 cells. It
remains an open question whether MAIT cells undergo agonist
selection in a similar manner as NKT cells.
Analysis of in vivo function of MAIT cells in immunity is com-
promised by their scarcity in mice. In addition, many Vα19Jα33
TCRα+ T cells in Vα19Jα33 TCR transgenic mice lack expression of
PLZF, indicating that they do not represent true MAIT cells [846].
These obstacles may be overcome by employing B6-MAITCAST con-
genic mice that contain high frequencies of MAIT cells due to
increased usage of Vα19 in TCR gene rearrangements [848].
This mouse model revealed that MAIT cells alleviated urinary
tract infections. MR1-deficient mice are more susceptible to a
broad range of bacterial infections (for review see ref. [849]).
Given that MAIT cells have also been implicated in clearance
of viral infections suggests that antigen-independent stimula-
tion via cytokines, such as IL-12 and IL-18, is also possible, in
keeping with their innate-like nature and overall similarity to
iNKT cells.
1.9.3 Step-by-step sample preparation.
1.9.3.1 Cell isolation. Single-cell suspensions of whole lym-
phoid organs (thymus, spleen, lymph nodes) are generated by
crushing organs through a 70-µm filter. RBCs are lysed (spleen
only) using Qiagen RBC Lysis Solution according to manufac-
turer’s instructions. For lymphocyte isolation from the lung and
liver, mice are euthanized and liver/lungs are immediately per-
fused with PBS. Lymphocytes are then isolated using standard
procedures for solid organs or using commercially available kits
for instance as described in ref. [837]. It is advisable to pool cell
suspensions from at least three animals to obtain sufficient cell
numbers for analysis.
1.9.3.2 Surface staining. Following incubation with Fc block
(anti-mouse CD16/32, clone 2.4G2) cells are first stained using
APC- or PE-conjugated MR1-5-OP-RU or MR1-6-FP (background
control) tetramers for 40 min at room temperature in FCM buffer
[850]. Cells are washed once in FCM buffer followed by Ab stain-
ing for surface markers for 10 min at 4°C. In order to minimize
background, it is pivotal to perform lineage exclusion by staining
for the following markers: B220, CD19, CD11b, and CD11c. Dead
cells are excluded using the Zombie Aqua Fixable Viability kit as
per manufacturer’s instructions (Biolegend).
1.9.3.3 Magnetic-bead enrichment. Due to the scarcity of
murine MAIT cells in typical laboratory strains it is strongly
advised to bead-enrich MAIT cells prior to downstream analy-
sis. Bead enrichment should be performed in between tetramer
staining and staining for additional surface markers. Single-cell
suspensions are stained with biotinylated CD19 mAb and anti-
B220 Abs. B cells are then depleted using streptavidin microbeads
as per the manufacturer’s instructions (Miltenyi Biotec). Follow-
ing MR1-5-OP-RU-APC tetramer staining, MAIT cells are enriched
using anti-APC magnetic microbeads following the manufacturer’s
instructions (Miltenyi Biotec). See also Chapter IV Section 1.4
Magnetic preenrichment for high-resolution detection and analy-
sis of rare cell populations.
1.9.3.4 Intracellular staining. To analyze transcription fac-
tor expression, magnetic-bead-enriched MR1-5-OP-RU tetramer+
cells from lymphoid organs are stained for surface markers and
viability as described above. Samples are then fixed and perme-
abilized using the Foxp3/Transcription Factor Staining Buffer Set
(eBioscience) as per the manufacturer’s instructions, followed by
antibody staining for 30 min or overnight.
1.9.4 Materials.
FCM buffer: PBS, 3% FCS
RBC lysis buffer (Qiagen)
Zombie Aqua Fixable Viability kit (Biolegend)
streptavidin microbeads (Miltenyi Biotec)
anti-APC magnetic microbeads (Miltenyi Biotec)
Foxp3/Transcription Factor Staining Buffer Set (eBioscience)
Tetramers: Mouse MR1-5-OP-RU-APC/-PE (NIH
tetramer core facility, Atlanta, USA)
Mouse MR1-6-FP-APC (NIH tetramer core
facility, Atlanta, USA)
Antibodies: CD16/32 mAb (clone 2.4G2)
CD19 mAb (clone 6D5)
Anti-B220 (clone RA3-6B2)
CD11b mAb (clone M1/70)
CD11c mAb (clone N418)
Anti-TCRβ (clone H57-597)
Anti-NK1.1 (clone PK136)
CD44 mAb (clone IM7)
CD24 mAb (clone M1/69)
Anti-PLZF (clone Mags.21F7)
Anti-T-bet (clone O4-46)
Anti-RORγt (clone Q31-378 or B2D)
1.9.5 Pitfalls. MAIT cells constitute an extremely rare cell pop-
ulation, rendering subset analysis prone to errors based on back-
ground staining (see Chapter V Section 1 Rare cells—General
rules). This difficulty is exacerbated in the analysis of genetically
modified mice with developmental defects in the MAIT cell lin-
eage. To minimize background, it is pivotal to include lineage
markers in a dump channel and/or enrich prior to downstream
analysis. B cells in particular show a high degree of nonspecific
binding of the MR1 tetramer (both 5-OP-RU and 6-FP loaded).
Simultaneous staining of cells with tetramer and anti-TCRβ is pos-
sible. However, due to distinct staining conditions it may result in
different staining intensities. CD24 antibody staining is sensitive
to EDTA.
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1.9.6 Top tricks. In order to overcome problems associated with
low frequencies of MAIT cells, it is generally recommended to
enrich for MR1-5-OP-RU-tet+ cells for subset analysis whenever
possible; see also Chapter IV Section 1.4 Magnetic pre-enrichment
for high-resolution detection and analysis of rare cell popula-
tions. Notably, it has been demonstrated that magnetic-bead-
based enrichment via tetramers essentially retains differences
between wild-type frequencies and reduced MAIT-cell frequencies
observed in genetically modified mice [841, 847]. The underly-
ing mechanism remains unclear, but may be related to the rel-
ative inefficiency of tetramer-based enrichment, which in turn
may be due to lower affinity of tetramer when compared to
antibody-mediated binding. Furthermore, it is absolutely essen-
tial to exclude non-T lineage cells, most notably B cells, during
gating to limit background staining. It is also advisable to include
nonbinding MR1-6-FP tetramers as background controls. Finally,
for exact quantitation of MAIT cells, dual tetramer staining using a
combination of MR1-5-OP-RU-APC and PE labeled tetramers may
help to reduce background [841]. We and others have employed
Rag-GFP reporter mice to delineate developmental progression of
MAIT cells in the thymus. Such a mouse model may help to further
resolve MAIT cell precursors and mature MAIT cell populations in
the thymus [828, 841].
1.9.7 Summary table.
Murine MAIT cell population
(Lin–TCRβ+MR1-5-OP-RU
tetramer+)
Phenotype/subphenotype
Thymus
stage 1 CD24+CD44–CCR7–PLZF–
stage 2 CD24–CD44–CCR7+PLZF–
stage 3 CD24–CD44+CCR7–PLZFhi
MAIT1 T-bet+RORγtlo
MAIT17 T-bet–RORγthi
Periphery
MAIT1 T-bet+RORγtlo
MAIT17 T-bet–RORγthi
1.10 Murine intestinal intraepithelial T cells
1.10.1 Overview. In this section, we describe protocols to isolate
and analyze murine intestinal intra-epithelial lymphocytes (iIELs)
and lamina propria lymphocytes (LPLs) by FCM. In particular, the
protocol iIEL isolation and most of the subsequent flow cytometric
analysis applies similarly to αβ and γδ iIELs, which are very similar
cell types.
1.10.2 Introduction. The intestinal epithelium constitutes one
of the greatest surface barriers in mammals and is in continu-
ous contact with the (gut luminal) environment. Composed by
a mucosa, the intestine wall is made up of primary two layers,
namely a one cell layer epithelium and the underlying lamina pro-
pria [851, 852]. In addition, the mouse small intestine contains
five to seven Peyer’s patches in anti-mesenteric position, which are
excised and removed during the protocol below, and numerous
smaller aggregates of immune cells called cryptopatches and iso-
lated lymphoid follicles, which will be largely included within the
fraction of lamina propria lymphocytes. Continuously exposed to
environmental cues and highly susceptible for pathogen assault,
the intestine bears sophisticated and complex immune cell net-
works specific to each of the compartments [853]. In order to study
the immune cells resident in both compartments of the murine
intestine, a refined isolation of intra-epithelial lymphocytes (IELs)
and lamina propria lymphocytes (LPLs) is advised according to
the following protocols.
1.10.3 Step-by-step sample preparation of lymphocytes from the
mouse small intestine.
1.10.3.1 Isolation of IELs.
1. Preheat the IEL isolation medium at 37°C at the water bath
(a) IEL isolation medium: 1 mM DTT + 10 µM KN-62
(stock at 50 mM) [854] + complete T cell medium (35
mL/sample)
(b) Complete T cell medium—RPMI 1640 + 10% FBS +1%
Penny-strep + 1% NEAMM +0.1% β- mercapto-ethanol
+ 1%HEPES 1M +1% Sodium Pyruvate
2. Harvest SI into ice cold PBS
3. Flush the intestine with ice cold PBS with a syringe and a
gavage needle until it’s clean.
4. Carefully remove fat and the Peyer’s patches
5. Open longitudinally and clean it again in a petri dish in ice
cold PBS. Transfer it to a 50 mL falcon tube (n1) in ice with
PBS
6. Vortex the tubes to further clean the intestine
7. Transfer the tissue to a new clean 50 mL falcon (n2) con-
taining 10mL of the pre-warmed IEL isolation medium. Note
that some protocols recommend to cut the small intestine into
smaller pieces (sized 0.5–2 cm), which may help to avoid the
formation of knots or clews.
8. Shake the tube in the vortex for 30seconds
9. Incubate the 50 mL falcon tubes at 37°C and 220 rpm for 15
min. (inside plastic beakers—4–5 tubes–or in a falcon tube
support fixed to the shaker plate)
10. After incubation vortex each tube for 10 s
11. Transfer the solution to a new 50 mL tube (n3) containing
15–20 mL of ice cold complete T cell medium. If you prefer
to cut the small intestine into pieces (see point 6), than you
should use a cell strainer here to retain the tissue.
12. Repeat steps 5–9 for two more times (using the same tube -
n2).
13. Wash the intestine one last time with 10 mL of cold com-
plete T cell medium and a kick vortex. Transfer the wash
to the respective tubes (n3). For the LPL isolation keep the
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Figure 113. Representative gating strategy for TCRγδ+ population analysis of (A) murine small intestine intraepithelial lymphocytes (IEL) and (B)
lamina propria (LPL). After isolation, lymphocytes were stainedwith Zombie (Live/Dead-Biolegend), CD45 (104 -Biolegend), Tcrß (REA318 -Miltenyi),
TCRγ/δ (GL3 -Biolegend), CD8α (53-6.7 -Biolegend), Vγ7 (F2.67 - provided by P. Pereira: Institut Pasteur, Paris, France), Vδ6.3 (C504.17C -eBioscience),
Vδ4 (GL2 -Biolegend) for the IEL cell suspension A and Vγ1 (2.11 -Biolegend) and Vγ4 (UC3-10A6 -Biolegend) for the LPL cell suspension.
intestines in a falcon tube on ice and proceed with the LPL
protocol.
14. Centrifuge the tubes (n3) at 1250 rpm for 10 min at 4°C
15. Aspirate the supernatant
16. Resuspend the pellet in 4mL of the 40% Percoll in complete
T cell medium (5 mL per sample) and transfer to a 15 mL
tube
17. Wash the 50 mL tube with 1 mL of the 40% Percoll solution
and transfer to the same 15 mL tube
18. Under lay the 80% Percoll in complete T cell medium (3 ml
per sample) and centrifuge the tubes at 2400 rpm for 30min
at RT (1 up and 1 down)
19. Remove the waste on top and recover the pinkish/white ring
in-between the two phases. Place it in another falcon contain-
ing 3–5 mL of the complete T cell medium or MACS R© Buffer
and top it up to 5mL
20. Centrifuge the samples for 10 min at 1250 rpm 4°C
21. Proceed to staining
1.10.3.2 Isolation of LPLs.
1. Prewarm the Digestion Medium in the water bath at 37°C
(a) Digestion medium: DNAse I 125 µg/mL (stock 10
mg/mL) + Collagenase D 250 µg/mL (stock 50 mg/mL)
+ Complete T cell Medium (32 mL/ sample)
2. After line 12. on IEL isolation protocol transfer the intestines
into a petri dish and cut the tissue into smaller pieces with
curved scissors (0.1cm).
3. Transfer the intestine to a 50 mL tube (n4) containing the
10mL digestion medium (at 37°C).
Figure 114. Representative gating strategy and analysis of A TCRαβ+ murine small intestine intraepithelial lymphocytes (IEL) and B lamina propria
(LPL). After isolation, lymphocytes were stained with Zombie (Live/Dead - Biolegend), CD45 (104- Biolegend), Tcrß (REA318 - Miltenyi), TCRγ/δ (GL3
- Biolegend), CD8α (53-6.7- Biolegend), CD8β (YTS156.7.7 - Biolegend) and CD4 (GK1.5 - Biolegend).
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4. Just like for the IEL isolation protocol: Incubate the 50mL
falcon tubes at 37°C and 220 rpm for 15 min. (inside plastic
beakers—4–5 tubes or in a falcon tube support fixed to the
shaker plate)
5. After incubation, with a plastic transfer-pipet pipet up and
down the solution containing the intestine.
6. With the same transfer-pipet transfer the solution and filter it
through a 70µm cell strainer placed on new 50mL tube (n5)
containing ice cold complete T cell Medium + 100µL of 4mM
EDTA.
7. Collect the tissue in the cell strainer and repeat the procedure
in steps 2–5, two more times (using the same tube n4).
8. After filtering the last time, with a syringe lid (green) smash
the pieces of tissue left behind in the strainer adding some
more 4°C complete T cell medium.
9. Centrifuge the tubes (n5) at 1250 rpm for 10 min at 4°C
10. Aspirate the supernatant
11. Resuspend the pellet in 4 mL of the 40% Percoll solution in
complete T cell medium (5 mL per sample) and transfer to a
15 mL tube
12. Wash the 50 mL tube with 1 mL of the 40% Percoll solution
and transfer to the same 15 mL tube
13. Under lay the 80% Percoll solution in complete T cell medium
(3 mL per sample) and centrifuge the tubes at 2400 rpm for
30 min at RT (1 up and 1 down)
14. Remove the waste on top and recover the pinkish/white ring
in-between the two phases. Place it in another falcon contain-
ing 3–5 mL of the complete T cell medium or MACS R© Buffer
and top it up to 5 mL
15. Centrifuge the samples for 10 min at 1250 rpm 4°C
16. Proceed to staining
1.10.4 Materials.
1.10.4.1 Reagents.
 Dithiothreitol (DTT) (Sigma–Aldrich, cat # 43816)
 KN-62 – Selleckchem, cat. number: S7422
 RPMI 1640 (Gibco, cat # 11875093)
 FBS (Sigma, cat # F7524)
 Penny-strep (Gibco, cat #: 1514-122)
 MEM Non-Essential Amino Acids solution (MEM NEAA) 100X
(Gibco, cat # 11140050)
 βmercapto-ethanol (Sigma, cat # M3148)
 HEPES (Sigma, cat # H0887)
 Sodium Pyruvate (Gibco, cat # 11360-039)
 Percoll (GE Healthcare, cat # 17-0891-01)
 PBS 1× (Gibco, cat # 1419-09)
 DNAse (Roche, cat # 11284932001)
 Collagenase D (Roche, cat # 1108886601)
 EDTA (Roth, cat # 8043.4)
 MACS R© Buffer – PBS 1X, 3% FBS, 5mM EDTA
1.10.4.2 Antibodies.
Antigen Company Clone
Catalog
number
CD45.2 Biolegend/
Miltenyi
104/104-2 109836/
130-103-787
CD4 Biolegend GK1.5 100453
CD8α Biolegend 53-6.7 100742
CD8ß Biolegend YTS156.7.7 126615
TCRß Miltenyi REA318 130-104-811
TCRδ Biolegend GL3 118120
Vδ4 BD Bioscience GL2 745116
Vδ6.3 eBioscience C504.17C 555321
Vγ1 Biolegend 2.11 141108
Vγ4 Biolegend UC3-10A6 137706
Vγ7 provided by P.
Pereira: Institut
Pasteur, Paris,
France
F2.67 -
Viability dye
(Zombie)
Biolegend - 423102
1.10.5 Data analyses of mouse iIELs and LPLs. The intestinal
mucosa harbors lymphocytes, which are responsible not only for
its protection but also to maintain integrity. Scattered along the
intestinal epithelia IELs are a heterogeneous population of T cells.
Distinguished by their development and origin, IELs can be divided
in two populations: the “natural” and the “induced” IELs. Derived
from conventional αß T cells expressing CD4 (TCRαß+CD4+) and
classical CD8αβmolecules (TCRαß+CD8αß+), “induced” IELs relo-
cate in the intestine mucosal tissue after cognate antigen engage-
ment in the periphery and accumulate over time [853]. On the
other hand, “natural” IELs differentiate in the thymus and charac-
terized by their TCRs ability to recognize self-antigens. Composed
of both γδ T cells and αβ T cells the large majority of “natural” IELs
express the homodimer CD8αα but neither CD4 or CD8αβ [855]
(Figs. 113A and 114A). Moreover, acquisition of surface markers
during development such as CD103 (αE integrin), α4β7 and CCR9
ensure homing and tissue residency of IELs [856]. In addition,
“natural” CD8αα+ IELs display a chronically activated phenotype
which can be translated by the expression of some activationmark-
ers such as CD69, CD122, and CD44 [857].
Interestingly, γδ T cells homing in the small intestine display a
biased expression of TCRγ chains according to their localization.
While γδ IELs are mostly Vγ7+, γδ T cells that home in the γδ LPLs
express a broader variety of TCRγ chains (Figure 113) [797, 802].
Whereas the small intestine epithelium is enriched in “uncon-
ventional” CD8αα+ γδ T cells, approximately 60% of all lympho-
cytes (Figure 114A), the lamina propria is mostly composed of
conventional αß T cells expressing CD8αß and CD4 (Figure 114B)
[855]. Thereby, frequencies of CD4+ αß T cells within the iIEL
preparation, and CD8αα+ αß T cells within the LPL preparation
serve as reliable indicators of the level of unavoidable cross con-
tamination during the isolation process.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1660 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
1.10.6 Pitfalls.
Be cautious to not exceed the incubation times point 8 (IEL) and
point 3 (LPL) as this would decrease viability and yield of the
protocols.
1.10.7 Top tricks.
Adding the KN-62 reagent is helpful to support the viability of the
cells once isolated, but does not increase the yield.
Do not omit the DTT or try to replace it with beta-mercaptoethanol.
Some IEL isolation protocols suggest to use HBSS medium, which
we did not find helpful as compared to RPMI-based complete
T cell medium.
Follow advises to pre-warm the isolation and digestion media and
to use chilled PBS for cleaning the intestine.
1.11 Human CD4 and CD8 T cells
1.11.1 Overview. The use of FCM allows for high resolution
delineation of T cell heterogeneity. Different features of the
remarkable heterogeneity of memory, but also seemingly na¨ıve,
T cells can be addressed depending on the questions raised. T cell
heterogeneity can be delineated by addressing surface markers
or intranuclear transcription factors indicative for differentiation
stages, chemokine receptors to address homing capacities, and
production of cytokines to assess functional stages. Depending on
the resolution required for monitoring T cell heterogeneity best is
to combine multiple of these aspects.
1.11.2 Introduction. The body is under constant threat of
pathogen attack. Microbes and viruses lurk in the environment
and are evolutionary adapted to seize every opportunity to invade
the system. The network of cells that make up the immune system
works tightly together to protect against novel but also persis-
tent pathogens. If pathogens manage to get through the body’s
physical barriers the first line of immunological defense is made
up of innate immune cells. Innate cells are rapidly activated by
pathogen-associated molecules in a nonantigen specific way. As
a consequence, innate cells can react equally well to a variety of
pathogens. Simultaneously, innate cell activation also paves the
way for the second line of immunological defense by presenting
antigen processed peptides, which primes the adaptive phase of
the T-cell response. After priming in the secondary organs, T cells
migrate to the affected tissue where they execute cytotoxicity and
other effector functions. In addition, antigen-specific T-cell mem-
ory is formed. T-cell immunity is complex and there are an increas-
ing number of subsets defined by differentiation stage, function,
and cellular location. In the last decades, FCM proved itself to be
the key technology to study heterogeneity among human T-cell
subsets. However, as the options for multicolor FCM panel design
emerged due to technical innovation, this went hand-in-hand with
the increasing complexity to define T-cell subsets. As new T cell
Table 22. A four-dimensional model to address T-cell differentiation
stages
Subset Expression
Number Name CD27 CD45RA CCR7 CD28
1 TN + + + +
2 TCM + – + +
3 Early + – – +
4 Intermediately + – – –
5 Early-like – – – +
6 TE RA- – – – –
7 TE RA+ – + – –
subsets are defined at increasing rates, it is virtually impossible
to be complete. Hence, in this section we will review the best-
established cellular markers that can be measured to shed light on
these complexities.
Conventional human T cells are a subpopulation of lympho-
cytes that can be characterized by the expression of a T-cell recep-
tor (TCR), through which they can recognize peptides presented
in the context of HLA-molecules. The conventional TCR is com-
posed of a transmembrane alpha- and beta-chain heterodimer that
is embedded in the cell membrane in combination with the CD3
protein complex. In the thymus, T cells mature and develop into
two main cell lineages of CD4+ and CD8+ single positive T cells
that are released as naive cells, bearing either an αβ-TCR or γδ-
TCR, into the circulation (Fig. 115). The lack of expression of
any of these markers identifies a third fraction of T cells in the
periphery. These so called double-negative T cells (DN) are a
legitimate component of the immune system but remain poorly
understood [858]. In the periphery, large numbers of na¨ıve T cells
(TN) survey the secondary lymphoid tissues and blood for cognate
antigen. In response to antigen exposure, TN start to proliferate
and differentiate rapidly into large numbers of effector and mem-
ory precursor T cells. Following pathogen clearance, the majority
of effector cells die while the memory precursor cells develop into
long-lived memory T cells [696, 859]. Although the precise model
of T-cell differentiation has not been fully deciphered, two mod-
els, progressive versus asymmetric differentiation, are currently
discussed that explain how T cells diversify into effector and mem-
ory subsets. Despite this discussion a consensus was reached about
markers that define naive and memory T-cell subsets [860]. Mark-
ers that can be used to phenotypically differentiate both CD4+
and CD8+ TN, effector, and memory cells are two of the four iso-
forms of the CD45 family. While TN and effector T cell (TE RA+)
express the CD45RA molecule, both the central memory (TCM)
and the effector type RA- (TE RA-) cells preferentially express
CD45R0 and lack CD45RA, CD45RB, and CD45RC. To identify
TN the CD45RA marker should be combined with minimally one
additional marker. Markers that can be used include the L-selectin
CD62L, which guides T cells to the lymph nodes. Expression of
this marker can only be honestly assessed using freshly isolated
cells, as cryopreservation results in a profound decrease of CD62L
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Figure 115. Gating of CD4+ and CD8+ T cells in peripheral blood. Lymphocytes are identified on based of the FSC and SSC. Single cells are
discriminated from doublets by plotting the pulse width and height against each other for both the SSC and FSC. CD3+ T cells are gated and
excluded from apoptotic cells by viability dye. Including dead cells can result in large errors because of their property to bind nonspecifically
to antibody conjugates. Although not applied here, in the same channel other cell types may be excluded by using a DUMP channel, meaning
a channel that contains all cellular markers in one color that should be excluded e.g. Abs against CD14 (monocytes), CD19, and CD21 (B cells).
Peripheral blood ratios of CD4+ and CD8+ T cells vary from donor to donor. A normal CD4:CD8 ratio is between 1 and 2. Low frequencies of double
negative CD3+CD4−CD8− cells are common and contain populations of NKT cells.
expression [861]. In addition the homing marker CCR7, costimu-
latory molecules CD27 and CD28 and adhesionmolecule CD31 are
used to define TN. Although the preferred marker to identify TN
appears redundant it is important to realize that little differences
may be observed by using different markers. Furthermore, there
will be small populations of na¨ıve-like but differentiated T cells
not accounted for that require the use of specific additional mark-
ers to be identified among na¨ıve T cells. These include regulatory
CD4+ T cells (Treg), stem cell memory T cells (Tscm), and virtual
memory T cells (TVM) [862].
Figure 116. A 4D model to address T-cell differentiation stages. At least seven stages of T-cell differentiation can be distinguished for peripheral
blood derived CD8+ T cells by using the markers; CD45RA, CD27, CD28, and CCR7. Phenotyping and gating of T cells in peripheral blood according
to backbone described in Figure 115.
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Figure 117. Adhesion, chemokine and cytokine receptor expression identify up to eight functional subsets within the human CD4+ memory pool.
Peripheral blood derived CD4+ T cells can be divided between naı¨ve, cytotoxic, and eight different T-helper subsets based on the surface expression
of (A) CCR4, CCR6, CXCR3, CXCR5, CX3CR1, CD28, and CD161 and (B) production of IFN-γ, IL-4, IL-10, IL-17, IL-21, and IL-22. For detection cells were
stimulated with Ionomycin and PMA in the presence of BFA and MN. Phenotyping and gating of T cells in peripheral blood according to backbone
described in Fig. 115.
Table 23. Gating on naive T cells
Subset Expression
Number Name CD27 CD45RA CCR7 CD28
8 Naive CD4 + + + +
1.11.3 CD4 T-cell differentiation. To date, the most appreci-
ated model to define CD4+ T-cell differentiation stages relies
on the differential expression of adhesion and chemokine recep-
tors (Fig. 117A, Tables 23 and 24). Naive CD4+ TN can be rec-
ognized by the mutual expression of CD45RA and CD27 com-
bined with a bright CCR7 staining. Below we describe a model
by which eight different antigen-experienced CD4+ T cell sub-
sets can be distinguished. Type 1 helper (TH1) cells are critical
for cell-mediated immunity as they produce vast amounts of the
anti-viral IFN-γ (Fig. 117B, Table 25). TH1 cells can be identi-
fied by the expression of CXCR3, which guides these cells to the
infected tissues. Other chemokine receptors expressed by TH1 are
CCR5 and CXCR6 [863]. While TH1 cells are critical for cell-
mediated immunity, CD4+ TH2 cells are traditionally considered
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Figure 118. Effector CD8+ T-cell differentiation during acute infection using KLRG1 and CD127. In humans four different effector populations can
be identified during acute infection based on the expression of KLRG1, CD127, CD45RA, and CD27. Phenotyping and gating of T cells in peripheral
blood according to backbone described in Fig. 115.
to support activation of other leucocytes such as B cells and are
associated with the production of the cytokines IL-4, IL-5, and
IL-13 (Fig. 117B, Table 25). However, latest insights suggest that
TH2 are not the principal B helper cells but are crucial for IL-
5 mediated activation of eosinophils. TH2 cells are enriched in
the CCR4 positive fraction and some express the surface marker
CRTH2 [864]. TH2 can be further distinguished by the variable co-
expression of other chemokine receptors including CCR3, CCR6,
CCR8, and CCR10 [865]. Caution is required when using CCR4
as expression is shared by TH17 and TH22 cells. Differentiation
of T cells into TH1 and TH2 subsets is controlled in a bipha-
sic model by the transcription factors T-bet and GATA binding
Table 24. Identification of CD4+ T cell subsets by surface marker expression
Subset Expression
Number Name CCR6 CD161 CXCR3 CCR4 CCR10 CCR3 CD28 CX3CR1 CXCR5
1 TH1 – + –
2+5 TH2 – – +
4 TH9 + + – +
3+5 TH17 + + – +
4 TH17/TH1 + + + –
2+5 TH22 + – + +
6 Cytotoxic CD4 – +
5 Tfh +
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Figure 119. T-cell subsets as identified by intracellular staining of transcription factors and cytolytic molecules. Peripheral blood derived CD3+
T cells are divided between CTL and TH cells. (A) CTL can be identified by the mutual expression of GZMB and Perforin. (B) CTL but also TH1 cells
can be identified within the CD8 and CD4 lineage by the expression of T-bet and further divided by the expression of Eomes. (C) Hobit expression
strongly correlates with T-bet expression in CD8+ T cells. (D) Treg cells can be identified among the CD25+CD4+ T cells by the expression of FoxP3
and Helios. Phenotyping and gating of T cells in peripheral blood according to backbone described in Figure 115.
protein 3 (GATA3) [720, 866]. T-bet has been shown to antagonize
GATA-3, the master regulator differentiation and maintenance of
TH2 cells [867]. In recent years, TH subsets have been identified
that differ from the traditional TH1 and TH2 subsets by the prefer-
ential production of IL-9 (TH9), IL-17 (TH17), and IL-22 (TH22)
(Fig. 117B, Table 25); multiple functions have been attributed
to the IFN regulatory factor 4 (IRF4) driven TH9 cells of which
a significant fraction expresses CCR3, CCR6, and CXCR3 [868],
and the pro-inflammatory TH17 cells play an important role in
pathogen clearance of extracellular pathogens at barrier sites. In
Figure 120. Detection of cytokine production and degranulation after stimulation of T cells. Peripheral blood T cells were stimulated for 4 h with
Iono and PMA or medium control in the presence of BFA and MN. (A) Stimulated CD8+ and CD4+ T cells were stained for expression of IFN-γ
and IL-2. (B) TNF-α production was captured in combination with degranulation of stimulated CD8+ T cells as detected by capture of CD107.
Phenotyping and gating of T cells in peripheral blood according to backbone described in Fig. 115.
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Table 25. Identification of CD4+ T cell subsets by cytokine production
Subset Expression
Number Name IL17A IL21 IFNƴ IL22 IL10 IL4
4 Th1 – – +
1 Th2 – +
2 Th17 +
7 reg Th17 + – +
8 TH17/TH1 + + –
5 Th22 – + –
3 Tfh – + –
6 Treg – – +
humans, TH17 cells can be identified by the mutual expression
of CCR6, and CD161 [869]. The TH17 lineage can be further
divided into more or less cytotoxic subsets based on the selective
expression of CXCR3 (TH17/TH1) and CCR4, respectively [870].
Several studies have demonstrated that a fraction of TH17 can
also secrete IFN-γ besides IL-17 [870–872] (Fig. 117B, Table 25).
These cells are generally referred to as TH17/TH1 cells. More
recently a third subset of TH17 was characterized that harbored
regulatory T cell features. These cells can be identified by the
production of IL-10, which can be also produced by subsets of
TREG, referred to as Type 1 regulatory (TR1) cells, and rare
effector CD4 T cells (Fig. 117B) [873–876]. Differentiation of
TH17 cells is driven by the expression of RAR-related orphan
receptor γ t (RORγt) which controls IL-17 transcription [721].
In addition, the skin-homing TH22 cells appeared to be regu-
lated by the aryl hydrocarbon receptor (AHR) transcription factor
and can be identified by the mutual expression of CCR6, CCR4,
and CCR10 [877, 878]. Finally, a decade ago a specific subset of
TH cells was discovered that resided in B-cell areas of follicular
regions in secondary lymphoid tissues. Consequently, these cells
were named follicular helper cells (TFH) and are identified by the
constitutive expression of the chemokine receptor CXCR5. Since
their discovery multiple TFH and TFH-like circulating cells have
been characterized based on the expression of programmed cell
death protein 1 (PD-1), CXCR3, CCR6, and the secretion of IL-21
(Fig. 117B, Table 25) [879]. TFH differentiation is orchestrated by
the transcription factor B-cell lymphoma 6 (BCL6) and is elemen-
tary for the activation of B cells in germinal centers and are there-
fore crucial for the induction of humoral immune responses [880].
The relationship between follicular BCL6+ TFH and circulating
TFH-like cells is still largely unclear. Finally, CD4+ T cells can
also directly mediate viral clearance and suppress tumor growth
through cytotoxic function. Loaded with cytotytic molecules such
as Granzyme B and perforin these cells can be identified by the
surface expression of the Fractalkine receptor CX3CR1 and the
lack of CD28 (Fig. 117A, Table 24) [881].
1.11.4 CD8+ T-cell differentiation. Several markers are proposed
in combination with CD45RA/R0 to precisely define phenotypi-
cally different CD8+ T-cell subsets. Among these markers is CD27,
a member of the TNF receptor family that promotes survival of
T cells, CCR7, a chemokine receptor that mediates LN homing,
and the co-stimulatory molecule CD28, which is required for
T-cell activation and survival (Fig. 116, Table 22) [882–885].
mAbs directed against these markers are widely available and
conjugated to plenty of different fluorescent dyes that enables
broad application in various multicolor phenotyping panels. The
4D model to address T-cell differentiation stages starts with TN
(CD27+CD28+CCR7+CD45RA+). After priming TN differentiate
through early-differentiated (CD27+CD28+CCR7−CD45RA−),
early-like (CD27−CD28+CCR7−CD45RA−), and inter-
mediately differentiated (CD27+CD28−CCR7−CD45RA−)
T cells to give rise to TE RA+ (CD27−CD28−CCR7−
CD45RA+), TE RA- (CD27−CD28−CCR7−CD45RA−) and
TCM (CD27+CD28+CCR7+CD45RA−) cells. TE RA- are memory
cells that in contrast to TCM lack constitutive expression of CCR7.
In healthy individuals without any clinical signs of viral infection,
from now on referred to as steady state, naive and early differenti-
ated type form the most abundant circulating CD8+ T-cell subsets.
In humans that are chronically infected with Cytomegalovirus
(CMV) or HIV the effector type RA+ also contributes substantially
to the CD8+ T cell compartment composition. Similar phenotypic
heterogeneity exists in the CD4+ T cell compartment although
subdivisions of differentiation stage based on the expression of
CD28 and CCR7 are not generally recognized. However, although
effector type CD4+ T cells are virtually absent during steady state,
increasing evidence suggests that cytolytic CD4+ T cells play an
important role during infections and these cells are appreciated
to lack CD28 expression [881, 886].
In multiple well established models of CD8+ T cell differen-
tiation during acute infection, expression of the IL-7 receptor α-
chain (CD127) is used to discriminate between the short-lived
effector cells (SLEC) and the memory-precursor effector cells
(MPEC) [887]. Although mice and human differ significantly in
life span and pathogen encounter, immune cell gene expression
demonstrated high similarities [888, 889]. In humans, the com-
bined use of these markers is less established and combinations of
different markers have been used to define T-cell differentiation
during acute infections. In combination with the cell-surface mark-
ers CD45RA and CD27, the human equivalent of MPEC cells can
be identified by an increased expression of CD127 that goes hand-
in-hand with a decreased expression of the killer cell lectin-like
receptor G1 (KLRG1) (Fig. 118). In addition, the human equiv-
alent of SLEC can be identified by the selective expression of
KLRG1. In contrast to the bi-phasic model in mice, the major-
ity of the human effector CD8+ T-cell compartment consists of
double positive effector cells (DPEC). In addition, low number of
early effector cells (EEC) can be identified that lack both CD127
and KLRG1 expression. Although these markers can be used to
define distinct subsets in the circulation and lymph nodes during
the acute phase and in “steady state” in humans [890], it remains
to be elucidated to what degree these populations are functionally
comparable between both species.
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1.11.5 Transcriptional regulation of human T-cell differentiation.
The relationship between phenotype and function has been sub-
ject of much investigation. Although the association between the
above mentioned surface markers and T-cell function are mostly
well established, ultimately not all phenotypically similar T cells
share the same cell fate and effector response. The emerging com-
plexity among T-cell subsets and their potential to elicit a plethora
of effector functions require a more thorough characterization of
each subset that would reflect its function. The actual regulator of
T-cell development and function is the circuitry of transcription
factor expression. Complex interactions of transcription factors
drive expression of target genes that ultimately determine T cell
functionality and many use opposing mechanisms to counter-
regulate each other [741]. Multicolor FCM is the preferred
method of choice to detect low frequent T-cell subsets with differ-
ential transcription factor expression within heterogeneous T-cell
populations. As these factors bind to DNA, they are concentrated
in the nucleus. To allow Abs to reach their nuclear epitopes
T cells need to be fixated and permeabilized. There is a variety of
commercial kits and procedures available to accommodate these
stainings. Permeabilization may induce cell shrinkage and loss of
surface marker staining intensity and protocols should therefore
be validated and optimized. Generally the FSC and SSC voltage
are amplified for intracellular protein staining. The CD8+ T-cell
lineage is enriched for cytolytic cells (CTL) that are very effective
in direct lysis of infected target cells. During chronic infections
CTL-like cells can also be detected among the CD4+ lineage. These
cells can be recognized by the expression of Granzyme B (GZMB)
and Perforin that are stored in acidic lysosomes (Fig. 119A). Differ-
entiation of CTL, but also TH1 differentiation was demonstrated
to be regulated by expression of the T-box transcription factor
Tbx21 (T-bet) [732]. While T-bet drives terminal differentiation of
effector T cells, expression of a second T-box transcription factor,
Eomesodermin (Eomes), enables TH1 cells to generate memory
with a certain degree of redundancy (Fig. 119B) [885, 891]. In
addition, Eomes expression can also be used to define a subset
of Treg cells, referred to as TR1 cells that lacks FoxP3 expression
and produces IL-10 [875, 876]. Recently, the zinc finger protein
ZNF683 (Hobit) was identified as a transcriptional regulator of
CD8+ and CD4+ effector type T cells in humans and the lack of
CD28 (Fig. 117A) [892, 893]. Expression of Hobit strongly corre-
lates with T-bet and regulates production of IFN-γ (Fig. 119C). To
prevent immune-mediated pathology by ongoing effector function
and unrestricted expansion of CTL and TH1 cells, the stimulatory
activities of these subsets are counterbalanced by natural and
induced Tregs. These suppressor cells are CD4+ T cells, exert their
modulatory function by direct interaction with target cells, by
the secretion of immunosuppressive cytokines such as TGF-β and
IL-10 and by increasing the consumption of IL-2. Two lineages of
Treg cells can be distinguished in humans. Both express the IL-2
receptor alpha chain (CD25) and the transcription factor forkhead
box 3 (FoxP3) and can be distinguished by the expression of the
transcription factor Helios [767, 768, 894] (Fig. 119D). Although
in mice the expression of Helios is used to identify natural and
peripheral induced Treg cells, that developed in the thymus
or periphery, respectively [775], this model is controversial in
humans.
1.11.6 Human T-cell effector function. To define specific T-cell
subsets on basis of cytokine production usually in vitro stimula-
tion is required. Since cytokines are not preformed, their levels
are typically low in resting cells. Accumulation of cytokines within
the ER is achieved by adding an inhibitor of protein transport to
stimulated cells. The two most frequently used inhibitors are Mon-
ensin (MN) and Brefeldin A (BFA). The choice of protein transport
inhibitor is very important as they can have differential effects on
surface and intracellular protein expression after stimulation. For
example, BFA will help to maximize the capture of TNF-α, IFN-γ,
and IL-17 but blocks the surface expression of the T-cell activation
marker CD69 (Fig. 120A). In addition, MN maximizes the detec-
tion of the T-cell degranulation marker CD107 (Fig. 120B). After
polyclonal stimulation of T cells cytokines are produced with dif-
ferent kinetics. For most cytokines a stimulation and accumulation
period of 4–6 h is optimal. However, for several cytokines such as
IL-10 and IL-12 the production kinetics are relatively slow and
up to 24 h stimulation may be required for optimal detection. As
both MN and BFA are toxic, exposure of stimulated cells should be
limited. Consequently, for the longer stimulations (>6 h) MN and
BFA may be added during the last 4–6 h. MN was demonstrated
to be less toxic and can be added for periods up to 24 h. When
there is no prior knowledge regarding the specific cytokines that
will be produced by the stimulated T cells, expression of activation
induced markers can be considered. Both CD4+ and CD8+ T cells
depict CD69 and HLA-DR expression as early as 4 h after stimula-
tion. Other markers like the CD8+ biased 4-1BB (CD137) and the
CD4+ T-cell biased CD40L (CD154) peak at 24 h after stimulation.
One problem with defining T-cell phenotypes after stimulation is
the internalization of TCR and the CD4 and CD8 coreceptors. This
will result in a decreased staining intensity for CD4, CD8, and
especially CD3, which makes it more difficult to define T cells.
By either staining the cells before stimulation or by intracellular
staining of these markers, this problem can be circumvented.
1.11.7 Step-by-step sample preparation.
1. Freezing PBMC
1. Isolate PBMC from heparinized blood or buffy coat by using
Ficoll or lymphoprep according to manufacturer’s protocol.
2. Collect the PBMC in 50 mL tubes.
3. Add washing medium up to 50 mL and centrifuge for 10
min at 500 × g at room temperature.
4. Aspirate supernatant, resuspend pellet in 50 mL washing
medium and centrifuge for 10 min at 250 × g at room
temperature.
5. Aspirate supernatant, resuspend pellet in 35 mL washing
medium and centrifuge for 10 min at 250 × g at room
temperature.
6. Resuspend in 1–2 mL of thawing medium and put on ice.
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7. Count cells and adjust concentration to 10—25 × 106
cells/mL.
8. Prepare a similar amount of freezing medium and put on
ice.
9. Make sure your cells, cryovials, and freezing medium are
cold before freezing.
10. Add drop by drop, while gently shaking, 1 mL of freezing
medium for every mL of cell suspension.
11. Transfer 2 mL of the cell suspension to each vial.
12. Freeze the cryovials by using a Mr. Frosty (Nalgene), Cool-
Cell (Corning), or a freezing apparatus at −80°C for a
period of four to 24 h.
13. Store the vials until further use in liquid nitrogen.
2. Thawing PBMC
1. Thaw the vials by gently shaking in a 37°C water bath,
until little ice remains.
2. Transfer the contents of the vial to a 50 mL tube.
3. Add drop by drop, while gently shaking, 18 mL of cold
thawing medium.
4. Let the cell suspension rest for 20 min and centrifuge for
10 min at 500 × g.
5. Aspirate supernatant, resuspend pellet in 50 mL washing
medium and centrifuge for 10 min at 250 × g at 4°C.
6. Aspirate supernatant, resuspend pellet in desired volume
of FCM buffer (for surface and intracellular stainings) or
culture medium (for stimulations) and count cells.
3. Surface staining
1. Transfer up to 2 × 106 PBMC to a 96-well round buttom
plate (Greiner BioOne).
2. Centrifuge the plate at 390 × g at 4°C for 3 min.
3. Aspirate supernatant and resuspend cells by gently vortex-
ing the plate.
4. Add 30 µL FCM buffer containing a pretitrated appropriate
amount of tetramer for each well (prepare 1× extra).
5. Incubate for 30 min at 4°C, shaking, protected from light.
6. Meanwhile prepare surface staining (including the
live/dead exclusion dye) in a total volume of 30 µL FCM-
buffer for each well (prepare 1 × extra).
7. Add 30 µL surface staining mix, without washing the cells,
directly into the well and incubate for a further 30 min at
4°C, shaking, protected from light.
8. Add 150 µL FCM buffer and centrifuge at 390 × g at 4°C
for 3 min.
9. Resuspend cells by gently vortexing the plate.
10. Add 100 µL FCM buffer, and analyze by FCM cell sorting
in the desired format, or continue with the intracellular
staining protocol.
Note: Always use appropriately titrated Abs and tetramers,
which is usually “not” the concentration suggested by the supplier.
The ins and outs of titrating Abs can be found in the ref. [608].
4. Intracellular stainings of transcription factors and cytolytic
molecules
1. After surface staining add 200 µL Fixation/Permeabilization
buffer.
2. Gently resuspend the cells by pipetting up and down three
times.
3. Incubate for 20 min at 4°C, shaking, protected from light.
4. Centrifuge for 5 min at 700 × g at 4°C.
5. Aspirate supernatant and resuspend cells in 200 µL FCM
buffer and centrifuge for 5 min at 700 × g at 4°C.
6. Aspirate supernatant and resuspend cells by pipetting up
and down 3 times in 50 µL of the intracellular staining mix
prepared in Permeabilization Buffer.
7. Incubate 30 min at 4°C, shaking, protected from light.
8. Add 150 µL Permeabilization Buffer to each well and cen-
trifuge for 5 min at 700 × g at 4°C.
9. Aspirate supernatant and resuspend cells in 200 µL Perme-
abilization Buffer and centrifuge for 5 min at 700 × g at
4°C.
10. Aspirate supernatant and resuspend cells in 100 µL FCM
buffer and analyze by FCM cell sorting in the desired for-
mat.
5. Cytokine staining
1. Transfer PBMC into suspension culture flasks (690 190,
Greiner) at 1 × 106 cells/mL in culture medium (flask
standing upright, or 45° tilted depending on volume) and
rest them overnight in a 37°C 5% CO2 incubator.
2. Transfer cells to a 15 mL tube and centrifuge for 10 min at
500 × g at room temperature.
3. Aspirate supernatant, resuspend cells and add 1 mL of cul-
ture medium.
4. Count the cells and adjust concentration to 10–20 × 106
cells/mL.
5. Add 100 µL control mix to the correct wells of a non-
tissue culture treated 96-well round bottom plate (3788,
Corning).
6. Add 100 µL stimulation mix to the correct wells of the
96-well plate.
7. Then add 100 µL cell suspension.
8. Incubate for 4 h in a 37°C 5% CO2 incubator.
9. Put plate on ice for 15 min after incubation.
10. Centrifuge plate for 5 min at 700 × g at 4°C.
11. Aspirate supernatant, resuspend cells in 200 µL FCM buffer
and centrifuge plate again for 5 min at 700 × g at 4°C.
12. Aspirate supernatant, resuspend cells in 50 µL FCM buffer
containing a pretitrated appropriate amount of surface
staining mix.
13. Incubate for 30 min at 4°C, shaking, protected from light.
14. Add 150 µL FCM buffer and centrifuge at 700 × g at 4°C
for 3 min.
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15. Aspirate supernatant and add 100 uL of Cytofix/Cytoperm
reagent (554722, BD Biosciences) to each well and resus-
pend by pipetting three times up and down.
16. Incubate for 20 min at room temperature protected from
light.
17. Add 100 µL FCM buffer and centrifuge at 700 × g at 4°C
for 3 min.
18. Aspirate supernatant and add 50 µL intracellular staining
mix prepared in 1× perm/wash and resuspend by pipetting
three times up and down.
19. Incubate for 30 min at 4°C, shaking, protected from light.
20. Add 150 µL 1 × perm/wash to each well and centrifuge
for 5 min at 700 × g at 4°C.
21. Aspirate supernatant, add 200 µL 1× perm/wash to each
well and centrifuge for 5 min at 700 × g at 4°C.
22. Aspirate supernatant and resuspend cells in 100 µL FCM
buffer and analyze by FCM cell sorting in the desired for-
mat.
Note: Protocol adapted from Lamoreaux et al. [608].
1.11.8 Materials.
6. Monoclonal antibodies
1. Surface staining:
BD Biosciences: CD4 BUV 395 (SK3), CD45RA BV421
(HI100), CCR7 BUV395 (150503), CD45RA BV650
(HI100), CXCR5 Alexa Fluor R 488 (clone RF8B2),
CD25 APC (clone 2A3) CD161 FITC (DX12).
eBioscience: CD3 PE (UCHT1), KLRG1 AF488 (clone
13F12F2), CD4 PerCP-eFluor 710 (clone SK3), CD127
PE-Cy7 (clone eBioRDR5), CD27 APC-eFluor 780 (clone
O323), CD107a FITC (clone H4A3)
Biolegend: CD27 APC-Fire 750 (O323), CCR6 Alexa
Fluor R 647 (clone G034E3), CCR7 BV421 (clone
G043H7), CX3CR1 FITC (clone 2A9-1), CCR4 BV421
(L291H4), CD28 Alexa Fluor 700 (CD28.2), CD127
BV650 (A019D5). R&D Systems: CXCR3 PE (clone
49801)
Sanquin: CD28 FITC (15E8)
2. Live/dead exclusion dyes: Live/dead fixable dyes (Ther-
mofisher) or Fixable viability dye (eBioscience); we here
use Fixable viability dye eFluor 506 (eBioscience).
3. Intracellular stainings:
BD Biosciences: IL-4 PE (3010.211), IFNγ BUV395 (B27),
granzyme B Alexa Fluor R 700 (clone GB11), IL-2
PE (clone 5344.111), IL-10 BV650 (JES3-9D7), TNF-
α Alexa Fluor R 700 (clone MAb11), Perforin BV421
(clone B-D48), Hobit (clone 5A);
eBioscience: IL-21 eFluor 660 (eBio3A3-N2), Eomes Per-
CPeFluor 710 (WD1928), Helios PE-Cy7 (22F6), IFN-
γ APCeFluor 780 (clone 4S.B3), FoxP3 PE (clone
PCH101), T-bet PE-Cy7 (clone 4B10)
Biolegend: IL-17A BV421 (BL168), IL22 PE (BG/IL22),
Anti-IgM PE (clone ma-69)
7 Flow cytometer
All experiments were performed on a LSR Fortessa flow
cytometer with a 365 nm, 405 nm, 488 nm, 561
nm and 640 nm configuration (BD Bioscience). Filters:
379/34(365) for BUV395; 530/30(488) for FITC or AF488;
665LP(488) for PerCP-eFluor 710; 450/50(405) for BV421;
525/50(405) for BV510, V500 and Fixable viability dye
eFluor 506; 660/20(405) for BV650; 710/40(405) for
BV711; 800/50(405) for BV785; 585/15(561) for PE;
780/60(561) for PE-Cy7; 675/20(640) for APC or AF647;
730/45(640) for AF700; 780/60(640) for APC-eF780 and
APC-FIRE 750.
8 Media and buffers:
Thawing medium:
 IMDM
 20% (v/v) FCS
 0.00036% (v/v) 2-ME
Freezing medium (after addition of DMSO use within 1 h):
 IMDM
 20% (v/v) FCS
 20% (v/v) DMSO
 0.00036% (v/v) 2-ME
Washing medium:
 HBSS
 5% (v/v) FCS
 10% (v/v) TRIS-HCL pH 7.0 (as extra buffering)
Culture medium:
 RPMI
 10% (v/v) FCS
FCM buffer:
 Phosphate buffered saline (PBS)
 0.5% (w/v) BSA
 0.01% (w/v) sodium azide
 2mM EDTA pH 8.0 (to prevent clots)
 Fixation/Permeabilization buffer (FOX-P3 kit eBioscience)
 75% Fixation/Permeabilization Diluent (cat. 00–5223)
 25% Fixation/Permeabilization Concentrate (cat. 00–5123)
 Permeabilization Buffer (FOX-P3 kit eBioscience)
 90% Fixation/Permeabilization Diluent (cat. 00–5223)
 10% Permeabilization Buffer (10 ×) (cat. 00–8333)
Stimulation mix:
 Culture medium
 2 µg/mL Ionomycin
 20 ng/mL PMA
 20 µg/mL BFA
 2.8 µLl/mL GolgiStop (BD Bioscience)
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Control mix:
 Culture medium
 20 µg/mL BFA
 2.8 µL/mL GolgiStop (BD Bioscience)
1 × perm/wash:
 10% 10 × perm/wash (554723 BD Biosciences)
 90% ddH2O
1.12 Human tissue resident memory T cells
1.12.1 Overview. Resident memory T cells (TRM) reside in
human tissues, ranging from peripheral organs such as skin to
internal organs such as the liver. These TRM are specifically pro-
grammed to remain within these tissue compartments there within
providing protection. Techniques to isolate and identify human
TRM by FCM were developed and verified by multiple research
groups and are described below.
1.12.2 Introduction. In the last decade a subset of memory
T cells has been identified that is specifically adapted for survival
and function within tissues. These so-called tissue resident mem-
ory T cells (TRM) are important for rapid local protection within
tissues and can be identified by a variety of markers, including
adhesion molecules and chemokine receptors. The vast majority
of human T cell knowledge has been based on T cells isolated from
peripheral blood due to the lack of tissue accessibility until recent
years. Both CD8+ and CD4+ TRM have been identified in human
skin, lung, intestines, salivary glands, bone marrow, brain, spleen,
tonsils, and lymph nodes [895–903]. In mice, the existence of TRM
was proven by parabiosis experiments (see Section 1.4 Murine res-
ident memory T cells). In humans, the possibilities of validating
TRM are far fewer, but recently the maintenance of TRM in the lung
was shown by transplantation [904].
TRM lack the expression of lymph node homing molecule CCR7
and tissue egress molecule S1PR1. Human TRM have a mem-
ory phenotype CD45RA−CD45RO+ and CCR7−CD27+/−CD28+/−.
The most widely/classical used marker of TRM is CD69. CD69 that
inhibits the function of S1PR1 so TRM are not attracted to the high
SIP gradient in the blood and lymph and therefore retains T cells
within tissues [905]. It should be noted that in mice it was shown
that CD69 is an imperfect marker of TRM as TRM lacking CD69 also
exist [906]. However, markers categorizing TRM within CD69−
T cells in human tissues are yet to be confirmed. Furthermore,
CD69 is a classical activation markers, which should be kept in
mind especially when performing functional assays. TRM do not
express other classical activation markers, such as CD25, CD38, or
HLA-DR [895, 897, 902, 907]. An identifier of TRM at mucosal sites
is CD103 (α subunit of αEβ7 integrin), which helps TRM dock to
E-cadherin expressing epithelial cells [908]. These TRM co-express
CD69 and CD103 and are found mainly in the skin, lung, sali-
vary glands, brain, and intestines [899–902]. TRM reside in other
tissues, such as the liver and bone marrow, and in these tissues
TRM express CD69 but not CD103. TRM also express chemokine
receptors CXCR6, CXCR3, CCR5, and integrin CD49a (α sub-
unit of α1β1 integrin) throughout the different tissues. CD69+
TRM lack the expression of CX3CR1, mainly expressed by effector
T cells.
TRM are polyfunctional and rapidly produce cytokines upon
stimulation [900, 901], which can be quantified with in vitro stim-
ulation in the presence of brefeldin A and staining for cytokines
intracellularly. In the skin CD49a identifies CD8+ TRM poised for
cytotoxic function [909]. This rapid effector function needs to
be tightly controlled in order to protect the tissues where TRM
reside. Inhibitory receptors PD-1, CTLA-4, and 2B4 are expressed
by TRM [899–901], which may control the effector function of
these TRM.
In the recent years, TRM have also taken the spotlight in cancer
immunotherapy. The use of tumor infiltrating lymphocytes (TILs)
and Ab immunotherapy were one of the big breakthroughs of
cancer immunotherapy. Further research revealed that the pres-
ence of CD103+CD8+ TILs are a positive prognostic marker in
several cancers [910–913]. A subset of TILs in tumors of NSCLC
share the phenotype of TRM in adjacent lung tissue (expression of
CD103, CD69, CXCR6, CD49a) [913, 914]. A proportion of PD-
1++ TILs with a TRM phenotype also express CXCL13, the ligand of
CXCR5 [914–916]. Furthermore, tumors consist of tumor-specific
TILs as well as tumor nonspecific T cells so-called bystander
T cells. While tumor-specific TILs express high levels of CD39,
the bystander T cells lack CD39 expression [917].
In order to further unravel the heterogeneity of human TRM
Single cell RNA-sequencing platforms should be utilized and the
results obtained from these experiments should be validated by
multicolor FCM and functional assay.
1.12.3 Step-by-step sample preparation.
1.12.3.1 Isolation of human TRM. The following protocol was
designed for isolating mononuclear cells from various tissues,
including intestines, lung, and tumor tissue, described previously
[895, 918].
1. Cut tissue into small pieces and incubated for 1–2 h at 37°C in
digestion medium while shaking/rolling
2. Dissociate the tissue using gentleMACS R© Tissue Dissociator
(Miltenyi)
3. Pass the digested tissue through a flow-through chamber to
achieve a single cell suspension
4. After centrifugation, incubate the samples with 50 µg/mL
DNase for 15 min in a 37°C water bath
5. To isolate mononuclear cells from the cell suspension, use stan-
dard Percoll density gradient technique
6. Isolated mononuclear cells can be used directly for experi-
mentation or cryopreserved in liquid nitrogen until further
analysis
7. For cryopreservation, resuspend cells in cold FCM buffer and
add the same volume of 2× freeze medium dropwise and take
directly to cryo.
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Figure 121. Gating strategy for human TRM. The above gating strategy is shown for human lung tissue TRM, but similar gating strategies apply
for other tissues. Side (SSC) and forward (FSC) scatter are used to gate on lymphocytes, followed by gating out doublets also using SSC and FSC.
Live/dead marker Near-IR is used to gate out dead cells and CD3 eVolve605 to gate on T cells. To gate out aggregates, CD45RA QDot655 and CD27
PE-CF594 are used. Whether or not this aggregate gating is necessary depends on your antibodies and cells used. To distinguish between CD4+
and CD8+ T cells, CD4 BUV737 and CD8 BUV805 are used. The most widely used markers of TRM are CD69 and CD103, which can be stained for on
both CD4+ and CD8+ T cells
1.12.3.2 FCM staining of human TRM.
1. Prepare surface staining mix in FCM buffer
2. For staining use 1 × 105–2 × 106 cells
3. Add cells to 96-well V-bottom plate and centrifuge (350 × g,
5 min, 4°C)
4. Remove the supernatant
5. Resuspend cells in 25–50 µL staining mix per well (amount
depends on number of cells)
6. Incubate for 15–20 min on ice
7. Wash cells by adding 150 µL FCM buffer and centrifuge
(350 × g, 5 min, 4°C)
8. Remove supernatant
9. For only surface staining, resuspend in 80–120 µL FCM buffer
(depending on amount of cells) and measure
10. Cells can also be fixed with a mild fixative (0.5% PFA)
11. For intracellular stainings, fix cells by resuspending the cells
in 50 µL of fixation solution
12. Incubate for 30 min on ice
13. In the meantime, prepare intracellular staining mix in 1×
permeabilization buffer
14. Wash cells by adding 150 µL FCM buffer and centrifuge
(550 × g, 5 min, 4°C)
15. Resuspend cells in 25–50 µL intracellular staining mix per
well (amount depends on number of cells)
16. Incubate for 30 min on ice
17. Wash by adding 150 uL 1× permeabilization buffer and cen-
trifuge (550 × g, 5 min, 4°C)
18. Remove supernatant and resuspend cells in 80–120 uL of
FCM buffer (depending on amount of cells) and measure
1.12.4 Materials.
 Medium: RPMI with 20 mM Hepes, 10% fFCS, 1% pen/strep,
1% L-glutamine
 Digestion mix: medium, 50 U/mL DNase type I (Sigma–
Aldrich), 300 U/mL collagenase D (Worthington)
 DNase (Sigma–Aldrich) (dilute in medium)
 Percoll (GE Healthcare)
 FCM buffer: 0.5% FCS PBS
 PFA: paraformaldehyde
 2× Freeze medium: 20% DMSO, 30% PBS, 50% FCS
 Fixation solution from Foxp3 Transcription Factor Staining kit
(Thermofisher)
 1× Permeabilization buffer from Foxp3 Transcription Factor
Staining kit (Thermofisher)
 Flow cytometer: LSR II, LSRFortessa or FACSymphony (BD)
 In Table 26 is a list of Abs that can be used to identify human
TRM, this list is not complete.
 Live/dead fixable dead cell dyes (Thermofisher)/Zombie fixable
vialibity kits (Biolegend) should be used in the surface staining
mix to distinguish live cells
1.12.5 Data analysis and gating. For analysis of FCM data FACS
Diva (BD) or FlowJo (Tree Star) software should be used. First,
lymphocytes and single cells should be gated, after which the
compensations should be checked. Single stainings should be used
for compensation controls. After the compensations are adjusted
the analysis can continue. General gating includes exclusion of
dead cells using a live/dead fixable dye (in this case Near-IR from
Thermofisher) and gating on CD3+ cells to distinguish T cells.
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Table 26. List of useful antibodies for identifying human TRM
Species Epitope Clone Company Fluorochrome
Human CD3 UCHT1 BD BUV661, BUV395
Human CD4 SK3 BD BUV737
Human CD8 SK1 BD BUV805
Human CD69 FN50 BD BUV395, BV421
Human CD28 CD28.2 BD BV605
Human CD103 Ber-ACT8 BD FITC
Human CD49a SR84 BD PE
Human TNFα Mab11 BD FITC, PeCy7
Human CD45RA HI100 BD BUV563
Human CD25 2A3 BD PE, BV605
Human GZMB GB11 BD AF700, AF647
Human CD137 4B4-1 Thermofisher AF647, PeCy7
Human CD4 S3.5 Invitrogen QD705
Human CD3 UCHT1 Invitrogen QD605
Human CD45RA MEM-56 Invitrogen QD655
Human CD3 OKT3 ThermoFisher eVolve605, SuperBright600
Human CD103 B-Ly7 ThermoFisher PE, PeCy7, FITC
Human Eomes WD1928 ThermoFisher eFluor660
Human HLA-DR LN3 ThermoFisher FITC
Human 2B4 eBioDM244 ThermoFisher APC
Human CXCR6 K041E5 Biolegend APC
Human CCR5 J418F1 Biolegend BV421
Human CD27 O323 Biolegend BV510, BV650
Human CD103 Ber-ACT8 Biolegend AF647, BV711, BV605, BV421
Human CD69 FN50 Biolegend PeDazzle594, AF647
Human Tbet 4B10 Biolegend BV421
Human IFNγ 4S.B3 Biolegend eF450, BV785, Pe
Human PD-1 EH12.2H7 Biolegend BV421, PeCy7
Human CTLA4 L3D10 Biolegend PE
Human TNFα Mab11 Biolegend PeDazzle594, BV421
CD3+ T cells should then be separated into CD4+ and CD8+ T cells.
The common markers of TRM are CD69 and CD103 (as shown in
Fig. 121), but many more markers have been identified up to now
(described above and listed in Tables 27 and 28).
1.12.6 Pitfalls. Isolation of T cells from human tissues often
requires enzymatic digestion with collagenases, which can affect
the expression of certain proteins, particularly chemokine recep-
tors, such as CCR6 [920], due to their large structure and multiple
transmembrane domains. This should be kept under consideration
when staining tissues that have undergone enzymatic digestion.
The preferred collagenase used by multiple research groups is col-
lagenase D [895, 899, 901]. Furthermore, cryopreservation can
also affect expression of proteins, such as L-selectin/CD62L. Var-
ious markers of TRM are shared between tissues, but it should be
kept in mind that some markers and ratios of certain populations
can vary per tissue compartment. The amount of unconventional
T cells, such as TCR-γδ, MAIT cells and NK T cells, should also
be determined, which varies per tissue. If there are significant
amounts of these unconventional T cells, a dump channel should
be applied.
1.12.7 Tips/tricks.
1. Careful panel design is important with more than 10 color
flow
(a) The major problem is the scatter caused by compensation
of some fluorochromes, not per se the amount needed to
compensate
2. Some examples of compensation issues
(a) To use BUV805, BV737, and BV785 in the same panel, BD
FACSymphony is required
(b) BUV661 spills into APC so BUV661 signal should not be
too bright and APC signal should be relatively bright
(c) BUV737 spills into BUV805 so using markers that are
clearly distinct from each other such as CD4 and CD8
is advisable
(d) A lot of compensation is required between BV605 and
BV650
(e) Properly titrating antibodies and not using antibodies at
too high concentrations can significantly help
3. Some tissues suffer from autofluorescence
(a) It can help to keep a Brilliant violet channel empty or
sometimes the autofluorescence can be gated out when
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Table 27. Markers used to identify human TRM
Marker Expression Functional implication Reference
CD69 + Tissue retention [895–903]
CD103 + (mucosa/skin) Tissue retention [895–897, 899–902]
CD45RA − Memory defining [895–897, 899–902]
CD45RO + Memory defining [895–897, 899–902]
CD27 +/− Co-stimulation [899, 901]
CD28 +/− Co-stimulation [896, 901]
CCR7 − Lymph node homing [895–902]
CD49a + Retention [900–902]
CXCR6 + Recruitment/retention [900–903]
CCR5 + Recruitment/retention [901–903]
CXCR3 + Recruitment/retention [901, 902]
CX3CR1 − Cytotoxic function/endothelial adhesion [900, 903]
IL-7Ra + Homeostasis [896, 900]
PD-1 + Inhibitory [899, 901, 902, 907]
CTLA-4 + Inhibitory [901, 902]
2B4 + Inhibitory [901]
CD101 + (CD8 TRM) Inhibitory [907]
NKG2A + (CD8 TRM) Inhibitory NK receptor [919]
CD94 + (CD8 TRM) Forms inhibitory receptor complex with NKG2A [919]
Eomes − Effector function/effector differentiation [899, 901, 902]
T-bet -/+ Effector function/differentiation/lineage defining [899, 901, 902]
HLA-DR − Activation [907]
CD25 − Activation [895, 897, 902, 907]
CD38 − Activation [907]
Ki67 − Proliferation [897, 902, 907]
two fluorochromes, where no double positive signal is
expected, are plotted against each other
4. Isotype controls or FMOs (fluorescence minus one) should be
used if there is only a shift in a population instead of a clear
staining/bimodal populations
5. To avoid aggregates caused by some fluorochromes, the anti-
body mixes can be centrifuged at 1400 rpm for 10 min. After-
wards the aggregates should be pelleted and the antibody mix
should not be pipetted from the bottom of the tube or resus-
pended again.
6. A dump channel may be necessary for unconventional T cells
such as TCR-γδ, MAIT cells, and NK T cells and these can be
for example put in the same channel as the live/dead marker
to exclude them
1.13 Immune senescence (aging) of human T cells
In human aging, the functionality of the adaptive immune sys-
tem diminishes, known as immunosenescence. Immunosenes-
cence leads among others to increased susceptibility to infectious
diseases through diminished responses to pathogens [921]. In
addition, a continual low-grade pro-inflammatory milieu is associ-
ated with aging (inflammaging), which is linked to several aging-
associated diseases with an inflammatory pathophysiology such as
various neurodegenerative [922] and metabolic diseases [923],
leading to increased mortality. There is great interest in the phys-
iology of aging to better understand the aging process and tech-
niques to monitor them. Within the T-cell repertoire, aging is
known to lead to a loss of na¨ıve T-cells, with a reciprocal increase
in effector memory T-cells [921]. This process is fueled among
others due to involution of the thymus from adolescence onward.
Table 28. Effector molecule expression/production by human TRM
Marker Expression Function Reference
IFN-γ + (upon stimulation) Kill or recruit cells [899–901]
TNF-α + (upon stimulation) Kill or recruit cells [901]
IL-2 + (upon stimulation) Survival/proliferation [900, 901]
IL-17a + (upon stimulation) Extracellular pathogen protection [900]
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Table 29. Examples of flow cytometry markers used to identify aged T-cells in humans
Marker Expression Functional implication References
Loss of naı¨ve cells
CD28 − Co-stimulation [430, 921, 924, 926, 927, 929, 931–933]
CD27 − Co-stimulation [924, 927, 928, 931]
CD45RA − Memory [925, 928, 930, 931, 933]
CCR7 − Homing to secondary lymphoid organs [924, 931, 933]
CD62L − Homing to secondary lymphoid organs [932]
Decrease in recent thymic emigrants
PTK7 − Tyrosine-kinase [933]
CD103 − Integrin [933]
Increase in senescent cells
CD57 + Terminal differentiation [430, 924, 926, 927, 930, 933]
KLRG1 + Immune checkpoint [924, 927, 931]
HLA-DR + T-cell activation [926]
Loss of mitochondrial function
MitoSOX + Mitochondrial reactive oxidative species [928]
MTG +/− Mitochondrial mass [928]
TMRM + Mitochondrial membrane potential [928]
Impaired autophagy
LC3 − Autophagosomes [427, 430, 928]
LysoID − Lysosomes [430]
This na¨ıve T-cells fraction is conventionally studied by FCM using
Abs against a panel of (co-stimulatory) surface antigens such as
CD28 [924]. See Table 29 for examples of commonly used FCM
markers for the identification of aged human T cells. The decrease
of the na¨ıve T-cell population is accompanied by an increase of
oligoclonal effector memory populations [925]. This process is
driven by latent viral infections, such as cytomegalovirus (CMV).
Especially in the oldest-old individuals, large proportions of the
T-cell repertoire seems to be occupied by CMV-specific effector
memory T-cells [926]. Therefore, when studying human aging in
T-cells, the CMV seroposivity status of the subject must be taken
into account. Age-associated T-cell dysfunction include replica-
tive senescence that is characterized by the expression of CD57
and KLRG1, which were found to be increased in both CD4 and
CD8+ T-cells in the elderly [927]. Other age related processes
include perturbations in T-cell homeostasis andmitochondrial dys-
function, which can both be assessed using FCM. For example, a
recent study found that while mitochondrial mass increased in
CD8+ T-cells with age, they exhibited a diminished membrane
potential, indicating a loss of mitochondrial function which was
accompanied by an increase of mitochondrial reactive oxygen
species [928]. Another process, which is known to be vital to T-cell
homeostasis during aging, is autophagy. Lysosomal degradation of
defective proteins and recycling thereof is critical for the home-
ostasis of the metabolically active T-cell. Indeed, in T-cells of older
individuals a decreased (basal) autophagy level was found [430],
with lower levels in effector memory T-cells [929]. Most meth-
ods to quantify changes in autophagy (see Chapter V Section 9:
Autophagy) use immunoblotting (requires a protein quantity that
is not always available in human aging studies) or immunofluo-
rescence imaging (laborious and not high-throughput), however
recently several flow-cytometric assays for quantifying autophagy
were developed. These assays require transfection with reporter
constructs which could potentially alter the characteristics of the
cells of interest [427]. To better understand healthy aging, one
approach is to study the offspring of long-lived individuals com-
pared to their partners. Interestingly, the T-cells of offspring pos-
sess higher proportions of na¨ıve T-cells [930], lower levels of
senescent T-cells [927], better responses after stimulation with
viral antigens [931] and improved activation-induced autophagic
activity [932]. Finally, markers of T-cell immunosenescence can
be used as biomarkers to monitor lifestyle interventions in the con-
text of human aging. For example, a recent study demonstrated
that high level of physical activity maintains higher levels of na¨ıve
T-cells and T-cells with phenotypes of recent thymic emigrants in
the elderly, as compared to inactive elderly [933].
1.14 Human FOXP3+ regulatory T cells
1.14.1 Overview. Regulatory T cells (Tregs) are necessary to pro-
tect against autoimmune disease and maintain immune home-
ostasis. Human Tregs are usually defined by high co-expression of
the FOXP3 transcription factor and CD25, as well as low expres-
sion of CD127. Other aspects of their phenotype can vary widely
depending on their state of activation and location throughout the
body. In order to identify human Tregs on the basis of FOXP3
expression, flow cytometric staining protocols need to ensure
effective permeabilisation of both cellular and nuclear mem-
branes. Another consideration is how to differentiate between
Tregs and activated conventional T cells (Tconvs) that tran-
siently express FOXP3 and CD25. In this section, we will discuss
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protocols and key considerations for staining human Tregs in
whole blood, peripheral blood mononuclear cells (PBMCs) and
intestinal biopsies.
1.14.2 Introduction.
1.14.2.1 Human Treg frequencies and distribution. Tregs are
present throughout the human body and their abundance in cir-
culation and tissues is age dependent [907, 934]. For exam-
ple, in early life (i.e., under two years), Tregs (defined as
CD25highCD127lowFOXP3+ cells) make up 30–40% of CD4+ T cells
in the lung and gut but these proportions decline to 1–10% in
adults [935]. In peripheral blood, Tregs decrease from 20% of
total CD4+ T cells in infants (i.e., under two years) to 5% in
healthy adults [935]. However, once adult proportions of Tregs
are reached, their frequencies in blood do not appear to change
with age (from 20 to 75 years; Tregs defined as CD25highCD127low
cells in this study) and they maintain suppressive capacity
[936, 937].
1.14.2.2 Human Treg subsets. As in mice, it is generally
accepted that human Tregs can be thymically derived or induced
from Tconvs in the periphery under specific conditions [938]. In
mice, high expression of Helios and low expression of Neuropillin-
1 (Nrp-1) has been proposed to discriminate between thymus
Treg and peripherally-induced Tregs [775, 776]. See also Chap-
ter VI Section 1.6 Murine Foxp3+ regulatory T cells. In humans,
however, the validity of these markers is less clear because not
all naive/thymus-derived Tregs express Helios [939] and it has
been reported that this protein can also be expressed by activated
T cells [779]. On the other hand, human Tregs that express high
levels of Helios have a potent suppressive phenotype and are more
stable [940], so it is still useful to monitor its expression. Nrp-1 is
almost undetectable in human peripheral Tregs [941].
Of particular interest is that Tregs subsets can be readily identi-
fied in healthy adults with phenotypes similar to thewell-described
CD4+ T helper (Th) cell subsets (see also Chapter VI Section
Human CD4 and CD8 T cells). Specifically, Th1, Th2, Th17,
and Th17.1-cell-like Tregs can be detected in peripheral blood
and identified on the basis of expression of Th-cell-associated
chemokine receptors and/or transcription factors [942]. In con-
trast to Th cell subsets, however, in healthy individuals, Treg sub-
sets typically do not make high amounts of lineage-associated
cytokines (e.g., IFN-γ, IL-2, IL-4, IL-13) [943], likely because of
the transcriptional repressor function of FOXP3. An exception is
IL-17: Th17 Tregs co-express FOXP3 and IL-17 yet remain func-
tionally suppressive [944, 945]. Although the relevance of Th-like
Tregs in human disease and homeostasis is an area of intense
investigation, it currently appears that they are tailored to regulate
immune responses driven by their corresponding Th cell subset.
Mechanistically, this could occur by differential homing receptor
expression, thus ensuring that Th-like Tregs co-localize with their
Th cell subset counterparts [946].
1.14.2.3 Measuring human Tregs by FCM. Identifying human
Tregs using FCM is complicated by the facts that FOXP3 is an
intranuclear marker with a relatively low intensity of expression,
and there is currently no known single marker that is unique to
human Tregs. Moreover, even within Tregs the intensity of FOXP3
expression can change, with naive or resting populations of Tregs
expressing lower levels of FOXP3 than activated Tregs [675, 947].
Hence, accurate separation between Tconvs, resting Tregs, and
activated Tregs can only be done if there is a relatively high
dynamic range of FOXP3 staining and often requires addition of
other makers such as CD45RA. Currently the only way to confi-
dently quantify human Tregs is to use a panel of different mark-
ers and then carry out parallel functional [672], gene expres-
sion [948], and/or epigenetic analyses [949, 950].
In terms of surface phenotype, the best accepted combination
of markers is high expression of the IL-2 receptor α chain (CD25)
and low expression of the IL-7R α chain (CD127) [936, 951].
Importantly this CD25highCD127low Treg definition can be used
to isolate relatively pure populations of viable peripheral Tregs
in both the memory (CD45RO+) and na¨ıve (CD45RA+) compart-
ments. As described above FOXP3, CD25 and CD127 are both
expressed as a continuum, so in order to be confident in gating
strategies, it is essential that there is good separation between low,
medium, and high expressing populations.
An outstanding question is should human Tregs be defined as
CD4+ cells that are CD25highCD127low, CD25highFOXP3+, FOXP3+,
or CD25highCD127lowFOXP3+. Currently the literature reports
“Tregs” as cells defined by any one of these different variations.
It is therefore critical to consider how studies define “Tregs”
and whether or not the gating strategies used are sufficiently
stringent. On the basis of current knowledge, the most rigor-
ous way to define Tregs is as CD25highCD127lowFOXP3+ cells.
However, use of FOXP3 is not possible when viable cells are
being sorted and sometimes it may not be feasible to include all
three markers due to instrument limitations. If all three mark-
ers are not possible then at a minimum two should be used,
either CD25highFOXP3+ or CD25highCD127low. Measuring only
CD25 or only FOXP3 does not provide sufficient resolution on
a dot plot to set an accurate gate. Since Tconvs can also upreg-
ulate CD25 and FOXP3, and downregulate CD127 [947, 952], it
is critical to set gates for all of these markers on resting popu-
lations of T cells, typically using blood cells from healthy indi-
viduals. This is particularly helpful when analyzing Tregs and
Tconvs in tissues where there can be a significant proportion
of activated Tconvs and it thus become important to differenti-
ate between these cells on the basis of the intensity of CD25 and
FOXP3 expression. Addition of other human Treg-associatedmark-
ers can help increase confidence in Treg identification in these
settings.
Here, we detail optimized protocols for detecting human Tregs
in whole blood, PBMCs, and intestinal biopsies. We also provide
some tips in Table 30 for staining additional human Treg mark-
ers that are not specifically included in the protocols outlined
and highlight some key differences between mouse and periph-
eral human Tregs. The reader is also referred to our previously
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Table 30. Summary of key functional and phenotypic human Treg markers
Marker Technical notes∗ References
Functional and/or phenotypic makers of human Tregs
IL-10 Difficult to detect in peripheral Tregs. PMA/Ionomycin stimulation for at
least 6 hours is required; staining with the IL-10 capture assay (Miltenyi
Biotech) or other stimuli may give better results. Recommended clone is
JES3-9D7.
[959–961]
LAP and GARP Expression is optimal after 24 h of TCR stimulation. [962, 963]
LAG-3 Low expression on non-activated Tregs. Recommended clone for activated
cells is REA351. Also described as a marker of type 1 regulatory T cells.
[961, 964, 965]
PD-1 Levels are increased after activation or with intracellular staining. [966]
AREG Expression is optimal after PMA/Ionomycin stimulation for 4 hours. Works
with FOXP3 buffers. Recommended Ab clone is BAF262 (RnD systems).
[967]
CD39 A common single nucleotide polymorphism (SNP) in humans results in low
CD39 expression. Individuals who are homozygous for this SNP have
<10% CD39+ Tregs compared to 50% CD39+ in heterozygotes or
noncarriers. Clone A1 does not block CD39 enzymatic function.
[968–970]
HLA-DR Not expressed on murine Tregs; defines a memory and highly suppressive
population.
[971]
CTLA-4; CD152 Due to rapid receptor internalization, staining is improved with intracellular
staining or inclusion of the mAb for a period of time in culture.
[972, 973]
Blimp-1 Expression is increased after activation and in the presence of IL-2.
Recommended clone is 6D3.
[974]
CD49d In combination with CD127, low level expression of CD49d can be used to
differentiate between activated Tconv and Treg.
[975]
Ki67 Marker of cell proliferation. Although anergic in vitro, when tested directly
ex vivo, Tregs show a high proportion of cells expressing Ki67.
[976]
Not known to be detectable on human peripheral blood Tregs
CD73 Despite being expressed on murine Tregs, low/no expression of these markers
(CD73, CD103, ST2, neuropilin-1 and OX40) has been observed on
non-activated, peripheral human Tregs in healthy individuals. More
research is needed to asses if these proteins may be expressed on
tissue-infiltrating Tregs, and/or in various disease/cell activation states
[977, 978]
CD103 [935, 979]
ST2 (IL33R) [953, 967]
Neuropilin-1 [941, 980]
OX40 [981, 982]
* Technical notes are from our experience and largely unpublished.
published methods for staining human Tregs within omental adi-
pose tissue [953], thymus tissue [954] and using a mass cytometry
platform [955, 956], as well as a review describing a comprehen-
sive comparison of mouse and human Treg markers [957]. The
methods described here are focused on studying Tregs in healthy
subjects. The markers of choice may vary in different disease con-
texts. For example, tumor infiltrating Tregs often have a distinctive
phenotype associated with T cell exhaustion and the addition of
markers such as PD-1 may be beneficial in a FCM panel [958].
The following points are key for analysing human Treg by
FCM:
1. In order to accurately define Tregs, at least two markers must
be used—either CD25 and CD127 or CD25 and FOXP3; use of
all three is optimal. If FOXP3 cannot be used then CD25 must
be used in combination with CD127.
2. To set an accurate FOXP3 gate, a biologically negative popula-
tion (e.g., CD4+ Tconvs or CD8+ T cells) is required.
3. The selected CD25 mAb and anti-FOXP3 mAbs must be conju-
gated to a bright fluorochrome so that there is good separation
between mid and high expressing cells (e.g., BB515, PE-Cy7 or
PE).
4. Separation of cells expressing mid and high levels of CD25
and FOXP3 can be enhanced by the use of two monoclonal Ab
clones recognising independent binding epitopes, conjugated
to the same fluorochome.
1.14.3 Staining Tregs from unmanipulated whole blood.
1.14.3.1 Step-by-step sample preparation. In a clinical con-
text, it is desirable to quantify Tregs in unmanipulated whole
blood. In contrast to the more widely used approach of pheno-
typing cryopreserved PBMCs, this method allows quantification of
absolute Treg numbers and avoids variability introduced by cryop-
reservation [983]. Several studies have compared different anti-
human FOXP3 Ab clones, and although there is some debate, there
is a general consensus that the 236A/E7 and 259D clones are opti-
mal [984–988]. The following protocols and associated Ab panels
should be used as a guide; substitution of Ab clones/conjugations
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Figure 122. Gating strategy to quantify
CD25highCD127lowFOXP3+ Tregs using whole
blood and DuraClone tubes. (A–C) From total
events, single cells were selected and CD45+
lymphocytes were gated based on SSC properties
and CD45 expression. (D) From CD4+CD3+ T cells
the CD25highCD127low gate was identified. If the
CD25 resolution is adequate then typically there
is a clear separation of this population on a
diagonal axis indicated by the grey dashed line.
(E and F) show the expression of FOXP3+ within
the indicated CD25highCD127low or Tconv cells
gates. (G) Identification of CD25highFOXP3+ Tregs
from total CD3+CD4+ T cells (panel C).
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Table 31. DuraClone Treg panel (Beckman Coulter #B53346)
Marker Fluorochrome Clone
CD3 APC-A750 UCHT-1
CD4 PE-Cy7 SFCI12T4D11(T4)
CD25 PE B1.49.9
FOXP3 AF647 259D
Helios PacBlue 22F6
CD39 PC5.5 BA54
CD45RA FITC 2H4LDH11LDB9(2H4)
CD45 KromeOrange J33
CD127∗∗ APC-AF700 R34.34
** An additional Ab added in liquid form in step 1. Beckman Coulter,
#A71116
requires titration and testing in combination with the selected
buffer system. Below we present two protocols using reagents
from different manufacturers to quantify Tregs in whole blood.
1.14.3.2 Whole Blood Protocol 1A. Staining
CD25highCD127lowFOXP3+ Tregs from whole blood using
pre-formatted DuraClone tubes from Beckman Coulter (Fig-
ure 122).
Beckman Coulter DuraClone tubes are precoated with dried
down Ab cocktails (Table 31), thus reducing pipetting time, and
increasing reproducibility because there is no variation introduced
by day-to-daymixing of wet Ab cocktails. The use of these reagents
is an ideal way to standardize the FCM of longitudinally samples
collected in multi-site clinical trials [983]. Many Beckman-Coulter
Abs are designed for clinical use so they have low lot-to-lot vari-
ation and are thus ideal for use as drop-in Abs with DuraClone
tubes (providing fluorochrome brightness, clone affinity, etc., is
acceptable). For optimal results with these tubes cytometers must
be calibrated with standardized beads to maintain target voltages
over time.
1.14.3.3 Surface and intracellular staining.
1. Add 100 µL of whole blood to the DuraClone Treg tube
(Table 31) and vortex immediately. Add any extracellular
drop in Abs at this step (e.g., we drop in 5 µL of CD127
APC-AF700, Beckman Coulter, #A71116).
2. Incubate for 15 mins at room temperature in the dark.
3. Wash with 3 mL of PBS.
4. Remove the supernatant with a 1 mL pipette followed by a
200 µL pipette.
5. Adjust volume to exactly 100 µL with FBS.
6. Add 10 µL of PerFix-nc reagent buffer 1 (Fixing buffer—
Beckman Coulter, #B31164).
7. Incubate for 15 min in the dark.
8. Add 800 µL of PerFix-nc Buffer 2 (Permeabilization buffer –
Beckman Coulter, #B31165).
9. Incubate for 15 min at RT in the dark.
10. Centrifuge for 3 min 500 × g and remove only the top 400 µL
of buffer with a 1 mL pipette.
11. Transfer contents from original to Treg Tube 2 and vortex at
high speed for 2 × 4 s.
12. Incubate at room temperature for 60 min in the dark.
13. Wash with 3 mL of PBS, vortex, and incubate at room tem-
perature for 5 mins.
14. Centrifuge at 500 × g for 5 min at room temperature.
15. Decant in one smooth motion and gently blot tube.
16. Vortex for 8 s.
17. Re-suspend the cell pellet in 3 mL of 1× perFix nc buffer 3
(Beckman Coulter, #B31166) and vortex.
18. Centrifuge at 500 × g for 5 min at room temperature
19. Decant supernatant in one smooth motion and gently blot
tube.
20. Vortex the cell pellet for 8 s.
21. Add 350 µL of 1× Perfix-nc Buffer 3 (final volume should be
400 µL as residual volume will be around 50 µL) for data
acquisition.
1.14.3.4 Data analysis. From total events, doublets were
excluded and CD45+ lymphocytes were gated based on SSC
properties and CD45 expression (Fig. 122A and B). CD4+CD3+
T cells were then gated and followed by CD25highCD127low cells
(Fig. 122C and D). If the CD25 resolution is adequate then typi-
cally there is a clear separation of this population on a diagonal
axis indicated by the grey dashed line (Fig. 122D). The remain-
der of the cells in the CD3+CD4+ gate were classified as Tconvs
(Fig. 122D). The FOXP3 gate is made on the basis of FOXP3 and
CD25 expression in Tconvs (gated as CD25– cell); i.e., the gate
should be set such that there are very few FOXP3+ cells in the
Tconv population (Fig. 122E). This FOXP3 gate is then applied to
the CD25highCD127low cells (Fig. 122F). If CD127 is not used, then
Tregs can be identified as CD25highFOXP3+ cells (Fig. 122G), but
this population is harder to clearly discriminate.
1.14.3.5 Pitfalls.
1. Ensure that the volume is exactly 100 µL before the fix-perm
buffers are added for optimal transcription factor staining. The
Beckman SOP suggests using 50 µL of whole blood but the
reagents also work well with 100 µL of blood. Use of more
blood allows collection of more cells and thus better quantifi-
cation of rare populations.
1.14.3.6 Top tricks.
1. In step 1, other markers of interest can be dropped in as wet
Abs (e.g., CD127–APC-AF700).
2. Dropping in CD25 mAb M-A251 PE improves CD25 resolution.
1.14.3.7 Whole Blood Protocol 1B. Staining
CD25highCD127lowFOXP3+ Tregs using Ab cocktails (Figure 123).
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Figure 123. Phenotyping CD25highCD127lowFOXP3+ Tregs in whole blood. Representative staining of healthy adult peripheral whole blood with the
Ab panel listed in Table 32. (A) Gating strategy and representative data for CD25highFOXP3+ staining following fixation and permeabilisation with
either BD or eBioscience FOXP3 buffer sets. Gates were set on the basis of an isotype control (for comparison the lack of utility of an FMO control
for setting the FOXP3 gate is shown). (B) Representative data for CD25highCD127low staining and FOXP3 MFI with the indicated gated populations of
CD25highCD127low or Tconv cells. Right graph shows the FOXP3 MFI if samples are processed with BD or eBioscience buffers. (C) CD25highFOXP3+
frequencies and FOXP3 MFI in CD25highCD127low cells if staining is performed with the 236A/E7 or 259D anti-FOXP3 mAbs. All graphs show data
from 6 healthy adults. Wilcoxon signed-rank tests were performed on paired samples.
This protocol was optimized by carrying out comparisons
between the BD FOXP3 Buffer Set (#560098) and Thermo
Fisher eBiosciences FOXP3 Fix/Perm Buffer Set (#00-5523-00),
as well as the anti-FOXP3 259D and 236A/E7 mAb clones, as per
Table 32.
1. Aliquot whole blood (up to 500 µL) into 5 mL round bottom
tubes.
2. Add extracellular Abs and stain for 15 min at room tempera-
ture.
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Figure 124. Quantification of
CD25highCD127low Tregs using whole
blood. (A) Count beads were gated
based on SSC properties and CD3
expression. (B-E) After the exclusion
of the beads, CD45+ whole blood
cells were selected, doublet cells were
excluded, and total lymphocytes were
gated based on SSC and FSC properties.
(F–H) From CD3+ T cells, CD4+CD8-
T cells were selected. Within the latter
gate, CD25highCD127low Tregs and T
conventional cells were identified. The
Trucount tubes contain a number of
beads that is used to calculate the abso-
lute counts of the Tregs per µL based
on the equation: (Number of positive
Treg events/Number of bead events) ×
(Number of beads per tube/Test blood
volume).
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Table 32. Panel for liquid Ab cocktail-based staining of CD25highCD127lowFOXP3+ Tregs in whole blood
Marker Dilution Fluorochrome Clone Company Catalog
CD3 1/100 BV786 UCHT1 BD 565491
CD4 1/100 AF700 RPA-T4 BD 557922
CD25 1/25 BB515 2A3 BD 564467
CD127 1/50 APC A019D5 BioLegend 351315
FOXP3∗ 1/25 PE 259D BioLegend 320207
FOXP3∗ 1/25 PE 236A/E7 Invitrogen 12-4777-42
* These FOXP3 clones are equivalent and either can be used in this panel.
3. Lyse red blood cells by adding 2 mL of BD FACSLyse solution
(10× concentrate diluted to 1× stock in distilled water). Vor-
tex to mix and incubate for 10–15 min at room temperature.
4. Add 2 mL staining buffer to wash and centrifuge at 500 × g
for 5 min.
5. Transfer cell pellet (usually up to 106 cells per condition) into
a V-bottom 96-well plate.∗∗
6. Add 200 µL of Buffer A solution fromBDHuman FOXP3 buffer
set (10× buffer A concentrate diluted to 1× stock in distilled
water) and incubate for 10 min at room temperature.
7. Centrifuge plate at 1000 × g for 3 min, flick off supernatant,
and blot to dry. It is important that the cell pellet is as dry as
possible.
8. Add 100 µL of Buffer C solution from the BD Human FOXP3
buffer set (50× buffer B concentrate diluted to 1× stock in
Buffer A) for at least 45 min in the dark at room temperature.
9. Add 100 µL of PBS and spin at 1000 × g for 3 min, flick off
supernatant.
10. Repeat step 9 as residual Buffer C can interfere with Ab stain-
ing.
11. Add intracellular Abs to cells and incubate for 30 min in the
dark at room temperature.
12. Wash cells in 100 µL of staining buffer, spin at 1000 x g for
3 min, flick off supernatant.
13. Resuspend in at least 150 µL of staining buffer for data acqui-
sition.
∗∗From step 6 onwards comparisons with eBiosciences FOXP3 staining kit used
method in section 1.14.4.2
1.14.3.8 Data analysis. Optimal staining of FOXP3 requires
efficient fixation and permeabilisation. Here, two commercially
available FOXP3 staining buffer kits were compared. Cells in whole
blood were stained as described above using either BD or eBio-
science FOXP3 staining buffers. FOXP3 and CD25 staining in total
CD3+CD4+ T cells was analyzed and the percent of cells that
were CD25highFOXP3+ was determined using a gate set on cells
stained with an isotype control (Figure 123A). The data show
that in this case there is better resolution of FOXP3 when cells
are prepared with BD buffers compared to eBioscience buffers
(Figure 123B). No difference in FOXP3 staining was observed
between the 236A/E7 or 259D anti-human FOXP3 Ab clones
(Figure 123C).
1.14.3.9 Pitfalls.
 Insufficient removal of residual buffer A will result in less effec-
tive permeabilization in buffer B. If staining in a 96-well V
bottom plate is not possible, then use a tube with a conical
(not round) bottom to aid in removing all residual buffer after
centrifugation steps.
 Buffer B deteriorates with exposure to light so always make
fresh (i.e., on the same day) working stocks of FOXP3 buffers.
1.14.3.10 Top tricks.
 Human FOXP3 buffer set (BD, #560098) is superior to FOXP3
Fix/Perm Buffer Set (Thermo Fisher eBiosciences, #00-5523-
00) for FOXP3 staining when whole blood is used.
 An alternate to step 2 is to add all extracellular and intracellular
Abs together in step 11 (provided extracellular Ab epitopes
are not affected by FOXP3 buffers; this must be determined
empirically).
1.14.3.11 Whole Blood Protocol 1C. Determination of
CD25highCD127low Treg absolute counts using BD Truecount
tubes, supplemented with drop in Abs (Figure 124)
As cells can be lost during wash and centrifugation steps
involved in routine FCM protocols, the use of a lyse-no-wash pro-
cedure (LNW) is optimal to accurately determine the absolute
count of leucocyte populations [989]. However, as LNW proce-
dures preclude fixing and permeabilization, in this protocol, Tregs
can only be identified using CD25 and CD127. The protocol is
based on combining of BD Trucount tubes and a 6 colour TBNK
Ab cocktail (commonly used for leucocyte enumeration in clinical
immunology laboratories) with drop in Abs to identify Tregs as
listed in Table 33. This procedure can be used to enumerate both
Tregs and other leucocyte populations (CD3, CD4, CD8, B cells,
and NK cells).
1.14.3.12 Staining Procedure.
1. Add the Abs listed in Table 33 to a Trucount tube (Cat number
340334).
2. Invert tube containing whole blood several times to ensure
homogeneity
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Table 33. Panel enumeration of Tregs (defined as CD25highCD127low) in whole blood
Marker Volume Fluorochrome Clone Company Catalog
CD3 20 µL BD 6 color
TBNK cocktail
FITC SK7 BD 644611 or 337166 (with 50
Trucount Tubes)
CD16/56 ′′ PE B73.1/NCAM16.2 ′′ ′′
CD45 ′′ PerCP-Cy5.5 2D1 ′′ ′′
CD4 ′′ PE-Cy7 SK3 ′′ ′′
CD19 ′′ APC SJ25 ′′ ′′
CD8 ′′ APC-Cy7 SK1 ′′ ′′
CD25 1 µL BV421 2A3 BD 564033
CD25 1 µL BV421 M-A251 BD 356114
CD127 1 µL PE-Dazzle 594 A019D5 Biolegend 351336
3. Aliquot exactly 100 µL whole blood into the bottom of a Tru-
count tube and vortex. Adopting a sound pipetting technique
(e.g., a low immersion depth of the pipette tip) and possibly
reverse pipetting in this step is advisable to ensure accuracy.
4. Incubate for 15 min at room temperature in the dark.
5. Prepare 1× lysing solution by adding 900 µL distilled water to
100 µL BD 10× Lysing solution (Cat number 349202).
6. Once 15 min incubation is complete, add 900 µL of diluted 1×
lysing Buffer and vortex immediately.
7. Incubate at room temperature for 15 min in the dark, vortex*
half way through incubation.
8. Vortex again and leave on ice until acquisition.
9. Vortex thoroughly immediately before acquisition.
Data analysis
Count beads were gated based on SSC properties and CD3
expression (Fig. 124A). After the exclusion of the beads, CD45+
whole blood cells were selected, doublet cells were excluded,
and total lymphocytes were gated based on SSC and FSC prop-
erties (Figure 124B-E). From CD3+ T cells, CD4+CD8- T cells
were selected. Within the latter gate, CD25highCD127low Tregs
and Tconvs were identified. The Trucount tubes contain a num-
ber of beads that is used to calculate the absolute counts of the
Tregs per µL based on the equation: (Number of positive Treg
events/Number of bead events)× (Number of beads per tube/Test
blood volume).
Top tricks
1. Efficient lysis of red blood cells is vital for optimal assay per-
formance. Ensure tubes are vortexed vigorously at each step
indicated.
2. Enumeration of Tregs is stable for up to 44 h post staining.
1.14.4 Staining Th-cell like Treg subsets in PBMCs.
1.14.4.1 Step-by-step sample preparation. The following pro-
tocol details how to stain Th-cell like Treg subsets in PBMCs (iso-
lated as previously described [983]). The gating strategy is in
Fig. 125 and the panel is detailed in Table 34. This gating strategy
is based on the current literature [863, 942, 990–992]. Additional
markers such as CD161 [869], CRTH2 [864] and CCR10 [878]
can also be added to further subcategorize the Th-cell like Treg
subsets (Table 35).
1.14.4.2 Staining of Th Treg subsets within PBMCs (Figure 125).
1. Transfer up to 105 cells per condition into a V-bottom 96-well
plate and wash in PBS.
2. Resuspend cells in PBS and add extracellular Abs and fixable
viability dye (FVD) (Table 34).
3. Incubate for 30 min in the dark at 4°C.
4. Top up with staining buffer, spin at 350 x g for 5 min at room
temperature, flick off supernatant and blot dry.
5. Wash cells with Fix/Permeabilization solution (1:4 dilution
of eBioscience fix/perm concentrate (#00-5123) in fix/perm
diluent (#00-5223)).
6. Add 100 µL Fix/Permeabilization solution and incubate either
for 1 h at room temperature, or for optimal results, at 4°C
overnight (NOTE: this is contrary to the manufacturer’s pro-
tocol).
7. Wash cells with 1× eBioscience permeabilization buffer (#00-
8333; diluted with distilled water) and centrifuge at 1000 ×
g for 7 min at room temperature.
8. Flick off supernatant and blot dry. It is critical that the cell
pellet is dry so that the subsequent step is optimal, see below.
9. Resuspend cells in 1× permeabilization buffer and add intra-
cellular Abs.
10. Incubate for 40 min in the dark at 4°C.
11. Wash cells in 100 µL of permeabilisation buffer.
12. Wash cells in 100 µL of staining buffer.
13. Resuspend in at least 150 µL of staining buffer for data acqui-
sition.
Note: This protocol can be modified to only carry out extra-
cellular staining so that viable Th-cell like Tregs can be iso-
lated. In this case, it is highly recommended to first perform a
CD25 pre- enrichment step, for example using Miltenyi Biotech’s
human CD25 microbeads II (#130-092- 983). Note that this
product blocks the epitope for the CD25 2A3 mAb, so alter-
nate mAb clones such as M-A251 or 4E3 are required for
staining.
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Figure 125. Identification of human Treg subsets in PBMCs. (A–C) Lymphocytes were gated according to their size and granularity, doublets
excluded and live CD4+ T cells gated. (D) Regulatory T cells (Treg) were identified as CD4+CD25highCD127low (red gate) and the remaining cells
were identified as “non-Treg” Tconvs (blue gate). (E & F) If the cells are fixed and permeabilized, FOXP3 staining can be performed. In (E), Dashed
lines show how CD25 negative, low and high expression are defined. In (F), FOXP3 expression in the CD4+CD25highCD127low Tregs (red line)
and non-Tregs (blue line) is shown, relative to a Treg FOXP3 FMO control (solid grey). Mean fluorescence intensity (MFI) values are provided. (G
and H) Memory Tregs and non-Tregs were selected as CD45RA– CD45RO+. (I–N) Treg and non-Treg Th subsets were defined according to their
expression of CXCR3, CCR4, and CCR6 as follows: Th17 (CXCR3–CCR4+CCR6+), Th1 (CXCR3+CCR4– CCR6–), Th17.1 (CXCR3+CCR4+CCR6+), and Th2
(CXCR3–CCR4+CCR6–).
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Figure 126. Gating strategy to identify CD25highFOXP3+ Tregs in human intestinal biopsies. (A) Representative Tregs staining from PBMCs and (B)
LPMCs. From total events, doublets were excluded based on FSC-H and FSC-A. Live cells were selected based on negative expression of FVD and
CD4+ T cells were gated based on CD3 and CD4 expression. From CD4+ T cells, Tregs were gated as CD25highFOXP3+ cells. From the Treg gate, the
expression of CD161 and Helios are shown. Dashed lines show how CD25 negative, low, and high expressions are defined.
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Table 34. List of Abs used for staining Tregs subsets from PBMCs
Marker Dilution∗∗ Fluorochrome Clone Company Catalog
Fixable viability dye 1/1000 eFluor780 eBioscience 65-0865-18
CD4 1/100 V500 RPA-T4 BD 560768
CD25 1/50 PE 2A3 STEMCELL Technologies 60153PE
CD127 1/50 APC-AF700 R3434 Beckman Coulter A71116
CCR4 1/50 BV605 L291H4 BioLegend 359418
CCR6 1/50 APC G034E3 BioLegend 353416
CXCR3 1/50 BV421 G025H7 BioLegend 353716
FOXP3 1/50 PE-CY7 236A/E7 Invitrogen 25-4777-42
CD45RA 1/50 BV785 HI100 BioLegend 304140
CD45RO 1/50 FITC UCHL1 BD 561887
** These dilutions have been optimised for our specific Ab lots. Each new mAb lot should be re-titrated.
Table 35. Treg populations in the blood
T cell
population Phenotype
Relative
frequency
Total Tregs CD4+CD25highCD127low 5% of CD4+
T cells
Th1 Tregs CCR6–CCR4–CXCR3+ 5% of CD25high
CD127low
Th17 Tregs CCR6+CCR4+CXCR3– 30% of CD25high
CD127low
Th17.1 Tregs CCR6+CCR4+CXCR3+ 20% of CD25high
CD127low
Th2 Tregs CCR6–CCR4+CXCR3– 5% of CD25high
CD127low
1.14.4.3 Data analysis. Total lymphocytes were gated
according to their forward and side scatter properties (Fig. 125A),
doublet events were excluded (Fig. 125B) and live CD4+ T cells
were gated (Fig. 125C). Tregs can be identified from the total
live CD4+ T cells according to their expression of CD25, CD127,
and/or FOXP3 (Fig. 125D and E). As previously mentioned, at
least two of these markers should be used to defined human
Tregs and where possible, the use of all three markers is ideal.
In this analysis, Tregs were defined as CD4+CD25highCD127low
(Fig. 125D) or CD4+CD25highFOXP3+ (Fig. 125E). As shown
in Fig. 125F, the majority of CD4+CD25highCD127low cells are
FOXP3+ but FOXP3– cells still exist in this population, empha-
sising the importance of using a combination of different mark-
ers to identify human Tregs. CD4 helper T cell and Treg sub-
populations can be delineated from CD45RA–CD45RO+ memory
cells (Fig. 125G and H) by analysing the expression of various
homing receptors. Here, Th cell subsets were defined accord-
ing to their expression of CXCR3, CCR4 and CCR6. Memory
cells were separated according to their expression of CXCR3
(Fig. 125I and J), after which CCR4 and CCR6 expression was
used to subgate Th cell subsets (Figure 125K–N). Th cell subsets
were defined as follows: Th17 (CXCR3–CCR4+CCR6+), Th17.1
(CXCR3+CCR4+CCR6+), Th1 (CXCR3+CCR4–CCR6–), and Th2
(CXCR3–CCR4+CCR6–).
1.14.4.4 Pitfalls.
1. If the cell pellet isn’t effectively dried before the fixation or
permeabilization steps, then fixation and intracellular staining
are not optimal. Use a V-bottom plate to stain and blot plate
dry after flicking off supernatant for best results. (Steps 5 and
8)
1.14.4.5 Top tricks.
1. Ensure Fixable Viability Dye is stained in PBS as the presence
of FCS will inhibit staining.
2. If the panel contains more than one Brilliant Violet conjugated
Ab, then staining should be performed in Brilliant Stain Buffer
(BD, #566385).
3. Make up FOXP3 buffers on the same day for each experiment.
4. Wash with fix/perm before step 5 and wash with perm buffer
before step 8.
1.14.5 Staining CD25highFOXP3+ Tregs from human intestinal
biopsies.
1.14.5.1 Step-by-step sample preparation. There is increasing
interest in the role of tissue-resident Tregs [787]. As discussed
above, it is significantly more difficult to confidently identify Tregs
in tissues versus blood because of the high proportion of activated
Tconv cells. In addition, tissues must often be treated with colla-
genase which can lead to removal of Treg-associated cell surface
proteins. Below we detail a protocol to stain Tregs in intestinal
biopsies and illustrate how the resulting data compare to that
obtained with PBMCs.
1.14.5.2 Isolation and analysis of lymphocytes from intestinal
biopsies (Figure 126).
 Intestinal biopsies (usually 4–6 punches 4 mm in diame-
ter) are collected in complete media at room temperature and
lamina propria mononuclear cells (LPMCs) are isolated within
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Table 36. List of Abs used for staining CD25highFOXP3+Tregs from intestinal biopsies
Marker Dilution∗∗ Fluorochrome Clone Company Catalog
Fixable viability dye 1/1000 eFluor780 eBioscience 65-0865-18
CD3 1/50 V500 UCHT1 BD Biosciences 561416
CD4 1/50 AF700 SK3 BioLegend 344622
CD25 1/25 BV421 BC96 BioLegend 302630
FoxP3 1/25 PECy7 236A/E7 eBioscience 25-4777-42
Helios 1/25 AF647 22F6 BioLegend 137218
CD161 1/25 BV875 DX12 BD Biosciences 744096
** These dilutions have been optimised for our specific Ab lots. Each new mAb lot should be re-titrated.
2—4 h of collection following the protocol described in
ref. [993].
 Briefly, biopsy specimens are transferred to a 10 mL solution
of Collagenase VIII and DNAse and incubated for 1 h at 37°C,
shaking vigorously every 20 min. After incubation, cells are
passed through a 100 µm cell strainer, washed and LPMCs are
isolated by centrifugation over a Percoll gradient (resuspended
in 40% Percoll, underlayed by an equal volume of 80% Percoll).
 After washing, cells are incubated in complete medium
overnight at a concentration of 2 × 106 cells/mL before stain-
ing. Expected average yields are 2 × 106 LPMCs per sample (if
—four to six biopsies are pooled together).
 Staining of LPMCs is then performed using the PBMC staining
protocol (Protocol 2) using the panel outlined in Table 36.
1.14.5.3 Data analysis. From total events, doublets were
excluded based on FSC-H and FSC-A and live CD4+ T cells were
selected based on negative expression of FVD and positive expres-
sion of CD3 and CD4 From CD4+ T cells, Tregs were gated as
CD25highFOXP3+ cells. From the Treg gate, the expression of
CD161 and Helios are shown. Dashed lines show how CD25 nega-
tive, low, and high expression are defined. This strategy was used
to gate Tregs based on CD25high and CD127low expression from
PBMCs and LPMCs.
1.14.5.4 Pitfalls.
 Many surfacemarkers are affected by collagenase digestion so it
is imperative to systematically test all Ab clones before finalizing
the staining panel (Summary table of validated clones is shown
in Table 37).
1.14.5.5 Top tricks.
 Ensure that the collagenase incubation is done in a 50 mL,
rather than a 14 mL, falcon tube even if only using 10 mL of
solution. The added room allows more vigorous shaking, which
is key to getting a good yield.
Subjects and samples. Human peripheral blood and human
colon biopsies were obtained following protocols approved by
Table 37. Collagenase VIII compatible Abs for human Treg staining.
Note that this compatibility may be affected by different tissue
digestion protocols
Marker Validated Clone
CD127 A019D2
LAG3 3D5223H
CD25 BC96
ICOS C398.4a
CD3 UCHT1
CD4 SK3
CD45 HI30
CD45RA HI100
CD45RO UCHL1
CD69 FNSO
CTLA-4 BN13
Clinical Research Ethics Boards of the University of British
Columbia (H18- 02553 and H15-01034).
1.14.5.6 Materials. Common Reagents:
 Staining buffer: 1× Dulbecco’s PBS (ThermoFisher Scientific,
#14190-144) supplementedwith 2%FBS (VWR,#97068-085).
 Complete media: RPMI 1640 (ThermoFisher Scientific,
#11879020) supplemented with 10% FBS, 1% Peni-
cillin/Streptomycin (ThermoFisher Scientific, #15140122),
and 1% GlutaMAX (ThermoFisher Scientific, #35050061).
 Lymphoprep (Stemcell Technologies, #07861).
 Ammonium Chloride (StemCell, #07850).
 FOXP3 Fix/Perm Buffer Set (Thermo Fisher eBiosciences, #00-
5523-00).
 Human FOXP3 buffer set (BD, #560098).
 BD FACSTM Lysing Solution (BD, #349202).
 Collagenase VIII (Sigma-Aldrich, #C2139).
 DNAse (STEMCELL Technologies, #7900).
 Percoll (GE Healthcare, #17-0891-02).
Cytometer and analysis
BD Fortessa X20, configuration as per Table 38. Analysis per-
formed using FlowjoTM Version X (Treestar Inc, v10.5.3).
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Table 38. Fortessa X20 cytometer configuration
Filters Mirrors
488 nm Blue Laser 488/10
530/30 505 LP
695/40 685 LP
640 nm Red Laser 670/30
730/45 710 LP
780/60 750 LP
561 nm Yellow-Green Laser 585/51
610/20 600 LP
670/30 635 LP
710/50 685 LP
780/60 750 LP
405 nm Violet Laser 450/50
525/50 505 LP
560/40 545 LP
585/52 570 LP
610/20 600 LP
670/30 630 LP
710/50 685 LP
780/60 750 LP
1.15 Human γδ T cells
1.15.1 Overview. Recently there has been a surge of interest in
γδ T cells, as this cell type is increasingly being recognized to play
important roles in multiple disease settings, such as in cancer,
autoimmune disorders, and microbial infections. A relatively easy
and quick method to analyze these cells is by FCM. Recently, new
markers and Ab combinations have been deployed that identify the
major γδ T cell subsets. However, phenotyping of γδ T cells using
FCM remains challenging and thus here we provide an optimized
protocol and mAb combinations to detect these human γδ T cell
subsets.
1.15.2 Introduction. γδ T cells represent an unconventional
T cell subset that express a T cell receptor (TCR) constructed of a
γ− and δ−chain. These immune cells play important roles in the
responses against microbes [994] and tumors [995]. In contrast to
classical αβ T cells, γδ cells have been described to respond to an
array of non-peptide antigens (Ags) [996] independent of MHC
proteins [997]; see also Chapter VI Section 1.7 Murine γδ T cells.
In humans, γδ T cells are typically divided into Vδ2+ and Vδ2− sub-
sets [998]. Most γδ T cells in the peripheral blood are Vγ9+/Vδ2+
and respond to phosphoAgs (pAgs) such as prenyl pyrophosphate
metabolites that are commonly produced by microbes and host
derived pAgs are upregulated in some tumor cells [999–1001].
Conversely, Vδ2− subsets are positioned across multiple tissues
and are a minor subset in the peripheral blood [798, 1002].
A current overview of human γδ T cell subsets is provided in
Fig. 127.
1.15.2.1 Human Vδ2+/Vγ9+ T cells (innate-like). Vδ2+/Vγ9+
T cells (also referred to as Vγ2+/Vδ2+ T cells in some publica-
tions) expand extra-thymically and microbial-derived pAgs poten-
tially trigger polyclonal expansion of these cells in the periphery
following birth [1003, 1004]. Enriched Vδ2+/Vγ9+ T cell num-
bers are already present in fetal peripheral blood and these cells
show restricted complementarity determining region 3 (CDR3) γ9
usage [1005]. In addition, similar Vγ9 TCR sequences are detected
in multiple donors (i.e., “public” sequences) and are shared in
samples from cord and adult blood [1000, 1006]. Vδ2+/Vγ9+
T cells are generally enriched in the circulation and respond to
pAgs such as isopentenyl pyrophosphate (IPP), which are elevated
in tumor cells and (E)-4-Hydroxy-3-methyl-but-2-enyl pyrophos-
phate (HMB-PP), which is produced by bacteria and parasites
[999]. Together, this evidence hints at the innate-like functions
of these γδ T cells.
1.15.2.2 Human Vδ2− and Vδ2+/Vγ9− T cells. The functions
of Vδ2− γδ T cells are currently unclear, but these cells have
been demonstrated to expand in response to tumor cells, bac-
teria, parasites, and viruses. The majority of Vδ2− γδ T cells
express a Vδ1 TCR chain pairing, while a minority express other
Vδ TCR chains, notably Vδ3, Vδ4, Vδ5, and Vδ8. Studies investi-
gating Vδ1 and Vδ3 have been aided by critical commercial Ab
reagents, although Vδ3 Abs are currently only available upon
request (from Beckman Coulter; clone P11.5B). The identifica-
tion of Vδ4, Vδ5, and Vδ8 has been restricted to sequencing based
approaches as commercial FCM reagents are not available. Stud-
ies that have focused on Vδ1 and Vδ3 have now shed light on
the receptor diversity and physiology of these subsets in the tis-
sues and in infection, such as cytomegalovirus [1000, 1007].
Vδ1+ T cells display a CD27lo/−CD45RA+ phenotype when clon-
ally expanded [1000, 1007] and display heterogeneous γ chain
usage [1000, 1007]. Moreover, uniformly in cord and, at mixed
levels, in adult blood, Vδ1+ T cells exhibit a diverse and polyclonal
population, expressing markers of a na¨ıve T cell population—this
is reviewed in ref. [1008]. This subset of γδ T cells is suggested to
play a role in the adaptive immune response, as clonal expansions
of these cells can be found in peripheral blood and liver tissue
of adults whereas this is not evident in cord blood [1000, 1009].
These clones are likely generated in response to cellular stress or
microbial infection, as observed in acute cytomegalovirus infec-
tion [1000, 1010]. Additionally, a sub-population of Vδ2+ T cells
has been identified that generally do not express the Vγ9 chain
pairing (termed Vδ2+/Vγ9− T cells). This population of γδ T cells
undergoes dramatic clonal expansion in cytomegalovirus infec-
tion and can be identified using FCMmarkers similar to Vδ1+, i.e.,
CD27lo/−CD45RA+ CX3CR1+ cells (effector) and a na¨ıve poly-
clonal compartment characterized as CD27hiCD45RA+/- CX3CR1−
[1000]. Together, these recent findings surrounding Vδ2− and
Vδ2+/Vγ9− γδ T cells indicated that these cells follow an adaptive
biology.
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Figure 127. Human γδ T cells found in the peripheral blood. Each population is divided based on their Vδ chain usage, primarily due to the
availability of TCR Vδ1 and TCR Vδ2 mAbs. Each subset is displayed alongside a set of cell surface markers that accurately define them in the
steady state. Vγ9−/Vδ2+ and Vδ2− γδ T cells seem to undergo postnatal selection in the periphery from a naı¨ve γδ T cell pool. Vδ2+/Vγ9+ T cells
are established in the perinatal period and are rapidly matured after birth, resulting in a uniform responsiveness to pAgs. Non-Vδ1 or -Vδ2 T cells
express a Vδ3-8 TCR chain pairing and are rare in the peripheral blood but enriched in the tissues, such as the liver. The markers that define them
and if they form further subsets is unclear.
1.15.2.3 Human γδ T cells in cancer immunotherapy. γδT cells
are now considered a major target for the development of novel
cellular immunotherapies. This is in part due to their ability to
recognize tumor cells through the γδTCR or natural killer cell
receptors (NKRs), such as NKG2D, NKp30, NKp44, and NKp46
that decorate their cell surface [1011]. The endogenous host pAg,
isopentenyl pyrophosphate, and the ligands for NKRs are often
overexpressed in transformed cells. As such, Vδ2+/Vγ9+ T cells
have been a principal candidate for immunotherapy as they exert
strong lytic activity toward tumor cell lines [1012], which can
be mediated via the production pro-inflammatory cytokines and
apoptosis-inducing molecules [1013]. More recently, Vδ1+ T cells
have rapidly become a major avenue for the creation of a cellular
immunotherapy and display potent cytolytic capacity toward a
range of tumor cell lines [1014]. The main avenue of delivery is
via adoptive transfer of in vitro expanded γδ T cells into cancer
patients and some clinical trials have shown that these cells may
be effective at limiting tumor progression.
1.15.2.4 FCM for human γδ T cells. A uniform staining and
gating strategy is needed to identify γδ T cells and their subsets.
The need for a well-optimized protocol has recently been high-
lighted, as it was shown that Vδ2+/Vγ9− T cells could only be
identified with FCMwhen using the anti-Vδ2 Ab clone 123R3 (Mil-
tenyi), while this population could not be identified when the anti-
Vδ2 Ab clone B6 (BD and BioLegend) was used [1000]. Moreover,
the combination of some commercial pan γδ TCR mAb (Biolegend
(B1), BD (11F2) and Beckman Coulter (IMMU510) can interact
with Vγ9, Vδ1, and Vδ2 (example in Fig. 128), causing disruption
to γδ TCR staining. Thus, here, we describe the materials and a
well-optimized protocol to identify subsets of human γδ T cells.
1.15.3 Step-by-step sample preparation.
1.15.3.1 PBMC Isolation. PBMCs can be isolated from hep-
arinized venous blood or a buffy coat. First, the buffy
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Figure 128. Representative dot plots of Vδ2+ γδ T cells in human peripheral blood mononuclear cells (hPBMCs). This gating strategy involves
gating of Lymphocytes > Single cells (FSC-W/FSC-H) > Single cells (SSC-W/SSC-H) > CD45+DAPI- cells > CD3+ T cells. CD3+ cells were stained
with Vδ2 clone 123R3 (top) or Vδ2 clone B6 (bottom) and anti-γδ TCR (clone 11F2). (Figure kindly contributed by Inga Sandrock [Hannover Medical
School, Germany]).
coat/peripheral blood has to be diluted 1× in PBS, followed by
transfer of the cell suspension on LymphoprepTM, which is density
gradient centrifuged according to the manufacturers’ instructions.
PBMCs are frozen in 90% FCS and 10% DMSO. See Table 39 for
details on buffers and reagents.
1.15.3.2 FCM: Surface marker staining. After mononuclear
cells have been obtained from either tissue or peripheral blood, the
following protocol should be followed for the staining of surface
markers on γδ T cells (subsets):
1. Thaw the PBMCs, centrifuge for 2 min at 400 × g at 4°C. Add
500 000 PBMCs to a U-bottomed 96-well plate.
2. Wash PBMCs in 200 µL PBS per well for 2 min at 400 × g at
4°C. Discard the supernatant.
3. Add 50 µL Zombie AquaTM diluted in PBS (to stain dead cells;
Table 39) per well and incubate for 10 min at room tempera-
ture in the dark.
4. Add 150 µL FACS buffer per well, consisting of sterile PBS +
20% FCS + 0.04% Sodium Azide, and centrifuge the plate for
2 min at 400 × g at 4°C. Discard the supernatant.
5. Block Fc receptors to prevent nonspecific binding of mAbs by
adding 50 µL TruStain FcX (diluted 1:100 in FACS buffer).
Incubate for 10 min on ice in the dark.
6. Prepare a cocktail of the mAbs according to Table 39. Dilute
the mAbs in FACS buffer. Stain the cells with 50 µL Ab cocktail
per well on ice in the dark for 15 min.
7. Add 150 µL FACS buffer per well and centrifuge the plate for
2 min at 400 × g at 4°C. Discard the supernatant.
8. Resuspend cells in 200 µL FACS buffer per well, transfer the
cell suspension to FACS tubes, and keep on ice until acquisition
at the BD LSRFortessaTM X-20 (BD Biosciences, San Jose, CA).
1.15.3.3 FCM: Intracellular marker staining. The protocol
can be extended by staining for intracellular targets, such as for
example, Granzyme A and B and perforin. The following steps
should be followed after step 6 of the surface marker staining
protocol:
1. Add 50 µL IC Fixation buffer (eBioscience; Table 39) per well
and incubate for 30 min at 4°C in the dark. Centrifuge the plate
for 2 min at 400 × g at 4°C. Discard the supernatant.
2. Add 50 µL Permeabilization buffer (Perm buffer; eBioscience;
Table 39) per well and centrifuge the plate for 2 min at 400 ×
g at 4°C. Discard the supernatant.
3. Add 50 µL Fc block, diluted 1:100 in Perm buffer to block
aspecific binding of mAbs to Fc receptors. Incubate for 10 min
at room temperature in the dark.
4. Prepare a cocktail of the mAbs (example for intracellular tar-
gets in Table 40). The mAbs should be diluted in Perm buffer.
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Figure 129. Gating strategy to define human γδ T cells in the peripheral blood. The gating strategy used to define human γδ T cells involvesmanual
gating of Lymphocytes > Single Cells > Live cells > CD3+ cells > TCRγδ+ T cells. The use of TCRγδ vs TCRαβ mAbs provides the consistent ability
to accurately discriminate γδ T cells even in the most challenging samples i.e. where γδ T cells numbers are very low or viability is poor. γδ T cell
subsets are then defined based on expression of TCRγδ+ T cells > Vδ1+, Vδ2+, Vδ1/2−. Vδ2+ T cells can then be sub-divided in those that express
Vγ9+ or not Vγ9− (rare in peripheral blood).
Per well, add 50 µL Ab cocktail and incubate for 30 min at
room temperature in the dark. Centrifuge the plate for 2 min
at 400 × g at 4°C. Discard the supernatant.
5. Resuspend cells in 200 µL FACS buffer per well, transfer
to FACS tubes, and keep on ice until acquisition at the BD
LSRFortessaTM X-20.
Table 39. Characteristics of mAbs to identify γδ T cell subsets in peripheral blood
Buffers/Reagents for FCM
Buffer/Reagent Provider City Country Catalogue Number Dilution
Lymphoprep Axis-Shield PoC Oslo Denmark NA NA
Zombie Aqua BioLegend San Diego, CA USA 423101 1:500
TruStain FcX Biolegend San Diego, CA USA 422302 1:100
IC Fixation Buffer eBioscience San Diego, CA USA NA 1:4
Perm Buffer eBioscience San Diego, CA USA NA 1:10
Abs for FCM
mAb Fluorochrome Clone Provider Catalog number Dilution
anti-CD3 BUV395 UCHT1 BD Biosciences 563546 1:150
anti-CD8 BUV496 RPA-T8 BD Biosciences 564804 1:200
anti-Vγ9 PE-Cy5 IMMU 360 Beckman Coulter A63663 1:400
anti-CD27 PE-Dazzle 594 M-T271 BioLegend 356422 1:150
anti-CD45RA BV711 HI100 BioLegend 304138 1:200
anti-CX3CR1 PE-Cy7 2A9-1 BioLegend 341612 1:150
anti-IL-7Rα BV605 A019D5 BioLegend 351333 1:100
anti-γδ TCR PE REA591 Miltenyi 130-114-038 1:200
anti-Vδ1 FITC REA173 Miltenyi 130-100-532 1:100
anti-Vδ2 APC 123R3 Miltenyi 130-095-803 1:200
anti-αβ TCR APC-Vio770 REA652 Miltenyi 130-114-062 1:100
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Table 40. Characteristics of mAbs to identify intracellular targets in γδ
T cell subsets in peripheral blood
mAb Clone Provider
Catalogue
Number Dilution
anti-Granzyme A CBO9 BioLegend 507221 1:100
anti-Granzyme B GB11 BioLegend 372209 1:100
anti-Perforin B-D48 BioLegend 353303 1:80
Figure 130. Functional sub-populations of human Vδ2+/Vγ9+ T cells.
After using the gating strategy to define human γδ T cells described
in Fig. 129, human Vδ2+/Vγ9+ T cells can be further split into effector
subsets based on CD27, CD28, and CD16 expression. These populations
are highly variable between individuals and it is unclear how these
populations are derived.
1.15.4 Data analysis/gating strategy. We analyzed our data
using the FlowJo software (version 10.5.3, Tree Star). In Fig. 129,
we show the gating strategy that we used. First, the lympho-
cytes are gated in the FSC-A/SSC-A plot. After exclusion of dou-
blets in the FSC-A/FSC-H plot, we gated on live CD3+ T cells in
the CD3/Live/dead (L/D) plot. In the αβ TCR/γδ TCR plot, γδ
TCR+ T cells and αβ TCR+ T cells were gated. The γδ TCR+
T cell population can be further divided into Vδ1+ and Vδ2+
T cells using the Vδ2/Vδ1 plot. Lastly, within the Vδ2+ T cells
we gated on Vδ2+/Vγ9+ T cells. Within the αβ TCR+ T cell popu-
lation, we gated on CD8+ T cells in the CD8/SSC-A plot (plot not
shown).
Vδ2+/Vγ9+ γδ T cells can be further delineated into func-
tional subsets based on the expression of CD27, CD28, and the
acquisition of CD16 (Fig. 130). Definitions of these subsets are
detailed in ref. [1015]. These subsets may play a role in the
Figure 131. Identifying naı¨ve and effector sub-groups of adaptive
Vδ2+/Vγ9− and Vδ2− γδ T cells. After application of the gating strat-
egy described in Fig. 129, the distribution of clonally diverse naı¨ve γδ
T cells can be identified by the expression of CD27 and CD45RA (CD27hi;
marked in red) and clonally expanded effector γδT cells (CD27lo;marked
in blue), see Davey et al. 2017 [1009]. These naı¨ve and effector subsets
display very distinct phenotypes and can be further defined by the
expression of CX3CR1, Granzyme A/B, or IL7Rα. The data shown here
is an example of the expression of these markers in human Vδ1+ γδ
T cells.
potent antimicrobial activity in bacterial infections producing
HMB-PP.
Vδ2+/Vγ9− and Vδ2− γδ T cell subsets can be further divided
into na¨ıve (CD27hi) and effector (CD27lo) cells (Fig. 131) [1000].
CD8+ T cells were included as a control subset. Within each subset,
CD27hi γδ T cells are characterized by the absence of CX3CR1
and presence of IL-7Rα expression (Fig. 128). On the other hand,
CD27lo γδ T cells do express CX3CR1, whereas these cells do not
express IL-7Rα (Figure 128).
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 Flow cytometric phenotyping of cells across species and tissues 1691
1.15.5 Pitfalls and top tricks. When analyzing γδ T cells by FCM,
several pitfalls should be kept in mind. First, with this 12-color
staining panel it is very important to have a well setup compensa-
tion. Second, themAbs should be tested and titrated so that correct
dilutions can be determined. This not only saves valuable mAbs
but also ensures that the dilution is matched to the expression
level of the target and fluorochrome intensity. Third, γδ T cells
represent only a small proportion within T cells in the periph-
eral blood and in a scatter plot it might be harder to set gates.
In this case a contour or pseudocolor plot might be used to be
better able to detect different populations. Lastly, flow cytometric
analysis of in vitro stimulated human γδ T cells expanded with
mitogenic CD3 mAb (OKT-3 or UCHT-1 clones), anti-Vδ1 (TS8.2),
or anti-TCRγδ (B1) mAbs, can be particularly challenging. The
internalization of the γδTCR complex upon stimulation with these
mAbs usually occurs within minutes, causing a decreased surface
expression of the γδTCR. Additionally, these mitogenic Abs remain
bound to their epitopes and can block the staining of γδTCR and
CD3 molecules in later Ab staining protocols, hampering the dis-
crimination of CD3+TCRγδ+ and CD3+TCRαβ+ cells. This problem
can be circumvented by sub-culturing cells for 2 to 3 days in the
absence of CD3 mAb and/or -TCRγδ mAbs, thereby restoring the
availability of the γδTCR complex. Of note that TCR internaliza-
tion does not occur when γδ T cells are cultured in the presence
of pAgs (IPP or HMB-PP).
Top tricks for the staining protocol are to work cold and quick
when following this staining protocol. When analyzing intracellu-
lar targets, the FoxP3 intranuclear staining buffer set should be
used as it gives the best staining results.
1.16 Human NKT cells
1.16.1 Overview. Natural Killer T cells (NKT cells) are a subset of
lipid-reactive T cells restricted to the MHC I-like molecule CD1d.
Like other “unconventional” T cell subsets (such as MAIT and
γδ T cells), NKT cells display a memory-like phenotype and rapidly
release a broad array of cytokines following activation [997].
Indeed, the functional diversity displayed by NKT cells under-
pins their appreciated immunomodulatory role in various diseases,
including infection, autoimmunity, and cancer [1016–1018]. The
NKT cell family can be subdivided into Type I and Type II NKT cells
based on TCR gene usage and/or CD1d-lipid antigen reactiv-
ity [1019]. As methods to definitively identify Type II NKT cells
are still developing, this section provides guidelines for the iden-
tification of the more extensively described Type I, or invariant
(iNKT) NKT cell subsets using FCM, with an emphasis upon the
different reagents and techniques required to study these evolu-
tionarily conserved cells.
1.16.2 Introduction. Initially, NKT cells were described in
mice as a lymphocyte population displaying restricted αβ TCR
usage and the co-expression of the NK cell-associated receptor
NK1.1, which resulted in the moniker “Natural Killer T cells”
being adopted [1020] (see also Chapter VI Section 1.8 Murine
NKT cells). However, expression of NK1.1 in mice, and the
ortholog CD161 in humans have since been shown to be ineffi-
cient markers for this T cell subset, which are now more definitely
categorized by their T cell receptor (TCR) composition, and their
recognition of particular CD1d-ligands. The canonical human
NKT cell TCR is composed of an invariant α-chain comprising
Vα24 and Jα18 (TRAV10 and TRAJ18) gene segments, paired
with a Vβ11+ (TRBV25-1) β-chain. This represents a TCR
heterodimer that is highly conserved throughout the human pop-
ulation, with orthologous sequences also being common to other
mammalian species [1021–1024]. Accordingly, this T cell subset
is often referred to as “invariant,” or iNKT cells from primates to
rodents [1020]. One of the hallmarks of iNKT cell TCRs is their
recognition of the prototypic CD1d-ligand α-galactosylceramide
(α-GalCer) [1025].While this interaction is also used to demarcate
Type I (α-GalCer-reactive) NKT cells from the more TCR-diverse
(α-GalCer-non-reactive) Type II NKT cell subset, not all T cells
capable of recognizing the CD1d-α-GalCer complex necessarily
express the Vα24-Jα18/Vβ11 iNKT cell TCR. For example, human
CD1d-α-GalCer reactive αβ T cells that lack Vα24 and/or Vβ11
expression have been widely described [1026–1030] and γδ T cells
that interact with CD1d-α-GalCer have also been reported [1031].
Thus, an appreciation of the complexities that exist within the
NKT/CD1d-restricted T cell pool is crucial for those designing
experiments to study these cells. Although it is common for the
terms “NKT cells,” “iNKT cells,” and “Type I NKT cells” to be used
synonymously, there are significant differences between these
classifications, and differences in the approaches used to identify
the cells. The best choice for individual researchers will depend on
the specific question(s) they are aiming to address. Herein, we dis-
cuss the various ways that NKT cells can be identified using FCM,
and the potential advantages and disadvantages of these alternate
methodologies.
1.16.3 Identifying human NKT cells via their antigenic-recognition.
The prototypic NKT cell antigen KRN7000 was developed by the
Kirin brewing company in the 1990’s [1025, 1032, 1033]. This
α-linked galactosylceramide compound was modeled on glycol-
ipids isolated from extracts of marine sponge displaying antitu-
mor activity in murine disease models. This reagent (KRN7000)
has since been widely used to study the functional properties of
both mouse and human NKT cells [1034]. Despite the curious ori-
gins of this T cell antigen, structurally similar glycolipids have
since been identified from numerous bacterial species [1035],
supporting the physiological relevance of NKT cell-specificity for
such compounds. In addition to KRN7000, various α-GalCer ana-
logues have also been synthesized, which elicit distinct functional
responses [1036–1038] and display varied affinities for NKT cell
TCRs [1039, 1040]. While the potency of KRN7000 has made it
the most widely used antigen for investigating NKT cell function-
ality, its saturated lipid-component renders it a relatively insolu-
ble reagent. Thus, for the purpose of identifying NKT cells using
CD1d-tetramers, it can prove suboptimal, due to its inefficient
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Figure 132. Gating on human blood NKT cells. (A) Lymphocytes are distinguished amongst PBMCs based on their relative FSC-A and SSC-A
intensities. Single cells are then isolated by their relationship between FSC-H versus FSC-A, and SSC-W versus SSC-A. To remove any non-specific
or TCR-independent CD1d-tetramer staining, dead cells are removed from analysis based on their uptake of LIVE/DEADTM Fixable Near-IR viability
dye. Monocytes and B cells are also excluded based on their CD14 and CD19 expression respectively. (B) The frequency of circulating Type I
NKT cells, as determined by co-staining for CD3ε and α-GalCer (PBS-44)-loaded CD1d-tetramer (left) in relation to a vehicle control CD1d-tetramer
(right). (C) The frequency of iNKT cells assessed by co-staining with 6B11 and anti-Vβ11. (D) Co-staining with anti-Vα24 and anti-Vβ11, which
nonexclusively enriches for iNKT cells.
loading into CD1d in a cell-free, in vitro setting. Due to this,
more soluble α-GalCer analogues (with unsaturated lipid frac-
tions), such as PBS-44 [1041] and PBS-57 [838] have become
preferred alternatives. For researchers wanting to investigate Type
I or iNKT cells, PBS-57-loaded CD1d tetramers are currently avail-
able from the NIH tetramer core facility [1042], conjugated to a
number of fluorochromes. Alternatively, the manufacture of solu-
ble CD1d for tetramer manufacture is a viable option, described
elsewhere within the literature [821, 1043, 1044]. For those wish-
ing to explore the differential antigenic-recognition characteris-
tics within the larger CD1d-restricted T cell pool [1019], the
“in-house” production of CD1d tetramers loaded with antigen
of choice, will provide scope to interrogate interactions with the
diverse range of established, and putative CD1d-ligands.
1.16.4 Identifying human NKT cells via their TCR usage. The
highly conserved TCR usage displayed by Type I or iNKT cells is
a factor that can be exploited to identify these cells via FCM, and
there are two approaches commonly used to achieve this. First, co-
staining with anti-Vα24 and anti-Vβ11, which enriches for T cells
expressing the canonical iNKT cell TCR αβ heterodimer. However,
there is no assurance that all cells isolated by this means will be
α-GalCer-reactive, or CD1d-restricted. The second, and arguably
more convincing, approach is using the mAb 6B11, which displays
specificity toward the CDR3α loop of the Vα24-Jα18 iNKT cell
TCR [1045, 1046]. This approach, in conjuncture with anti-Vβ11
staining, will further ensure isolation of cells that express the
canonical iNKT cell TCR.
1.16.5 Step-by-step sample preparation. The following method-
ologies specifically relate to the experiment depicted in
Fig. 132. However, adherence to these general principles
will enable the specifics to be adjusted to suit other experimental
requirements.
1.16.5.1 Protocol: Generating α-GalCer-loaded CD1d-tetramer.
Human CD1d was generated in modified human embryonic kid-
ney 293S cells (HEK293S cells) and enzymatically biotinylated as
previously described [1047, 1048].
 Biotinylated monomeric CD1d was loaded with α-GalCer (0.5%
[v/v] tyloxapol in TBS) by incubation overnight at 37°C at a
6:1 molar ratio (α-GalCer:CD1d). Vehicle control included the
tyloxapol in TBS, but not did not contain α-GalCer.
 CD1d tetramers were generated in house using 10 µg of biotiny-
lated CD1d monomer, mixed with a total 2 µg of streptavidin
BV421 added in eight sequential steps (in order to optimize
CD1d tetramerization) at 10 min intervals at 4°C.
1.16.5.2 Protocol: Isolation and analysis of NKT cells in cryop-
reserved PBMCs.
 Add thawed PBMCs (5 × 107 cells) to a 50 mL conical tube
containing 40 mL of RF-10 (Gibco) media.
 Centrifuge cell suspension for 4 min with 400 × g at 4°C.
 Aspirate supernatant and resuspend cellular pellet with 20 mL
RF-10 (Gibco) containing 100 µg DNAse I (Sigma–Aldrich) then
keep cell suspension at 4°C for 30 min.
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1.16.5.3 Protocol: Surface staining.
 Centrifuge cell suspension for 4 min with 400 × g at 4°C.
 Aspirate supernatant and resuspend cellular pellet with 500 µL
of (1:10 diluted) human FcR-blocking reagent (Miltenyi Biotec)
in FCM buffer and incubate at 4°C for 20 min.
 Aspirate supernatant and resuspend cellular pellet with 500 µL
of LIVE/DEADTM Fixable Near-IR (ThermoFisher) diluted in
PBS, keep cell suspension in the dark at 4°C for 30 min (The
concentration of this reagent should be titrated to ensure opti-
mal staining).
 Add 20 mL of FCM buffer and centrifuge cell suspension for 4
min with 400 × g at 4°C.
 Aspirate supernatant and resuspend cellular pellet with 200 µL
FCM buffer with diluted CD3ε mAb, CD14 mAb, and CD19 mAb
(see FCM Ab table). Keep cell suspension in the dark at 4°C for
30 min.
 Add 20 mL of FCM buffer and centrifuge cell suspension for 4
min with 400 × g at 4°C.
 Aspirate supernatant and resuspend cellular pellet in 20 mL of
FCM buffer, then split sample evenly into four 10 mL conical
tubes.
 Centrifuge cell suspensions for 4 min with 400 × g at 4°C.
 Aspirate supernatant and resuspend cellular pellet with 100 µL
FCM buffer containing CD1d tetramers (1 µg/mL), or a com-
bination of anti-Vβ11 and anti-Vα24, or anti-Vβ11 and 6B11
(FCM Ab table). Keep cell suspension in the dark at 4°C for 30
min.
 Add 5 mL of FCM buffer and centrifuge cell suspension for 4
min with 400 × g at 4°C. Aspirate supernatant and repeat this
step.
 Aspirate supernatant and resuspend cellular pellet with 400 µL
FCM buffer.
 Analyze samples on the flow cytometer.
1.16.6 Materials: Isolation and analysis of NKT cells in human
blood.
RF-10 media
 Base Medium RPMI media 1640, no glutamine (Gibco)
 10% Heat-inactivated fetal calf serum (Gibco)
 2 mM L-Glutamine (Gibco)
 0.1 mM Nonessential amino acids (Gibco)
 15 mM HEPES (Gibco)
 100 U/mL of Penicillin/Streptomycin (Gibco)
 1 mM Sodium pyruvate (Gibco)
 50 mM 2-Mercaptoethanol (Sigma-Aldrich)
Flow cytometry (FCM) buffer
 Base Medium 1× PBS (made in-house)
 2% heat-inactivated FBS (Gibco)
DNAse I (Sigma–Aldrich)
Human FcR-blocking reagent (Miltenyi Biotec)
LIVE/DEADTM Fixable Near-IR Dead Cell Stain Kit, for 633 or
635 nm excitation (ThermoFisher)
Tyloxapol (Sigma–Aldrich)
Streptavidin BV421 (BioLegend)
α-GalCer (PBS-44) was supplied by Prof. P. Savage, Brigham
Young University
 α-GalCer (KRN7000) is commercially available from several
suppliers [1049, 1050]
 α-GalCer (PBS-57)-loaded CD1d tetramer is available from the
NIH tetramer core facility [1042]
Flow cytometry antibodies table: Isolation and analysis of
NKT cells in human blood
Antibody Manufacturer
BUV395 CD3ε mAb (UCHT1) BD Biosciences
BUV805 CD14 mAb (M5E2) BD Biosciences
PE/DazzleTM CD19 BUV805 (HIB19) BioLegend
anti-Vβ11 FITC or PE (C21) Beckman Coulter
anti-Vα24 FITC (C15) Beckman Coulter
6B11 PE BD Biosciences
*Antibodies should be individually titrated to ensure optimal staining
Flow Cytometer
BD LSR FortessaTM 5-laser configuration (UV, Violet, Blue,
Yellow-Green, Red) was used in the experiments depicted here.
However, similar results can be achieved using other multi-
parameter flow cytometers.
Analysis
FlowJo (TreeStar)
1.16.7 Data analysis. The following descriptions and figures
specifically relate to the identification of NKT cells from human
blood samples. However, these general principles can also be
applied to the detection of NKT cells from other tissues. Stan-
dard procedures for the isolation of PBMCs can be used for the
study of human NKT cells, including density gradient centrifu-
gation with Ficoll-Paque at a density of 1.077 g/mL [1051]. A
typical gating strategy for detecting human blood NKT cells is
depicted in Fig. 132. This first involves gating on lymphocytes
based on a combination of their size and granularity, assessed
by their FSC area (FSC-A) and SSC area (SSC-A) intensities,
respectively (Fig. 132A). The exclusion of doublets should also
be included, as the failure to do so may lead to false-positive
staining being incorporated during analysis. There are several
techniques to exclude doublets, Fig. 132A depicts an example of
single cells being identified based on their relative FSC-A and FSC
height (FSC-H). As these two parameters both provide readouts
of cell-size, single cells exhibit a linear relationship between these
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two parameters, enabling doublets to be excluded. While a sec-
ondary doublet exclusion gate is not essential, their elimination
can be further assured based on assessing relative SSC intensities.
For example, the relationship between SSC-A and SSC-H is used
to further exclude doublets within Fig. 132A. Although it is not
uncommon for researchers to rely solely on FSC and SSC to dif-
ferentiate between live and dead cells, this technique is not 100%
effective, as seen in Fig. 132A. In this example, LIVE/DEAD fixable
Near-IR cell viability dye has been used, which shows that some
dead cells have been incorporated within the previous gates. Thus,
the inclusion of a viability dye is highly recommended to exclude
nonspecific Ab, or CD1d-tetramer staining of dead cells, or cellu-
lar debris – a consideration that is particularly important when
investigating rare populations, such as NKT cells. In order to fur-
ther discount any TCR-independent CD1d-tetramer binding that
may occur, B cell (CD19+) and monocyte (CD14+) markers are
typically included within Ab cocktails to facilitate their exclusion
(Fig. 132A). From this point, Type I, or iNKT cells can be identified,
enumerated, or sort-purified by the methods described below.
1.16.7.1 α-GalCer-loaded CD1d-tetramer. Type I NKT cells
can be identified based on their double positive staining for α-
GalCer-loaded CD1d-tetramer and CD3ε mAb. This is depicted
within Fig. 132B in relation to a CD1d-tetramer control, which
has been exposed to the vehicle reagent (0.5% tyloxapol/TBS)
used to solubilize α-GalCer (PBS-44). As this technique relies on
CD1d-antigen recognition rather than TCR usage, it has the poten-
tial to isolate cells that do not express the canonical iNKT cell
TCR [1026–1031]. As such, cells isolated by this manner are more
accurately described as Type I NKT cells, rather than iNKT cells.
However, iNKT cell TCR usage among α-GalCer-loaded CD1d-
tetramer positive cells can be addressed by co-staining with anti-
Vα24 [1052].
1.16.7.2 6B11 and Anti-Vβ11 co-staining. The 6B11 Ab clone
recognizes the canonical iNKT cells TCR α-chain [1045, 1046].
Hence, the vast majority of 6B11-reactive T cells from indi-
vidual donors will also co-stain with anti-Vβ11, as seen within
Fig. 132C. However, a point worth mentioning is that the propor-
tion of 6B11+, Vβ11+ cells detected within any given sample may
differ from that of α-GalCer-loaded CD1d-tetramer+ CD3+ cells
(Fig. 132B), as the recognition of this complex can be achieved by
T cells with atypical sequences [1026–1031].While in themajority
of cases these differences may appear negligible [1053], variations
can occur based on the technique being employed (Fig. 132B and
C).
1.16.7.3 Anti-Vα24 and anti-Vβ11 co-staining. T cells
expressing the canonical iNKT αβ TCR heterodimer can be
enriched for by co-staining with Abs against both Vα24 and Vβ11,
as depicted within Fig. 132D. While this technique may iden-
tify a population of cells that largely overlap with that of Type
I (Fig. 132B), or iNKT cells (Fig. 132C), there is no assurance
that cells isolated by this approach will contain the iNKT cell TCR,
or even be CD1d-restricted. Hence, despite this method provid-
ing a useful means of enriching for, or approximating “NKT cell”
numbers, this technique is considered the less stringent of those
exemplified here.
1.16.8 Pitfalls: Isolation and analysis of NKT cells in human blood.
 Adherence to the strategies described above should prevent
autofluorescent cells from being falsely incorporated within
NKT cell (α-GalCer-loaded CD1d-tetramer vs. CD3ε) gates dur-
ing the analysis of human PBMC samples. However, the pres-
ence of autofluorescent cells can be more pronounced with
other tissue samples. Therefore, an appreciation of the poten-
tial for autofluorescence to adversely impact flow cytometric
data [406], and the knowledge of techniques that can prevent
such complications are crucial for all FCM users, particularly
those wishing to study rare populations such as NKT cells. When
designing Ab cocktails it is advisable to leave a channel open
for autofluorescence detection, such as 530/30-blue (FITC),
450/40-violet (BV421), or 525/50-violet (BV510). If spectral
overlap has been correctly compensated for, positive signaling
within this parameter can be used to exclude autofluorescence.
1.16.9 Top tricks: Isolation and analysis of NKT cells in human
blood.
 While not typically required when working with fresh PBMCs,
it can be beneficial to treat cryopreserved PBMCs with DNAse
after thawing. This will digest “sticky” DNA released by cells
lysed during this process, preventing cellular-pellets from irre-
versibly clumping following centrifugation steps.
 The efficiency of glycolipid-loading into CD1d in an in vitro-
setting is typically antigen-dependent. Therefore, various con-
ditions such asmolar loading ratio, loading temperature and the
pH condition all need to be considered when assessing NKT cell-
recognition of CD1d-ligands via the use of lipid-loaded CD1d-
tetramers.
 Despite CD1d-ligands such as α-GalCer typically being solubi-
lized in Tween 20-based (0.5% [v/v] Tween 20, sucrose [56
mg/mL] and L-histidine [7.5 mg/mL] in PBS) vehicle reagent
or DMSO for in vitro studies, the use of a tyloxapol-based
(0.5% [v/v] tyloxapol in TBS) vehicle may enhance loading
efficiencies of some glycolipid-antigens for CD1d-tetramer stud-
ies [1054].
 Although the strength of the interaction between the iNKT cell
TCR and α-GalCer-loaded CD1d-tetramer is sufficient to enable
clear detection of iNKT cells with CD1d-tetramers generated
with streptavidin conjugated to a number of different fluo-
rochromes [1042], the study of lower avidity interactions may
require the use of streptavidin conjugated to fluorochromes dis-
playing optimal SNRs, such as PE.
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 Due to the rarity of NKT cells within human blood (typically
ranging from 0.01 to 0.1% of lymphocytes) [1052, 1053], it
can be useful to enrich for these cells prior to cell-sorting,
or general FCM analysis using techniques such as anti-PE-
magnetic microbead enrichment [1055]. These procedures can
be employed to enrich for α-GalCer-loaded CD1d-tetramer,
Vα24, Vβ11, or 6B11 positive cells. The choice depending on
the individual needs of the researcher, and the availability of
reagents conjugated to a suitable fluorochrome.
1.17 Human mucosal-associated invariant T (MAIT) cells
1.17.1 Overview. Mucosal-associated invariant T (MAIT) cells
are a population of unconventional T cell with potent antimicro-
bial function. In humans, these cells are highly abundant and have
been implicated in wide-ranging disease settings including infec-
tious disease, autoimmunity, allergy, and cancer [997]. Accord-
ingly, the high abundance and unique biology of MAIT cells has
garnered the attention of researchers and clinicians alike, and
there is great interest in studying the biology of these cells and
understanding how they may contribute to disease clearance or
pathology or be manipulated for novel immunotherapies. Key
to studying MAIT cells is the efficient use of tools for isolating
them from biological samples. This was a major challenge for the
field for many years, however, the advent of MR1-Ag tetramers to
detect and isolate MAIT cells has facilitated a rapid progression in
our understanding of these cells. In this section, we provide rec-
ommended guidelines for FCM-based identification strategies for
human peripheral blood MAIT cells, with particular emphasis on
comparing tetramer and Ab-based identification techniques, and
analysis of MAIT cell phenotypic diversity.
1.17.2 Introduction. In contrast to conventional CD8+ and CD4+
TCRαβ T cells that express diverse T cell receptors to recog-
nize polymorphic MHC class I and II molecules, respectively
[1056], MAIT cells are defined by expression of a semi-invariant
TCR that recognizes microbial-derived vitamin-B2 (riboflavin)
derivatives, presented by the monomorphic MHC-related protein
1 (MR1) [850, 1057, 1058] (see also Chapter VI Section 1.9
Murine MAIT cells). This unique antigen-restriction drives a diver-
gent thymic developmental pathway relative to conventional αβ
T cells, resulting in a unique, transcriptional landscape charac-
terized by expression of the innate transcription factor promyelo-
cytic leukemia zinc finger (PLZF) [823, 847, 1059] that drives an
innate-like, antimicrobial functional capacity. In humans, mature
MAIT cells comprise 3% of total T cells within adult periph-
eral blood, although this can range from 0.1 to 10% depend-
ing on the individual [1060, 1061]. MAIT cells are also highly
enriched in liver where they can comprise up to 40% of T cells
[1062, 1063], and are abundant in certain mucosal sites, such
as the gut [842, 846]. Moreover, upon activation, MAIT cells
rapidly produce large quantities of proinflammatory cytokines
and chemokines [1063, 1064] and lyse infected cells [1065].
Accordingly, MAIT cells are emerging as key players in antimi-
crobial immunity [1066–1068]. More recently, MAIT cells have
been shown to respond to inflammatory queues independent
of TCR-mediated signaling [1069], providing a mechanism for
MAIT cells to play a role during the many viral [1070–1072]
and nonmicrobial diseases in which MAIT cells have been impli-
cated, including autoimmune disease [1073] and cancer [1018].
In humans, there is evidence of distinct functionality in peripheral
tissues [1074]. MAIT cells are largely CD8+, expressing either
CD8αα homodimers or CD8αβ heterodimers, or are CD4-CD8-
double negative (DN) [846, 1060, 1063]. Rare populations of
CD4+ and CD4+CD8+ DP MAIT cells also exist [1060, 1075].
Whether these populations represent functionally distinct sub-
sets remains unclear, although some reports suggest the CD8+
population may have enhanced cytotoxic capacity [1076], while
CD8αα+ cells only emerge post-thymic development of mature
MAIT cells [847]. Likewise, CD4+ MAIT cells may have distinct
tissue localization [1077] and cytokine profiles [1060]. Further
studies on this axis are needed, but nonetheless, inclusion of CD4
and CD8 mAbs in FCM experiments analyzing MAIT cells may
prove informative. Indeed, several studies have noted modulation
of these markers during progression of diverse diseases [1078].
Central to MAIT cell biology is their expression of a “semi-
invariant” αβTCR that binds MR1-Ag complexes. The MAIT TCR-
α chain is composed of the TRAV1-2 gene segment, which is
joined with TRAJ33, or less commonly TRAJ12 or TRAJ20. These
TRAV1-2+ TCR α-chains display heavily biased pairing with TCR-
β gene segments including TRBV6 family members and TRBV20-
1 [1079]. The development of an mAb against the TRAV1-2 TCR-
α chain segment of the MAIT TCR provided the first means to
isolate these cells from human samples [1080]. This was then
further refined to include surface-markers highly expressed by
MAIT cells, such as the C-type-lectin CD161, the IL-18Rα CD218,
and the ectopeptidase CD26. Co-staining of samples with anti-
TRAV1-2 and either CD161 mAb, CD218, or CD26 mAbs was the
gold standard to identify MAIT cells for many years. MAIT cells
were thus identified as TRAV1-2+ and either CD161HI [1080],
IL-18RαHI [1061], or CD26HI [1081]. To date, four clones of
anti-TRAV1-2 have been produced (3C10 [1080], D5 [1057],
OF5A12 [1082], and REA179 (Miltenyi), however the original
clone, 3C10, produced by Lantz and colleagues [1080] is by far
the most widely used. A major drawback to the use of this surro-
gate identification technique, however, is that is has been unclear
as to whether all MAIT cells express high levels of the surrogate
markers, and likewise, whether all TRAV1-2+ cells that express
high levels of the surrogate markers are MAIT cells, particularly in
tissues. Indeed, clinical studies analyzingMAIT cells in HIV [1083]
and rheumatoid arthritis [1084] have suggested that MAIT cells
may downregulate CD161 during disease progression, raising con-
cerns about the use of surrogate markers to identify MAIT cells in
disease settings.
The discovery that the MAIT TCR specifically recognizes the
antigen (Ag) 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil
(5-OP-RU), derived from an intermediate in the microbial
riboflavin biosynthesis pathway, facilitated the development of
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tetramerised soluble MR1 molecules, loaded with 5-OP-RU (MR1-
5-OP-RU tetramers) [846, 850]. These fluorescently tagged
tetramers bind all cells expressing TCRs that confer reactivity to
MR1-5-OP-RU and provide a highly specific method for the detec-
tion and isolation of MAIT cells from human blood and other
tissues. As a control, MR1 tetramers loaded with non-stimulatory
antigen 6-FP (MR1-6-FP) [846] or synthetic analog Acetyl (Ac)-
6-FP [1085] (MR1-Ac-6-FP) are used to validate the specificity of
MR1-5-OP-RU tetramers, similar to a conventional isotype control.
A recent direct comparison of MR1 tetramers and surro-
gate mAb-based identification techniques revealed that while
the surrogate markers generally highly enriched for CD8+ and
CD4−CD8− DN MAIT cells, they were poor at identifying CD4+
MAIT cells, as many TRAV1-2+ CD4+ T cells expressing high lev-
els of CD161, IL-18Rα, or CD26 were not labeled with MR1-5-OP-
RU tetramer [1060, 1075, 1086]. Similarly, the existence of many
CD161+ TRAV1-2+ T cells in thymus and neonatal blood samples
that do not stain with MR1 tetramer (and are not MAIT cells)
[847, 1060, 1087] also limits the use of these surrogate marker
combinations in developmental studies. Moreover, across a large
cohort of healthy blood donors, there were outliers in which a
substantial proportion of MAIT cells lacked expression of surro-
gate markers, and immature MAIT cells in thymus are defined by
a lack of CD161 expression [847]. More recently, MR1 tetramers
have been used to identify a population of nonclassical MAIT cells
that are phenotypically equivalent to TRAV1-2+ MAIT cells, but
utilize a TRAV36+ TCR and thus do not stain with anti-TRAV1-2
mAbs [1088]. Accordingly, where possible, MR1 tetramers should
be used for the highly specific isolation of MAIT cells, particu-
larly when studying CD4+ MAIT cells, or when analyzing samples
from patient cohorts where the modulation of MAIT cell surface
marker expression is unknown, or in developmental studies where
thymus or neonatal blood is being assessed. MR1 tetramers are
available from the NIH tetramer core-facility upon request conju-
gated to a variety of fluorochromes or in the form of biotinylated
monomers [1089].
1.17.3 Isolation and staining of MAIT cells from single cell suspen-
sions using MR1-tetramers.
1.17.3.1 Step-by-step sample preparation.
1. If using biotinylated MR1monomers, tetramerize with Strepta-
vidin conjugated to fluorochrome of choice at a 4:1 to 8:1 ratio
of monomers to streptavidin, adding Streptavidin sequentially
(one-fourth of the required volume) at a series of 10-min incu-
bations at 4°C. This sequential addition facilitates the forma-
tion of tetramers and prevents a final mixture of lower degree
monomers/dimers/trimers [1090]. A titration of monomer to
streptavidin ratio assessed by optimal staining is recommended
as monomer and streptavidin conjugate stock concentration
can differ between batches or companies.
2. The simplest staining protocol when using fluorochrome-
conjugated-MR1-tetramers (hereafter referred to as MR1-
tetramers) is to include them within an appropriate Ab cock-
tail (see Table 41 for a list of Abs), as the interaction between
MR1-5-OP-RU tetramers and MAIT cells is of sufficient avidity
to achieve clear staining during a standard 30 min incubation
at room temperature or 4°C.
1.17.3.2 Data analysis. When identifying any T cell popu-
lation using tetramer staining, a negative control tetramer is
recommended, particularly when the target population is rare,
of low intensity staining, or there is possible non-TCR-specific
background staining. Thus, MR1-5-OP-RU tetramers that bind
MAIT cells are used in parallel with MR1-6-FP or MR1-Ac-6-FP
that do not stain the majority of MAIT cells [846, 1091]. As such,
MR1-6-FP or MR1-Ac-6-FP tetramers provide a valuable negative
control for the vast majority of donors, as shown in a representa-
tive example of MAIT cell staining of human blood (Figure 133).
The following descriptions and figures specifically relate to the
identification of MAIT cells from human PBMCs, however, these
general principles can also be applied to the detection ofMAIT cells
in single cell suspensions prepared from other human tissue sam-
ples. As these cells can be relatively rare, it is important to carefully
apply gates to focus on viable lymphoid cells. A typical gating strat-
egy for detecting human blood MAIT cells by FCM is depicted in
(Fig. 134A).
The most commonly utilized surrogate identification method
prior to the advent of MR1-tetramers was co-expression of the
TRAV1-2 TCR-α chain and high levels of CD161 (CD161++ or
CD161HI), often including a gate on CD8α+ T cells. By comparing
these markers to MR1-5-OP-RU tetramer stained cells, it has been
shown that these surrogate markers are generally quite effective
for detecting human CD8+ MAIT cells in the absence of MR1-
tetramer [1060, 1086, 1092], however, this efficiency can vary
somewhat between individuals and is less stringent when studying
CD8– and CD4+ MAIT cells [1060] (Figure 134B and Table 42).
1.17.3.3 Top Tricks: Isolation and staining of MAIT cells using
MR1-tetramers.
 Like standard Abs, MR1-tetramers should be titrated prior to
use in formal experiments to ensure optimal signal-to-noise
separation of staining. MR1-tetramers provided from the NIH
facility are used within a staining concentration range of
1:500 to 1:1000 [1089] depending on the fluorochrome con-
jugated. MR1 tetramer staining conditions (time and temper-
ature) should also be initially tested to ensure best signal-
to-noise results. MR1 tetramers work at 4°C, room tem-
perature, and 37°C, with staining intensity proportional to
temperature.
 The protein-kinase inhibitor dasatinib can greatly enhance the
detection of lower affinity TCR interactions that may otherwise
go undetected via tetramer staining [1093]. While unneces-
sary for the identification of MR1-5-OP-RU tetramer-reactive,
TRAV1-2+ MAIT cells, pretreating cells with dasatinib (working
concentration 50 nM) may prove advantageous for detecting
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Figure 133. MR1-tetramer staining controls. Representative
plots depict MR1-5-OP-RU tetramer staining among CD19– lym-
phocytes from human PBMCs in comparison to a MR1-Ac-6-FP
tetramer control and a fluorescence minus one (FMO) control.
Refer to Fig. 134A for gating strategy.
other populations of MR1-reactive T cells with lower affinity
for the MR1 ligands being assessed [1091].
 If staining includes more than one tetramer (such as MR1-
5-OP-RU tetramer on one color with MR1-6-FP tetramer on
another color), it is highly recommended that tetramer incu-
bations are sequentially applied, with an intervening avidin
and biotin blocking step [1094], such as with the Dako Biotin
blocking system (see Materials). This will prevent any potential
excess streptavidin-conjugated fluorochrome from one tetramer
binding available biotin sites that may be present on the other
tetramer, which may falsely lead to double-positive tetramer
staining.
 In order to exclude any TCR-independent MR1-5-OP-RU
tetramer binding andmaximize the potential scope of MAIT cell
phenotyping that can be achievedwithin a single antibody cock-
tail, the detection of B cells, monocytes and dead cells can
be restricted to one fluorescence parameter or ‘dump channel’
akin to a lineage marker dump. For example, a combination
that can be used to achieve this is: APC-Cy7 CD14 mAb, APC-
Cy7 CD19 mAb, and Live/Dead fixable Near-IR (ThermoFisher)
(Fig. 134A). Gating on CD3/TCR+ cells can also be helpful to
exclude TCR-independent MR1 tetramer binding (Fig. 134A).
1.17.3.4 Pitfalls: Isolation and staining of MAIT cells using MR1-
tetramers.
 It should be noted that in most individuals, minor populations
of TRAV1-2+ MAIT cells can be isolated that display reactivity to
both 5-OP-RU and 6-FP. Further, populations of cells that lack
the classical MAIT cell TRAV1-2+ TCR α-chain have been iden-
tified that preferentially bind MR1-6-FP in comparison to MR1-
5-OP-RU [1091]. Therefore, while these atypical MAIT cell sub-
sets may be rare in comparison to classical MAIT cells, caution
needs to be taken when using MR1-6-FP tetramers as a negative
Figure 134. (A) Gating on human peripheral blood MAIT cells. Lymphocytes are distinguished from PBMC preparations based on their FSC-A
and SSC-A. Single cells are identified by their linear relationship between FSC-H versus FSC-A, enabling doublets to be excluded. To remove any
nonspecific or TCR-independent MR1-5-OP-RU tetramer staining, dead cells are excluded with the use of a viability dye (7-AAD), and monocytes
and B cells are excluded based on the expression of CD14 and CD19, respectively. MAIT cell frequencies can be presented as a percentage of
CD19– lymphocytes, or as a percentage of T cells. (B) MAIT cells can be divided into subsets based on expression of CD4 and CD8 co-receptors and,
relative to non-MAIT T cells, are typically enriched for CD8+ and CD4–CD8– double negative (DN) subsets, with only minor populations of CD4+ or
CD4+CD8+ double positive (DP) cells.
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Figure 135. Identifying MAIT cells using surrogate markers. Gating strategy utilized similar to Fig. 134A. Plots depict the identification of human
MAIT cells among CD19–, CD3+ lymphocytes via their expression of TRAV1-2 and CD161 and how this relates to MR1-5-OP-RU tetramer staining
from a normal donor (top) and an abnormal donor (bottom).
control, as positive staining cannot automatically be ascribed as
non-specific or background.
 Surrogate markers are slightly less reliable for CD4–CD8–
MAIT cells, and they do not work well for CD4+ MAIT cells
[1060, 1086, 1092]. Therefore, when using surrogate mark-
ers to study these populations, it is important to consider that
not all TRAV1-2+, CD161++ cells will necessarily be MAIT cells
and not all MAIT cells will necessarily be TRAV1-2+, CD161++,
and that CD4+ MAIT cells cannot be reliably detected using this
approach. The inclusion of other cell-surface receptors typically
expressed at high levels by MAIT cells such as the IL-18 receptor
alpha chain CD218a (IL-18αR), the ectopeptidase CD26 and the
chemokine receptor CD195 (CCR5) may be useful to improve
the stringency of their identification [1061, 1063, 1081, 1092].
Figure 136. MAIT cell enrichment. Gating strategy utilized similar to Fig. 134A. Top panel depict plots with the percentages of MAIT cells among
CD19–, CD3+ lymphocytes from PBMCs either prior to (first panel) or following MR1-5-OP-RU tetramer enrichment (second panel). Bottom panel
depict plots with the percentages of MAIT cells among CD19–, CD3+ thymocytes either prior to (first panel) or following TRAV1-2 Ab enrichment
(second panel). Further phenotypic analysis of MAIT cells reveal heterogeneous subpopulations based on CD4, CD8, CD27, and CD161 (third and
fourth panel).
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Table 41. Table of Abs used
Dilution Antigen Clone Stock Concentration Fluorophore Manufacturer
1:50 CD3 UCHT1 100 tests BUV395 BD Pharmingen
1:50 CD3 UCHT1 100 tests PE BD Pharmingen
1:50 CD3 UCHT1 100 tests AF700 BD Pharmingen
1:100 CD4 SK3 100 tests BV510 BD Pharmingen
1:100 CD4 SK3 100 tests APC-Cy7 BD Pharmingen
1:100 CD8 SK1 100 tests BUV805 BD Pharmingen
1:200 CD8 SK1 100 tests BV650 BD Pharmingen
1:50 CD14 MφP9 100 tests APC-Cy7 BD Pharmingen
1:50 CD19 SJ25C1 100 tests APC-Cy7 BD Pharmingen
1:50 CD27 O323 100 µg/ml BV785 Biolegend
1:50 CD161 HP-3G8 100 µg/ml BV650 Biolegend
1:100 CD161 HP-3G8 100 µg/ml PE-Cy7 Biolegend
1:50 TRAV1-2 3C10 100 µg/ml BV711 Biolegend
1:50 TRAV1-2 3C10 100 µg/ml APC Biolegend
1:50 TRAV1-2 3C10 200 µg/ml FITC Biolegend
Table 42. Summary of subpopulations as part of this section and
figures
T cell population Phenotype/sub-phenotype
G4: CD3 cells CD14− CD19− CD3ε+
G5: MR1-5-OP-RU+ MAIT CD3+ TRAV1-2+ MR1-5-OP-RU+
G6: CD4+ MAIT CD3+ TRAV1-2+ MR1-5-OP-RU+
CD4+ CD8−
G7: CD4+ CD8+ MAIT CD3+ TRAV1-2+ MR1-5-OP-RU+
CD4+ CD8+
G8: CD4−CD8− MAIT CD3+ TRAV1-2+ MR1-5-OP-RU+
CD4− CD8−
G9: CD8+ MAIT CD3+ TRAV1-2+ MR1-5-OP-RU+
CD4− CD8+
G10: Non TRAV1-2
MR1-5-OP-RU+
CD3+ TRAV1-2− MR1-5-OP-RU+
G11: Thymic MR1-5-OP-RU+
TRAV1-2 MAIT
CD3+ TRAV1-2+ MR1-5-OP-RU+
G12: Immature Stage 1
Thymic MAIT
CD3+ TRAV1-2+ MR1-5-OP-RU+
CD27− CD161−
G13: Immature Stage 2
Thymic MAIT
CD3+ TRAV1-2+ MR1-5-OP-RU+
CD27+ CD161−
G14: Mature Stage 3 Thymic
MAIT
CD3+ TRAV1-2+ MR1-5-OP-RU+
CD27+/− CD161+
Of note, these markers are validated to be associated with
MAIT cells in the blood, but not as extensively in tissues, where
some of them can be expressed by conventional T cells both at
steady state and during disease.
 There are potential problems in using these surrogate mark-
ers to detect MAIT cells in settings other than healthy adult
human blood. For example, there is growing evidence that
the normal CD161++ phenotype of MAIT cells may be per-
turbed among donors (Figure 135), under certain disease set-
tings [1083, 1084], and the proportion of CD161++ cells that
are MAIT cells as defined by MR1 tetramer also alters with
age [847, 1087]. Furthermore, it is also worth considering
that a reliance on TRAV1-2 expression to detect MAIT cells
will fail to detect those with atypical TCR α-chain usages
[847, 1079, 1095, 1096].
 It should be noted particularly for functional studies that the use
of either TRAV1-2 mAb or MR1-tetramer poses the possibility
of positive selection or activation of MAIT cells. Furthermore,
antigen (such as 5-OP-RU) originally on the tetramers may
be recycled for presentation causing subsequent cell-mediated
MAIT cell activation. In cases like this, it is worth considering a
mAb cocktail that enriches for MAIT cells but does not include
tetramers for labeling or isolating. Alternatively, cells isolated
by tetramer can be rested 37°C overnight prior to performing
downstream functional assays.
1.17.4 MAIT cell enrichment.
1.17.4.1 Step-by-step sample preparation.
1. Resuspend cells in 107 cells/mL of FCM buffer, stain with PE-
conjugated MR1-tetramer OR PE-conjugated anti-TRAV1-2.
2. Wash cells twice with FCMbuffer after staining and resuspend
cells in 80 µL of MACS R© buffer/107 total cells.
3. Mix in 20 µL of Anti-PE MACS R© MicroBeads/107 total cells
and incubate for 30 min at 4°C.
4. Wash cells twice with MACS R© buffer and resuspend up to 108
cells in 5 mL MACS R© buffer.
5. Prepare LS column on LS separator by rinsing with 5 mL
MACS R© buffer, and discard flow-through.
6. Prepare a flow-through collection tube under the column.
7. Apply 5 mL cell suspension onto the column reservoir.
8. After column reservoir is empty, wash column with 3 mL
of MACS R© buffer as the unlabeled cells pass into the flow-
through.
9. Wash column with 3 mL of MACS R© buffer three times.
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10. Remove LS column and place away from magnet separator,
on top of a new 10 mL collection tube.
11. Elute magnetically labeled cells by adding 5 mL MACS R©
buffer in column reservoir, and firmly pushing the LS plunger
into the LS column.
12. Centrifuge to pellet the cells and to use for FCM without
further staining with PE-conjugated Abs or tetramers.
1.17.4.2 Data analysis. MAIT cell numbers vary widely
among individuals, and the factors influencing that remain poorly
understood. Therefore, while it is possible to analyze or sort-purify
MAIT cells via FCM directly from PBMC preparations, this is not
always sufficient to get enough cells for downstream experiments.
Thus, a useful approach is to first enrich for either MR1-5-OP-RU
tetramer+ or TRAV1-2+ cells using magnetic-activated cell sorting
(MACS R©). Figure 136 depicts the enrichment of MAIT cells fol-
lowing PE-microbead enrichment of PBMCs that have been labeled
with PE-conjugated MR1-5-OP-RU tetramer. This technique may
also prove useful for investigating minor population of MAIT cells,
such as the TRAV1-2− cells that can become evident following
the enrichment of MR1-tetramer+ cells (Fig. 136). Furthermore,
MAIT cell numbers can be extremely rare in organs such as the thy-
mus, but become clearly detectable following enrichment based on
TRAV1-2 expression (Fig. 136 and Table 42).
1.17.4.3 Top tricks: MAIT cell enrichment. This protocol
describes the use of PE-conjugated MR1-5-OP-RU tetramer or PE-
conjugated anti-TRAV1-2 enrichment using anti-PE microbeads,
but can be adapted to use with the other fluorochrome options
available via MACS R© technology or from other manufacturers
offering similar magnetic strategies. It is highly recommended that
researchers familiarize themselves with detailed tools, resources,
and manufacturers’ datasheets to determine the most suitable
enrichment strategy.
1.17.4.4 Pitfalls: MAIT cell enrichment. The choice of either
TRAV1-2 or MR1-tetramer to enrich for MAIT cells will depend on
the particular aims of the experiment. While both approaches are
highly effective, the enrichment of TRAV1-2+ cells will not enrich
for MAIT cells with atypical TCR usages [1091]. This technique
may also prove advantageous when aiming to isolate MAIT cells
from tissues where they are consistently present at low frequen-
cies, such as the thymus (Figure 136) [847].
1.17.4.5 Materials. Ligand loaded MR1-monomers or
tetramers [1089]
FCM buffer
1× PBS
2% FCS
Ficoll-Paque density 1.077 g/mL (Sigma, #GE17-1440-02)
Dako Biotin blocking system (Agilent Dako, #X059030)
Dasatinib (Sigma–Aldrich, #CDS023389)
Magnetic-activated cell sorting (MACS R©) buffer
1× PBS
0.5% FCS and 2 mM EDTA.
Anti-PE MACS R© MicroBeads for magnetic labelling of cells
(Miltenyi Biotec, Order no: 130-048-801)
MACS R© LS Columns (Miltenyi Biotec, Order no: 130-042-401)
MACS R© Separator with LS column adaptor (Miltenyi Biotec,
Order no: 130-091-051)
Flow Cytometer: example: BD LSR Fortessa equipped with
yellow-green laser or similar.
Analysis: Flowjo Version 10 (macOS)
2 B cells and their subsets
2.1 Murine B cells and their subsets, including Bregs
2.1.1 Overview. Several murine B cell subsets are known that
differ with respect to differentiation stage, B cell receptor reper-
toire, contribution to the production of natural and adoptive
Abs, pro-, and anti-inflammatory capacity, tissue localization, and
distribution within tissues. In addition to various B cell sub-
sets, the bone marrow (BM) also contains B cell precursors,
which express the prominent “B cell markers” CD19 and B220
(CD45R). Here, we describe strategies to identify the most promi-
nent murine B cell precursors and mature B cell subsets in the
BM, as well as secondary lymphoid organs. Plasma cells are
not included but are described separately in Section 3 of this
chapter.
2.1.2 Introduction. Human andmurine B cells exhibit many sim-
ilarities in terms of their subpopulations, development, and func-
tion. Therefore, results obtained in studies investigating B cell
compartments in murine models have significantly contributed
to our current understanding of immunity. Three murine B lym-
phocyte lineages B-1a, B-1b, and B-2 cells have been described
to exhibit different ontogenies [1097], and can be further sub-
divided into several subsets and developmental stages, including
immature and mature, follicular, marginal zone (MZ), germinal
center (GC) B cells, among others. While all B cell lineages are
capable of giving rise to Ab-secreting plasma cells, they exhibit
different B cell receptor repertoires (BCR), recognize different
antigens (protein-, lipid-, or carbohydrate antigen), express dif-
ferent Toll-like receptors and contribute preferentially either to
T-independent (B-1a, B-1b; MZ) or to T-dependent (follicular B
cells) Ab responses [1098–1101].
B-1 cells are the major B cell subset in the body cavities,
e.g., the peritoneum. These cells represent an important source
of innate Abs that are produced independently of foreign antigen
and T cells, and resemble an important first line of defense against
infection [1102]. Stall et al. were the first that described the exis-
tence of two distinct subsets of B-1 B cells, termed B-1a and B-
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Figure 137. Discrimination of B cell progenitors in BM. Single cell suspensions from BM were stained for B220, CD43, IgM, and IgD. (A) Left plot:
Gating strategy to exclude debris. Middle plot: Gating strategy to exclude doublets. Right plot: Pre-B cells (gate I), pro-B cells (gate II) and pre-pro-B
cells (gate III) are identified by their distinct B220/CD43 phenotypes. (B) Cells were gated through the gates I, II or III as indicated. Exclusion of
IgDpos and IgMpos cells eliminates contaminating immature and mature B cells.
1b [1103]. Self-renewing populations of CD5pos B-1a and CD5neg
B-1b cells are found in the peritoneal cavity of adult mice, a small
population of B-1a cells is also present in spleen [1104, 1105]. B-
2 cells are continuously generated from progenitors found in the
adult BM [1097]. This tissue contains various B cell progenitors,
including a small population of CD19pos/B220low/neg B-1 B cell
progenitors, CD19neg/B220pos B-2 progenitors, immature B cells,
but also a significant population of re-circulating mature B cells,
representing successive developmental stages defined according
to surface marker expression and Ig gene rearrangement sta-
tus [1106, 1107]. The complex rearrangements that produce
complete Ig heavy and light chains occur during B cell devel-
opment. This process of somatic mutation is described in detail
elsewhere [1106, 1108–1111]. The principal B cell progenitor
populations in the BM are pre-pro B cells, pro-B cells, and pre-B
cells, which can still be further subdivided into various develop-
mental stages such as early pro-, late pro-, large pre-, small pre-B
cells, among others [1112, 1113]. Of note, these distinct B cell
developmental stages are associated with particular Ig-gene rear-
rangement patterns [1113–1115].
Immature B cells leave the bone marrow and migrate to the
spleen to eventually become mature B cells. This process involves
the three transitional stages T1, T2, and T3 that are subjected
to negative selection of autoreactive cells, while only non-self-
reactive cells become fully mature and functional [1116]. The
main mature B cell populations in the spleen are follicular B cells
and MZ B cells, while B-1 cells represent only a minor population
[1117, 1118].
Controlled by autocrine expression of low levels of IFN-γ,
immature B cells selectively migrate to the spleen neglecting other
secondary lymphoid organs [1119]. An MZ is not existing in
these tissues. Therefore, lymph nodes and Peyer’s patches con-
tain mainly follicular B cells of the B-2 lineage. Here, we provide
strategies for the analysis of the main B cell and B cell progenitor
stages, with a focus on the analysis of BM and secondary lymphoid
tissues, each containing several different B cell subpopulations.
2.1.3 Step-by-step sample preparation. Single cell suspension of
murine spleens, bone marrow (femurs and tibia) and the peri-
toneal cavity were prepared and filtered through a 70 µm cell
strainer (BD Falcon). The primary cells were resuspended (107
cells/ml) in PBS containing 0.5% BSA. Fc receptors were blocked
with CD16/CD32 mAb for 10 min at 40C (5µg/ml in PBS/BSA,
clone 2.4G2, in house production). Subsequently, cells were
washed with ice-cold PBS/0.5%BSA, and incubated with fluores-
cent labeled Abs for 15 min at 40C. After washing twice, cells were
resuspended in PBS/0.5% BSA/ supplemented with 100 µg/ml
DNase I, and analyzed by FCM.
2.1.4 Materials.
2.1.4.1 Abs and buffers. PBS (8 g/l NaCl, 0.2 g/l KCl, 1.44
g/l Na2HPO4) containing 0.5% BSA was used for washing
and as staining solution. Anti-mouse Abs used in FCM staining
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Figure 138. Discrimination of immature and
mature B cells in BM. Single cell suspensions from
BM were stained for CD19, B220, IgM, and IgD. (A)
Gating strategy to exclude doublets and debris. (B)
B220high/CD19neg cells (gate I) include pre-pro B
cells, while all other B cell subtypes (except plasma
cells) are included in the B220 high/CD19pos popu-
lation (gate II). (C) Cells were gated through gate
II. Immature (gate III) and mature B cells (gate IV)
were identified according to their IgM/IgD pheno-
types. Gate V includes a mixture of pre- and pro B
cells.
analysis: CD11b mAb (clone M1/70.15.11, in house produc-
tion); CD19 mAb (clone 1D3, BioLegend, Fell, Germany); anti-
B220 (clone RA3.B2, in house production); anti-IgM (clone M41,
in house production), anti-IgD (clone 11–26c.2a, BioLegend),
CD21/CD35 mAb (clone 7E9, BioLegend), CD23 mAb (clone
B3B4, BioLegend), CD43 (clone S11, BioLegend), CD5mAb (clone
53–7.3, BioLegend), CD3 mAb (clone 90/CD38, BD Pharmin-
gen), anti-GL7 (clone GL7, BioLegend), Fixable Viability Dye
(eBioscience).
2.1.4.2 Flow cytometer and analyzing software. Samples were
measured in an LSRII flow cytometer (BD Biosciences) and the
resulting data were analyzed using the FlowJo software (TreeStar,
Ashland, OR).
2.1.5 Data analysis: Murine B lineage cells in BM. After isolation
and generation of single cell suspensions, typically from femurs
and/or tibia, BM lymphocytes should be gated according to their
scatter properties, and doublets should be excluded from the anal-
ysis (Fig. 137A). Several B lineage developmental stages within
this tissue include proliferating blasts, therefore the FSC gate
should be not too restrictive. Removal of dead cells by using either
DNA stains such as PI, DAPI or 7AAD, or alternative stains that
bind to amines of proteins can be used to further improve the
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Figure 139. Analysis of follicular and
MZ B cells. Single cell suspensions from
spleen were stained for B220, CD21,
CD23, IgM, and IgD. (A) Gating strat-
egy to exclude doublets and debris. (B)
B cells are gated according to B220
expression and follicular and MZ B cells
were further discriminated by their CD21
intmed/CD23high and CD21high/CD23low/neg
phenotype, respectively. (C) Gated follicu-
lar and MZ B cells exhibit distinct IgD/IgM
expression characteristics.
quality of the data. The choice of the most suitable live/dead dis-
crimination reagent depends on the individual project, e.g., if the
samples need to be fixed [1].
In order to cover the major B lineage developmental stages in
BM from very early progenitors to the mature B cell stage using
only a minimum number of different markers, we suggest to stain
with a combination of CD19, B220, CD43, IgM, and IgD mAb.
Depending on the specific purpose of the study and the availabil-
ity of more fluorescent channels, these markers could be comple-
mented by additional ones.
CD19 and B220 serve as specific surface markers for the iden-
tification of B lineage cells. CD19 is a co-receptor of the B-cell
receptor that is expressed under the control of the PAX5 encoded
“B-cell lineage specific activator protein” [1120]. B220 and CD19
are found on the surface of all later B lineage cells except for a
subpopulation of terminally differentiated plasma cells [547].
As originally described by Hardy and colleagues, pre-pro B
cells, pro-B cells, and pre-B cells are defined according to their
distinct expression pattern of B220 and CD43 [1121], Pre-pro B
cells resemble very early precursors showing a B220pos/CD43pos
phenotype. Pro-B cells and pre-B cells are B220pos/int/CD43pos
and B220low/CD43neg, respectively (Fig. 137A). All three progen-
itor populations are distinguishable from the later immature and
mature stages by the absence of IgM and IgD expression. Hence,
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Figure 140. Analysis of B-1 cells. Single cell
suspensions from the peritoneal cavity were
stained for CD19, CD5, CD23, CD43 and IgM. (A)
Gating strategy to exclude doublets and debris.
(B) B-1 cells were identified by CD19, CD43 and
IgM expression. (C) B-1a and B-1b cells are dis-
tinguished according to CD5 expression.
exclusion of IgMpos and IgDpos cells could help to test for the accu-
racy of the gating (Fig. 137B).
Immature and mature B cells exhibit a
CD19pos/B220pos/CD43neg/IgMpos/IgDneg and CD19pos/B220pos/
CD43neg/IgMpos/IgDpos phenotype, respectively [1122, 1123].
Following staining with CD19, B220, CD43, IgD, and IgM, all B
lineage cells except plasma cells and pre-pro B cells are included
within the CD19pos/B220pos population (Fig. 138A and B). Pre-pro
B cells are found within the B220high/CD19neg fraction. However,
this population does also contain non-B lineage cells [1124].
Pro-B cells, pre-B cells, immature, and mature B cells are included
within the CD19pos/B220pos populations. Immature and mature
B cells can be further discriminated by the expression of surface
IgM and IgD (Fig. 138C).
According to the complexity of the B cell development and
heterogeneity of B lineage cells, other marker combinations are
useful to study B lineage cells in bone marrow as well. The Basel
nomenclature of B cell development classifies B cell progenitors
differently from the Hardy system described above [1125]. B cell
progenitor phenotypes defined by the surface markers CD25 and
CD117 (c-kit) correlate with the stepwise rearrangements of the
genes coding for the Ig heavy and light chains [1126, 1127].
The Ig gene loci are rearranged in an ordered fashion, with the
D-heavy (DH) segments being first rearranged to -J-heavy (JH)
segments, followed by V heavy (VH) to DH JH. The gene loci
coding for the Ig light chains are rearranged later, after suc-
cessful rearrangement of the Ig heavy gene segments [1128].
B220pos/CD117pos/CD25neg cells typically exhibit rearrangements
of the DH–JH Ig-gene segments, with light chain loci in germline
configuration. This population resemble early pre-B cells (pre-B I
cells) that are the precursors of large B220pos/ CD25pos cells that,
in turn, are the precursors of small B220pos/CD25pos cells [1129].
Since all these progenitor stages do not have completed their
Ig gene rearrangements yet, they are surface IgMneg/IgDneg. The
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Table 43. Identification of B lineage cells in bone marrow
Subpopulation Marker combination Ig gene status References
Pre-pro B220high / CD19neg / IgMneg / CD43pos germline
configuration
[1108, 1123, 1126, 1129, 1132]
B220pos / CD19neg / CD43pos / AA4.1pos /
HSAneg
[1113, 1121, 1130]
*Pro CD19pos / B220pos / CD43pos / IgMneg / IgDneg [1123]
CD19pos / B220pos / CD43pos / AA4.1pos
/HSApos
[1113, 1121, 1130]
Early pro CD19pos / B220pos / CD43pos / IgMneg / HSApos
/ BP-1neg
**DH - JH [1108, 1126, 1129]
Late pro CD19pos / B220pos / CD43pos / IgMneg / HSApos
/ BP-1pos
VH - DJH [1106, 1108, 1126, 1129]
*Pre CD19pos / B220pos / CD43neg / IgMneg / IgDneg [1108, 1123]
CD19pos / CD43neg / IgMneg / AA4.1pos /
HSApos
[1113, 1121]
***Early pre (pre B I) B220pos / CD117pos / CD25neg DH - JH [1126, 1129]
***Late pre (pre B II) B220pos / CD25pos VHDHJH [1126, 1129]
Large pre CD19pos / B220low / CD43neg / HSApos /
AA4.1neg / preBcRpos (VpreBpos / λ5pos)
VHDHJH [1113, 1114, 1121, 1129]
Small pre CD19pos / B220pos / HSApos / IgMneg rearrangement of the
VL-JL starts **
[1113, 1121, 1129]
Immature CD19pos / B220pos / CD43neg / IgMpos / IgDneg Ig rearrangement
complete
[1116, 1117]
CD19pos / B220pos / HSApos / IgMpos / IgDneg [1113, 1121, 1131]
Mature CD19pos / B220pos / CD43neg / IgMpos / IgDpos [1123]
* Refers to the Hardy nomenclature. **DH, JH, VH, are the respective gene segments of the Ig heavy chain. **VL and JL are the respective gene
segments of the Ig light chain. ***Refers to the Basel nomenclature.
great majority of large B220pos/CD25pos/IgMneg/IgDneg cells have
at least one heavy chain locus VHDHJH rearranged. These cells
are called large pre-B cells (pre-B II cells). Staining for addi-
tional markers such as AA.4.1, heat-stable antigen (HSA), surro-
gate light (SL) chains VpreB and lambda5 can be used to per-
form a more detailed analysis of B lineage subpopulations in
BM [1113, 1114, 1121–1123, 1130, 1131] (Table 43).
2.1.6 Data analysis: Murine B cells in secondary lymphoid organs.
For identification of B cells in the spleen and other secondary
lymphoid organs, single cells should be gated according to their
scatter properties, and doublets should be excluded from the
analysis (Figure 139A). In order to avoid exclusion of acti-
vated/proliferating B cells, the FSC gate should be not too restric-
tive. Exclusion of dead cells through application of live/dead dis-
crimination reagents is strongly recommended [1], this measure
is of crucial importance particularly when smaller subpopulations
are included in the analyses.
The spleen contains MZ B cells that are unique to this organ.
The immature B cells stages T1, T2 and T3 are also selectively
found in the spleen. In contrast, lymph nodes and Peyer’s patches
contain neither MZ nor immature B cells, but harbor mainly fol-
licular B cells.
In spleen and other secondary lymphoid tissues, all B cells
are CD19pos and B220pos (of note, not all plasma cells express
these twomarkers, see Chapter VI Section 3.1Murine Ab-secreting
plasmablasts and plasma cells). Therefore, CD19 or B220 can be
used as alternative markers for the identification of B lineage cells
in these tissues. In spleen, staining for B220 (or CD19), CD21,
CD23 and IgM allows identification of follicular B cells and MZ B
cells [1132, 1133]. We also recommend to stain additionally for
IgD. Using this marker combination, follicular B cells are identified
by their B220pos/CD21intmed/CD23high phenotype, MZ B cells are
B220pos/CD21high/CD23low/neg (Fig. 139B). While their character-
istic B220/CD21/CD23 expression profile is sufficient to identify
follicular and MZ B cells, their identity can be further proofed by
their distinct IgDpos/IgMintmed and IgDlow/neg/IgMhigh phenotype,
respectively (Fig. 139C). After further gating B220pos cells on IgM
vs CD21 and CD23, this marker combination also allows to identify
T1 and T2 cells [1134].
All secondary lymphoid organs can contain GCs where B cells
can develop Abs of increased affinity, after proper stimulation in
the context of a T-dependent immunization. GCs are transient
structures present after immunization with T-dependent (pro-
tein) antigens which are absent in steady state. Flow cytomet-
ric analysis of GC B cells is described in section Chapter VI Sec-
tion 2.2 Murine Germinal Center B cells. Eventually, the GC reac-
tion gives rise to plasma cells and memory B cells. Plasma cells
are described in detail in Section 3 of this chapter (Murine Ab-
secreting plasmablasts and plasma cells. Memory B cells are found
in spleen and in the peripheral blood. The murine B cell memory
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compartment appears in several subsets and exhibits a very het-
erogeneous phenotype [1135].
Memory B cells specific for one particular antigen can be iden-
tified by staining with fluorescent-labeled antigen. However, due
to the low frequencies of these cells and unspecific binding to
other B cells, this method is challenging and needs careful con-
trols [1136, 1137]. Usage of adoptive transfer of B cells from BCR
transgenic mice allows to increase the frequencies of monospe-
cific B cells. In the recipients, these cells could be identified by
staining with a fluorescent-labelled antigen or by an idiotype spe-
cific marker. Staining for CD35, CD73, CD80, and CD273 (PD-L2)
defines functionally distinct subsets of murine memory B cells,
including IgMpos and IgGpos cells [1138–1143]. The spleen also
contains a small population of B-1 cells. An overview of marker
combinations suitable to identify B lineage cells in spleen is pro-
vided in Table 44.
2.1.7 Data analysis: B-1 cells in peritoneum. B-1 cells mainly
reside in the peritoneum, the pleura and other body cavities
[1154]. Compared to other B cells, they express lower levels of
B220, but normal or high levels of CD19. Therefore, we recom-
mend usage of CD19 mAb to identify B cells in body cavities.
B-1 cells come in two flavors, B-1a and B-1b which are distin-
guishable by differential expression of CD5.
After isolation, peritoneal lymphocytes should be gated accord-
ing to their scatter properties, and doublets should be excluded
from the analysis (Figure 140A). To some extent, B-1 cells rec-
ognize self-antigens and may often exhibit an activated blast
phenotype even in the absence of an external stimulus [1146].
Therefore we recommend to set the FSC gate not too restrictive.
Removal of dead cells is recommended in case the peritoneal
immune cells were activated, e.g. by infectious agents, thiogly-
collate, or other stimuli. B-1 cells could be identified according to
their CD19pos/CD23neg/CD43pos/IgMposphenotye (Figure 140B).
B-1a and B-1b are discriminated by their CD5pos and CD5neg phe-
notype, respectively (Figure 140D).
2.1.8 Data analysis: Regulatory B cells. B cells can modulate
immune responses and induce or suppress inflammation through
the production of Abs, but also by contact-dependent interactions
and through the secretion of various pro-and anti-inflammatory
cytokines such as IFN-gamma, GM-CSF, IL-10, IL-17, and IL-
35 [1155–1160].
B cells with a suppressive function are generally termed “reg-
ulatory B cells” (Bregs) [1161]. Breg subtypes typically express
immunosuppressive IL-10 but otherwise exhibit a very heteroge-
neous phenotype [1162]. Several protocols are in use to identify
Breg subtypes by distinct combinations of markers such as IL-
10, IgM, IgD, CD1d, CD5, CD21, CD23, CD24, CD43, and CD93,
among others [1146, 1156, 1162–1175] (Table 45).
At least one of the IL-10 producing Breg subtypes termed
B10 cells, which exhibits a CD1dhi/CD5pos/CD19pos phenotype,
represents a direct precursor stage of Ab-secreting cells [1163].
Interestingly, production of immunosuppressive IL-10 is common
among Ab-secreting plasmablasts and plasma cells [1164–1166].
Recently, the inhibitory receptor LAG-3 was identified as a marker
for a population of natural regulatory plasma cells [1167].
2.1.9 Pitfalls and tricks. B lineage cells exhibit a broadly het-
erogeneous phenotype. This includes proliferating and/or acti-
vated cells that are larger than resting lymphocytes and might
be excluded by the usually lymphocyte scatter gate. Moreover, B
cell subsets can express markers typical for other lineages, i.e.,
the “myeloid marker” CD11b that is found on B-1 cells in the
body cavities. Therefore, we recommend to start the analysis of
the cytometric data with an unbiased approach, avoiding exclu-
sion of cells potentially belonging to the B lineage. This could be
achieved by analyzing all CD19 or B220 positive cells among the
total, ungated population. In a second step, non B lineage cells
could be excluded by appropriate gating.
2.2 Murine germinal center B cells
2.2.1 Overview. Germinal centers (GCs) are the sites of antigen-
dependent clonal expansion and affinity maturation of B lym-
phocytes, thereby generating high-affinity B cell clones that can
develop into memory B cells and long-lived plasma cells secret-
ing high amounts of Abs. Here, we describe a staining protocol
to unambiguously identify murine GC B cells, as well as B cell
subpopulations within the GC.
2.2.2 Introduction. Upon the encounter with antigen, antigen-
activated T cells interact with B cells at the T-B cell border.
Antigen-specific B cells that present antigen on MHC class II
molecules to activated T cells in turn secrete cytokines to induce
survival and proliferation of B cells (see also Chapter VI Sections
2.3 Human B cells and their subsets and 2.4 Human B cells recog-
nizing defined (auto)antigens), which can then enter the B cell
follicles [1176, 1177]. Germinal centers (GCs) arise in B cell
follicles in secondary lymphoid organs like the spleen or lymph
nodes [1178]. These GCs are the site of antigen-dependent clonal
expansion and affinity maturation and lead to the development of
high-affinity Abs [1179].
GCs can be divided into anatomically defined zones, namely the
dark zone (DZ) and the light zone (LZ) that were historically clas-
sified based on their appearance under a light microscope [1180].
In a Darwinian evolution process, B cells with low affin-
ity undergo apoptosis whereas B cell clones with higher
affinity for their cognate antigen are positively selected to
survive.
Within the DZ, a massive proliferation of B cells takes place.
Additionally, the enzyme activation-induced cytidine deaminase
(AID) generates mostly point mutations within the variable region
of the heavy chain (HC) and the light chain (LC) of the BCR, which
is known as somatic hypermutation [1181]. These mutations alter
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Table 44. Identification of B lineage cells in spleen
Subpopulation Marker combination References
T1 B220pos / CD21low/ CD23low/neg / IgDlow/neg / IgMhigh [1134, 1144, 1145]
B220pos / CD23neg / IgMhigh / AA4.1pos [1116]
T2 B220pos / CD21high / CD23pos/ IgDlow/neg / IgMhigh [1134]
B220pos / CD23pos / IgMhigh / AA4.1pos [1116]
B220pos / CD21high / CD23pos / IgDhigh / IgMhigh [1144]
T3 B220pos / CD23pos / IgMlow / AA4.1pos [1116]
FO B220pos / CD21intmed / CD23high / IgDpos / IgMintmed [1133, 1134]
B220high / CD23pos / IgMlow / AA4.1neg [1132]
CD19intmed / CD1dintmed / CD23pos / CD43neg /
IgMlow / IgDhigh / CD5neg
[1146]
MZ B220pos / CD21high / CD23low/neg / IgDlow/neg /
IgMhigh
[1133, 1134, 1144]
CD9pos / CD21pos / CD23neg / IgDlow / IgMhigh [1132]
CD19intmed / CD1dhigh / CD21high / CD23neg /
CD43neg / IgMhigh / IgDlow / CD5neg
[1146, 1147]
B-1 IgMhigh / CD43pos / IgDlow/neg / CD23low/neg [1132]
CD19pos / B220low / CD43pos / CD23neg / AA4.1neg [1118, 1148]
B-1a CD19pos / IgMpos / CD43pos / CD5pos [1149, 1150]
CD19high / CD1dintmed / CD23neg / CD43pos / IgMhigh
/ IgDlow / CD5pos
[1146]
B-1b CD19pos / IgMpos / CD43pos / CD5neg [1149]
CD19high / CD1dintmed / CD23neg / CD43pos / IgMhigh
/ IgDlow / CD5neg
[1146]
Memory antigenpos, CD73low / CD80low / CD273low [1138–1143]
antigenpos, CD73hi / CD80hi / CD273hi
antigenpos, CD73hi / CD80low / CD273low
antigenpos, CD73low / CD80hi / CD273hi
*antigenpos, CD73hi / CD80low
GC CD19pos / B220pos / CD38neg / GL7pos [1151, 1152]
B220pos / GL7pos / Faspos [1134]
B220pos / GL7pos / PNApos [1153]
*Antigenpos = cells are specific for the immunizing (memory) antigen
the binding of the BCR to its cognate antigen, allowing the B cells
to acquire higher affinity. The process of class switch recombina-
tion (CSR), also known as isotype switching, is mediated by the
same enzyme and leads to the replacement of the Cµ heavy chain
by either Cɣ, Cɛ, or Cɑ, resulting in the expression of IgG, IgE, or
IgA, respectively [1182].
The selection of B cell clones with enhanced affinity to their
cognate antigen occurs in the LZ of the GC and is mediated
Table 45. Identification of regulatory B cell subsetsa)
Subpopulation Marker combination References
Breg CD5pos / CD19high / CD1dhigh / CD21high/intmed /
CD23pos/neg / CD43neg / IgMhigh / IgDlow/intmed
[1146]
T2-MZP CD19pos / CD21high / CD23high / IgMhigh / HSAhigh /
CD1dhigh /IL-10 pos
[1162, 1168, 1169]
MZ CD19pos / CD21high / CD23neg / IL-10pos [1170, 1171]
B10 CD5pos / CD1dhigh / CD19pos / IL-10pos [1156, 1163, 1172]
Tim-1+ cells Tim-1pos / CD19pos / IL-10pos [1173, 1174]
Plasma cells CD138pos / B220pos / MHC-IIlow / IL-10pos [1164, 1166]
Plasmablasts CD138pos / CD44high / IL-10pos [1165]
Natural
regulatory PCs
CD19pos/neg / B220neg / LAG-3pos / CD138high /
IL-10pos
[1167, 1175]
a)including “regulatory plasma cells”
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Figure 141. Two gating strategies for the identification of murine splenic GC B cells from single cell suspensions by flow cytometry. C57BL/6 mice
were immunized with sheep red blood cells (SRBC) and analyzed on d10 post-immunization. In (A) GC B cells were stained as being CD19+ CD38low
and GL7+ PNA+. In (B) GC B cells were stained as being CD19+ CD38low and GL7+ Fas+. Both variants unambiguously help to identify GC B cells.
by two cell types: follicular dendritic cells (FDCs) capture anti-
gen in the form of immune complexes that is presented to
B cells [1183]. Antigen-specific B cells internalize antigen and
load it onto MHCII peptides for the presentation to T follicu-
lar helper (Tfh) cells. Besides FDCs, these are the other class
of cells that mediate selection of high-affinity B cell clones. It
has been proposed that peptide-MHCII density on GC B cells
is the limiting factor that leads to positive survival signals by
Tfh cells [1179]—that means the higher the affinity of the BCR
of the B cell, the more antigen it will capture, internalize and
finally present to Tfh cells. However, Yeh et al. have shown that
halving peptide-MHCII density on B cells does not alter selec-
tion of high-affinity B cell clones but rather their initial entry
into early GCs [1184] and therefore the precise mechanism for
Figure 142. Staining of murine splenic GC B cells from single cell suspensions to identify GC subpopulations by flow cytometry. C57BL/6mice were
immunized with sheep red blood cells (SRBC) and analyzed on d10 post-immunization. The GC can be divided into the dark zone (DZ, CXCR4hi
CD86low) and the light zone (LZ, CXCR4low CD86hi) and can be distinguished by their respective surface makers.
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positive selection of high-affinity B cells within the LZ still remains
unclear.
B cells can then either leave the GCs to become memory B
cells [1185, 1186] or plasma cells [1187, 1188] or cycle back to
the dark zone to undergo further rounds of division and somatic
hypermutation to increase affinity even more [1189, 1190]. See
also Chapter VI Sections 2.1 Murine B cells and their subsets, incl
Breg cells and 3.1 Murine Ab-secreting plasmablasts and plasma
cells.
2.2.3 Step-by-step sample preparation. For the generation of sin-
gle cell splenocytes, spleens of mice were harvested and crushed
through a 100 µM nylon mesh filter and finally resuspended in
FCM buffer (PBS, 2% FCS, 2 mM EDTA). Lysis of erythrocytes
was performed at room temperature for 5 min, cells were washed
two times and Fc-blocking solution was added (20 min at 4°C).
Finally, cells were incubated with FCM buffer containing respec-
tive directly conjugated Abs (20 min at 4°C) and resuspended in
FCM buffer for analysis. All centrifugation steps were performed
at 400 × g and 4°C for 8 min.
2.2.4 Materials. FCM buffer: PBS (137 mM NaCl + 2.7 mM KCl
+ 4.3 mM Na2HPO4 + 1.4 mM KH2PO4, pH 7.3), 2% FCS (PAN
Biotech), 2 mM EDTA (Lonza).
Erythrocyte lysis buffer: 0.15 M NH4Cl, 0.02 MHEPES, 0.1 mM
EDTA.
Fc-blocking solution: CD16/32mAb (clone 2.4G2, Ho¨lzel Diag-
nostika) in FCM buffer.
Antibodies: Anti-mouse Abs that were used for FCM analy-
sis: CD19 APC-Cy7 (clone 1D3, BioLegend), CD19 BV421 (clone
6D5, BioLegend), B220 PerCP-Cy5.5 (clone RA3-6B2, BioLegend),
CD38 PE (clone 90, BioLegend), PNA FITC (Vector Laboratories),
GL7 AF647 (clone GL7, BioLegend), Fas PE-Cy7 (clone Jo2, BD
Biosciences), CD86 FITC (clone GL1, eBioscience), and CXCR4
BV421 (clone, L276F12, BioLegend). FCM analysis was performed
on a Cytoflex instrument (Beckman Coulter) and FlowJo v10.5.3
analysis software (FlowJo, LLC).
2.2.5 Data analysis: Germinal Center B cells. Although the sam-
ple preparation leads to a single cell suspension, doublets can
occur through cell–cell interactions (which can be reduced by
adding EDTA to the FCM buffer) and can be easily excluded
from the analysis by a plot that shows FSC Height versus Area
(Fig. 141A). The lymphocytes gate should not be too stringent, as
GC B cells tend to be larger in size. In order to stain for murine GC
B cells, we suggest to use the markers CD19 or B220, CD38, GL7,
and either PNA (Fig. 141A) or Fas (Fig. 141B). (See also Chapter
VI Section 2.1, why to use CD19 or B220). In contrast to human
GC B cells, murine GC B cells show reduced expression of the
surface marker CD38 and can be gated accordingly [1191]. Here,
it is important to set a larger gate for CD38 to not exclude any
GC B cells, since these cells tend to have varying CD38 expres-
sion levels. Further, the rat mAb GL7 that reacts with a sialic
acid glycan moiety called Neu5Ac [1152], previously reported as
a marker for polyclonally activated B and T cells [1192], can be
used in the staining protocol. In addition, the plant lectin peanut
agglutinin (PNA) from Arachis hypogaea with specificity for ter-
minal galactosyl residues on cell surface oligosaccharides [1193]
has been shown to bind GC B cells and can be used to specifi-
cally identify these cells [1194–1196]. Instead of using PNA (see
“pitfalls”), the Fas receptor (CD95, Apo-1) can be used to iden-
tify GC B cells (Fig. 141B), which is highly upregulated in these
cells [1197].
With the mentioned four colors, CD19 or B220, CD38, GL7,
and either PNA (Fig. 141A) or Fas (Fig. 141B), GC B cells can
unambiguously be identified. Since GC B cells also downregulate
IgD [1194, 1198, 1199], this is an additional marker that can be
added to the staining protocol.
Pitfalls
One pitfall of the staining in Fig. 141A is that the PNA signal
is downregulated quite fast if the time between staining and mea-
surement of the samples is long (own observation). Constantly
keeping samples on ice however helps to counteract this down-
regulation.
2.2.6 Data analysis: Germinal Center B cell subpopulations. The
GC has a certain microanatomic structure that can be divided into
the DZ, where B cell proliferation and somatic hypermutation take
place, and a LZ, where selection of high-affine B cell clones occurs.
In order to stain for these two zones, GC B cells are first stained as
described in the section “Murine Germinal Center B cells” above
(Fig. 141).
CD86 (also known as B7-2) is a surface protein that is expressed
on activated B cells [1200, 1201] and has a costimulatory func-
tion for T cell proliferation [1202]. Together with the chemokine
receptor CXCR4, that has been shown to be important for GC orga-
nization [1203], Victora et al. used the combination of CD86 and
CXCR4 to differentiate DZ cells (CXCR4hi CD86low) from LZ cells
(CXCR4low CD86hi) [1204]. The staining for DZ/LZ cells is shown
in Fig. 142.
Pitfalls
A pitfall of this staining is the difficulty to set an accurate
gate for the DZ/LZ, since these two populations are not clearly
separable from each other by FCM. Especially if fluorochromes
for CXCR4 and CD86 are used that are known for fluorescence
spillover, proper compensation is very important to not distort
DZ/LZ ratios. See also Chapter II Section 1 Compensation.
2.3 Human B cells and their subsets
2.3.1 Overview. B cells represent the Ab-producing cells devel-
oping from na¨ıve B cells to Ab-secreting PC. One feature of B
cells is their capacity to differentiate upon antigen dependent and
independent stimulation to Ab secreting cells, also called plasma
cells. The stages of B cell differentiation share several common
features between the human and the rodent immune system. In
this section, we focus on human B cells.
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Figure 143. Gating strategy for the identification of human B cells. (A–E) Gating example for peripheral blood: (A) Lymphocytes are identified by
their light scattering properties. (B) Exclusion of doublets. (C) Cells positive for CD3 and CD14 and DAPI stained dead cells are excluded. (D) B
cells are identified by their expression of CD19 and CD20 including CD20low plasmablasts. (E) B cell subsets are discriminated by CD27 and IgD:
CD27−IgD+ naı¨ve B cells, CD27+IgD+ pre-switch memory B cells, CD27+IgD− switched memory B cells, CD27−IgD− B cells containing switched
memory B cells. (F) B cell subsets discriminated by CD27 and CD20 in peripheral blood, spleen, tonsil, and bone marrow: conventional naive B cells
are CD27− CD20+ (containing CD27− memory B cells) memory B cells CD27+ CD20+ and plasmablasts CD27++ CD20low. Cell subsets defined by
CD27 and CD20 expression were color-coded and depicted in a CD27 versus CD38 plot (pink: CD27−CD20+ B cells, dark blue: CD27+CD20+ B cells,
green (only in tonsil): CD27intCD20high, turquois (only in bone marrow): CD27−CD20−).
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Figure 144. Ig isotype expression of B cell sub-
sets in different human tissues. Gating strat-
egy is the same as depicted in Figure 143A–
D. B cell subsets discriminated by CD27 and
CD20 in peripheral blood, spleen, tonsil and
bone marrow: conventional naive B cells are
CD27− CD20+ (containing CD27− memory B
cells) memory B cells CD27+ CD20+ and plas-
mablasts CD27++ and CD20low. Cell subsets
defined by CD27 and CD20 expression were
color-coded and depicted in a IgD versus IgM
and IgA versus IgG plot to show Ig surface
expression of each subset (pink: CD27−CD20+
B cells, dark blue: CD27+CD20+ B cells, green
(only in tonsil): CD27intCD20high, turquois (only
in bone marrow): CD27−CD20−).
2.3.2 Introduction. To identify B cells, the B cell specific
molecules CD19 and/or CD20 serve as specific surface mark-
ers (Fig. 143). CD19 is a B cell surface molecule expressed at
the time of immunoglobulin heavy chain rearrangement [1205],
CD20 is expressed by all mature B cells beyond the pro B cell
stage in the bone marrow and disappears on the surface of mature
plasma cells [1206, 1207]. For further discrimination of B cell
developmental stages, combinations of additional markers such as
CD27, CD38, CD23, CD77, and expression of surface Igs are used.
Immature CD19+ B cells in the bone marrow express high lev-
els of CD38 and variable levels of CD20 and IgM, which increase
with their further differentiation (Figs. 143F and 144) [1208].
CD38++ CD20++ immature B cells express IgM and IgD, leave
the bone marrow and become CD38++ CD24++ CD10+ transi-
tional B cells [1208]. Na¨ıve B cells express IgM and IgD and
are CD27− and CD38−, they comprise about 60% of B cells in
the peripheral blood (Figs. 143F and 144) [1209, 1210]. After
antigen encounter and T cell help, memory B cells and Ab-
secreting plasma cells are generated in the germinal center reac-
tion. Human memory B cells (mBCs) can be identified by the
expression of CD27 and carrying of mutated Ig VDJ gene rear-
rangements [1209, 1211]. In the peripheral blood, between 30
and 40% of circulating B cells express CD27 (Fig. 143F, Fig. 144)
[1209, 1212]. PC carry distinct FSC and SSC characteristics,
express high levels of CD27 and lack the expression of CD20 but
are also highly positive for CD38 and partially CD138++ [1213].
A CD19− PC population is uniquely enriched in the bone marrow
[1214].
An alternative staining protocol of CD20+/CD19+ B cells has
applied co-staining of CD38 and IgD together with CD77 and CD23
to mark differentiation stages of B cells in human tonsils [1215].
CD23 is a low-affinity Fcε receptor and associated with the acti-
vation of B cells. It was found to be co-expressed with IgM and
IgD in the tonsil and in peripheral blood but not with IgA and IgG
and hence is lost during isotype class-switching [1216]. CD77 is
strongly expressed by germinal center B cells and can be used to
differentiate centroblasts from centrocytes [1215, 1217]. In this
protocol, naive IgD+ CD38− B cells are separated by CD23 into
Bm1 (CD23−) and Bm2 (CD23+) B cells. IgD− CD38+ germinal
center B cells can be further discriminated into CD77+ centrob-
lasts (Bm3) and CD77− centrocytes (Bm4). IgD− CD38− B cells
comprise the memory compartment (Bm5).
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The expression of IgD can be used as a marker to further dis-
criminate certain na¨ıve and memory B cell populations. CD19+
CD20+ B cells can be separated in a CD27 versus IgD dot plot
(Fig. 143E). In this regard, na¨ıve B cells express IgD and are
CD27−. Further quadrants represent different subsets of mem-
ory B cells: in detail, CD27+ IgD+ are memory B cells that mostly
express high levels of IgM and carry somatic mutations of their
V(D)J rearrangements, whereas CD27+ IgD− memory B cells are
class-switched and also carry somatic mutations [1209]. Interest-
ingly, the CD27− IgD− B cell subset appears to be very heteroge-
neous and contains IgA- and IgG-expressing cells [1218, 1219]. It
has been shown that this phenotypic population contains a mem-
ory B cell subset expressing CD95 with an activated phenotype,
which is especially enhanced in patients with systemic lupus ery-
thematosus (SLE) and correlated with disease activity and sero-
logic abnormalities, whereas healthy donors only show minor fre-
quencies of CD95+ cells [1220]. Among other disturbances, B cells
lacking expression of the complement receptor CD21, which is part
of a signaling complex, together with CD19 have been reported
to be expanded in patients with SLE [1221, 1222]. An overview
of markers expressed on different B cell subsets can be found in
Table 47.
2.3.3 Step-by-step sample preparation. Depending on the start-
ing material, different methods for cell isolation can be applied.
A common start is to isolate mononuclear cells (MNCs) by den-
sity gradient centrifugation (see also Chapter IV Section 1.2 Pre-
enrichment by physical properties). When starting with tissue, a
lysate of the minced material can be layered over the Ficoll (e.g.,
GE Healthcare) solution, when starting with blood, this is carried
out with a mixture of blood and PBS according to the manufac-
turer’s instructions. After collecting the MNC layer and subsequent
washing steps, the number of isolated cells can be assessed and
one can start with the staining procedure or further experiments.
The washing buffer should be chosen according to the following
experiments, for example PBS containing a carrier protein like BSA
(e.g., 0.1–0.5%) for staining or medium for subsequent stimula-
tion experiments. One should be aware that using EDTA in wash
buffers might have an effect on following stimulation experiments
by chelating calcium ions. For basic staining of B cells, 1–2 × 106
MNCs should suffice as input. For analysis of antigen-specific cells,
a higher input number might be useful.
For further applications, enrichment of B cells, e.g., by MACS R©
technology (Miltenyi) might be necessary (see Chapter IV Sec-
tion 1.3 Pre-enrichment by immunological properties). Depending
on the experiment planned after enrichment, an approach with
untouched cells of interest (negative selection) can be applied
(e.g., B cell isolation kit II). If specific subpopulations are desired,
a positive selection might be required. MACS R© sorting gives high
purities, nonetheless the purity check of the desired fraction by
FCM staining should be performed.
A different approach for staining starting with peripheral blood
is a lysis protocol of red blood cells (see also Chapter IV Section
2.5 Erythrocyte lysis, e.g., with BD PharmLyse, Qiagen EL buffer).
After erythrocyte lysis and washing, the obtained cell suspension
can be stained.
Depending on the application, blocking of Fc receptors can
be useful prior to staining. One should be aware that Ig staining
might not work after adding Fc blocking reagents to cell suspen-
sions. Most manufacturers recommend surface staining at 4°C for
15–30 min but some molecules might require different staining
conditions.
For intracellular staining, isolated MNCs can be lysed and per-
meabilized directly or after stimulation experiments to assess for
example phosphorylation of intracellular proteins (see Chapter III
Section 5: Cell fixation and permeabilization for flow cytomet-
ric analyses). There are different protocols and reagents avail-
able depending on the intracellular location of the antigen to be
stained (e.g., BD, Biolegend, eBioscience and others). For antigens
in the cytoplasm, a less harsh permeabilization buffer can be used
than for example for antigens located in the nucleus. Blood or tis-
sue lysates can also be prepared for intracellular staining directly
(whole blood staining) by lysis and permeabilization and stained
after washing steps. Twenty to 60 minutes at room temperature
are frequently used for intracellular staining. One should be aware
that some epitopes might be destroyed after lysis and permeabi-
lization and thus may not be identified. This should be validated
for each application.
2.3.4 Materials.
1. Ficoll Paque (GE Healthcare)
2. PBS (Biochrom)
3. Staining buffer (PBS/0,5% BSA/EDTA (Miltenyi autoMACS R©
Rinsing Solution/MACS R© BSA Stock Solution))
4. Buffers for cell permeabilization (e.g., Phosflow Lyse/Fix
Buffer (BD Biosciences), Phosflow Perm Buffer II (BD Bio-
sciences))
5. Buffers for erythrocyte lysis (e.g., Lysing Buffer (BD PharmLyse
TM BD Biosciences, Buffer EL (Qiagen)),
6. Anti-Mouse Ig, κ/Negative Control Compensation Particles
Set (BD Biosciences)
7. Live/Dead stain (e.g., DAPI (Molecular Probes) or LIVE/DEAD
Fixable Dead Cell Stain Kit, (Invitrogen))
8. Instrument: LSR Fortessa X-20 (BD Biosciences)
9. Fluorescently labeled mAbs (Table 46):
2.3.5 Gating for human B cells subsets. After MNC preparation
or lysing whole blood, lymphocytes should be gated according to
their scatter properties and by the exclusion of doublets and dead
cells from the analysis (Fig. 143A–C). In order to detect plasma
cells simultaneously, the initial FSC/SSC gating should be larger
and not limited to a conventional lymphocyte gate [1213].
When gating on CD19+ B cells, CD3+ T cells and CD14+ mono-
cytes need to be excluded. If these cells are not of further interest,
they can be assigned to a so called “dump channel” with CD3
mAb and CD14 mAb together with other markers for cells that
should be excluded from subsequent analyses, e.g., CD16/CD56
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Table 46. Fluorescently labeled monoclonal antibodies used for the
stainings in Figs. 143 and 144
Fluorophore Marker Manufacturer Clone Isotype
BUV395 CD3 BD UCHT1 mouse IgG1κ
BUV395 CD14 BD M5E2 mouse IgG2aκ
BV711 CD19 BD SJ25C1 mouse IgG1κ
BV510 CD20 Biolegend 2H7 mouse IgG2bκ
BV786 CD27 BD L128 mouse IgG1κ
APC-Cy7 CD38 Biolegend HIT2 mouse IgG1κ
BV421 IgM BD G20-127 mouse IgG1κ
PE-Dazzle594 IgD Biolegend IA6-2 mouse IgG2aκ
PE-Cy7 IgG BD G18-145 mouse IgG1κ
FITC IgA Chemicon M24A mouse IgG1
mAb for NK cells. One approach frequently applied is to gate on
CD3− CD14− DAPI− cells (Fig. 143C) and, in a subsequent step,
identification of CD19+ and CD20+/- cells (Fig. 143D). This gating
permits reliable identification of CD20+ B cells and additionally
of CD20low plasmablasts. For the analysis of B cell subsets, a clas-
sical combination using CD27 and CD20 of CD19+ B cells has
been established. Using CD27, a number of B cell subsets can be
identified independent of the expressed Ig subclasses. As a result,
conventional CD27− CD20+ na¨ıve B cells, CD27+ CD20+ mBCs,
including both preswitched and class-switched memory B cells, as
well as CD27++ CD20low PBs can be identified (Fig. 143F). While
the distribution of these subsets can vary between different dis-
eases with slight variations [1223], it has been demonstrated that
CD27 can serve as a reliable marker for human healthy controls
memory B cells, since CD27-expressing B cells differentiate timely
into Ab-secreting cells after stimulation and carry somatic muta-
tions in their immunoglobulin V regions [1209, 1211]. Of note,
this gating strategy will not allow to identify class-switched B cells
that lack the expression of CD27 [1218, 1219] and occur at higher
frequencies among patients with systemic autoimmune diseases
When comparing the CD27 versus CD20 plot in the different
tissues (Fig. 143F), an additional population has been found in
the tonsil and another population in the bone marrow compared
to peripheral blood and spleen. In the tonsil, a subset express-
ing high levels of CD20, intermediate levels of CD27 and CD38
expression appears in this plot and represent germinal center B
cells that lack IgD expression [1224]. In the bone marrow, an
additional population positive for CD19 but lacking the expres-
sion of CD20 and CD27 can be found. These B cells express CD38,
do not show surface IgD expression and low to no IgM surface
expression (Fig. 144) and represent immature B cells [1225].
2.3.6 Pitfalls.
1. Blocking Fc receptor prior to staining might interfere with
staining of immunoglobulins on B cells
2. Choose an appropriate buffer for cell isolation: Buffers con-
taining EDTA can decrease effects of stimulation by chelating
calcium ions
2.3.7 Summary Table.
Table 47. Phenotypic differentiation of human B-lineage cell subsets
based on their characteristic expression of surface markers
B cell population (CD19+) Phenotype/Subphenotype
Transitional
T1+T2 CD24++CD38++CD10+CD27−IgM++
Naive
Resting CD24+/−CD38+/−CD27−IgM++/+
IgD++CD21+CD95−
Activated CD24−CD38−CD27−IgM++IgD++
CD21−CD95+MTG+
Memory (Ki−67−)
Preswitched IgM+IgD+/−CD27+CD1c+
Switched IgG/IgA+CD27+CD21+
Atypical memory
a) Double negative IgD−CD27−
b) activated double
negative
IgD−CD27−CD95+
c) Syk++ IgD+/−CD27−CD95+/−CD21+/−
CD38−MTO−Syk++
d) tissue-resident IgM/IgG/IgA+CD27−FcRL4+
Marginal Zone
Spleen IgD+IgM+CD27++CD21++CD1c+
Circulating IgD+IgM+CD27+CD1c+
Ab secreting cells
Circulating
PB CD38++CD27++CD138−Ki−67+
PC CD38++CD27++CD138+/−Ki−67+/−
Bone marrow
a) CD19+ PC CD19+CD38++CD27++CD138+
Ki−67−
b) CD19− PC CD19−CD38++CD27++CD138+
Ki−67−
2.4 Human B cells recognizing defined (auto)antigens
2.4.1 Overview. Detection of human antigen-specific B cells has
been challenging mainly due to their low frequency and the poten-
tial biases introduced by their ex vivo expansion. Naive B cells
present with a diverse BCR repertoire that is usually of low avid-
ity to the antigen. Upon antigen challenge, naive B cells undergo
processes of somatic hypermutation, class switch recombination,
and selection giving rise to memory B cells with high-avidity BCRs
and PCs secreting highly specific Abs. Memory B cells and long-
lived plasma cells are responsible for generation and maintenance
of serologic memory. In some conditions, serum Ab titers corre-
late with the frequency of antigen-specific memory B cells in the
circulation [1226, 1227]. Here, we present two recently estab-
lished methodologies to identify human antigen-specific B cells
by FCM.
2.4.2 Introduction. The identification of human antigen-specific
B cell populations by FCM has become an extremely valuable
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Figure 145. (A) After gating on lymphocytes, doublets, and in the subsequent gating step, CD3+ T cells, CD14+ monocytes, and dead cells are
excluded. B cells including CD20low plasmablasts are gated by their CD19 and CD20 expression. Conventional naı¨ve and memory B cells and
plasmablasts are identified by using CD20 and CD27. (B) Identification of TT-specific memory B cells and plasmablasts before (day 0) and after TT
vaccination (day 7 and day 14) in peripheral blood. Staining and block with unlabeled TT are shown.
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Figure 146. Determining optimal concentrations of multimerized antigen-tetramers for staining. (A) titration of CCP2-SA-APC, CArgP2-SA-APC,
and of “empty” streptavidin APC tetramers on ACPA-expressing HEK 293T (HEK-ACPATM) and wild-type HEK 293T (HEKWT) cells. Gates are based
on unstained controls. The red square marks the optimal concentration of CCP2-SA-APC. (B) Staining of HEK-ACPATM and HEKWT cells with
combinatorial CCP2 and CArgP2 tetramers.
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Figure 147. Gating strategy to identify
ACPA-expressing B cells. (A) Setting up
a “B cell store gate” that will be used
during sample measurement to store
data in order to obtain a manageable
size of data to be analyzed. (B) Gating
strategy to identify ACPA-expressing
B cell subsets. The CD20 versus CD27
gates for ACPA-expressing B cells are
copies of the same gates from the
CCP2−/− population. (C) Back-gating of
ACPA-expressing B cells as an addi-
tional measure of control to verify cell
size and granularity within the large
pool of PBMC-derived B cells.
tool for a detailed understanding of both protective and autoreac-
tive human immune responses. Depending on the research ques-
tions, antigen-specific B cell responses can be analyzed and moni-
tored upon vaccination, during “steady state,” in different diseases
including different disease stages, phases of treatment, and in dif-
ferent compartments of the human body [1228–1231]. It allows
for the phenotypic analysis of antigen-induced B cells by assess-
ing various markers on the cell surface and inside the cell. In
combination with cell sorting, it also allows subsequent analysis,
such as transcriptomic profiling by single cell-based (“next gener-
ation”) sequencing techniques. Furthermore, it is possible to ana-
lyze antigen-specific B cell receptor (BCR) repertoires, to obtain
full-length BCR sequences for mAb generation, and to perform
functional studies of isolated single B cells or B cell populations,
which includes the generation of immortalized, antigen-specific
B cell clones [1232, 1233]. This wealth of possibilities permits
unprecedented insights into humanB cell biology; it requires, how-
ever, particular care and adherence to relevant and tedious control
steps to ensure that the antigen-specific B cell populations identi-
fied by FCM, which are frequently very rare, indeed represent the
antigen-specific B cell population of interest. Here, we provide a
detailed description of the necessary considerations prior to start-
ing out, the technological possibilities, approaches and necessary
tools, and the relevant steps for performing experiments. We do so
by using two examples of human antigen-specific B cell responses:
(i) a vaccine-induced, high-avidity immune response identified by
direct labeling of antigen with a fluorescent dye; and (ii) an auto-
reactive, low-avidity B cell response identified in an autoimmune
disease setting using biotinylated self-antigens tetramerized with
fluorescently labeled streptavidin molecules. In general, the exam-
ples described aim at identifying antigen-specific B cells within a
polyclonal B cell repertoire to the highest validity. This implies
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that strong emphasis is placed on the exclusion of nonspecific
background signals and on several steps aimed at the verification
of antigen-specificity. Notably, certain research questions might
not require this strive for purity but can be answered by mere
enrichment of the antigen-specific cell population. In other cases,
such as single-cell transcriptomics, purity is crucial. In both cases,
it is important to consider a number of general aspects before
choosing the most suitable technical approach.
2.4.3 General considerations before starting out.
2.4.3.1 Estimated frequency of the antigen-specific B cell popula-
tion of interest. In contrast to murine studies, in which the spleen
and other lymphoid organs are readily accessible, most attempts
to identify antigen-specific human B cells will need to rely on
peripheral blood. In this compartment, CD19+ B cells comprise
around 4% of total PBMCs in adult healthy individuals (See also
ChVI Section 2.3 Human B cells and their subsets). Frequencies
of antigen-specific B cell populations, however, can be very low
(<0.01% of total B cells). In an ideal setting, this requires, for
example, 1 × 106 B cells to identify 100 antigen-specific B cells,
and hence, a starting population of 25× 106 PBMCs. In other com-
partments such as bone marrow, tonsils, or spleen, CD19+ B cells
are more frequent (mean of 19% in BM, 33% in the spleen, 43% in
tonsils [1234]), as might be the frequency of antigen-specific sub-
sets. Depending on the compartment studied, it can be important
to estimate the expected frequency of the antigen-specific B cell
population in order to determine the amount of starting material
required for the identification of a minimum number of antigen-
specific cells. This can be achieved by culturing ex vivo isolated
PBMC or pre-enriched B cells in limiting dilution, followed by the
assessment of antigen-specific B cell presence by either ELISA or
ELISPOT [1235, 1236]. These approaches will likely underesti-
mate the number of antigen-specific B cells in the circulation, but
will provide a minimum estimate of the cell numbers that can be
expected. In addition, this initial estimate can provide informa-
tion on isotype usage of the antigen-specific B cell response to be
studied, and allow determining whether the frequency of circu-
lating, antigen-specific B cells correlates with serum titers of the
corresponding Abs. This, in turn, will help in selecting donors and,
hence, increase the yield of antigen-specific B cells for the eventual
assessment.
2.4.3.2 Expected phenotype of the cell population of interest.
Next, to determining compartmental frequencies, it can be rele-
vant to use additional phenotypic markers in the eventual panel
that allow to more specifically select the B cell subpopulation in
which the antigen-specific cells are expected. For example, mark-
ers could identify the isotype or the Ig subclass that appears to be
most prominent for the Ig produced by PC measured by ELISA.
Also, if IgM-expressing B cells are to be identified, low-affinity
antigen binding can be expected, which in turn indicates that mul-
timerization of antigens can be helpful to increase the fluorescent
signal. Other antigen-specific responses, for example, might be
enriched in IgG4 expressing B cells, which allows to significantly
narrow the cell numbers that need to be studied (see also Chapter
VI Section 2.3 Human B cells and their subsets). The identification
of plasma cells that lack surface Ig expression, on the other hand,
might require an intracellular staining approach. If the expres-
sion of such phenotypic characteristics is known, these should be
incorporated in the staining panel and included in the frequency
estimation described above.
2.4.3.3 Source of cells. In general, any single cell suspension
that contains B cells, whether derived from peripheral blood, bone
marrow, spleen, tonsils, or solid tissues, can be assessed for the
presence of antigen-specific B cells. Limitations are caused by the
frequency of the antigen-specific population of interest, and by
the viability of cells (including pre-analytical treatment, i.e., ship-
ment). Freezing cells, for example, is likely to compromise the
plasmablast compartment, while na¨ıve andmemory B cells are less
sensitive (See also Chapter III Section 4.6 Freezing cell samples).
Pre-enrichment of B cells from larger populations by positive or
negative selection can increase the percentage of antigen-specific
B cells and shortens the time required on the flow-cytometer; it
can, however, also compromise B cell subsets, depending on the
isolation technique used. Therefore, due to the usually very low
frequency of antigen-specific B cell populations, we recommend—
whenever possible—using fresh, directly ex-vivo isolated B cells
or B-cell containing suspensions such as PBMC as a starting point.
This will minimize the loss of antigen-specific cells during work-
up. For certain B cell populations and research questions, however,
the use of frozen cells can be acceptable [1237].
2.4.3.4 Choice of antigen. In most cases, the antigen used for
flow-cytometric assessment will be the antigen for which reactivity
has been demonstrated in serum ELISA measurements or epitope
mapping studies, or which has been used for inducing the immune
response in, for example, vaccination studies. Both peptide and
protein antigens are possible candidates. Protein antigens might
be preferred in case of conformational epitopes; in addition, pro-
teins are more likely to carry multiple epitopes, which increases
the chance for higher avidity interactions with the BCRs. How-
ever, protein synthesis usually requires cells or expression systems
and purification steps after which impurities (such as LPS) can
remain that can influence and confound binding properties and
introduce nonspecific background signals. Peptides are easier to
synthesize to high purity and contain one or more, sometimes syn-
thetic, defined epitopes. Small sequence modifications can easily
be introduced to generate nonbinding control peptides. However,
peptides are usually too short to build appropriate 3D epitopes
or structures that crosslink BCRs and, hence, monomeric peptides
are usually insufficient for B cell identification. Therefore, peptide
antigens aremultimerized by generating either biotin–streptavidin
tetramer complexes, or by coupling peptides to dextran backbones
or other scaffolds using click-chemistry.
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2.4.3.5 Choice of fluorescent labels. In general, and in par-
ticular for low-avidity B cell immune responses, it is strongly
recommended to reserve at least two fluorescent channels in a
given staining panel for the identification of ultra-low frequency
antigen-specific B cells. For reasons described below, identification
of antigen-specific B cells by double-positivity for two identical
yet differentially labeled antigens significantly reduces nonspe-
cific background signals and, hence, the risk for misinterpretation
of fluorescent signals as antigen-specific cells. This concept of a
dual labeling approach has been described in detail elsewhere, an
example is provided bellow [1230, 1238, 1239]. We recommend
using fluorescent dyes with emission spectra that show no or very
little spectral overlap in order to reduce the need for extensive
compensation. Use of single label antigens might suffice for cer-
tain, high avidity B cell responses in combination with blocking
studies (see below), but additional measures should then be taken
to demonstrate staining specificity, in particular in cases in which
blocking with access, unlabeled antigen is incomplete.
2.4.3.6 Establishing positive and negative controls. To ensure
the highest reliability, we strongly recommend the use of both
positive and negative controls in the establishment of antigen-
specific staining approaches. In the specific setting described here,
controls need to be established at two levels:
1. Control cells that do or do not express the BCR of choice.
Such cells allow determining the specificity of antigen bind-
ing, the use of optimal concentrations of labeled antigen or
antigen-multimers, and the degree of nonspecific background
binding. Furthermore, they allow controlling for variations
between batches of labeled antigens and can be used to
determine the sensitivity of the approach to detect antigen-
specific cells within a larger pool of cells. Such control cells
are particularly useful during the experimental setup phase
of antigen-specific staining approaches aimed at identifying
very low-frequency B cells. However, they maintain their rele-
vance also once protocols have been established. Examples for
control cells include B cell hybridomas that have maintained
cell surface Ig expression [1240], immortalized human B cell
clones of known specificity [1232, 1233], or cell lines trans-
fectedwithmAb sequences with or without the transmembrane
domain of IgG [1230]. An example of the latter option using
HEK293T cells is provided below. Non-transfected cells or cells
with known specificity to an unrelated antigen can serve as
negative controls.
2. Control populations of donors that do or do not harbor the
antigen-specific B cell population of interest. In disease set-
tings, these should include matched healthy donors but also
disease controls [1230]. In this context, a particular point for
careful consideration lies in the possibility that control donors
might harbor na¨ıve B cells in their unmutated repertoire that
specifically recognize the antigen of interest. Such recogni-
tion patterns have been described for nuclear autoantigens
and studies suggest that healthy individuals harbor a consid-
erable proportion of mature na¨ıve B cells capable of recogniz-
ing autoantigens. For protective antigens, vaccinated donors
can be analyzed as a control. Secondary vaccinations, e.g.,
with Tetanus Toxoid (TT), give rise to antigen-specific plas-
mablasts and memory B cells, which can be analyzed 1 and 2
weeks after vaccination, respectively [1241]. FCM is limited in
the possibility to discern whether such staining signals reflect
true antigen-specific B cells or nonspecific interaction between
labeled antigens and cell surfaces by, for example, hydropho-
bic interaction or charge. If positive signals are observed in
control donors in FCM, we highly recommend that additional
measures be taken to determine/verify antigen specificity. Pos-
sible steps to do so are described below.
2.4.3.7 Verification of antigen-specificity. Different direct and
indirect measures are available to determine whether fluorescent
signals detected by FCM indeed identify B cells that specifically
bind the antigen of interest via the BCR. Given that detection of
ultra-low frequency B cells requires the assessment of large cell
numbers of a given total B cell pool, it is almost inevitable that
also nonspecific background signals are detected. Using a dual
staining approach as described above significantly reduces such
non-specific signals but does not suffice as a single argument to
claim antigen-specificity. Additional options include:
1. Blocking (also called competition) experiments in which the
binding of fluorescently labeled antigens to the BCR is blocked
by an excess of unlabeled antigen. Note that an excess of unla-
beled antigen should completely block the fluorescent signal. If
this is not the case, nonspecific interaction between the labeled
antigen and the cell cannot be excluded and additional verifi-
cation steps (see below) should be taken. This method can also
be applied in a stepwise approach with increasing amounts of
unlabeled antigen where the increase of competing for binding
sites results in a gradual decrease of labeled antigen occupying
the BCR.
2. Single cell isolation by FCM followed by immediate cell lysis,
mRNA isolation, and BCR sequencing using published proto-
cols; alternatively, single cells can be cultured with relevant
stimuli followed by the assessment of supernatants for the pro-
duction of total and antigen-specific Ig by ELISA [1242]. Cells
obtained from supernatants containing antigen-specific Ig can
subsequently be lysed followed by mRNA isolation and BCR
sequencing. In both cases, full-length BCR sequences can be
obtained by primer-binding bias-free PCR protocols, which can
subsequently be used for mAb expression [1243]. Note that it
can be extremely useful during experimental setup to use the
“index sort” function for single cell isolation protocols as this
option allows to identify the localization of antigen-specific
cells in the FCM dot plot.
Together, verification of antigen specificity is crucial as this step
is, in the end, the only way to determine whether cells identified
by FCM indeed represent the cell population of interest. Next
to blocking experiments, the ultimate golden standard relies on
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single cell isolation followed by BCR cloning and monoclonal Ab
expression.
2.4.4 Step-by-step sample preparation.
1. Identification of a vaccine-induced, high-avidity immune
response identified by direct labeling of antigen with a fluo-
rescent dye
In order to detect B cells specific for a certain antigen, we here
make use of the ability of B cells to bind the proteins they recognize
through the BCR in a 3D manner. To illustrate this approach, we
provide an example of the detection of TT-specific human memory
B cells and plasmablasts in the circulation at several time points
before and after TT vaccination (Fig. 145). Vaccination can be a
highly useful tool in the initial setup of the staining procedure,
but will not be available to aid the detection of autoreactive B
cells described below. Nonetheless, the technological approach
presented in this example has also successfully been used for the
detection of autoreactive B cells [1244]. Therefore, the example
provided can be seen as a template, which can be adapted to the
identification of other antigen-specific B cell responses with similar
characteristics.
In order to assure specificity of the staining, we show how the
fluorescent signal in the same sample can be blocked with uncon-
jugated protein used in excess. This methodology has been used
successfully to analyze B cells specific for TT [1241, 1245]; cholera
toxin B (CTB) [1246]; Keyhole Limpet Hemocyanin (KLH) [1227];
and Pentraxin-3 (PTX-3) [1244]. The possibility to down-titrate
binding of antigen-specific cells (competitive assay principle) has
long been recognized to ensure specificity.
Notes:
1. As discussed above, antigen-specific B cells are found at very
low frequencies in the circulation; therefore, it is crucial to start
with more input cells/blood that one would usually do to stain
B cell subsets. The input depends on the estimated frequency
of the antigen-specific B cells in the population of interest.
2. For sample preparation and staining of naive, memory B cells,
and plasmablasts (see section 2 - B cells and their subsets).
3. For intracellular staining, permeabilize and fix the cells (see
Section III.5: Cell fixation and permeabilization for flow cyto-
metric analyses).
Steps:
1. Preparation of fluorescently labeled antigens. The fluorescently
labeled antigens should be titrated (see ChIII Sect Titration:
Determining optimal reagent concentration) independently for
surface and intracellular detection. (Note: for intracellular
staining usually a smaller quantity of labeled antigen is suf-
ficient).
2. Upon sample preparation, wash cells twice with PBS before
incubation with fluorescently labeled antigen.
3. Divide the sample in two: incubate half of the cells with fluores-
cently labeled antigen and the second half with unconjugated
antigen. Incubate both at 4°C for 15–30 min.
4. Wash with PBS and prepare for acquisition on a flow cytometer
of choice.
2. Identification of an auto-reactive, low-avidity B cell
response identified in an autoimmune disease setting using
biotinylated peptide self-antigens tetramerized with fluores-
cently labeled streptavidin molecules.
The example provided demonstrates the identification of B
cells directed against citrullinated protein antigens in patients with
rheumatoid arthritis (RA). Citrullination represents the posttrans-
lational modification of arginine residues in a given protein to
the amino acid citrulline. The citrulline-directed, auto-reactive B
cell response is a hallmark of this disease and can be detected
in >70% of patients by serum measurement of anti-citrullinated
antigen Ig reactivity in ELISA. The humoral immune response uses
all Ig isotypes and is, on the polyclonal level, of remarkably low
avidity [1247]. Circulating, antigen-specific B cells in peripheral
blood are expected at a frequency of 1:10 000 total B cells and
can comprise na¨ıve and memory B cells as well as plasmablasts
and plasma cells [1230, 1235, 1236]. Specific antigen recognition
is determined by BCR binding to citrullinated antigens but not to
the arginine-containing peptide control variants. A biotinylated,
cyclic citrullinated peptide (CCP2) and its arginine control vari-
ant (CArgP2) are used for specific detection. HEK293T cells that
express, in membrane-bound form, a mAb that specifically rec-
ognizes the citrullinated peptide antigen of choice (HEKACPA-TM),
serve as controls during experimental setup [1230]. Note that this
example can be seen as a template, which can be adapted to the
identification of other antigen-specific B cell responses with similar
characteristics.
1. Generating biotinylated peptide-avidin tetramers.
1. Incubate biotinylated peptides in excess with fluorescently
labeled streptavidin or extravidin overnight at 4°C. The molar
ratio between peptide and streptavidin should exceed 4:1.
Note: In the example provided, six different peptide tetramers
have been generated.
- CCP2-biotin coupled to APC-labeled streptavidin (CCP2-SA-
APC)
- CArgP2-biotin coupled to APC-labeled streptavidin (CArgP2-
SA-APC)
- CCP2-biotin coupled to BV605-labeled streptavidin (CCP2-
SA-BV605)
- CArgP2-biotin coupled to BV605-labeled streptavidin
(CArgP2-SA-BV605)
- CCP2-biotin coupled to PE-labeled extravidin (CCP2-EA-PE)
- CArgP2-biotin coupled to PE-labeled extravidin (CArgP2-EA-
PE)
2. Remove unlabeled peptide with Bio-Spin R© Columns with Bio-
Gel R© P-30. This will trap the free peptide in the gel and
release peptide–streptavidin tetramers in the flow through.
The removal of unlabeled peptides is crucial to avoid bind-
ing competition between unlabeled and labeled antigen during
staining.
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3. Store the labeled antigen tetramers at 4°C. In case of longer
storage times (weeks to months), perform regular testing of
the stability of the tetramers and fluorescent signal by using
the positive/negative control cells (see below).
2. Determining optimal concentrations of multimerized
antigen-tetramers for staining.
Notes:
 The optimal concentration of labeled peptide tetramers to be
used for staining needs to be determined by titrating the labeled
antigens on a fixed number of positive and negative control
cells. Here, HEKACPA-TM cells are used as positive control; non-
transfected HEK293T wild-type cells (HEKWT) serve as negative
controls.
 For each tetramer, use the concentration at which the posi-
tive control stains highly positive and the negative control is
negative.
 Combine the differentially labeled peptide tetramers at their
optimal concentration to stain the positive (HEKACPA-TM) and
negative (HEKWT) control cells and determine whether a dou-
ble positive population emerges in the diagonal of a FCM dot
plot (Fig. 146). Should the double positive population deviate
from the diagonal, adjust the concentrations of differentially
labeled peptide tetramers accordingly until the double positive
population falls into the diagonal. No signals should fall into
this diagonal upon staining of the negative control cells.
 Upon determination of the optimal concentrations of labeled
peptide tetramers to use, it can be helpful to spike positive con-
trol cells (HEKACPA-TM) in different numbers into healthy donor
PBMC and to determine by subsequent antigen-specific stain-
ing whether the predetermined optimal concentrations remain
optimal in a mixed population of cells.
Steps:
1. Prepare serial dilutions of peptide tetramers and of “empty”-
labeled avidin molecules.
2. Stain a fixed number (here: 2 × 105) of positive and negative
control cells with labeled peptide tetramers diluted in FCM
buffer to 20 µL staining volume. Incubate for 30 minutes at
4°C.
3. Wash cells twice with FCM buffer and suspend in 100 µL FCM
buffer for analysis on a flow cytometer.
4. In the example, CCP2-SA-APC tetramers at a dilution of 1:2000
stain >90% of HEKACPA-TM cells, and less than 1% of HEKWT
cells (Fig. 146A). At the same concentration, CArgP2-SA-APC
control tetramers show minimal background staining. Also,
the empty labeled streptavidin molecules give minimal back-
ground at all concentrations. Therefore, a dilution of 1:2000
for this particular batch of CCP2-SA-APC tetramers is chosen
for the subsequent combinatorial staining.
5. Perform similar titrations for BV605 and PE-labeled tetramers
to obtain optimal dilutions for the subsequent combinato-
rial staining. To decide which concentration of CArgP2-EA-PE
tetramers to use, choose the concentration at which CCP2-
EA-PE tetramers give the highest signal and CArgP2-EA-PE
tetramers minimal background HEKACPA-TM cells.
6. In the example, dilutions of 1:2000 are optimal for CCP2-
SA-APC, 1:400 for CCP2-SA-BV605, and 1:800 for CArgP2-
EA-PE tetramers for the combinatorial staining. This combi-
nation identifies HEKACPA-TM cells positive for CCP2-SA-APC
and CCP2-SA-BV605 in the upper-right quadrant of the CCP2-
APC versus CCP2-BV605 dot plot, while the CCP2 double pos-
itive population remains negative in the PE control channel
(Fig. 146B). Also, no APC/BV605 double positive signal is
observed for HEKWT cells.
3. Staining of a sample containing human antigen-specific
B cells.
Notes:
 Given the very low frequency of antigen-specific, ACPA-
expressing B cells in the circulation, we here used 50 mL of
freshly drawn peripheral blood as starting material.
 Here, we deliberately chose to stain whole PBMC and not to
enrich B cells by subsequent isolation techniques in order not
to compromise B cell subpopulations such as plasmablasts.
 In the example provided, DAPI is used to identify and exclude
dead cells.
 We assume in this example that all labeled mAbs and their
respective isotype control Abs have been titrated and tested
in appropriate FMO-stainings to determine optimal concen-
trations. These steps are necessary but not mentioned in the
description below.
Steps:
Identification of ACPA-expressing B cells in a peripheral blood
sample of an ACPA-positive rheumatoid arthritis patient.
1. Isolate PBMC from a peripheral blood sample using Ficoll-
Paque gradient centrifugation following standard protocols.
Count the isolated PBMCs.
2. Suspend the PBMCs at 8 × 106 cells per 100 µL in FCM
buffer in a 15mL tube and stain with the fluorescently labeled
Abs/streptavidin tetramers for 30 min on ice protected from
light. In the example, we used: CD3 Pacific Blue (PB), CD14
Pacific Blue (PB), CD19 APC-Cy7, CD20 AF700, CD27 PE-Cy7,
CCP2-SA-BV605, CCP2-SA-APC, and arginine peptide control
CArgP2-Extravidin-PE at the appropriate concentrations.
The emission wavelength of Pacific Blue is used in this exam-
ple as a “dump channel” in which markers are combined that
identify cells that are to be excluded from further analysis.
3. Add 1ml FCM buffer and centrifuge the cells for 5 min at
1500 rpm on ice.
4. Repeat the washing step at least two times.
5. Resuspend the cell pellet with 100 µL FCM buffer and transfer
to an FCM tube (we use Micronic tube MP32022). Keep the
sample on ice and in the dark at all times.
6. To compensate for spectral overlap between fluorescent dyes,
we employ compensation beads (BD Biosciences) that bind
to mouse IgG (provided that all of the fluorescently labeled
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Abs used are of a murine IgG isotype). The beads are used
to compensate for CD3 PB, CD19 APC-Cy, CD20 AF700, and
CD27 PE-Cy7 spectral overlaps. For the tetramers, however,
surrogate murine IgG that is conjugated with BV605, APC,
and PE are used to allow fluorescence compensation using
beads.
7. Set up a flow cytometer of choice (here: BD LSRFortessa)
that allows simultaneously detecting and discriminating flu-
orescent signals from PB, APC-Cy7, AF700, PE-Cy7, BV605,
APC, and PE dyes. For the analysis, we here used BD FACS-
DIVA software (version 8.0.2).
8. Perform fluorescence compensation using single-stained com-
pensation beads and apply the compensation setup to the
whole experiment.
9. Add 100 µL of 200 nM DAPI to the cell suspension (leading
to a final concentration of 400 nM).
10. Place the sample into the cytometer and record 50 000
events. Put the sample back on ice and keep protected from
light.
11. Place gates in a Global Worksheet of the DIVA program on
the cell populations as follows (Fig. 147a):
(a) In the FSC-A versus SSC-A plot, make an inclusive gate
containing lymphocytes and monocytes to include plas-
mablasts that are larger in size and more granular than
other subsets of B cells.
(b) Subsequently, exclude duplicates using SSC-H versus
SSC-W and FSC-H and FSC-W plots. The gates for dupli-
cate exclusion should not be strict at this moment.
(c) Lastly, in a PB versus CD19-APC-Cy7 plot, gate loosely
on CD19 positive cells that are PB-negative. This gate is
referred to as “B cell Store” (Fig. 147A).
12. Click “Next Tube” on the Acquisition Dashboard of the BD
FACSDIVA workspace.
13. In the Acquisition Dashboard, choose “B cell Store” for both
Stopping and Storage Gates. Set 10 000 000 events for both
“Events to Record” and “Maximum Events to Display.” This
step is necessary to obtain a manageable size of data to ana-
lyze the antigen-specific cell population of interest (here:
ACPA-expressing B cells).
14. Place the sample back into the flow cytometer. Record the
“B cell store” and adjust the threshold rate to a maximum of
20 000 events/s. Measure the sample until it is finished.
15. Store the data appropriately.
2.4.5 Materials. Purified or Biotinylated peptide or protein anti-
gens of choice depending on the protective/auto-reactive B cell
response(s) to be studied.
 Fluorescently labeled streptavidin and/or extravidin molecules,
e.g., BV605-streptavidin (Biolegend, catalog nr.: 405229), APC-
labeled streptavidin (Invitrogen, catalog nr.: S32362), and PE-
labeled extravidin (Sigma–Aldrich, catalog nr.: E4011-1ml).
 Fluorochrome for labeling of respective antigen, e.g. Cy5
 Bio-Spin R© Columns with Bio-Gel R© P-30 (BIO-RAD, catalog nr.:
732–6006)
Table 48. Fluorescently labeled monoclonal antibodies used in the
example provided
No. Marker Clone Fluorophore Supplier
Catalog
number
1 CD3 UCHT1 PB BD 558117
2 CD14 M5E2 PB BD 558121
3 CD19 Sj25C1 APC-Cy7 BD 557791
4 CD20 2H7 AF700 Biolegend 302322
5 CD27 M-T271 PE-Cy7 BD 560609
Table 49. Abs used as “surrogate” Abs for the compensation of
avidin-tetramer derived fluorescent signals
No. Marker Clone Fluorophore Supplier
Catalog
number
1 CD56 HCD56 BV605 Biolegend 318333
2 CD4 SK3 APC BD 345771
3 CD8 RPA-T8 PE BD 555367
 PBS
 BSA (Sigma–Aldrich, catalog nr.: A7906-1KG).
 FCM buffer (PBS, 0.5% BSA and 0.02% Azide)
 DAPI (Invitrogen, catalog-nr.: D1306)
 Fluorescently labeledmAbs (all Abs used in the present example
are of mouse origin, expressed as IgG isotypes and directed
against the respective human proteins, Table 48):
 Fluorescently labeled Abs to be used as “surrogate” Abs for
the compensation of avidin-tetramer derived fluorescent signals
(all Abs used in the example provided are murine Abs express-
ing the IgG1 isotype directed against the respective human pro-
teins indicated, Table 49):
 BDTM CompBeads anti-mouse Ig, κ (BD Biosciences, Catalog
nr.: 51-90-9001229)
 BDTM CompBeads negative control (BD Biosciences, Catalog
nr.: 51-90-9001291)
 Instrument: BD LSRFortessa (BD Biosciences)
 Software: BD FACSDIVA version 8.0.2 (BD Biosciences),
 Appropriate positive and negative control cells (here:
HEKACPA-TM and HEKWT).
2.4.6 Data analysis/gating.
1. Identification of a vaccine-induced, high-avidity immune
response identified by direct labeling of antigen with a fluo-
rescent dye
Analysis and gating for the example provided are straight-
forward. B cell subsets can be gated as described in Section
2 B cells and their subsets. Following this step, fluorochrome
specific plasmablasts, memory B cells, and naive B cells can be
determined as shown for plasmablasts and memory B cells in
Fig. 145.
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2. Identification of an auto-reactive, low-avidity B cell
response identified in an autoimmune disease setting using
biotinylated peptide self-antigens tetramerized with fluores-
cently labeled streptavidin molecules
1. Open the experiment file using BD FACSDIVA version 8.0.2
(BD Biosciences)
2. Check and adjust the compensation of spectral overlap accord-
ing to standard procedures.
3. Create a new “Normal Worksheet” in the file that stored only
the “B cell store” gate, gate lymphocytes, single cells, and live
B cells strictly (Fig. 147B)
4. Starting from the “live single B cell gate,” create a CCP2-
SA-BV605 versus CCP2-SA-APC plot to identify CCP2+/+ and
CCP2–/– populations. Place a gate around those CCP2+/+ cells
that strictly fall into the diagonal.
5. Display the cells identified in this gate (the CCP2+/+ popula-
tion) in a CCP2-SA-APC versus CArgP2-Extravidin-PE plot and
place a gate on the CArgP2-PE negative population. These cells
represent the antigen-specific B cell population of interest (i.e.,
ACPA-expressing B cells).
6. In the CCP2-SA-BV605 versus CCP2-SA-APC plot, place a
gate on the CCP2-/- population, create a CD20-AF700 versus
CD27-PE-Cy7 plot and gate on na¨ıve (CD20+CD27-), memory
(CD20+CD27+) and plasmablast (CD20–CD27high) subsets of
these avidin-tetramer negative B cells.
7. From the gate identifying the ACPA-expressing B cell pop-
ulation (the CCP2+/+ CArgP2- population), create a CD20-
AF700 versus CD27-PE-Cy7 plot. Copy the gates identify-
ing na¨ıve (CD20+CD27-), memory (CD20+CD27+) and plas-
mablast (CD20-CD27high) subsets from the avidin-tetramer
negative B cell population to the plot displaying the ACPA-
expressing B cell population. This step is taken as it can be
difficult to define the gates for these B cell subsets on the
basis of very few cells. Therefore, copying the gates from a
larger population (the avidin-tetramer negative B cells) to the
antigen-specific B cell population (the ACPA-expressing B cells)
is necessary for further analysis.
8. In the given example, the majority of ACPA-expressing B cells
displays a memory (CD20+CD27+) phenotype, while avidin-
tetramer-negative B cells mostly fall in the na¨ıve B cell gate
(CD20+CD27-) (Fig. 147B).
9. As an additional step of control, perform “back-gating” of the
ACPA-expressing B cell population. Should some cells fall at
the edge of the gates identifying lymphocytes, single cells, and
live B cells, adjustment of these gates might be necessary to
minimize the possibility that doublets or otherwise nonspecif-
ically stained cells are misinterpreted (Fig. 147C).
2.4.7 Pitfalls.
 Be aware that the quality of the fluorescent signal of the labeled
avidin-tetramers decreases overtime. Take along a staining con-
trol using the positive and negative control cells with each sam-
ple to control for such signal decay and/or an increase of non-
specific background staining.
 The fluorochrome itself can be recognized by B cells giving rise
to false positive signals; this can be overcome by using the same
antigen labeled with a second fluorochrome, as described.
2.4.8 Top tricks.
 During setup and once a cell population has been identified
that meets the criteria of antigen-specific cells delineated above,
subsequent verification of antigen-specificity is indispensable.
Please refer to the section “Verification of antigen-specificity”
in the introduction for details on how antigen-specificity can be
determined, and refer to [1230], supplementary data section,
for examples.
 For differential labeling of antigens, we recommend using flu-
orescent dyes with emission spectra that show no or very little
spectral overlap in order to reduce the need for extensive com-
pensation.
2.4.9 Summary Table. See Summary Table 47 of Chapter VI Sec-
tion 2.3 Human B cells and their subsets.
2.5 Human regulatory B cells
2.5.1 Overview. B cells play a key role in immune responses
through the production of Abs, antigen presentation to other
immune cells, and production of cytokines. Suppressive cytokines,
such as IL-10, play a pivotal role in controlling inflammation and
immune tolerance. Importance of regulatory B cells (Bregs) pro-
ducing suppressive cytokines was described in murine models
and in several human diseases. Depending on the disease stud-
ied or on the in vitro stimulation, different functional Breg subsets
were described. Detailed characterization of individual Breg sub-
sets, therefore, can improve our understanding of regulation of
immune responses. This section describes a method for detection
of individual Breg subsets in human PBMC samples. This panel
can be considered a basis in which additional markers can be
included to interrogate their expression among the different Breg
subsets.
2.5.2 Introduction. The existence of B cells with regulatory func-
tion (Breg) was first proposed in studies using B cell-depleted
rodents, which showed reduced suppressive capacity of the lym-
phocyte fraction and were unable to recover from experimental
autoimmune encephalitis [1248–1250]. Later, Mizoguchi et al.
[1251] and Fillatreau et al. [1252] demonstrated that B cells
can suppress immunity through production of immunosuppres-
sive cytokines.
Bregs is an umbrella term used for immunosuppressive B
cells [1253]. Bregs were often described in the context of chronic
inflammatory diseases and in human they aremostly characterized
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Figure 148. Identification of regu-
latory B cell subsets from CpG-
stimulated PBMC. PBMC fromhealthy
female adult subject cultured for 72 h
with media alone or media contain-
ing 1µM CpG-ODN 2006. Before stain-
ing, cells stimulated for 5 h with 25
ng/mL PMA and 1 µg/mL Iono and for
the last 2 h with 10 µg/mL Brefeldin
A. Cells harvested and surface and
intracellular antibody stainings per-
formed. Total viable B cells gated
from lymphocytes after doublet dis-
crimination (A). Breg subsets gated
from viable single CD19+ B cells (B–
E). IL-10+ B cells gated from (B) CD19+
CD24high CD38high B cells, (C) B10/pro-
B10 cells (CD19+ CD24high CD27+),
(D) suppressive plasmablasts (CD19+
CD27int CD38+), and (E) CD19+ CD73−
CD25+ CD71+ B cells. Breg subsets
gated from IL-10+ CD19+ B cells based
on surface markers showing enrich-
ment of IL-10+ B cells (F).
by production of the suppressive cytokine IL-10 [1162, 1253].
Generally, expression of IL-10 has been a very useful marker for
B cells with suppressive phenotype [1162, 1253]. However, sev-
eral Breg-related surface markers can be either down- or upreg-
ulated upon stimulation, making it difficult when Breg subsets
are compared among different stimulatory environments [1162].
For example, CD25 and CD71 are often upregulated in activated
B cells [1254, 1255] and they are widely used also as activa-
tion markers. Another activation marker, CD38, is expressed in
na¨ıve B cells and plasmablasts (the main IL-10 producing subsets)
but is downregulated when na¨ıve B cells develop into memory
B cells [1256]. Furthermore, CD1d can be downregulated upon
stimulation [1254]. In contrast to regulatory T cells, no Breg-
specific transcription factor could be identified so far [1162]. Fur-
thermore, the high diversity of B cell subsets with suppressive
capacity strongly suggests that there is not one single lineage of B
cells giving rise to Bregs but that there are precursors from vari-
ous stages of B cell ontogeny that gain suppressive phenotype in
response to stimulation.
In mice, Bregs were reported to act mainly via production
of suppressive cytokines IL-10, IL-35, and TGF-β [1162] and
inhibitory receptors such as LAG-3 [1167]. IL-10 can suppress pro-
duction of pro-inflammatory cytokines by antigen presenting cells
and induce T regulatory cells [1165, 1257]. IL-35 was reported
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Table 50. Human B cell subsets
Name Marker Suppressor molecules Induction Associated disease
Immature B cells CD19+ CD24high
CD38high CD1d+
IL-10 CD40 ligation Suppressive role in RA, SLE
and CHB virus
infection [1277–1279]
B10/pro-B10 cells CD19+ CD24high CD27+
CD48high CD148high
IL-10 CpG-ODN, LPS (+
CD40 ligation)
Various autoimmune
diseases [1280].
Br1 cells CD19+ CD73− CD25+
CD71+ B cells
IL-10, IgG4, PD-L1 CpG-ODN Allergen tolerance [1255]
Suppressive
plasmablasts
CD19+ CD27int CD38+ IL-10, immunoglobulins CpG-ODN + IL-2,
IL-6, and
IFN-α/γ
Healthy subjects [1165]
Suppressive
plasma cells
CD138+ IL-10 n/a Multiple sclerosis
lesions [1281]
to inhibit T helper 1 (Th1) cell responses [1159], while TGF-
β can inhibit APCs and induce apoptosis in Th1 cells as well
as bring on anergy in CD8+ T cell [1258, 1259]. In murine
spleen, CD19+, CD21hi CD23hi CD24hi B cells (T2-MZP cells)
[1168, 1169, 1260, 1261] and CD19+, CD21hi CD23- B cells (MZ
B cells) [1170, 1262, 1263] were found suppressing CD4+ and
CD8+ T cells while inducing Tregs. Similarly, IL-10-producing
CD1dhigh CD5+ B cells (B10) were found in the spleen, suppressing
CD4+ T cells, dendritic cells (DC), as well as monocytes thereby
playing a protective role in a plethora of mouse models includ-
ing EAE [1264, 1265], lupus [1266], myasthenia-gravis [1267],
collagen-induced arthritis [1268], colitis [1269], allergic inflam-
mation [1270, 1271], and contact hypersensitivity [1272]. In
spleen, also CD19+ TIM-1+ B cells were identified, suppressing
CD4+ T cells [1173, 1273]. Interestingly, suppressive phenotype
was also found among B cells of later differentiation stages, such as
CD138+ CD44hi plasmablasts [1165], CD138+ MHC-11lo B220+
plasma cells [1159, 1274] and LAG-3+ plasma cells [1167]. Sup-
pressive plasmablasts were found in LN, suppressing CD4+ T cells
and DCs [1165] while IL-10 and IL-35 secreting plasma cells were
found in spleen, suppressing effector CD4+ T cells as well as
neutrophils and NK cells [1159, 1274]. LAG-3+ plasma cells, in
addition to LAG-3 also expressed additional inhibitory receptors,
including CD200, PD-L1, and PD-L2 [1167]. A common character-
istic among all the above-mentioned murine Breg subsets is their
capability to produce of IL-10 [1162].
In this section, we focus on human Breg cell subsets (see
Table 50 for a summary of human B cell subsets). The first data
that indicated a potential role for regulatory B cells in humans
came from the reports of new onset of colitis and psoriasis after
CD20 mAb treatment with rituximab [1275, 1276]. In human
Bregs, regulatory function is mainly conferred via secretion of IL-
10. IL-10 can be produced by na¨ıve B cells [1255, 1277–1280],
plasmablasts [1165] from the blood and plasma cells from tis-
sue [1281] while it is unclear which subset is the most potent
producer. IL-10 can be induced from peripheral human B cells by
ligation of TLR9 (using CpG-ODN) [1165, 1255, 1280] or CD40
[1277, 1280] in vitro. Bregs originating from immature CD19+
CD24high CD38high B cells were found in blood and in inflamed
tissue having a suppressive role in rheumatoid arthritis (RA), sys-
temic lupus erythematosus (SLE), and chronic hepatitis B (CHB)
virus infection [1277–1279]. These cells suppress Th1, TH17 cells,
and virus-specific CD8+ T cells while inducing Tregs [1277–1279].
Suppressive B10/pro-B10 cells (CD19+ CD24high CD27+ CD48high
CD148high) were found in blood suppressing CD4+ T cells, mono-
cytes, and DCs [1280]. B10/pro-B10 cells regulate innate immu-
nity and are upregulated in patients with various autoimmune
diseases [1280]. IL-10-producing CD19+ CD73− CD25+ CD71+
Bregs play an important role in developing tolerance to aller-
gens. This subset was shown to mature at increased frequency into
plasma cells that secrete the suppressive Ab isotype IgG4 [1255].
In addition, CD27int CD38+ plasmablasts derived either from na¨ıve
immature B cells or na¨ıve mature B cells suppress effector CD4+
T cells and DCs by expressing IL-10 [1165]. Recently, it was shown
that in multiple sclerosis lesions, plasma cells (but not B cells) pro-
duced large amounts of suppressive IL-10 [1281]. An FCM panel
was described combining several Breg-associated markers, includ-
ing CD19, CD1d, CD5, CD24, CD25, CD38, CD71, CD73, and
IL-10 [1254]. This allows to identify CD24hi CD38hi IL-10+ Bregs
(Fig. 148B), CD73− CD25+ CD71+ IL-10+ Bregs (Fig. 148E), and
a CD5+ CD1dhigh IL-10+ Breg subset, which was mainly described
in mice. In humans, CD1d was also reported to more expressed in
regulatory B cell subsets [1280, 1282]. Here, we included CD27, a
marker for memory B cells, which allows additional distinction of
CD19+ CD24high CD27+ B10/pro-B10 cells (Fig. 148C) and CD19+
CD27int CD38+ suppressive plasmablasts (Fig. 148D). These Breg
subsets show enrichment for IL-10-producing B cells compared to
total IL-10 producing B cells (Figure 149).
2.5.3 Step-by-step sample preparation. This staining protocol is
optimized for human peripheral B cells. PBMCs were isolated
from heparinized blood of healthy individuals by density gradi-
ent centrifugation (Biochrom, Berlin, Germany). Isolated PBMC
were directly plated and stimulated for 72 h with CpG-ODN.
Before staining, cells were incubated with PMA and Iono (5 h)
and Brefeldin A (2 h), followed by viability staining with zombie
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Figure 149. IL-10 staining and con-
trol stainings. PBMC cultured for 72 h
with media alone or media contain-
ing 1 µM CpG-ODN 2006. The last
5 h before staining, PBMC additionally
stimulated with 25 ng/mL PMA and
1 µg/mL ionomycin and for the last
2 h with 10 µg/mL Brefeldin A (A and
C) ormediumcontrol (B). IL-10+ B cells
gated fromsingle viable CD19+ B cells.
Upstream gating was performed as in
Fig. 148. Anti-IL-10 antibody staining
(A) after stimulation with PMA, Iono,
and Brefeldin-A or (B) without stimu-
lation and (C) isotype control staining.
yellow viability dye (Biolegend, San Diego, CA) and staining for
surface markers with the Abs listed in Table 51 in staining buffer.
Cells were washed, permeabilized, and Ab staining for intra-
cellular IL-10 was performed. Then, samples were washed and
measured on a BD LSR Fortessa with BD FACSDiva Software Ver-
sion 8.0.1 and analyzed using Flowjo version 10.4.
Detailed protocol:
1. Collect fresh blood in heparinized containers (BD vacutainer
170 I.U. of lithium heparin)
2. Isolate PBMC:
(a) Dilute blood samples at a 1:1 ratio with PBS supplemented
with 2 mM EDTA.
(b) For each 30 mL of diluted blood prepare a tube of Biocoll.
Add 15 ml of Biocoll separating solution (room tempera-
ture) to a 50 mL blood-sep-filter tube. Spin down 1 min at
1100 × g to collect the Biocoll at the bottom of the tube
below the filter.
(c) Slowly add 30 mL of diluted blood to each filter tube and
centrifuge the tubes at 800 × g for 20 min at 18°C and no
break at end of program.
(d) Collect the interphases and pool up to two interphases
and transfer them to a new 50 mL centrifugation tube.
Fill up tube with PBS supplemented with 2 mM EDTA.
Centrifuge tubes at 780 × g for 10 min at 18°C.
(e) Remove supernatant and resuspend cell pellet in 2 mL
PBS supplemented with 2 mM EDTA. Pass cells through a
70 µM cell strainer into a new 50 mL centrifugation tube.
Fill up tube with PBS supplemented with 2 mM EDTA.
Centrifuge tubes at 220 × g for 10 min at 4°C.
(f) Discard supernatant and resuspend PBMC in 5 mL of
complete RPMI (cRPMI; RPMI 1640 medium supple-
mented with MEM Vitamin Solution, penicillin, strepto-
mycin, kanamycin, MEM Non-essential Amino Acid Solu-
tion, Sodium pyruvate solution (Sigma-Aldrich Chemie
GmbH), and 10% heat-inactivated FCS (Sigma–Aldrich
Chemie GmbH).
3. Count PBMC and plate two million PBMC at concentration of
1 million/mL in cRPMI in 12-well tissue culture plate.
Table 51. Antibodies
Marker Label Clone Manufacturer Product number Dilution
CD38 BV785 HIT2 Biolegend, San Diego, CA, USA 303530 1:50
CD27 Brilliant Violet 510 L128 BD Biosciences, Pharmingen,
San Diego, CA, USA
563092 1:33
CD24 Brilliant Violet 421 ML5 Biolegend, San Diego, CA, USA 311122 1:40
CD71 FITC CY1G4 Biolegend, San Diego, CA, USA 334104 1:20
CD25 PE-CF594 M-A251 BD Biosciences, Pharmingen,
San Diego, CA, USA
562403 1:40
CD1d PE 51.1 eBioscience, Affymetrix Inc.,
San Diego, CA, USA
12-0016-42 1:40
CD19 APC-Cy7 HIB19 Biolegend, San Diego, CA, USA 302218 1:100
CD73 APC AD2 Biolegend, San Diego, CA, USA 344006 1:40
IL-10 PE-Cy7 JES3-9D7 Biolegend, San Diego, CA, USA 501420 1:200
Isotype ctrl PE-Cy7 RTK2071 Biolegend, San Diego, CA, USA 400416 1:200
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4. Stimulate PBMC with 1 µM CpG ODN 2006 or medium (con-
trol) for 72 h.
5. Harvest PBMC and spin down (300 × g, 10 min).
6. Staining for FCM:
(a) Briefly vortex cell pellet and stain cells with 100 µL of
Zombie yellow viability dye diluted 1:100 in staining
buffer. Incubate 20 min at room temperature in dark.
Wash once with 1 mL of staining buffer.
(b) Stain cells with Abs specific for surface markers listed in
Table 51 in a total staining volume of 100 µL. Incubate
15 min at 4°C in dark. Wash once with 1 mL of staining
buffer.
(c) Briefly vortex the cell pellet and resuspend with 250 µL
of Fixation/Permeabilization solution (BD Biosciences,
554714) for 20 min at 4°C.
(d) Wash the cell pellet two times with 1 mL BD
Perm/WashTM buffer (BD Biosciences, 554714).
(e) For intracellular staining of IL-10, dilute Ab in 50 µL BD
Perm/WashTM buffer. As isotype staining control for IL-10,
use isotype control Ab in equal concentration. Incubate 30
min in the dark at 4°C.
(f) Wash the cells two times with 1 mL BD Perm/WashTM
buffer (BD Biosciences, 554714).
7. Resuspend cell pellet in 200 µL staining buffer and measure
sample.
2.5.4 Materials.
Reagent Product number Manufacturer
BD vacutainer 170 I.U. of lithium heparin 367526 BD, Plymouth, UK
Blood separation filter tube 03-7100SI Dacos, Esbjerg N, Denmark
Biocoll L 6115 Biochrom, Berlin, Germany
BD Falcon 70 µM cell strainer 431751 BD Biosciences, Franklin Lakes, NJ, USA
Cell culture medium:
RPMI-1640 Medium, with sodium
bicarbonate and L-glutamine
R8758-500ML Sigma–Aldrich Chemie GmbH
Fetal calf serum (FCS) F7524 Sigma–Aldrich Chemie GmbH
MEM Vitamin Solution (100×) M6895-100ML Sigma–Aldrich Chemie GmbH
Penicillin-Streptomycin (100×) P4333-100ML Sigma–Aldrich Chemie GmbH
Kanamycin (100×) 15160-047 GIBCO, Paisley, UK
MEM Nonessential Amino Acid
Solution (100×)
M7145-100ML Sigma–Aldrich Chemie GmbH
Sodium pyruvate solution S8636-100ML Sigma–Aldrich Chemie GmbH
TPP R© tissue culture plates, 12-well plate,
polystyrene
Z707775-126EA Sigma–Aldrich Chemie GmbH
CpG ODN 2006 MicroSynth, Balgach, Switzerland
PMA P-8139 Sigma–Aldrich Chemie GmbH
Ionomycin I9657-1MG Sigma–Aldrich Chemie GmbH
Brefeldin A B7651 Sigma–Aldrich Chemie GmbH
FCM staining buffer:
PBS GIBCO, Paisley, UK
2 mM EDTA
BSA A3294-500G Sigma–Aldrich Chemie GmbH, Buchs,
Switzerland
Zombie YellowTM Fixable Viability Kit 423104 Biolegend, San Diego, CA, USA
Fixation/Permeabilization Solution Kit 554714 BD Biosciences, Pharmingen, San Diego,
CA, USA
2.5.5 Data analysis. We first gate on lymphocytes in FSC versus
SSC, followed by doubled discrimination (Fig. 148A). From single
cells we gate on viable (Zombie Yellow negative) CD19+ B cells.
Total IL-10+ cells are gated from viable B cells (Fig. 149A). B cells
can be sub-gated into CD24+ CD38+ IL-10+ Bregs (Fig. 148B),
CD19+ CD24+ CD27+ B10/pro-B10 cells (Fig. 148C), CD19+
CD27int CD38+ suppressive plasmablasts (Fig. 148D), and CD73−
CD25+ CD71+ IL-10+ Bregs (Fig. 148E). These four Breg sub-
sets contain increased percentage of IL-10+ B cells compared to
total IL-10 producing B cells (Figs. 148B–E and 149A). Alterna-
tively, when we gate Breg subsets based on their surface marker
expression from total IL-10+ B cells, we find that these Breg sub-
sets are enriched among total IL-10+ B cells (Fig 148F). However,
even though IL-10+ B cell are enriched among gated Breg subsets,
there are also other IL-10-producing B cells, which are not falling
into a described Breg gate. Also, Breg subsets are overlaping to
some extent.
2.5.6 Pitfalls. Some of the surface expressed proteins used as
markers for Bregs are also known as general activation mark-
ers. Depending on the stimulation used, surface markers of Bregs
therefore might be up- or downregulated. For example, upon
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stimulation with CpG or BCR ligation+CD40L for 72 h, it was seen
that while number of CD19+ CD73− CD25+ CD71+ B cells (Br1
cells) showed a tendency to be increased among total IL-10 pro-
ducing B cells, CD19+ CD24+ CD38+ B cells and CD19+ CD1d+
CD5+ B cells were decreased [1254]. Therefore, it is important
to carefully consider the length of the stimulation period when
performing in vitro stimulation of regulatory B cells.
2.5.7 Top tricks. Depending the exact research question and on
the flow cytometer available, several other Abs can be included to
the panel. Since B cells sometimes produce inflammatory cytokines
(e.g., TNF) together with IL-10 [1283], it can be useful to include
Abs for exclusion of inflammatory cytokine-producing cells.
2.6 Human immunoglobulin heavy chain isotypes
2.6.1 Overview. B cells play a key role in immune responses
through the production of Abs. Detailed characterization of indi-
vidual subsets of B cells that have switched to distinct Ig heavy
chain isotypes can improve our understanding of the development
of humoral immune responses. This section describes a method for
detection of individual Ig heavy chain expressing B cells in human
PBMC samples. This panel can be considered a basis in which
additional markers can be included to interrogate their expression
among the different B cell subsets.
2.6.2 Introduction. B cells develop in the bone marrow and are
released into the circulation, after which they mature predom-
inantly in the spleen to become mature naive B cells. Mature
B cells can be roughly divided into two subsets: conventional
follicular B cells (frequently referred to as B-2 cells) and non-
conventional extrafollicular B cells (including B-1 cells, which
have been mainly characterized in the mouse, and marginal zone
(MZ) B cells) [1284, 1285].
Extrafollicular B cellsmount thymus-independent (TI) humoral
responses, which are rapidly induced in response to conserved
microbial carbohydrate or glycolipid structures. These responses
often result in the production of polyspecific low-affinity IgM Abs,
and typically do not involve somatic hypermutation or class switch
recombination (CSR) [1286]. T-independent CSR and somatic
hypermutation have been reported [1287]. Follicular B cells par-
ticipate in thymus-dependent (TD) responses. These cells interact
with follicular helper T (Tfh) cells in germinal centers, which are
mainly found in secondary lymphoid organs [1288]. Follicular
B cells that receive T cell help (through CD40L and cytokines)
will become germinal center B cells and upregulate BCL6 and
activation-induced deaminase expression, and will undergo CSR
and somatic hypermutation [1286, 1289]. The B cells that emerge
from such a germinal center reaction will either become circulat-
ing memory B cells or plasma cells. Some plasma cells will home
to the bone marrow where they can survive for many years as
long-living immunoglobulin-secreting plasma cells [1290].
B cell activation to T-cell dependent antigens requires BCR
stimulation and CD40 ligation. Antigens can be captured directly
by B cells or can be presented by follicular DCs in the lymphoid
follicles. BCR stimulation is typically mediated through binding
of a specific antigen to the BCR leading to internalization, pro-
cessing and presentation of antigenic peptides in MHC class II
molecules. Antigens are presented to CD4+ T cells, which are acti-
vated in this manner. Activated CD4+ T cells upregulate CD40L
and secrete cytokines. The type of cytokines that are produced
by these T cells depends on how these cells were primed as na¨ıve
T cells. CD40-CD40L interaction and the local cytokine milieu pro-
vide the second signal that is required for efficient B cell activation
including proliferation, CSR, and plasma cell differentiation.
Abs are identical to the BCR of the B cell from which they
originate, with the exception of a C-terminal sequence that anchors
the molecule to the cell membrane. As a result, Abs are secreted
and do not form surface-bound receptors. Abs have a functionally
polarized structure, with on one side the Fab region harboring
a hypervariable region, which is responsible for antigen binding,
and on the other side a constant Fc region. The structure of the
constant region determines the effector function of the Ig. Abs are
typically classified according to the isotype of their heavy chain.
Humans have nine major Ig heavy chain isotypes: IgM, IgD, IgG1,
IgG2, IgG3, IgG4, IgA1, IgA2, and IgE [1291] while there are eight
murine Ig isotypes: IgM, IgD, IgG1, IgG2a, IgG2b, IgG3, IgA and
IgE [1291]. Each of these Ab isotypes mediates distinct functions
through interaction with specific receptors on effector cells and
serum factors.
Each Ig molecule consists of two heavy (IgH) and two light
chains, both of which contain variable (V) and constant (C)
regions. The region of the heavy chain that determines antigen-
specificity is made up by the variable (VH), diversity (D), and join-
ing (JH) segments that are rearranged during early B cell develop-
ment to form a VDJ cassette or V-region. The V-region is located
upstream of the CH exons. The C region of the IgH chain deter-
mines the isotype of the Ig. In mature na¨ıve B cells, the V-region is
linked to the constant region of the µ chain (Cµ) [1292]. Conse-
quently, mature na¨ıve B cells express surface IgM and, as a result
of alternative splicing, IgD as their BCR. A population of IgM–IgD+
class switched B cell has been reported. These cells are primarily
found in secondary lymphoid organs and are not readily detected
in peripheral blood [1293].
Upon activation, na¨ıve IgM+IgD+ B cells can undergo CSR,
resulting in a change of the heavy chain isotype of the produced
immunoglobulin, while its antigen-specificity is retained. Non-
switched B cells are CD19+ and express IgM and IgD on their
cell surface (Fig. 150A and B). The nonswitched IgM+IgD+ B
cell population contains transitional B cells, Na¨ıve mature B cells,
and IgM+CD27+ memory B cells. The staining procedure outlined
below is designed for detection of human immunoglobulin heavy
chain isotypes expressed as BCRs on B cells.
2.6.3 Step-by-step sample preparation. This staining procedure
is designed for human peripheral B cells. PBMCs were isolated
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Figure 150. Identification of B cells express-
ing different Immunoglobulin heavy chain iso-
types in a human PBMC sample (healthy indi-
vidual age 47, male). (A) Lymphocytes were
identified based on their FSC and SSC, Doublet
exclusion was performed on FSC-H vs FSC-A,
and B cells were gated as CD19+ and zombie
yellow (viability dye) negative. (B) Nonswitched
B cells (IgD+) and class-switched (IgM–IgD–)
were gated. (C) Within the IgM–IgD– popula-
tion, IgA+ B cells, IgA2+, and IgA– cells can
be distinguished. IgA1+ B cells were defined as
IgA+IgA2–. (D and E) IgA– B cell were further dif-
ferentiated based on expression of IgG1, IgG2
(D), IgG3, and IgG4 (E).
from heparinized blood of healthy individuals by density gradient
centrifugation (Biochrom, Berlin, Germany). PBMC were counted
and stained in PBS with zombie yellow viability dye (Biolegend,
San Diego, CA). Samples were washed and incubated with anti-
bodies listed in Table 52 and measured on a BD LSR Fortessa with
BD FACSDiva Software Version 8.0.1 and analyzed using Flowjo
version 10.4.
Detailed protocol:
1. Collect fresh blood in heparinized containers (BD vacutainer
170 I.U. of lithium heparin)
2. Isolate PBMC:
(a) Dilute blood samples at a 1:1 ratio with PBS supplemented
with 2 mM EDTA.
(b) For each 30 mL of diluted blood prepare a tube of Biocoll.
Add 15mL of Biocoll separating solution to a 50mL blood-
sep-filter tube. The Biocoll should be at room temperature.
Spin down 1 min 1100 × g to collect the Biocoll at the
bottom of the tube.
(c) Slowly add 30 mL of diluted blood to each filter tube and
centrifuge the tubes at 800 × g for 20 min at 18°C and no
break at end of program.
(d) Collect the interphases and pool up to two interphases
and transfer them to a new 50 ml centrifugation tube.
Fill up tube with PBS supplemented with 2 mM EDTA.
Centrifuge tubes at 780 × g for 10 min at 4°C.
(e) Remove supernatant and resuspend cell pellet in 2 mL
PBS supplemented with 2 mM EDTA. Pass cells through a
70 µM cell strainer into a new 50 mL centrifugation tube.
Fill up tube with PBS supplemented with 2 mM EDTA.
Centrifuge tubes at 220 × g for 10 min at 4°C.
Figure 151. FMO controls for IgG
subclasses. (A) FMO for IgG1-Dylight-
405. (B) FMO for IgG2-PE-Cy5.5. (C)
FMO for IgG4-APC. (D) FMO for IgG3-
PC7. Upstream gatingwas performed
as in Fig. 150.
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(f) Discard supernatant and resuspend PBMC in 5 ml PBS
supplemented with 2 mM EDTA.
3. Count PBMC and use between one and five million PBMC per
staining.
4. Stain cells with Zombie yellow viability dye. Incubate 20 min
at 4°C in dark. Wash 1x with staining buffer
5. Stain cells with Abs listed in Table 53 in a total staining volume
of 100 µL. Incubate 15 min at 4°C in dark. Wash 1x with
staining buffer
6. Stain cells with Streptavidin-PC7, incubate 15 min at 4°C in
dark. Wash 1x with staining buffer.
7. Resuspend cells in 200 µL staining buffer and measure sample.
2.6.4 Materials.
Table 52.
Reagent Manufacturer
Biocoll Biochrom, Berlin, Germany
Blood separation filter tube Dacos, Esbjerg N, Denmark
BD Falcon 70 µM cell strainer BD Biosciences, Franklin
Lakes, NJ, USA
Staining buffer: PBS + 2 mM
EDTA + 2% BSA
Sigma, St Louis, MO, USA
2.6.5 Data analysis. B cells that undergo CSR will lose expres-
sion of IgM and IgD and can be gated as CD19+IgM–IgD–
(Fig. 150B). A major fraction of the switched B cell compartment
consists of IgA+ B cells, which can be subdivided into IgA1+ and
IgA2+ B cells. Here, we used an Ab against total IgA to iden-
tify all IgA+ B cells combined with an anti-IgA2 Ab to separate
IgA2+ and IgA2– (i.e., IgA1+) B cells (Fig. 150C). The IgA– B cells
can be further separated into IgG1+, IgG2+, IgG3+, and IgG4+
B cells (Fig. 150D and E), of which the IgG1+ population is the
most abundant (Fig. 150D). IgE+ B cells are hardly detectable in
healthy individuals and this population is not shown in this analy-
sis. Expression of most Ig heavy chain isotypes, with the exception
of IgM and IgD on non-switched B cells, is mutually exclusive.
Thus a class-switched (IgM–IgD–) B cell will only express a BCR
with one immunoglobulin heavy chain isotype. FMO controls for
IgG subclasses are shown in Fig. 151.
2.6.6 Pitfalls. This protocol has been established for staining of
PBMC samples. It may be applicable to other material such as ton-
sil, or other tissue-derived single cell suspensions. Cell suspensions
from B cell rich tissues such as tonsils may require optimization of
the antibody dilutions. Also when staining more than five million
PBMCs, the amount of antibodies and/or the staining volume may
need to be adjusted.
To the best of our knowledge, the heavy chain isotype-specific
Abs that were used in this staining panel have do not cross-react
with other isotypes. We did not observe significant populations of
cells that were double positive for more than one Ig heavy chain
isotype (other than IgM and IgD double positive non-switched
cells). This can be easily confirmed by plotting every heavy chain
isotype against every other.
2.6.7 Top tricks. This panel can be extended by adding selected
surface markers of interest to study, in detail, the different heavy
stain isotype-switched B cell subsets. The addition of fluorescently
labeled antigens to the panel allows the measurement of the dis-
tribution of antigen-specific B cells among different heavy chain
isotypes as we have demonstrated before [1294].
2.6.8 Summary table.
B cell population
(CD19+)
Phenotype (all
CD19+)
Expected frequency range
within total CD19+ B cells
Expected frequency range
within parent population
Non-switched IgM+IgD+ 40-95% 40-95%
IgA1-switched IgM–IgD–IgA+IgA2– 2-10% 10-40%
IgA2-switched IgM–IgD–IgA+IgA2+ 1-5% 5-20%
IgG1-switched IgM–IgD–IgA–IgG1+ 5-10% 40-70%
IgG2-switched IgM–IgD–IgA–IgG2+ 0.5-6% 5-30%
IgG3-switched IgM–IgD–IgA–IgG3+ 0.2-1% 3-15%
IgG4-switched IgM–IgD–IgA–IgG4+ 0.01-1% 0.1-8%
3 Ab-secreting cells (plasmablasts and plasma cells)
3.1 Murine Ab-secreting plasmablasts and plasma cells
3.1.1 Overview. Plasma cells are terminally differentiated B lin-
eage cells that secrete large amounts of Abs, a key step in estab-
lishing effective adaptive humoral immunity against pathogens
and other toxic substances. After being activated in either a T cell-
dependent or T cell-independent manner, B cells proliferate and
initiate a transcriptional program (controlled by e.g., Irf4 and
Blimp1) to adapt to the challenge of secreting enormous quan-
tities of Abs. The induction of the plasma cell program begins with
the transition of activated B cells to the proliferating plasmablast
stage, where Ab secretion starts. Ab-secreting cells enter the blood
stream, migrate to effector sites or survival niches, e.g., in the
bone marrow, spleen, gut, or sites of inflammation and develop
into mature, nondividing plasma cells. Some of these cells may
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Figure 152. Comparison of common two-color
flow cytometric analyses of plasma cell popu-
lations. (A) Exemplary gating strategy for single
extended lymphocytes in spleen. (B) Single cell
suspensions from bonemarrow (BM), spleen and
mesenteric lymph nodes (mLN) of Blimp1:GFP-
reporter mice were isolated and stained as
described with Abs against CD138 and one addi-
tional surface marker indicated on the y-axis.
The Blimp1:GFPhi/CD138hi gate was used as the
reference gate for the plasmablast/plasma cell
populations and events in this gate are high-
lighted in green in the following plots.
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Table 53. Antibodies and other reagents used for staining
Antibody Clone
Species
reactivity isotype Company Dilution
IgA-AF488 Polyclonal Human polyclonal goat IgG Jackson Immunoresearch, West
Grove PA, USA
1:1500
IgA2-PE REA995 Human human IgG1 Miltenyi biotec, Bergisch
Gladbach, DE
1:100
IgG1-Dylight405* HP6188 Human mouse IgG2b,k Sanquin, Amsterdam, NL 1:1000
IgG2-PE/Cy5.5* HP6014 Human mouse IgG1,k Sanquin, Amsterdam, NL 1:1000
IgG3-biotin* (followed
by Streptavidin-PC7
HP6095 Human mouse IgG1,k Sanquin, Amsterdam, NL 1:1000
IgG4-APC SAG4 Human mouse IgG1,k Cytognos, Salamanca, Spain 1:400
IgM-PerCP/Cy5.5 MHM-88 Human mouse IgG1,k Biolegend, San Diego, CA, USA 1:100
IgD-PE-CF594 IA6-2 Human mouse IgG2a,k BD Biosciences, Franklin Lakes,
NJ, USA
1:35
CD19-APC/FIRE750 HIB19 Human mouse IgG1,k Biolegend, San Diego, CA, USA 1:100
CD27-BV510# L128 Human mIgG1,k BD Biosciences, Franklin Lakes,
NJ, USA
1:100
CD38-BV786# HIT2 Human mIgG1,k Biolegend, San Diego, CA, USA 1:100
Zombie yellow
viability dye
− − − Biolegend, San Diego, CA, USA 1:100
Streptavidin-PC7 − − − Biolegend, San Diego, CA, USA 1:2000
*These antibodies were labeled using lightning link labeling kits from Novus Biologicals, Centennial, CO, USA.
#These antibodies were included in the staining panel but are not applied in the gating strategy shown in Fig. 150.
persist for weeks up to years and continuously provide protec-
tive as well as pathogenic Abs. The following chapter will provide
an overview of surface markers and detailed protocols to identify
proliferating plasmablasts and nondividing plasma cells in various
murine lymphatic tissues by FCM.
3.1.2 Introduction. Ab-secreting cells are a heterogeneous pop-
ulation ranging from very early proliferating (i.e., plasmablasts)
to late nondividing and long-lived Ab-secreting cells (i.e., plasma
cells); see also Chapter VI Section 3.2 Human Ab-secreting cells.
Utilizing the Blimp1:GFP-reporter mouse line, which is frequently
used to detect Ab-secreting cells [1295], we tested the efficiency
of different surface marker combinations and gating strategies to
distinguish plasmablasts from early and late plasma cells with a
single staining panel.
Maturation of proliferating early Ab-secreting plasmablasts
into resting long-lived plasma cells is accompanied by an increased
abundance of immunoglobulins (Ig), Blimp1, CD138 (Syndecan-
1), Transmembrane activator, and CAML interactor (TACI) and
B cell maturation antigen (BCMA), while B cell-specific surface
proteins such as CD19, CD20, MHCII, and B220 are downreg-
ulated [1296]. Combinations of these markers can be used to
track the various subsets of Ab-secreting cells. In addition, Blimp1-
reporter mouse lines (e.g., Blimp1:GFP) represent a handy tool to
identify Ab-secreting cells by FCM or fluorescence microscopy.
However, there are several limitations to consider when using the
Blimp1:GFP reporter mouse. Most importantly, the GFP reporter
signal alone is not sufficient for a reliable analysis of plas-
mablasts/plasma cells because Blimp1 is also produced by other
immune cells, e.g., effector T cell subsets in the spleen and
other lymphatic and nonlymphatic tissues [1297]. In addition,
the knock-in of the GFP reporter cassette into the Prdm1 gene
(encodes Blimp1) results in an inactive Prdm1 allele [1295]. Fur-
thermore, in contrast to formaldehyde fixation the fluorescence
of the GFP molecule is abolished by methanol/ethanol-based fix-
ation protocols. Finally, the Blimp1:GFP reporter mouse might
either be not available, or it might be too time consuming to cross
the Prdm1 reporter allele into other transgenic lines or disease
mouse models. Therefore, alternative surface staining protocols to
detect Ab-secreting cells on a single-cell basis by FCM have been
developed.
As plasma cells produce large amounts of Igs, surface CD138
staining together with staining of intracellular Ig-kappa and Ig-
lambda light chains was considered the gold standard for iden-
tifying Ab-secreting cells by FCM for many years [1298, 1299].
However, this protocol does not allow sorting of live cells. This
can be accomplished by using a combination of a variety of other
surface markers. Among the available markers, CD138 is most
commonly used to analyze plasma cells, albeit its expression is not
restricted to Ab-secreting cells. Therefore, CD138 staining with the
detection of Blimp1-reporter expression, e.g., in the Blimp1:GFP
mouse [1295], is frequently used as a reference staining to detect
murine plasma cells. However, to allow the detection of Ab-
secreting cells in mice that do not carry a Blimp1 reporter allele,
CD138 staining togetherwith a surfacemarkers, e.g., TACI [1300],
Sca-1 [1301], CD98 [1302], Ly6-C [1303], and B220 [1304], have
been described in recent years. A caveat is that most of these
double-stainings do not differentiate between early dividing plas-
mablasts and late nondividing plasma cells.
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Figure 153. Flow cytometric distinction between plasmablasts, early- and late mature plasma cells. Single cell suspensions from the bonemarrow
(femur and tibia) of Blimp1:GFP-reporter mice were analyzed for their surface expression of CD138, TACI, CD19, and B220. Viable cells were
defined using FSc/SSc characteristics. (A) CD138+/TACI+ cells and subpopulations defined on their B220 and CD19 abundance were analyzed for
their Blimp1:GFP-expression (MdFI: Median fluorescence intensity); MdFI values are indicated in the depicted histograms. CD19 and B220 surface
expression was used to further subdivide the CD138+TACI+ population (P1: CD19+/B220+; P2: CD19+/B220low; P3: CD19low/B220low). CD138−/−TACI−
cells were used as a negative control for Blimp1:GFP-expression. (B) Blimp1:GFP+/CD138+ cells were divided based on their fluorescence intensities
in high-expressing population (CD138high/Blimp1:GFPhigh) and low- expressing population (CD138+/Blimp1:GFP+). These two subpopulations are
further subdivided based on heterogeneous CD19/B220 expression.
To distinguish dividing plasmablasts from nondividing plasma
cells, analysis of the proliferation marker Ki-67 can be useful.
However, for staining of Ki-67, cells have to be fixed and per-
meabilized, which is incompatible with cell viability [547, 1214].
Another frequently used method to analyze Ab-secreting cells in
mice is the treatment with the nucleotide analog BrdU (bromod-
eoxyuridine) or EdU (5-Ethynyl-2’-deoxyuridine) via the drink-
ing water [1305, 1306]. In combination with additional surface
markers such as CD138, this allows to (i) distinguish between
BrdU/EdU-positive proliferating plasmablasts or freshly differen-
tiated plasma cells and previously generated BrdU/EdU-negative
mature plasma cells, as well as (ii) the tracking of BrdU/EdU-
positive mature resting plasma cells over time.
Although the combined analysis of B220 and CD138 has also
been used to identify plasmablasts and plasma cells for many
years, the recently published four-color staining including CD138,
TACI, B220, and CD19 is superior in separating proliferating
plasmablasts from early and late plasma cell subsets because it
(1) does not require intracellular Ki67-staining or a plasma cell
reporter-mouse line, (2) it clearly excludes CD138-positive B cell
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progenitors in the bone marrow (Fig. 153A), and (3) it allows the
sorting of viable plasma cell subsets [547].
3.1.3 Step-by-step sample preparation.
3.1.3.1 Bone marrow. Bones (e.g., femurs, tibiae, humeri,
vertebrae) were isolated, cleaned from surrounding tissue, and
crushed with mortar and pestle in PBS + 2% FCS or RPMI 1640
medium supplemented with 10% FCS (R10). Residual bone frag-
ments were removed by using a 70 µm cell strainer or decapped
and flushed with 27G cannula and PBS+ 2%FCS or R10. The bone
marrow suspension was subsequently centrifuged at 300 × g for
5 min at 4°C. The pellet was resuspended in RBC-lysis buffer and
incubated for 5 min at room temperature. Lysis was stopped by
addition of PBS+ 2% FCS or R10medium, and the cell suspension
was filtered through a 30 µm mesh filter.
3.1.3.2 Spleen. The spleen was isolated, cleaned from sur-
rounding tissue, and gently disrupted in PBS + 2% FCS or R10
through a 70 µm cell strainer using the plunger of a 2 mL syringe.
The cells were pelleted by centrifugation at 300 × g for 5 min at
4°C, resuspended in RBC-Lysis buffer and incubated for 5 min at
room temperature. The lysis was stopped by addition of PBS + 2%
FCS or R10 medium, and the cell suspension was filtered through
a 3 0µm mesh filter.
3.1.3.3 Mesenteric lymph node. Mesenteric lymph nodes (typ-
ically about 4) were isolated and cleaned from surrounding fatty
tissue. The lymph nodes were then gently disrupted in PBS +
2% FCS or R10 medium through a 70 µm cell strainer using the
plunger of a 2 mL syringe.
3.1.3.4 Staining protocol. Cells from organ suspensions were
pelleted by centrifugation at 300× g for 5min at 4°C, resuspended
in PBS + 2% FCS and adjusted to a density of 2 × 107 cells/mL. A
total of 4 × 106 cells from each tissue were washed in PBS + 2%
FCS + 0.05% NaN3and pelleted at 300 × g for 5 min at 4°C. To
avoid unspecific binding, cell pellets were resuspended in 50 µL of
unlabeled CD16/32 mAb (1:100 in PBS+ 2% FCS+ 0.05%NaN3)
and blocked for 15 min on ice (or 5 min at room temperature).
Cells were washed again in PBS + 2% FCS + 0.05% NaN3and
centrifuged at 300 × g for 5 min at 4°C. The pellet was then
resuspended in 50 µL PBS + 2% FCS + 0.05% NaN3containing
the respective fluorochrome-coupled Abs and incubated for 20min
on ice in the dark. After staining, the cells were washed twice with
PBS+ 2% FCS+ 0.05%NaN3 and centrifuged at 300× g for 5 min
at 4°C. The pellet was resuspended in PBS + 2% FCS + 0.05%
NaN3 for flow cytometric analysis.
3.1.4 Materials.
 Dulbecco’s PBS
 FCS, heat-inactivated (56°C, 1 h)
 Sodium azide (NaN3)
 Falcon R© 70 µm cell strainer (Becton Dickinson)
 CellTrics R© 30 µm filter (Sysmex)
 Red blood cell (RBC) lysis buffer (BioLegend, product number
420301)
 Gallios flow cytometer (Beckman Coulter)
Antigen Fluorochrome Supplier Clone Identifier
B220 (CD45R) BV421 BioLegend Ra3-6b2 103251
B220 (CD45R) PerCP/Cy5.5 ThermoFisher Ra3-6b2 103236
CD16/32 unlabeled eBioscience 93 14-0161-86
CD19 APC/Fire750 BioLegend 6D5 115558
CD98 PE BioLegend RL388 128207
CD138 (Sdc1) PE/Cy7 BioLegend 281-2 142514
CD138 (Sdc1) BV421 BioLegend 281-2 142507
Ly6-C PerCP/Cy5.5 ThermoFisher HK1.4 45-5932-82
Sca-1 (Ly6-A/E) APC/Cy7 BioLegend D7 108125
TACI (Tnfrsf13b) APC ThermoFisher eBio8F10-3 17-5942
TACI (Tnfrsf13b) PE ThermoFisher eBio8F10-3 12-5942
3.1.5 Gating and analysis. In Fig. 152, we compared the pres-
ence or absence of one additional commonly used surface markers
on CD138+ cells to the CD138+/Blimp1:GFP+ reference popula-
tion in bone marrow, spleen, and mesenteric lymph node. CD138
together with a B cell marker, e.g., B220 [1304], is the most com-
monly used staining protocol to distinguish between early divid-
ing plasmablasts (CD138+/B220+) and mature CD138+/B220−
plasma cells (Fig. 152B, first row). However, without the addi-
tion of a Blimp1:GFP reporter (Fig. 152B, second row), it is
difficult to clearly separate bone marrow B220+/CD138+ plas-
mablasts from B220+ pro-B/pre-B cells with a moderate staining
for CD138 [1097, 1307]. The detection of the survival receptor
TACI on CD138+ cells prevents these problems because almost
all Blimp1:GFP-positive cells are included within a clearly sep-
arated TACI+/CD138+ population (Fig. 152B, compare row 1
with row 3 and [547]). CD98 and Sca-1 can also be used in
conjunction with CD138 staining to detect Ab-secreting cells
in bone marrow and spleen, but these populations are more
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diffuse, and especially in the lymph node, are interspersed by cells
outside of the CD138+/Blimp1:GFP+ reference gate (Fig. 152B
rows 4 and 5). These protocols might be improved by the use
of “dump” markers, e.g., F4/80 and CD4/CD8 as suggested by
Wilmore et al. [1301]. Despite being described as a plasma cell
marker, in our hands Ly6C is not suitable for the detection of
all Ab-secreting cells, as it is not ubiquitously expressed in the
Blimp1+/CD138+ plasmablast/plasma cell population (compare
row 1 with row 6 in Fig. 152B). Therefore, the combination of
CD138 and TACI staining is a robust protocol to detect a clearly
separated plasmablast/plasma cell population in very high con-
cordance with the CD138+/Blimp1:GFP+ reference across all ana-
lyzed lymphatic organs.
The double staining strategies described in Fig. 152 do not dis-
criminate plasmablasts and plasma cells. Therefore, it is necessary
to add additional surface markers. For example, the inclusion of
the B cell markers CD19 and B220 into the TACI/CD138 stain-
ing protocol resulted in three sub-populations. All three subsets
(P1–P3) were Blimp1:GFP-positive with a stepwise increase in the
abundance of Blimp1:GFP fluorescence from P1 to P3 (Fig. 153A),
indicating an increase in maturity from the P1 (dividing plas-
mablasts) to the P2 (early predominantly nondividing plasma cell)
and the P3 (late nondividing plasma cells) subpopulation. While
the B220+/CD19+ P1 population contains a high frequency of pro-
liferating (Ki-67+) cells, most of the cells in the subpopulations P2
and P3 are mature Ki-67-negative resting plasma cells [547]. In
the spleen of non-immunized mice, the P1- and P2- subpopula-
tions are dominant, while in the bone marrow the CD19−/B220−
P3 population is most prevalent.
In humans, CD19-negative plasma cell subpopulations have
been described [1214]. However the biological origin and func-
tional differences between the CD19+ and CD19− plasma cell
subpopulations remain largely unclear [1308].
3.1.6 Pitfalls and top tricks. To guarantee a reliable flow cyto-
metric analysis of plasma cells in mice, some points should be
considered. As mentioned before, other cells express markers used
for detecting plasmablast/plasma cells such as Blimp1 (T cells)
or CD138 (pro-B /pre-B cells). Therefore, strategies to identify
plasma cells based on only one marker should be avoided. In
addition, plasma cells express markers usually associated with
other cell types (e.g., Ly6C [1303], CD11c [1309], CD56 [1310]).
Therefore, care has to be taken when using “dump” gate mark-
ers. Furthermore, methanol/ethanol-based fixation methods will
often result in a loss of the GFP-reporter signal. A prefixation step
can prevent the leakage of cytosolic GFP and enable the retention
of GFP fluorescence in a co-staining for cytosolic/nuclear anti-
gens [522].
TACI/CD138 staining is also sensitive to different fixation
strategies, e.g., formaldehyde fixation. In addition, TACI harbors
protease cleavage sites (shedding) [1311] and can, therefore, be
degraded when enzymes, e.g., collagenases are used to dissoci-
ate tissues. Plasma cells are also quite sensitive to mechanical
stress due to their enlarged cytoplasm; therefore, vortexing of the
samples should be avoided and cell pellets should rather be resus-
pended by finger tipping the reaction tube or careful pipetting.
Higher abundance of Blimp1 and CD138 is associated with
a more mature stage of plasma cell differentiation [1295,
1296]. As demonstrated in Fig. 153B, the CD138+/Blimp1:GFP+-
population in the bone marrow of mice contains two
clearly separated subpopulations, CD138+/Blimp1:GFP+cells and
CD138high/Blimp1:GFPhigh cells. Analysis of CD138 and B220
abundances revealed that the CD138+/Blimp1:GFP+population
still expresses surface B220, while the majority of the
CD138high/Blimp1:GFPhigh cells is negative for surface B220.
Therefore, cells gated on Blimp1:GFP and CD138 contain early
and late plasma cells.
In the bone marrow of unimmunized mice, frequencies of
plasma cells range between 0.4 and 0.6% of viable cells, while
frequencies in spleen and lymph nodes vary between 0.3 and 0.5%
and 0.1 and 0.2%, respectively. Therefore, at least 1 × 106 events
(optimally 3–4 × 106 events) should be acquired during the flow
analysis in order to collect a sufficient number of events in the
plasma cell gate for valid conclusions. As plasma cells have a
larger cell size compared to other lymphocytes, the regularly used
“lymphocyte gate” in the FSC/SSC plot has to be extended.
The paradigm of plasma cell differentiation includes the ter-
mination of membrane-bound IgH chain and a switch toward the
production of only the soluble form of the B cell receptor. How-
ever, Pinto and colleagues found that human plasma cells still
express functional IgM and IgA receptors on the cell surface, over-
turning the dogma of complete membrane-BCR loss upon plasma
cell differentiation [1312]. We and others confirmed this finding
in mice, i.e., almost all IgM- and IgA-producing CD138+/TACI+-
plasmablasts and mature plasma cells present these IgH-isotypes
as BCRs on their cell surface [547, 1166]. In contrast, IgG-
producing mature plasma cells have lost the expression of surface
IgG. Therefore, one could determine the frequency of IgH-isotype-
expressing plasmablasts/plasma cells by including the detection of
surface IgM and IgA in the previously described four-color staining
(see Fig. 153).
3.2 Human antibody-secreting cells
3.2.1 Overview. Plasma cells (PC) are terminally differentiated
B lymphocytes specialized on large-scale Ab production and secre-
tion. PC are implicated in both protective and pathogenic humoral
immunity, and, as long-lived cells, in humoral memory. Thus,
they are being studied as therapeutic targets for the treatment
of Ab-mediated diseases and as biomarkers for B cell activation
in various clinical settings such as infection, inflammation, and
vaccination.
In this chapter, we describe human ASC analyses by FCM.
The vast majority of PC and their immediate precursors, the plas-
mablasts (PB), are characterized by high expression of CD27 and
CD38, low or no expression of CD20, and variable expression
of CD19, HLA-DR, and CD138. PB/PC represent approximately
0.01–1% of leukocytes in different tissues, and phenotypical
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Figure 154. Representative gating strategy and analysis of human peripheral blood PB/PC. Whole blood from a patient with systemic lupus
erythematosus (SLE) was diluted with PBS at room temperature, and subjected to density gradient centrifugation over Ficoll (GE Healthcare,
Uppsala, Sweden) to isolate PBMC. Active SLE patients exhibit significant B lymphopenia, with increased frequencies and absolute numbers of
PB/PC in peripheral blood [1246, 1315]. PBMC were washed with PBS/0.2% BSA, and stained at 4°C for 15 min with a cocktail of the following mAbs:
CD19 (clone SJ25C1, BD), CD27 (clone 2E4; Sanquine), CD20 (L27, BD), CD14 (M5E2, BD), CD3 (UCHT1, BD), CD38 (HIT2, BD), CD138 (B-B4, Miltenyi
Biotec). Cells were washed with PBS/0.2% BSA. DAPI was added prior to acquisition of the sample on a BD FacsCANTO II instrument for dead cell
labeling. In total, 300 000 events were collected. (A) Gating strategy. Data were analyzed for changes of scatter or fluorescence parameters over
the time of data acquisition, and optionally gated to remove parts of the acquisition that show irregular or discontinuous cytometric patterns.
Then, a large light scatter parameter gate was used to identify lymphocytes and monocytes. FSChigh cells represent doublets and were excluded.
SSChigh cells correspond to remaining granulocytes, likely low density granulocytes described before in SLE [1332] that were co-enriched along
with PBMC. Next, cell aggregates were removed by gating on cells showing closely correlating area and height values of the FSC signal. Most cell
doublets are characterized by a relatively increased FSC-area vs. FSC-height ratio. Live B cells were detected by staining for CD19, and exclusion of
T cells, monocytes and dead cells according to CD3, CD14, and DAPI staining. Note that the B cell gate captures CD19dim cells, which can be strongly
enriched for PB/PC. CD19 expression itself is subject to regulation in, e.g., autoimmune conditions [1328, 1333], so that boundaries of the CD19 B cell
gate should be carefully validated. CD19+CD3−CD14−DAPI− B cells were then analyzed for CD20 and CD27 expression, revealing CD20+ subsets of
naive and memory B cells besides PB/PC with a CD27highCD20low/− phenotype. In this (SLE) sample, PB/PC are detectable at increased frequencies;
normal donors show commonly less than 2% PB/PC among CD19+ B cells. (B) PB/PC were then analyzed for expression of CD38 and CD138. Virtually
all CD27highCD20low/− gated PB/PC (red) expressed high levels of CD38, and two thirds expressed CD138. CD3+ T cells and CD14+ monocytes not
expressing CD138 and containing very few CD38high cells are shown for comparison (grey). (C) As an alternative to the PB/PC gating shown in (A-B),
total PB/PC, or CD138+ PB/PC can be gated in various combinations of the markers CD20, CD38, CD27 and CD138, with consistent results. (D) PB/PC
show a unique FSC and SSC profile distinct from that of total lymphocytes, B lymphocytes, and monocytes. (E) Backgating confirms the validity of
the gating strategy. In particular, it shows that the entire PB/PC subsets was included during light scatter gating, some PB/PC events were excluded
as doublets, and that significant amounts of T cells and/or monocytes share the CD27highCD20−/low phenotype of PB/PC and may contaminate this
population unless careful CD19 gating and DUMP channel exclusion is employed. An example for the detection of blood PB/PC by icIg staining is
published in ref. [1322].
characteristics of PB/PC are associated with tissue origin, matu-
rity level, and clinical context. Their low frequency, variable phe-
notype, and their uncommon light scatter properties should be
considered when analyzing PB and PC by FCM.
3.2.2 Introduction. Plasma cells are terminally differentiated B
cells capable of continuous production of Ab [1313]. Next to
their immediate precursors, the PB, they are the only cells of
the body that secrete Ab and contribute the vast majority of
Ig detectable in serum and mucosal secretions. Thus, PC (also
termed plasmacytes, plasmocytes, or named according to detec-
tion assays other than FCM: spot-forming cells (SFC), Ab-secreting
cells (ASC), Ab-forming cells (AFC), plaque-forming cells (PFC),
or Ig-secreting cells (ISC)) are the foundation and the cellular
correlates of humoral immunity by secreting specific, commonly
adaptively shaped Abs that neutralize or opsonize pathogens.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1736 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
Figure 155. Representative gating strategy and analysis of human bone marrow PC. Bone marrow (BM) cells were flushed from a femoral head
piece of a healthy donor using PBS/0.2% BSA/5 mM EDTA buffer and mononuclear cells were isolated via density gradient centrifugation over
Ficoll. BM cells were washed with PBS/0.2% BSA/5 mM EDTA and stained at 4°C for 15 min with a cocktail of the following Abs:CD3-VioBlue
(BW264/56, Miltenyi), CD16-VioBlue (REA423, Miltenyi), CD38-BV 510 (HIT2, BioLegend), CD138-FITC (44F9, Miltenyi), CD45-PE (HI30, BioLegend),
HLA-DR-PerCP (L243, BioLegend), CD19-PE-Cy7 (HIB19, BioLegend), CD10-APC-Fire 750 (HI10a, BioLegend), CD14-APC-Fire 750 (M5E2, BioLegend).
Cells were then washed with PBS/0.2% BSA/5 mM EDTA and stained with DAPI for later dead cells exclusion prior to acquisition of the sample on a
MACS R© Quant Analyzer. (A) Analytical gating strategy. Time/CD45 visualization confirms the stability of the cytometric measurement over time.
Time frames showing discontinuous data should be excluded. As PC exhibit particular light scatter and background fluorescence properties, the
CD138+CD38high PC population was gated first, followed by cell aggregate exclusion and gating on CD3−, CD16−, CD10−, CD14−, and DAPI− cells,
for exclusion of dead cells and cell types potentially contaminating the gated PC population. Then, the FSC-A/SSC-A plot reveals that PC show
a broader light scatter value distribution than typical lymphocytes, which is in agreement with their increased size and ellipsoid shape. Should
the FSC-A/SSC-A plot reveal remaining FSClow and/or SSClow cell debris or electronic artifacts, these should be excluded by gating at this step. (B)
Human BM PC consistently display distinct populations with either high or low to no expression of CD19 [1214, 1324]. The absence of HLA-DR
expression confirms at large the absence of PB [1245, 1322], and remaining HLA-DR+ PB are excluded. (C) Backgating analyses of the procedure
shown in (A). (D) Comparison of antibody staining and light scatter properties of total CD138+CD38+ BM PC vs total, ungated BM mononuclear
cells. PC exhibit increased background fluorescence signals compared to other cells (possibly integrating cell size effects, autofluorescence, and
nonspecific binding of labelled antibodies) stressing that subset gating should be adjusted at the level of PC rather than at global levels. Consistent
with their increased size, nonspherical shape, and high organelle content, BM PC show a FSC/SSC pattern distinct from that of other BM cells.
So-called long-lived or memory PC can gain longevity and directly
contribute to immune memory by long-term secretion of specific
Ab [1305, 1314], a phenomenon termed humoral (or serological)
memory.
Plasma cells are of interest to medical and biological research
in various regards. Vaccines are tailored to induce long-lasting and
specific Ab titres that result from the generation and persistence
of vaccine-specific PC. On the other hand, PC are also the source
of pathogenic Abs in autoimmune diseases and humoral trans-
plant rejection, and constitute a potential therapeutic target in
these conditions. Furthermore, the abundance of PB and PC in the
peripheral blood serves as a biomarker for acute B cell responses in
systemic autoimmune disease such as SLE [1315, 1316]. Upon vac-
cination and infection, especially antigen-specific PB are expanded
in the blood [1214, 1246, 1317–1319]. The diagnosis, treatment,
monitoring, and research in lymphoid tumors recapitulating PC
features and biology, such as multiple myeloma, monoclonal gam-
mopathy of undetermined significance (MGUS), reactive plasma-
cytoma, or Morbus Waldenstrom, are commonly associated with
PC analyses by FCM.
Technically, antigen-specific PC can serve as a template for
cloning Abs for new biomedical assays, diagnostics or therapeu-
tic purposes. Furthermore, PC are investigated in a number of
interrelated biological contexts such as apoptosis and survival
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mechanism(s), large-scale protein production, and balancing the
consequential cellular stress, transcriptional reprogramming, cell
adhesion, and homing.
3.2.3 Activated B cells become plasma cells. Upon activation of
B cells by B cell antigen receptor (BCR) stimulation by anti-
gen, by cytokines, TLR ligands, cognate T cells, or combina-
tions thereof, they start proliferating and differentiating into PB,
or memory B cells. In vivo, this activation can target na¨ıve, or
antigen-experienced memory B cells, and leads to B cell differen-
tiation within germinal centers (including somatic hypermutation
and class-switching of Ig gene rearrangements, or in follicular
or extrafollicular processes. In line with the observation that the
differentiation of PB is fairly easy to mimic in vitro by different
stimuli [1320, 1321], PB differentiation appears as the default
differentiation pathway upon B cell activation.
Once formed, PB may either reside at the site of their gen-
eration (such as spleen or lymph nodes), or emigrate and tran-
sit via the blood to PC deposits in the gut lamina propria (LP)
or the bone marrow (BM), or die. Immunization studies have
been particularly useful for determining PB dynamics and biol-
ogy in man [1214, 1245, 1246, 1313, 1319, 1322]. While PB
and PC types are common in lymphoid tissues such as spleen
and BM [1214, 1313], and are present at very low frequencies in
peripheral blood at all times [1322], additional PB specific for the
vaccination antigen appear in the blood as a sharp peak approx-
imately 1 week after intramuscular or subcutaneous immuniza-
tions [1241, 1245]. Their presence in blood lasted longer when the
immunization was applied via mucosal routes [1323]. At the PB
stage circulating in peripheral blood, the cells have already started
to secrete antibody that is detectable by Elispot assays [1245],
express the proliferation marker Ki-67 [1214, 1322], and migrate
along gradients of the chemokines CXCL12 and/or CCL28 (using
CXCR4 and CCR10, respectively), navigating them into their BM
or mucosal niches.
Besides primary and secondary lymphoid tissues including
mucosa-associated lymphoid tissues, PB/PC can also be found
at different sites under pathological conditions, such as inflam-
mation (brain, cerebrospinal fluid, kidney, joints, and synovial
fluid [1214], or in the form of multiple myeloma metastases.
3.2.4 Detection of PB and PC according to unique cell-surface recep-
tor expression profiles. In the blood, PB and PC express the unique
phenotype CD19+CD27highCD38high and show low or no expres-
sion of CD20 [1213, 1322, 1324]. CD138, often referred to as
a PC marker, is expressed to only variable extents in the blood
[1324, 1325] (Figure 154). Besides CD38high PB/PC, a minor
CD38low subset has been defined in tonsils [1326], and CD27-
negative differentiation stages have been described in in vitro
studies [1327]. Blood PB/PC can show downregulated, yet still
present levels of the B cell marker CD19 [1328]. During steady-
state, PB/PC make up about 1% of peripheral blood B cells. One
week after immunization, antigen-specific PB circulating in blood
express high levels of HLA-DR, distinguishing them from HLA-
DRlow cells sharing the typical CD19+CD27high phenotype, but
being non-migratory and non-proliferating, thus resembling BM
PC [1313, 1322]. Taken together, blood PB and PC can be well
distinguished from other B cells and other leukocytes according
to their unique cell-surface marker expression profile. However,
as all mentioned markers alone are also expressed by other cell
types or B cell differentiation stages, multiple markers need to
be co-stained to obtain a PB/PC population (i) that covers most
of the PB/PC present in the sample under normal conditions and
(ii) is sufficiently pure to permit their reliable quantification and
phenotypical characterization. PC in deposit tissue such as the
bone marrow (BM) express intermediate to high levels of CD138,
usually very high levels of CD38 (a molecule that candidates as
a therapy target for depletion of malignant PC in patients with
MM [1329], lack CD20 expression, and show low or no expres-
sion of HLA-DR. Notably, CD19 is differentially expressed among
mature BM and LP PC, and CD19− PC show consistent features of
PC that have reached an exceptionally mature state [1214, 1330,
1331]. A representative analysis of human BM PC is shown in
Fig. 155.
3.2.5 Detection of PB/PC according to high expression of intracellu-
lar Ig and by cellular affinity matrix assay. Apart from cell-surface
staining, PB and PC can be detected by staining intracellular Ig
(icIG) [1322]. Consistent with large-scale Ab production by PB
and PC, they accumulate large amounts of it in their cytoplasm,
and intracellular flow cytometric staining without prior in vitro
stimulation and/or secretion inhibition yields high signal intensi-
ties that are suitable to distinguish icIghigh PB/PC from Ig+ B cells,
which do not express extraordinarily high levels of icIg and to
which anti-Ig Abs bind mainly via their cell-surface Ig (BCR). Fix-
ation with 1.5% formaldehyde solution and mild permeabilization
with 0.1–0.5% saponin solution is sufficient to permit detection of
icIg in PB/PC.
The above cell-surface markers, IgD, and intracellular (ic)IgM,
icIgA, and icIgG, were combined in an optimized multicolor panel
(OMIP) for the detection of PB/PC [1334].
Furthermore, affinity matrix technology has been developed
to cytometrically capture PB and PC according to their ability to
secrete Ab, thus providing access to live and functional PB/PC
[621, 1326]. Abs capturing the Ig of interest are immobilized on
the cell surface, and the cell suspension is short-term cultured
to permit antibody secretion by PB/PC. The secreted antibody
is bound by the cell-bound capture antibody and detected by a
second, fluorochrome-labeled anti-Ig antibody, which specifically
stains the cells that have secreted Ig during the culture phase.
Activated B cells undergoing PC differentiation gradually
downregulate the expression of the membrane B cell receptor,
and start to secrete the soluble form of Ab. At the PB stage in the
blood, cell-surface IgM+, and IgA+ PB are detectable, and cell-
surface IgG is also expressed at least after recent vaccination, as
evidenced by specific cell-surface binding of fluorescently labeled
antigen) [1241] Notably, cell-surface BCR is not detectable
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anymore in mature IgG+ PC, while IgM+, and IgA+ PC in deposit
tissues can maintain expression of cell-surface Ig [1312, 1335].
3.2.6 Receptors expressed by plasma cells. Besides Ig of different
classes and subclasses, PB and PC, or their subsets express recep-
tors and transcription factors that are implicated in their survival,
maturity, and homing, such as, for example, the cytokine recep-
tors IL-6R (CD126), BCMA, and TACI, selectins, integrins, and
chemokine receptors such as CD62L, α4β1, and α4β7 integrins,
CXCR4, CXCR3, CCR9, and CCR10, transcription factors BLIMP-
1, IRF4, and the anti-apoptotic protein Bcl-2 [1214, 1245, 1313,
1324, 1330, 1336, 1337]. Notably, highly mature PC lose expres-
sion of PAX5, leading to the expression of a number of receptors
that are typically absent from B lineage cells such as CD56, CD28,
and CCR2 [1214, 1338].
3.2.7 Light scatter properties of plasma cells. PB and PC exhibit
a unique morphology reflecting their role as protein factories.
They show an enlarged cytoplasm with expanded Golgi apparatus
and endoplasmatic reticulum content, and an eccentrically located
nucleus. Coherently, PB/PC show increased FSC/SSC light scat-
ter signals, and a broader distribution, compared to small lym-
phocytes (Figs. 154 and 155). This entails an important caveat
when analyzing PB/PC in routine immune profiling studies in
which gating strategies start off from a small lymphocyte gate.
Any gating performed “upstream” of the PB/PC gate should be
carefully checked for unwanted selection against PB/PC fractions.
The increased cell size may also lead to increased fluorescent
background signal of PB/PC compared to smaller lymphocytes
(Figs. 154 and 155), thus, control staining (such as isotope con-
trols if helpful, or FMO controls) should always be evaluated on
the same PB/PC fraction that is subject to analysis.
3.2.8 Sample preparation. Flow cytometric assessment of PB/PC
is commonly performed from single-cell suspensions obtained by
either red blood cell lysis of whole blood, density gradient cen-
trifugation to obtain mononuclear cells (such as PBMC), or tis-
sue cell suspensions obtained by protocols tailored for individual
tissue types. Since collagenase treatment has been shown to lib-
erate additional fractions of PC from tonsillar tissue compared
to mechanical processing alone [1339], digestion protocols can
be considered to retrieve PC or certain fractions of PC. It should
be noted that different enzymes used for this purpose may differ-
ently impact on the detectability of different cell-surface receptors,
including the above mentioned used to detect human PC. PB/PC
tend to die rapidly during longer preparation protocols and when
cultured in the absence of survival promoting cytokines. Thus,
keeping cells cool and working quickly is key. Protocols should be
kept short to avoid excessive death of PB/PC after preparation,
and dead cell detection and exclusion should be performed.
When analyzing rare fractions of PB/PC such as antigen-
specific cells, PB/PC may be pre-enriched for FCM analyses by
magnetic cell sorting, e.g., by depleting large, unwanted sample
fractions such as granulocytes, T cells, and monocytes, etc., or by
direct enrichment of CD138+ cells. One should carefully choose
depletion markers (and DUMP channel markers) as mature PC
subsets (and especially malignant PC) can express markers like
CD28, CCR2, and CD56 commonly associated with T cells, mono-
cytes, or NK cells, respectively.
Live-cell cryopreservation using standard procedures and
media such as FCS/DMSO impacts on detection of PB/PC. Usually,
after freezing and thawing, frequencies of PB/PC are much lower
compared to fresh cell preparations, and the detection of some
receptors including CD138 have been described to be impaired
after cryopreservation [1340].
Since PB/PC are commonly found at low to very low frequency
in cell suspensions, the separation of PB/PC from cells that share
elements of the PC phenotype is key, and the use of carefully
designed DUMP channels is advised. For example, PBMC contain
high frequencies of CD27high expressing T cells that may contami-
nate the CD19dim/CD27high PB/PC gate unless T cells are excluded
from the analysis. Since PB/PC are infrequent in many cell sus-
pensions from primary tissue, care must be taken to acquire suit-
able total cell numbers, which ensure that sufficient PB/PC are
recorded for the desired statistical analysis.
Generally, it must be stressed that, to deliver accurate results,
PB/PC analyses require careful experimental and cytometric setup
and validation that can be very specific to a certain project (consid-
ering what readout parameters are to be measured), tissue specific
phenotypes and sample logistics.
4 Innate lymphoid cells
4.1 Overview
This section will give an overview on the flow cytometric strategy
to gate on different subsets of tissue-derived innate lymphoid cells
(ILCs) in humans and mice. While only murine small intestine
and human tonsils are representatively shown, the use of mas-
ter transcription factors in combination with established surface
markers can be generally used across different tissues to identify
ILC subsets.
4.2 Introduction
During the past years, an emerging family of CD45+ innate
lymphoid cells (ILCs) has been described in both mouse and man.
CD45+ ILCs lack rearranged antigen receptors as well as lineage
(Lin) markers typically expressed on T cells, B cells, or dendritic
cells (DCs) [1341]. ILCs can be classified into distinct groups
according to the expression of surface markers, transcription
factors and effector cytokines (reviewed in ref. [1342]). ILC1
express T-box transcription factor T-bet (T-bet) and produce
IFN-γ in response to IL-12 and IL-18 or activating receptor
engagement, thus contributing to the response against viruses
and intracellular pathogens [1343–1346]. ILC2 express GATA
binding protein-3 (GATA3), produce IL-13 and IL-5 in response
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Figure 156. Identification of murine SI LP ILCs. Representative gating strategy of ILCs derived from the small intestinal (SI) lamina propria LP of
6-week-old C57BL/6 mice. Mononuclear cells (MCs) were prepared as previously described [1350]. Cells were gated as viable (LD−), B220− CD11c−
Gr-1− F4/80− FcεR1α− (Lin−) CD45+ TCRβ− TCRγδ− and either as NKp46+ (grey gate) T-bet+ Eomes− ILC1, Eomes+ T-bet+ NK cells or as CD127+
(black gate) GATA3+ RORγt− ILC2 and RORγt+ GATA3lo ILC3 which can be further separated according to NKp46 and CD4 expression.
Figure 157. Identification of human tonsil ILCs. Representative gating strategy (upper panel) and expression of transcription factors (lower panel)
of human tonsil ILCs. After magnetic depletion of CD3+ cells, cells were gated as viable (LD−), CD3− CD14− CD19− FcεRIα− CD123− CD11c− BDCA3−
(Lin−) and either CD94+ CD127−/lo CD56+ NK cells; CD94− CD127hi CD117+ CRTH2− ILC3; CD94− CD127hi CD117+/lo CRTH2+ ILC2; or CD94− CD127hi
CD117− CRTH2− NKp44− CD56− ILC1.
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to IL-25, IL-33, and Thymic stromal lymphopoietin (TSLP) and
contribute to the defense against helminthic infections as well
as to the pathogenesis of allergic inflammation [1347]. ILC3
express retinoic acid receptor (RAR)-related orphan receptor
RORγt, and produce IL-17 and/or IL-22 in response to IL-1β
and IL-23 or activating receptor engagement. ILC3 include both
fetal-derived lymphoid tissue-inducer (LTi) cells (considered as a
distinct subset [1342]) and post-natal ILC3; LTi are required for
the embryonic development of lymph nodes and Peyer’s patches,
while ILC3 contribute after birth to defense against extracellular
pathogens, containment of commensals, epithelial tissue home-
ostasis, and regulation of inflammatory disorders, such as IBD and
psoriasis [1348]. As such, ILC1, ILC2, and ILC3 show similarities
with CD4+ T helper (Th) subsets Th1, Th2, and Th17 and mirror
the functional analogies between natural killer (NK) cells and
adaptive CD8+ cytotoxic T lymphocytes (CTL) [1341, 1349].
Accordingly, the International Union of Immunological Societies
(IUIS) now recognizes five related innate lymphoid subsets: NK
cells, ILC1, ILC2, ILC3, and LTi cells [1342].
4.3 Step-by-step sample preparation
For isolation of murine SI LP MCs a previously described protocol
was used [1350]: residual fat tissue, Peyer’s Patches and feces
were removed, and the intestine was cut open longitudinal and
washed with PBS. After clearing, tissue was cut into pieces of 1 cm
length and digested with a lamina propria dissociation kit (Mil-
tenyi), according to the manufacturer’s instructions. Lymphocytes
were further enriched on a 40%/80% Percoll gradient.
Written informed consent was obtained from all patients prior
to sample acquisition and experiments have been approved by
the Ethics Committee of the Charite´ Medical University, Berlin
(EA2-078-16, EA1/149/1). Mononuclear cells (MCs) from human
tonsils were isolated from patients undergoing tonsillectomy as
previously described [1351]. After mashing and density gradient
centrifugation using Ficoll-Paque PLUS, ILCs were enriched
by using magnetic cell depletion of CD3+ T cells with CD3
mAb microbeads and LD columns (Miltenyi) according to the
manufacturer’s instructions.
4.4 Materials
Flow cytometry:
Phenotypic analysis of murine lymphocytes was performed
using the following Abs reactive to murine surface or intracel-
lular antigens: eFluor780 Fixable Viability Dye, APC-eFluor780
anti-FcεRIα (MAR-1), PerCP-Cy5.5 anti-TCRβ (H57-597), PerCP-
eFluor710 anti-TCRγδ (GL-3), eFluor660 anti-T-bet (4B10),
Alexa488 anti-Eomes (Dan11mag) (eBioscience); APC-Vio770
anti-B220 (RA3-6B2), PE anti-GATA3 (REA174) (Miltenyi); APC-
Cy7 CD11b mAb (M1/70), CD11c mAb (N418), anti-Gr-1 (RB6-
8C5), anti-F4/80 (BM8), BV785 CD127 mAb (A7R34), BV605
anti-KLRG1 (2F1/KLRG1), BV711 CD4 mAb (RM4-5), PE-Cy7
anti-NKp46 (29A1.4) (BioLegend); V500 CD45 mAb (30F11), and
BV421 anti-RORγt (Q31-378) (BD).
Staining for transcription factors was performed using the
Foxp3 Transcription factor staining buffer set (eBioscience)
according to manufacturer’s instructions and cells were immedi-
ately analyzed. Flow cytometric analysis was performed by using
BD LSRII or Fortessa employing FACSDiva Software (BD Bio-
sciences), and data were analyzed by using FlowJo software (Tree
Star).
Phenotypic analysis of human lymphocytes was performed
using the following Abs reactive to human surface or intracel-
lular antigens: eFluor780 Fixable Viability Dye, APC-eFluor780
CD14 mAb (61D3), CD19 mAb (HIB19), CD3 mAb (SK7),
CD123 mAb (6H6), eFluor660 anti-Eomes (WD1928), PE anti-
T-bet (eBio4B10), or anti-GATA-3 (TWAJ), PE-Cy7 anti-T-bet
(eBio4B10), APC anti-RORγt (AFKJS-9) (eBioscience); APC -
Vio770 CD141 mAb (AD5-14H12), anti-FcεRIα (CRA1), and
CD11c mAb (MJ4-27G12), Fitc CD127 mAb (MB15-18C9), PE-
Dazzle594 CD56 mAb (HCD56), PE-Vio770 NKp44 (2.29) (Mil-
tenyi Biotec); BV605 CD117 mAb (104D2), PerCP-Cy 5.5 anti-
CRTH2 (BM16), Pacific Blue CD94 mAb (XA185) (conjugated in
house).
4.5 Data analysis
How can we identify these different NK cell and ILC subsets in
different tissues from different species? The analysis of NK cells
is described in the NK chapter by Moretta et al., where readers
can find more details (See also Chapter VI Section 5 Natural Killer
cells). ILCs are present in diverse organs as tissue-resident cells
but are also detected in the circulation [1346, 1352]. In mouse
small intestinal (SI) lamina propria (LP), all ILCs, namely NK
cells, ILC1, ILC2, and ILC3 could be described [1345, 1353]. In
Fig. 156 a gating strategy for murine ILCs derived from SI LP is
shown; however, it should be stressed that ILC populations are not
equally distributed in all organs and display some tissue-specific
phenotypic differences. Combination of intranuclear staining of
master transcription factors, namely T-bet (expressed on ILC1,
NK cells and a subset of murine ILC3), Eomes (NK cells), RORγt
(ILC3), and GATA3 (ILC2) together with NKp46 and CD127 (IL-
7Rα) (Figure 156) or CD90 (not shown) enables identification
of ILC subsets in all organs analyzed. Among SI LP CD45+ Lin−
cells, NKp46 (or NK1.1) can be expressed not only on NK cells
but also on ILC1 and a subset of ILC3. Thus, staining of transcrip-
tion factors is helpful to dissect their identity (see also Chapter V
Section 13 Transcription factors). It has been proposed that SI LP
NK cells can be defined as NKp46+ RORγt− T-bet+ Eomes+ cells,
while ILC1 are NKp46+RORγt− T-bet+ Eomes− cells [1345] (Fig-
ure 156). However, a population of cytotoxic NKp46+ RORγt− T-
bet+ Eomes+ intraepithelial ILC1 has been also described [1354].
Moreover, the analysis of NK/ILC1 in different mouse compart-
ments revealed a high degree of phenotypic and functional com-
plexity [1346, 1355], suggesting that distinction between NK and
ILC1 cells might be more challenging.
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ILC2 and ILC3 are enriched among SI LP CD45+ Lin− CD127+
lymphocytes and can be identified after intranuclear staining of
GATA3 and RORγt as GATA3hi RORγt− ILC2 and of GATA3lo
RORγt+ ILC3 (Figure 156) [1353, 1356]. Surface markers such
as ST2 (IL-33R), CD25, ICOS, or KLRG1 have also been com-
monly used to identify ILC2 [1353, 1357, 1358]. As previously
mentioned, expression of these markers slightly varies in different
compartments.
SI LP RORγt+ ILC3 can be dissected into three major subsets
according to NKp46 and CD4 expression (Figure 156), namely
CD4+ ILC3, which functionally and phenotypically resemble fetal
LTi and preferentially produce IL-17 and IL-22; NKp46+ ILC3,
which expand postnatally, co-express RORγt and T-bet and pro-
duce IL-22 and IFN-γ; and CD4− NKp46− ILC3, which actually
represent a heterogeneous population of CCR6+ cells (related
to LTi) and CCR6− ILC3, co-expressing RORγt and T-bet, sim-
ilar to NKp46+ ILC3 [1359–1361]. As it has been shown that
ILC3 can be plastic in vivo, and downregulate RORγt expression
while acquiring NK/ILC1-cell features such as T-bet expression
and IFN-γ production, the use of RORγt fate mapping (RORγtfm)
can be helpful to distinguish ex-ILC3 (RORγtfm+ RORγt− T-bet+)
from ILC1 [1361, 1362]. Although this distinction is conceptually
important, ex-ILC3 behave functionally similar to NK/ILC1 cells.
In humans, ILCs have been documented in several tissues and
in the circulation, although a larger characterization has been
performed in tonsils, where all ILC subsets have been described
Table 54. Selection of important markers for flow cytometry analysis of mouse and human ILC
Mouse Human
NK cells CD127+ ILC1 ILC2 NCR− ILC3 NCR+ ILC3 NK cells CD127+ ILC1 ILC2 NCR− ILC3 NCR+ ILC3
Marker
CD127 − + + + + lo/- + + + +
CD117 lo/- − + − lo lo/- − +/− + +
CD25 − lo + + ND +/− lo + +/− lo
IL-23R − lo/- ND + + lo +/− lo + +
IL-17RB − − + − − − lo/- + ND −
ST2 − − + − − − ND + ND −
IL-1R1 − lo ND + + +/− lo/- lo + +
CCR6 − − − +/− − − + + + +
RANKL lo/- ND ND + + − ND ND + +
CRTH2 ND ND ND ND ND − − + − −
ICOS − ND + ND + − − + ND +
NK1.1/CD161 + + − − lo/- +/lo + + + +
CD56 NA NA NA NA NA + − − +/− +/−
CD94 +/− ND +/− − +/− +/− − − − −
CD16 +/− ND − − − +/− − − − −
NKp30 NA NA NA NA NA + ND +/lo +/− +
NKp44 NA NA NA NA NA +a − − − +
NKp46 + + − − + + − − +/− +
Ly49/KIR +/− lo − − − +/− − − − −
CD57 NA NA NA NA NA +/− ND ND ND ND
CD27 +/− + − − − +/− + − − −
CD11b +/− − − ND ND +/− ND ND ND ND
Perforin + lo − − − + − − − −
Transcription factors
T-bet + + − +/− + + + − − −
Eomes + − − − + + − − − −
RORγt − − − + + − − − + +
GATA3 − lo + lo lo lo/- lo/- + lo/- lo/-
Cytokines
IFNγ + + -/lo -/lo -/lo + + − − −
IL-22 − − + + + − − lo lo/- +
IL-17 − − − +/− − − − − + −
IL-13 − − + − − lo − + − lo
IL-5 − − + − − − − + − −
+ Indicates high expression, - indicates no expression, +/− indicates bimodal expression, lo indicates low expression, a indicates expression on
activated cells, ND indicates not determined, and NA indicates not applicable according to published reports [1344–1347, 1350, 1353, 1354, 1356–
1365, 1367, 1374–1384]
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[1354, 1363–1365]. In tonsils, magnetic depletion of CD3+ T cells
and of CD19+ B cells is recommended for better detection of
ILCs, due to their low frequency. After pre-enrichment and fur-
ther gating on Lineage negative cells, staining of CD94 and CD127
enables the identification of NK cells, as CD94+/lo CD127neg/lo
CD56+ cells, which express high levels of T-bet and Eomes,
and of other ILCs enriched among Lin− CD127hi CD94− cells
(Fig. 157).
It has been proposed that staining of CD117 (the receptor for
stem cell factor, c-kit) and CRTH2 (prostaglandin D2 receptor
chemoattractant receptor-homologous molecule expressed on T
helper type 2 cells) facilitates identification of ILC3 and ILC2 in
tonsils [1366]. ILC3 are enriched among CD117+ CRTH2− cells
and express NKp44 and RORγt, while lacking T-bet and Eomes
[1365, 1367]. ILC2 are enriched among CD117−/lo CRTH2+ cells
and express GATA-3, while lacking T-bet and Eomes (Figure 157)
[1364, 1365]. Among Lin− CD127hi CD94− CD117− CRTH2−
cells, a population of ILC1 has been described that lacks NKp44
and CD56 and is enriched in the SI LP of patients affected with
inflammatory bowel diseases [1365]. This population displays
only low amount of T-bet protein expression (Figure 157). In line
with mouse data, additional populations of NK cells/ILC1 sub-
sets with different phenotypic characteristics have been described
in human tissues, including tonsils [1354, 1368–1371], making
the selection of markers for the identification of NK/ILC1 quite
challenging.
Recently, a human CD117+ NKp44− ILC subset was identified
in peripheral blood and in tissues that represents a “na¨ıve” ILC
precursor [1372]. This population was able to give rise to all ILC
subsets in vitro and in vivo and did not express signature transcrip-
tion factors associated with mature ILCs (T-bet, Eomes, GATA-3,
RORγt). Accordingly, CD117 staining on human ILCs should not
be equatedwith ILC3 identification but should additionally include
markers such as NKp44.
Notably, the resolution of transcription factor staining in
humans is not as good as in murine tissues and, therefore, com-
bined staining of the above-mentioned surface markers is highly
recommended in order to reliably gate on different human ILC
subsets. However, as for their murine ILC counterparts, tissue-
specific differences of surface markers should be taken into
account as it has been shown for expression of CRTH2 for lung
ILC2 [1373]. A selection of markers shown to be expressed by
human and/or mouse ILC subsets is depicted in Table 54 (see also
ref. [1342]).
5 Natural killer cells
5.1 Overview
NK cells represent a first fundamental line of defense against
tumors and virus infected cells. In this section, we describe
for both humans and mice, the most important strategies used
to isolate and identify their subpopulations in an unequivocal
manner.
Figure 158. Identification of NK cells in the blood and spleen of C57BL/6
mice. Whole blood (A) was stained in BD Trucount tubes and analyzed
after red blood cell lysis. Lymphocytes were gated among CD45+ leu-
cocytes based on their morphology and, after exclusion of CD3+ T cells
and CD19+ B cells, NK cells were gated as NK1.1+NKp46+ cells. For the
analysis of spleen NK cells (B), due to extraction techniques, doublets
and dead cells need to be gated out. CD3+ T cells and CD19+ B cells
were excluded and NK cells were gated as NK1.1+NKp46+ splenocytes.
5.2 Murine NK cells
5.2.1 Introduction. Mouse NK cells are commonly identified by
FCM by the expression of the surface markers NK1.1, NKp46, and
CD49b. The lack of expression of the T cell marker CD3 is used to
exclude from the NK cell gate contaminating T cell subsets, such
as NKT cells and NK-like T cells, that express NK1.1 and NKp46
respectively [1385]. In blood and spleen NK cells represent the
most abundant innate lymphoid cell (ILC) subset, and the expres-
sion of NKp46 and NK1.1 is sufficient to identify them (Fig. 158).
However, these NK markers vary depending on the mouse strain.
NK cells from C57B/6 and SJL mice can be identified by NK1.1
expression, while in other mouse strains, such as BALB/c, NK
cells display no reaction to the widely used anti-NK1.1 Ab PK136,
because of allelic variations in Nkrp1b and Nkrp1c [1386]. In this
case, NK cells can be identified only with CD49b and NKp46.
Even if mouse NK cells share many characteristics with human
NK cells, it is not easy to identify functionally comparable NK cell
subpopulations in the two species. Indeed, mouse NK cells lack
the expression of human NK cell surface markers, including CD56
and some activating and inhibitory receptors. Murine NK cells lack
KIRs, but express structurally divergent lectin-like Ly49 receptors
that are functionally equivalent to the human KIRs and recognize
MHC class I molecules. Most mouse Ly49 receptors recognize the
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Table 55. Human- and mouse-specific and shared NK cell receptors
Receptor Ligand Human Mouse
KIR2DL1 (CD158a) Group 2 HLA-C X
KIR2DL2, KIR2DL3 (CD158b1,
-b2)
Group 1 HLA-C, some group 2 HLA-C and some HLA-B X
KIR3DL1 (CD158e1) HLA-Bw4 X
KIR2DS1 (CD158h) HLA-C2 X
KIR2DS4 (CD158i) Some HLA-C1 and HLA-C2, HLA-A11 X
KIR2DL4 (CD158d) HLA-G X
Ly49A (Klra1) H2-Dd, H2-Dk, H2-Ld, H2-Db, H2-Kb, H2-Dp, H2-M3 X
Ly49C (Klra3) H2-Db, H2-Kb, H2-Dd, H2-Kd, H2-Dk X
Ly49E (Klra5) Urokinase plasminogen X
Ly49G (Klra7) H2-Dd, H2-Kd, H2-Ld, H2-Db, H2-Dk, H2-Dr X
Ly49I (Klra9) H2-Kb, H2-Kd, H2-Dk, H2-Kk, m157 (MCMV) X
Ly49D (Klra4) H2-Dd, H2-Dr, Dsp2 X
Ly49H (Klra8) m157 (MCMV) X
Ly49P (Klra16) H2-Dd, H2-Dk, m04 (MCMV) X
NKG2A (CD159A)/CD94 HLA-E (human), Qa-1b (mouse) X X
NKG2C (CD159C)/CD94, HLA-E (human), Qa-1b (mouse) X X
NKG2D (CD314) Human: MICA/B, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6
Mouse: RAE-1a, RAE-1b, RAE-1d, RAE-1e, RAE-1g, H60a, H60b,
H60c, MULT1
X X
KLRG1 E-, N-, and R-cadherin X X
NKp46 (NCR1; CD335) CFP (properdin), hemagglutinin, PfEMP1 X X
NKp30 (NCR3; CD337) B7-H6, BAT3 X
NKp44 (NCR2; CD336) 21spe-MLL5 X
NKp80 (KLRF1) AICL (activation-induced C-type lectin) X
DNAM-1 (CD226) Nectin-2, PVR X X
2B4 (CD244) CD48 X X
classical MHC class I molecules H2-K and –D/L, while Ly49H and
Ly49I recognize the MHC class I-related m157 molecule encoded
by cytomegalovirus (CMV). The CD94/NKG2 heterodimer is con-
served between mouse and human and, in mice, it recognizes the
non-polymorphic Qa-1. The activating receptor NKG2D is also con-
served between the species, and it is triggered by stress-induced
MHC class I-related ligands retinoic acid early inducible (RAE)-1
and, in mice, the minor histocompatibility complex H60. Among
the natural cytotoxicity receptors (NCRs), NKp30, and NKp44 are
not expressed in mice, while NKp46 is considered to be the most
specific NK cell marker, as it is expressed by all NK cells in mam-
mals (Table 55) [1385].
Analogously to human NK cells for which the levels of CD56
and CD16 expression are used to define the maturation from
immature CD56bright CD16− NK cells to mature CD56dim CD16+
cells [1387], CD27 and CD11b expressions are used to iden-
tify several murine NK cell maturation steps. Immature NK cells
are CD11blow CD27high, then they mature into double-positive
CD27+CD11b+ cells and, finally, into fully mature CD27low
CD11bhigh NK cells (Table 56). This developmental program
is associated with the acquisition of NK cell effector functions
[1376]. Both CD27+ and CD27− subsets express equivalent lev-
els of activating Ly49 receptors and CD94/NKG2 receptors, but
CD27− NK cells contain higher levels of inhibitory Ly49s.
Recently, using high-throughput single-cell-RNA-seq, the gene
expression of human and murine NK cells from spleen and blood
was analyzed at the single cell level. In this study, two major
NK cell subsets transcriptionally similar across organ and species
were identified: it was shown a correspondence between the
CD27−CD11b+ and the CD27+CD11b− mouse NK cell subsets
and the CD56dim and CD56bright human NK cell subsets, respec-
tively [1388]. Moreover, this study revealed spleen- and blood-
specific NK cell signatures common in both species, highlighting
the importance of the organ of origin in the definition of a cell
population.
While in blood and spleen NK cells represent the most abun-
dant ILC subset, in tissues, there are high proportions of the other
ILCs subsets, which are largely tissue-resident. CD127 is classi-
cally used to identify ILCs and distinguish them from NK cells,
as it is not expressed by NK cells of liver, intestine, skin, uterus,
salivary gland, bone marrow, or lymph nodes. However, CD127
is expressed by NK cells in the thymus and in some spleen pop-
ulations, and it is not expressed by liver and intraepithelial gut
ILC1s. Thus, the phenotypic characterization of tissue-resident NK
cells is more complicated and requires the analysis of additional
markers. In particular, NK cells share many features with ILC1s,
they both produce IFN-γ as the main cytokine and require Tbet
for this function. However, while NK cells require Eomes for their
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Figure 159. Identification of liver NK
cells in C57BL/6 mice. After Percoll
density gradient centrifugation of sin-
gle cell suspension obtained scratch-
ing the liver, lymphocytes were ana-
lyzed. Doublets, dead cells, CD45−
cells, CD3+ T cells, and CD19+ B cells
were sequentially excluded. Among
NK1.1+NKp46+ cells NK cellswere gated
as CD49b+CD49a− cells, and distin-
guished from CD49b−CD49a+ ILC1s.
development process, ILC1s develop in the absence of this tran-
scription factor. Moreover, ILC1s are generally noncytotoxic and
express lower levels of perforin compared to NK cells [1342].
Regardless these developmental and functional differences, ILC1s
have some phenotypic markers in common with NK cells (see
Chapter VI Section 4 Innate lymphoid cells), including NK1.1 in
mice and NKp46 in both humans and mice. In the liver, for exam-
ple, to distinguish these two populations, it is useful to include
additional markers such as CD49b, exclusively expressed by NK
cells in mice, and CD49a and TRAIL, preferentially expressed by
ILC1s in both humans and mice (Fig. 159). Recently, CD200R has
been shown to be an additional marker to distinguish ILC1s from
NK cells in mice (Table 56) [1389].
In addition to ILC1s, NK cells share the expression of some
markers with ILC3s. In mice ILC3s are dependent on RORγt for
their development and function [1381] and two subsets can be
distinguished on the basis of NKp46 expression: NCR+ and NCR−
ILC3s. As NK cells and NCR+ ILC3s both express NKp46, the analy-
sis of the expression of the transcription factors RORγt and Eomes
can be useful to distinguish them (Figure 160, See also Chapter
VI Section 4 Innate lymphoid cells).
Unlike NK cells, ILC2s are characterized by the capacity to
produce type 2 cytokines. They contain larger amounts of the
transcription factor GATA3 compared to the other ILC subsets but
upon activation can express high levels of KLRG1, an inhibitory
receptor also expressed by mature NK cells [1390].
For the identification and distinction of NK cells from other
ILCs by FCM, it must be considered that, like T helper cell sub-
sets, ILC subsets also display a certain degree of plasticity. For
example, fate mapping and adoptive transfer studies in mice have
shown that gut CCR6−NKp46− ILC3s can convert into IFN-γ pro-
ducing NK1.1+NKp46+ ILC1s via a CCR6−NKp46+ intermediate
through a decrease in RORγt expression and parallel increase in
Tbet [1362, 1391].
5.2.2 Step-by step sample preparation. Cell isolation: Spleens
and livers were scratched through 70 and 100 µm cell strainers,
respectively. Liver lymphocytes were isolated on a 37.5–67.5%
Percoll gradient. For isolation of small intestine lamina propria
cells, intestines were cut longitudinally, then transversally in 2–3
cm pieces, thoroughly rinsed with PBS, and shaken for 30 min
in PBS containing 10% FBS, 15 mM Hepes and 5 mM EDTA to
remove intraepithelial and epithelial cells. Intestines were then
digested with collagenase VIII (300 UI/mL) in complete RPMI for
45 min at 37°C under agitation, and lamina propria lymphocytes
were isolated on a 40–100% Percoll gradient. Whole blood was
analyzed using BD Trucount tubes according to themanufacturer’s
instructions (BD Biosciences) [1392].
5.2.3 Materials. The following Abs were used and/or are sug-
gested for the surface and intracellular staining of mouse NK cells:
BD Biosciences: CD45.2 AlexaFluor700 (1:200, clone 104), CD3
PE CF594 (1:100, clone 145-2C11), CD19 PE CF594 (1:200,
clone 1D3), NK1.1 BV510 (1:50, clone PK136), CD49a Alex-
aFluor647 (1:400, clone Ha31/8), CD11b BV510 (1:400, clone
M1/70), NKp46 BV421 (1:50, clone 29A1.4), TCRb FITC
(1:400, clone H57-597), granzyme B PE (1:50, clone GB11),
Rorγt PE (1:100, clone Q31-378), CD107a FITC (1:60, clone
1D4B), Fc block CD16/CD32 (1:200, clone 24G2);
eBiosciences: NKp46 PerCP-eFluor710 (1:50, clone 29A1.4),
CD49b PE-Cy7 (1:200, clone DX5), Eomes APC (1:100,
Dan11mag);
Biolegend: IFN-g BV421 (1:100, clone XMG1.2), CD19 APC-Cy7
(1:200, clone 6D5), NKp46 APC (1:50, clone 29A1.4), NK1.1
PE-Cy7 (1:50, clone PK136), CD3 FITC (1:100, clone 145-
2C11), CD19 FITC (1:100, clone 6D5).
Dead cells were identified using the fixable blue dead cell stain
kit (Invitrogen). For surface staining cells, Abs were diluted in
PBS 5 mM EDTA (Euroclone). For intracellular staining, cells were
fixed and permeabilized with an intracellular staining kit (eBio-
science). Flow cytometric data were acquired with a BD LSR II flow
cytometer equipped with FACS DIVA software (BD Biosciences),
and analyzed by using FlowJo software (FlowKo, LLC).
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Figure 160. Identification of small intestine
lamina propria NK cells in C57BL/6 mice.
After enzymatic digestion and Percoll density
gradient centifugation, single cell suspension
obtained from the small intestine was anal-
ysed. As in figure 159, doublets, dead cells,
CD45− and CD19+ B cells were sequentially
excluded. T cells were gated out based on their
expression of TCRβ. RORγt+ cells represent
ILC3s, which can be further distinguished in
NCR+ and NCR− ILC3s. Among RORγt− NKp46+
cells, NK cells are gated as NK1.1+Eomes+ cells.
Table 56. Key markers for murine NK cell identification and
characterization
Marker Expression
NK lineage
NK1.1 (CD161) Surface
NKp46 (NCR1; CD335) surface
CD49b Surface
T-bet Nucleus
Distintion from other ILCs
IL7Rα (CD127) Surface, ILC1, ILC2, ILC3
CD49a Surface, ILC1
CD200R Surface, ILC1
TRAIL Surface, ILC1
Eomes Nucleus, NK cells
Rorγt Nucleus, ILC3
Development/ maturation stages
CD27 Surface, immature NK cells
CD11b (Mac-1/CD18) Surface, mature NK cells
KLRG1 Surface, mature NK cells
CD43 Surface, mature NK cells
CXCR6 Surface, “memory” NK cells
in the liver
5.2.4 Pitfalls. When including CD11b in cytometry panels to
exclude myeloid cells from the analysis, it must be taken into
account that mature murine NK cells express this marker too.
Therefore, one must check carefully that NK1.1+ and/or NKp46+
CD11b+ cells do not get excluded in the associated gating strategy.
5.3 Human NK cells
5.3.1 Introduction. Natural killer (NK) cells were described over
40 years ago as cells capable of killing tumor cells without prior
sensitization. They are lymphoid cells derived from hemopoietic
stem cells (HSCs) [1393, 1394] and belong to the innate immu-
nity cell family. In contrast to T and B cells, NK cells do not
express receptors encoded by rearranging genes and they play
a major role in innate immunity as both effector and regulatory
cells, participating in the first line of defense against pathogens
and tumors. Notably, NK-cell-susceptible tumors are primarily
those lacking or expressing insufficient amounts of MHC class I
molecules (missing-self hypothesis) [1395]. Another requirement
for NK-cell-mediated tumor cell killing is the surface expression
of a series of different stress-induced structures [1396]. The NK
cell function appears to complement the cytolytic T cell–mediated
MHC-I-dependent activity [1397].
The recognition ofMHC class-I is mediated by a family of recep-
tors termed Killer Ig-like receptors (KIRs), by the NKG2A/CD94
heterodimer and by LIR-1 (CD85j). In particular, NKG2A/CD94,
expressed early during the process of NK cell maturation, rec-
ognizes the nonclassical HLA-E molecule [1398, 1399] while
KIRs, expressed at later stages of NK cell maturation, recognize
allelic determinants of HLA-A -B or -C [1400, 1401]. Other non-
HLA-related inhibitory receptors including Siglec7 (CD328), PD1
(CD279), and IRP60 (CD300a) may be expressed at the surface
of NK cells (see Tables 57 and 58). In most instances, the NK
receptors that mediate their activation upon binding to target cells
are non-HLA-specific and recognize cell stress-induced molecules.
These receptors include NKp30, NKp44, and NKp46 (which consti-
tute the natural cytotoxicity [NCR] family), NKp80, 2B4 (CD244),
and NKG2D [1402–1404]. Of note, activating isoforms of KIRs also
exist [1405]. While inhibitory KIRs are characterized by immune-
receptor tyrosine-based inhibition motif (ITIM) domains in their
long intracytoplasmic tail, the various activating receptors bear
a short intracytoplasmic tail and are associated with signaling
polypeptides containing immune-receptor tyrosine-based activat-
ing motifs (ITAM) domains [1406]. A fundamental activating
receptor is also CD16, the low affinity Fcγ receptor, which bind-
ing to IgG complexes mediates the Ab-dependent cell-cytotoxicity
(ADCC). In resting conditions, the bright expression of CD16 is
restricted to mature NK cells.
Among peripheral NK cells, two major subsets have been
identified on the basis of the cell surface density of CD56
molecules (neural cell adhesion molecule, N-CAM). CD56bright
(CD3−CD56++CD16−/+) represent approximately 10% of the
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1746 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
Figure 161. In this PB samples, lymphocytes are first gated based on their physical parameters (upper left grey dot plot) then human NK cells can
be identified for their CD56 surface expression and lack of CD3. The CD56bright NK subpopulation (in blue) is positive for NKG2A, negative for KIRs
and CD57 while CD16 can be either negative or dimly expressed (as shown). NKG2A and KIR surface expression allows three subpopulations of
CD56dim NK cells (in red), namely “maturing” (NKG2A+KIR− in dark red), “double positive” (NKG2A+KIR+ in dark red) and “mature” (NKG2A−KIR+
in light red), to be identified. To discriminate among these CD56dim maturation steps, we used a cocktail of anti-KIR (clones: EB6B, GL183, Z27) that
did not include anti-LIR1, for this reason in the dot plot also a double negative population is present. Among the mature population (in light red),
CD57 molecule is expressed on the, so called, “terminally differentiated” NK cells. In CMV positive donors, a percentage of this latter population
could also express NKG2C representing the so called “memory NK cells.” Recently it has been demonstrated that in some CMV positive individuals
a fraction of the NKG2C subset can also express PD1. Percentage of subpopulation are not specified because they are extremely diverse among
different individuals and do not give additional information to the gate strategy.
circulating PB NK cells while they prevail in secondary lym-
phoid organs (liver, synovial fluid and decidua). CD56dim
(CD3−CD56+/− CD16++) cells are largely predominant (90%)
in PB NK cells. They derive from CD56bright NK cells, as revealed
by different studies in vitro (differentiation from HSC) and in vivo
after HSC transplantation [1407, 1408]. Moreover, the existence
of a third NK cell population totally lacking CD56 has been widely
demonstrated both on virus infected patients and, more rarely,
on healthy donors. This population is characterized by a reduced
expression of NCRs and, in in vitro studies, by a poor cytotoxic
activity [1409–1412].
5.3.2 CD56bright NK cells. In resting conditions all CD56bright, in
contrast to CD56dim, NK cells are poorly cytolytic but secrete
cytokines, primarily IFN-γ and TNF-α and express both high
(CD25) and intermediate (CD122/CD132) affinity IL-2 receptors
and c-Kit (CD117), rendering them highly susceptible to IL-2–
induced cell proliferation [1413, 1414]. Moreover, CD56bright NK
cells express high levels of both CD62L [1415] and CXCR3 which,
together with the surface expression of CCR7, dictates their pref-
erential homing into secondary lymphoid organs [1416–1418]
Notably, although poorly cytotoxic under resting conditions,
CD56bright NK cells may acquire cytolytic activity comparable to
that of CD56dim cells upon stimulation with cytokines, such as IL-
2, IL-12, IL-15. While CD56bright NK cells express CD94/NKG2A
(i.e., the receptor for HLA-E) they lack KIRs. Regarding activating
NK receptors, CD56bright cells express higher levels of NKp46 and
NKp30 than CD56dim cells, while CD56bright cells lack or express
low amounts of CD16.
5.3.3 CD56dim NK cells. CD56dim NK cells under resting condi-
tions express granules containing perforin and granzymes, and
display cytolytic activity. Until recently, CD56dim NK cells were
mainly associated with cytotoxicity while cytokine production was
thought to be confined to the CD56bright subset. However, more
recently, it has been shown that, upon stimulation via activating
receptors, CD56dim NK cells rapidly release cytokines such as IFN-
γ- and TNF-α (even more efficiently than CD56bright cells) and
chemokines such as MIP-1β and MIP-1α [1419, 1420]. In contrast
to CD56bright NK cells, the CD56dim population is phenotypically
heterogeneous. Thus, as shown in Fig. 161, NKG2A versus KIR
expression allows identification of three distinct subset of human
NK cells that recapitulate the consecutive steps of PB NK cell mat-
uration to be distinguished.
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Table 57. Human NK cell inhibitory and activating receptors
Receptor Ligand CD56bright CD56dim
Activation
NKG2C (CD159a) HLA-E − Subsets
NKG2D (CD314) MIC-A - MIC-B - ULPBs All PB NK cells
KIR2DS1 (CD158h) HLA-C2 − Subsets
KIR2DS2/3 (CD158j) ??? − Subsets
KIR2DL4 (CD158d) HLA-G − Subsets
KIR2DS4 (CD158i) HLA-A*11 and some HLA-C − Subsets
KIR2DS5 (CD158f) ??? − Subsets
KIR3DS1 (CD158e1) HLA-Bw4, HLA-F − Subsets
NKp30 (CD337) B7-H6 - BAG6/BAT3 ++ +
NKp44 (CD336) 21spe-MLL5, Nidogen 1 On activated NK cells
NKp46 (CD335) CFP (properdin), haemagglutinin,
PfEMP1
++ +
NKp80 AICL + +
DNAM1 (CD226) Nectin-2 (CD112), PVR (CD155) + +
2B4 (CD244) CD48 All PB NK cells
NTB-A (CD352) NTB-A (CD352) All PB NK cells
CRACC/CS1 (CD319) CRACC/CS1 (CD319) All PB NK cells
Tactile (CD96) PVR (CD155) All PB NK cells
FcγRIII (CD16) IgG −/+ +/++
Inhibition
NKG2A/KLRD1 (CD159a/CD94) HLA-E + Subsets
KIR2DL1 (CD158a) HLA-C2 − Subsets
KIR2DL2/3 (CD158b) HLA-C1, few HLA-C2 − Subsets
KIR2DL4 (CD158d) HLA-G − Subsets
KIR2DL5 (CD158f) ??? − Subsets
KIR3DL1 (CD158e1) HLA-A-Bw4 and HLA-B-Bw4 − Subsets
KIR3DL2 (CD158k) HLA-A*03 and *11 − Subsets
ILT2/LIR-1 (CD85J) Different MHC-I alles − Subsets
PD-1 (CD279) PDL1 (CD274) and PDL2 (CD273) − Subsets
Siglec-7 (CD328) Ganglioside DSGb5 Most of PB
NK cells
IRP60 (CD300a) α-herpes virus
Pseudorabide virus
Phosphatidylserine
Phosphatidylethnolamine
+ +
TIGIT PVR (CD155) PB NK cells
The “maturing” population (NKG2A+KIR−) is characterized by
the NKG2A+/KIR− phenotype, similar to that of CD56bright cells,
while the “mature” population expresses the NKG2A−KIR+ phe-
notype. An intermediate step of maturation is identified by the
“double positive” NKG2A+KIR+ cells [1377, 1387]. The unidirec-
tional nature of NK cell differentiation is further supported by
the presence of CD57 on the surface of the “terminally differenti-
ated” NK subset. When compared with the CD57-negative coun-
terpart, the NKG2A−KIR+CD57+ population shows a decreased
surface expression of NKp30 and NKp46, and a reduced prolifera-
tive potential, possibly as the result of downmodulation of IL-2Rβ
(CD122) and IL-18Rα (CD218a) [1377, 1379].
In CMV-positive healthy donors, it is possible to identify an
additional subset of mature cells that expresses CD57 and the
activating HLA-E-specific receptor NKG2C dimerizing with CD94
[1421]. This subset appears to contain cells endowed with an
adaptive/memory-like capability (i.e., clonal expansion, prompt
response to restimulation, and epigenetic modification including
that of the intracytoplasmic FcεRγ chain) [1411, 1422, 1423].
Recent data have shown that, in CMV positive individuals, a frac-
tion of CD57 positive cells may also express PD-1 [1412].
The recruitment of CD56dim NK cells to inflamed peripheral tis-
sues is driven by several chemokines and homing receptors includ-
ing, for example, CXCR1, CX3CR1, and in certain subsets CD62L
and CXCR3low also [1416].
5.3.4 NK cells present in decidua. During the first trimester of
pregnancy, NK cells represent the main lymphoid population (50–
70%) in human decidua where they bear a unique phenotypic
and functional profile. Their phenotypic features resemble to an
extent those of CD56bright PB NK cells; however, in addition to
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1748 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
Table 58. Other human NK cell receptors
Receptor Ligand CD56bright CD56dim
Adhesion
LFA-1 (CD11a/CD18) ICAM-1, ICAM-2, ICAM-3 −/+ ++
LFA-2 (CD2) CD15, CD58, CD59 Most of mature NK cells
LFA-3 (CD58) CD2, CD48, CD58 Most of mature NK cells
MAC-1 (CD11b/CD18) iC3b, C4b, ICAM-1, fibrinogen Most of circulating NK,
up-regulated upon activation
ICAM-1 (CD54) LFA-1, MAC-1 ++ +/−
N-CAM (CD56) ???, FGFR ++ +
HNK-1 (CD57) ??? − Subsets
L-Selectin (CD62L) GLyCAM-1 MadCAM-1 ++ Subsets
Cytokine /Chemokine receptors
IL-2Rα (CD25) IL-2 + −
IL-2Rβ/IL-2Rγ (CD122/CD132) IL-2 AND IL.15 Almost all PB NK cells
c-Kit (CD117) SCF (KL) + −
IL7Rα (CD127) IL-7 + −
CXCR1 (CD181) CXCL8 (IL-8) − +
CXCR2 IL8-RB − +
CXCR3 (CD183) CXCL9, CXCL10, CXCL11 ++ Subsets
CXCR4 (CD184) CXCL2 Subsets of PB NK cells
CCR5 (CD195) RANTES, CCL3 (MIP1α) and CCL4
(MIP1β)
Subsets of PB NK cells
CCR7 (CD197) CCL19, CCL21 + −
IL-18R (CD218a) IL-18 ++ +
ChemR23 Chemerin − +
CX3CR1 Fraktaline − +
Death Receptors
Fas/APO-1 (CD95) Fas ligand (CD95L) Activated NK cells
They induce target apoptosis
Fas ligand (CD95L) Fas/APO-1 (CD95)
CD40L (CD154) CD40
TRAIL (CD253) DR4 (TRAIL-R1), DR5 (TRAIL-R2)
Other surface molecules
LAMP1 (CD107a) — Briefly expressed on NK cell
surface after degranulation
LAMP2 (CD107b) —
LAMP3 (CD63) —
TNFRSF7 (CD27) CD70 + −
the NKG2AhighNKp30highNKp46high surface phenotype, they also
display characteristics of CD56dim NK cells including high expres-
sion of KIR and lytic granules. Of note, in contrast to PB NK
cells, the 2B4 (CD244) receptor on decidual NK cells displays
a strong inhibitory (and not activating) activity, similar to that
seen in NK cell precursors [1424], that renders this population
poorly cytolytic [1425, 1426] [Moreover, in contrast to PB NK
cells, decidual NK cells release a unique set of cytokines, includ-
ing IL-8 (CXCL8), VEGF, CXCL12 (stromal-derived factor–1 [SDF-
1α]), and IFN-γ–inducing protein 10 (IP-10, CXCL10), that play
a pivotal role in tissue remodeling (i.e., placenta development
processes) and neo-angiogenesis [1427].
5.3.5 NK cells present in lymph nodes. In normal conditions, NK
cells are present in lymph nodes where they occupy the T-cell
areas [1428]. They are consistently CD56brightCD16negKIRneg and
lack perforin and granzymes. In contrast to PB CD56bright NK cells,
lymph node NK cells do not express CCR7 or CD62L. Concerning
the NCR family, lymph node NK cells express low levels of NKp46
and may lack NKp30. Remarkably, however, upon IL-2 activation,
lymph node NK cells may express KIRs and CD16, and upregulate
NCR [1428, 1429].
5.3.6 Step-by-step sample preparation. PB NK cell surface stain-
ing:
1. Put 100 µL of heparinized whole blood in a sample tube
2. Add 50 µL of Brilliant Stain Buffer to each tube
3. (a) To study PB subpopulations, add the following antibodies:
CD158a FITC (10 µL) CD158b FITC (10 µL), CD158e FITC
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Figure 162. Flow cytometric analysis of mouse blood DCs and monocytes. Example for basic gating strategy from FSC-A/SSC-A, over doublet
exclusion and gating on Live, CD45+ LIN− cells (defined as CD3/CD19/CD49b/Ly6G−) on a blood sample (A), as used for all tissues. Conventional
DCs are identified as CD11chiMHCII+ cells and can be divided into cDC1 (CD8/CD24+CD11b−, red gates) and cDC2 (CD8−CD11b+, blue gates) (B).
Plasmacytoid DCs are identified as CD11cintSiglecH+ and can be further purified by gating on B220+mPDCA-1+ cells (pink gates; C). Monocytes are
identified as CD115+CD11b+ cells and can be further divided into Ly6Clo and Ly6Chi monocytes (blue and red gates, respectivley; D).
(5 µL), CD279 PE (10 µL), CD159a PE-Cy7 (3 µL), NKG2C
A700 (3 µL), CD3 APC-A750 (3 µL), CD57 BV421 (3 µL),
CD16 BV510 (3 µL), CD56 BV650 (3 µL).
(b) To study only NKG2C/PD1 co-expression this simpler
cocktail can be used: NKG2C VioBright FITC, CD279 PE
(10 µL), CD56 PC7 (3 µL) CD3 APC-A750 (3 µL).
4. Incubate 20 min at 4°C.
5. After incubation, lyse sample in 2 mL of Pharm LyseTM, for 5–8
min
6. Centrifuge 5 min at 1300 rpm
7. Discard supernatant
8. Resuspended in 300 µL of PBS for acquisition.
5.3.7 Materials. Pharm LyseTM and Brilliant Stain buffer are
from Becton Dickinson (San Jose`, CA), PBS is from (Sigma–
Aldrich).
Beckman Coulter: CD3 APC or APC-Alexa Fluor 750 (UCHT1,
IgG1), CD56 PC7 (N901), CD158a PE (EB6B, IgG1), CD158b
PE (GL183), CD158e FITC or PE (Z27, IgG2a), CD159a PE-Cy7
(Z199 IgG2b), NKp30 (Z25, IgG1), NKp44 (Z231, IgG1) NKp46
(BAB281, IgG1), NKp80 (MA152, IgG1) NKG2D (ON72, IgG1).
Becton Dickinson: CD16 BV510 (3G8, IgG1), CD56 BV650
(NCAM16.2, IgG2b), CD57 BV421 (NK-1, IgM), CD158b (CH-L,
IgG2b).
Miltenyi: PD1 PE (PD1.3.1.3, IgG1), NKG2C VioBright FITC
(REA205, Ig1).
R&D System: NKG2C Alexa Fluor 700 (134591, IgG2a).
Flow cytometric data were acquired with a BD LSR II
flow cytometer equipped with FACS DIVA software (BD Bio-
sciences), and analyzed by using Kaluza software (Beckman
Coulter).
5.3.8 Top Tricks. When using many different Brilliant Violet flu-
orochromes in the same sample, in order to avoid aspecific inter-
actions between these polymer dyes, it is better to add always
Brilliant Stain Buffer to the sample before adding the conjugated
mAbs.
While for PD1 detection in human T cells most of commercial
mAb clones are equally good, when working with human NK cells
the situation is totally different. In our experience, the best clone
to discriminate PD1 positive NK cells is PD1.3.1.3 conjugated with
PE.
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6 Mononuclear phagocytes: Monocytes,
macrophages, and dendritic cells
6.1 Overview
This chapter aims to provide basic guidelines for researchers inter-
ested in analyzing mononuclear phagocytes that include mono-
cytes, macrophages, and dendritic cells. We describe here process-
ing and FCM-staining techniques for various murine and human
tissues such as blood, bone marrow, spleen, lung, skin, intestine,
or lymph nodes. Furthermore, this chapter provides basic gating
strategies as well as tips and tricks and background information for
each tissue in order to easily identify the various subpopulations
of monocytes, macrophages, and dendritic cells.
6.2 Introduction
Both mouse and human lymphoid and non-lymphoid tissues con-
tain a high number of mononuclear phagocytes, innate myeloid
cells that play crucial roles in homeostasis as well as host–pathogen
interactions. This pool is composed of monocytes, macrophages,
and dendritic cells (DCs). Ontogeny, heterogeneity and specific
functions of these cells have been extensively described in various
recent reviews (e.g., [1430–1435]).
Briefly, the murine DC compartment is currently divided into
classical DCs (cDCs) and plasmacytoid DCs (pDCs), with cDCs
being further subdivided into cDC1 (CD11b− CD8+ in lymphoid
tissues or CD11b− CD103+ in non-lymphoid tissues) or cDC2
(CD8/CD103− CD11b+SIRPα+ cells) [1433, 1436, 1437] (Table
60). While all cDCs express high levels of CD11c and MHCII across
tissues, pDCs are rather CD11cint cells that are characterized by the
expression of markers such as SiglecH, B220, and mPDCA-1, while
lacking expression of CD11b. Note that the dendritic cell nature of
pDCs is currently being challenged as recent studies have reported
that pDCs arise rather from a lymphoid lineage [1438–1440].
Langerhans cells (LCs) are epidermal-specific antigen presenting
cells that were originally classified as members of the DC family
as they express CD11c, CD11b, and MHCII and shown to migrate
to lymphoid organs. However, LCs were shown to be more of
fetal macrophage origin, hence, these cells are now rather classi-
fied as the resident macrophages of the epidermis [1441–1443].
Monocytes are also heterogeneous and have been categorized into
two subsets: inflammatory CXCR1hiCCR2−CD62L−CD43hiLy6Clo
and patrolling CX3CR1intCCR2+CD62L+CD43loLy6Chi monocytes
[1444, 1445]. Ly6ChiMHCIIlo monocytes recruited in tissues
in steady state continually differentiate into Ly6CloMHCIIhi
macrophages, a phenomon referred to as the monocyte to
macrophage “waterfall,” mostly described in the gut and skin
[1446, 1447].
Human mononuclear phagocytes also include cDCs, namely
CD1c+ cDC2 and CLEC9A+XCR1+CADM1+CD141+ cDC1;
CD123+ pDCs; monocyte-derived cells (termed CD14+ cells here)
and tissue-resident macrophages [1431, 1448, 1449]. We have
recently described cDC progenitors in the blood, namely pre-
DC [1450], that were previously included into the classic HLA-
DR+CD123+ pDC gate. Similar to mouse, in humans, mono-
cytes can be distinguished into CD14hiCD16− classical versus
CD14loCD16+ non-classical monocytes [1451], that are the equiv-
alent of the inflammatory CXCR1hiCCR2−CD62L−CD43hiLy6Clo
and patroling CX3CR1intCCR2+CD62L+CD43loLy6Chi monocytes,
respectively, with an additional minor population of CD14+CD16+
intermediate monocytes.
The efficient processing of both mouse and human tis-
sues is highly valuable to properly characterize tissue-associated
mononuclear phagocytes in steady state or inflammation. Here,
we explain techniques for the enrichment and FCM-based identifi-
cation of all mononuclear phagocyte populations across a number
of mouse and human tissues.
6.3 Materials
6.3.1 Mouse tissue processing materials.
6.3.1.1 General reagents and materials.
Reagent Manufacturer
Catalog
number
Bovine Serum Albumin,
lyophilized powder
(BSA)
Sigma–Aldrich A2058
Collagenase IV Sigma C5138
DAPI Life Technologies D1306
Dispase Gibco 17105041
DNase I Roche 10104159001
Dulbecco’s Phosphate
Buffered Saline (PBS)
Dithiothreitol (DTT) Gold Biotechnology DTT50
Foetal Bovine Serum
(FBS)
Serana S-FBS-SA-015
n-mouse serum Sigma-Aldrich M5905-10ML
n-rat serum Sigma-Aldrich R9759-10ML
1× RBC Lysis Buffer eBioscience 00-4333-57
RPMI 1640 HyClone SH30255.01
Prepare:
 RPMI 1640 containing 10% FBS (or FCS)
 FCM buffer: 0.5% w/v BSA + 2 mM EDTA in 1X PBS
 FCM staining buffer (as used for indicated tissues): 1% n-mouse
serum + 1% n-rat serum in FCM buffer
 Digestion buffer (solution 1): 0.2 mg/ml collagenase IV + 0.03
mg/ml DNase I in RPMI + 10% FBS/FCS
 Fine scissors and forceps/tweezers
 5 mL FCM tubes, round bottom, polystyrene
 Six-well/12-well plates for harvesting tissues/digestion of tis-
sues
 15 mL/50 mL conical tubes
 70 µm cell strainer
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6.3.1.2 Additional materials for mouse bone marrow processing.
 25 G needles and 20 mL syringes to flush bone marrow
6.3.1.3 Additional materials for mouse lung processing.
 70 µm nylon mesh sheet—cut into approximately 1 × 1 cm
squares
 18 G blunt needles and 3 mL syringes for dissociation
6.3.1.4 Additional reagents and materials for mouse intestine
processing.
 Six-well plates: one well per mouse for harvesting; one well per
mouse for digestion of small intestine and one well per mouse
for digestion of large intestine
 Beaker of cold PBS (keep on ice)
 Metal trays or petri dishes for various washing steps
 Three 50 mL centrifuge tubes for each small intestine and colon
sample (four if the epithelial compartment is to be isolated for
analysis as well)
 Epithelium dissociation solution (50 mM EDTA + 100 µL 20
mM DTT in PBS)
 Digestion solution 1 (0.2 mg/mL collagenase IV, 0.03 mg/mL
DNase in RPMI + 10% FCS)
 Digestion solution 2 (0.4 mg/mL collagenase IV, 0.03 mg/mL
DNase in RPMI + 10% FCS)
 70 µm cell strainers
 Percoll* (see * in chapter)
6.3.1.5 Additional reagents and materials for mouse skin (ears)
processing.
 Dispase solution (4 U/mL in RPMI 1640)
 Six-well plate for Dispase incubation
 12-well plate for digestion incubation
 Digestion solution 1 (0.2 mg/mL collagenase IV, 0.03 mg/mL
DNase in RPMI + 10% FCS)
 Flat clean surface for separating dorsal and ventral halves, and
epidermis from dermis
 70 µm nylon mesh sheet—cut into approximately 6 × 6 cm
squares
6.3.1.6 Additional reagents for mouse lymph node (LN) process-
ing.
 Digestion solution 3: 0.4 mg/mL collagenase IV + 0.06 mg/mL
DNase I in RPMI + 10% FBS/FCS (2× concentrated digestion
buffer/solution 1)
 25 G needles and 1 mL syringes for dissociation of LNs for
digestion
 70 µm nylon mesh sheet—cut into approximately 6 × 6 cm
squares
6.3.2 Abs for murine mononuclear phagocyte identification.
Antibody Fluorochrome Clone Provider Cat #
CD3ε APC 145-2C11 BioLegend 100312
CD8α BV605 53-6.7 BioLegend 100744
CD11b BV650 M1/70 BioLegend 101259
CD11c PE-Cy7 N418 BioLegend 117318
CD11c BV605 N418 BioLegend 117334
CD16/32 Pure 2.4G2 BD 553142
CD19 APC eBio1D3 eBioscience 17-0193-82
CD24 eFluor 450 M1/69 eBioscience 48-0242-82
CD45 BUV395 30-F11 BD 564279
CD49b APC DX5 BioLegend 108909
CD64 / FcγRI PE X54-5/7.1 BD 558455
CD64 / FcγRI BV711 X54-5/7.1 BioLegend 139311
CD103 APC 2E7 eBioscience 17-1031-82
CD115 PerCP AFS98 eBioscience 46-1152-82
CD172α Biotin P84 BioLegend 144006
CD317/m-PDCA-1 PE eBio97 eBioscience 13-1721-82
B220/CD45R BV421 RA3-6B2 BioLegend 103240
CCR2 FITC FAB5538F R&D 475301
CX3CR1 PE SA011F11 BioLegend 149006
EpCAM BV605 G8.8 BioLegend 118227
F4/80 Biotin BM8 BioLegend 123106
F4/80 PE-CF594 T45-2342 BD Horizon 565613
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1752 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
Figure 163. Flow cytometric analysis of mouse bone marrow DCs, macrophages, and monocytes. Example for basic gating strategy from FSC-
A/SSC-A, over doublet exclusion and gating on Live, CD45+ LIN− cells (defined as CD3/CD19/CD49b/Ly6G−) on a BM sample (A). Conventional
DCs are identified as CD11chiMHCII+ cells and can be divided into cDC1 (CD8/CD24+CD11b−, red gates) and cDC2 (CD8−CD11b+, blue gates) (B).
Plasmacytoid DCs are identified as CD11cintSiglecH+B220+mPDCA-1+ cells (pink gates; C). Monocytes are identified as CD115+CD11b+ cells and
can be further divided into Ly6Clo and Ly6Chi monocytes (blue and red gates, respectivley; D), while macrophages can be gated as CD11b+F4/80+
(green gate; E). Backgating of monocyte and macrophage populations, that were gated independently of CD115 expression, onto CD115 versus
CD11b expression confirms CD115 as a valid marker for these populations (F).
Figure 164. Flow cytometric analysis of mouse spleen DCs, macrophages, and monocytes. Example for basic gating strategy from FSC-A/SSC-A,
over doublet exclusion and gating on Live, CD45+ LIN− cells (defined as CD3/CD19/CD49b/Ly6G−) on a spleen sample (A). Conventional DCs are
identified as CD11chiMHCII+ cells and can be divided into cDC1 (CD8+/XCR1+CD11b−, red gate) and cDC2 (CD8−CD11b+, blue gate) (B). Plasmacytoid
DCs are identified as CD11cintSiglecH+ but can also be identified by using B220 or mPDCA-1 (pink gates; C). Red pulp macrophages are identified as
CD11bloF4/80+ or CD11bloCD64+ (green gate; D). Monocytes are identified as CD115+CD11b+ cells and can be further divided into Ly6Clo and Ly6Chi
monocytes (blue and red gates, respectivley; E). Backgating of Ly6Clo and Ly6Chi monocytes that were gated independently of CD115 expression
confirms CD115 as a valid marker for both populations (F).
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Antibody Fluorochrome Clone Provider Cat #
MerTK PE-Cy7 DS5MMER Invitrogen 25-5751-82
MHCII Alexa Fluor 700 M5-114.15.2 BioLegend 107622
Ly6C APC-Cy7 HK1.4 BioLegend 128026
Ly6G APC 1A8 BioLegend 127614
SiglecF BV421 E50-2440 BD 562681
SiglecH PerCP-Cy5.5 551 BioLegend 129614
XCR1 PE ZET BioLegend 148204
Streptavidin PE-Cy7 BioLegend 405206
Streptavidin PE-CF594 BD 562284
Streptavidin PerCP-Cy5.5 BioLegend 405214
Figure 165. Flow cytometric analysis of mouse lung macrophages and DCs. Example for basic gating strategy from FSC-A/SSC-A, over doublet
exclusion and gating on Live, CD45+ cells on a lung sample (A). Conventional DCs are gated as MerTK− CD64− MHCII+ CD11c+ before being
identified for cDC1 (red) and cDC2 (blue) (A and B). Macrophages are first gated as MerTK+ CD64+ cells, before being separated into SiglecF+ CD11b−
Alveolar Macrophages (AM, green) and SiglecF− CD11b+ Interstitial Macrophages (IM, pink) (A and C).
Figure 166. Flow cytometric analysis of mouse small intestine macrophages and DCs. Example for basic gating strategy from FSC-A/SSC-A, over
doublet exclusion and gating on Live, CD45+ cells on a small intestine sample (A). Conventional DCs are gated as CD64− MHCII+ CD11c+ before
being identified as CD103+ CD11b− cDC1 (red), CD103− CD11b+ cDC2 (blue), and CD103+ CD11b+ “double positive” cDC2 (black) (B). Macrophages
can be identified as CD64+ F4/80lo MHCII+ CD11c+ CD11b+ (green) (C) or alternatively can be gated from the CD11b+ CD11clo population. From this
gate cells can be split into Ly6Chi MHCII− monocytes (pink), Ly6C+ MHCII+ transitional monocytes (tMono, black) and Ly6C+ MHCII+ macrophages
(green; D).
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Figure 167. Flow cytometric analysis of mouse skin macrophages and DCs. Example for basic gating strategy from FSC-A/SSC-A, over doublet
exclusion and gating on Live, CD45+ cells on an epidermis sample (A). Langerhans cells (LC) are mainly found in the epidermis and are gated
as F4/80+ CD11b+ (blue), while mature LC can be further identified by being CD24+ EpCAM+ (red; A). Example for basic gating strategy from
FSC-A/SSC-A, over doublet exclusion and gating on Live, CD45+ cells on a dermis sample (B). Conventional DCs are gated as EpCAM− MHCII+
CD11c+ before being identified as CD103+ CD11b− cDC1 (red) or CD24+ CD11b+ cDC2 (blue; C) Within this last gate macrophages can be identified
as CD64+ cells (green; C).
6.3.3 Human tissue processing materials.
6.3.3.1 General reagents and materials.
Reagent Manufacturer Catalog number
Collagenase IV Sigma C5138
Worthington’s
Collagenase, Type IV
Worthington
Biochemical
LS004188
DNase I Roche 10104159001
Dulbecco’s Phosphate
Buffered Saline (PBS)
Ficoll-Paque GE Healthcare 17-1440-02
FCS Sigma–Aldrich F2442
L-Glutamine Sigma–Aldrich G7513-100ML
LIVE/DEADTM Fixable
Blue Dead Cell Stain
Kit
Life Technologies L23105
Penicillin-Streptomycin Sigma–Aldrich F4333
1× RBC Lysis Buffer eBioscience 00-4333-57
RPMI 1640 HyClone SH30255.01
Prepare:
 FCM buffer: 2% FCS + 2 mM EDTA in PBS + 0.05% Azide in
1× PBS
 Digestion solution: 0.2 mg/mL collagenase + 0.05 mg/mL of
DNase I in RPMI1640 + 10% FCS.
6.3.4 Antibodies for human mononuclear phagocyte identification.
see Table 59.
6.3.5 General Remarks.
 All staining procedures in this chapter are described for stain-
ing in 5 mL FCM polystyrene tubes (in ”lab slang”: FACS tubes)
but alternatively one may choose to do the staining in 96-well
round or V-bottom plates. Note: This is very convenient when
handling larger numbers of samples (or for in vitro assays
where cells where cultured in these plates) but will increase
the risk of cross-contamination during staining/washing
steps!
 In general, we recommend aspirating any supernatant after
centrifugation steps, as this will yield consistent staining results.
An alternative method is to discard the supernatant by simply
pouring it out. This usually results in a higher loss of cells (as
compared to aspirating) and may leave an unknown volume
of residual supernatant in the tube that might affect staining
efficiency and therefore results! Fun Fact: We calculated the
time it takes to aspirate larger numbers of FCM tubes containing
2mL of buffer. Result: 5 min for 100 tubes (n= 3 experiments
with 70 to 130 tubes each, SEM ±1 min).
 It is highly recommended to count cell numbers wherever pos-
sible (ideally after RBC lysis), so one can calculate absolute
numbers of individual cell populations per tissue, once the data
are obtained. Depending on your lab
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Figure 168. Flow cytometric analysis of mouse lymph node macrophages and DCs in steady-state. Example for basic gating strategy from FSC-
A/SSC-A, over doublet exclusion and gating on Live, CD45+ cells on lung draining (dr.) LN sample (A), skin draining LN sample (B), mesenteric LN
sample (C) and for Peyer’s Patches (D). Generally, migratory cDCs express higher levels of MHCII but lower levels of CD11c on their surfaces as
compared to lymphoid resident cDCs (MHCIIlo CD11chi). Lymphoid-resident cDC1 are further gated as CD8+ CD11b− (red), cDC2 as CD8− CD11b+
(blue) (A–D). Migratory cDC1s (MHCIIhi CD11clo) can be identified by their subsequent expression of CD103 (red) whilemigratory cDC2s are identified
as CD103− CD11b+ (blue; A–D). The skin dr. LN migratory fraction further consists of EpCAM+ Langerhans cells (green; B). In the mesenteric LNs
and Peyer’s Patches the migratory cDC2 population can be divided into CD103− CD11b+ cDC2 (blue) and CD103+ CD11b+ “double positive” cDC2
(black; C and D).
or institute you might have access to, e.g., Neubauer cham-
bers for manual counting, to automatic cell counters or be able
to include cell counting beads to your sample (e.g., Count-
Bright Absolute Counting Beads, Invitrogen, catalog number
C36950). All methods are equally fine and should be chosen
by the researcher fitting to their experimental setup/question.
We simply recommend to use the same method for all related
experiments to gain comparable and consistent results.
 Ab concentrations/dilutions stated in the protocols are meant
as a guideline for first-time users and can be used as a start-
ing point. Alternatively, check the manufacturer’s recommen-
dations when trying a new Ab. Ideally, the exact concentration
needed should be determined by titration.
 Be aware that EDTA may interfere with the staining quality
specifically for lectin receptors and youmay opt to use an EDTA-
free staining buffer.
 In the protocols, 1350 rpm equals roughly 400 × g.
6.4 Step-by-step sample preparation for mouse tissues
6.4.1 Step-by-step sample preparation for mouse blood DCs and
monocytes.
1. Collect blood (e.g., from the heart, retro-orbital plexus, facial
vein, etc.) and immediately transfer into a sample tube con-
taining either PBS + 10 mM EDTA or heparin (e.g., from
Sigma–Aldrich, catalog number H3393). This will prevent
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1756 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
Table 59. Primary and secondary antibodies for staining of human DCs and monocytes/macrophages in different tissues
Target Molecule Fluoro chrome Isotype Clone Dilution Provider Cat# Target Cell Target Tissue
Primary ab
CADM1 Purified chicken IgY 3E1 1/400 MBL CM004-3 cDC1 Bl, Sp, Lu, Sk*
CD1a AF700 mouse IgG2a NA1/34-HLK 1/20 Novus Bio NB100-64852AF700 LCs Sk
CD1c PE/Cy7 mouse IgG1 L161 1/200 Biolegend 331516 cDC2 Bl, Sp, Lu
CD1c BV421 mouse IgG1 L161 1/20 Biolegend 331526 cDC1, cDC2 Sk
CD3 BV650 Mouse IgG2a OKT3 1/20 Biolegend 317324 T cell Bl, Sp, Lu, Sk
CD5 BV711 mouse IgG1 UCHT2 1/20 BD Biosciences 563170 Early pre-DC Bl
CD11c BV605 mouse IgG1 3.9 1/20 Biolegend 301636 cDC2 Sk, Bl, Sp, Lu
CD14 BV711 mouse IgG2a M5E2 1/20 Biolegend 301838 DCs, Mac Sk
CD14 ECD mouse IgG2a RMO52 1/10 Beckman Coulter IM2707U DCs, Mo Bl, Sp, Lu
CD16 APC/Cy7 mouse IgG1 3G8 1/40 Biolegend 302018 Mo/Mac, NK cell Bl, Sp, Lu, Sk
CD19 BV650 mouse IgG1 HIB19 1/20 Biolegend 302238 B cell Bl, Sp, Lu, Sk
CD20 BV650 mouse IgG2b 2H7 1/20 Biolegend 302336 B cell Bl, Sp, Lu, Sk
CD26 PE/Cy7 mouse IgG2a BA5b 1/20 Biolegend 302714 cDC1, cDC2 Sk
CD26 PE mouse IgG2a BA5b 1/20 Biolegend 302706 cDC1, cDC2 Bl, Sp, Lu
CD45 V500 mouse IgG1 HI30 1/20 BD Biosciences 560777 DCs, Mo/Mac Bl, Sp, Lu, Sk
CD123 BUV395 mouse IgG2a 7G3 1/40 BD Biosciences 564195 pDC, early pr-DC Bl, Sp, Lu
CD169 (Siglec-1) PE/eFluor610 mouse IgG1 7-239 1/20 eBioscience 61-1699-42 Early pre-DC Bl
HLADR BV786 mouse IgG2a L243 1/20 Biolegend 307642 DCs, Mo/Mac Bl, Sp, Lu, Sk
SIRPa (CD172a) Purified mouse IgG1 DH59B 1/400 King Fischer
Biotech Inc
WS0567B-100 LCs Sk
Secondary ab
anti-Chicken IgY Alexa Fluor 647 Donkey Fab’2 N/A 1/200 Jackson
Immunore-
search
703-606-155 cDC1 Bl, Sp, Lu, Sk
* Bl, blood; Sp, spleen; Lu, lungs; and SK, skin.
blood from coagulating. Place tubes on ice till further pro-
cessing.
2. Centrifuge at 1350 rpm, 4°C for 4 min.
3. Carefully aspirate supernatant. Try to avoid aspirating the
blood and containing cells, as the pellet will be rather fluid.
4. Resuspend pellet in 2 mL of RBC lysis buffer, incubate for 5
min at room temperature.
5. After 5 min stop reaction by adding 10 mL of FCM buffer.
6. Centrifuge at 1350 rpm, 4°C for 4 min.
7. Carefully aspirate supernatant. Tip: If the pellet still contains
a lot of red blood cells, you might want to repeat RBC lysis
step a second time for 3 min. Try avoiding further RBC lysis
rounds, as the lysis buffer is very harsh on your immune cells.
8. Resuspend pellet in FCM buffer and transfer 1–10 × 106 cells
to FCM tube for cell surface staining.
9. Centrifuge at 1350 rpm, 4°C for 4 min, aspirate supernatant.
10. Prepare blocking buffer (FCM buffer+ 1:50 rat/mouse serum
or purified CD16/32 (FC-block)) and cocktail containing all
Abs required (dilution as recommended by manufacturer, or
1:100) for primary staining, store in the dark on ice or at 4°C.
11. Add 25 µL of blocking buffer to the pellet, vortex, incubate
for 10–15 min in the dark, at 4°C. This will help prevent
unspecific binding of subsequently used antibodies.
12. Add 25 µl of Ab cocktail* to the cell suspension, vortex, incu-
bate for 15–30 min in the dark, at 4°C.
13. Add 2–3 mL of FCM buffer to the cell suspension to wash off
Ab cocktail.
14. Centrifuge at 1350 rpm, 4°C for 4 min, aspirate supernatant.
15. Optional: If required, add secondary Ab, e.g., fluorochrome-
conjugated Streptavidin (dilution 1:300 usually is sufficient),
vortex, incubate for 15 min in the dark, at 4°C. Wash off with
2–3 mL of FCM buffer, centrifuge at 1350 rpm, 4°C for 4 min,
aspirate supernatant.
16. Resuspend pellet in 200 µL of FCM buffer containing DAPI
(1:200).
17. Proceed to analyze sample on flow cytometer. Note: Filter
sample using a 70 µm nylon mesh/cell strainer prior acquisi-
tion to avoid clogging of the analyzer.
*Staining Abs: CD45 (30-F11), F4/80 (BM8), CD64/FcγRI
(X54-5/7.1), MHC Class II IA/IE (M5/114.15.2), CD11c (N418),
CD11b (M1/70), Ly6C (HK1.4), CD115 (AFS98), CD24 (M1/69),
CD3 (145-2C11), CD19 (eBio1D3), CD49b (DX5), Ly6G (1A8),
mPDCA-1 (eBio97), SiglecH (551), B220 (RA3-6B2). Lineage
(LIN) consists of CD3, CD19, CD49b (alternatively NK1.1), and
Ly6G.
6.4.1.1 Gating for mouse blood DCs and monocytes (Fig. 162).
Gating from single, live, CD45+ LIN− cells:
 Dendritic cells: CD64−, F4/80−, MHCII+, CD11c+
cDC1: CD8α+/CD24+ CD11b−
cDC2: CD8α− CD11b+
 pDCs: CD11cint CD11b− SiglecH+ mPDCA-1+ B220+
 Monocytes: CD115+ CD11b+ Ly6Clo/hi
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Table 60. Phenotypic characterization of DC subsets in mouse and human tissues
Peripheral or
Migratory cDC1
Lymphoid-resident
cDC1 cDC2 Plasmacytoid DCs
Early
pre-DC
Marker Mouse Human Mouse Human Mouse Human Mouse Human Human
CD4 − + − + + + +/− + +
CD8a − − + − − − +/− +/− *2 −
CD9 + + + +/− + +
CD11b − − − − + (gut +) 0 − −
CD11c + lo/- ++ lo/- + + int − +/−
CD24 + − + − + − − − −
CD26 + + + + + + (bl
−/+)
+ + +
CD45 + + + + + + + + +
CD64 − − − (spl +) − +/− − − −
CD80 +/− *2 − − +/− *2 (mat +) +/− *2 − −
CD86 +/− *2 + lo/+ +/− *2 + +/− *2 lo/+ +
CD103 + - (gut+) − + −/+ *1 - (gut +) − − −
CD115 − − − − − − − − −
CD117 − + − + − − − − −
CD169 − − − − +
CD172a − − − − + + + + int
B220 − − − − − − + n/a n/a
CADM1 + + + + − − − − −
CCR7 +/− *2 +/− *2 +/− *2 +/− *2 +/− *2 +/− *2 lo/+ *2 + −
CCR9 +/−
Clec9a + + + + − − +/− − −
EpCAM − − − − − − −
F4/80 − − n/a −/+ n/a − n/a n/a
mPDCA-1 − − − − − − + n/a n/a
MHCII *3 + + + + + + +/− *2 + +
Langerin - (der
+)
− − − − − − − −
Ly6C − − − − − − +/− n/a n/a
Ly49Q +/− n/a n/a
XCR1 + − + − − − − − −
IRF4 − − − − + + + + +
IRF8 + + + + − − + + +
CD1a n/a - (der
+)
n/a − n/a - (der
+)
n/a − −
CD1c n/a - (der
+)
n/a − n/a + n/a − −
CD14 n/a − n/a − n/a −/+ n/a − −
CD16 n/a − n/a − n/a − n/a − −
CD123 n/a − n/a − n/a − n/a + +
CD141 n/a + n/a + n/a − n/a − int
CD303 n/a − n/a − n/a − n/a + +
CD304 n/a − n/a − n/a − n/a + +
bl, blood; der, dermis; int, intermediate; sple, spleen; mat, mature.
n/a: gene coding this protein absent in this species
Not defined
*1: CD103+ CD11b+ DP cDC2 population of gut, mesenteric LN, and Peyer’s patches
*2: + upon activation
*3: HLA-DR in humans
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Table 61. Phenotypic characterization of monocytes/macrophages in mouse and human tissues
Classical Monocyte
Intermediate
Monocyte
Non-classical
Monocyte Macrophages
Marker Mouse Human Mouse Human Mouse Human Mouse Human
CD11b + hi + + lo +/− + (skin)
CD14 (+) hi + (+) lo + (skin
CD16 lo − + + + lo/- (skin)
CD43 lo + + hi + +
CD45 + + + + + + +
CD62L + lo lo/- − − −
CD64 − + + − lo/- + +
CD115 + lo hi + int + +
CD169 +/− +/− +/− +/− + +
CCR2 + hi int − − +/− −
CX3CR1 int lo int hi hi +
F4/80 − n/a n/a − n/a + n/a
HLA-DR + hi lo + (skin)
MerTK +/− +/− + +
Ly6C hi n/a n/a lo n/a − n/a
Lyve-1 − − +/−
n/a: gene coding this protein absent in this species
Not defined
6.4.1.2 Top tricks and pitfalls.
 Additionally to CD11b and Ly6C other monocyte marker may
be included for further/more detailed separation of Ly6Chi and
Ly6Clo monocytes, such as, e.g., CX3CR1, CCR2, or TremL4
(see Table 61; [1452]).
6.4.2 Step-by-step sample preparation for mouse bone marrow DCs,
monocytes, and macrophages.
1. Remove femur and tibia from euthanized mouse and, using
scissors, free bones from surrounding muscle tissue and ten-
dons. Tip: Use a paper towel to gently remove tissue that is
stuck to the bones. This will also make it easier to detach the
knee to separate femur and tibia, and to detach the foot from
the tibia—use a turning/rotating motion to gently remove the
foot/knee without breaking the bone.
2. Place clean bones in ice-cold PBS in a six-well plate, on ice,
till all tissues have been harvested.
3. To flush out the bone marrow: take bones out of PBS, e.g.,
place on the inside of the lid of your six-well plate and care-
fully cut off a tiny bit at both ends of the bone.
4. Fill a 20 ml syringe with ice-cold FCM buffer. Use a 23 G
needle to flush out the bone marrow, directly into a 15 mL
or 50 mL conical tube. Note: This needle size should fit into
most mouse bones, allowing to sufficiently flush out all the
bone marrow but other G sizes will work just as well. Tip: For
best results flush bone from both sides, moving the needle up
and down within the bone while flushing.
5. Centrifuge at 1350 rpm, 4°C for 4 min.
6. Aspirate supernatant.
7. Thoroughly suspend pellet in about 1 mL of RBC lysis buffer,
incubate for 3 min at room temperature. Note: You want to
reach a single cell suspension at this step to ensure proper
RBC lysis. Make sure you have no BM “pieces” left.
8. After 3 min stop reaction by adding 10 mL of FCM buffer.
Note: Youmay want to filter the single cell suspension using a
70 µm nylon mesh/cell strainer to remove lose bone particles
and clumps.
9. Centrifuge at 1350 rpm, 4°C for 4 min.
10. Resuspend pellet in ice-cold FCM buffer and transfer 1–10 ×
106 cells to FCM tube for cell surface staining.
11. Centrifuge at 1350 rpm, 4°C for 4 min, aspirate supernatant.
12. Prepare blocking buffer (FCM buffer+ 1:50 rat/mouse serum
or purified CD16/32 (FC-block)) and cocktail containing all
Abs required (dilution as recommended by manufacturer, or
1:100) for primary staining, store in the dark on ice or at 4°C.
13. Add 25 µL of blocking buffer to the pellet, vortex, incubate
for 10–15 min in the dark, at 4°C. This will help prevent
unspecific binding of subsequently used Abs.
14. Add 25 µl of Ab cocktail* to the cell suspension, vortex, incu-
bate for 15–30 min in the dark, at 4°C.
15. Add 2–3 mL of FCM buffer to the cell suspension to wash off
Ab cocktail.
16. Centrifuge at 1350 rpm, 4°C for 4 min, aspirate supernatant.
17. Optional: If required, add secondary Ab, e.g., fluorochrome-
conjugated Streptavidin (dilution 1:300 usually is sufficient),
vortex, incubate for 15 min in the dark, at 4°C. Wash off with
2–3 mL of FCM buffer, centrifuge at 1350 rpm, 4°C for 4 min,
aspirate supernatant.
18. Resuspend pellet in 200 µL of FCM buffer containing DAPI
(1:200).
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19. Proceed to analyze sample on flow cytometer. Note: Filter
sample using a 70 µm nylon mesh/cell strainer prior acquisi-
tion to avoid clogging of the analyzer.
*Staining Abs: CD45 (30-F11), F4/80 (BM8), CD64/FcγRI
(X54-5/7.1), MHC Class II IA/IE (M5/114.15.2), CD11c (N418),
CD11b (M1/70), Ly6C (HK1.4), CD115 (AFS98), MerTK
(DS5MMER), CD24 (M1/69), CD3 (145-2C11), CD19 (eBio1D3),
CD49b (DX5), Ly6G (1A8), mPDCA-1 (eBio97), SiglecH (551),
B220 (RA3-6B2). LIN consists of CD3, CD19, CD49b (alternatively
NK1.1), and Ly6G.
6.4.2.1 Gating for mouse bone marrow DCs/monocytes/
macrophages (Fig. 163). Gating from single, live, CD45+ LIN−
cells:
 Dendritic cells: CD64−, F4/80−, MHCII+, CD11c+
cDC1: CD8α+/CD24+ CD11b−
cDC2: CD8α− CD11b+
 pDCs: CD11cint CD11b− SiglecH+ mPDCA-1+ B220+
 Macrophages: F4/80+ CD11b+ MerTK+ CD64+
 Monocytes: CD115+ CD11b+ Ly6Clo/hi
6.4.2.2 Top tricks and pitfalls.
 Cytokine receptors such as CSF-1R (CD115) are often shed off
if samples are treated too harsh or processed over long periods
or even internalized. Avoid receptor shedding/internalization
by working quickly and keeping samples chilled.
 If working with frozen/thawed bone marrow samples one may
incubate the freshly thawed samples in RPMI1640 for 6 h at
37°C to allow for proper expression of cell surface receptors.
This will improve staining results.
 When gating on pDCs in the bone marrow, it is advisable to
include SiglecH, mPDCA-1 and B220, as SiglecH also labels
pDC progenitors, which either do not or only express low levels
of B220 and mPDCA-1 yet.
 Inclusion of CD117 into the panel, followed by gating on
CD117− LIN− cells prior the monocyte gating can lead to a
better resolution of these populations.
6.4.3 Step-by-step sample preparation for mouse spleen DCs, mono-
cytes, and macrophages.
 Harvest spleen from euthanized mouse and place in ice-cold
PBS in a six-well plate, on ice, till all tissues have been har-
vested.
 Prepare digestion buffer (as described in reagents list), keep at
room temperature.
 Aliquot 2 mL of digestion buffer into a fresh well in a six-well
plate.
 Take spleen out of PBS, quickly dry off on clean paper towel, if
necessary remove fat and place spleen in digestion buffer.
 Use fine tweezers (or scissors) to tear spleen into very fine
pieces.
 Incubate in digestion buffer at 37°C for 30 min.
 Stop digestion by adding 3 mL of PBS + 10 mM EDTA.
 Carefully, but thoroughly, pipette spleen suspension up and
down using either a 5 mL pipette or a 18 G needle with a 5 mL
syringe, up to 20 times to gain a single cell suspension.
 Transfer spleen cell suspension over a 70 µm nylon mesh/cell
strainer into a 50 mL conical tube.
 Centrifuge at 1350 rpm, 4°C for 4 min.
 Aspirate supernatant.
 Thoroughly suspend pellet in about 1 mL of RBC lysis buffer,
incubate for 3 min at room temperature.
 After 3 min stop reaction by adding 10 ml of FCM buffer.
 Centrifuge at 1350 rpm, 4°C for 4 min.
 Resuspend pellet in ice-cold FCM buffer and transfer 1–10 ×
106 cells to FCM tube for cell surface staining.
 Centrifuge at 1350 rpm, 4°C for 4 min, aspirate supernatant.
 Prepare blocking buffer (FCM buffer + 1:50 rat/mouse serum
or purified CD16/32 (FC-block)) and cocktail containing all Abs
required (dilution as recommended by manufacturer, or 1:100)
for primary staining, store in the dark on ice or at 4°C.
 Add 25 µL of blocking buffer to the pellet, vortex, incubate for
10–15 min in the dark, at 4°C. This will help prevent unspecific
binding of subsequently used antibodies.
 Add 25 µL of Ab cocktail* to the cell suspension, vortex, incu-
bate for 15–30 min in the dark, at 4°C.
 Add 2–3 mL of FCM buffer to the cell suspension to wash off
Ab cocktail.
 Centrifuge at 1350 rpm, 4°C for 4 min, aspirate supernatant.
 Optional: If required, add secondary Ab, e.g., fluorochrome-
conjugated Streptavidin (dilution 1:300 usually is sufficient),
vortex, incubate for 15 min in the dark, at 4°C. Wash off with
2–3 mL of FCM buffer, centrifuge at 1350 rpm, 4°C for 4 min,
aspirate supernatant.
 Resuspend pellet in approximately 200 µL of FCM buffer con-
taining DAPI (1:200).
 Proceed to analyze sample on flow cytometer. Note: Filter sam-
ple using a 70 µm nylon mesh/cell strainer prior acquisition to
avoid clogging of the analyzer.
*Staining Abs: CD45 (30-F11), F4/80 (BM8), CD64/FcγRI
(X54-5/7.1), MHC Class II IA/IE (M5/114.15.2), CD11c (N418),
CD11b (M1/70), Ly6C (HK1.4), CD115 (AFS98), CD8α (53-6.7),
XCR1 (ZET), CD3 (145-2C11), CD19 (eBio1D3), CD49b (DX5),
Ly6G (1A8), mPDCA-1 (eBio97), SiglecH (551), B220 (RA3-6B2).
LIN consists of CD3, CD19, CD49b (alternatively NK1.1), and
Ly6G.
6.4.3.1 Gating for mouse spleen DCs/monocytes/macrophages.
Gating from single, live, CD45+ LIN− cells:
 Dendritic cells: CD64−, F4/80−, MHCII+, CD11c+
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cDC1: CD8α+ CD11b− or XCR1+ CD11b−
cDC2: CD8α− CD11b+
 pDCs: CD11cint CD11b− SiglecH+ mPDCA-1+ B220+
 Macrophages: F4/80+ CD11b+
 Monocytes: CD115+ CD11b+ Ly6Clo/hi
6.4.3.2 Top tricks and pitfalls.
 Note that this protocol will yield mainly red pulp macrophages,
while other splenic macrophages subsets such as marginal zone
macrophages are more difficult to isolate. These can be better
identified by inclusion of a Tim4 Ab into the panel [1453].
 cDC1 traditionally were identified using CD8α but we highly
recommend the use of XCR1 instead, as this marker is more
specific than CD8α and yields a better discrimination of cDC1
from cDC2 (as can be seen in Figure 164) [1437, 1454, 1455].
6.4.4 Step-by step sample preparation of mouse lung
macrophages/DCs.
1. Thoroughly perfuse freshly euthanized mouse intracardially
with cold PBS, and harvest lungs into a 12-well plate contain-
ing cold PBS, on ice.
2. Place individual lung samples into 1.5 mL microcentrifuge
tube containing 500 µL of digestion solution 1.
3. Mince lung into small pieces using fine scissors (in the tube).
4. Transfer to 12-well plate containing additional 1–1.5 mL
digestion solution (final volume 1.5–2 mL of digestion solu-
tion 1).
5. Incubate at 37°C for 30 min.
6. Homogenizeminced and digested sample using a 18G syringe
needle and 3 mL syringe and filter through 70 µm cell strainer
(you may use the syringe plunger to push tissue through the
strainer) into 50 mL conical tube.
7. Wash remaining cells from strainer with 20 mL FCM buffer.
8. Centrifuge at 400 × g for 5 min, at 4°C
9. Lyse any remaining erythrocytes by resuspending cell pellet
in 500 µL of RBC lysis buffer for 3 min, at room temperature.
Then stop reaction by topping up with FCM buffer.
10. Centrifuge at 400 × g for 5 min, at 4°C
11. Resuspend pellet in FCM buffer.
12. Filter cell suspension again through a 70 µm cell strainer to
remove any clumps that may have formed after erythrocyte
lysis and transfer cells to FCM tube.
13. Resuspend the appropriate number of cells (e.g., 1–10 × 106
cells) in FCM staining buffer (see 6.2.2.1) containing the
required Abs* and incubate in the dark at 4°C.
14. Wash with FCM buffer.
15. Centrifuge at 400 × g for 5 min, at 4°C
16. Resuspend cells in an appropriate amount of FCM buffer.
17. Filter with 70 µm nylon mesh into a new (clean) FCM tube
and analyze sample in FCM cell sorting machine.
*Staining Abs: CD45 mAb (30-F11), CD64/FcγRI mAb (X54-
5/7.1), SiglecF (E50-2440), MerTK (DS5MMER), MHC Class II
IA/IE mAb (M5/114.15.2), CD24 (M1/69), CD11c mAb (N418),
XCR1 mAb (ZET) or CD103 mAb (2E7), SIRPα/CD172a mAb
(P84) or CD11b mAb (M1/70), and Ly6C mAb (HK1.4).
6.4.4.1 Gating for mouse lung macrophages/DCs. Gating from
single, live, CD45+ cells:
 Alveolar macrophages (AMs): CD64+, MerTK+, SiglecF+,
CD11b−
 Interstitial macrophages (IMs): CD64+, MerTK+, SiglecF−,
CD11b+
 Dendritic cells: CD64−, MerTK−, MHCII+, CD11chi
cDC1: XCR1/CD103+, SIRPα/CD11b−
cDC2: XCR1/CD103−, SIRPα/CD11b+, CD24+
6.4.4.2 Top tricks and pitfalls.
 The two major macrophage populations in the mouse steady-
state lung are the AMs and IMs. They express MerTK+ CD64+,
but can also be differentiated from each other according to
differences in SiglecF, MHCII, CD11c, and CD11b expression.
Further markers like Lyve-1 and others (not included in the
example FCM plots) have been shown to be very useful for AM
versus IM discrimination [1456, 1457].
 In addition, if the configuration of the used flow cytome-
ter allows for it, a “blank” channel (e.g., the FITC channel)
is useful for discriminating “auto-fluorescent” AMs from non-
autofluorescent IMs.
 Note that “aggressive” perfusion can lead to loss of alveolar
resident cells.
 Two major conventional DC subsets in the lung are cDC1 and
cDC2. cDC1s express XCR1 and CD103, while cDC2s express
CD172α/SIRPα or CD11b, and CD24 [1437, 1456, 1458]. A
minor fraction of CD103/CD11b-double-positive cDC2 can be
found as well (Figure 165).
6.4.5 Step-by-step sample preparation of mouse intestinal
macrophages/DCs.
1. From a freshly euthanizedmouse, open up the abdominal cav-
ity by dissecting through the skin and peritoneal membrane
in a line along the ventral midline.
2. Remove the intestinal tract by dissecting the small intestine
just after the pyloric sphincter, dissecting the colon by sec-
tioning it as caudally as possible, and then carefully lift the
intestines out while severing any places of attachment to the
abdominal cavity and other organs.
3. Place the dissected intestine into six-well plate with cold PBS
on ice. Note: At this point you may retrieve the mesenteric
LNs from the mesenteric fat for analysis, if desired.
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4. Remove as much attached mesenteric fat from intestines as
possible, pulling the fat from one end and following through
to the other end until the intestines have been linearized.
5. Follow the following steps for cleaning the fecal content of
small intestine and colon, respectively:
(a) For the small intestine: Dissect just above the caecum,
retrieve the Peyer’s Patches that lie along the length of
the intestine by either cutting or plucking them (they can
be analyzed separately or discarded), open the lumen
lengthwise with scissors, and wash away fecal content
from the opened small intestine in a beaker containing
cold PBS before sectioning washed small intestine into
0.5–1 cm long pieces and placing into 50 m conical tube.
(b) For the colon: Separate away from the cecum (discard
the cecum), use two pairs of forceps to squeeze solid fecal
content out of the lumen, open the lumen lengthwise
wish scissors, and wash away remaining fecal content
from the opened colon in beaker containing cold PBS
before placing washed colon into a 50 mL conical tube.
6. Add 25 mL of cold PBS into the 50 mL conical tube with the
washed intestinal sections and place on ice while completing
previous steps for other samples.
7. Vigorously shake the intestinal sections in 50 mL conical tube
with cold PBS to get rid of the mucus for around 10 s each
round (four rounds with fresh cold PBS each round for small
intestine, only once for colon).
8. Put the washed pieces into a new 50mL conical tube and keep
on ice while completing the wash step(s) for other samples.
9. When all samples are ready, add 10–12.5 mL of epithelial
dissociation buffer to each sample and incubate for 20 min at
37°C in an orbital shaker set to 250 rpm.
(a) During this incubation prepare two Petri dishes, one
clean and the other filled with cold PBS, and 1.5 mL
microcentrifuge tubes with 300–500 µL of digestion
buffer 1 (for small intestine) or digestion buffer 2 (for
colon).
(b) If the epithelial compartment is to be retained, prepare
the additional 50 mL conical tubes and cell strainers for
collection.
10. Dilute epithelium dissociation buffer with 25 mL of cold PBS
and shake vigorously for 10 s in the 50 mL conical tube.
11. Pour out the tube contents into the first clean Petri dish (or
through a cell strainer into an additional 50 mL conical tube
if the epithelium compartment is to be retained for further
analysis).
12. Transfer the pieces to the second Petri dish with cold PBS and
move them around to wash away traces of DTT/EDTA and
epithelium cells.
13. Dry briefly on a piece of tissue before transferring the tissue
pieces to the 1.5 mL microcentrifuge tube with the appropri-
ate digestion buffer.
14. Mince tissue into small pieces with fine scissors, and then
pour into six-well plate, washing out the remaining tissue
from the microcentrifuge tube with digestion solution 1 (to a
final volume of 2.5–3 mL in the well).
15. Incubate for 45 min at 37°C. Note: Some protocols state that
agitation at this step will enhance the digestion process but
usually this does not have any effect on digestion efficiency.
16. Homogenize minced digested sample with 18 G syringe nee-
dle and 3 mL syringe and filter through a 70 µm cell strainer
(you may use the syringe plunger to push tissue through the
strainer) into the final 50 mL conical tube.
17. Centrifuge at 400 × g for 5 min, at 4°C.
18. If cell pellet is still loose after centrifugation, repeat step 17.
19. Resuspend pellet in FCM buffer* (see Top Tricks and Pitfalls
below)
20. Resuspend the appropriate number of cells in FCM staining
buffer (see 6.2.2.1) containing the Abs*1, incubate in the dark
at 4°C.
21. Wash with FCM buffer.
22. Centrifuge at 400 × g for 5 min, at 4°C.
23. Resuspend cells in an appropriate amount of FCM buffer.
24. Filter with 70 µm nylon mesh into a new, clean FCM tube and
analyze sample using a FCM cell sorting machine.
*1Staining Abs: CD45 mAb (30-F11), F4/80 mAb (BM8),
CD64/FcγRI mAb (X54-5/7.1), MHC Class II IA/IE mAb
(M5/114.15.2), CD11c mAb (N418), CD103 mAb (2E7), CD11b
mAb (M1/70), Ly6C mAb (HK1.4).
6.4.5.1 Gating for intestinal macrophages/DCs. Gating from
single, live, CD45+ cells:
 Macrophages (Mac): CD64+, F4/80lo, CD11b+, CD11clo,
Ly6C−, MHCII+
 Monocytes (Mono): CD11b+, CD11clo, MHCII−, Ly6C+
 Transitional Monocytes (tMono): CD11b+, CD11clo, MHCII+,
Ly6C+ [1459]
 Dendritic cells: CD64−, MHCII+, CD11c+
cDC1: CD103+, CD11b−
cDC2: CD103−, CD11b+
DPs: CD103+, CD11b+
6.4.5.2 Top tricks and pitfalls.
 *At this point, some protocols opt to perform a 45/65% [1460]
or 45/70% [1461] Percoll separation to further enrich for
macrophages and DCs while removing debris. However, in our
experience (and previously reported by [1462], cell yield is
greatly reduced when this step is performed.
 The processing of both small intestine and large intestine for the
purpose of analyzing macrophages/DCs in the lamina propria
(LP) is detailed here. There are little to no macrophages/DCs in
the gut epithelium compartment at steady state, hence in this
protocol the dissociated epithelium is normally discarded. How-
ever, if desired, simple modifications that are mentioned here
can be made to the protocol to retain the dissociated epithelium
for separate analysis
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 The intestinal LP contains a substantial population of
eosinophils; exclusion of these can be achieved by inclu-
sion of SiglecF (an eosinophil-specific marker) and CD64
(LP macrophage specific) into the panel. Monocyte-derived
macrophages can be further gated using Ly6C [1463].
 Tim4 can be a useful marker to be added, for further delineation
of macrophage populations [1453].
 There are three main subsets of lamina propria DCs: cDC1,
cDC2, and an intestine-specific subset of “double positive”
CD103+ CD11b+ DP cDC2 (Fig. 166). While in some publica-
tions intestinal cDC1 are delineated from cDC2 using XCR1 and
SIRPα [1437], these markers alone are not sufficient to delin-
eate the DP cDC2 fraction from the CD103− CD11b+ cDC2.
 In general, inclusion of a lineage channel containing B, T, or
neutrophil markers (e.g., CD19, CD3, Ly6G, respecitively) and
gating on LIN− cells prior gating on mononuclear phagocytes
might lead to a cleaner separation of these populations and will
lower the risk of contamination with other cell types.
6.4.6 Step-by-step sample preparation of mouse skin (ears).
1. Harvest ears from euthanized mouse by dissection with a fine
scissors.
2. The following steps depend if total skin is analyzed, or if the
epidermis and dermis are analyzed separately:
(a) If processing total skin, proceed to place ears directly into
digestion solution 1 and mince into small pieces using a
pair of fine scissors, and then proceed on with step 7.
(b) If analyzing the epidermis and dermis separately proceed
on to step 3.
3. Using two pairs of fine forceps, split each ear into dorsal and
ventral halves to expose the inner dermal layer.
4. Float the ear halves dermis side down in 3 mL of Dispase solu-
tion/well in 6-well plate, ensuring that they are sufficiently
spread out on the solution surface.
5. Incubate for 1 h at 37°C.
6. Place each ear half on a suitable clean flat surface (polystyrene
dish or lid, stainless steel tray, or a dark ceramic tile are all
suitable) dermis side down.
7. In order to separate epidermis and dermis, carefully scrape
the epidermis from the dermis using forceps and wash the
dermis thoroughly in PBS or medium to remove any remain-
ing epidermis.
8. Using forceps, place tissues into microcentrifuge tubes con-
taining 500 µL digestion solution 1, and mince into small
pieces with fine scissors.
9. Pour out the cut up tissue into a 12-well plate and wash
remaining minced tissue into same well using an additional
1 mL of digestion solution 1 (final volume 2 mL)
10. Incubate for 1 h at 37°C.
11. Homogenize with 3 mL syringe and 18 G needle and siphon
it through 70 µm nylon mesh into FCM tube, using a 1 mL
pipette tip as a funnel.
12. Centrifuge at 400 × g for 5 min, at 4°C.
13. Resuspend the cell pellet in FCM staining buffer (see 6.2.2.1)
containing the Abs*, incubate in the dark at 4°C.
14. Wash with FCM buffer.
15. Centrifuge at 400 × g for 5 min, at 4°C.
16. Resuspend cells in an appropriate amount of FCM buffer.
17. Filter with 70 µm nylon mesh into a new, clean FCM tube,
and analyze sample using a FCM cell sorting machine.
*Staining Abs: CD45 mAb (30-F11), F4/80 mAb (BM8), CD64
mAb (X54-5/7.1), MHC Class II IA/IE mAb (M5/114.15.2),
CD11c mAb (N418), XCR1 mAb (ZET) or CD103 mAb (2E7),
SIRPα/CD172a mAb (P84) or CD11b mAb (M1/70), EpCAM mAb
(G8.8).
6.4.6.1 Gating for mouse skin macrophages/DCs. Gating from
single, live, CD45+ cells:
 LCs: F4/80+, CD11b+, EpCAM+
 Dendritic cells: MHCII+, CD11c+
cDC1 – CD103+, CD11b−
cDC2 – CD103−, CD11b+, CD24+, CD64−
 Macrophages (Mac): CD64+, CD11clo, MHCII+
6.4.6.2 Top tricks and pitfalls.
 This protocol can be used for analysis for total skin, or the
epidermis and dermis separately. However, each method comes
with its own drawbacks. Total skin preparations tend to have
significantly less Langerhans cells (LCs) but better yield of DCs.
Separation of the epidermis and dermis has good yield of LCs
in the epidermal compartment, but results in a decreased yield
of dermal DCs in the dermal compartment.
 Various methods whereby different enzymes are used for pro-
cessingmouse skin have been reported [1464–1466]. The effect
certain enzymes can have on the surface expression of some
markers should be considered.
 LCs are the main macrophage population in the epidermis. LCs
express numerous markers including F4/80, CD11b, EpCAM,
Langerin, and CD24 [1467, 1468]. However, EpCAM alone is
sufficient to distinguish them from other CD45+ cells in the skin
if there are limitations to machine configuration.
 Do note that some populations of mouse DCs express Langerin
as well [1467]. The dermis may contain some migratory LCs
and these can be identified using EpCAM [1469] before gating
for dermal cDC1 and cDC2 (Fig. 167).
6.4.7 Sample preparation of mouse LNs.
1. Harvest lymph nodes of interest from euthanized mouse into
12-well plate with 1 mL of RPMI + 10% FCS in each well.
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2. Add 1mL of 2× concentrated digestion solution 1 (=digestion
solution 3; hence, the final digestion solutionwill be 1×work-
ing concentration).
3. Tear apart lymph nodes in the well and digestion solution
using two 25 G needles mounted on 1 mL syringes.
4. Incubate for 30 min at 37°C.
5. Homogenize with 3 mL syringe and 18 G needle and siphon
it through 70 µm nylon mesh into FCM tube, using a 1 mL
pipette tip as a funnel.
6. Centrifuge at 400 × g for 5 min, at 4°C.
7. Resuspend the cell pellet in FCM staining buffer (see Section
6.3.1.1) containing the Abs*, incubate in the dark at 4°C.
8. Wash with FCM buffer
9. Centrifuge at 400 × g for 5 min, at 4°C.
10. Resuspend cells in an appropriate amount of FCM buffer
11. Filter with 70 µm nylon mesh into a new, clean FCM tube and
analyze sample using a FCM cell sorting machine
*Staining antibodies: CD45 mAb (30-F11), MHC Class II IA/IE
mAb (M5/114.15.2), CD11c mAb (N418), XCR1 mAb (ZET), or
CD103 mAb (2E7) and CD8α mAb (53-6.7), SIRPα/CD172a mAb
(P84) or CD11 mAb (M1/70).
Additional staining Abs: EpCAM mAb (G8.8) for skin draining
LNs.
6.4.7.1 Gating for mouse LN DCs. Gating from single, live
cells:
 Migratory DCs: CD45+, MHCII+, CD11c+
 Migratory cDC1: XCR1/CD103+, SIRPα/CD11b−
 Migratory cDC2: XCR1/CD103−, SIRPα/CD11b+
 Migratory LCs: EpCAM+
 Migratory intestinal DP cDC2: CD103+, SIRPα/CD11b+
 Lymphoid resident DCs: CD45+, MHCII+, CD11c+
Lymphoid resident cDC1: XCR1/CD8a+, SIRPα/CD11b−
 Lymphoid resident cDC2: XCR1/CD8a−, SIRPα/CD11b+
6.4.7.2 Top tricks and pitfalls.
 This protocol is used to digest all LNs including Peyer’s patches.
 As LNs are small pieces of tissue, we opted to do digest the LNs
in the same well they are harvested into, to avoid the need to
transfer LNs into a separate plate for digestion.
 Also, as LNs are highly concentrated in lymphocytes, it is rec-
ommended not to stain too many cells (especially in the case of
mesenteric LNs and Peyer’s patches) to avoid saturating the Ab
staining mix.
 Further, inclusion of a lineage channel containing, e.g., B, T, NK
cell, or neutrophil markers (e.g., CD19, CD3, CD49b/NK1.1, or
Ly6G, respecitively) and gating on LIN- cells prior gating on
mononuclear phagocytes might lead to a cleaner separation of
these populations and will lower the risk of contamination with
other cell types.
 Mouse lymph nodes at steady-state contain two fractions of
conventional DCs. The first fraction are migratory DCs that
come from the peripheral tissues and express high levels of
MCHII and lower levels of CD11c, and can be further split into
cDC1 and cDC2 subsets using similar markers used for gating
peripheral tissue DCs [1430]. The second fraction are lymph
node resident conventional DCs, which express high levels of
CD11c and lower levels MHCII, are also comprised of cDC1 and
cDC2, and are gated using either XCR1 or CD8a, and SIRPα or
CD11b for cDC1 and cDC2, respectively [1430] (Figure 168).
6.5 Step-by-step sample preparation for human tissues
6.5.1 Step-by-step sample preparation for human blood DCs, mono-
cytes, and macrophages. Critical: This protocol is designed for 10
ml of human blood. If working with lower blood volumes ensure
to keep the appropriate ratio for blood versus PBS versus Ficoll-
paque.
1. Aliquot 10 mL of Ficoll-paque (pre-warmed to RT) into a 50
mL conical tube.
2. Dilute 10 mL of blood with PBS to a final volume of 40 mL.
3. Carefully layer the 40 mL of diluted blood on top of the Ficoll-
Paque layer.
4. Centrifuge at 1800 × g for 25 min, at room temperature.
Critical: set centrifuge to acceleration = 0 - 1 and brake = 0
- 1.
5. Collect the PBMC layer, which is found at the Plasma (PBS)–
Ficoll interface, and transfer it into a 50 mL conical tube. Top
up with PBS to a final volume of 50 mL.
6. Centrifuge at 365× g for 5 min, at 4°C. Critical: set centrifuge
to maximum acceleration and maximum brake.
7. Aspirate the supernatant.
8. Re-suspend the pellet in 1 mL of RBC lysis buffer, incubate
for 5 min, at room tempertaure in the dark.
9. Top up with PBS to a final volume of 50 mL
10. Centrifuge at 365 × g for 5 min, at 4°C.
11. Aspirate the supernatant and re-suspend the pellet (which
contains the immune cells) in 1 mL of PBS.
12. Transfer cells into a 1.5 mL microcentrifuge tube, perform
cell count, and proceed with staining protocol as described in
6.4.5.
6.5.2 Step-by-step sample preparation for human spleen DCs, mono-
cytes, and macrophages.
1. Prepare 20 mL of digestion buffer (see Section 6.3.3.1).
2. Transfer spleen sample into 2 mL microcentrifuge tube con-
taining 0.5 mL of the digestion solution. Using a small sterile
pair of scissors mince spleen tissue into small pieces.
3. Transfer the tissue suspension into one well of a six-well plate
and add on 4 mL (per well) of the digestion solution.
4. Incubate for 1 h at 37 °C.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1764 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
5. Pipette up and down –six to eight times with a 10 mL dis-
posable transfer pipette in order to disrupt the remaining
tissue/gain a single cell suspension, and transfer suspen-
sion over a 70 µm cell strainer into a 50 mL conical tube.
Rinse the well with PBS and add to cell suspension in the
50 mL conical tube (via filter; to ensure minimum cell loss).
Adjust the volume of the suspension with PBS to a total of
50 mL.
6. Centrifuge at 365 × g for 5 min, at 25°C.
7. Aspirate supernatant and re-suspend the pellet in 40 mL of
PBS, to achieve a proper dilution of the spleen cell suspension.
8. Aliquot 10 mL of pre-warmed (room temperature) Ficoll-
paque into a new (clean) 50 mL conical tube.
9. Carefully transfer the 40 mL of the diluted spleen cell sus-
pension as a top layer onto the 10 mL of pre-warmed (room
temperature) Ficoll-paque.
10. Follow steps 4–12 from Chapter 6.5.1 (Sample preparation
for human blood DCs, monocytes and macrophages).
6.5.3 Step-by-step sample preparation for human lung DCs, mono-
cytes, and macrophages.
1. Follow Steps 1–7 from Chapter 6.5.2 (Sample preparation for
human spleen DCs, monocytes, and macrophages).
2. Then, follow Steps 4–12 from Chapter 6.5.1 (Sample prepara-
tion for human blood DCs, monocytes and macrophages).
6.5.4 Step-by-step sample preparation for human skin (epidermis)
DCs, monocytes, andmacrophages. Critical: Skin should be imme-
diately immersed in RPMI1640 upon collection and incubated on
ice until further processing.
1. Cut skin into strips (1 × 5–10 cm) using disposable scalpels,
in a large petri dish.
2. Cover circular Styrofoam with a rubber mat and place a sterile
silicon mat on top.
3. Pin down the skin longitudinally at one end with 2 × 25 G
needles, keeping it stretchedwhile pulling down from the other
end.
4. Shave skin using a Goulian knife by applying a side-to-side
slow motion, to make it thinner. Critical: Blades should not be
re-used (to avoid contamination).
5. Spread shaved strips in a 15 cm Petri dish containing 50 mL of
RPMI1640 supplemented with: 10% FCS, 1% L-glutamine, 1%
Pen/Strep, 0.8 mg/mL Worthington’s collagenase (1×), and
0.05 mg/mL DNase.
6. Cut the skin strips into pieces of 1 cm2 and incubate them for
a minimum of 18 h, at 4°C.
7. Pipette up and down for about –eight to ten times using a 10mL
disposable transfer pipette, in order to disrupt the epidermis
and dermis layers. Filter through a 70 µm cell strainer into a 50
mL conical tube. Rinse the Petri dish with PBS and add through
filter to cell suspension to ensure minimum loss of cells.
8. Adjust volume of the skin cell suspension with PBS, to a total
of 50 mL.
9. Follow steps 6–12 from Chapter 6.5.1 (Sample preparation for
human blood DCs, monocytes, and macrophages).
6.5.5 Staining for human DCs and monocytes/macrophages from
different tissues. Notes:
 The following protocol is used for staining DCs and mono-
cytes/macrophages (optimal 1–5 × 106 cells/tube for staining)
isolated from human blood (see Section 6.5.1), spleen (see
Section 6.5.2), lungs (see Section 6.5.3), and skin (see Section
6.5.4).
 For Abs and reagents, see Table 59
 Staining can be performed either in a 1.5 mL microcentrifuge
tube or a V-shaped 96-well plate (non-culture-treated).
1. Aliquot required number of cells, and centrifuge at 650 × g for
2 min, at 4°C.
2. Aspirate/discard the supernatant and re-suspend the cell pel-
let in 1 mL of PBS containing Live/Dead blue dye (1:1000),
incubate for 20 min, at 4°C in the dark.
3. Add human AB serum or FCS, at a final dilution of 5%, and
incubate for 15 min, at 4°C in the dark, in order to block FC
receptors on the immune cells and to neutralize free Live/Dead
molecules that bind protein N-terminal amines. Tip: During the
incubation time for steps 2 and 3 prepare the Ab pre-mix at
final dilutions as described in Table 59.
4. Add 200 µL of FCM buffer and centrifuge at 650 × g for 2 min,
at 4°C.
5. Aspirate/discard the supernatant and re-suspend the cell pellet
in 50 µL of Ab pre-mix. Incubate for 30 min, at 4°C in the dark.
6. Add 200 µL of FCM buffer, and centrifuge at 650 × g for 2
min, at 4°C.
7. Aspirate/discard the supernatant, then:
(a) For staining monocytes/macrophages: proceed to step 9.
(b) For staining DCs: since a purified Ab is used to stain
CADM1 you will need to perform an additional staining
step, as described in step 8 before proceeding to step 9.
8. Re-suspend the cell pellet in 50 µL of FCM buffer containing
anti-Chicken-IgY-Alexa-Fluor 647. Incubate for 15 min, at 4°C.
Then add 200 µL of FCM buffer and centrifuge at 650 × g for
2 min, at 4°C. Aspirate/discard the supernatant.
9. Re-suspend the cell pellet in 200–400 µL of FCM buffer, filter
through a 70 µm cell strainer into a new (clean) FCM tube and
analyze using a suitable flow cytometer.
6.5.6 Gating strategies for identification of human DCs and mono-
cytes/macrophages in tissues. As depicted in Figs. 169 and 170,
a similar gating strategy is adopted for human blood, spleen, and
lung samples to characterize their cDC1, cDC2, as well as clas-
sical monocytes (cMo), intermediate monocytes (iMo) and non-
classical monocytes (ncMo) subsets. We also recently described
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Figure 169. Gating strategies for flow cytometric analysis of human DCs and monocytes in blood and spleen. For blood and spleen: (A) Exclusion of
doublets, (B) exclusion of doublets, (C) identification of cells based on their Forward and Side Scatter profile, (D) gating on CD45+ cells, (E) exclusion
of Live/Dead+ dead cells, (F) gating on Lin(CD3/CD19/CD20)− cells, and (G) gating on HLA-DR+ cells. (H) Gating on CD14−/lo CD16− DCs, CD14−/+
CD16+ monocytes and identification of CD14hi CD16− classical monocytes (cMo). (I) Identification of HLA-DRlo/+ CD14lo/+ nonclassical monocytes
(ncMo) and HLA-DRhiCD14hi intermediate monocytes (iMo). For Blood: (J) Gating on HLA-DR+ CD123+ cells for identification of early pre-DCs and
pDCs as well as HLA-DR+ CD123− cDCs. (K) Gating on classical DCs (cDC) based on expression of CD11c and CD26 (exclusion of CD11c− CD26−
non-cDCs). (L) Identification of CD1c− CADM1+ cDC1 and CD1c+ CADM1− cDC2 (M) Identification of CD123+ CD5+ CD169+ pre-DCs and CD123+
CD5− CD169− pDCs. For spleen: (J) Identification of HLA-DR+ CD123+ pDCs. (K) Gating on classical DCs (cDC) based on expression of CD11c and
CD26 (exclusion of CD11c− CD26− non-cDCs). (L) Identification of CD1c− CADM1+ cDC1 and CD1c+ CADM1− cDC2.
cDC progenitors in the blood, namely early pre-DC [1450], that
fall into the pDC gate and their respective gating is thus described
for human blood. A distinct gating strategy is also used to define
Langerhans cells (LCs) and macrophages in addition to cDC1,
cDC2, and pDC in the skin.
In the blood, spleen and lungs, DCs are identified by gating on
CD45+Lin−(CD3−CD20−) HLADR+CD14−/loCD16− cells, among
which cDC1 is identified as CD1c−/loCD11c−CD123−CADM1+
and cDC2 as CD1c+CD11c+CD123−CADM1−. In addition, for
blood, a unique gate is added to define CD123+CD5−CD169−
pDC and the recently described human cDC progenitors, that
is CD123+CD5+CD169+ early pre-DC [1450], while the spleen
and lungs’ pDCs are defined as HLADR+CD123+. Moreover,
cMo in the blood, spleen, and lungs are initially identi-
fied by gating on CD45+Lin−HLADR+CD14hiCD16− cells, while
CD45+Lin−HLADRlo-hiCD14lo-hiCD16+ cells are further classi-
fied into two subsets of HLA-DRlo/+CD14lo/+ ncMo and HLA-
DRhiCD14hi iMo.
In the skin, DCs are identified by gating on
CD45+Lin−(CD3−CD19−CD20−)HLADR+CD14−CD16−
cells, among which LCs are defined as CD1ahiCD11c−/lo
cells, while CD1a−/+CD11c−/+ non-LCs are classi-
fied as two subsets of CD1c+CD11c−SIRPα−CADM1+
cDC1 and CD1c+CD11c+SIRPα+CADM1− cDC2. In addi-
tion, skin macrophages are identified by gating on
CD45+Lin−HLADR+CD14+CD16−/lo cells.
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Figure 170. Gating strategies for flow cytometric analysis of human DCs and monocytes in lung and skin. For lung and skin: (A) Exclusion of
doublets, (B) exclusion of doublets, (C) identification of cells based on their Forward and Side Scatter profile, (D) gating on CD45+ cells, (E) exclusion
of Live/Dead+ dead cells, (F) gating on Lin(CD3/CD19/CD20)− cells, and (G) gating on HLA-DR+ cells. For lung: (H) Gating on SSC-Ahi CD206hi alveolar
macrophages (AM) (blue), SSC-Alo CD206hi interstitial macrophages (IM) (red) and SSC-Ahi CD206− monocytes. (I) Monocytes are divided into CD14+
CD16− classical monocytes (cMo) (red) and CD16+ monocytes (blue), and from there (J) into HLA-DRlo CD14lo non-classical monocytes (ncMo) and
HLA-DRlo CD14+ intermediate monocytes (iMo). (K) Gating on LIN- cells and (L) HLA-DR+ cells. (M) Gating on CD14−/lo CD16− DCs (and also CD14−/+
CD16+ monocytes (blue) and identification of CD14hi CD16− classical monocytes (cMo; red)). (N) Identification of CD123+ pDCs. (O, P) Gating on
classical DCs (cDC) based on expression of CD11c and CD26 (exclusion of CD11c− CD26− non-cDCs) and identification of CD1c− CADM1+ cDC1 and
CD1c+ CADM1− cDC2. For Skin: (H) Identification of CD14+ CD16−/lo macrophages, (I) Identification of CD1ahi CD11c−/lo Langerhans cells (LCs), (J)
Gating on cDC based on expression of CD11c and CD26, (K) Identification of SIRPα− CADM1+ cDC1 and SIRPα+ CADM1− cDC2, (L) Alternative way
to identify CD1c−/+ CADM1+ cDC1 and CD1c+ CADM1− cDC2 if using the same strategy as the other organs.
6.6 Pitfalls
First, generating qualitative FCM data requires proper combina-
tions of fluorochromes/markers. It should be avoided to use Abs
binding co-expressed markers conjugated with fluorochromes that
have a lot of fluorescence spill-over into channels in which they
are detected. Second, analyzing DC and monocyte/macrophages
by FCM requires using more than ten Abs and thus complexifies
the definition of a correct compensation matrix. Third, when ana-
lyzing FCM data using manual gating, a major challenge is to
avoid dropping out cells of interest along the gates. To facilitate
these two latter critical aspects of FCM data analysis, an initial
manual gating should be done to define major DC and monocyte
subsets.
Then, using a compatible software (Diva, Kaluza, and even-
tually Flow Jo), n dot plot (for an n color FCM panel) should
be defined (fluorochrome A on the x-axis vs. all the other flu-
orochromes on the y-axis) all displaying CD45+ cells with all
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the DC and monocyte subsets overlayed (each having a defined
color). This will allow the proper setting of “all fluorochromes-
the A fluorochrome” compensations. When all “fluorochrome X-
fluorochrome A” compensations are properly set, the next fluo-
rochrome must be displayed on the x-axis, and so on, until all
fluorochromes have been properly compensated.
Once compensations are properly set, twomethods can be used
for analysis, manual gating or unsupervised dimensionality reduc-
tion, latter being the most reliable method.
For manual gating, the different cell subsets must be displayed
in all gates defined to reach them by “back gating” to ensure that
each of them are present at all steps of the gating strategy. To
ensure that all populations can be properly visualized in all gates,
back gated cell subsets should be ordered by count, with the rarest
populations displayed above all the other cell subsets.
A major drawback of manual gating is that gates are defined
based on one (histogram) or two markers’ (dot plot) expression,
which in some cases does not allow the proper separation of cell
populations that share overlapping phenotypes. Thus, unsuper-
vised dimensionality reduction is now becoming the gold standard
method to avoid this, since it reduces all dimensions (one marker
= one dimension) into a 2D or 3D space. Machine learning-based
algorithms such as t-SNE [144], or UMAP [1470]; [1470, 1471]
combined with clustering algorithms [1450, 1472, 1473] allow
the proper identification and separation of cell subsets by integrat-
ing all markers analyzed. When performing dimensionality reduc-
tion on a very heterogeneous population, such as total CD45+
leukocytes, minor cell subsets will not be finely resolved, such as
DC subsets. Thus, dimensionality reduction can be first done on
total CD45+ cells using a dimensionality reduction method such as
UMAP that contrary to tSNE, allows the analysis of millions of cells
(events). As an illustration, total Live CD45+ cells from the same
FCM data of human blood, spleen, and lung from Fig. 169 and 170
were analyzed using the UMAP algorithm (Fig. 171A–C). The same
manual gating strategy was applied and for each step, the corre-
sponding populations were overlayed on the UMAP space, demon-
strating that manual gating leads to minor contaminations as illus-
trated by cells falling into the dashed black delimited regions (Fig.
171A).We next plottedmajor cell subsets definingmarkers expres-
sion as meaning plots to guide the unsupervised delineation of
all major mononuclear cell subsets (Fig. 171B–C). In the UMAP
bidimensional space obtained, Lin−HLA-DR+ cells (DC and mono-
cyte/macrophages) were not clearly resolved and thus, were gated
and reanalyzed with both the UMAP and t-SNE dimensionality
reduction algorithm together with the Phenograph clustering algo-
rithm to obtain a higher resolution of the cells comprised in this
gate (Fig. 171D–F). Analysis of the expression of DC and mono-
cyte/macrophage markers allowed the delineation of Phenograph
clusters corresponding to DC and monocyte/macrophage subsets
(Fig. 171D,E), and to compare the relative phenotype and distri-
bution of cell subsets in the blood, spleen, and lung (Fig. 171E–F).
This subgating can be done again in a particular subpopulation
of the second dimensionality reduced space obtained to further
increase the resolution of discrete cell populations.
7 Granulocytes
7.1 Neutrophils, eosinophils, and basophils
7.1.1 Overview. This chapter aims to provide guidelines for
researchers interested in analyzing polymorphonuclear leuco-
cytes. We describe a gating strategy to distinguish different subsets
of PMNs via FCM staining for human and murine blood samples.
Furthermore, we provide a simple method to examine phagocyto-
sis via FCM staining as well as basic tips and tricks for handling
neutrophils appropriately to prevent activation.
7.1.2 Introduction. Granulocytes are highly granular cells with
a distinct lobed nuclear morphology. They can further be divided
in basophils (0.5–1% of WBC), eosinophils (1–3% of WBC) and
neutrophils (50–70% ofWBC). Neutrophils exert potent antibacte-
rial functions and are involved in inflammatory diseases (see also
Chapter VI Section 7.2 Bone marrow and umbilical cord blood
neutrophils), whereas basophils and eosinophils help to control
parasitic infections and contribute to allergic reactions. Granulo-
cytes are rapidly recruited to sites of infection, providing robust
early microbial control. This feature is essential for the survival of
the host, however, comes with the need for special arrangements
when working with isolated granulocytes: All instrumentation and
buffers/media need to free of LPS and other pathogen-associated
molecular patterns (PAMPS) to prevent undesired activation. Fur-
ther, granulocyte exhibit a relatively short life span of only a few
hours to a few days and are sensitive to inappropriate treatment,
for example, harsh physical handling or high concentrations of cal-
cium. It is advisable to work rapidly, reduce manipulation steps
that could mechanically activate the cells and use the cells imme-
diately upon isolation. Therefore, it is necessary to use optimized
protocols for the dissociation of different tissues to prepare single
cell suspensions for FCM. The easiest way to obtain granulocytes
for analysis is to use whole blood (human or mouse) and perform
lysis of erythrocytes.
7.1.3 Step-by-step sample preparation. Successful FCM analysis
requires high quality single cell suspensions. Minimal manipula-
tion of the cells is essential for the quality of both Ab and cell
death staining. Human granulocytes are abundantly present in
peripheral blood and can be isolated via density centrifugation or
analyzed as a subpopulation of total leukocytes. Note that some
inflammatory disorders are characterized by low density granulo-
cytes that colocalize with PBMCs during density centrifugation. In
mice, granulocytes can be obtained from peritoneal lavage, i.e.,
after intraperitoneal injection of thioglycolate, whole blood, or
bone marrow (see Isolation Chapter VI: Section 8 Murine bone
marrow stromal cells). In some cases, enrichment for granulo-
cytes might be necessary and this can be achieved via density gra-
dient centrifugation (see Chapter IV Section 1.2 Pre-enrichment
by physical properties) or negative selection via magnetic beads
(see Chapter IV Section 1.3 Pre-enrichment by immunological
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Figure 171. Unsupervised analysis of
human DCs and monocyte/macrophages
in different tissues. Lin−HLA-DR+ cells
from Blood, Spleen and Lung data from
Figures 169 and 170 were analysed using
two dimensionality reduction methods,
Uniform Manifold Approximation and
Projection (UMAP) and t-Distributed
Stochastic Neighbor Embedding (t-SNE)
combined with the Phenograph auto-
mated clustering method. (A) Manual
gating strategy of the concatenated data
obtained from blood, spleen and lung
starting from Live CD45+ cells. The upper
panels show the different steps of the
manual gating strategy and the lower
panels show the projection of each step
of the gating strategy into a UMAP space.
(B) Meaning pots of lineage-defining
markers overlayed on the UMAP plot. (C)
UMAP plot showing the concatenated
data obtained in the three organs (upper
left panel), in the blood (red, upper left
panel), in the spleen (green, lower left
panel) and in the lung (brown, lower
right panel) where Lin−HLA-DR+ cells are
defined. (D) Meaning pots of the relative
expression of all parameters overlayed
on the tSNE and UMAP plots of the con-
catenated data (blood, spleen and Lung)
from Lin−HLA-DR+ cells exportes as
shown in (C). (E) Visualisation of pheno-
graph clusters overlayed on the tSNE
and UMAP plots of the concatenated
data (left panel), or of each individual
sample. Clusters corresponding to
pDC (pink), cDC1 (red), cDC2 (yellow =
enriched in DC2 to brown -= enriched
in DC3 [1474, 1475], CD14+CD16−
(blue to purple), CD14+CD16+
(cyan), CD14loCD16+ (green) mono-
cyte/macrophages, and three minor
undetermined clusters are shown. (F)
Frequencies of Phenograph clusters
defined in (B) regrouped by cell subsets
defined in (B).
properties). For FCM analysis, the initial cell suspension should
be depleted of erythrocytes (e.g., short hypotonic lysis with water,
ammonium chloride treatment, or use of commercially available
RBC lysis buffers).
7.1.3.1 Flow cytometric characterization of human and murine
granulocytes. Staining can either be performed before or after
lysis of RBC. In the protocol described below, lysis of erythrocytes
was performed prior to Ab staining. Due to the abundant expres-
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sion of Fc receptors on granulocytes, use of an Fc block is strongly
advised.
1. A total of 100 µL of human or murine whole blood is pel-
leted via centrifugation at 300 × g for 5 min. The cell pellet
is resuspended in a small volume and subjected to lysis with
hypotonic water (900 µL) for 20 s to lyse erythrocytes. Phys-
iological osmolality is re-obtained by addition of 100 µL of
10× PBS.
2. Cells are pelleted via centrifugation at 300 × g for 5 min and
resuspended in 100 µL HBSS (with 2% heat inactivated FCS
and Fc block). The samples are incubated for 15 min on ice.
3. Cells are pelleted via centrifugation at 300 × g for 5 min and
resuspended in 100 µL HBSS (with 2% heat inactivated FCS
and Abs). The samples are incubated for 30 min on ice in the
absence of light.
4. One milliliter of HBSS (with 2% heat inactivated FCS) is added
to the suspension and cells are pelleted via centrifugation at
300 × g for 5 min, resuspended in an appropriate volume of
HBSS (with 2% heat inactivated FCS) and subjected to FCM
analysis.
7.1.3.2 Flow cytometric detection of cell death in human granu-
locytes. Human granulocytes can easily be obtained via density
gradient centrifugation of human blood. Several different proto-
cols have been published, with some involving dextran sedimen-
tation of RBCs. The protocol we describe here omits the lengthy
dextran sedimentation step without affecting the purity of the
granulocyte fraction.
1. A total of 20 mL of anti-coagulated blood is diluted with 15 mL
PBS and gently layered on top of 15 mL Lymphoflot. Cells
are separated via centrifugation at 300 × g for 30 min with-
out break. The granulocytes layer directly on top of the RBCs
(whitish veil) and are collected and washed once in PBS. Note
that this fraction contains mainly neutrophils and eosinophils,
whereas basophils sediment in the PBMC fraction.
2. The cell pellet is resuspended in 200 µL of PBS. Hypotonic
lysis of erythrocytes is performed by addition of 36 mL of ice-
cold water for 20 s. Physiological osmolality is re-obtained by
addition of 4 mL of 10× PBS.
3. The granulocytes are resuspended in RPMI-1640 supple-
mented with 100 U/mL penicillin/streptomycin, 2 mM glu-
tamine, and 10% heat-inactivated FCS and 25 mM HEPES
at a concentration of 2 × 106 cells/mL and cultivated at
37°C/5% CO2. Due to the short life span of granulocytes,
detectable cell death will occur in less than 12 h.
4. Cell death is assessed by harvesting of cells via centrifugation
at 300× g for 5 min and resuspension at a concentration of 1×
106 cells/mL in HBSS supplemented with 2% heat inactivated
FCS, 100 ng/mL PI, and 1 µg/mL ANX-V. Staining is performed
on ice for 30 min.
5. Without an additional washing step, samples are directly sub-
jected to FCM analysis. Note that washing is not recommended
as this can result in the loss of subcellular particles and com-
promise integrity of apoptotic cells.
7.1.3.3 Flow cytometric detection of particle uptake in human
granulocytes.
1. A total of 20 mL of anti-coagulated blood is diluted with 15 mL
PBS and gently layered on top of 15 mL Lymphoflot. Cells
are separated via centrifugation at 300 × g for 30 min with-
out break. The granulocytes layer directly on top of the RBCs
(whitish veil) and are collected and washed once in PBS. Note
that this fraction contains mainly neutrophils and eosinophils,
whereas basophils sediment in the PBMC fraction.
2. The cell pellet is re-suspended in 200 µL of PBS. Hypotonic
lysis of erythrocytes is performed by addition of 36 mL of ice-
cold water for 20 s. Physiological osmolality is re-obtained by
addition of 4 mL of 10× PBS.
3. The granulocytes are re-suspended in in HBSS supplemented
with 2% heat inactivated FCS. A total of 20 µg/mL micro
monosodium urate crystals and 250 µg/mL Lucifer Yellow are
added and cells are incubated at 37°C/5% CO2 for various time
points.
4. Cells are collected and without additional washing directly
subjected to FCM analysis.
7.1.4 Materials.
7.1.4.1 Reagents. HBSS, calcium, magnesium, no phenol red
(ThermoFisher Scientific, 14025050)
Lymphoflot (Bio-Rad, #824012)
Lucifer Yellow CH (ThermoFisher Scientific, L453)
RPMI 1640 Medium (ThermoFisher Scientific, 21875034)
L-Glutamine (ThermoFisher Scientific, 25030081)
Penicillin–Streptomycin (ThermoFisher Scientific, 15140122)
HEPES (ThermoFisher Scientific, 15630056)
Fetal Calf Serum (Biochrom, S 0115)
Propidium iodide (Sigma, P4170)
Anx-V-FITC (Immunotools, 31490013)
Human TruStain FcXTM (Biolegend, 422301)
TruStain FcXTM PLUS (anti-mouse CD16/32) (Biolegend,
156603)
7.1.4.2 Instruments/Software.
GALLIOS flow cytometer (Beckman-Coulter)
Kaluza Analysis Software (Beckman-Coulter)
Prism 7 (Graphpad)
7.1.5 Data Analysis. Differential light scattering of cells depend-
ing on the size and morphology is useful to discriminate subsets
of cells. The SSC is considered to be an indicator for the inter-
nal structure of the cell (e.g., nuclear morphology) and the FSC
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Figure 172. Discrimination of granulocyte subpopulations. (A) Human cells were displayed in a SSC versus FSC dot plot to show the location of
eosinophils (green, high SSC), neutrophils (blue, high SSC), and basophils (red, low SSC). (B) Human cells were stained with Abs against CD45,
CD11b, CD15, CD16, CCR3, Siglec-F, and FcεRIα. CD45+/CD11b+ cells were gated on CD15 versus CD16 to distinguish granulocyte subpopulations.
CD15+/CD16+ cells were determined as neutrophils, CD15+CD16– were further designated as eosinophils by their expression of Siglec-8 and CCR3,
and the CD15–/CD16– population was depicted in a FcεRIα versus CCR3 plot to identify the double positive basophil fraction. (C) CD45+ murine
cells were gated on CD11b/Ly6C to display the CD11b+/Ly6int population that was further analyzed using Ly6G to identify neutrophils (blue).
CD11b+/Ly6Cneg-low cells were gated on Siglec-F versus CD200R3 and were subsequently analyzed for expression of additional cell subset markers.
CD200R3-cells expressing Siglec-F and CCR3 were designated as eosinophils (green) and Siglec-F-cells were marked as basophils (red) supported
by their expression of CD200R3 and CD49b.
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Table 62. List of Abs used for characterization of human granulocyte populations
Target Fluorophore Supplier Cat# Clone Host Isotype Cross-Reactivity
CCR3 PerCp/Cy5.5 BioLegend 310717 5E8 Mouse IgG2b, κ None
CD11b PE/Cy7 BioLegend 301321 ICRF44 Mouse IgG1, κ Yes
CD15 APC BioLegend 301907 HI98 Mouse IgM, κ Yes
CD16 APC/Cy7 BioLegend 302017 3G8 Mouse IgG1, κ Yes
CD45 FITC BioLegend 304005 HI30 Mouse IgG1, κ Yes
FcRε1 eFluor450 eBioscience 14-5899-82 AER-37 Mouse IgG2b, κ None
Siglec-8 PE BioLegend 347103 7C9 Mouse IgG1, κ None
reflects cellular size. Since both human and murine neutrophils
and eosinophils have a multi-lobulated nucleus, they exhibit a
high SSC signal, with eosinophils showing a slightly higher sig-
nal in this parameter. The nuclear morphology of basophils is less
complex and therefore they are found among the lymphocyte pop-
ulation and cannot be distinguished in such manner (Fig. 172A).
Furthermore, changes in SSC and FSC may also represent other
morphological features of various cellular processes (e.g., phago-
cytosis, cell death). These changes can also be detected in this
manner as described below in this section. It is recommended
to start your analysis with excluding doublets by gating on FS
PEAK Log versus FS INT Log to prevent an impact of doublets
on, e.g., population frequencies. Then, to detect either human
or murine granulocytes, it is useful to start with a staining for
CD45 to define WBCs accompanied by the simultaneous stain-
ing for CD11b. These two markers together with FSC and SSC
features are enough to roughly narrow down granulocytes from
whole blood preparations (Fig. 172A and C). Human neutrophils
are the most abundant cell type within the granulocyte family.
They can be further distinguished from other granulocytes by
their positivity for both CD15 and CD16. Eosinophils are pos-
itive for CD15, but do not express CD16. Additional staining
for CCR3 and Siglec-8 allows a specific detection of eosinophils.
Basophils neither express CD15 nor CD16; therefore staining with
anti-FcεRIα identifies them in the CD15neg/CD16neg population
(Fig. 172B).
Murine neutrophils and eosinophils are CD11b positive and
exhibit an intermediate to low expression of Ly6C. Neutrophils are
detected as Ly6G positive cells, whereas eosinophils are identified
by their expression of CCR3 and Siglec-F. Basophils also show
positivity for CD11b, but have only a low expression of Ly6C.
They can be further identified by the expression of CD200R3 and
CD49b (Fig. 172C).
Especially in the context of inflammatory infiltrates it is some-
times necessary to further determine neutrophil viability. During
the resolution of inflammation, neutrophils undergo apoptosis,
mediate anti-inflammatory and immunosuppressive effects, and
secrete factors that prevent the additional influx of neutrophils.
Apoptosis and necrosis can be detected by a combination of PI
and fluorophore-conjugated ANX-V. PI is a DNA-intercalating sub-
stance that only enters cells that have lost theirmembrane integrity
(necrotic cells and NETotic cells). ANX-V binds to phosphatidylser-
ine exposed by cells undergoing apoptosis (Fig. 173A). If granulo-
cytes have been purified prior to the L/D analysis, no Ab staining
is needed. However, if more than one cell type is present, the
cell death staining should be supplemented with an Ab combi-
nation allowing the identification of granulocytes as mentioned
above. FCM allow the simultaneous use of multiple fluorophores.
If such an instrument is available, the classical apoptosis stain-
ing deploying ANX-V-conjugates and PI can be supplemented
with two additional dyes (e.g. Hoechst33342 and 1,1′,3,3,3′,3′-
hexamethylindodicarbo-cyanine iodide (DilC1(5)) that allow a
more detailed characterization of cell death. This staining takes
into account the condition of the nucleus and the mitochondrial
membrane potential, respectively, and can also be deployed for
live-cell imaging [2256, 2257].
Further, neutrophils show a strong capacity to take up par-
ticulate matter. If confronted with nanoparticles or small-sized
monosodium urate crystals, neutrophils engulf these particles and
respond in an appropriate manner. Since such material cannot
be easily conjugated with fluorophores, one has to rely on other
methods to monitor their uptake. Soluble dyes, such as Lucifer
Table 63. List of Abs used for characterization of murine granulocyte populations
Target Fluorophore Supplier Cat# Clone Host Isotype Cross-Reactivity
CCR3 APC/Fire750 BioLegend 144521 J073E5 Rat IgG2a, κ None
CD11b eFluor450 eBioscience 48-0112-82 M1/70 Rat IgG2b, κ Yes
CD45 BV785 BioLegend 103149 30-F11 Rat IgG2b, κ None
CD49b APC BioLegend 108909 DX5 Rat IgM None
CD200R3 PE BioLegend 142205 Ba13 Rat IgG2a, κ None
Ly6C AlexaFluor 488 BioLegend 128021 HK1.4 Rat IgG2c, κ None
Ly6G PE/Cy7 BioLegend 127617 1A8 Rat IgG2a, κ None
Siglec-F PerCP-eFluor710 eBioscience 46-1702-82 1RNM44N Rat IgG2a, κ None
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1772 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
Figure 173. Apoptosis detection and uptake of nanoparticles in purified human granulocytes. (A) Granulocytes were cultivated at 37°C/5% CO2
for indicated time points and stained according to the cell death protocol. Subsequently, they were subjected to FCM analysis. During apoptosis,
granulocytes shrink and increase in granularity, as indicated by a decrease in FSC and an increase in SSC. Viable cells (V) first start to expose
ANX-V-FITC and become apoptotic (A), before they lose their plasma membrane integrity and become necrotic as indicated by PI-positivity (N).
Note that in the N-gate the population high in PI reflects cells without the loss of nuclear content. In contrast, the population low in PI reflects cells
with a subG1 DNA content, which is considered a hallmark of apoptosis. (B) A total of 20 µg/mL micro monosodium urate crystals and 250 µg/mL
Lucifer Yellow were added to the granulocytes and the suspension was incubated at 37°C/5% CO2 for the time points indicated. Subsequently,
FCM analysis was performed. The increase in Lucifer Yellow (in red) is restricted to the population of cells that increase in granularity. Therefore,
the simultaneous increase in Lucifer Yellow and SSC can be used to monitor the uptake of nanoparticles by granulocytes.
Yellow, can be added together with the prey that will subsequently
be co-ingested during phagocytosis. In addition, the uptake of par-
ticulate matter tends to increase the complexity of the phagocyte.
As shown in Fig. 173B, the increase in SSC and in Lucifer Yellow
strongly correlates. Combined observation of both represents a
feasible method for addressing such questions.
7.1.6 Pitfalls and top tricks.
 Neutrophil released from the BM are following a circadian
rhythm [1476]. To ensure the highest comparability, neu-
trophils from different donors (murine and human) should be
isolated roughly at the same time of the day.
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Figure 174. Flow cytometric analysis of murine bone marrow neutrophil subsets. Samples are first gated to exclude doublets and dead cells.
Debris are also excluded based on FSC and SSC information. Lineage positive cells (T, B, and NK cells) are then excluded followed by the exclusion
of eosinophils and monocytes. Ly6C is then used to further remove any Ly6Chi and Ly6Clo monocyte contamination. Gr-1 and CD11b gates for
total bone marrow neutrophils. cKit and CXCR4 is used to gate proliferative pre-neutrophils and CD101 distinguishes mature neutrophils from
immature neutrophils.
 When FCM analysis is performed, proper arrangements are
necessary to prevent neutrophil adhesion. Neutrophils show
a tendency to adhere under serum free conditions, to glass or
adhesive plastic surfaces and especially fast in response to stim-
ulation.
 Neutrophils are susceptible to changes in pH and readily form
NETs even under mildly alkaline conditions. Buffers should be
checked for pH prior to use. RPMI and HBSS can be supple-
mented with HEPES to stabilize the pH [1477].
 Neutrophils have a very limited life time. They undergo full
blown apoptosis in less than 24 h. In addition, several stimuli
induce the formation of neutrophil extracellular traps. Although
it is possible to detect NETs as material with very high SSC, FCM
is not robust enough to quantify NETs. Furthermore, NETs tend
to aggregate and form material that cannot be collected by
standard needles.
 Phagocytic uptake of particles alters themorphology of a variety
of cell types. It is therefore not advisable to identify granulocyte
populations only by SSC.
 Activation of leucocytes is usually accompanied by shedding
or membrane renewal consequently changing their phenotype
(e.g., CD16 downregulation).
 L/D stainings deploying ANX-V must be performed in the pres-
ence of at least 2 mM calcium, since binding of ANX-V to phos-
phatidylserine is calcium-dependent. Avoid washing to prevent
loss of subcellular particles and impairment of apoptotic cell
integrity.
 Granulocytes express a variety of Fc receptors. To prevent false-
positive staining’s and to reduce the background fluorescence,
we advise to always block unspecific bindings with 2% FCS and
to prevent Fc-mediated Ab binding via the use of an Fc blocking
agent.
7.2 Bone marrow and umbilical cord blood neutrophils
7.2.1 Overview. The developmental pathway of neutrophils
has been recently investigated with great interest [1478–1480].
However, there is still no universally accepted characterization of
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Figure 175. Flow cytometric analysis of human umbilical cord blood neutrophil subsets. Similarly, to the mouse neutrophil subsets, doublets, and
dead cells are first excluded, followed by the exclusion of CD45− cells and debris. Lineage cells and CD14+ conventional monocytes are excluded
before total granulocytes are gated with CD15 and CD66b. From there, eosinophils are excluded before gating on the classical nomenclature of
neutrophil subsets using CD11b and CD16. P M = Promyelocytes and Myelocytes, MM = Meta-myelocytes, BN = Band cells, SN = Segmented
neutrophils. Gating is adapted from ref. [1487, 1494].
neutrophils by FCM. Moreover, tissues such as bone marrow and
spleen contain multiple cell types, which may share overlapping
surface markers that can lead to contamination and improper
identification. Here, we propose an FCM framework to identify
and isolate pure populations of neutrophil subsets, which can be
generally applied to most tissues in mice and human. We provide
the necessary surface markers, reagents, and tips for successful
characterization of neutrophil subsets.
7.2.2 Introduction. Granulocytes are the granule-producing
branch of the myeloid cell lineage that includes neutrophils,
eosinophils, and basophils [1481]. Neutrophils represent the
large majority of granulocytes and are involved in a myriad
of immune functions and diseases [1482–1484]. Flow cytomet-
ric analysis and characterization of neutrophils has been per-
formed over 20 years ago [1485]. The stages of granulopoiesis—
myeloblasts, promyelocytes, myelocytes, metamyelocytes, band
cells, and hyper-segmented neutrophil—have been characterized
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Figure 176. Potential improvements to classical nomenclature and gating. Using proliferation as a marker, total neutrophils can be first gated
(according to Figure 175) before gating on proliferative CD11b+ preNeus using CD101 and CD49d as shown previously [1478]. The remaining
non-proliferative pool of neutrophils can be separated with CD10 as described recently [1489].
by the use of markers such as CD11b, CD15, and CD16. Tradition-
ally, these analyses were performed by correlating surface marker
expression levels with the morphological characteristics of the dif-
ferent stages of terminal granulopoiesis [1486, 1487].
Recently, neutrophil heterogeneity in disease has been of a
growing interest with the introduction of neutrophil subsets with
the underappreciated roles previously [1484, 1488, 1489]. Many
of these reports suggest an immature phenotype of granulo-
cytes [1480, 1490–1492], suggesting the importance of investigat-
ing neutrophil function in relation to the various developmental
stages.
Therefore, understanding the stages of neutrophil maturation
provides a firm foundation to study these novel functions of
neutrophils. Indeed, recent evidence shows how clearly defined
subsets of neutrophils can specifically perform distinct functions
that influence the disease progression of arteriosclerosis [1493].
In this section, we provide guidelines in analyzing neutrophil
subsets characterized by their distinct functions and the roles
they play during inflammatory states [1478].
7.2.3 Step-by-step sample preparation.
7.2.3.1 Step-by-step sample preparation of murine bone marrow
neutrophils.
1. Isolate femur bone with a scalpel by dislocating ball–socket
joint at the hip. Detach kneecap joint connecting the tibia.
Table 64. Most important markers for FCM analysis of human and
murine granulocytes. All cell types were first gated on CD45 and
CD11b positivity
Cell type Human Mouse
Neutrophil CD15pos, CD16pos,
CD66bpos
Ly6Cint, Ly6Gpos
Eosinophil CD15pos, CD16neg,
Siglec-8pos, CCR3pos
Ly6Clow/int, Siglec-Fpos,
CCR3pos
Basophil CD15neg, CD16neg,
CD117neg, *FcεRIαpos,
CCR3pos, *CD203cpos
Ly6Clow, CD200R3pos,
CD49bpos, *FcεRIαpos
* These markers were not used in our analysis, but are valid markers
for the given cell types.
Clean off muscle tissue and cut off the ball of the femur to
create an opening.
2. Using a 1mL syringe with a 19-gauge needle containing 1 mL
wash buffer (PBS + 2% FCS + 2 mM EDTA), flush marrow out
through the opening into a 15 mL falcon tube containing 1 mL
of buffer. Aspirate and repeat twice. Flush marrow from the
opposite end. Aspirate and repeat twice.
3. Filter suspension through a 70 µM strainer to remove clumps
and bone chips. Wash strainer with 4 mL of buffer. Centrifuge
cells at 4°C, 400 × g for 5 min.
4. Discard supernatant and re-suspend pellet with 1 mL of buffer.
Aliquot a fraction out for staining purposes. One-fifth is typi-
cally adequate.
5. Wash and centrifuge sample aliquot with buffer. Discard super-
natant and re-suspend cells in 50 µL blocking buffer. Add 50 µL
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of staining buffer with the Abs (See Tables 63 and 64). Incu-
bate at 4°C for 30 min.
6. Add 2 mL of wash buffer and centrifuge. Discard supernatant.
7. Lyse erythrocytes with 200 µL 1× RBC lysis buffer for 3 min.
Wash.
8. Re-suspend in wash buffer, add DAPI, and filter sample before
acquisition.
#Gating: pre-Neutrophils are defined as Lin− Gr-1+ CD11b+
cKithi CXCR4hi cells. Immature Neutrophils are defined as
Lin− Gr-1+ CD11b+ cKit− CXCR4lo CD101− cells. Mature Neu-
trophils are defined as Gr-1+ CD11b+ Ly6G+ CD101+ cells (See
Fig. 174).
7.2.3.2 Step-by-step sample preparation of human bone marrow
neutrophils.
1. Collect donor bone marrow aspirate in heparin saline contain-
ing ACD-A (acid-citrate-dextrose formula A).
2. Wash sample aliquot with 2 mL of 1× PBS. Centrifuge at
4°C, 400 × g for 5 min. Discard supernatant. Perform cell
count.
3. Using 5 million cells, block Fc-receptors using purified anti-
human CD16/32 Ab for 30 min at 4°C. Add staining buffer
containing Abs (see Tables 62 and 64). Incubate at 4°C for
30 min.
4. Wash sample with PBS and centrifuge at 4°C, 400 × g for 5
min. Discard supernatant.
5. Lyse erythrocytes with 500 µL 1× RBC lysis buffer for 3 min.
Wash.
6. Add DAPI and acquire cells.
7.2.3.3 Step-by-step sample preparation of human cord blood
neutrophils.
1. Lyse erythrocytes with 1 mL of 1× RBC buffer for every 100 µL
of cord blood. Incubate at room temperature for 6 min or until
sample becomes translucent.
2. Neutralize with 1× PBS. Centrifuge at 4°C, 400 × g for
5 min.
3. Using 5 million cells, block Fc-receptors using purified anti-
human CD16/32 Ab for 30 min at 4°C (See Table 64).
Add staining buffer containing Abs. Incubate at 4°C for
30 min.
4. Wash sample with PBS and centrifuge at 4°C, 400 × g for
5 min. Discard supernatant. Add DAPI and acquire cells (See
Figs. 175 and 176 for gating strategies).
7.2.3.4 Materials.
General reagents.
 Dulbecco’s PBS with calcium and magnesium
 Wash buffer: PBS with 2% heat-inactivated FCS and 2 mM
EDTA.
 70 µM Cell-strainer mesh
 1× RBC lysis buffer (eBiosciences)
Staining reagents for murine neutrophils
Table 64. List of antibodies used for characterisation of neu-
trophil subsets
Marker Fluorophore Supplier Catalog number Clone Host Isotype
CD101 PE eBioscience 12-1011 Moushi101 Rat IgG2a, к
Siglec-F PE-Texas Red BD Biosciences 562757 E50-2440 Rat IgG2a, к
Ly6G PE-Cy7 Biolegend 127618 1A8 Rat IgG2a, к
B220 PE-Cy7 eBioscience 25-0452 53-6.7 Rat IgG2a, к
NK1.1 PE-Cy7 eBioscience 25-5941 PK136 Mouse IgG2a, к
CD90.2 PE-Cy7 eBioscience 25-0902-82 53-2.1 Rat IgG2a, к
Gr-1 PerCP-Cy5.5 eBioscience 45-5931-80 RB6-8C5 Rat IgG2b,к
cKit SB436 eBioscience 62-1171 2B8 Rat IgG2b, κ
CD11b BV655 Biolegend 101259 M1/70 Rat IgG2b, к
CD115 APC eBioscience 61-1152 AFS98 Rat IgG2a, к
Ly6C APC/Cy7 eBioscience 47-5932 HK1.4 Rat IgG2a, к
CXCR4 Biotin eBioscience 13-9991-80 2B11 Rat IgG2b, к
Streptavidin BUV395 BD Biosciences 564176 − − −
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Staining reagents for human neutrophils
Marker Fluorophore Supplier Catalogue Number Clone Host Isotype
CD10 FITC Biolegend 312208 HI10a Mouse IgG1, κ
CD33 PE Biolegend 303404 WM53 Mouse IgG1, κ
CD49d PE-Texas Red BD Biosciences 563645 9F10 Mouse IgG1, κ
CD3 PE-Cy7 Biolegend 300420 UCHT1 Mouse IgG1, к
CD19 PE-Cy7 eBioscience 25-0199 HIB19 Mouse IgG1, к
CD56 PE-Cy7 Biolegend 318318 HCD56 Mouse IgG1, к
CD34 PE-Cy7 Biolegend 343516 581 Mouse IgG1, к
CD66b BV421 BD Biosciences 562940 G10F5 Mouse IgM, к
CD15 BV655 BD Biosciences 564232 HI98 Mouse Ig2M, к
CD14 BV711 Biolegend 301838 M5E2 Mouse IgG2a, к
CD101 APC Biolegend 331010 BB27 Mouse IgG1, к
CD45 APC-Cy7 Biolegend 304014 HI30 Mouse IgG1, к
CD16 BUV737 BD Biosciences 564434 3G8 Mouse IgG1, к
CD16/32 Purified BD Biosciences 564219 2.4G2 Mouse IgG2b, к
CD11b BUV395 BD Biosciences 563839 ICRF44 Mouse IgG1, к
Flow Cytometer. All experiments were performed on a
LSRII flow cytometer with a 365, 405, 488 nm, 561, and
640 nm configuration (BD Bioscience). Filters: 379/34(365)
for BUV395; 740/35(365) for BUV737; 450/50(365) for DAPI;
530/30(488) for FITC or AF488; 685/35(488) for PerCP-Cy5.5;
450/50(405) for BV421 or SB436; 525/50(405) for BV510
or V500; 660/20(405) for BV650; 710/40(405) for BV711;
800/50(405) for BV785; 585/15(561) for PE; 610/20(561) for
PE-Texas Red; 780/60(561) for PE-Cy7; 675/20(640) for APC or
AF647; 730/45(640) for AF700; 780/60(640) for APC-eF780 and
APC-Cy7.
7.2.3.5 Pitfalls.
 Human neutrophils are sensitive to Ficoll, and will change the
expression of certain markers. For example, Ficoll will down-
regulate CD49d expression that prevents the isolation of prolif-
erative preNeus from immature Neus.
 Besides Ficoll, temperature can affect marker expression.
Therefore, keep cells on ice throughout sample preparation as
markers like CD115 will down-regulate.
Eosinophils can be a big source of contamination as they share
manymarkers like CD15 and CD11b with neutrophil subsets. They
are CD101+CD49d+CD16− and express Siglec-8. Gating them out
is essential, especially in eosinophilic patient samples.
7.2.3.6 Top tricks.
 In certain inflammatory conditions, such as a bacterial chal-
lenge, neutrophils may lose Ly6G expression. Make use
of SSC information and Ly6C expression level to gate for
neutrophils.
 Perform titration of Abs for optimal staining index. Typically,
0.25 µL is used for mouse Abs for one-fifth of femur marrow
and 2 µL per 5 million cells is used for human Abs.
 Bonemarrow composition in tibias, humeri, pelvis, and sternum
are similar to the femur. Therefore, use these bones if large
numbers of neutrophils are required for sorting purposes.
 Gr-1 labels both Ly6G and Ly6C. When staining, use twice the
amount of Ly-6G to prevent competitive binding by Gr-1.
7.2.3.7 Table summary of neutrophil subset phenotypes inmouse
and human.
Neutrophil Subset Mouse Human
Pre-Neutrophils CD115−SiglecF−Gr-1hiCD11b+CXCR4hicKithiLy6GloCD101− CD66b+CD15+CD49dloCD101−CD16+CD10−
Immature Neutrophils CD115−SiglecF−Gr-1hiCD11b+CXCR4locKitloLy6G−/+CD101− CD66b+CD15+CD49d−CD101+CD16++CD10−
Mature Neutrophils CD115−SiglecF−Gr-1hiCD11b+CXCR4locKitloLy6G+CD101+ CD66b+CD15+CD49d−CD101+CD16++CD10+
Classical Human
Nomenclature Markers
Promyelocyte/Myelocyte CD66b+CD15+CD11b− CD16−
Metamyelocyte CD66b+CD15+CD11b+ CD16−
Band Cells CD66b+CD15+CD11b+ CD16+
Segmented Neutrophil CD66b+CD15+CD11b+ CD16++
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8 Murine bone marrow stromal cells
8.1 Overview
The bone marrow (BM) stroma plays a critical role in the main-
tenance of hematopoietic homeostasis. The ability to isolate BM
stromal cells at high efficiency is critical to maximize cell recovery
and reproducibility of the isolation procedure. In this section, we
describe the processing of BM samples through sequential enzy-
matic digestion and the gating strategy used to identify stromal
and mesenchymal stem cells (MSCs).
8.2 Introduction
The bone marrow stroma is composed of non-hematopoietic cells
responsible for the structural organization of the marrow cav-
ity where they support blood cell development. Early work by
Friedenstein et al. has shown that stromal cells could be distin-
guished from hematopoietic cells by their adherence to plastic
culture dish and their ability to form fibroblastic colonies (called
CFU fibroblasts or CFU-F) when plated at clonal density [1495].
Subsequently, a single CFU-F was shown to generate heterotopic
ossicles when transplanted in vivo [1496]. These studies paved the
way to our understanding of how BM stromal cells regulate devel-
opmental and steady-state hematopoiesis. MSCs located at the top
of the stromal hierarchy can self-renew and differentiate into bone,
fat, and cartilage [1497]. MSC populations are found in distinct
perivascular niches where they regulate hematopoietic stem and
progenitor functions through the action of cell-bound or secreted
cytokines [1498]. In the developing mouse marrow, CD45– Tie2–
Thy1.1– CD105+ CD51+ progenitors undergo endochondral ossi-
fication and contribute to the formation of the BM cavity by pro-
moting vascularization and the formation of an hematopoietic
stem cell (HSC) niche [1499]. In the adult mice BM, MSCs can
be labeled by GFP in Nestin-GFP transgenic mice, wherein Nestin-
GFP+ cells contain all CFU-F activity or mesensphere formation
capacity of the BM [1500]. Nestin-GFPbright cells mark periarteri-
olar stromal cells that are significantly associated with quiescent
HSCs and secrete niche factors such as Cxcl12 and Stem Cell Fac-
tor (SCF) that contributes to HSC localization and maintenance
[1501]. Nestin-GFP+ cells also highly overlap with stromal cells
expressing the Leptin receptor [1502], Cxcl12-abundant reticu-
lar (CAR) cells [1503] or Prx-1-cre cells [1504] that have also
been described as regulators of hematopoietic stem and progen-
itors functions. Lineage tracing has also revealed the osteogenic
and stromal contribution of MSCs during development [1505].
Furthermore, skeletal stem cells found in the periosteum of long
bones have been shown to contribute to bone formation at steady
state or after injury [1506–1508].
To study murine BM stromal cells populations, cell surface
markers have been proposed to facilitate their identification, but
many of these markers are expressed on cultured cells and may
differ from freshly isolated stromal cells [1509]. In addition, dis-
tinct stromal cell populations can be extracted depending on the
isolation methods. Sequential digestion of BM plugs results in effi-
cient extraction of stromal cells with MSC activity [1510]. CD51+
PDGFRa+ CD45– Ter119– CD31– cells comprise most of detectable
BM MSC activity isolated from flushed BM plugs and can recon-
stitute an ectopic HSC niche when transplanted under the kid-
ney capsule [1511]. Crushed bone can result in an enrichment
of PDGFRa+ Sca-1+ CD45– Ter119– CD31– MSCs [1512, 1513] or
skeletal stem cells expressing Gremlin1 [1514] and CD200 [1506].
While a hierarchal organization for skeletal stem cells and down-
stream progenitors responsible for cartilage, bone, and stromal
cell generation has been proposed [1506], it remains unclear
how the bone-associated skeletal stem cells and BM-associated
MSCs relate to each other. Therefore, the isolation method
(enzymatic treatments, bone crushing, or flushing) will influ-
ence the content and heterogeneity found within the stromal cell
fraction.
8.3 Step-by-step sample preparation
The stromal fraction of the BM is classically defined by the
absence of CD45 (hematopoietic), Ter119 (erythroid) and CD31
(endothelial) marker expression. CD45– Ter119– CD31– or triple-
negative cells (TNCs) are known to contain stromal cells as well
as hematopoietic cells [1515]. In order to isolate BM stromal
cells, femurs or tibias from mice can be cut below the metaph-
ysis toward the epiphysis and the BM is flushed out as an intact
plug using syringe with 21G (femur) or 25 ½ G (tibia) needle con-
taining digestion buffer (collagenase type IV 2 mg/mL and dispase
1 mg/mL in HBSS). While CD45, CD31, Ter119, and CD51 epi-
topes have been shown to be resistant to cell digestion [1515], it
is important to compare the sensitivity of each marker to be tested
on digested cells and undigested or flushed cells. BM plugs are
sequentially digested three times for 10 min at 37°C. The super-
natant, which contains cells released by the digestion process, is
collected after each digestion and pooled into a 50 mL tube con-
taining ice-cold FCM buffer (PBS, EDTA 2 mM, BSA 0.1%) to
prevent any loss of cell surface markers or cell viability. Following
the digestion process, enzymatically dissociated cells can be cen-
trifuged and the pellet can be subjected to RBC lysis. Cells are then
filtered through a 100 µm cell strainer to remove any clumps prior
to staining for FCM analysis. For cell sorting, it is recommended to
perform CD45+ cells depletion using microbeads directly conju-
gated with CD45 mAb (Miltenyi Biotec) that will enrich for TNCs.
After incubation with CD45 microbeads the cell suspension is
washed, pelleted and resuspended in 500 µL FCM buffer. Cells
are applied to a column (Miltenyi Biotec) coupled with a magnet
which will retain CD45+ hematopoietic cells. Cells are eluted by
washing the column with 2 × 1mL of FCM buffer and can be used
for antibody staining (Table 65) for 15 min at 4°C. Stained cells
are washed and resuspended in FCM buffer containing a viability
dye such as DAPI or 7-AAD.
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Figure 177. Gating strategy for murine BM stroma. Live single cells are separated using CD45, Ter119, and CD31 markers (left panel). Gated
TNCs are then analyzed for their expression of stromal marker CD51 and for excluding hematopoietic cells by using CD44 (middle panel). MSC
populations can be found within CD51+ TNCs where PDGFRα expression can be detected (right panel).
Table 65. Antibodies to analyze mouse bone marrow stromal cells
Antibody Fluorochrome Clone Company
CD45 Alexa Fluor 700 30-F11 BioLegend
Ter119 Alexa Fluor 700 Ter-119 BioLegend
CD31 Pacific Blue 390 BioLegend
CD51 Biotin RMV-7 eBioscience
CD44 PE-Cy7 IM7 eBioscience
PDGFRα APC APA5 eBioscience
Streptavidin APC-eFluor 780 − eBioscience
8.4 Materials
8.4.1 Animals. Adult mice such as C57BL/6 (8–12 weeks old).
8.4.2 Reagents.
1. Collagenase type IV (Gibco, Cat #17104019)
2. Dispase (Gibco, Cat #17105-041)
3. Ammonium chloride (Sigma, Cat #A4514)
4. DAPI (Sigma, Cat #D9542)
8.4.3 Solutions.
1. HBSS (Corning, Cat #21-023-CV)
2. FCM buffer (PBS 1×, EDTA 2 mM, BSA 0.1%)
3. RBC lysis buffer (NH4Cl 0.17 M, KHCO3 0.01 M, EDTA 0.1
mM)
4. Digestion buffer (Collagenase IV 2 mg/mL, Dipase II 1 mg/mL
in HBSS)
5. DAPI (0.05 µg/mL in FCM buffer)
8.4.4 Equipment.
1. 1 mL syringe with 21G × 1 needle (for femurs) or 25 G × 5/8
needle (for tibias)
2. 100 µM cell strainer (Falcon, Cat #08-771-19)
3. CD45microbeads, mouse (Miltenyi Biotec, Cat #130-052-301)
4. MACSR R© LS column (Miltenyi Biotec, Cat #130-042-401)
5. QuadroMACSR R© separator (Miltenyi Biotec, Cat #130-090-
976)
6. FCM cell sorter (at least five colors and equippedwith UV laser)
8.5 Data analysis
When using adult mice, TNCs represent approximately 0.5% of
total single live BM cells (Figure 177). The TNC fraction contains
mostly hematopoietic cells (85%), which are found in the CD44+
CD51– and CD44– CD51– TNCs. Gating on CD51+ cells allows the
separation of bona fide stromal cells from hematopoietic TNCs,
while MSCs can be further selected by gating on CD51+ PDGFRa+
TNCs (Fig. 177). Cell surface markers such as CD200, Thy-1, and
6C3 can be used to distinguish among cartilage, bone, and stromal
cells when samples are made from crushed bones [1499, 1506,
1513]. Consistency in the processing of BM plugs should limit the
variation in the frequency of isolated TNCs or MSCs.
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8.6 Pitfalls
In the event that additional markers are to be included in the
gating strategy, their sensitivity to the enzymatic digestion should
be addressed. Samples should be analyzed as soon as possible
after processing and staining since digested BM cells have a higher
tendency of clumping together than undigested samples.
8.7 Top tricks
To ensure equal digestion throughout all samples, first harvest all
bones and place on ice, in PBS. Then, flush the first sample with
digestion buffer and directly put at 37°C. Start timer for the first
10 min of incubation and proceed with the second sample and
so on. A constant digestion incubation time is critical in order to
avoid overdigestion which could result in a loss of cell surface
markers, and to reduce variation among samples.
9 Hematopoietic Stem Cells
9.1 Overview
This chapter deals with the characterization, isolation, and prepa-
ration of murine and human hematopoietic stem cells (HSCs).
9.2 Introduction
Throughout life of mice and humans the major site of HSCs
is bone marrow [1516–1518]. HSCs are thought to reside in
cellular niches [1519–1521], generated by environmental non-
hematopoietic stromal cells of mesenchymal and endothelial ori-
gin (See Chapter VI Section 8 Murine bone marrow stromal cells)
and of other, hematopoietic cells, which ensure their quiescence
and longevity and their capacity to proliferate and/or differentiate
to more lineage restricted progenies. This proliferation and dif-
ferentiation continuously regenerates, and thereby maintains the
differentiated compartments of erythroid, myeloid, and lymphoid
cell lineages. Differentiation can occur in a hierarchical order
from LT-HSC to ST-HSC, to erythroid and megakaryocytic pro-
genitors and to lymphoid–myeloid progenitors (LMPP, MPP) and
from them to common lymphoid progenitors (CLP) and common
myeloid progenitors (CMP). These progenies give rise to erythro-
cytes, megakaryocytes, and platelets, monocytes, macrophages,
and granulocytes, and to lymphoid cells (T- and B-, dendritic,
innate, and natural killers and innate lymphoid cells). A part
of the generation of myeloid and erythroid cells can be initi-
ated directly from a special subpopulation of HSCs. Under stress,
such as a bacterial or viral infection, this direct differentiation to
granulopoiesis, erythropoiesis, and the development of megakary-
ocytes and platelets is increased and accelerated directly from
HSC [1522–1524].
Transplantation of HSC into suitably recipient hosts populates
all HSC and progenitor compartments in bone marrow of the host
and regenerates erythroid, myeloid, and lymphoid compartments
with donor-derived cells to normal sizes.
9.3 Murine hematopoietic stem cells
The first part of this chapter describes the methods for adult
murine hematopoietic stem cells.
In mice, HSCs are generated during embryonic development,
first extra-embryonically from cells in yolk sac, then from cells in
the embryonic aorta-gonad-mesonephros area via hemangioblasts,
which are common progenitors of vascular endothelium and
hematopoietic cells [1525, 1526]. These early progenitors seed
into fetal liver and fetal thymus to generate first, transient waves
of hematopoiesis. Shortly before birth, the developing marrow
of bone becomes the site, where HSC find an environment for
their life-long residence, hematopoietic renewal and differentia-
tion capacities [1527].
HSCs are identified by FCM, based on surface-marker expres-
sion. One set of fluorescent mAb combinations, and the FCM pro-
files of the stained bone marrow cells is given in Fig. 178. HSCs
are found in the 0.1% of all CD45+ bone marrow cells, which
do not yet express the markers of differentiated hematopoietic
cells, i.e., of F4/80+/Mac1+ monocytes and macrophages, Gr1+
granulocytes, CD11c+ dendritic cells, CD4+/CD8+/CD3+ T cells,
CD5+CD19+B220+ B cells, NK1.1+ NK cells, and Ter119+ ery-
throcytes. Thus, they are “lineage-negative” (Lin-. L). The absence
of these antigens and expression of CD45 is necessary to identify
the hematopoietic population within the lineage-negative (Lin−)
cells of the bone marrow. On the other hand, HSC express Sca-1
(S) and c-Kit (K), thus are called LSK-cells.
Furthermore, differences in surface expression of the CD150
and CD48 “SLAM” markers allow to distinguish long-term self-
renewing HSCs and transiently reconstituting multipotent pro-
genitors [1531–1533]. Thus, a Lin–c-Kit+Sca-1+−CD150+CD48–
population contains mainly long-term self-renewing HSCs, a
Lin–c-Kit+Sca-1+ CD150+CD48+ population mainly transiently
self-renewing multipotent progenitors, and a Lin–c-Kit+Sca-
1+CD150−CD48+ population mainly non-self-renewing multipo-
tent progenitors [1531–1533]. Their functions have been deter-
mined by transplantation analyses. These three distinct popu-
lations vary with each stage in the progression toward lineage
commitment in their frequency, engraftment-kinetics, self-renewal
potential, cell-cycle status, gene expression, and lineage distribu-
tion of the mature cells they can generate in vivo.
In the bone marrow of 2–3 month-old mice between 1 and 3 ×
103 LSK, CD150+CD48− cells remain in a non-proliferating, cell
cycle Go-resting state for life [1534, 1535].
Barcoding of these early progenitors shows that most of them
have clone sizes of less than ten cells, andmost of them retain these
small clone sizes, because they divide at best once a year in the
life of a mouse [1534, 1535]. A part of this HSC population can
be transplanted, remarkably even as single (e.g. CD45.1+) HSC
with carrier (CD45.2+) bone marrow cells into lethally irradiated
(ideally histocompatible CD45.1xCD45.2) recipients. They home
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Figure 178. Gating strategy of mouse
hematopoietic stem cells. Pheno-
typic characterization of mouse bone
marrow derived HSCs. LSK cells
were identified as c-kit+ Sca1+ cells
within the CD45+ Lin- compart-
ment. LT-HSCs were further identi-
fied as CD150+ CD48−, ST-HSCs as
CD150+ CD48+, and MPPs as CD150−
CD48+cells. LT-pHSCs can be further
characterized as Flk2−EPCR+ (CD201)
population within the CD150+ CD48−
gate. Gating for all colors were set
according to the isotype control stain-
ing (not shown). Forward and side
scatter voltages can be increased to
dissect bone marrow cell populations
into more differentiated subpopula-
tions, differing in size and density
(see general introduction).
to bone marrow and then repopulate all HSC compartments, all
hematopoietic progenitors and all mature cell lineages, except of
the long-lived resident myeloid cells generated from fetal liver
progenitors during embryonic development [1536]. These HSC
are called long-term repopulating (LT-HSC). Upon transplantation
LT-HSC can home back to bone marrow into special niches near
hypoxic areas of arteriolar vascular endothelium and barcoding
reveals a smaller number of these LT-HSC with much larger clone
sizes [1522].
Between 4 and 8 × 103 HSC are lin-sca1+c-kit+CD150+CD48+
HSC, which are in active G1-S-G2-M cell cycle, renewing their HSC
state by symmetric or asymmetric cell divisions. In asymmetric
cell divisions a fraction of them can enter differentiation to more
mature states of hematopoietic developments. When transplanted,
these HSC repopulate all different lymphoid and myeloid cell lin-
eages in subsiding waves, again without populating the embryon-
ically derived resident myeloid cell lineages. They do not repopu-
late the LT-HSC. Since they repopulate the transplanted host only
for a short time, they are short-term active HSC (ST-HSC). ST-
HSCs have also been described to be lin-sca1+c-kit+CD150-CD48-
cells [1534]. The relationship of these “SLAM”-negative HSC to the
double “SLAM”-positive ST-HSC remains to be investigated.
HSC can be mobilized to enter blood circulation. They might
differentiate in the periphery or pick up intracellular infections,
such as Mycobacterium tuberculosis, and then use their exception-
ally efficient capacity to return to bone marrow and become again
resident in their niches [1537].
9.3.1 Isolation of murine HSCs. The first step in the preparative
isolation of adult mouse HSCs from BM is the erythrolysis with
hypothonic ACK (ammonium-chloride-potassium) solution. The
next step usually consists of removing mature cells that express
“lineage” (Lin) antigens specific to terminally differentiated blood
cells, including F4/80+/Mac1+ monocytes and macrophages,
Gr1+ granulocytes, CD11c+ dendritic cells, CD4+/CD8+/CD3+
T cells, CD5+CD19+B220+ B cells, NK1.1+ NK cells, and Ter119+
erythrocytes. HSC are then enriched from the remaining cells as
Lin– CD45+ cells that express combinations of cell surfacemarkers,
c-Kit and Sca1. Multipotent hematopoietic progenitors, purified as
LSK (Lin− c-Kit+Sca-1+) make up <0.1% of nucleated BM cells.
They contain all multipotent progenitors in mice [1538–1541].
However, they are still heterogeneous, containing transiently
reconstituting multipotent progenitors in addition to long-term
reconstituting HSCs.
The differences in “SLAM”-marker expression between long-
term self-renewing HSCs and transiently reconstituting multipo-
tent progenitors permit the separation and independent isola-
tion of these different progenitor populations [1531–1533] as
Lin–c-Kit+Sca-1+ CD150+CD48–, mainly long-term self-renewing
(LT-)HSCs, Lin–c-Kit+Sca-1+ CD150+CD48+, mainly transiently
renewing HSC (ST-HSC), and Lin–c-Kit+Sca-1+ CD150−CD48+,
mainly non-renewing multipotent progenitors (MPP), as charac-
terized by transplantation analyses. These three distinct popu-
lations vary with each stage in the progression toward lineage
commitment in their frequency, engraftment-kinetics, self-renewal
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potential, cell-cycle status, gene expression, and lineage distribu-
tion of the mature cells they can generate in vivo.
However, “SLAM”-defined cells themselves are still heteroge-
neous populations in which HSCs represent, at most, 20% of all
cells. Further enrichment of LT-HSCs can be achieved by the purifi-
cation of SLAM-defined cells that express high levels of EPCR
(CD201) [1542]. The expression of CD34 and Flk2 further defines
the ST-HSC and MPP sub-populations, respectively [1543, 1544]
(Fig. 178A). Although transiently reconstituting multipotent pro-
genitors are enriched in the CD34+ fraction, they usually are not
purified based on CD34 expression. Rather, the current purifi-
cation protocols are based on the LSK, SLAM, and endothelial
protein C receptor (EPCR) expression patterns of these HSCs and
progenitors.
Alternatively, HSCs can be isolated due to their hypoxia-
induced high expression of the multidrug transporter proteins
MDR1 and ABCG2, thus, cells that retain only low levels of
DNA dyes, such as Rhodamine-123 (Rho123) and Hoechst 33342.
Rho123lo or Hoechstlo cells (“side population,” SP cells), and that
are Lin–c-Kit+Sca-1+ are nearly pure populations of long-term
reconstituting HSCs [1545, 1546] (Fig. 178B).
It should be kept in mind, that all these purified HSC pop-
ulations are still a heterogeneous collection of cells, when their
functions are considered. Thus, it is believed that myeloid-biased
HSCs express higher levels of CD150 and efflux Hoechst 33342
more efficiently than lymphoid-biased HSCs. They also exhibit
higher self-renewal ability as demonstrated by serial transplan-
tation of BM cells from primary recipients into secondary hosts.
Quantitative analyses of the frequencies of single HSC/progenitors
for a given function “in vitro” or “in vivo” (e.g., as done with sin-
gle cells) should be attempted to define their potencies [1547]
or [1522] or [1548] or [1549–1551].
9.3.2 Materials.
1. Adult mice such as C57BL/6, typically, 6- to 10-week-old mice
are used for the isolation of HSCs.
2. Staining medium: PBS Solution (1xPBS) with 0.5% BSA frac-
tion V, 2 mM EDTA, without azide.
3. Nylon screen (40 µm nylon mesh) to filter the cells after isola-
tion.
4. 10-mL syringes with 25-gauge needles to flush marrow out of
femurs and tibias.
5. Use 15-mL tubes to stain BM cells. Abs described in this proto-
col are available from eBioscience and BioLegend.
6. Lineage-marker Abs: anti-Mac1/CD11b (M1/70), anti-Gr1
(RB6-8C5), anti-Ter119 (TER-119), CD19 mAb (6D5), anti-
B220 (RA3-6B2), CD5 mAb (53-7.3), CD3ε mAb (145-2C11),
CD11c mAb (N418), CD4 mAb (GK1.5), CD8 mAb (53-6.7),
and anti-NK1.1 (PK136). Note that all Abs should be titrated
before use, and used at dilutions that brightly stain antigen
positive cells without nonspecific staining.
7. Anti-CD45 (30-F11), anti-Flk2 (A2F10), anti-EPCR/CD201
mAb (RCR-16), anti-Sca-1 (D7), anti-c-kit (ACK2), CD150mAb
(TC15-12F12.2), CD34mAb (RAM34), and CD48mAb (HM48-
1).
8. SP buffer (PBS, 2% FCS, 2 mM HEPES buffer; GIBCO, Life
Technologies), Hoechst 33342 (5 µg/mL, Molecular Probes,
Life Technologies).
9. A viability dye such as PI or 7-AAD.
9.4 Human hematopoietic stem cells
In this chapter we provide an overview on the identification and
isolation of human hematopoietic stem cells (HSCs) from different
sources (see Fig. 179 for identification of HSCs from BM).
9.4.1 Isolation of human HSCs. Primary sources of human HSCs
are human bone marrow, G-CSF-mobilized blood, umbilical cord
blood, and fetal liver. Human HSCs can also be isolated from
immune-deficient mouse models engrafted with primary human
HSCs.
Isolation from human sources: Mononuclear cells are prepared
from human bone marrow, peripheral blood, or umbilical cord
blood using Ficoll-Paque density gradient centrifugation (e.g., 3–
5 mL bone marrow for 1–10 × 107 MNCs or 15–20 mL cord blood
for 1–15 × 107 MNCs). After collection of the MNCs, cells are
washed three times in PBS/2% FCS. If the cell pellet is very red
after two washes of the MNCs, a RBC lysis may be performed (5
minutes in ACK lysing buffer).
Isolation frommouse recipients: Bone marrow cell suspensions
are prepared as outlined above (See Chapter V Section 9.3.1 Iso-
lation of murine HSCs).
Perform Ab staining in PBS/2% FCS (100 µL Ab mix for 1–2
× 107 MNCs) for 40 min at 4°C. Refer to Table 66 for a list of
the antibodies. Wash cells once in PBS/2% FCS and resuspend
in appropriate volume of PBS/ 2% FCS containing a viability dye
such as DAPI, PI, or Sytox Green.
Filter cells prior to analysis through a 40 µm filter.
Analyze cells on a flow cytometer or cell sorter with at least
eight-color capability.
Gatings to determine positivity are performed using FMO.
Isotype controls are used to show that no unspecific binding is
observed in the chosen gates.
HSCs from all sources display a similar pattern of surface
marker expression and can therefore be isolated using the same
panel of antibodies (See Table 66). Like murine HSCs, human
HSCs do not express antigens of mature blood cell lineages (Lin−).
Further, the glycoprotein Thy-1 (CD90) has been shown to be
expressed on human HSCs [1552, 1553]. But other than this,
there is not much correspondence of cell surface markers identi-
fying HSCs in mice and humans.
The most important surface marker used to enrich human
hematopoietic progenitor cells (HPCs) is the glycoprotein CD34,
which is expressed on HSCs and committed progenitors but not
mature blood cells [1554]. In mice, LT-HSCs do not express
CD34 whereas ST-HSCs and progenitors are CD34+ [1543, 1555].
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Figure 179. Phenotypic characteriza-
tion of HSCs from human BM. HSPCs
were identified as CD34+ CD38− cells
within the CD45+ Lin− compartment.
HSCs were identified as CD34+ CD38−
CD90+ CD45RA− cells and MPPs as
CD34+ CD38− CD90− CD45RA− cells
[1528, 1529]. LT-HSCs canbe identified
using CD49f [1529] or Kit (CD117) (Cos-
gun et al., [1530]). Gatings for CD38,
CD90, CD49f, and Kit were performed
according to isotype controls, which
are depicted in the right side of each
plot.
CD34-enriched cells from human bone marrow or mobilized
peripheral blood are frequently used in clinical stem cell trans-
plantation [1556]. However, HSC activity has also been reported
in the CD34− population of human cord blood and bone marrow,
even though those cells are extremely rare [1557–1559].
However, CD34 expression alone does not provide an accurate
measure of HSCs because also hematopoietic progenitor cells are
positive for CD34, and additional markers are required to identify
and isolate the most primitive HSCs [1560]. Multilineage reconsti-
tution in vivo models in combination with FCM allowed to further
separate the Lin- CD34+ population using markers that are differ-
entially expressed on immature andmore differentiated cells. Bha-
tia et al. showed that the CD38− fraction of CD34+ human bone
marrow and cord blood cells was highly enriched for cells with the
ability to repopulate immune-deficient mice [1561]. Limiting dilu-
tion analysis showed that one in 617 purified CD34+ CD38− cells
was able to engraft in a NOD/SCIDmouse for at least 8 weeks. Ten
years later, Majeti et al. showed that Lin− CD34+ CD38− human
bone marrow and cord blood cells could be further subdivided
using the cell surface markers CD90 and CD45RA [1528]. They
identified Lin− CD34+ CD38− CD90+ CD45RA− cells as HSCs
with long-term repopulation capacity for up to 30 weeks with as
few as ten transplanted cells being able to engraft NOG newborn
mice. Purified Lin− CD34+ CD38− CD90− CD45RA− cells were
also capable of long-term multilineage engraftment in immunode-
ficient mice, but more cells were required to achieve engraftment
and the cellular output per transplanted stem cell was lower. Sec-
ondary transplantations showed that CD90+ HSCs generated sec-
ondary transplants at a significantly higher frequency than CD90−
cells. Thus, Majeti and colleagues postulated that human HSCs
with long-term repopulation and self-renewal capacity are con-
tained within the Lin− CD34+ CD38− CD90+ CD45RA− popula-
tion of human cord blood and bone marrow cells whereas Lin−
CD34+ CD38− CD90− CD45RA− cells mainly contain the less
primitive multipotent progenitors [1528].
The group of John Dick identified CD49f (VLA-6) as an addi-
tional marker for human long-term HSCs using limiting dilution
assays and single-cell transplantation into NSG mice [1562]. They
showed that one of ten Lin− CD34+ CD38− CD90+ CD45RA−
CD49f+ cells had long-term repopulation activity and could be
serially transplanted, representing the most purified population of
human HSCs to date. Recently, the laboratory of Claudia Waskow
showed that human HSCs with increased long-term repopulating
activity could be further enriched by high expression of the Kit
receptor on the cell surface of CD34+ CD38− CD90+ CD45RA−
human HSCs [1530]. Transplanted Lin− CD34+ CD38− CD90+
CD45RA− Kithi cord blood cells led to a human chimerism of
around 60% in peripheral blood for up to 30 weeks and an
increased frequency of human HPCs in bone marrow of recipient
mice compared to Lin− CD34+ CD38− CD90+ CD45RA− Kitlo cells
(22% blood chimerism). Whether HSCs with long-term repop-
ulation potential within the CD49f+ and the Kithi HSC popula-
tions are overlapping remains to be shown in future studies. The
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Table 66. Abs used for the identification of human cell types
Antibody Clone Conjugate Supplier
CD2 RPA-2.10 FITC eBioscience Lineage mix
CD3 HIT3a FITC eBioscience
CD10 SN5c L4-1A1 FITC eBioscience
CD11b CBRM1/5 FITC eBioscience
CD14 61D3 FITC eBioscience
CD15 HI98 FITC eBioscience
CD16 CB16 FITC eBioscience
CD19 HIB19 FITC eBioscience
CD56 MEM188 FITC eBioscience
CD235a HIR2 FITC eBioscience
CD34 581 APC BioLegend
CD38 HIT2 PE-Cy7 eBioscience
CD45 HI30 Alexa Fluor R© 700 BioLegend
CD45RA HI100 eFluor R© 450 eBioscience
CD49f GoH3 PE-Cy5 BD Biosciences
CD90 5E10 PE BD Biosciences
CD117 A3C6E2 APC Vio770 Miltenyi
Isotype Controls
Mouse IgG1 κ MOPC-21 PE BioLegend
Mouse IgG1 κ P3.6.2.8.1 PE-Cy7 eBioscience
Rat IgG2a κ eBR2a PE-Cy5 eBioscience
Mouse IgG1 κ APC Vio770 Miltenyi
Table 67. Cell surface phenotype for the identification of human
HSPC populations
HPC
population
(CD45+ Lin−)
Phenotype/
subphenotype
Reference
HPCs CD34+ CD38− [1561]
HSCs CD34+ CD38− CD90+
CD45RA−
[1528]
MPPs CD34+ CD38− CD90−
CD45RA−
[1528, 1529] add PMID
26541609
LT-HSCs CD34+ CD38− CD90+
CD45RA− CD49f+
[1562]
LT-HSCs CD34+ CD38− CD90+
CD45RA− CD117hi
[1530]
different cell surface phenotypes of human HSPC populations are
summarized in Table 67.
Another marker, which was only lately proposed to identify a
subset of human HSCs in cord blood, is the EPCR [1563]. The
group of Guy Sauvageau showed that only EPCR+ CD34+ but not
EPCR− CD34+ cord blood cells were able to engraft secondary
NSG recipients. Interestingly, EPCR can also be used to identify
murine bone marrow and fetal liver HSCs [1542, 1564]. However,
it remains unknown whether EPCR is also expressed on human
bone marrow and mobilized blood HSCs.
To discriminate human from murine HSCs in a humanized
mouse model, Abs specific for murine and human CD45 need to
be used. The high amount of RBCs in samples of any source may
result in background dots. To avoid that, a gate can be set on
Ter119 and CD235 negative cells to exclude mouse or human
erythrocytes, respectively.
9.4.2 Materials.
1. Source of adult human HSCs such as bone marrow, G-CSF
mobilized peripheral blood or umbilical cord blood, or human-
ized mice.
2. Ficoll-Paque solution (d= 1.077) (e.g., Biocoll separating solu-
tion, Biochrom)
3. PBS containing 2% FCS
4. Optional: ACK lysing buffer
5. Flow cytometer able to measure FITC, PE, PE-Cy7, PE-Cy5,
APC, Alexa Fluor700, Alexa Flour780, and Pacific Blue (eFluor
450)
9.4.3 Pitfalls.
1. The quality of primary samples may differ depending on the
donor, the way of extraction, and the used anti-coagulant.
Thus, frequencies of HSCs might not always be comparable
between specimens.
2. If there is no clear cell fraction after Ficoll-Paque density gra-
dient centrifugation, check whether the centrifuge break was
set to 0 or 1.
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9.4.4 Top tricks.
1. Try to use samples as fresh as possible to obtain a high HSC
yield.
2. Dilute bone marrow or blood with PBS (1:1 to 1:2) prior to
Ficoll-Paque density gradient centrifugation.
3. To avoid surplus hours at the sorting machine, you can enrich
human CD34+ cells with magnetic beads prior to staining and
sorting.
10 Tumor cells
10.1 Overview
The FCM-based characterization of tumors is instrumental for the
improvement of existing, and the development of novel, therapeu-
tic strategies against all types of cancers [1565]. The various alter-
ations involved in malignant transformation are elegantly summa-
rized in “Hallmarks of cancer—the next generation” by Hanahan
and Weinberg 2011 [1566].
Many of the proteins involved in transformation mechanisms
can be detected using FCM. The most relevant examples are
summarized in this section, detailing the surface expression
of hematopoietic, epithelial, endothelial, and neuroectodermal
markers for the classification of tumor cells according to their
cellular origin. Importantly, flow cytometric analysis of surface
receptors associated with the tissue of origin is helpful for a
detailed characterization of solid and hematopoietic tumor types
with respect to their surface expression of growth factor receptors,
as well as molecules important for the interaction with immune
effectors cells, such as MHC molecules as ligands for T cells, as
well as adhesion molecules. The most common strategies for the
definition and characterization of human and murine tumor cells
are presented, along with several practical examples.
10.2 Introduction
Tumor cells are derived from nontransformed cells of either
hematopoietic, epithelial, endothelial, neuroectdermal, or mes-
enchymal origin, resulting from a sophisticated process of malig-
nant transformation. Therefore, the origin of a tumor cell indi-
cates which markers are suitable for its flow cytometric char-
acterization. Since hematopoietic tumor cells, i.e., leukemias
and lymphomas, are derived from their non-malignant counter-
parts, they retain expression of the pan-leukocyte marker CD45,
originally defined as the leukocyte common antigen (LCA). In
this section, the definition of subsets of leukemias and lym-
phomas will be briefly mentioned in the context of EuroFlow
(http://euroflow.org/usr/pub/pub.php), a consortium develop-
ing novel flow cytometric diagnostic tests. Solid tumor cells, on
the other hand, do not express hematopoietic markers and there-
fore the absence of CD45 can be used to discriminate solid tumor
cells from all hematopoietic cells, including progenitor cells (HCS,
see Chapter VI Section 9: Hematopoietic stem cells [1567]). In the
case of tumor tissue preparations, this basic discrimination of solid
tumor cells from hematopoietic cells is especially helpful because
it represents the first step for a detailed characterization of solid
tumor cells.
10.2.1 Hematological malignancies. The classification of
leukemias and lymphomas can be guided by FCM and the
procedure has been harmonized, standardized and successfully
integrated into the clinical immunophenotying routine [1568]. Of
note, the EuroFlow (www.euroflow.org) consortium, represented
and headed by Jacques M. van Dongen, has designed panels for
n-dimensional flow cytometric immunophenotyping of leukemias
and lymphomas. Beyond the staining and gating protocols,
the group has developed novel computerized evaluation pro-
cedures for the characterization and quantification of human
hematopoietic malignancies. The EuroFlow guidelines represent
the gold standard of hematopoietic malignancy immunophe-
notyping (http://euroflow.org/usr/pub/pub.php). For research
laboratories working on hematopoietic malignancies in patients,
it is important to mention that virtually all hematopoietic
malignancies are accompanied by a disturbed distribution of the
lymphocyte subsets in peripheral blood. Therefore, a detailed
knowledge of the “normal” distribution of leukocytes in healthy
individuals is instrumental for the analysis of the influence of
malignant cells on hematopoiesis and immune function. To
this end, “The ONE Study” group guided by Birgit Sawitzki
and Edward Geissler has established an advanced FCM panel
for human immune-cell phenotyping in order to define the
distribution of the most important T-cell, B-cell, NK-cell and
monocyte, dendritic cell subsets in healthy individuals [1569].
In addition, the International Society for Advancement of
Cytometry (ISAC, https://isac-net.org/), the CIP consortium
(CIMT immunoguiding program, https://www.cimt.eu/about-
cip-1) of the Cancer Immunotherapy Consortium (CIMT,
http://www.cimt.eu), the International Clinical Cytometry
Society (ICCS, http://www.cytometry.org/web/index.php),
the Federation of Clinical Immunology Societies (FOCIS,
http://www.focisnet.org/) represent other initiatives that aim to
harmonize and standardize protocols for immunophenotyping,
primarily of human peripheral blood. The tremendous efforts of
these consortia to establish guidelines, protocols and tools for the
quantification of leukocytes, tumor cells, and immune responses
will be instrumental not only for research projects but also for
future clinical studies, in particular those with immunological
endpoints.
10.2.2 Solid tumors. Due to their origin from a given tissue,
solid tumor cells are not, or only at very low frequencies, present
as circulating tumor cells in the blood, rather being located in the
primary or metastatic tumor tissue. Since tumor tissue comprises
a peculiar “contexture” of tumor cells, stroma, endothelial, and
other parenchymal cells, as well as infiltrating immune cells, it
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Figure 180. Single cell preparations fromhuman tumor versus nontumor tissues and characterization of human tumor versus nontumor epithelial
cells. (A) Human tumor (upper row) and adjacent nontumor tissue (lower row) was obtained as surplus tissue in the course of a pulmonary tumor
resection with informed consent (MHH number 1747). After tissue digestion, single cells were stained with a live/dead dye (QDot585) and anti-
human CD45 (Alexa-Fluor700) mAb. The hierarchical gating strategy starts with exclusion of doubles and aggregates in the FSC-A/FSC-H plot,
followed by exclusion of dead cells in the QDot585/SSC-A plot and leukocytes, i.e., CD45-positive cells in the CD45/SSC-A plot. The remaining
living CD45-negative single cells are shown in the FSC-A/SSC-A plot and in the blue gate, epithelial cells including tumor cells in the tumor tissue,
can be identified according to their relative size and granularity. (B) A renal tubular cancer cell (RTCC) and the corresponding nontumor tubular
cell line (RNTC) derived from tumor and adjacent non-tumor tissue of the same patient are compared with respect to surface expression of the
following markers: HLA class I (mAb W6/32) and the adhesion molecule ICAM-1 (CD54, mAb gp89). All primary mAb are mouse IgG2a and were
stained with a goat-anti-mouse PE-labeled secondary Ab.
is important to discriminate the tumor cells from all the non-
malignant cells by tailored FCM panels.
This chapter will give an overview on suitable surface markers
to use for the characterization of human and murine tumor cells.
10.3 Procedure for the staining of surface markers for the
characterization of solid tumor cells
For the establishment of FCM panels for hematopoietic and solid
tumors, it is helpful to start with tumor cell lines that available
from research groups, several vendors, and the ATCC (Ameri-
can Type Tissue Collection, https://www.lgcstandards-atcc.org/).
Recommended surface antigens for FCM staining of human solid
tumor cells are listed in Table 68 and for murine tumor cells in
Table 69. The procedures for cell staining, fixation, sample acqui-
sition, data analysis, and visualization are identical to the general
recommendations for direct and indirect surface marker stain-
ing and the intracellular staining protocols, which are presented
in Chapters I: Cytometry equipment, Chapter II: Setup – Instru-
ment setup and quality control and Chapter III: Before you start:
Reagent and sample preparation, experimental design.
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Table 68. Collection of surface molecules for staining of human solid
tumor cells
Antigen Molecules/synonyms
Antibodies/clones
(selection)
HLA class I all HLA-A, -B, -C, -G,
-E alleles
W6/32, HC10
beta2-
microglobuline,
β2m
HB28, B2M-01, 2M2
HLA class II HLA-DR
HLA-DQ
HLA-DP
L243
TU¨169, SK10
B7/21
NKG2D ligands MICA
MICB
ULBP1
ULBP2
ULBP3
clone #159227
clone #236511
clone #170818
clone #165903
clone #166510
ICAM-1 CD54 9H21L19, LB-2, gp98
VCAM CD106 51-10C9
Ep-CAM CD326 EBA-1, 9C4, 22HCLC
VE-cadherin CD144 BV13, 55–7H1, BV9
E-cadherin CD234 36/E-cadherin,
5HCLC, 67A4
EGFR HER1 EGFR.1, H11, 199.12
PDGFR CD140a (alpha chain)
CD140b (beta
chain)
AlphaR1, 16A1
28D4, 18A2, Y92
c-Met HGF-receptor 3D6, ebioclone97
Pan-cytokeratin pan-cytokeratin C-11, PAN-CK
Cytokeratin 18 CK18 CK2, C-04, DC10,
AE1, E431-1
Cytokeratin 8 CK8 K8.8, 5D3, C-43, M20
CD99 MIC2; single-chain
type-1 glycoprotein
TU¨12, 3B2/TA8,
EPR3096
10.3.1 Preparation of tissue, staining of samples, and gating strat-
egy. The staining protocols for human or murine tumor cell
lines, or tumor cells derived from fresh tumor tissue after enzy-
matic digestion, follow the general recommendations summa-
rized in Chapters I to III. With respect to mechanical disso-
ciation for instance, by Gentle-MACS R© procedures, and enzy-
matic digestion, the protocols do not differ between human or
murine tumor tissue. The experimental protocols presented Chap-
ter III Section 3 “Preparation of Single Cell Suspensions” are rec-
ommended using enzymatic digestion with DNAse, collagenase,
and/or hyaluronidase, which are known not to affect surface
expression of the molecules listed in Tables 68 and 69. In brief,
after enzymatic digestion of tumor tissue, Ficoll or Percoll density
centrifugation and optional lysis of erythrocytes, the resulting sin-
gle cell suspensions should be comprised of tumor cells, endothe-
lial cells, fibroblasts, and infiltrating immune cells. Ideally, these
cells should be immediately applied to flow cytometric analyses
using the FCM staining protocols provided in Chapters I to III for
single cell suspensions but they can also be cryopreserved in liquid
nitrogen as living cells for later analyses but the potential instabil-
ity of some surface markers should be taken into account. Below
Table 69. Collection of surface molecules for staining of murine solid
tumor cells
Antigen Molecules/synonyms
Antibody/clone
(selection)
MHC class I MHC class I, all H-2
molecules
M1/42
H-2K
H-2D
H-2L
Kd+Dd (ab131404);
Dd (ab25590)
Kb (ab93364)
beta2-
microglobuline,
β2m
S19.8
MHC class II I-A, I-E M5/114.15.2
NKG2D ligands Rae-1γ
H60
MULT1
CX1
MAB1155
MULT1 (5D0)
ICAM-1 CD54 YN1/1.7.4
VCAM CD106 429
Ep-CAM CD326 G8.8
VE-cadherin CD144 ab33168, MC13.3
E-cadherin CD234 DECMA-1, M168
EGFR HER1 EP38Y
PDGFR CD140a (alpha chain)
CD140b (beta
chain)
APA-5
APB-5
c-Met HGFR ebioclone7, EP1454Y
Pan-cytokeratin pan-cytokeratin C-11, ab9377,
AE1/AE3
Cytokeratin 18 CK18 6-19
Cytokeratin 8 CK8+CK18 EP1628Y
CD24 J11d, M1/69, 30-F1
CD34 RAM34, MEC14.7,
MAB6518
CD44 IM7
CD133 13A4, 315-2C11
some examples of staining protocols are provided in more detail
(10.3.2 to 10.3.4).
10.3.2 Direct and indirect staining of surface molecules expressed by
solid tumor cells isolated from tissue or in vitro culture. Single cell
suspensions from tumor tissue:
After preparation of single cell suspensions (see Chapters I to
III) from tumor tissue, solid tumor cells, for instance carcinoma
cells of epithelial origin, can be detected by a FCM panel, using
the CD45 marker to exclude hematopoietic cells, in combination
with epithelial markers for the identification of carcinoma cells. In
the following protocol, steps a or b should be followed depending
on the indicated circumstances. Steps indicated by a number only
are common for all circumstances.
1a. Staining strategy for single cell suspensions derived from
tumor tissue:
Single cell suspensions of tumor tissue should be stained first with
the unlabeled mAb that is specific for the surface molecule
of interest on the tumor cells, followed by the respective sec-
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ondary mAb and finally a directly labeled CD45 Ab to exclude
hematopoietic cells. Figure 180A, 10.3.2 shows single cell
preparations from human tumor tissue and the nontumor tissue
counterpart, stained with CD45 to discriminate between leuko-
cytes and parenchymal cells. Details of the gating strategy are
given in section 10.3.4.
1b. Staining strategy for cultured tumor cells:
Cultured adherent tumor cells are detached and singularized by
washing with 5 mL PBS followed by treatment with 0.05%
trypsin/0.02% EDTA solution (1 mL per T25 culture flask)
for 2–5 min, gentle shaking, and detachment by adding 5 mL
medium (RPMI1640 + 5% heat-inactivated FBS).
2. The cell count of the single cell suspension is determined using
trypan blue solution for discrimination of dead cells.
3. A total of 1 × 105 cells of the tumor suspension or 1 × 105
cultured tumor cells for each tube are pelleted by centrifugation
(800 × g, 5 min) in FCM tubes and resuspended (15 s vortex)
in PBS or FCM buffer (PBS, 1% FBS, 0.1% Na-azide).
4a. For indirect staining, unlabeled mAb or isotype control mAb
solutions (previously titrated for each antigen to determine the
optimum concentration to use) are added in a volume of 50 µL
to the single cell suspensions for 30 min at 4°C. After wash-
ing twice with 500 µL PBS or FCM buffer, and vortexing, goat-
antimouse Ab solutions labeled with FITC, PE, APC, pacific blue,
or other fluorochromes (100 µL of dilutions between 1:100 and
1:200) are added for 30 min at 4°C in the dark. Many reagents
(e.g., fixable live/dead dyes such as the frequently used Zombie-
series) cannot be used with FCM buffer but require PBS
instead.
4b. For direct staining, cells are resuspended in 50 µL FCM buffer
and directly labeled titrated mAb (usually 1–5 µL) are added
for 30 min at 4°C in the dark.
5. After two washing steps with 500 µL PBS or FCM buffer, cell
suspensions are stained with a titrated directly labeled CD45 Ab
for 30 min at 4°C in the dark for the exclusion of hematopoietic
cells.
6. After three washing steps, cells are resuspended in 150 µL
FCM buffer if measured immediately or in FCM fixation buffer
(PBS, 1% FCS, 1% paraformaldehyde) and stored at 4°C until
measurement.
7. Exclusion of dead cells without cell fixation is highly rec-
ommended, for instance by live/dead staining with 2 µL PI
stock solution (20 µg/mL PI, PE channel) that requires imme-
diate acquisition of the cells. Other live/dead staining protocols
for instance using 7AAD or other live/dead fluorochromes are
available in different colors. Most protocols recommend stain-
ing for 10 to 15 min and washing steps are according to the
manufacturer’s instructions.
An example of the comparison between human renal tubular
cancer cells (RTCC) and renal nontumor tubular cells (RNTC)
from the same individuum is shown in Fig. 180B (10.3.2). Surface
expression of HLA class I, CD155, CD166, and CD54was compared
between tumor (RTCC) and renal nontumor tubular epithelial
cells (RNTC) showing indeed some differences in the density of
these molecules.
10.3.3 Detection of circulating tumor cells in the peripheral blood
and bone marrow. The detection of circulating tumor cells in the
peripheral blood and bone marrow has clinical relevance for sev-
eral forms of carcinomas and sarcomas in terms of disease staging
and treatment response [1570]. Althoughmolecularmethods such
as real-time PCR of tumor-specific mRNA expressed by carcinoma,
sarcoma, or melanoma tumor cells, and so on, recently called “real
time liquid biopsy,” have a higher sensitivity compared to FCM,
FCM is still valid for the quantification and characterization of
circulating cancer cells [1571]. Under nonmalignant conditions,
cells of epithelial, mesenchymal, or neuroectodermal origin can-
not be detected in blood or bone marrow aspirates. However, the
process of metastasis formation is associated with dissemination
of malignant cells through the blood stream and bone marrow.
Therefore, disseminating cancer cells are detectable in these com-
partments but at very low frequencies that are close to the detec-
tion limit of <0.01% cells within the gate for living cells. Hence,
enrichment techniques such as Ab -based magnetic positive or
negative selection are used to increase the sensitivity of detection.
For the quantification of tumor cells, the direct or indirect stain-
ing protocol outlined in 10.3.2 can be combined with the CD45
marker for the exclusion of all leukocytes. The epithelial markers
Ep-CAM (CD326) or cytokeratin 18 (CK18) are suitable mark-
ers for the detection of carcinoma cells. For sarcomas, the mes-
enchymal marker (CD99) is recommended and for the detection
of melanoma cells, growth factor receptors like c-Met or PDGF-
R are appropriate markers, and although not tumor-specific are
characteristic for the tissues of origin.
10.3.4 Gating strategy for the identification of tumor cells. The
hierarchical gating strategy should follow the recommendations
shown in Fig. 180A 10.3.2. starting with FSC-A/FAC-H to exclude
doublets and cell aggregates but taking into account the different
sizes for leukocytes and the non-immune cell fractions contain-
ing tumor cells as well as other cell types. In this FSC-A/FSC-H
gate, dead cells should be excluded by live/dead staining (in this
case with a QDot585 dye). In the case of staining tumor cells
in single cell suspensions derived from tumor tissue, leukocytes
should be excluded by gating only on single cells negative for
CD45 in the plot showing CD45 versus SSC-A. Then, the non-
immune (CD45-negative) cells are displayed in a FSC-A/SSC-A
plot to allow detection of the postulated tumor cell proportion,
which can be further identified by surface markers of interest,
for example, EGFR for carcinoma cells using histogram or dot
plot images depending on the marker combinations. In Fig. 180B,
renal tubular cancer cells (RTCC) are compared to renal nontu-
mor tubular epithelial cells (RNTC) with respect to expression of
HLA class I, CD155 (poliovirus receptor), CD166 (ALCAM), ICAM-
1 (CD54) molecules (Figure 180B). Although pairs of tumor vs.
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non-tumor cells from one individuum are rare, they allow a
comparison of the expression density of several surface mark-
ers involved in immune recognition like HLA class I or adhesion
molecules (CD54).
10.4 Specific recommendations for human and murine solid
tumors
Details of suitable antigens and the respective mAbs are given in
Table 68 for human tumor cells and Table 69 for murine tumor
cells.
In contrast to leukemias and lymphomas, solid tumor cells are
classified according to their originating cell type, i.e., tumor cells
derived from (i) epithelial cells are defined as carcinoma cells, (ii)
mesenchymal cells as sarcoma cells, (iii) neuroendocrine tumors
are defined as originating from endocrine glands, and (iv) neu-
roectodermal tumors are defined as originating from neuroecto-
dermal cells of the skin or brain. This classification is identical
for all species, such as humans, nonhuman primates, dogs, cats,
and rodents. Although many solid tumor cells can express a vari-
ety of tumor-associated antigens (TAA), including cancer-testis
(CT), carcinoembryonal (CEA), and neo-antigens, most of these
antigens are not suitable for flow cytometric characterization of
tumor cells due to either their poor expression, intracellular local-
ization or simply the lack of specific Abs [1572, 1573]. Therefore,
the characterization of solid tumor cells relies on surface markers
associated with their tissue origin, in combination with exclusion
markers for hematopoietic cells such as CD45.
The induction of tumor-specific immune responses can result
in immune escape mechanisms through which the tumor cells aim
to evade their recognition and elimination by effector cells, in par-
ticular T cells and NK cells. One frequent mechanism of immune
evasion is mediated by loss or downregulation of major histocom-
patibility complex (MHC) or human leukocyte antigen (HLA) class
I molecules because, in the absence of MHC class I molecules,
recognition of tumor cells by T cells is prevented. Mutation or
deletion of beta-2-microglobulin (ß2m), leading to MHC class I-
deficiency, represents a major tumor escape strategy occurring in
vivo in cancer patients, as well as in murine tumor models. Thus,
MHC class I (mouse H-2) or HLA class I (human) surface staining
by FCM is highly recommended for all immunological experiments
with solid tumor cells [1574]
In addition to T cells, NK cells can also recognize tumor cells
but via other receptor/ligand interactions. Expression of ligands
for NK-cell receptors, for instance NKG2D ligands (NKG2DL), are
important for recognition by the activating NKG2D receptor and
for the sensitivity of tumor cells to NK cell-mediated recognition
and tumor-cell elimination [1575]. NKG2D (CD314) belongs to
the group of activating receptors that are conserved between
humans, nonhuman primates, and rodents and are expressed
by NK and CD8+ T cells. In contrast to NKG2D, MHC class I
molecules, human HLA-C in particular, serve as inhibitory lig-
ands for NK cells by specific binding to inhibitory receptors of the
killer-immunoglobulin–like (KIR) or C-type lectin (CD94/NKG2A)
families. Thus, NK-cell recognition of tumor cells is regulated by
a balance between activating and inhibitory signals derived from
interactions with the respective ligands on the surface of tumor
cells. In order to investigate the immunogenicity of tumor cells,
it is therefore, recommended to determine the surface expression
of NKG2D ligands on human or mouse tumor cells (Tables 68
and 69). Moreover, these ligands for T-cell and NK-cell receptors
can be modulated during tumorigenesis, for instance MHC class I
and NKG2D are targeted by oncogenic signaling via mutated MAP
kinase signaling [1576].
In addition, surface expression of adhesion molecules such as
ICAM-1, and VCAM should also be included in the flow cytometric
characterization of solid tumor cells due to their increased expres-
sion upon development of metastases in human tumors andmouse
models and, thus, their relevance for T-cell and NK-cell activation,
as well as for the formation of metastases. Besides these surface
molecules, which are commonly expressed by non-malignant as
well as malignant cells of both hematopoietic and parenchymal
origin, solid tumor cells can be also characterized by cell fatemark-
ers. For instance, splice variants of CD44, especially CD44v6, have
a long-standing and controversial history as potential “tumor stem
cell” markers, together with the hematopoietic stem cell markers
CD34, CD133 with a recent revival of CD24 as potential prognos-
tic marker for some carcinomas [1577, 1578]. A selection of the
most relevant human cancers, grouped into carcinomas, sarcomas,
neuroectodermal tumors, and their tumor biology, “the hallmarks
of cancer,” is given below with the respective recommendation for
their flow cytometric characterization.
10.4.1 Human carcinomas. Carcinomas, i.e., epithelial tumors,
represent the most frequent human cancers [1579] and their
malignant transformation is often based on “driver mutations”
in growth factor receptors, receptor tyrosine kinases in particular,
as well as their downstream signaling pathways. For the identi-
fication of carcinoma cells, epithelial markers such as CK18 and
CK8 are useful, although they have to be detected by intracellular
staining procedures [1580]. In addition, epithelial cells selectively
express growth factors such as epidermal growth factor recep-
tor (EGFR), platelet-derived growth factor receptor (PDGFR),
fibroblast growth factor receptor (FGFR), Her-2, c-Met, and oth-
ers [1581]. These surface receptors often directly contribute to
tumorigenesis by carrying “tumor-driving mutations” in their sig-
naling domains; providing constitutive proliferative signals inde-
pendently of the availability of growth factors. Therefore, these
receptors can be useful for the identification and characteri-
zation of tumor cells in terms of their growth factor receptor
repertoire. Importantly, the intracellular protein vimentin serves
as a specific marker for the discrimination of tumor cells from
fibroblasts.
Some of the most frequent human carcinomas are listed in
Table 70 together with their originating epithelial cell type [1579,
1582–1587].
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Table 70. Overview of the most frequent human carcinomas
Carcinoma tissue Most frequent form of
carcinoma
Originating cell Reference
Lung cancer Non-small cell lung
cancer (NSCLC)
Type I / II alveolar epithelial
cells
[1579]
Breast cancer Mammary carcinoma Epithelial cells of the milk duct [1582]
Colon cancer Colorectal carcinoma
(CRC)
Epithelial cells of inner mucosal
layer
[1579]
Prostate cancer Prostate carcinoma Epithelial basal cells of the
prostate
[1583]
Liver cancer Hepatocellular
carcinoma (HCC)
Hepatocytes [1579]
Stomach cancer Stomach carcinoma Epithelial cells transformed by
H. pylori
[1579]
Cervical cancer Cervical carcinoma Cervical epithelial cells after
HPV infection
[1584]
Esophagus cancer Esophagus carcinoma Epithelial cells lining the
oesophagus
[1585]
Bladder cancer Bladder carcinoma Transitional epithelium of the
bladder wall
[1586]
Pancreatic cancer Pancreatic carcinoma Endocrine ductal epithelial cells [1587]
Kidney cancer Renal cell carcinoma
(RCC)
Proximal tubular epithelial cells [1579]
Ovarian cancer Ovarian carcinoma Ovarian tubal-type epithelium [1579]
Squamous cancer Squamous cell
carcinoma
Epithelial cells of skin or glands [1579]
10.4.2 Human sarcomas. Mesenchymal tumors, i.e., sarcomas
[2254], develop from tissue cells originating from mesenchymal
progenitors and manifest primarily in soft tissue like fat, muscle,
tendons, nerve or connective tissue cells, blood and lymph vessels,
or fibroblasts (Table 71). The family of osteosarcomas, including
Ewing osteosarcomas, comprises a severe form of juvenile sarcoma
with manifestations preferentially in the bone, bone marrow, and
organs like the lung or, in rare occasions, the kidney. For the
flow cytometric detection of Ewing sarcoma cells in the peripheral
blood of patients, CD99, theMIC2 gene product, which is normally
expressed by osteoclasts and leukocytes, has been proposed in con-
junction with the absence of CD45 [1588]. Kaposi’s sarcoma rep-
resents a virally induced form of sarcoma mediated by the human
herpesvirus 8 (HHV8), also called Kaposi’s sarcoma-associated
herpesvirus (KSHV). The viral HHV8 genome contributes to dys-
regulation and tumorigenesis by its manipulation of mechanisms
regulating viral latency and lytic replication [1589]. For bone and
soft tissue sarcomas, dysregulation of the Hippo signaling pathway
has been shown to affect several surface receptors including EGFR,
E-cadherin, CD44, and tight junctions indicating that oncogenic
signaling can impinge on the stability of these surface receptors as
markers for sarcoma cells [1590].
10.4.3 Human neuroectodermal tumors. Neuroectodermal
tumors, i.e., malignant cells derived from neuroectodermal cells,
belong to less prevalent but life-threatening cancers such as
melanoma (black skin cancer) and several forms of brain cancer
(Table 72). In malignant melanoma, melanocytes originating from
neuroectodermal cells acquire “driver” mutations in components
of the MAK kinase signaling, most frequently in the BRaf kinase
(with the highest prevalence being the BRafV600E mutation) or
in the upstream NRas GTPase [1591]. Although these mutations
cannot directly be utilized for the FCM of melanoma cells, their
mutation status may have an impact on the recognition by
T-cells and NK-cells [1592, 1593]. Since melanoma cells do not
express unique tumor-associated surface molecules, there are no
specific FCM panels available for the discrimination of malignant
Table 71. Overview of the most frequent human sarcomas
Sarcoma tissue Mesenchymal tumor Originating cell Reference
Ewing sarcoma Ewing’s sarcomas (bone, bone marrow, lung, kidney) Soft tissue cell of the respective organ [1587, 1588]
Kaposi’s sarcoma Soft tissue sarcoma Induced after infection with HHV-8 [2254]
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Table 72. Overview of the most frequent human neuroectodermal tumors
Tumor tissue Neuroectodermal tumor Originating cell Reference
Black skin cancer Malignant melanoma Melanocytes of the skin [1589–1591]
Brain cancer Gioblastoma, glioma Glial cells of the brain [1592, 1593]
Brain cancer Astrocytoma Astrocytes of the brain [1594]
melanoma cells from melanocytes. However, melanoma cells can
be detected in single cell suspensions of tumor tissue, by combi-
nations of ICAM-1, MUC18/MCAM (CD146) and the exclusion of
CD45.
Several forms of brain cancers are derived from neuroectoder-
mal cells including some of the most aggressive brain tumors like
glioblastoma with the malignant cells being derived from glial
cells [1594]. Besides their poor MHC expression, glioblastoma
cells utilize a broad selection of immune evasion strategies that
are in part responsible for their aggressive nature and the result-
ing poor survival of glioma patients [1595]. Other forms of brain
tumors are represented by astrocytomas, a group of differentially
graded variants, i.e., diffuse, polycystic, and anaplastic astrocy-
toma with different degrees of aggressiveness. For gliobastoma,
the GD2 and CD90 antigens are accepted as tumor-associated sur-
face molecules for FCM and also as targets for chimeric antigen-
specific T cell (CAR-T cell) therapeutic strategies. Due to the lack
of additional, reliable and tumor-specific surface markers for FCM,
molecular characterization, i.e., expression profiling, is currently
used for a more detailed classification at the level of gene pro-
files, signaling pathways, and regulatory networks. Despite these
molecular analyses, the cellular origin is still controversial ranging
from stem cell-like precursors to neuronal stem cells [1596].
10.5 Characterization of murine tumor cells
For the flow cytometric characterization of murine tumor cells,
both hematopoietic tumors like mouse leukemias and lymphomas,
and solid tumors like carcinomas of the mouse breast, liver, or
colon, melanomas, or sarcomas, the same recommendations can
be applied as outlined above for human tumor cells. Since the
numerous mouse tumor models cannot be discussed here compre-
hensively, only general remarks are provided regarding FCM of
murine tumor cells. Mouse solid tumor cells are also classified into
carcinomas, sarcomas, and neuroectodermal tumors according to
their originating tissue. Therefore, the same surface molecules
can be utilized for their characterization by FCM as are listed in
Table 69 showing a selection of known mAbs for mouse antigens.
In addition, the protocols do not differ from the general protocols
of direct, indirect surface and intracellular staining (Chapters I to
III). Furthermore, the protocol in section 10.3.2 can also be used
for staining of murine tumor cells. In the case of unlabeled mAbs,
the secondary mAb needs to be adapted to the species of the mAb,
rat or goat for instance, and then, fluorochrome-labeled goat-anti-
rat or rabbit-anti-goat secondary antibodies have to be utilized for
indirect FCM.
Final remarks: The recent clinical advances in immunother-
apy of human solid tumors could only be achieved using sophis-
ticated preclinical mouse models. Since the early days of trans-
planted tumor cells into immunodeficient mice, numerous ele-
gant mouse models with spontaneously developing tumors based
on germline or inducible mutations have been developed over
the past decade [1597]. More recently, humanized mouse mod-
els utilizing severely immunodeficient mice reconstituted with
human peripheral or even hematopoietic stem cells have gained
tremendous insight into immune recognition of human tumor
cells, escape mechanisms and opened the door for new thera-
peutic approaches that finally made their way into clinical appli-
cation [1598].
10.6 Pitfalls
The major pitfalls in the characterization of tumor cells are the
selection of surface antigens suitable for either the discrimination
between tumor and nonmalignant cell or the definition of their
antigenicity, respectively. Since many tumor cells maintain their
overall surface expression profile and rather modulate the density
of certain surface receptors or ligands, it is highly recommended to
perform a rather broad analysis of their receptor and ligand profile
with standardized protocols that allow a quantitative assessment
for each surface molecule. In Fig. 180B, the quantitative differ-
ences between a tumor and nontumor renal epithelial cell line as
shown with respect to HLA class I and ICAM-1 (CD54) expression.
In the case of single cell preparations derived from fresh tissue, it
is important to include live/dead staining in combination with an
exclusion of leukocytes in order to identify tumor cells that may
represent a minor cell type within the entire complex tumor tissue.
Therefore, a stepwise hierarchical gating strategy is instrumental
for the identification of tumor cells.
10.7 Top tricks
In the context of tumor cell analyses, one of the top tricks is the
direct comparison of tumor versus nontumor samples, i.e., tissue
or cell lines because the genetic alterations in the course of malig-
nant transformation result in a gradient of changes rather than
in an on/off situation for most surface markers. Therefore, a side
by side analysis of tumor and nontumor samples allows a direct
comparison of the expression levels of the marker of interest and,
hence, this facilitates the interpretation of general or even individ-
ual changes associated with tumor development or progression,
respectively. Addition of genetic analyses can of course further
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improve tumor cell and tissue characterization at the molecular
level.
11 Human plasma cells in multiple myeloma
11.1 Overview
Multiple myeloma is defined by the accumulation of mono-
clonal plasma cells in the bone marrow and usually preceded by
non-malignant monoclonal gammopathy of undetermined signifi-
cance. FCM can accurately identify multiple myeloma cells, associ-
ated immune phenotypes, and confirm clonal expansion by detec-
tion of immunoglobulin light chain restriction. The technology
can critically contribute to initial diagnostics, definition of disease
heterogeneity, risk stratification, selection of targeted therapeu-
tics, decisions in clinical trials, and detection of minimal residual
disease among others.
11.2 Introduction
Plasma cells are terminally differentiated B cells and the major
source of circulating soluble Abs. Plasma cell differentiation is
thought to be driven by B cell receptor–target antigen affin-
ity [689, 1599]. Upon stimulation, B cells can proliferate and
increase in size, a process referred to as becoming a B cell blast.
B cell blasts that secrete Ab are termed plasmablasts. Plasma cells
are plasmablasts without proliferation [1600] and circulate in the
peripheral blood of healthy individuals at very low frequencies
(<0.1% of PBMCs).
More than 90% of plasma cells are so-called long-lived plasma
cells, which are assumed to arise from germinal centers. In con-
trast, short-lived plasma cells can develop independent from ger-
minal centers and consequently mostly lack somatic hypermuta-
tions [689, 1214, 1599, 1601].
Multiple myeloma is defined by the accumulation of mono-
clonal plasma cells in the bone marrow. In contrast to plasma
cells from healthy individuals, in multiple myeloma, (epi-)genetic
aberrations are assumed to restore proliferative capacity in vari-
able proportions of plasma cells, enabling malignant clonal expan-
sion [1602]. Their substantial number of somatic hypermutations
and completed class switch recombination suggest that malig-
nant transformation of plasma cells occurs at the (post) germinal
center stage of B cell development [1603–1605]. Consequently,
immunoglobulin gene sequences can act as unique molecular bar-
codes for disease tracking at the single cell level [1606]. In the
clinical setting, immunoglobulin light chain restriction can indi-
cate clonal plasma cell expansion.
Multiple myeloma uniquely programs its microenvironment to
support tumor growth [1607], and to protect from T cell responses
[1608] and chemotherapeutics [1609–1611]. Microenvironmen-
tal features in combination with (epi-)genetic aberrations [1612–
1616] result in intra- and interclonal diversity of the malig-
nant plasma cells including their expression of aberrant (surface)
molecules.
FCM can accurately identify multiple myeloma cells, associated
immune phenotypes, and confirm clonal expansion by detection
of Ig light chain restriction. The technology can critically con-
tribute to initial diagnostics, definition of disease heterogeneity,
risk stratification, selection of targeted therapeutics, decisions in
clinical trials, and detection of minimal residual disease among
others. In this section, we present a basic FCM panel and give
technical advice for the reliable identification of plasma- and mul-
tiple myeloma cells in human bone marrow. The experimental
setup can serve as a possible foundation for individual design of
detailed immunological studies of the plasma cell compartment.
11.3 Step-by-step sample preparation
1. Collect bone marrow samples, use EDTA as in vitro anticoag-
ulant (1.2–2.0 mg EDTA/mL bone marrow sample).
2. Filter the bone marrow sample through cell strainer with
100 µm pore size (Falcon).
3. Pipette 100 µL of bone marrow blood into a FCM tube.
4. Add 2 mL lysing solution and incubate for 10 min.
5. Wash three times: add 2 mL wash medium, re-suspend, cen-
trifuge for 3 min at 420 × g, and aspirate supernatant.
6. Vortex to fully re-suspend the cell pellet.
7. Add mAbs for surface staining: 3 µL CD138 (V500C, MI15,
BD Biosciences), 3 µL CD19 (PECy7, HIB19, BD Biosciences),
3 µL CD45 (V450, 2D1, BD Biosciences), 5 µL CD38 (PE,
HB-7, BD Biosciences), and 5 µL CD56 (FITC, NCM16.2, BD
Biosciences).
8. Incubate for 15 min in the dark at room temperature.
9. Add 100 µL of Reagent A (FIX&PERM Cell Fixation and Per-
meabilization Kit, Nordic-MUbio) and incubate for 15 min in
the dark at room temperature.
10. Wash once: add 2 mL wash medium, re-suspend, centrifuge
for 3 min at 420 × g, aspirate supernatant.
11. Add 100 µL of Reagent B (FIX&PERM Cell Fixation and Per-
meabilization Kit, Nordic-MUbio).
12. Add mAbs for intracellular staining: 3 µL kappa light chain
(APC, TB28-2, BD Biosciences) and 3 µL lambda light chain
(APC-H7, 1-155-2, BD Biosciences).
13. Incubate for 15 min in the dark at room temperature.
14. Wash once: add 2 mL wash medium, re-suspend, centrifuge
for 3 min at 420 × g, and aspirate supernatant.
15. Resuspend cells in sheath fluid for immediate analysis.
11.4 Materials
11.4.1 Media and buffers.
Wash medium: 100 mL 10× PBS (Gibco) + 900 mL Aqua dest
(Braun)
FIX&PERM Cell Fixation and Permeabilization Kit, Nordic-MUbio
Lysing solution: Lysing Solution 10x Concentrate (BD FACSTM)
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Figure 181. Identification of aberrant plasma cells in human multiple myeloma bone marrow. Plasma cells are defined as the CD38- and CD138-
positive population (gate shown in C, purple in D and E) among leukocytes (black) after exclusion of debris (A) and doublets (B). No live/dead
staining is performed. Aberrant plasma cells in this sample are partially CD56-positive, homogeneously negative for CD19 and CD45-low (D and
E). Moreover, aberrant plasma cells do show immunoglobulin light chain restriction (in this case lambda, indicated in red, F), which ultimately
characterizes them as abnormal plasma cells. As an internal comparison, B cells (gate shown in D) present characteristic CD19 and heterogeneous
kappa/lambda expression (F). The hierarchy of defined populations as well as absolute and relative numbers of events are shown in (G). Open
circles indicate population centers. Gating was performed with InfinicytTM Flow Cytometry Software. SSC-A, side scatter area; FSC-A, forward
scatter area; FSC-H, forward scatter height.
11.4.2 Monoclonal antibodies.
11.4.2.1 Surface staining.
CD138 (V500C, MI15, BD Biosciences)
CD19 (PECy7, HIB19, BD Biosciences)
CD45 (V450, 2D1, BD Biosciences)
CD38 (PE, HB-7, BD Biosciences)
CD56 (FITC, NCM16.2, BD Biosciences)
11.4.2.2 Intracellular staining.
kappa light chain (APC, TB28-2, BD Biosciences)
lambda light chain (APC-H7, 1-155-2, BD Biosciences)
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Figure 182. Identification of non-malignant plasma cells in human bone marrow. An example of a normal plasma cell population is shown. The
gating strategy for identification of single nucleated cells, plasma cells, and B cells as well as color coding are identical to Fig. 181. Plasma cells are
defined as the CD38- and CD138-positive population (purple, A) among leukocytes (black). Normal plasma cells usually express CD19 and CD45 (B)
in combination with heterogeneous kappa/lambda light chain expression (C). The hierarchy of defined populations as well as absolute and relative
numbers of events are shown in (D). Open circles indicate population centers. Gating was performed with InfinicytTM Flow Cytometry Software.
SSC-A, side scatter area; FSC-A, forward scatter area; FSC-H, forward scatter height.
11.4.3 Flow cytometer. All experiments were performed on a BD
FACSLyric (BD Biosciences).
11.5 Data analysis/gating
FCM can identify plasma and multiple myeloma cells by for-
ward/side scatter characteristics in combination with uniquely
high expression of CD38 and CD138 (Fig. 181A–C) [1617–1619].
While CD45 and heterogeneous CD19 expression indicate differ-
ent maturation states of normal plasma cells [1618, 1620], the
identification of malignant plasma cells can be complicated by
considerable variation in marker expression between and within
individual patients. For example, phenotypes frequently associ-
atedwithmultiple myeloma cells (absence of CD19 and expression
of CD56, example in Fig. 181D and E) can also be part of nonma-
lignant differentiation [1214, 1330, 1331, 1621]. The detection
of Ig light chain restriction (Fig. 181F) can help identifying clonal
expansion inmost cases [1622] but may be technically challenging
(intracellular staining, low target cell numbers, absence of light
chain expression). In comparison to normal plasma cells that do
not show light chain restriction (Fig. 182) the light chain restric-
tion on aberrant plasma cells is particularly convincing.
11.6 Pitfalls
11.6.1 FCM underestimates the number of plasma cells in bone mar-
row aspirates. Although, providing key information on plasma
cell clonality and aberrant phenotype, FCM consistently underes-
timates the number of plasma cells in bone marrow samples com-
pared to morphological assessment [1623]. This might result from
an increased fragility of plasma cells compared to other leukocytes,
loss of plasma cells during sample preparation, hemodilution, and
a discrepancy in content of plasma cells in different samples (first
versus subsequent pulls during bone marrow aspirate collection).
As an accurate plasma cell quantification is crucial for diagnosis
of plasma cell disorders, a morphologic assessment of bone mar-
row smears and/or histopathological evaluation of bone marrow
biopsies should be performed. However, providing an immedi-
ately available lower limit estimate and differentiating between
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normal and aberrant plasma cells, FCM is a powerful method in
first diagnosis and determination of minimal residual disease.
11.6.2 mAbs used in multiple myeloma treatment can inter-
fere with flow cytometric analysis. As CD38 is frequently
expressed on a high percentage of normal and aberrant plasma
cells, immunotherapeutical approaches in multiple myeloma
target CD38 with mAbs, such as daratumumab, isatuximab
(SAR650984), MOR03087 (MOR202) and Ab79 [1623–1625].
Recent studies have shown that CD38 mAb treatment, in par-
ticular daratumumab, can interfere with diagnostic plasma cell
detection caused by a long-term CD38 saturation leading to an
absence of CD38-positive events [1626, 1627]. As plasma cells
are identified as CD38 and CD138-positive cells, CD38 mAb treat-
ment might lead to false negative results in plasma cell detection.
It can be assumed that also further therapeutically used mAbs
directed against plasma cell surface antigens that are crucial for
detection of plasma cells (e.g., CD138) may also interfere with
flow cytometric analysis. Therefore, bone marrow samples from
patients treated with mAbs should also be evaluated by morpho-
logic techniques as aspirate smears and immunohistopathology.
Moreover, alternative plasma cell-specific antigens, as SLAMF7,
or intracellular transcription factors, as BLIMP1 and IRF4, might
be used for plasma cell identification in FCM [1621, 1628, 1629].
Furthermore, CD27 and CD81 expression indicates different mat-
uration stages of normal plasma cells and might be helpful in
detection of an aberrant phenotype (Table 73) [1618, 1620].
11.7 Top tricks: Focus on minimal residual disease detection
Minimal residual disease (MRD) is defined as a small number of
malignant plasma cells that persist after treatment. MRD repre-
sents the treatment efficacy, is highly predictive for outcome and
is considered as the major cause of relapse in multiple myeloma
[1631, 1632]. Multicolor FCM is one of the available MRD detec-
tion methods that can reach a sensitivity of up to 10−5–10−6. The
simultaneous detection of multiple sets of surface and intracel-
lular markers enables reliable and fast identification of multiple
myeloma cells making FCM an indispensable tool in basic research
and clinical diagnostics alike. The high-throughput characteriza-
tion of millions of cells in a reasonable amount of time allows min-
imal residual disease detection with high sensitivity comparable
to next generation sequencing [1633]. Similarly to the detection
of aberrant plasma cells at first diagnosis the antigen panel for
MRD detection includes CD38, CD138, CD45, CD19, kappa, and
lambda light chains. However, assessment of >106 nucleated cells
is crucial to reach adequate MRD sensitivity levels. Moreover, high
level of standardization with regard to used Abs, sample prepara-
tion and measurement and data analysis is crucial. The Multiple
Myeloma MRD Kit, a EuroFlowTM approach to monitor MRD by
FCM, offers a ready-to-use solution for sensitive and accurateMRD
detection [1633]. Automatic software tools lead to an automated
identification of cell populations and aberrant plasma cells offer-
ing high levels of standardization. These approaches are expected
to overcome heterogeneity of MRD detection protocols [1634]
across different FCM laboratories and provide reliable MRD data
particularly within clinical trials.
11.8 Summary table
Table 73. Frequent immunophenotypes of normal and aberrant
plasma cell populations
Plasma cell
population Frequent phenotype
Normal Positive: CD38, CD138, CD319 (SLAMF7)
Usually positive: CD19, CD45, CD27, CD81
Usually negative: CD56
Immunoglobulin light chain restriction: none
Aberrant Positive: CD38, CD138, CD319 (SLAMF7)
Usually positive: CD56
Usually negative: CD19, CD45, CD27, CD81
Immunoglobulin light chain restriction: yes
References: [1621, 1630].
12 Brain/neural cells
12.1 Overview
In contrast to peripheral immune cells, the application of FCM
for cells from the central nervous system (CNS) is most often not
the method of choice. It is limited mainly due to the lack of CNS
cell-specific markers, high lipid content (through myelin), and the
high integration of cells within the parenchyma. Preparing brain
homogenates without severely damaging cells and their processes
has proven technically challenging and special caution has to be
taken toward keeping the integrity of the antigens during tissue
digestion. For any of the non-hematopoietic cells of the CNS, FCM
sorting and subsequent culturing therefore requires specific pro-
tocols and is facilitated by the use of reporter mouse lines. Yet
FCM can also be a useful tool if the expression of genes or pro-
teins directly after isolation are of interest [1635] but also in
the analysis of resident microglia or infiltrating and nonparenchy-
mal myeloid cells. Another complication of FCM analysis of CNS-
resident cells, however, is the identification of pan-neuronal, astro-
cyte, microglia, and oligodendrocyte markers due to the common
origin of many CNS cells as well as the regional and intracellu-
lar heterogeneity of the CNS [1636]. Different cell types, species,
and even regions and age of the brain will need different dissoci-
ation protocols. We here provide three exemplary approaches for
tissue preparation and subsequent FCM of brain cells. Two proto-
cols describe the isolation of murine CNS cells and one outlines
the isolation of nuclei, yet we advise to establish individual tis-
sue dissociation procedures to account for cell-, region-, age-, and
species-specific requirements.
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Figure 183. FCM analysis of murine neonatal astrocytes. (A) Neonatal astrocytes were harvested and stained with the cell surface marker ACSA-
2 (recombinant human anti-mouse, APC-conjugated, 1:10 dilution, Miltenyi Biotec). (B) Neonatal astrocytes were harvested, fixed in 2% PFA
and permeabilized in 0.5% saponin. Cells were stained with the intracellular marker GFAP (mouse monoclonal, Alexa Fluor-488-conjugated, 1:20
dilution, BD Biosciences). Ab gates were based on unstained controls for each Ab as shown on the far right. A total of 10 000 cells of the SSC-A/FSC-A
gate were set as a stopping point during FCM. FSC and SSC axes are linear, fluorochrome axes are log.
12.2 Introduction
The human and rodent CNS, which include the brain and spinal
cord, are composed of many various cell types that together
orchestrate brain metabolism, neuronal signal transduction, and
all bodily functions. The primary difference between the human
brain and that of other species is the enormous expansion of the
neocortex (with its neurons) relative to total brain volume [1637].
Neurons are the primary components of the CNS and trans-
fer chemical and electrical signals throughout the central and
peripheral nervous systems. Depending on region and function,
several neuronal subtypes exist [1638]. Next to the subsets of
neuronal cells, the CNS is also composed of glia cell populations.
The cells belonging to the glial compartment are oligodendro-
cytes, astrocytes and microglia. Oligodendrocytes are cells that
form myelin sheaths around neurons, insulating the neuronal
processes to enable fast electric signal transduction (reviewed in
ref. [1639]). Astrocytes are the most numerous cells in the CNS
that have essential roles in its development, homeostasis, and dis-
ease contexts. Astrocytes are linked via vast intercellular networks,
yet despite this global connectivity, astrocytic microenvironments
are formed within specific brain regions or within astrocytic sub-
populations (reviewed in ref. [1640]). Neurons, astrocytes, and
oligodendrocytes all originate from neural stem cells (NSCs) with
patterned migration and maturation phases during development
(reviewed in ref. [1641]). Microglia as well as perivascular and
subdural meningeal macrophages, on the other hand, originate
from hematopoietic stem cells in the yolk sac that migrate to the
brain throughout development [1642, 1643]. Microglia are the
innate immune cells of the brain and constantly surveil the CNS
parenchyma for pathogens and cellular changes.
12.2.1 Astrocytes. FCM sorting can be used to obtain astrocytes
from neonatal to adult tissue. Depending on the downstream
application of the sorted astrocytes (culturing, freezing, etc.),
some considerations need to be kept in mind. Most cell surface
Abs found on astrocytes are not cell-specific and often also found
on NSCs, oligodendrocytes, and/or neurons. Additionally, only
few fluorochrome-conjugated FCM Abs are commercially avail-
able (see summary table at the end of the chapter). A suitable
Ab for FCM sorting both neonatal and adult murine astrocyte is
ATP1B2/ACSA-2 [1644, 1645]. Labeling of intracellular markers
such as GFAP requires cell permeabilization and is therefore not
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Figure 184. FCM strategy for the classifica-
tion of brain-resident microglia and infiltrating
macrophages and lymphocytes. (A) Analysis of
brain cell suspension from a non-immunized
wild-type mouse via CD45 and CD11b marker
expression. (B) Analysis of monocyte-derived
macrophages, infiltrating lymphocytes, and
microglia in a mouse immunized with MOG35-
55 at chronic phase. Cell populations were
distinguished by CD45 and CD11b expression
levels with macrophages showing CD11b pos-
itive, CD45 high expression (CD11b+CD45hi),
microglia showing CD11b positive, CD45 inter-
mediate expression (CD11b+,CD45int), infiltrat-
ing lymphocytes showing CD11b negative,
CD45 high expression (CD11b–CD45hi) and non-
leukocytes being CD11b and CD45 negative
(CD11b-CD45-). Abs used: rat anti-mouse CD45,
PerCP-conjugated, 1:200 clone 30-F11, Biole-
gend; rat anti-mouse CD11b, APC-conjugated,
1:400 clone M1/70, Biolegend. A total of 100 000
cells of the SSC-A/FSC-A gatewere set as a stop-
ping point during FCM. FSC and SSC axes are
linear, fluorochrome axes are log.
suitable for subsequent culture. Combining different Abs can also
assist in generating pure astrocyte populations and even distin-
guish between astrocytic subpopulations. For example, [1646])
identified astrocyte populations based on Aldh1l1 expression com-
bined with CD51, CD71, and/or CD63 cell surface expression,
which showed clear regional specificities. Mouse lines containing
fluorescent labeling of astrocytes also provide a useful tool for FCM
(Table 74). Currently, the Aldh1l1-EGFP reporter line [1647] is
the only line labeling solely mature astrocytes in the mouse brain.
All other lines are therefore only useful in astrocyte enrichment
and contamination by other neural cell types needs to be consid-
ered.
12.2.2 Neurons. Neurons are cells that are very sensitive to iso-
lation methods. Traditionally, neurons have been isolated from
late-embryonal or early-postnatal murine brain tissue with cul-
ture conditions removing contaminating glial cells. This method
provides a large number of cells; however, still faces the risk of
contamination by other cell types. To obtain purer cultures, FCM
sorting of neuron-labeled reportedmice can be used [1666–1668].
Figure 185. Fluorescence-activated nuclear sorted analysis of nuclei prepared from human surgical brain tissue. Nuclei were prepared from
frozen adult brain tissue (>100 mg), stained with nuclear marker NeuN (monoclonal mouse anti-NeuN, clone A60, 1:1000 and PE-conjugated goat
anti-mouse IgG 1:1000) and submitted to sorting. Gating for identification of NeuN-PE positive neuronal and non-neuronal cell populations or
respective nuclei was based on the first 20 000 events. FITC fluorescence was included to identify and exclude autofluorescent nuclei. FSC and SSC
axes are linear, fluorochrome axes are log.
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Table 74. List of all astrocyte- and microglia- targeted fluorescent reporter lines. Modified from ref. [1648] with permission
Reporter gene CNS cells targeted Reference
Aldh1l1 Astrocytes [1635, 1647]
GFAP Astrocytes + NSCs
But not expressed in all
astrocytes/different expression levels
[1649–1652]
SLC1A3 (GLAST/EAAT1) Astrocytes + NSCs [1653, 1654]
SLC1A2 (GLT1/EAAT2) Astrocytes + ependymal cells [1653–1655]
Vimentin Astrocytes + NSCs [1656]
CX3CR1 Microglia, NK cells, monocytes, dendritic
cells and some macrophages
[1657, 1658]
Sall1 Microglia [1659]
Iba1/Aif1 Microglia, macrophages, other leukocytes [1660]
CSF1R Microglia, macrophages, other leukocytes [1661]
CD11b Microglia, macrophages, other leukocytes [1662]
TMEM119 Mature microglia The Jackson Laboratory #031823
CD45 Microglia, macrophages, other leukocytes [1663]
CD68 Phagocytic microglia, macrophages [1664, 1665]
Again, this is only possible with neonatal tissue and thus only
certain aspects of neuronal development and physiology can be
analyzed using this technique.
Limited neuronal cell surface markers and their respective Abs
exist. CD24 labeling has been used for neuronal cell sorting,
however sorting procedures dramatically decrease cell integrity
and viability of neurons. Thus, FCM sorting of neurons for cell
culture from both adult murine and human tissue is not pos-
sible. Reports exist that describe tissue fixation for subsequent
analysis of cytoplasmic or nuclear neuronal proteins or genes
[1669]. Another method to analyze neurons is via nuclei sort-
ing that has proven successful for many applications including
genetic [1670, 1671], epigenetic [1672], transcription factor, or
gene expression profiling [1638]. The Akbarian method of neu-
ronal nuclei isolation provides a useful alternative to analyzing
neurons [1673].
12.2.3 Oligodendrocytes. The study of oligodendrocytes has pro-
vided valuable insights into neuronal signal transduction and
its changes in disease settings. Especially in demyelinating dis-
eases such as multiple sclerosis (MS) the relationship between
myelin sheath integrity and neuronal health has become appar-
ent. As with other brain cells, oligodendrocytes have tradition-
ally been analyzed in vitro and a plethora of culture proto-
cols exist [1674–1677]. Based on varying medium supplements
and other culture conditions, it is thus possible to grow each
of the oligodendrocyte subsets and maturation stages ranging
from oligodendrocyte precursors cells (OPCs) to pre-myelinating
and mature oligodendrocytes. Again, these cultures are derived
from neonatal brain and contain multiple cell types. FCM is
mainly used to enrich oligodendrocytes from these cultures
and only very few studies are published using FCM [1678] or
immunopanning [1679] to isolate oligodendrocyte lineage cells
from the CNS directly and reduced yield and viability need to
be considered. An overview of oligodendrocyte markers avail-
able for FCM can be found at the end of the chapter. Addi-
tionally, oligodendrocyte reporter mice are also available such
as EGFP-labeled CNP mice [1680], Olig2 mice [1656], and NG2
mice [1681].
12.2.4 Microglia. Microglia are CNS-resident phagocytes that
are distinct from macrophages originating in the periphery. To
date, microglia have been distinguished from other CNS or
myeloid cells by FCM sorting mainly based on CD45 expression
levels. Non-myeloid CNS cells are CD45-negative, while perivascu-
lar macrophages or infiltrating myeloid cells and leukocytes show
CD45 high expression. Microglia on the other hand can be sorted
by selecting for intermediate CD45 expression (CD45 int) in the
combination with CD11b [1682]. However, it needs to be con-
sidered that CD45 expression may change due to activation of
the cells. Similar to other CNS cells, the same limitations regard-
ing the need of tissue dissociation and myelin removal hold true
for microglia, yet the overlap with antigens shared with other
glial/neuronal cell types is not very extensive. The main challenge
therefore is not to separatemicroglia from other CNS cells but from
macrophages originating in the periphery. Microglial expression
of the fractalkine receptor, CX3CR1 and CCR2, overcame some
of these limitations. CX3CR1, however, is also highly expressed
by circulating monocytes (Ly6Clo) and other tissue resident
macrophages [1657, 1658]. Only recently, new microglia-specific
markers such as Tmem119 were identified, enabling robust selec-
tion of mature microglia independent of activation status in
humans and in mice [1683]. Reporter lines for microglia/myeloid
cells also exist for facilitating FCM sorting (Table 74). Mass cytom-
etry, or CyTOF, has also proven a very successful tool in charac-
terizing heterogeneity of human and murine CNS-specific myeloid
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and microglial cell populations in both health and disease based
on expression profiles of up to 50 cell and functional markers
[1684–1688].
12.3 Step-by-step brain preparation
12.3.1 From integrated cells to a single cell suspension (example for
glial cells). Obtaining single cell suspensions from adult brain
tissue can be challenging due to the vast extension of cellular
processes within the brain parenchyma that upon disruption can
influence cell viability and morphology. The commercially avail-
able Neural Tissue Dissociation Kit (NTDK, Miltenyi Biotec) or
Adult Brain Dissociation Kit (ABDK, Miltenyi Biotec) provide gen-
tle methods to homogenize rodent brain tissue for downstream
applications such as cell enrichment and/or culture. The NTDK
is recommended for dissociation of neonatal mouse tissue and
adult mouse tissue with subsequent microglia isolation. Use of
the ABDK is recommended for dissociation of adult mouse tis-
sue with subsequent astrocyte, neuron, or oligodendrocyte iso-
lation. A list of Abs available can be found at the end of this
chapter.
Detailed protocol:
1. Obtain fresh mouse brain tissue and store in HBSS without
Ca2+ and Mg2+ (for NTDK) or D-PBS supplemented with
glucose, sodium pyruvate, CaCl, and MgCl (D-PBS (w), for
ABDK). For microglia isolation from adult tissue, perfuse
mouse brain with PBS before dissociation.
2. Transfer 400–1000 mg neural tissue into C tube (Miltenyi
Biotec) and add NTDK or ABDK enzyme mixes according to
manufacturer’s protocol.
(a) For neonatal murine tissue and murine adult microglia
use NTDK
(b) For murine adult astrocytes, neurons, and oligodendro-
cytes use ABDK
3. Run the samples on the gentleMACS R© with heaters (Miltenyi
Biotec):
(a) Neonatal murine cells: 37C NTDK 1.
(b) Murine adult cells: Program 37C ABDK 01
4. Resuspend cell suspensions and pass through a 70 µM cell
strainer placed on a 50 mL tube.
5. Wash cell strainer with 10 mL HBSS with Ca2+ and Mg2+ (for
NTDK) and 10 mL D-PBS (w) (for ABDK).
6. Centrifuge samples at 300 × g for 10 min, 4°C and remove
the supernatant.
7. Resuspend pellet according to kit used:
(a) NTDK: Resuspend in buffer and volume required for fur-
ther applications.
(b) ABDK: Resuspend in D-PBS (w) according to input mate-
rial and transfer to 15 mL tube
i) 400–500 mg tissue: 3100 µL D-PBS (w)
ii) 800–1000 mg tissue: 6200 µL D-PBS (w)
8. (ABDK only) Add cold Debris Removal Solution depending
on input material, mix well, and overlay very gently with 4
mL of D-PBS (w). Centrifuge at 3000 × g for 10 min, 4°C with
full acceleration and brake.
(a) 400–500 mg tissue: 900 µL
(b) 800–1000 mg tissue: 1800 µL
9. (ABDK only) Aspirate the top two phases and fill up with
D-PBS to a final volume of 15 mL. Invert tube three times.
10. (ABDK only) Centrifuge samples at 1000 × g for 10 min, 4°C
with full acceleration and brake.
11. (ABDK only) Discard supernatant and resuspend cell pellet
in 1 mL 1× Red Blood Cell Removal Solution (diluted in
ddH2O). Incubate for 10 min at 4°C.
12. (ABDK only) Add 10 ml cold PBS + 0.5% BSA and centrifuge
samples at 300 x g for 10 min, 4°C.
13. (ABDK only) Remove the supernatant and resuspend pellet
in buffer and volume required for further applications.
12.3.2 From integrated cells to a single cell suspension 2 (example
for immune cells). Depending on the immune cell subtype of
interest different Percoll-based protocols are available that can
additionally be combined with enzymatic digestion, whilst the
resistance of antigens to digestion enzymes needs to be considered
and protocols optimized accordingly. We present here a rapid,
easy and cheap protocol not requiring enzymatic digestion that
is suitable for the isolation of the majority of peripheral immune
cells as well as microglia.
Detailed protocol:
1. Mechanically dissociate neural tissue using a 70 µmnylon cell
strainer and the plunger of a 5 mL syringe into 15 mL tubes
containing complete RPMI medium or HBSS.
2. Centrifuge at 400 × g for 10 min at 4°C.
3. Aspirate supernatant and vortex pellet.
4. Add 6 mL 37% Percoll (dissolved in Percoll mix, recipe in
table with materials) to each tube at room temperature.
5. Resuspend pellet thoroughly by repeated pipetting.
6. Spin in swinging bucket centrifuge at 2800 × g, 20 min, no
brake, at room temperature. It is important to use a centrifuge
in which the buckets swing out a full 90° to ensure good
separation of the myelin layer.
7. Aspirate myelin, take care to clean the sides of the tube.
8. Aspirate Percoll solution, down to 500 µL and do not break
up the pellet, as you are trying to dilute the residual Percoll.
9. Add 6 mL complete medium (or HBSS) (1st wash).
10. Centrifuge at 400 × g for 10 min at 4°C.
11. Completely aspirate medium, vortex pellet, add 10 mL com-
plete medium (2nd wash).
12. Centrifuge at 400 × g for 10 min at 4°C.
13. Resuspend in FCM Fc-block (see materials table) for 15 min
and count a diluted fraction of cells (e.g., for a mouse brain,
resuspend in 1 mL FCM Fc-block, for a single murine spinal
cord, use 0.5 mL).
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14. Wash the cells in medium and subsequently stain with Abs as
desired.
15. Following antibody stain, cells may be fixed in 4%
paraformaldehyde (Electron Microscopy Science) for 10 min
at room temperature. Following a wash step the cells can be
resuspended and stored at 4°C until measurement.
12.3.3 From integrated cells to nuclei (example for neurons). This
method can be used to extract nuclei from >100 mg of fresh or
frozen human cortical tissue. Immunotagging with an anti-NeuN
Ab robustly stains human cortical neuron nuclei for subsequent
FCM sorting. Other cell populations beyond neurons can be cap-
tured the same way (e.g., astrocytes, oligodendrocytes) if specific
nuclear antigens are known and respective Abs available. Other
methods to study single neurons in the adult human brain include
the use of microfluidic devices as the Fluigdime C1 and ultra-high-
throughput droplet-based technologies [1689].
Detailed protocol:
1. Chill a clean B-type 7 mL pestle on ice and add 5 mL of
lysis buffer (see materials section). Note: Lysis buffer can be
prepared on day prior to sorting, but DTT should be added
fresh on the day of use.
2. Cut 100—500mg fresh-frozen human surgical or postmortem
brain tissue and transfer to lysis buffer in homogenizer.
Homogenize tissue on ice using pestle.
3. Put 8 mL sucrose cushion buffer in a Beckman Ultra-clear 14
× 95 mm centrifuge tube.
4. Note: Tube size and type have to fit with the ultracentrifuge
and rotor system used (here, e.g., Beckmann OPTIMA XE –
90 ultracentrifuge and SW-40Ti rotor).
5. Carefully overlay homogenized sample on top of sucrose cush-
ion without mixing the two solutions.
6. Centrifuge for 2 h in pre-chilled swing-out rotor at 4°C,
30 000 × g.
7. After centrifugation, put tube on ice and carefully remove
supernatant. Add 500 µL of 3 mMMgCl2 in PBS and let stand
on ice. After 10 min very gently re-disperse pellet. Note: Do
not vortex nuclei. Always keep nuclei on ice.
8. Pass nuclei suspension through a 40 µM cell strainer into a
clean 1.5 mL tube and dilute with 3 mM MgCl2 in PBS. Keep
a fraction for manual counting.
9. Add mouse anti-NeuN Ab (1:1000), Goat anti-Mouse IgG
(H+L) Secondary Ab, PE-conjugated (1:1000), and incubate
for at least 30 min at 4°C on a rotator.
10. Manual counting of a fraction of nuclei and quality control
with bright field microscopy.
11. Proceed to sorting.
12.4 Materials
12.4.1 Cell suspension (glial protocol).
Reagent Manufacturer
OctoMACS R© with Heaters Miltenyi Biotec
Adult Brain Dissociation Kit Miltenyi Biotec
Neural Tissue Dissociation Kit (P) Miltenyi Biotec
C tubes Miltenyi Biotec
HBSS with Ca2+ and Mg2+ (NTDK only) Life technologies
HBSS without Ca2+ and Mg2+ (NTDK only) Life technologies
D-PBS with 0.55 mM glucose, 0.033 mM
sodium pyruvate, 0.9 mM CaCl, 0.49 mM
MgCl (pH 7.2, keep cold) (ABDK only)
−
PBS + 0.5% BSA (pH 7.2, keep cold) −
12.4.2 Cell suspension (immune cell protocol).
Reagent Manufacturer
Cell Strainer size 70 µm Nylon BD Falcon
5 mL syringe BD Falcon
15 mL tubes BD Falcon
Complete RPMI medium (5% FCS,
Penicillin/Strepdavidine, b-Mercapto) or
HBSS
Sigma
37% Percoll (100% Percoll mixed with
respective amount of mastermix of 45 mL
10× PBS, 3 mL 0.6 N HCl, 132 mL H2O, pH
7–7.2 filter sterilized)
Sigma
FCM Fc-block (to a given volume of FCM
buffer add 50 µg/mL rat IgG and 1 µg/mL
CD16/CD32 mAb
eBioscience
12.4.3 Nuclei preparation (neurons).
Reagent Specifications
7 mL Dounce tissue grinder Wheaton #357542
Lysis buffer 0.32M Sucrose, 5 mM CaCl2, 3
mM MgAc2, 0.1 mM EDTA, 10
mM Tris-HCL pH 8, 1 mM
fresh DTT, 0.1% Triton X100
Sucrose cushion buffer 1.8 M Sucrose, 3 mM MgAc2, 10
mM Tris-HCL pH 8, 1 mM
fresh DTT
Beckman ultra-clear 14 ×
95mm centrifuge tube
Beckman Coulter #344060
3 mM MgCl2 in PBS −
40 µM nylon cell strainer BD Falcon
Mouse anti-NeuN Ab,
Clone A60 (1:1000)
Millipore
Goat anti-Mouse IgG (H+L)
Secondary Ab, PE (1:1000)
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12.5 Data analysis/gating
Fig. 183 provides representative FCM blots of neonatal murine
astrocytes labeled with the cell surface marker ACSA-2 (Fig. 183A)
and the intracellular marker GFAP (Fig. 183B). For the intracellu-
lar GFAP stain, cells were fixed in 2% PFA and permeabilized with
0.5% saponin.
12.6 Microglia (human/mouse)
To analyze microglia and macrophages, brain tissue from a
mouse immunized with MOG35-55 peptide in the chronic phase
of experimental autoimmune encephalomyelitis (EAE) and tis-
sue from non-immunized mice was mechanically dissected and
myelin removed via Percoll layering as described in the step-by-
step preparation. Fig. 184 provides representative FCM blots of
gating strategies for macrophages (CD11b positive, CD45 high
expression), microglia (CD11b positive, CD45 intermediate (int)
expression), infiltrating lymphocytes (CD11b negative, CD45 high
expression), and non-leukocytes (CD11b negative, CD45 nega-
tive expression). In contrast to non-immunized mice, where only
brain-resident microglia and some perivascular macrophages are
present (Fig. 184A), infiltratingmacrophages and lymphocytes are
present in MOG35-55 immunized mice (Figure 184B).
12.7 Neurons
Figure 185 shows a representative blot of fluorescence-activated
nuclear sorted nuclei prepared from human surgical brain tissue.
Nuclei were prepared from frozen adult brain tissue and stained
with the neuronal nuclear marker NeuN. FITC fluorescence was
included in order to select for autofluorescence.
12.8 Pitfalls
As already mentioned in the introduction, the low yield and
reduced cell viability are challenging when wanting to FCM sort
CNS cells. Cell purity is also an issue in the CNS as cell markers are
often expressed by more than one cell type and are region specific.
Since neurons, astrocytes and oligodendrocytes share the same
precursor, many cell markers are shared between them. Microglia
and peripheral myeloid cells also share many of the same cell sur-
facemarkers, that change during activation state and/or pathology
and which need to be carefully selected for.
Special attention should be also paid during analysis of anti-
gens on the surface of microglia/macrophages and astrocytes as
unspecific binding via Fc receptors or membrane absorption can
create false positive results. These cells do express different Ig Fc
receptors. By incubating cells in the presence of blocking reagents,
Fc receptor-mediated binding of Igs can be suppressed. Blocking
can be performed by purified Igs, serum, or purified CD16/32,
but also different commercial special blocking solutions are avail-
able or included in kit protocols. When Fc receptors itself are of
interest as antigen it has to be checked whether the used block-
ing approach enables a detection after blocking. Besides binding
to Fc receptors membrane adsorption can generate false positive
results. Fast processing, repeated washing steps as well as addi-
tion of EDTA and BSA to the buffer solutions are helping to reduce
unwantedmembrane adsorption (see Chapter V Section 5: Surface
Parameters).
In some experiments, microglia and/or macrophages can affect
the analysis/sorting of other cells from the CNS. In setups where
the focus is, e.g., on astrocytes, nonspecific Ab binding can be
reduced by an additional microglia/macrophage depletion step.
Additionally, myelin debris can lead to essential problems dur-
ing data acquisition and labeling of cells with Abs and protocols
need to be adapted accordingly [1690, 1691]. This is especially
important for the analysis of adult white matter regions. Through
high myelin content, clogging of the instruments may occur and
cells of interest might not be detectable in the sample. Therefore,
we highly recommend including an effective but gentle myelin
removal step when analyzing CNS tissue with FCM.
When wanting to analyze human tissue, it needs to be taken
into account that it can only be obtained from very limited fresh
biopsies or from postmortem autopsies. Fresh healthy controls are
therefore not available and in the case of autopsy material, a high
postmortem interval can dramatically reduce tissue quality.
12.9 Top tricks
In the past, the study of CNS resident cells has largely relied on
ex vivo slice cultures, histological means or the in vitro culture
of neonatal cells. FCM analysis was traditionally used only on
microglial cells that show similar expression of cell surface mark-
ers to peripheral myeloid cells. Advances in brain dissociation
techniques and the vast array of reporter mice have made the
analysis of other brain cells amenable to methods such as FCM,
MACS R©, immunopanning, and single cell or nuclear sequencing.
Each of these methods has limitations with regards to cell viability,
purity, yield, and Ab availability. It is thus essential to choose the
most appropriate method depending on the scientific question.
For studies using neonatal murine CNS tissue, obtaining
enriched cell suspensions frommixed cultures or by FCM/MACS R©,
offers a high yield of cells, however cultures may be contam-
inated by other CNS cells. Additionally, some cells only reach
maturity at late postnatal stages and these cultures thus contain
many precursor cells. Here, selecting the appropriate cell culture
medium before FCM sorting may help in selecting for a specific
cell type [1692]. Obtaining adult cells from murine brain or cells
from human tissue is best achieved using gentle dissociation tech-
niques. Enriched cell populations can then be generated by FCM
or MACS R©, yet reduced cell viability, yield, and Ab availability
need to be considered. CyTOF also offers a high-throughput tech-
nique for analyzing cells of myeloid origin including microglia on
a single-cell level. For mouse tissue, reporter lines are a valuable
tool for FCM sorting of specific cell populations. When interested
in isolating more than one cell type, immunopanning is a suit-
able method since all cells are sequentially purified from whole
brain suspensions [1693]. Neuron isolation of both adult murine
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and human tissue remains challenging to this day. A suitable
alternative when interested in gene expression or nuclear pro-
teins/transcription factors is nuclei sorting via FCM, which also is
applicable to immunolabeled neurons and methods such as single-
nuclei RNA sequencing.
12.10 Summary table (Table 75)
Table 75. Selection of molecules that discriminate subpopulations of brain cells
Antigen Cells targeted Species reactivity Cellular compartment Company
ACSA-2 Astrocytes Mouse Cell surface Miltenyi Biotec
SLC1A3 (GLAST/EAAT1) Astrocytes + NSCs Human, Mouse, Rat Cell surface Miltenyi Biotec
SLC1A2 (GLT-1/EAAT2) Astrocytes + ependymal cells Human, Mouse, Rat Cell surface Biorbyt
ITGAV (CD51) Specific astrocyte populations Mouse/Human Cell surface BD Biosciences/
Biolegend
CD63 Specific astrocyte populations Mouse/Human Cell surface eBioscience/BD
Biosciences
CD71 Specific astrocyte populations Mouse, Human Cell surface BD Biosciences
GFAP Astrocytes + NPCs Human, Mouse, Rat Intracellular BD Biosciences
AQP4 Astrocytes + ependymal cells Human, Mouse, Rat Cell surface Biorbyt
CD45 Microglia, macrophages, other
leukocytes
Mouse, human Cell surface eBioscience
CD11b Microglia, macrophages, other
leukocytes
Mouse, human Cell surface eBioscience
CD68 Phagocytic microglia,
macrophages
Mouse, human Intracellular eBioscience
CX3CR1 Microglia, NK cells, monocytes,
dendritic cells and some
macrophages
Mouse, human Cell surface Biolegend
Tmem119 Mature microglia Mouse, human Cell surface Abcam
Iba-1 (AIF-1) Microglia, macrophages, other
leukocytes
Mouse, human Intracellular Abcam
NG2/AN2 OPCs Human, Mouse Cell surface Miltenyi Biotec
CD140a (PDGFRα) OPCs Human, Mouse Cell surface Miltenyi Biotec
GalC/O1 Pre-myelinating and mature
oligodendrocyte
Human, Mouse, Rat Cell surface Merck
O4 Pre-myelinating and mature
oligodendrocytes
Human, Mouse, Rat Cell surface Miltenyi Biotec
MOG Mature oligodendrocytes Mouse, Rat Cell surface Merck
CNPase Mature oligodendrocytes Human Cell surface Merck
Nestin NSCs Human, Mouse, Rat Intracellular R&D systems
NeuN Neurons Human, Mouse, Rat Nuclear Merck
CD24 Neurons and peripheral cells Human, Mouse, Rat Cell surface Biolegend
Thy-1 Neurons Human Intracellular Biolegend
Tuj-1 (beta III tubulin) Neurons Human, Mouse, Rat Intracellular R&D systems
13 Cells from liver
13.1 Overview
The section gives a short introduction into the unique immuno-
logical milieu of the liver and the different hepatic immune cells
of the innate and adaptive immune system. Moreover, this section
provides detailed protocols for isolation and subsequent staining
of hepatic immune cells from murine and human liver tissue.
13.2 Introduction
The liver is an organ that exerts both metabolic and immunologi-
cal functions. Due to a dual blood supply, the liver receives blood
from the hepatic artery as well as from the portal vein contain-
ing gut-derived food and microbial antigens. There are unique
hepatic immune regulatory mechanisms, which induce tolerance
against innocuous antigens including nutrients and microbiome-
derived degradation products like LPS. The liver is a site of primary
T-cell activation mediated by local conventional and unconven-
tional antigen-presenting cells, such as liver sinusoidal endothe-
lial cells, which promote tolerance by induction of T-cell anergy
and apoptosis as well as generation and expansion of Tregs. The
tolerogenic properties of the liver ensure the maintenance of local
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Figure 186. Gating strategy for T-cell populations in the murine liver. Hepatic leukocytes from TNFR1−/− x Mdr2−/− mice, which develop chronic
liver inflammation, were used for analysis. Single cells were discriminated from doublets by plotting FSC-A against FSC-H. To exclude dead cells,
a fixable dead cell staining was performed. Hepatic leukocytes were stained with anti-TCRβ-PE/Cy7 (H57-597; BioLegend), BV711 CD4 mAb (RM4-5;
BioLegend), BV785 CD8 mAb (53-6.7; BioLegend), anti-Foxp3-PerCP/Cy5.5 (FJK-16s; ThermoFisher Scientific), anti-IL-17A-V450 (TC11-18H10; BD
Pharmingen), and anti-IFNγ-APC (XMG1.2; ThermoFisher Scientific) Abs to distinguish between TCRαβ+ CD4+ T cells, TCRαβ+ CD8+ T cells, CD4+
Foxp3+ Tregs, and CD4+ T cells expressing IFN-γ and/or IL-17A.
and systemic immune tolerance, but they also contribute to the
persistence of hepatic viral infections and tumor metastasis. How-
ever, the liver is also able to mount effective immune responses
against pathogens. The liver consists of parenchymal cells (hepato-
cytes and cholangiocytes) and non-parenchymal cells comprising
liver sinusoidal endothelial cells, hepatic stellate cells, and vari-
ous immune cell populations belonging to the innate and adaptive
immune system. The quantitative and qualitative composition of
hepatic immune cells markedly differs from secondary lymphoid
organs. The majority of hepatic DCs display an inactive pheno-
type. Moreover, the liver contains the largest population of resi-
dent macrophages, termed Kupffer cells, and there is an increased
proportion of hepatic NK cells, NKT cells, and γδ T cells compared
to secondary lymphoid organs [1694–1698].
To study the complex network of hepatic immune cell popula-
tions in healthy and diseased liver, flow cytometric analysis is the
best validated method. In this section, we provide detailed proto-
cols for the isolation of leukocytes from murine and human liver
as well as for surface and intracellular/intranuclear hepatic leuko-
cyte staining. In the murine section, we further provide Ab panels
for the analysis of T cells, Tregs (Fig. 186), NK cells, NKT cells,
γδ T cells (Fig. 187), and macrophage subsets (Fig. 188). In the
human section, we provide Ab panels for the analysis of NK cells
(Fig. 189), T cells (Fig. 190), and myeloid cells (Fig. 191). The
phenotypic markers in T-cell and NK-cell subsets, and monocytes
and macrophages are summarised in Tables 75 and 76 respec-
tively.
Figure 187. Gating strategy for NK cells, NKT cells, and γδ T cells in themurine liver. Hepatic leukocytes fromMdr2−/− mice, which develop chronic
liver inflammation, were used for analysis. Single cells were discriminated from doublets by plotting FSC-A against FSC-H. To exclude dead cells,
a fixable dead cell staining was performed. Hepatic leukocytes were stained with anti-TCRβ-PE/Cy7 (H57-597; BioLegend), anti-TCRδ-PerCP/Cy5.5
(GL3; BioLegend), anti-NKp46-BV421 (29A1.4; BioLegend), and CD1d tetramer-AF647 (NIH Tetramer Core Facility) Abs to distinguish between TCRαβ−
TCRγδ+ T cells, TCRαβ+ CD1d tetramer+ NKT cells, and TCRαβ− NKp46+ NK cells.
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Figure 188. Gating strategy for macrophage subsets in themurine liver. Hepatic leukocytes from naive C57Bl/6 mice were used for analysis. Single
cells were discriminated from doublets by plotting FSC-A against FSC-H. To exclude dead cells, a fixable dead cell staining was performed. Hepatic
leukocytes were stained with PerCP/Cy5.5 CD11b mAb (M1/70; BioLegend), anti-F4/80-APC (BM8; BioLegend), PE/Cy7 CD11c mAb (N418; BioLegend),
anti-Ly6C-BV421 (AL-2l; BD Pharmingen), anti-CCR2-PE (475301; R&D Systems), and anti-CX3CR1-BV785 (SA011F11; BioLegend) Abs. CD11b+ F4/80+
macrophages can be further divided into CD11c− Ly6Cint, CD11c− Ly6Chi, CD11c+ Ly6C−, CD11c+ Ly6Cint, and CD11C+ Ly6Chi subsets, which differ
from each other by distinct expression of the chemokine receptors CCR2 and CX3CR1.
13.3 Murine
13.3.1 Protocol for liver tissue harvest and leukocyte isolation.
Reagents
 1× HBSS (for 1 L): 403 mg KCl, 53 mg Na2HPO4 × 2 H2O,
54 mg KH2PO4, 353 mg NaHCO3, 191 mg CaCl2 × 2H2O,
102 mg MgCl2 × 6 H2O, 148 mg MgSO4 × 7 H2O, 8.006 g
NaCl, 1.11 g D-glucose-monohydrate
Add ddH2O and adjust to pH 7.2–7.4; filtrate solution through
0.22 µm filter
 Liver Digest Medium (ThermoFisher Scientific)
 Liver Perfusion Medium (ThermoFisher Scientific)
 ACK-lysis buffer (for 1 L): 8.25 g NH4Cl, 1 g KHCO3, 29.2 mg
EDTA
Add ddH2O and adjust to pH: 7.2-7.4
 PercollTM, density 1.130 g/mol (GE Healthcare)
 10× PBS (for 1 L): 80 g NaCl, 11.6 g Na2HPO4 × 2H2O, 2 g
KH2PO4, 2 g KCl
add dH2O and adjust to pH7.2–7.4; autoclave
 7.5% NaHCO3 in ddH2O
 Heparin 5000 I: E/mL (Ratiopharm)
 ddH2O
 Percoll solution A: 3.70 mL Percoll, 0.29 mL 10× PBS, 0.05 mL
7.5% NaHCO3
 Percoll working solution (10 mL; for one liver): Add 6 mL HBSS
and 0.2 mL Heparin to Percoll solution A and store it at room
temperature
 4% PFA
Equipment
 CO2/O2 vaporizer
 Styrofoam pad
 70% EtOH v/v
 Half-curved blunt microsurgery scissors
 Curved forceps
 FalconTM Cell Strainer, 100 µm (Fisher Scientific)
 Petri dishes with scratched bottom
Figure 189. Gating strategy to identify NK cells in cells derived from the human liver. Hepatic leukocytes from individuals undergoing liver
resection due to liver tumor metastases were used after leukocyte purification (see 16.3.1). Gating on CD45+ cells (anti-human CD45; 2D1; AF700;
Biolegend) was performed followed by standard leukocyte size gating and doublet exclusion. T cells, B cells, monocytes, and dead cells were
excluded by employing a fixable dead cell staining (LIVE/DEAD Blue; Invitrogen) as well as Abs against CD3 (anti-human CD3; UCHT1; PerCP-
Cy5.5; Biolegend), CD14 (anti-human CD14; HCD14; PerCP-Cy5.5; Biolegend), and CD19 (anti-human CD19; HIB19; PerCP-Cy5.5 Biolegend). CD56
(anti-human CD56; HCD56; BUV395, BD Biosciences) and CD16 (anti-human CD16; EG8; BV785; Biolegend) were used to identify NK cells.
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Figure 190. Gating strategy to identify T cells in cells derived from the human liver. Hepatic leukocytes from individuals undergoing liver resection
due to liver tumor metastases were used without leukocyte purification (see 16.3.1). Leukocytes were exported in and subsequently analyzed.
Gating on standard leukocyte sized cells, followed by doublet exclusion and gating on CD45+ cells (anti-human CD45; HI30; BV785; Biolegend).
CD3+ T cells (antihuman CD3; OKT3; PerCP-Cy5.5; Biolegend) and subsequently CD4+ and CD8+ (anti-human BV510; RPA-T8; BV510; Biolegend)
T cells were identified. Finally, regulator T cells were identified through CD127 (antihuman CD127; A019D5; BV650; Biolegend) and CD25 (antihuman
CD25; BC96; BV421; Biolegend). We would like to thank Tobias Poch and Gloria Martrus for providing the T cell and myeloid cell flow plots.
 50 mL centrifugation tube
 15 mL centrifugation tube
 2 mL syringes
 Centrifuge (Eppendorf 5810R)
 Optional:
◦ Histology cassettes
◦ 1.5 mL centrifugation tubes with safe lock
◦ Liquid nitrogen
Procedure
 Place the mice into the CO2/O2 vaporizer and anesthetize by
gently flowing the chamber*
 Once the mice are anesthetized, euthanize the animal by cervi-
cal dislocation, and confirm death
 Place the mouse on a styrofoam pad with the ventral side
upward and fix the animal
 Spread the abdomen with 70% EtOH and open the abdomen
by making an incision in the cranial direction
 Flap the skin to the side and fix with a needle
 Take blood by cardiac puncture (1 mL) to prevent contam-
ination with peripheral blood cells Alternatively, the liver can
be perfused in situ as described in Blom et al. [1699]
 Push the intestine sideward by using the blunt end of a forceps
to get access to the liver
 Optional: if no blood sampling is required, in situ perfusion of
the liver is recommended, using liver perfusion media or PBS
◦ Perfuse the liver by gently injecting Liver Perfusion Media
or PBS into the vena cava
◦ The liver becomes blanched and swollen
◦ Cut the portal vein, once the liver is swollen. Blood and
media should visibly flow from the vein
◦ Continue perfusion with a total volume of 10 mL
 Remove the gall bladder**
 Remove the liver and transfer it into 5 mL HBSS; store at room
temperature
 Discard the HBSS and transfer the liver on a scribed petri dish
 Homogenize the liver by rubbing over the scribed surface using
the pistil of a 2 ml syringe
 Fill 5 mL of HBSS (room temperature) into the petri dish and
transfer the homogenate into a 100 µm cell strainer placed on a
50 mL centrifugation tube. Alternatively, digestion of smashed
liver tissue might improve cellular recovery, especially from
fibrotic or cirrhotic livers as this procedure degrades extracellu-
lar matrix components, to which immune cells might adhere.
◦ If choosing liver digestion, take up the smashed
homogenate in 10 mL Liver Digest Medium and transfer
it into a fresh 50 mL centrifugation tube
◦ Incubate the cells for 30 min at 37°C
 Mince the homogenate through the cell strainer and wash with
HBSS (room temperature) thereby removing fatty debris
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Figure 191. Gating strategy to identify myeloid cells in cells derived from human liver. Hepatic leukocytes from individuals undergoing liver
resection due to liver tumor metastases were used without leukocyte purification (see 16.3.1). Gating on standard leukocyte sized cells, followed
by doublet exclusion and gating on CD45+ cells (antihuman CD45; HI30; AF700; Biolegend). Gating on HLA-DR+ cells (antihuman HLA-DR; L243;
PE-Dazzle; Biolegend) followed by lineage (antihuman CD3; UCHT1; BV510/antihuman CD19; HIB19; BV510/antihuman CD56; HCD56; BV510; all
Biolegend) and L/D negative gating. Finally macrophages, dendritic cells and macrophage subsets were identified using CD14 (antihuman CD14;
MP9; BUV395; BD Biosciences) and CD16 (antihuman CD16; 3G8; BUV737; BD Biosciences). We would like to thank Tobias Poch and Gloria Martrus
for providing the T cell and myeloid cell flow plots.
 Fill up with HBSS to 20–25 mL and centrifuge for 5 min at
500 × g, room temperature
 Carefully discard the supernatant and re-suspend the pellet in
10 mL 37% Percoll working solution
 Transfer the Percoll suspension into a 15mL centrifugation tube
and centrifuge for 20 min at 800 × g, room temperature
Caution: Switch off the brake to assure proper assembly of the
different phases
 Leukocytes and erythrocytes are pelleted on the bottom of the
tube. Remove the upper, light brown layer, which contains hep-
atocyte debris and carefully discard the supernatant
 For erythrocyte lysis, re-suspend the pellet in 3 mL ACK-lysis
buffer and transfer the suspension into a fresh 50 mL centrifu-
gation tube
 Incubate the cells for 3 to 5 min at room temperature and stop
the reaction by adding 12 mL cold HBSS
 Centrifuge for 5 min at 500 × g, 4°C
 Discard the supernatant and re-suspend the pellet in 1 mL cold
HBSS
 Determine the cell number
 Centrifuge for 5 min at 500 × g, 4°C
 Discard the supernatant and re-suspend the pellet in an appro-
priate volume of HBSS, depending on the amount of FCM-
panels, which are designated for analysis***
*If whole blood is required for analysis of hepatic enzyme activ-
ity, euthanize the animals by intravenous injection of a mixture of
ketamine (120mg/kg), xylazine (16mg/kg), and heparin (8333 I:
E/kg). Harvest blood by cardiac puncture as this allows a high yield
and does not interfere with subsequent procedures such as liver
perfusion. Caution: This treatment requires a specific approval
according to national laws and institutional regulations.
**If liver tissue is used for histology (i) or RNA isolation (ii),
take little pieces for each procedure prior to removal of the liver.
(i) Cut a piece of 1–2 cm2 and transfer into a histology cassette;
fix tissue in 4% PFA
(ii) Cut 2 to 3 small pieces of liver tissue and transfer into a 1.5 mL
centrifugation tube with safe lock; immediately shock freeze
tissue in liquid nitrogen and subsequently store the samples
at -20°C***200 µL HBSS per FCM panel is recommended.
Caution: For analysis of cell populations with rare frequency,
such as ILCs, a maximum of three different FCM panels per
liver is recommended.
13.3.2 Protocol for hepatic leukocyte staining. Reagents
 1× PBS, optional 1× PBS/1% FCS (v/v)
 RPMI 1640 media (ThermoFisher Scientific)
 PMA, ionomycin, brefeldin A (all Sigma Aldrich), monensin
(BioLegend)
 TruStain FcXTM (anti-mouse CD16/32) Antibody (Fc-receptor
blocking solution; BioLegend)
 LIVE/DEADTM Fixable Red Dead Cell Stain Kit or LIVE/DEADTM
Fixable Aqua Dead Cell Stain Kit (both ThermoFisher Scientific)
 Antibodies (see staining panels)
 Foxp3/Transcription Factor Staining Buffer Set (ThermoFisher
Scientific)
 ddH2O
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Equipment
 96-well microtiter plate, v-bottom (NuncTM)
 Centrifuge (Eppendorf 5810R)
 FCM tubes
 Flow cytometer BD LSR FortessaTM
◦ Laser: violet (405 nm), blue (488 nm), green (561 nm),
red (640 nm)
◦ Filter: 530/30(488) for FITC and AF488, 695/40(488) for
PerCP/Cy5.5, 780/60(561) for PE/Cy7, 582/15(561) for
PE, 780/60(640) for APC/Cy7, 670/14(640) for APC and
AF647, 450/50(405) for BV421 and V450, 525/50(405)
for AmCyan, 710/50(405) for BV711, 785/60(405) for
BV785
Procedure
Note: the following protocol is described in the absence of pro-
tein carrier such as FCS. However, the addition of protein carrier
(i.e., 1% FCS (v/v)) to the blocking and extracellular staining solu-
tions might improve cellular vitality and reduce unspecific binding
of the respective Abs.
 Transfer the cells into a 96-well microtiter plate
 Centrifuge for 5 min at 500 × g, 4°C; discard supernatant
 Prepare a working solution of 5 µg/mL Fc-receptor block in 1×
PBS and store it at 4°C*
 To block unspecific Ab binding, incubate the cells in 50 µL Fc-
receptor blocking solution/well for 10 min at 4°C
 Fill 150 µl 1× PBS to each well and centrifuge for 5 min at
500 x g, 4°C; discard supernatant
 For detection of death cells, prepare a live/dead staining solu-
tion in 1× PBS*
 Add 50 µL live/dead staining solution/well and re-suspend the
cells
 Incubate for 30 min at 4°C in the dark**
 Fill 150 µL 1× PBS/well and centrifuge for 5 min at 500 × g,
4°C; discard supernatant
 For detection of surface molecules, prepare an Ab solution in
1× PBS* and re-suspend the cells in 50 µL Ab solution/well
 Incubate for 30 min at 4°C in the dark
 Fill 150 µL 1× PBS/well and centrifuge for 5 min at 500 × g,
4°C; discard supernatant
 Repeat the washing step
 If no intracellular staining is required, take up the cells in 150 µL
PBS/well and proceed to flow cytometric analysis
 Note: For detection of cytokines and transcription factors,
an intracellular and intranuclear Ab staining is required. For
cytokine expression analysis, a re-stimulation of cells is recom-
mended prior to cell staining. Incubate the cells in RPMI 1640
medium supplemented with 10% FCS, PMA (20 ng/mL) and
Iono (1 µg/mL) for 5 h. After 30min, add brefeldin A (1 µg/mL)
and/or monensin (2 µM) to the cell culture medium.
Monensin impairs protein secretion by blocking the Na++/H+
transport from the Golgi apparatus while brefeldin A causes a
re-shuttling of proteins from the Golgi apparatus to the endo-
plasmic reticulum. Overall, this results in intracellular aggrega-
tion of proteins and thus, cellular stress, which might impact
cellular viability. Although both methods allow subsequent
analysis of produced cytokines, it is recommended to do previ-
ous literature search in order to select the respective transport
inhibitor for the specific cytokine.
 Prepare a Fixation/Permeabilization working solution by
mixing 1 volume Fixation/Permeabilization concentrate
with three volumes Fixation/Permeabilization diluent
(Foxp3/Transcription Factor Staining Buffer Set)
 Add 100 µL Fixation/Permeabilization working solution/well,
immediately re-suspend the cells and incubate for 30 min at
4°C in the dark***
 Prepare 1× Permeabilization Buffer by mixing one volume
10× Permeabilization buffer (Foxp3/ Transcription Factor
Staining Buffer Set) with nine volumes ddH2O
 Fill 150 µL 1× Permeabilization Buffer/well and centrifuge for
5 min at 500 × g, 4°C***; discard supernatant
 Repeat the washing step
 Prepare an antibody solution in 1x Permeabilization Buffer and
re-suspend the cells in 50 µl Ab solution/well
 Incubate for 30 min at 4°C in the dark***
 Add 150 µl 1× Permeabilization Buffer/well and centrifuge for
5 min at 500 × g, 4°C; discard supernatant
 Repeat the washing step
 Take up the cells in 150 µL 1× PBS and proceed to flow cyto-
metric analysis or store at 4°C in the dark. The staining is stable
for at least three days.
 Prior to acquisition, re-suspend the cells in the 96-well
microtiter plate and transfer them into flow cytometry-tubes
supplemented with 150 µl 1x PBS
*Solution can be prepared on the day before and stored at 4°C
in the dark
**To our experience, LIVE/DEADTM Fixable Red Dead Cell
Stain Solution can be directly added to the antibody cocktail with-
out an additional incubation step. However, we cannot recom-
mend this for the LIVE/DEADTM Fixable Aqua Dead Cell Stain
Solution.
***Incubation at 4°C is approved for detection of Foxp3 and
cytokines. If staining of other transcription factors, such as T-Bet,
Eomes, GATA3, or RORγt is required, all incubation and washing
steps should be performed at room temperature.
13.4 Human
13.4.1 Protocol for hepatic leukocyte isolation. Reagents
 OptiPrep Density Gradient Medium (e.g., Sigma–Aldrich)
 R10 (RPMI+10% FBS+1% Pen/Strep)
 PBS or HBSS
 ACK Lysing Buffer (e.g., Biozym)
 Freezing solution (90% FBS+10% DMSO)
Equipment
 Petri dish
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 Tweezers
 Scalpel
 gentleMACS R©
 gentleMACS R© tubes
 Cell strainers (300/200/100/70/40 µm)
 15/50 mL conical tubes
 1.5 mL Eppendorf tubes
 Cryo tubes
 10 mL syringes
Procedure
Sample preparation
 Obtain fresh liver tissue and transport on 4°C to the lab for
further downstream processing immediatelya
 Weigh liver piece in petri dish
 Cut Liver into pieces of 5 × 5 × 5 mm
 Split up into —four to six C-Tubesb (in general 5 g per C-Tube
works best)
 Add 1–2 mL of R10
Mechanical dissociation
 Put tubes onto gentleMACS R© (should go in easy) and hash for
36 sc
 Remove tubes from machine (do not twist!)
 Remove pieces stuck in hashing blades with a pipette tip
 Repeat procedure five times
Serial Filtering
 Pour contents through 300 µm strainers into a 50 mL conical
and push hashed liver through filter carefully with the plunger
of a syringe
 Pour the 300 µm filtered content through a 200 µm cell strainer
into a new 50 mL conical
 Pour the 200 µm filtered content through a 100 µm cell strainer
into a new 50 mL conical
 Pour the 100 µm filtered content through a 70 µm cell strainer
into a new 50 mL conical
 Pour the 70 µm filtered content through a 40 µm cell strainer
into a new 50 mL conical
 Fill up to 50 mL with PBS or Hank’s
Sample assessment
 Centrifuge 10 min/500 × g/room temperature, discard super-
natant
 Resuspend pellet in 10 mL of R10
 Count cellsd,g
 Move on to lymphocyte purification
Lymphocyte purification
 Distribute the (remaining, see d) cells into 50 mL conicals (1
tube per 109 cells)
 Fill up to 50 mL with PBS/Hank’s
 Centrifuge 4 min/40 × g/room temperature
 Transfer supernatant carefully with 25 mL Pipette to 50 mL
conical, discard pellet
 Fill up to 50 mL with PBS/Hank’s
 Centrifuge 4 min/40 × g/room temperature
 Transfer supernatant carefully with 25 mL Pipette to 50 mL
conical, discard pellet
 Fill up to 50 mL with PBS/Hank’s
 Centrifuge 4 min/500 × g/room temperature
 Discard supernatant
 Fill up to 50 mL with PBS/Hank’s
 Centrifuge 4 min/500 × g/room temperature
 Discard supernatant
 Resuspend each pellets in PBS at a final volume of 4.5 mL
 Pipette 25 mL of OptiPrepTM* (2.5 mL each) into 15 mL conicals
(1 tube per 109 cells)
 Add the 4.5 mL of cell suspension per tube and mix it by care-
fully pipetting up and down (avoid any bubbles)
 Layer 1 mL of PBS above the OptiPrep suspension
 Centrifuge 20 min/400 × g/room temperature without brakee
 Carefully take erythrocyte/leukocyte containing interphases
and pool them
 Fill up to 50 mL with PBS/Hank’s
 Centrifuge 4 min/500 × g/room temperature → discard super-
natant
 Resuspend pellet (redish) in 3 mL ACK lysis buffer and incubate
for 3 min/room temperature
 Fill up to 50 mL with PBS/Hank’s
 Centrifuge 5 min/500 × g/room temperature discard super-
natant
 Resuspend pellet (should be white) in 10 mL R10
 Count cells
Move forward to perform either direct staining’s of the isolated
leukocytes or cyro preservef,g them for later use
aIf liver tissue is used for histology (i) or RNA isolation (ii),
take little pieces for each procedure prior to weighting the tissue
depending on the size we would recommend storing tissue pieces
in
(i) In 4% PFA as well as Tissue-TekTM (depending on the planned
procedures)
(ii) In cyro-tubes and freeze immediately at –80°C
bFor the mechanical dissociation of the tissue, we use a
gentleMACSTM Octo Dissociator, other means of mechanical dis-
sociation could also be viable, but have not been tested with this
procedure.
cWe refrain from using any enzymes during the mechanical
dissociation as in our experience this leads to alterations in or loss
of expression of surface proteins (e.g., CD56) without leading to
improvements in cell yield or higher viability
dDepending on cell yield storing 10 aliquots of 1.5 × 107cell
in 1 mL of freezing medium can be performed. The following
procedure has been tested:
 Centrifuge 1.5× 108 cells at 5 min/500× g/room temperature,
discard supernatant
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 Resuspend pellet in freezing medium for a final concentration
of 1.5 × 107 cells/mL
 Pipette cells into 10 cryo tubes
 Put tubes into precooled stratacooler (4°C) and store at –80°C
for 24 h before transferring into liquid nitrogen
eAdhering to basic density centrifugation protocol is relevant
for this step. Use minimum acceleration and no brakes on the
centrifuge.
fCyro preservation of isolate leukocytes can be performed at
this step (see also d):
 Centrifuge 5 min/500 × g/room temperature discard super-
natant
 Resuspend pellet in freezing medium for a final concentration
of 1 × 107 cells/mL
 Pipette cells into cryo tubes (1 mL each)
 Put tubes into precooled stratacooler and store at –80°C for
24 h before transferring into liquid nitrogen
gCells stored at these points have been successfully used for
both phenotypical as well as functional analysis. When using
cells stored without leukocyte purification stepd, we advise using
a method of depleting dead cells (e.g., EasySepTM Dead Cell
Removal (Annexin V) Kit) as well as resting the cells before func-
tional assessment.
13.4.2 Protocol for hepatic leukocyte staining. Reagents
 1× PBS
 LIVE/DEADTM Fixable Dead Cell Stain Kit
 Antibodies (see staining panels)
 Foxp3/Transcription Factor Staining Buffer Set (or compara-
ble)
 ddH2O
Equipment
 96-well microtiter plate, u- or v-bottom
 Centrifuge
 FCM tubes
 Flow cytometer BD LSR FortessaTM
◦ Laser: ultraviolet (355), violet (405 nm), blue (488 nm),
green (561 nm), red (633 nm)
◦ Filter: 740/35, 380/14 for 355; 780/60, 710/40, 675/50,
610/20, 586/15, 525/50, 450/50 for 405; 710/40,
530/30, 488/10 for 488; 780/60, 670/30, 610/20, 586/15
for 561; 780/60. 730/45, 670/14 for 633
Procedure
Continued from 16.3.1 or after thawing of cryo-preserved sam-
ples
Surface staining
 Transfer the cells into a 96-well microtiter (preferably u- or
v-bottom) plate
 Centrifuge for 5 min/500 × g/room temperature, discard
supernatant
 Fill add 150–200 µL 1× PBS to each well and centrifuge for 5
min at 500 × g, discard supernatant
 For detection of surface molecules, prepare an Ab master mix
in PBS and re-suspend the cells in 100 µL Ab solution/wella,b
 Incubate for 30 min/4°C in the dark
 Fill 150–200 µL PBS/well and centrifuge for 5 min/500 ×
g/room temperature, discard supernatant
 Repeat the washing step
 Resuspend the cells in 150 µL PBS/well and proceed to flow
cytometric analysisc
Intracellular stainingd
 Add 100 µL of Fixation/Perneabilization working solution per
well, resuspend the cells, and incubate for 30 min at 4°C in the
darke
 Add 150 µL 1× Permeabilization Buffer/well and centrifuge for
5 min/500 × g/4°C; discard supernatant
 Repeat the washing step
 Prepare the Ab solution for intracellular staining in Permeabi-
lization Buffer and re-suspend the cells in 100 µL Ab solu-
tion/well
 Incubate for 30 min at 4°C in the dark
 Add 150 µL Permeabilization Buffer/well and centrifuge for 5
min/500 × g/4°C; discard supernatant
 Repeat the washing step
 Resuspend the cells in 150 µL PBS/well and proceed to flow
cytometric analysis, alternatively stained cells can be keep at
4°C in the dark
aThe use of Ab master mixes is recommend, these can be pre-
pared either fresh before the experiments or prepared beforehand
and stored at 4°C in the dark. Preparation beforehand should be
tested and validated against freshly prepared master mixes for
each panel. The volume of the antibody master mix added might
be modified based on panel size or cell numbers.
bIn our experience, LIVE/DEAD Fixable Viability Dye’s can
be added directly to the Ab master mix and stained simultane-
ously. Alternatively, an additional staining and washing step can
be included beforehand:
 For detection of death cells, prepare a live/dead staining solu-
tion in PBS
 Add 50 µL live/dead staining solution/well and re-suspend the
cells
 Incubate for 30 min at 4°C in the dark
 Fill 150 µL PBS/well and centrifuge for 5 min/500 × g/4°C;
discard supernatant
cAlternatively and depending on time-to-flow, we can recom-
mend fixing the cells with 100 µL 4%PFA for 20 min at 4°C (or
similar fixation reagents, e.g., BD CellFIXTM) before washing once
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and resuspending in 150 µL PBS. Keep stained cells at 4°C in the
dark until proceeding to flow cytometric analysis
dFor dection of cytotoxic properties, cytokines and transcrip-
tion factors, an intracellular and intranuclear Ab staining is
required. Some functional properties of immune cells might only
be detectable after stimulation with the appropriate stimulus
(e.g., target cells, cytokines). In general we add protein transport
inhibitors containing Monensin and Brefeldin A (e.g., GolgiStopTM
& GolgiPlugTM, BD Bioscience) after 1 h of stimulation for the rest
of the stimulation period.
Table 76. Phenotypic marker molecules of murine and human T-cell and NK-cell subsets according to references [1342, 1700–1703]
Mouse Human
Cell surface CTL Th Treg γδ NK NKT Cell surface CTL Th Treg γδ NK NKT
CD45 + + + + + + CD45 + + + + + +
CD3 + + + + − + CD3 + + + + − +
CD4 − + + +/− − +/− CD4 − + + +/− − −
CD8 + − − +/− − − CD8 + − − +/− − −
CD25 +/−i +/−i +i + +/−i − CD25 +/−i +/−i + + +/−i −
CD107a + − − − CD107a + − − − +/−i −
CD127 +/− +/− + + − + CD127 +/− +/− + + − +
CD1 specific − − − + − + CD1 specific − − − + − +
FasL + − − − +/− − FasL + − − − − −
NK1.1 − − − + + + CD56 − − − + + +
NKp46 − − − − + + CD335 − − − − + +
NKG2D − − − + + + CD314 − − − + + +
TCRαβ + + + − − + TCRαβ + + + − − +
TCRγδ − − − + − − TCRγδ − − − + − −
TRAIL + − − + − TRAIL + − − − + −
Surface activation/exhaustion markers
CD44ii + + + + − + CD45ROii + + + + − +
CD69iii +/− +/− +/− +/− − − CD69 +/− +/− +/− +/− +/− −
CD62Liv +/− + +/− − − − CD62L +/− + +/− − − −
PD-1v +/− +/− + +/− +/− +/− PD-1 +/− +/− + +/− +/− +/−
Secreted cytokines
GZMB + − − + + + GZMB + − − + + +
IFNγ + + − + − + IFNγ + + − + − +
IL-5 − + − − − − IL-5 − + − − − −
IL-10 − − + + − + IL-10 − + + − +
IL-13 − + − − − + IL-13 − + − − − +
IL-17A − + − + − − IL-17A − + − + − −
Perforin + − − + + − Perforin + − − + + −
TNFα + + − − + TNFα + + − +/−i +
Transcription factors
Eomes + − − − + + Eomes + − − − + +
Foxp3 − − + − − − Foxp3 − − + − − −
GATA3 − +vi − − − − GATA3 − +vi − − − −
RORyt − +vi − + − − RORyt − +vi − + − −
T-bet + +vi − + + + T-bet + +vi − + +/− +
iExpressed following activation; downregulated on effector Tregs
iiLow expression by naive T cells
iiiEarly activation marker
ivExpressed on naive and central memory T cells; downregulated on effector T cells
vExpressed by activated and/or exhausted T cells
viDepending on Th subset
eWe have tested and successful used a number of dif-
ferent fixation and permeabilization reagents, e.g., BD Fixa-
tion/Permeabilization Solution Kit, eBioscience Intracellular Fix-
ation & Permeabilization Buffer Set, FIX & PERMTM Cell Perme-
abilization Kit or Foxp3/Transcription Factor Staining Buffer Set
(ThermoFisher Scientific). Following the provided protocols, all of
those yield satisfying results. Depending on the panel and staining
used testing of different reagents is recommend.
13.5 Summary of immune cell subsets in murine and
human liver
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Table 77. Phenotypic marker molecules of murine and human monocyte and macrophage subsets according to references [1444, 1704–1707]
Mouse Human
Cell surface Mo M1 M2 KC DC Cell surface Mo M1 M2 KC DC
CD45 + + + + + CD45 + + + + +
CD11b + + + + +/− CD11b + + + + +/−
CD11c − − − − + CD11c + + − − +
CD80 − + + low + CD80 − + + low +
CD86 + + + − + CD86 + + + − +
CD206 + − + + +/− CD206 + − + + +/−
F4/80 + + + + low CD14 + high + + +/−
IL-4Rα + − + ND ND IL-4Rα + − + ND −
Ly6c + high low low +/− CD16 +/− − high + −
MHC-II + + + + + HLA-DR + + + + +
PDL-1 − − + + − PDL-1 − − + + −
Chemokine receptors
CCR2 +/− + +/− − − CCR2 +/− high low − −
CCR5 + + + ND ND CCR5 + + + ND −
CX3CR1 +/− +/− + − +/− CX3CR1 − low high − +/−
Secreted cytokines
IL-6 − + − − + IL-6 − + − − +
IL-10 − − + + +/− IL-10 − − + + +/−
IL-12 − + − − + IL-12 − + − − +
TNF-α − + − − + TNF-α − + − − +
Mo, monocytes; M1, inflammatory Mo-derived macrophages; M2, alternatively activated Mo-derived macrophages; KC, Kupffer cells; ND, not
detected
13.6 Pitfalls
Albeit sampling of whole blood by cardiac puncture minimizes the
risk of contamination, this can further be reduced by in situ perfu-
sion of liver tissue prior to organ isolation. Additionally, incubation
of liver homogenate in Liver Digest Medium may reduce intercel-
lular junctions and thus, increase the total recovery of immune
cells within the tissue. If choosing additional incubation in diges-
tion medium, the incubation time should not be prolonged as
this might impact cell viability and shed surface molecules from
the cells of interest and thus, might cause false results during
analysis.
13.7 Top tricks
If performing cellular stimulation for subsequent analysis of intra-
cellular effector cytokines, the choice of the respective transport
inhibitor should be considered. For instance, brefeldin A is rec-
ommended to block intracellular transport of murine IL-6, IL-12,
or TNF-α, while monensin is recommended to impair secretion
of IL-10, IL-5, or GM-CSF. Please compare the recommendations
of pharmaceutical companies for the right choice of transport
inhibitors.
14 Porcine cells
14.1 Overview. This chapter will introduce FCM for immune
cells of the pig (Sus scrofa) with a strong focus on T-cell phenotypes
and myeloid cells. Best practice staining examples and step-by-
step sample preparations are provided, mainly for blood-derived
cells. Protocols describe the isolation of porcine immune cells from
blood and spleen, however, we advise to establish individual tissue
dissociation protocols to account for age-, cell-, and organ-specific
differences. Phenotypes of immune cells present in lymphatic and
nonlymphatic organs are briefly described and referenced.
14.2 Introduction. Pigs represent an excellent model for various
human diseases, in particular infectious diseases [1708]. Exploita-
tion of the pig as human-relevant model but also the study of pig
diseases requires a detailed knowledge of the pig’s immune sys-
tem and adequate detection tools. In contrast to SPF mice, but
comparable to human individuals, conventionally raised pigs are
exposed to persistent and non-persistent pathogens, diverse food
and environmental antigens and are routinely vaccinated. There-
fore, the pig’s immune system undergoes similar priming processes
as observed in humans.
For flow cytometric assessment of porcine immune cells,
recent updates summarize available reagents reacting with
porcine CD markers including pig-specific mAbs and poly-
clonal Abs, but also cross-reactive mAbs from different species
[1709, 1710]. In addition, a website listing Abs specific
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Figure 192. Identification of CD4+,
CD4CD8α double-positive, conven-
tional CD8+, and γδ T cells in porcine
peripheral blood. Lymphocytes are
identified based on the forward (FSC)
and side (SSC) scatter. Single cells
are discriminated from doublets by
plotting FSC area against height.
Dead cells are excluded by a via-
bility dye and total CD3+ T cells
(mAb clone BB23-8E6-8C8) are gated
further. γδ T cells are identified
by mAb PPT16. Remaining T cells
can be considered as αβ T cells
(currently no TCR-αβ-specific mAb
available). Within this subpopula-
tion, cells can be distinguished on
their expression of CD4 (mAb clone
74-12-4) with CD4+ T cells separat-
ing into a CD8α+ population (mAb
clone 11/295/33) and CD8α− pop-
ulation. CD3+TCR-γδ−CD4−CD8αhigh
cells represent conventional CD8+
T cells. Data are generated from
defrosted PBMC from an animal of
approximately 6 months of age.
for porcine immune-related molecules (but also for cattle,
sheep, goat, horse and chicken) has been launched in 2019
(https://www.immunologicaltoolbox.co.uk/). According to the
human CD nomenclature, currently listing 419 human CD mark-
ers, 359 corresponding orthologous swine CD proteins have been
identified [1710]. However, many CD orthologs have been iden-
tified based on genomic data, but still lack species-specific func-
tional description or specific Abs and imply an urgent need for
developing pig specific immune reagents. As a major remark, anti-
human CD mAb cross-reactivity to porcine immune cell molecules
should be experimentally defined (see Chapter VI Section 15
Cross-reactive Ab clones).
Figure 193. Identification of porcine
γδ T-cell subpopulations in periph-
eral blood. Lymphocytes are iden-
tified based on the forward and
side scatter. Single cells are dis-
criminated from doublets by plot-
ting FSC area against height. Dead
cells are excluded by a viability dye.
Two subsets of γδ T cells (mAb clone
PGBL22A) can be distinguished in the
pig by their CD2 expression (mAb
clone MSA4). The majority of CD2+
γδ T cells express CD8α (mAb clone
11/295/33) and SLA-DR (mAb clone
MSA3). In contrast, the majority of
CD2− γδ T cells have a CD8α/SLA-
DR double-negative phenotype. Data
is generated from defrosted PBMC
from an animal of approximately 6
months of age.
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Figure 194. Identification of porcine CD4+ T-cell subpopulations in peripheral blood. Lymphocytes are identified based on the forward and side
scatter. Single cells are discriminated from doublets by plotting FSC area against height. Dead cells are excluded by a viability dye and cells were
gated on CD4+ cells (mAb clone 74-12-4) for further analysis. Naı¨ve CD4+ T cells are defined as CD8α− CD27+ (mAb clone CD8α 11/295/33; mAb
clone CD27 b30c7), while CD8α+CD27+ cells represent central memory cells and CD8α+CD27− effector memory cells in the pig. Different SLA-DR
expression patterns (mAb clone MSA3) of the three subsets are shown in the histograms. Data is generated from freshly isolated PBMC from an
animal of approximately 2.5 months of age.
Porcine CD marker expression as compared to humans and
mice include several peculiarities such as
(i) The expression of CD8αα homodimers and MHC-II (swine
leukocyte antigen-DR) molecules on activated or memory
CD4 T cells [1711–1713],
(ii) Major subsets of NK cells that lack CD335 (NKp46) [1714],
(iii) Expression of CD33 on neutrophils and monocytes [1715],
(iv) Varying levels of CD45RA expression on plasmacytoid DCs
(pDCs) [1716]
(v) Siglec-10 expression on B cells [1717].
(vi) The high abundance of peripheral γδ T cells, ranging from
8 to 57% within total peripheral blood lymphocytes (PBL)
[1718].
14.3 Porcine T cells. Porcine T cells from peripheral blood can
be identified by gating on lymphocytes according to scatter,
excluding doublets and dead cells and gating on CD3+ cells.
Compared to humans, pigs have a high proportion of circu-
lating γδ T cells identified by mAbs recognizing the constant
region of porcine TCR-δ chain or TCRγδ-associated CD3 molecules
(Fig. 192). Pig γδ T-cell numbers are highest in young animals
and decrease with age [1719]. The different porcine γδ T-cell
subsets currently known are phenotypically divided based on
CD2 expression into TCRγδ+CD4−CD8α−CD2− γδ T cells and
TCRγδ+CD4−CD8α−/+CD2+ γδ T cells [1720, 1721] (Fig. 193).
Current studies suggest that similar to human γδ T cells, CD2+
γδ T cells can be activated either in direct response to PAMPs
via TLRs or upon APC interaction [1722, 1723], secrete vari-
ous cytokines involved in pathogen defense analogous to porcine
αβ T cells and partially express MHC-II molecules on their sur-
face [1724] (Fig. 193). In addition, cytotoxic activity, antigen- and
MHC-independent, is reported for TCRγδ+CD4−CD8αlowCD2+ γδ
T cells (H. [1725, 1726]). The role of TCRγδ+CD4−CD8α−CD2−
γδ T cells is less clear since those cells remain unresponsive for
antigenic stimuli tested so far. More recently, it was shown that
these cells express high levels of GATA-3, but the functional rele-
vance of this phenotype is not clear yet [1727].
Porcine CD4+CD8α+ T cells recall antigens in a MHC-II depen-
dent manner and increase strongly in number over life time
[1728, 1729]. CD8α expression on porcine Th cells is therefore
perceived as marker for activated and memory T helper cells.
While na¨ıve, porcine Th cells are defined as CD4+CD8α−CD27+,
differential expression of CD27 on CD4+CD8α+ defines termi-
nally differentiated effector memory cells (CD4+CD8α+CD27−)
and central memory cells (CD4+CD8α+CD27+) (Fig. 194) [1713].
Additional markers that have been investigated to characterize dif-
ferentiation of activated/memory Th cells are CD45RC and SLA-
DR (MHC-II) but there is currently no unifying differentiation
model based on all four molecules (i.e., CD8α, CD27, CD45RC,
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Figure 195. Functional subsets of porcine CD4+ T cells can be identified based on expression of master transcription factors using cross-reactive
mAbs developed against mouse and human. (A) Lymphocytes are identified based on the FSC and SSC. Single cells are discriminated from doublets
by plotting FSC area against height. Dead cells are excluded by a viability dye. (B) Following surface staining of CD4 (mAb clone 74-12-4), cells
were fixed and permeabilized to perform intranuclear transcription factor staining. Master transcription factors are used to identify distinct CD4+
subsets: Tregs – Foxp3+ (cross-reactive mAb clone FJK-16s) with CD25high expression (mAb clone 3B2), Th1 – T-bet+ (cross-reactive mAb clone 4B10)
that are mainly negative for CD27 (mAb clone b30c7), Th2 –GATA- 3+T-bet− (cross-reactive mAb clone TWAJ). (C) CD4+ Th17 cells can be identified
by their IL-17A expression (cross-reactive mAb clone SCPL1362) after PMA/ Ionomycin stimulation for 4 h. Data was generated from defrosted
PBMC of healthy, uninfected pigs of approximately 6 months of age.
and SLA-DR) (Fig. 194). While all CD4+ T cells have a CD27+ phe-
notype in newborn piglets, a distinct subpopulation of CD45RC−
cells could already be detected in neonates [1730].
Porcine CD4+ T-cell subsets can be further discriminated using
cross-reactive mAbs against master transcription factors. Treg cells
are identified by Foxp3/CD25 co-expression [1731] (Fig. 195). T-
bet expression correlates with the capacity for IFN-γ production
and appears to be suitable to identify Th1 cells [1729]. GATA-
3 expression is inducible in a subset of porcine CD4+ T cells
in vitro by ConA + IL-4 stimulation and in vivo after helminth
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Figure 196. Proliferation- and activation-associated markers of porcine CD4+ T cells. Porcine CD4+ T cells are identified according to the gating
strategies shown. (A) Nuclear staining of Ki-67 and Foxp3 using cross-reactive mAbs (mAb clone Ki-67 SolA15, mAb clone Foxp3 FJK-16s) before
(left) and after (right) cyclophosphamide and methylprednisolone induced immunosuppression of a piglet aged 8 weeks. (B) PBL from an Ascaris
suum infected pig (9 days post-infection) were subjected to short-term stimulation (7h) with Ascaris suum larval worm antigen (40 µg/mL) (right), or
left untreated (left), followed by intracellular staining of CD154 (CD40L) using a cross-reactive mAb (mAb clone 5C8). Data is generated from fresh
PBMC from an animal of approximately 3 month of age.
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Figure 197. Identification of porcine
CD8+ T cells in peripheral blood.
Lymphocytes are identified based on
the forward and side scatter. Sin-
gle cells are discriminated from dou-
blets by plotting FSC area against
height. Dead cells are excluded by
a viability dye and porcine CD8+
T cells are gated as CD8β+ cells (mAb
clone PPT23). Three subsets can fur-
ther be identified on the basis of
CD27 (mAb clone b30c7) and per-
forin expression (cross-reactive mAb
clone δG9). Both, perforin+CD27dim
and perforin+CD27− CD8+ T cells
express T-bet. Data is generated
fromdefrosted PBMC from an animal
of approximately 6 months of age.
infection [1732]. However, in pigs kept under conventional hous-
ing conditions, the frequency of GATA-3+ CD4+ T cells is quite
low. Instead, the majority of na¨ıve CD4+ T cells express low lev-
els of GATA-3 (Fig. 195) [1729]. Th17 cells can be identified
by intracellular cytokine staining with various cross-reactive anti-
human IL-17A mAbs (Fig. 195 and Chapter VI 15). Nuclear stain-
ing using cross-reactive anti-mouse Ki-67 mAb identifies prolifer-
ating porcine cells [1733] (Fig. 196).
The CD4 T-cell activation marker CD154 (CD40L) is upreg-
ulated shortly (5–16 h) after TCR-dependent antigen encounter
and is, also in porcine CD4+ T cells, found to be co-expressed
with cytokines [1734]. An anti-human cross-reactive mAb reac-
tive to CD154 can be used to identify antigen-reactive porcine
CD4+ T cells by intracellular staining (Fig. 196) [1734].
In contrast to the abundant expression of CD8αα homodimers
on subsets of CD4+ and γδ T cells, porcine CD8+ T cells with the
capacity to differentiate into CTLs express CD8αβ heterodimers
and hence can be identified by using mAbs against CD8β. Alter-
natively, they can be identified by a CD3+TCR-γδ−CD4− CD8αhigh
phenotype (Fig. 192). Perforin expression can be identified by
cross-reactive anti-human mAbs and perforin expression has been
suggested to identify antigen-experienced CD8+ T cells. T-bet
shows a clear positive correlation with perforin expression and
ex vivo time course studies with aging pigs suggest that a lack of
CD27 expression identifies terminally differentiated CTLs [1730]
(Fig. 197).
Porcine T-cell development in the thymus follows the pheno-
typic pattern described in other vertebrates, with CD4−CD8α−
thymocytes representing the most immature stage, followed
by a CD4+CD8α+ phenotype and further development into
CD4+CD8α− and CD4+CD8α+ thymocytes [1711, 1719]. The
more immature phenotypes express high levels of GATA-3 [1729].
TCR-γδ T cells separate already in the thymus into a CD2+ and
CD2− subset [1735]. In lymph nodes, T cells with a na¨ıve pheno-
type dominate, whereas in non-lymphatic organs effector (mem-
ory) phenotypes are enriched [1736]. Recently, tissue-resident
memory T cells were described in porcine lung tissue and bron-
choalveolar lavage [1737]. Abs for porcine CD103 are currently
not available and pig-specific mAbs for CD69 were described just
recently [1738] but are not yet commercialized. All reagents and
Abs for porcine T-cell stainings shown in Figs. 192 to 197 are listed
in Table 78.
14.4 Porcine NK cells and B cells. In contrast to NK cells in
humans and mice, porcine NK cells are small dense lympho-
cytes [1739, 1740]. Porcine NK cells can be found within the
CD3−CD16+ subset of lymphocytes, representing non-T and non-
B cells. Up to date, no pan-NK cell marker exists in swine as
the activating receptor NKp46 (CD335, NCR1) that is proposed
as marker for NK cells across mammalian species [1741], is dif-
ferentially expressed in pigs. Three distinct NK-cell subsets can
be identified on the basis of their NKp46 expression: NKp46−,
NKp46+, and NKp46high [1714, 1742] (Fig. 198). NKp46high NK
cells are more abundant in spleen and non-lymphatic organs
compared to blood and show a reduced or lacking expression
of CD8α (dim/-) compared to the NKp46- and NKp46+ CD8α+
subsets [1714, 1742, 1743]. All porcine NK-cell subsets express
perforin, CD2, and CD27. For the latter, a positive correlation to
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Figure 198. Identification of porcine NK cells in cells isolated from peripheral blood and spleen. Lymphocytes are identified based on the forward
and side scatter. Single cells are discriminated from doublets by plotting FSC area against height and dead cells are excluded by a viability dye.
CD3−CD16+ non-T and non-B cells (mAb clone CD3 B23-8E6-8C8; mAb clone CD16 G7) are further gated on three NK-cell subsets on the basis of
their different CD8α (mAb clone 11/295/33) and NKp46 (mAb clone VIV-KM1) expression in blood as well as spleen. Perforin expression (cross-
reactive mAb clone δG9) can be detected in all three NK-cell subsets in contrast to CD8α−NKp46− non-NK cells. Data is generated from defrosted
PBMC and lymphocytes isolated from spleen of an animal of approximately 6 months of age.
NKp46 expression is described [1742]. In contrast to human NK
cells that show a functional dichotomy of the CD16brightCD56dim
(higher cytotoxicity) and CD16dim/−CD56bright (higher potential to
produce cytokines) subsets, porcine NKp46highCD8αdim/− NK cells
have the highest capacity for both functions [1742].
Up to date, a detailed phenotypic and functional analysis on
porcine B cells is hampered due to the lack of a pan-B cell marker
like CD19 as used in humans and mice. For the detection of
total porcine B cells a cross-reactive mAb against CD79α can be
used [1744] (Fig. 199). As the mAb recognizes a cytoplasmic epi-
tope, fixation and permeabilization of the cells is required prior to
CD79α staining with this mAb, excluding subsequent functional
analyses with sorted B cells. Furthermore, no species-specific or
cross-reactive mAbs for the identification of distinct functional B-
cell subsets like transitional B cells and plasma cells/plasmablasts
(e.g., CD38 and CD138) are available. In humans, CD27 is used
to distinguish memory from na¨ıve B cells, whereas in the pig, no
CD27 expression was detected on B cells [1745]. Cross-reactive
mAbs against CD21 have been used to distinguish more mature
(CD21−) from less mature B cells (CD21+) in the pig [1746].
Monoclonal Abs against IgM, IgG, and IgA [1747] can also be
used in FCM and recently IgM+CD21− B cells have been proposed
to represent B1-like B cells [1748]. Interestingly, this cell popula-
tion also express high levels of CD11R1 and CD11c, markers that
are also found in high levels on myeloid cells [1748]. Intracellular
staining for Ig-molecules, to identify plasma cells and memory B
cells, has not been thoroughly applied yet in the phenotyping of
porcine B cells. All reagents and Abs for porcine NK- and B-cell
staining shown in Figs. 198 and 199 are listed in Table 79 and 80.
14.5 Porcine myeloid cells. Although common features are found
betweenmononuclear phagocytes of mice, humans, and pigs, each
species has its own features in terms of marker expression and sub-
set function [1749]. Only recently, cross-species similarities were
addressed by, e.g., cross-species transcriptome comparison [1750]
and phenotypic differences were investigated at the protein and
transcriptome level to identify different dendritic cell (DC) and
macrophage subsets in swine [1751–1753].
The porcine equivalents of conventional DCs (cDC) cDC1,
cDC2, and plasmacytoid DCs (pDCs) in the peripheral blood
can be discriminated from monocytes by the absence of
CD14 expression as follows: cDC1 are CD14−CD172alowCADM1+
cells, cDC2 are CD14−CD172ahighCADM1+ cells, and pDCs are
CD14−CD172a+CADM1−CD4+cells (Fig. 200) (based on the
results and gating described in ref. [1752]). The phenotypic char-
acterization of porcine blood cDC1 revealed species-conserved fea-
tures such as high surface expression of CD135, CADM1, CD205,
low levels of CD172a, and a lack of CD115 [1752]. Opposing
to murine DC, where CD11b is used as a cDC2-specific marker,
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Figure 199. Identification of porcine B cells in peripheral blood. (A) Lymphocytes are identified based on the forward and side scatter. Single
cells are discriminated from doublets by plotting FSC area against height and dead cells are excluded by a viability dye. (B) CD79α+ B cells (cross-
reactive mAb clone HM57) within live PBL can be further analyzed for expression of CD21 (cross-reactive mAb clone B-ly4), IgM (mAb clone K52
1C3), IgG (mAb clone 23.7.1b) and IgA (mAb clone K61 1B4). A comprehensive functional characterization of the various porcine B-cell subsets
has not been performed so far. (C) Bulk staining for CD3 (mAb clone PPT3), CD8α (mAb clone 11/295/33), and CD52 (mAb clone 11/305/44) in
combination with a co-staining for CD79α and CD21 shows that CD79α+ B cells are CD3−CD8α−CD52− but contain CD21− and CD21+ cells. Non-B
cells (CD3+CD8α+CD52+) are CD21−. Data is generated from freshly isolated PBMC from an animal of approximately 6 months of age.
porcine CD11R1 (equivalent to murine and human CD11b) is
highly expressed on circulating cDC1 and cDC2 [1752]. The phe-
notypic characterization of the porcine blood cDC2 subset is dif-
ficult as different markers (e.g., CD163, CSF1R) are expressed
also on porcine monocytes, but the lack of the porcine monocyte-
specific marker CD14 and high FLT3 expression approved these
as DCs [1752]. Species-specific characteristics of porcine cDC2
are reflected by the high surface expression of CD1.1 (equiv-
alent to CD1a [1754]), which is restricted to dermal cDC2 in
humans [1755], and CADM1, which is a feature of other mam-
malian cDC1 subsets [1756]. Like in other species, the porcine
pDC subset (typically CD4+SLA-DRlowCD80/86low), produces high
amounts of type I IFNs after virus stimulation [1716] and pro-
duces high amounts of cytokines following TLR ligand stimulation
(e.g., IL-12p35 after CpG stimulation) compared to the porcine
cDC subsets. Similar to human pDC, porcine pDC express CD303
(BDCA-2), and CD304 (BDCA-4) [1752].
In contrast to human monocyte classification based on CD14
and CD16, and mouse monocyte classification based on Ly6C+/−,
porcine monocytes can be identified as CD14+CD172a+ mononu-
clear leukocytes that can be further divided into different sub-
populations based on the expression levels of CD163, SLA-DR,
and CD14 (Fig. 201) [1757, 1758]. Two major subpopulations of
blood monocytes have been described in pigs (CD14highCD163−
SLA-DR− and CD14lowCD163+SLA-DR+) that show differences
in CD11a, wCD11R1 (α-integrins), CD29 (integrin β1), CD49d
(integrin α4), CD61 (integrin β3), CD80/86, and CD1a expres-
sion [1757, 1759, 1760] and also differ in chemokine receptor
expression of CX3CR1 and CCR2 [1761]. So far state of the art
is that these cells divide into distinct subsets in the bone marrow,
thereafter circulating monocyte subpopulations represent differ-
ent maturation stages and comprise distinct functional capaci-
ties [1758, 1762, 1763]. Compared tomouse, gene expression pro-
files suggest that porcine blood-derivedmonocyte subsets are close
to humanmonocytes as certain genes (e.g., CD36, CLEC4E, TREM-
1 expressed in human monocytes) were selectively expressed in
pig monocyte subsets [1759]. The same profiles revealed also
that the pig CD14lowCD163+ cells are actually equivalent to
intermediate human monocytes (CD14highCD16+), and that there
is no CD14+CD16+ “nonclassical” population [1759]. Porcine
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Figure 200. Identification of porcine conventional dendritic cells (cDC) and plasmacytoid dendritic cells (pDC) in peripheral blood. Large mononu-
clear cells are identified based on FSC and SSC. Single cells are discriminated from doublets by plotting FSC area against height. Dead cells are
excluded by a viability dye combined with a dump channel for exclusion of porcine CD21+ B cells (mAb clone B-ly4). Viable CD3− non-T cells
(mAb clone BB23-8E6-8C8) can be further discriminated from porcine monocytes by the absence of CD14 expression (mAb clone TU¨K4). Sub-
sequently, three different DC subsets can be identified based on the expression of CD172a (mAb clone 74-22-15), CADM1 (mAb clone 3E1) and
CD4α (mAb clone 74-12-4) as follows: cDC1 are CD14− CD172alowCADM1+ cells, cDC2 are CD14−CD172ahighCADM1+ cells and pDC are CD14−
CD172a+CADM1−CD4+cells. Data are generated from fresh PBMC of a sow of approximately 2 years of age.
CD14highCD163− monocytes likely correspond to classical mono-
cytes (CD14highCD16−) in humans [1762]. However, cross-species
subset comparison of blood monocytes among human, bovine,
murine, and pig cells using transcriptomics indicated that CD163-
based discrimination of porcine monocytes into classical and non-
classical monocytes might need to be reevaluated [1750, 1764].
CD14 expression can also be found at lower levels on granulocytes
in the pig [1762]. Of note, porcine granulocytes are also positive
for CD172a and some mature B cells can be induced to express
low levels of CD172a after antigen stimulation [1762, 1765].
Quite recently, the phenotypic characterization of lung
tissue resident DC and macrophage network segregated
porcine mononuclear phagocytes as follows: conventional
cDC1 (MHCII++CD172a−CD163−CD1−CADM1+CD14−) and
cDC2 (MHCII++CD172a+CD163−CD1lowCADM1lowCD14−),
inflammatory monocyte-derived DCs (MHCII++
CD172a+CD163lowCD1−CADM1+CD14−), monocyte-derived
macrophages (MHCII++CD172a+CD163intCD1−CADM1lowCD14+),
and alveolar macrophage-like cells/interstitial macrophages
(MHCII++CD172a+CD163++CD1−CADM1−CD14−) and alveolar
macrophages (MHCII++CD172a+CD163++CD1−CADM1−/low
CD14−) [1753, 1766, 1767]. This nomenclature is based on the
origin and the function of the myeloid cells [1768], and offers
the advantage to assign one single name per DC/Macrophage
subpopulation for all the species facilitating trans-species com-
parisons [1753, 1766]. The FLT3-dependent cDC being Sirpα
(CD172a) negative or low are named cDC1 in the pig lung and
correspond to the BDCA3+ cDC and CD103+ cDC in human and
mouse, respectively [1753, 1766]. Referring to the BDCA1+ and
CD11b+ DC subset in human and mouse, the CD172a++/CD11b+
cDC in the porcine respiratory tract are named cDC2 [1753].
Porcine alveolar macrophages express high levels of CD172a,
CD163, CD169, CD16, and SLA-II molecules, whereas CD14
and CD11R1 expression is minimal or negative on alveolar
macrophages [1762]. Moreover, CD203a (originally clustered
as SWC9) is expressed widely in porcine macrophage popula-
tions with notably high levels on alveolar macrophages, but is
not expressed on monocyte populations [1762]. Like in other
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Figure 201. Identification of porcinemonocyte subsets in peripheral blood. Mononuclear cells are identified based on the forward and side scatter.
Single cells are discriminated from doublets by plotting FSC area against height. Dead cells are excluded by a viability dye combined with a dump
channel for exclusion of porcine CD21+ B cells (cross-reactive mAb clone B-ly4). Monocytes can be further discriminated from viable CD3− non-
T cells (mAb clone BB23-8E6-8C8) as CD14+CD172a+ cells (mAb clone CD14 TU¨K4; mAb clone CD172a 74-22-15). Different monocyte subsets can be
identified based on the expression of CD163 (mAb clone 2A10/11) and SLA-DR (mAb clone 2E9/13). The histogram shows CD14 expression (mAb
clone TU¨K4) of the two monocyte subsets representing the major “steady-state” subsets (CD14highCD163−SLA-DR− and CD14lowCD163+SLA-DR+)
in porcine peripheral blood. Data is generated from fresh PBMC of a sow of approximately 2 years of age.
species, alveolar macrophages of the pig are also highly aut-
ofluorescent [1753]. Contrary to porcine alveolar macrophages
those in mice do not express MHC-II and are all negative for
CD11b [1456], whereas human alveolar macrophages widely
express CD11b and MHC-II [1769]. Porcine alveolar macrophage-
like cells are pulmonary intravascular macrophages that have not
been observed yet at steady-state in mice or non-human primates,
and have nearly the same phenotype like porcine alveolar
macrophages [1767, 1770]. Interstitial CD169− macrophages are
a prominent cell type in human lung tissue, whereas CD169+
macrophages are located in the alveolar space/airway, defining
them as alveolar macrophages [1771]. Whether this CD169−
negative macrophage population in the human lung refers to the
porcine alveolar macrophage-like cells is not resolved yet.
In the skin of pigs, similar to humans, the classical DC
subsets of epidermal Langerhans cells (LC) and dermal DC
are found [1772]. Dermal DC can be divided into three main
subsets according to their CD163 and CD172a expression:
CD163−CD172a−, CD163+CD172a+, and CD163lowCD172a+ that
differ in the expression of CD16, CD206, CD207, CD209, and
CADM1 [1772]. Based on comparative transcriptomics, pheno-
typic analysis, and functional studies, Marquet and colleagues
proposed the allocation of porcine dermal DC to those of the
human system as follows: the porcine CD163−CD172a− subset
corresponds to the human CD141+ dermal DC subset, the porcine
CD163lowCD172a+ subset to the human CD1c+ dermal DC, and
the porcine CD163+CD172a+ subset to the monocyte-derived
human CD14+ dermal DC subset.
In porcine tonsils, plasmacytoid DC
(CD172alowCD4+MHCIIlow) and conventional DC
(cDC1, CD172a−/lowCADM1++MHCII++ and cDC2,
CD172a++CD14−CD163−MHCII++CADM1low) but also
monocyte-derived cells (CD172a++CD163−CD14+MHCII++)
and macrophage-like cells (CD172a++, CD163+CD14−MHCII++)
have been identified [1751]. Compared to blood, not all tonsil-
resident cDC1 and cDC2 cells express the C-type lectin receptor
DEC205 [1773]. All reagents and Abs for porcine myeloid cell
staining shown in Figs. 200 and 201 are listed in Table 81.
For analyzing neutrophils, eosinophils and basophils in
porcine whole blood, granulocytes are identified based
on their high SSC and FSC properties and expression
of CD172a. To separate between them, SWC8, a marker
defined by the International Workshop on Swine Leukocyte
Differentiation Antigen (A. [1774]), SWC1 (now identi-
fied being porcine CD52 [1775]) and the antigens 2B2 and
6D10 [1776] can be used. Mature neutrophils in blood express
CD172a+SWC8++CD52+6D10+2B2+CD14+, whereas mature
eosinophils are CD172a+SWC8++CD52−6D10−2B2+CD14−
and mature basophils will identify as CD172a+SWC8−
CD52+6D10−2B2+CD14− [1762].
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Table 78. Reagents and Abs for T-cell staining
Reagent/antibody Clone Manufacturer
Mouse anti-pig CD2 - Alexa Fluor R© 488 MSA4 In house1
Mouse anti-pig CD3 - PerCP-CyTM5.5 BB23-8E6-8C8 BD Biosciences
Mouse anti-pig CD4 74-12-4 In house2
Mouse anti-pig CD4 - FITC 74-12-4 BD Biosciences
Mouse anti-pig CD4 - Alexa Fluor R© 647 74-12-4 BD Biosciences
Mouse anti-pig CD8α - Alexa Fluor R© 647 11/295/33 In house3
Mouse anti-pig CD8α - Biotin 11/295/33 In house4,5
Mouse anti-pig CD8β - Biotin PPT23 In house4,6
Mouse anti-human CD14 - VioGreen TU¨K4 Miltenyi Biotec
Mouse anti-pig CD25 3B2 In house7
Mouse anti-pig CD27 b30c7 BioRad
Mouse anti-pig CD27 - Alexa Fluor R© 647 b30c7 In house8
Mouse anti-pig TCRγδ PGBL22A Kingfisher Biotech
Mouse anti-pig TCRγδ - Biotin PPT16 In house4,9
Mouse anti-pig SLA-DR - Biotin MSA3 In house4,10
Mouse anti-human Perforin - PerCP-eFluor710 δG9 ThermoFisher Scientific
Rat anti-mouse Foxp3 - PE FJK-16s ThermoFisher Scientific
Rat anti-mouse Foxp3 - eFluorTM 450 FJK-16s ThermoFisher Scientific
Mouse anti-human T-bet - PE 4B10 ThermoFisher Scientific
Rat anti-human/ mouse GATA-3 - PerCP-eFluor710 TWAJ ThermoFisher Scientific
Mouse anti-human IL-17A - Alexa Fluor R© 647 SCPL1362 BD Biosciences
Mouse anti-human TNFα - FITC MAb11 BD Biosciences
Rat anti-mouse Ki-67 - PE-Cy7 SolA15 ThermoFisher Scientific
Mouse anti-human CD154 - PE 5C8 Miltenyi Biotec
Goat anti-mouse IgG1 - PE − SouthernBiotech
Goat anti-mouse IgG2b - Alexa Fluor R© 488 − ThermoFisher Scientific
Streptavidin - Brilliant Violet 421TM − BioLegend
Fixable Viability Dye eFluorTM 780 − ThermoFisher Scientific
Fixable Viability Dye eFluorTM 506 − ThermoFisher Scientific
1Conjugation with Alexa Fluor R© 488 Protein Labeling Kit (ThermoFisher Scientific); non-conjugated mAb available from Kingfisher Biotech
2Commercially available from BD Biosciences
3Conjugation with Alexa Fluor R© 647 Protein Labeling Kit (ThermoFisher Scientific); mAb commercially available from BD Biosciences
4Biotinylation with EZ-LinkTM Sulfo-NHS-LC-Biotin (ThermoFisher Scientific)
5Alternative mAb clone 76-2-11 available from BD Biosciences and ThermoFisher Scientific
6Non-biotinylated mAb commercially available from Bio-Rad
7mAb commercially available from Bio-Rad (clone name K231.3B2)
8Conjugation with Alexa Fluor R© 647 Protein Labeling Kit (ThermoFisher Scientific); mAb commercially available from Bio-Rad
9mAb currently not commercially available, alternative clone: PGBL22A, available from Kingfisher Biotech
10mAb commercially available from Kingfisher Biotech
14.6 Step-by step-sample preparation.
14.6.1 General comments. Blood samples from pigs are most
commonly taken by venipuncture from the external jugular vein
and require fixation but no sedation. Terminal blood samples
are obtained intracardially under deep anesthesia and Lithium–
Heparin or Sodium–Heparin as anticoagulants are recommended
with respect to the duration of large animal dissections.
14.6.2 Step-by-step sample preparation of porcine PBMC.
1. Draw blood and transfer to an anti-coagulant containing tube.
2. Dilute blood 1:2 in 0.9% sodium chloride solution or PBS.
3. Carefully overlay Pancoll (e.g. Pancoll human, Cat# P04-
601000 by PAN-Biotech, density 1.077 g/mL) with diluted
blood in a ratio of 1:3.
4. Centrifuge at room temperature at 800 × g without brake for
20 min.
5. Collect interphase, transfer to new tube and wash with 0.9%
sodium chloride solution or PBS.
6. [optional] Perform erythrocyte lysis (for example using 3 mL
ACK lysis buffer at RT for 3 min).
7. Wash with staining buffer.
8. Pellet cells (300 × g, 4°C, 6 min) and discard supernatant.
14.6.3 Step-by-step sample preparation of porcine lymphocytes
from spleen.
1. Cut dissected spleen into small pieces.
2. Mechanically dissociate tissue pieces by forcing through a sieve
and rinse with PBS.
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3. Centrifuge at 4°C at 350 × g and discard supernatant.
4. Resuspend cells in 20 mL PBS and force through a cell strainer
(70 µm).
5. Carefully overlay Pancoll (for example Pancoll human, Cat#
P04-601000 by PAN-Biotech) with cell suspension in a ratio of
1:3.
6. Centrifuge at room temperature at 800 × g without brake for
20 min.
7. Collect interphase, transfer to new tube and wash twice with
PBS at 300 × g, 4°C, 6 min and discard supernatant.
14.6.4 FCM staining of porcine leukocytes from blood and spleen.
1. Transfer up to 2 × 106 cells into a 96-well conical or U-bottom
shaped plate.
2. Centrifuge the plate at 300 × g at 4°C for 3 min.
3. Aspirate or decant supernatant.
4. [optional] For blocking of Fc receptors add 1:200 to 1:500
diluted mouse serum (in staining buffer) for 5 min at 4°C or
use 10% porcine plasma in PBS staining buffer.
5. [optional] Add True-Stain Monocyte BlockerTM according to
the manufacturer’s instruction.
6. Add a max of 30 µL surface staining mix per well and incubate
for 15 min at 4°C.
7. Two washing steps: add up to 200 µL staining buffer and cen-
trifuge the plate at 300 × g at 4°C for 3 min and aspirate or
decant supernatant.
8. [optional] Add secondary reagents as described above includ-
ing the two washing steps.
9. [optional] Add Fix/ Perm reagent for 20 min at 4°C, follow-
ing two washing steps in permeabilization buffer as described
above.
10. [optional] Add mAbs specific for intracellular or intranuclear
antigens for 20 min at 4°C, following two washing steps in
permeabilization buffer as described above.
N.B. If unlabeled and directly-conjugated Abs with identical
isotypes are used in the same sample, a sequential staining should
be performed: After labeling with unconjugated primary mAb and
isotype-specific dye-conjugated secondary Abs, free binding sites
should be blocked by whole mouse IgG molecules (typically 2 µg
per sample, vendor: Jackson ImmunoResearch).
14.7 Materials. Flow cytometer:
 FACSCanto II flow cytometer
 FACSAria III sorter (both BD Biosciences)
Media and buffers:
 RPMI+AB: RPMI 1640 (PAN-Biotech) supplemented with 100
U/mL Penicillin, and 100 µg/mL Streptomycin (PAN-Biotech)
Table 79. Reagents and Abs for NK-cell staining
Reagent/antibody Clone Manufacturer
Mouse anti-pig CD3 -
PerCP-CyTM5.5
BB23-8E6-8C8 BD Biosciences
Mouse anti-pig CD8α -
Biotin
11/295/33 In house1
Mouse anti-pig CD16 -
FITC
G7 BioRad
Mouse anti-pig NKp46 -
Alexa Fluor R© 647
VIV-KM1 In house2
Mouse anti-human
Perforin - PE
δG9 ThermoFisher
Scientific
Streptavidin - PE-Cy7 − ThermoFisher
Scientific
Fixable Viability Dye
eFluorTM 780
− ThermoFisher
Scientific
1Biotinylation with EZ-LinkTM Sulfo-NHS-LC-Biotin (ThermoFisher Sci-
entific), alternative mAb clone 76-2-11 available from BD Biosciences
and ThermoFisher Scientific
2Conjugation with Alexa Fluor R© 647 Protein Labeling Kit (ThermoFisher
Scientific), mAb commercially available from Bio-Rad
Table 80. Reagents and Abs for B-cell staining
Reagent/Antibody Clone Manufacturer
Mouse anti-pig CD3 PPT3 In house
Mouse anti-pig CD8α 11/295/33 In house
Mouse anti-human CD21 -
APC
B-ly4 BD Biosciences
Mouse anti-pig CD52 11/305/44 In house1
Mouse anti-human CD79α -
PE
HM57 Dako
Mouse anti-pig IgM K52 1C3 Bio-Rad
Mouse anti-pig IgA K61 1B4 Bio-Rad
Mouse anti-pig IgG 23.7.1b ThermoFisher
Scientific
Rat anti-mouse-IgG1 -
Brilliant Violet 421TM
RMG1-1 BioLegend
Goat anti-mouse-IgG2a -
Brilliant Violet 421TM
− Jackson Immuno
Research
Goat anti-mouse-IgG2b -
Brilliant Violet 421TM
− Jackson Immuno
Research
Fixable Viability Dye
eFluorTM 780
− ThermoFisher
Scientific
1mAb commercially available from Bio-Rad
 cRPMI: Complete RPMI 1640 (PAN-Biotech) supplemented
with 10% FCS (PAN-Biotech), 100 U/mL Penicillin, and
100 µg/mL Streptomycin (PAN-Biotech)
 cIMDM: Complete IMDM (PAN-Biotech) supplemented with
10% FCS (PAN-Biotech), 100 U/mL Penicillin, and 100 µg/mL
Streptomycin (PAN-Biotech)
 ACK lysis buffer: 150 mM NH4Cl, 10 mM KHCO3, and 0.1 mM
Na2EDTA
 Fixation and Permeabilization reagents: for detection of intra-
cellular cytokines: Fixation/Permeabilization solution kit (BD
Biosciences); For detection of intranuclear molecules and per-
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Table 81. Reagents and Abs for the staining of mononuclear
phagocytes
Reagent/antibody Clone Manufacturer
Mouse anti-pig CD163 – PE 2A10/11 BioRad
Chicken anti-human
CADM1 - FITC
3E1 MBL
Mouse anti-human CD21 -
BV510
B-ly4 BD Biosciences
Mouse anti-pig CD3 -
PerCP-CyTM5.5
BB23-8E6-8C8 BD Biosciences
Mouse anti-pig CD4 - Alexa
Fluor R© 647
74-12-4 BD Biosciences
Mouse anti-human CD14 -
APC-Vio770
TU¨K4 Miltenyi Biotec
Mouse anti-pig CD172a -
Biotin
74-22-15 SouthernBiotech
Mouse anti-pig SLA-DR -
FITC
2E9/13 BioRad
Streptavidin - PE-Cy R©7 − ThermoFisher
Scientific
Streptavidin - eFluorTM 450 − ThermoFisher
Scientific
eBioscienceTM Fixable
Viability Dye eFluorTM 506
− ThermoFisher
Scientific
True-Stain Monocyte
BlockerTM
− BioLegend R©
forin: Foxp3/Transcription factor staining buffer set (Ther-
moFisher Scientific)
 Staining buffer: PBS (PAN-Biotech) supplemented with 2 mM
EDTA and 0.5% BSA (AppliChem) or PBS (PAN-Biotech) sup-
plemented with 10% porcine plasma
In vitro stimulation
 PMA (50 ng/mL) and Ionomycin (500 ng/mL, both Sigma–
Aldrich) for 4 h in combination with Brefeldin A (GolgiPlug,
BD Biosciences, 1 µg/mL)
 Antigen preparation of selected pathogens for antigen induced
T-cell responses (in total 6–8 h, in titrated concentrations (e.g.,
25–80 µg/mL) and for 4 h in combination with Brefeldin A
(Brefeldin A solution, 1000×, ThermoFisher Scientific)
14.8 Data Analysis. Flow cytometric analysis was performed
by using FACSCanto II flow cytometer and FACSAria III sorter
employing FACSDiva Software v6.1.3 (BD Biosciences), and data
were analyzed by using FlowJo software v9.9.4 and v10.5 (FlowJo,
LLC).
14.9 Pitfalls.
 Be aware that CD8α does not identify conventional CD8+ T cells
per se, but is also expressed on CD4 T cells, NK cells, and subsets
of γδ T cells.
 Keep in mind the strong age-dependency of the expression of
several porcine markers (e.g., CD8α, MHC-II).
 Porcine monocytes do not separate from peripheral blood lym-
phocytes by FSC/SSC properties as clearly as human mono-
cytes.
 Carefully test cross-reactivity of anti-human or anti-murine Abs
before use (see also section 15.6).
14.10 Top tricks.
 If working with frozen/thawed samples we advise to incubate
freshly thawed samples in cRPMI overnight at 37°C to improve
cytokine responses after subsequent stimulation.
Summary of major porcine immune cell subpopulations
γδ T-cell populations Phenotype/sub-phenotype
TCRγδ+CD4−CD8−CD2−
TCRγδ+CD4−CD8−/+CD2+
CD4+ T-cell populations Phenotype/sub-phenotype
Naı¨ve CD4+CD8α−CD27+
Effector-memory CD4+CD8α+CD27−
Central-memory CD4+CD8α+CD27+
Treg CD25highFoxp3+
Th1 Tbet+
Th2 GATA3high
CD8+ T-cell populations Phenotype/sub-phenotype
Naı¨ve CD3+TCR-γδ−CD4−CD8αhighCD8β+
CD27+perforin−
Effector-(memory) CD3+TCR-γδ−CD4−CD8αhighCD8β+
CD27−/dimperforin+
NK-cell populations Phenotype/sub-phenotype
highly activated CD3−CD8αdimCD16+NKp46high
less activated CD3−CD8α+CD16+NKp46−/+
B-cell populations Phenotype/sub-phenotype
Naı¨ve CD79α+CD21+IgM+
B-1 CD79α+CD21−IgM++
Class-switched memory CD79α+CD21−/+IgG+/IgA+
Myeloid populations
in blood Phenotype/sub-phenotype
Monocytes CD14+CD16+CD163+/−CD135−
Steady state CD14++CD163−/low
CD14lowCD163+/++
Inflammatory CD14lowCD163+SLA-DR−
cDC1 CD14−CD172alowCADM1+CD4−
wCD11R1+CD135+
cDC2 CD14−CD172a+CADM1+CD4−CD115+
wCD11R1+CD135+CD1+
pDC CD14−CD172a+CADM1−CD4+CD135+
CD123+CD303+
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Myeloid populations
in lung Phenotype/sub-phenotype
Alveolar macrophages SLA-DR++CD172a+CD163++CD1−
CADM1−/lowCD14−
Pulmonary
intravascular
macrophages
SLA-DR++CD172a+CD163++CD1−
CADM1−CD14−
Monocyte-derived
macrophages
SLA-DR++CD172a+CD163intCD1−
CADM1lowCD14+
Monocyte-derived DC SLR-DR++CD172a+CD163lowCD1−
CADM1+CD14−
cDC1 SLA-DR++CD172a−CD163−CD1−
CADM1+CD14−
cDC2 CD14−CD172a+CADM1+CD4−
CD115+wCD11R1+CD135+CD1+
pDC CD14−CD172a+CADM1−CD4+
CD135+CD123+CD303+
Myeloid populations
in tonsils Phenotype/sub-phenotype
Macrophages CD172a++CD163+CD14−MHCII+
Monocyte-derived DC CD172a++CD163−CD14+MHCII++
cDC1 SLA-DR++CD172alow/−CD4−CADM1++
CD14−CD163−
cDC2 SLA-DR++CD172a++CD4−CADM1low
CD14−CD163−
pDC SLA-DRlowCD172alow/−CD4+CADM1−
CD14−CD163−
Myeloid
populations in
skin Phenotype/sub-phenotype
Langerhans cells CD172a+CD1+CD16−CD163−CADM1+
CD207+MHCII+
Dermal DC CD163−CD172a−CD16−CD206−CADM1+
CD163+CD172a+CD1+CD14+CD16+
CD209lowCD206low
CD163lowCD172a+CD1+CD14lowCD16low
Granulocyte
populations in
blood Phenotype/sub-phenotype
Neutrophils CD172a+SWC8++CD52+6D10+2B2+CD14+
Eosinophils CD172a+SWC8++CD52−6D10−2B2+CD14−
Basophils CD172a+SWC8−CD52+6D10−2B2+CD14−
15 Cross-reactive Ab clones
15.1 Overview. The testing of existing mAbs for reactivity with
orthologous molecules in species different from the one the Ab
was originally raised for is a frequent task to overcome limitations
in the toolbox of available mAbs. This section provides an outline
how experiments for cross-reactivity testing should be performed
and what pitfalls might be encountered.
15.2 Introduction. For immunophenotyping studies in mice and
humans researchers can choose from a large variety of mAbs
specific for cluster of differentiation (CD) molecules, but also
cytokines, transcription factors, and molecules involved in sig-
nal transduction. However, when it comes to other animal species
this collection is severely diminished. One possibility to overcome
this limited availability of mAbs is to test already existing mAbs for
cross-reactivity with the orthologous molecule of the species under
investigation. Although thismight sound like a simple and straight-
forward task, likewith any other immunophenotyping experiment,
certain problems and pitfalls might be encountered. Hence, this
chapter will give an outline for solid and successful cross-reactivity
testing.
In the framework of the 8th Human Leukocyte Differentiation
AntigenWorkshop (HLDA8) a community-based effort was under-
taken to identify commercially available mAbs for cross- reactivity
with 17 different animal species, ranging from more frequently
studied ones like swine, dog, or cattle up to more “exotic” species
like mink and carp. This study revealed that for the typical cell
membrane-located CD-molecule, the likelihood of cross-reactivity
even within mammalian species is relatively low. A few excep-
tions applied to this observation, including mAbs against CD18,
CD29, or CD49d, all forming either α or β-chains of integrins, or
the cartilage link protein CD44 [1777, 1778].
15.3 General considerations on cross-reactivity testing. This study
was far from being comprehensive and hence new tests for cross-
reactivity are a frequent task if species different from mice and
humans are studied. Work from our team and others on the cross-
reactivity of mAbs with various porcine immune-related molecules
revealed certain approaches that can be used not only to identify
cross-reactive mAbs but also to scrutinize specific binding to the
molecule of interest (see Fig. 202 for a general overview). In a
first step commercially available Abs for the molecule of inter-
est need to be identified. Online search tools like “biocompare”
(https://www.biocompare.com/Antibodies/) or “antibodypedia”
(https://www.antibodypedia.com/) might be helpful for this task,
but the online catalogs of established producers for FCM-approved
Abs are also a good source. Numerous Ab data sheets from the
respective companies do provide information on cross-reactivity
but such statements should be treated with caution as the claim
of cross-reactivity is frequently based on sequence alignments
and lacking solid experimental testing (see also Fig. 205 for an
example). Under ideal circumstances, references are provided
that demonstrate the claimed cross-reactivity, allowing a further
scrutiny of the Ab.
If no information on cross-reactivity is provided, sequence
alignments comparing the amino acid sequence of the target anti-
gen in the species under investigation with the sequence of the
species the Ab is specific for give a first indication of the like-
lihood of cross-reactivity. Our empirical observations show that
homology rates below 75% usually indicate a low probability
for cross- reactivity. However, for some Abs the sequence of the
immunogen is provided in the data sheet, allowing a more focused
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Figure 202. Strategies on cross-reactivity test-
ing for mAbs for FCM. After identification
of mAb candidates for cross-reativity testing,
sequence homology analyses, ideally for the
immunogen used to generate the Ab, will pro-
vide a first prognosis of the likelihood of cross-
reactivity testing. Homologies higher than 90%
indicate a good chance for cross-reactivity.
High homology of target antigens across sev-
eral species increases the likelihood of cross-
reactivity further (typical examples: transcrip-
tion factors or molecules involved in signal
transduction). FCM staining experiments with
the Ab under investigation in combinationwith
an established marker or larger marker pan-
els helps to evaluate cross-reactivity. As a final
proof for cross-reactivity, cells transfected for
expression of the target antigen should be gen-
erated and tested. Alternatively, the mAb can-
didate might be tested for its suitability in
immunoprecipitation and precipitates can be
subjected to mass spectroscopy for the identi-
fication of the target antigen.
Figure 203. Test of anti-mouse Pax-5 mAb for cross-reactivity with the porcine orthologue. (A) Protein sequence alignment of murine (NCBI
accession no. NP 032808.1) and porcine (NCBI accession no. XP 003122067.3) Pax-5 sequence. The homology of Pax-5 between the two species is
98.2%. The anti-mouse Pax-5 mAb clone 1H9 (BD Biosciences, catalogue no. 562814) is derived from an immunization of mice with recombinant
mouse Pax-5 protein spanning amino acid residues 154–284. The alignment of the region of the immunogen is framed in red and has a homology
of 96.9% between the two species. (B) Test of anti-mouse Pax-5 mAb on porcine PBMC. Lymphocytes were gated according to their light scatter
properties and single cells are discriminated from doublets by plotting FSC area against height. Dead cells are excluded by a viability dye. The
anti-Pax-5 mAb was tested in combination with a CD79α-specific mAb for the staining of porcine B cells, as Pax-5 is expressed from the pro-B
to the mature B cell stage and only repressed during terminal plasma cell differentiation [1779]. A distinct co-staining of both mAbs is observed,
indicating cross-reactivity of the 1H9 mAb clone with porcine Pax-5. The final proof of cross-reactivity still needs to be obtained by testing the
mAb on cells transfected with recombinant porcine Pax-5.
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Figure 204. Test of anti-mouse Blimp-1 mAb for cross-reactivity with the porcine ortholog. For the anti-mouse Blimp-1 mAb clone 3H2-E8
(ThermoFisher Scientific, catalogue no. 13207588) cross-reactivity to the porcine protein is indicated on the data sheet. Flow cytometric analyses of
themAb on porcine PBMCwere performed. (A) Lymphocytes were gated according to their light scatter properties and single cells are discriminated
from doublets by plotting FSC area against height. Dead cells are excluded by a viability dye. The gating strategy is shown for freshly isolated PBMC
and is representative for all experiments shown. (B) The anti-Blimp-1 mAb was tested in combination with a CD79α-specific mAb for staining of
porcine B cells, as the transcription factor Blimp-1 is known to be essential for the generation of plasma cells [1781]. Only obscure staining patterns
were observed when analyses were performed on defrosted cells. A more distinct population of porcine Blimp-1+CD79α+ B cells was detected
with freshly isolated cells. For further analyses on the cross-reactivity of clone 3H2-E8, PBMC were stimulated with the TLR7/8 agonist resiquimod
(R848, 2.5 mg/ml) as TLR-mediated activation is described to promote expression of Blimp-1 [1782, 1783]. After three days of in vitro stimulation,
a clear increase in Blimp-1+CD79α+ B cells was detected. The final proof of cross-reactivity still needs to be obtained by testing the mAb on cells
transfected with recombinant porcine Blimp-1.
Figure 205. Test of anti-bovine IgM mAb for cross-reactivity with the porcine orthologue. For the anti-bovine IgM mAb clone PIG45A2 (Kingfisher
Biotech, catalogue no. WS0620B-100) cross- reactivity to the porcine protein is indicated on the Kingfisher Biotech data sheet. (A) Porcine and
bovine lymphocytes were gated according to their light scatter properties and single cells are discriminated from doublets by plotting FSC area
against height. Dead cells are excluded by a viability dye. A representative gating strategy for bovine PBMC is shown. (B) The anti-IgM mAb was
tested in combination with a CD79α-specific mAb for staining of either bovine or porcine B cells. A clear IgM-specific staining was obtained with
the mAb on bovine B cells in contrast to a FMO control by using only secondary antibodies. No clear difference in the staining of the anti-IgM mAb
on porcine B cells in comparison to the FMO control could be observed. The same staining patterns were obtained by different concentrations of
the anti-IgM mAb (data not shown).
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sequence alignment. High homology rates here (> 90%) are usu-
ally a strong indicator of Ab cross-reactivity. An example on this
given in Fig. 203A. According to the data sheet for the anti-mouse
paired box protein-5 (Pax-5) mAb clone 1H9, distributed by BD
Biosciences, the immunogen used for its generation spanned the
amino acid residues 154 to 284 of the murine Pax-5 sequence.
This part of the murine sequence has a homology of 96.9% with
the corresponding porcine Pax-5 sequence. Of note, also the entire
murine Pax-5 sequence has 98.2% homology with porcine Pax-5,
suggesting in general a high likelihood that anti-murine Pax-5 Abs
will cross-react with porcine Pax-5. Indeed, this Ab showed a clear
co-staining with CD79α+ porcine B cells (see further details below
and Fig. 203B).
Sequence alignments are also helpful to get a first impression
on the likelihood of Ab cross-reactivity between closely related
species e.g. within the families of Bovidae or Suidae. However,
this requires that sequence data is available at all. If sequence data
is lacking or the sequence alignments reveal a number of amino
acid changes in the region of interest (for example the binding site
of the mAb) carefully performed experiments for cross-reactivity
testing become inevitable, as described in the following.
15.4 Practical guidelines for cross-reactivity testing. In any case,
once one or several Ab candidates have been identified for cross-
reactivity testing, first FCM experiments become inevitable. Pru-
dent planning is required, since negative results will be frequently
encountered. This leads to the question whether the Ab under
investigation is indeed not cross-reactive or whether other con-
ditions may have caused a failure of the experiment. Hence, one
important aspect is to make sure that cells used in the exper-
iment have a high likelihood to express the molecule of inter-
est. For example, if Abs specific for homing markers from the
gut tissue are investigated, leukocytes isolated from the intestine
should be used. Similarly, chemokine receptor expression might
be affected by freezing/ thawing procedures or the staining tem-
perature [1780]. Additionally, particular cell subsets can be more
affected by freezing/ thawing procedures than others, e.g. plasma
cells. Therefore, here likewise testing on freshly isolated cells is
highly recommendable. If the subset to be stained with the puta-
tive cross-reactive mAb is very small or likely to be expected on
activated cells, in vitro stimulation of cells prior to staining can also
increase the likelihood of a positive result. An example on these
phenomena is shown in Fig. 204. The anti-mouse B lymphocyte–
induced maturation protein-1 (Blimp-1) mAb clone 3H2-E8 was
tested for cross-reactivity with its orthologous molecule in swine.
With thawed porcine PBMC only a small and somewhat obscure
positively stained subset was found (Fig. 204B, left plot). With
freshly isolated PBMC, a more distinct subset of CD79α+ that
co-stained with the anti-Blimp-1 mAb became visible. Finally, in
porcine PBMC, which were in vitro stimulated with the Toll-like
receptor (TLR) 7/8 agonist resiquimod, a clear CD79α+ putatively
Blimp-1 double-positive subset was observed.
To ensure that the tested Ab is of sufficient quality, especially
when encountering negative results, we frequently test it in paral-
lel on cells from the species the Ab has been raised for. In this way,
potential doubts on the quality of the mAb or the overall perfor-
mance of the staining procedure can be ruled out. An example on
this is shown in Fig. 205. The anti-bovine IgMmAb clone PIG45A2,
distributed by Kingfisher Biotech, is claimed to be cross-reactive
with porcine IgM in the Ab data sheet. Hence, we tested the Ab on
bovine and porcine PBMC in parallel. Whereas in bovine PBMC a
clear IgM/CD79α double-positive population was observed, with
porcine PBMC putatively IgM+ cells were on the level of an FMO-
control, whichwas only stainedwith the isotype-specific secondary
Ab (Fig. 205B). Hence, anti-bovine IgM mAb clone PIG45A2 does
not seem to cross-react with its porcine orthologue.
In a comparable way, also positive findings for a newly tested
mAb should be thoroughly questioned. One first approach is to
test putatively cross-reactive mAbs from the very beginning (i.e.
already during the initial titration) in combination with other
established mAbs that allow the identification of phenotypes on
which expression of the target antigen is expected. For exam-
ple, for a target antigen that is expected to be expressed only
by B cells, a co-staining with pan-B cell-specific mAbs allows a
first assessment whether the cells stained by the putatively cross-
reactive mAb are indeed labeled in a specific manner. As shown in
Fig. 203B, the anti-mouse Pax-5mAb clone 1H9was tested in com-
bination with CD79α, an anti-human mAb that cross-reacts with
CD79α in multiple mammalian species [1744]. As expected from
the high sequence homology between murine and porcine Pax-5
(Fig. 203A), a clear CD79α+ putatively Pax-5 double-positive sub-
set was observed. In the samemanner, also in Figures 204 and 205
a co-staining against CD79α was performed in order to test Abs
against Blimp-1 and IgM for their reactivity with porcine B cells
(see also above for further details).
Once the optimal quantity or dilution of the mAb under inves-
tigation has been established, more complex phenotyping experi-
ments should be performed to ensure that the stained cell popula-
tions match with phenotypes identified in more thoroughly stud-
ied species like human or mouse. Like for any other experiment,
investigations with cells from several animals of the new species
and different lymphatic and non-lymphatic organs should be per-
formed to further scrutinize the obtained results. Nevertheless, it
should be noted that expression patterns for particular immune-
related molecules might not be completely conserved between dif-
ferent species. Examples for this would be the abundant expression
of CD8αα homodimers on porcine NK cells as well as substantial
subsets of CD4 and γδ T cells [1784], a phenomenon not seen in
the corresponding human or mouse lymphocyte subsets. Likewise,
differently from human or mouse T cells, MHC-II molecules are
frequently expressed on activated and memory T-cell subsets in
pigs [1712, 1785].
From a pedantic view, the aforementioned experimental strate-
gies do not provide the final proof of cross-reactivity. This proof
can be achieved by cloning and recombinant expression of the
species-specific protein in a cell line with the subsequent analy-
sis in immunofluorescence staining as performed to demonstrate
the cross-reactivity of mAbs against porcine and ovine Foxp3
[1786, 1787] as well as porcine Helios [1788]. Also, Abs against
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Table 82. Abs cross-reacting with porcine immune-related non-CD molecules in FCM1
Molecule Species Ab was raised for Clone name Vendor(s) References
Transcription factors
Eomes human WD1928 ThermoFisher Scientific [1729]
Foxp 3 mouse/ rat FJK-16s ThermoFisher Scientific [1786]
GATA-3 human/ mouse TWAJ ThermoFisher Scientific [1732]
Helios human/ mouse 22F6 BioLegend [1788]
T-bet human eBio4B10 ThermoFisher Scientific [1732]
Cytokines
IFN-γ cattle CC302 Bio-Rad [1791]
IL-17A human SCPL1362 BD Biosciences [1724]
TNF-α human MAb11 BioLegend [1792]
Miscellaneous
Ki-67 human B56 BD Biosciences [1793]
Perforin human δG9 BD Biosciences, ThermoFisher Scientific [1740]
1 Table is not claimed to be complete
ovine TNF-α [1789] and bovine and ovine IL-17A [1790] have
been tested in this way. Similar experiments are currently under
way in our laboratory to confirm the cross-reactivity of the anti-
mouse Pax-5 mAb 1H5 and anti-mouse Blimp-1 mAb 3H2 2E8
with the respective porcine orthologs. However, it is important to
state that numerous cross-reactive Abs, which are in use in the pig
(and in other species), have not been tested in this way. Indeed,
in those cases where the amino acid sequence of the immunogen
used to raise the Ab is known and has a 100% identity to the
orthologous sequence of the species under investigation, the test-
ing on a recombinant protein is irrelevant. For all other cases, the
authors of this chapter strongly recommend a testing on recombi-
nant proteins in order to achieve the highest possible quality stan-
dards. Finally, an alternative approach to prove cross-reactivity
is an immunoprecipitation of the target antigen by the putatively
cross-reactive mAb and subsequent analysis of the precipitate by
mass spectroscopy.
15.5 Examples on cross-reactive mAbs in pigs. Pigs have received
increasing interest as a large animal model in recent years
[1708], which has also resulted in publications on the knowl-
edge of CD-molecule expression in porcine leukocytes, includ-
ing listings of available mAbs to study their expression [1709,
1710]. Moreover, very recently a website was launched that
lists currently available mAbs not only for the pig but also
cattle, sheep, goat, chicken, horse, cat, and some fish species:
https://www.immunologicaltoolbox.co.uk/. Cross-reactive mAbs
are also interspersed in these sources of information, but should
be treated with caution since several of these mAbs have not been
scrutinized according to the guidelines above. In addition, these
publications do not cover intracellular molecules, which are also
of high relevance in immunophenotyping. Hence, Table 82 pro-
vides a list of miscellaneous molecules that are not CD-molecules
and for which mAbs that cross-react with the porcine orthologue
have been identified.
Table 83. Reagents and Abs used for cross-reactivity testing
Reagent/ Antibody Clone Manufacturer
Mouse anti-human
CD79α - PE
HM57 Dako
Rat anti-human/ mouse
Pax-5 - AlexaFluor R©
647
1H9 BD Biosciences
Mouse anti-human/
mouse Blimp-1 -
DyLight650
3H2-E8 ThermoFisher Scientific
Mouse anti-bovine sIgM PIG45A2 Kingfisher Biotech
Goat anti-mouse IgG2b -
AlexaFluor R© 488
− ThermoFisher Scientific
Fixable Viability Dye
eFluorTM 780
− ThermoFisher Scientific
15.6 Step-by-step sample preparation.
Step-by-step sample preparation of porcine PBMC
1. Draw blood and transfer to an anti-coagulant containing tube.
2. Dilute blood 1:2 in PBS (PAN-Biotech)
3. Carefully overlay Pancoll (for example Pancoll human, Cat#
P04-601000 by PAN-Biotech) with diluted blood in a ratio of
1:3.
4. Centrifuge at room temperature at 800 × g without brake for
20 min.
5. Collect interphase, transfer to new tube and wash twice with
PBS at 300 × g, 4°C, 6 min and discard supernatant.
6. Wash with staining buffer
7. Pellet cells (300 × g, 4°C, 6 min) and discard supernatant.
Step-by-step FCM staining of porcine leukocytes from blood and
spleen
1. Transfer up to 2 × 106 cells into a 96-well conical or U-bottom
shaped plate.
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2. Centrifuge the plate at 300 × g at 4°C for 3 min. Aspirate or
decant supernatant.
3. Add a max of 30 µL surface staining mix per well and incubate
for 15 min at 4°C.
4. Two washing steps: add up to 200 µL staining buffer and cen-
trifuge the plate at 300 × g at 4°C for 3 min and aspirate or
decant supernatant.
5. Add secondary reagents as described above including the two
washing steps.
6. Add Fix/ Perm reagent for 20 min at 4°C, following two wash-
ing steps in permeabilization buffer as described above.
7. Add mAbs specific for intracellular or intranuclear antigens
(Table 83) for 20 min at 4°C, following two washing steps in
permeabilization buffer as described above.
Materials
Flow cytometer:
 FACSCanto II (BD Biosciences)
Media and buffers:
 cRPMI: complete RPMI 1640 (PAN-Biotech) supplementedwith
10% FCS (Sigma-Aldrich), 100 U/mL Penicillin, and 100 µg/mL
Streptomycin (PAN-Biotech)
 Fixation and Permeabilization reagents for detection of intranu-
clear molecules: Foxp3/ Transcription factor staining buffer set
(ThermoFisher Scientific)
 Staining buffer: PBS (PAN-Biotech) supplemented with 10%
porcine plasma (in house preparation) for freshly isolated or
thawed cells and PBS (PAN-Biotech) supplemented with 3%
FCS (Sigma–Aldrich) for cells that were cultivated in vitro
In vitro stimulation
 TLR7/8 agonist resiquimod (R848, 2.5 mg/mL, InvivoGen) for
3 days
VII Data handling, evaluation, storage and
repositories
1 Data analysis
1.1 Introduction
During the last decade, the field of FCM has gone through a num-
ber of revolutionary, technological advances that have resulted in
a wide array of novel single-cell platforms. These include classi-
cal, multiparameter FCM, mass cytometry, spectral FCM, imag-
ing FCM, and imaging mass cytometry, to name only a few (See
Chapter VIII: Advanced techniques in, and management of, FCM).
Many of these novel technologies generate large and/or high-
dimensional data sets, which cannot be analyzed adequately any-
more using the classical, manual analysis techniques. For example,
current flow andmass cytometers can measure tens of parameters,
while techniques such as imaging FCM are producing several hun-
dreds of parameters at the single cell level. In addition, manual
analysis techniques, such as manual gating to identify cell pop-
ulations, have a number of important limitations [1794]. These
include the fact that they are hard to reproduce, are subjective
and biased, and are inefficient when exploring high-dimensional
parameter spaces [599]. In addition, manual analysis is very time
consuming when analyzing large cohorts of samples.
Tomitigate these limitations ofmanual analysis, computational
techniques can be used to take full advantage of the power of
high-dimensional cytometry data analysis [1795]. However, this
does not mean computational techniques completely replace the
manual analysis. Rather, they should be considered as comple-
mentary tools that offer new insights, and performing an addi-
tional, manual inspection is still good practice as a quality control
check. Computational methods can be used at several stages of
the data analysis pipeline, including storage of the well-annotated
data in repositories, during data cleaning and pre-processing, and
for different types of analyses such as data visualization, popula-
tion identification, and biomarker detection. Figure 206 presents
an overview of the different stages of the data analysis pipeline
where computational techniques can be used. Crucial to all these
data analysis techniques is the fact that data should be of the
best quality, and thus care should be taken to correctly design the
experiment, take into account all the appropriate controls, and
generate the data in such a way that is suited for all the computa-
tional analyses to be performed afterward.
A wide variety of methods from the fields of statistics, data
mining, and machine learning is used to extract knowledge from
cytometry data [1796]. These techniques can be broadly cate-
gorized into two groups: unsupervised learning and supervised
learning strategies. Unsupervised learning techniques are descrip-
tive models that aim at better characterizing the data, and are
typically used to explore the structure of the data. These include
techniques such as dimensionality reduction, clustering, and tra-
jectory inference. Briefly, dimensionality reduction techniques aim
at transforming the original, high-dimensional data set to a lower-
dimensional space, often two or three dimensions, where it is
easy to visually appreciate the structure in the data. This would,
for example, allow detecting population structures, outliers, batch
effects, or other trends present in the data. Clustering and trajec-
tory inference methods aim to look for specific structures present
in the data. Clustering techniques typically look for groups of cells
(clusters) that are similar within a group, but different between
groups, and mostly assume groups are well separated. Trajectory
inference methods on the other hand rather look for structures
that behave more like gradients, e.g., cells smoothly transitioning
between different stages of a developmental process. These gra-
dients should not necessarily be linear gradients, but can include
branching processes and cycles as well.
Supervised methods take another approach to data analysis,
and are typically used to construct predictive models. In this case,
one wants to relate the cellular data to an outcome variable of
interest, for example, the disease status of a patient, or the cell
type of a particular cell of interest. Different types of supervised
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methods exist, the most important of which are classification tech-
niques, regression techniques, and techniques for survival analysis.
The typical use of these methods is to construct a model based on
data for which the outcome variable is already known, which is
referred to as training the model. Such a trained model can later
be used to predict the outcome variable for new data, not seen
before.
1.2 Cell-population analysis: Data preprocessing, manual
and automated gating, and quality control
1.2.1 Overview. Manual analysis is still an important component
of FCM experiments in many labs, however, automated methods
for identifying cell subpopulations in FCM data have proliferated
rapidly [1797]. As manual gating is inherently subjective, it is
important to follow defined protocols to improve analysis repro-
ducibility. Preprocessing of data is necessary to remove errors and
establish the appropriate data transformation parameters. Gat-
ing decisions should carefully consider different types of controls,
and populations represented as a shoulder of a larger popula-
tion should be analyzed with caution. Back-gating is critical for
determining whether the initial gates are appropriate for the final
subpopulation being analyzed, instead of being appropriate for
the majority populations.
1.2.2 Complementary manual and automated analysis methods.
FCM data analysis presents a complex problem because of
recent rapid increases in the number of parameters measured,
and because of some peculiarities of flow data. Current datasets
include 20 or more parameters even by conventional fluores-
cence cytometry, and other methods yield 35 or more channels.
Traditional bivariate gating (manually drawing boundaries on
sequential two-parameter plots) can still be performed on high-
dimensional data sets, but this becomes progressively more time
consuming and less thorough as the parameter number increases.
The current generation of flow cytometers is capable of simulta-
neously measuring 50 characteristics per single cell. These can be
combined in 350 possible ways using traditional bivariate gating,
resulting in a massive data space to be explored [1798]. There has
been rapid development of unsupervised clustering algorithms,
which are ideally suited to biomarker discovery and exploration
of high-dimension datasets [599, 1795, 1796, 1799–1804], and
these strategies are described in more detail in Chapter VI, Sec-
tion 1.2. However, the directed identification of specific cell pop-
ulations of interest is still critically important in flow analysis for
providing “reality checks” for the results returned by different
algorithmic strategies, and for the generation of reportable data
for clinical trials and investigations. This is the approach used
by investigators who prefer to continue manual gating for consis-
tency with previous results, now complemented by the availability
of supervised cell population identification methods. This section
will describe common issues in this type of analysis, in three stages:
preprocessing, gating, and postprocessing (Fig. 207).
1.2.3 Principles of analysis.
1. Preprocessing flow data in preparation for subpopulation
identification:
Batch effects: FCM data are difficult to standardize between
batches analyzed days or months apart, because cytometer set-
tings can change with time, or reagents may fade. Imperfect pro-
tocol adherence may also lead to changes in staining intensity or
machine settings. Such variations need to be identified, and where
possible corrected. In addition to batch variation, individual out-
lier samples can occur, e.g., due to temporary fluidics blockage
during sample acquisition. Identification of these changes can be
performed by detailed manual examination of all samples. How-
ever, this involves evaluating theMFI between samples after gating
Figure 206. Computational methods offer
great potential to automatemany stages in
the analysis of cytometry data. For every
stage, computational pipelines can greatly
contribute to standardization and quality
control, leading to better standards in the
FCM field.
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Figure 207. Typical analysis workflows in
FCM for the identification of specific cell
populations of interest by either man-
ual of automated analysis. Analysis usu-
ally startswith several preprocessing steps
on compensated data, including quality
assessment, data normalization, and data
transformation (blue boxes). Preprocess-
ing is followed by identifying cell popula-
tions of interest (orange boxes), and finally
visualization and interpretation (green
boxes).
down to meaningful subpopulations. For high-dimensional data,
this is difficult to perform exhaustively by manual analysis, and is
more easily achieved by automated methods. As an example, sam-
ples from a study performed in two batches, on two cytometers,
were analyzed by the clustering algorithm SWIFT [1801, 1805],
and the resulting cluster sizes were compared by correlation coef-
ficients between all pairs of samples in the study (Fig. 208). The
most consistent results (yellow squares) were seen within samples
from one subject, analyzed on 1 day and one cytometer. Sam-
ples analyzed on the same day and cytometer, but from different
subjects, showed the next smallest diversity (compare subjects 1
vs. 2, and 4 vs. 5). Weaker correlations (blue shades) occurred
between samples analyzed on different days, or different cytome-
ters. Similar batch effects are seen in data sets from many labs.
These effects should be addressed at two levels: experimental and
computational. At the experimental level, day-to-day variation can
be minimized by stringent adherence to good protocols for sam-
ple handling, staining, and cytometer settings (see Chapter III,
Sections 1 and 2). For multisite studies, cross-center proficiency
training can help to improve compliance with standard protocols.
If shipping samples is possible, a central laboratory can reduce
variability in the staining and flow cytometer settings. Clearly,
performing a study in a single batch is ideal, but in many cases
this is not possible.
Ameliorating batch effects during analysis: At the analysis
level, some batch effects can be reduced during further analysis. In
experiments in which batch effects occur due to variability in stain-
ing or cytometer settings, algorithms for reducing this variation
by channel-specific normalization have been developed (below).
Batch effects due to other causes may be more difficult to correct.
For example, increased cell death is another potential batch prob-
lem that is not completely solved by just gating out dead cells,
because marker levels on other subpopulations can also be altered
before the cells die.
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Figure 208. Quality control anal-
ysis to detect batch effects. Eight
sequential blood samples each
from six subjects were analyzed
by FCM, clustered using the SWIFT
algorithm, and Pearson correlation
coefficients in the number of cells
per cluster were calculated between
all pairs of subjects. Samples were
analyzed for 2 days, and on two
identically configured LSR-II cytome-
ters. Data files can be found here:
https://flowrepository.org/id/FR-
FCM-ZZ8W
Curation of datasets: In some datasets, curating names
and metadata may be necessary, especially when following
the MIFlowCyt Standard (See Chapter VIII Section 3 Anal-
ysis presentation and publication (MIFlowCyt)). The manual
entry error rate can be greatly reduced by using an automated
Laboratory Information Management System (e.g., FlowLIMS,
http://sourceforge.net/projects/flowlims) and automated sample
data entry. As manual keyboard input is a major source of error,
an LIMS system can achieve a lower error rate by minimizing
operator input through automated data input (e.g., by scanning
2D barcodes) or pre-assigned label choices on pull-down menus.
Although compensation is conveniently performed by automated
“wizards” in popular FCM analysis programs, this does not always
provide the best values, and should be checked by, e.g., N×N dis-
plays showing all possible two-parameter plots. Further informa-
tion on compensation can be found in [60]. CyTOFmass spectrom-
etry data needs much less compensation, but some cross-channel
adjustment may be necessary in case of isotope impurities, or the
possibility of M+16 peaks due to metal oxidation [1806].
In some data sets, further data curation is necessary. Defects
at specific times during data collection, e.g., bubbles or changes
in flow rate, can be detected and the suspect events removed by
programs such as flowClean [1807]. Furthermore, compensation
cannot be performed correctly on boundary events (i.e., events
with at least one uncompensated channel value outside the upper
or lower limits of its detector) because at least one channel value
is unknown. The upper and lower detection limits can be deter-
mined experimentally by manual inspection or by programs such
as SWIFT [1801]. The investigator then must decide whether to
exclude such events from further analysis, or to keep the saturated
events but note how this may affect downstream analysis.
Transformation of raw flow data. Fluorescence intensity and
scatter data tend to be log-normally distributed, often exhibiting
highly skewed distributions. Flow data also typically contain some
negative values, mainly due to compensation spreading but also
partly because of subtractions in the initial collection of data. Data
transformations (e.g., inverse hyperbolic sine, or logicle) should
be used to facilitate visualization and interpretation by reducing
fluorescence intensity variability of individual events within sim-
ilar subpopulations across samples [1808]. Several transforma-
tion methods are available in the package flowTrans [1809], and
should be evaluated experimentally to determine their effects on
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the data with regard to the automated methods used and further
downstream analysis.
Registration/normalization of fluorescence intensity values:
Normalization between data sets with regard to fluorescence
intensities can be accomplished either by adjusting gates (i.e.,
manually specified filters or probabilistic models designed to enu-
merate events within defined regions of the data) between sam-
ples, or by moving sample data closer to the gates via fluorescence
intensity registration. Auto-positioning “magnetic” gates can rec-
oncile slight differences between samples in programs like FlowJo
(Tree Star) and WinList (Verity Software House), but large shifts
in subpopulation locations are difficult to accommodate. Several
semi-automated methods of fluorescence intensity registration are
available (e.g., fdaNorm and gaussNorm [1810, 1811]). These
attempt to move the actual data-points across samples to similar
regions, thus allowing gates to be applied to all samples without
adjustment. Both fdaNorm and gaussNorm register one channel
at a time, and do not address multidimensional linkages between
biological sub-populations. The methods further require pregating
to expose subpopulation “landmarks” (peaks or valleys in 1D his-
tograms) to register effectively. However, this “global” approach
does not adequately capture the semantics of biologically interest-
ing rare subpopulations that are often obscured by high-density
data regions. A recent extension [1811] of the fdaNorm method
attempts to address this shortcoming by tightly integrating “local”
(subpopulation specific) registration with the manual gating pro-
cess, thus preserving the multidimensional linkages of rare sub-
populations, but still requiring a hierarchy of manual gates derived
from a reference sample. Fully automated fluorescence intensity
registration methods are in development.
2 Identification of subpopulation sizes and properties
by gating
Sequential bivariate gating: Once data preprocessing steps
are complete, users can identify cell populations using manual
analysis or one or more of more than 50+ automated gating
algorithms currently available [599, 1812]. Sequential gating in
2D plots is the standard method for manual analysis. Rectangu-
lar gates are convenient for well-separated sub-populations, but
more subtle gates are often required, e.g., elliptical gates to define
subpopulations in close proximity, or “spider” gates (available in
FlowJo) to allow for fluorescence spreading due to compensa-
tion. The sequence of gates can be important because the desired
subpopulation may be visualized more effectively by particular
marker combinations.
Back-gating: A critically important step for gating high-
dimensional data is to optimize the gates using back-gating,
which involves examining the cell subpopulations that satisfy all
but one of the final gates. This procedure is performed for each
gate in turn, and is critically important because small cell sub-
populations may be defined by boundaries that are different from
the boundaries of bulk subpopulations, e.g., stimulated cytokine-
producing T cells display less CD3 and CD4 than unstimulated T
cells, so setting the CD3+ and CD4+ gates on the bulk T-cell sub-
population will give suboptimal gates for the stimulated T cells
(Fig. 209). Back-gating partly compensates for the inability of
manual gating to use all dimensions simultaneously, as can be
achieved in algorithmic clustering.
Validation of gated or clustered sub-populations: Another
critical issue is to examine the final gated sub-populations
carefully, using prior knowledge and expectations from the biol-
ogy. Figure 210 illustrates the importance of detailed examination
using three artificial samples—a negative control that has no posi-
tive cells in either dimension (left); a positive sample that has small
subpopulations of A+B– and A–B+ cells (middle); and a sample
that has no obvious positive subpopulations, but has a slightly
increased fluorescence intensity resulting in cells appearing in the
A+B– and A–B+ gates (right). If the results of gating are accepted
blindly, then samples 2 and 3 will be evaluated as having simi-
lar A+B– and A–B+ responses, whereas examination of the plots
suggests a very different interpretation. Biological insight is also
very useful—if a large subpopulation appears to be positive for a
marker that is usually expressed only on a minor subpopulation,
it should be suspected that there is an unusually high background
for that marker on some cells and further experiments should be
done to confirm the specificity of binding.
A limitation of manual gating in sequential two-dimensional
plots is that two sub-populations may not be fully resolved in any
combination of two dimensions, even though the sub-populations
are fully resolved if all dimensions are considered simultaneously
(which is only possible by algorithmic analysis). Thus in manual
gating, it is sometimes necessary to make choices based either on
recovering the largest number of the target cells (wider gates, at
the expense of increased contamination), or identifying cells with
the most certainty (narrower gates, at the expense of some loss of
positive cells).
Another limitation of manual gating in sequential 2D plots is
that human subjectivity has been identified as a primary source of
variation within analyzed results [609, 1804]. Automated analysis
methods have reached a state where they can now provide a solu-
tion to the challenge of analyzing big sets of FCM data. If chosen
and used with care, many of these automated tools show as good,
or even better, as well asmore consistent analytic results compared
with those performed by “human” users [1795, 1802, 1813, 1814].
Automated gating algorithms can be categorized as supervised
or unsupervised. Supervised approaches to cell population
identification incorporate user knowledge into the algorithm at
various points. As such, supervised approaches are especially
beneficial when users have project-specific expectations (e.g.,
target cell populations of interest, based on an existing gating
strategy the user is trying to replicate). The most general type of
supervised learning is where the method takes as input one or
few training sample(s) in which all cells are manually gated and
assigned to a cell population. This sample(s) trains a classification
model that then classifies the cells of similar ungated samples.
Examples of models tested in this category include the neural
network [1815], support vector machine [1816], and hierarchical
agglomerative hierarchy construction [1817]. On the other hand,
OpenCyto [1818] and flowDensity [1819] approach the problem
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Figure 209. Importance of back-gating for minor subpopulations. A sample from the study described in Fig. 207 was stimulated in vitro with
influenza peptides, and cytokine-producing cells were then identified by Intracellular Cytokine Staining and FCM. The top row shows the sequential
gating of memory CD4 T cells (CD3+CD4+CD8–CD14– Live CD45RA–), using gates appropriate for the bulk memory population. However, backgating
in FlowJo (row 2) shows that these gates do not capturemany of the CD4 T cells secreting cytokines in response to the influenza peptides. Adjusting
the gates by back gating results in much better identification of the stimulated, cytokine-expressing T cells that have slightly different values for
several parameters (rows 3 and 4). The negative control sample contained zero cells in the final TNFα+ IFNγ+ gate. Data files can be found here:
https://flowrepository.org/id/FR-FCM-ZZ8H
by mimicking the manual gating process. Machine learning
methods such as flowLearn aim to automate the parameterization
of supervised methods [1820]. Users can specify everything
from desired gate characteristics to the dimensions on which the
algorithm should gate. Users can even provide a single or few
gated samples for the algorithm to learn gate characteristics from
ref. [1820]. When usingmachine-learningmethods, these samples
must have similar fluorescent value and shape distributions as
their ungated counterparts for the methods to work [1815, 1820].
The development of machine learning approaches for supervised
gating is still in its infancy, but holds great potential to ease the
burden of automating the identification of specific cell populations
of interest based on a prescribed gating hierarchy. The resulting
gates can then be extracted, plotted, and adjusted until they are
satisfactory. Since the plots produced can be specified to match
a gating strategy, they can easily be used to communicate with
those who are not familiar with the computational aspects of
analysis. Moreover, comprehensive analysis of state-of-the-art
supervised algorithms through the FlowCAP effort has shown
that these approaches produce unbiased results and can reduce
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Figure 210. Model data illustrating the very different interpretations of two samples with similar proportions of cells in a positive gate. Left: A
double-negative (A–B–) population with a random normal distribution is modeled. Middle: Two extra small sub-populations with random normal
distributions are added to the A–B– sub-population. The red and green subpopulations contain few cells, but are well-separated from the A–B–
population. Right: The “negative” subpopulation has been shifted slightly, but no distinct smaller subpopulations are present.
analysis variability by up to 94% compared with that occurring
with manual analysis [1802]. Given the inputs required, it is ideal
to have a well-made or established gating strategy in hand when
operating these methods, as indicated in refs. [1802, 1821].
While supervised algorithms take into account user specified
cell populations, unsupervised algorithms, such as flowMerge
[1800] and flowMeans [1822], “cluster” or group cells with sim-
ilar fluorescent intensities for similar groups of markers directly
in high-dimensional space. In contrast with supervised methods,
unsupervised methods often do not require user input. How-
ever, many methods do allow users to tweak results by chang-
ing few global parameter(s), such as the number of cell popu-
lations expected. Clustering procedures are great for discovering
new natural cell populations which can then be manually vali-
dated and gated for using optimized gating strategies generated
by tools such as GateFinder [1823] (convex hull gates) and Hyper-
Gate [147] (rectangular gates)—note that these are also good for
finding optimized gates that may differ for sorting and gating pur-
poses. These approaches are described more fully in the Clustering
section (Chapter VII section 1.5).
Regardless of whether manual or automated gating is used to
identify cell populations, careful examination of the results on test
data sets through examination of familiar bivariate scatter plots
is necessary to validate the results. Dimensional reduction tools
such as t-distributed stochastic neighbor embedding [144, 1824]
can be helpful in this regard. Tools for examining the output of
automated methods are built in to programs such as FLOCK and
SWIFT, and available as plugins in FlowJo, Cytobank, and FCS
Express.
For scientists interested in adopting automated methods, col-
laboration with bioinformaticians is perhaps the quickest path to
explore. Learning how to use the algorithms is another option.
The most comprehensive library of FCM analysis tools built to
date can be found on R/Bioconductor [599]. Although not the
most user-friendly choice, R uses a command-line interface to
provide a powerful foundation for many data mining and statisti-
cal computational tools. A subset of Bioconductor tools are avail-
able and can be integrated with more user friendly graphical user
interfaces [1825] such as FlowJo, CytoBank [1826], FCSExpress,
SPICE [1827], and GenePattern [1828].
With the growing amount of data becoming available, auto-
mated analysis is becoming an essential part of the analysis proce-
dure [1829]. Only by taking advantage of cutting-edge computa-
tional abilities will we be able to realize the full potential of data
sets now being generated.
Description of final sub-populations: The final subpopula-
tions identified by analysis are identified mainly by their fluores-
cence intensities for each marker. For some markers, e.g., CD4
on T cells, the positive cells comprise a log-symmetrical, clearly
separated peak, and the center of this peak can be described by
the geometric mean, the mode, or the median with very similar
results. However, if a positive peak is incompletely separated from
negative cells, the fluorescence values obtained by these methods
can vary substantially, and are also highly dependent on the exact
positioning of a manual gate. If a subpopulation is present as a
shoulder of a larger, negative peak, there may not be a mode,
and the geomean and median may have substantially different
values.
3 Post-processing of subpopulation data: Comparison of
experimental groups and identification of significantly
altered subpopulations.
Regardless of the primary analysis method, the output of most
FCM analyses consists of the sizes (cell numbers) and MdFIs of
many cell subpopulations. Differences between samples (e.g., in
different groups of a clinical study) can be performed by standard
statistical analysis, using methods appropriate for each particular
study. It is very important to address the problem of multiple out-
comes, and this is even more critical in high-dimensional datasets
because the potential number of subpopulations is very large, and
so there is a large potential multiple outcome error. By automated
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analysis, hundreds or even thousands of subpopulations can be
identified [1801, 1805], and manual analysis also addresses sim-
ilar complexity even if each subpopulation is not explicitly identi-
fied. As in the analysis of microarray and deep sequencing data,
it is important to consider the false discovery rate, using a strong
multiple outcomes correction such as the Benjamini–Hochberg
strategy [1830] or alternative strategies [1831]. Applying correc-
tions to data from automated analysis is relatively easy because
the total number N of subpopulations is known [1832], but it is
very difficult to identify N for manual bivariate gating, because a
skilled operator exploring a dataset will consider many subpopu-
lations before intuitively focusing on a smaller number of “popu-
lations of interest.” To avoid errors in evaluating significance due
to multiple outcomes in manual gating, strategies include: per-
forming the exploratory gating analysis on half of the data, and
calculating the statistics on the other half; or performing a con-
firmatory study with one or a few predictions; or specifying the
target subpopulation before starting to analyze the study.
Comprehensible visualizations are essential for the com-
munication, validation, exploration, and discovery of possibly
significant cell populations. In conjunction with cell population
identification algorithms, visualization is an often overlooked but
essential part of the discovery and diagnosis process (see green
box in Fig. 207).
Visualization can be a challenge for unsupervised clustering
algorithms, as it is difficult for users to comprehend the cell pop-
ulations identified in high-dimensional space. Therefore, dimen-
sion reduction is increasingly being applied to map multidimen-
sional (i.e., samples using more than two markers) results onto a
2D plane for viewing. For instance, the SPADE algorithm colors
and connects significant, structurally similar immunophenotypes
together in the form of a minimum spanning tree, or a tree-like
form [1804]. Dimensionality reduction techniques such as those
based on t-distributed stochastic neighbor embedding arrange cell
populations in a way that conserves the spatial structure of the cell
populations in high-dimensional space (See Chapter VII Section
1.4 Dimensionality reduction). This way, users get a more repre-
sentative view of cluster distributions [1833]. However, these and
some other dimensionality reduction methods do not explicitly
identify and partition cells into subpopulations. Other methods,
such as PhenoGraph [2252] and Cytometree [2250], opt to com-
bine all the analysis processes—segmenting cells into their phe-
notypically similar subpopulations, which are then labeled and
visualized—without loss in performance and accuracy [1814].
Conversely, RchyOptimyx [1834, 1835], gEM/GANN [1836],
and FloReMi [1837] use already-labeled samples (e.g., subject has
or does not have a certain disease) to extract and display only the
cell populations that most significantly discriminate between the
differently labeled samples. These cell populations can then be
used as indicators, and thus one can target these cell populations,
when determining the label of future samples [1813]. Such visual-
izations aim to focus in on only the most important data structures
present to facilitate human interpretation of the data. A compre-
hensive review of the available visualization algorithms is covered
in ref. [1838].
1.3 Artificial intelligence in FCM
Since the advent of the first computing devices, scientists have
been fascinated by the possibility to use these machines to mimic
the remarkable capacities of the human brain. The broad field of
artificial intelligence (AI) spans a wide variety of different tech-
niques to represent knowledge and infer new knowledge from it.
For FCM data analysis, the machine learning field, a subfield of
AI that focuses on learning models from data, can be considered
the most relevant. These techniques include the various types of
supervised and unsupervised learning that we have discussed ear-
lier. However, some novel types of machine learning approaches
are making their way into the single cell field, most notably the
novel types of deep learning approaches.
Deep neural networks are a recent development in the AI
field [1839], building further on the classical techniques of neural
networks that have already been proposed in the 1950’s [1840].
Deep neural networks further build on classical neural networks,
but include a much larger number of feature transformations that
allow them to make high-level abstractions that are useful for
model learning. These networks have been shown particularly
suited to work on image types of representations [1841]. There-
fore, deep learning methods are suitable models for different types
of cytometry where image data is produced [1842], such as imag-
ing FCM [1843] and imaging mass cytometry [1844].
However, deep learning models are generally applicable, and
recent work in the field has shown promising results, such as the
CellCNN network [1845], an adaptation of convolutional neural
networks (CNNs) for cytometry data, or DeepCyTof [1846], a deep
learning framework for automated gating. As the number of deep
learning papers on single-cell data has recently exploded in the
literature, it can be expected that also many of these new tech-
niques will be applicable for FCM data, including novel methods
for batch effect correction, data visualization, and automated cell
type identification.
1.4 Dimensionality reduction
Visual data exploration is a powerful tool for hypothesis genera-
tion. Traditionally, FCM data are being visualized by a set of 2D
scatter plots, where in each plot two of the available markers are
selected and plotted against each other on the two axes of the plot.
With the increasing number of markers provided by novel acquisi-
tion techniques [31, 1847] pairwise analysis becomes infeasible.
Instead, so-called dimensionality reduction techniques aim to visu-
alize the data by finding a low-dimensional representation that
preserves as much structure as possible from a high-dimensional
input. In the context of FCM, the original high-dimensional space
is formed by treating each marker as a dimension.
However, unless the original data is of low-dimensional nature,
embedded in the high-dimensional space, the dimensionality-
reduced representation cannot preserve all existing structure. A
number of approaches with different goals with regard to the
preserved structure have been employed in single-cell analy-
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sis. The most common ones are Principal Component Analysis
(PCA) [1848], t-distributed stochastic neighbor embedding (t-
SNE) [144], and very recently Uniform Manifold Approximation
and Projection (UMAP) [1471].
1.4.1 PCA. PCA is a well-known technique that has been used
early on for cytometry analysis [1849, 1850]. In short, PCA uses
a set of linear transformations, on the original high-dimensional
space, such that the axes of main variation (the principal compo-
nents) in the data are mapped to the axes of the resulting space in
order of the amount of variation. For visualization in a 2D scatter-
plot, the two principal components with the highest variation are
then chosen as the axes of the plot and the other components are
simply projected onto the given 2D plane. The resulting mapping
preserves relative distances, however, due to its rigid transforma-
tions, it cannot faithfully represent nonlinear structure, typically
present in single-cell cytometry data [1824].
1.4.2 t-Distributed stochastic neighbor embedding. Recently, t-
SNEwas established as the gold standard for dimensionality reduc-
tion of cytometry data. Introduced into the field under the name
viSNE [1824], it is implemented in a plethora of widely used
cytometry analysis platforms such as Cytobank [1851], Cytosplore
[1852], or cytofkit [1853]. t-SNE is a nonlinear dimensionality
reduction technique and as such has largely different goals than
the above described PCA. Instead of using only transformations
that conserve relative distances, t-SNE aims at preserving local
neighborhoods. For a detailed description of the mathematical
background of t-SNE, we refer to the original publication [144].
In short, t-SNE first computes local neighborhoods in the high-
dimensional space. Such neighborhoods are described by low
pairwise distances between data points, for example in Euclidean
space. Intuitively, the size of these neighborhoods is defined by the
perplexity parameter. In a second step, t-SNE iteratively optimizes
the point placement in the low-dimensional space, such that the
resultingmapping groups neighbors of the high-dimensional space
into neighborhoods in the low dimensional space. In practice, cells
with a similar expression over all markers will group into “islands"
or visual clusters of similar density in the resulting plot while sep-
arate islands indicate different cell types (Fig. 211). When inter-
preting the resulting t-SNE maps, it is important to understand
that the optimization only preserves relative distances within these
islands, while the distances between islands are largely meaning-
less. While this effect can be softened, by using large perplexity
values [1854], this hampers the ability to resolve fine-grained
structure and comes at large computational cost.
The perplexity is only one of several parameters that can have
major impact on the quality of a final t-SNE embedding. Watten-
berg et al. provide an interactive tool to get a general intuition
for the impact of the different parameters [1855]. In the context
of FCM rigorous parameter exploration and optimization, partic-
ularly for large data, has been carried out recently by Belkina
et al. [1856].
While t-SNE has gained wide traction due to its ability to effec-
tively separate and visualize different cell type in a single plot,
it is limited by its computational performance. The exact t-SNE
implementation becomes computationally infeasible with a few
thousand points [1857]. Barnes Hut SNE [1858] improves on this
by optimizing the pairwise distances in the low dimensional space
only close data points exactly and grouping large distance data
points. A-tSNE [1859] only approximates neighborhoods in the
high-dimensional space. FIt-SNE [1860] also uses approximated
neighborhood computation and optimizes the low dimensional
placement on a grid in the Fourier domain. All these techniques
can also be combined with automated optimal parameter estima-
tion [1856].
1.4.3 Uniform Manifold Approximation and Projection. As a
result of these optimizations, t-SNE embeddings for millions of
data-points are feasible. A similar technique called UMAP [1471]
has recently been evaluated for the analysis of cytometry data
[1470]. UMAP has similar goals as t-SNE, however, also models
global distances and, compared to the exact calculation, provides
a significant performances improvement.
While UMAP as well as optimized t-SNE methods provide the
possibility to show millions of points in a single plot, such a plot
will often lack detail for fine-grained structures, simply due to the
limited visual space. Hierarchical SNE [1861] builds a hierarchy on
the data, respecting the nonlinear structure, and allows interactive
exploration through a divide and conquer approach. It has been
adapted and tested with cytometry data in Cytosplore [1862].
Generally, dimensionality reduction provides means to visual-
ize the structure of high-dimensional data in a 2D or 3D plot, how-
ever it does not provide automated cell classification or clustering.
For biological interpretation or quantification, the dimensionality
reduced data needs to be augmented with additional information
and tools. viSNE [1824] allows to overlay a single marker as color
on each of the plotted cells. Multiple plots with different markers
overlayed can then be used to interpret the biological meaning
of each cell and manually gate. It has been shown that t-SNE
relates to spectral clustering [1863], meaning that visual clusters
in the t-SNE embedding can be extracted using automatic cluster-
ing techniques as is being done with tools like ACCENSE [1864],
or mean shift clustering implemented in Cytosplore [1852] where
the resulting clusters can also directly be inspected in standard
visualizations such as heatmaps.
1.5 Clustering
To identify subpopulations of cells with similar marker expres-
sions, most researchers apply hierarchical gating, an iterative pro-
cedure of selecting subpopulations based on scatter plots showing
two markers at a time. To automate the detection of cell popula-
tions, clustering algorithms are well suited. These algorithms do
not make any assumptions about expected populations and take
all markers for all cells into account when grouping cells with
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Figure 211. A t-SNE embedding of a mass cytometry dataset consisting of 100.000 cells. Each dot represents a cell. The typical islands of similar
cells can be seen. Color overlay in (A) represents expression of one marker, in (B) identified islands of similar cells and the median expression for
all markers/islands as a heatmap in (C).
similar marker expressions. The results correspond with cell pop-
ulations, like typically obtained by manual gating, but without any
assumptions about the optimal order in which markers should be
evaluated or which markers are most relevant for which subpop-
ulations, allowing the detection of unexpected populations. This
is especially valuable for bigger panels, as the possible amount of
2D scatter plots to explore increases quadratically.
The first time a clustering approachwas proposed for cytometry
data was in 1985, by Robert F. Murphy [1865]. Since then, many
clustering algorithms have been proposed for cytometry data and
benchmark studies have shown that in many cases they obtain
solutions very similar to manual gating results [1795, 1814].
From the many clustering algorithms proposed, several types
can be distinguished. Model-based tools try to identify clus-
ters by fitting specific models to the distribution of the data
(e.g., flowClust, flowMerge, FLAME, immunoclust, Aspire, SWIFT,
BayesFlow, flowGM), while others rather try to fit an optimal
representative per cluster (e.g., kMeans, flowMeans, FlowSOM).
Some use hierarchical clustering approaches (Rclusterpp, SPADE,
Citrus), while others use an underlying graph-structure to model
the data (e.g., SamSPECTRAL, PhenoGraph). Finally, several algo-
rithms use the data density (e.g., FLOCK, flowPeaks, X-shift, Flow-
Grid) or the density of a reduced data space (ACCENSE, DensVM,
ClusterX). Overall, these algorithms make different assumptions,
and it is important to understand their main ideas to have a correct
interpretation of their results.
All these clustering algorithms belong to the group of unsu-
pervised machine learning algorithms, meaning that there are no
example labels or groupings given for any of the cells. Only the
measurements of the flow cytometer and a few parameter set-
tings (e.g., the expected number of clusters) are given as input to
the algorithm. It should be noted that most clustering algorithms
thus only identify groups of cells with similar marker expressions,
and do not yet label the subpopulations found. The researcher
still needs to look at the descriptive marker patterns to iden-
tify which known cell populations the clusters correspond with.
Some tools have been developed which can help with this, such
as GateFinder [146] or MEM [1866]. Alternatively, if the user is
mainly interested in replicating a well-known gating strategy, it
would be more relevant to apply a supervised strategy instead of
a clustering approach (e.g., making use of OpenCyto [1818] or
flowLearn [1820]).
One important aspect of an automated cell population clus-
tering is choosing the number of clusters. Several clustering tools
take the number of clusters explicitly as input. Others have other
parameters that are directly correlated with the number of clusters
(e.g., neighborhood size in density based clustering algorithms).
Finally, there also exist approaches that will try several param-
eter settings and evaluate which clustering was most successful.
In this case, it is important that the evaluation criterion corre-
sponds well with the biological interpretation of the data. In those
cases where the number of clusters is not automatically optimized,
it is important that the end user does several quality checks on
the clusters to ensure they are cohesive and not over- or under-
clustered.
1.6 Integration of cytometric data into multiomics analysis
While FCM enables detailed analysis of cellular systems, complete
biological profiling in clinical settings can only be achieved using a
coordinated set of omics assays targeting various levels of biology.
Such assays include, transcriptomics [1867–1869], proteomics
[1870–1872], metabolomics analysis of plasma [1873–1875],
serum [1876–1878] and urine [1879, 1880], microbiome anal-
ysis of various sources [1881], imaging assays [1882, 1883],
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data from wearable devices [1884], and electronic health record
data [1885]. The large amount of data produced by each of
these sources often requires specialized machine learning tools.
Integration of such datasets in a “multiomics” setting requires
a more complex machine learning pipeline that would remain
robust in the face of inconsistent intrinsic properties of these
high throughput assays and cohort specific variations. Such efforts
often require close collaborations between biorepositories, labo-
ratories specializing in modern assays, and machine learning con-
sortiums [1795, 1813, 1886, 1887].
Several factors play a key role in integration of FCM and mass
cytometry data with other high-throughput biological factors.
First, much of the existing data integration pipelines are focused
on measurements of the same entities at various biological levels
(e.g., genomics [1867, 1888] profiled with transcriptomics [1869]
and epigenetics [1889] analysis of the same samples). FCM, being
a cellular assay with unique characteristics, lacks the biological
basis that is shared among other popular datasets. This makes
horizontal data integration across a shared concept (e.g., genes)
challenging and has inspired the bioinformatics subfield of “mul-
tiomics” data fusion and integration [1890–1893]. In order to
facilitate meaningful sample subgroup discovery and to uncover
between-modality correlations, recently developed methodologies
apply a variety of existing machine learning techniques, such
as, matrix factorization and latent space modeling [1894, 1895],
graph-based analysis [1896, 1897], consensus clustering [1898],
and canonical correlation analysis [1899]. The implementation of
principled multiomics analysis techniques therefore help to reveal
the joint biological system and crosstalk between all measured
biological datasets.
A second consideration for integration of FCM data with other
omics modalities is the targeted nature of FCM. While FCM typi-
cally produces fewer measurements compared to genomics, tran-
scriptomics, and proteomics datasets, the panel of markers mea-
sured is often carefully curated to target key cell types and signal-
ing pathways. Therefore, if FCM data are simply combined with
other high-throughput and high-content data modalities, the pre-
dictions will be primarily driven by the larger datasets [1900]. This
is further complicated by the facts that large untargeted datasets
often include highly correlated measurements (e.g., a large num-
ber of gene expressions measured from the same biological path-
way). Therefore, an FCM data set, despite its smaller size, may
have a higher information context than traditional untargeted
assay. An example of this is demonstrated in a recent study of
normal pregnancy in which a mass cytometry data set, despite
its relatively small number of cell types and signaling pathways
measured, required a higher number of principal components to
account for 90% variance than large microbiome and transcrip-
tomics datasets with tens of thousands of measurements [1901].
Therefore, computationally accounting for not only the number of
measurements but also the redundancy of the measurements is of
critical importance when integrating FCM data with other omics
platforms [1901–1903].
1.7 Modeling cell dynamics using trajectory inference
While automated population identification techniques, such as the
ones based on clustering, often make the assumption that cell pop-
ulations are well separated in the space defined by all markers,
trajectory inference methods intent to model dynamic biological
processes. In this case, the assumption is made that differences
between populations might not be well separated, but rather can
be modeled as a continuum. This continuum then represents dif-
ferent stages, e.g., of a cell developmental process, and when
sufficient cells are present in the different stages of the contin-
uum, a model can be learned to represent this gradient. The
first method to describe this novel class of techniques, Wander-
lust [1904], was applied to mass cytometry, but since the advent
of single-cell sequencing techniques the field of trajectory infer-
encemethods has exploded and currentlymore than 70 techniques
are available [1905]. Many of these techniques have been devel-
oped for single-cell transcriptomics data, but often they can be
applied equally well to cytometry data.
An example of the result of a trajectory inference method
applied to a dataset of reprogramming fibroblasts is presented
in Fig. 212. Here the black, bifurcating curve represents the
model, where MEF cells either develop further to neurons or to
myocytes [1906]. As cell developmental processes can be quite
complex, e.g., resulting in very complex tree structures, accurately
reconstructing the underlying topology of the trajectory is a very
complex and challenging computational problem.
Conceptually, trajectory inference methods (sometimes also
referred to as pseudo-temporal ordering methods) typically con-
sist of two steps: a dimensionality reduction step, and a trajectory
modeling step [1907]. Since manymethods exist to perform either
of those steps, a wide variety of combinations is available, and the
current next challenge in the field is to compare thesemethods and
find out which ones work best for which situation, providing a bio-
logical user with guidelines on good practices in the field [1905],
along with novel ways of extracting dynamics of the system under
investigation [1908].
2 Statistics for flow cytometry
2.1 Background
One of the attributes of cytometric systems is that a large number
of cells can be analyzed. However, the data sets produced are
just a series of numbers that need to be converted to information.
Measuring large numbers of cells enables meaningful statistical
analysis, which “transforms” a list of numbers to information.
At the most basic level, the objective of cytometric measure-
ments is to determine if there is more than one population in a
sample. In the case that two or more populations are completely
separated, e.g., the subsets studied can be gated by virtue of phe-
notypic markers or easily separated by cluster analysis (for more
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Figure 212. Example of a bifurcating trajec-
tory, automatically constructed for a data set
of reprogramming fibroblasts from ref. [1906].
detail please see Chapter VI Section 2: Automated data analysis:
Automated FCM cell population identification and visualization),
then the proportions of cells within each subset and additional
measurement parameters for each subset can easily be calculated,
and the analysis would be problem-free. However, problems arise
when there is overlap between subsets, based on the parameters of
the specific measurement, e.g., fluorescence or light scatter inten-
sity.
Those performing DNA histogram cell-cycle cytometric analysis
are accustomed to resolving the problem of overlap as this occurs
at the G1:S and the S:G2+M interfaces of the histogram. G0, G1,
S, and G2+M are phases during cell division and obviously have
different DNA contents, which can be measured with DNA reac-
tive fluorescent dyes by flow or image cytometry. A considerable
body of analytical work has addressed this problem [1909–1912].
In contrast, relatively little such work has been carried out in
immunocytochemical studies, where the time-honored method of
resolving histogram data has been to place a delimiter at the upper
end of the control and then score any cells above this point as
(positively) labeled. This approach can lead to large errors and
is best overcome by improvements in reagent quality to increase
the separation between labeled and unlabeled populations in a
cytometric data set, or by the addition of extra independent mea-
surements like additional fluorescence parameters [1795]. But,
this may not always be possible and any subset overlap needs to
be resolved. See Chapter VII Section 1.2 that discusses data analy-
sis and display. The tools available to resolve any subset overlap in
mixed populations require an understanding of (i) probability, (ii)
the type of distribution, (iii) the parameters of that distribution,
and (iv) significance testing. An overlapping immunofluorescence
example is shown below in subsection 3.6-Immunofluorescence
example Table 91. Additionally the use of statistical methods for
drawing conclusions at the level of data, derived from cytometric
measurements, is essential, but not covered here specifically.
2.2 Probability
Qualitative statements on probability are not very useful for quan-
titative analysis of cytometric data, which are affected by variabil-
ity of sample collection, sample preparation, sampling, measure-
ment imprecision, and variability in manual or automated data
analysis. Statistics allows us to derive quantitative probabilities
from cytometric data, especially as many data points are gen-
erally measured in FCM. Probability designated with a p-value
has a measurement range of zero, or absolutely impossible, to
unity, or absolute certainty. Very few events, if any, occur with
a p-value at these extremes. “The sun will rise tomorrow,” is a
statement with a p-value very close to unity. In contrast, “Man,
one day, will run the 100 meters in 1 second,” has a p-value of
zero.
2.3 Types of distributions
There are many distributions but those most commonly encoun-
tered in the biological sciences are the Gaussian, binomial, and
Poisson distributions.
2.3.1 The Gaussian distribution. The Gaussian distribution
(error function, “normal” distribution) is a bell-shaped curve sym-
metrical about a mean value with the following formula
Y = 1
σ
√
2π
e−(X−X )
2/2σ2 (1)
where σ is the SD and X¯ is themean of the distribution. Algorithms,
based on the Gaussian distribution, have been used extensively for
cell cycle analysis by FCM [1912].
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2.3.2 The binomial distribution. The binomial distribution is con-
cerned with occurrences of mutually exclusive events and is given
by the formula
(p + q)n = 1 (2)
where p is the chance of something happening and q is the chance
of that same something not happening. If we throw two regular
six-faced dice, n in the binomial equation is 2 and this expands
the equation to p2 + 2pq + q2 = 1. The chance of getting 2 threes
on a single paired throw is p2 = (1/6)2, the chance of getting
one three and any other number is 2 pq = 2 × 1/6 × 5/6 and
the chance that neither die will be a three is (5/6)2. Hence, the
total probability is given by ((1/6) × (1/6)) + (2 × 1/6 × 5/6)
+ ((5/6) × 5/6)), which sums to unity. Rosenblatt et al. describe
the use of a binomial distribution based algorithm to optimize flow
cytometric cell sorting [1913].
2.3.3 The Poisson distribution. The Poisson distribution is used
to describe the distribution of isolated events occurring in a con-
tinuum, originally formulated by Poisson [1914]. A good example
is the number of cells passing the analysis point in the cytometer
per second. Clearly you cannot ask the question of how many cells
did not pass the analysis point per second, so neither the Gaussian
nor the binomial distributions can handle this type of problem. In
order to use the Poisson distribution all we need is z, the average
number of times the event occurs within the continuum, where
the probability of observing the event n times, p(n), is given by
p(n) = 2ne−z/n! (3)
where n! is factorial n. The notation for the whole distribution that
sums to unity is
P =
n−∞∑
n−0
Zne−s/n! (4)
The Poisson distribution is important in cytometric cell sort-
ing purity for investigating coincidence in which there could be a
possibility of two or more cells being in the analysis point simulta-
neously. Poisson statistics also applies to the measurement of low
intensity signals, where just a few photons contribute to the mea-
surement, and to the counting of rare subpopulations, discussed
in some more detail below.
2.4 Distribution parameters
These include measurement of (i) central tendency namely, the
mean, percentiles, median, and mode, and (ii) dispersion param-
eters namely, the mean deviation, variance, SD, and CV, wherein
the last of these, the CV of limited statistical significance, is the
SD divided by the mean.
Figure 213. Measurements of central tendencies for cytometric inten-
sity histograms. The curve is an ideal distribution, showing key mea-
surements. Cytometric intensity histograms span a finite intensity
range with a noisy curve and frequently with off-scale events at the
lower and/or upper end(s) of the scale. Generally the median is the
most robust measure, because the mean is heavily influenced by off-
scale events and the mode by noise.
2.4.1 Central tendency. The goal of many cytometry measure-
ments is the determination of the expression level of a given
marker in a cell and its distribution in a cell population. The
mean of a distribution is the sum of all the data points divided
by the number of the values in the distribution. The median is
the point in the distribution where half the data lie on either
side; it is also known as the 50th percentile, the point, where 50%
of the data has been accumulated. Twenty-fifth percentiles and
75th percentiles are also determined for distributions. The mode
is the maximum frequency. But, this is an unreliable measure-
ment of central tendency in cytometry for two reasons. First, the
mode is meaningless if this is located in the first or last chan-
nel of the histogram. In some cases cytometry histograms have
many off-scale events, which makes the fist or last channel in the
histogram the highest point. Second, even though a large num-
ber of cells will have been sampled, the distribution is not con-
tinuous, due to the analog-to-digital conversion (ADC) step, i.e.,
intensity values are used as indices for incrementing histogram
channels (e.g., 0 to 1023), and counting statistics as the SD of a
count in a discrete “channel” is equal to the square root of the
count (more below in Chapter VII Section 2.7: Rare cell analysis).
Therefore, typical unsmoothed cytometry histograms are often
very noisy. Any “noise” around the mode will give an erroneous
result. The relationship between these parameters is shown in
Fig. 213.
2.4.2 Dispersion parameters. Just as central tendency gives a
measure of the overall “average” difference between Gaussian
distributions, the dispersion parameters give a measure of the
different spreads within and between those distributions.
The mean deviation is given by (X − X¯ ).
The variance, mean squared deviation, is given by (X − X¯ )2.
The SD is given by
√
[(X − X¯ )2].
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1842 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
2.5 Significance testing
The central axiom in statistical theory is that the variance of the
sum or difference of two independent and noncorrelated random
variables is equal to the sum of their variances. These tests are
designed to give a measure of how different two or more dis-
tributed populations might be.
The most commonly asked questions in cytometry are (i) is
there more than one subset? and (ii) if there is more than one,
how many cells are in each? This is far too naive a perspective,
and with the statistical tools available we should be asking the
following:
1. Is there more than one subset?
2. If there is more than one, how far “separated” are they?
3. What is the significance of that separation?
4. If the subsets are significantly separated, then what are the
estimates of the relative proportions of cells in each ?
5. What significance can be assigned to the estimated propor-
tions?
The statistical tests can be divided into two groups. (i) Para-
metric tests include the SE of difference, Student’s t-test, and vari-
ance analysis. (ii) Non-parametric tests include the Mann-Whitney
U-test, Kolmogorov–Smirnov test, and rank correlation.
2.5.1 Parametric tests. These may best be described as functions
that have an analytic and mathematical basis where the distribu-
tion is known.
2.5.1.1 Standard error of difference. Every cytometric anal-
ysis is a sampling procedure as the total population cannot be
analyzed. And, the SD of a sample, s, is inversely proportional to
the square root of the sample size, N, hence the SEM, SEm =
s/N. Squaring this gives the variance, Vm, where
Vm = s2/N (5)
We can now extend this notation to two distributions with X¯1,
s1, N1, and X¯2, s2, N2 representing, respectively, the mean, SD,
and number of items in the two samples. The combined variance
of the two distributions, Vc, can now be obtained as
Vc = (s21/N1) + (s22/N2) (6)
Taking the square root of Equation (6), we get the SE of differ-
ence between means of the two samples. The difference between
means is (X¯1 − X¯2) and dividing this byVc (the SE of difference)
gives the number of “standardized” SE difference units between
the means; this standardized SE is associated with a probability
derived from the cumulative frequency of the normal distribution.
2.5.1.2 Student’s t-test. The approach outlined in the previ-
ous section is perfectly satisfactory if the number of items in the
two samples is “large,” as the variances of the two samples will
approximate closely to the true population variance from which
the samples were drawn. However, this is not entirely satisfac-
tory if the sample numbers are “small.” This is overcome with the
t-test, invented by W.S. Gosset, a research chemist who very mod-
estly published under the pseudonym “Student” [1915]. Student’s
t was later consolidated by Fisher [1916]. It is similar to the SE of
difference but, it takes into account the dependence of variance
on numbers in the samples and includes Bessel’s correction for
small sample size. Student’s t is defined formally as the absolute
difference between means divided by the SE of difference:
Student’s t = |X¯1 − X¯2|
√
N
σ
(7)
When using Student’s t, we assume the null hypothesis, mean-
ing we believe there is no difference between the two populations
and as a consequence, the two samples can be combined to calcu-
late a pooled variance. The derivation of Student’s t is discussed
in greater detail in ref. [1917].
2.5.1.3 Variance analysis. A tacit assumption in using the null
hypothesis for Student’s t is that there is no difference between
the means. But, when calculating the pooled variance, it is also
assumed that no difference in the variances exists, and this should
be shown to be true when using Student’s t. This can first be
addressed with the standard-error-of-difference method similar
to Section 2.5.1.1 Standard Error of Difference, where Vars, the
sample variance after Bessel’s correction, is given by
Vars =
{
(n1 × s21) + (n2 × s22)
n1 + n2 − 2
}
×
{
1
2n1
+ 1
2n2
}
(8)
The SE of the SD, SEs, is obtained as the square root of this
best estimate of the sample variance (equation (8)). This is now
divided into the difference between the two sample deviations.
The second method of addressing the variance analysis is to
use the variance ratio [1918], designated the F-test by Snedcore
[1919]. F is calculated as the ratio of the greater variance estimate
of sample variance to the lesser estimate of sample variance. After
Bessel’s correction, we get the best estimate of the variances, σ2,
as,
σ2 = Vars ×
{
N
N − 1
}
(9)
2.5.2 Nonparametric tests. These rely on ranking methods when
there is no known, or suspected, distribution that can be assigned
to samples being analyzed.
2.5.2.1 Mann–Whitney U. This problem was originally
addressed by Wilcoxon [1920] and was later refined by Mann
and Whitney [1921]. Consider two sets of data, the X-group and
Y-group, containing 5 and 4 values respectively; these are illus-
trated in Table 84. These values have been ordered according to
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Table 84. Comparison of two data sets X and Y in a rank analysisa)
Y-group y1 y2 y3 y4
X-group x1 x2 x3 x4 x5
Values 3 7 9 15 23 31 36 44 51
Rank 1 2 3 4 5 6 7 8 9
a)The values have been ordered according to magnitude in the third
row with their rank position in the last row. The populations from
which the data were drawn are shown in rows 1 and 2, the Y-group
and X-group, respectively. It is clear that the Y-group is tending to
be more to the right (greater magnitude) than the X-group, and the
question is whether this arrangement could have occurred purely on
a random basis. Reproduced with permission from ref. [1917].
magnitude in the third row with their rank position in the last row.
The populations from which the data were drawn are shown in
rows 1 and 2, the Y-group and X-group, respectively. It is clear that
the Y-group is tending to be more to the right (greater magnitude)
than the X-group, and the question is whether this arrangement
could have occurred purely on a random basis. To do this, we
determine how many x-values lie to the right of every y-value and
sum the result to get Uy for the Y-group. There are three x-values
(x3, x4, and x5) to the right of y1 and one x-value to the right of
y2, thus Uy sums to four. The same process is now carried out for
the x-group to give Ux equal to 16. For small sample numbers,
this procedure is satisfactory but it can be prohibitively time con-
suming for large samples for which the following expressions are
used.
Uy = NxNy + Ny(Ny − 1)2 − Ty
Ux = NxNy + Nx(Nx − 1)2 − Tx (10)
Nx and Ny are the number of values in the X- and Y-groups,
respectively, and Ty and Tx are the sums of the rank positions for
the Y- and X-groups, respectively.
If the X- and Y-values are randomly distributed in the rank, the
sum of the rank position T has a mean value of T and a variance
of σ2T given by the following expressions:
T¯x = Nx(Nx + Ny + 1)2 and T¯y =
Ny(Nx + Ny + 1)
2
(11)
These values of T¯x and T¯y will be identical if Nx and Ny are
equal, but the variance, σ2T, will be the same irrespective of the
numbers in each group and is given as
σTa = NxNy(Nx + Ny + 1)12 (12)
If both samples are large, >20, we take the values of T and T¯
associated with the smaller of the pair of U-values, in this example
the Y-group, to calculate the Z-statistic as follows:
Z = |Ty − T¯y|√
((NxNy(Nx + Ny + 1))/12) (13)
The numerator in equation (13) represents the difference
between the values of T for the Y-group and the mean, T¯ , that
Table 85. Part of the Mann–Whitney probability table example for the
X-group size of Table 84 (N2 = 5)a)
U N1 = 1 N1 = 2 N1 = 3 N1 = 4 N1 = 5
0 .167 .047 .018 .008 .004
1 .323 .095 .036 .016 .008
2 .500 .190 .071 .032 .016
3 .667 .286 .125 .056 .023
4 .429 .196 .095 .048
5 .571 .286 .143 .075
6 .393 .206 .111
7 .500 .278 .155
8 .607 .365 .210
9 .452 .271
a)Reproduced with permission from ref. [1917].
would be expected if the numbers were randomly distributed
within the rank structure and the denominator is the square root
of the variance. Hence, Z represents the observed deviation from
the mean in SD units and the associated probability can be read
off from the cumulative frequency of the normal curve because,
for large samples, the Z-distribution approximates very closely to
the Gaussian distribution.
With small sample sizes, e.g., with less than 30 values, the Z-
distribution does not approximate to a Gaussian curve, andMann–
Whitney computed the probabilities associated with U-values for
different-sized samples. These data are arranged in tables for N2
= 3, 4, 5, 6, and so on and within each table there are sample sizes
for N1 = 1, 2, 3, 4, 5 and so on versus the U-values and associated
probabilities for the N2 and N1 sample sizes. The example for N2
= 5 is shown in Table 85. The sample size of the X-group (N2 in
Table 85) is 5, and the associated U-value is 4. The number of data
points in the Y-group is also 4, and hence, the probability that this
distribution of data points in Table 84 is different can be read off
as 0.095 in Table 85 and does not reach “significance” at the 1:20
level (0.05).
2.5.2.2 Kolmogorov–Smirnov statistic. In the Kolmogorov–
Smirnov (K–S) statistic, D is a measure of the maximum verti-
cal displacement between two cumulative frequency distributions.
The one-tailed test compares an experimentally derived distribu-
tion with a theoretical cumulative frequency distribution and, the
two-tailed test compares two experimentally derived distributions
(for more detail, see Chapter 6 in ref. [1922]). In any biological
system, a test sample should always be compared with a con-
trol, i.e., the two-tailed test, and this was first used in FCM by
Young [1923].
The cumulative frequency distributions containing n1 and n2
cells in the control and test samples respectively can be calculated
as follows for i = 1  256,
Fn1(i) =
j=i∑
j=1
f n1( j) and Fn2(i) =
j=i∑
j=1
f n2( j) (14)
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Table 86. Kolmogorov–Smirnov (K–S) statistic critical values, Dc, with
their associated p-values (probabilities)a)
Dc 1.0727 1.2238 1.3581 1.5174 1.6276 1.7317 1.8585 1.9525
p 0.200 0.100 0.050 0.020 0.010 0.005 0.002 0.001
a)Reproduced with permission from ref. [1917].
Table 87. Hypothetical results of the same determinations from two
different laboratoriesa)
Sample 1 2 3 4 5 6 7 8 9 10
Lab A .61 .23 .31 .11 .41 .19 .10 .03 .07 .17
Lab B .54 .38 .42 .20 .36 .27 .21 .11 .14 .12
a)Reproduced with permission from ref. [1917].
These cumulative frequencies are now normalized to unity and
the null hypothesis is assumed (i.e., both distributions are samples
derived from the same population) where the probability functions
P1(j) and P2(j) that underlie the respective frequency density func-
tions (the histograms) ƒ n1(j) andƒ n2(j) are samples assumed to
be drawn from the same populations so that
P1( j) = P2(i), −∞ ≤ j ≤ +∞ (15)
The D-statistic is computed as the maximum absolute differ-
ence between the two normalized cumulative frequency distribu-
tions over the whole of the two distributions, where
D = max
j
| f n1( j) − f n2( j)| (16)
As with the Mann–Whitney U, there is a variance, Var, associ-
ated with the assumed common population from which the two
samples, containing n1 and n2 items, respectively, are drawn. This
is given by
V ar = (n1 + n2)
n1 × n2 (17)
The SD s can now be found by taking the square root of this
relationship, then dividing D by s gives Dcrit, where
Dcrit = max |Fn1 − Fn2|√
((n1 + n2)/(n1 × n2))
(18)
This type of relationship, in which we divide a difference by
a measure of dispersion, has been seen in all the other statistical
tests described previously. Two-tailed critical Dc for large samples,
along with their probabilities, are shown in Table 86.
2.5.2.3 Rank correlation. Correlation between two or more
sets of measurements can be determined with Spearman’s rank
correlation coefficient [1924]. This enables an objective assess-
ment to be made regarding the consistency between paired labo-
ratory results as in the purely hypothetical data shown in Table 87.
When we look through these data, we find that both laborato-
ries score sample 8 with the lowest results and in both cases these
Table 88. Ranking of the data from Table 87 with rank differences
(d, and d2)a)
Sample 1 2 3 4 5 6 7 8 9 10
Lab A 10 7 8 4 9 6 3 1 2 5
Lab B 10 8 9 4 7 6 5 1 3 2
Rank difference, d 0 –1 –1 0 2 0 –2 0 –1 3
d2 0 1 1 0 4 0 4 0 1 9
a)Reproduced with permission from ref. [1917].
are ranked 1. Sample 9 from lab A has the next lowest value (0.07)
and is ranked 2 but, it is sample 10 (0.12) that is ranked 2 in the
lab B series, and these ranking positions are shown in Table 88.
In terms of ranking alone, the two laboratories agree exactly
for only four of the ten samples, namely 1, 4, 6, and 8. Spearman’s
rank correlation coefficient R is given by the expression:
R = 1 −
{
6d2
n3 − n
}
(19)
d2 is the sum of the squared rank differences and n is the number
of samples; in our particular example, these values are 20 and 10,
which gives R = 0.8787. This coefficient was designed to have a
value of +1 if there is perfect ranking agreement and –1 where
there is total ranking disagreement.
This value of 0.8787 for R would suggest that there is fairly
close agreement between laboratories and where there are ten or
more samples being compared we can use Student’s t to assess the
significance of comparison:
Student’s t = R ×
√
((n− 2)/(1 − R2)) (20)
which gives t = 5.2 with eight degrees of freedom associated with
P < 0.01, which is highly significant and suggests there is close
agreement between laboratories. However, this does not tell us
anything about the quality of the “intersample” agreement from
the two laboratories. This can be addressed by analysis of the
differences in results from the laboratories as shown in Table 89.
Themean difference X¯ is calculated by summing the data in the
difference row and dividing by n, the number of samples, which
gives –0.052. If there are no differences between laboratories, this
mean value should not differ significantly from zero since any
random differences should cancel out.
The variance, s2, is calculated from the convenient relationship
as
s2 = (X 2/n)− X¯ 2 (21)
where X2 is equivalent to d2 = 0.0824 yielding s2 = 0.0055.
After Bessel’s correction and using equation (6), we get Student’s
t = 2.1. This value of t, with nine degrees of freedom, does not
quite reach the 5% probability level and we can conclude that
the inter-laboratory differences are not significant. However, in a
quality control exercise such as this, we would be justified in set-
ting more stringent statistical criteria. If we now take a probabil-
ity level of 0.1 for magnitude discrepancies between laboratories,
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Table 89. Differences between values from Table 87 by subtracting Lab B results from those of Lab A
Sample 1 2 3 4 5 6 7 8 9 10
Lab A 0.61 0.23 0.31 0.11 0.41 0.19 0.10 0.03 0.07 0.17
Lab B 0.54 0.38 0.42 0.20 0.36 0.27 0.21 0.11 0.14 0.12
Sample difference, d 0.07 –0.15 –0.11 -0.09 0.05 –0.08 –0.11 –0.08 –0.07 0.05
d2 0.0049 0.0225 0.0121 0.0081 0.0025 0.0064 0.0121 0.0064 0.0029 0.0025
which would be reasonable as we know they should be getting
the same results, we must conclude there is something suspicious
occurring in the generation of the results, which would require
further investigation.
2.6 An example of immunofluorescent staining in cytometry
Figure 214 shows a histogram representation of weak staining of
a small population. Statistical analysis of this datum must ask a
number of questions.
First, is there any difference between these two datasets? This
is addressed with a K–S analysis, which reveals that there is a max-
imum normalized vertical displacement of 0.0655 at channel 37
with 8976, N1, and 8570, N2, cells in the control and test sample,
respectively (Fig. 215). K–S statistic gave P < 0.05, suggesting
there is a statistical difference between the two datasets at the
1:20 probability level. The remaining data shown in this figure
will become apparent later.
Second, can we establish the “meaning” of the discernible
shoulder in the lower histogram of Fig. 214? This is addressed
analytically using a concept derived from mechanics; namely, tak-
ing moments about a point. Imagine a weightless beam with two
different weights hanging from the beam that will balance accord-
ing to equation (22)
W1(B − X¯1) = W2(X¯2 − B) (22)
where W1 and W2 are the “weights” hung from the beam, B is the
balance point, and X¯1 and X¯2 are the distances of the respective
weights from the balance point, B. On rearranging equation (22),
we get
B = ((W1 X¯1) + (W2 X¯2))/(W1 + W2) (23)
Let us suppose that the distances X¯1, X¯2, and B are known for
a normalized total mass of unity, where W1 + W2 = 1. We can
now calculate the relative proportion of W2 by replacing W1 with
(1.0 – W2) in equation (23) and simplifying to give
W2 = (B − X¯1)/(X¯2 − X¯1) (24)
The “weight” in equation (24) that will now be referred to
as “labeled cells,” is defined by three distances namely, X¯1, X¯2,
and B. X¯1 is the mean of the control unlabeled fraction, B is the
mean of the test sample containing labeled and unlabeled cells,
Figure 214. The histogram representation of fluorescence from aweak
staining of a small (rare) population. The upper histogram shows an
unstained control. A small shoulder from the staining of the rare pop-
ulation is visible in the lower histogram. Reproduced with permission
from ref. [1925].
and both of these can be obtained directly from the experimental
data. We now need to obtain X¯2, the mean of the labeled fraction,
as follows:
It has been shown in ref. [1925] that the mean of the distribu-
tion obtained by subtracting the N2 cumulative frequency from the
cumulative frequency of N1, is independent of the number of cells
in N1, and the mean of the subtracted distribution Dm, depicted in
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Figure 215. Cumulative frequencies from the two histograms in Fig.
214 and difference. Details on the calculation of X ̅1 ̅, X ̅2 ̅, and Dm are
described in the text. Reproduced with permission from ref. [1925].
Fig. 215, is exactly halfway between the means ofN1 andN2. How-
ever, this applies to a continuous distribution and all cytometric
distributions are not continuous due to the ADC conversion and a
half channel correction must be applied to give the mean of the
N2 distribution as
X¯2 = (2.0 × (Dm + 0.5)) − X¯1 (25)
All the data have now been derived to calculate the propor-
tion of cells in the N2 distribution as W2 from equation (24) by
substituting the X¯2 of equation (25) and simplifying to give
W2 = (B − X¯1)/(2.0 × (Dm + 0.5 − X¯1)) (26)
The data depicted in Fig. 214 were analyzed according to this
ratio analysis of means to give X1 = 29.1,Dm = 37.4 and X¯2 = 46.7
as shown in the figure and the predicted proportion inN2 was 0.08.
These data are shown in Fig. 216 where the control, test sample,
and the predicted labeled fraction are labeled in the figure. The
test sample results are shown Table 90. We now have to ask if this
result is reasonable and what significance can be placed on the
result.
2.6.1 K–S analysis. The cumulative frequency distributions of
the control and test sample were re-analyzed over a range of ±3
SD about the mean of the predicted labeled distribution, X2. With
the number of cells involved, the K–S analysis showed that the
two cumulative frequency distributions over this ±3 SD range had
Figure 216. Result of the histogram analysis. The two original his-
tograms and the calculated stained population are shown with pop-
ulation means. Reproduced with permission from ref. [1925].
a probability of being different at the 99% confidence interval, P
< 0.01.
2.6.2 Student’s t. The results from the analysis of the test sample
shown in Table 90 were also submitted to Student’s t analysis
(Chapter 7 in ref. [1917]). This gave t = 65.58 with 8568 degrees
of freedom, P < 0.001.
Hence, we can present the results in probabilistic terms by
saying the analysis was compatible with two subsets with means
separated by 17.6 channels containing 92% and 8% of the popu-
lation at the 99% confidence interval.
This analysis should only be used for symmetrical data sets with
constant, or near constant, variance, and these data were chosen
for illustration as they conformed to this condition. However, there
are a number of other factors that should be considered, including
positive skew that tends to be minimized with log-amplification
as discussed elsewhere [1925]. Nevertheless, this analysis goes
some way to producing a more statistically convincing method of
presenting results of immunofluorescence data.
2.7 Rare cell analysis
Flow cytometric analysis of cell samples is often applied to
characterize subsets of very low frequency, ranging from 1% to
less than 1 ppm. In those cases, it is very important to understand
the inherent variation when randomly sampling a small number
of events. As mentioned above, the SD of a count is the square
root of the number, e.g., when sampling from a cell/particle
Table 90. Results of the immunofluorescence analysis example, data from Watson [1925]
Test sample Number of cells proportion Mean Standard deviation
Unlabeled 7889, N1 0.92 29.1,′X1 6.69, s1
Labeled 681, N2 0.08 46.7,′X2 7.13, s2
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Table 91. Illustration of potential interpretation problems, when
counting extremely rare cells
Run 1 2 3 4
11 11 9 9
15 13 9 10
15 13 11 7
10 7 9 8
5 8 9 7
Mean 11.2 10.4 9.4 8.2
St.Dev 4.1 2.8 0.9 1.3
Overall mean: 9.8
Overall St.Dev: 2.7
aThe table shows integers from four different runs with five measure-
ments each from a random number generator. This could reflect a
study with four conditions with five replicates each. The table indi-
cates a trend from run 1 to 4; however, all of the data is from the same
distribution, and there is no change from runs 1 to 4 (generated with
ROUND(NORMINV(RAND(),9,3),0) with a mean of 9.0 and an SD of 3.0 in
MS Excel. The cumulativemean and SD from the 20 values approximate
the real population numbers well.)
suspension several times a volume, which should contain four
cells per particles the SD will be 2, the CV 50%.
If enough cells in the full sample are available, cytometric
data acquisition should be continued until a number of cells is
reached in the rare subset that assures the desired measurement
precision—a feature available in most commercial data acquisition
software. If not enough cells are available, care must be taken to
not come to conclusions, which are not supported by the limited
precision associated with limited acquisition.
Table 91 shows an example, where four consecutive determi-
nations indicated a progressive change of a property; but all of the
data are from the same distribution, and there is no change from
series 1 to series 4 (the data is from a simulation with a Gaussian
random number generator with a mean of 9.0 and a SD of 3.0).
This issue is discussed in more detail in a paper by [196].
In certain cases the limitation of the imprecision of counting
small numbers of cells can be overcome. For example, one can
evaluate a bulk cell separation technology by dispensing a known
number of cells into a sample, subjecting the sample to a sepa-
ration process, and analyzing the total volumes of the resulting
fractions.
2.8 Measurements of central tendency. Arithmetic mean,
geometric mean, median, and mode
In order to accurately measure the average of a population, mea-
surements of central tendency such as the arithmetic mean, geo-
metric mean, median, and mode can be used. The arithmetic
mean, often referred to as just mean, is the sum of all events
divided by the total number of events. The geometric mean is the
nth root of the product of events. The median is the middle point
in a number series, while the mode is simply the most common
number. These measures of central tendency are applied to fluo-
rescence intensity, generated by a flow cytometer to give the MFI,
geometric MFI (gMFI), or MdFI. The mode is rarely appropriate
as a single measure of central tendency and is not commonly used
in this context.
2.9 MFI, gMFI, MdFI which to use?
Which of these measurements is appropriate is dependent on the
distribution of the data itself. The MFI is appropriate where data
has a normal (Gaussian) distribution. The gMFI is appropriate
where data has a log-normal distribution, i.e., the logs of the raw
data are normally distributed, but is influenced by outliers and can-
not account for any values below zero that may be created during
compensation. The median, on the other hand, is robust, i.e., it is
not affected by the data distribution and is not strongly influenced
by outliers. In practice, most fluorescence data collected on mod-
ern flow cytometers, is skewed and conforms to an approximately
log-normal distribution, indicating that the gMFI andMdFI may be
better choices than the MFI. For example, in the logarithmic num-
ber series 1, 10, 100, 1000, 10 000; the arithmetic mean is 1700,
the geometric mean is 100, and the median is 100, indicating that
the arithmetic mean is not appropriate for estimating the average
of log-normally distributed data. While no one measurement may
be suitable for all purposes, generally speaking, the MdFI is the
most reliable and, as a result, is the basis for many machine cal-
ibration methods (BD Cytometer Setup and Tracking Application
Guide V3.0 [41, 48]). However, while the MdFI is advantageous
due to its insensitivity to extreme outlier events and skewness, this
loss of sensitivity may also prove a disadvantage where outliers
are of interest, in which case the gMFI is also a valid option. Use of
MFI, despite its enduring popularity, is likely to be inappropriate
unless the raw data is confirmed to have a normal distribution.
2.10 Pitfalls
Measurements of central tendency are useful to estimate the aver-
age of a unimodal population. However, when data is bimodal or
multimodal (has two or more distinct populations), measurements
of central tendency may be misleading. For example, if the data
has two equally numbered populations centered at 0 and 1000,
the average would be 500 despite there being no events in this
area. In these situations, it is more effective to use gating to enu-
merate the percentage of cells in the different peaks rather than
relying on measurements of average fluorescence.
3 Analysis presentation and publication (MIFlowCyt)
3.1 Overview
Basic research is often criticized to be non-reproducible. To ensure
reproducibility of cytometry data, it is the aim of journals to
express standards that data should be minimally provided to
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Figure 217. Uni-, bi-, andmulti-parameter presentation of flow data. Comparison of two gender and agematched patients: a healthy one (67 years)
and a patient with B-CLL (64 years). (A) 1D-Histogram presentation of CD3 expression on lymphocytes (red, B-CLL; grey, healthy), (B) 2D-Dot-plot
presentation of CD3 expression on x-axis versus CD16/56 expression on y-axis, (C)multivariate presentation of expression of 13 different antibodies
on ten colors (OMIP-023 [1926]) for nine different leukocyte subsets in a radar-plot. Abbreviations: B-CLL, B-cell chronic lymphocytic leukemia; Th,
CD4+ T-helper cell; Tc, CD8+ cytotoxic T-cell; NK, natural killer cell. Data analysis: (A and B) FlowJo, V10.2; (C) Kaluza, Beckman-Coulter, V 1.1.
understand the paper and in the best case to reproduce these
data. This section describes the MIFlowCyt standard, gives exam-
ples for good and current data visualization, and highlights the
necessity of providing example data for the readers.
3.2 Introduction
The complexity of cytometric data requires careful consideration
of how to display results in scientific presentations and publica-
tions in order to make them understandable “at a glance.” To eas-
ily reproduce published cytometric experiments, the usedmethods
and results need to be described and presented comprehensively.
By FCM, thousands of cells are acquired within seconds by
gaining information of their scatter properties and expression of
multiple markers. Manual analysis of these multidimensional and
complex data requires special software skills, gating knowledge,
time, and can be quite laborious. Manual gating is still consid-
ered by most cytometrists to be the “standard,” although semi-
automated algorithms exist (see Chapter VII, Sections 1 and 2).
Some basic rules for data visualization allow presenting these data
in a directly comprehensible format.
3.3 Principles of the technique
What data should be minimally displayed to fully understand
research papers? First of all, the full gating strategy should be dis-
played so that data analysis strategy used is obvious to the reader.
This display should also include the position of positive and neg-
ative controls and essential statistical information, such as the
percentage of cells in the region or gate or event count. Axis leg-
ends should include the marker (e.g., antigen) and the dye used,
and show the scaling (log/lin; Fig. 217). Simple experiments with
one or two colors can be presented in 1D histograms; this allows
easy comparison of the expression level of the marker of interest
for different samples (positive, negative controls, and samples) in
overlay histograms (Fig. 217A). Within these histograms, positive
and negative populations can be easily distinguished from one
another. For better comparison, the histograms should be normal-
ized, i.e., the maximum values set to 100%.
More common is a display using 2D pseudocolor density plots
(Fig. 217B). Plotting the expression of two markers against each
other allows a more precise distinction of double negative, single
positive, and double positive, as well as weakly or strongly labeled
subsets. The 2D-plot presentation also helps to identify errors of
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automated compensation for manual correction, as needed. Mul-
ticolor experiments are normally analyzed by a sequential gating
strategy. A full gating strategy is performed in a step-by-step pro-
cedure (examples can be found in ref. [1926, 1927]). To analyze
discrete populations such as T-cell subsets within blood samples
in a first step CD45 negative red blood cells (CD45 expression vs.
scatter) are excluded. Furthermore, only lymphocytes are gated
based on their scattering (FSClow, SSClow). By exclusion of CD3
negative B cells (CD16/56–) and NK cells (CD16/56+) only CD3
positive cells will be analyzed in the next step. By the expression
of CD16/56, NKT-cells (CD3 vs. CD16/56) can be excluded from
T-cells. In a final step, CD4+ T-helper cells and CD8+ cytotoxic
T cells (CD4 vs. CD8) can be analyzed. This process is strongly
driven by a priori expectation and knowledge of the scientist ana-
lyzing the data. That means the scientists will expect, for example,
to analyze within the T-cells at least four subsets: CD4+ CD8– T-
helper cells, CD8+ CD4– cytotoxic T-cells, CD4+ CD8+ immature
T-cells and CD4– CD8– mature T-cells. But within these subsets
additional T-cell subsets might be neglected that will be taken into
count by automated approached. Keep in mind that by using small
(conservative) gates instead of overlapping gates, disease-specific
cells might be excluded already in the first step of the analysis, or
novel subsets might not be recognized. Analyzing data by the con-
ventional step by step method in sequential 2D-plots has several
drawbacks: for example, loss of information by the loss of rare cell
subsets by pregating, and some marker combinations that might
help to further subdivide a subset might not be analyzed. With the
constant increase of the complexity of cytometric measurements
and data (in the last year several standardized OMIP protocols
with 28 colors became available; [1928]), there is also a need to
develop new algorithms to analyze and visualize these complex
data (see Chapter VII, Section 1.3.–1.6).
One example for a user-friendly visualization of multidimen-
sional data at one glance is the radar plot (e.g., provided as a
visualization tool in the Kaluza R© software by Beckman–Coulter),
which plots pregated subpopulations in a multiparameter way
(Fig. 217C); this allows analysis of the heterogeneity of the pre-
gated populations and to identify new subpopulations (For fur-
ther details see Cossarizza et al. Eur J Immunol 2017, 47:1584-
1797).
Besides manual analysis and their visualization, several meth-
ods exist to perform software-assisted, unsupervised, or super-
vised analysis [1838]. For example, using several open source
R packages and R source codes often requires manual pregat-
ing, so that they finally work just as a semi-automated computa-
tional method. For identification of cell populations, for example,
FLAME (suitable for rare cell detection based on clustering tech-
niques), flowKoh (self-organizing map networks are produced),
or NMFcurvHDR (density-based clustering algorithm) are avail-
able [1795]. Histograms (2DhistSVM, DREAM–A, fivebyfive), mul-
tidimensional clustermaps (flowBin), spanning trees (SPADE), and
tSNE (stochastic neighbor embedding) maps are suitable visu-
alization tools for sample classification [1795, 1838, 1929]. To
find and identify new cellular subsets of the immune system
in the context of inflammation or other diseases analysis in an
Figure 218. Semi-automated clustering and analysis of flow cytometric
data by SPADE (Qui et al., 2011) and hierarchical clustering. (A) SPADE
tree display and CD3 expression on blood cells from two male patients.
Dot-plot analysis reveals groups of cluster (circles) belonging to the
same cell type. (B) Color codes correlate with expression level from
low (blue) to high (red) and size of the nodes correlate with cell fre-
quencies. Data of (A) and (B) are from a healthy (B1 and 3; 67 years)
and a B-CLL patient (B.2 and 4; 64 years). (C) Hierarchical clustering
of flow-cytometry data to visualize and distinguish immune response
of pediatric patients (columns) who underwent elective cardiovascular
surgerywith (left of the yellow line) or without synthetic steroid admin-
istration (right) before surgery. PBL were immunophenotyped at day 1
after surgery. FCM parameters (MFI and cell counts) are displayed hor-
izontally. Red indicates relative upregulation and green relative down-
regulation of the respective parameter. Reproduced with permission
from ref. [1931]. (SPADE analysis by Cytoscape, V 3.4.0, Nolan Lab; hier-
archical clustering by free software Genes@Work).
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Figure 219. Semi-automated analysis of flow cytometry data by tSNE. (A) 16-Part differential of ten individuals (five smokers, five nonsmokers) by
OMIP-23 (ten colors, 13 antibodies; [1926]) showing the location of regular T-helper (Th) and cytotoxic T-cells (Tc) with high side scatter (Th hiSSC,
Tc hiSSC), T-regulatory cells (Treg), natural killer (NK), and NK-T cells on the tSNE map. Bottom left box contains information for calculating the
tSNE plot. (B) Heat map display of expression level of 5 activation markers in nonsmokers and smokers and distribution of cell count (All). Scale
bars right of each tSNE plot show color coding of fluorescence intensity or cell count levels. (Data of individuals from the LIFE study [1934]; data
analysis by FCS Express V.6, De Novo Software.)
unsupervised manner, such as by SPADE (spanning-tree progres-
sion analysis of density-normalized data [1804]) can be a better
approach.
SPADE is a density normalization, agglomerative clustering,
and minimum-spanning tree algorithm that reduces multidimen-
sional single cell data down to a number of user-defined clusters of
abundant but also of rare populations in a color-coded tree plot. In
near vicinity, nodes with cells of similar phenotype are arranged.
Therefore, related nodes can be summarized in immunological
populations determined by their expression pattern. SPADE trees
are in general interpreted as a map of phenotypic relationships
between different cell populations and not as a developmen-
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tal hierarchical map. But finally SPADE tree maps help to (1)
reduce multiparameter cytometry data in a simple graphical for-
mat with cell types of different surface expression, to (2) overcome
the bias of subjective, manual gating, to (3) resolve unexpected,
new cell populations, and to (4) identify disease-specific changes
(Fig. 218A,B). Other ways for comprehensive analysis and dis-
play of complex data by unsupervised approaches can be found
in ref. [1930] and include Heatmap Clustering (Fig. 218C, for
details, see captions and ref. [1931]), viSNE/tSNE (Fig. 219 new)
and Phenograph, and FlowSOM [1932] (Chapter VII, section 2,
3). Fig. 219 shows an example of tSNE display of immunopheno-
typing data (10 colors, 13 antibodies) from 10 individuals (five
smokers, five nonsmokers). The position of the various leukocyte
types in the tSNA map can be color coded based on their anti-
gen expression from 2D dot-plots (Fig. 219A). As displayed in the
Fig. 219A, sufficient information should be provided to reproduce
the calculations. Then (Fig. 219B) for example antigen expression
levels for the different patient groups can be visualized (for more
detail see captions).
Data reduction and display aids also improved visualization of
between group differences and generally different tools are used
in combination to achieve this aim. A useful tool is hierarchical
clustering cytometry data indicating by color differences [1931];
Fig. 218 and/or color intensity differences [1933] highly discrim-
inative parameters. These can then be further visualized using
SPADE or tSNE display. There are several new tools such as Pheno-
graph, FlowSOM and others for patient or experiment group dis-
crimination that are explained in detail elsewhere (Chapter VII,
Section 1).
Finally, irrespective of which dimensionality approaches are
used, it is essential that all preprocessing information is provided
(pregating procedures, data normalization; see Chapter VII, Sec-
tion 1.2) either with the graphs or as supplementary material.
Also, authors should provide information of the calculation of the
SPADE. tSNE, etc. graphs (e.g., n iterations, perplexity, n nodes,
Fig. 218, Fig. 219). Also software tools used have to be named
and in case of own development also made available for the read-
ership.
Next to the appropriate illustration of flow cytometry data it
is crucial that the essential details of flow experiments are dis-
played in order to allow others to accurately reproduce the exper-
iments. Lack of reproducibility is of great concern in biomedical
research and rough estimates say that up to 50% of the results
published are not reproducible, meaning billions or trillions US$
of funding money lost [1935]. To reduce this problem, the MIBBI
(Minimum Information for Biological and Biomedical Investiga-
tions) project was launched in 2008 [1936]. Its goal is to pro-
vide comprehensive checklists for different types of experiments
so that all essential information for repeating the experiment is
provided. Relevant for flow cytometry is MIFlowCyt (Minimum
Information about a Flow Cytometry Experiment) [39]. These
standards were defined by an international group of cytometry
experts from bioinformatics, computational statistics, software
development, and instrument manufacturers, from clinical and
basic research. With this information, cross-experiment compar-
isons are possible. Several scientific journals, first of all Cytom-
etry Part A, have adopted these regulations, but also journals
from the Nature Publishing Group have accepted these standards.
MIFlowCyt-compliant manuscripts should have a checklist table
containing information on reagents, instrumentation, and experi-
mental setup, including information on controls, gating strategies,
among others (for details see ref. [39], Table 92). Importantly, it
is required that original primary list-mode data are made publicly
available in an open access data base such as the FlowReposi-
tory (See Chapter VII Section 4 Data repositories: Sharing your
data). This allows others to analyze published data by alterna-
tive methods and better understand the published material. In
the following manuscripts, you can find examples for MIFlow-
Cyt checklists with different MIFlowCyt score values and original
FCS data in the FlowRepository for Flow [1937, 1938] and mass
cytometry [1939]. Since October 2018MIFlowCyt compliance and
reposition of original data are mandatory for Cytometry Part A
publications [1940].
Although several MIFlowCyt-compliant manuscripts for flow
data have been published in Cytometry Part A, comparable guide-
lines for image cytometry (e.g. MIImaCyt) have not been adapted
so far [1941, 1942]. In order to improve the quality of polychro-
matic flow cytometry, a special publication type for multicolor
flow cytometry protocols, Optimized Multicolor Immunofluores-
cence Panels (OMIP), was developed in Cytometry Part A [1943].
The central issue in multicolor flow cytometry is to demonstrate
that the developed multiplexed panel has been optimized by test-
ing different reagents and reagent combinations. Until now, over
50 different OMIPs have been published with the aims of (1)
reducing the time to develop similar panels and (2) providing
a starting point for the development of new panels, or (3) for
optimizing existing ones. OMIPs present unique reagent combina-
tions, document the developing progress, explain the final choice
Table 92. Important provided data for cytometric publications. (*part of MiFlowCyt)
Data set Details
Sample/specimen Type*, source*, source treatment*, taxonomy, age*, gender*, phenotype*, genotype*, location*
Sample treatment Analytes*, Ab clone*, names/numbers*, manufacturer*, catalogue numbers*
Reagents Concentration, purity
Controls Quality Control Measures*, FMOs*, Positive/negative control*
Instrument Manufacturer*, model*, configuration*, settings*, detector voltages*, optical filters*
Data analysis List-mode data file*, compensation*, gating*, flow repository data access code*
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and should be useful to a wide range of readers. OMIPs are by
nature MIFlowCyt compliant.
To avoid biases by manual analysis of high complex flow,
data software tools are available that work partly operator inde-
pendent. This stresses also the importance of the reproducibil-
ity in complex, (semi)-automated data analysis [1944]. O’Neill
and Brinkman have suggested that certain data besides compen-
sation, gating details and mathematical algorithms, should be
shared for reproducible FCM bioinformatics [1945]. One major
aim is to make FCM data easily accessible to the users by open-
access databases for flow data (e.g., FlowRepository), as well as
the code sources. A series of data sets have already been pro-
vided by the FlowCAP (Critical Assessment of Population Identifi-
cation Methods) project, comparing different mathematical mod-
els and automated methods for analysis. The cytometry commu-
nity has already made great steps toward reproducible research by
standardizing instrumentation, measurement, and data analysis,
but still looks forward to optimize the reproducibility in different
cytometry fields.
3.4 Advantages
The major advantage of the MIFlowCyt concept is that each reader
of MIFlowCyt-compliant manuscripts can access all necessary data
so that experiments can be reproduced step by step as easily as
cooking recipes, because the focus is on the transparency of scien-
tific data.
Advanced data analysis tools offer the advantage of objective
data evaluation that works completely user-independently. To be
able to reproduce these analyzes, essential data such as the seeding
cell must be provided.
3.5 Pitfalls
In order to be able to evaluate data by means of automated meth-
ods, it is necessary to pre-purify the data beforehand; this includes,
for example, normalization or downsampling of data. On the one
hand, these processes are time consuming and on the other hand,
they can also be sources of error (data loss, data distortion), since
a minimum of expert knowledge is necessary for the correct exe-
cution. The output of the visualized data subsequently requires a
high manual effort to e.g. identify the populations. If high data
sets are to be evaluated, the user is often limited to the computing
power of the used device. And since not every user has a super-
computer with high computing power available, long times for
the calculation can be expected or even multiple crashes of the
software might be obtained before the optimal result is achieved.
Since automated data visualization methods (SPADE, SNE, etc.)
are stochastics, small changes in the initial algorithm setting will
results in (sometimes totally) different maps or trees. For repro-
ducibility, it is therefore important to document the exact setup of
the algorithm (example see Fig. 219A).
Also, it is not always easy to meet the MIFlowCyt require-
ments. For example, the provision of original data is required.
This can sometimes face a privacy problem. First, it is necessary to
anonymize patient data, which in turn may require the presence
of special software tools, which are however in the most cases
open access. Sometimes the studies may be designed in such a
way that it is not allowed to share data with third parties or to
make it publicly available, so that the MIFlowCyt/Flowrepository
requirements cannot be sufficiently met in all cases of manuscript
submission.
4 Data repositories: Sharing your data
Scientific research is more data intensive and collaborative than
ever before. Transparency and public availability of well anno-
tated data is crucial for independent validation, verification, and
extending research from prior results [1946]. The availability of
primary data is therefore increasingly required by national poli-
cies, international regulatory bodies, scientific journals as well as
research funding agencies [1947–1951].
In both, fluorescence-based andmass-based FCM, primary data
is generally represented by FCS files that contain a matrix (table)
of expression values of all measured “channels” (characteristics)
of all particles (cells) analyzed by the instrument. These files
should be properly annotated as per applicable domain-specific
guidelines. In FCM, such guidelines are represented by the Mini-
mum Information about a Flow Cytometry Experiment (MIFlow-
Cyt) [39]. The MIFlowCyt standard includes recommendations
about descriptions of the specimens and reagents included in
the FCM experiment, the configuration of the instrument used
to perform the assays, and the data processing approaches used
to interpret the primary output data. In additional, the bioshar-
ing.org portal (Minimum Information for Biological and Biomedi-
cal Investigations (MIBBI) project) [1936] should be checked for
extra requirements that may be applicable. MIBBI is a common
portal to a group of nearly 40 checklists of Minimum Information
for various biological disciplines.
Depositing data in a public repository is generally the recom-
mended, and increasingly the required way of sharing FCM data.
Below,we introduce four public repositories suitable for FCMdata:
Cytobank [1826, 1851] (http://www.cytobank.org/), FlowRepos-
itory [1941, 1952] (https://flowrepository.org/), ImmPort
[1953, 1954] (https://immport.niaid.nih.gov), and ImmuneS-
pace [1955] (https://www.immunespace.org/). An overviewwith
technical notes and highlighted features is provided in Table 93.
Cytobank is an online data analysis and management platform
developed and hosted by Cytobank Incorporated. A community
(basic) version of Cytobank provides free functionality including
web access, data storage, experiment sharing, and basic online
analysis. The Community version of Cytobank contains close to
300 public experiments (data sets). In addition, Cytobank offers
paid Premium and Enterprise versions with advanced data analysis
options (including SPADE [1804], t-SNE [144, 1824], and Flow-
SOM [1932]), better customer support, and dedicated computing
resources. If your lab is using Cytobank already, then choosing its
Community version presents a straightforward option of sharing
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Table 93. Public repository sites: technical notes and highlighted features
Name URLs and references Technical notes and highlighted features
Cytobank  http://www.cytobank.org/
 PMID: 24590675
 PMID: 20578106
 Free community version, requires registration
 Web access
 Advanced online data analysis options in paid versions
FlowRepository  https://flowrepository.org/
 PMID: 22887982
 PMID: 22752950
 Free and open source, no registration required to download
data
 Web access, R library, FlowJo plugin
 Full MIFlowCyt support
 Basic online data analysis options
 Integrated FCS de-identification (optional)
 Recommended by Nature, Cytometry Part A and PLOS journals
ImmPort  https://immport.niaid.nih.gov/
 PMID: 24791905
 Free, requires registration and approval
 Web access
 Data from dozens of assay types including cytometry
 Online data analysis tools
 Templates for data deposition, management and
dissemination
 Used mainly for NIAID/DAIT funded studies
ImmuneSpace  https://www.immunespace.org/
 PMID: 24441472
 Free, requires registration
 Web access, R library
 Database and analysis engine that leverages ImmPort
infrastructure
 Exploring, integration and analyses of data across assays
 Ontology support through standards-aware data templates
 Used mainly for HIPC data
your data publicly. In addition, all versions of Cytobank give you
the option of sharing data privately with your collaborators. A
potential drawback of Cytobank is that public datasets can be set
back to private—and thus “disappear.”
FlowRepository is a public repository allowing researchers to
deposit, annotate, analyze, share, and publish FCM data, mainly
those associated with peer-reviewed manuscripts. The reposi-
tory is provided free of charge by the International Society for
Advancement of Cytometry. While FlowRepository was developed
by extending Cytobank’s code base, the two platforms drifted
apart significantly over the past 8 years. However, there are still
some common aspects allowing users of one system to adapt to
the other easily. While Cytobank’s platform offers more advanced
data analysis options, FlowRepository focuses on data sharing and
annotations, including a full support of MIFlowCyt. In addition,
FlowRepository works closely with several scientific journals and
allows for linking data with related publications. Unlike with most
other repositories, users do not need to register in order to down-
load public data from FlowRepository. They can do so anony-
mously by using a web-based interface, or from within the R sta-
tistical language using the FlowRepositoryR BioConductor library,
or from within FlowJo using the FlowRepositoryServer plugin. At
this point, FlowRepository contains over 1500 data sets from 1700
scientists and links to papers in 40 different journals. Half of the
data sets are currently public and most of the remaining data are
related to ongoing studies where underlying data will be released
along with publication of the study results. Depositing data to
FlowRepository is recommended by Nature, Cytometry Part A, and
PLoS journals.
The Immunology Database and Analysis Portal (ImmPort) sys-
tem provides an archive of immunology research data generated
by investigators mainly funded through the National Institutes
of Health (NIH), National Institute of Allergy and Infectious Dis-
eases (NIAID), and Division of Allergy, Immunology, and Trans-
plantation (DAIT). It is an extensive data warehouse containing
an integration of experimental and clinical trial data generated
by dozens of assay types, including 131 FCM and 24 CyTOF data
sets. In addition, the ImmPort system also provides data analysis
tools and it contains implicit knowledge and ‘‘best practices’’ for
clinical and genomic studies in the form of50 templates for data
deposition, management, and dissemination. ImmPort has been
developed under the Bioinformatics Integration Support Contract
(BISC) by the Northrop Grumman Information Technology Health
Solutions team for the NIH NIAID/DAIT. If your research funding
comes from this source and you are generating immunology data,
you should deposit it in ImmPort. Immport’s support for different
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data types can be another reason to choose it if you are gener-
ating FCM data as well as data from different types of assays. A
(free) registration and approval by DAIT is required in order to
deposit and access data from ImmPort. A potential drawback of
using this resource is that there can be a long delay in publication
of deposited datasets.
ImmuneSpace is a database and analysis engine built by cus-
tomizing the LabKey server for the Human Immunology Project
Consortium (HIPC). ImmuneSpace can be used to find and explore
studies, integrate, and analyze data across assays, and perform
custom analysis directly from within R. ImmmuneSpace takes
advantage of the infrastructure already developed for ImmPort,
and in many cases, ImmuneSpace provides a new interface and
new complimentary tools to data that are also available in Imm-
Port. Currently, ImmuneSpace can be used to access several large
HIPC studies with FCM and CYTOF data. The typical data submis-
sion work flow consists of data submission to ImmPort using a set
of standardized data templates. If you are a HIPC participant, then
your data should be deposited to ImmuneSpace; otherwise, you
can still use ImmuneSpace as a valuable resource of HIPC data
and analysis tools.
If you are in a clinical setting, there is one important thing to
consider before you start sharing your FCM data by depositing
it in any of the repositories. Besides the expression matrix, FCS
data files contain a segment with keyword/value pairs. Most of the
keyword values keep basic information essential for the interpreta-
tion of the raw data matrix and acquisition settings related values.
These include the number of acquired parameters, their names,
acquisition voltage settings, the total number of events (parti-
cles), and many other keywords as specified in the FCS data file
standard. In clinical settings, some of the keywords may include
information that could be used to identify the subject that was the
source to generate the data in the file. Such information has to
be removed prior to sharing the data file in order to comply with
patient privacy requirements as specified by the Health Insurance
Portability and Accountability Act (HIPAA) [1956] in the United
States and similar rules enforced by regulatory agencies in most
other countries. Patient data must be properly protected and can-
not be publicly shared; however, those rules generally do not apply
as long as the data is properly de-identified. De-identification is the
process of removing identifiers that could be used to identify an
individual. Identifiers include items such as patient name, social
security number, other public ID numbers, date of birth, and so
on as specified by HIPAA and other applicable regulations. There
are several standalone tools available for the de-identification of
FCS files as listed, for example, in the FlowRepository Quick Start
Guide (http://flowrepository.org/quick_start_guide).
There is widespread agreement in the biomedical research
community that data sharing is a primary ingredient for ensur-
ing that science is more transparent and reproducible [1957].
While FCM has lagged behind other technologies in this area, the
recent availability of public repositories provides the means to sat-
isfy this necessary component for data sharing and its long-term
stewardship.
VIII Advanced techniques in, and
management of, flow cytometry
1 Imaging flow cytometry
1.1 Overview
Imaging FCM (IFC) adds to the power of conventional FCM by also
providing spatial and morphological information within the cell.
IFC combines the statistical power and phenotyping capabilities of
FCM with the image analysis of microscopy. The following section
is an overview to the principles of the technology, thewide range of
areas of research where it is utilized, detail into the experimental
workflow and analysis, and finally any pitfalls to look out for
and tips that may assist researchers based on experience with the
platforms.
1.2 Introduction
IFC was first introduced in the late 1970’s with a slit-scan cytome-
ter [1958] and since then improvements to the original concept
came slowly until the development of the ImageStream (Amnis
Corp; now part of Luminex Corp) [1959]. Imaging cytometry also
includes technologies such as laser scanning cytometry and high-
throughput microscopy where cells are interrogated in situ on a
slide [1960]. This is useful in circumstances where placing cells in
laminar flow would disrupt their phenotype or where spatial con-
text within tissue is important. The slit-scan cytometry technology
has also been developed into a microfluidic imaging assay [1961]
and, most recently, into a microfluidic chip capable of sorting
cells [1962]. This section will focus on the ImageStream IFC.
1.3 Principles of IFC
In IFC, the cells enter the flow cell in much the same way as
conventional FCM, where they are placed in a hydrodynamically
focused flow cell. Cells are then illuminated by both LEDs, for
bright-field images, and lasers, for fluorescent images, and this
light is collected by the objective lens. The light then intersects
with a spectral decomposition element, a stack of angled wide BP
filters that separate the light based on wavelength into six individ-
ual channels (Fig. 220). On the ImageStream Mk-II, these filters
are 457/45, 528/65, 577/35, 610/30, 702/85, and 762/35. The
major difference in IFC is the use of charge-coupled device (CCD)
detectors instead of PMTs. The six separated images are collected
using time delay integration (TDI) technology. The CCD converts
photons from images into photocharges on a pixel array contain-
ing 256 rows. With TDI, as the cell moves through the flow cell
the information collected from the pixels from the first row are
integrated into subsequent rows until the light leaves the detec-
tor. The collective images’ pixel content is then formed from the
pixels on the last row. For this technology to be successful, the
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Figure 220. The optical layout of the
ImageStreamX Mk-II one camera, six channel
(A), and two camera, 12 channel (B) sys-
tems. Figure modified with permission from
ref. [1959] and reproduced with permission
from Luminex.
CCD camera must maintain synchrony with the flow cell speed.
This is achieved by tracking the speed of 1 µ polystyrene beads
(speedbeads) that continually run through the flow cell during
operation. An advantage of using CCD detection with TDI is that
cells can be running through the flow cell at high speed and will
still produce a focused image thus allowing for image analysis of
large numbers of cells per sample. In order to achieve 12 channels
fromwhich to image, the ImageStreamMk-II can be equippedwith
two CCD cameras (Fig. 220) and two spectral decomposition ele-
ments to which different lasers are directed toward, e.g., the 375,
488, and 561 nm lasers would be directed toward camera 1, while
405, 592, 642, and 730 nm lasers would be directed toward the
second camera. The cameras capture sequential images from the
cells allowing for fluorochromes emitting at the same wavelength
but excited by different lasers to be interrogated sequentially. A
bright-field image is taken on both cameras so that images can
be accurately spatially correlated in analysis. To eliminate scatter
from each of the lasers, narrow BP notch filters are placed in front
of the cameras.
1.4 Applications
The applications of IFC are wide and varied. Not intended to be an
exhaustive list, this section describes some of the most common
applications to date. It is useful to remember that any research
question that would be answered by microscopy or FCM could
potentially be answered by IFC. The IDEAS software used to ana-
lyze ImageStream data contains a large number of possible image
analysis parameter or “features” that may be applied based on the
question.
IFC is particularly useful in cell signaling. Expression of pro-
teins, such as transcription factors, that are part of signaling cas-
cades are typically unchanged during activation. Instead, activa-
tion is determined by relocation of the transcription factor into
the nucleus to initiate transcription of downstream targets. Stain-
ing the transcription factor of interest alongside the nucleus can
determine activation based on “Similarity” of the two images.
This information alongside the ability to simultaneously pheno-
type cells enables detection of heterogeneity of activation in sub-
populations. Examples of cell signaling pathways studied in this
way include NF-κB, NFAT, JNK, IRF, and STAT [1963–1969].
Phagocytosis has been extensively studied using this tech-
nology with phagocytes or macrophages stained for a particu-
lar marker, and the cell to be taken up stained with another
[1970, 1971]. The level of “Internalization” can then be quan-
tified. As the name suggests, internalization is performed by mea-
suring the uptake of a protein/cell or other material into a specific
cell. More recently, this feature has been utilized to determine
exosome uptake into a cell [1972, 1973].
In addition to internalization, the protein/marker of interest
can also be tracked to where in the cell it traffics to or whether
it interacts with a specific marker in the cell. For example, dyes
can be used to stain mitochondria, endosomes, and/or lysosomes
and their ‘Co-localization’ with certain markers can be assessed.
Co-localization uses a feature known as Bright Detail Similarity.
This takes the brightest pixels (with a choice of radius of 3 or 7
pixels) of both markers and determines their similarity in spatial
distribution, if they overlap, the value will be higher indicating
co-localization [1974].
Since a bright-field image is collected by the ImageStream,
changes in morphology can be studied. Chemotaxis is a good
example when change in cell shape can be measured using its
“Circularity.” A normal monocyte would be circular, whereas one
undergoing chemotaxis would have an irregular shape. The bright-
field is also a useful parameter in the measurement of apoptosis.
Those cells undergoing apoptosis will have a relatively higher con-
trast in their bright-field images than healthy cells. This can be
combined with a DNA stain such as PI, DRAQ5, or DAPI where the
area of the nucleus can also be measured, showing cells undergo-
ing apoptosis with a lower nuclear area. Stains such as for caspases
or Annexin-V can also be added to obtain information regarding
the specific stage of the apoptotic process [1975, 1976].
Antigen presentation is central to the immune response and
this event can be quantified using IFC. The antigen presenting
cells and T cells are stained alongside actin. Those doublets
that contain one of each cell and have a high actin expression
concentrated at the “Interface” between the two are involved in
the immune synapse [1977, 1978].
IFC can also be used to characterize cytotoxic immune synapses
for multiparametric analysis of molecular mechanism involved in
the cytotoxicity of human CD8 T-cells [668].
The extended depth of field (EDF) component of the
ImageStream, where the focal plane can be expanded to 16
microns, makes analysis of small areas of fluorescence within
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the cell possible. Fluorescent in site hybridization has been
successfully adapted to cells in suspension, and recently with phe-
notyping, thus allowing measurement of numerical chromosomal
aberrations in large number of cells, increasing the sensitivity of
the assay [928, 1979].
A major advantage of IFC is the high volume of information
available from the data acquired. Recently, researchers have begun
to expand how this may be analyzed. An open source machine
learning model has been developed (Cell Profiler Analyst), which
can process hundreds of different features and morphological
information in the thousands of data rich images [1980].
1.5 Equipment
The original ImageStream platform beganwith the IS-100 in 2004,
followed by the ImageStreamX and most recently the third genera-
tion instrument; the ImageStreamX Mk-II. The ImageStreamX Mk-
II can be configured for up to seven lasers (the standard 488, 375,
405, 561, 592, 642, and 730 nm) as well as the dedicated 785 nm
laser for darkfield (side) scatter, and a dedicated 830 nm laser
for autofocus. Most common configurations contain four or five
of the seven lasers offered. There are 12 channels with up to ten
fluorescent channels available. The Mk-II has a 40× magnification
that has resolution of 0.5 µ/pixel. With the optional 60× magni-
fication, this resolution increases to 0.3 µ/pixel making the Mk-II
a potentially useful instrument in the emerging field of microvesi-
cle research [1972, 1973]. The 60× magnification combined with
the EDF function is useful when measuring small organelles such
as mitochrondria, or small chromosomal spots by fluorescent in
site hybridization -IS [928, 1979]. EDF extends the focal depth
from 4 to 16 µ to allow for the entire cell (in most circumstances)
or nucleus to be in focus [1981]. The EDF image is automati-
cally deconvoluted in the analysis software resulting in a focused
image. The Mk-II may also have the 20× magnification for larger
cells/aggregates. The FlowSight (Amnis) is a more compact IFC
with a 20× magnification only, with a resolution of 1 µ/pixel. It
also has 12 channels but with a maximum of four lasers (the stan-
dard 488, 405, 561, and 642 nm). The lower resolution indicates
that it is limited in its image analysis when compared to the Mk-II.
A third cytometer from Amnis, part of Luminex Corp. is the Cell-
Stream. While not strictly an imaging flow cytometer since images
cannot be saved, this instrument can save morphology data from
the brightfield image during acquisition. The remaining sections
will apply to the two camera Mk-II unless otherwise specified.
1.6 Experimental workflow and acquisition
For the daily start up, the ImageStream has a fluidics initialization
routine and a quality control software suite (ASSIST) that checks
that the instrument performance is within the factory-set margins.
Any test that falls outside of these margins will be flagged and may
require adjustments. Depending on the comfort level of the user,
these adjustments can be made by the operator themselves or may
require intervention by the manufacturer. For the latter, in many
cases, troubleshooting and making adjustments can be performed
remotely by establishing an internet screen sharing connection.
For the daily shutdown, the ImageStream has an instrument
shutdown routine that soaks the fluidics with bleach and rinses
it with water. The shutdown procedure ends by turning the elec-
tronics of the ImageStream off and optionally, the instrument can
be instructed to shut down the computer workstation as well.
Both the startup and shutdown procedures, once initiated, pro-
ceed automatically without the need of operator interaction.
The same rules for panel design that are applicable to conven-
tional FCM apply to ImageStream cytometry. The proper balance
between epitope density and fluorochrome intensity needs to be
observed. The use of too many tandem conjugate dyes simulta-
neously should be avoided to reduce cross-excitation problems
by multiple lasers. Single color controls need to be prepared for
multicolor panels. Note that the volume of sample loaded can
be as low as 20 up to 200 µL. Rule of thumb is to prepare the
same cell number as would be prepared for conventional FCM;
commonly between 0.5 and 1 x 106 cells per sample if possible.
Since the standard sample acquisition rate is 1.2 µL/min, which
is 20 nL/s, a concentration of 106 cells/mL would therefore only
yield 20 total events/s. Therefore, following the staining proce-
dure samples should be resuspended in 50 µL instead of 500 µL as
is common in conventional FCM to achieve amuch higher cell den-
sity; the higher the cell density, the faster the event rate. However,
be careful not to exceed a cell density above 30 × 106 cells/mL
since this may lead to cavitation/bubble formation and loss of
laminar flow (see Pitfalls section). When a sample is loaded, the
INSPIRE acquisition software displays a volume gauge that shows
how much acquisition time is left.
The single color controls are acquiredwith the bright-field LEDs
and scatter laser off but with the full complement of lasers that
are used for the experimental samples on and set at the laser out-
puts that will be used for the experimental samples. The number
of events needed to be acquired for single color controls is low,
commonly between 500 and 1000 positive events.
When desired, compensation can be applied during acquisition
but this would only be necessary, for example, if acquisition gates
are used based on a fluorescence intensity signal that may suffer
highly from spectral overlap from a neighboring fluorochrome.
For most applications, post-acquisition compensation is recom-
mended.
During acquisition, acquisition gates can be set with the options
to collect the desired number of events to include only events
within the gate or include all events with the acquisition time
determined by the number of events defined within the set acqui-
sition gate. When setting the laser intensities saturation of the
intensity signal should be avoided. This can be monitored with
the “raw max pixel” parameter, which reaches saturation above
the value of 4096.
If the detection channels of the designed panel are spread over
both cameras (camera 1: channels 1–6 and camera 2: channels
7–12), and spatial correlative analysis is desired, the acquisition
of two bright-fields (one in each camera) is required. The two
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bright-field images are used by the software to spatially align the
acquired images by each camera. The bright-field pairs can be
selected not to interfere with the optimal detection wavelengths
of the fluorochromes in the panel.
If SSC measurements are desired, the ImageStream uses a ded-
icated 785 nm laser for SSC. The SSC signal can be collected either
in channel 6 (camera 1) or camera 12 (camera 2), the preferred
choice of which is dependent on the fluorochromes used in the
panel.
1.7 Data analysis
The acquisition of data with the ImageStream platform produces
proprietary raw image files with a .rif extension. The data analy-
sis is performed with the IDEAS software package. For multicolor
experiments, a compensation matrix (.ctm file) is first calculated
using appropriately acquired single color controls [1982]. IDEAS
can then open a .rif file with a corresponding .ctm to produce a
compensated image file (.cif) and a data analysis file (.daf). The
IDEAS software has a separate work space area for the image
gallery and one for data analysis in which single and dual param-
eter plots can be created using default or custom-made features
and regions can be drawn on and applied to plots for which statis-
tical information can be derived. The image gallery and the data
analysis workspaces are interactively correlated in that images of
interest can be clicked and their position in the data analysis plots
be identified by a cursor and vice versa, that the image galley can
display individual events or regional events of interest identified
from the data analysis plots.
The most challenging part of introducing imaging FCM data
analysis to someone who is familiar with conventional FCM is the
concept of “masks”—defining the region of interest of an image
(e.g., the nucleus, the cytoplasm, the immunological synapse
region)—and “features”—what parameter is measured in that
mask (e.g., intensity, co-localization, area). Although the soft-
ware calculates numerous features related to size, location, shape,
texture, and signal strength by default, these features are calcu-
lated for the default masks only. Commonly, a custom feature
would be created depending on the specific experimental setup
and analysis question. The software also by default will create
several default masks (regions of interest), which in turn can
be modified to suit the specific experimental setup and analy-
sis question. The software has a guided analysis function (wizard)
in which the user is guided through the sequential data analysis
steps of creating masks and features for many of the most com-
monly used applications such as nuclear translocation, internal-
ization, co-localization, immune synapse formation, and so on. A
data analysis commonly follows a hierarchical gating strategy that
starts with the identification of single cells that are in focus from
which then various subpopulation can be derived and features can
be calculated. Once the analysis strategy has been completed, this
can be saved as an analysis template (.ist file) that can be applied
to subsequent data files through batch processing.
Following data analysis, images can be exported as .TIFF files
and data files of the parameters of interest as .fcs files, which
then can be read in any FCM analysis software package. Of note,
FCSExpress has the ability to directly read .daf files for use in
its analysis package. It is important to be aware that any image
analysis such as designing masks and features will still have to be
done in the IDEAS software package before exporting as .fcs files
or reading in the .daf files in FCSExpress.
1.8 Advantages
The obvious major advantage of imaging FCM is the added spatial
information that is provided with the intensity parameters. That
spatial information enables the study of co-localization, cellular
redistribution, cell morphology beyond what is possible based in
FSC and SSC only (e.g., shape), and verification that obtained
signals are not artificial (e.g., a nuclear parameter should not be
detected in the cytoplasm or cell membrane). Even with the study
of events that are not dependent on spatial parameters, such as the
study of exosomes, the inherent differences between sensitivity of
the CCD cameras with detectors used in conventional FCM (PMTs)
are advantageous.
1.9 Pitfalls
Not all panel designs that work well for FCMwill work for imaging
FCM (See Fig. 221). Among themain reasons for this are the vastly
larger bandwidths for the collection filters used making spectral
overlap correction more challenging; the use of so-called notch
filters to block the scatter of the excitation lasers from reaching
the detector that will also block the corresponding emission wave-
lengths of any fluorochrome; the fact that instead of the sensitivity
of the detector, the output of the excitation laser is adjustable thus
any intensity adjustment will affect all fluorochromes excited by
the same laser; the colinear arrangement of the lasers that are
directed to the same camera that prevents the application of laser-
delays to discriminate between excitation sources.
Air bubbles should be eliminated from sample before loading.
Bubbles can create a break in the sample volume loaded in the flu-
idics that the equipment will sense as a small volume (the volume
detected is the first contiguous volume until a bubble is detected).
The acquisition is limited by the sample acquisition rate that in
turn is dependent on the cell density of the sample. As a general
rule of thumb, do not exceed a cell density of 30 × 106 cells/mL
since too high of a cell concentration (dependent on size and stick-
iness of cells) will lead to cavitation/bubble formation and loss of
laminar flow, leading to reduced sample recovery. Depending on
the desired number of events to be acquired, long acquisition times
may be necessary that requires one to take into consideration how
long acquisition times at room temperature may affect the biolog-
ical sample analyzed since no temperature control is applied once
sample is taken up into injection syringe.
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Figure 221. Excitation (broken lines) and emission spectra (solid lines) of APC and PerCP-Cy5.5 and BP emission filters used on the ImagestreamX
MkII demonstrate that APC is suboptimally detected and therefore may appear less bright in a panel compared to the same panel acquired on a
conventional flow cytometer that would typically be configuredwith a 660/20 BP. The problem is that by attempting tomake the APC signal brighter
by increasing the 642 laser output the cross-excitation of PerCP-Cy5.5 by the 642 laser is also increased making the compensation challenging. In
this case, the use of AlexaFluor 647 instead of APC would be a suitable alternative.
1.10 Top tricks
 Data file sizes (and subsequent computer processing time) can
be reduced by acquiring only images for the acquisition chan-
nels of interest to the experiment. Each omission of a chan-
nel will reduce the file size by 10%. For example, a three-
color experiment only requires the three fluorescence channels
of interest, the scatter channel if desired, and two bright-field
channels.
 When large numbers of cells are required for analysis, it is more
efficient to acquire and analyze ten 10 000 event files than one
100 000 event file since for analysis all the information of the
events within one file are stored in memory. Once the analysis
is finished, the files can be merged into one if desired.
 When analysis of co-localization is required (for example, by
calculating a similarity score), it is advisable to choose the
fluorescent markers associated with the analysis to be on the
acquisition channels within the same camera (within channels
1–6 or 7–12) for the most accurate assessment. For any other
multicolor experiment, spread out the choice of fluorochromes
evenly between the two camera systems.
 When studying signal transduction events (e.g., nuclear translo-
cation of transcription factors), it is important to be aware that
cell enrichment procedures that are very common to flow cyto-
metric immunophenotyping (e.g., Ficoll density gradient sep-
aration or RBC lysis) can affect the activity of the signaling
pathway especially those involved with stress response such as
NF-κB.
 Displaying a graph of the raw max pixel intensity during the
setup is helpful to determine that the laser powers are not set
too high to a level where pixel saturation will occur (>4096).
 For accurate measurement of punctate images (e.g., spot count-
ing), the optional EDF optics are necessary.
 The system should be flushed with 10% bleach after the use of
dyes that stick to the fluidics tubing such as DAPI and PI. This
is especially important when collecting the single color controls
required to construct the compensation matrix.
 The algorithm used to calculate the compensation matrix for
multicolor experiments requires information on all available
channels. When the number of acquisition channels has been
reduced during acquisition make sure that when acquiring the
single color controls that all channels are being collected.
 For day-to-day consistency between ImageStream measure-
ments, a standardized fluorescence intensity bead set should
be acquired and laser settings adjusted so that the intensities
are consistent between runs.
 In the experimental setup, include biological positive and nega-
tive controls, not just single-color and FMO compensation con-
trols. This would be stimulated or unstimulated cells, i.e., in
which you see populations positive or negative for the feature
of interest (nuclear translocation, internalization, colocaliza-
tion, immune synapse formation, etc.).
2 Barcoding in cytometric assays
2.1 Overview
Sample barcoding denotes a procedure in which distinct cell sam-
ples are stained with unique labels, pooled, and then further pro-
cessed and acquired as a mixture of samples, often referred to
as a “sample convolute.” After acquisition of the convolute, data
of the original samples are recovered by resolving the label sig-
nature used for sample tagging (Fig. 222). Barcoding allows for
multiplexed analyses in FCM and mass cytometry. Importantly,
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Figure 222. Workflow of cell sample barcoding for FCM and mass cytometry. (A) Schematic overview of sample barcoding. Individual reagents
and reagent combinations are indicated by different color; schematic 2D plots are shown in the same corresponding colors. Individual sample
properties are illustrated by staining patterns, the sample 2 plot depicting a pattern clearly deviating from the others. (B) Example of fluorescent
sample barcoding for a Phospho-Flow experiment. PBMCwere stimulated in vitro with eight different stimuli or controls, fixed with formaldehyde,
and permeabilized with ice-cold methanol. Cells from each condition were barcoded using different concentrations and combinations of Alexa
Fluor 750 and/or PacificOrange succinimidyl esters (eBioscience). Following the barcoding reaction, single samples were washed, pooled, and
further stained for major lymphocyte lineage antigens and phosphorylated STAT3 in the pooled sample. After selecting CD33+ monocytes by
gating, the barcode was deconvoluted by gating in the two barcode dimensions. The left plot depicts the barcode labeling of all cells in that pool.
Eightmajor populations corresponding to different stimulation conditions can be discriminated (indicated by gating). Cells of a given single sample
group together as a “population” with homogeneous Alexa Fluor 750 and PacificOrange labeling, respectively. Annotations indicate stimulation
conditions applied prior to barcoding, as well as the frequencies of gated populations. The similarity of these frequency values confirms that the
pool contains similar amounts of cells from each barcoded condition. On the right side, the histogram overlay representation depicts pSTAT1
expression in the different stimulation conditions. pSTAT1 signal was induced in B cells treated with IFN-α and IFN- γ, but not or only minimally
in the other conditions, which are visually indifferent in pSTAT1 signal from the “unstimulated” control. Data were generated by Patty Lovelace,
HIMC, Stanford.
this contributes to harmonization of assay conditions, and reduc-
tions in the amount of wet work, technical errors resulting from
pipetting and staining variability, and reagent consumption, as
compared to preparing and acquiring multiple single samples. For
example, minimizing the number of total pipetting steps means
an overall reduction of pipetting error along the entire sample
preparation, and since all individual samples are stained, washed,
and optionally fixed and permeabilized in the very same sample
tube, no sample-specific artifacts can arise from these procedures.
This results in increased data consistency and robustness. After
samples have been pooled, the assay is performed in a single
vial, which reduces the complexity of sample preparation work
and allows for sample acquisition with only a minimal need for
manual interference. Compared to running multiple single sam-
ples, no instrument cleaning cycles are necessary when acquiring
one barcoded convolute, thereby reducing instrument run-time.
Similarly, barcoding practically excludes sample-to-sample carry-
over, which can occur during one-by-one sample acquisition by the
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cytometer. Barcoding of samples is particularly useful when high
data consistency is required, e.g., when shifts in median signal are
used as the assay readout, such as in the case of cell signaling
studies. The reduction of unwanted noise in cytometric data by
sample barcoding/pooling benefits the quality of results achieved
with algorithmic data analyses, which require a high degree of
technical data consistency [1794, 1983].
2.2 Introduction—Benefits and caveats of cell sample
barcoding
Cytometric sample barcoding was first developed as intracellular
barcoding for phospho-flow applications [1984]. Barcoding was
later similarly applied to mass cytometry [1985] with two bar-
code staining intensity levels (present/absent) for each channel
(see also Chapter VIII Section 3 Mass Cytometry). More recent
efforts moved barcoding to earlier steps in the sample preparation
protocol to extend the number of protocol steps that benefit from
sample barcoding. Behbehani et al. [1986] introduced intracel-
lular barcoding with only minimal permeabilization using 0.02%
saponin buffer. Mei and colleagues and Lai et al. [1987–1989]
used differently labeled CD45 Abs to achieve cell surface bar-
coding of PBMCs in mass cytometry. The concept has also been
transferred to FCM [1990] using Abs against murine CD4 and
B220.
While barcoding of samples has many benefits, it represents an
additional step in the protocol, needs to be optimized on its own,
and usually occupies cytometric channels that would be other-
wise available to the measurement of target analytes. Preparation
of larger barcoding reagent mixtures can be time consuming and
require a high degree of precision. For larger studies, and to avoid
errors and variability in barcoding from experiment to experi-
ment, one should consider automating the generation of barcode
reagent mixtures [1991], and/or to prepare them in batches that
can be stored frozen or lyophilized. A drawback of using sam-
ple barcoding is that any error associated with only one or a few
samples in the convolute will not be discovered until deconvolu-
tion, such as the lack of cells in a sample, unexpectedly low cell
number, high frequency of dead cells, excess presence of debris,
or contamination events such as erythrocytes in PBMCs. Addition-
ally, errors in barcoding can result in issues during deconvolu-
tion, which can lead to the loss of some or all data of the bar-
coded sample convolute. When using unrestricted combinatorial
barcoding schemes (Fig. 223), mishaps during barcode prepara-
tion result in miscoding of the sample(s), while with restricted
schemes, only the miscoded sample will be lost in most of the
cases.
2.3 Barcoding schemes
Principally, any number of samples can be processed as a bar-
coded sample convolute. The capacity of a barcoding scheme is
determined by the number of cytometric channels reserved for
barcode markers and the number of different signal intensity lev-
els per channel. The simplest approach is to label each sample
by one unique marker (Fig. 223A). By leveraging the capacity
of some barcoding reagents to stain at different signal intensities
when used at different dilutions in the assay [1984], more samples
can be barcoded using the same number of channels, multiplying
the capacity by the number of intensity levels used (Fig. 223B).
This strategy is frequently used in FCM, while barcode labeling for
mass cytometry assays typically makes use of two intensity levels
(stained and unstained) to achieve robust barcode labeling. This is
mainly due to the fact that (i) more channels are available in mass
cytometry, and that resolution-limiting, lower sensitivity channels
or reagents, e.g., in the palladium range are used for barcoding
to keep higher sensitivity ones for analytical readouts. In combi-
natorial barcoding, samples are labeled by unique combinations
of multiple markers rather than by a single marker (Fig. 223C).
In a scheme with two intensities per channel (i.e., “positive” and
“negative”), the capacity of such a scheme is 2n. However, using
the full combinatorial capacity entails certain limitations. Different
barcode labels often compete for identical binding sites, leading to
different barcode marker signal intensities. For example, a sample
marked by one label usually exhibits higher signal than another
sample where that label is one of four different labels. In addi-
tion, nonhomogeneous barcode labeling of a sample may limit or
even entirely preclude the retrieval of the original sample cells
from the barcoded convolute. Doublet events, containing differ-
ently barcoded cells (intersample doublets), can mimic cells of
a third sample that carries the marker combination of the other
two cells combined. This is especially relevant in mass cytometry,
which lacks the light scatter parameters available in FCM, which
are applicable for cell doublet removal. When occupying the full
capacity of a combinatorial barcoding scheme, such issues can
neither be reliably detected nor corrected. Mislabeled cells will be
lost for analysis, and will contaminate another barcoded sample
of the convolute.
As a consequence, a restricted combinatorial scheme has
been developed, in which only unique combinations, with equal
numbers of barcode labels per sample are used. This strategy
allows for the detection of samples erroneously labeled by more or
fewer of the fixed number of labels, thereby permitting exclusion
of wrongly labeled cells, as well as virtually all intersample
doublets [1988, 1992]. With identical numbers of barcoding
channels, the capacity of restricted schemes is significantly
lower, but this is justified by the removal of doublets, especially
in mass cytometry. Technically, intrasample doublets are not
removed by barcoding. However, with increasing numbers of
samples barcoded and pooled, the likelihood of cell doublets
being intersample (removed in restricted barcoding schemes)
increases relative to intrasample doublets, and leads to indirect
but significant reduction of intrasample doublets [1988]. The
sample accommodation capacity of restricted barcoding schemes
equals n!/(k!(n – k)!), with n being the number of barcode
channels and k being the number of labels per sample [1992].
Pascal’s triangle provides quick visual access to the sample capac-
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Figure 223. Barcoding schemes. (A–C) Schematic 2D dot plot representations of (A) three samples, each barcoded by presence or absence of one
of two barcode labeling reagents, (B) 13 samples barcoded by gradually increasing label signals (six levels each) in two channels, or by the absence
of a label, or (C) nine barcoded samples using a combinatorial barcoding scheme based on three intensity levels per channel. Circles/ellipses
indicate different barcode-labeled samples. Note that the samples characterized by the absence of barcode labels (lower left populations), tend
to accumulate insufficiently labeled cells of other samples and debris, and is therefore recommended not to be used for barcoding. (D) Pascal’s
triangle can be used as a tool for the construction of barcoding schemes. The line numbering indicates the number of barcode channels, and the
ordering of numbers in each line reflects the number of labels per sample, not counting the “1.” Different scenarios are indicated by the numbers
highlighted. Four samples labeled by onemarker each consumes four barcoding channels (red), dual barcodemarker labeling in six channels (blue)
can be used to barcode and pool 15 unique samples, and, in theory, 210 samples could be barcoded by quadruple combinations in ten cytometric
channels (green). Blue numbers denote sums of each line that equal the capacity of unrestricted combinatorial barcoding schemes consuming the
indicated number of barcoding channels.
ity of restricted and exhaustive combinatorial barcoding schemes
(Fig. 223D).
2.4 Establishing and validating barcoding schemes
The effort required to establish sample barcoding for FCM or
mass cytometry depends on the complexity of the desired scheme,
and includes its development and validation. Development steps
include the selection of the barcode scheme fitting the study’s
needs, the barcoding reagent type (depending on sample type,
aspired protocol coverage, and the available mass/flow cytometer
in combination with available dyes or mass-tags), the titration of
barcoding reagents and the optimization of labeling conditions,
which is especially key when more than two signal intensity levels
per cytometric channel are desired. Optimal reagent concentra-
tions and labeling conditions need to be experimentally deter-
mined, using the type and number of target cells the barcoding
is finally intended for. This is specifically important when using
intracellular, protein-reactive barcoding reagents, as these bind to
proteins in a stoichiometric fashion, under commonly nonsaturat-
ing conditions, so that fluctuations in cell numbers (or protein con-
tent and composition), buffer composition, incubation time, and
temperature can lead to differing barcode label staining intensi-
ties, which can complicate deconvolution of data. It is important to
use protein-free media for covalent barcode labeling to avoid reac-
tion of barcode reagents with buffer proteins instead of cellular
proteins. CD45 or other cell surface Ab-based barcoding operates
at ideally saturating conditions, which make the barcode stainings
more robust to small assay fluctuations, but leads to competition
between Ab conjugates for target epitopes in the case of combina-
torial barcoding, causing a decrease in barcode staining intensity
depending on how many different Ab conjugates are combined
on the same cell sample. It is therefore essential to incubate cells
with premixed cocktails of barcoding Abs rather than adding bar-
coding reagents one by one to the cell suspension. Finally, cell
washing conditions following the barcode labeling reaction prior
to sample pooling have to be established. Careful washing of cells
is required to minimize the carryover of barcode reagents into the
sample pool. Remaining reagents can cause unwanted low-level
labeling of all cells in the pool, which negatively impacts on cyto-
metric resolution of barcode signals, thereby complicating decon-
volution. More washing steps usually mean a better separation of
barcode/labeled cells from unlabeled background but also cause
greater cell loss due to removal of supernatant. In our hands, three
to five washing cycles are usually sufficient to achieve a clean bar-
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code staining pattern. As for covalent barcoding reagents, washing
buffer should contain protein such as BSA or FCS, which serves to
catch unbound barcode reagents. The barcoding reaction typically
lasts 10–15 min.
Experiments such as the checkerboard test or the retrieval
of sample-specific traits should be conducted, which address the
reproducibility of results achieved by measuring the samples sep-
arately (without barcoding) [1985, 1987, 1992, 1993] to estab-
lish and validate sample barcoding protocols. Analyses of unique
sample characteristics, such as the known lack of a certain cell
population within PBMCs in individual samples, which are either
run barcoded or separately must provide matching results. The
checkerboard test is an extension of the above strategy that takes
into account that many experiments involving sample barcoding
are prepared in microtiter plates. When plotting data (e.g., cell
frequencies or signal intensities) of samples with and without a
known characteristic that have been plated in different orders,
heatmap representations generate a characteristic checkerboard
or similar pattern. It should also be confirmed that barcoding does
not introduce systematic error, e.g., by interfering with the bind-
ing of specific probes post-barcoding, or due to spill-over between
barcode marker and analyte-specific signals.
Barcoded sample convolutes typically contain unusually large
amounts of cells that mandates titration of the post-barcoding Ab
staining cocktail on the same amount of cells. Nevertheless, this
generally still results in a several-fold reduction of Ab use per
sample, especially if the staining volume of the convolute is kept
to a minimum. Careful control of the staining volume is of course
an important aspect of consistent staining results.
2.5 De-multiplexing of barcoded data
Original sample data can be extracted from barcoded, pooled
samples by deconvolution through consecutive manual gating in
standard FCM software, by Boolean gating for combinatorically
barcoded samples [1988], or using scripts developed for that pur-
pose [1992, 1994, 1995]. Debarcoding software can be developed
in-house or retrieved from https://github.com/nolanlab/single-
cell-debarcoder (accessed August 15, 2016) [1992], Premessa
(https://github.com/ParkerICI/premessa), and has been imple-
mented in the regular CyTOF software (Fluidigm). The better the
cytometric separation of the barcoded samples from each other,
the better the recovery of original sample cells in the deconvolu-
tion. When different cell types in a given sample show heteroge-
neous barcoding marker staining intensity, resulting in suboptimal
cytometric separation in the barcode channels, one should con-
sider separating those first (e.g., by gating for lineage markers),
and then deconvoluting the data of different cell types separately.
2.6 Barcoding reagents
Different barcoding reagents have been explored. Usu-
ally, sample barcoding is achieved by covalently labeling
cellular proteins with dyes or mass tags via reactive thi-
ols or primary amines [1984–1986, 1992, 1996], or by
Abs [1987–1990, 1997–1999]. In mass cytometry, lipid-reactive
RuO4 and OsO4 have also been demonstrated as applicable for
barcoding [1993]. Covalent labeling is usually used for barcoding
of fixed and permeabilized cells, giving the reagent access to the
cell interior with many more binding sites than present on the
cell surface. In principle, dead cell labeling reagents that function
by binding to the cellular protein content (“fixable” viability
reagents) should work well as intracellular sample barcode
labels. In flow cytometry, succinimidyl derivatives of fluorescent
dyes such as PacificBlueTM, PacificOrangeTM, or Alexa Fluor
dyes [2000, 2001] are frequently applied [1984, 2002–2007].
In mass cytometry, thiol-reactive mDOTA loaded with lan-
thanide isotopes [1985, 1996], thiol-reactive BABE, or amine-
reactive isothiocyanobenzyl-EDTA loaded with palladium
isotopes [1986, 1992, 2008] have been used for intracellular
barcoding. DNA intercalators (containing rhodium or iridium)
are also candidates for intracellular barcode labels, as are cis-
platins that are available in different formats holding isotopically
enriched platinums [2009]. A commercial kit suitable for intracel-
lular barcoding of up to 20 samples is available from Fluidigm. For
intracellular barcoding, cells require fixation and at least “partial”
permeabilization [1986] prior to barcode labeling, which limits
the benefits of barcoding to subsequent steps in the protocol. Sam-
ple barcoding by Abs [1987–1989, 1998] is implemented earlier
in sample preparation protocols. Because of this, more protocol
steps—including surface staining of live cells—are performed
on the barcoded sample convolute, facilitating the staining of
fixation-sensitive markers in barcoded samples [1988]. When
using Ab-based sample barcoding, choosing the right target is key.
The selected Ab target should be stably and abundantly expressed
by the cells of interest and should not be modified by the clinical
or experimental conditions applied in the assay prior to sample
barcoding. Since CD45 is expressed by all mature leukocytes cir-
culating in blood, and particularly by lymphocytes and PBMCs at
high levels, combinations of CD45-Ab conjugates have been used
to barcode PBMCs in immune phenotyping experiments [1988].
For other cell types or conditions, such as immature leukocytes
in thymus and BM, or malignant progenitors, using CD45 must
be treated with caution, and different Ab targets might be more
suitable, such as β2 microglobulin to capture leukocytes including
CD45low neutrophils [2010], or by combined targeting of CD298
and β2 microglobulin to additionally capture tumor and stem
cells [1997]. The use of multiple noncompeting Ab targets also
increased the overall barcode signal intensity. It should be kept
in mind that antibody labeling of live cells can induce biologically
functional responses to Ab-based sample barcoding. Barcode
labeling can be applied to fixed cells, if target epitopes are
fixation-insensitive, which is the case for, e.g., CD45 (Mei et al.,
unpublished observation). Recently, barcoding of live and fixed
cells by a tellurium compound was described [2011], expanding
the available options for live-cell barcoding to situations in which
cell-surface markers suitable for barcoding are not known or avail-
able. Another variation is ratiometric barcoding, in which signal
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intensities relative to each other rather than discrete absence or
presence of signals are used as barcode labels, and for deconvolu-
tion, removing the strict requirement for cytometric separation in
each individual barcoding channel. While this has been demon-
strated using lanthanide-coordinated polymer dots [2012, 2013],
similar scenarios can be envisioned using different reagents.
Ratiometric barcoding increases the barcoding capacity, but com-
plicates the depletion of cell doublets through the application of
barcoding.
2.7 Application of cytometric barcoding to different cell
types
The decision regarding using cell-surface versus intracellular
barcoding is usually determined by the overall study outline
and protocol. For complex immune phenotyping of live cells,
cell-surface barcoding prior to fixation will be more suitable.
Intracellular barcoding is often used in signaling studies in which
cell activation is stopped by fixation, and therefore all cytometric
stainings are performed post-fixation. Sample barcoding has
been frequently applied not only to human and mouse primary
leukocytes, PBMCs, and cell lines, but also to platelets [2006], and
erythrocytes [2007]. The technique is often used in cell signaling
analysis using FCM and mass cytometry. Since the induction of
phosphorylated states of intracellular signaling mediators is usu-
ally characterized by shifts in staining intensity/signal, which can
be small and can therefore be affected by technical tube-to-tube
variations, barcoding of sample aliquots that underwent different
stimulation conditions and their pooling for joint acquisition
and analysis is often employed to protect against such error
and resulting misinterpretation. Fluorescent and/or mass-tag
barcoding has been employed in B cell signaling studies [2014]
and various other cell signaling studies [2001, 2004], in the
characterization of the effects of pharmacological inhibitors on
primary mouse and human immune cell subsets [1985, 2003],
in the mapping of myeloid cells in mice [2008], in stem
cell research [1992], and also in clinical immune monitoring
[2015].
3 Mass cytometry
3.1 Overview
Mass cytometry takes advantage of metal-conjugated Abs and
other metal-containing probes for cell characterization that are
detected by time-of-flight mass spectrometry, providing a cyto-
metric platform that is able to assess up to 135 parameters, 50
of which are being used. It facilitates high-dimensional single-
cell cytometry, especially in experimental setups where fluores-
cent spillover and autofluorescence are limiting in conventional
FCM. This chapter outlines the principles, specifics, applications,
advantages, and bottlenecks and of mass cytometry, and outlines
workflow details promoting its successful implementation.
3.2 Introduction
Since its introduction in 2009 [2016], mass cytometry (or Cytom-
etry by Time-Of-Flight technology, CyTOF) has pioneered a new
era of high-dimensional single-cell analysis, surpassing the lim-
its set by the availability of spectrally resolvable fluorochromes
in conventional FCM [1849, 2017]. The innovative concept of
mass cytometry is the use of stable rare earth metal isotopes of
very high isotopic purity coupled to Abs or other target-specific
probes for labeling of single-cell suspensions. These probes are
characterized by and detected based on the metals’ mass/charge
ratios by inductively-coupled plasma time of flight mass spec-
trometry [2018]. Thereby, it is comparatively easy to perform
single-cell cytometric experiments with currently more than 50
parameters in a single measurement in which typical obstacles
inherent to fluorescence-based cytometry, such as spectral over-
lap/compensation and autofluorescence are absent or have only
minimal, and manageable, impact.
3.3 Mass cytometry in biomedical research
Mass cytometry is ideally applied to research requiring high
parametrization at single-cell resolution, e.g. for resolving cel-
lular heterogeneity in complex mixtures of cells (such as blood
or tissue cells); complex phenotypes of isolated cell types (such
as T-cell subsets according to intracellular cytokine expression
and chemokine receptor expression) [561, 1850, 2019]; or
when a maximum of information is to be extracted from a
given, limited sample, such as from certain cell cultures, flu-
ids, tissue biopsies, children’s or certain patients’ blood sam-
ples [1688, 2015, 2020–2023]. While mass cytometry is able to
assess many parameters from a single cell sample, the information
gained by high parametrization needs to be balanced against the
limited sample transmission efficacy of mass cytometry.
Metal-labeled Abs used in mass cytometry largely resist the
methanol treatment that is used for permeabilization of cells in
order to detect phosphorylated states of intracellular signaling
mediators. Therefore, mass cytometry is a sought-after tool in
cell signaling studies [1849, 1985, 2015]. Mass cytometry also
facilitates large-scale immune monitoring and drug effect screen-
ing in clinical/translational research and systems immunology
[1849, 1985, 2024]. To date, mass cytometry has been performed
not only on leukocytes from different species including mouse,
man, and nonhuman primates [2025], but also on cell lines and
bacteria [2026, 2027], and has been used to track metal nanopar-
ticles [2027, 2028]. Metal-containing polystyrene or Ab capture
beads [1994, 2029] are used as internal standards in mass cytom-
etry measurements and could potentially be modified to work as
capture beads for serological analysis using the CyTOF platform,
similar to fluorescence-based Luminex technology.
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Figure 224. Schematic overview of a mass cytometric measurement. A suspension of cells stained with different rare-earth-metal-conjugated
Abs (metal, Me, different sizes reflect different isotopically enriched metals) is injected into the CyTOF instrument. First, an aerosol of single-
cell-carrying water droplets is generated by spray nebulization, which is then dried on the fly and introduced into the inductively-coupled argon
plasma. In the hot plasma, cellular matter is completely atomized and ionized, resulting in the formation of a single ion cloud from each individual
cell. Next, uncharged material and low weight ions (<80 Da), such as carbon (C), nitrogen (N), or oxygen (O) are removed from the ion cloud by
quadrupole ion guides. The remaining heavier ions, including the rare earthmetal ions are then separated by time-of-flight (TOF) analysis according
to their mass-to-charge ratio, and analyzed for their abundance. An entire TOF spectrum is recorded every 13 µs, so that a single ion cloud is
represented by a series of about 10–40 consecutive TOF spectra. The abundance of each atomic mass (defined by TOF windows) in each spectrum
belonging to one cell is then integrated to yield a data format in which each cell event is assigned an ion count (similar to a “signal intensity”)
reflecting the amount of the respective metal-conjugated antibody that was bound to the cell.
3.4 The mass cytometer: Cell introduction and signal
detection
The mass cytometer combines a cell introduction system with a
mass spectrometer consisting of three basic components: the ion
source, the ion analyzer, and the ion detector. Essential parts and
steps of the measurement are summarized in Fig. 224. During
a CyTOF measurement, single cells labeled with metal-tagged
probes typically suspended in water are injected at a flow rate
of 30 µL/min into a nebulizer. Using argon as a carrier gas, the
nebulizer creates an aerosol that is guided into the mass cytome-
ter. The nebulizer orifice of about 80–150 µm diameter limits in
theory the size of cells or particles measurable by mass cytom-
etry, while in practice, a large variety of primary cells and cell
lines have been successfully analyzed. The CyTOF instrument uti-
lizes an inductively-coupled argon plasma. At a plasma tempera-
ture of 8000 K, injected cells traveling through the plasma are
vaporized, and entirely disintegrate into their atomic, ionized con-
stituents. Thus, each cell generates an ion cloud that expands by
diffusion and charge repulsion and enters the vacuum of the mass
cytometer. Afterward, the vast majority of matter is removed from
these ion clouds: uncharged material is depleted by an electro-
static deflector, and low-weight ions, including those of elements
abundant in organic material such as C, O, H, N, and Ar (serving
as carrier gas), as well as ions carrying multiple charges, filtered
out by a quadrupole ion guide. Only heavy-weight single-charged
ions pass on to the time-of-flight (TOF) analyzer. There, ions are
separated and identified by their flight time difference after accel-
eration in an electric field of a defined strength, in which all ions
receive the same energy. Since the TOF of a given ion depends on
its mass and on its charge, the charge has to be the same (+1)
for all ions to correctly determine the mass an ion by its TOF.
The velocity of lighter ions is higher and they reach the detector
first, followed by heavier (and slower) ions, in the sequence of
increasing ion mass.
The ion cloud of a given cell is measured in small portions,
termed pushes. The CyTOF instrument performs 76 800 measure-
ments (pushes) per second, which means that one mass spec-
trum is captured every 13 microseconds. Since the CyTOF tech-
nology is currently limited to detection of metal isotopes with
high atomic mass, only the segment of the spectrum correspond-
ing to atomic masses higher than 75 Da is taken in considera-
tion. Typically, a single ion cloud is captured by 10–40 spectra.
An electron multiplier is used for ion detection and consists of a
series of dynodes maintained at increasing potentials, resulting
in serial amplification of the original signal. The output signal
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of the detector is further amplified and subsequently digitized
by an analog-to-digital converter. The spectra are then analyzed
by two successive integration steps, to obtain information about
the amount of metal associated with each ion cloud correspond-
ing to a single cell event. The first integration is an area under
curve calculated over an around 19–26 ns interval according to
the region of a given mass spectrum and represents the inten-
sity of the peak for a given isotope. The region used for the first
integration is determined during the instrument setup procedure
termed mass calibration, using a tuning solution. The second inte-
gration summarizes consecutive positive peaks corresponding to a
single (cell) event. The signal with the maximum number of con-
secutive spectra is taken as reference to identify the spectra con-
tributing to an ion cloud representing a single-cell event. Finally,
the integrated signal intensities obtained for one cell in the dif-
ferent mass channels are converted into FCM standard (FCS) 3.0
format files. Thus, mass cytometric data can be viewed and ana-
lyzed manually using standard FCM software packages. However,
considering the high complexity of mass cytometric data, man-
ual data analysis is time consuming, subjective, and may miss
much information contained in complex mass cytometric data.
It is advisable to employ automated cell clustering, population
identification, and dimensionality reduction techniques such as
PCA or t-stochastic neighbor embedding (t-SNE)-based, UMAP, or
similar methods [1470, 1794, 1983, 2030, 2031] for the analy-
sis of high-content mass cytometry data (see also Section VI.1:
Data analysis: An overview; and Section VI.5: Data repositories:
Sharing your data). An important point to consider is that data
analyses of a given study increasingly employ several algorithms
organized in an analysis pipeline, very similar to an experimental
procedure that needs to be described and annotated in appropri-
ate detail [2032]. Finally, the technical identity of cell populations
defined by mass cytometry in combination with, e.g., data cluster-
ing approaches can be validated by algorithms that break down
high dimensionality into a lower dimensionality that can be han-
dled by routine FCM analyzers, so that cell populations can be
gated by conventional human-defined analysis [146, 147]. The
same tools help to further characterize identified cell populations
by providing a lead that markers to use for isolating them for
further functional or molecular analyses.
3.5 Equipment
At present, Fluidigm Corp. is the only commercial provider of mass
cytometry instruments and of almost all mass cytometry-tailored
reagents. Mass cytometers can be run in a high-throughput man-
ner by employing either an autosampler suitable for consecutive
measurements of larger number of samples of limited sample size
(from a 96-well plate), or an add-on device that permits acqui-
sition of larger samples of any volume (Supersampler, Victorian
Airship LLC), which is ideally used in combination with sample
barcoding approaches (for more details, see Section VIII.2 Bar-
coding in cytometric assays). The latest mass cytometer version
(“Helios”) can sample volumes of up to 5 mL. A tube is placed in a
chamber where an applied pressure drives the intermittently agi-
tated sample from the tube to the injection line. More recent mass
cytometer versions (CyTOF version 2 and Helios) do not neces-
sarily require in-depth technical knowledge of mass spectrometry,
as the daily tuning and instrument alignment is largely performed
automatically. However, it is advisable to have the instrument
maintained and managed by an expert operator. The installation
of a mass cytometry platform usually requires the additional setup
of air conditioning, an exhaust system, argon gas supply and an
IT infrastructure suitable to store and manage mass cytometry
data.
Mass cytometry has also been used for imaging of tissue sec-
tions stained with metal-conjugated Abs, similar to those used
in immunofluorescence microscopy [1883, 2033, 2034] (see also
Sections IMC and microscopy). The stained section is dissected
into a series of vaporized samples corresponding to µm-sized
tissue section spots by high-resolution laser ablation; these tis-
sue section spots are then consecutively analyzed on a CyTOF
instrument [1883]. The data of each spot reveal the amount of
metal isotopes that was bound to the spot when the tissue sec-
tion was stained with metal-tagged Abs. By plotting the single-
spot data next to each other in the order they were ablated
from the entire tissue section, highly multiplexed images are
reconstructed. Similar data can be generated using an alterna-
tive approach, i.e., multiplexed ion beam imaging (MIBI) that,
does not rely on the mass cytometry equipment discussed here
[2035, 2214].
3.6 Coping with bottlenecks in mass cytometry
While the advantages of mass cytometry are striking for various
applications, it should be noted that due to the destruction of
the cells in the argon plasma, CyTOF instruments cannot recover
the original cell sample for subsequent experiments. Instrument
sensitivity, cell throughput, and overall recovery should be taken
in consideration when planning a study involving mass cytome-
try. Cells labeled with metal-conjugated Abs usually deliver signal
intensities sufficient for gating and quantitative analyses. Current
mass cytometers have a manufacturer-specified dynamic range of
4.5 orders of magnitude, which is comparable to fluorescence-
based FCM. The variability in sensitivity for the detection of dif-
ferent reporters is lower in mass cytometry compared with that in
FCM [2017]. However, mass cytometry currently lacks reporters
that provide a specifically “bright” signal such as PE in conven-
tional FCM [2017], due to an upper limit of metal ions that can
currently be loaded onto a probe (140 lanthanide ions per Ab
using MAXPAR labeling kits [1987]). In addition, of any 10 000
heavy metal ions of the CyTOF detection mass range injected, only
about 3–10 are counted by the instrument [2036]. These limita-
tions are in part compensated for by the lack of inherent biologi-
cal background signal (no “autofluorescence”) and minimal signal
spillover, which both can negatively impact fluorescent FCM data
(see also Chapter II Section 1.2 Principle of spillover and com-
pensation for a complete discussion about spillover). However,
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this principally does not protect from background signals due to
nonspecific binding of metal-labeled probes to cells. Significant
background binding of MAXPAR-labeled Abs has been reported
for fixed eosinophils, which could be eliminated by pre-incubation
of cells with heparin [2037]. The sensitivity could be improved by
probes that carry more metal per specific probe, such as heavy
metal nanoparticles [2038–2040].
The volume of a single-cell derived ion cloud expands by dif-
fusion to 2 mm in size, restricting the instrument’s throughput
to 1000 cells per second. A lower throughput (<500 events per
second) usually delivers data comprising fewer doublet events.
Thus, in contrast to most fluorescence-based flow cytometers with
event acquisition rates of usually up to 10 000 events/s, acquisi-
tion times in mass cytometry are significantly longer and might
necessitate pre-enrichment of target cells prior to mass cytometric
analysis [2041]. In addition, a CyTOF measurement recovers data
for about 30–50% of the injected cells, while the remaining sam-
ple is lost, e.g., by accumulating on the walls of the spray cham-
ber and injector. Mass cytometers need to be set up and tuned
daily (procedure detailed in ref. [1806], and instrument manu-
als) to confer stable instrument performance during day-to-day
operations, while only very minor variations, e.g., due to slightly
differing oxide ratios may remain.
Generally, the implementation of standardized tuning, sample
barcoding (described in greater detail in Chapter VIII Section 2
Barcoding in cytometric assays) [1985, 1988, 1992], signal nor-
malization according to bead standards [2042], and spillover com-
pensation [1994], and Ab cocktail cryopreservation [2043] secure
the generation of high quality data in mass cytometry.
All above approaches however do not account for experimental
variability at the time of sample biobanking. To further improve
data consistency, sample banking and assay automation are
actively pursued in the mass cytometry field (covered in Chapter
VIII section 11 Sample banking and Section 12 High throughput
screening). Concerns for potential batch effects introduced at
the time of sample banking and their long-term storage are
particularly relevant to mass cytometry, as algorithmic analyses
are particular sensitive to batch effects, complicating and limiting
the discovery of biological features. Since different cell types
behave differently during, e.g., cryostorage procedures [2044],
proper sample banking must be confirmed for individual target
cell populations.
In addition, the inclusion of a reference sample, that is, an
aliquot of cells isolated from a single batch of sample material sim-
ilar in nature to the study material, spiked into a series of batches
of jointly processed samples that belong to a given study [2045],
inform about remaining staining, and measurement variability
across batches and may serve for normalization of batch effects in
the future.
Ring trials have been adopted as a means to analyze the com-
parability of mass cytometry data generated by on different instru-
ments and locations, showing that sample and reagent distribution
rather than individual instrument performance were determinants
of variability [2046].
3.7 Experimental workflow, reagents, and controls
The experimental workflow for preparing mass cytometry assays
is typically very similar to that for conventional FCM, except for
the strict requirement of cell fixation and their resuspension in
water or cell acquisition solution prior to acquisition on the CyTOF
instrument. Briefly, cells are subjected to cell surface staining and
optional dead cell label incubation, fixed (usually using formalde-
hyde), permeabilized, stained for intracellular antigens and DNA
content, finally resuspended in water or commercially available
cell acquisition solution, and optionally supplemented with nor-
malization beads for injection into the mass cytometer. Cryostor-
age of stained cell samples has been explored to improve the logis-
tics of assay preparation and acquisition [2047]. Cell-surface and
intracellular sample barcoding solutions are available and can be
applied prior to surface staining or after permeabilization, respec-
tively. Protocols are available for in-depth surface marker-based
immune phenotyping [2024, 2048, 2049], intracellular cytokine
staining [1850], tetramer-based detection of antigen-specific T
cells [561, 1850], cell signaling analyses based on the detection
of phosphorylated signaling mediators [1849, 1985, 2015], in
vitro proliferation assays [2050] and the detection of RNA in sin-
gle cells [2051, 2052]. In addition, recent developments in mass
cytometry reagents allow the single-cell assessment of global epi-
genetic modifications [2053]. As such, the EpiTOF (Epigenetic
landscape-profiling using cytometry by time-of-flight) Ab panel
allows the assessment of different classes of histone modifica-
tions and variants. Functional probes available for mass cytom-
etry include 5-iodo-2-deoxyuridine for assessing cell prolifera-
tion [2050], enzymatic activity [2054], and a tellurium-based
hypoxia probe [2055].Wheat germ agglutinin (WGA) and osmium
tetroxide staining were proposed as a proxy for cell size in mass
cytometry [2056], besides ASCQ-Ru for cell volume respectively,
which, in conjunctionwith the Celltracer software has been used to
correct for confounding cell size effects in signaling studies [2057].
Further, osmium tetroxide has been used to stain functional-
ized polystyrene beads, making beads manufactured for conven-
tional FCM readily detectable by mass cytometry (Budzinski et al.,
2019). Ab-binding quantum simply cellular beads modified by this
method have been used to determine antibody binding capacities
of immune cells [2058], and to study receptor occupancy after
mAb therapy [2059] by mass cytometry.
Mass cytometers do not measure the light scatter parameters
usually employed in FCM for detection of cell events and sepa-
ration of cell aggregates; cells (or any other particles) are solely
detected by the metal associated with them. Nucleated cells are
typically revealed by rhodium- or iridium-based DNA intercala-
tors [2060], and probes specific to characteristic cell antigens can
be envisaged to reveal non-nucleated cells such as erythrocytes or
platelets [2061]. Doublet events can be minimized by (i) filter-
ing cells prior to injection, (ii) avoiding high cell densities in the
injected sample, (iii) excluding cell events with high DNA signal
and/or high cell/event length parameter values by gating, or (iv)
sample barcoding using a restricted barcoding scheme efficiently
filtering out doublet events formed between cells of differently bar-
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Figure 225. Typical gating strategy for PBMC analyzed by mass cytometry. Intact cells are identified by staining of DNA. Normalization beads
elicit high signals in defined channels such as 140Ce in the present example. Cells (unless stained with 140Ce conjugated Abs) do not elicit high
140Ce signals, and beads do not elicit high DNA/iridium signals. Events that appear in the upper right are cell-bead doublets, which could be
either physical aggregates, or due to timely overlapping acquisition of two ion clouds with one cloud representing a cell, and the other one a bead
event. Events not stained in either channel (lower left) are usually debris associated with metal amounts sufficient to be detected by the CyTOF
instrument (first dotplot). Cell events are further restricted to events showing strongly correlating DNA signals according to their 193Ir and 191Ir
staining. Both Ir isotopes almost equally contribute to the natural abundance iridium used in the DNA intercalator. Thus, signals are expected to
correlate. Events with high iridium staining intensity are excluded since the DNAhigh fraction is enriched for cell doublets. This procedure does not
fully eliminate doublets but reliably reduces their presence when barcoding was not used to filter out doublets. However, back gating should be
used to confirm that target cells are not excluded in this step (second dotplot). Gating according to “cell length” or “event length” is often employed
in order to minimize the presence of doublets. The “length” parameter corresponds to the number of spectra that belong to a given event. Events
labeled with large amounts of metal (and doublets) tend to show higher, and those with little metal tend to show lower “length” values. Upper
and lower cell length boundaries are defined in the acquisition software. The length parameter is not indicative of cell size. Again, backgating
should be employed to ensure that target cells are not excluded (third dotplot). Next, dead cells are excluded by gating on 103Rh low/– cell events.
High 103Rh signals result from stronger labeling of dead cells by 103Rh-mDOTA compared to live cells. PBMC identity is confirmed by CD45 staining
(in-house 104Pd conjugate, fourth dotplot), and CD36 and CD20 staining differentiate between monocytes/dendritic cells and B cells, respectively
(in-house conjugates, fifth dotplot). Total cell events and/or select subsets are typically subjected to further computational analysis.
coded samples [1988, 1992]. Gaussian discrimination parameters
have also been suggested for doublet identification and exclu-
sion [2062]. Finally, DNA intercalators, cisplatin [2063], DCED-
Pd [1997], or metal-loaded DOTA-maleimide [2048, 2064], are
used for cell viability staining. A typical initial gating strategy is
provided in Fig. 225.
The CyTOF instrument (“Helios” version) quantifies ions with
atomic masses between 75 and 209, providing 135 channels. More
than 50 of these can be used for detection metal-conjugated Abs,
and additional channels accommodate DNA intercalators or dead
cell detection. A central part of any mass cytometry experiment
is Ab panel design, for which various mass tagged-Abs and pre-
designed panels are commercially available. Abs can be labeled in-
house using commercial kits for lanthanides and indium isotopes,
or according to published protocols with isotopes of palladium,
yttrium, bismuth, and platinum [1987, 1988, 2047, 2065, 2066].
Moreover, metal-containing nanoparticles such as Qdots contain-
ing cadmium [1850, 2067] and silver nanoparticles [2038] have
been successfully employed as mass tags for reporting binding of
specific probes to cells. The design of mass cytometry panels is
generally easier as compared to fluorescent flow cytometric pan-
els of similar marker capacity, since signal spillover and sensitivity
differences are comparably minor issues [2017]. However, the
mere number of parameters and the implementation of quality
control for Abs, as well as choosing appropriate Ab clones [2049]
make panel design a significant effort. Panel design includes opti-
mizing the pairing of specific probes with unique heavy metal iso-
topes considering instrument sensitivity for that particular isotope
mass, target antigen abundance, and additionally potential sig-
nal spillover (see ref. [2068] for details). Signal spillover in mass
cytometry can arise from (i) isotopic and elemental impurities
of mass tags, (ii) between adjacent mass channels at high signal
abundance (usually Mass (M) +1 spillover, but M-1 spillover is
also possible), and (iii) because of metal oxide formation (M+16
spillover) [2049, 2068]. A careful panel design, an optimally tuned
instrument and highly pure reagents, however, canminimize these
spillovers to very low levels that are orders of magnitude lower
than fluorescent spectral overlaps. In addition, residual spillover
effects in mass cytometry and imaging mass cytometry data can
be compensated [1994] using a nonnegative least square (NNLS)
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approach [37] that applies correction at the single cell level and
constrains data to signals higher than zero after compensation.
Isotype and FMO controls are typically used in conventional
FCM experiments to distinguish between specific and background
signal (for further detail see Section III.1 Controls: Determining
positivity by eliminating false positives). In theory, isotype and
FMO controls (termed in mass cytometry as Signal-minus-one or
Metal-minus-one controls, SMO andMMO, respectively) are easily
applicable to mass cytometry. However, the sole fact that, in mass
cytometry, typical panels include approximately 40 Abs renders
the routine and consistent realization of these controls laborious
and complicated, and often unfeasible. Isotope controls require
the use of an antibody with a matching isotype and the same
amount of metal per antibody as the reagent that is to be con-
trolled, and are presently not commercially available. As a result of
these practical limitations, the SMO/MMO controls are either per-
formed exemplarily or combined in a metal-minus-many (MMM)
strategy, in which several rather than individual Ab conjugates are
omitted during the staining procedure, e.g., a group of markers
specific to a certain panel on the backbone lineage marker panel.
In addition to these, biological controls are particularly adapted
to mass cytometry, since they take advantage of the high dimen-
sional level of the data. Counterstaining for multiple cell lineage
markers in Ab conjugate evaluation experiments enables the iden-
tification of reference cell populations in the sample serving as
positive and negative controls for a given Ab conjugate in the mul-
titude of populations commonly identifiable by a 40-parameter
panel. For example, B cells also present in the sample could be
used as a negative control for a T-cell-specific marker. Ab titra-
tions can also benefit from the high dimensional level of the data
since multiple markers can be titrated concurrently across sub-
sets defined by a backbone of lineage markers to facilitate assess-
ment of the titration results on specifically gated populations of
interest. Finally, mass cytometry data sets and their evaluation,
especially by computational means, benefit from bundled, batch-
wise sample processing, and data acquisition (as compared to
processing samples individually) to achieve a high degree of data
consistency.
Generally, experimental workflows for mass cytometry are
typically very specific to individual studies, and many factors
should be considered during the setup of mass cytometry studies
[2069].
3.8 Conclusions
Mass cytometry is a recent hybrid technology employing prin-
ciples of FCM and mass spectrometry. The core technology is
rapidly developing along with bioinformatics and reagent chem-
istry, thereby creating a largely universal and extendable next
generation platform for high-dimensional single-cell cytometry
applied in translational research, systems biology, and biomarker
discovery.
4 Combinatorial cytometry
Combinatorial cytometry is the subfield of cytometry, or single-cell
analysis, whereby researchers describe, study, and model com-
plex relationships between multiple combined cytometry samples
exposed to varying stimuli, environment, treatment, and so on.
Examples include various techniques of multiplexing, such as
fluorescence barcoding [1984], high-throughput cytometry, and
cytometry-based compound screening [2070], as well as multiple
computational techniques that combine multiple data files either
during the data collection [2071] or post hoc in order to create
multifactorial and multidimensional datasets to allow for analyti-
cal comparisons across properties not readily available or accessi-
ble via a single experiment [1795].
Combinatorial cytometry approaches have been implemented
successfully with innovative mass cytometry (CyTOF) systems
(For more information on the equipment and concept, see Sec-
tion VIII.3 Mass cytometry) [2072], multispectral cytometry
[31], multi-angle elastic light scatter cytometry [2073], high-
throughput screening FCM [2070], and computational clinical and
research cytometry of the immune system [2074–2076].
There is often a significant difference in the design of a tradi-
tional FCM and a high-throughput or high-content assay. This can
be visualized in Fig. 226 where both traditional tube (or even plate
based) FCM assays are performed, and high-throughput assays
exclusively using 96 or 384 or larger plates. Using such large
arrays of data creates a fundamental difference in how the data
are both collected and analyzed. What is clear is that a high degree
of organization and structure, complete with significant metadata
is required to establish high-throughput or high-content FCMassay
systems.
One of the key advantages of the combinatorial cytometry
approach is the opportunity to employ advanced statistical and
machine-learning methods, such as various techniques of cluster-
ing, supervised learning/classification, Bayesian techniques, and
other state-of-the-art methodologies. On the other hand, combi-
natorial methodologies introduce complexity to the experimental
planning and design. As a result, they may increase the cost of the
experiential setup and heighten the risk of failure. Ultimately, the
benefits of complex, information-rich “all-in-one” assays, must be
balanced against the cost of assay development which is likely to
be greater than that of performing assays using regular techniques.
Compound screening is a prime example of a combinato-
rial cytometry approach. Multiple multicolor flow-cytometry cell-
stress assays can be rapidly executed in a sequential manner
using an automated robotic sampler. The cellular populations are
exposed to different concentrations of the compounds tested, but
they can also be measured in different environments (different
media) and/or at different times after exposure to the stress. The
assay can scan a dense grid of possible combinations incorporating
all the stress factors in various permutations. Consequently, a huge
number of individual cytometry measurements may be required to
complete the screen. It is self-evident that the key requirement for
successful execution of such an assay is a well-defined, repeatable,
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Figure 226. This is an example of how a traditional FCM assay might be designed using test tubes or even a 96-well plate assay. Because of
the limitation in the number of tubes or samples that can be run by traditional instruments, it is not possible to create very large arrays. Using
high-throughput cytometry, typical assays might be 384-well plates that can be processed in 10–20 min and produce a huge amount of data that
can be processed using advanced statistical operations.
and reproducible assay layout (sample organization), which must
be consistent throughout the entire cycle of experiments.
The assay sample organization defines the resultant data struc-
ture and organization as well, as schematically indicated in
Fig. 227. A typical automated phenotypic assay executed using
a cytometry screen would employ a 96- or even a 384-well layout
that provides space for up to 32 drugs at 10 doses each, as well
as negative and positive controls. Preparing such a layout in an
automated, repeatable fashion allows glitch-free assay execution
and subsequent feature extraction. Figure 228 shows a window of
one example of a custom-built screening software package, Plate-
Analyzer, which automatically outputs response curves and fits
log-logistic models on the basis of the templates and gates pre-
defined by an operator [2077]. Since such a system performs the
operations involving up to 384 FCS files per plate, it is crucial that
all the steps in the analytical procedure be fully automated and be
executed without the need for any interactive operator input.
A screening system such as the one described above also relies
on automated sample preparation and robotic liquid handling, as
the probability of pipetting errors and inaccuracies is too high to
allow for a manual assay setup. Automation of sample preparation
not only ensures a high level of reproducibility, but also shortens
the preparation time and guarantees that the minimal required
amount of sample and reagents can be accommodated to make
the assay more cost effective.
Opportunities for automated or semi-automated analysis of FC
screens can be achieved using many available toolsets for FCM
data processing. R-language for statistical computing is a com-
monly used environment for cytometrists who are interested in
developing their own analysis tools and unique data process-
ing pipelines. Combinatorial FCM incorporating dimensions of
time, concentration, media, and other factors certainly expands
the horizons for this field. Conversely, the availability of rapid
development tools for custom design of data processing pipelines
is a condition sine qua non for successful implementation of the
described combinatorial and multifactorial approaches, see also
Section VII.1 Data analysis an overview. When it is desirable
to measure biological responses across multiple conditions (e.g.,
concentration, medium type, stress, temperature, time, etc.) with
FCM, it is advantageous to approach the assay in an organized
fashion. The technique is enabled by fast autosamplers, and infor-
matics pathways aware of themultifactorial nature of the collected
data as demonstrated in Fig. 227 where the differences in analysis
of traditional flow data are compared with combinatorial analysis
routines. These routines can be highly complex, but depend upon
the ability to automatically extract features for all samples in the
array.
Other examples of combinatorial cytometry are the well-known
bead-based assays. Among those, cytokine assays are probably the
most widely used and broadly accepted [2078]. In this technology,
two to ten types of cytometry-compatible beads of various sizes
(recognized by FCM by forward light scatter) can be dyed with
increasing amounts of a tracer dye to encode their ability for cap-
turing/measuring different analytes. For example, Fig. 228 shows
13 cytokines simultaneously recognizable by a commercially avail-
able FCM assay (any commercial plate could be entered into the
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Figure 227. Combinatorial cytometry
integrates the ideas of screening bio-
logical responses. Biological responses
can be screened across multiple con-
ditions (e.g., concentration, medium
type, stress, temperature, time, etc.)
with FCM. The technique is enabled
by fast autosamplers, and informatics
pathways aware of the multifactorial
nature of the collected data.
Table 94. Cytokine assay reagents. This table shows the multiplex
cytokine assay with bead location and target molecule. Using beads of
different sizes, with increasing amount of bead fluorescence, many
assays can be performed on very small samples of plasma (<15 µL).
This example demonstrates how one particular kit (which uses beads
identities as A4, A5 . . . .B2, B3, etc.) where each bead is associated with
one particular analyte. Each of these beads are in a small size (A) or
larger size (B) group. These are shown graphically in the upper right
panel of Fig. 228
Target Bead ID
IL-10 A4
IFN-g A5
IL-5 A6
IL-2 A7
TNF-a A8
CM-CSF A10
IL-4 B2
IL-17F B3
IL-9 B4
IL-17A B5
IL-13 B6
IL-22 B7
IL-6 B9
system). In this system there are two bead sizes, and each bead
type carries a different amount of target marker, in this case APC
(see Table 94). Although the discussed technique employs only
a 13-plex method, frequently up to 20 or 30 different cytokine
tags can easily be simultaneously quantified in a minimal volume
of plasma. If the organization of samples on multiwell plates is
consistent, one can execute an automated data-processing task
immediately after assay completion. Gating, recognition of dif-
ferent bead types, computation of calibration curves, and other
necessary tasks can be executed automatically without operator
intervention or a manual setup.
As mentioned before, multiplexing offers a huge advantage in
terms of assay execution time and reagent/sample cost saving. As
a result, the multiplexed bead assays allow researchers to iden-
tify concentration of analytes of interest in many samples essen-
tially simultaneously. A dedicated software package (such as the
PlateAnalyzer Cytokine edition in Fig. 229) provides the means
to show all the calibration and to visualize the concentration of
analytes across the entire plate. Such visualization techniques are
commonly used for other combinatorial approaches in biomedical
research and are equally valuable for FCM data.
A third example of a combinatorial cytometry technique is mul-
tispectral single-cell analysis. In contrast to traditional multicolor
cytometry, which uses a dedicated detection channel for each flu-
orescent label in the hope of separating signals from multiple
labels, the spectral system essentially acts as a superfast spectro-
scope connected to a flow cytometer. An approximation of the
entire spectrum using about 30–40 bands for every cell is mea-
sured, and the data can be further processed via spectral unmix-
ing techniques or directly used for spectral classification. There
are a number of advantages to the spectral approach, mainly
related to the less complex hardware as traditional optical fil-
ters are not utilized and neither are individual detectors. This
approach creates a new opportunity for combining fluorescent
probes that may not be feasible in conventional FCM [2079].
For example, dyes such as GFP and FITC can be used together
because chemometric techniques to process spectral cytometry
data can be utilized to classify and/or unmix the resultant sig-
nals. There are several excellent recent examples of this approach
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Figure 228. Automated processing of bead-based cytokine assay. Results obtained in a cytometric bead assay in graphical representation of
the cytokine concentration in every well of the multi-well plate. Samples were run on an Attune NxT flow cytometer (ThermoFisher) using the
instrument plate reader. On the left side of the figure is a list of the analytes used in the assay. In the center part of the figure is a 96-well
plate layout showing a representation of each cytokine in a 13-piece pie chart. The colors represent the values in picograms per milliliter. The
top right figure shows the bead populations used to define each cytokine. On the bottom left, the heat map describes the fluorescence intensity
measurements for each well and each cytokine. The figure on the bottom right shows the standard curve derived from the standards run for this
assay.
in FCM [32, 33] in which combinations of fluorescent proteins,
together with a variety of fluorochromes, allowed a total of 11
markers to be used simultaneously and then separated by spectral
unmixing.
A final example of combinatorial cytometry and one that
demonstrates the extraordinary power of multiparameter datasets
can be seen in data collected by the CyTOF technology and demon-
strated in Fig. 230 (for an overview of the equipment, see Section
VIII.3 Mass cytometry). This approach uses lanthanide-conjugated
Abs, as opposed to the fluorescently labeled probes of a conven-
tional FC system, and time-of-flight mass spectroscopy for ana-
lyzing single cells to produce information-rich population statis-
tics [1849]. The final complexity of such data can be very high
indeed, requiring innovative techniques for data processing and
visualization. An ad hoc “what-if” analysis is possible using visual
development environments allowing for interactive construction
and modifications of data processing pipelines. A demonstration
of such a pipeline, capable of tackling an input of 30–40 different
biological parameters encoded by lanthanides, is represented in
Fig. 230. The data processed in this example (courtesy of B. Boden-
miller, University of Zurich, Institute of Molecular Life Sciences)
were produced by analyzing a bulk sample with seven lanthanide
tags used to encode the position of individual subsamples in a 96-
well plate. This experimental approachwas applied to characterize
human PBMC signaling dynamics and cell-to-cell communication,
signaling variability between PBMCs from human donors, and the
effects of various inhibitors on this biological system. For each
inhibitor, 14 phosphorylation sites in 14 PBMC phenotypes were
measured [1985].
The demonstrated data pipeline (or “logic map,” in PlateAn-
alyzer terminology) can extract individual dose-response curves
for the 14 phosphorylation states from each of the 14 cell phe-
notypes. This is a striking example of combinatorial FC analy-
sis, which first creates relationships between different vectors of
FC measurements and subsequently explores and quantifies these
relationships. Where traditional cytometry is focusing on map-
ping individual cells in a multidimensional space of phenotypic
descriptors, combinatorial cytometry looks at vectors of multidi-
mensional measurements and explores the differences and simi-
larities between those under various conditions.
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Figure 229. Response curves automatically pro-
duced from data extracted from multiple FCS
files. Data across FCS files are collected using a
robotic sampler connected to a flow cytometer.
The PlateAnalyzer software recognizes the plate
layout and creates response curves on the basis of
pre-defined gates. Each curve results in an auto-
matically calculated IC50 value as shown on the
right side of the figure.
Conclusion. The key requirements for combinatorial cytometry
are (i) well-defined reproducible assay layout, (ii) highly con-
trolled, preferably automated, assay setup and preparation, (iii)
data-collection method recognizing the relationships between the
collected FCS files and organizing the measurements in higher-
order data structures, and (iv) automated data analysis and report-
ing software. When this combination of tools is available, complex
multiparameter and multifactorial experiment designs can be exe-
cuted and the resultant data can be rapidly processed to produce
Figure 230. The pipeline design canvas of the PlateAnalyzer. This particular example of an analysis package (http://vault.cyto.purdue.edu) allows
rapid development of data-processing maps for complex combinatorial cytometry experiments. In contrast to traditional FC software packages,
all the operations are by definition applied to vectors or matrices of FCS files, rather than to individual datasets. On the left of the figure are
shown histograms of each of the phosphorylated proteins in the assay, the central group identifies the phenotype of cells being evaluated, and
the two boxes on the far right show the stimulating molecules (12 rows) each of which contains eight concentrations. Yellow lines show the active
analysis connection pathway—i.e., the resulting dose response curves would be based on the phenotypic result of each component linked within
this pathway. As an example in the figure, the phosphorylation state is ZAP70- and the phenotype is NK cells (CD3–, CD7+).
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useful insight leading to mechanistic models of the studied bio-
logical systems.
5 High dimensional FCM
5.1 Overview
The characterization of the complex nature of immunological
processes in health and disease requires multi-dimensionality as
well as high resolution to detect all targets of interest. While
the availability of novel technologies such as mass cytometry
by time of flight (CyTOF) and single-cell RNA sequencing
(sc-RNAseq) have greatly increased the number of features
(protein and/or transcript) that can be measured at the single-
cell level, fluorescence-based FCM remains a primary tool for
immunophenotyping due to its low cost, high dynamic range,
and high throughput. Furthermore, the most recent generation
of instruments with five or even more spatially different laser
lines allows the detection of 30 parameters, with up to 40 on the
horizon (based on personal communication).
Though the general principles of experimental design have not
changed (for review, see ref. [56]), reliable fluorescent panels of
more than 10 parameters require not only a more thorough and
systematic planning to ensure optimal resolution of all markers
even at low Ag expression, but they also critically depend on vali-
dation and controls as a means to avoid misinterpretation of data.
Within this section we describe a step-by-step approach for panel
design based on the concept of the spillover spreading matrix
(SSM), pointing out important considerations for fluorochrome–
antigen combinations and address some of the most common mis-
conceptions and caveats. In addition, we outline key steps in visual
quality control of the obtained data to ensure a meaningful sub-
sequent multidimensional data analysis.
5.2 Introduction
Most commonly, fluorescent flow cytometers dedicate one
detector to the measurement of one fluorophore and use a
compensation-based approach to correct for spectral overlap
between the different fluorophores used. Improvements in elec-
tronics and the usage of multiple spatially separated laser lines
have resulted in the latest generation of instruments that can mea-
sure up to 28 fluorescent parameters (such as the BioRad ZE5 or
the BD FACSymphony) [2080]. In turn, spectral cytometry instru-
ments have been developed that detect every single fluorochrome
across all available detectors, thus measuring a complex composite
spectrum for every cell, with individual signals being separated by
spectral unmixing algorithms (originally developed at Purdue Uni-
versity and now commercialized by Sony Biotechnology as well as
Cytek Biosciences) [33, 2081]. Currently, these instruments have
reportedly been used for the measurement of up to 24 param-
eters. The availability of new dyes, dyes are presently limiting
all fluorescent-based cytometers, will advance the field and push
these limits toward 40, and possibly even beyond. While this sec-
tion focuses on conventional, compensation-based FCM, most of
the principles discussed are applicable to spectral cytometry as
well.
Systematic panel design for a high-dimensional experiment
requires multiple considerations. Inevitably, the used fluo-
rochromes will show some degree of spectral overlap into more
than one detector. The detector intended to capture the major
emission peak of the respective fluorochrome is usually called the
primary detector, and the secondary detector(s) is (are) the one(s)
collecting the spillover. The mathematical process used to correct
for spectral overlap is termed compensation [2082] (See Chapter
II, Section 1- Compensation), and reports a percent value describ-
ing the relative fluorescence detected in the secondary detector
compared to the primary detector. This signal portion is subtracted
from the total signal detected in the secondary detector. A com-
mon misconception is that the magnitude of the compensation
value is used as a representation for the amount of spectral over-
lap between fluorophores, while in fact the compensation value is
highly dependent on detector voltages [2083].
The most useful metric in this context is the so-called spreading
error, which was first described by the Roederer laboratory at NIH
[38]. In short, the spreading error quantifies the spreading that the
fluorochrome-positive population (in the primary detector) shows
in any secondary detector. This increased spread (as measured by
SD of the positive population) is sometimes erroneously attributed
to compensation. In fact, compensation does not generate the
spreading error, but rather makes it visible at the low end of
the bi-exponential or logarithmic scale (Fig. 231a, left panel).
Spreading error is a consequence of the imprecise measurement
of fluorescent signals at the detector (typically a PMT), which
show some variance due to the Poisson error in photon counting.
In short, there are three key aspects of spreading error that
need to be considered for panel design: First, spreading error is
proportional to signal intensity, i.e., the brighter a signal in the
primary detector, the more pronounced the spreading error in
the secondary detector will be (Fig. 231A, right panel). Second,
spreading error reduces the resolution in the secondary detector,
i.e., the detector that is collecting spillover (Fig. 231B). Third,
spreading error is additive, i.e., if a detector collects spreading
error from multiple different fluorophores, the overall loss of sen-
sitivity will be more pronounced (Table 95).
Besides considering spreading error, which will be discussed
in more detail in the next section, other relevant aspects of panel
design include the relative expression level of target antigens per
cell, co-expression of target markers, and the relative brightness of
the used fluorochromes. Importantly, the consideration of spread-
ing error is overall more relevant than fluorochrome brightness
if dealing with co-expressed markers (Fig. 231C and D). Further-
more, for any high-dimensional fluorescence experiment the qual-
ity of single-stained controls is of utmost importance, thus these
have to follow the four basic rules as described in detail in Chapter
II Sections 1.3 (Measuring SOVs/compensation controls) and 1.4
(Compensation controls) and in ref. [165]. Finally, the chemical
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Figure 231. Spreading error and fluorochrome brightness in panel design and common compensation artifacts in quality control. (A) A typical
example of spreading error is illustrated: BV786 shows significant spectral overlap in the U-780 detector (excitation by UV laser), which manifests
as visible spread of the positive population. The relative loss of resolution on this population compared to the negatives is indicated by black bars
on the left plot. Right plot shows how spreading error is proportional to signal intensity, and decreases with lower titers of the respective Ab. (B)
The absolute compensation value and spreading error are not directly related, as exemplified for BV650+ events in different detectors (spreading
error and compensation values for each combination are displayed above the plot). (C) Examples of staining intensities for different fluorochromes:
FITC (dim), BV421 and APC (medium), and PE-CF594 (bright). Note that fluorochrome brightness can be instrument-specific. (D) Overview on the
critical considerations for fluorochrome assignment for co-expressed markers. Highly expressed targets should preferably be paired with dim
fluorochromes generating little spreading error. Dimly expressed (or unknown) targets should be paired with bright fluorochromes and utilize
detectors that receive little spreading error. Numbers 1–3 indicate the relevance of the considerations. (E) and (F) show erroneous patterns that
usually indicate incorrectly compensated data: (E) example of a correctly compensated plot, and respective over- and undercompensation of
marker CD X into detector for CD Y. (F) Example of an incorrectly compensated population CD X (right plot) appearing as “super-negative”
population if displayed against an unrelated detector measuring CD Z (left plot). The erroneous pattern is only visible if displayed against the
detector measuring CD Y.
properties of the used dyes can impact complex panels, as unex-
pected dye–dye interactions or dye–cell/dye–buffer interactions
can change the fluorescence spectrum of a given dye (also see
“Top tricks” of this chapter). This aspect needs to be addressed by
using appropriate controls, which will be discussed together with
spreading error in the next section.
5.3 Principles of the technique being described
The SSM is a fundamental tool for successful panel design. It is
specific for each instrument and provides comprehensive informa-
tion on the relative contribution of any fluorochrome to spreading
error in secondary detectors, and the relative loss of resolution
in all the available detectors. As such, the SSM provides a way
to tackle spreading error in a systematic manner. It is important
to note that the extent of spreading error cannot be predicted
from the corresponding value in the compensation matrix, which
is exemplified in the plots displayed in Fig. 231B.
The SSM can be calculated from single-cell stained controls in a
common data analysis package, FlowJo (version 10.4 and higher),
or manually using the formulas provided by Nguyen et al. [38].
The information on spreading error obtained from the SSM can
be translated into panel design in two ways: First, the SSM high-
lights individual fluorophore-detector pairs with high spreading
error, which in turn should be used for mutually exclusive mark-
ers (e.g., CD3 and CD19) as in this case spreading error will not
interfere with detection of either signal. Second, the SSM can be
used to assess the additive loss of resolution in a secondary detec-
tor by calculating the column sums, and to assess the additive
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
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contribution of spreading error from a single fluorochrome across
all detectors by calculating the row sums. An example of a SSM
and how to interpret it is shown in Table 95 and described in
“Experimental workflow.”
In many applications, researchers aim to target as many
markers of interest on the same cell type as possible. Hence, for
these applications, the antigen expression levels play an important
role and need to be assessed beforehand—either experimentally
or by utilizing published work. Useful resources in this context
are optimized multicolor immunophenotyping panels (OMIPs)
(See Chapter VIII, Section 3 Analysis presentation and publication
(MIFlowCyt)), which usually show raw data of every Ab in their
supplementary material [1943]. Using the information of antigen
density, low-expression antigens should be detected in channels
receiving little spreading error and fluorochromes generating
large spreading error can be used for their detection, as this will
decrease the relative spreading error (which is proportional to
signal intensity). In turn, highly expressed antigens should be
paired with fluorochromes generating little spreading error. Alter-
natively, one can assign highly expressed targets to detectors that
receive a lot of spreading error, as a bright signal will typically still
remain above the spreading error. A step-by-step approach for this
process is outlined in the section “Experimental workflow” below.
In order to draw accurate conclusion and to avoid interpret-
ing artifacts that result from spreading error, validation of Ab
combinations and using the right controls is mandatory. In most
cases, and especially for markers with unknown Ag expression lev-
els FMO controls are required as they can help to identify gating
boundaries, especially in detectors with spreading error [2084]
(See Chapter III 1.2 Fluorescence spreading into the channel of
interest: Fluorescence minus one controls before you start con-
trols). However, it is important to note that FMO controls cannot
account for unspecific binding of the Ab that it controlled for,
which can cause a shift of the entire negative population in the
fully stained sample that is absent in the FMO control. In this case,
either a biological control is required, or one can use another cell
type in the same experimental sample as a gating control. Iso-
type controls can serve the function to identify staining issues,
especially when secondary Abs are used. Unstained controls have
historically often been used to give information about the back-
ground autofluorescence of the measured cells, but these controls
are of little use in most complex polychromatic experiments.
Finally, high-dimensional cytometry data can only partially be
analyzed by traditional manual gating, but rather requires compu-
tational data analysis approaches. Prior to this, appropriate quality
control and preprocessing of the data is mandatory, as specified
below. For details on computational analysis techniques, we refer
the reader to several recent reviews [1794, 1838, 1983] and to
the corresponding section of the guidelines (see Chapter VII).
5.4 Applications
Multidimensional FCM with up to 30 parameters enables a deeper
phenotyping and characterization of the immune system, which
is required as cellular subsets require more and more mark-
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ers for accurate definition [2085]. Besides basic research, clini-
cal research can especially benefit from this analysis as a high
amount of information can be extracted from limited, and thus
precious, sample sources. Especially for longitudinal high-content
immunomonitoring of big patient cohorts, multidimensional FCM
serves a fast and highly sensitive tool to correlate responses and
observe changes of treatment as the basis to predict outcome of
the myriads of immunotherapeutic approaches to treat diseases.
The computational approaches allow for interrogating large data
sets generated in these types of studies and enable the unbiased
analysis of the data, possibly leading to the detection of rare cell
types and can be of predictive value for treatment outcome.
5.5 Experimental workflow
Here, we describe the key steps that should be taken for a system-
atic panel design approach.
1. Define the experimental hypothesis and the relevant cellular
populations (e.g., CD8+ T cells)
2. Make a list of lineage markers that are necessary for consistent
identification of the populations of interest (e.g., CD3/CD8 and
CD45 for CD8+ T cells).
3. List all target markers of interest and categorize expected
expression patterns and (if known) antigen density into low,
medium, and high.
4. Generate an SSM on your instrument by running single-stained
controls with all desired fluorochromes and calculating the
SSM in FlowJo or another suitable analysis program.
5. Look for the three highest values in the SSM and assign the
corresponding fluorochromes to mutually exclusive antigen
targets, i.e., targets not expressed on the same cell (in our
example SSM in Table 95 the most problematic pair would be
BUV563 spread into the YG-586 PE detector).
6. Calculate the row sums in the SSM. The fluorophores with the
lowest row sum overall contribute the least spreading error
to your experiment—these should be assigned to your lineage
markers, e.g., CD3 and CD8 for a CD8 T cell-centric analysis
(in our example SSM in Table 95 this would be BV421 and
BUV395).
7. Calculate the column sums in the SSM. The detectors with
the lowest column sums receive the least amount of spreading
error—these detectors are suitable for dim or unknown tar-
get markers (in our example SSM in Table 95 good examples
would be the B-515 and V-510 detectors). Utilize bright fluo-
rochromes for these antigens, if possible. The detectors with
the highest column sums receive more spreading error—for
these detectors perform preliminary experiments to assign tar-
get markers that deliver a bright enough signal to be above
the spread (in our example SSM in Table 95 this would be
YG-586 and YG-610 detectors). However, one has to keep in
mind that there might be a single contribution that drives the
total spreading error in a detector, and if not used on the target
cell, this can improve the total spreading error received (e.g.,
in our example SSM in Table 95 the contribution of BUV661
and BUV563 to the YG-586 detector).
8. Run a test experiment including all relevant FMO controls.
Perform data analysis and quality control as outlined in the
next section.
5.6 Data analysis
For general concepts of computational analysis of high-
dimensional single-cell data, we refer the reader to Chapter VII
“Data handling, evaluation, storage and repositories” High dimen-
sional FCM of the guidelines. Within this section, we focus primar-
ily on quality control aspects prior to data analysis.
Most technical artifacts occur when samples are acquired over
multiple days (i.e., batch effect), however, sometimes they also
happen within one experiment due to the lack of appropriate con-
trols or inconsistencies in instrument handling. In the authors
experience, a common cause of artifacts in fluorescent cytometry
is incorrect compensation, which in turn is mostly due to poorly
prepared single-stained controls. To pinpoint suchmistakes, visual
inspection of N×N views of the final data should be performed,
with N being the number of fluorescent parameters acquired, i.e.,
every marker against every marker. Within these plots, one should
screen the data for typical erroneous patterns such as “leaning” tri-
angular populations and “super-negative” events. Examples pat-
terns are given in Fig. 231E and F.
Sometimes fluorescent signals vary across different experi-
mental days or even within one experiment even though the
same staining panel was applied. Correct data transformation
can help to diminish this effect [2086]. Different transforma-
tion approaches such as the biexponential, arcsinh, and hyper-
log display can be used, and the optimal transformation depends
on the specific data and cannot always be computationally pre-
dicted [1808].
Dead cells, doublets or staining artifacts, e.g., by Ab aggregates,
can appear as false positive data points or outliers in the analysis,
potentially leading to wrong interpretation of the data. Thus, it is
important to exclude these prior to unsupervised computational
analysis by appropriate pregating or “data cleaning.” Depending
on the immunological question asked a pregating on the popula-
tion of interest can be part of the preprocessing and may speed
up the computational procedure of the analysis (e.g., per-gating
and exporting of live singlet CD45+ CD3+ cells). Even though
conventional manual gating may not be suitable to capture all the
correlations between the up to 28 fluorescent parameters, it still
serves as an important quality check before, during and after the
computational data analysis.
5.7 Advantages
Thorough panel design, not only for multiparametric FCM panels,
will award the researcher with robust and reproducible FCM data
with a satisfying resolution also of dimly expressed markers. Even
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though the optimization of a panel may appear time consuming
and requires various controls to assure reliable interpretation, it
will save time in the downstream analysis and interpretation of
the generated data. Usage and correct interpretation of an SSM
will improve the process tremendously. It may not be obvious at
first, but cost will be reduced, as the unnecessary repetition of
experiments due to non-interpretable data will be minimized.
5.8 Pitfalls
Pitfalls in high-dimensional fluorescent cytometry often arise from
inappropriate planning of experiments and lack of controls. This
can be avoided by systematic panel design and the inclusion of
FMO controls as described above. Also, an inherent disadvantage
is the necessity to obtain single-cell suspensions, which disrupts
the natural architecture and interaction of cells in situ. Several
emerging techniques allow high-dimensional cytometric measure-
ments directly within tissues, as has been shown by Histocytome-
try [2087] or the recent commercial release of an imaging CyTOF
system (Hyperion, Fluidigm) [1883].
5.9 Top tricks
1. It is important that the detector voltages of the used flow
cytometer have been optimized using an appropriate tech-
nique. The most widely accepted approach for this is a voltage
titration [48], which will determine the minimally acceptable
voltage yielding optimal resolution for each detector. Voltages
should not be adjusted solely for the purpose of lowering com-
pensation values [2088].
2. To deal with spreading error beyond the above-mentioned
approaches, one can utilize the fact that spreading error is
directly proportional to the signal intensity. If assigning a flu-
orochrome to a lineage marker showing high and bimodal
expression (e.g., CD8), one can utilize lower Ab titers (below
saturating concentration) to lower the positive signal and in
turn the spreading error generated. However, it is important to
note that this approach requires consistent staining conditions
in terms of cell numbers, staining temperature, and staining
duration.
3. Many recent fluorochromes are based on organic polymers,
which can under certain conditions show interaction due to
their chemical properties. To alleviate this issue some manu-
facturers have released commercial buffers that are designed to
minimize these unspecific interactions, and thus it is strongly
encouraged to use these buffers whenever more than one
polymer-based dye (e.g., all Brilliant Violet and Brilliant Ultra
Violet dyes, SuperBright dyes, etc.) is included in a staining.
4. When performing experiments with staining and acquisition
over several days, it is recommended to follow best prac-
tices for consistent setup of the used instrumentry [48] and to
include a reference sample on every experimental day in order
to detect irregularities in staining, compensation or transfor-
mation. These control samples can then be overlayed in his-
tograms of all markers to visually control for the aforemen-
tioned errors. Should artifacts occur in the control samples, it
might be useful to either exclude specific parameters or sam-
ples from the computational analysis.
6 Single cell genomics and cytometry
6.1 Overview
Cells for single-cell genomics are in almost all cases collected
using FCM. FCM can be used to isolate cells of interest from more
complex biological samples, to perform index sorting upstream of
single-cell genomics workflows or to provide fluorescence intensity
measurements from single cells, that can be merged into single-
cell gene expression matrices as an additional layer of informa-
tion. Here, we provide an overview on how FCM complements
single-cell genomics technologies, together with a basic overview
on currently available technologies.
6.2 Introduction
Single-cell technologies provide an unprecedented view on the
complexity of biological systems, by uncovering how organisms
are build up from single cells and how these cells are different.
Classical bulk analysis tools analyze cell populations and conse-
quently, a whole layer of biological processes stays invisible, like,
for example, the presence of rare cell-types in tissues or gene-
expression heterogeneity that can depend on highly time-resolved
gene-expression bursts. Single-cell technologies depend on the
separation of cells from tissues or cell culture and their sorting into
separate reaction volumes, eventually containing a single cell per
reaction. Then, DNA- or RNA-sequencing technologies are applied,
specialized on low-input material. This allows to characterize the
genome, epigenome, or transcriptome of each cell. Bioinformatic
analysis, that takes into account the technical noise of sparse input
material data, is used to extract biologically meaningful processes.
Although single-cell technologies can be technically challeng-
ing, advances in sample and library preparation methods have
made single-cell analysis broadly available (Fig. 232):
1. FCM-based multiwell plate methods: Here, cells are sorted
into multiwell plates and allow optional indexing of the
sorted cells. Then, sequencing libraries are prepared from
wells, most frequently using SMART-seq2 [2089]. Option-
ally, library preparation can be done using robotics, which
increases throughput and at the same time, decreases batch
effects [2090].
2. Microfluidics- and nanowell-based methods significantly
increase throughput and decrease pipetting effort of single-
cell transcriptomics. DropSeq [2091] and InDrop [2092] are
frequently used and based on microfluidic chips that com-
bine barcoded beads and cells within droplets. Especially
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Figure 232. Examples of frequently used single-cell transcriptomics platforms. Comparison of different technologies for single-cell RNAseq,
including SMART-seqs, DropSeq, 10× Chromium, BD Rhapsody and sci-RNA-seq. Basic differences are explained in the main text. Here, we only
provide a collection of single-cell RNAseq methods to cover the key principles of the different technologies.
the invention of commercially available systems from 10×
Genomics, Dolomite Bio, and 1Cell Bio, made these technolo-
gies broadly available. Nanowell-based systems process thou-
sands of cells in a single step by depositing barcoded beads
and cells into nanowells on a printed chip [2090, 2093]. These
systems are commercially available, e. g., from BD Biosciences
(Rhapsody), Fluidigm (C1), or Clontech (ICell8). Compared
to microfluidics-based methods, nanowell systems have lower
throughput, however, improved control over the deposition of
beads and cells into wells using microscopy.
3. FCM-based single-cell combinatorial indexing uses a multi-
step barcoding strategy to increase throughput of single-cell
RNAseq without the need to set up microfluidics and nanow-
ell systems. Cells or nuclei are sorted into wells of a mul-
tiwell plate, indexed with a primary barcode, pooled, and
sorted again into wells, followed by a secondary barcoding
step. Consequently, each cell receives a unique combination of
barcodes, enabling RNA-molecules to be assigned to individual
cells [2094].
6.3 Obtaining single cells for single-cell applications
We will focus here on the application of FCM in combination with
different single-cell transcriptomics technologies. FCM upstream
of single-cell RNAseq library preparation allows to enrich for sin-
glet cells (essential for any single-cell method) and if needed, to
enrich for subpopulations of interest. These subpopulations may
be viable cells, non-apoptotic cells, cells in a specific cell cycle
phase, or cells expressing a sortable marker to enrich for specific
or rare cell types.
1. True, viable, and non-apoptotic cells can be isolated using
FCM. FCM markers and dyes are available, including Caspase
3/7 or AnnexinV for apoptosis and nonpermeable nucleic acid
dyes for cell membrane permeability assessment or DNA stain-
ing. Cell separation from tissues or cell culture results in imper-
fect single-cell separation and enables efficient identification
and isolation of singlets on an FSC/SSC plot. For such complex
samples, including organ biopsies or whole embryos, it is pos-
sible to identify cells using a cell permeable DNA dye such as
Hoechst 33342 or DRAQ5 [2095, 2096]. Figure 233 shows a
DRAQ5 and singlet gating on Drosophila larvae neuronal stem
cells, containing small cells that overlay with cellular debris
and yolk particles.
In addition to nonviable cells, pro-apoptotic and apoptotic cells
can be highly abundant in tissue preparations, but can be
removed using FCM. Such stainings can be done using Annex-
inV or Caspase3/7 [2097, 2098] (See Chapter V Biological
assays Section 7Measuring cell deathmechanisms). Figure 234
shows example apoptosis staining in bone marrow and brain
tissue preparations. The staining of pro-apoptotic cells is espe-
cially important, since these cells are difficult or impossible to
distinguish from live cells computationally. Apoptosis is a bio-
chemical process that can be initiated without prior changes in
gene-expression that can be identified on transcriptome level
(EMBL Genomics Core and Flow Cytometry Facility, unpub-
lished data). There is no objection to combine the apoptosis
staining with the viability stain on the same colour when the
panel is tight (see Chapter V Section 7 for details). Importantly,
we do not observe any influence of Hoechst, DAPI, or DRAQ5
stains on library preparation for RNAseq and single-cell tran-
scriptome data quality.
2. Singlet gating is key to ensure that only single cells are ana-
lyzed, as multiple cells are difficult to filter out during bioin-
formatics analysis. The combination of sequential FSC and
SSC height versus area pulse-shape analysis are reliable single
cell gates [2099]. However, pulse-shape analysis-based singlet
gates can become challenging when working with tissue mate-
rial composed of diverse cell types (e.g., bone marrow, lung,
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Figure 233. Cleaning up the scatter with a DNA stain resolves the masking of yolk and debris. Drosophila melanogaster larvae preparations were
stained with 2µM/mL DRAQ5 to identify DNA containing particles from debris. Clear gates for fluorescence-reporter expressing cells can be drawn.
intestine, skin). In these cases, the scatter-based singlet gates
(area vs. height) appear slightly spread and are often not effi-
cient in isolating single cells. This scatter heterogeneity results
from different optical densities, cell sizes, and shapes. To cir-
cumvent such limitations, the cell suspension can be stained
with a cell permeable DNA dye (e.g., DRAQ5 or DAPI) and
the signal is used for singlet gating (see Chapter V Biological
assays Section 6 DNA synthesis, cell cycle, and proliferation).
This method is independent of the scattering activity of cells,
since DNA content is always the same. Implementing this strat-
egy also allows to limit analysis to certain cell cycle phases, an
often unwanted source of cellular heterogeneity important to
consider during data analysis.
3. Gated cells should be of high purity and have a high chance to
end up either in a microtiter-well or in the bulk sort tube for
microfluidics/nanowell-based methods. Efficiency and purity
of sorting depend on the sorting mode; therefore, it is impor-
tant to select the best mode for the respective single-cell library
preparation method. For microfluidics/nanowell-based meth-
ods, bulk sorts are done, based on sort modes ensuring purity
of the sorted cells and fast sorting. Purity modes, however, suf-
fer of reduced probability that the gated cell is actually sorted,
because themode does not take into account the actual position
of the cell within the interrogated drop: If a cell is close to the
edge of the interrogated drop, it can move into the neighboring
drop during its travel time between detection and the actual
drop charging (Fig. 235). Generally, purity modes that are run
at an optimal sampling speed have an efficiency of 80 to 90%,
i.e., the number of cells within the bulk sort tube will be only
80 to 90% of the assumed cell number [2100]. It is therefore
important to count cells again after sorting and if necessary,
to concentrate cells again. Injection of cells at defined con-
centration into microfluidics/nanowell-based devices is key to
prevent doublet formation (too high cell density) or an unnec-
essary high number of empty droplets (too low cell density).
For microtiter-plate based methods, cells are sorted directly
into thewells of a plate using a single-cell sortingmode. Inmost
instruments, such modes implement a positional limitation for
the cell to be in the center third of the drop, on top of the purity
mask (Fig. 235). BD Aria systems use the phase mask scanning
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Figure 234. Advantage of combined apoptosis and viability stains upstream of single-cell RNAseq methods. (A) Scatterplots showing DRAQ5
staining (for singlet gating and cell cycle restriction) in combination with AnnexinV (apoptosis staining). Cells show a low frequency of dead cells
when assessing cell death purely by staining membrane-permeability. However, adding AnnexinV or Capase3/7 probes reveals that the viability of
the samples is rather mixed as many cells have started to become apoptotic. (B) High amount of pro- and late-apoptotic cells in dissected mouse
brain tissue. In both cases, a significant number of non-perfectly viable cells would have been sorted for downstream sequencing if only simple
live-dead staining with DNA-dyes was utilized.
the inside of the interrogated drop: If a cell falls within the
phase mask, the drop will not be sorted due to a high risk of
the cell moving into the leading or lagging drop (Fig. 235 and
http://www.bdbiosciences.com/ds/is/others/23-6579.pdf).
This results in a high probability of cells being sorted into the
tube/well, but at the cost of a high number of aborted cell
sorts due to phase mask violation (on average >50%) when
using manufacturer’s settings. Therefore, large bulk sorts are
not operated using single-cell mode.
In addition to the sorting mode, the performance of sorters
strongly depends on a perfect flow of the cells along the stream,
which depends for example on sample properties including cell
shape. One way to evaluate the machine derived drop delay
for new or difficult to handle cell types is an easy to set up
single-cell qPCR test, that is described in the Tips & Tricks
section.
4. Both microfluidics-based (e.g., 10× Genomics) and nanowell-
based (e.g., BD Rhapsody) single-cell transcriptomics solu-
Figure 235. Technical details of different single-cell isolation modes. The single-cell mode in DiVa and FACSChorus includes a purity mask
scanning the leading and lagging drop for contaminations plus a phase mask that scans the ends of the interrogated drop for the position of the
cell of interest. Any violation of the purity or phase mask will lead to the termination of the drop. This results in a general loss of >50% of potential
target cells—however, the mode has the highest precision for the cell to be delivered with the prospective drop while ensuring the purity and that
only one cell is deposited.
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tions use cell suspensions as input material that should ful-
fill the following requirements: (i) Cell viability must be high,
ideally above 90%, as measured with a dye exclusion assay,
e.g., Trypan blue (visual counting) or DAPI/Draq7 (FCM). Cell
death inside the single-cell suspension and prior to droplet-
generation results in ambient RNA that will be present in every
droplet, reducing data quality. (ii) Only singlet cells should be
present, as multiplets are packaged into droplets or wells at
similar efficiency as singlet cells. (iii) Measurement of cell den-
sity should be exact and done directly before loading cells into
the device. Loading too many cells results in a high multiplet
rate, loading too less cells results in an unnecessary high num-
ber of empty droplets/wells and consequently, increases costs
per cell. For 10× genomics, ideal cell density is between 600
and 1500 cells/µL. (iv) Cells should be suspended in a buffer
like PBS or PBS + 0.04% (w/v) BSA and stored at 4°C until
loading. Buffers that include residual RNase or DNase from
upstream cell preparation should be replaced. Other buffers
have been validated for different single-cell protocols (see
respective manufacturers protocols), as for example DMEM +
10% FCS. Cell viability must be stable under these conditions,
which can be tested in advance by prolonged incubation in the
buffer and dye exclusion test before and after incubation. As
cells settle fast, they should be mixed prior to loading. This can
be done by pipetting or vortexing, depending on the cell type
requirements. In case of longer runs, as often necessary when
running DropSeq and other custom-built setups, cells can be
constantly mixed using a magnetic mixer, preventing changes
in injected cell concentration over time.
Of note, some cell types are more difficult to capture using
microfluidics/microwell-based single-cell methods than others
[2090, 2101]. Especially when working with complex tissues,
this can result in underrepresentation of specific cell types and
consequently, wrong conclusions regarding tissue biology. This is
especially true using microfluidics- and nanowell-based methods,
since it is not possible to see which types of cells are less efficiently
packed into the reaction volumes. Here, it can make sense to do
plate-based single-cell libraries using SMARTseq2.
6.4 Applications
Single-cell transcriptomics
Single cell transcriptome sequencing measures the expression
level of polyadenylated transcripts within single cells. Further-
more, data contains transcript sequence information that can be
used for structural variant analysis or the identification of splice-
variants. Depending on the protocol and technology used, either
whole transcripts or transcript 5’ or 3’-ends are sequenced, with
3’-RNAseq being the most widely used technology for gene expres-
sion analysis.
Other single-cell omics technologies
Transcriptomes are highly informative, but alternative read-
outs reveal different views on cell-to-cell differences. These tech-
nologies include whole or targeted genome sequencing and epige-
nomics, for which both commercial and non-commercial plat-
forms are available. Furthermore, proteomics and metabolomics
are entering the single-cell field. Single-cell multiomics, i.e., the
simultaneous analysis of two or more omics (e.g., genome and
transcriptome) in the same cell, will become less technically chal-
lenging. Analyzing phenotypes on top of these -omics technolo-
gies, for example, by imaging-based FCM (see Chapter VIII Section
1 Imaging FCM) will become available in the future. Currently,
these technologies suffer of low image quality, function at com-
paratively low throughput and depend on technically challenging
setups that are not widely applicable.
CRISPR-screening technologies
CRISPR/Cas9 technologies can be combined with FCM and
single-cell technologies, providing a powerful tool for large-scale
functional genomics. CRISPR/Cas9-sgRNA libraries are applied
to cells under conditions in which one cell expresses one sgRNA
along with Cas9. The functional consequence of such a perturba-
tion is then analyzed using simple or complex readouts: Simple
readouts rely on FCM, e.g., by analysis of a fluorescent reporter
or a proliferation dye. Then, sgRNA enrichment analysis within
the binned and sorted populations is done by extracting genomic
DNA and sequencing of the integrated sgRNA sequences. This
allows conclusions on the influence of each sgRNA in the library
on the respective phenotype. Even simpler, positive or negative
selection screens analyze sgRNA enrichment after 1–3 weeks of
growth with sgRNAs being either enriched or depleted depend-
ing on the function of the targeted gene. Complex readouts can
be generated by coupling CRISPR/Cas9 with single-cell transcrip-
tome readouts (CROP-Seq and similar methods). Here, the sgRNA
sequence or a coupled barcode is sequenced along with the tran-
scriptome, allowing to compute transcriptomic changes upon each
perturbation in intermediate to high throughput.
6.5 Data analysis
Single-cell RNA sequencing (scRNA seq) development opened in
the last couple of years new approaches to answer important ques-
tions in developmental biology [2102], cancer [2103], and neural
network analysis [2104].
Detection and quantification of gene expression at single-cell
level encompasses many challenges regarding data analysis. As an
example, the very low starting material from a single-cell can lead
to dropout genes in some cells and not in others. The stochas-
tic nature of gene expression might imply an important cell-to-
cell biological variability in single cell measurements although the
specific cell is currently in a different expression cycle. These con-
founding factors, including variable detection sensitivity, batch
effects, and transcriptional noise, complicate the analysis and
interpretation of scRNA sequencing datasets.
Before using sequencing reads to extract valuable biological
information, crucial considerations need to be put into the
design of the experiment to lower at its minimum the impact of
confounding elements and technical artifacts. These aspects have
been discussed in detail in refs. [2090, 2105].
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Analysis tools for bulk RNAseq have been first used and adapted
to address the specific properties of scRNAseq data [1869, 2105].
Normalization is an essential first process in the global analysis
workflow for scRNAseq due to high data variability and noise.
The aim is to correct the biases introduced by gene expression
dropouts, amplification, low library heterogeneity or batch effects
(e.g., different platforms, time points, technical handling, reagent
lots, etc.). External synthetic spike-in controls help to disentangle
the technical noise from natural biological variability [2106].
Adaptation of formerly developed methods for bulk RNA sequenc-
ing could also be used [2107–2109]. More recent approaches are
normalizing the data between sample [2110] or cell-based factors
derived from the deconvolution of pool-based size factors [2111].
The popular R package Seurat integrates a comprehensive work-
flow from the quality assessment of each cell to analyze, exploring
scRNA-seq data as well as integrating different datasets [2112].
The transcriptional landscape of a single cell can be compared
based on co-expressed genes. Here, cells are grouped into clus-
ters and marker genes, which are driving the expression signature
of sub-clusters, are identified and annotated. Before the identifi-
cation of cell clusters, visual exploration is usually achieved by
dimensional reduction, where the dataset is projected to only a
couple of dimensional spaces. Among these approaches, principal
component analysis (PCA) [2113], t-SNE [2114], or UMAP [2115]
are frequently used. Different clustering approaches and tools have
been compared using a similarity index, i.e., the adjusted Rand
index [144]. Annotation of differentially expressed (DE) genes
between clusters allows biological hints on the nature of the sub-
population [145] and provides a comprehensive overview of the
available DE methods. Finally, methods aiming to infer the differ-
entiation trajectory of the clusters have been also compared in a
comprehensive study [2116].We would also like to mention two
interesting resources, listing software packages dedicated to the
different scRNAseq applications (https://www.scrna-tools.org/
and https://github.com/seandavi/awesome-single-cell).
6.6 Top tricks
A simple single-cell qPCR protocol to test sorting efficiency
prior to single-cell sequencing
Since single-cell sequencing can be cost-intensive and not all
handling errors during sample preparation can be identified later
during data analysis, We therefore provide a protocol allow-
ing to check FCM instrument performance in advance, if using
novel or difficult to sort cell types, This protocol was developed
by the Stahlberg lab and is currently taught in the EMBO and
EMBL single-cell trainings courses on single cell omics technolo-
gies [1905, 2117].
Testing whether the sort-stream hits the center of test tubes and
microtiter plates is straight-forward. However, it is more difficult
to validate if the drop-delay (as most frequently assessed with
fluorescent beads) works with novel cell types or cells that show
difficult behavior within the stream: Some cells, especially larger
and more structured cells, have the tendency to tumble in the
stream, slowing them slightly down due to potential drag. This
could lead to a reduced number of positively seeded wells or to
reduced cell numbers in a bulk sort. Sorting single cells into a
multiwell-plate followed by qPCR of a highly expressed gene will
give a precise measurement of sorting efficacy.
Protocol
Materials required:
 Human GAPDH primers:
GAPDHv2 Fwd CCCACTCCTCCACCTTTGAC
GAPDHv2 Rev GCCAAATTCGTTGTCATACCAGG
 BioRAD Hard-Shell R© 96-Well PCR Plates, low profile, thin wall,
skirted, red/clear #hsp9611
 TATAA SYBR R© GrandMaster R© Mix ROX - TA01R
 TATAA GrandScript cDNA Synthesis Kit - A103c (1000 rxn)
A103b (200 rxn)
 CelluLyserTM Micro lysis buffer - H104
 RNAse and nucleotide free water
Procedure:
Cell sorting into plates
In addition to standard FCM calibration, the instrument needs
to be calibrated to deposit cells in the center of each collection
tube. This can be tested by sorting 10–20 beads/cells on plas-
tic film covering the plate or by checking drop formation on the
bottom of a hard-skirted BioRAD PCR plate (Fig. 236). In case
of non-optically tracked arms, we suggest to check the calibration
every second plate, because the sorting armmay be displaced over
time. A too small volume of provided buffer (here: lysis buffer)
increases the risk of a cell not reaching the buffer but sticking to
the tube wall, while too large volumes might not work with down-
stream applications. We recommend sorting two wells with each
ten cells (positive control), to include at least two wells that will
intentionally not receive a cell (negative control) and the rest of
wells with single cells.
PCR plates (96-well) with lysis buffer should be prepared in
advance: We found that 5 µL of provided Cellulyser weak lysis
buffer per well works well. Immediately after sorting into the
plates, place the plate on carbon ice, and store at –80°C until
proceeding with reverse transcription.
Reverse transcription
We have good experience with TATAA GrandScript cDNA syn-
thesis Kit using a mix of oligo-dT and random hexamers. We
generally use the following reverse transcription protocol (added
directly to the frozen cells, per well): 2 µL 5× TATAA Grand-
Script RT reaction mix, 0.5 µL TATAA GrandScript RT enzyme,
and 2.5 µL nuclease-free water (according to the manufacturer’s
instructions). The total volume per well is 10 µL. Reverse tran-
scription is done using the following temperature profile: 22°C for
5 min, 42°C for 30 min, and 85°C for 5 min.
Quatitative PCR
GAPDH is highly and ubiquitously expressed and can be used
to detect the presence of a single cells using qPCR amplification
irrespective of the cell type. Normal qPCR-MIQE guidelines apply
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Figure 236. (A) Transparent hard-shell PCR plates can be used to check the correct deposition of sorted drops into 96-well PCR plates; controlling
the aim at the bottom of the well is superior to only checking on a seal or lid above. (B) An example outcome of the single-cell qPCR protocol
checking single-cell deposition of HeLa cells with GAPDH qPCR. Positive controls (ctrl) contained 10 cells per well, negative controls were empty
wells. All single cells show formation of a specific PCR-product, indicating that all wells with expected single cells contained a single cell.
to the described qPCR assay For using a high number of amplifi-
cation cycles due to low input material, consequently we suggest
to check melt curves for byproducts and primer-dimers after PCR.
Dilute cDNA samples to a final volume of 30 µL with H2O.
Prepare qPCR reactions for a total volume of 10 µL per well: 5 µL
qPCR 2×Mix, 0.4 µL 10 µM fwd/ref primer mix, 2.1 µl H2O, 2.5 µL
cDNA. A mastermix of qPCR 2×Mix, fwd/rev primer, and H2O
should be prepared. qPCR is run using SYBR Green ROX protocol
for 50 cycles followed by melt curve: 30 s 95°C, 50× (5 s 95°C,
20 s 60°C, 20 sec 70°C), 65 °C to 95 °C with 0.5°C increment.
Exemplary results are shown in Fig. 236.
7 Microbial cells
7.1 Overview
Recent insights into the impact of the microbiota for the environ-
ment and for human health has led to an explosion of research
efforts to try to understand the role and mechanisms of bacteria,
bacterial communities, and their products in regulating homeosta-
sis and pathology. With the advent of high-throughput sequencing
technologies, 16S rRNA gene amplicon sequencing and metage-
nomic approaches are widely applied to resolve the community
structure while proteomic approaches are used to reveal func-
tional relationships. However, these methods are still expensive,
time consuming, and have high requirements for data analysis.
FCM offers a fast and inexpensive alternative for the single-cell
based characterization and analysis of microbial communities. Yet,
flow cytometric measurement of microbial cells is still challenging
and several issues that have to be considered will be discussed in
this section. If done correctly, FCM of bacteria can surpass simple
applications such as counting cells or determining live/dead cell
states [2118].
7.2 Introduction
Complex microbial communities occur almost everywhere, from
natural environments such as fresh water systems, marine envi-
ronments and soil, to managed systems such as drinking water
facilities or wastewater treatment plants, to the gut or skin of
humans and animals. Recent research efforts have highlighted
the importance of microbial communities, not only in the environ-
ment, where they are responsible for all biogeochemical processes,
but also as integral part of multicellular organisms. As bacterial
microbiota, they colonize all body surfaces and have been shown
to educate the immune system but also play a crucial role in
inflammatory diseases such as asthma, inflammatory bowel dis-
ease (IBD), and obesity.
Bacteria can vary up to two orders of magnitude in size, but 0.8
to 3 µm are common dimensions. Unlike eukaryotic cells, bacterial
cells are not compartmentalized, i.e., they do not have organelles,
allowing dyes to move freely in the cytoplasm unless they bind to
specific structures such as DNA. This and the small volume of the
bacteria can favor interactions of fluorescent dyes leading to loss
of fluorescence intensity, making the simultaneous intracellular
use of more than one or two dyes challenging. Most bacteria also
have a cell wall that prevents the intracellular uptake of almost all
larger probes such as Abs. The major challenge but also the major
advantage of bacterial cytometry is the inability to grow many
bacteria as pure culture. While “culturomics” has led to a large
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Figure 237. Flow cytometric analysis of cell states in pure cultures of Escherichia coli K12 grown on complex DSM 381 medium. Cells were sampled,
treated with 2% PFA and fixed in 70% ice-cold ethanol. Following, cells were stained with a 0.24 µM DAPI solution and measured using a 355
nm Genesis CX laser (100 mW, both Coherent, Santa Clara, CA). Scatter was measured using a 488 nm Sapphire OPS laser (400 mW). 0.5 µm and
1 µm Fluoresbrite Microspheres (both Polysciences, 18339 and 17458, Warrington, PA, USA) were added to every sample as internal standards. A
and C show nearly identical proliferation patterns during lag and stationary phases of growth. B shows the proliferation pattern (uncoupled DNA
synthesis) in the log-phase. The right graph D shows the growth curve where samples were taken from 500 ml batch cultures with 200 ml medium
for a time range of 24 hours. After a short lag phase the cells immediately started exponential growth which ended after about 20 hours.
increase in the number of bacteria that can be grown in culture,
still many bacteria cannot. Lack of pure strains of bacteria pre-
cludes calibration and verification of specific staining. In addition,
cells of the same bacterial strain change their physical and physi-
ological properties depending on micro-environmental conditions
and growth phase. Bacterial cells tend to be small in unfavorable
growth conditions and increase in size during optimal growth
conditions. While bacteria typically have one molecule of genomic
DNA, some can have multiple copies of the same genomic DNA
or have two or three genomic equivalents of different length and
composition. The numbers of genomic DNA equivalents are also
not evenly distributed among cells of a population as asymmetric
cell division and uncoupled DNA synthesis is widespread among
bacteria. The number of genomic DNA copies does not indicate
the condition of the cell, as the cells often do not divide under
stress conditions and retain the high copy number of genomic
DNA [2119].
When considering these caveats, some of which can also be
used as discriminating parameters, FCM is a well-suited method
to study bacteria at the single-cell level. While the diversity of
such natural communities can reach up to several thousands of
different phylotypes per 1 g of sample, making cell type-specific
labeling impossible [2120], approaches such as cytometric finger-
printing of natural microbial communities can be used to analyze
community structures, complexity and alterations. New bioinfor-
matics tools for quantitative and automatic evaluation of bacterial
cytometric fingerprints are becoming available enabling the identi-
fication of subpopulations or sub-communities of interest for sub-
sequent cell sorting and downstream analyses, such as NGS or
proteomics approaches [2121, 2122].
7.3 Applications
A common application is the discrimination and enumeration of
live bacteria using live/dead dyes. Both in biotechnology and in
the environment changes in cell numbers can have major implica-
tions. Also recently, it has been shown that cell numbers are impor-
tant for the standardization and normalization of 16S rRNA gene
sequencing data [2123]. Flow cytometric applications achieving
high resolution of light scatter and DNA content discrimination
can be used to characterize and resolve complex microbial com-
munity structures, such as environmental microbiota or intestinal
microbiota by generating community patterns.
There is a wealth of methods available to analyze states of cells
in pure culture [2124]. Such methods are often used to describe
segregated cell states of different activity. Besides the measure-
ment of intracellular components also the determination of energy
or growth states are in the focus to understand cell behavior.
Especially in medicine, the detection of pathogens and their dif-
ferentiation from other bacteria is desirable. Cell type labeling
and cell proliferation can give information on active cell growth.
Uncoupled and fast DNA synthesis can easily be visualized by FCM
(Fig. 237B) and discriminated easily from non-growing cell states
(Fig. 237A and C).
7.4 Equipment
Not all flow cytometers are suitable for the measurement of bac-
teria but we have good experiences with the BD Influx v7 Sorter
and MoFlo Legacy cell sorters [2125]. Due to the small size the
amount of dyes bacterial cells bind is significantly lower resulting
in the generation of low number of photons when excited com-
pared to eukaryotic cells. Thus, high laser power starting at 50
mW and going up to 400 mW lasers, highly sensitive PMTs for
signal detection and clear tubes and water streams to provide low
background signals are important prerequisites for the measure-
ment of bacteria. Forward (information related to cell size) and
side (information on granularity and surface structure) scatter sig-
nals of cells are best recorded at lower laser wavelengths (i.e., 350
nm or at least 488 nm). Using machines that lack sensitive scatter
detection, using fluorescence of, e.g., nucleic acid stain as trigger
signal for acquisition is an option. All solutions should be filtered
(0.1 µm) before use. Samples isolated from natural environments
may require a sensitive shaking or even an ultrasonic treatment
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to dissolve flocs (see below). Samples should be filtered before
measurement through a 50 µm mesh to avoid the clogging of the
nozzle.
7.5 Experimental workflow and acquisition
Whenmeasuring viable bacterial cells by FCM, one has to be aware
that some bacteria have generation times of only few minutes.
Although bacteria are generally easy to handle, their physiological
cell states can change from one minute to the next. Therefore,
techniques that include fixation tend to be more robust. Several
fixation methods have been described [2126]. In short, bacterial
cells are incubated for 2% PFA at for 30 min at room temperature
to stabilize the cell wall and finally fixedwith 70% ice-cold ethanol.
As this stage, samples are stable for weeks to month at –20°C.
When staining methods are sensitive to PFA pretreatment cells can
be stored stably in 20% glycerol at –20°C. Alternatively, samples
can be stabilized for storage and shipping at ambient temperatures
by infrared supported drying [2125]. However, it is crucial to test
the optimal stabilization method for the samples in questions and
the downstream application.
Bacterial communities can comprise cells of different sizes and
shapes. Thus, classical doublet discrimination using, e.g., width
signal versus height signal is not possible. For samples, where
clumping of bacteria is expected, ultrasound sonification should
be considered to resolve cellular aggregates. Also here, conditions
of sonification have to be established for different types of samples
to maintain cellular integrity. A typical treatment is exposure to
35 kHz and 80 W effective output power for 1 min in an ultrasonic
bath to disband large cell aggregates [2125].
One also has to be aware that some bacteria can be permeable
to otherwise cell-impermeable dyes, such as PI, and other bacte-
ria very efficiently shuttle out otherwise cell-permeable dyes, such
as SYTO9, easily resulting in false positives and negatives when
looking at complex microbial communities [2123, 2124, 2127].
Again, the non-cultivability of many bacteria precludes the vali-
dation and calibration of such staining procedures. This applies
also to other viability dye approaches, such as the measurement
of membrane potential. Inhibition of the respiratory chain and
depolarization of the membrane potential are important controls
for this method, but is not feasible for all the different cell types
in complex microbial communities.
Protocols should be optimized for staining all cells to mark and
visualize each cell in a community. Good dyes for this are nucleic
acid dyes such as DAPI used on fixed cells together with a cell
wall permeabilizing detergent to allow quantitative penetration
of DAPI through the cell wall [2125]. SYBR R© Green I has also
been described for staining of nucleic acids of viable cells [2128],
although one should be aware of the above mentioned limita-
tions. When available, specific Abs can be used to identify specific
phylotypes in communities. Further differentiation of cell types in
communities can be performed by themore qualitative approaches
of fluorescent in situ hybridization (FISH) and lectin probes, while
cell constituents such as lipid inclusion bodies can be stained by
highly lipophilic dyes [2124].
A major limitation of microbial community cytometry as
described here is the lack of any taxonomic or functional infor-
mation in comparison to sequencing approaches, where cell phy-
lotypes can be determined or genes with certain functions be
detected or even metagenomics analyses be performed. To get
a deeper insight, cell sorting can be used to separate interesting
sub-communities [2122] or even single cells [2129] for further
analyses by, e.g., NGS or proteomic technologies. Cell sorting not
only provides access to bacteria that are currently not culturable,
but also reduces background, as all cells outside of the sorted
gates will not be included in downstream analyses increasing the
resolution of the data obtained.
The positions of gates (subcommunities) to be sorted are still
defined manually. Cell sorting should be done in the ‘1.0 Drop
Pure’ sort mode (BD Influx v7 Sorter). Between 500 000 and
5 000 000 cells within the selected gates should be sorted into
tubes at rates from 200 up to 1000 cells/s. Sorted cells are har-
vested by two successive centrifugation steps (20 000 × g, 6°C,
20 min), and the cell pellets can be stored at –20°C for subse-
quent analyses [for proteomics: [2130]; for 16S amplicon profil-
ing: [2122, 2131]].
7.6 Data analysis
High resolution FCM can resolve microbial community structures
by generating community patterns. It is highly recommended to
use a stain that labels every cell for this purpose. These communi-
ties are interpreted as pattern (see below post-processing of data)
and are generally used to determine community dynamics and to
allow for sort decisions.
To evaluate data as shown in Fig. 238, a master gate should
be defined that contains all cell events excluding the beads
(Fig. 238D). It is advisable to always measure the same number of
cells. Usually 200 000 cells are sufficient for downstream analysis
pipelines. For cytometric fingerprinting, a gate template has to be
generated by marking all apparent sub-communities by a gate and
combining all defined gates to the gate template (Fig. 238D and
G). The gate template allows the determination of the cell num-
ber per gate across the different samples. The dynamic variation
of community structure can then be described by quantifying the
changes of events per gate [2132].
For the analysis of the cytometric microbial commu-
nity fingerprint some evaluation tools are already avail-
able. FlowFP [2133, 2134] uses a geometrical grid as an
alternative to cluster-based gating of FCM profiles. Alterna-
tively, flowCHIC (cytometric histogram image comparison,
http://www.bioconductor.org/packages/release/bioc/html/
flowCHIC.html, [2135]), is also a grid-based algorithm that
transforms 2D cytometric profiles (e.g., DAPI vs. FSC) into
grey-scale images and compares the pixel density between
two successive samples. FlowCybar (cytometric barcoding,
http://www.bioconductor.org/packages/release/bioc/html/flow
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Figure 238. (A–D) A microbial community originating from a wastewater treatment plant cultivated in an aerobic and continuously operated
bioreactor on a peptone medium for (A) 34, (B) 44, and (C) 58 weeks [2131], and (E–G) microbial community derived from a fecal sample of a mouse
(E) before and (F) after induction of T cell-transfer colitis [2122]. Samples were taken and stained with a 0.24 µMDAPI solution and measured using
a 355 nm Genesis CX laser (100 mW, Coherent, Santa Clara, CA, USA, MoFlo Legacy cell sorter, (Beckman Coulter, Brea, California, USA). Scatter
was measured using a 488 nm Sapphire OPS laser (400 mW). Beads of sizes 0.5 µm and 1 µm Fluoresbrite Microspheres (both Polysciences, 18339
and 17458, Warrington, PA, USA) were amended into every sample as internal standards. Amaster gate (D and G: grey) was defined that comprised
200 000 cells for each measurement. Each upcoming subcommunity was marked by a gate in the three samples and a combined gate template
generated (D and G: black ellipses). The three chosen samples show the highly diverse cytometric structure of the community and its evolution
over time.
CyBar.html, [2132]) produces the cytometric fingerprint on
the basis of the gate template as described that represents the
microbial community structure by the number of clusters, the
position of these clusters in the histogram, and the number of
cells within each cluster. The direct comparison of cell abundance
changes between gates with high and low cell numbers is facili-
tated by data normalization. FlowCybar can visualize variations
of the cytometric fingerprint over time or in dependence on
experimental/abiotic factors.
7.7 Advantages
– Relatively quick and cheap
– Absolute cell counts
– Sorting of bacteria for downstream genetic, proteomic, and
functional analyses possible
7.8 Pitfalls
– Membrane-permeable DNA/viability dyes can be excluded or
shuttled out by certain viable bacteria
– Taxonomic information requires FISH probes or specific anti-
bodies
– Limited data analysis tools available
– Specific instrument requirements for high-resolution bacterial
community structure measurements
– Standardization required for cross-sample comparison
7.9 Top tricks
The flow cytometer should be aligned before measurement using
1 µm or 2 µm beads that are fluorescent in the required range
of light. In addition, we strongly advise to spike both 0.5 µm
and 1 µm beads into each sample to guarantee comparability
between samples. Creation of a gate template for these two types
of beads and aligning the beads always inside the same gate tem-
plate allows the comparison of data over weeks and months. It
should be ensured that the beads lie outside of the cell popula-
tions to be analyzed (see Figs. 237 and 238). Beads, however, do
not control for identical sample handling. When cells are stained
using solutions in nanomolar concentration ranges, even small
experimental variations result in handling-dependent changes of
the fluorescence of the cells. To control for variations in handling,
we recommend the additional use of a biological standard (with
respective gate template). For this, fixed Escherichia coli cells that
undergo the same procedure as the samples to be analyzed can
be very helpful. For all published data, the cytometer setup and
the applied standardizations should be specified together with the
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experimental data deposited, for example, in the FlowRepository
(https://flowrepository.org/).
8 Detailed and standardized methods to detect
inflammasome assembly and activation in immune
cells (FlowSight AMNIS)
8.1 Overview
Inflammasome is a multimeric protein platform involved in the
regulation of inflammatory responses whose activity results in the
production of IL-1β and IL-18.The evidences of inflammasome
activation are the concentration of the inflammasome adapter pro-
tein apoptosis-associated speck like protein containing a caspase
recruitment domain (ASC) into a single speck and a rapid lytic
form of cell death termed pyroptosis. In this section, we will show
inflammasome activation by ASC speck detection at single cell
level using imaging cytometer technology by FlowSight.
8.2 Introduction
The inflammasomes are intracellular multimeric protein com-
plexes, mainly expressed inmyeloid cells, whose aggregation leads
to the activation of the caspase-1 and the downstream secre-
tion of three of its substrates, the proinflammatory cytokines
IL-1β, IL-18 and gasdermin-D that in turn leads to pyroptotic
cell death [2136–2138]. Nod-like receptors (NLRs), in partic-
ular, are cytoplasmic pattern recognition receptors that detect
invading pathogens and initiate inflammasome-dependent innate
immune responses. NLRs are activated by bacterial, fungal, or
viral molecules that contain PAMPs, or by non-microbial danger
signals (DAMPs) released by damaged cells [2139, 2140]. Upon
activation, some NLRs oligomerize to form multiprotein inflam-
masome complexes that serve as platforms for the recruitment,
cleavage, and activation of inflammatory caspases. At least four
inflammasome complexes (NLRP1, NLRP3, IPAF, and AIM2) have
been identified. These complexes contain either a specific NLR
family protein or AIM2, the apoptosis-associated speck-like pro-
tein containing CARD (ASC) and/or the Cardinal adaptor pro-
teins, and pro-caspases-1, 5 and 8 [2141, 2142]. NLRP3 is the
best-characterized inflammasome; its formation requires multiple
steps. In a priming step, transcriptionally active signaling recep-
tors induce the NF-kB-dependent induction of NLRP3 itself as
well as that of the caspase 1 substrates of the pro-IL-1β fam-
ily [2143, 2144]. The NLRP3 is, at this stage, in a signaling incom-
petent conformation; this is modified upon a second signal which
will result in the assembly of a multimolecular complex with ASC
and caspase 1. Notably the inflammasome activation consists in
the assembly of NLRP3 with ASC that in turn recruits procaspase-
1 by its caspase recruitment domain (CARD) or procaspase-8 by
pyrin domain (PYD) [2145] forming ASC speck [2146] and lead-
ing to caspases activation. The assembled ASC speck is the main
feature of inflammasome formation and it occurs within min-
utes of activation, and it stabilizes, finally it is released into the
intercellular space, collected by myeloid cells spreading inflam-
mation [2147–2149]. Notably the resting myeloid cell show ASC
protein diffuse in cytoplasm, after inflammasome activation the
ASC shifts to form a speck.
The activated caspase-1 leads to the cleavage and release of
bioactive cytokines including IL-1β and IL-18 and also of pro-
tein GSDMD causing membrane rupture and pyroptotic cell death
[332]. The pyroptosis plays an important role in inflammatory
response and its assessment could be of interest for therapeutic
intervention (see Chapter V: Biological Applications, Section 7.4:
Pyroptosis).
8.3 Applications
The assembly of a functional NLRP3 inflammasome complex
results in the production of proinflammatory cytokines; although
these cytokines have a beneficial role in promoting inflamma-
tion and eliminating infectious pathogens, mutations that result
in constitutive inflammasome activation and overproduction of
IL-1β and IL-18 were linked to inflammatory and autoimmune
disorders [2150–2152]. A number of recent data strongly suggest
that an excessive activation of the NLRP3 inflammasome can be
observed as well in neurological diseases includingmultiple sclero-
sis as well as Parkinson’s and Alzheimer’s diseases, in which neu-
roinflammation plays a central role [2153–2157]. Indeed given
that the neuroinflammation is the probable consequence of the
activation of inflammasomes in immune cells that infiltrate the
central nervous system, dampening of the inflammasome assem-
bly could be beneficial in these diseases and could be envisioned as
a possible therapeutic approach to these conditions. For these rea-
sons, the quick and accurate evaluation of inflammasome assembly
in peripheral immune cell could be a good methodology approach
to monitoring inflammation in a number of diseases.
8.4 Principles of the technique being described and
Equipment
Sester and colleagues performed an FCM method to detect ASC
redistribution in myeloid cell defining speck formation by changes
in fluorescence peak height and width [2156, 2157]. This proto-
col permits to define the true activated inflammasome by assess-
ment ASC speck formation, because until then the detection of
inflammasome, activation was made by monitor its end products,
IL-1β or IL-18, or activated caspase-1 detection. Notably different
pathways can secrete IL-1β and the methods to analyze caspase-1
activity are not always specific, in both cases the outcomes could
be inflammasome independent. Despite to ASC speck formation
microscopy analysis, used in the past, this methodology is faster,
more accurate, and sensitive. Recently a better method to analyze
simultaneously ASC speck and caspase-1 activity was performed
by Amnis ImageStreamX [2158]. This protocol eliminates false
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positive events detected by flow-cytometry method, by specific
masks to select only single cell, excluding cells with nonspecific-
like aggregation of ASC and also defining ASC speck size. Finally
the study analyze the presence and distribution of active caspase-1,
detected by FLICA spots, and ASC speck simultaneously, evaluat-
ing inflammasome activation.
In this section we show the analysis of inflammasome activa-
tion by FlowSight, performed utilizing ASC speck formation in
LPS+Nig stimulated-THP1derived macrophage.
8.5 Experimental workflow and acquisition
8.5.1 THP1 cell differentiation. THP-1 human monocytes
(IZSLER, Istituto Zooprofilattico Sperimentale della Lombardia
e Dell’Emilia Romagna, IT) are grown in RPMI 1640 supple-
mented with 10% FBS, 2mM L- glutamine, and 1% penicillin
(medium)(Invitrogen Ltd, Paisley, UK). To differentiate these cells
into macrophages, THP-1 humanmonocytes are seeded in six-well
plates at a density of 1.0× 106 cells/well inmedium that contained
50 ηM of PMA (Sigma–Aldrich, St. Louis, MO) and incubated for
12 h at 37°C in 5% CO2.
THP1-derived macrophage culture and intracellular inflamma-
some protein staining
THP-1-derived macrophages are cultured with medium alone
(negative control) or are incubated with LPS (1 µg/mL) (Sigma-
Aldrich) for 2 h and Nigericin (Nig; 5 µM; Sigma–Aldrich) for the
last 1 h.
THP-1-derived macrophages (1 × 106) are harvested by 0.05%
(w/v) trypsin (Seromed, Biochrom KG) in EDTA solution for
5 min at 37°C, washed once in RPMI supplemented with 10%
FBS, seeded in polystyrene round-bottom tubes (Falcon 2052,
Becton Dickinson Labware, Franklin Lakes, NJ) and centrifuged
for 10 min at 1500 rcf at 4°C. Tubes containing THP-1-derived
macrophages are placed on ice; cell are permeabilized with 100 µL
of Saponine in PBS (0.1%; Life Science VWR, Lutterworth, Leices-
tershire,LE) and 5 µL (25 µg/mL) of the PE-antihuman ASC (clone
HASC-71, isotype mouse IgG1,Biolegend, San Diego, CA) mAbs
are added to the tubes for 1 h at 4°C. Cells are then washed
with PBS and centrifuged at 1500 rcf for 10 min at 4°C. Finally,
cells are fixed with 100 µL of PFA in PBS (1%) (BDH, UK) for 15
min, washed with PBS, centrifuged at 1500 rcf for 10 min at 4°C,
resuspended in 50 µL of iced PBS, and immediately analyzed by
FlowSight.
8.5.2 Human peripheral monocyte cell cultures. PBMC
(1 × 106/mL) are cultured in RPMI 1640 supplemented
with 10% human serum, 2 mM L-glutamine, and 1% penicillin
(Invitrogen Ltd, Paisley, UK) and incubated at 37°C in a humid-
ified 5% CO2 atmosphere for 2 h in a 12-well plate. After 2 h,
non-adhering PBMCs are harvested and discarded; monocytes
(adhering cells) are culture in medium alone (unstimulated) or
primed with 2 µg/mL LPS for 2 h (Sigma–Aldrich, St. Louis,
MO) before stimulation with Nigericine (5 µM) (Sigma–Aldrich)
for 1 h at 37°C in a humidified 5% CO2 atmosphere. Adhering
cells (monocytes) are then collected by trypsin treatment and
prepared for FlowSight analysis by immunofluorescence staining
as THP1-derived macrophage (see above).
8.6 Data analysis
ASC-speck formation is analyzed by FlowSight (Amnis Corpora-
tion, Seattle, WA, USA) (see chapter VIII, Section 1 “Imaging flow
cytometry”).
8.6.1 FlowSight acquisition parameters. The FlowSight (Milli-
poreSigma) equipped with 488, and 642 nm lasers with two cam-
era and twelve standard detection channels is used to acquire
experimental samples using the INSPIRE software.
The flow rate is set tominimum and the objectivemagnification
is set to 20x for all samples.
A multifluorophore-labeled sample (Flowsight Calibration
Beads) is used to determine accurate laser and focus settings and
avoid oversaturation.
Masks are defined region of interests that are computationally
calculated by INSPIRE.
A mask defines a specific region of an image that can be used
for specific feature calculations.
The saturation of an individual fluorophore in its corresponding
channel is determined by plotting the Raw Max pixel feature for
every channel.
Aspect ratio feature measures circularity, to distinguish
between singlets, doublets, and cell clumps when used together
with the area feature.
Area versus aspect ratio of the default mask on the brightfield
is used during acquisition to ensure collection of single-cell events.
A region is created to exclude debris and to record 2000 events
for every sample.
For the compensation control, 1000 events for single-stained
samples are acquired turning the Ch01 (brightfield) and Ch06
(side scatter) off.
All samples and controls are acquired as raw image files (.rif).
8.6.2 FlowSight image analysis. All sample and compensation
analysis are performed using analysis software (IDEAS).
The IDEAS image analysis software allows quantification
of cellular morphology and fluorescence at different cellular
localizations by defining specific cellular regions (masks) and
mathematical expressions that uses image pixel data or masks
(feature).
Individual compensation controls of single-stained samples are
loaded into the compensation wizard in IDEAS. A compensation
matrix file (.ctm) is generated and applied to a positive control
(nigericin-treated sample) raw data file (.rif) to generate both a
compensated image file (.cif) and a corresponding data analysis
file (.daf). A data analysis template (.ast) is developed by
analyzing the.daf file of positive control sample. We applied the
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Figure 239. Representative images from unstimulated THP-1-derived macrophages (1 × 106). Identifying focused cell (A): The default mask (M
Brightfield) used in acquisition does not discriminate between focused and unfocused cells; the object mask alows the exclusion of unfocused cell.
Identifying single cells (B): Focused cells are plotted on AREA brightfield versus Aspect Ratio Brightfield scatterplot to exclude doublets cell. Events
with an Aspect ratio of 0.6–1.0 and an area of 50–500 U representing single cell are selected (R1). Identifying ASC positive cell (C): Single cells (R1) are
plotted on Max Pixel MC (Ch03) and intensity MC Ch03 scatterplot to indentify ASC positive cells (R2). Identifying ASC speck (D): ASC positive cell (R2)
are plotted on Max Pixel MC (Ch03) versus Area threshold (M03,Ch03,70) scatter plot. This mask allows to discriminate between cells characterized
by speck formation, in which a functional inflammasome complex is assembled, and cells with an ASC diffuse pattern.
template along with the compensation matrix to the rest of the
experimental samples using the multiple file batch tool in IDEAS.
Focused cells
Unstimulated (cells kept in medium alone; Fig. 239) and
LPS+Nig (Fig. 240)-stimulated THP-1-derived macrophages (1 ×
106) are resuspended in 50 µL of PBS and analyzed by FlowSight.
The Gradient root mean square (RMN) of Brightfield channel
is used to identify focused cells (Figs. 239A and 240A).
The focused cells are plotted on AREA bright field vs. Aspect
Ratio Bright field scatterplot to exclude aggregates from single
cells (R1) (Figs. 239B and 240B)
ASC speck mask
An intensity mask defined byMax Pixel MC (Ch03) vs. Intensity
(Ch03) is created from the R1 gate to identify total ASC positive
cells (Figs. 239C and 240C).
To define cell with ASC speck from cells with an ASC diffuse
pattern a Threshold mask plotting Max Pixel MC (Ch03) vs. Area
threshold (M03, Ch03,70) is created. This mask allows to separate
within the population of ASC-fluorescent cells those with small
area and high max pixel (ASC speck) from those with large area
and low max pixel (ASC diffuse) (Figs. 239D and 240D).
8.7 Advantages
This protocol allows to identify quickly and in an extremely accu-
rate way inflammasome activation at single cell level. The gate
strategy identifying the different size and brightness of ASC flu-
orescence differentiates between cells with speck formation, in
which a functional inflammasome complex is assembled, and cells
characterized by an ASC diffuse pattern.
8.8 Pitfalls/Top tricks
Inflammasome activation leads to pyroptosis and release of ASC
specks into extracellular space, to avoid cellular breakdown, it is
essential to keep cells on ice after detachment by trypsinization
and during the staining procedure.
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Figure 240. Representative images from LPS+Nig-stimulated THP-1-derived macrophages (1 × 106). Identifying focused cell (A): The default mask (M
Brightfield) used in acquisition does not discriminate between focused and unfocused cells; the object mask alows the exclusion of unfocused cell.
Identifying single cells (B): Focused cells are plotted on AREA brightfield versus Aspect Ratio Brightfield scatterplot to exclude doublets cell. Events
with an Aspect ratio of 0.6–1.0 and an area of 50–500 U representing single cell are selected (R1). Identifying ASC positive cell (C): Single cells (R1) are
plotted on Max Pixel MC (Ch03) and intensity MC Ch03 scatterplot to indentify ASC positive cells (R2). Identifying ASC speck (D): ASC positive cell (R2)
are plotted on Max Pixel MC (Ch03) versus Area threshold (M03,Ch03,70) scatter plot. This mask allows to discriminate between cells characterized
by speck formation, in which a functional inflammasome complex is assembled, and cells with an ASC diffuse pattern.
9 Multidrug resistance activity
9.1 Overview
Multidrug transporters, in particular MDR1, MRP1, and BCRP
serve as independent biomarkers to monitor treatment efficiency
and to support treatment decision in numerous clinical conditions,
as the most prevalently used small molecule drugs are substrates
of these efflux pumps.
Transporter activity measurement using fluorescent reporter
substrates and transporter inhibitors is a simple and cost-effective
assay that can be performed on primary cells or cell lines. Impor-
tantly, reagents used in transporter activity measurements are
compatible with fluorescently labeled Abs, thus it is possible to
perform the assay simultaneously on several cell types of interest.
9.2 Introduction
Multidrug resistance (MDR) transporters play an essential role in
the extrusion of xenobiotics from the cell, however, small molecule
drugs, like methotrexate (MTX), Vinca alkaloids, and other stan-
dard chemotherapeutics are also removed from target cells via
these molecules. In the clinical routine, MDR1 (also known as P-
gp, or ABCB1), MRP1 (also known as ABCC1), and BCRP (also
known as ABCG2, or MXR) are the most important players in the
development of resistance against these drugs [2159–2162].
Currently, qRT-PCR, immunohistochemistry, and Western
blots are the most frequently used methods to determine the MDR
transporter status in clinical samples. On the other hand, several
polymorphisms affecting transporter function have been reported
[2163, 2164]. Therefore, the relevance of quantitative descrip-
tion of these transporters is questionable. Transporter trafficking is
affected by genetic variation. Therefore, FCM-based determination
of cell surface expression of MDR transporters would be a signifi-
cant progress [2165]. However, Abs recognizing the extracellular
MDR1 and BCRP epitopes are conformation sensitive, making their
accurate determination challenging [2166–2168]. Furthermore,
the functional activity of these molecules still remains elusive.
Performing real-time transporter activity measurements using
fluorescent reporter substrates is highly beneficial in the clini-
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cal setting for personalized therapy and monitoring in certain
hematologic malignancies and in autoimmune diseases, since the
activities of MDR1, MRP1, and BCRP serve as biomarkers to pre-
dict the patient’s response to small molecule therapy in treat-
ment na¨ıve conditions and during small molecule drug treat-
ment [2169, 2170]. Furthermore, the determination of transporter
activity is also relevant in cell lines in pharmaceutical research.
The following protocol provides a cost-effective method with
a short turnaround time to determine MDR transporter activity.
These measurements can be performed on various cell types,
including cell lines, peripheral blood or bone marrow-derived
cells.
9.3 Principles of the technique being described
Measuring the functional activities of MDR1, MRP1, and BCRP is
based on the application of fluorescent transporter reporter sub-
strates along with specific and pan-inhibitors of these transporters.
Reporter substrates readily penetrate the cell membrane. Prefer-
ably, the non-fluorescent reporter substrate, such as calcein-AM,
is cleaved by endogenous esterases to form a highly fluorescent
derivative of the dye that becomes trapped in the cytoplasm due
to its high hydrophilicity. However, many fluorescent substrates
that are not cleaved by esterases are also used in drug discovery
and in clinical practice, including mitoxantrone, Rhodamine 123,
and Hoechst stains. The activity of the efflux transporters results in
lower cellular accumulation of the fluorescent reporter dye. In cells
expressing transporters the addition of specific inhibitors blocks
dye exclusion activity of the relevant transporter and increases
dye accumulation in the cells. In the absence of significant trans-
porter activity, the net reporter substrate accumulation is faster
in the cells due to a lack of transporter mediated efflux, which
in turn is not influenced by the presence of an MDR transporter
inhibitor [2171].
9.4 Applications
 Basic research applications: To characterize transporter biol-
ogy and functionality, to study the pathobiology of transporter-
mediated diseases, to test cell lines overexpressing multidrug
transporters, to test drug–transporter interactions, and to exam-
ine drug or herb–drug interactions in the context of drug dis-
covery and in the study of drug disposition
 Cohort selection in Phase I trials: Data show that up to 20%
of healthy adults are characterized by high baseline transporter
functions [2172]. Enrollment of these individuals in a Phase I
trial may cause bias, which can be excluded by a preliminary
screening of transporter function, saving cost and effort
 Therapy tailoring to support personalized treatment: Small
molecule drugs are widely used in cancer and autoimmune dis-
eases. As these drugs are removed from the target cell via mul-
tidrug transporters, transporter activity measurements would
be highly beneficial at the time of diagnosis and during therapy
to support treatment decisions
9.5 Equipment
The flow cytometer used for measurements does not require any
special features. The lasers and channels applied for the detection
of the fluorescent substrate depends on the specific fluorescent
substrate molecule used. For example, the 488 nm laser and the
515 nm channel is recommended for calcein-AMwhile the 633 nm
laser and the 684 nm channel is recommended for mitoxantrone.
The configuration of the instrument will determine the number of
additional cell surface markers that can simultaneously be used in
order to identify individual cell subsets. In conclusion, no specific
flow cytometer is required for running transporter activity mea-
surements. The following assay is not suitable for high-throughput
screening format.
9.6 Experimental workflow and acquisition
9.6.1 Sample preparation. Transporter activity measurements
can easily be performed on human and rodent cell lines and pri-
mary cells. Importantly, transporter activity measurements require
viable cells (2–5 × 106) in good condition, not depleted of intra-
cellular energy stores. ATP depletion tends to decrease the activity
of membrane transporters and may lead to inaccurate results.
If primary human blood or bone marrow samples are used,
K3EDTA or Na-citrate is recommended to be used as anticoagulant,
since other anticoagulants, e.g., heparine may interfere with trans-
porter activity measurements. For collecting PBMCs, Ficoll den-
sity gradient centrifugation is suggested. Primary samples should
be processed within six hours after drawing, as samples stored
beyond 6 h may undergo serious ATP depletion, leading to inac-
curate results. If samples are stored over 6 h, PI counterstaining
is recommended to exclude dead cells. Blood samples should be
stored at room temperature before testing. Do not freeze samples.
Cells should be diluted in HBSS buffer.
9.6.2 Assay procedure. The specific steps of the procedure may
vary depending on the instructions supplied by the manufacturer
of the kit used. Here, we provide general considerations for the
assays.
Prepare and measure samples under same inhibitor treatment
and staining conditions in triplicates.Mix cells thoroughly by gentle
pipetting rather than vortexing to avoid forming bubbles in the test
tube. Always include a control sample with no inhibitors applied.
The concentrations of the respective inhibitors are specified in the
manufacturer’s instructions of the kit used. Samples are incubated
at 37°C.
To start the staining reaction, add the transporter reporter sub-
strate into all tubes simultaneously. After incubation, stop reaction
in all tubes simultaneously by rapid centrifugation (1 min at 2000
rpm) with rapid acceleration and deceleration. Discard supernatant
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and stain resuspended cells with labeled Abs if required. Stain cells
with PI solution to demonstrate viability if necessary.
9.6.3 Staining the cells with labeled cell surface Abs. For measur-
ing transporter activities on your cell type of interest, the use of
fluorescently labeled Abs are recommended. Both immunolabel-
ing and conjugate labeling methodologies can be followed. Please
note that some Abs may interfere with transporter activity mea-
surements. To avoid such interference, the staining of cells with
Abs as per the manufacturer’s instructions should be carried out
following the staining with the transporter reporter substrates.
Cells must not be fixed or permeabilized. The necessary isotype
controls or unlabeled cell controls should be used according to the
manufacturer’s instructions.
9.7 Data acquisition
Mix samples thoroughly before measurement and use only the
viable cell population for data analysis. In case of using com-
mercially available kits (e.g., the SOLVO MDQ KitTM), the assay
contains internal standardization, thus the results will become
independent from the PMT settings, whenever the acquisition
occurs within the linear range of the equipment. However, sam-
ples belonging to the same assay must be measured using the same
settings for PMT amplification.
9.8 Data analysis
Apply sequential gating strategy for the analysis (an example is
provided in ref. [2173]). Within the desired cell subset gate, deter-
mine the corresponding geo-MFI values of the reporter substrate
applied. For this, the inclusion of at least 10 000 cells within the
desired cell subset gate is recommended.
9.8.1 Calculation of multidrug resistance activity factors. Take the
median geo-MFIs of triplicate parallel measurements with and
without the transporter inhibitors (“F” values). We provide an
example below of the equations used to calculate multidrug resis-
tance activity factor (MAF) values for each multidrug transporter,
plus the composite activity of MDR1 and MRP1 (MAFC) using
the SOLVO MDQ KitTM. These calculations may differ when using
other kit assays.
 MAFC= 100 × (FMAX – F0) / FMAX
 MAFMRP1 = 100 × (FMRP1 – F0) /FMAX
 MAFMDR1 = MAFC – MAFMRP1
 MAFBCRP = 100 × (FMX – FB) / FMX
FMAX and FMX represent reporter substrate fluorescence (cal-
cein and mitoxantrone, respectively) with inhibitors of MRP1 and
MDR1 as well as of BCRP, respectively. F0 represents fluorescence
without inhibitors. FMRP1 represents reporter substrate fluores-
cence (calcein) with specific inhibitor of MRP1.
9.8.2 Expected results and interpretations. Theoretical MAF val-
ues can range between 0 and 100. The MAFC found in normal
PBMCs are in the range of 0–20, while in drug selected cell lines
exhibiting extreme high levels of MDR1/MRP1 expression, the
MAFC values might be as high as 95–98. In case of hematologi-
cal malignancies, the MAFC values in tumor cell populations are
usually found between 0 and 50, but in extreme cases, values can
be as high as 70. Reference values of MAF values in CD3+ lym-
phocytes were determined in a healthy population of 120 indi-
viduals [2173]. Importantly, MAF values are independent from
gender. MAFMRP1 and MAFBCRP are also independent from age,
while MAFC and MAFMDR1 showed a negative correlation with age
in healthy adults.
9.9 Advantages
 Functional data: In contrast with other methods detecting
the presence or absence of MDR transporters at relative gene
expression or protein level, transporter activity measurements
by FCM assess whether efflux transporters are functionally
active.
 Clinical application: The assay works on both primary cells
and cell lines. As little as 5 mL of peripheral blood is sufficient
to study transporter activity in patient samples. A CE-IVD kit
(SOLVO MDQ KitTM) is available for clinical use.
 Short turnaround time: Functional data can be obtained
within 2 h following sampling as compared with much longer
turnaround times of next generation sequencing methods.
Moreover, a single sample can be measured cost-effectively
without the need of batching multiple samples.
 Cost effective: Transporter reporter substrates and inhibitors
are commercially available compounds that are far cheaper
than Abs and reagents required for gene expression assays.
 Flexible: The use of fluorescent cell surface markers allows the
simultaneous detection of transporter activity in various cell
subsets of interest.
9.10 Pitfalls
 It is recommended to start the assay within 6 h after obtain-
ing the primary sample to avoid depletion of intracellular ATP
stores. Detection of dead cells with PI is recommended beyond
this time limit.
 As timing of the staining steps is crucial in measuring trans-
porter activity, the addition of the fluorescent reporter substrate
to the samples should be take place within 20 s. Therefore, it
is not recommended to start the reaction on more than 12 test
tubes at the same time. Allow 2-min intervals between start-
ing the reactions when multiple samples are measured. It is
recommended to use a repeater pipette to add substrates and
inhibitors to multiple test tubes.
 Sample measurement should preferably be performed immedi-
ately (within 2 h) after staining. Keep the samples on ice and
protect them from light until the measurement.
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9.11 Top tricks
 In case of cell lines growing adherently, trypsinization is a crit-
ical step to keep cell membranes intact: for this, trypsinization
time should be established for the cell line of interest.
10 Index sorting
10.1 Overview
Index sorting records fluorescence information and scatter charac-
teristics indexed for each individual sorted event. This technology
is especially powerful when sorting single events and allows the
retrospective identification of highly accurate multidimensional
phenotypes.
10.2 Introduction
Fluorescence-activated cell sorting is broadly available and its
applications reach from large-scale sorting of millions of cells into
tubes to the targeted deposition of single events into multiwell
plates or onto slides. For conventional sorting, target populations
have to be defined before the sorting process involving more or
less sophisticated gating strategies. The advantage of index sorting
is that fluorescence data for each individual sorted event can be
read out retrospectively. This technology, especially when applied
as single cell sorting, is invaluable for specific research questions
in which sorted events of interest can only be identified with
downstream technologies. Most currently commercially available
sorters are capable of index sorting.
We will illustrate the technology with one example combining
12 fluorescent parameter single T cell index sorting of a T lym-
phoblastic lymphoma sample with downstream single cell TCRαβ
sequencing (Fig. 241).
10.3 Principles of the technique being described
Indexed fluorescence data and scatter characteristics are recorded
for each single sorted event so they can be assigned retrospec-
tively. Index sorting itself is not different from regular cell sorting
except it has to be activated in the sorter software. After sort-
ing, scatter characteristics and fluorescence data for each single
event can be exported from the sorter software—usually as a table
(comma separated list). Exported data have to be individually
processed and, if desired, can be combined with data from down-
stream assays depending on the purpose of the experiment (see
example in Fig. 241).
10.4 Applications
Index sorting has been applied in a variety of research areas includ-
ing the isolation and characterization of single circulating tumor
Table 96. Parameter panel for single cell index sorting in Fig. 241
Specificity Clone Fluorochrome Vendor
CD8 RPA-T8 BV510 BioLegend
CD57 HCD574 FITC BioLegend
PD-1 EH12.2H7 PerCP-Cy5.5 BioLegend
BTLA J168-570 PE-CF594 BD Biosciences
TCRαβ IP26 APC BioLegend
CD45RA HI100 AF700 BioLegend
CD25 CD25-4E3 PE-Cy7 Affymetrix
CTLA-4 BNI3 PE Invitrogen
CCR7 G043H7 BV650 BioLegend
CD28 CD28.2 BV421 BioLegend
CD4 SK3 APC-Fire 750 BioLegend
live/dead zombie yellow BioLegend
cells [2174], the determination of cell cycle states and immune
phenotypes of stem cell populations [2175–2177], the combina-
tion of genotype with phenotype data in healthy and malignant
B lineage cells [1606, 2178], the definition of the phenotypic
range of individual T cell clones [2179–2181], and the deter-
mination of cell size in combination with microbial single cell
genomics [2129], among others.
As an example, we used index sorting to define the phenotypic
range associated with clonal T cell expansion in one T lymphoblas-
tic lymphoma lymph node (Fig. 241). The conventional approach
would be to sort various T cell populations and sequence their
TCR genes to detect clonal expansion. This approach is tedious
and may not lead to the desired results due to shortcomings of 2D
gating strategies for the definition of high-dimensional phenotypes
(“Chapter VII: Data handling, evaluation, storage and repositories”
and “Chapter VIII Section 5: High dimensional FCM”). Index sort-
ing allows to stain with a multiparameter set of Abs (example
in Table 96), randomly sort single T cells, sequence their TCRs,
and retrospectively identify the multi-dimensional immune phe-
notype of each single cell belonging to the T cell clone of interest
(Fig. 241).
Equipment
Most currently commercially available cell sorters are capable
of index sorting. Sorting for the example in Fig. 241 was done
using a FACSAriaTM Fusion high-speed cell sorter equipped with
a 70 µm nozzle and FACSDiva software version 8.02 (BD Bio-
sciences). Sorter setup and preparation for index sorting does not
differ from regular cell sorting with special attention on accurate
drop delay (“Chapter II: Setup-Instrument setup and quality con-
trol,” here). Single cells were sorted directly into 96-well plates
prefilled with PCR buffer [2180].
Depending on the sorter hardware and target devices (e.g.,
96-well plate), accurate and consistent mounting of the target
device onto the robot can be difficult. Custom-made adapters and
mounting plates onto 96-well racks can help to reduce alignment
variability between plates [2176].
Experimental workflow and acquisition
Staining, preparation of single cell/particle suspensions, and
the sorting process are identical to (single cell) sorting without
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Figure 241. Determination of the phenotypic range of T lymphoblastic lymphoma cells as an application example for single cell index sorting. We
combined 12 fluorescent parameter index sorting of αβ T cells with single cell TCRαβ sequencing of one single lymph node from a T lymphoblastic
lymphoma patient. (A) Immunohistochemistry of a paraffin-embedded lymph node section demonstrates substantial infiltration with CD3+
predominantly CD8- T lymphoblastic lymphomaT cells. CD3+ (left image) or CD8+ (right image) cells are stained in red. Polyclonal rabbit antihuman
CD3 (A0452, Dako) and mouse antihuman CD8 (clone C8/144B, Agilent) were used for immunohistochemistry. Arrows in the right image point at
single CD8+ cells as examples. We aimed to determine the phenotypic range of T lymphoblastic lymphoma cells and asked whether interspersed
CD8+ T cells were polyclonal lymphoma-infiltrating T cells or part of the malignant clone. (B) Sequential gating for single cell index sorting of
lymph node T cells. Upper row left: gating on lymphocytes; middle and right: gating on single cells by forward and side scatter characteristics.
Lower row left: exclusion of dead cells; middle: gating on αβ T cells; right: gating on CD4+ or CD8+ T cells. Red indicates gates fromwhich cells were
ultimately sorted. (C) Combined paired TCRαβ sequencing and FCM data from cells sorted in (B). Single T cells are arranged in columns. The top bar
color-codes TCRαβ CDR3 amino acid sequences; adjacent columns with the same color indicate expanded T cell clones. A clone was determined
expanded if we detected at least two cells with identical TCRαβ CDR3 sequences. Grey indicates non-expanded T cells. FCM data were trimmed
at the 2nd and 98th expression percentiles and scaled for each individual marker. While CD4+ T cells were in parts polyclonal, the dominant
proportion of CD8+ T cells was part of themalignant clone. Data represent n = 1 experiment and illustrate an application example of index sorting.
General findings on T lymphoblastic lymphoma biology cannot be concluded from these data. The lymph node and immunohistochemistry were
provided by Martin-Leo Hansmann, Universita¨tsklinikum Frankfurt am Main, Dr. Senckenberg Institut fu¨r Pathologie, Germany.
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index (see Chapter IV: Cell sorting). Index sorting has to be acti-
vated in the sorter software before starting the sorting process.
When sorting single events into multi-well plates or onto slides,
special attention should be paid to plate targeting. Accurate plate
alignment should be confirmed in regular intervals (e.g., after
every fourth plate). Singlet gates should be defined stringently
to reduce the chance of sorting doublets. Make sure to activate
the “single cell mode” (or equivalent) in the sorter software when
sorting single cells. It is recommended to run the sorter at a low
flow rate (<200 events/s), which has been shown to improve the
yield of rare events [2182].
Depending on the research questions and materials used, we
recommend the inclusion of live/dead discriminatory dyes in the
gating strategy.
For the example in Fig. 241B and C, cryopreserved cells from
a lymph node sample of a T lymphoblastic lymphoma patient
were stained with a 12 fluorescent parameter panel (Table 96).
The panel included markers for the identification of major T cell
differentiation states in combination with selected immune check-
point molecules. Two-hundred single TCRαβ+ cells were randomly
index sorted into 96-well plates. Since CD4+ and CD8+ T cell fre-
quencies were below 5% of all αβ T cells, we additionally sorted
88 CD4+ T cells and 88 CD8+ T cells. Paired TCRαβ sequences
were obtained from a total of 216 T cells.
10.5 Data analysis
Index sort data can usually be exported from the sorter software
as FCM standard (fcs) files or as tables (comma-separated values
or equivalent). Detailed procedures for data export depend on the
instrument manufacturer, software, and software versions. When
exported as fcs files, index sort data can be visualized using com-
mercially available software for FCM data visualization (“Chapter
VII: Data handling, evaluation, storage and repositories”). If it
comes to sub-setting of index sort data based on certain criteria,
the combination with other data formats (e.g., single cell sequenc-
ing), data visualization as heatmaps and/or multidimensional
plots, commercially available tools are rarely available. Data anal-
ysis involving programming/statistical computer languages such
as R (https://www.r-project.org/) among others is the approach
of choice, highly flexible and powerful but requires knowledge in
(bio-) informatics.
10.6 Advantages
Index sorting makes exact scatter and fluorescence characteristics
of each single sorted event available for downstream analyses
and can help identifying multidimensional phenotypes where
conventional sorting approaches are limited. With immune
phenotypes being correct in >99% of sorted cells [2180], index
sorting is one of the most accurate technologies for isolation and
multidimensional phenotyping of single cells at the protein level.
10.7 Pitfalls
Currently, there are no ready-to-use software solutions that make
the entire richness of index sort information available to users
with limited access to advanced bioinformatics.
10.8 Top tricks
For single cell index sorting, accuracy of the assigned phenotypes
is critical. In addition to general requirements for cell sorting
(“Chapter II: Setup - Instrument setup and quality control” and
“Chapter III: Before you start: Reagent and sample preparation,
experimental design”), stringent gating on live single events and
plate targeting are critical. Parameters that could indicate data
inconsistency should be included whenever possible. For example,
in healthy individuals, particular T cell clones show characteris-
tic CD4/CD8 expression. The identification of CD4+ T cells in an
otherwise CD8+ T cell clone could hint to data inaccuracy.
When sorting into multi-well plates, depending on the desired
downstream applications and the type of sorted events, immediate
centrifugation after sorting may increase yield.
11 Sample banking for FCM
11.1 Overview
Sample banking provides benefits for FCM, namely, that sam-
ples can be batched for a more efficient workflow and reduced
sample-to-sample variability. The most common banking method
involves cryopreservation of PBMC, and the principles to be fol-
lowed are the same for FCM as for other downstream methods
that require viable cells. Consideration should be given to opti-
mization and standardization of the procedure, including time to
processing. Alternatives to cryopreservation of PBMC include the
use of transport stabilizers (Streck, Smart Tube) or methods for
cryopreservation of whole blood/granulocytes. These systems can
allow interrogation of cells depleted in the generation of PBMC;
and the Smart Tube system captures functional readouts through
stimulation of fresh whole blood prior to fixation/stabilization.
11.2 Introduction
With time after collection, biological samples begin to degrade
with regard to their functions and phenotypic markers. Depend-
ing on the target function(s) or phenotype(s), this degradation
may be on the order of hours or days. But running fresh samples
immediately by FCM is often not logistically feasible. It is also not
necessarily the best workflow choice for all studies, due to the
inefficiency of running single samples, and the variability that can
be introduced from day to day. Biobanking offers a good alter-
native to running fresh samples immediately after collection. By
far the most common biobanking approach is cryopreservation of
PBMC (or other sources of immune cells). This has the advantage
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that cells can be viably stored for many years in liquid nitrogen or
equivalent cryogenic storage [2183], allowing for many different
types of assays to be performed downstream. An important disad-
vantage is the loss of granulocytes, which are generally removed
by Ficoll density gradient centrifugation prior to cryopreserving
the PBMC. Another limitation is the partial loss of certain labile
cell-surface markers and some functional characteristics with cry-
opreservation, as well as differential recovery of certain subtypes
of cells (discussed under “Principles” below). If these affected cells,
markers, or functions are critical to the FCM assays being used,
then an alternative strategy needs to be taken. This could include
viable cryopreservation of whole blood/granulocytes, which may
bring additional caveats in terms of cell viability and function;
or activation/fix/freeze systems, which are ideal for capturing a
functional and phenotypic state, but which limit the downstream
applications. As such, the choice of whether and how to bank
samples prior to FCM involves a set of trade-offs, in which the
investigator needs to evaluate the factors of greatest importance
for a particular study, as well as the logistical constraints, prior to
picking a sample banking approach.
11.3 Principles
With any sample banking method, it is necessary to minimize
pre-analytical variations in the collection, processing, and storage
stages. The pre-analytical variations can be different depending
on the type of biosample, the type of analyte, and the method
of analysis. PBMC isolation methods based on density gradient
centrifugation, for example, Ficoll-Paque, Lymphoprep, and cell
preparation tubes (CPT, Becton Dickinson) show comparable cell
counts and viability [2184], but the different handling of cells
may affect their detailed phenotypes and functions. For example,
compared to Ficoll-Paque density gradient centrifugation, Lym-
phoprep showed a higher SEB-induced cytokine response from
human PBMC [2185]. CPT, on the other hand, have a potential for
increased erythrocyte contamination [2185], though they provide
an easier workflow than other methods. In general, the selection
of a specific PBMC isolation technique, aside from the cost, should
be based on the downstream analysis.
In addition to the choice of the PBMC isolation technique, key
protocol factors (e.g., time to processing, buffer, DMSO mixing,
cell density, freezing rate, transfer to LN2, and thawing) also play
a role in good cryopreservation [2186, 2187].
The time delay between blood sampling and handling of the
sample may affect the immune cell subsets, their function, and
activation markers [2188]. A standardized processing time for
all samples (which still preserves the desired functions and/or
phenotypes) will give the most comparable results. In addition to
the time interval between the collection and the processing, the
time of day of blood collectionmay also play a role in the recovered
phenotypes and functions, due to circadian effects (reviewed in
ref. [2189]).
Tompa et al. [2190] compared fresh versus cryopreserved
PBMC (stored for 6 or 12 months) for three different isolation
techniques, analyzing the subsets of CD4+, CD8+, and CD25hi lym-
phocytes. In general, there was no influence of isolation method
or long-term cryopreservation. However, slightly different subsets
of cryopreserved PBMC were described, e.g., naive and early-
differentiated CD4+ and CD8+ effector memory T cells were
affected by isolation and cryopreservation. Another group has
reported changes in CD4+CD25+ T cell numbers in HIV+ indi-
viduals as a result of cryopreservation [2191], highlighting the
possibility of disease-specific affects. Minor differences in B and T
cell numbers with Ficoll separation versus whole blood have also
been reported [2192]. Finally, resting cells post-thaw can have
differential effects on T cell fine phenotyping [2193, 2194].
Some investigators havemade further efforts to optimize meth-
ods and implement quality control to achieve improved cell via-
bility [2195]. Both the centrifugation and washing conditions can
be varied and a higher DMSO concentration (15%) in the freezing
medium can be beneficial. A controlled cooling rate of –1°C/min
can be achieved in different ways and is discussed in a previous
section (see Chapter III Section 4 Dead cell exclusion, cell viability,
and sample freezing).
Once banked, samples need to be kept at a constant optimal
temperature. Fluctuations from liquid nitrogen to vapor phase,
or frequent exposure to ambient temperatures as samples are
removed will degrade their viability. Even fixed samples stored
using Smart Tube proteomic stabilizer become clumped when
exposed to repeated temperature fluctuations or storage above
–80°C. For this reason, it may be advantageous to separate loca-
tions of samples intended for long-term storage versus those to
which frequent access is needed. Additionally, when working with
open sample boxes to retrieve specimens, the use of a liquid nitro-
gen tray is recommended, to minimize temperature fluctuation.
Similarly, shipping in nitrogen dry shippers is preferable to dry ice
shipments of frozen PBMC; however, a single, short-term expo-
sure to dry ice during shipping will not result in any noticeable
sample degradation [2186].
Another important consideration whenever biobanking
extends to larger numbers of samples and studies is inventory
management software and protocols. There are several good soft-
ware packages designed specifically for freezer/biobank manage-
ment (e.g., LabVantage, CentraXX, STARLIMS, SMARTLIS, Freez-
erworks, Biobank, Open Specimen, etc.), and they have advan-
tages over simple solutions such as spreadsheets. These advan-
tages may include audit controls, study–subject–sample hierar-
chy definition, searchability, access control, and so on, depending
upon the particular software. Consideration should also be given
to protocols for sample annotation. For example, a naming scheme
can be used that follows the format 01-002-03, where 01=the
study ID, 002=the subject ID, and 03=the visit ID. Further suf-
fixes can designate derivative sample types, e.g., PBMC, serum,
and so on. When combined with a barcode and barcode read-
ers, such systematic naming can aid in organization and retrieval
efforts. Linking relevant clinical information, de-identified to meet
privacy requirements, can further make searching for desired sam-
ples much faster.
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Table 97. Markers affected by cryopreservation and/or whole blood
stabilization∗
Affected by PBMC
cryopreservation
Affected by Smart Tube
stabilization
CD62L
[861, 2187, 2194, 2196]
CCR6 (our unpublished data)
CCR5 [861] CXCR5 (our unpublished data)
PD-1 [2197] CD11b (our unpublished data)
PD-L1 [2197] CD16 (our unpublished data)
CD20b [2198] CD45RA (our unpublished data)
CD45RO [2187] CD127 (our unpublished data)
CD28 [2194]
* These lists are not exhaustive, nor do we rule out the use of the listed
markers in cryopreservation or whole blood stabilization protocols.
Results will depend upon the antibody clone/epitope targeted, as well
as the permeabilization conditions used.
11.4 Applications
We can divide approaches for FCM sample banking into three gen-
eral categories. The first is to run all samples fresh without any
banking. This avoids any loss of cells, markers, or functions and
thus allows for the full gamut of FCM assays to be performed. How-
ever, it also carries logistical challenges that may make it impos-
sible for many studies; and the workflow creates more sample-to-
sample variability, assuming that sample collection is staggered
(i.e., not all samples are collected at once). Finally, unless com-
bined with another method, it means no samples are available for
later assays that are yet to be determined.
A second approach involves viable cryopreservation of cells for
later FCM analysis. For human blood samples, this usually means
cryopreservation of PBMC. While there are protocols for viable
freezing of granulocytes and/orwhole blood, these tend to be asso-
ciated with greater loss of viability and/or staining resolution. In
any case, cryopreservation allows for any number of later assays to
be performed, subject only to how many cells are available. It also
avoids much of the variability inherent in fresh real-time analysis
of individual samples, since samples can be batched and therefore
results are more comparable. However, it also means potential
loss of certain cell types, markers, or functions (see Table 97).
For example, CD62L is known to be variably lost upon PBMC
cryopreservation [861, 2196]. Certain chemokine receptors (e.g.,
CCR5, [861]) can also lose some staining intensity, as can PD-1
and PD-L1 [2197]. Monocytes and their associated antigen pro-
cessing functions can be preferentially lost with cryopreservation,
such that functional assays that rely on protein antigen processing
will be significantly compromised [638].
Both of the above approaches may be combined with initial
shipping of fresh samples from a collection to an analysis or pro-
cessing site. Obviously, this increases sample degradation, in ways
that may be variable depending upon time and temperature in
transit, and so on. NK and B cell frequencies and functional capac-
ity may be most vulnerable to shipping [2199]. However, this
may be an unavoidable sacrifice in multicenter studies. Even in
cases where each individual collection site could in theory per-
form cryopreservation, it may be preferable to ship samples to a
single processing site where there is better control of the proce-
dure [2199].
A final approach involves using a sample preservation method
(generally some type of fixation) that allows for later FCManalysis,
even though the cells are no longer viable. A simple example
is a blood collection tube such as Cyto-Chex (Steck, Inc.), that
fixes cells upon blood draw, and confers stability of major lineage
epitopes (e.g., for assays like CD4 counting) for up to 1 week. A
more complex example is the Smart Tube system (Smart Tube,
Inc.), which allows for stimulation of fresh blood, followed by
timed release of a stabilizer solution, after which samples can
be stored at –80°C for later analysis. This system has been used
for signaling studies, where signals degrade quickly after sample
collection (e.g., Gaudilliere et al. [2015]). Similarly, investigators
have performed erythrocyte lysis followed by fixation and freezing,
for later staining and analysis of leukocyte counts [2200]. Such
schemes require time-dependent work at the collection site, in
terms of pipetting and freezing samples. They also compromise the
staining of certain cell-surface epitopes, due to fixation. Of course,
these systems preserve granulocytes as well as PBMC, which may
be useful in certain studies. Finally, it goes without saying that the
fixed cells are no longer useful for further stimulation or functional
assays not previously anticipated.
When performing an animal study, it is often possible to syn-
chronize sampling such that fresh parallel analysis of all samples at
a given time point is feasible. However, if the intent is to compare
longitudinal samples from the same animals, it may be preferable
to cryopreserve or stimulate/fix/freeze samples, so that all time-
points from a given animal can be run in a single batch. This of
course assumes that the readouts being assessed can be adequately
preserved with such methods.
With clinical studies, the sample collection is almost always
staggered with subject enrollment, so biobanking becomes even
more attractive, to allow batching of samples for analysis. The
exception, again, is if the cells, markers, and/or functions of inter-
est can only be assessed in fresh cells. With multicenter clinical
studies, the considerations become even more complex, as one
needs to balance the advantages of well-controlled procedures at a
single central lab with the reduced sample degradation of process-
ing and/or assays done at multiple sample collection sites [2199].
Alternately, a central lab can provide SOPs, analysis templates,
training, and so on, to collection sites that then perform the assays
in parallel [2201]. Inclusion of replicate control samples into the
workflow can help determine reproducibility in the context of such
workflows [2202].
11.5 Equipment
The viability and concentration of isolated PBMCs are impor-
tant for the planned analysis. Besides manual conventional cell
counting with trypan blue (TB) and a hemacytometer, there
are advanced methods for PBMC cell counting, which provide
automated documentation options, e.g., ScepterTM, CASY R©, and
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CountessTM II. However, these devices require specialized con-
sumables that result in additional costs. Also, the accuracy of
automated cell counting varies, and is still limited by factors such
as cell density, erythrocyte contamination, and so on. Thus, the
“Gold standard” remains the experienced laboratory professional
and validation withmanual cell counting using trypan blue stained
cells. However, in a multicenter study with several employees
working at different levels, automated counting instruments have
a great advantage because the results remain consistent.
Among the aspects of PBMC processing and cell counting, the
freezing conditions of PBMC on the survival of immune cells are
crucial. The point should be made to avoid defrosting cysts as well
as long storage at –70°C. If interim storage is necessary, a dry
shipper may be an alternative, which is provided for the transport
of PBMC to the final storage site. Especially in multicenter clini-
cal studies, it is important to minimize the artifacts from freezing
and intermediate storage. In addition, the long-term storage con-
ditions are crucial. Thus, the PBMC should be stored in controlled
conditions with a permanent alarm and monitoring system.
In order to keep the quality of biobanks high, excellent manage-
ment of the many biosamples is required. This requires complete
documentation of the work processes in real time, including the
tracking of aliquots and biosamples. Other important points are
logistics management and cold chain monitoring. Large biobanks
use modern laboratory information management systems (LIMS)
to meet these requirements [2203]. These systems are advan-
tageous for biobanks with multiple sites or multicenter studies.
There are a variety of LIMS software that includes sample acquisi-
tion and sample storage with recorded sample and related factual
information [2204–2206].
Additional features such as barcodes and barcode scanners
are helpful to ensure that biosamples can be easily searched in
biobanks. In addition to the individually coded tubes and racks,
the LIMS also visually records the storage locations, thus ensuring
a genealogy of the samples with process tracking. There are many
barcode-coded tubes and the corresponding SBS racks on the mar-
ket. Here, there is still a great need for investigations of the shelf
life and permeability of the tubes. Since the tubes with PBMC are
stored in nitrogen, they have to meet appropriate conditions. The
coded tubes simplify handling by eliminating the need for time-
consuming labeling. However, further purchases such as barcode
scanners and other software will then be required.
11.6 Experimental workflow and acquisition
From the above discussion, there are clearly many different work-
flows possible with regard to sample banking. These vary from
exclusive analysis of fresh samples to shipping, cryopreservation,
and later batch analysis. Hybrid workflows are of course possible,
with some assays done fresh, or aliquots of samples stimulated
and/or fixed in real time for certain assays. Figure 242 shows a
small selection of options and customizations available for PBMC
isolation or whole blood stabilization, detailing the studies under-
lying these options/customisations [2198, 2207–2213, 2215]. In
addition to the time of the possible processing steps, the different
handling and cryopreservation media are also important.
In any case, once a sample banking workflow has been deter-
mined, it may be useful to test it using several control or pilot
samples, prior to embarking on a large study. This will not only
insure that the proposed logistics are workable, but can also give
an idea of the variability to be expected, if, for example, replicate
samples are drawn from the same healthy subject(s).
It is also worth considering acceptance criteria for large stud-
ies. These can be applied at multiple levels. For example, one
might stipulate that fresh shipped samples that are not processed
within 48 h of draw should be discarded. Or, that cryopreserved
PBMC that do not yield a viability of >50% should not be further
analyzed. While these types of rules will not eliminate technical
variability in the results, they can at least reduce it, while at the
same time saving reagents and technician time. The danger, of
course, is that criteria that are too strict may result in loss of data
that would still have been useful.
11.7 Advantages
As already detailed above, the advantages of sample banking can
include a more efficient workflow, availability of samples for later,
unforeseen assays, and better comparability between samples due
to batching. In some cases, logistics strongly influence certain pre-
ferred banking workflows; for example, shipping blood to a central
site in multicenter studies [2199]. But, because some FCM ana-
lytes are labile to shipping and/or cryopreservation, it may be
necessary to set up hybrid schemes, where some assays are done
fresh onsite, or at least some sample preparation is done fresh
onsite (e.g., using Smart Tube or similar systems).
11.8 Pitfalls
As also outlined above, PBMC cryopreservation can result in
preferential loss of certain cell types, markers, and functions.
Well-known examples include loss of CD62L, certain chemokine
receptors, and PD-1/PD-L1 with cryopreservation and thawing
[861, 2196, 2197]; and loss of antigen-processing capabilities for
functional assays. Restimulation assays are of course still possible
after cryopreservation, particularly if using preprocessed antigens,
i.e., peptides [638]. More globally, cryopreservation always results
in some loss of cells versus fresh blood; and of course PBMC iso-
lation results in loss of the granulocyte fraction.
11.9 Top tricks
While also mentioned above, we collect here certain generaliza-
tions that help to create high-quality sample banking studies for
FCM.
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Figure 242. Brief overview of PBMC isolation or whole blood stabilization. References for each process are indicated.
1. Preanalytical variables, including time to processing, and
choice of PBMC processing protocol, should be chosen accord-
ing to the needs of the downstream assays, and should be
tightly controlled.
2. If there are highly labile cells, markers, or functions that are
key analytes for a given study, some level of fresh assays and/or
fresh processing may be required.
3. Consider adopting a biobanking software, and create a logical
scheme for sample annotation, prior to embarking on a banking
study.
4. Equipment such as automated cell counters should be vali-
dated against manual methods. Although frequently biased
with regards to accuracy, they may be preferable for their
reproducibility across labs and operators.
5. Keep banked samples at a constant optimal temperature. For
cryopreserved PBMC, use a liquid nitrogen tray when opening
boxes to select samples. As much as possible, keep long-term
samples separate from those that are actively being retrieved.
Consider using nitrogen dry shippers for large or long (inter-
national) shipments. Use monitors and alarms to avoid undis-
covered equipment failures.
6. Implement appropriate acceptance criteria (time limit to pro-
cessing, viability post-thaw, etc.). These should help to reduce
technical variability as well as wasted time and reagents; but
they should not be so restrictive that samples are discarded
that could still generate useful data.
12 High throughput screening
12.1 Overview
High-throughput screening is as a process by which a large num-
ber of samples are acquired in an automated fashion to identify
molecules that exert biological activity on either a specific target
or a cell population. Different technologies are used to detect the
readout signal in a high-throughput screening assay such as auto-
mated microscopy, cell impedance measurement, time resolved
fluorescence energy transfer (TR-FRET), or FCM. In this section,
the use of high-throughput FCM (HTFC) will be described and
examples for devices, screening assays, experimental setup, and
data analysis as well as tricks and pitfalls will be shown.
12.2 Introduction
FCM has been used in almost every stage of the drug discovery pro-
cess, including target identification and validation, lead and can-
didate selection, and safety studies for more than 30 years [2216].
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This analytical technology has become very popular for drug
development because of the possibility to analyze living cells out of
a culture that is still available for further processing (e.g., nucleic
acid extraction). However, only recently FCM has been applied
also for primary high-throughput screenings. This might be due
to the fact that for several years the drug screening field was
dominated by target-based approaches, while cell based pheno-
typic assays were considered as too unspecific and risky [2217].
In addition, technical limitations of flow cytometers to process
multiple samples did not make the technology very attractive for
large screening campaigns. However, since microplate-based cell
sampling and software capable of handling large data sets were
developed the use of HTFC has become increasingly popular. In
addition, affordable high quality HTFC devices were developed
which also contributed to the popularity of HTFC not only in big
pharma but also small companies and especially academic institu-
tions. The possibility to use small sample and acquisition volumes
and simultaneously monitor phenotypic responses of single cells in
the presence of a large variety of compounds are major benefits of
HTFC. The introduction of barcoding (See Chapter VIII Section 2
Barcoding) [1984] and the development of multiplex bead-based
assays [2218] even allows measurement of secreted proteins or
gene expression.
Recent development of laboratory automation even enable
fully automated processes allowing cell culture, staining, wash-
ing, and measurement [2219]. The increasing popularity of this
technology for modern drug discovery can be observed by the
increasing diversity of applications in this field such as inhibition
of non-homologous end joining in B cells [2220], identification
of molecules inhibiting hantavirus cell entry [2221], Ab develop-
ment [2222], or examination of CAR-T cell mediated cytotoxic-
ity [2223].
12.3 Principles of the technique being described
HTFC is the combination of classical single cell multiparamet-
ric FCM with an autosampler delivering the sample to the FCM.
The term high throughput refers to the number of samples being
acquired and not to the number of cells being measured. Usu-
ally only short acquisition periods (1–3 s) are applied to ensure
measurement ofmultiple samples in short time. Different plate for-
mats (96, 384, or even 1536 well plates) can be handled by mod-
ern autosamplers. The preferred plate format for primary drug
screenings depends on the format that the compound library is
stored. Compatible plate formats are used to allow easy trans-
fer of compounds from the storage plate to the assay plate. The
most common screening format is 384-well plates, as most small
molecule libraries are stored in this format. Almost all vendors
of FCM offer machines capable of handling 96-well and 384-well
plates. However, sampling of microvolumes (down to 1 µL) from
1536 well plates is so far only possible with the iQue screener
(intellicyt). The acquisition time per sample can be individually
adjusted which in turn influences the measurement time per plate.
In the setup described below (Fig. 243), ten 384-well plates were
measured per day resulting in a throughput of 3840 samples per
day. However, it is still possible to increase the throughput when
fully automated systems like liquid handling robotics are used.
Other high-throughput flow cytometers (HTFCM) on the market
are based on single sample acquisition and generation of indi-
vidual FCM standard (FCS) files. They also come with optional
washing steps in between the samples (e.g., MACS R© QuantX,
Miltenyi) to prevent sample carryover. Depending on the sys-
tem, there are differences in speed and sample acquisition time
but usually a 384-well plate can be measured in about 30 min.
Data analysis can be performed with software shaped for high-
throughput data analysis, e.g., Forecyt (intellicyt) or Genedata
Screener (Genedata) that displays the samples in plate format and
is designed to help the user to easily identify hits on a plate, calcu-
late thresholds, Z-factor, and even combine and overlay results
from different screening campaigns. However, it is also possi-
ble to analyze the samples with software like FlowJo (FlowJo,
LLC), WinList, or even free (mostly R-based) FCM software
[2077].
12.4 Applications
High-throughput screening technologies such as automated
microscopy, cell impedance measurement, or TR-FRET mostly
generate only a single readout. In contrast, HTFC offers the
multiparameter analysis of particles and cells. This is especially
useful for phenotypic screening assays where different cellular
parameters (e.g., size, viability, surface molecule expression) or
even different cell populations can be simultaneously analyzed
to identify the most potent and less toxic hit compounds. HTFC
can be performed using living cells, fixed cells, suspension cells,
or even adherent cells [2224] and bead based assays. Exam-
ples for applications are Ab development [2222, 2225], toxicol-
ogy [2226, 2227] and apoptosis studies [2228], analysis of pro-
tein phosphorylation [2003], identification of stem cell expanding
compounds [2229], identification of immune enhancing [2230] or
immune inhibiting compounds [2231], monitoring of chemother-
apy side effects [2232], and characterization and cytotoxicity
monitoring of engineered T cells [2223]. In addition, secreted
molecules such as chemokines or cytokines as well as gene expres-
sion can be quantified using barcoded bead based multiplex assays
[2233, 2234]. Specialized HTFCM canmeasure up to 500 analytes
per sample in high throughput (e.g., FLEXMAP 3D, Luminex).
Even the simultaneous analysis of cells and beads in one sam-
ple can be performed [2235]. Thus, the variety of different HTFC
applications illustrates the flexibility this method offers for assay
design and high-throughput screening. The HTFC assay described
in Fig. 243 was designed to identify compounds inducing the
expression of Foxp3–the master transcription factor of regulatory
T cells. Therefore, spleen and lymph node cells from reporter mice
were incubated with 40 000 small synthetic molecules (provided
by the screening unit of the FMP Berlin) and the expression of
enhanced green fluorescent protein (EGFP) under the control of
the Foxp3 promotor was analyzed by FCM.
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Figure 243. Experimental workflow, data deconvolution, and hit selection of an HTFC drug screen. (A) Primary immune cells from Foxp3-eGFP
reportermice are cultured in the presence of specific stimuli and compounds from a small molecule library. The autosampler is harvesting the cells
from 384-plates and delivers it consecutively, without washing steps, to a connected cytometer. Air gaps in between samples created by position
change of the sampling probe are necessary for sample deconvolution. (B) Data deconvolution to identify Foxp3-eGFP inducing hit compounds.
Data of the entire 384-well plate is displayed. Hits and positive controls can be located on the plate heat map. (C) Single well analysis for hit
verification, analysis of assay robustness, quality of controls, and exclusion of false positives (autofluorescence).
12.5 Equipment
To perform HTFC with reasonable throughput the assays should
at least be set up in 96-well formats. Necessary hardware com-
ponents are the autosampler, a FCM, and a computer with data
analysis software. Several FCM offer already build in autosam-
pler for 96- or even 384-well formats: iQue screener (intelli-
cyt), MACS R© Quant X (Miltenyi), ZE5 (BioRad), Cyte (ACEA
Biosciences), Cytoflex (Beckman Coulter), and the spectral ana-
lyzer SA3800 (Sony). Other distributors offer compatible add-
on autosampler for their devices like Attune (Thermo Fisher) or
Beckton Dickinson instruments that can be easily connected. For
the phenotypic assay described here, the HyperCyt R© autosampler
(intellicyt) [2236] connected to a FCM (Accuri) and a computer
equipped with a specialized software capable of handling and ana-
lyzing the data (ForeCyt R©) (Fig. 243A) was used.
12.6 Experimental workflow and acquisition
The assay described in Fig. 243 was performed in 384-well
polypropylene U-bottom plates. Compounds were diluted in RPMI
medium (10% FCS, 1% Pen/Strep, 1% Pyruvat, 2.5% HEPES,
0.5% Gentamycin, 0,01% Mercaptoethanol) and spotted on the
assay plate. The final concentration of the screened compounds
was 1 µM. Primary immune cells of Foxp3-eGFP reporter mice
(DEREGxDo11.10) [2237] were isolated from spleen and lymph
nodes and depleted of CD8+ T cells by magnetic separation (Mil-
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tenyi). Ovalbumin (1 µg/mL) and IL-2 (10 ng/mL) was added to
the cell suspension for stimulation. The positive control addition-
ally contained TGF-ß (5 ng/mL) as inducer of Foxp3 expression.
The number of cells seeded per well was 3 × 105 cells. Experience
showed that CD8+ depleted cells from one animal are sufficient for
up to four plates. The plate included 352 wells with compounds
and 16 wells each for negative and positive controls (Fig. 243A).
This number of controls is necessary to obtain statistical power
for calculation of assay robustness (Z-factor). Incubation was per-
formed at 37°C for 72 h and plates were subsequently centrifuged.
The supernatant was discarded and staining solution containing
CD4-Alexa647 mAb (GK 1.5; DRFZ) and PI (1 µg/mL) was added.
The plates were shaken at 3000 rpm for 10 s on the plate shaker
included in the HyperCyt autosampler and subsequently incubated
for 15 min at 4°C with. Acquisition was performed right after incu-
bation without washing. The acquisition time was set to 3 s, which
results in approximately 1 × 104 recorded events per sample.
Washing steps of 3 s were programmed after every 16 samples (1
column). The autosampler harvests the cells from 384-plates and
delivers it consecutively, without washing steps, to a connected
cytometer. When the sampling probe switches between individ-
ual wells, air gaps are created which interrupt the sample flow
(Fig. 243A). As only one single FCS file is recorded for the whole
plate these air gaps serve as reference point for the software to
recognize individual samples and allocate them to the wells. Using
these acquisition settings, the measurement time per plate was 37
min. The daily throughput was 3840 samples.
12.7 Data analysis
Following acquisition, the data are uploaded to the ForeCyt soft-
ware where the data was processed andwell gates were positioned
automatically according to time and position of air gaps that sep-
arated the sample flow. The correct allocation of the well gates
should be manually controlled to avoid misallocation and thereby
misinterpretation of data. Gating of lymphocytes, live cells, CD4+
T cell, and Foxp3+ T cell populations was performed and per-
centages of Foxp3+ cells are displayed in a 384-well heat map to
facilitate hit identification (Fig. 243B). Frequencies of viable and
Foxp3-eGFP+ cells are exported to an excel sheet. Mean and SD of
negative and positive controls are calculated and accordingly the
Z-factor [2238] is calculated to obtain a measure of assay quality.
Hit identification thresholds are set according to reporter expres-
sion (mean of negative control +3xσ) and cell viability (mean
of negative control -3xσ). Hits passing the thresholds are again
reanalyzed to exclude false positives (e.g., caused by autofluores-
cent compounds; Fig. 243C). The final hits are selected for further
validation.
12.8 Advantages
– Speedy automated acquisition of hundreds of samples
– Simultaneous multiparameter analysis of cells (cellular size,
viability, surface molecule expression)
– Multifactorial analysis [2077] of different cell populations in
one sample in the presence of screening compounds
– Identification of toxic compounds already at screening stage of
the drug discovery process helps to identify and focus on the
right drug candidates
– Autosampler capable of acquiring samples from 96-, 384-, or
even 1536-well plates help to drastically reduce the sample
size which in turn reduces screening material (e.g. cells, less
animals if primary cells are used), costs for reagents (Abs,
buffers)
– False positive results resulting, e.g., from interaction of autoflu-
orescent compounds with cells can be easily excluded which is
not possible by, e.g., automated microscopic screenings
– label-free screenings are now possible with the use of spectral
analyzers (e.g., SA3800, Sony).
12.9 Pitfalls
– Cells will accumulate at the well bottom if plates (especially
384- and 1536-well) are not properly shaken.
– Clogging of the device might occur but the software does
always recognize and warn.
– Make sure that samples do not evaporate during measurement
especially whenworking with very small volumes. Plate sealing
helps and autosampler probe can perforate certain seals but
make sure that the glue of the seals does not clog the probe.
FCM manufacturers will help identifying the right seals.
– Check for unusual high signals. False positives might result
from autofluorescent compounds sticking to cells.
– Check for carry over effect of the autosampler probe.
12.10 Top tricks
– Before starting the screen perform test runs to check the follow-
ing: (1) quality of the assay by comparing negative and positive
controls and calculate the Z-factor to determine the quality of
the assay (SNR and signal to background ratio) [2238]. A Z-
factor > 0.6 is desirable, (2) check for DMSO sensitivity of the
cells. DMSO concentrations should be <1%.
– The washing step after cell staining can be omitted that saves
time and limits eventual loss of cells
– Determine carry over effect of autosampler probe to prevent
intersample contamination. To prevent carry over includewells
containing wash buffer in the assay well.
– To prevent clogging of the sampling probe or tubing QSol
Buffer (intellicyt) can be used.
– Calibrate plate alignment and sampling probe depth before
and if possible, also during screen to ensure proper sample
uptake.
– Frequently shake the plate or mix the samples during the mea-
surement to prevent cell accumulation at the well bottom.
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– Frequently monitor data acquisition and sample flow during
measurement to detect eventual problems (clogging of sam-
pling probe, low event rate).
– Make sure to reserve enough space for positive and negative
controls. On a 384-well plate it´s usually 16 positive and 16
negative controls that serve to calculate the assay robustness.
– Personalized R-based programs might help to process data as
flow analysis software is often not designed to handle screening
data and help with hit identification.
13 Core Facility setup and housekeeping/shared
resource laboratory (SRL) management
Technologies and instrumentation are rapidly evolving and there
is an increasing demand for sophisticated and high-priced tech-
nologies across the life sciences. Access to state-of-the-art infras-
tructure has become essential for success in scientific research.
This has led to the development of Core Facilities also known
as Shared Resource Laboratories (SRLs), core resources of insti-
tutions that provide highly skilled technology scientists and
advanced instrumentation to enhance the scope and quality of
biomedical research [2239]. The term “Shared Resource Labora-
tory” has been adopted to better define the role of shared instru-
mentation laboratories as a scientific partnership with researchers
within an institution. SRLs and core facilities are called the pre-
requisite for breakthroughs in the life sciences, because they are
collaborators who will not say “no,” unless there are technical
feasibility concerns [2240].
Cell sorters, high-end flow cytometers, imaging flow cytome-
ters, and mass cytometers are usually placed in SRLs. There are
two different approaches for setting up a shared resource lab-
oratory: (i) a pool of existing instrumentation from different
groups/principal investigators is put together into an SRL (bottom-
up approach) or (ii) the management of an institution makes a
strategic investment in central research infrastructure (top-down
approach). In order to achieve the desired result—the many syn-
ergistic effects of a successful SRL—several points must be taken
into consideration. Operational best practice manuals have been
published recently for both FCM and advanced light microscopy
SRLs, two classes of core facilities that share many challenges
in common [2241, 2242]. In this section, we will give a short
overview of important aspects for successful SRL management.
Key topics for SRL management are staffing, education, finances,
data management, quality assurance (QA)/quality control (QC),
laboratory space, and safety/biosafety.
13.1 Staffing
An SRL needs a head or director to oversee andmanage the facility,
who consults with researchers and laboratory staff across a large
range of disciplines with different level of technical expertise. The
head should have a scientific background reflecting the need for
scientific and research expertise in SRLs. In addition to the head,
more personnel are needed to successfully operate a larger SRL,
to ensure continuous operation and cover vacations, sick leave,
and business trips. Cell sorters are commonly operated by sorter
operators, who need to be highly qualified, knowledgeable, and
service-oriented people. In an SRL, the ability to interact with peo-
ple is as important as technical skill. A recent publication describes
careers in SRLs and lists skills and qualifications, because SRL posi-
tions require certain common sets of skills [2243]. Among themost
important qualifications are a love of learning, the ability to keep
up with new technologies, and a passion for solving problems,
such as troubleshooting equipment problems. SRL staff acts in
a service/customer-support-type manner, and reacts to changing
tasks and priorities throughout the day. Up to hundreds of people
use an SRL, therefore an ability to work with individuals with very
different personalities is required [2243]. Working in an SRL is a
very rewarding job if one has the right skills, interests, talents, and
service-oriented attitude. Determining staffing levels is a difficult
challenge for SRLs. Key factors are the number and complexity of
shared instruments, and the number of users needing support and
training. The best practices for FCM SRLs published by the Inter-
national Society for Advancement of Cytometry (ISAC) give some
advice on this topic [2241]. A certain amount of SRL staff time
should be reserved for consultation with users, educational activ-
ities, and optimization and development of new techniques. Such
developments may be formally published as SRL Communications
within the journal Cytometry Part A, a new publication format
created to provide a vehicle for SRL-focused subjects [2244]. SRL
staff members need ongoing continuing education, for example
through regular attendance of conferences or courses, in order to
optimally support users.
13.2 Education
In addition to the needs of SRL staff, the users of the SRL also
require education. Depending on the institution, researchers with
varying and diverse expertise levels will use the SRL. The first
step with a new project should always be an initial consultation
in which the project is discussed between the user and SRL staff.
It is crucial to offer a training program, consisting of theoretical
and practical education, which includes experimental planning
and data analysis. If independent usage of equipment by users is
a goal, users should be made aware of all required training steps,
and facilities should implement measures to ensure users’ compe-
tency, for example by checking the users’ skills with a practical
exam at the instrument. The users must understand that training
is mandatory prior to instrument usage. They should be reminded
that they are operating expensive equipment that is needed for
numerous scientific projects, and therefore any instrument down-
time due to careless handling will affect their own projects and
also those of their colleagues. Instructions are best placed next to
the instruments in a written form or as standard operating proce-
dure (SOP). Each SRL should have user guidelines in which the
main topics are clarified.
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13.3 Finances
SRLs should provide high-quality, cost-effective services. Signifi-
cant costs are associated with cytometry services; depending on
the institution, different financial models are in place. Usually,
SRLs charge usage fees, but some institutions cover costs under a
central budget. Nevertheless, the preparation and periodic review
of an annual operational budget is critical. The calculation of usage
fees can be based on a full economic cost calculation; in this case,
institutions and facility heads must consider which costs should
be covered by SRL users and which costs will be subsidized by
the institution. Ferrando-May et al. published an example cost
calculation; although it is for a microscopy SRL, the approach
is very similar for a flow cytometry SRL [2242]. Other publica-
tions show an approach for a cost accounting method [2245],
and metrics for evaluating cell sorting services [2246]. Indepen-
dent of whether usage fees are charged by a facility or not, the
role of the SRL should be mentioned in scientific publications in
the acknowledgements section, together with any grant numbers
through which instruments have been purchased. This is not just a
kind way of saying ‘Thank you!’ for the effort SRL staff has put into
a published result. It very important that SRLs and SRL staff are
formally acknowledged for their contributions, because the evalu-
ation of SRL performance is often based on numbers of published
acknowledgements.
13.4 Data management
Data management and data analysis are critical to the experiments
performed in an SRL. It is in the interest of research institutions
that data obtained in their SRLs complies with the highest sci-
entific standards. If the flow cytometers are not operated by SRL
staff, the users operate the instruments independently. Therefore,
the large number of users with their diverse projects does not
allow for a proper quality control by SRL staff. Thus, responsi-
bility for data, including experimental design and compliance to
scientific best practices, lies in the hands of the users and their PIs.
To ensure the proper description of experiments, SRLs can offer
proof-reading of methods parts of scientific publications. Transfer-
ring data off instrument PCs is the first step to accessing to data.
Here, users should refrain from using USB devices (flash drives,
external hard drives) due to the high risk of spreading computer
viruses and malware. A centrally accessible file server is an option
to overcome this problem. The facility should state clearly who
has the responsibility to transfer and store data and when data
will be deleted from SRL computers and file servers. In clinical
environment, there may be additional regulations addressing data
management.
13.5 Quality assurance and quality control
SRLs must monitor instruments to maintain optimal performance.
In a multi-user environment such as an SRL, contamination, opti-
cal misalignment, damage, or careless handling can happen on a
daily basis. Regular system checks and performance tracking must
be common practice, and the quality control (QC) data should
be stored and made available to the SRL users, if needed. It is
important to perform preventative maintenance for the instru-
ments. Here, maintenance contracts with instrument vendors can
help minimize instrument downtime. QC criteria can be rather
different depending on the equipment, but Barsky et al. give some
advice on this topic [2241].
13.6 Laboratory space
SRLs should occupy highly visible space that has the same quality
as research labs. The quality of laboratory space expresses the com-
mitment of the institution to state-of-the-art technologies [2239].
Large instrumentation, such as cell sorters, image cytometers, or
mass cytometers have special room requirements, especially in
regard to temperature stability. Other important physical environ-
mental factors are square footage, humidity, presence of vibra-
tions, electricity, and gas supplies [2241, 2242]. SRL lab space
should be designed and equipped in close collaboration with SRL
staff, as reconstruction after installation is expensive and will
always interfere with SRL operations. High quality lab space also
makes it feasible to fulfil safety and biosafety requirements.
13.7 Safety/Biosafety
Biosafety regulations vary depending on regional authorities; nev-
ertheless, the main goal is always to protect people from biological
hazards, such as infectious diseases caused by human pathogens.
The potential of cytometers and especially cell sorters to create
aerosols during cell sorting procedures places SRL staff and users
at risk of laboratory-associated infections (LAI). A risk assess-
ment must be performed, resulting in a risk management solution,
encompassing personal protective equipment, safe laboratory pro-
cedures, and laboratory design for containment [143]. Placing cell
sorters in biosafety cabinets for aerosol containment is onemethod
to reduce the risk to sorter operators [2247]. The Biosafety Com-
mittee of the International Society for Advancement of Cytom-
etry (ISAC) published cell sorter biosafety standards [143] and
offers additional information on the ISAC webpage (https://isac-
net.org/page/Biosafety). In an SRL, users bring a diverse range
of samples to be analyzed or sorted. It is very important that the
SRL keep track of the biosafety levels of all samples, including
genetically modified organisms. This can be achieved by asking
users to fill out questionnaires about their samples before use in
the SRL. An institutional biosafety committee can help to deter-
mine the rules how to handle potentially infectious samples. SRLs
may need to keep records for regional authorities. There are many
additional safety topics that must be considered, including laser
safety, waste management, and protection from chemical hazards,
although these topics can vary due to regional regulations. Emer-
gency and disaster planning is described elsewhere [2248].
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In addition to the resources cited above, the Shared Resource
Lab section of CYTOUniversity (CYTOU) offers a seven-part series
of webinars on SRL best practices, four webinars on Finance 101,
and webinars on a great many other topics related to establishing
and operating an SRL. CYTO U is ISAC’s online portal for on-
demand, peer-reviewed cytometry education, a great educational
resource (http://cytou.org).
Acknowledgements: Work in the laboratory of Dieter Adam is
supported by the Deutsche Forschungsgemeinschaft (DFG, Ger-
man Research Foundation)—Projektnummer 125440785 – SFB
877, Project B2.
Petra Hoffmann, Andrea Hauser, and Matthias Edinger thank
BD Biosciences R©, San Jose´, CA, USA, and SKAN AG, Bale, Switzer-
land for fruitful cooperation during the development, construc-
tion, and installation of the GMP-compliant cell sorting equip-
ment and the Bavarian Immune Therapy Network (BayImmuNet)
for financial support.
Edwin van der Pol and Paola Lanuti acknowledge Aleksandra
Ga˛secka M.D. for excellent experimental support and Dr. Rienk
Nieuwland for textual suggestions. This work was supported by
the Netherlands Organisation for Scientific Research – Domain
Applied and Engineering Sciences (NWO-TTW), research program
VENI 15924.
Jessica G Borger, Kylie M Quinn, Mairi McGrath, and Regina
Stark thank Francesco Siracusa and Patrick Maschmeyer for pro-
viding data.
Larissa Nogueira Almeida was supported by DFG research grant
MA 2273/14-1. Rudolf A. Manz was supported by the Excellence
Cluster “Inflammation at Interfaces” (EXC 306/2).
Susanne Hartmann and Friederike Ebner were supported by the
German Research Foundation (GRK 2046).
Hans Minderman was supported by NIH R50CA211108.
This work was funded by the Deutsche Forschungsgemeinschaft
through the grant TRR130 (project P11 and C03) to Thomas H.
Winkler.
Ramon Bellma`s Sanz, Jenny Ku¨hne, and Christine S. Falk thank
Jana Keil and Kerstin Daemen for excellent technical support.
The work was funded by the Germany Research Foundation
CRC738/B3 (CSF).
The work by the Mei laboratory was supported by German
Research Foundation Grant ME 3644/5-1 and TRR130 TP24, the
German Rheumatism Research Centre Berlin, European Union
InnovativeMedicines Initiative - Joint Undertaking - RTCure Grant
Agreement 777357, the Else Kro¨ner-Fresenius-Foundation, Ger-
man Federal Ministry of Education and Research e:Med sysIN-
FLAME Program Grant 01ZX1306B and KMU-innovativ “Inno-
Cyt”, and the Leibniz Science Campus for Chronic Inflammation
(http://www.chronische-entzuendung.org).
Axel Ronald Schulz, Antonio Cosma, Sabine Baumgart, Brice
Gaudilliere, Helen M. McGuire, and Henrik E. Mei thank Michael
D. Leipold for critically reading the manuscript.
Christian Kukat acknowledges support from the ISAC SRL
Emerging Leaders program.
John Trowsdale received funding from the European Research
Council under the European Union’s Horizon 2020 research and
innovation program (Grant Agreement 695551).
The following formed the writing committees for the indicated
sections:
Andrea Cossarizza (Introduction: Guidelines for the use of flow
cytometry and cell sorting in immunological studies (second edi-
tion)); Christoph Goettlinger (I.1 Fluidic system of a flow cytome-
ter); Toralf Kaiser, Konrad von Volkmann (I.2 Optics and elec-
tronics); Toralf Kaiser, Mark Dessing (I.3 Flow cytometry, includ-
ing flow cytometry cell sorting); Alan M. Stall (II.1 Compen-
sation); Steffen Schmitt (II.2. Maintenance); James Wing (II.3
PMT voltage optimization); Hyun-Dong Chang, Andreas Radbruch
(III.1 Controls: Determining positivity by eliminating false posi-
tives); Hyun-Dong Chang, Van Duc Dang, Andreas Radbruch (III.2
Titration: Determining optimal reagent concentration); Wolfgang
Beisker (III.3 Preparation of single-cell suspensions); Gemma A.
Foulds, Gabriele Multhoff, A. Graham Pockley (III.4 Dead cell
exclusion, cell viability and sample freezing); Vincent Shankey,
Sue Chow, David Hedley (III.5 Cell fixation and permeabiliza-
tion for flow cytometric analyses); Srijit Khan, Yanling Liu, Leslie
Y.T. Leung, Go¨tz R.A. Ehrhardt (III.6 Variable Lymphocyte Recep-
tor Antibodies); Marcus Eich (III.7 New antibody reagents);
Steffen Schmitt (Pre-enrichment of low abundant cell popula-
tions prior to acquisition/cell sorting); Charlotte Esser, Liping Yu,
Diether Recktenwald, Steffen Schmitt (IV.2 Parallel cell sorting);
Joe Trotter, Toralf Kaiser, Sarah Warth, De´sire´e Kunkel, Mar-
tin Bu¨scher, Christian Peth, Esther Schimisky, Leonie Wegener,
Daryl Grummitt, John Foster (IV.3 Serial cell sorting); Toralf
Kaiser (IV.4 Collecting cells); Petra Hoffmann, Andrea Hauser,
Matthias Edinger (IV.5 Flow-Cytometric Cell Sorting under GMP
Conditions); Sara De Biasi, Milena Nasi, Lara Gibellini, Marcello
Pinti, Andrea Cossarizza (V.1 Rare cells: General rules); Derek
Davies, Rachael Walker (V.2 Organisms, cells, organelles, chro-
mosomes and extracellular vesicles); Lara Gibellini, Marcello Pinti,
Anna Iannone, Milena Nasi, Sara De Biasi, Andrea Cossarizza (V.3
Mitochondria); Edwin van der Pol, Paola Lanuti (V.4 Extracel-
lular vesicles); Alexander Scheffold, Andreas Gru¨tzkau (V.5 Sur-
face parameters); A. Graham Pockley, Gabriele Multhoff (V.6 DNA
synthesis, cell cycle and proliferation); Graham Pockley, Gemma
A. Foulds, Gabriele Multhoff (V.7 Measuring cell death mecha-
nisms); Rieke Winkelmann, Sabine Adam-Klages, Dieter Adam
(V.7.3 Necroptosis); Rieke Winkelmann, Sabine Adam-Klages,
Dieter Adam (V.7.4 Pyroptosis); Mar Felipo-Benavent, Guadalupe
Herrera, Beatriz Ja´vega, Alicia Mart´ınez-Romero, Jose´-Enrique
O’Connor, Francisco Sala-de-Oyanguren (V.8 Phagocytosis); Han-
lin Zhang, Isabel Panse, Sharon Sanderson, Anna Katharina Simon
(V.9 Autophagy); Laura G. Rico, Michael D. Ward, Jolene A. Brad-
ford, Jordi Petriz (V.10 Reactive oxygen species production with
minimal sample perturbation); Baerbel Keller, Marie Follo, Klaus
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1906 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
Warnatz (V.11 Intracellular Ca2+ mobilization by means of Indo-1
AM); Linda Schadt, Maries van den Broek, Susanne Ziegler, Glo`ria
Martrus (V.12 mRNA); Derek Davies, Alfonso Blanco, Andrew
Filby, Timothy P. Bushnell (V.13 Transcription factors); Jakob
Zimmermann, Christina Stehle, Hyun-Dong Chang, Andreas Rad-
bruch (V.14 Intracellular parameters); T. Vincent Shankey, Sue
Chow, Lilly Lopez, David Hedley (V.15 Measurement of sig-
nal transduction pathways by flow cytometry); Katharina Pracht,
Sophia Urbanczyk, Tobit Steinmetz, Hans-Martin Ja¨ck, Dirk Mie-
lenz (V.16 Assessing Lymphocyte metabolism through functional
dyes); Alessio Mazzoni, Laura Maggi, Francesco Annunziato
(V.17.1 Measurement of signal transduction pathways in human
T cells); Steven L.C. Ketelaars, Anastasia Gangaev, Pia Kvistborg
(V.17.2 Measuring antigen specific T cell responses); Matthias
Schiemann, Immanuel Andra¨, Kilian Schober, Dirk H. Busch (T cell
assays-MHCmultimers); Alexander Scheffold, Petra Bacher (Func-
tional readouts); Alessio Mazzoni, Laura Maggi, Lorenzo Cosmi
(V.17.6 Live cytokine-producing cell sorting with cytokine secre-
tion assayTM); Laura Maggi, Alessio Mazzoni, Francesco Liotta
(V.17.7 Quantification of soluble cytokines with cytometric bead
array); Thomas Schu¨ler, Gerald Willimsky, Tristan Holland, Sal-
vador Vento-Asturias, Natalio Garbi (V.17.8 Cytotoxicity); James
Wing, Ilenia Cammarata, Vincenzo Barnaba, Shimon Sakaguchi
(V.17.9 Treg suppression assays); Johanna E. Huber, Dirk Baumjo-
hann (V.18 Adoptive T and B cell transfer as a read-out for
antigen-specific immune responses in mice); Jessica G. Borger,
Kylie M. Quinn, Mairi McGrath, Regina Stark (VI.1.1 Murine CD4
and CD8 T cells); Kylie M. Quinn, Luka Cˇicˇin-Sˇain, Katarzyna
M. Sitnik (VI.1.5 Immune senescence (aging) in murine T cells);
Michael Delacher, Juhao Yang, Markus Feuerer, Jochen Huehn
(VI.1.6 Murine Foxp3+ regulatory T cells); Immo Prinz, Anneke
Wilharm, Inga Sandrock (VI.1.7 Murine γδ T cells); Heike Kunze-
Schumacher, Andreas Krueger (VI.1.8 Murine NKT cells); Heike
Kunze-Schumacher, Andreas Krueger (VI.1.9 Murine mucosal-
associated invariant T (MAIT) cells); Immo Prinz, Joana Barros-
Martins (VI.1.10 Murine intestinal intraepithelial T cells); Pleun
Hombrink, Ester B.M. Remmerswaal (VI.1.11 Human CD4 and
CD8 T cells); Anna Oja, Pleun Hombrink (VI.1.12 Human tissue
resident memory T cells); Yotam Raz (VI.1.13 Immune senes-
cence (aging) of human T cells); Kirsten A Ward-Hartstonge,
Laura Cook, Dominic A Boardman, Sabine M Ivison, Jennie H.
M. Yang, Eleni Christakou, Timothy I.M. Tree, Megan K Levings
(VI.1.14 Human FOXP3+ regulatory T cells); Anouk von Bors-
tel, Martin S. Davey (VI.1.15 Human γδ T cells); Christopher M.
Harpur, Dale I. Godfrey, Garth Cameron (VI.1.16 Human NKT
cells); Garth Cameron, Nicholas A. Gherardin, Alexandra J. Cor-
bett, Sidonia B. G. Eckle, James McCluskey, Dale I. Godfrey,
Hui-Fern Koay (VI.1.17 Human mucosal-associated invariant T
(MAIT) cells); Larissa Nogueira Almeida, Britta Frehse, Rudolf
Armin Manz (VI.2.1 Murine B cells and their subsets, including
Bregs); Thomas Weisenburger, Andreas Acs, Thomas H. Winkler
(VI.2.2 Murine Germinal Center B cells); Annika Wiedemann,
Andreia Lino, Thomas Do¨rner (VI.2.3 Human B cells and their
subsets); Annika Wiedemann, Andreia C. Lino, H. Kristyanto,
Hans U. Scherer, Thomas Do¨rner (VI.2.4 Human B cells recog-
nizing defined (auto)antigens); Oliver Wirz, Willem van de Veen,
Mu¨beccel Akdis (VI.2.5 Human regulatory B cells); Willem van de
Veen, Oliver Wirz, Mu¨beccel Akdis (VI.2.6 Human immunoglobu-
lin heavy chain isotypes); Sebastian Schulz, Katharina Pracht, Ljil-
jana Cvetkovic, Dirk Mielenz, Dorothea Reimer, Wolfgang Schuh,
Hans-Martin Ja¨ck (VI.3.1 Murine antibody-secreting plasmablasts
and plasma cells); Antonia Niedobitek, Henrik E. Mei (VI.3.2
Human antibody-secreting cells); Daniela C Herna´ndez, Christina
Stehle, Andreas Diefenbach, James Di Santo, Chiara Romag-
nani (VI.4 Innate Lymphoid cells); Lorenzo Moretta, Linda Qua-
trini, Genny del Zotto (VI.5 Natural Killer (NK) cells); Regine J.
Dress, Alicia Wong, Ahad Khalilnezhad, Wan Ting Kong, Charles-
Antoine Dutertre, Florent Ginhoux (VI.6 Mononuclear phago-
cytes: Monocytes, macrophages and dendritic cells); Jonas Hahn,
Christian Mauero¨der, Jasmin Knopf, Malgorzata Justyna Podol-
ska, Luis Enrique Mun˜oz, Martin Herrmann (VI.7.1 Neutrophils,
eosinophils and basophils); Immanuel Kwok, Leonard Tan, Max-
imilien Evrard, Lai Guan Ng (VI.7.2 Bone marrow and umbili-
cal cord blood neutrophils); Philip E. Boulais, Paul S. Frenette
(VI.8 Murine bone marrow stromal cells); Peter K. Jani, Julia Tor-
nack, Wolfgang Bauer, Fritz Melchers, Susann Rahmig, Claudia
Waskow (VI.9 Hematopoietic Stem Cells); Ramon Bellma`s Sanz,
Jenny Ku¨hne, Christine S. Falk (VI.10 Tumor cells); Katharina
Kriegsmann, Michael Hundemer, Leo Hansmann (VI.11 Human
plasma cells in multiple myeloma); Pascale Eede, Katja Kobow,
Helena Radbruch (VI.12 Brain/neural cells); Katrin Neumann,
Aaron Ochel, Gevitha Ravichandran, Gisa Tiegs, Sebastian Lune-
mann (VI.13 Cells from liver); Friederike Ebner, Kerstin H. Mair,
Josephine Schlosser, Susanne Hartmann, Armin Saalmu¨ller, Wil-
helm Gerner (VI.14.1 Porcine cells); Kerstin H. Mair, Armin
Saalmu¨ller, Wilhelm Gerner (VI.14.2 Cross-reactive Ab clones);
Yvan Saeys (Introduction and Artificial intelligence in flow cytom-
etry); Tim Mosmann, Alice Yue, Sally Quataert, Jonathan Reb-
hahn, Ryan R. Brinkman (Cell-population analysis: Data pre-
processing, manual and automated gating, and quality control);
Thomas Ho¨llt (Dimensionality reduction); Sofie Van Gassen (VII.1
Clustering); Natalie Stanley and Nima Aghaeepour (Integration of
cytometric data intomultiomics analysis) James VWatson, Diether
Recktenwald, James Wing (VII.2 Statistics for flow cytometry);
Susanne Melzer, Attila Tarnok (VII.3 Analysis presentation and
publication (MIFlowCyt)); Josef Spidlen, Ryan R. Brinkman (VII.4
Data repositories: Sharing your data); Orla Maguire, Hans Min-
derman (VIII.1 Imaging Flow Cytometry); Henrik E. Mei, Michael
D. Leipold, Holden T. Maecker (VIII.2 Barcoding in cytometric
assays); Axel Ronald Schulz, Antonio Cosma, Sabine Baumgart,
Brice Gaudilliere, Helen M. McGuire, Henrik E. Mei (VIII.3 Mass
cytometry); J. Paul Robinson, Bartek Rajwa (VIII.4 Combina-
torial cytometry); Claudia Haftmann, Florian Mair (VIII.5 High
dimensional flow cytometry); Daniel Schraivogel, Dinko Pavlinic,
Bianka Baying, Diana Ordonez, Anders Stahlberg, Vladimir Benes,
Malte Paulsen (VIII.6 Single cell genomics and cytometry); Hyun-
Dong Chang, Jakob Zimmermann, SusannMu¨ller (VIII.7Microbial
cells); Marina Saresella, Ivana Marventano, Federica Piancone,
Francesca LaRosa, Mario Clerici (VIII.8 Detailed and standard-
ized methods to detect inflammasome assembly and activation
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1907
in immune cells (FlowSight AMNIS); Kata Filkor, Gergely Toldi
(VIII.9 Multidrug resistance activity); Leo Hansmann, Livius Pen-
ter, Hans-Peter Rahn (VIII.10 Index sorting); Chantip Dang-Heine,
Holden T. Maecker (VIII.11 Sample banking for flow cytometry);
Stefan Frischbutter (VIII.12 High throughput screening); Chris-
tian Kukat (VIII.13 Core Facility setup and housekeeping /Shared
Resource Laboratory (SRL) management).
Conflict of interest
Some of the authors of these guidelines work for companies manu-
facturing FCM equipment and reagents. The mention of a particu-
lar company’s equipment or reagents does not imply endorsement
of these products but are included as examples. The content of
these guidelines is editorially independent of any company and
has been peer-reviewed.
References
1 Cossarizza, A., Chang, H.-D., Radbruch, A., Akdis, M., Andra¨, I.,
Annunziato, F., Bacher, P. et al., Guidelines for the use of flow cytome-
try and cell sorting in immunological studies. Eur. J. Immunol. 2017. 47:
1584–1797.
2 Mack, J., Fulwyler Particle Separator. US patent US 3380584 A.
3 Kachel, V., Fellner-Feldegg, H. and Menke, E., Hydrodynamic proper-
ties of flow cytometry instruments. In M. R. Melamed, T. Lindmo and
M. L. Mendelsohn (Eds.), Flow cytometry and sorting, 2nd ed., Wiley, New
York, NY, 1990, pp. 27–44.
4 Crosland-Taylor, P. J., A device for counting small particles suspended
in a fluid through a tube. Nature 1953. 171: 37–38.
5 Gucker, F. T., Jr., O’Konski, C. T., Pickard, H. B. and Pitts, J. N., Jr., A
photoelectronic counter for colloidal particles. J. Am. Chem. Soc. 1947.
69: 2422–2431.
6 Van den Engh, G. J., Flow cytometer droplet formation system. US
patent US 6861265 B1.
7 Van den Engh, G. J., Particle separating apparatus and method. US
patent US 5819948 A.
8 Norton, P. O.,Vane, D. R. and Javadi, S., Fixedmounted sorting cuvette
with user replaceable nozzle. US patent US 7201875 B2.
9 Dolezˇel, J. and Go¨hde, W., Sex determination in dioecious plants
Melandrium album and M. rubrum using high-resolution flow cytom-
etry. Cytometry 1995. 19: 103–106.
10 Steen, H. B., Lindau, T. and Sorensen, O., A simple, high resolution
flow cytometer based on a standard fluorescence microscope. In O. D.
Laerum, T. Lindmo and E. Thorud (Eds.), Proceedings of the IVth interna-
tional symposium on flow cytometry (pulse cytophotometry), Bergen, Nor-
way, 1980, pp. 31–33.
11 Pinkel, D. and Stovel, R., Flow chambers and sample handling. In M.
A., Van Dilla, P. N. Dean, O. D. Laerum, and M. R. Melame (Eds.), Flow
cytometry: Instrumentation and data analysis, Academic Press, London,
1985, pp. 77–128.
12 Kaduchak, G. et al., Ultrasonic analyte concentration and application
in flow cytometry. US patent US 7340957 B2.
13 Kaduchak, G. et al., Systemandmethod for acoustic focusing hardware
and implementations. US patent US 8714014 B2.
14 Ward, M., Turner, P., DeJohn, M. and Kaduchak, G., Fundamentals of
acoustic cytometry. Curr. Protoc. Cytometry 2009. 53: 1.22.1–1.22.12.
15 Sweet, R. G., Fluid droplet recorder. US patent US 3596275 A.
16 Go¨ttlinger, C., Mechtold, B., Meyer, K. L. and Radbruch, A., Setup of a
flow sorter. In Radbruch, A. (Ed.), Flow cytometry and cell sorting. Springer
Laboratory, Berlin, Germany 1992, pp. 153–158.
17 Petersen, T. W. and Van den Engh, G., Stability of the breakoff point
in a high-speed cell sorter. Cytometry Part A 2003. 56: 63–70.
18 Kaiser, T., Raba, K., Scheffold, A. and Radbruch, A., A sheath-
cooling system to stabilize side-streams and drop delay during
long-term sorts for FACS-Aria R© cell-sorter, http://fccf.drfz.de/uploads/
pdf/poster_zentrallabor_A0.pdf
19 Lawrence,W. G.,Varadi, G., Entine, G., Podniesinski, E. andWallace, P.
K., Enhanced red and near infrared detection in flow cytometry using
avalanche photodiodes. Cytometry A 2008. 73: 767–776.
20 Kester, W., Understand SINAD, ENOB, SNR, THD, THD+ N, and
SFDR so you don’t get lost in the noise floor. MT-003 Tutorial, 2009,
http://www.analog.com/media/en/training-seminars/tutorials/MT-
003.pdf
21 AD9240AS by Analog Devices | Data Acquisition, Arrow.com. [Online].
Available: https://www.arrow.com/de-de/products/ad9240as/analog-
devices. [Accessed: 18-Jan-2017].
22 Snow, C., Flow cytometer electronics.Cytometry Part A 2004. 57A: 63–69.
23 Asbury, C. L.,Uy, J. L. and van den Engh, G., Polarization of scatter and
fluorescence signals in flow cytometry. Cytometry 2000. 40: 88–101.
24 Shapiro, H. M., Practical flow cytometry, 4th ed., John Wiley & Sons, Inc.,
Hoboken, NJ 2003, pp. 184–197.
25 Watson, D. A., Brown, L. O., Gaskill, D. F., Naivar, M., Graves, S. W.,
Doorn, S. K. and Nolan, J. P., A flow cytometer for the measurement of
Raman spectra. Cytometry A 2008. 73A: 119–128.
26 Nolan, J. P., Condello, D., Duggan, E., Naivar, M. and Novo, D., Visible
and near infrared fluorescence spectral flow cytometry. Cytometry A
2012. 83: 253–264.
27 Wade, C. G., Rhyne, R. H., Woodruff, W. H., Bloch, D. P. and
Bartholomew, J. C., Spectra of cells in flow cytometry using a vidicon
detector. J. Histochem. Cytochem. 1979. 27: 1049–1052.
28 Robinson, J. P., Multispectral cytometry: the next generation. Biophoton.
Int. 2004, 36–40.
29 Robinson, J. P., Rajwa, B., Gregori, G., Jones, V and Patsekin, V, Multi-
spectral cytometry of single bio-particles using a 32-channel detector.
In T. Tuan Vo-Dinh, W. S. Grundfest, D. A. Benaron and G. E. Cohn,
(Eds.), Advanced biomedical and clinical diagnostic systems III, 5692 ed.
Springer, Berlin/Heidelberg, 2005, Pp. 359–365.
30 Robinson, J. P., Rajwa, B., Patsekin, V., Gregori, G. and Jones, J. Multi-
spectral detector and analysis system US patent US7280204 B2.
31 Gre´gori, G., Patsekin, V., Rajwa, B., Jones, J., Ragheb, K., Holdman, C.,
Robinson, J. P. et al., Hyperspectral cytometry at the single cell level
using a 32 channel photodetector. Cytometry A 2012. 81A: 35–44.
32 Goddard, G., Martin, J. C., Naivar, M., Goodwin, P. M., Graves, S. W.,
Habbersett, R., Nolan, J. P. et al., Single particle high resolution spectral
analysis flow cytometry. Cytometry 2006. 69A: 842–851.
33 Futamura, K., Sekino,M., Hata, A., Ikebuchi, R., Nakanishi, Y., Egawa,
G., Kabashima, K. et al., Novel full-spectral flow cytometry with mul-
tiple spectrally-adjacent fluorescent proteins and fluorochromes and
visualization of in vivo cellularmovement. Cytometry 2015. 87: 830–842.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1908 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
34 Feher, K., von Volkmann, K., Kirsch, J., Radbruch, A., Popien, J.
and Kaiser, T., Multispectral flow cytometry: The consequences of
increased light collection. Cytometry 2016. 89: 681–689.
35 Roederer, M., Distributions of autofluorescence after compensation: Be
panglossian, fret not. Cytometry A 2016. 89: 398–402.
36 Szalo´ki, G. and Goda, K., Compensation in multicolor flow cytometry.
Cytometry A 2015. 87: 982–985.
37 Novo, D., Gre´gori, G. and Rajwa, B., Generalized unmixing model
for multispectral flow cytometry utilizing nonsquare compensation
matrices. Cytometry A 2013. 83: 508–520.
38 Nguyen, R., Perfetto, S., Mahnke, Y. D., Chattopadhyay, P. and Roed-
erer, M., Quantifying spillover spreading for comparing instrument
performance and aiding in multicolor panel design. Cytometry A 2013.
83: 306–315.
39 Lee, J. A., Spidlen, J., Boyce, K.,Cai, J.,Crosbie, N.,Dalphin, M., Furlong,
J., et al. MIFlowCyt: the Minimum Information about a Flow Cytometry
Experiment. Cytometry A 2008. 73: 926–930.
40 Tung, J. W., Parks, D. R., Moore, W. A. and Herzenberg, L. A., New
approaches to fluorescence compensation and visualization of FACS
data. Clin. Immunol. 2004. 110: 277–283.
41 BD Cytometer Setup and Tracking Application Guide V3.0, 2013, BD
Biosciences, San Jose, CA.
42 Wood, J. and Hoffman, R., Evaluating fluorescence sensitivity on flow
cytometers: an overview. Cytometry 1998. 33: 256–259.
43 Wood, J., Fundamental flow cytometer properties governing sensitivity
and resolution. Cytometry 1998. 33: 260–266.
44 Hoffman, R. A., Standardization, calibration, and control in flow
cytometry. Curr. Protoc. Cytom. 2005. 79: 1.3.1–1.3.21.
45 Wood, J. C. S., 2009, Establishing and maintaining system linearity.
Curr. Protoc. Cytom. Chapter 1: 1.4.1–1.4.14.
46 Jett, J. H.,Martin, J. C.,Habbersett, R. C., Techniques for flow cytometer
alignment. Curr. Protoc. Cytom. 2009. Chapter 1: 1.10.1–1.10.7.
47 Perfetto, S. P., Chattopadhyay, P. K., Wood, J., Nguyen, R., Ambrozak,
D., Hill, J. P. and Roederer, M., Q and B Values are Critical Measure-
ments Required for Inter-Instrument Standardization and Develop-
ment of Multicolor Flow Cytometry Staining Panels. Cytometry 2014.
85A: 1037–1048.
48 Perfetto, S. P., Ambrozak, D., Nguyen, R., Chattopadhyay, P. K. and
Roederer, M., Quality assurance for polychromatic flow cytometry
using a suite of calibration beads. Nat. Protoc. 2012. 7: 2067–2079.
49 Steen, H. B., Noise, Sensitivity, and Resolution of Flow Cytometers.
Cytometry 1992. 13: 822–830.
50 Friend, M., Franklin, G. B. and Quinn, B., An LED pulser for measuring
photomultiplier linearity. Nucl. Instr. And Meth. A 2012. 676: 66–69.
51 Giesecke, C., Feher, K., von Volkmann, K., Kirsch, J., Radbruch, A.
and Kaiser, T., Determination of background, signal-to-noise, and
dynamic range of a flow cytometer: a novel practicalmethod for instru-
ment characterization and standardization. Cytometry 2017. 91A: 1104–
1114.
52 ReferenceManuals for discussed instruments: a) BD FACSCanto II Flow
Cytometer Reference Manual, 2006, BD Biosciences, San Jose, USA; b)
MACSQuant Instrument User Manual, V6, 2015, Miltenyi Biotec, Ber-
gisch Gladbach, Germany; c) CyFlow Cube 6 Instrument Operating
Manual, 2012, Partec GmbH, Germany; d) Attune NxT Acoustic Focus-
ing Cytometer User Guide, 2015, Life Technologies, USA part of Thermo
Fisher Scientific; e) Gallios Flow Cytometer Instructions for use, 2009,
Beckman Coulter, USA
53 Flow Cell Care & Maintenance; Feb 2011, Precision Cells,
Inc. http://ezinearticles.com/?Flow-Cytometry—Flow-Cell-Care-and-
Maintenance&id=5898431
54 A Guide to Absolute Counting Using the BD Accuri C6 Flow Cytometer,
Jan. 2012, BD Biosciences, Technical Bulletin.
55 BD FACSDIVA Software v 8.0 Reference Manual
56 Maciorowski, Z., Chattopadhyay, P. K. and Jain, P., Basic Multicolor
Flow Cytometry. Curr. Protoc. Immunol. 2017. 117: 5.4.1–5.4.38.
57 Maecker, H. T. and Trotter, J., Flow cytometry controls, instrument
setup, and the determination of positivity. Cytometry A 2006. 69: 1037–
1042.
58 Chase, E. S. and Hoffman, R. A., Resolution of dimly fluorescent par-
ticles: a practical measure of fluorescence sensitivity. Cytometry 1998.
33: 267–279.
59 Meinelt, E., Reunanen, M., Edinger, M., Jaimes, M., Stall, A., Sasaki, D.
and Trotter, J., Standardizing Application Setup Across Multiple Flow
Cytometers Using BD FACSDivaTM Version 6. Software. BD Biosciences
Technical Bulletin. 2012.
60 Roederer, M., Compensation in flow cytometry. Curr. Protoc. Cytom.
2002. 22: 1.14.1–1.14.20.
61 Biburger, M., Trenkwald, I. and Nimmerjahn, F., Three blocks are not
enough—blocking of the murine IgG receptor FcgammaRIV is crucial
for proper characterization of cells by FACS analysis. Eur. J. Immunol.
2015. 45: 2694–2697.
62 Maecker, H. T., Frey, T., Nomura, L. E. and Trotter, J., Selecting fluo-
rochrome conjugates for maximum sensitivity. Cytometry A 2004. 62:
169–173.
63 Nu¨sse, M., Beisker,W.,Kramer, J.,Miller, B. M., Schreiber, G. A.,Viaggi,
S.,Weller, E. M. et al., Measurement of micronuclei by flow cytometry.
Methods Cell Biol. 1994. 42: 149–158.
64 Hengst, J., Theorell, J., Deterding, K., Potthoff, Dettmer, A., Ljunggren,
H. G.,Wedemeyer, H. and Bjo¨rkstro¨m, N. K., High-resolution determi-
nation of human immune cell signatures from fine-needle liver aspi-
rates. Eur. J. Immunol. 2015. 45: 2154–2157.
65 Johnson, S., Nguyen, V. and Coder, D., Assessment of cell viability.
Curr. Protoc. Cytom. 2013.64: 9.2.1–9.2.26
66 Edward, R. and Dimmick, I., Compensation-free dead cell exclu-
sion: multi-beam excitation of the far-red DNA binding viability dye-
DRAQ7.(TECH2P. 873). J. Immunol. 2014. 192: 135.4
67 Pieper, I. L., Radley, G., Chan, C. H., Friedmann, Y., Foster, G. and
Thornton, C. A., Quantification methods for human and large animal
leukocytes using DNA dyes by flow cytometry. Cytometry A 2016. 89:
565–574.
68 Reardon, A. J., Elliott, J. A. and McGann, L. E., Fluorescence as an alter-
native to light-scatter gating strategies to identify frozen-thawed cells
with flow cytometry. Cryobiology 2014. 69: 91–99.
69 Hønge, B. L., Petersen, M. S., Olesen, R., Møller, B. K. and Erikstrup, C.
Optimizing recovery of frozen human peripheral blood mononuclear
cells for flow cytometry. PLoS One. 2017. 12: e0187440
70 Alsayed, H.,Owaidah, T. andAl Rawas, F., Validation of amodifiedcry-
opreservation method for leukemic blasts for flow cytometry assess-
ment. Hematol. Oncol. Stem Cell Ther. 2008. 1: 94–97.
71 Chow, S., Hedley, D., Grom, P., Magari, R., Jacobberger, J. W. and
Shankey, T. V., Whole blood fixation and permeabilization protocol
with red blood cell lysis for flow cytometry of intracellular phospho-
rylated epitopes in leukocyte subpopulations. Cytometry A. 2005. 67:
4–17.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1909
72 Woost, P. C., Solchaga, L. A.,Meyerson, H. J., Shankey, T. V., Goolsby,
C. L. and Jacobberger, J. W., High-resolution kinetics of cytokine sig-
naling in human CD34/CD117-positive cells in unfractionated bone
marrow. Blood 2011. 117: e131–e141.
73 Marvin, J., Swiminathan, S., Kraker, G., Chadburn, A., Jacobberger, J.
W. and Goolsby, C., Normal bonemarrow signal-transduction profiles:
a requisite for enhanced detection of signaling dysregulations in AML.
Blood 2011. 117: e120–e130.
74 Shankey, T. V., Forman, M. F., Scibelli, P., Cobb, J., Smith, C. M.,Mills,
R.,Holdiway, K. et al., An optimizedwhole bloodmethod for flow cyto-
metric measurement of ZAP-70 protein expression in chronic lympho-
cytic leukemia. Cytometry 2006. 70: 259–269.
75 Jacobberger, J. W., Sramkowski, R. M., Frisa, P. S., Peng Ye, P., Gottlieb,
M. A., Hedley, D. W., Shankey, T. V. et al., Immunoreactivity of STAT5
phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase
activity. Cytometry 2003. 54: 75–88.
76 Boehm, T., McCurley, N., Sutoh, Y., Schorpp, M., Kasahara, M. and
Cooper, M. D., VLR-based adaptive immunity.Annu. Rev. Immunol. 2012.
30: 203–220.
77 Pancer, Z., Amemiya, C. T., Ehrhardt, G. R., Ceitlin, J., Gartland, G.
L. and Cooper, M. D., Somatic diversification of variable lymphocyte
receptors in the Agnathan sea lamprey. Nature 2004. 430: 174–180.
78 Velikovsky, C. A., Deng, L., Tasumi, S., Iyer, L. M., Kerzic, M. C.,
Aravind, L., Pancer, Z. et al., Structure of a lamprey variable lympho-
cyte receptor in complex with a protein antigen. Nat. Struct. Mol. Biol.
2009. 16: 725–730.
79 Han, B. W., Herrin, B. R., Cooper, M. D. and Wilson, I. A., Antigen
recognition by variable lymphocyte receptors. Science 2008. 321: 1834–
1837.
80 Luo, M., Velikovsky, C. A., Yang, X., Siddiqui, M. A.,Hong, X., Barchi, J.
J., Jr.,Gildersleeve, J. C. et al., Recognition of the Thomsen-Friedenreich
pancarcinoma carbohydrate antigen by a lamprey variable lymphocyte
receptor. J. Biol. Chem. 2013. 288: 23597–23606.
81 Collins, B. C., Gunn, R. J., McKitrick, T. R., Cummings, R. D., Cooper,
M. D., Herrin, B. R. and Wilson, I. A., Structural Insights into VLR Fine
Specificity for Blood Group Carbohydrates. Structure 2017. 25: 1667–
1678.
82 Chan, J. T. H., Liu, Y., Khan, S., St-Germain, J. R., Zou, C., Leung, L.
Y., Yang, T. et al., A tyrosine sulfation-dependent HLA-I modification
identifies memory B cells and plasma cells. Sci. Adv. 2018. 4: eaar7653.
83 Herrin, B. R., Alder, M. N., Roux, K. H., Sina, C., Ehrhardt, G. R., Boyd-
ston, J. A., Turnbough, C. L., Jr. et al., Structure and specificity of
lamprey monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 2008. 105:
2040–2045.
84 Haas, J., Roth, S., Arnold, K., Kiefer, F., Schmidt, T., Bordoli, L. and
Schwede, T., The Protein Model Portal–a comprehensive resource for
protein structure and model information. Database 2013. 2013: bat031.
85 Yu, C., Liu, Y., Chan, J. T., Tong, J., Li, Z., Shi, M.,Davani, D. et al., Iden-
tification of human plasma cells with a lamprey monoclonal antibody.
JCI Insight 2016. 1: e84738.
86 Alder, M. N., Rogozin, I. B., Iyer, L. M., Glazko, G. V., Cooper, M. D. and
Pancer, Z., Diversity and function of adaptive immune receptors in a
jawless vertebrate. Science 2005. 310: 1970–1973.
87 Yu, C., Ali, S., St-Germain, J., Liu, Y., Yu, X., Jaye, D. L., Moran, M.
F. et al., Purification and identification of cell surface antigens using
lamprey monoclonal antibodies. J. Immunol. Methods 2012. 386: 43–49.
88 Baker, M., Antibody anarchy: a call to order. Nature 2015. 527: 545–551.
89 Zhang, X., Calvert, R. A., Sutton, B. J. and Dore, K. A., IgY: a key isotype
in antibody evolution. Biol. Rev. Camb. Philos. Soc. 2017. 92: 2144–2156.
90 Mucci, I., Legitimo, A., Compagnino, M., Consolini, R., Miglidaccio,
P., Metelli, M. R. and Scatena, F., The methodological approach for
the generation of human dendritic cells from monocytes affects the
maturation state of the resultant dendritic cells. Biologicals 2009. 37:
288–96.
91 Delirezh, N. and Shojaeefar, E., Phenotypic and functional comparison
between flask adherent and magnetic activated cell sorted monocytes
derived dendritic cells. Iran J. Immunol. 2012. 9: 98–108.
92 Pribush, A., Meyerstein, D. and Meyerstein, N., Kinetics of erythro-
cyte swelling and membrane hole formation in hypotonic media.
BBABiomembrane 2002. 1558: 119–132.
93 Tiirikainen, M. I., Evaluation of red blood cell lysing solutions for the
detection of intracellular antigens by flow cytometry. Cytometry 1995.
20: 341–348.
94 Einwallner, E., Subasic, A., Strasser, A.,Augustin, D., Thalhammer, R.,
Steiner, I. and Schwarzinger, I., Lysis matters: red cell lysis with FACS
Lyse affects the flow cytometric enumeration of circulating leukemic
blasts. J. Immunol. Methods 2013. 390: 127–132.
95 Lindahl, P. E., Principle of a counter-streaming centrifuge for the sep-
aration of particles of different sizes. Nature 1948. 161: 648–649.
96 McEwen, C. R., Stallard, R. W. and Juhos, E. T., Separation of biological
particles by centrifugal elutriation. Anal. Biochem. 1968. 23: 369–77.
97 Pretlow, T. G. and Pretlow, T. P., Centrifugal elutriation (counter-
streaming centrifugation) of cells. Cell Biophys. 1979. 1: 195–210.
98 www.biologydiscussion.com/cell-biology/8-methods-involved-in-
separation-of-whole-cells-with-diagram/3494
99 Ferrone, S., Cooper, N. R., Pellegrino, M. A. and Reisfeld, R. A., Inter-
action of histocompatibility (HL-A) antibodies and complement with
synchronized human lymphoid cells in continuous culture. J. Exp. Med.
1973. 137: 55–68.
100 Lustig, H. and Bianco, C., Antibody-mediated cell cytotoxicity in a
defined system: regulation by antigen, antibody, and complement. J.
Immunol. 1976. 116: 253–60.
101 Esser, C., Historical and useful methods of preselection and prepar-
ative scale cell sorting. In D. Recktenwald and A. Radbruch (Eds.),
Cell separation methods and applications. Marcel Dekker Inc., New
York/Basel/Hong Kong, 1998, pp. 1–14.
102 www.pluriselect.com
103 www.miltenyibiotec.com
104 Thomas, T. E., Miller, C. L. and Eaves, C. J., Purification of hematopoi-
etic stem cells for further biological study. Methods. 1999. 17: 202–218.
105 Van der Toom, E. E., Verdone, J. E., Gorin, M. A. and Pienta, K. J.,
Technical challenges in the isolation and analysis of circulating tumor
cells. Oncotarget 2016. 7: 62754–62766.
106 Donnenberg, V. S. and Donnenberg, A. D., Identification, rare-event
detection and analysis of dendritic cell subsets in bronchio-alveolar
lavage fluid and peripheral blood by flow cytometry. Front. Biosci. 2003.
8: s1175–s1180.
107 Bacher, P. and Scheffold, A., New technologies for monitoring human
antigen-specific T cells and regulatory T cells by flow-cytometry. Curr.
Opin. Pharmacol. 2015. 23: 17–24.
108 www.thermofisher.com/de/de/home/brands/product-
brand/dynal.html
109 www.bdbiosciences.com/us/reagents/research/magnetic-cell-
separation/other-species-cell-separation-reagents/cell-separation-
magnet/p/552311
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1910 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
110 Recktenwald, D. and Radbruch, A. (Eds.), Cell separation methods and
applications. Marcel Dekker Inc., New York/ Basel/ Hong Kong, 1998.
111 Miltenyi, S. and Pflueger, E., High gradient magnetic cell sorting.
In A. Radbruch (Ed.), Flow cytometry and sorting. Springer-Verlag,
Berlin/Heidelberg, 1992, pp. 141–152.
112 Ruffert, C., Magnetic bead—Magic bullet (review). Micromachines 2016.
7: 21.
113 McCloskey, K. E., Chalmers, J. J. and Zborowski, M., Magnetic cell
separation: Characterization of magnetophoretic mobility. Anal. Chem.
2003. 75: 6868–6874.
114 Boyum, A., Isolation of leucocytes from human blood. Further obser-
vations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating
agents. Scand. J. Clin. Lab. Invest. Suppl. 1968. 97: 31–50.
115 Boyum, A., Isolation of lymphocytes, granulocytes and macrophages.
Scand. J. Immunol. 1976. Suppl 5: 9–15.
116 Yeo, C., Saunders, N., Locca, D., Flett, A., Preston, M., Brookman, P.,
Davy, B. et al., Ficoll-Paque versus Lymphoprep: A comparative study
of two density gradient media for therapeutic bone marrow mononu-
clear cell preparations. Regen. Med. 2009. 4: 689–696.
117 Boyum, A., Brincker, F. H.,Martinsen, I., Lea, T. and Lovhaug, D., Sep-
aration of human lymphocytes from citrated blood by density gradient
(NycoPrep) centrifugation: Monocyte depletion depending upon acti-
vation of membrane potassium channels. Scand. J. Immunol. 2002. 56:
76–84.
118 Kuhns, D. B., Priel, D. A., Chu, J. and Zarember, K. A., Isolation and
functional analysis of human neutrophils. Curr. Protoc. Immunol. 2015.
111: 7.23.1–7.23.16.
119 Maqbool, M., Vidyadaran, S., George, E. and Ramasamy, R., Optimi-
sation of laboratory procedures for isolating human peripheral blood
derived neutrophils. Med. J. Malaysia 2011. 66: 296–299.
120 Bruyninckx, W. J. and Blancquaert, A. M., Isolation of horse mononu-
clear cells, especially of monocytes, on Isopaque-Ficoll neutral density
gradient. Vet. Immunol. Immunopathol. 1983. 4: 493–504.
121 Pertoft, H., Fractionation of cells and subcellular particles with Percoll.
J. Biochem. Biophys. Methods 2000. 44: 1–30.
122 Yu, L.,Warner, P.,Warner, B.,Recktenwald, D.,Yamanishi, D.,Guia, A.
and Ghetti, A., Whole blood leukocytes isolation with microfabricated
filter for cell analysis, Cytometry 2011. 79A: 1009–1015.
123 Higuchi, A., Wang, C.-T., Ling, Q.-D., Lee, H. H.-C., Suresh Kumar, S.,
Chang, Y., Alarfaj, A. A. et al., A hybrid-membrane migration method
to isolate high-purity adipose-derived stem cells from fat tissues. Sci.
Rep. 2015. 5: 10217.
124 Huang, L. R., Cox, E. C., Austin, R. H. and Sturm, J. C., Continuous
particle separation through deterministic lateral displacement. Science
2004. 304: 987–990.
125 Davis, J. A., Inglis, D. W., Morton, K. J., Lawrence, D. A., Huang, L. R.,
Chou, S. Y., Sturm, J. C. et al., Deterministic hydrodynamics: Taking
blood apart, Proc. Nat. Acad. Sci. 2008. 103: 14779–14784.
126 Loutherback, K., D’Silva1, J., Liu, L.,Wu, A., Austin, R. H. and Sturm, J.
C., Deterministic separation of cancer cells from blood at 10 mL/min.
AIP Adv. 2012. 2: 042107.1–042107.7.
127 D’Silva, J., Austin, H. and Sturm, C., Inhibition of clot formation in
deterministic lateral displacement arrays for processing large volumes
of blood for rare cell capture. Lab Chip 2015. 15: 2240–2247.
128 Civin, C. I.,Ward, T., Skelley, A.M.,Gandhi, K., Peilun Lee, Z.,Dosier, C.
R., D’Silva, J. L. et al., Automated leukocyte processing by microfluidic
deterministic lateral displacement. Cytometry A. 2016. 89: 1073–1083.
129 Campos-Gonza´lez, R., Skelley, A. M., Gandhi, K., Inglis, D. W., Sturm,
J. C., Civin, C. I. and Ward, T., Deterministic lateral displacement: the
next-generationCART-cell processing? SLAS Technol. 2018. 23: 338–351.
130 Laurell, T., Petersson, F. and Nilsson, A., Chip integrated strategies for
acoustic separation and manipulation of cells and particles. Chem. Soc.
Rev. 2007. 36: 492–506.
131 Dykes, J., Lenshof, A., A˚strand-Grundstro¨m, I.-B., Laurell, T. and
Scheding, S., Efficient removal of platelets from peripheral blood pro-
genitor cell products using a novel micro-chip based acoustophoretic
platform. PLoS ONE 2011. 6: e23074.
132 Urbansky, A., Ohlsson, P., Lenshof, A., Garofalo, F., Scheding, S. and
Laurell, T., Rapid and effective enrichment of mononuclear cells from
blood using acoustophoresis. Sci. Rep. 2017. 7: 17161.
133 Wysocki, L. J. and Sato, V. L., Panning for lymphocytes: A method for
cell selection. Proc. Natl. Acad. Sci. U S A 1978. 75: 2844–2848.
134 Weiner, M. S., Bianco, C. and Nussenzweig, V., Enhanced binding of
neuraminidase-treated sheep erythrocytes to human T lymphocytes.
Blood 1973. 42: 939–946.
135 Indiviri, F., Huddlestone, J., Pellegrino, M. A. and Ferroni, S., Isolation
of human T lymphocytes: Comparison between wool filtration and
rosetting with neuraminidase (VCN) and 2-aminoethylisothiouronium
(AET)-treated sheep red blood cells. J. Immunol. Methods 1980. 34: 107–
112.
136 Lepe-Zuniga, J. L., Zigler, J. S. and Gery, I., Toxicity of light-exposed
Hepes media. J. Immunol. Methods 1987. 103: 145.
137 Cowan, C. M. and Basu, S., Heng, B. C., Comparison of enzymatic and
nonenzymatic means of dissociating adherent monolayers of mes-
enchymal stem cells. Biol. Proc. Online 2009. 11: 161–169.
138 Amaral, K., Rogero, M., Fock, R., Borelli, P. and Gavini, G., Cytotox-
icity analysis of EDTA and citric acid applied on murine resident
macrophages culture. Int. Endod. J. 2007. 40(5): 338–343.
139 Wiesman, U., Segregating cells—proteases in tissue culture. In Ster-
chi, E. E. and Sto¨cker, W. (Eds.), Proteolytic enzymes: Tools and targets.
Springer, Berlin, Germany, 1999, pp. 298–311.
140 Stovel, R. T., The influence of particles on jet breakoff. J. Histochem.
Cytochem. 1977. 25: 813–820.
141 Pinkel, D. and Stovel, R., Flow chambers and sample handling. In Van
Dilla, M. A., Dean, P. N., Laerum, O. D. and Melame, M. R. (Eds.), Flow
cytometry: Instrumentation and data analysis, Academic Press, London,
UK, 1985, pp. 77–128.
142 Houtz, B., Trotter, J. and Sasaki, D., Tips on cell preparation for flow
cytometric analysis and sorting. BD FACService Technotes 2004. 9.
143 Holmes, K. L., Fontes, B.,Hogarth, P., Konz, R.,Monard, S., Pletcher, Jr.,
C. H., Wadley, R. B. et al., International Society for the Advancement
of Cytometry cell sorter biosafety standards. Cytometry A 2014. 85: 434–
453.
144 van der Maaten, L. J. P. andHinton, G. E., Visualizing high-dimensional
data using t-SNE. J. Mach. Learn. Res. 2008. 9: 2579–2605.
145 McInnes, L., Healy, J and Melville, J., UMAP: uniformmanifold approx-
imation and projection for dimension reduction arXiv:1802.03426
146 Aghaeepour, N, Simonds, E. F., Knapp, D. J. H. F., Bruggner, R. V.,
Sachs, K., Culos, A., Gherardini, P. F. et al., GateFinder: projection-
based gating strategy optimization for flow andmass cytometry. Bioin-
formatics 2018. 34(23): 4131–4133.
147 Becht, E., Simoni, Y., Coustan-Smith, E.,Maximilien, E., Cheng, Y.,Ng,
L. G., Campana, D. et al., Reverse-engineering flow-cytometry gating
strategies for phenotypic labelling and high-performance cell sorting.
Bioinformatics 2019. 35: 301–308.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1911
148 Samusik, N., Irvine, A.,Aghaeepour, A., Spidlen, J. and Trotter, J. Com-
putational Sorting with HyperFinder, CYTO 2019, Session Parallel 06,
24 June 2019.
149 Bøyum, A., Løvhaug, D., Tresland, L. and Nordlie, E. M., Separation
of leucocytes: improved cell purity by fine adjustments of gradient
medium density and osmolality. Scand. J. Immunol. 1991. 34: 697–712.
150 Loos, H., Blok-Schut, B., van Doorn, R., Hoksbergen, R., Brutel de la
Rivie`re, A. and Meerhof, L., A method for the recognition and separa-
tion of human blood monocytes on density gradients. Blood 1976. 48:
731–742.
151 BD FACSAria user’s guide, BD Biosciences, San Jose, USA, 2006.
152 Wixforth, A., Acoustically driven programmable microfluidics for bio-
logical and chemical applications. J. Lab. Automat. 2006. 11: 399–405.
153 Kaiser, T., Raba, K., Sickert, M., Radbruch, A. and Scheffold, A., Inte-
gration of an ultrasonic wave device in a FACS-Aria cell sorter for
continuous, noninvasive mixing of cell suspensions. Poster, Budapest,
2008 ISAC congress. https://doi.org/10.13140/RG.2.1.1760.2966
154 Radbruch, A. (Ed.), Flow cytometry and cell sorting, 2nd ed., Springer,
Berlin/Heidelberg 2000.
155 Freyer, J. P., Fillak, D. and Jett, J. H., Use of xantham gum to suspend
large particles during flow cytometric analysis and sorting. Cytometry
1989. 10: 803–806.
156 Fu, L.-M., Yang, R.-J., Lin, C.-H., Pan, Y.-J. and Gwo-Bin, L., Electroki-
netically driven micro flow cytometers with integrated fiber optics for
on-line cell/particle detection. Anal. Chim. Acta 2004. 507: 163–169.
157 Telleman, P., Larsen, U. D., Philip, J., Blankenstein, G. and Wolff, A.,
Cell Sorting in Microfluidic Systems. In Jed Harrison, D. and van den
Berg, A. (Eds.).Micro total analysis systems ’98. Springer, Amsterdam, the
Netherlands, 1998, pp. 39–44.
158 Wang, X., Chen, S., Kong, M., Wang, Z., Costa, K. D., Li, R. A. and
Sun, D., Enhanced cell sorting and manipulation with combined opti-
cal tweezer andmicrofluidic chip technologies. Lab Chip 2011. 11: 3656–
3662.
159 Bhagat, A. A., Bow, H., Hou, H. W., Tan, S. J., Han, J. and Lim, C. T.,
Microfluidics for cell separation. Med. Biol. Eng. Comput. 2010. 48: 999–
1014.
160 Chapman, G. V., Instrumentation for flow cytometry. J. Immunol. Meth-
ods 2000. 243: 3–12.
161 Abate, A. R., Agresti, J. J. and Weitz, D. A., Microfluidic sorting with
highspeed single-layer membrane valves. Appl. Phys. Lett. 2010. 96:
203509.
162 Shemesh, J., Bransky, A., Khoury, M. and Levenberg, S., Advanced
microfluidic droplet manipulation based on piezoelectric actuation.
Biomed. Microdevices 2010. 12: 907–914.
163 Chen, C. H., Cho, S. H., Tsai, F., Erten, A. and Lo, Y. H., Microfluidic
cell sorter with integrated piezoelectric actuator. Biomed. Microdevices
2009. 11: 1223–1231.
164 Wang, M. M., Tu, E., Raymond, D. E., Yang, J. M., Zhang, H., Hagen,
N., Dees, B. et al., Microfluidic sorting of mammalian cells by optical
force switching. Nat. Biotechnol. 2005. 23: 83–87.
165 Roederer, M., Spectral compensation for flow cytometry: visualization
artifacts, limitations, and caveats. Cytometry 2001. 45: 194–205.
166 Rockefeller University BD FACSAria2-3 Water-Cooled Sort Collection
Integrated Tube Holder 5-15-;5-5 | NIH 3D Print Exchange. Available
at: http://3dprint.nih.gov/discover/3dpx-002415. (Accessed: 20th April
2016)
167 Sasaki, D. T., Tichenor, E. H., Lopez, F., Combs, J., Uchida, N., Smith,
C. R., Stokdijk, W. et al., Development of a clinically applicable
high-speed flow cytometer for the isolation of transplantable human
hematopoietic stem cells. J. Hematother. 1995. 4: 503–514.
168 June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., Milone,
M. C., CAR T cell immunotherapy for human cancer. Science 2018. 359:
1361–1365.
169 Hoffmann, P., Eder, R., Boeld, T. J., Doser, K., Piseshka, B., Andreesen,
R. et al., Only the CD45RA+ subpopulation of CD4+CD25high T cells
gives rise to homogeneous regulatory T-cell lines upon in vitro expan-
sion. Blood 2006. 108: 4260–4267.
170 GMP EudraLex Volume 4, Part I, with guidance in Annex 1 on ‘Manu-
facture of Sterile Medicinal Products’ and Annex 2 on ‘Manufacture of
Biological active substances and Medicinal Products for Human Use’;
https://ec.europa.eu/health/documents/eudralex/vol-4_de.
171 Good Manufacturing Practice for Advanced Therapy Medici-
nal Products, published in Part IV of Eudralex Volume 4;
https://ec.europa.eu/health/documents/eudralex/vol-4_de
172 Reflection paper on classification of advanced therapymedicinal prod-
ucts. EMA/CAT/600280/2010 (ed. EMA) (EMA-CAT, http://www.ema.
europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_
guideline/2012/04/WC500126681.pdf, 2012).
173 Commission Directive 2009/120/EC of 14 September 2009 amending
Directive 2001/83/EC of the European Parliament and of the Council on
the Community code relating to medicinal products for human use as
regards advanced therapy medicinal product.
174 Regulation (EC) No 1394/ 2007 of the European Parliament and of the
Council of 13 November 2007 on advanced therapymedicinal products
and amending Directive 2001/83/EC and Regulation (EC) No 726/2004.
175 Guideline on process validation for finished products - infor-
mation and data to be provided in regulatory submissions,
EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1. 27 February 2014:
European Medicines Agency (EMA).
176 USFDA. Guidance for industry. Process validation: General principles and
practices, U.S. Department of Health and Human Services Food and
Drug Administration Washington, DC 2011.
177 ICH Q6B: Specifications: Test Procedures and Acceptance Criteria
for Biotechnological / Biological Products, ICH Harmonised Tripartite
Guideline. International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use.
178 ICH Q2(R1): Validation of Analytical Procedures: Text and Methodol-
ogy, ICH Harmonised Tripartite Guideline. International Conference
on Harmonisation of Technical Requirements for Registration of Phar-
maceuticals for Human Use.
179 Leslie, D. S., Johnston, W. W., Daly, L., Ring, D. B., Shpall, E. J., Peters,
W. P. and Bast, R. C., Jr., Detection of breast carcinoma cells in human
bone marrow using fluorescence-activated cell sorting and conven-
tional cytology. Am. J. Clin. Pathol. 1990. 94: 8–13.
180 Frantz, C. N., Ryan, D. H., Cheung, N. V., Duerst, R. E. and Wilbur, D.
C., Sensitive detection of rare metastatic human neuroblastoma cells
in bone marrow by two-color immunofluorescence and cell sorting.
Prog. Clin. Biol. Res. 1988. 271: 249–262.
181 Ryan, D. H., Mitchell, S. J., Hennessy, L. A., Bauer, K. D., Horan, P.
K. and Cohen, H. J., Improved detection of rare CALLA-positive cells
in peripheral blood using multiparameter flow cytometry. J. Immunol.
Methods 1984. 74: 115–128.
182 Visser, J. W. and De Vries, P., Identification and purification of murine
hematopoietic stem cells by flow cytometry.Methods Cell Biol. 1990. 33:
451–468.
183 Cory, J. M., Ohlsson-Wilhelm, B. M., Brock, E. J., Sheaffer, N. A., Steck,
M. E., Eyster, M. E. and Rapp, F., Detection of human immunodefi-
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1912 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
ciency virus-infected lymphoid cells at low frequency by flow cytom-
etry. J. Immunol. Methods 1987. 105: 71–78.
184 Jensen, R. H. and Leary, J. F., Mutagenesis asmeasured by flow cytome-
try and cell sorting. In M. R. Melamed, M. L. Mendelsohn and T. Lindmo
(Eds.) Flow cytometry and sorting, 2nd ed., Wiley-LISS, New York, NY,
1990.
185 Cossarizza, A. andCousins, D., Overcoming challenges in cellular anal-
ysis: multiparameter analysis of rare cells. Science 2015. 347: 443.
186 Gross, H. J.,Verwer, B.,Houck, D.,Hoffman, R. A. and Recktenwald, D.,
Model study detecting breast cancer cells in peripheral bloodmononu-
clear cells at frequencies as low as 10–7. Proc. Natl. Acad. Sci. U.S.A. 1995.
92: 537–541.
187 Donnenberg, A. D. and Donnenberg, V. S., Rare-event analysis in flow
cytometry. Clin. Lab. Med. 2007. 27: 627–652.
188 De Biasi, S., Bianchini, E., Nasi, M., Digaetano, M., Gibellini, L.,
Carnevale, G., Borghi, V. et al., Th1 and Th17 pro-inflammatory profile
characterizes iNKT cells in virologically suppressed HIV+ patients with
low CD4/CD8 ratio. AIDS 2016. 30: 2599–2610.
189 Duda, D. G., Cohen, K. S., Scadden, D. T. and Jain, R. K., A protocol for
phenotypic detection and enumeration of circulating endothelial cells
and circulating progenitor cells in human blood. Nat. Protoc. 2007. 2:
805–810.
190 Mancuso, P., Antoniotti, P., Quarna, J., Calleri, A., Rabascio, C., Tac-
chetti, C. and Braidotti, P., Validation of a standardized method for
enumerating circulating endothelial cells and progenitors: flow cytom-
etry and molecular and ultrastructural analyses. Clin. Cancer Res. 2009.
15: 267–273.
191 Van Craenenbroeck, E. M., Conraads, V. M., Van Bockstaele, D. R.,
Haine, S. E.,Vermeulen, K.,Van Tendeloo, V. F. and Vrints, C. J., Quan-
tification of circulating endothelial progenitor cells: A methodologi-
cal comparison of six flow cytometric approaches. J. Immunol. Methods
2008. 332: 31–40.
192 Estes, M. L., Mund, J. A., Ingram, D. A. and Case, J., Identification
of endothelial cells and progenitor cell subsets in human peripheral
blood. Curr. Protoc. Cytom. 2010. 52: 9.33.1–9.33.11.
193 De Biasi, S., Cerri, S., Bianchini, E., Gibellini, L., Persiani, E., Monta-
nari, G. and Luppi, F., Levels of circulating endothelial cells are low in
idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic
treatments. BMC Med. 2015. 13: 277.
194 Cox, C., Reeder, J. E., Robinson, R. D., Suppes, S. B. and Wheeless, L.
L., Comparison of frequency distribution in flow cytometry. Cytometry
1988. 9: 291–298.
195 Haight, F. A., Handbook of the Poisson distribution. John Wiley & Sons,
New York, NY, 1967.
196 Roederer, M., Howmany events is enough? Are you positive? Cytometry
2008. 73: 384–385.
197 Boyd, W. A., Smith, M. V. and Freedman, J. H., Caenorhabditis elegans
as a model in developmental toxicology. Methods Cell. Biol. 2012. 889:
15-24.
198 Steffen, A., Ludwig, B., Krautz, C., Bornstein, S. and Solimena, M.,
Functional assessment of automatically sorted pancreatic islets using
large particle flow cytometry. Islet. 2011. 3: 67–270.
199 Li, C. Y.,Wood, D. K.,Huang, J. H. andBhatia, S. N., Flow-basedpipeline
for systematic modulation and analysis of 3D tumor microenviron-
ments. Lab. Chip. 2013. 13: 1969–1978.
200 Coder, D. M., Assessment of cell viability. Curr. Protoc. Cytom. 2001. 15:
9.2:9.2.1–9.2.14.
201 Perfetto, S. P., Chattopadhyay, P. K., Lamoreaux, L., Nguyen, R.,
Ambrozak, D., Koup, R. A. and Roederer, M. Amine reactive dyes: an
effective tool to discriminate live and dead cells in polychromatic flow
cytometry. J. Immunol. Methods 2006. 313: 199–208.
202 Zuba-Surman, E. K., Kucia, M. and Ratajczak, M. Z., Decoding the dots:
the ImageStream system (ISS) as a novel and powerful tool for flow
cytometric analysis. Cent. Eur. J. Biol. 2008. 3: 1–10.
203 Vindelov, L. L., Christensen, I. J. and Nissen, N. I., A detergent-trypsin
method for the preparation of nuclei for flow cytometric DNA analysis.
Cytometry 1983. 3: 323–327.
204 Hedley, D. W., Friedlander, M. L., Taylor, I. W., Rugg, C. A. and Mus-
grove, E. A., Method for analysis of cellular DNA content of paraffin-
embedded pathological material using flow cytometry. J. Histochem.
Cytochem. 1983. 31: 1333–1335.
205 Degtyarev, M., Reichelt, M. and Lin, K., Novel quantitative autophagy
analysis by organelle flow cytometry after cell sonication. PLoS One.
2014. 9: e87707
206 Poot, M., Gibson, L. L. and Singer, V. L., Detection of apoptosis in live
cells by MitoTracker CMXRos and SYTO dye flow cytometry. Cytometry.
1997. 27: 358–364.
207 Poot, M., Analysis of intracellular organelles by flow cytometry or
microscopy. Curr. Protoc. Cytom. 2001. 14: 9.4:9.4.1–9.4.24.
208 Bailey, S. and Macardle, P. J., A flow cytometric comparison of Indo-
1 to fluo-3 and Fura Red excited with low power lasers for detecting
Ca(2+) flux. J. Immunol. Methods 2006. 311: 220–225.
209 Leverrier, S., Bergamaschi, D., Ghali, L., Ola, A., Warnes, G., Akgul,
B. et al., Role of HPV E6 proteins in preventing UVB-induced release
of pro-apoptotic factors from the mitochondria. Apoptosis. 2007. 12:
549–560.
210 Dolezel, J., Vrana, J., Safar, J., Bartos, J., Kubalakova, M. and Simkova,
H., Chromosomes in the flow to simplify genome analysis. Funct. Integr.
Genomics. 2012. 12: 97–416.
211 Davies, D. C., Monard, S. P. and Young, B. D. Chromosome analysis
and sorting by flow cytometry. In MG Ormerod (Ed.), Flow cytometry:
A practical approach, 3rd edition, Oxford University Press, Oxford, U.K.,
2000.
212 Ng, B. L., Fu, B., Graham, J., Hall, C. and Thompson, S., Chromosome
analysis using benchtop cell analysers and high speed cell sorters.
Cytometry A 2018. 95: 323–331.
213 Rhys, H. I., Dell’Accio, F., Pitzalis, C., Moore, A., Norling, L. V.
and Perretti, M., Neutrophil microvesicles from healthy control and
rheumatoid arthritis patients prevent the inflammatory activation of
macrophages. EBioMedicine. 2018. 29: 60–69.
214 Orozco, A. and Lewis, D., Flow cytometric analysis of circulating
microparticles in plasma. Cytometry A. 2010. 77A: 502–514.
215 Zucker, R. M., Ortenzio, J. N. R., Boyes, W. K., Characterization, detec-
tion, and counting ofmetal nanoparticles using flow cytometry. Cytom-
etry A. 2016. 89A: 69–183.
216 Morales-Kastresana, A., Telford, W., Musich, T. A., McKinnon, K.,
Clayborne, C., Braig, Z., Rosner, A. et al., Labeling extracellular vesicles
for nanoscale flow cytometry. Sci. Rep. 2017. 7: 1878
217 Kastelowitz, N. andYin, H., Exosomes andmicrovesicles: identification
and targeting by particle size and lipid chemical probes. ChemBioChem.
2014. 15: 923–928.
218 Erdbru¨gger, U., Rudy, C. K., Etter, M. E., Dryden, K. A., Yeager, M.,
Kibanov, A. L. and Lannigan, J., Imaging flow cytometry elucidates
limitations of microparticle analysis by conventional flow cytometry.
Cytometry A. 2014. 85A: 756–770.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1913
219 Marcoux, G., Duchez, A. C., Clouthier, N., Provost, P., Nigrovic, P. A.
and Boilard, E., Revealing the diversity of extracellular vesicles using
high-dimensional flow cytometry analyses. Sci. Rep. 2016. 6: 35928
220 Wallace, D. C., Mitochondria and cancer. Nat. Rev. Cancer 2012. 12:
685–698.
221 Wallace, D. C., Mitochondrial diseases inman andmouse. Science 1999.
283: 1482–1488.
222 Brand, M. D. and Nicholls, D. G., Assessing mitochondrial dysfunction
in cells. Biochem. J. 2011. 435: 297–312.
223 Cottet-Rousselle, C., Ronot, X., Leverve, X. and Mayol, J. F., Cytomet-
ric assessment of mitochondria using fluorescent probes. Cytometry A
2011. 79: 405–425.
224 Lay, A. W. L. and Burton, A. C., Direct measurement of potential dif-
ference across the human red blood cell membrane. Biophys. J. 1969. 9:
115–121.
225 Perry, S. W., Norman, J. P., Barbieri, J., Brown, E. B. and Gelbard, H. A.,
Mitochondrial membrane potential probes and the proton gradient: A
practical usage guide. Biotechniques 2011. 50: 98–115.
226 Petit, P. X., Susin, S. A., Zamzami, N., Mignotte, B. and Kroemer, G.,
Mitochondria and programmed cell death: Back to the future. FEBS Lett.
1996. 396: 7–13.
227 Rottenberg, H. and Wu, S., Quantitative assay by flow cytometry of
the mitochondrial membrane potential in intact cells. Biochim. Biophys.
Acta 1998. 1404: 393–404.
228 Johnson, L. V.,Walsh, M. L. and Chen, L. B., Localization of mitochon-
dria in living cells with rhodamine 123. Proc. Natl. Acad. Sci. U.S.A. 1980.
77: 990–994.
229 Troiano, L., Granata, A. R., Cossarizza, A., Kalashnikova, G., Bianchi,
R., Pini, G., Tropea, F. et al., Mitochondrial membrane potential and
DNA stainability in human sperm cells: a flow cytometry analysis with
implications for male infertility. Exp. Cell. Res. 1998. 241: 384–393.
230 Ehrenberg, B.,Montana, V.,Wei, M. D.,Wuskell, J. P. and Loew, L. M.,
Membrane potential can be determined in individual cells from the
nernstian distribution of cationic dyes. Biophys. J. 1988. 53: 785–794.
231 Nicholls, D. G. and Ward, M. W., Mitochondrial membrane potential
and neuronal glutamate excitotoxicity: Mortality andmillivolts. Trends
Neurosci. 2000. 23: 166–174.
232 Cossarizza, A., Baccarani-Contri, M., Kalashnikova, G. and Franceschi,
C., A new method for the cytofluorimetric analysis of mitochondrial
membrane potential using the J-aggregate forming lipophilic cation
5,5′,6,6′-tetrachloro-1,1′,3,3′;-tetraethylbenzimidazolcarbocyanine
iodide (JC-1). Biochem. Biophys. Res. Commun. 1993. 197: 40–45.
233 Smiley, S. T.,Reers,M.,Mottola-Hartshorn,C., Lin,M., Chen,A., Smith,
T. W., Steele, G. D. et al., Intracellular heterogeneity in mitochon-
drialmembrane potentials revealed by a J-aggregate-forming lipophilic
cation JC-1. Proc. Natl. Acad. Sci. U.S.A. 1991. 88: 3671–3675.
234 Reers, M., Smith, T. W. and Chen, L. B., J-aggregate formation of a car-
bocyanine as a quantitative fluorescent indicator of membrane poten-
tial. Biochemistry 1991. 30: 4480–4486.
235 Moudy, A. M., Handran, S. D., Goldberg, M. P., Ruffin, N., Karl, I.,
Kranz-Eble, P., DeVivo, D. C. et al., Abnormal calcium homeostasis
and mitochondrial polarization in a human encephalomyopathy. Proc.
Natl. Acad. Sci. U.S.A. 1995. 92: 729–733.
236 Perelman, A.,Wachtel, C., Cohen, M., Haupt, S., Shapiro, H. and Tzur,
A., JC-1: alternative excitation wavelengths facilitate mitochondrial
membrane potential cytometry. Cell Death Dis. 2012. 3: e430.
237 De Biasi, S., Gibellini, L. and Cossarizza, A., Uncompensated poly-
chromatic analysis of mitochondrial membrane potential using JC-1
and multilaser excitation. Curr. Prot. Cytom. 2015. 72: 7.32.1–7.32.11.
238 Troiano, L., Ferraresi, R., Lugli, E., Nemes, E., Roat, E., Nasi, M., Pinti,
M. et al., Multiparametric analysis of cells with differentmitochondrial
membrane potential during apoptosis by polychromatic flow cytome-
try. Nat. Protoc. 2007. 2: 2719–2727.
239 Poot, M., Zhang, Y. Z., Kramer, J. A., Wells, K. S., Jones, L. J., Hanzel,
D. K., Lugade, A. G. et al., Analysis of mitochondrial morphology and
function with novel fixable fluorescent stains. J. Histochem. Cytochem.
1996. 44: 1363–1372.
240 Septinus, M., Seiffert, W. and Zimmermann, H. W., Hydrophobic acri-
dine dyes for fluorescence staining of mitochondria in living cells.
1. Thermodynamic and spectroscopic properties of 10-n-alkylacridine
orange chlorides. Histochemistry 1983. 79: 443–456.
241 Dickinson, B. C., Lin, V. S. and Chang, C. J., Preparation and use of
MitoPY1 for imaging hydrogen peroxide in mitochondria of live cells.
Nat. Protoc. 2013. 8: 1249–1259.
242 Mukhopadhyay, P., Rajesh, M., Hasko, G., Hawkins, B. J., Madesh, M.
and Pacher, P., Simultaneous detection of apoptosis andmitochondrial
superoxide production in live cells by flow cytometry and confocal
microscopy. Nat. Protoc. 2007. 2: 2295–2301.
243 Mukhopadhyay, P., Rajesh, M., Yoshihiro, K.,Hasko, G. and Pacher, P.,
Simple quantitative detection of mitochondrial superoxide production
in live cells. Biochem. Biophys. Res. Commun. 2007. 358: 203–208.
244 Robinson, K. M., Janes, M. S., Pehar, M., Monette, J. S., Ross, M. F.,
Hagen, T. M., Murphy, M. P. et al., Selective fluorescent imaging of
superoxide in vivo using ethidium-based probes. Proc. Natl. Acad. Sci.
U.S.A. 2006. 103: 15038–15043.
245 Cossarizza, A., Ferraresi, R., Troiano, L., Roat, E., Gibellini, L., Berton-
celli, L., Nasi, M. et al., Simultaneous analysis of reactive oxygen
species and reduced glutathione content in living cells by polychro-
matic flow cytometry. Nat. Protoc. 2009. 4: 1790–1797.
246 Gibellini, L., Pinti,M., Bartolomeo, R., De Biasi, S., Cormio,A., Musicco,
C., Carnevale,G. et al., Inhibition of Lon protease by triterpenoids alters
mitochondria and is associated to cell death in human cancer cells.
Oncotarget 2015. 6: 25466–25483.
247 Hawkins, B. J.,Madesh, M.,Kirkpatrick, C. J. and Fisher, A. B., Superox-
ide flux in endothelial cells via the chloride channel-3 mediates intra-
cellular signaling. Mol. Biol. Cell 2007. 18: 2002–2012.
248 Iuso, A., Scacco, S., Piccoli, C., Bellomo, F., Petruzzella, V., Trentadue,
R., Minuto, M. et al., Dysfunctions of cellular oxidative metabolism in
patients with mutations in the NDUFS1 and NDUFS4 genes of complex
I. Biol. Chem. 2006. 281: 10374–10380.
249 Rezvani, H. R., Dedieu, S., North, S., Belloc, F., Rossignol, R., Letellier,
T., de Verneuil, H. et al., Hypoxia-inducible factor-1alpha, a key factor
in the keratinocyte response to UVB exposure. J. Biol. Chem. 2007. 282:
16413–16422.
250 van der Pol, E., Bo¨ing, A. N., Harrison, P., Sturk, A. and Nieuwland, R.,
Classification, functions, and clinical relevance of extracellular vesi-
cles. Pharmacol. Rev. 2012. 64: 676–705.
251 van der Pol, E., Coumans, F. A. W., Grootemaat, A. E., Gardiner, C.,
Sargent, I. L., Harrison, P., Sturk, A. et al., Particle size distribution
of exosomes and microvesicles determined by transmission electron
microscopy, flow cytometry, nanoparticle tracking analysis, and resis-
tive pulse sensing. J. Thromb. Haemost. 2014. 12: 1182–1192.
252 De Rond, L., Coumans, F. A. W., Nieuwland, R., Van Leeuwen, T. G.
and van der Pol, E., Deriving extracellular vesicle size from scatter
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1914 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
intensities measured by flow cytometry. Blood Coagul. Fibrinolysis 2018.
1–14.
253 van der Pol, E., de Rond, L., Coumans, F. A. W., Gool, E. L., Bo¨ing, A. N.,
Sturk, A.,Nieuwland, R. et al., Absolute sizing and label-free identifica-
tion of extracellular vesicles by flow cytometry. Nanomed. Nanotechnol.
Biol. Med. 2018. 14: 801–810.
254 White, J. G., Platelet structure. In: Michelson AD, ed. Platelets. 2nd
ed.Academic Press, San Diego, CA 2006:45–73.
255 Arraud, N., Linares, R., Tan, S., Gounou, C., Pasquet, J. M., Mornet,
S. and Brisson, A. R., Extracellular vesicles from blood plasma: deter-
mination of their morphology, size, phenotype and concentration. J.
Thromb. Haemost. 2014. 12: 614–627.
256 Brisson, A. R., Tan, S., Linares, R., Gounou, C. and Arraud, N., Extra-
cellular vesicles from activated platelets: a semiquantitative cryo-
electron microscopy and immuno-gold labeling study. Platelets. 2017.
28: 263–271.
257 Dragovic, R. A.,Gardiner, C., Brooks, A. S.,Tannetta, D. S., Ferguson, D.
J. P.,Hole, P., Carr, B. et al., Sizing and phenotyping of cellulars vesicles
using nanoparticle tracking analysis. Nanomed. Nanotechnol. Biol. Med.
2011. 7: 780–788.
258 van der Pol, E., Hoekstra, A. G., Sturk, A., Otto, C., van Leeuwen, T. G.
and Nieuwland, R., Optical and non-optical methods for detection and
characterization of microparticles and exosomes. J. Thromb. Haemost.
2010. 8: 2596–2607.
259 van der Pol, E., Sturk, A., van Leeuwen, T. G., Nieuwland, R. and
Coumans, F. A. W., Standardization of extracellular vesicle measure-
ments by flow cytometry through vesicle diameter approximation. J.
Thromb. Haemost. 2018. 16: 1236–1245.
260 van der Pol, E., van Gemert, M. J. C., Sturk, A., Nieuwland, R. and
van Leeuwen, T. G., Single vs. swarm detection of microparticles and
exosomes by flow cytometry. J. Thromb. Haemost. 2012. 10: 919–930.
261 Chandler, W. L., Yeung, W. and Tait, J. F., A new microparticle size
calibration standard for use inmeasuring smaller microparticles using
a new flow cytometer. J. Thromb. Haemost. 2011. 9: 1216–1224.
262 Coumans, F. A.W., Brisson, A. R., Buzas, E. I.,Dignat-George, F.,Drees,
E. E. E., El-Andaloussi, S., Emanueli, C. et al.,Methodological guidelines
to study extracellular vesicles. Circ. Res. 2017. 120: 1632–1648.
263 Yuana, Y., Bo¨ing, A. N., Grootemaat, A. E., van der Pol, E., Hau, C. M.,
Cizmar, P., Buhr, E. et al., Handling and storage of human body fluids
for analysis of extracellular vesicles. J. Extracell. Vesicles. 2015. 4: 29260.
264 Witwer, K. W., Buza´s, E. I., Bemis, L. T., Bora, A., La¨sser, C., Lo¨tvall, J.,
Nolte-’t Hoen, E. N. et al., Standardization of sample collection, isola-
tion and analysis methods in extracellular vesicle research. J. Extracell.
Vesicles 2013. 2: 1–25.
265 Lacroix, R., Judicone, C., Mooberry, M., Boucekine, M., Key, N.
S., Dignat-George, F., Ambrozic, A. et al., Standardization of pre-
analytical variables in plasma microparticle determination: results of
the International Society on Thrombosis and Haemostasis SSC collab-
orative workshop. J. Thromb. Haemost. 2013. 11: 1190–1193.
266 Wachalska, M., Koppers-Lalic, D., van Eijndhoven, M., Pegtel, M.,
Geldof, A. A., Lipinska, A. D., van Moorselaar, R. J. et al., Protein com-
plexes in urine interfere with extracellular vesicle biomarker studies.
J. Circ. biomarkers. 2016. 5: 4.
267 Berckmans, R. J., Sturk, A., Schaap, M. C. and Nieuwland, R., Cell-
derived vesicles exposing coagulant tissue factor in saliva. Blood. 2011.
117: 3172–3180.
268 Lippi, G., Salvagno, G. L.,Montagnana, M., Franchini, M. and Guidi, G.
C., Venous stasis and routine hematologic testing. Clin. Lab. Haematol.
2006. 28: 332–337.
269 Jy,W.,Horstman, L. L., Jimenez, J. J. andAhn, Y. S., Measuring circulat-
ing cell-derived microparticles. J. Thromb. Haemost. 2004. 2: 1842–1843.
270 Lippi, G., Salvagno, G. L., Montagnana, M., Poli, G. and Guidi, G. C.,
Influence of the needle bore size on platelet count and routine coagu-
lation testing. Blood Coagul. Fibrinolysis 2006. 17: 557–561.
271 Piccin, A., Murphy, W. G. and Smith, O. P., Circulating microparticles:
pathophysiology and clinical implications. Blood Rev. 2007. 21: 157–171.
272 Hefler, L., Grimm, C., Leodolter, S. and Tempfer, C., To butterfly or to
needle: the pilot phase. Ann. Intern. Med. 2004. 140: 935–936.
273 Van Ierssel, S. H.,VanCraenenbroeck, E.M.,Conraads, V.M.,VanTen-
deloo, V. F., Vrints, C. J., Jorens, P. G. and Hoymans, V. Y., Flow cyto-
metric detection of endothelial microparticles (EMP): effects of cen-
trifugation and storage alter with the phenotype studied. Thromb. Res.
2010. 125: 332–339.
274 Rikkert, L. G., van der Pol, E., van Leeuwen, T. G., Nieuwland, R. and
Coumans, F. A. W., Centrifugation affects the purity of liquid biopsy-
based tumor biomarkers. Cytometry A 2018. 93: 1207–1212.
275 Stoner, S. A., Duggan, E., Condello, D., Guerrero, A., Turk, J. R.,
Narayanan, P. K. and Nolan, J. P., High sensitivity flow cytometry of
membrane vesicles. Cytometry A 2016. 89: 196–206.
276 Bo¨ing, A. N., van der Pol, E., Grootemaat, A. E., Coumans, F. A. W.,
Sturk, A. and Nieuwland, R., Single-step isolation of extracellular vesi-
cles by size-exclusion chromatography. J. Extracell. Vesicles. 2014. 3:
23430.
277 Yuana, Y., Bertina, R. M. and Osanto, S., Pre-analytical and analytical
issues in the analysis of blood microparticles. Thromb. Haemost. 2011.
105: 396–408.
278 Biro, E., Sturk-Maquelin, K. N., Vogel, G. M. T.,Meuleman, D. G., Smit,
M. J., Hack, C. E., Sturk, A. et al., Human cell-derived microparti-
cles promote thrombus formation in vivo in a tissue factor-dependent
manner. J. Thromb. Haemost. 2003. 1: 2561–2568.
279 Simak, J. and Gelderman, M. P., Cell membrane microparticles in
blood and blood products: Potentially pathogenic agents and diagnos-
tic markers. Transfus. Med. Rev. 2006. 20: 1–26.
280 Trummer, A., De Rop, C., Tiede, A., Ganser, A. and Eisert, R., Recov-
ery and composition of microparticles after snap-freezing depends on
thawing temperature. Blood Coagul. Fibrinolysis 2009. 20: 52–56.
281 de Rond, L., van der Pol, E., Hau, C. M., Varga, Z., Sturk, A., van
Leeuwen, T. G., Nieuwland, R. et al., Comparison of generic fluores-
cent markers for detection of extracellular vesicles by flow cytometry.
Clin. Chem. 2018. 64: 680–689.
282 Baumgarth, N. and Roederer, M., A practical approach to multicolor
flow cytometry for immunophenotyping. J. Immunol. Methods. 2000.
243: 77–97.
283 Chattopadhyay, P. K., Gaylord, B., Palmer, A., Jiang, N., Raven, M. A.,
Lewis, G., Reuter, M. A. et al., Brilliant violet fluorophores: a new class
of ultrabright fluorescent compounds for immunofluorescence exper-
iments. Cytometry A 2012. 81: 456–466.
284 Pieragostino, D., Lanuti, P., Cicalini, I., Cufaro, M. C., Ciccocioppo, F.,
Ronci, M., Simeone, P. et al., Proteomics characterization of extracellu-
lar vesicles sorted by flow cytometry reveals a disease-specific molec-
ular cross-talk from cerebrospinal fluid and tears in multiple sclerosis.
Proteomics. 2019. In press https://doi.org/10.1016/j.jprot.2019.103403
285 Nolan, J. P. and Stoner, S. A., A trigger channel threshold artifact in
nanoparticle analysis. Cytometry A 2013. 83: 301–305.
286 Arraud, N., Gounou, C., Turpin, D. and Brisson, A. R. Fluorescence
triggering: a general strategy for enumerating and phenotyping extra-
cellular vesicles by flow cytometry. Cytometry A 2016. 89: 184–195.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1915
287 Steen, H. B., Noise, sensitivity, and resolution of flow cytometers.
Cytometry 1992. 13: 822–830.
288 Giesecke, C., Feher, K., von Volkmann, K., Kirsch, J., Radbruch, A. and
Kaiser, T., Determination of background, signal-to-noise, and dynamic
range of a flow cytometer: A novel practical method for instrument
characterization and standardization. Cytometry A 2017. 91: 1104–1114.
289 Poncelet, P., Robert, S., Bouriche, T., Bez, J., Lacroix, R. and Dignat-
George, F., Standardized counting of circulating plateletmicroparticles
using currently available flow cytometers and scatter-based triggering:
Forward or side scatter? Cytometry A 2016. 89: 148–158.
290 Hoen, E. N. M., van der Vlist, E. J., Aalberts, M., Mertens, H. C. H.,
Bosch, B. J., Bartelink, W., Mastrobattista, E. et al., Quantitative and
qualitative flow cytometric analysis of nanosized cell-derived mem-
brane vesicles. Nanomed. Nanotechnol. Biol. Med. 2012. 8: 712–720.
291 Lanuti, P., Rotta, G., Almici, C., Avvisati, G., Budillon, A., Doretto, P.,
Malara, N. et al., Endothelial progenitor cells, defined by the simulta-
neous surface expression of VEGFR 2 and CD 133, are not detectable in
healthy peripheral and cord blood. Cytometry A 2016. 89: 259–270.
292 van der Vlist, E. J.,Nolte-’t Hoen, E. N. M., Stoorvogel,W.,Arkesteijn, G.
J. A. andWauben, M. H. M., Fluorescent labeling of nano-sized vesicles
released by cells and subsequent quantitative and qualitative analysis
by high-resolution flow cytometry. Nat. Protoc. 2012. 7: 1311–26.
293 Osteikoetxea, X., So´dar, B., Ne´meth, A., Szabo´-Taylor, K., Pa´lo´czi, K.,
Vukman, K. V., Tama´si, V. et al., Differential detergent sensitivity of
extracellular vesicle subpopulations. Org. Biomol. Chem. 2015. 13: 9775–
9782.
294 Schwartz, A., Gaigalas, A. K., Wang, L., Marti, G. E., Vogt, R. F. and
Fernandez-Repollet, E., Formalization of the MESF unit of fluorescence
intensity. Cytometry B Clin. Cytom. 2004. 57: 1–6.
295 Wang, L., Gaigalas, A. K., Abbasi, F., Marti, G. E., Vogt, R. F. and
Schwartz, A., Quantitating fluorescence intensity from fluorophores:
practical use of MESF values. J. Res. Natl. Inst. Stand. Technol. 2002. 107:
339.
296 Wang, L. and Gaigalas, A. K., Development of multicolor flow cytom-
etry calibration standards: assignment of equivalent reference fluo-
rophores (ERF) unit. J. Res. Natl. Inst. Stand. Technol. 2011. 116: 671.
297 Welsh, J., Kepley, J., Rosner, A., Horak, P., Berzofsky, J. and Jones, J.,
Prospective use of high-refractive index materials for single molecule
detection in flow cytometry. Sensors. 2018. 18: 2461.
298 Lacroix, R., Robert, S., Poncelet, P., Kasthuri, R. S., Key, N. S. and
Dignat-George, F., Standardization of platelet-derived microparticle
enumeration by flow cytometry with calibrated beads: results of the
International Society on Thrombosis and Haemostasis SSC Collabora-
tive workshop. J. Thromb. Haemost. 2010. 8: 2571–2574.
299 Lacroix, R., Robert, S., Poncelet, P. and Dignat-George, F., Overcoming
limitations of microparticle measurement by flow cytometry. Semin.
Thromb. Hemost. 2010. 36: 807–818.
300 Zhu, S., Ma, L., Wang, S., Chen, C., Zhang, W., Yang, L., Hang, W.
et al., Light-scattering detection below the level of single fluorescent
molecules for high-resolution characterization of functional nanopar-
ticles. ACS Nano. 2014. 8: 10998–11006.
301 Welsh, J. A., Horak, P., Wilkinson, J. S., Ford, V. J., Jones, J. C., Smith,
D., Holloway, J. A., and Englyst, N. A., FCMPASS Software Aids Extra-
cellular Vesicle Light Scatter Standardization. Cytometry Part A. 2019.
https://doi.org/10.1002/cyto.a.23782
302 Scheffold, A., Radbruch, A. and Assenmacher, M., Phenotyping and
separation of leukocyte populations based on affinity labelling.Methods
Microbiol. 2002. 32: 23–58.
303 Bradbury, A. M. and Plu¨ckthun, A., Antibodies: validate recombinants
once. Nature. 2015. 520: 295.
304 Jain, R. and Gray, D. H., Isolation of thymic epithelial cells and analysis
by flow cytometry. Curr. Protoc. Immunol. 2014.107: 3.26.1–3.26.15.
305 Gru¨tzkau, A., Kru¨ger-Krasagakes, S., Baumeister, H., Schwarz, C.,
Ko¨gel, H., Welker, P., Lippert, U. et al., Synthesis, storage, and release
of vascular endothelial growth factor/vascular permeability factor
(VEGF/VPF) by human mast cells: implications for the biological sig-
nificance of VEGF206. Mol. Biol. Cell. 1998. 9: 875–84.
306 Santangelo, C., Worthington Biochemical Corporation tissue dissociation
guide. Worthington Biochemical Corporation, Lakewood, NJ 2008.
307 Wong, K. H. K., Sandlin, R. D., Carey, T. R., Miller, K. L., Shank, A. T.,
Oklu, R., Maheswaran, S. et al., The role of physical stabilization in
whole blood preservation. Sci. Rep. 2016. 6: 21023.
308 Plate, M. M., Louzao, R., Steele, P. M., Greengrass, V., Morris, L. M.,
Lewis, J., Barnett, D. et al., Evaluation of the blood stabilizers Trans-
Fix and Cyto-Chex BCT for low-cost CD4 T-cell methodologies. Viral
Immunol. 2009. 22: 329–32.
309 Hayashida, K., Bartlett, A. H., Chen, Y., Park, P. W., Molecular and
cellular mechanisms of ectodomain shedding. Anat. Rec. 2010. 293:
925–37.
310 Berhanu, D., Mortari, F., De Rosa, S. C. and Roederer, M., Optimized
lymphocyte isolation methods for analysis of chemokine receptor
expression. J. Immunol. Methods. 2003. 279: 199–207.
311 Kivisa¨kk, P., Liu, Z., Trebst, C., Tucky, B., Wu, L., Stine, J., Mack, M.
et al., Flow cytometric analysis of chemokine receptor expression on
cerebrospinal fluid leukocytes. Methods 2003. 29: 319–325.
312 Liu, H., Rhodes, M., Wiest, D. L., Vignali, D. A., On the dynamic of
TCR:CD3 complex cell surface expression and downmodulation. Immu-
nity 2000. 192: 1529–1534.
313 Mueller, A., Kelly, E. and Strange, P. G., Pathways for internalization
and recycling of the chemokine receptor CCR5. Blood 2002.99: 785–791.
314 Campana, S.,De Pasquale, C., Carrega, P., Ferlazzo, G. and Bonaccorsi,
I., Cross-dressing: an alternative mechanism for antigen presentation.
Immunol. Lett. 2015. 168: 349–354.
315 Anselmo, A.,Mazzon, C., Borroni, E. M., Bonecchi, R.,Graham, G. J. and
Locati, M., Flow cytometry applications for the analysis of chemokine
receptor expression and function. Cytometry A 2014. 85: 292–301.
316 Pockley, A. G., Foulds, G. A., Oughton, J. A., Kerkvliet, N. I. and
Multhoff, G., Immune cell phenotyping using flow cytometry. Curr.
Protoc. Toxicol. 2015. 66:18.8.1—18.8.34.
317 Darzynkiewicz, Z., Halicka, H. D. and Zhao, H., Analysis of cellular
DNA content by flow and laser scanning cytometry. Adv. Exp. Med. Biol.
2010. 676: 137–147.
318 Hamelik, R. M. and Krishan, A., Click-iT assay with improved DNA
distribution histograms. Cytometry A. 2009. 75: 862–865.
319 Krishan, A. and Hamelik, R. M., Click-iT proliferation assay with
improved DNA histograms. Curr. Protoc. Cytom. 2010. Chapter 7:Unit7
36.
320 Lyons, A. B. and Parish, C. R., Determination of lymphocyte division
by flow cytometry. J. Immunol. Methods 1994. 171: 131–137.
321 Wersto, R. P., Chrest, F. J., Leary, J. F., Morris, C., Stetler-Stevenson,
M. A. and Gabrielson, E., Doublet discrimination in DNA cell-cycle
analysis. Cytometry 2001. 46: 296–306.
322 van Engeland, M., Nieland, L. J., Ramaekers, F. C., Schutte, B. and
Reutelingsperger, C. P., Annexin V-affinity assay: a review on an apop-
tosis detection system based on phosphatidylserine exposure. Cytom-
etry 1998. 31: 1–9.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1916 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
323 Gehrmann, M., Doss, B. T.,Wagner, M., Zettlitz, K. A., Kontermann, R.
E., Foulds, G. et al., A novel expression and purification system for the
production of enzymatic and biologically active human granzyme B. J.
Immunol. Methods 2011. 371: 8–17.
324 Gehrmann, M., Stangl, S., Kirschner, A., Foulds, G. A., Sievert, W.,
Doss, B. T. et al., Immunotherapeutic targeting of membrane HSP70-
expressing tumors using recombinant human granzyme B. PLoS One
2012. 7: e41341
325 Abate, M, Festa, A, Falco, M, Lombardi, A, Luce, A, Grimaldi, A, Zap-
pavigna, S et al., Mitochondria as playmakers of apoptosis, autophagy
and senescence. Semin Cell Dev Biol. 2019. S1084-9521(18)30187-3.
326 Shalini, S., Dorstyn, L., Dawar, S. and Kumar, S., Old, new and emerg-
ing functions of caspases. Cell Death Differ. 2015. 22: 526–539.
327 Galluzzi, L., Lopez-Soto, A., Kumar, S. and Kroemer, G., Caspases con-
nect cell-death signaling to organismal homeostasis. Immunity 2016.
44: 221–231.
328 Van Opdenbosch, N and Lamkanfi, M, Caspases in cell death, inflam-
mation, and disease. Immunity. 2019. 50: 1352–1364.
329 Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agos-
tinis, P., Alnemri, E. S. et al., Molecular mechanisms of cell death: rec-
ommendations of the Nomenclature Committee on Cell Death 2018.
Cell Death Differ. 2018. 25: 486–541.
330 Galluzzi, L., Kepp, O., Chan, F. K. and Kroemer, G., Necroptosis: mech-
anisms and relevance to disease. Annu. Rev. Pathol. Mech. Dis. 2017. 12:
103–130.
331 He, S. and Wang, X., RIP kinases as modulators of inflammation and
immunity. Nat. Immunol. 2018. 19: 912–922.
332 Frank, D. and Vince, J. E., Pyroptosis versus necroptosis: similarities,
differences, and crosstalk. Cell Death Differ. 2019. 26: 99–114.
333 Weinlich, R., Oberst, A., Beere, H. M. and Green, D. R., Necroptosis in
development, inflammation and disease. Nat. Rev. Mol. Cell Biol. 2017.
18: 127–136.
334 Fuchslocher Chico, J., Saggau, C. and Adam, D., Proteolytic control of
regulated necrosis. Biochim. Biophys. Acta 2017. 1864: 2147–2161.
335 Newton, K. and Manning, G., Necroptosis and inflammation. Annu.
Rev. Biochem. 2016. 85: 743–763.
336 Lin, Y., Devin, A., Rodriguez, Y. and Liu, Z. G., Cleavage of the death
domain kinase RIP by caspase-8 prompts TNF-induced apoptosis.Genes
Dev. 1999. 13: 2514–2526.
337 Feng, S., Yang, Y., Mei, Y., Ma, L., Zhu, D. E., Hoti, N., Castanares, M.
et al., Cleavage of RIP3 inactivates its caspase-independent apoptosis
pathway by removal of kinase domain. Cell Signal. 2007. 19: 2056–2067.
338 O’Donnell, M. A., Perez-Jimenez, E., Oberst, A., Ng, A., Massoumi, R.,
Xavier, R., Green, D. R. et al., Caspase 8 inhibits programmed necrosis
by processing CYLD. Nat. Cell Biol. 2011. 13: 1437–1442.
339 Vandenabeele, P., Galluzzi, L., Vanden Berghe, T. and Kroemer, G.,
Molecular mechanisms of necroptosis: an ordered cellular explosion.
Nat. Rev. Mol. Cell Biol. 2010. 11: 700–714.
340 Tait, S. W., Oberst, A., Quarato, G., Milasta, S., Haller, M., Wang, R.,
Karvela, M. et al., Widespread mitochondrial depletion via mitophagy
does not compromise necroptosis. Cell Rep. 2013. 5: 878–885.
341 He, S., Huang, S. and Shen, Z., Biomarkers for the detection of necrop-
tosis. Cell Mol. Life Sci. 2016. 73: 2177–2181.
342 Ting, A. T. (Ed.), Programmed necrosis—Methods and protocols. Humana
Press, New York, NY, 2018.
343 Zargarian, S., Shlomovitz, I., Erlich, Z., Hourizadeh, A., Ofir-Birin, Y.,
Croker, B. A., Regev-Rudzki, N. et al., Phosphatidylserine externaliza-
tion, “necroptotic bodies" release, and phagocytosis during necropto-
sis. PLoS Biol. 2017. 15: e2002711.
344 Gong, Y. N., Guy, C., Olauson, H., Becker, J. U., Yang, M., Fitzgerald, P.,
Linkermann, A. et al., Escrt-III acts downstream of MLKL to regulate
necroptotic cell death and its consequences. Cell 2017. 169: 286–300.
345 Lee, H. L., Pike, R., Chong, M. H. A., Vossenkamper, A. and Warnes,
G., Simultaneous flow cytometric immunophenotyping of necroptosis,
apoptosis and RIP1-dependent apoptosis. Methods 2018. 134-135: 56–
66.
346 Moriwaki, K., Balaji, S., Bertin, J., Gough, P. J. and Chan, F. K., Distinct
kinase-independent role of RIPK3 in CD11c+ mononuclear phagocytes
in cytokine-induced tissue repair. Cell Rep. 2017. 18: 2441–2451.
347 Pietkiewicz, S., Schmidt, J. H. and Lavrik, I. N., Quantification of apop-
tosis and necroptosis at the single cell level by a combination of Imag-
ing Flow Cytometry with classical Annexin V/propidium iodide stain-
ing. J. Immunol. Methods 2015. 423: 99–103.
348 Giampietri, C., Starace, D., Petrungaro, S., Filippini, A. and Ziparo, E.,
Necroptosis: molecular signalling and translational implications. Int. J.
Cell Biol. 2014. 2014: 490275.
349 Richter, J., Schlesner, M.,Hoffmann, S., Kreuz, M., Leich, E., Burkhardt,
B., Rosolowski, M. et al., Recurrent mutation of the ID3 gene in Burkitt
lymphoma identified by integrated genome, exome and transcriptome
sequencing. Nat. Genet. 2012. 44: 1316–1320.
350 Lu¨schen, S., Ussat, S., Scherer, G., Kabelitz, D. and Adam-Klages,
S., Sensitization to death receptor cytotoxicity by inhibition of Fas-
associated death domain protein (FADD)/caspase signaling - Require-
ment of cell cycle progression. J. Biol. Chem. 2000. 275: 24670–24678.
351 Falk, M., Ussat, S., Reiling, N., Wesch, D., Kabelitz, D. and Adam-
Klages, S., Caspase inhibition blocks humanT cell proliferation by sup-
pressing appropriate regulation of IL-2, CD25, and cell cycle-associated
proteins. J. Immunol. 2004. 173: 5077–5085.
352 Philipp, S., Sosna, J., Plenge, J., Kalthoff, H. and Adam, D., Homohar-
ringtonine, a clinically approved anti-leukemia drug, sensitizes tumor
cells for TRAIL-induced necroptosis. Cell Commun. Signal. 2015. 13: 25.
353 Aglietti, R. A. and Dueber, E. C., Recent insights into the molecular
mechanisms underlying pyroptosis and gasdermin family functions.
Trends Immunol. 2017. 38: 261–271.
354 Man, S.M.,Karki, R. andKanneganti, T. D., Molecularmechanisms and
functions of pyroptosis, inflammatory caspases and inflammasomes
in infectious diseases. Immunol. Rev. 2017. 277: 61–75.
355 Jorgensen, I., Rayamajhi, M. and Miao, E. A., Programmed cell death
as a defence against infection. Nat. Rev. Immunol. 2017. 17: 151–164.
356 den Hartigh, A. B. and Fink, S. L., Pyroptosis induction and detection.
Curr. Protoc. Immunol. 2018. e52.
357 Zhang, Y., Chen, X., Gueydan, C. and Han, J., Plasma membrane
changes during programmed cell deaths. Cell Res. 2018. 28: 9–21.
358 Yuan, J., Najafov, A. and Py, B. F., Roles of caspases in necrotic cell
death. Cell 2016. 167: 1693–1704.
359 Sester, D. P., Zamoshnikova, A., Thygesen, S. J., Vajjhala, P. R., Crid-
land, S. O., Schroder, K. and Stacey, K. J., Assessment of inflammasome
formation by flow cytometry. Curr. Protoc. Immunol. 2016. 114: 14.40.11–
14.40.29.
360 Cui, J., Zhou, Z., Yang, H., Jiao, F., Li, N., Gao, Y.,Wang, L. et al., MST1
suppresses pancreatic cancer progression via ROS-induced pyroptosis.
Mol. Cancer Res. 2019. 17: 1316–1325.
361 Paddenberg, R., Wulf, S., Weber, A., Heimann, P., Beck, L. A. and
Mannherz, H. G., Internucleosomal DNA fragmentation in cultured
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1917
cells under conditions reported to induce apoptosis may be caused by
mycoplasma endonucleases. Eur. J. Cell Biol. 1996. 71: 105–119.
362 Zhang, D. W., Shao, J., Lin, J., Zhang, N., Lu, B. J., Lin, S. C.,Dong, M. Q.
et al., RIP3, an energymetabolism regulator that switches TNF-induced
cell death from apoptosis to necrosis. Science 2009. 325: 332–336.
363 Pozarowski, P., Huang, X., Halicka, D. H., Lee, B., Johnson, G.
and Darzynkiewicz, Z., Interactions of fluorochrome-labeled caspase
inhibitors with apoptotic cells: a caution in data interpretation. Cytom-
etry A 2003. 55: 50–60.
364 Darzynkiewicz, Z., Zhao, H., Dorota Halicka, H., Pozarowski, P. and
Lee, B., Fluorochrome-labeled inhibitors of caspases: expedient in vitro
and in vivo markers of apoptotic cells for rapid cytometric analysis.
Methods Mol. Biol. 2017. 1644: 61–73.
365 Tran, T. A. T., Grievink, H. W., Lipinska, K., Kluft, C., Burggraaf, J.,
Moerland, M., Tasev, D. et al., Whole blood assay as a model for in
vitro evaluation of inflammasome activation and subsequent caspase-
mediated interleukin-1 beta release. PLoS One 2019. 14: e0214999.
366 Sokolovska, A., Becker, C. E., Ip, W. K., Rathinam, V. A., Brudner, M.,
Paquette, N., Tanne, A. et al., Activation of caspase-1 by the NLRP3
inflammasome regulates the NADPH oxidase NOX2 to control phago-
some function. Nat. Immunol. 2013. 14: 543–553.
367 Fuchslocher Chico, J., Falk-Paulsen, M., Luzius, A., Ruder, B., Bolik, J.,
Schmidt-Arras, D., Linkermann, A. et al., The enhanced susceptibility
of ADAM-17 hypomorphic mice to DSS-induced colitis is not amelio-
rated by loss of RIPK3, revealing an unexpected function of ADAM-17
in necroptosis. Oncotarget 2018. 9: 12941–12958.
368 Gordon, S., Phagocytosis: An Immunobiologic Process. Immunity. 2016.
44: 463–475.
369 Cooper, E. L., Kauschke, E. and Cossarizza, A., Digging for innate
immunity since Darwin and Metchnikoff. Bioessays 2002. 24: 319–333.
370 Navarre, W. W. and Zychlinsky, A., Pathogen-induced apoptosis of
macrophages: a common end for different pathogenic strategies. Cell
Microbiol. 2000. 2: 265–273.
371 Savill, J., Recognition and phagocytosis of cells undergoing apoptosis.
Br. Med. Bull. 1997. 53: 491–508.
372 Brown, G. C., Vilalta, A. and Fricker, M., Phagoptosis—cell death
by phagocytosis plays central roles in physiology, host defense and
pathology. Curr. Mol. Med. 2015. 15: 842–851.
373 Lunov, O., Syrovets, T., Loos, C., Beil, J., Delacher, M., Tron, K., Nien-
haus, G. U. et al., Differential uptake of functionalized polystyrene
nanoparticles by human macrophages and a monocytic cell line, ACS
Nano 2011. 5: 1657–1669.
374 Valet, G., Jenssen, H. L., Krefft, M. and Ruhenstroth-Baued, G.,
Flow-cytometric measurements of the transmembrane potential, the
surface charge density and the phagocytic activity of guinea pig
macrophages after incubation with lymphokines. Blut 1981. 42: 379–
382.
375 Dunn, P. A. and Tyrer, H. W., Quantitation of neutrophil phagocyto-
sis, using fluorescent latex beads. Correlation of microscopy and flow
cytometry. J. Lab. Clin. Med. 1981. 98: 374–381.
376 Bjerknes, R. and Bassøe, C. F., Human leukocyte phagocytosis of
zymosan particles measured by flow cytometry. Acta Pathol. Microbiol.
Immunol. Scand. C. 1983. 91: 341–348.
377 Lehmann, A. K., Sørnes, S. andHalstensen, A., Phagocytosis:measure-
ment by flow cytometry. J. Immunol. Methods 2000. 243: 229–242.
378 Bassøe, C. F., Assessment of phagocyte functions by flow cytometry.
Curr. Prot. Cytom. 2002. 21: 9.19.1–9.19.22.
379 Simons, E. R., Measurement of phagocytosis and of the phagosomal
environment in polymorphonuclear phagocytes by flow cytometry.
Curr. Protoc. Cytom. 2010. 9.31.1–9.31.10.
380 Sokolovska, A., Becker, C. E. and Stuart, L. M., Measurement of phago-
cytosis, phagosome acidification, and intracellular killing of Staphylo-
coccus aureus. Curr. Protoc. Immunol. 2012. 99: 14.30.1–14.30.12.
381 Elbim, C. and Lizard, G., Flow cytometric investigation of neutrophil
oxidative burst and apoptosis physiological and pathological situation.
Cytometry Part A. 2009. 75A: 475–481.
382 Thomason, J., Archer, T.,Mackin, A., Stokes, J. and Pinchuk, L., Appli-
cations of flow cytometry in veterinary research and small animal
clinical practice. J. Vet. Med. Res. 2014. 1: 1004–1012.
383 Keogh, M. J., Spoon, T., Ridgway, S. H., Jensen, E., Van Bonn, W.
and Romano, T. A., Simultaneous measurement of phagocytosis
and respiratory burst of leukocytes in whole blood from bottlenose
dolphins (Tursiops truncatus) utilizing flow cytometry. Vet. Immunol.
Immunopathol. 2011. 144: 468–475.
384 Frankenberg, T., Kirschnek, S., Ha¨cker, H. and Ha¨cker, G.,
Phagocytosis-induced apoptosis of macrophages is linked to uptake,
killing and degradation of bacteria. Eur. J. Immunol. 2008. 38: 204–215.
385 Tartaro, K., VanVolkenburg, M., Wilkie, D., Coskran, T. M., Kreeger,
J. M., Kawabata, T. T. and Casinghino, S., Development of a
fluorescence-based in vivo phagocytosis assay to measure mononu-
clear phagocyte system function in the rat. J. Immunotoxicol. 2015. 12:
239–246.
386 Webb, C., McCord, K. and Dow, S., Neutrophil function in septic dogs.
J. Vet. Intern. Med. 2007. 21: 982–989.
387 Rossi, G, Capitani, L., Ceciliani, F., Restelli, L. and Paltrinieri, S.,
Hyposialylated α1-acid glycoprotein inhibits phagocytosis of feline
neutrophils. Res. Vet. Sci. 2013. 95: 465–471.
388 Moya, S. L., Go´mez, M. A., Boyle, L. A., Mee, J. F., O’Brien, B. and
Arkins, S., Effects of milking frequency on phagocytosis and oxidative
burst activity of phagocytes from primiparous and multiparous dairy
cows during early lactation. J. Dairy Sci. 2008. 91: 587–595.
389 Stent, G., Reece, J. C., Baylis, D. C., Ivinson, K., Paukovics, G., Thomson,
M. and Cameron, P. U., Heterogeneity of freshly isolated human tonsil
dendritic cells demonstrated by intracellular markers, phagocytosis,
and membrane dye transfer. Cytometry. 2002. 48: 167–176.
390 Becker, S.,Halme, J. andHaskill, S., Heterogeneity of humanperitoneal
macrophages: Cytochemical and flow cytometric studies. J. Reticuloen-
dothelial Soc. 1983. 33: 127–138.
391 Jersmann, H. P. A., Ross, K. A., Vivers, S., Brown, S. B., Haslett, C. and
Dransfield, I., Phagocytosis of apoptotic cells by human macrophages:
analysis by multiparameter flow cytometry. Cytometry A. 2003. 51A:
7–15.
392 Linehan, E., Dombrowski, Y., Snoddy, R., Fallon, P. G., Kissenpfennig,
A. and Fitzgerald, D. C., Aging impairs peritoneal but not bonemarrow-
derived macrophage phagocytosis. Aging Cell. 2014. 13: 699–708.
393 Fuller-Espie, S. L., Using flow cytometry tomeasure phagocytic uptake
in earthworms. J. Microbiol. Biol. Educ. 2010. 11: 144–151.
394 http://www.lgcstandards-atcc.org/
395 Rothwell, D. J. and Doumas, B. T., The effect of heparin and EDTA on
the NBT test. J. Lab. Clin. Med. 1975. 85: 950–956.
396 Li, W. and Chung, S. C., Flow cytometric evaluation of leukocyte func-
tion in rat whole blood. In Vitro Cell Dev. Biol. Anim. 2003. 39(10):413–419.
397 Ducusin, R. J., Sarashina, T., Uzuka, Y., Tanabe, S. and Ohtani, M.,
Phagocytic response of bovine polymorphonuclear leukocytes to dif-
ferent incubation conditions and following exposure to some effectors
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1918 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
of phagocytosis and different anticoagulants in vitro. Can. J. Vet. Res.
2001. 65: 38–44.
398 van derMaten, E.,de Jonge,M. I.,deGroot, R., van der Flier,M. andLan-
gereis, J. D., A versatile assay to determine bacterial and host factors
contributing to opsonophagocytotic killing in hirudin-anticoagulated
whole blood. Sci. Rep. 2017.7: 42137.
399 Sustrova, T., Ondrackova, P., Leva, L. and Sladek, Z., Isolation tech-
niques of neutrophils and peripheral blood mononuclear cells for the
comparative experiments in humans and pigs model organisms in
flow cytometry. Mendelnet 2014. 516–521.
400 Carneiro, C., Vaz, C., Carvalho-Pereira, J., Pais, C. and Sampaio, P.,
A new method for yeast phagocytosis analysis by flow cytometry. J.
Microbiol. Methods 2014. 101: 56–62.
401 Murciano, C., Villamo´n, E., O’Connor, J. E., Gozalbo, D. and Gil, M. L.,
Killed candida albicans yeasts and hyphae inhibit gamma interferon
release bymurine natural killer cells. Infect. Immun. 2006. 74: 1403–1406.
402 Anding, K., Rost, J. M., Jacobs, E. and Daschner, F. D., Flow cytometric
measurements of neutrophil functions: the dependence on the stimu-
lus to cell ratio. FEMS Immunol. Med. Microbiol. 2003. 35: 147–152.
403 Chan, C. L., Re´nia, L. and Tan, K. S. W., A simplified, sensitive
phagocytic assay for malaria cultures facilitated by flow cytometry
of differentially-stained cell populations. PLoS One. 2012. 7: e38523.
404 Lee, C. Y., Herant, M. and Heinrich, M., Target-specific mechanics of
phagocytosis: Protrusive neutrophil response to zymosan differs from
the uptake of antibody-tagged pathogens. Cell Sci. 2011. 124: 1106–1114.
405 Salih, H. R., Husfeld, L. and Adam, D., Simultaneous cytofluorometric
measurement of phagocytosis, burst production and killing of human
phagocytes using Candida albicans and Staphylococcus aureus as target
organisms. Clin. Microbiol. Infect. 2000. 6: 251–258.
406 Li, F., Yang, M., Wang, L., Williamson, I., Tian, F., Qin, M., Shah, P.
K. et al., Autofluorescence contributes to false-positive intracellular
Foxp3 staining in macrophages: a lesson learned from flow cytometry.
J. Immunol. Meth. 2012. 386: 101–107.
407 Ya´n˜ez, A., Flores, A., Murciano, C., O’Connor, J. E., Gozalbo, D. and
Gil, M. L., Signalling through TLR2/MyD88 induces differentiation of
murine bone marrow stem and progenitor cells to functional phago-
cytes in response to Candida albicans. Cell. Microbiol. 2010.12: 114–128.
408 Bicker, H., Ho¨flich, C., Wolk, K., Vogt, K., Volk, H. D. and Sabat, R., A
simple assay tomeasure phagocytosis of live bacteria. Clin. Chem. 2008.
54: 5 911–915.
409 Schreiner, L., Huber-Lang, M., Weiss, M. E., Hohmann, H., Schmolz,
M. and Schneider, E. M., Phagocytosis and digestion of pH-sensitive
fluorescent dye (Eos-FP) transfected E. coli in whole blood assays from
patients with severe sepsis and septic shock. J. Cell. Commun. Signal.
2011. 5: 135–144.
410 Bajno, L. and Grinstein, S., Fluorescent proteins: powerful tools in
phagocyte biology. J. Immunol. Methods. 1999. 232: 67–75.
411 Zawada, A. M., Rogacev, K. S., Schirmer, S. H., Sester, M., Bo¨hm, M.,
Fliser, D. and Heine, G. H., Monocyte heterogeneity in human cardio-
vascular disease. Immunobiology. 2012. 217: 1273–1284.
412 Neaga, A., Lefor, J., Lich, K. E., Liparoto, S. F. and Xiao, Y. Q., Develop-
ment and validation of a flow cytometric method to evaluate phago-
cytosis of pHrodoTM BioParticles R© by granulocytes in multiple species.
J. Immunol. Methods. 2013. 390: 9–17.
413 Schrijvers, D. M, Martinet, W., De Meyer, G. R. Y, Andries, L. Herman
and Kockx, M. M., Flow cytometric evaluation of a model for phago-
cytosis of cells undergoing apoptosis. J. Immunol. Methods 2004. 287:
101–108.
414 Basiji, D. A., Ortyn, W. E., Liang, L., Venkatachalam, V. and Morrissey,
P., Cellular image analysis and imaging by flow cytometry. Clin. Lab.
Med. 2007. 27: 653–670.
415 Kapellos, T. S., Taylor, L., Lee, H., Cowley, S. A., James, W. S., Iqbal, A.
J. and Greaves, D. R., A novel real time imaging platform to quantify
macrophage phagocytosis. Biochem. Pharmacol. 2016. 116: 107–119.
416 Lu, S. M., Grinstein, S. and Fairn, G. D., Quantitative live-cell fluores-
cence microscopy during phagocytosis. Methods Mol. Biol. 2017. 1519:
79–91.
417 McFarlin, B. K.,Williams, R. R., Venable, A. S., Dwyer, K. C. and, Havi-
land, D. L., Image-based cytometry reveals three distinct subsets of
activated granulocytes based on phagocytosis and oxidative burst.
Cytometry A. 2013. 83A: 745–751.
418 Pul, R.,Morbiducci, F., Sˇkuljec, J., Skripuletz, T., Singh, V., Diederichs,
U., Garde, N. et al., Glatiramer acetate increases phagocytic activity of
humanmonocytes in vitro and inmultiple sclerosis patients. PLoS One.
2012. 7: e51867.
419 Boya, P., Reggiori, F. and Codogno, P., Emerging regulation and func-
tions of autophagy. Nat. Cell Biol. 2013. 15: 713–720.
420 Cuervo, A. M. and Wong, E., Chaperone-mediated autophagy: roles in
disease and aging. Cell Res. 2014. 24: 92–104.
421 Li, W. W., Li, J., Bao, J. K., Microautophagy: lesser-known self-eating.
Cell Mol. Life Sci. 2012. 69: 1125–1136.
422 Mizushima, N., Yoshimori, T. and Ohsumi, Y., The role of Atg proteins
in autophagosome formation. Annu. Rev. Cell Dev. Biol. 2011. 27: 107–
132.
423 Zhang, H., Puleston, D. J. and Simon, A. K., Autophagy and immune
senescence. Trends Mol. Med. 2016. 22: 671–686.
424 Pasquier, B., Autophagy inhibitors. Cell Mol. Life Sci. 2016. 73: 985–1001.
425 Mauthe, M., Orhon, I., Rocchi, C., Zhou, X., Luhr, M., Hijlkema, K. J.,
Coppes, R. P. et al., Chloroquine inhibits autophagic flux by decreasing
autophagosome-lysosome fusion. Autophagy 2018. 14: 1435–1455.
426 Mauvezin, C.,Nagy, P., Juhasz, G. and Neufeld, T. P., Autophagosome-
lysosome fusion is independent of V-ATPase-mediated acidification.
Nat. Commun. 2015. 6: 7007.
427 Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H.,
Acevedo Arozena, A.,Adachi, H. et al., Guidelines for the use and inter-
pretation of assays for monitoring autophagy (3rd edition). Autophagy
2016. 12: 1–222.
428 Eng, K. E., Panas, M. D., Karlsson Hedestam, G. B. and McInerney, G.
M., A novel quantitative flow cytometry-based assay for autophagy.
Autophagy 2010. 6: 634–641.
429 Chikte, S., Panchal, N. andWarnes, G., Use of LysoTracker dyes: a flow
cytometric study of autophagy. Cytometry A 2014. 85: 169–178.
430 Phadwal, K., Alegre-Abarrategui, J., Watson, A. S., Pike, L., Anbala-
gan, S., Hammond, E. M., Wade-Martins, R. et al., A novel method
for autophagy detection in primary cells: impaired levels of macroau-
tophagy in immunosenescent T cells. Autophagy 2012. 8: 677–689.
431 Puleston, D. J., Zhang, H., Powell, T. J., Lipina, E., Sims, S., Panse, I.,
Watson, A. S. et al., Autophagy is a critical regulator ofmemory CD8(+)
T cell formation. eLife 2014. 3: 03706.
432 Watson, A. S., Riffelmacher, T., Stranks, A., Williams, O., De Boer,
J., Cain, K., MacFarlane, M. et al., Autophagy limits proliferation and
glycolytic metabolism in acute myeloid leukemia. Cell Death Discov.
2015. 1: 15008.
433 Clarke, A. J. and Simon, A. K., Autophagy in the renewal, differenti-
ation and homeostasis of immune cells. Nat. Rev. Immunol. 2018. 19:
170–183.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1919
434 Song, Y. M., Song, S. O., Jung, Y. K., Kang, E. S., Cha, B. S., Lee, H. C.
and Lee, B. W., Dimethyl sulfoxide reduces hepatocellular lipid accu-
mulation through autophagy induction. Autophagy 2012. 8: 1085–1097.
435 Caro, L. H., Plomp, P. J., Wolvetang, E. J., Kerkhof, C. and Meijer, A.
J., 3-Methyladenine, an inhibitor of autophagy, has multiple effects on
metabolism. Eur. J. Biochem. 1988. 175: 325–329.
436 Klionsky, D. J., Elazar, Z., Seglen, P. O. and Rubinsztein, D. C., Does
bafilomycin A1 block the fusion of autophagosomes with lysosomes?
Autophagy 2008. 4: 849–850.
437 Spielberg, S. P., Boxer, L. A., Oliver, J. M., Allen, J. M. and Schulman,
J. D., Oxidative damage to neutrophils in glutathione synthetase defi-
ciency. Br. J. Haematol. 1979. 42: 215–223.
438 Min-Wen, J. C., Jun-Hao, E. T. and Shyh-Chang, N., Stem cell mito-
chondria during aging. Semin Cell Dev. Biol. 2016. 52: 110–118.
439 Watanabe, R., Fujii, H., Shirai, T., Saito, S., Ishii, T. and Harigae, H.,
Autophagy plays a protective role as an anti-oxidant system in human
T cells and represents a novel strategy for induction of T-cell apoptosis.
Eur. J. Immunol. 2014. 44: 2508–2520.
440 Chen, L. M., Peng, F., Li, G. D., Jie, X. M., Cai, K. R., Cai, C., Zhong, Y.
et al., The studies on the cytotoxicity in vitro, cellular uptake, cell cycle
arrest and apoptosis-inducing properties of ruthenium methylimida-
zole complex [Ru(MeIm)4(p-cpip)](2.). J. Inorg. Biochem. 2016. 156: 64–74.
441 Alfadda, A. A. and Sallam, R. M., Reactive oxygen species in health
and disease. J. Biomed. Biotechnol. 2012. 2012: 936486.
442 Ilkun, O. and Boudina, S., Cardiac dysfunction and oxidative stress
in the metabolic syndrome: an update on antioxidant therapies. Curr.
Pharm. Des. 2013. 19: 4806–4817.
443 Zhou, T.,Chuang, C. C. and Zuo, L., Molecular characterization of reac-
tive oxygen species inmyocardial ischemia-reperfusion injury. Biomed.
Res. Int. 2015. 2015: 864946.
444 Gabelloni, M. L., Sabbione, F., Jancic, C., Fuxman Bass, J., Keitelman,
I., Iula, L., Oleastro, M. et al., NADPH oxidase derived reactive oxygen
species are involved in human neutrophil IL-1beta secretion but not in
inflammasome activation. Eur. J. Immunol. 2013. 43: 3324–3335.
445 Vogel, D. Y., Kooij, G., Heijnen, P. D., Breur, M., Peferoen, L. A., van der
Valk, P., de Vries, H. E., Amor, S. and Dijkstra, C. D., GM-CSF promotes
migration of human monocytes across the blood brain barrier. Eur. J.
Immunol. 2015. 45: 1808–1819.
446 D’Autreaux, B. and Toledano, M. B., ROS as signalling molecules:
mechanisms that generate specificity in ROS homeostasis. Nat. Rev.
Mol. Cell Biol. 2007. 8: 813–824.
447 Ray, P. D., Huang, B. W. and Tsuji, Y., Reactive oxygen species (ROS)
homeostasis and redox regulation in cellular signaling.Cell Signal. 2012.
24: 981–990.
448 Reth, M., Hydrogen peroxide as secondmessenger in lymphocyte acti-
vation. Nat. Immunol. 2002. 3: 1129–1134.
449 Nathan, C., Specificity of a third kind: reactive oxygen and nitrogen
intermediates in cell signaling. J. Clin. Invest. 2003. 111: 769–778.
450 Nathan, C. and Cunningham-Bussel, A, Beyond oxidative stress: an
immunologist’s guide to reactive oxygen species. Nat. Rev. Immunol.
2013. 13: 349–361.
451 Solaini, G., Baracca, A., Lenaz, G. and Sgarbi, G., Hypoxia and mito-
chondrial oxidative metabolism. Biochim. Biophys. Acta. 2010. 1797:
1171–1177.
452 Wang, L., Duan, Q.,Wang, T., Ahmed, M., Zhang, N., Li, Y., Li, L. et al.,
Mitochondrial respiratory chain inhibitors involved in ROS production
induced by acute high concentrations of iodide and the effects of SOD
as a protective factor. Oxid. Med. Cell Longev. 2015. 2015: 217670.
453 Halliwell, B. and Gutteridge, J. M., Oxygen toxicity, oxygen radicals,
transition metals and disease. Biochem. J. 1984. 219: 1–14.
454 Diacovich, L. and Gorvel, J. P., Bacterial manipulation of innate immu-
nity to promote infection. Nat. Rev. Microbiol. 2010. 8: 117–128.
455 Nauseef, W. M., Biological roles for the NOX family NADPH oxidases.
J. Biol. Chem. 2008. 283: 16961–16965.
456 Belaaouaj, A., Neutrophil elastase-mediated killing of bacteria: lessons
from targeted mutagenesis. Microbes Infect. 2002. 4: 1259–1264.
457 Nathan, C. and Shiloh, M. U., Reactive oxygen and nitrogen interme-
diates in the relationship between mammalian hosts and microbial
pathogens. Proc. Natl. Acad. Sci. U.S.A. 2000. 97(16):8841–8848.
458 Bogdan, C., Ro¨llinghoff, M. and Diefenbach, A., Reactive oxygen and
reactive nitrogen intermediates in innate and specific immunity. Curr.
Opin. Immunol. 2000. 12(1): 64–76.
459 Nauseef, W. M., Nox enzymes in immune cells. Semin. Immunopathol.
2008. 30(3): 195–208.
460 Gonzalez-Navajas, J. M., Corr, M. P. and Raz, E., The immediate pro-
tective response to microbial challenge. Eur. J. Immunol. 2014. 44: 2536–
2549.
461 Fang, F. C., Antimicrobial actions of reactive oxygen species. MBio.
2011. 2: e00141–11.
462 Rahal, A., Kumar, A., Singh, V., Yadav, B., Tiwari, R., Chakraborty, S.
and Dhama, K., Oxidative stress, prooxidants, and antioxidants: the
interplay. Biomed. Res. Int. 2014. 2014: 761264.
463 Schieber, M. and Chandel, N. S., ROS function in redox signaling and
oxidative stress. Curr. Biol. 2014. 24: R453–R462.
464 Wu, Z., Zhao, Y. and Zhao, B., Superoxide anion, uncoupling proteins
and Alzheimer’s disease. J. Clin. Biochem. Nutr. 2010. 46: 187–194.
465 Baehner, R. L., Murrmann, S. K., Davis, J. and Johnston, R. B., Jr.,
The role of superoxide anion and hydrogen peroxide in phagocytosis-
associated oxidative metabolic reactions. J. Clin. Invest. 1975. 56: 571–
576.
466 Kohen, R. and Nyska, A., Oxidation of biological systems: oxidative
stress phenomena, antioxidants, redox reactions, and methods for
their quantification. Toxicol. Pathol. 2002. 30: 620–650.
467 Tafazoli, S. and O’Brien, P. J., Amodiaquine-induced oxidative stress
in a hepatocyte inflammation model. Toxicology 2009. 256: 101–109.
468 Klebanoff, S. J., Kettle, A. J., Rosen, H.,Winterbourn, C. C. and Nauseef,
W. M., Myeloperoxidase: a front-line defender against phagocytosed
microorganisms. J. Leukoc. Biol. 2013. 93(2): 185–198.
469 Okado-Matsumoto, A. and Fridovich, I., Assay of superoxide dismu-
tase: cautions relevant to the use of cytochrome c, a sulfonated tetra-
zolium, and cyanide. Anal. Biochem. 2001. 298: 337–342.
470 Trevithick, J. R. and Dzialoszynski, T., A new technique for enhancing
luminol luminescent detection of free radicals and reactive oxygen
species. Biochem. Mol. Biol. Int. 1994. 33: 1179–1190.
471 Soh, N., Recent advances in fluorescent probes for the detection of
reactive oxygen species. Anal. Bioanal. Chem. 2006. 386: 532–543.
472 Emmendorffer, A., Hecht, M., Lohmann-Matthes, M. L. and Roesler,
J., A fast and easy method to determine the production of reactive
oxygen intermediates by human and murine phagocytes using dihy-
drorhodamine 123. J. Immunol. Methods 1990. 131: 269–275.
473 Amini, P., Stojkov, D., Wang, X., Wicki, S., Kaufmann, T., Wong, W.
W., Simon, H. U. et al., NET formation can occur independently of
RIPK3 and MLKL signaling. Eur. J. Immunol. 2016. 46: 178–184.
474 Sheyn, U., Rosenwasser, S., Ben-Dor, S., Porat, Z. and Vardi, A., Mod-
ulation of host ROS metabolism is essential for viral infection of a
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1920 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
bloom-forming coccolithophore in the ocean. ISME J. 2016. 10: 1742–
1754.
475 van Eeden, S. F., Klut, M. E., Walker, B. A. and Hogg, J. C., The use
of flow cytometry to measure neutrophil function. J. Immunol. Methods
1999. 232: 23–43.
476 Fornas, O., Garcia, J. and Petriz, J., Flow cytometry counting of CD34+
cells in whole blood. Nat. Med. 2000. 6: 833–836.
477 Fornas, O., Domingo, J. C., Marin, P. and Petriz, J., Flow cytometric-
based isolation of nucleated erythroid cells during maturation: an
approach to cell surface antigen studies. Cytometry 2002. 50: 305–312.
478 Berridge, M. J., Lipp, P. and Bootman, M. D., The versatility and uni-
versality of calcium signalling. Nat. Rev. Mol. Cell Biol. 2000. 1: 11–21.
479 Feske, S.,Okamura, H.,Hogan, P. G. and Rao, A., Ca2+/calcineurin sig-
nalling in cells of the immune system. Biochem. Biophys. Res. Commun.
2003. 311: 1117–1132.
480 Gwack, Y., Feske, S., Srikanth, S., Hogan, P. G. and Rao, A., Signalling
to transcription: store-operated Ca2+ entry and NFAT activation in
lymphocytes. Cell Calcium 2007. 42: 145–156.
481 Trebak, M. and Kinet, J. P., Calcium signalling in T cells. Nat. Rev.
Immunol. 2019. 19: 154–169.
482 Varga-Szabo, D., Braun, A. and Nieswandt, B., Calcium signaling in
platelets. J. Thromb. Haemost. 2009. 7: 1057–1066.
483 Feske, S., Skolnik, E. Y. and Prakriya,M., Ion channels and transporters
in lymphocyte function and immunity. Nat. Rev. Immunol. 12: 532–547.
484 Putney, J. W., Jr., A model for receptor-regulated calcium entry. Cell
Calcium 1986. 7: 1–12.
485 Armstrong, D. L., Erxleben, C. and White, J. A., Patch clamp methods
for studying calcium channels. Methods Cell Biol. 2010. 99: 183–197.
486 Hoth, M. and Penner, R., Depletion of intracellular calcium stores acti-
vates a calcium current in mast cells. Nature 1992. 355: 353–356.
487 Grynkiewicz, G., Poenie, M. and Tsien, R. Y., A new generation of Ca2+
indicators with greatly improved fluorescence properties. J. Biol. Chem.
1985. 260: 3440–3450.
488 Greimers, R., Trebak, M., Moutschen, M., Jacobs, N. and Boniver, J.,
Improved four-color flow cytometry method using fluo-3 and triple
immunofluorescence for analysis of intracellular calcium ion ([Ca2+]i)
fluxes amongmouse lymph node B- and T-lymphocyte subsets. Cytom-
etry 1996. 23: 205–217.
489 Minta, A. and Tsien, R. Y., Fluorescent indicators for cytosolic sodium.
J. Biol. Chem. 1989. 264: 19449–19457.
490 Burchiel, S. W., Edwards, B. S., Kuckuck, F. W., Lauer, F. T., Prossnitz,
E. R.,Ransom, J. T. and Sklar, L. A.Analysis of free intracellular calcium
by flow cytometry: multiparameter and pharmacologic applications.
Methods 2000. 21: 221–230.
491 Wendt, E. R., Ferry, H., Greaves, D. R. and Keshav, S., Ratiometric anal-
ysis of fura red by flow cytometry: a technique for monitoring intracel-
lular calcium flux in primary cell subsets. PLoS One 2015. 10:e0119532.
492 Foerster, C., Voelxen, N., Rakhmanov, M., Keller, B., Gutenberger, S.,
Goldacker, S.,Thiel, J. et al., B cell receptor-mediated calcium signaling
is impaired in B lymphocytes of type Ia patients with common variable
immunodeficiency. J. Immunol. 184: 7305–7313.
493 Dolmetsch, R. E., Lewis, R. S., Goodnow, C. C. and Healy, J. I., Dif-
ferential activation of transcription factors induced by Ca2+ response
amplitude and duration. Nature 1997. 386: 855–858.
494 Griesbeck, M., Ziegler, S., Laffont, S., Smith, N., Chauveau, L.,
Tomezsko, P., Sharei, A. et al., Sex differences in plasmacytoid den-
dritic cell levels of IRF5 drive higher IFNα production in women. J.
Immunol. 2015. 195: 5327–5336.
495 Martrus, G., Niehrs, A., Cornelis, R., Rechtien, A., Garc´ıa-Beltran, W.,
Lo¨utgehetmann, M., Hoffmann, C. et al., Kinetics of HIV-1 latency
reversal quantified on the single-cell level using a novel flow-based
technique. J. Virol. Sep. 2016. 90: 9018–9028.
496 Baxter, A. E., Niessl, J., Fromentin, R., Richard, J., Porichis, F.,
Charlebois, R., Massanella, M. et al., Single-cell characterization of
viral translation-competent reservoirs in HIV-infected individuals. Cell
Host Microbe 2016. 20: 368–380.
497 Taghizadeh, R. R., Cetrulo, K. J. and Cetrulo, C. L., Collagenase impacts
the quantity and quality of native mesenchymal stem/stromal cells
derived during processing of umbilical cord tissue.Cell Transplant. 2018.
27: 181–193.
498 Martrus, G., Kautz, T., Lunemann, S., Richert, L., Glau, L., Salzberger,
W., Goebels, H. et al., Proliferative capacity exhibited by human liver-
resident CD49a+CD25+ NK cells. PLoS One. 2017. 12:e0182532.
499 Sun, H., Sun, R., Hao, M., Wang, Y., Zhang, X., Liu, Y., Cong, X., Effect
of duration of ex vivo ischemia time and storage period on RNA quality
in biobanked human renal cell carcinoma tissue.Ann. Surg. Oncol. 2016.
23: 297–304.
500 Garcia-Beltran, W. F., Ho¨lzemer, A., Martrus, G., Chung, A. W.,
Pacheco, Y., Simoneau, C. R., Rucevic, M. et al., Open conformers
of HLA-F are high-affinity ligands of the activating NK-cell receptor
KIR3DS1. Nat. Immunol. Sep. 2016. 17: 1067–1074.
501 Thaler, B.,Hohensinner, P. J.,Krychtiuk, K. A.,Matzneller, P.,Koller, L.,
Brekalo, M., Maurer, G. et al., Differential in vivo activation of mono-
cyte subsets during low-grade inflammation through experimental
endotoxemia in humans. Sci. Rep. 2016. 6: 30162.
502 Krutzik, P. O. and Nolan, G. P., Intracellular phospho-protein staining
techniques for flow cytometry: monitoring single cell signaling events.
Cytometry 2003. 55: 61–70.
503 Pozarowski, P. and Darzykiewicz, Z., Analysis of cell cycle by flow
cytometry. In A. H. Scho¨nthal, (Ed.) Checkpoint controls and cancer. Meth-
ods in molecular biology, vol 281. Humana Press, Totowa, NJ 2004, 301–
311.
504 Schmid, I. and Sakamoto, K. M., Analysis of DNA content and green
fluorescent protein expression. Curr. Protoc. Cytom. 2001. 16: 7.16.1–
7.16.10.
505 Lanier, L. L. and Warner, N. L., Paraformaldehyde fixation of
hematopoietic cells for quantitative flow cytometry (FACS) analysis.
J. Immunol. Methods 1981. 47: 25–30.
506 Filby, A., Seddon, B., Kleczkowska, J., Salmond, R., Tomlinson, P.,
Smida, M., Lindquist, J. A. et al., Fyn regulates the duration of
TCR engagement needed for commitment to effector function. The J.
Immunol. 2007. 179: 4635–4644.
507 Filby, A., Perucha, E., Summers, H., Rees, P., Chana, P., Heck, S., Lord,
G. M. et al., An imaging flow cytometric method for measuring cell
division history andmolecular symmetry duringmitosis. Cytometry Part
A 2011. 79: 496–506.
508 Fan, J., Nishanian, P., Breen, E. C., McDonald, M. and Fahey, J. L.,
Cytokine gene expression in normal human lymphocytes in response
to stimulation. Clin. Diagn. Lab. Immunol. 1998. 5: 335–340.
509 Lo¨hning, M., Richter, A. and Stamm, T., Establishment of memory for
IL-10 expression in developing T helper 2 cells requires repetitive IL-4
costimulation and does not impair proliferation. Proc. Natl. Acad. Sci.
U.S.A. 2003. 100: 12307–12312.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1921
510 Sanos, S. L., Vonarbourg, C., Mortha, A. and Diefenbach, A., Control
of epithelial cell function by interleukin-22-producing RORgammat+
innate lymphoid cells. Immunology 2011. 132: 453–465.
511 Nussbaum, J. C., Dyken, S. J. and Moltke, J., Type 2 innate lymphoid
cells control eosinophil homeostasis. Nature 2013. 502: 245–248.
512 Robinson, D., Shibuya, K., Mui, A., Zonin, F., Murphy, E., Sana, T.,
Hartley, S. B. et al., IGIF does not drive Th1 development but synergizes
with IL-12 for interferon-gamma production and activates IRAK and
NFκB. Immunity 1997. 7: 571–581.
513 Sattler, A., Wagner, U., Rossol, M., Sieper, J., Wu, P., Krause, A.,
Schmidt, W. A. et al., Cytokine-induced human IFN-γ-secreting
effector-memory Th cells in chronic autoimmune inflammation. Blood
2009. 113: 1948–1956.
514 Zimmermann, J., Radbruch, A. and Chang, H. D., A Ca(2+) concen-
tration of 1.5 mM, as present in IMDM but not in RPMI, is critical for
maximal response of Th cells to PMA/ionomycin. Eur. J. Immunol. 2015.
45: 1270–1273.
515 Lohning, M., Richter, A., Stamm, T., Hu-Li, J., Assenmacher, M., Paul,
W. E. and Radbruch, A., Establishment of memory for IL-10 expression
in developing T helper 2 cells requires repetitive IL-4 costimulation
and does not impair proliferation. Proc. Natl. Acad. Sci. U. S. A. 2003.
100: 12307–12312.
516 Assenmacher, M., Schmitz, J. and Radbruch, A., Flow cytometric deter-
mination of cytokines in activated murine T helper lymphocytes:
Expression of interleukin-10 in interferon-gamma and in interleukin-
4-expressing cells. Eur. J. Immunol. 1994. 24: 1097–1101.
517 Lorenz, H., Hailey, D. W., Wunder, C. and Lippincott-Schwartz, J.,
The fluorescence protease protection (FPP) assay to determine protein
localization and membrane topology. Nat. Protoc. 2006. 1: 276–279.
518 Francis, G., Kerem, Z., Makkar, H. P. and Becker, K., The biological
action of saponins in animal systems: a review. Br. J. Nutr. 2002. 88:
587–605.
519 Moller, B. K., Andresen, B. S., Christensen, E. I. and Petersen, C.
M., Surface membrane CD4 turnover in phorbol ester stimulated T-
lymphocytes. Evidence of degradation and increased synthesis. FEBS
Lett. 1990. 276: 59–62.
520 Boyer, C.,Auphan, N., Luton, F.,Malburet, J. M., Barad, M., Bizozzero, J.
P., Reggio, H. et al., T cell receptor/CD3 complex internalization follow-
ing activation of a cytolytic T cell clone: evidence for a protein kinase
C-independent staurosporine-sensitive step. Eur. J. Immunol. 1991. 21:
1623–1634.
521 Grupillo, M., Lakomy, R., Geng, X., Styche, A., Rudert, W. A., Trucco,
M. and Fan, Y., An improved intracellular staining protocol for effi-
cient detection of nuclear proteins in YFP-expressing cells. Biotech-
niques 2011. 51: 417–420.
522 Heinen, A. P.,Wanke, F.,Moos, S.,Attig, S., Luche, H., Pal, P. P., Budisa,
N. et al., Improved method to retain cytosolic reporter protein fluores-
cence while staining for nuclear proteins: transcription factor staining
with retention of fluorescent proteins. Cytometry 2014. 85: 621–627.
523 Watson, M., Chow, S., Barsyte, D., Arrowsmith, C., Shankey, T. V.,
Minden, M. andHedley, D., The study of epigeneticmechanisms based
on the analysis of histone modification patterns by flow cytometry.
Cytometry 2013. 85: 78–87.
524 Guha, M. and Mackman, N., LPS induction of gene expression in
human monocytes. Cell. Signal. 2001. 13: 85–94.
525 Gantke, T., Sriskantharajah, S. and Ley, S. C., Regulation and function
of TPL-2, an IκB kinase-regulated MAP Kinase Kinase. Cell Res. 2011. 21:
131–134.
526 Dufner, A. and Thomas, G., Ribosomal S6 kinase signaling and the
control of translation. Exp. Cell Res. 1999. 253: 100–109.
527 Firaguay, G. F. and Nune`s, J. A., Analysis of signaling events by
dynamic phosphoflow cytometry. Sci. Signal 2009. 2: pl3.
528 West, M. A., Koons, A., Crandall, M., Skinner, R., Worley, M. and
Shapiro, M. B., Whole blood leukocyte mitogen activated protein
kinases activation differentiates intensive care unit patients with sys-
temic inflammatory response syndrome and sepsis. J. Trauma 2007. 62:
805–811.
529 Donnelly, R. P. and Finlay, D. K., Glucose, glycolysis and lymphocyte
responses. Mol. Immunol. 2015. 68: 513–519.
530 Caro-Maldonado, A., Wang, R., Nichols, A. G., Kuraoka, M., Milasta,
S., Sun, L. D., Gavin, A. L. et al., Metabolic reprogramming is required
for antibody production that is suppressed in anergic but exaggerated
in chronically BAFF-exposed B cells. J. Immunol. 2014. 192: 3626–3636.
531 Warburg, O. On the Origin of Cancer Cells. Science 1956. 123: 309–14.
532 Michalek, R. D., Gerriets, V. A., Jacobs, S. R.,Macintyre, A. N.,MacIver,
N. J.,Mason, E. F., Sullivan, S. A. et al., CD4+, cutting edge: distinct gly-
colytic and lipid oxidativemetabolic programs are essential for effector
and regulatory cell, T subsets. J Immunol. Author. 2012. 186: 3299–3303.
533 Berod, L., Friedrich, C., Nandan, A., Freitag, J., Hagemann, S., Harm-
rolfs, K., Sandouk, A. et al., De novo fatty acid synthesis controls the
fate between regulatory T and T helper 17 cells. Nat. Med. 2014. 20:
1327–1333.
534 Hale, L. P., Braun, R. O. D. D., Gwinn, W. M., Greer, P. K., Dewhirst, M.
W., Laura, P., Braun, R. O. D. D. et al., Hypoxia in the thymus: role of
oxygen tension in thymocyte survival. Am. J. Physiol. Heart Circ. Physiol.
2002. 282: H1467–H1477.
535 Parmar, K., Mauch, P., Vergilio, J.-A., Sackstein, R. and Down, J. D.,
Distribution of hematopoietic stem cells in the bonemarrow according
to regional hypoxia. Proc. Natl. Acad. Sci. U.S.A. 2007. 104: 5431–5436.
536 Chandel, N. S., McClintock, D. S., Feliciano, C. E., Wood, T. M., Melen-
dez, J. A., Rodriguez, A. M. and Schumacker, P. T., Reactive oxy-
gen species generated at mitochondrial Complex III stabilize hypoxia-
inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. J.
Biol. Chem. 2000. 275: 25130–25138.
537 Bigarella, C. L., Liang, R. and Ghaffari, S., Stem cells and the impact of
ROS signaling. Development. 2014. 141: 4206–4218.
538 Jang, K.-J.,Mano, H., Aoki, K., Hayashi, T.,Muto, A., Nambu, Y., Taka-
hashi, K. et al., Mitochondrial function provides instructive signals for
activation-induced B-cell fates. Nat. Commun. 2015. 6: 6750.
539 Barros, L. F., Bittner, C. X., Loaiza, A., Ruminot, I., Larenas, V., Mold-
enhauer, H., Oyarzu´n, C. et al., Kinetic validation of 6-NBDG as a probe
for the glucose transporter GLUT1 in astrocytes. J Neurochem. 2009. 109:
94–100.
540 Zou, C., Wang, Y. and Shen, Z., 2-NBDG as a fluorescent indicator for
direct glucose uptake measurement. J. Biochem. Biophys. Methods 2005.
64: 207–215.
541 Lam, W. Y., Jash, A., Yao, C. H., D’Souza, L., Wong, R., Nunley, R. M.,
Meares, G. P. et al., Metabolic and transcriptional modules indepen-
dently diversify plasma cell lifespan and function. Cell Rep. 2018. 24:
2479–2492.e6.
542 Byersdorfer, C. A., Tkachev, V., Opipari, A. W., Goodell, S., Swanson,
J., Sandquist, S., Glick, G. D. et al., Effector T cells require fatty acid
metabolism during murine graft-versus-host disease. Blood. 2013. 122:
3230–3237.
543 Kolahi, K., Louey, S., Varlamov, O. and Thornburg, K., Real-time track-
ing of BODIPY-C12 long-chain fatty acid in human term placenta
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1922 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
reveals unique lipid dynamics in cytotrophoblast cells. PLoS One. 2016.
11: e0153522.
544 Muroski, M. E., Miska, J., Chang, A. L., Zhang, P., Rashidi, A., Moore,
H., Lopez-Rosas, A. et al., Fatty acid uptake in T cell subsets using a
quantum dot fatty acid conjugate. Sci. Rep. 2017. 7: 5790.
545 Xiao, B., Deng, X., Zhou, W. and Tan, E.-K., Flow cytometry-based
assessment of mitophagy using MitoTracker. Front. Cell. Neurosci. 2016.
10: 76.
546 Avramidou, A., Kroczek, C., Lang, C., Schuh, W., Ja¨ck, H.-M. and Mie-
lenz, D., The novel adaptor protein Swiprosin-1 enhances BCR signals
and contributes to BCR-induced apoptosis. Cell Death Differ. 2007. 14:
1936–1947.
547 Pracht, K., Meinzinger, J., Daum, P., Schulz, S. R., Reimer, D., Hauke,
M., Roth, E. et al., A new staining protocol for detection of murine
antibody-secreting plasma cell subsets by flow cytometry. Eur. J.
Immunol. 2017. 47: 1389–1392.
548 Eruslanov, E. and Kusmartsev, S. Identification of ROS using oxidized
DCFDA and flow-cytometry. Methods Mol. Biol. 2010. 594: 57–72.
549 Kalyanaraman, B., Darley-Usmar, V., Davies, K. J. A., Dennery, P. A.,
Forman, H. J., Grisham, M. B., Mann, G. E. et al., Measuring reactive
oxygen and nitrogen species with fluorescent probes: challenges and
limitations. Free Radic. Biol. Med. 2012. 52: 1–6.
550 Hempel, S. L., Buettner, G. R., O’Malley, Y. Q., Wessels
D. A. and Flaherty D. M., Dihydrofluorescein diacetate is
superior for detecting intracellular oxidants: comparison with
2’,7’-dichlorodihydrofluorescein diacetate, 5 (and 6)-caboxy-2’,7’-
dichlorodihydrofluorescein diacetate, and dihydrorhodamine 123. Free
Radic. Biol. Med. 1999. 27: 146–159.
551 Anon. Thermo Fisher. CellROX R© Oxidative Stress Reagents:
User manual. Available at: https://assets.thermofisher.com/TFS-
Assets/LSG/manuals/mp10422.pdf
552 Anon. Thermo Fisher. MitoSOXTM Red mitochondrial super-
oxide indicator *for live-cell imaging* (M36008): User
manual. Available at: https://assets.thermofisher.com/TFS-
Assets/LSG/manuals/mp36008.pdf
553 Tzur, A., Moore, J. K., Jorgensen, P., Shapiro, H. M. and Kirschner, M.
W., Optimizing optical flow cytometry for cell volume-based sorting
and analysis. PLoS One. 2011. 6: 1–9.
554 Stein, M., Du¨tting, S., Di, M., Bo¨sl, M., Fritsch, K., Reimer, D.,
Urbanczyk, S. et al., A defined metabolic state in pre B cells governs
B-cell development and is counterbalanced by Swiprosin-2/EFhd1. Cell
Death Differ. 2017. 24: 1239–1252.
555 Henzi, T. and Schwaller, B. Antagonistic regulation of parvalbumin
expression and mitochondrial calcium handling capacity in renal
epithelial cells. PLoS One. 2015. 10: e0142005.
556 Santarlasci, V., Maggi, L., Capone, M., Querci, V., Beltrame, L., Cava-
lieri, D., D’Aiuto, E. et al., Rarity of human T helper 17 cells is due to
retinoic acid orphan receptor-dependent mechanisms that limit their
expansion. Immunity. 2012. 36: 201–214.
557 Santarlasci, V, Mazzoni, A, Capone, M, Rossi, MC, Maggi, L, Mon-
taini, G, Rossettini, B et al., Musculin inhibits human T-helper 17
cell response to interleukin 2 by controlling STAT5B activity. Eur. J.
Immunol. 2017. 47: 1427–1442.
558 Altman, J. D., Moss, P. A., Goulder, P. J., Barouch, D. H., McHeyzer-
Williams, M. G., Bell, J. I., McMichael, A. J. et al., Phenotypic analysis
of antigen-specific T lymphocytes. Science 1996. 274: 94–96.
559 Newell, E. W., Klein, L. O., Yu, W. and Davis, M. M., Simultaneous
detection of many T-cell specificities using combinatorial tetramer
staining. Nat. Methods 2009. 6: 497–499.
560 Hadrup, S. R., Bakker, A. H., Shu, C. J., Andersen, R. S., van Veluw,
J., Hombrink, P., Castermans, E. et al., Parallel detection of antigen-
specific T-cell responses by multidimensional encoding of MHC mul-
timers. Nat. Methods 2009. 6: 520–526.
561 Newell, E.W., Sigal, N.,Nair, N.,Kidd, B. A.,Greenberg, H. B. andDavis,
M. M., Combinatorial tetramer staining and mass cytometry analysis
facilitate T-cell epitope mapping and characterization. Nat. Biotechnol.
2013. 31: 623–629.
562 Bentzen, A. K., Marquard, A. M., Lyngaa, R., Saini, S. K., Ramskov,
S., Donia, M., Such, L. et al., Large-scale detection of antigen-specific
T cells using peptide-MHC-I multimers labeled with DNA barcodes.
Nat. Biotechnol. 2016. 34: 1037–1045.
563 Dolton, G.,Zervoudi, E.,Rius, C.,Wall, A.,Thomas, H. L., Fuller, A.,Yeo,
L. et al., Optimized peptide–MHCmultimer protocols for detection and
isolation of autoimmune T-cells. Front Immunol. 2018. 9: 1378.
564 Zhang, S. Q., Ma, K. Y., Schonnesen, A. A., Zhang, M., He, C., Sun, E.,
Williams, C. M. et al., High-throughput determination of the antigen
specificities of T cell receptors in single cells. Nat. Biotechnol. 2018. 36:
1156.
565 Toebes, M., Coccoris, M., Bins, A., Rodenko, B., Gomez, R., Nieuwkoop,
N. J., van de Kasteele, W. et al., Design and use of conditional MHC
class I ligands. Nat. Med. 2006. 12: 246–251.
566 Luimstra, J. J., Garstka, M. A., Roex, M. C., Redeker, A., Janssen, G.
M., van Veelen, P. A. and Neefjes, J., A flexible MHC class I multimer
loading system for large-scale detection of antigen-specific T cells. J.
Exp. Med. 2018. 215(5): 1493–1504.
567 Amore, A.,Wals, K., Koekoek, E.,Hoppes, R., Toebes, M., Schumacher,
T. N., Rodenko, B. et al., Development of a hypersensitive periodate-
cleavable amino acid that is methionine-and disulfide-compatible and
its application in MHC exchange reagents for T cell characterisation.
ChemBioChem 2013. 14: 123–131.
568 Choo, J. A., Thong, S. Y., Yap, J., van Esch, W. J., Raida, M.,Meijers, R.,
Lescar, J. et al., Bioorthogonal cleavage and exchange of major histo-
compatibility complex ligands by employing azobenzene-containing
peptides. Angew. Chem. Int. Ed. 2014. 53: 13390–13394.
569 Saini, S. K., Schuster, H., Ramnarayan, V. R., Rammensee, H.-G.,
Stevanovic´, S. and Springer, S., Dipeptides catalyze rapid peptide
exchange on MHC class I molecules. Proc. Natl. Acad. Sci. USA 2015.
112: 202–207.
570 Kuball, J., Hauptrock, B., Malina, V., Antunes, E., Voss, R. H., Wolfl,
M., Strong, R. et al., Increasing functional avidity of TCR-redirected
T cells by removing defined N-glycosylation sites in the TCR constant
domain. J. Exp. Med. 2009. 206: 463–475.
571 Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C.,
Joseph-Pietras, D., Welters, M. J. et al., Anti-CTLA-4 therapy broadens
the melanoma-reactive CD8+ T cell response. Sci. Transl. Med. 2014. 6:
254ra128.
572 Kvistborg, P., Shu, C. J., Heemskerk, B., Fankhauser, M., Thrue, C.
A., Toebes, M., van Rooij, N. et al., TIL therapy broadens the tumor-
reactive CD8(+) T cell compartment in melanoma patients. Oncoim-
munology 2012. 1: 409–418.
573 Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V.,
Havel, J. J., Lee, W. et al., Mutational landscape determines sensitivity
to PD-1 blockade in non-small cell lung cancer. Science 2015. 348: 124–
128.
574 van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M.,
Heemskerk, B., van Dijk, L. J. et al., Tumor exome analysis reveals
neoantigen-specific T-cell reactivity in an ipilimumab-responsive
melanoma. J. Clin. Oncol. 2013. 31: e439–442.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1923
575 Schneck, J. P., Monitoring antigen-specific T cells usingMHC-Ig dimers.
Immunol. Invest. 2000. 29: 163–169.
576 Selin, L. K.,Vergilis, K.,Welsh, R. M. andNahill, S. R., Reduction of oth-
erwise remarkably stable virus-specific cytotoxic T lymphocyte mem-
ory by heterologous viral infections. J. Exp. Med. 1996. 183: 2489–2499.
577 Martinez, R. J., Andargachew, R., Martinez, H. A. and Evavold, B. D.,
Low-affinity CD4+T cells aremajor responders in the primary immune
response. Nat. Commun. 2016. 7: 13848.
578 Xiao, Z., Mescher, M. F. and Jameson, S. C., Detuning CD8 T cells:
down-regulation of CD8 expression, tetramer binding, and response
during CTL activation. J. Exp. Med. 2007. 204: 2667–2677.
579 Bakker, A. H., Schumacher TNM. MHC multimer technology: current
status and future prospects. Curr. Opin. Immunol. 2005. 17: 428–433.
580 McMichael, A. J. and O’Callaghan, C. A., A new look at T cells. J. Exp.
Med. 1998. 187: 1367–1371.
581 Ogg, G. S., King, A. S., Dunbar, P. R. and McMichael, A. J., Isola-
tion of HIV-1-specific cytotoxic T lymphocytes using human leukocyte
antigen-coated beads. AIDS 1999. 13: 1991–1993.
582 Luxembourg, A. T., Borrow, P.,Teyton, L., Brunmark, A. B., Peterson, P.
A. and Jackson, M. R., Biomagnetic isolation of antigen-specific CD8+
T cells usable in immunotherapy. Nat. Biotechnol. 1998. 16: 281–285.
583 Xu, X. N., Purbhoo,M. A.,Chen, N.,Mongkolsapaya, J.,Cox, J. H.,Meier,
U. C., Tafuro, S. et al., A novel approach to antigen-specific deletion of
CTL with minimal cellular activation using alpha3 domain mutants of
MHC class I/peptide complex. Immunity 2001. 14: 591–602.
584 Whelan, J. A., Dunbar, P. R., Price, D. A., Purbhoo, M. A., Lechner,
F., Ogg, G. S., Griffiths, G. et al., Specificity of CTL interactions with
peptide-MHC class I tetrameric complexes is temperature dependent.
J. Immunol. 1999. 163: 4342–4348.
585 Daniels, M. A. and Jameson, S. C. Critical role for CD8 in T cell receptor
binding and activation by peptide/major histocompatibility complex
multimers. J. Exp. Med. 2000. 191: 335–346.
586 Knabel, M., Franz, T. J., Schiemann, M.,Wulf, A.,Villmow, B., Schmidt,
B., Bernhard, H. et al., ReversibleMHCmultimer staining for functional
isolation of T-cell populations and effective adoptive transfer.Nat.Med.
2002. 8: 631–637.
587 Neuenhahn, M., Albrecht, J., Odendahl, M., Schlott, F., Do¨ssinger, G.,
Schiemann, M., Lakshmipathi, S. et al., Transfer ofminimallymanipu-
lated CMV-specific T cells from stem cell or third-party donors to treat
CMV infection after allo-HSCT. Leukemia 2017. 31: 2161–2171.
588 Nauerth, M., Weißbrich, B., Knall, R., Franz, T., Do¨ssinger, G., Bet, J.,
Paszkiewicz, P. J. et al., TCR-ligand koff rate correlates with the pro-
tective capacity of antigen-specific CD8+ T cells for adoptive transfer.
Sci. Transl. Med. 2013. 5: 192ra87.
589 Nauerth, M., Stemberger, C., Mohr, F., Weißbrich, B., Schiemann, M.,
Germeroth, L. and Busch, D. H., Flow cytometry-based TCR-ligand K
off -rate assay for fast avidity screening of even very small antigen-
specific T cell populations ex vivo. Cytometry A 2016. 89: 816–825.
590 Stemberger, C., Dreher, S., Tschulik, C., Piossek, C., Bet, J., Yamamoto,
T. N., Schiemann, M. et al., Novel serial positive enrichment tech-
nology enables clinical multiparameter cell sorting. PLoS One 2012. 7:
e35798.
591 Davis, D. M., Reyburn, H. T., Pazmany, L., Chiu, I.,Mandelboim, O. and
Strominger, J. L., Impaired spontaneous endocytosis of HLA-G. Eur. J.
Immunol. 1997. 27: 2714–2719.
592 Effenberger, M., Stengl, A., Schober, K., Gerget, M., Kampick, M.,
Mu¨ller, T. R., Schumacher, D. et al., FLEXamers: a double tag for uni-
versal generation of versatile peptide-MHCmultimers. J. Immunol. 2019.
https://doi.org/10.4049/jimmunol.1801435
593 Lund-Johansen, F., Bjerknes, R. and Laerum, O. D., Flow cytometric
assay for the measurement of human bone marrow phenotype, func-
tion and cell cycle. Cytometry 1990. 11: 610–616.
594 Vollers, S. S. and Stern, L. J., Class II major histocompatibility complex
tetramer staining: progress, problems, andprospects. Immunology 2008.
123: 305–313.
595 James, E. A., LaFond, R., Durinovic-Bello, I. and Kwok, W., Visualizing
antigen specific CD4+ T cells using MHC class II tetramers. J. Vis. Exp.
2009: 1–4.
596 Scheffold, A., Busch, D. H. and Kern, F., Detection of antigen-specific T-
cells using major histocompatibility complex multimers or functional
parameters. In Sack, U. (Eds.), Cellular diagnostics.KARGER, Basel 2008:
476–502.
597 Chattopadhyay, P. K., Gierahn, T. M., Roederer, M. and Love, J.
C., Single-cell technologies for monitoring immune systems. Nat.
Immunol. 2014. 15: 128–135.
598 Chattopadhyay, P. K. and Roederer, M., A mine is a terrible thing
to waste: high content, single cell technologies for comprehensive
immune analysis. Am. J. Transplant. 2015. 15: 1155–1161.
599 Kvistborg, P., Gouttefangeas, C., Aghaeepour, N., Cazaly, A., Chat-
topadhyay, P. K., Chan, C., Eckl, J. et al., Thinking outside the gate:
single-cell assessments in multiple dimensions. Immunity 2015. 42:
591–592.
600 Mahnke, Y. D. and Roederer, M., Optimizing amulticolor immunophe-
notyping assay. Clin. Lab. Med. 2007. 27: 469–485.
601 Newell, E. W. and Davis, M. M., Beyond model antigens: high-
dimensional methods for the analysis of antigen-specific T cells. Nat.
Biotechnol. 2014. 32: 149–157.
602 Bacher, P. and Scheffold, A., Flow-cytometric analysis of rare antigen-
specific T cells. Cytometry A 2013. 83: 692–701.
603 Dimitrov, S., Gouttefangeas, C., Besedovsky, L., Jensen, A. T. R., Chan-
dran, P. A., Rusch, E., Businger, R. et al., Activated integrins identify
functional antigen-specific CD8(+) T cells withinminutes after antigen
stimulation. Proc. Natl. Acad. Sci. USA 2018. 115: E5536–E5545.
604 Kutscher, S., Dembek, C. J., Deckert, S., Russo, C., Korber, N., Bogner,
J. R., Geisler, F. et al., Overnight resting of PBMC changes functional
signatures of antigen specific T- cell responses: impact for immune
monitoring within clinical trials. PLoS One 2013. 8: e76215.
605 Owen, R. E., Sinclair, E., Emu, B., Heitman, J. W., Hirschkorn, D. F.,
Epling, C. L., Tan, Q. X. et al., Loss of T cell responses following long-
term cryopreservation. J. Immunol. Methods 2007. 326: 93–115.
606 Romer, P. S., Berr, S., Avota, E., Na, S. Y., Battaglia, M., ten Berge, I.,
Einsele, H. et al., Preculture of PBMCs at high cell density increases sen-
sitivity of T-cell responses, revealing cytokine release by CD28 super-
agonist TGN1412. Blood 2011. 118: 6772–6782.
607 Wegner, J., Hackenberg, S., Scholz, C. J., Chuvpilo, S., Tyrsin, D.,
Matskevich, A. A., Grigoleit, G. U. et al., High-density preculture of
PBMCs restores defective sensitivity of circulating CD8 T cells to virus-
and tumor-derived antigens. Blood 2015. 126: 185–194.
608 Lamoreaux, L., Roederer, M. and Koup, R., Intracellular cytokine opti-
mization and standard operating procedure. Nat. Protoc. 2006. 1: 1507–
1516.
609 Maecker, H. T., Rinfret, A., D’Souza, P., Darden, J., Roig, E., Landry,
C., Hayes, P. et al., Standardization of cytokine flow cytometry assays.
BMC Immunol. 2005. 6: 13.
610 Reddy, M., Eirikis, E., Davis, C., Davis, H. M. and Prabhakar, U.,
Comparative analysis of lymphocyte activation marker expression
and cytokine secretion profile in stimulated human peripheral blood
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1924 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
mononuclear cell cultures: an in vitro model to monitor cellular
immune function. J. Immunol. Methods 2004. 293: 127–142.
611 Redmond, W. L., Ruby, C. E. and Weinberg, A. D., The role of OX40-
mediated co-stimulation in T-cell activation and survival. Crit. Rev.
Immunol. 2009. 29: 187–201.
612 Zaunders, J. J.,Munier, M. L., Seddiki, N., Pett, S., Ip, S., Bailey, M., Xu,
Y. et al., High levels of human antigen-specific CD4+ T cells in periph-
eral blood revealed by stimulated coexpression of CD25 and CD134
(OX40). J. Immunol. 2009. 183: 2827–2836.
613 Chattopadhyay, P. K.,Yu, J. and Roederer, M., A live-cell assay to detect
antigen-specific CD4+ T cells with diverse cytokine profiles. Nat. Med.
2005. 11: 1113–1117.
614 Frentsch, M., Arbach, O., Kirchhoff, D., Moewes, B., Worm, M., Rothe,
M., Scheffold, A. et al., Direct access to CD4+ T cells specific for defined
antigens according to CD154 expression. Nat. Med. 2005. 11: 1118–1124.
615 Bacher, P., Kniemeyer, O., Schonbrunn, A., Sawitzki, B.,Assenmacher,
M., Rietschel, E., Steinbach, A. et al., Antigen-specific expansion of
human regulatory T cells as a major tolerance mechanism against
mucosal fungi. Mucosal. Immunol. 2014. 7: 916–928.
616 Schoenbrunn, A., Frentsch, M.,Kohler, S.,Keye, J.,Dooms, H.,Moewes,
B.,Dong, J. et al., A converse 4-1BB and CD40 ligand expression pattern
delineates activated regulatory T cells (Treg) and conventional T cells
enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg.
J. Immunol. 2012. 189: 5985–5994.
617 Bacher, P., Heinrich, F., Stervbo, U., Nienen, M., Vahldieck, M., Iwert,
C., Vogt, K. et al., Regulatory T cell specificity directs tolerance versus
allergy against aeroantigens in humans. Cell 2016. 167: 1067–1078.
618 Wolfl, M., Kuball, J., Eyrich, M., Schlegel, P. G. and Greenberg, P. D.,
Use of CD137 to study the full repertoire of CD8+ T cells without the
need to know epitope specificities. Cytometry A 2008. 73: 1043–1049.
619 Wolfl, M., Kuball, J., Ho, W. Y., Nguyen, H., Manley, T. J., Bleakley,
M. and Greenberg, P. D., Activation-induced expression of CD137 per-
mits detection, isolation, and expansion of the full repertoire of CD8+
T cells responding to antigen without requiring knowledge of epitope
specificities. Blood 2007. 110: 201–210.
620 Brosterhus, H., Brings, S., Leyendeckers, H., Manz, R. A., Miltenyi, S.,
Radbruch, A.,Assenmacher, M. et al., Enrichment and detection of live
antigen-specific CD4(+) andCD8(+) T cells based on cytokine secretion.
Eur. J. Immunol. 1999. 29: 4053–4059.
621 Manz, R., Assenmacher, M., Pfluger, E., Miltenyi, S. and Radbruch,
A., Analysis and sorting of live cells according to secreted molecules,
relocated to a cell-surface affinitymatrix. Proc. Natl. Acad. Sci. USA 1995.
92: 1921–1925.
622 Jung, T., Schauer, U., Heusser, C., Neumann, C. and Rieger, C., Detec-
tion of intracellular cytokines by flow cytometry. J. Immunol. Methods
1993. 159: 197–207.
623 O’Neil-Andersen, N. J. and Lawrence, D. A., Differential modulation of
surface and intracellular protein expression by T cells after stimulation
in the presence of monensin or brefeldin A. Clin. Diagn. Lab. Immunol.
2002. 9: 243–250.
624 Bacher, P., Schink, C., Teutschbein, J., Kniemeyer, O., Assenmacher,
M., Brakhage, A. A. and Scheffold, A., Antigen-reactive T cell enrich-
ment for direct, high-resolution analysis of thehumannaive andmem-
ory Th cell repertoire. J. Immunol. 2013. 190: 3967–3976.
625 Bacher, P., Hohnstein, T., Beerbaum, E., Rocker, M., Blango, M. G.,
Kaufmann, S., Rohmel, J. et al., Human Anti-fungal Th17 Immunity
and Pathology Rely on Cross-Reactivity against Candida albicans. Cell
2019. 176: 1340–1355.e1315.
626 Wehler, T. C., Karg, M., Distler, E., Konur, A., Nonn, M., Meyer, R.
G., Huber, C. et al., Rapid identification and sorting of viable virus-
reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137
expression. J. Immunol. Methods 2008. 339: 23–37.
627 Betts, M. R., Brenchley, J. M., Price, D. A., De Rosa, S. C., Douek, D.
C., Roederer, M. and Koup, R. A., Sensitive and viable identification of
antigen-specific CD8+ T cells by a flow cytometric assay for degranu-
lation. J. Immunol. Methods 2003. 281: 65–78.
628 Betts, M. R. and Koup, R. A., Detection of T-cell degranulation: CD107a
and b. Methods Cell Biol. 2004. 75: 497–512.
629 Dimitrov, S., Benedict, C., Heutling, D., Westermann, J., Born, J.
and Lange, T., Cortisol and epinephrine control opposing circadian
rhythms in T cell subsets. Blood 2009. 113: 5134–5143.
630 Dimitrov, S., Lange, T. and Born, J., Selective mobilization of cytotoxic
leukocytes by epinephrine. J. Immunol. 2010. 184: 503–511.
631 Day, C. L., Seth, N. P., Lucas, M., Appel, H., Gauthier, L., Lauer, G. M.,
Robbins, G. K. et al., Ex vivo analysis of human memory CD4 T cells
specific for hepatitis C virus using MHC class II tetramers. J. Clin. Invest.
2003. 112: 831–842.
632 Miltenyi, S., Muller, W., Weichel, W. and Radbruch, A., High gradient
magnetic cell separation with MACS. Cytometry 1990. 11: 231–238.
633 Moon, J. J., Chu, H. H., Pepper, M., McSorley, S. J., Jameson, S. C.,
Kedl, R. M. and Jenkins, M. K., Naive CD4(+) T cell frequency varies
for different epitopes and predicts repertoire diversity and response
magnitude. Immunity 2007. 27: 203–213.
634 Obar, J. J., Khanna, K. M. and Lefrancois, L., Endogenous naive CD8+
T cell precursor frequency regulates primary and memory responses
to infection. Immunity 2008. 28: 859–869.
635 Macey, M. G., Flow cytometry: Principles and applications. Humana Press,
New York, NY, 2007.
636 Krensky, A. M., The HLA system, antigen processing and presentation.
Kidney Int. Suppl. 1997. 58: S2–7.
637 Kern, F., Faulhaber, N., Frommel, C.,Khatamzas, E., Prosch, S.,Schone-
mann, C., Kretzschmar, I. et al., Analysis of CD8 T cell reactivity to
cytomegalovirus using protein-spanning pools of overlapping pen-
tadecapeptides. Eur. J. Immunol. 2000. 30: 1676–1682.
638 Maecker, H. T., Dunn, H. S., Suni, M. A., Khatamzas, E., Pitcher, C. J.,
Bunde, T., Persaud, N. et al., Use of overlapping peptide mixtures as
antigens for cytokine flow cytometry. J. Immunol. Methods 2001. 255:
27–40.
639 Eberl, G., Renggli, J.,Men, Y., Roggero, M. A., Lopez, J. A. and Corradin,
G., Extracellular processing and presentation of a 69-mer synthetic
polypetide to MHC class I-restricted T cells. Mol. Immunol. 1999. 36:
103–112.
640 Sherman, L. A., Burke, T. A. and Biggs, J. A., Extracellular processing of
peptide antigens that bind class I major histocompatibility molecules.
J. Exp. Med. 1992. 175: 1221–1226.
641 Alanio, C., Lemaitre, F., Law, H. K., Hasan, M. and Albert, M. L., Enu-
meration of human antigen-specific naive CD8+ T cells reveals con-
served precursor frequencies. Blood 2010. 115: 3718–3725.
642 Campion, S. L., Brodie, T. M., Fischer, W., Korber, B. T., Rossetti, A.,
Goonetilleke, N.,McMichael, A. J. et al., Proteome-wide analysis of HIV-
specific naive and memory CD4(+) T cells in unexposed blood donors.
J. Exp. Med. 2014. 211: 1273–1280.
643 Geiger, R., Duhen, T., Lanzavecchia, A. and Sallusto, F., Human naive
and memory CD4+ T cell repertoires specific for naturally processed
antigens analyzed using libraries of amplified T cells. J. Exp. Med. 2009.
206: 1525–1534.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1925
644 Su, L. F.,Kidd, B. A.,Han, A.,Kotzin, J. J. andDavis, M.M., Virus-specific
CD4(+) memory-phenotype T cells are abundant in unexposed adults.
Immunity 2013. 38: 373–383.
645 Annunziato, F., Romagnani, C. and Romagnani, S., The 3 major types
of innate and adaptive cell-mediated effector immunity. J. Allergy Clin.
Immunol. 2015. 135: 626-635.
646 Brugnolo, F., Sampognaro, S., Liotta, F., Cosmi, L., Annunziato, F.,
Manuelli, C., Campi, P. et al., The novel synthetic immune response
modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2
lymphocytes into IFN-gamma-producing cells. J. Allergy Clin. Immunol.
2003. 111: 380–388.
647 Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazz-
inghi, B., Parente, E. et al., Phenotypic and functional features of
human Th17 cells. J. Exp. Med. 2007. 204: 1849–1861.
648 Cosmi, L.,Maggi, L., Santarlasci, V., Capone, M., Cardilicchia, E., Fros-
ali, F., Querci, V. et al., Identification of a novel subset of human cir-
culating memory CD4(+) T cells that produce both IL-17A and IL-4. J.
Allergy Clin. Immunol. 2010. 125(1): 222-230.e1-4.
649 Becattini, S., Latorre, D., Mele, F., Foglierini, M., De Gregorio, C., Cas-
sotta, A., Fernandez, B. et al., T cell immunity. Functional heterogene-
ity of human memory CD4+ T cell clones primed by pathogens or
vaccines. Science 2015. 347: 400–406.
650 Mazzoni, A., Maggi, L., Siracusa, F., Ramazzotti, M., Rossi, M. C., San-
tarlasci, V., Montaini, G. et al., Eomes controls the development of
Th17-derived (non-classic) Th1 cells during chronic inflammation. Eur.
J. Immunol. 2019. 49: 79–95.
651 Mazzoni, A., Santarlasci, V.,Maggi, L.,Capone, M., Rossi, M. C.,Querci,
V.,De Palma, R. et al., Demethylation of the RORC2 and IL17A inhuman
CD4+ T lymphocytes defines Th17 origin of nonclassic Th1 cells. J.
Immunol. 2015. 194: 3116–3126.
652 Mueller, S. N., Gebhardt, T., Carbone, F. R. and Heath, W. R., Memory
T cell subsets, migration patterns, and tissue residence. Annu. Rev.
Immunol. 2013. 31: 137–161.
653 Masopust, D. and Schenkel, J. M., The integration of T cell migration,
differentiation and function. Nat. Rev. Immunol. 2013. 13: 309–320.
654 Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J., Zajac, A.
J., Miller, J. D., Slansky, J. et al., Immunity 1998. 8: 177–187.
655 Masopust, D., Vezys, V., Marzo, A. L. and Lefrancois, L., Preferential
localization of effector memory cells in nonlymphoid tissue. Science
2001. 291: 2413–2417.
656 Barber, D. L.,Wherry, E. J. and Ahmed, R., J. Immunol. 2003. 171: 27–31.
657 Brunner, K. T., Mauel, J., Cerottini, J. C. and Chapuis, B., Immunology
1968. 14: 181–196.
658 Nagata, S. and Golstein, P., The Fas death factor. Science 1995. 267:
1449–1456.
659 Lopez, J. A., Susanto, O., Jenkins, M. R., Lukoyanova, N., Sutton, V. R.,
Law, R. H., Johnston, A. et al., Blood 2013. 121: 2659–2668.
660 Liu, L., Chahroudi, A., Silvestri, G.,Wernett, M. E., Kaiser, W. J., Safrit,
J. T., Komoriya, A. et al., Visualization and quantification of T cell-
mediated cytotoxicity using cell-permeable fluorogenic caspase sub-
strates. Nat. Med. 2002. 8: 185–189.
661 Bedner, E., Smolewski, P., Amstad, P. and Darzynkiewicz, Z., Exp. Cell
Res. 2000. 259: 308–313.
662 Amstad, P. A.,Yu, G., Johnson, G. L., Lee, B.W.,Dhawan, S. and Phelps,
D. J., BioTechniques 2001. 31: 608–10, 612, 614, passim
663 Sheehy, M. E., McDermott, A. B., Furlan, S. N., Klenerman, P. and
Nixon, D. F., J. Immunol. Methods 2001. 249: 99–110.
664 Michonneau, D., Sagoo, P., Breart, B., Garcia, Z., Celli, S. and Bousso,
P., Immunity 2016. 44: 143–154.
665 Aichele, P., Brduscha-Riem, K., Oehen, S., Odermatt, B., Zinkernagel,
R. M., Hengartner, H. and Pircher, H., Immunity 1997. 6: 519–529.
666 Coles, R. M., Mueller, S. N., Heath, W. R., Carbone, F. R. and Brooks,
A. G., Progression of armed CTL from draining lymph node to spleen
shortly after localized infectionwith herpes simplex virus 1. J. Immunol.
2002. 168: 834–838.
667 Wabnitz, G. H., Balta, E., Schindler, S., Kirchgessner, H., Jahraus, B.,
Meuer, S. and Samstag, Y., The pro-oxidative drug WF-10 inhibits
serial killing by primary human cytotoxic T-cells. Cell Death Discov.
2016. 2: 16057.
668 Wabnitz, G. H., Kirchgessner, H. and Samstag, Y. Multiparamet-
ric analysis of molecular mechanism involved in the cytotoxicity of
human CD8 T-cells. J. Cell. Biochem. 2017. 118: 2528–2533.
669 Mahnke, Y. D., Devevre, E., Baumgaertner, P., Matter, M., Rufer, N.,
Romero, P. and Speiser, D. E., Human melanoma-specific CD8(+) T-
cells from metastases are capable of antigen-specific degranulation
and cytolysis directly ex vivo. Oncoimmunology 2012. 1: 467–530.
670 Kurioka, A., Ussher, J. E., Cosgrove, C., Clough, C., Fergusson, J. R.,
Smith, K., Kang, Y. H. et al., MAIT cells are licensed through granzyme
exchange to kill bacterially sensitized targets. Mucosal. Immunol. 2015.
8: 429–440.
671 Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M.,
Fehervari, Z., Nomura, T. et al., CTLA-4 control over Foxp3(+) regu-
latory T cell function. Science 2008. 322: 271–275.
672 McMurchy, A. N. and Levings, M. K., Suppression assays with human
T regulatory cells: a technical guide. Eur. J. Immunol. 2012. 42: 27–34.
673 Cammarata, I., Martire, C., Citro, A., Raimondo, D., Fruci, D., Melaiu,
O., D’Oria, V. et al., Counter-regulation of regulatory T cells by autore-
active CD8(+) T cells in rheumatoid arthritis. J. Autoimmun. 2019. 99:
81–97.
674 Walker, L. S., Regulatory T cells overturned: the effectors fight back.
Immunology 2009. 126: 466–474.
675 Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T.,Wing, K.,Niwa, A., Pari-
zot, C. et al., Functional delineation and differentiation dynamics of
human CD4+ T cells expressing the FoxP3 transcription factor. Immu-
nity 2009. 30: 899–911.
676 Wing, J. B.,Kitagawa, Y., Locci, M.,Hume, H.,Tay, C.,Morita, T.,Kidani,
Y. et al., A distinct subpopulation of CD25(−) T-follicular regulatory
cells localizes in the germinal centers. Proc. Natl. Acad. Sci. USA 2017.
114: E6400–E6409.
677 Roederer, M., Interpretation of cellular proliferation data: avoid the
panglossian. Cytometry A 2011. 79: 95–101.
678 Grossman, W. J., Verbsky, J. W., Barchet, W., Colonna, M., Atkinson, J.
P. and Ley, T. J., HumanT regulatory cells can use the perforin pathway
to cause autologous target cell death. Immunity 2004. 21: 589–601.
679 Koristka, S., Cartellieri, M., Arndt, C., Feldmann, A., Topfer, K.,
Michalk, I., Temme, A. et al., Cytotoxic response of human regulatory
T cells upon T-cell receptor-mediated activation: a matter of purity.
Blood Cancer J. 2014. 4: e199.
680 Pircher, H., Burki, K., Lang, R., Hengartner, H. and Zinkernagel, R. M.,
Tolerance induction in double specific T-cell receptor transgenic mice
varies with antigen. Nature 1989. 342: 559–561.
681 Hogquist, K. A., Jameson, S. C.,Heath, W. R.,Howard, J. L., Bevan, M. J.
and Carbone, F. R., T cell receptor antagonist peptides induce positive
selection. Cell 1994. 76: 17–27.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1926 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
682 Oxenius, A., Bachmann, M. F., Zinkernagel, R. M. and Hengartner, H.,
Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on
humoral and cellular immune responses after viral infection. Eur. J.
Immunol. 1998. 28: 390–400.
683 Barnden, M. J., Allison, J., Heath, W. R. and Carbone, F. R., Defec-
tive TCR expression in transgenic mice constructed using cDNA-based
alpha- and beta-chain genes under the control of heterologous regu-
latory elements. Immunol. Cell. Biol. 1998. 76: 34–40.
684 Murphy, K. M., Heimberger, A. B. and Loh, D. Y., Induction by anti-
gen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo.
Science 1990. 250: 1720–1723.
685 Kagi, D., Odermatt, B., Ohashi, P. S., Zinkernagel, R. M. and Hengart-
ner, H., Development of insulitis without diabetes in transgenic mice
lacking perforin-dependent cytotoxicity. J. Exp. Med. 1996. 183: 2143–
2152.
686 Bettelli, E., Pagany, M., Weiner, H. L., Linington, C., Sobel, R. A. and
Kuchroo, V. K., Myelin oligodendrocyte glycoprotein-specific T cell
receptor transgenicmice develop spontaneous autoimmuneoptic neu-
ritis. J. Exp. Med. 2003. 197: 1073–1081.
687 Mason, D. Y., Jones, M. and Goodnow, C. C., Development and follicu-
lar localization of tolerant B lymphocytes in lysozyme/anti-lysozyme
IgM/IgD transgenic mice. Int. Immunol. 1992. 4: 163–175.
688 Phan, T. G.,Amesbury,M.,Gardam, S.,Crosbie, J.,Hasbold, J.,Hodgkin,
P. D., Basten, A. et al., B cell receptor-independent stimuli trigger
immunoglobulin (Ig) class switch recombination and production of IgG
autoantibodies by anergic self-reactive B cells. J. Exp. Med. 2003. 197:
845–860.
689 Allen, C. D.,Okada, T.,Tang, H. L. andCyster, J. G., Imaging of germinal
center selection events during affinity maturation. Science 2007. 315:
528–531.
690 Shih, T. A., Roederer, M. and Nussenzweig, M. C., Role of antigen
receptor affinity in T cell-independent antibody responses in vivo.Nat.
Immunol. 2002. 3: 399–406.
691 Garside, P., Ingulli, E., Merica, R. R., Johnson, J. G., Noelle, R. J. and
Jenkins, M. K., Visualization of specific B and T lymphocyte interac-
tions in the lymph node. Science 1998. 281: 96–99.
692 Litzenburger, T., Fassler, R., Bauer, J., Lassmann, H., Linington, C.,
Wekerle, H. and Iglesias, A., B lymphocytes producing demyelinating
autoantibodies: development and function in gene-targeted transgenic
mice. J. Exp. Med. 1998. 188: 169–180.
693 Bettelli, E., Baeten, D., Jager, A., Sobel, R. A. and Kuchroo, V. K., Myelin
oligodendrocyte glycoprotein-specific T and B cells cooperate to induce
a Devic-like disease in mice. J. Clin. Invest. 2006. 116: 2393–2402.
694 Jenkins, M. K. and Moon, J. J., The role of naive T cell precursor fre-
quency and recruitment in dictating immune response magnitude. J.
Immunol. 2012. 188: 4135–4140.
695 Buchholz, V. R., Schumacher, T. N. and Busch, D. H., T cell fate at the
single-cell level. Annu. Rev. Immunol. 2016. 34: 65–92.
696 Stemberger, C., Huster, K. M., Koffler, M., Anderl, F., Schiemann, M.,
Wagner, H. and Busch, D. H., A single naive CD8+ T cell precursor can
develop into diverse effector and memory subsets. Immunity 2007. 27:
985–997.
697 Baumjohann, D. and Ansel, K. M., Tracking early T follicular helper
cell differentiation in vivo. Methods Mol. Biol. 2015. 1291: 27–38.
698 Paus, D., Phan, T. G., Chan, T. D., Gardam, S., Basten, A. and Brink, R.,
Antigen recognition strength regulates the choice between extrafollic-
ular plasma cell and germinal center B cell differentiation. J. Exp. Med.
2006. 203: 1081–1091.
699 Boesch, M., Cosma, A. and Sopper, S., Flow cytometry: to dump or not
to dump. J. Immunol. 2018. 201: 1813.
700 Beura, L. K., Hamilton, S. E., Bi, K., Schenkel, J. M., Odumade, O. A.,
Casey, K. A., Thompson, E. A. et al., Normalizing the environment
recapitulates adult human immune traits in laboratory mice. Nature
2016. 532: 512–516.
701 Akondy, R. S., Monson, N. D., Miller, J. D., Edupuganti, S., Teuwen,
D., Wu, H., Quyyumi, F. et al., The yellow fever virus vaccine induces
a broad and polyfunctional human memory CD8+ T cell response. J.
Immunol. 2009. 183: 7919–7930.
702 Schulz, A. R., Malzer, J. N., Domingo, C., Jurchott, K., Grutzkau, A.,
Babel, N., Nienen, M. et al., Low thymic activity and dendritic cell
numbers are associated with the immune response to primary viral
infection in elderly humans. J. Immunol. 2015. 195: 4699–4711.
703 van Leeuwen, E. M., de Bree, G. J., Remmerswaal, E. B.,Yong, S. L.,Tes-
selaar, K., ten Berge, I. J. and van Lier, R. A., IL-7 receptor alpha chain
expression distinguishes functional subsets of virus-specific human
CD8+ T cells. Blood 2005. 106: 2091–2098.
704 Zhou, L., Chong, M. M. and Littman, D. R., Plasticity of CD4+ T cell
lineage differentiation. Immunity 2009. 30: 646–655.
705 Luckheeram, R. V., Zhou, R., Verma, A. D. and Xia, B., CD4(+)T cells:
differentiation and functions. Clin. Dev. Immunol. 2012. 2012: 925135.
706 Zhu, J., Yamane, H. and Paul, W. E., Differentiation of effector CD4
T cell populations (*). Annu. Rev. Immunol. 2010. 28: 445–489.
707 Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B.,
Lucian, L. et al., Interleukin-23 rather than interleukin-12 is the critical
cytokine for autoimmune inflammation of the brain. Nature 2003. 421:
744–748.
708 Murphy, C. A., Langrish, C. L., Chen, Y., Blumenschein, W., McClana-
han, T., Kastelein, R. A., Sedgwick, J. D. et al., Divergent pro- and anti-
inflammatory roles for IL-23 and IL-12 in joint autoimmune inflamma-
tion. J. Exp. Med. 2003. 198: 1951–1957.
709 Iwakura, Y., Ishigame, H., Saijo, S. and Nakae, S., Functional special-
ization of interleukin-17 family members. Immunity 2011. 34: 149–162.
710 Brown, D. M., Dilzer, A. M., Meents, D. L. and Swain, S. L., CD4 T cell-
mediated protection from lethal influenza: perforin and antibody-
mediated mechanisms give a one-two punch. J. Immunol. 2006. 177:
2888–2898.
711 Lord, G. M., Rao, R. M., Choe, H., Sullivan, B. M., Lichtman, A. H.,
Luscinskas, F. W. and Glimcher, L. H., T-bet is required for optimal
proinflammatory CD4+ T-cell trafficking. Blood 2005. 106: 3432–3439.
712 Sundrud, M. S., Grill, S. M., Ni, D., Nagata, K., Alkan, S. S., Subrama-
niam, A. and Unutmaz, D., Genetic reprogramming of primary human
T cells reveals functional plasticity in Th cell differentiation. J. Immunol.
2003. 171: 3542–3549.
713 Hirota, K., Yoshitomi, H., Hashimoto, M., Maeda, S., Teradaira, S.,
Sugimoto, N., Yamaguchi, T. et al., Preferential recruitment of CCR6-
expressing Th17 cells to inflamed joints via CCL20 in rheumatoid
arthritis and its animal model. J. Exp. Med. 2007. 204: 2803–2812.
714 Breitfeld, D., Ohl, L., Kremmer, E., Ellwart, J., Sallusto, F., Lipp, M. and
Forster, R., Follicular B helper T cells express CXC chemokine receptor
5, localize to B cell follicles, and support immunoglobulin production.
J. Exp. Med. 2000. 192: 1545–1552.
715 Hsieh, C. S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O’Garra, A.
and Murphy, K. M., Development of TH1 CD4+ T cells through IL-12
produced by Listeria-inducedmacrophages. Science 1993. 260: 547–549.
716 Lighvani, A. A., Frucht, D. M., Jankovic, D., Yamane, H., Aliberti,
J., Hissong, B. D., Nguyen, B. V. et al., T-bet is rapidly induced by
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1927
interferon-gamma in lymphoid and myeloid cells. Proc. Natl. Acad. Sci.
U S A 2001. 98: 15137–15142.
717 Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C. G. and
Glimcher, L. H., A novel transcription factor, T-bet, directs Th1 lineage
commitment. Cell 2000. 100: 655–669.
718 Le Gros, G., Ben-Sasson, S. Z., Seder, R., Finkelman, F. D. and Paul,
W. E., Generation of interleukin 4 (IL-4)-producing cells in vivo and in
vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing
cells. J. Exp. Med. 1990. 172: 921–929.
719 Swain, S. L., Weinberg, A. D., English, M. and Huston, G., IL-4 directs
the development of Th2-like helper effectors. J. Immunol. 1990. 145:
3796–3806.
720 Zheng, W. and Flavell, R. A., The transcription factor GATA-3 is nec-
essary and sufficient for Th2 cytokine gene expression in CD4 T cells.
Cell 1997. 89: 587–596.
721 Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A.,
Lafaille, J. J., Cua, D. J. et al., The orphan nuclear receptor RORgammat
directs the differentiation programof proinflammatory IL-17+Thelper
cells. Cell 2006. 126: 1121–1133.
722 Baba, N., Rubio, M., Kenins, L., Regairaz, C., Woisetschlager, M., Car-
ballido, J. M. and Sarfati, M., The aryl hydrocarbon receptor (AhR) lig-
and VAF347 selectively acts on monocytes and naive CD4(+) Th cells
to promote the development of IL-22-secreting Th cells. Hum. Immunol.
2012. 73: 795–800.
723 Gerlach, K., Hwang, Y., Nikolaev, A., Atreya, R., Dornhoff, H., Steiner,
S., Lehr, H. A. et al., TH9 cells that express the transcription factor PU.1
drive T cell-mediated colitis via IL-9 receptor signaling in intestinal
epithelial cells. Nat. Immunol. 2014. 15: 676–686.
724 Chtanova, T., Tangye, S. G.,Newton, R., Frank, N.,Hodge, M. R., Rolph,
M. S. and Mackay, C. R., T follicular helper cells express a distinctive
transcriptional profile, reflecting their role as non-Th1/Th2 effector
cells that provide help for B cells. J. Immunol. 2004. 173: 68–78.
725 Zhu, J., Jankovic, D.,Oler, A. J.,Wei, G., Sharma, S.,Hu, G.,Guo, L. et al.,
The transcription factor T-bet is induced by multiple pathways and
prevents an endogenous Th2 cell program during Th1 cell responses.
Immunity 2012. 37: 660–673.
726 Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. and
Coffman, R. L., Two types of murine helper T cell clone. I. Definition
according to profiles of lymphokine activities and secreted proteins. J.
Immunol. 1986. 136: 2348–2357.
727 Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T.
L., Murphy, K. M. and Weaver, C. T., Interleukin 17-producing CD4+
effector T cells develop via a lineage distinct from the T helper type 1
and 2 lineages. Nat. Immunol. 2005. 6: 1123–1132.
728 Grewal, I. S., Xu, J. and Flavell, R. A., Impairment of antigen-specific
T-cell priming in mice lacking CD40 ligand. Nature 1995. 378: 617–620.
729 Liu, F. and Whitton, J. L., Cutting edge: re-evaluating the in vivo
cytokine responses of CD8+ T cells during primary and secondary viral
infections. J. Immunol. 2005. 5936–5940.
730 Kirchhoff, D., Frentsch, M., Leclerk, P., Bumann, D., Rausch, S., Hart-
mann, S.,Thiel, A. et al., Identification and isolation ofmurine antigen-
reactive T cells according to CD154 expression. Eur J Immunol 2007. 37:
2370–2377.
731 Shore, D. A., Issafras, H., Landais, E., Teyton, L. and Wilson, I. A., The
crystal structure of CD8 in complex with YTS156.7.7 Fab and interac-
tion with other CD8 antibodies define the binding mode of CD8 alpha-
beta to MHC class I. J. Mol. Biol. 2008. 384: 1190–1202.
732 Joshi, N. S., Cui, W., Chandele, A., Lee, H. K., Urso, D. R., Hagman,
J., Gapin, L. et al., Inflammation directs memory precursor and short-
lived effector CD8(+) T cell fates via the graded expression of T-bet
transcription factor. Immunity 2007. 27: 281–295.
733 Kaech, S. M., Tan, J. T., Wherry, E. J., Konieczny, B. T., Surh, C. D. and
Ahmed, R., Selective expression of the interleukin 7 receptor identifies
effector CD8 T cells that give rise to long-lived memory cells. Nat.
Immunol. 2003. 1191–1198.
734 Obar, J. J., Jellison, E. R., Sheridan, B. S., Blair, D. A., Pham, Q. M., Zick-
ovich, J. M. and Lefrancois, L., Pathogen-induced inflammatory envi-
ronment controls effector and memory CD8+ T cell differentiation. J.
Immunol. 2011. 4967–4978.
735 Gerlach, C., Moseman, E. A., Loughhead, S. M., Alvarez, D., Zwij-
nenburg, A. J., Waanders, L., Garg, R. et al., The chemokine recep-
tor CX3CR1 defines three antigen-experienced CD8 T cell subsets with
distinct roles in immune surveillance and homeostasis. Immunity 2016.
45: 1270–1284.
736 Sosinowski, T., White, J. T., Cross, E. W., Haluszczak, C., Marrack, P.,
Gapin, L. and Kedl, R. M., CD8α+ dendritic cell trans presentation of
IL-15 to naive CD8+ T cells produces antigen-inexperienced T cells in
the periphery with memory phenotype and function. J. Immunol. 2013.
190: 1936–1947.
737 White, J. T., Cross, E. W. and Kedl, R. M., Antigen-inexperiencedmem-
ory CD8(+) T cells: where they come from and why we need them. Nat.
Rev. Immunol. 2017. 17: 391–400.
738 Chiu, B. C., Martin, B. E., Stolberg, V. R. and Chensue, S. W., Cutting
edge: central memory CD8 T cells in aged mice are virtual memory
cells. J. Immunol. 2013. 191: 5793–5796.
739 Quinn, K. M., Fox, A., Harland, K. L., Russ, B. E., Li, J.,Nguyen, T. H. O.,
Loh, L. et al., Age-related decline in primary CD8(+) T cell responses
is associated with the development of senescence in virtual memory
CD8(+) T cells. Cell Rep 2018. 23: 3512–3524.
740 Tsukumo, S.-i., Unno, M., Muto, A., Takeuchi, A., Kometani, K.,
Kurosaki, T., Igarashi, K. et al., Bach2 maintains T cells in a naive
state by suppressing effector memory-related genes. Proc. Natl. Acad.
Sci. USA 2013. 10735–10740.
741 Kaech, S. M. and Cui, W., Transcriptional control of effector andmem-
ory CD8+ T cell differentiation. Nat. Rev. Immunol. 2012. 12: 749–761.
742 Mackay, L. K., Minnich, M., Kragten, N. A., Liao, Y., Nota, B., Seillet,
C., Zaid, A. et al., Hobit and Blimp1 instruct a universal transcriptional
program of tissue residency in lymphocytes. Science 2016. 352: 459–463.
743 Mittrucker, H. W., Visekruna, A. and Huber, M., Heterogeneity in the
differentiation and function of CD8(+) T cells. Arch. Immunol. Ther. Exp.
2014. 62: 449–458.
744 Frentsch, M., Stark, R.,Matzmohr, N.,Meier, S.,Durlanik, S., Schulz, A.
R., Stervbo, U. et al., CD40L expression permits CD8+ T cells to execute
immunologic helper functions. Blood 2013. 122: 405–412.
745 van Stipdonk, M. J., Hardenberg, G., Bijker, M. S., Lemmens, E. E.,
Droin, N. M., Green, D. R. and Schoenberger, S. P., Dynamic program-
ming of CD8+ T lymphocyte responses. Nat. Immunol. 2003. 4: 361–365.
746 Masopust, D., Murali-Krishna, K. and Ahmed, R., Quantitating the
magnitude of the lymphocytic choriomeningitis virus-specific CD8 T-
cell response: it is even bigger than we thought. J. Virol. 2007. 81: 2002–
2011.
747 Mueller, S. N. and Mackay, L. K., Tissue-resident memory T cells: local
specialists in immune defence. Nat. Rev. Immunol. 2016. 16: 79–89.
748 Behr, F. M., Chuwonpad, A., Stark, R. and van Gisbergen, K., Armed
and ready: transcriptional regulation of tissue-resident memory CD8
T cells. Front. Immunol. 2018. 9: 1770.
749 Beura, L. K., Fares-Frederickson, N. J., Steinert, E. M., Scott, M. C.,
Thompson, E. A., Fraser, K. A., Schenkel, J. M. et al., CD4(+) resident
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1928 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
memory T cells dominate immunosurveillance and orchestrate local
recall responses. J. Exp. Med. 2019.
750 Autengruber, A., Gereke, M., Hansen, G., Hennig, C. and Bruder,
D., Impact of enzymatic tissue disintegration on the level of sur-
face molecule expression and immune cell function. Eur. J. Microbiol.
Immunol. 2012. 2: 112–120.
751 Rissiek, B., Haag, F., Boyer, O., Koch-Nolte, F. and Adriouch, S., P2X7
on mouse T cells: one channel, many functions. Front. Immunol. 2015.
6: 204.
752 Rissiek, B., Lukowiak, M., Raczkowski, F., Magnus, T., Mittrucker, H.
W. and Koch-Nolte, F., In vivo blockade of murine ARTC2.2 during cell
preparation preserves the vitality and function of liver tissue-resident
memory T cells. Front. Immunol. 2018. 9: 1580.
753 Stark, R., Wesselink, T. H., Behr, F. M., Kragten, N. A. M., Arens, R.,
Koch-Nolte, F., van Gisbergen, K. and van Lier, R. A. W., T RM main-
tenance is regulated by tissue damage via P2RX7. Sci. Immunol. 2018. 3:
eaau1022.
754 Steinert, E. M., Schenkel, J. M., Fraser, K. A., Beura, L. K., Manlove, L.
S., Igyarto, B. Z., Southern, P. J. et al., Quantifying memory CD8 T cells
reveals regionalization of immunosurveillance. Cell 2015. 161: 737–749.
755 Anderson, K. G., Mayer-Barber, K., Sung, H., Beura, L., James, B. R.,
Taylor, J. J., Qunaj, L. et al., Intravascular staining for discrimination
of vascular and tissue leukocytes. Nat. Protoc. 2014. 9: 209–222.
756 Nikolich-Zˇugich, J. and Cˇicˇin-Sˇain, L., Aging of the Immune System
Across Different Species. In N. S. Wolf (Ed.), The comparative biology
of aging, Springer Netherlands, Dordrecht, the Netherlands, 2010. pp.
353–376.
757 Calado, R. T. and Dumitriu, B., Telomere dynamics in mice and
humans. Semin. Hematol. 2013. 50: 165–174.
758 Cicin-Sain, L., Brien, J. D., Uhrlaub, J. L., Drabig, A., Marandu, T. F.
and Nikolich-Zugich, J., Cytomegalovirus infection impairs immune
responses and accentuates T-cell pool changes observed in mice with
aging. PLoS Pathog. 2012. 8: e1002849.
759 Reese, T. A., Bi, K., Kambal, A., Filali-Mouhim, A., Beura, L. K.,
Burger, M. C., Pulendran, B. et al., Sequential infection with common
pathogens promotes human-like immune gene expression and altered
vaccine response. Cell Host Microbe 2016. 19: 713–719.
760 Pinchuk, L. M. and Filipov, N. M., Differential effects of age on circu-
lating and splenic leukocyte populations in C57BL/6 and BALB/c male
mice. Immun. Ageing: I&A 2008. 5: 1–1.
761 Yuan, R., Meng, Q., Nautiyal, J., Flurkey, K., Tsaih, S. W., Krier, R.,
Parker, M. G. et al., Genetic coregulation of age of female sexual mat-
uration and lifespan through circulating IGF1 among inbred mouse
strains. Proc. Natl. Acad. Sci. USA 2012. 109: 8224–8229.
762 Xu, W. and Larbi, A., Markers of T cell senescence in humans. Int. J.
Mol. Sci. 2017. 18: 1742.
763 Lanna, A., Gomes, D. C.,Muller-Durovic, B.,McDonnell, T., Escors, D.,
Gilroy, D. W., Lee, J. H. et al., A sestrin-dependent Erk-Jnk-p38 MAPK
activation complex inhibits immunity during aging.Nat. Immunol. 2017.
18: 354–363.
764 White, J. T., Cross, E. W., Burchill, M. A., Danhorn, T., McCarter, M.
D., Rosen, H. R., O’Connor, B. et al., Virtual memory T cells develop
and mediate bystander protective immunity in an IL-15-dependent
manner. Nat. Commun. 2016. 7: 11291.
765 Marandu, T. F.,Oduro, J. D., Borkner, L.,Dekhtiarenko, I.,Uhrlaub, J. L.,
Drabig, A., Kroger, A. et al., Immune protection against virus challenge
in aging mice is not affected by latent herpesviral infections. J. Virol.
2015. 89: 11715–11717.
766 Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. and Toda, M.,
Immunologic self-tolerancemaintained by activated T cells expressing
IL-2 receptor alpha-chains (CD25). Breakdownof a singlemechanismof
self-tolerance causes various autoimmune diseases. J. Immunol. 1995.
155: 1151–1164.
767 Hori, S., Nomura, T. and Sakaguchi, S., Control of regulatory T cell
development by the transcription factor Foxp3. Science 2003. 299: 1057–
1061.
768 Fontenot, J. D., Gavin, M. A. and Rudensky, A. Y., Foxp3 programs
the development and function of CD4+CD25+ regulatory T cells. Nat.
Immunol. 2003. 4: 330–336.
769 Hill, J. A., Feuerer, M., Tash, K., Haxhinasto, S., Perez, J., Melamed,
R., Mathis, D. et al., Foxp3 transcription-factor-dependent and -
independent regulation of the regulatory T cell transcriptional signa-
ture. Immunity 2007. 27: 786–800.
770 Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J.,
Whitesell, L., Kelly, T. E. et al., The immune dysregulation, polyen-
docrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by
mutations of FOXP3. Nat. Genet. 2001. 27: 20–21.
771 Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark,
L. B., Yasayko, S. A., Wilkinson, J. E. et al., Disruption of a new
forkhead/winged-helix protein, scurfin, results in the fatal lympho-
proliferative disorder of the scurfy mouse. Nat. Genet. 2001. 27: 68–73.
772 Bacchetta, R., Passerini, L., Gambineri, E., Dai, M., Allan, S. E., Perroni,
L., Dagna-Bricarelli, F. et al., Defective regulatory and effector T cell
functions in patients with FOXP3 mutations. J. Clin. Invest. 2006. 116:
1713–1722.
773 Klein, L., Robey, E. A. and Hsieh, C. S., Central CD4+ T cell tolerance:
deletion versus regulatory T cell differentiation. Nat. Rev. Immunol.
2019. 19: 7–18.
774 Tanoue, T.,Atarashi, K. andHonda, K., Development andmaintenance
of intestinal regulatory T cells. Nat. Rev. Immunol. 2016. 16: 295–309.
775 Thornton, A. M., Korty, P. E., Tran, D. Q., Wohlfert, E. A., Murray, P.
E., Belkaid, Y. and Shevach, E. M., Expression of Helios, an Ikaros tran-
scription factor family member, differentiates thymic-derived from
peripherally induced Foxp3+ T regulatory cells. J. Immunol. 2010. 184:
3433–3441.
776 Weiss, J. M., Bilate, A. M., Gobert, M., Ding, Y., Curotto de Lafaille,
M. A., Parkhust, C. N., Xiong, H. et al., Neuropilin-1 is expressed on
thymus-derived natural regulatory T cells, but not mucosa-generated
induced Foxp3+ Treg cells. J. Exp. Med. 2012. 209: 1723–1742.
777 Sefik, E., Geva-Zatorsky, N., Oh, S., Konnikova, L., Zemmour, D.,
McGuire, A. M., Burzyn, D. et al., Individual intestinal symbionts
induce a distinct population of RORgamma+ regulatory T cells. Science
2015. 349: 993–997.
778 Ohnmacht, C., Park, J. H., Cording, S., Wing, J. B., Atarashi, K., Obata,
Y.,Gaboriau-Routhiau, V. et al., Themicrobiota regulates type 2 immu-
nity through RORgammat+ T cells. Science 2015. 349: 989–993.
779 Akimova, T., Beier, U. H., Wang, L., Levine, M. H. and Hancock, W.
W., Helios expression is a marker of T cell activation and proliferation.
PLoS One 2011. 6: e24226.
780 Kim, B.-S., Lu, H., Ichiyama, K., Chen, X., Zhang, Y.-B., Mistry, N. A.,
Tanaka, K. et al., Generation of RORγt+ Antigen-Specific T Regulatory
17 Cells from Foxp3+ Precursors in Autoimmunity. Cell Rep. 2017. 21:
195–207.
781 Yang, J., Zou, M., Pezoldt, J., Zhou, X. and Huehn, J., Thymus-derived
Foxp3+ regulatory T cells upregulate RORgammat expression under
inflammatory conditions. J. Mol. Med. (Berl) 2018. 96: 1387–1394.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1929
782 Delacher, M., Schreiber, L., Richards, D. M., Farah, C., Feuerer, M. and
Huehn, J., Transcriptional Control of Regulatory T cells. Curr. Topics
Microbiol. Immunol. 2014. 381: 83–124.
783 Owen, D. L., Mahmud, S. A., Sjaastad, L. E., Williams, J. B., Spanier,
J. A., Simeonov, D. R., Ruscher, R. et al., Thymic regulatory T cells
arise via two distinct developmental programs. Nat. Immunol. 2019. 20:
195–205.
784 Toker, A., Engelbert, D., Garg, G., Polansky, J. K., Floess, S., Miyao, T.,
Baron, U. et al., Active demethylation of the Foxp3 locus leads to the
generation of stable regulatory T cells within the thymus. J. Immunol.
2013. 190: 3180–3188.
785 Thiault, N., Darrigues, J., Adoue, V., Gros, M., Binet, B., Perals, C.,
Leobon, B. et al., Peripheral regulatory T lymphocytes recirculating
to the thymus suppress the development of their precursors. Nat.
Immunol. 2015. 16: 628–634.
786 Cowan, J. E., McCarthy, N. I. and Anderson, G., CCR7 controls thymus
recirculation, but not production and emigration, of Foxp3+ T cells.
Cell Rep. 2016. 14: 1041–1048.
787 Panduro, M., Benoist, C. and Mathis, D., Tissue Tregs. Annu. Rev.
Immunol. 2016. 34: 609–633.
788 Feuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A.,
Lee, J. et al., Lean, but not obese, fat is enriched for a unique population
of regulatory T cells that affect metabolic parameters. Nat. Med. 2009.
15: 930–939.
789 Cipolletta, D., Feuerer, M., Li, A., Kamei, N., Lee, J., Shoelson, S. E.,
Benoist, C. et al., PPAR-gamma is a major driver of the accumulation
and phenotype of adipose tissue Treg cells. Nature 2012. 486: 549–553.
790 Kolodin, D., van Panhuys, N., Li, C., Magnuson, A. M., Cipolletta, D.,
Miller, C. M.,Wagers, A., Germain, R. N. et al., Antigen- and cytokine-
driven accumulation of regulatory T cells in visceral adipose tissue of
lean mice. Cell Metab. 2015. 21: 543–557.
791 Burzyn, D., Kuswanto, W., Kolodin, D., Shadrach, J. L., Cerletti, M.,
Jang, Y., Sefik, E. et al., A special population of regulatory T cells poten-
tiates muscle repair. Cell 2013. 155: 1282–1295.
792 Arpaia, N., Green, J. A., Moltedo, B., Arvey, A., Hemmers, S., Yuan, S.,
Treuting, P. M. et al., A distinct function of regulatory T cells in tissue
protection. Cell 2015. 162: 1078–1089.
793 Dombrowski, Y., O’Hagan, T., Dittmer, M., Penalva, R., Mayoral, S.
R., Bankhead, P., Fleville, S. et al., Regulatory T cells promote myelin
regeneration in the central nervous system. Nat Neurosci 2017. 20: 674–
680.
794 Ali, N., Zirak, B., Rodriguez, R. S., Pauli, M. L., Truong, H. A., Lai, K.,
Ahn, R. et al., Regulatory T cells in skin facilitate epithelial stem cell
differentiation. Cell 2017. 169: 1119–1129 e1111.
795 Delacher, M., Imbusch, C. D., Weichenhan, D., Breiling, A., Hotz-
Wagenblatt, A., Trager, U., Hofer, A. C. et al., Genome-wide DNA-
methylation landscape defines specialization of regulatory T cells in
tissues. Nat. Immunol. 2017.
796 Delacher,M., Schmidl, C.,Herzig, Y.,Breloer, M.,Hartmann,W.,Brunk,
F., Ka¨gebein, D. et al., Rbpj expression in regulatory T cells is critical
for restraining TH2 responses. Nat. Commun. 2019. 10: 1621.
797 Carding, S. R. and Egan, P. J., Gammadelta T cells: functional plasticity
and heterogeneity. Nat. Rev. Immunol. 2002. 2: 336–345.
798 Bonneville, M., O’Brien, R. L. and Born, W. K., γδ T cell effector func-
tions: a blend of innate programming and acquired plasticity. Nat. Rev.
Immunol. 2010. 10: 467–478.
799 Prinz, I., Silva-Santos, B. and Pennington, D. J., Functional develop-
ment of gammadelta T cells. Eur. J. Immunol. 2013. 43: 1988–1994.
800 Heilig, J. S. and Tonegawa, S., Diversity of murine gamma genes and
expression in fetal and adult T lymphocytes.Nature 1986. 322: 836–840.
801 Garman, R. D., Doherty, P. J. and Raulet, D. H., Diversity, rearrange-
ment, and expression of murine T cell gamma genes. Cell 1986. 45:
733–742.
802 Pereira, P., Hermitte, V., Lembezat, M. P., Boucontet, L., Azuara, V.
and Grigoriadou, K., Developmentally regulated and lineage-specific
rearrangement of T cell receptor Valpha/delta gene segments. Eur. J.
Immunol. 2000. 30: 1988–1997.
803 Mallick-Wood, C. A., Lewis, J. M., Richie, L. I., Owen, M. J., Tigelaar,
R. E. and Hayday, A. C., Conservation of T cell receptor conformation
in epidermal gammadelta cells with disrupted primary Vgamma gene
usage. Science 1998. 279: 1729–1733.
804 Roark, C. L., Aydintug, M. K., Lewis, J., Yin, X., Lahn, M., Hahn, Y. S.,
Born, W. K. et al., Subset-specific, uniform activation among V gamma
6/V delta 1+ gamma delta T cells elicited by inflammation. J. Leukoc.
Biol. 2004. 75: 68–75.
805 Goodman, T. and Lefrancois, L., Intraepithelial lymphocytes. Anatom-
ical site, not T cell receptor form, dictates phenotype and function. J.
Exp. Med. 1989. 170: 1569–1581.
806 Prinz, I., Sansoni, A., Kissenpfennig, A., Ardouin, L., Malissen, M. and
Malissen, B., Visualization of the earliest steps of gammadelta T cell
development in the adult thymus. Nat. Immunol. 2006. 7: 995–1003.
807 Koenecke, C., Chennupati, V., Schmitz, S.,Malissen, B., Forster, R. and
Prinz, I., In vivo application of mAb directed against the gammadelta
TCR does not deplete but generates “invisible” gammadelta T cells.
Eur. J. Immunol. 2009. 39: 372–379.
808 Sandrock, I., Reinhardt, A., Ravens, S., Binz, C., Wilharm, A., Martins,
J., Oberdorfer, L. et al., Genetic models reveal origin, persistence and
non-redundant functions of IL-17-producing gammadelta T cells. J.
Exp. Med. 2018. 215: 3006–3018.
809 Ribot, J. C., deBarros, A., Pang, D. J., Neves, J. F., Peperzak, V., Roberts,
S. J., Girardi, M. et al., CD27 is a thymic determinant of the bal-
ance between interferon-gamma- and interleukin 17-producing gam-
madelta T cell subsets. Nat. Immunol. 2009. 10: 427–436.
810 Haas, J. D., Gonzalez, F. H., Schmitz, S., Chennupati, V., Fohse, L.,
Kremmer, E., Forster, R. et al., CCR6 and NK1.1 distinguish between
IL-17A and IFN-gamma-producing gammadelta effector T cells. Eur. J.
Immunol. 2009. 39: 3488–3497.
811 Lombes, A., Durand, A., Charvet, C., Riviere, M., Bonilla, N., Auffray,
C., Lucas, B. et al., Adaptive Immune-like gamma/delta T Lymphocytes
Share Many Common Features with Their alpha/beta T Cell Counter-
parts. J. Immunol. 2015. 195: 1449–1458.
812 Itohara, S., Farr, A. G., Lafaille, J. J., Bonneville, M., Takagaki, Y., Haas,
W. and Tonegawa, S., Homing of a gamma delta thymocyte subset
with homogeneous T-cell receptors to mucosal epithelia. Nature 1990.
343: 754–757.
813 Shibata, K., Yamada, H., Hara, H., Kishihara, K. and Yoshikai, Y., Res-
ident Vdelta1+ gammadelta T cells control early infiltration of neu-
trophils after Escherichia coli infection via IL-17 production. J. Immunol.
2007. 178: 4466–4472.
814 Papotto, P. H., Reinhardt, A., Prinz, I. and Silva-Santos, B., Innately
versatile: gammadelta17 T cells in inflammatory and autoimmune dis-
eases. J. Autoimmun. 2018. 87: 26–37.
815 Ohteki, T. and MacDonald, H. R., Major histocompatibility complex
class I related molecules control the development of CD4+8- and CD4-
8- subsets of natural killer 1.1+ T cell receptor-alpha/beta+ cells in the
liver of mice. J. Exp. Med. 1994. 180: 699–704.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1930 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
816 Makino, Y., Kanno, R., Ito, T., Higashino, K. and Taniguchi, M., Pre-
dominant expression of invariant V alpha 14+ TCR alpha chain in
NK1.1+ T cell populations. Int. Immunol. 1995. 7: 1157–1161.
817 Wei, D. G., Curran, S. A., Savage, P. B., Teyton, L. and Bendelac, A.,
Mechanisms imposing the Vbeta bias of Valpha14 natural killer T cells
and consequences for microbial glycolipid recognition. J. Exp. Med.
2006. 203: 1197–1207.
818 Lantz, O. and Bendelac, A., An invariant T cell receptor alpha chain
is used by a unique subset of major histocompatibility complex class
I-specific CD4+ and CD4-8- T cells in mice and humans. J. Exp. Med.
1994. 180: 1097–1106.
819 Bendelac, A., Lantz, O., Quimby, M. E., Yewdell, J. W., Bennink, J. R.
andBrutkiewicz, R. R., CD1 recognition bymouseNK1+T lymphocytes.
Science. 1995. 268: 863–865.
820 Benlagha, K.,Weiss, A., Beavis, A., Teyton, L. and Bendelac, A., In vivo
identification of glycolipid antigen–specific T cells using fluorescent
Cd1d tetramers. J. Exp. Med. 2000. 191: 1895–1904.
821 Matsuda, J. L., Naidenko, O. V., Gapin, L., Nakayama, T., Taniguchi,
M., Wang, C. R., Koezuka, Y. et al., Tracking the response of natural
killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med.
2000. 192: 741–754.
822 Moran, A. E., Holzapfel, K. L., Xing, Y., Cunningham, N. R.,Maltzman,
J. S., Punt, J. and Hogquist, K. A., T cell receptor signal strength in
Treg and iNKT cell development demonstrated by a novel fluorescent
reporter mouse. J. Exp. Med. 2011. 208: 1279–1289.
823 Savage, A. K., Constantinides, M. G., Han, J., Picard, D., Martin, E., Li,
B., Lantz, O. et al., The transcription factor PLZF directs the effector
program of the NKT cell lineage. Immunity 2008. 29: 391–403.
824 Kovalovsky, D.,Uche, O. U., Eladad, S.,Hobbs, R. M., Yi, W.,Alonzo, E.,
Chua, K. et al., The BTB-zinc finger transcriptional regulator PLZF con-
trols the development of invariant natural killer T cell effector func-
tions. Nat. Immunol. 2008. 9: 1055–1064.
825 Benlagha, K.,Kyin, T., Beavis, A., Teyton, L. and Bendelac, A., A thymic
precursor to the NK T cell lineage. Science 2002. 296: 553–555.
826 Benlagha, K., Wei, D. G., Veiga, J., Teyton, L. and Bendelac, A., Char-
acterization of the early stages of thymic NKT cell development. J. Exp.
Med. 2005. 202: 485–492.
827 Pellicci, D. G.,Hammond, K. J. L.,Uldrich, A. P., Baxter, A. G., Smyth, M.
J. and Godfrey, D. I., A natural killer T (NKT) cell developmental path-
way iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent
precursor stage. J. Exp. Med. 2002. 195: 835–844.
828 Wang, H. and Hogquist, K. A., CCR7 defines a precursor for murine
iNKT cells in thymus and periphery. Elife 2018. 7.
829 Berzins, S. P.,McNab, F. W., Jones, C. M., Smyth, M. J. and Godfrey, D.
I., Long-term retention of mature NK1.1+ NKT cells in the thymus. J.
Immunol. 2006. 176: 4059–4065.
830 Lee, Y. J., Holzapfel, K. L., Zhu, J., Jameson, S. C. and Hogquist, K. A.,
Steady-state production of IL-4 modulates immunity in mouse strains
and is determined by lineage diversity of iNKT cells.Nat. Immunol. 2013.
14: 1146–1154.
831 Crosby, C. M. and Kronenberg, M., Tissue-specific functions of invari-
ant natural killer T cells. Nat. Rev. Immunol. 2018. 18: 559–574.
832 Salou, M., Legoux, F., Gilet, J., Darbois, A., Du Halgouet, A., Alonso, R.,
Richer, W. et al., A common transcriptomic program acquired in the
thymus defines tissue residency of MAIT and NKT subsets. J. Exp. Med.
2019. 216: 133–151.
833 Brigl, M., Tatituri, R. V. V., Watts, G. F. M., Bhowruth, V., Leadbetter,
E. A., Barton, N., Cohen, N. R. et al., Innate and cytokine-driven sig-
nals, rather than microbial antigens, dominate in natural killer T cell
activation during microbial infection. J. Exp. Med. 2011. 208: 1163–1177.
834 Velazquez, P., Cameron, T. O., Kinjo, Y., Nagarajan, N., Kronenberg,
M. and Dustin, M. L., Cutting edge: activation by innate cytokines or
microbial antigens can cause arrest of natural killer T cell patrolling of
liver sinusoids. J. Immunol. 2008. 180: 2024–2028.
835 Salio, M., Silk, J. D., Jones, E. Y. and Cerundolo, V., Biology of CD1- and
MR1-restricted T cells. Annu. Rev. Immunol. 2014. 32: 323–366.
836 Wang, H. and Hogquist, K. A., How lipid-specific T cells become effec-
tors: the differentiation of iNKT subsets. Front. Immunol. 2018. 9: 1450.
837 Jungblut, M., Oeltze, K., Zehnter, I., Hasselmann, D. and Bosio, A.,
Standardized preparation of single-cell suspensions from mouse lung
tissue using the gentleMACS dissociator. J. Vis. Exp. 2009.
838 Liu, Y., Goff, R. D., Zhou, D., Mattner, J., Sullivan, B. A., Khurana, A.,
Cantu, C. et al., A modified alpha-galactosyl ceramide for staining and
stimulating natural killer T cells. J. Immunol. Methods 2006. 312: 34–39.
839 Lee, Y. J., Wang, H., Starrett, G. J., Phuong, V., Jameson, S. C. and
Hogquist, K. A., Tissue-specific distribution of iNKT cells impacts their
cytokine response. Immunity 2015. 43: 566–578.
840 Zie˛tara, N., Łyszkiewicz, M., Witzlau, K., Naumann, R., Hurwitz, R.,
Langemeier, J., Bohne, J. et al., Critical role for miR-181a/b-1 in agonist
selection of invariant natural killer T cells. Proc. Natl. Acad. Sci. U S A.
2013. 110: 7407–7412.
841 Winter, S. J., Kunze-Schumacher, H., Imelmann, E., Grewers, Z.,
Osthues, T. and Krueger, A., MicroRNA miR-181a/b-1 controls
MAIT cell development. Immunol. Cell. Biol. 2019. 97: 190–202.
842 Treiner, E., Duban, L., Bahram, S., Radosavljevic, M., Wanner, V.,
Tilloy, F., Affaticati, P. et al., Selection of evolutionarily conserved
mucosal-associated invariant T cells by MR1. Nature 2003. 422: 164–
169.
843 Porcelli, S., Yockey, C. E., Brenner, M. B. and Balk, S. P., Analysis of
T cell antigen receptor (TCR) expression by human peripheral blood
CD4-8- alpha/beta T cells demonstrates preferential use of several V
beta genes and an invariant TCR alpha chain. J. Exp. Med. 1993. 178:
1–16.
844 Tilloy, F., Treiner, E., Park, S. H., Garcia, C., Lemonnier, F., La Salle, H.
de, Bendelac, A., Bonneville, M. et al., An invariant T cell receptor alpha
chain defines a novel TAP-independentmajor histocompatibility com-
plex class Ib-restricted alpha/beta T cell subpopulation in mammals.
J. Exp. Med. 1999. 189: 1907–1921.
845 Rahimpour, A., Koay, H. F., Enders, A., Clanchy, R., Eckle, S. B. G.,Mee-
han, B.,Chen, Z. et al., Identification of phenotypically and functionally
heterogeneous mouse mucosal-associated invariant T cells using MR1
tetramers. J. Exp. Med. 2015. 212: 1095–1108.
846 Reantragoon, R., Corbett, A. J., Sakala, I. G., Gherardin, N. A., Furness,
J. B.,Chen, Z., Eckle, S. B. G. et al., Antigen-loadedMR1 tetramers define
T cell receptor heterogeneity in mucosal-associated invariant T cells.
J. Exp. Med. 2013. 210: 2305–2320.
847 Koay, H. F., Gherardin, N. A., Enders, A., Loh, L., Mackay, L. K.,
Almeida, C. F., Russ, B. E. et al., A three-stage intrathymic develop-
ment pathway for themucosal-associated invariant T cell lineage.Nat.
Immunol. 2016. 17: 1300–1311.
848 Cui, Y., Franciszkiewicz, K., Mburu, Y. K., Mondot, S., Le Bourhis, L.,
Premel, V., Martin, E. et al., Mucosal-associated invariant T cell-rich
congenicmouse strain allows functional evaluation. J. Clin. Invest. 2015.
125: 4171–4185.
849 Salou, M., Franciszkiewicz, K. and Lantz, O., MAIT cells in infectious
diseases. Curr. Opin. Immunol. 2017. 48: 7–14.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1931
850 Corbett, A. J., Eckle, S. B., Birkinshaw, R. W., Liu, L., Patel, O.,Mahony,
J., Chen, Z. et al., T-cell activation by transitory neo-antigens derived
from distinct microbial pathways. Nature 2014. 509: 361–365.
851 Olivares-Villagomez, D. and Van Kaer, L., Intestinal Intraepithelial
Lymphocytes: Sentinels of the Mucosal Barrier. Trends Immunol. 2018.
39: 264–275.
852 Ma, H., Tao, W. and Zhu, S., T lymphocytes in the intestinal mucosa:
defense and tolerance. Cell Mol. Immunol. 2019.
853 Cheroutre, H., Lambolez, F. and Mucida, D., The light and dark sides
of intestinal intraepithelial lymphocytes. Nat. Rev. Immunol. 2011. 11:
445–456.
854 Georgiev, H., Ravens, I., Papadogianni, G.,Malissen, B., Forster, R. and
Bernhardt, G., Blocking the ART2.2/P2X7-system is essential to avoid a
detrimental bias in functional CD4 T cell studies. Eur. J. Immunol. 2018.
48: 1078–1081.
855 Konjar, S., Ferreira, C., Blankenhaus, B. and Veldhoen, M., Intestinal
Barrier Interactions with Specialized CD8 T Cells. Front. Immunol. 2017.
8: 1281.
856 Chennupati, V.,Worbs, T., Liu, X.,Malinarich, F. H., Schmitz, S., Haas,
J. D., Malissen, B. et al., Intra- and intercompartmental movement
of gammadelta T cells: intestinal intraepithelial and peripheral gam-
madelta T cells represent exclusive nonoverlapping populations with
distinct migration characteristics. J. Immunol. 2010. 185: 5160–5168.
857 Malinarich, F. H., Grabski, E., Worbs, T., Chennupati, V., Haas, J. D.,
Schmitz, S., Candia, E. et al., Constant TCR triggering suggests that
the TCR expressed on intestinal intraepithelial gammadelta T cells is
functional in vivo. Eur. J. Immunol. 2010. 40: 3378–3388.
858 Martina, M. N.,Noel, S., Saxena, A., Rabb, H. and Hamad, A. R., Double
negative (DN) alphabeta T cells: misperception and overdue recogni-
tion. Immunol. Cell Biol. 2015. 93: 305–310.
859 Gerlach, C., van Heijst, J. W., Swart, E., Sie, D., Armstrong, N.,
Kerkhoven, R. M., Zehn, D. et al., One naive T cell, multiple fates in
CD8+ T cell differentiation. J. Exp. Med. 2010. 207: 1235–1246.
860 Appay, V., van Lier, R. A., Sallusto, F. and Roederer, M., Phenotype
and function of human T lymphocyte subsets: consensus and issues.
Cytometry A 2008. 73: 975–983.
861 Costantini, A., Mancini, S., Giuliodoro, S., Butini, L., Regnery, C. M.,
Silvestri, G. and Montroni, M., Effects of cryopreservation on lympho-
cyte immunophenotype and function. J. Immunol. Methods 2003. 278:
145–155.
862 van den Broek, T., Borghans, J. A. M. and van Wijk, F., The full spec-
trum of human naive T cells. Nat. Rev. Immunol. 2018. 18: 363–373.
863 Sallusto, F., Lenig, D., Mackay, C. R. and Lanzavecchia, A., Flexible
programs of chemokine receptor expression on human polarized T
helper 1 and 2 lymphocytes. J. Exp. Med. 1998. 187: 875–883.
864 Cosmi, L.,Annunziato, F., Galli, M. I. G.,Maggi, R. M. E.,Nagata, K. and
Romagnani, S., CRTH2 is the most reliable marker for the detection of
circulating human type 2 Th and type 2 T cytotoxic cells in health and
disease. Eur. J. Immunol. 2000. 30: 2972–2979.
865 Mahnke, Y. D., Beddall, M. H. and Roederer, M., OMIP-017: human
CD4(+) helper T-cell subsets including follicular helper cells. Cytometry
A 2013. 83: 439–440.
866 Ouyang, W., Ranganath, S. H.,Weindel, K., Bhattacharya, D.,Murphy,
T. L., Sha, W. C. and Murphy, K. M., Inhibition of Th1 development
mediated by GATA-3 through an IL-4-independent mechanism. Immu-
nity 1998. 9: 745–755.
867 Kanhere, A.,Hertweck, A., Bhatia, U.,Gokmen, M. R., Perucha, E., Jack-
son, I., Lord, G. M. et al., T-bet and GATA3 orchestrate Th1 and Th2
differentiation through lineage-specific targeting of distal regulatory
elements. Nat. Commun. 2012. 3: 1268.
868 Staudt, V., Bothur, E., Klein, M., Lingnau, K., Reuter, S., Grebe, N.,
Gerlitzki, B. et al., Interferon-regulatory factor 4 is essential for the
developmental program of T helper 9 cells. Immunity 2010. 33: 192–202.
869 Maggi, L., Santarlasci, V., Capone, M., Peired, A., Frosali, F., Crome, S.
Q., Querci, V. et al., CD161 is a marker of all human IL-17-producing
T-cell subsets and is induced by RORC. Eur. J. Immunol. 2010. 40: 2174–
2181.
870 Zielinski, C. E., Mele, F., Aschenbrenner, D., Jarrossay, D., Ronchi, F.,
Gattorno, M.,Monticelli, S. et al., Pathogen-induced human TH17 cells
produce IFN-gammaor IL-10 and are regulated by IL-1beta.Nature 2012.
484: 514–518.
871 Cosmi, L., Maggi, L., Santarlasci, V., Liotta, F. and Annunziato, F., T
helper cells plasticity in inflammation. Cytometry A 2014. 85: 36–42.
872 Acosta-Rodriguez, E. V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno,
M., Lanzavecchia, A., Sallusto, F. et al., Surface phenotype and anti-
genic specificity of human interleukin 17-producing T helper memory
cells. Nat. Immunol. 2007. 8: 639–646.
873 Gagliani, N., Amezcua Vesely, M. C., Iseppon, A., Brockmann, L., Xu,
H., Palm, N. W., de Zoete, M. R., Licona-Limon, P. et al., Th17 cells
transdifferentiate into regulatory T cells during resolution of inflam-
mation. Nature 2015. 523: 221–225.
874 Jankovic, D.,Kugler, D. G. and Sher, A., IL-10 production by CD4+ effec-
tor T cells: a mechanism for self-regulation. Mucosal Immunol. 2010. 3:
239–246.
875 Zhang, P., Lee, J. S., Gartlan, K. H., Schuster, I. S., Comerford, I., Vare-
lias, A., Ullah, M. A. et al., Eomesodermin promotes the development
of type 1 regulatory T (TR1) cells. Sci. Immunol. 2017. 2: eaah7152.
876 Gruarin, P.,Maglie, S.,De Simone, M.,Haringer, B., Vasco, C., Ranzani,
V., Bosotti, R., Noddings, J. S. et al., Eomesodermin controls a unique
differentiation program in human IL-10 and IFN-gamma coproducing
regulatory T cells. Eur. J. Immunol. 2019. 49: 96–111.
877 Basu, R., O’Quinn, D. B., Silberger, D. J., Schoeb, T. R., Fouser, L.,
Ouyang, W., Hatton, R. D. et al., Th22 cells are an important source of
IL-22 for host protection against enteropathogenic bacteria. Immunity
2012. 37: 1061–1075.
878 Duhen, T., Geiger, R., Jarrossay, D., Lanzavecchia, A. and Sallusto,
F., Production of interleukin 22 but not interleukin 17 by a subset of
human skin-homing memory T cells. Nat. Immunol. 2009. 10: 857–863.
879 Morita, R., Schmitt, N., Bentebibel, S. E., Ranganathan, R., Bourdery,
L., Zurawski, G., Foucat, E. et al., Human blood CXCR5(+)CD4(+) T cells
are counterparts of T follicular cells and contain specific subsets that
differentially support antibody secretion. Immunity 2011. 34: 108–121.
880 Glatman Zaretsky, A., Taylor, J. J., King, I. L., Marshall, F. A., Mohrs,
M. and Pearce, E. J., T follicular helper cells differentiate from Th2 cells
in response to helminth antigens. J. Exp. Med. 2009. 206: 991–999.
881 Oja, A. E., Vieira Braga, F. A., Remmerswaal, E. B., Kragten, N. A.,
Hertoghs, K. M., Zuo, J., Moss, P. A., van Lier, R. A., van Gisbergen,
K. P. et al., The transcription factor Hobit identifies human cytotoxic
CD4(+) T cells. Front. Immunol. 2017. 8: 325.
882 Hamann, D., Baars, P. A., Rep, M. H., Hooibrink, B., Kerkhof-Garde, S.
R., Klein, M. R. and van Lier, R. A., Phenotypic and functional sepa-
ration of memory and effector human CD8+ T cells. J. Exp. Med. 1997.
186: 1407–1418.
883 Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M.,
Papagno, L., Ogg, G. S. et al., Memory CD8+ T cells vary in differentia-
tion phenotype in different persistent virus infections. Nat. Med. 2002.
8: 379–385.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1932 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
884 Sallusto, F., Lenig, D., Forster, R., Lipp, M. and Lanzavecchia, A., Two
subsets ofmemory T lymphocyteswith distinct homing potentials and
effector functions. Nature 1999. 401: 708–712.
885 van Aalderen, M. C., Remmerswaal, E. B., Verstegen, N. J., Hombrink,
P., ten Brinke, A., Pircher, H., Kootstra, N. A., ten Berge, I. J. et al.,
Infection history determines the differentiation state of human CD8+
T cells. J. Virol. 2015. 89: 5110–5123.
886 van Leeuwen, E. M., Remmerswaal, E. B., Vossen, M. T., Rowshani,
A. T., Wertheim-van Dillen, P. M., van Lier, R. A. and ten Berge, I.
J., Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific
T cell subset after recovery of primary cytomegalovirus infection. J.
Immunol. 2004. 173: 1834–1841.
887 Huster, K. M., Busch, V., Schiemann, M., Linkemann, K., Kerksiek, K.
M., Wagner, H. and Busch, D. H., Selective expression of IL-7 recep-
tor on memory T cells identifies early CD40L-dependent generation of
distinct CD8+ memory T cell subsets. Proc. Natl. Acad. Sci. U. S. A. 2004.
101: 5610–5615.
888 Hand, T. W., Morre, M. and Kaech, S. M., Expression of IL-7 receptor
alpha is necessary but not sufficient for the formation of memory CD8
T cells during viral infection. Proc. Natl. Acad. Sci. USA 2007. 104: 11730–
11735.
889 Shay, T., Jojic, V., Zuk, O., Rothamel, K., Puyraimond-Zemmour, D.,
Feng, T., Wakamatsu, E. et al., Conservation and divergence in the
transcriptional programs of the human and mouse immune systems.
Proc. Natl. Acad. Sci. USA 2013. 110: 2946–2951.
890 Remmerswaal, E. B. M., Hombrink, P., Nota, B., Pircher, H., Ten Berge,
I. J. M., van Lier, R. A. W. and van Aalderen, M. C., Expression of
IL-7Ralpha and KLRG1 defines functionally distinct CD8(+) T-cell pop-
ulations in humans. Eur. J. Immunol. 2019. 49: 694–708.
891 Intlekofer, A. M., Takemoto, N., Wherry, E. J., Longworth, S. A.,
Northrup, J. T., Palanivel, V. R.,Mullen, A. C. et al., Effector and mem-
ory CD8+T cell fate coupled by T-bet and eomesodermin.Nat. Immunol.
2005. 6: 1236–1244.
892 Kragten, N. A. M., Behr, F. M., Vieira Braga, F. A., Remmerswaal, E. B.
M., Wesselink, T. H., Oja, A. E., Hombrink, P. et al., Blimp-1 induces
and Hobit maintains the cytotoxic mediator granzyme B in CD8 T cells.
Eur. J. Immunol. 2018. 48: 1644–1662.
893 Vieira Braga, F. A., Hertoghs, K. M., Kragten, N. A., Doody, G. M.,
Barnes, N. A., Remmerswaal, E. B., Hsiao, C. C. et al., Blimp-1 homolog
Hobit identifies effector-type lymphocytes in humans. Eur. J. Immunol.
2015. 45: 2945–2958.
894 Kim, H. J., Barnitz, R. A., Kreslavsky, T., Brown, F. D., Moffett, H.,
Lemieux, M. E., Kaygusuz, Y. et al., Stable inhibitory activity of regu-
latory T cells requires the transcription factor Helios. Science 2015. 350:
334–339.
895 Sathaliyawala, T., Kubota, M., Yudanin, N., Turner, D., Camp, P.,
Thome, J. J., Bickham, K. L. et al., Distribution and compartmentaliza-
tion of human circulating and tissue-resident memory T cell subsets.
Immunity 2013. 38: 187–197.
896 Thome, J. J. C., Yudanin, N., Ohmura, Y., Kubota, M., Grinshpun, B.,
Sathaliyawala, T., Kato, T. et al., Spatial map of human t cell compart-
mentalization and maintenance over decades of life. Cell 2014. 159:
814–828.
897 Okhrimenko, A., Gru¨n, J. R., Westendorf, K., Fang, Z., Reinke, S., von
Roth, P., Wassilew, G. et al., Human memory T cells from the bone
marrow are resting andmaintain long-lasting systemicmemory. 2014.
111: 9229–9234.
898 Watanabe, R., Gehad, A., Yang, C., Scott, L. L., Teague, J. E., Schlap-
bach, C., Elco, C. P. et al., Human skin is protected by four functionally
and phenotypically discrete populations of resident and recirculating
memory T cells. Sci. Transl. Med. 2015. 7: 279ra39.
899 Hombrink, P., Helbig, C., Backer, R. A., Piet, B., Oja, A. E., Stark, R.,
Brasser, G., Jongejan, A., Jonkers, R. E., Nota, B., Basak, O., Clevers, H.
C.,Moerland, P. D., Amsen, D., van Lier, R. A. Programs for the persis-
tence, vigilance and control of human CD8+ lung-resident memory T
cells. Nat. Immunol. 2016. 17: 1467–1478.
900 Kumar, B. V., Ma, W., Miron, M., Granot, T., Guyer, R. S., Carpen-
ter, D. J., Senda, T. et al., Human tissue-resident memory T cells are
defined by core transcriptional and functional signatures in lymphoid
and mucosal sites. Cell Rep. 2017. 20: 2921–2934.
901 Oja, A. E., Piet, B., Helbig, C., Stark, R., van der Zwan, D., Blaauwgeers,
H., Remmerswaal, E. B. M. et al., Trigger-happy residentmemory CD4+
T cells inhabit the human lungs. Mucosal Immunol. 2018. 11: 654–667.
902 Smolders, J., Heutinck, K. M., Fransen, N. L., Remmerswaal, E. B. M.,
Hombrink, P., Ten Berge, I. J. M., van Lier, R. A. W. et al., Tissue-
residentmemory T cells populate the human brain.Nat. Commun. 2018.
9: 4593.
903 Pascutti, M. F., Geerman, S., Collins, N., Brasser, G., Nota, B., Stark,
R., Behr, F. et al., Peripheral and systemic antigens elicit an expand-
able pool of resident memory CD8+ T cells in the bone marrow. Eur. J.
Immunol. 2019. 49: 853–872.
904 Snyder, M. E., Finlayson, M. O., Connors, T. J., Dogra, P., Senda, T.,
Bush, E., Carpenter, D. et al., Generation and persistence of human
tissue-resident memory T cells in lung transplantation. Sci. Immunol.
2019. 4: eaav5581.
905 Skon, C. N., Lee, J. Y., Anderson, K. G., Masopust, D., Hogquist, K.
A. and Jameson, S. C., Transcriptional downregulation of S1pr1 is
required for the establishment of resident memory CD8+ T cells. Nat.
Immunol. 2013. 14: 1285–1293.
906 Steinert, E. M. et al., Quantifying memory CD8 T cells reveals region-
alization of immunosurveillance. Cell 2015. 161: 737–749.
907 Kumar, B. V., Connors, T. J. and Farber, D. L., Human T Cell Develop-
ment, Localization, and Function throughout Life. Immunity 2018. 48:
202–213.
908 Cepek, K. L. et al., Adhesion between epithelial cells andT lymphocytes
mediated by E-cadherin and the alpha E beta 7 integrin. Nature 1994.
372: 190–193.
909 Cheuk, S., Schlums, H., Bryceson, Y. T., Eidsmo, L. and Tjern-
lund, A., CD49a Expression Defines Tissue-Resident CD8 + T Cells
Poised for Cytotoxic Function in Human Skin. Immunity 2017. 1–14.
https://doi.org/10.1016/j.immuni.2017.01.009
910 Webb, J. R., Milne, K., Watson, P., DeLeeuw, R. J. and Nelson, B. H.,
Tumor-infiltrating lymphocytes expressing the tissue resident mem-
ory marker cd103 are associated with increased survival in high-grade
serous ovarian cancer. Clin. Cancer Res. 2014. 20: 434–444.
911 Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de
Montpre´ville, V., Validire, P. et al., CD8 + CD103 + Tumor–Infiltrating
Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and
a Prognostic Factor for Survival in Lung Cancer Patients. J. Immunol.
2015. 194: 3475–3486.
912 Koh, J., Kim, S., Kim, M. Y., Go, H., Jeon, Y. K. and Chung, D. H., Prog-
nostic implications of intratumoral CD103+ tumor-infiltrating lym-
phocytes in pulmonary squamous cell carcinoma. Oncotarget 2017. 8:
13762–13769.
913 Ganesan, A.-P., Clarke, J., Wood, O., Garrido-Martin, E. M., Chee,
S. J., Mellows, T., Samaniego-Castruita, D., Singh, D. et al., Tissue-
resident memory features are linked to the magnitude of cytotoxic
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1933
T cell responses in human lung cancer. Nat. Immunol. 2017. 18: 940–
950.
914 Oja, A. E., Piet, B., van der Zwan, D., Blaauwgeers, H., Mensink, M.,
de Kivit, S., Borst, J. et al., Functional heterogeneity of CD4+ tumor-
infiltrating lymphocytes with a residentmemory phenotype in NSCLC.
Front. Immunol. 2018. 9: 2654.
915 Gu-Trantien, C. et al., CXCL13-producing T FH cells link immune sup-
pression and adaptive memory in human breast cancer. JCI Insight
2017. 2: 1–17.
916 Thommen, D. D., Koelzer, V. H., Herzig, P., Roller, A., Trefny, M.,
Dimeloe, S., Kiialainen, A. et al., A transcriptionally and functionally
distinct PD-1+ CD8+ T cell pool with predictive potential in non-small
cell lung cancer treated with PD-1 blockade. Nat. Med. 2018.24.
917 Simoni, Y. et al., Bystander CD8+ T cells are abundant and phenotyp-
ically distinct in human tumour infiltrates. Nature 2018. 557: 575–579.
918 Holt, P. G., Robinson, B. W., Reid, M., Kees, U. R.,Warton, A., Dawson,
V. H., Rose, A., Schon-Hegrad, M. et al., Extraction of immune and
inflammatory cells from human lung parenchyma: evaluation of an
enzymatic digestion procedure. Clin. Exp. Immunol. 1986. 66: 188–200.
919 Piet, B., de Bree, G. J., Smids-Dierdorp, B. S., van der Loos, C. M., Rem-
merswaal, E. B., von der Thu¨sen, J. H., van Haarst, J. M. et al., CD8+
T cells with an intraepithelial phenotype upregulate cytotoxic func-
tion upon influenza infection in human lung. J. Clin. Invest. 2011. 121:
2254–2263.
920 Clark, R. A., Chong, B.,Mirchandani, N., Brinster, N. K., Yamanaka, K.,
Dowgiert, R. K. and Kupper, T. S., The Vast Majority of CLA + T Cells
Are Resident in Normal Skin. J. Immunol. 2006. 176: 4431–4439.
921 Bektas, A., Schurman, S. H., Sen, R. and Ferrucci, L., Human T cell
immunosenescence and inflammation in aging. J. Leukoc. Biol. 2017.
102: 977–988.
922 Costantini, E., D’Angelo, C. and Reale, M., The role of immunosenes-
cence in neurodegenerative diseases. Mediators Inflamm. 2018. 2018:
6039171.
923 Franceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F.,
Panourgia, M. P. et al., Inflammaging and anti-inflammaging: a sys-
temic perspective on aging and longevity emerged from studies in
humans. Mech. Ageing Dev. 2007. 128: 92–105.
924 Derhovanessian, E., Maier, A. B., Hahnel, K., Zelba, H., de Craen, A. J.,
Roelofs, H., Slagboom, E. P. et al., Lower proportion of naive peripheral
CD8+ T cells and an unopposed pro-inflammatory response to human
Cytomegalovirus proteins in vitro are associated with longer survival
in very elderly people. Age (Dordr) 2013. 35: 1387–1399.
925 Naylor, K., Li, G., Vallejo, A. N., Lee, W. W., Koetz, K., Bryl, E.,
Witkowski, J. et al., The influence of age on T cell generation and
TCR diversity. J. Immunol. 2005. 174: 7446–7452.
926 Olsson, J.,Wikby, A., Johansson, B., Lofgren, S., Nilsson, B. O. and Fer-
guson, F. G., Age-related change in peripheral blood T-lymphocyte
subpopulations and cytomegalovirus infection in the very old: the
Swedish longitudinal OCTO immune study. Mech. Ageing Dev. 2000.
121: 187–201.
927 Rubino, G., Bulati, M., Aiello, A., Aprile, S., Gambino, C. M., Gervasi,
F., Caruso, C. et al., Sicilian centenarian offspring are more resistant
to immune ageing. Aging Clin. Exp. Res. 2019. 31: 125–133.
928 Sanderson, S. L. and Simon, A. K., In aged primary T cells, mitochon-
drial stress contributes to telomere attritionmeasured by anovel imag-
ing flow cytometry assay. Aging Cell 2017. 16: 1234–1243.
929 Arnold, C. R., Pritz, T., Brunner, S., Knabb, C., Salvenmoser, W.,
Holzwarth, B.,Thedieck, K. et al., T cell receptor-mediated activation is
a potent inducer of macroautophagy in human CD8(+)CD28(+) T cells
but not in CD8(+)CD28(-) T cells. Exp. Gerontol. 2014. 54: 75–83.
930 Pellicano, M., Buffa, S., Goldeck, D., Bulati, M., Martorana, A., Caruso,
C., Colonna-Romano, G. et al., Evidence for lessmarked potential signs
of T-cell immunosenescence in centenarian offspring than in the gen-
eral age-matched population. J. Gerontol. A Biol. Sci. Med. Sci. 2014. 69:
495–504.
931 Derhovanessian, E., Maier, A. B., Beck, R., Jahn, G., Hahnel, K., Slag-
boom, P. E., de Craen, A. J. et al., Hallmark features of immunosenes-
cence are absent in familial longevity. J. Immunol. 2010. 185: 4618–4624.
932 Raz, Y., Guerrero-Ros, I.,Maier, A., Slagboom, P. E., Atzmon, G., Barzi-
lai, N. and Macian, F., Activation-induced autophagy is preserved in
CD4+ T-cells in familial longevity. J. Gerontol. A Biol. Sci. Med. Sci. 2017.
72: 1201–1206.
933 Duggal, N. A., Pollock, R. D., Lazarus, N. R., Harridge, S. and Lord,
J. M., Major features of immunesenescence, including reduced thymic
output, are ameliorated by high levels of physical activity in adulthood.
Aging Cell 2018. 17.
934 Senda, T.,Dogra, P.,Granot, T., Furuhashi, K., Snyder, M. E.,Carpenter,
D. J., Szabo, P. A. et al., Microanatomical dissection of human intestinal
T-cell immunity reveals site-specific changes in gut-associated lym-
phoid tissues over life. Mucosal Immunol. 2019. 12(2): 378–389.
935 Thome, J. J., Bickham, K. L., Ohmura, Y., Kubota, M., Matsuoka, N.,
Gordon, C.,Granot, T. et al., Early-life compartmentalization of human
T cell differentiation and regulatory function inmucosal and lymphoid
tissues. Nat. Med. 2016. 22(1): 72–77.
936 Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S.,
Landay, A., Solomon, M. et al., Expression of interleukin (IL)-2 and
IL-7 receptors discriminates between human regulatory and activated
T cells. J. Exp. Med. 2006. 203(7): 1693–1700.
937 Kverneland, A. H., Streitz, M., Geissler, E., Hutchinson, J., Vogt, K.,
Boes, D., Niemann, N. et al., Age and gender leucocytes variances and
references values generated using the standardized ONE-Study proto-
col. Cytometry A 2016. 89(6): 543–564.
938 Abbas, A. K., Benoist, C., Bluestone, J. A., Campbell, D. J., Ghosh, S.,
Hori, S., Jiang, S. et al., Regulatory T cells: recommendations to simplify
the nomenclature. Nat. Immunol. 2013. 14(4): 307–308.
939 Himmel, M. E., MacDonald, K. G., Garcia, R. V., Steiner, T. S. and Lev-
ings, M. K., Helios+ andHelios- cells coexistwithin the natural FOXP3+
T regulatory cell subset in humans. J. Immunol. 2013. 190(5): 2001–2008.
940 Bin Dhuban, K., d’Hennezel, E., Nashi, E., Bar-Or, A., Rieder, S., She-
vach, E. M., Nagata, S. et al., Coexpression of TIGIT and FCRL3 identi-
fies Helios+ humanmemory regulatory T cells. J. Immunol. 2015. 194(8):
3687–3696.
941 Milpied, P., Renand, A., Bruneau, J.,Mendes-da-Cruz, D. A., Jacquelin,
S.,Asnafi, V., Rubio, M. T. et al., Neuropilin-1 is not amarker of human
Foxp3+ Treg. Eur. J. Immunol. 2009. 39(6): 1466–1471.
942 Duhen, T., Duhen, R., Lanzavecchia, A., Sallusto, F. and Campbell,
D. J., Functionally distinct subsets of human FOXP3+ Treg cells that
phenotypically mirror effector Th cells. Blood 2012. 119(19): 4430–4440.
943 MacDonald, K. G., Dawson, N. A., Huang, Q., Dunne, J. V., Levings,
M. K. and Broady, R., Regulatory T cells produce profibrotic cytokines
in the skin of patients with systemic sclerosis. J. Allergy Clin. Immunol.
2015. 135(4): e946–e949.
944 Pesenacker, A. M., Bending, D., Ursu, S., Wu, Q., Nistala, K. and Wed-
derburn, L. R., CD161 defines the subset of FoxP3+ T cells capable of
producing proinflammatory cytokines. Blood 2013. 121(14): 2647–2658.
945 Ferreira, R. C., Rainbow, D. B., Rubio Garcia, A., Pekalski, M. L., Porter,
L., Oliveira, J. J., Waldron-Lynch, F. et al., Human IL-6R(hi)TIGIT(-)
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1934 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
CD4(+)CD127(low)CD25(+) T cells display potent in vitro suppressive
capacity and a distinct Th17 profile. Clin. Immunol. 2017. 179: 25–39.
946 Hoeppli, R. E., MacDonald, K. N., Leclair, P., Fung, V. C. W., Mojibian,
M., Gillies, J., Rahavi, S. M. R. et al., Tailoring the homing capacity of
human Tregs for directed migration to sites of Th1-inflammation or
intestinal regions. Am. J. Transplant 2019. 19: 62–76.
947 Allan, S. E., Crome, S. Q., Crellin, N. K., Passerini, L., Steiner, T. S., Bac-
chetta, R., Roncarolo, M. G. et al., Activation-induced FOXP3 in human
T effector cells does not suppress proliferation or cytokine production.
Int. Immunol. 2007. 19(4): 345–354.
948 Pesenacker, A. M.,Wang, A. Y., Singh, A., Gillies, J., Kim, Y., Piccirillo,
C. A., Nguyen, D. et al., A regulatory T-cell gene signature is a specific
and sensitive biomarker to identify children with new-onset type 1
diabetes. Diabetes 2016. 65(4): 1031–1039.
949 Spreafico, R., Rossetti, M., van den Broek, T., Jansen, N. J., Zhang, H.,
Moshref, M., Prakken, B., van Loosdregt, J., van Wijk, F. and Albani,
S., A sensitive protocol for FOXP3 epigenetic analysis in scarce human
samples. Eur. J. Immunol. 2014. 44(10): 3141–3143.
950 Rainbow, D. B., Yang, X., Burren, O., Pekalski, M. L., Smyth, D. J., Klar-
qvist, M. D., Penkett, C. J. et al., Epigenetic analysis of regulatory T cells
usingmultiplex bisulfite sequencing. Eur. J. Immunol. 2015. 45(11): 3200–
3203.
951 Liu, W., Putnam, A. L., Xu-Yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Got-
tlieb, P. A. et al., CD127 expression inversely correlates with FoxP3
and suppressive function of human CD4+ T reg cells. J. Exp. Med. 2006.
203(7): 1701–1711.
952 Wang, J., Ioan-Facsinay, A., van der Voort, E. I., Huizinga, T. W. and
Toes, R. E., Transient expression of FOXP3 in human activated non-
regulatory CD4+ T cells. Eur. J. Immunol. 2007. 37(1): 129–138.
953 Wu, D., Han, J. M., Yu, X., Lam, A. J., Hoeppli, R. E., Pesenacker, A. M.,
Huang, Q. et al., Characterization of regulatory T cells in obese omental
adipose tissue in humans. Eur. J. Immunol. 2019. 49(2): 336–347.
954 Dijke, I. E., Hoeppli, R. E., Ellis, T., Pearcey, J., Huang, Q., McMurchy,
A. N., Boer, K. et al., Discarded human thymus is a novel source of
stable and long-lived therapeutic regulatory T cells. Am. J. Transplant
2016. 16(1): 58–71.
955 Mason, G. M., Lowe, K., Melchiotti, R., Ellis, R., de Rinaldis, E., Peak-
man, M., Heck, S., Lombardi, G. et al., Phenotypic complexity of the
human regulatory T cell compartment revealed by mass cytometry. J.
Immunol. 2015. 195(5): 2030–2037.
956 Dawson, N. A. J., Lam, A. J., Cook, L., Hoeppli, R. E., Broady, R., Pese-
nacker, A. M. and Levings, M. K., An optimized method to measure
human FOXP3(+) regulatory T cells from multiple tissue types using
mass cytometry. Eur. J. Immunol. 2018. 48(8): 1415–1419.
957 Chen, X. and Oppenheim, J. J., Resolving the identity myth: key mark-
ers of functional CD4+FoxP3+ regulatory T cells. Int. Immunopharmacol.
2011. 11(10): 1489–1496.
958 Ward-Hartstonge, K. A. and Kemp, R. A., Regulatory T-cell heterogene-
ity and the cancer immune response. Clin. Transl. Immunol. 2017. 6(9):
e154.
959 Groux, H.,O’Garra, A., Bigler, M., Rouleau, M.,Antonenko, S., de Vries,
J. E. and Roncarolo, M. G., A CD4+ T-cell subset inhibits antigen-
specific T-cell responses and prevents colitis. Nature 1997. 389(6652):
737–742.
960 Jeurink, P. V., Vissers, Y. M., Rappard, B. and Savelkoul, H. F., T cell
responses in fresh and cryopreserved peripheral blood mononuclear
cells: kinetics of cell viability, cellular subsets, proliferation, and
cytokine production. Cryobiology 2008. 57(2): 91–103.
961 White, A. M. and Wraith, D. C., Tr1-like T cells—an enigmatic regula-
tory T cell lineage. Front. Immunol. 2016. 7: 355.
962 Tran, D. Q., Andersson, J., Wang, R., Ramsey, H., Unutmaz, D. and
Shevach, E. M., GARP (LRRC32) is essential for the surface expression
of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells.
Proc. Natl. Acad. Sci. USA 2009. 106(32): 13445–13450.
963 Wang, R., Kozhaya, L., Mercer, F., Khaitan, A., Fujii, H. and Unutmaz,
D., Expression of GARP selectively identifies activated human FOXP3+
regulatory T cells. Proc. Natl. Acad. Sci. USA 2009. 106(32): 13439–13444.
964 Camisaschi, C., Casati, C., Rini, F., Perego, M., De Filippo, A.,
Triebel, F., Parmiani, G. et al., LAG-3 expression defines a subset of
CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at
tumor sites. J. Immunol. 2010. 184(11): 6545–6551.
965 Gagliani, N.,Magnani, C. F.,Huber, S.,Gianolini, M. E., Pala,M., Licona-
Limon, P., Guo, B. et al., Coexpression of CD49b and LAG-3 identifies
human and mouse T regulatory type 1 cells. Nat. Med. 2013. 19(6): 739–
746.
966 Raimondi, G., Shufesky, W. J., Tokita, D., Morelli, A. E. and Thomson,
A. W., Regulated compartmentalization of programmed cell death-
1 discriminates CD4+CD25+ resting regulatory T cells from activated
T cells. J. Immunol. 2006. 176(5): 2808–2816.
967 Lam, A., MacDonald, J. K. N., Pesenacker, A. M., Juvet, S. C., Mor-
ishita, K. A., Bressler, B., iGenoMed, C. et al., Innate control of tissue-
reparative human regulatory T cells. J. Immunol. 2019. 202: 2195–2209.
968 Borsellino, G.,Kleinewietfeld, M.,DiMitri, D., Sternjak, A.,Diamantini,
A., Giometto, R.,Hopner, S. et al., Expression of ectonucleotidase CD39
by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune sup-
pression. Blood 2007. 110(4): 1225–1232.
969 Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A.,
Chen, J. F. et al., Adenosine generation catalyzed by CD39 and CD73
expressed on regulatory T cells mediates immune suppression. J. Exp.
Med. 2007. 204(6): 1257–1265.
970 Rissiek, A., Baumann, I., Cuapio, A., Mautner, A., Kolster, M., Arck,
P. C., Dodge-Khatami, A. et al., The expression of CD39 on regulatory
T cells is genetically driven and further upregulated at sites of inflam-
mation. J. Autoimmun. 2015. 58: 12–20.
971 Baecher-Allan, C., Wolf, E. and Hafler, D. A., MHC class II expression
identifies functionally distinct human regulatory T cells. J. Immunol.
2006. 176(8): 4622–4631.
972 Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K. and
Ledbetter, J. A., CTLA-4 is a second receptor for the B cell activation
antigen B7. J. Exp. Med. 1991. 174(3): 561–569.
973 Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C.,
Schmidt, E. M., Baker, J. et al., Trans-endocytosis of CD80 and CD86: a
molecular basis for the cell-extrinsic function of CTLA-4. Science 2011.
332(6029): 600–603.
974 Norton, S. E., Ward-Hartstonge, K. A., McCall, J. L., Leman, J. K. H.,
Taylor, E. S., Munro, F., Black, M. A. et al., High-dimensional mass
cytometric analysis reveals an increase in effector regulatory T cells
as a distinguishing feature of colorectal tumors. J. Immunol. 2019. 202:
1871–1884.
975 Kleinewietfeld, M., Starke, M., Di Mitri, D., Borsellino, G., Battistini,
L., Rotzschke, O. and Falk, K., CD49d provides access to ”untouched"
human Foxp3+ Treg free of contaminating effector cells. Blood 2009.
113(4): 827–836.
976 Santegoets, S. J., Dijkgraaf, E. M., Battaglia, A., Beckhove, P., Britten,
C. M., Gallimore, A., Godkin, A. et al., Monitoring regulatory T cells
in clinical samples: consensus on an essential marker set and gat-
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1935
ing strategy for regulatory T cell analysis by flow cytometry. Cancer
Immunol. Immunother. 2015. 64(10): 1271–1286.
977 Dwyer, K. M., Hanidziar, D., Putheti, P., Hill, P. A., Pommey, S.,McRae,
J. L., Winterhalter, A. et al., Expression of CD39 by human peripheral
blood CD4+ CD25+ T cells denotes a regulatory memory phenotype.
Am. J. Transplant 2010. 10(11): 2410–2420.
978 Schuler, P. J., Schilling, B.,Harasymczuk,M.,Hoffmann, T. K., Johnson,
J., Lang, S. andWhiteside, T. L., Phenotypic and functional characteris-
tics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets
in cancer patients. Eur. J. Immunol. 2012. 42(7): 1876–1885.
979 Iellem, A., Colantonio, L. and D’Ambrosio, D., Skin-versus gut-skewed
homing receptor expression and intrinsic CCR4 expression on human
peripheral blood CD4+CD25+ suppressor T cells. Eur. J. Immunol. 2003.
33(6): 1488–1496.
980 Battaglia, A., Buzzonetti, A., Monego, G., Peri, L., Ferrandina, G., Fan-
fani, F., Scambia, G. et al., Neuropilin-1 expression identifies a subset
of regulatory T cells in human lymph nodes that is modulated by pre-
operative chemoradiation therapy in cervical cancer. Immunology 2008.
123(1): 129–138.
981 Griseri, T., Asquith, M., Thompson, C. and Powrie, F., OX40 is required
for regulatory T cell-mediated control of colitis. J. Exp.Med. 2010. 207(4):
699–709.
982 Seddiki, N., Cook, L., Hsu, D. C., Phetsouphanh, C., Brown, K., Xu,
Y., Kerr, S. J. et al., Human antigen-specific CD4(+) CD25(+) CD134(+)
CD39(+) T cells are enriched for regulatory T cells and comprise a
substantial proportion of recall responses. Eur. J. Immunol. 2014. 44(6):
1644–1661.
983 Ivison, S., Malek, M., Garcia, R. V., Broady, R., Halpin, A., Richaud, M.,
Brant, R. F. et al., A standardized immune phenotyping and automated
data analysis platform for multicenter biomarker studies. JCI Insight
2018. 3(23).
984 Fox, B. C., Bignone, P. A., Brown, P. J. and Banham, A. H., Defense of
the clone: antibody 259D effectively labels human FOXP3 in a variety
of applications. Blood 2008. 111(7): 3897–3899.
985 Pillai, V. and Karandikar, N. J., Attack on the clones? Human FOXP3
detection by PCH101, 236A/E7, 206D, and 259D reveals 259D as the
outlier with lower sensitivity. Blood 2008. 111(1): 463–464; author reply
464–466.
986 Law, J. P., Hirschkorn, D. F., Owen, R. E., Biswas, H. H., Nor-
ris, P. J. and Lanteri, M. C., The importance of Foxp3 antibody
and fixation/permeabilization buffer combinations in identifying
CD4+CD25+Foxp3+ regulatory T cells. Cytometry A 2009. 75(12): 1040–
1050.
987 Kaur, G., Goodall, J. C., Jarvis, L. B. and Hill Gaston, J. S., Charac-
terisation of Foxp3 splice variants in human CD4+ and CD8+ T cells–
identification of Foxp3Delta7 inhuman regulatory T cells.Mol. Immunol.
2010. 48(1-3): 321–332.
988 Mahnke, Y. D., Beddall, M. H. and Roederer, M., OMIP-015: human reg-
ulatory and activated T-cells without intracellular staining. Cytometry
A 2013. 83(2): 179–181.
989 Terstappen, L. W., Meiners, H. and Loken, M. R., A rapid sample
preparation technique for flow cytometric analysis of immunoflu-
orescence allowing absolute enumeration of cell subpopulations. J.
Immunol. Methods 1989. 123(1): 103–112.
990 Bonecchi, R., Bianchi, G., Bordignon, P. P., D’Ambrosio, D., Lang, R.,
Borsatti, A., Sozzani, S. et al., Differential expression of chemokine
receptors and chemotactic responsiveness of type 1 T helper cells
(Th1s) and Th2s. J. Exp. Med. 1998. 187(1): 129–134.
991 Gosselin, A., Monteiro, P., Chomont, N., Diaz-Griffero, F., Said, E. A.,
Fonseca, S., Wacleche, V. et al., Peripheral blood CCR4+CCR6+ and
CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection.
J. Immunol. 2010. 184(3): 1604–1616.
992 Halim, L., Romano, M., McGregor, R., Correa, I., Pavlidis, P., Grageda,
N., Hoong, S. J. et al., An atlas of human regulatory T helper-like cells
reveals features of Th2-like Tregs that support a tumorigenic environ-
ment. Cell Rep. 2017. 20(3): 757–770.
993 Bowcutt, R.,Malter, L. B., Chen, L. A.,Wolff, M. J., Robertson, I., Rifkin,
D. B., Poles, M. et al., Isolation and cytokine analysis of lamina propria
lymphocytes from mucosal biopsies of the human colon. J. Immunol.
Methods 2015. 421: 27–35.
994 Zheng, J., Liu, Y., Lau, Y. L. and Tu,W., γδ-T cells: An unpolished sword
in human anti-infection immunity. Cell. Mol. Immunol. 2013. 10: 50–57.
995 Silva-Santos, B., Serre, K. and Norell, H., γδ T cells in cancer. Nat. Rev.
Immunol. 2015. 15: 23–38.
996 Tanaka, Y., Sano, S., Nieves, E., De Libero, G., Rosa, D., Modlin, R. L.,
Brenner, M. B. et al., Nonpeptide ligands for γδ T cells. Proc. Natl. Acad.
Sci. USA 1994. 91: 8175–8179.
997 Godfrey, D. I., Uldrich, A. P., McCluskey, J., Rossjohn, J. and Moody,
D. B., The burgeoning family of unconventional T cells. Nat. Immunol.
2015. 16: 1114–1123.
998 Halary, F., Pitard, V., Dlubek, D., Krzysiek, R., de la Salle, H., Merville,
P., Dromer, C. et al., Shared reactivity of Vδ2neg γδ T cells against
cytomegalovirus-infected cells and tumor intestinal epithelial cells. J.
Exp. Med. 2005. 201: 1567–1578.
999 Morita, C. T., Chenggang, J., Sarikonda, G. and Wong, H., Nonpep-
tide antigens, presentation mechanisms, and immunological memory
of human Vγ2Vδ2 T cells: discriminating friend from foe through the
recognition of prenyl pyrophosphate antigens. Immunol. Rev. 2007. 215:
59–76.
1000 Davey, M. S., Willcox, C. R., Hunter, S., Kasatskaya, S. A., Remmer-
swaal, E. B. M., Salim, M., Mohammed, F. et al., The human Vδ2+
T-cell compartment comprises distinct innate-like Vγ9+ and adaptive
Vγ9- subsets. Nat. Commun. 2018. 9: 1–14.
1001 Riganti, C., Massaia, M., Davey, M. S. and Eberl, M., Human gam-
madelta T-cell responses in infection and immunotherapy: common
mechanisms, commonmediators? Eur. J. Immunol. 2012. 42: 1668–1676.
1002 Chien, Y. H.,Meyer, C. and Bonneville, M., γδT cells: first line of defense
and beyond. Annu. Rev. Immunol. 2014. 32: 121–155.
1003 Davodeau, F., Peyrat, M. A., Hallet, M. M., Houde, I., And, H. V. and
Bonneville, M., Peripheral selection of antigen receptor junctional fea-
tures in a major human γδ subset. Eur. J. Immunol. 1993. 23: 804–808.
1004 Parker, C. M., Groh, V., Band, H., Porcelli, S. A., Morita, C., Fabbi, M.,
Glass, D. et al., Evidence for extrathymic changes in the T cell receptor
gamma/delta repertoire. J. Exp. Med. 1990. 171: 1597–1612.
1005 Dimova, T., Brouwer, M., Gosselin, F., Tassignon, J., Leo, O., Donner,
C., Marchant, A. et al., Effector Vγ9Vδ2 T cells dominate the human
fetal γδ T-cell repertoire. Proc. Natl. Acad. Sci. USA 2015. 112: E556–E565.
1006 Willcox, C. R., Davey, M. S. andWillcox, B. E., Development and selec-
tion of the human Vγ9Vδ2+T-cell repertoire. Front. Immunol. 2018. 9:
1501.
1007 Hunter, S., Willcox, C. R., Davey, M. S., Kasatskaya, Sofya, A., Jeffery,
H. C., Chudakov, D. M. et al., Human liver infiltrating γδ T cells are
composed of clonally expanded circulating and tissue-resident popu-
lations. J. Hepatol. 2018. 69: 654–665.
1008 Davey, M. S., Willcox, C. R., Baker, A. T., Hunter, S. and Willcox, B. E.,
Recasting humanVδ1 lymphocytes in an adaptive role. Trends Immunol.
2018. 39: 446–459.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1936 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
1009 Davey, M. S., Willcox, C. R., Joyce, S. P., Ladell, K., Kasatskaya, S. A.,
McLaren, J. E.,Hunter, S. et al., Clonal selection in the humanVδ1 T cell
repertoire indicates γδ TCR-dependent adaptive immune surveillance.
Nat. Commun. 2017. 8: 1–15.
1010 Ravens, S., Schultze-Florey, C., Raha, S., Sandrock, I., Drenker, M.,
Oberdo¨rfer, L., Reinhardt, A. et al., Human γδ T cells are quickly
reconstituted after stem-cell transplantation and showadaptive clonal
expansion in response to viral infection. Nat. Immunol. 2017. 18: 393–
401.
1011 Correia, D., Fogli, M.,Hudspeth, K.,Gomes da Silva, M.,Mavilio, D. and
Silva-Santos, B., Differentiation of human peripheral blood Vδ1+ T cell
expressing the natural cytotoxicity receptor NKp30 for recognition of
lymphoid leukemia cells. Blood 2011. 118: 992–1001.
1012 Bouet-Toussaint, F., Cabillic, F., Toutirais, O., Le Gallo, M., Thomas de
la Pintiere, C., Genetet, N., Meunier, B. et al., Vγ9Vδ2 T cell-mediated
recognition of human solid tumors. Potential for immunotherapy of
hepatocellular and colorectal carcinomas. Cancer Immunol. Immunother.
2008. 57: 531–539.
1013 Mattarollo, S. R., Kenna, T., Nieda, M. and Nicol, A. J., Chemotherapy
and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxi-
city. Cancer Immunol. Immunother. 2007. 56: 1285–1297.
1014 Almeida, A. R. M.,Correia, D. V., Fernandes-Platzgummer, A., da Silva,
C. L., Gomes da Silva, M., Anjos, D. R. and Silva-Santos, B., Delta one
T cells for immunotherapy of chronic lymphocytic leukemia: clinical-
grade expansion/differentiation and preclinical proof-of-concept. Clin.
Cancer Res. 2016. 22: 5795–5804.
1015 Ryan, P. L., Sumaria, N., Holland, C. J., Bradford, C. M., Izotova, N.,
Grandjean, C. L., Jawad, A. S. et al., Heterogeneous yet stable Vδ2(+)
T-cell profiles define distinct cytotoxic effector potentials in healthy
human individuals. Proc. Natl. Acad. Sci. USA 2016. 113: 14378–14383.
1016 Kinjo, Y. and Ueno, K., iNKT cells in microbial immunity: recognition
of microbial glycolipids. Microbiol. Immunol. 2011. 55: 472–482.
1017 Shissler, S. C., Bollino, D. R., Tiper, I. V., Bates, J. P.,Derakhshandeh, R.
andWebb, T. J., Immunotherapeutic strategies targeting natural killer
T cell responses in cancer. Immunogenetics 2016. 68: 623–638.
1018 Godfrey, D. I., Le Nours, J.,Andrews, D. M.,Uldrich, A. P. and Rossjohn,
J., Unconventional T cell targets for cancer immunotherapy. Immunity
2018. 48: 453–473.
1019 Pellicci, D. G. and Uldrich, A. P., Unappreciated diversity within the
pool of CD1d-restricted T cells. Semin. Cell. Dev. Biol. 2018. 84: 42–47.
1020 Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J. and
Van Kaer, L., NKT cells: what’s in a name? Nat. Rev. Immunol. 2004. 4:
231–237.
1021 Thierry, A., Robin, A., Giraud, S., Minouflet, S., Barra, A., Bridoux,
F., Hauet, T. et al., Identification of invariant natural killer T cells in
porcine peripheral blood. Vet. Immunol. Immunopathol. 2012. 149: 272–
279.
1022 Monzon-Casanova, E., Paletta, D., Starick, L., Muller, I., Sant’Angelo,
D. B., Pyz, E. and Herrmann, T., Direct identification of rat iNKT cells
reveals remarkable similarities to human iNKT cells and a profound
deficiency in LEW rats. Eur. J. Immunol. 2013. 43: 404–415.
1023 Gansuvd, B., Hubbard, W. J., Hutchings, A., Thomas, F. T., Goodwin,
J., Wilson, S. B., Exley, M. A. et al., Phenotypic and functional char-
acterization of long-term cultured rhesus macaque spleen-derived
NKT cells. J. Immunol. 2003. 171: 2904–2911.
1024 Yasuda, N.,Masuda, K.,Tsukui, T.,Teng, A. and Ishii, Y., Identification
of canine natural CD3-positive T cells expressing an invariant T-cell
receptor alpha chain. Vet. Immunol. Immunopathol. 2009. 132: 224–231.
1025 Kawano, T.,Cui, J.,Koezuka, Y.,Toura, I.,Kaneko, Y.,Motoki, K.,Ueno,
H. et al., CD1d-restricted and TCR-mediated activation of valpha14
NKT cells by glycosylceramides. Science 1997. 278: 1626–1629.
1026 Lopez-Sagaseta, J., Kung, J. E., Savage, P. B., Gumperz, J. and
Adams, E. J., The molecular basis for recognition of CD1d/alpha-
galactosylceramide by a human non-Valpha24 T cell receptor. PLoS
Biol. 2012. 10: e1001412.
1027 Gadola, S. D., Dulphy, N., Salio, M. and Cerundolo, V.,
Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-
galactosylceramide by human CD4(+) and CD8alphabeta(+) T lympho-
cytes. J. Immunol. 2002. 168: 5514–5520.
1028 Le Nours, J., Praveena, T., Pellicci, D. G., Gherardin, N. A., Ross, F. J.,
Lim, R. T., Besra, G. S., Keshipeddy, S. et al., Atypical natural killer
T-cell receptor recognition of CD1d-lipid antigens. Nat. Commun. 2016.
7: 10570.
1029 Gadola, S. D., Koch, M., Marles-Wright, J., Lissin, N. M., Shepherd,
D.,Matulis, G., Harlos, K. et al., Structure and binding kinetics of three
different human CD1d-alpha-galactosylceramide-specific T cell recep-
tors. J. Exp. Med. 2006. 203: 699–710.
1030 Brigl, M., van den Elzen, P., Chen, X., Meyers, J. H., Wu, D., Wong, C.
H., Reddington, F. et al., Conserved and heterogeneous lipid antigen
specificities of CD1d-restricted NKT cell receptors. J. Immunol. 2006.
176: 3625–3634.
1031 Uldrich, A. P., Le Nours, J., Pellicci, D. G., Gherardin, N. A.,McPherson,
K. G., Lim, R. T., Patel, O., Beddoe, T. et al., CD1d-lipid antigen recog-
nition by the gammadelta TCR. Nat. Immunol. 2013. 14: 1137–1145.
1032 Kobayashi, E., Motoki, K., Uchida, T., Fukushima, H. and Koezuka,
Y., KRN7000, a novel immunomodulator, and its antitumor activities.
Oncol. Res. 1995. 7: 529–534.
1033 Morita, M., Motoki, K., Akimoto, K., Natori, T., Sakai, T., Sawa,
E., Yamaji, K. et al., Structure-activity relationship of alpha-
galactosylceramides against B16-bearing mice. J. Med. Chem. 1995. 38:
2176–2187.
1034 Nair, S. and Dhodapkar, M. V., Natural killer T cells in cancer
immunotherapy. Front. Immunol. 2017. 8: 1178.
1035 Rossjohn, J., Pellicci, D. G., Patel, O.,Gapin, L. and Godfrey, D. I., Recog-
nition of CD1d-restricted antigens by natural killer T cells. Nat. Rev.
Immunol. 2012. 12: 845–857.
1036 Miyamoto, K., Miyake, S. and Yamamura, T., A synthetic glycolipid
prevents autoimmune encephalomyelitis by inducing TH2 bias of nat-
ural killer T cells. Nature 2001. 413: 531–534.
1037 Yu, K. O., Im, J. S., Molano, A., Dutronc, Y., Illarionov, P. A.,
Forestier, C., Fujiwara, N. et al., Modulation of CD1d-restrictedNKT cell
responses by using N-acyl variants of alpha-galactosylceramides. Proc.
Natl. Acad. Sci. USA 2005. 102: 3383–3388.
1038 Schmieg, J., Yang, G., Franck, R. W. and Tsuji, M., Superior protection
against malaria and melanoma metastases by a C-glycoside analogue
of the natural killer T cell ligand alpha-Galactosylceramide. J. Exp. Med.
2003. 198: 1631–1641.
1039 Wun, K. S., Cameron, G., Patel, O., Pang, S. S., Pellicci, D. G., Sullivan,
L. C., Keshipeddy, S. et al., A molecular basis for the exquisite CD1d-
restricted antigen specificity and functional responses of natural killer
T cells. Immunity 2011. 34: 327–339.
1040 Wun, K. S., Ross, F., Patel, O., Besra, G. S., Porcelli, S. A., Richardson, S.
K., Keshipeddy, S. et al., Human and mouse type I natural killer T cell
antigen receptors exhibit different fine specificities for CD1d-antigen
complex. J. Biol. Chem. 2012. 287: 39139–39148.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1937
1041 Freigang, S., Landais, E., Zadorozhny, V., Kain, L., Yoshida, K., Liu, Y.,
Deng, S. et al., Scavenger receptors target glycolipids for natural killer
T cell activation. J. Clin. Invest. 2012. 122: 3943–3954.
1042 http://tetramer.yerkes.emory.edu/reagents/cd1
1043 Gumperz, J. E.,Miyake, S.,Yamamura, T. and Brenner, M. B., Function-
ally distinct subsets of CD1d-restricted natural killer T cells revealed
by CD1d tetramer staining. J. Exp. Med. 2002. 195: 625–636.
1044 Sidobre, S. and Kronenberg, M., CD1 tetramers: a powerful tool for the
analysis of glycolipid-reactive T cells. J. Immunol. Methods 2002. 268:
107–121.
1045 Boyson, J. E., Rybalov, B., Koopman, L. A., Exley, M., Balk, S. P., Racke,
F. K., Schatz, F. et al., CD1d and invariant NKT cells at the human
maternal-fetal interface. Proc. Natl. Acad. Sci. USA 2002. 99: 13741–13746.
1046 Thomas, S. Y.,Hou, R., Boyson, J. E.,Means, T. K.,Hess, C.,Olson, D. P.,
Strominger, J. L. et al., CD1d-restricted NKT cells express a chemokine
receptor profile indicative of Th1-type inflammatory homing cells. J.
Immunol. 2003. 171: 2571–2580.
1047 Aricescu, A. R., Lu, W. and Jones, E. Y., A time- and cost-efficient
system for high-level protein production in mammalian cells. Acta
Crystallogr. D Biol. Crystallogr. 2006. 62: 1243–1250.
1048 Ng, S. S., Souza-Fonseca-Guimaraes, F., Rivera, F. L., Amante, F. H.,
Kumar, R., Gao, Y., Sheel, M. et al., Rapid loss of group 1 innate
lymphoid cells during blood stage Plasmodium infection. Clin. Transl.
Immunol. 2018. 7: e1003.
1049 http://www.enzolifesciences.com/BML-SL232/krn7000/
1050 https://avantilipids.com/product/867000
1051 Boyum, A., Separation of leukocytes from blood and bone marrow.
Introduction. Scand. J. Clin. Lab. Invest. Suppl. 1968. 97: 7.
1052 Lee, P. T., Benlagha, K.,Teyton, L. and Bendelac, A., Distinct functional
lineages of human V(alpha)24 natural killer T cells. J. Exp. Med. 2002.
195: 637–641.
1053 Montoya, C. J., Pollard, D., Martinson, J., Kumari, K., Wasserfall, C.,
Mulder, C. B.,Rugeles, M. T. et al., Characterization of human invariant
natural killer T subsets in health and disease using a novel invariant
natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology
2007. 122: 1–14.
1054 Cameron, G., Pellicci, D. G., Uldrich, A. P., Besra, G. S., Illarionov, P.,
Williams, S. J., La Gruta, N. L. et al., Antigen Specificity of Type I NKT
Cells Is Governed by TCR beta-Chain Diversity. J Immunol 2015. 195:
4604–4614.
1055 https://www.miltenyibiotec.com/AU-en/products/macs-cell-
separation/cell-separation-reagents/microbeads-and-isolation-
kits/any-cell-type/anti-pe-microbeads.html
1056 Rossjohn, J., Gras, S., Miles, J. J., Turner, S. J., Godfrey, D. I. and
McCluskey, J., T cell antigen receptor recognition of antigen-presenting
molecules. Annu. Rev. Immunol. 2015. 33: 169–200.
1057 Kjer-Nielsen, L., Patel, O.,Corbett, A. J., Le Nours, J.,Meehan, B., Liu, L.,
Bhati, M., Chen, Z. et al., MR1 presentsmicrobial vitamin Bmetabolites
to MAIT cells. Nature 2012. 491: 717–723.
1058 Kjer-Nielsen, L., Corbett, A. J., Chen, Z., Liu, L., Mak, J. Y., Godfrey, D.
I., Rossjohn, J. et al., An overview on the identification of MAIT cell
antigens. Immunol. Cell. Biol. 2018. 96: 573–587.
1059 Koay, H. F., Godfrey, D. I. and Pellicci, D. G., Development of mucosal-
associated invariant T cells. Immunol. Cell. Biol. 2018.
1060 Gherardin, N. A., Souter, M. N., Koay, H. F., Mangas, K. M., Seemann,
T., Stinear, T. P., Eckle, S. B. et al., Human blood MAIT cell subsets
defined using MR1 tetramers. Immunol. Cell. Biol. 2018. 96: 507–525.
1061 Le Bourhis, L., Martin, E., Peguillet, I., Guihot, A., Froux, N., Core,
M., Levy, E., Dusseaux, M. et al., Antimicrobial activity of mucosal-
associated invariant T cells. Nat. Immunol. 2010. 11: 701–708.
1062 Tang, X. Z., Jo, J.,Tan, A. T., Sandalova, E.,Chia, A.,Tan, K. C., Lee, K. H.
et al., IL-7 licenses activation of human liver intrasinusoidal mucosal-
associated invariant T cells. J. Immunol. 2013. 190: 3142–3152.
1063 Dusseaux, M., Martin, E., Serriari, N., Peguillet, I., Premel, V., Louis,
D.,Milder, M. et al., HumanMAIT cells are xenobiotic-resistant, tissue-
targeted, CD161hi IL-17-secreting T cells. Blood 2011. 117: 1250–1259.
1064 Walker, L. J., Kang, Y. H., Smith, M. O., Tharmalingham, H., Rama-
murthy, N., Fleming, V. M., Sahgal, N. et al., Human MAIT and
CD8alphaalpha cells develop from a pool of type-17 precommitted
CD8+ T cells. Blood 2012. 119: 422–433.
1065 Le Bourhis, L., Dusseaux, M., Bohineust, A., Bessoles, S., Martin, E.,
Premel, V., Core, M., Sleurs, D. et al., MAIT cells detect and efficiently
lyse bacterially-infected epithelial cells. PLoS Pathog. 2013. 9: e1003681.
1066 Meermeier, E. W., Harriff, M. J., Karamooz, E. and Lewinsohn, D. M.,
MAIT cells and microbial immunity. Immunol. Cell. Biol. 2018.
1067 Wang, H., D’Souza, C., Lim, X. Y., Kostenko, L., Pediongco, T. J., Eckle,
S. B. G., Meehan, B. S. et al., MAIT cells protect against pulmonary
Legionella longbeachae infection. Nat. Commun. 2018. 9: 3350.
1068 D’Souza, C., Chen, Z. and Corbett, A. J., Revealing the protective and
pathogenic potential of MAIT cells. Mol. Immunol. 2018. 103: 46–54.
1069 Ussher, J. E.,Bilton,M.,Attwod, E., Shadwell, J.,Richardson, R.,de Lara,
C., Mettke, E., Kurioka, A. et al., CD161++ CD8+ T cells, including the
MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-
independent manner. Eur. J. Immunol. 2014. 44: 195–203.
1070 Ussher, J. E.,Willberg, C. B. and Klenerman, P., MAIT cells and viruses.
Immunol. Cell. Biol. 2018. 96: 630–641.
1071 vanWilgenburg, B., Scherwitzl, I.,Hutchinson, E. C., Leng, T., Kurioka,
A.,Kulicke, C.,de Lara, C.,Cole, S.,Vasanawathana, S. et al., MAIT cells
are activated during human viral infections. Nat. Commun. 2016. 7:
11653.
1072 Loh, L., Wang, Z., Sant, S., Koutsakos, M., Jegaskanda, S., Corbett, A.
J., Liu, L. et al., Humanmucosal-associated invariant T cells contribute
to antiviral influenza immunity via IL-18-dependent activation. Proc.
Natl. Acad. Sci. USA 2016. 113: 10133–10138.
1073 Rouxel, O. and Lehuen, A., Mucosal-associated invariant T cells in
autoimmune and immune-mediated diseases. Immunol. Cell. Biol. 2018.
96: 618–629.
1074 Gibbs, A., Leeansyah, E., Introini, A., Paquin-Proulx, D., Hasselrot, K.,
Andersson, E., Broliden, K. et al., MAIT cells reside in the female genital
mucosa and are biased towards IL-17 and IL-22 production in response
to bacterial stimulation. Mucosal Immunol. 2017. 10: 35–45.
1075 Dias, J., Boulouis, C.,Gorin, J. B., van den Biggelaar, R., Lal, K. G.,Gibbs,
A., Loh, L. et al., The CD4(-)CD8(-) MAIT cell subpopulation is a func-
tionally distinct subset developmentally related to the main CD8(+)
MAIT cell pool. Proc. Natl. Acad. Sci. USA 2018. 115: E11513–E11522.
1076 Brozova, J., Karlova, I. and Novak, J., Analysis of the phenotype and
function of the subpopulations ofmucosal-associated invariant T cells.
Scand. J. Immunol. 2016. 84: 245–251.
1077 Davanian, H., Gaiser, R. A., Silfverberg, M.,Hugerth, L. W., Sobkowiak,
M. J., Lu, L., Healy, K. et al., Mucosal-associated invariant T cells and
oral microbiome in persistent apical periodontitis. Int. J. Oral. Sci. 2019.
11: 16.
1078 Mori, L., Lepore, M. and De Libero, G., The immunology of CD1- and
MR1-restricted T cells. Annu. Rev. Immunol. 2016. 34: 479–510.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1938 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
1079 Gherardin, N. A., McCluskey, J., Rossjohn, J. and Godfrey, D. I., The
diverse family of MR1-restricted T cells. J. Immunol. 2018. 201: 2862–
2871.
1080 Martin, E., Treiner, E.,Duban, L., Guerri, L., Laude, H., Toly, C., Premel,
V. et al., Stepwise development of MAIT cells in mouse and human.
PLoS Biol. 2009. 7: e54.
1081 Sharma, P. K., Wong, E. B., Napier, R. J., Bishai, W. R., Ndung’u,
T., Kasprowicz, V. O., Lewinsohn, D. A. et al., High expression of
CD26 accurately identifies human bacteria-reactive MR1-restricted
MAIT cells. Immunology 2015. 145: 443–453.
1082 Gold, M. C., Eid, T., Smyk-Pearson, S., Eberling, Y., Swarbrick, G. M.,
Langley, S. M., Streeter, P. R. et al., Human thymic MR1-restricted
MAIT cells are innate pathogen-reactive effectors that adapt following
thymic egress. Mucosal Immunol. 2013. 6: 35–44.
1083 Leeansyah, E., Ganesh, A., Quigley, M. F., Sonnerborg, A., Andersson,
J., Hunt, P. W., Somsouk, M. et al., Activation, exhaustion, and persis-
tent decline of the antimicrobial MR1-restricted MAIT-cell population
in chronic HIV-1 infection. Blood 2013. 121: 1124–1135.
1084 Koppejan, H., Jansen, D., Hameetman, M., Thomas, R., Toes, R. E. M.
and van Gaalen, F. A., Altered composition and phenotype ofmucosal-
associated invariant T cells in early untreated rheumatoid arthritis.
Arthritis Res. Ther. 2019. 21: 3.
1085 Eckle, S. B., Birkinshaw, R. W., Kostenko, L., Corbett, A. J.,McWilliam,
H. E., Reantragoon, R., Chen, Z. et al., A molecular basis underpin-
ning the T cell receptor heterogeneity of mucosal-associated invariant
T cells. J. Exp. Med. 2014. 211: 1585–1600.
1086 Kurioka, A., Jahun, A. S., Hannaway, R. F., Walker, L. J., Fergusson,
J. R., Sverremark-Ekstrom, E., Corbett, A. J. et al., Shared and distinct
phenotypes and functions of human CD161++ Valpha7.2+ T cell sub-
sets. Front. Immunol. 2017. 8: 1031.
1087 Ben Youssef, G., Tourret, M., Salou, M., Ghazarian, L., Houdouin, V.,
Mondot, S., Mburu, Y. et al., Ontogeny of human mucosal-associated
invariant T cells and related T cell subsets. J. Exp. Med. 2018. 215: 459–
479.
1088 Koay, H. F., Gherardin, N. A., Xu, C., Seneviratna, R., Zhao, Z., Chen, Z.,
Fairlie, D. P. et al., Diverse MR1-restricted T cells in mice and humans.
Nat. Commun. 2019. 10: 2243.
1089 NTCF,NIHTetramerCore Facility: HumanMR1Tetramer Staining 2016.
https://tetramer.yerkes.emory.edu/sites/default/files/shared/human_
mr1_tetramer_staining.pdf
1090 NTCF, NIH Tetramer Core Facility: Tetramer Preparation - Addition
of streptavidin, emory.edu 2010. https://tetramer.yerkes.emory.edu/
support/protocols#10
1091 Gherardin, N. A.,Keller, A. N.,Woolley, R. E., Le Nours, J., Ritchie, D. S.,
Neeson, P. J., Birkinshaw, R. W. et al., Diversity of T cells restricted by
the MHC class I-related molecule MR1 facilitates differential antigen
recognition. Immunity 2016. 44: 32–45.
1092 Dias, J., Leeansyah, E. and Sandberg, J. K., Multiple layers of hetero-
geneity and subset diversity in human MAIT cell responses to distinct
microorganisms and to innate cytokines. Proc. Natl. Acad. Sci. USA 2017.
114: E5434–E5443.
1093 Lissina, A., Ladell, K., Skowera, A., Clement, M., Edwards, E.,
Seggewiss, R., van den Berg, H. A., Gostick, E. et al., Protein kinase
inhibitors substantially improve the physical detection of T-cells with
peptide-MHC tetramers. J. Immunol. Methods 2009. 340: 11–24.
1094 Wood, G. S. and Warnke, R., Suppression of endogenous avidin-
binding activity in tissues and its relevance to biotin-avidin detection
systems. J. Histochem. Cytochem. 1981. 29: 1196–1204.
1095 Harriff, M. J., McMurtrey, C., Froyd, C. A., Jin, H., Cansler, M., Null,
M., Worley, A. et al., MR1 displays the microbial metabolome driving
selective MR1-restricted T cell receptor usage. Sci. Immunol. 2018. 3.
1096 Lepore, M., Kalinichenko, A., Calogero, S., Kumar, P., Paleja, B.,
Schmaler, M., Narang, V. et al., Functionally diverse human T cells
recognize non-microbial antigens presented by MR1. Elife 2017. 6.
1097 Tung, J.W.,Mrazek, M. D.,Yang, Y.,Herzenberg, L. A. andHerzenberg,
L. A., Phenotypically distinct B cell development pathways map to the
three B cell lineages in the mouse. Proc. Natl. Acad. Sci. USA 2006. 103:
6293–6298.
1098 Manz, R. A., Hauser, A. E., Hiepe, F. and Radbruch, A., Maintenance of
serum antibody levels. Annu. Rev. Immunol. 2005. 23: 367–386.
1099 Wen, L., Brill-Dashoff, J., Shinton, S. A., Asano, M., Hardy, R. R. and
Hayakawa, K., Evidence of marginal-zone B cell-positive selection in
spleen. Immunity 2005. 23: 297–308.
1100 Fillatreau, S. and Manz, R. A., Tolls for B cells. Eur. J. Immunol. 2006. 36:
798–801.
1101 Tornberg, U. C. and Holmberg, D., B-1a, B-1b and B-2 B cells display
unique VHDJH repertoires formed at different stages of ontogeny and
under different selection pressures. EMBO J. 1995. 14: 1680–1689.
1102 Ochsenbein, A. F., Fehr, T., Lutz, C., Suter, M., Brombacher, F., Hen-
gartner, H. and Zinkernagel, R. M., Control of early viral and bacterial
distribution and disease by natural antibodies. Science 1999. 286: 2156–
2159.
1103 Stall, A.M.,Adams, S.,Herzenberg, L. A. andKantor, A. B., Characteris-
tics and development of themurine B-1b (Ly-1 B sister) cell population.
Ann. N. Y. Acad. Sci. 1992. 651: 33–43.
1104 Kristiansen, T. A., Jaensson Gyllenba¨ck, E., Zriwil, A., Bjo¨rklund, T.,
Daniel, J. A., Sitnicka, E., Soneji, S. et al., Cellular barcoding links B-1a
B cell potential to a fetal hematopoietic stem cell state at the single-cell
level. Immunity 2016. 45: 346–357.
1105 Pedersen, G. K., Li, X., Khoenkhoen, S., A´dori, M., Beutler, B. and Karls-
son Hedestam, G. B., B-1a cell development in splenectomized neona-
tal mice. Front. Immunol. 2018. 9: 1738.
1106 Melchers, F., ten Boekel, E., Seidl, T.,Kong, X. C.,Yamagami, T.,Onishi,
K., Shimizu, T. et al., Repertoire selection by pre-B-cell receptors and
B-cell receptors, and genetic control of B-cell development from imma-
ture to mature B cells. Immunol. Rev. 2000. 175: 33–46.
1107 Montecino-Rodriguez, E., Leathers, H. and Dorshkind, K., Identifica-
tion of a B-1 B cell-specified progenitor. Nat. Immunol. 2006. 7: 293–301.
1108 Rajewsky, K., Early and late B-cell development in the mouse. Curr.
Opin. Immunol. 1992. 4: 171–176.
1109 ten Boekel, E., Melchers, F. and Rolink, A., The status of Ig loci rear-
rangements in single cells from different stages of B cell development.
Int. Immunol. 1995. 7: 1013–1019.
1110 Grawunder, U., Leu, T. M., Schatz, D. G., Werner, A., Rolink, A. G.,
Melchers, F. and Winkler, T. H., Down-regulation of RAG1 and RAG2
gene expression in preB cells after functional immunoglobulin heavy
chain rearrangement. Immunity 1995. 3: 601–608.
1111 Rolink, A. and Melchers, F., Molecular and cellular origins of B lym-
phocyte diversity. Cell 1991. 66: 1081–1094.
1112 Lu, L., Smithson, G., Kincade, P. W. and Osmond, D. G., Two models
of murine B lymphopoiesis: a correlation. Eur. J. Immunol. 1998. 28:
1755–1761.
1113 Hardy, R. R., Carmack, C. E., Shinton, S. A., Kemp, J. D. and Hayakawa,
K., Resolution and characterization of pro-B and pre-pro-B cell stages
in normal mouse bone marrow. J. Exp. Med. 1991. 173: 1213–1225.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1939
1114 Melchers, F., Rolink, A., Grawunder, U., Winkler, T. H., Karasuyama,
H., Ghia, P. and Andersson, J., Positive and negative selection events
during B lymphopoiesis. Curr. Opin. Immunol. 1995. 7: 214–227.
1115 Ghia, P., ten Boekel, E., Sanz, E., de la Hera, A., Rolink, A. and Melch-
ers, F., Ordering of human bone marrow B lymphocyte precursors by
single-cell polymerase chain reaction analyses of the rearrangement
status of the immunoglobulin H and L chain gene loci. J. Exp. Med. 1996.
184: 2217–2229.
1116 Allman, D., Lindsley, R. C., DeMuth, W., Rudd, K., Shinton, S. A. and
Hardy, R. R., Resolution of three nonproliferative immature splenic B
cell subsets reveals multiple selection points during peripheral B cell
maturation. J. Immunol. 2001. 167: 6834–6840.
1117 Hao, Z. and Rajewsky, K., Homeostasis of peripheral B cells in the
absence of B cell influx from the bone marrow. J. Exp. Med. 2001. 194:
1151–1164.
1118 Wells, S. M., Kantor, A. B. and Stall, A. M., CD43 (S7) expression iden-
tifies peripheral B cell subsets. J. Immunol. 1994. 153: 5503–5515.
1119 Hart, G., Flaishon, L., Becker-Herman, S. and Shachar, I., Ly49D recep-
tor expressed on immature B cells regulates their IFN-gamma secre-
tion, actin polymerization, and homing. J. Immunol. 2003. 171: 4630–
4638.
1120 Kozmik, Z., Wang, S., Do¨rfler, P., Adams, B. and Busslinger, M., The
promoter of the CD19 gene is a target for the B-cell-specific transcrip-
tion factor BSAP. Mol. Cell. Biol. 1992. 12: 2662–2672.
1121 Li, Y. S.,Wasserman, R., Hayakawa, K. and Hardy, R. R., Identification
of the earliest B lineage stage in mouse bone marrow. Immunity 1996.
5: 527–535.
1122 Koni, P. A., Joshi, S. K., Temann, U.-A.,Olson, D., Burkly, L. and Flavell,
R. A., Conditional Vascular Cell Adhesion Molecule 1 Deletion in Mice:
Impaired LymphocyteMigration to BoneMarrow. J. Exp. Med. 2001. 193:
741–754.
1123 Kikuchi, K., Lai, A. Y.,Hsu, C.-L. and Kondo, M., IL-7 receptor signaling
is necessary for stage transition in adult B cell development through
up-regulation of EBF. J. Exp. Med. 2005. 201: 1197–1203.
1124 Rolink, A., ten Boekel, E.,Melchers, F., Fearon, D. T.,Krop, I. andAnder-
sson, J., A subpopulation of B220+ cells in murine bone marrow does
not express CD19 and contains natural killer cell progenitors. J. Exp.
Med. 1996. 183: 187–194.
1125 Osmond, D. G., Rolink, A. and Melchers, F., Murine B lymphopoiesis:
towards a unified model. Immunol. Today 1998. 19: 65–68.
1126 Melchers, F., Haasner, D., Grawunder, U., Kalberer, C., Karasuyama,
H., Winkler, T. and Rolink, A. G., Roles of IgH and L chains and of sur-
rogate H and L chains in the development of cells of the B lymphocyte
lineage. Annu. Rev. Immunol. 1994. 12: 209–225.
1127 Rolink, A., Streb, M.,Nishikawa, S. andMelchers, F., The c-kit-encoded
tyrosine kinase regulates the proliferation of early pre-B cells. Eur. J.
Immunol. 1991. 21: 2609–2612.
1128 Tonegawa, S., Somatic generation of antibody diversity. Nature 1983.
302: 575–581.
1129 ten Boekel, E.,Melchers, F. and Rolink, A. G., Precursor B cells showing
H chain allelic inclusion display allelic exclusion at the level of pre-B
cell receptor surface expression. Immunity 1998. 8: 199–207.
1130 Rumfelt, L. L., Zhou, Y., Rowley, B. M., Shinton, S. A. and Hardy, R. R.,
Lineage specification and plasticity in CD19- early B cell precursors. J.
Exp. Med. 2006. 203: 675–687.
1131 Osmond, D. G., B cell development in the bonemarrow. Semin. Immunol.
1990. 2: 173–180.
1132 Cancro, M. P., Peripheral B-cell maturation: the intersection of selec-
tion and homeostasis. Immunol. Rev. 2004. 197: 89–101.
1133 Oliver, A. M., Martin, F., Gartland, G. L., Carter, R. H. and Kearney, J.
F., Marginal zone B cells exhibit unique activation, proliferative and
immunoglobulin secretory responses. Eur. J. Immunol. 1997. 27: 2366–
2374.
1134 Krzyzak, L., Seitz, C., Urbat, A., Hutzler, S., Ostalecki, C., Gla¨sner, J.,
Hiergeist, A. et al., CD83 modulates B cell activation and germinal
center responses. J. Immunol. 2016. 196: 3581–3594.
1135 Dogan, I., Bertocci, B., Vilmont, V., Delbos, F., Me´gret, J., Storck, S.,
Reynaud, C.-A. et al., Multiple layers of B cell memory with different
effector functions. Nat. Immunol. 2009. 10: 1292–1299.
1136 Bell, J. and Gray, D., Antigen-capturing cells can masquerade as mem-
ory B cells. J. Exp. Med. 2003. 197: 1233–1244.
1137 Schittek, B. and Rajewsky, K., Maintenance of B-cell memory by long-
lived cells generated from proliferating precursors. Nature 1990. 346:
749–751.
1138 Anderson, S. M., Tomayko, M. M., Ahuja, A., Haberman, A. M. and
Shlomchik, M. J., New markers for murine memory B cells that define
mutated and unmutated subsets. J. Exp. Med. 2007. 204: 2103–2114.
1139 Good-Jacobson, K. L., Song, E., Anderson, S., Sharpe, A. H. and Shlom-
chik, M. J., CD80 expression on B cells regulates murine T follicular
helper development, germinal center B cell survival, and plasma cell
generation. J. Immunol. 2012. 188: 4217–4225.
1140 Zuccarino-Catania, G. V., Sadanand, S.,Weisel, F. J., Tomayko, M. M.,
Meng, H., Kleinstein, S. H., Good-Jacobson, K. L. et al., CD80 and PD-L2
define functionally distinct memory B cell subsets that are indepen-
dent of antibody isotype. Nat. Immunol. 2014. 15: 631–637.
1141 Tomayko, M. M., Steinel, N. C., Anderson, S. M. and Shlomchik, M. J.,
Cutting edge: Hierarchy of maturity of murine memory B cell subsets.
J. Immunol. 2010. 185: 7146–7150.
1142 Weisel, F. J., Zuccarino-Catania, G. V., Chikina, M. and Shlomchik, M.
J., A temporal switch in the germinal center determines differential
output of memory B and plasma cells. Immunity 2016. 44: 116–130.
1143 Weisel, F. and Shlomchik, M., Memory B cells of mice and humans.
Annu. Rev. Immunol. 2017. 35: 255–284.
1144 Loder, F., Mutschler, B., Ray, R. J., Paige, C. J., Sideras, P., Torres, R.,
Lamers, M. C. et al., B cell development in the spleen takes place
in discrete steps and is determined by the quality of B cell receptor-
derived signals. J. Exp. Med. 1999. 190: 75–89.
1145 Carsetti, R., Ko¨hler, G. and Lamers, M. C., Transitional B cells are the
target of negative selection in the B cell compartment. J. Exp. Med. 1995.
181: 2129–2140.
1146 Baumgarth, N., The double life of a B-1 cell: self-reactivity selects for
protective effector functions. Nat. Rev. Immunol. 2011. 11: 34–46.
1147 Haas, K. M., Poe, J. C., Steeber, D. A. and Tedder, T. F., B-1a and B-
1b cells exhibit distinct developmental requirements and have unique
functional roles in innate and adaptive immunity to S. pneumoniae.
Immunity 2005. 23: 7–18.
1148 Hardy, R. R.,Hayakawa, K., Parks, D. R.,Herzenberg, L. A. and Herzen-
berg, L. A., Murine B cell differentiation lineages. J. Exp. Med. 1984. 159:
1169–1188.
1149 Pedersen, G. K., A`dori, M., Khoenkhoen, S., Dosenovic, P., Beutler, B.
and Karlsson Hedestam, G. B., B-1a transitional cells are phenotypi-
cally distinct and are lacking inmice deficient in IκBNS. Proc. Natl. Acad.
Sci. USA 2014. 111: E4119–4126.
1150 Herzenberg, L. A., Stall, A. M., Braun, J., Weaver, D., Baltimore, D.,
Herzenberg, L. A. and Grosschedl, R., Depletion of the predominant B-
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1940 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
cell population in immunoglobulin mu heavy-chain transgenic mice.
Nature 1987. 329: 71–73.
1151 Shinall, S. M., Gonzalez-Fernandez, M.,Noelle, R. J. andWaldschmidt,
T. J., Identification of murine germinal center B cell subsets defined
by the expression of surface isotypes and differentiation antigens. J.
Immunol. 2000. 164: 5729–5738.
1152 Naito, Y., Takematsu, H., Koyama, S., Miyake, S., Yamamoto, H.,
Fujinawa, R., Sugai, M. et al., Germinal center marker GL7 probes
activation-dependent repression of N-glycolylneuraminic acid, a sialic
acid species involved in the negative modulation of B-cell activation.
Mol. Cell. Biol. 2007. 27: 3008–3022.
1153 Gro¨tsch, B., Brachs, S., Lang, C., Luther, J., Derer, A., Schlo¨tzer-
Schrehardt, U., Bozec, A. et al., The AP-1 transcription factor Fra1
inhibits follicular B cell differentiation into plasma cells. J. Exp. Med.
2014. 211: 2199–2212.
1154 Arnold, L. W., Pennell, C. A., McCray, S. K. and Clarke, S. H., Develop-
ment of B-1 cells: segregation of phosphatidyl choline-specific B cells
to the B-1 population occurs after immunoglobulin gene expression. J.
Exp. Med. 1994. 179: 1585–1595.
1155 Rauch, P. J., Chudnovskiy, A., Robbins, C. S., Weber, G. F., Etzrodt, M.,
Hilgendorf, I., Tiglao, E. et al., Innate response activator B cells protect
against microbial sepsis. Science 2012. 335: 597–601.
1156 Bouaziz, J.-D., Yanaba, K. and Tedder, T. F., Regulatory B cells as
inhibitors of immune responses and inflammation. Immunol. Rev. 2008.
224: 201–214.
1157 Shen, P. and Fillatreau, S., Antibody-independent functions of B cells:
a focus on cytokines. Nat. Rev. Immunol. 2015. 15: 441–451.
1158 Bermejo, D. A., Jackson, S. W., Gorosito-Serran, M., Acosta-Rodriguez,
E. V., Amezcua-Vesely, M. C., Sather, B. D., Singh, A. K. et al., Try-
panosoma cruzi trans-sialidase initiates a program independent of the
transcription factors RORγt and Ahr that leads to IL-17 production by
activated B cells. Nat. Immunol. 2013. 14: 514–522.
1159 Shen, P., Roch, T., Lampropoulou, V., O’Connor, R. A., Stervbo, U.,
Hilgenberg, E., Ries, S. et al., IL-35-producing B cells are critical regula-
tors of immunity during autoimmune and infectious diseases. Nature
2014. 507: 366–370.
1160 Fillatreau, S., Pathogenic functions of B cells in autoimmune diseases:
IFN-γ production joins the criminal gang. Eur. J. Immunol. 2015. 45: 966–
970.
1161 Mizoguchi, A. and Bhan, A. K., A case for regulatory B cells. J. Immunol.
2006. 176: 705–710.
1162 Rosser, E. C. and Mauri, C., Regulatory B cells: origin, phenotype, and
function. Immunity 2015. 42: 607–612.
1163 Maseda, D., Smith, S. H., DiLillo, D. J., Bryant, J. M., Candando, K.
M., Weaver, C. T. and Tedder, T. F., Regulatory B10 cells differentiate
into antibody-secreting cells after transient IL-10 production in vivo. J.
Immunol. 2012. 188: 1036–1048.
1164 Kulkarni, U., Karsten, C. M., Kohler, T.,Hammerschmidt, S., Bommert,
K.,Tiburzy, B.,Meng, L. et al., IL-10mediates plasmacytosis-associated
immunodeficiency by inhibiting complement-mediated neutrophil
migration. J. Allergy Clin. Immunol. 2016. 137: 1487–1497.e6.
1165 Matsumoto, M., Baba, A., Yokota, T., Nishikawa, H., Ohkawa, Y.,
Kayama, H., Kallies, A. et al., Interleukin-10-producing plasmablasts
exert regulatory function in autoimmune inflammation. Immunity
2014. 41: 1040–1051.
1166 Blanc, P.,Moro-Sibilot, L., Barthly, L., Jagot, F., This, S., de Bernard, S.,
Buffat, L. et al., Mature IgM-expressing plasma cells sense antigen and
develop competence for cytokine productionuponantigenic challenge.
Nat. Commun. 2016. 7: 13600.
1167 Lino, A. C., Dang, V. D., Lampropoulou, V., Welle, A., Joedicke, J.,
Pohar, J., Simon, Q. et al., LAG-3 inhibitory receptor expression iden-
tifies immunosuppressive natural regulatory plasma cells. Immunity
2018. 49: 120–133.e129.
1168 Evans, J. G., Chavez-Rueda, K. A., Eddaoudi, A., Meyer-Bahlburg, A.,
Rawlings, D. J., Ehrenstein, M. R. and Mauri, C., Novel suppressive
function of transitional 2 B cells in experimental arthritis. J. Immunol.
2007. 178: 7868–7878.
1169 Blair, P. A., Chavez-Rueda, K. A., Evans, J. G., Shlomchik, M. J.,
Eddaoudi, A., Isenberg, D. A., Ehrenstein, M. R. et al., Selective tar-
geting of B cells with agonistic anti-CD40 is an efficacious strategy for
the generation of induced regulatory T2-like B cells and for the sup-
pression of lupus in MRL/lpr mice. J. Immunol. 2009. 182: 3492–3502.
1170 Miles, K., Heaney, J., Sibinska, Z., Salter, D., Savill, J., Gray, D. and
Gray, M., A tolerogenic role for Toll-like receptor 9 is revealed by B-cell
interaction with DNA complexes expressed on apoptotic cells. Proc.
Natl. Acad. Sci. USA 2012. 109: 887–892.
1171 Bankoti, R., Gupta, K., Levchenko, A. and Sta¨ger, S., Marginal zone
B cells regulate antigen-specific T cell responses during infection. J.
Immunol. 2012. 188: 3961–3971.
1172 Tedder, T. F., B10 cells: a functionally defined regulatory B cell subset.
J. Immunol. 2015. 194: 1395–1401.
1173 Ding, Q., Yeung, M., Camirand, G., Zeng, Q., Akiba, H., Yagita, H.,
Chalasani, G. et al., Regulatory B cells are identified by expression of
TIM-1 and can be induced through TIM-1 ligation to promote tolerance
in mice. J. Clin. Invest. 2011. 121: 3645–3656.
1174 Xiao, S., Brooks, C. R., Sobel, R. A. andKuchroo, V. K., Tim-1 is essential
for induction and maintenance of IL-10 in regulatory B cells and their
regulation of tissue inflammation. J. Immunol. 2015. 194: 1602–1608.
1175 Fillatreau, S., Natural regulatory plasma cells. Curr. Opin. Immunol.
2018. 55: 62–66.
1176 Mills, D. M. and Cambier, J. C., B lymphocyte activation during cog-
nate interactions with CD4+ T lymphocytes: molecular dynamics and
immunologic consequences. Semin. Immunol. 2003. 15: 325–329.
1177 Okada, T.,Miller, M., Parker, I.,Krummel,M. F.,Neighbors, M.,Hartley,
S. B., O’Garra, A. et al., Antigen-engaged B cells undergo chemotaxis
toward the T zone and formmotile conjugates with helper T cells. PLoS
Biol. 2005. 3: e150.
1178 MacLennan, I., Germinal centers.Annu. Rev. Immunol. 1994. 12: 117–139.
1179 Victora, G. D. and Nussenzweig, M. C., Germinal centers. Annu. Rev.
Immunol. 2012. 30: 429–457.
1180 Nieuwenhuis, P. and Opstelten, D., Functional anatomy of germinal
centers. Am. J. Anat. 1984. 170: 421–435.
1181 Wagner, S. and Neuberger, Somatic hypermutation of immunoglobu-
lin genes. Annu. Rev. Immunol. 1996. 14: 441–457.
1182 Li, Z., Woo, C. J., Iglesias-Ussel, M. D., Ronai, D. and Scharff, M. D.,
The generation of antibody diversity through somatic hypermutation
and class switch recombination. Genes Dev. 2004. 18: 1–11.
1183 Wu, J., Qin, D., Burton, G., Szakal, A. and Tew, J., Follicular dendritic
cell-derived antigen and accessory activity in initiation of memory IgG
responses in vitro. J. Immunol. 1996. 157: 3404–3411.
1184 Yeh, C.-H. H., Nojima, T., Kuraoka, M. and Kelsoe, G., Germinal center
entry not selection of B cells is controlled by peptide-MHCII complex
density. Nat. Commun. 2018. 9: 928.
1185 Klaus, G., Humphrey, J., Kunkl, A. and Dongworth, D., The follicu-
lar dendritic cell: its role in antigen presentation in the generation of
immunological memory. Immunol. Rev. 1980. 53: 3–28.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1941
1186 Coico, R., Bhogal, B. and Thorbecke, G., Relationship of germinal cen-
ters in lymphoid tissue to immunologic memory. VI. Transfer of B cell
memory with lymph node cells fractionated according to their recep-
tors for peanut agglutinin. J. Immunol. 1983. 131: 2254–2257.
1187 Benner, R.,Hijmans,W. andHaaijman, J., The bonemarrow: themajor
source of serum immunoglobulins, but still a neglected site of antibody
formation. Clin. Exp. Immunol. 1981. 46: 1–8.
1188 Dilosa, R., Maeda, K., Masuda, A., Szakal, A. and Tew, J., Germinal
center B cells and antibody production in the bonemarrow. J. Immunol.
1991. 146: 4071–4077.
1189 Meyer-Hermann,M.,Deutsch, A. andOr-Guil, M., Recycling probability
and dynamical properties of germinal center reactions. J. Theor. Biol.
2001. 210: 265–285.
1190 Oprea, M. and Perelson, A., Somatic mutation leads to efficient affinity
maturation when centrocytes recycle back to centroblasts. J. Immunol.
1997. 158: 5155–5162.
1191 Oliver, A., Martin, F. and Kearney, J., Mouse CD38 is down-regulated
on germinal center B cells and mature plasma cells. J. Immunol. 1997.
158: 1108–1115.
1192 Laszlo, G.,Hathcock, K.,Dickler, H. andHodes, R., Characterization of a
novel cell-surface molecule expressed on subpopulations of activated
T and B cells. J. Immunol. 1993. 150: 5252–5262.
1193 Reichert, R., Gallatin, W.,Weissman, I. and Butcher, E., Germinal cen-
ter B cells lack homing receptors necessary for normal lymphocyte
recirculation. J Exp. Med. 1983. 157: 813–827.
1194 Butcher, E. et al., Surface phenotype of Peyer’s patch germinal center
cells: implications for the role of germinal centers in B cell differenti-
ation. J. Immunol. 1982. 129: 2698–2707.
1195 Davies, A., Forrester, J., Rose, M., Birbeck and Wallis, V., Peanut lectin
binding properties of germinal centers of mouse lymphoid tissue.
Nature 1980. 284: 364.
1196 Kraal, G.,Weissman, I. andButcher, E., Germinal centre B cells: antigen
specificity and changes in heavy chain class expression. Nature 1982.
298: 377–379.
1197 Smith, K., Nossal, G. and Tarlinton, D., FAS is highly expressed in the
germinal center but is not required for regulation of the B-cell response
to antigen. Proc. Natl. Acad. Sci. USA 1995. 92: 11628–11632.
1198 Bourgois, A., Kitajima, K., Hunter, I. and Askonas, Surface
immunoglobulins of lipopolysaccharide-stimulated spleen cells. The
behavior of IgM, IgD and IgG. Eur. J. Immunol. 1977. 7: 151–153.
1199 Monroe, J.,Havran, W. and Cambier, J., B lymphocyte activation: entry
into cell cycle is accompanied by decreased expression of IgD but not
IgM. Eur. J. Immunol. 1983. 13: 208–213.
1200 Hathcock, K. et al., Identification of an alternative CTLA-4 ligand cos-
timulatory for T cell activation. Science 1993. 262: 905–907.
1201 Freeman, G., Borriello, F., Hodes, R. J., Reiser, H., Hathcock, K. S.,
Laszlo, G., McKnight, A. J. et al., Uncovering of functional alternative
CTLA-4 counter-receptor in B7-deficient mice. Science (New York, N.Y.)
1993. 262: 907–909.
1202 Freeman, G., Borriello, F., Hodes, R. J., Reiser, H., Gribben, J. G., Ng, J.
W., Kim, J. et al., Murine B7-2, an alternative CTLA4 counter-receptor
that costimulates T cell proliferation and interleukin 2 production. J.
Exp. Med. 1993. 178: 2185–2192.
1203 Allen, C. D., Ansel, K. M., Low, C., Lesley, R., Tamamura, H., Fujii, N.
and Cyster, J. G., Germinal center dark and light zone organization is
mediated by CXCR4 and CXCR5. Nat. Immunol. 2004. 5: 943–952.
1204 Victora, G. D., Schwickert, T. A., Fooksman, D. R., Kamphorst, A. O.,
Meyer-Hermann, M., Dustin, M. L., Nussenzweig, M. C. et al., Ger-
minal center dynamics revealed by multiphoton microscopy with a
photoactivatable fluorescent reporter. Cell 2010. 143: 592–605.
1205 Anderson, K. C., Bates, M. P., Slaughenhoupt, B. L., Pinkus, G. S.,
Schlossman, S. F. and Nadler, L. M., Expression of human B cell-
associated antigens on leukemias and lymphomas: a model of human
B cell differentiation. Blood 1984. 63: 1424–1433.
1206 Stashenko, P., Nadler, L. M., Hardy, R. and Schlossman, S. F., Charac-
terization of a human B lymphocyte-specific antigen. J. Immunol. 1980.
125: 1678–1685.
1207 LeBien, T. W. and Tedder, T. F., B lymphocytes: how they develop and
function. Blood 2008. 112: 1570–1580.
1208 Sims, G. P., Ettinger, R., Shirota, Y., Yarboro, C. H., Illei, G. G. and
Lipsky, P. E., Identification and characterization of circulating human
transitional B cells. Blood 2005. 105: 4390–4398.
1209 Klein, U., Rajewsky, K. and Kuppers, R., Human immunoglobulin
(Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface
antigen carry somatically mutated variable region genes: CD27 as a
general marker for somatically mutated (memory) B cells. J. Exp. Med.
1998. 188: 1679–1689.
1210 Kuppers, R., Klein, U., Hansmann, M. L. and Rajewsky, K., Cellular
origin of human B-cell lymphomas. N. Engl. J. Med. 1999. 341: 1520–
1529.
1211 Agematsu, K., Hokibara, S., Nagumo, H. and Komiyama, A., CD27: a
memory B-cell marker. Immunol. Today 2000. 21: 204–206.
1212 Agematsu, K., Nagumo, H., Yang, F. C., Nakazawa, T., Fukushima,
K., Ito, S., Sugita, K. et al., B cell subpopulations separated by CD27
and crucial collaboration of CD27+ B cells and helper T cells in
immunoglobulin production. Eur. J. Immunol. 1997. 27: 2073–2079.
1213 Odendahl, M., Jacobi, A., Hansen, A., Feist, E., Hiepe, F., Burmester, G.
R., Lipsky, P. E. et al., Disturbed peripheral B lymphocyte homeostasis
in systemic lupus erythematosus. J. Immunol. 2000. 165: 5970–5979.
1214 Mei, H. E., Wirries, I., Frolich, D., Brisslert, M., Giesecke, C., Grun, J.
R. et al., A unique population of IgG-expressing plasma cells lacking
CD19 is enriched in human bone marrow. Blood 2015. 125: 1739–1748.
1215 Pascual, V., Liu, Y. J., Magalski, A., de Bouteiller, O., Banchereau, J.
and Capra, J. D., Analysis of somatic mutation in five B cell subsets of
human tonsil. J. Exp. Med. 1994. 180: 329–339.
1216 Kikutani, H., Suemura, M., Owaki, H., Nakamura, H., Sato, R.,
Yamasaki, K., Barsumian, E. L. et al., Fc epsilon receptor, a specific
differentiation marker transiently expressed on mature B cells before
isotype switching. J. Exp. Med. 1986. 164: 1455–1469.
1217 Clark, E. A. and Lane, P. J., Regulation of human B-cell activation and
adhesion. Annu. Rev. Immunol. 1991. 9: 97–127.
1218 Wu, Y. C., Kipling, D. and Dunn-Walters, D. K., The relationship
between CD27 negative and positive B cell populations in human
peripheral blood. Front. Immunol. 2011. 2: 81.
1219 Wei, C., Anolik, J., Cappione, A., Zheng, B., Pugh-Bernard, A., Brooks,
J., Lee, E. H. et al., A new population of cells lacking expression of CD27
represents a notable component of the B cell memory compartment in
systemic lupus erythematosus. J. Immunol. 2007. 178: 6624–6633.
1220 Jacobi, A. M., Reiter, K., Mackay, M., Aranow, C., Hiepe, F., Rad-
bruch, A., Hansen, A. et al., Activated memory B cell subsets correlate
with disease activity in systemic lupus erythematosus: delineation by
expression of CD27, IgD, and CD95.Arthritis Rheum. 2008. 58: 1762–1773.
1221 Wehr, C., Eibel, H., Masilamani, M., Illges, H., Schlesier, M., Peter, H.
H. andWarnatz, K., A new CD21low B cell population in the peripheral
blood of patients with SLE. Clin. Immunol. 2004. 113: 161–171.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1942 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
1222 Tedder, T. F., Zhou, L. J. and Engel, P., The CD19/CD21 signal trans-
duction complex of B lymphocytes. Immunol. Today 1994. 15: 437–442.
1223 Jacobi, A. M. and Dorner, T., B-cell-directed therapy in patients with
connective tissue diseases. Dtsch. Med. Wochenschr. 2012. 137: 1755–
1757.
1224 Polikowsky, H. G., Wogsland, C. E., Diggins, K. E., Huse, K. and Irish,
J. M., Cutting edge: redox signaling hypersensitivity distinguishes
human germinal center B Cells. J. Immunol. 2015. 195: 1364–1367.
1225 Carrion, C.,Guerin, E.,Gachard, N., le Guyader, A.,Giraut, S. and Feuil-
lard, J., Adult bone marrow three-dimensional phenotypic landscape
of B-cell differentiation. Cytometry B Clin. Cytom. 2019. 96: 30–38.
1226 Bernasconi, N. L., Traggiai, E. and Lanzavecchia, A., Maintenance of
serologicalmemory by polyclonal activation of humanmemory B cells.
Science 2002. 298: 2199–2202.
1227 Giesecke, C., Meyer, T., Durek, P., Maul, J., Preiss, J., Jacobs, J. F. M.
et al., simultaneous presence of non- and highly mutated keyhole
limpet hemocyanin (KLH)-specific plasmablasts early after primary
KLH immunization suggests cross-reactive memory B cell activation.
J. Immunol. 2018. 200(12): 3981–3992.
1228 Liao, H. Y.,Tao, L., Zhao, J.,Qin, J., Zeng, G. C.,Cai, S.W. et al., Clostrid-
ium butyricum in combination with specific immunotherapy converts
antigen-specific B cells to regulatory B cells in asthmatic patients. Sci.
Rep. 2016. 6: 20481.
1229 Ellebedy, A. H., Jackson, K. J., Kissick, H. T.,Nakaya, H. I.,Davis, C. W.,
Roskin, K. M. et al., Defining antigen-specific plasmablast andmemory
B cell subsets in human blood after viral infection or vaccination. Nat.
Immunol. 2016. 17(10): 1226–1234.
1230 Kerkman, P. F., Fabre, E., van der Voort, E. I., Zaldumbide, A., Rom-
bouts, Y., Rispens, T. et al., Identification and characterisation of cit-
rullinated antigen-specific B cells in peripheral blood of patients with
rheumatoid arthritis. Ann. Rheum. Dis. 2016. 75: 1170–1176.
1231 Murugan, R., Buchauer, L., Triller, G., Kreschel, C., Costa, G., Pide-
laserra Marti, G. et al., Clonal selection drives protective memory B
cell responses in controlled human malaria infection. Sci. Immunol.
2018. 3(20): eaap8029.
1232 Germar, K., Fehres, C. M., Scherer, H. U., van Uden, N., Pollastro,
S., Yeremenko, N. et al., Generation and characterization of anti-
citrullinated protein antibody-producing B-cell clones from rheuma-
toid arthritis patients. Arthritis Rheumatol. 2019. 71: 340–350.
1233 Kwakkenbos, M. J., Diehl, S. A., Yasuda, E., Bakker, A. Q., van Geelen,
C. M., Lukens, M. V. et al., Generation of stable monoclonal antibody-
producing B cell receptor-positive human memory B cells by genetic
programming. Nat. Med. 2010. 16(1): 123–128.
1234 Giesecke, C., Frolich, D., Reiter, K., Mei, H. E., Wirries, I., Kuhly, R.
et al., Tissue distribution and dependence of responsiveness of human
antigen-specific memory B cells. J. Immunol. 2014. 192(7): 3091–3100.
1235 Kerkman, P. F., Kempers, A. C., van der Voort, E. I., van Oosterhout,
M., Huizinga, T. W., Toes, R. E. et al., Synovial fluid mononuclear cells
provide an environment for long-term survival of antibody-secreting
cells and promote the spontaneous production of anti-citrullinated
protein antibodies. Ann. Rheum. Dis. 2016. 75(12): 2201–2207.
1236 Kerkman, P. F., Rombouts, Y., van der Voort, E. I., Trouw, L. A.,
Huizinga, T.W.,Toes, R. E. et al., Circulating plasmablasts/plasmacells
as a source of anticitrullinated protein antibodies in patients with
rheumatoid arthritis. Ann. Rheum. Dis. 2013. 72(7): 1259–1263.
1237 Hansen, A., Reiter, K., Dorner, T. and Pruss, A., Cryopreserved human
B cells as an alternative source for single cellmRNA analysis. Cell Tissue
Bank 2005. 6(4): 299–308.
1238 Townsend, S. E., Goodnow, C. C. and Cornall, R. J., Single epitope mul-
tiple staining to detect ultralow frequency B cells. J. Immunol. Methods
2001. 249(1-2): 137–146.
1239 Brooks, J. F., Liu, X., Davies, J. M., Wells, J. W. and Steptoe, R. J.,
Tetramer-based identification of naive antigen-specific B cells within
a polyclonal repertoire. Eur. J. Immunol. 2018. 48(7): 1251–1254.
1240 Cornec, D., Berti, A., Hummel, A., Peikert, T., Pers, J. O. and Specks, U.,
Identification and phenotyping of circulating autoreactive proteinase
3-specific B cells in patients with PR3-ANCA associated vasculitis and
healthy controls. J. Autoimmun. 2017. 84: 122–131.
1241 Frolich, D., Giesecke, C., Mei, H. E., Reiter, K., Daridon, C., Lipsky, P.
E. and Dorner, T., Secondary immunization generates clonally related
antigen-specific plasma cells andmemory B cells. J. Immunol. 2010. 185:
3103–3110.
1242 Lighaam, L. C., Vermeulen, E., Bleker, T., Meijlink, K. J., Aalberse, R.
C., Barnes, E. et al., Phenotypic differences between IgG4+ and IgG1+
B cells point to distinct regulation of the IgG4 response. J. Allergy Clin.
Immunol. 2014. 133(1): 267–270 e1-6.
1243 Koning, M. T., Kielbasa, S. M., Boersma, V., Buermans, H. P. J., van
der Zeeuw, S. A. J., van Bergen, C. A. M. et al., ARTISAN PCR: rapid
identification of full-length immunoglobulin rearrangements without
primer binding bias. Br. J. Haematol. 2017. 178(6): 983–986.
1244 Gatto, M., Wiedemann, A., Nomovi, N., Reiter, K., Schrezenmeier, E.,
Rose, T. et al., Circulating Pentraxin3-Specific B Cells Are Decreased in
Lupus Nephritis. Front. Immunol. 2019. 10: 29.
1245 Odendahl, M.,Mei, H.,Hoyer, B. F., Jacobi, A. M.,Hansen, A.,Muehling-
haus, G., Berek, C. et al., Generation of migratory antigen-specific
plasma blasts andmobilization of resident plasma cells in a secondary
immune response. Blood 2005. 105: 1614–1621.
1246 Mei, H. E., Hahne, S., Redlin, A., Hoyer, B. F., Wu, K., Baganz, L. et al.,
Plasmablasts With a Mucosal Phenotype Contribute to Plasmacytosis
in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017. 69: 2018–
2028.
1247 Willemze, A., Trouw, L. A., Toes, R. E. and Huizinga, T. W., The influ-
ence of ACPA status and characteristics on the course of RA. Nat. Rev.
Rheumatol. 2012. 8(3): 144–152.
1248 Katz, S. I., Parker, D. and Turk, J. L., B-cell suppression of delayed
hypersensitivity reactions. Nature 1974. 251: 550–551.
1249 Neta, R. and Salvin, S. B., Specific suppression of delayed hypersensi-
tivity: the possible presence of a suppressor B cell in the regulation of
delayed hypersensitivity. J. Immunol. 1974. 113: 1716–1725.
1250 Wolf, S. D.,Dittel, B. N.,Hardardottir, F. and Janeway, C. A., Jr., Experi-
mental autoimmune encephalomyelitis induction in genetically B cell-
deficient mice. J. Exp. Med. 1996. 184: 2271–2278.
1251 Mizoguchi, A., Mizoguchi, E., Takedatsu, H., Blumberg, R. S. and
Bhan, A. K., Chronic intestinal inflammatory condition generates IL-
10-producing regulatory B cell subset characterized by CD1d upregu-
lation. Immunity 2002. 16: 219–230.
1252 Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D. and Anderton,
S. M., B cells regulate autoimmunity by provision of IL-10.Nat. Immunol.
2002. 3: 944–950.
1253 van de Veen, W., Stanic, B., Wirz, O. F., Jansen, K., Globinska, A. and
Akdis, M., Role of regulatory B cells in immune tolerance to allergens
and beyond. J. Allergy Clin. Immunol. 2016. 138: 654–665.
1254 Wirz, O. F., Globinska, A., Ochsner, U., van de Veen, W., Eller, E.,
Christiansen, E. S., Halken, S. et al., Comparison of regulatory B cells
in asthma and allergic rhinitis. Allergy 2019. 74: 815–818.
1255 van de Veen, W., Stanic, B., Yaman, G., Wawrzyniak, M., Sollner, S.,
Akdis, D. G., Ruckert, B. et al., IgG4 production is confined to human IL-
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1943
10-producing regulatory B cells that suppress antigen-specific immune
responses. J. Allergy Clin. Immunol. 2013. 131: 1204–1212.
1256 Kaminski, D. A., Wei, C., Qian, Y., Rosenberg, A. F. and Sanz, I.,
Advances in human B cell phenotypic profiling. Front. Immunol. 2012.
3: 302.
1257 Carter, N. A., Rosser, E. C. and Mauri, C., Interleukin-10 produced by
B cells is crucial for the suppression of Th17/Th1 responses, induction
of T regulatory type 1 cells and reduction of collagen-induced arthritis.
Arthritis Res. Ther. 2012. 14: R32.
1258 Parekh, V. V., Prasad, D. V., Banerjee, P. P., Joshi, B. N., Kumar, A.
and Mishra, G. C., B cells activated by lipopolysaccharide, but not by
anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of
TGF-beta 1. J. Immunol. 2003. 170: 5897–5911.
1259 Tian, J., Zekzer, D., Hanssen, L., Lu, Y., Olcott, A. and Kaufman, D. L.,
Lipopolysaccharide-activated B cells down-regulate Th1 immunity and
prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol.
2001. 167: 1081–1089.
1260 Carter, N. A., Vasconcellos, R., Rosser, E. C., Tulone, C.,Munoz-Suano,
A., Kamanaka, M., Ehrenstein, M. R. et al., Mice lacking endogenous
IL-10-producing regulatory B cells develop exacerbated disease and
present with an increased frequency of Th1/Th17 but a decrease in
regulatory T cells. J. Immunol. 2011. 186: 5569–5579.
1261 Schioppa, T., Moore, R., Thompson, R. G., Rosser, E. C., Kulbe, H.,
Nedospasov, S., Mauri, C. et al., B regulatory cells and the tumor-
promoting actions of TNF-alphaduring squamous carcinogenesis. Proc.
Natl. Acad. Sci. USA 2011. 108: 10662–10667.
1262 Gray, M., Miles, K., Salter, D., Gray, D. and Savill, J., Apoptotic cells
protect mice from autoimmune inflammation by the induction of reg-
ulatory B cells. Proc. Natl. Acad. Sci. USA 2007. 104: 14080–14085.
1263 Bankoti, R., Gupta, K., Levchenko, A. and Stager, S., Marginal zone
B cells regulate antigen-specific T cell responses during infection. J.
Immunol. 2012. 188: 3961–3971.
1264 Matsushita, T.,Horikawa, M., Iwata, Y. and Tedder, T. F., Regulatory B
cells (B10 cells) and regulatory T cells have independent roles in con-
trolling experimental autoimmune encephalomyelitis initiation and
late-phase immunopathogenesis. J. Immunol. 2010. 185: 2240–2252.
1265 Kalampokis, I., Yoshizaki, A. and Tedder, T. F., IL-10-producing reg-
ulatory B cells (B10 cells) in autoimmune disease. Arthritis Res. Ther.
2013. 15 (Suppl 1): S1.
1266 Watanabe, R., Ishiura, N., Nakashima, H., Kuwano, Y., Okochi, H.,
Tamaki, K., Sato, S. et al., Regulatory B cells (B10 cells) have a suppres-
sive role in murine lupus: CD19 and B10 cell deficiency exacerbates
systemic autoimmunity. J. Immunol. 2010. 184: 4801–4809.
1267 Sheng, J. R., Quan, S. and Soliven, B., CD1d(hi)CD5+ B cells expanded
by GM-CSF in vivo suppress experimental autoimmune myasthenia
gravis. J. Immunol. 2014. 193: 2669–2677.
1268 Yang,M.,Deng, J.,Liu, Y.,Ko, K. H.,Wang, X., Jiao, Z.,Wang, S. et al., IL-
10-producing regulatory B10 cells ameliorate collagen-induced arthri-
tis via suppressing Th17 cell generation. Am. J. Pathol. 2012. 180: 2375–
2385.
1269 Yanaba, K., Yoshizaki, A., Asano, Y., Kadono, T., Tedder, T. F. and
Sato, S., IL-10-producing regulatory B10 cells inhibit intestinal injury
in a mouse model. Am. J. Pathol. 2011. 178: 735–743.
1270 Khan, A. R., Amu, S., Saunders, S. P., Hams, E., Blackshields, G.,
Leonard, M. O., Weaver, C. T. et al., Ligation of TLR7 on CD19(+)
CD1d(hi) B cells suppresses allergic lung inflammation via regulatory
T cells. Eur. J. Immunol. 2015. 45: 1842–1854.
1271 Amu, S., Saunders, S. P., Kronenberg, M.,Mangan, N. E., Atzberger, A.
and Fallon, P. G., Regulatory B cells prevent and reverse allergic airway
inflammation via FoxP3-positive T regulatory cells in a murine model.
J. Allergy Clin. Immunol. 2010. 125: 1114–1124.e1118.
1272 Yanaba, K., Bouaziz, J. D., Haas, K. M., Poe, J. C., Fujimoto, M. and
Tedder, T. F., A regulatory B cell subset with a unique CD1dhiCD5+
phenotype controls T cell-dependent inflammatory responses. Immu-
nity 2008. 28: 639–650.
1273 Xiao, S., Brooks, C. R., Zhu, C., Wu, C., Sweere, J. M., Petecka, S.,
Yeste, A. et al., Defect in regulatory B-cell function and development
of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-
mutant mice. Proc. Natl. Acad. Sci. USA 2012. 109: 12105–12110.
1274 Neves, P., Lampropoulou, V.,Calderon-Gomez, E.,Roch, T.,Stervbo, U.,
Shen, P., Kuhl, A. A. et al., Signaling via theMyD88 adaptor protein in B
cells suppresses protective immunity during Salmonella typhimurium
infection. Immunity 2010. 33: 777–790.
1275 Dass, S., Vital, E. M. and Emery, P., Development of psoriasis after B
cell depletion with rituximab. Arthritis Rheum. 2007. 56: 2715–2718.
1276 Goetz, M., Atreya, R., Ghalibafian, M., Galle, P. R. and Neurath, M.
F., Exacerbation of ulcerative colitis after rituximab salvage therapy.
Inflamm. Bowel Dis. 2007. 13: 1365–1368.
1277 Blair, P. A., Norena, L. Y., Flores-Borja, F., Rawlings, D. J., Isenberg, D.
A., Ehrenstein, M. R. and Mauri, C., CD19(+)CD24(hi)CD38(hi) B cells
exhibit regulatory capacity in healthy individuals but are functionally
impaired in systemic Lupus Erythematosus patients. Immunity 2010.
32: 129–140.
1278 Das, A., Ellis, G., Pallant, C., Lopes, A. R., Khanna, P., Peppa, D., Chen,
A. et al., IL-10-producing regulatory B cells in the pathogenesis of
chronic hepatitis B virus infection. J. Immunol. 2012. 189: 3925–3935.
1279 Flores-Borja, F., Bosma, A., Ng, D., Reddy, V., Ehrenstein, M. R., Isen-
berg, D. A. and Mauri, C., CD19+CD24hiCD38hi B cells maintain regu-
latory T cells while limiting TH1 and TH17 differentiation. Sci. Transl.
Med. 2013. 5: 173ra123.
1280 Iwata, Y., Matsushita, T., Horikawa, M., Dilillo, D. J., Yanaba, K., Ven-
turi, G. M., Szabolcs, P. M. et al., Characterization of a rare IL-10-
competent B-cell subset in humans that parallels mouse regulatory
B10 cells. Blood 2011. 117: 530–541.
1281 Machado-Santos, J., Saji, E., Troscher, A. R., Paunovic, M., Liblau, R.,
Gabriely, G., Bien, C. G. et al., The compartmentalized inflammatory
response in themultiple sclerosis brain is composed of tissue-resident
CD8+ T lymphocytes and B cells. Brain 2018. 141: 2066–2082.
1282 Horikawa, M., Weimer, E. T., DiLillo, D. J., Venturi, G. M., Spolski, R.,
Leonard, W. J., Heise, M. T. et al., Regulatory B cell (B10 Cell) expan-
sion during Listeria infection governs innate and cellular immune
responses in mice. J Immunol 2013. 190: 1158–1168.
1283 Menon, M., Blair, P. A., Isenberg, D. A. and Mauri, C., A regulatory
feedback between plasmacytoid dendritic cells and regulatory B cells
is aberrant in systemic lupus erythematosus. Immunity 2016. 44: 683–
697.
1284 Ramirez, J., Lukin, K. and Hagman, J., From hematopoietic progenitors
to B cells: mechanisms of lineage restriction and commitment. Curr.
Opin. Immunol. 2010. 22: 177–184.
1285 Hardy, R. R., Kincade, P. W. and Dorshkind, K., The protean nature of
cells in the B lymphocyte lineage. Immunity 2007. 26: 703–714.
1286 Cerutti, A., Puga, I. and Cols, M., New helping friends for B cells. Eur. J.
Immunol. 2012. 42: 1956–1968.
1287 Xu, Z., Zan, H., Pone, E. J.,Mai, T. and Casali, P., Immunoglobulin class-
switch DNA recombination: induction, targeting and beyond. Nat. Rev.
Immunol. 2012. 12: 517–531.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1944 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
1288 King, C., Tangye, S. G. and Mackay, C. R., T follicular helper (TFH) cells
in normal and dysregulated immune responses. Annu. Rev. Immunol.
2008. 26: 741–766.
1289 Papavasiliou, F. N. and Schatz, D. G., Somatic hypermutation of
immunoglobulin genes:mergingmechanisms for genetic diversity.Cell
2002. 109 Suppl: S35–4.
1290 Radbruch, A.,Muehlinghaus, G., Luger, E. O., Inamine, A., Smith, K. G.,
Dorner, T. and Hiepe, F., Competence and competition: the challenge
of becoming a long-lived plasma cell. Nat. Rev. Immunol. 2006. 6: 741–
750.
1291 Honjo, T., Immunoglobulin genes.Annu. Rev. Immunol. 1983. 1: 499–528.
1292 Schatz, D. G. and Ji, Y., Recombination centres and the orchestration
of V(D)J recombination. Nat. Rev. Immunol. 2011. 11: 251–263.
1293 Shan,M.,Carrillo, J.,Yeste, A.,Gutzeit, C., Segura-Garzon, D.,Walland,
A. C., Pybus, M. et al., Secreted IgD amplifies humoral T helper 2 cell
responses by binding basophils via galectin-9 andCD44. Immunity 2018.
49: 709–724 e708.
1294 Boonpiyathad, T., Meyer, N., Moniuszko, M., Sokolowska, M.,
Eljaszewicz, A., Wirz, O. F., Tomasiak-Lozowska, M. M. et al., High-
dose bee venom exposure induces similar tolerogenic B-cell responses
in allergic patients and healthy beekeepers. Allergy 2017. 72: 407–415.
1295 Kallies, A., Hasbold, J., Tarlinton, D. M., Dietrich, W., Corcoran, L. M.,
Hodgkin, P. D. and Nutt, S. L., Plasma cell ontogeny defined by quan-
titative changes in blimp-1 expression. J. Exp. Med. 2004. 200: 967–977.
1296 Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. and Corcoran, L. M., The
generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 2015.
15: 160–171.
1297 Bankoti, R., Ogawa, C., Nguyen, T., Emadi, L., Couse, M., Salehi, S.,
Fan, X. et al., Differential regulation of Effector and Regulatory T cell
function by Blimp1. Sci. Rep. 2017. 7: 12078.
1298 Fukushima, P. I., Nguyen, P. K. T., O’Grady, P. and Stetler-Stevenson,
M., Flow cytometric analysis of kappa and lambda light chain expres-
sion in evaluation of specimens for B-cell neoplasia. Cytometry 1996.
26: 243–252.
1299 Pelz, A., Schaffert, H., Diallo, R., Hiepe, F., Meisel, A. and Kohler, S.,
S1P receptor antagonists fingolimod and siponimod do not improve
the outcome of experimental autoimmune myasthenia gravis mice
after disease onset. Eur. J. Immunol. 2018. 48: 498–508.
1300 Chu, V. T., Fro¨hlich, A., Steinhauser, G., Scheel, T., Roch, T., Fillatreau,
S., Lee, J. J. et al., Eosinophils are required for the maintenance of
plasma cells in the bone marrow. Nat. Immunol. 2011. 12: 151–159.
1301 Wilmore, J. R., Jones, D. D. and Allman, D., Protocol for improved reso-
lution of plasma cell subpopulations by flow cytometry. Eur. J. Immunol.
2017. 47: 1386–1388.
1302 Cantor, J., Browne, C. D., Ruppert, R., Fe´ral, C. C., Fa¨ssler, R., Rickert,
R. C. and Ginsberg, M. H., CD98hc facilitates B cell proliferation and
adaptive humoral immunity. Nat. Immunol. 2009. 10: 412–419.
1303 Wrammert, J., Ka¨llberg, E., Agace, W. W. and Leanderson, T., Ly6C
expression differentiates plasma cells from other B cell subsets in
mice. Eur. J. Immunol. 2002. 32: 97–103.
1304 Smith, K. G. C., Hewitson, T. D., Nossal, G. J. V. and Tarlinton, D. M.,
The phenotype and fate of the antibody-forming cells of the splenic
foci. Eur. J. Immunol. 1996. 26: 444–448.
1305 Manz, R. A., Thiel, A. and Radbruch, A., Lifetime of plasma cells in the
bone marrow. Nature 1997. 388: 133–134.
1306 Zehentmeier, S., Roth, K., Cseresnyes, Z., Sercan, O¨.,Horn, K.,Niesner,
R. A., Chang, H.-D. et al., Static and dynamic components synergize
to form a stable survival niche for bone marrow plasma cells: cellular
immune response. Eur. J. Immunol. 2014. 44: 2306–2317.
1307 Sanderson, R. D., Lalor, P. and Bernfield, M., B lymphocytes express
and lose syndecan at specific stages of differentiation. Cell Regul. 1989.
1: 27–35.
1308 Arumugakani, G., Stephenson, S. J., Newton, D. J., Rawstron, A.,
Emery, P.,Doody, G. M.,McGonagle, D. et al., Early emergence of CD19-
negative human antibody-secreting cells at the plasmablast to plasma
cell transition. J. Immunol. 2017. 198: 4618–4628.
1309 Racine, R., Chatterjee, M. and Winslow, G. M., CD11c expression
identifies a population of extrafollicular antigen-specific splenic plas-
mablasts responsible for CD4 T-independent antibody responses dur-
ing intracellular bacterial infection. J. Immunol. 2008. 181: 1375–1385.
1310 Van Camp, B.,Durie, B. G., Spier, C.,DeWaele, M.,Van Riet, I.,Vela, E.,
Frutiger, Y. et al., Plasma cells in multiple myeloma express a natural
killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990. 76:
377–382.
1311 Hoffmann, F. S., Kuhn, P.-H., Laurent, S. A., Hauck, S. M., Berer, K.,
Wendlinger, S. A., Krumbholz, M. et al., The immunoregulator soluble
TACI is released by ADAM10 and reflects B cell activation in autoim-
munity. J. Immunol. 2015. 194: 542–552.
1312 Pinto, D., Montani, E., Bolli, M., Garavaglia, G., Sallusto, F., Lanzavec-
chia, A. and Jarrossay, D., A functional BCR in human IgA and IgM
plasma cells. Blood 2013. 121: 4110–4114.
1313 Yoshida, T., Mei, H., Do¨rner, T., Hiepe, F., Radbruch, A., Fillatreau, S.
and Hoyer, B. F., Memory B and memory plasma cells. Immunol. Rev.
2010. 237: 117–139.
1314 Slifka, M. K., Antia, R.,Whitmire, J. K. and Ahmed, R., Humoral immu-
nity due to long-lived plasma cells. Immunity 1998. 8: 363–372.
1315 Jacobi, A. M.,Mei, H., Hoyer, B. F.,Mumtaz, I. M., Thiele, K., Radbruch,
A., Burmester, G. R. et al., HLA-DRhigh/CD27high plasmablasts indi-
cate active disease in patients with systemic lupus erythematosus.
Ann. Rheum. Dis. 2010. 69: 305–308.
1316 Hoyer, B. F., Mumtaz, I. M., Loddenkemper, K., Bruns, A., Sengler, C.,
Hermann, K. G., Maza, S. et al., Takayasu arteritis is characterised by
disturbances of B cell homeostasis and responds to B cell depletion
therapy with rituximab. Ann. Rheum. Dis. 2012. 71: 75–79.
1317 Sarkander, J.,Hojyo, S. and Tokoyoda, K., Vaccination to gain humoral
immune memory. Clin. Transl. Immunol. 2016. 5: e120.
1318 Wrammert, J., Onlamoon, N., Akondy, R. S., Perng, G. C., Polsrila, K.,
Chandele, A., Kwissa, M. et al., Rapid and massive virus-specific plas-
mablast responses during acute dengue virus infection in humans. J.
Virol. 2012. 86: 2911–2918.
1319 Mei, H. E., Frolich, D., Giesecke, C., Loddenkemper, C., Reiter, K.,
Schmidt, S., Feist, E. et al., Steady-state generation of mucosal IgA+
plasmablasts is not abrogated by B-cell depletion therapy with ritux-
imab. Blood 2010. 116: 5181–5190.
1320 Huggins, J., Pellegrin, T., Felgar, R. E., Wei, C., Brown, M., Zheng, B.,
Milner, E. C. et al., CpG DNA activation and plasma-cell differentiation
of CD27- naive human B cells. Blood 2007. 109: 1611–1619.
1321 Cocco, M., Stephenson, S., Care, M. A.,Newton, D., Barnes, N. A.,Davi-
son, A., Rawstron, A. et al., In vitro generation of long-lived human
plasma cells. J. Immunol. 2012. 189: 5773–5785.
1322 Mei, H. E., Yoshida, T., Sime, W., Hiepe, F., Thiele, K., Manz, R. A.,
Radbruch, A. et al., Blood-borne human plasma cells in steady state
are derived from mucosal immune responses. Blood 2009. 113: 2461–
2469.
1323 Kantele, A., Hakkinen, M., Moldoveanu, Z., Lu, A., Savilahti, E.,
Alvarez, R. D., Michalek, S. et al., Differences in immune responses
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1945
induced by oral and rectal immunizations with Salmonella typhi
Ty21a: evidence for compartmentalization within the common
mucosal immune system in humans. Infect. Immun. 1998. 66: 5630–
5635.
1324 Medina, F., Segundo, C., Campos-Caro, A., Gonzalez-Garcia, I. and
Brieva, J. A., The heterogeneity shown by human plasma cells from
tonsil, blood, and bone marrow reveals graded stages of increasing
maturity, but local profiles of adhesion molecule expression. Blood
2002. 99: 2154–2161.
1325 Caraux, A., Klein, B., Paiva, B., Bret, C., Schmitz, A., Fuhler, G. M.,
Bos, N. A. et al., Circulating human B and plasma cells. Age-associated
changes in counts and detailed characterization of circulating normal
CD138– and CD138+ plasma cells. Haematologica 2010. 95: 1016–1020.
1326 Arce, S., Luger, E., Muehlinghaus, G., Cassese, G., Hauser, A., Horst,
A., Lehnert, K. et al., CD38 low IgG-secreting cells are precursors of
various CD38 high-expressing plasma cell populations. J. Leukoc. Biol.
2004. 75: 1022–1028.
1327 Jourdan,M.,Caraux, A.,Caron, G.,Robert, N., Fiol, G.,Reme, T.,Bollore,
K. et al., Characterization of a transitional preplasmablast population
in the process of human B cell to plasma cell differentiation. J. Immunol.
2011. 187: 3931–3941.
1328 Mei, H. E., Schmidt, S. and Dorner, T., Rationale of anti-CD19
immunotherapy: an option to target autoreactive plasma cells in
autoimmunity. Arthritis Res. Ther. 2012. 14 Suppl 5: S1.
1329 Lokhorst, H. M., Plesner, T., Laubach, J. P.,Nahi, H., Gimsing, P.,Hans-
son, M., Minnema, M. C. et al., Targeting CD38 with daratumumab
monotherapy in multiple myeloma. N Engl J Med 2015. 373: 1207–1219.
1330 Halliley, J. L., Tipton, C. M., Liesveld, J., Rosenberg, A. F., Darce, J.,
Gregoretti, I. V., Popova, L. et al., Long-lived plasma cells are contained
within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow.
Immunity 2015. 43: 132–145.
1331 Landsverk, O. J., Snir, O., Casado, R. B., Richter, L., Mold, J. E., Reu,
P., Horneland, R. et al., Antibody-secreting plasma cells persist for
decades in human intestine. J. Exp. Med. 2017. 214: 309–317.
1332 Hacbarth, E. and Kajdacsy-Balla, A., Low density neutrophils in
patients with systemic lupus erythematosus, rheumatoid arthritis,
and acute rheumatic fever. Arthritis Rheum. 1986. 29: 1334–1342.
1333 Sato, S., Fujimoto, M.,Hasegawa, M. and Takehara, K., Altered blood B
lymphocyte homeostasis in systemic sclerosis: expanded naive B cells
and diminished but activated memory B cells. Arthritis Rheum. 2004.
50: 1918–1927.
1334 Carrell, J. and Groves, C. J., OMIP-043: Identification of human antibody
secreting cell subsets. Cytometry A 2018. 93: 190–193.
1335 Mesin, L., Di Niro, R., Thompson, K. M., Lundin, K. E. and Sollid, L. M.,
Long-lived plasma cells from human small intestine biopsies secrete
immunoglobulins for many weeks in vitro. J. Immunol. 2011. 187: 2867–
2874.
1336 Laurent, S. A., Hoffmann, F. S., Kuhn, P.-H., Cheng, Q., Chu, Y.,
Schmidt-Supprian, M., Hauck, S. M. et al., γ-Secretase directly sheds
the survival receptor BCMA from plasma cells. Nat. Commun. 2015. 6:
7333.
1337 Kunkel, E. J. and Butcher, E. C., Plasma-cell homing. Nat. Rev. Immunol.
2003. 3: 822–829.
1338 Delogu, A., Schebesta, A., Sun, Q., Aschenbrenner, K., Perlot, T. and
Busslinger, M., Gene repression by Pax5 in B cells is essential for blood
cell homeostasis and is reversed in plasma cells. Immunity 2006. 24:
269–281.
1339 Medina, F., Segundo, C., Jimenez-Gomez, G., Gonzalez-Garcia, I.,
Campos-Caro, A. and Brieva, J. A., Higher maturity and connective tis-
sue association distinguish resident from recently generated human
tonsil plasma cells. J. Leukoc. Biol. 2007. 82: 1430–1436.
1340 Frigyesi, I., Adolfsson, J., Ali, M., Christophersen, M. K., Johnsson, E.,
Turesson, I., Gullberg, U. et al., Robust isolation of malignant plasma
cells in multiple myeloma. Blood 2014. 123: 1336–1340.
1341 Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl,
G., Koyasu, S. et al., Innate lymphoid cells—a proposal for uniform
nomenclature. Nat. Rev. Immunol. 2013. 13: 145–149.
1342 Vivier, E., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl,
G., Koyasu, S. et al., Innate lymphoid cells: 10 years on. Cell 2018. 174:
1054–1066.
1343 Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P. and Salazar-
Mather, T. P., Natural killer cells in antiviral defense: function and
regulation by innate cytokines. Annu. Rev. Immunol. 1999. 17: 189–220.
1344 Daussy, C., Faure, F., Mayol, K., Viel, S., Gasteiger, G., Charrier, E.,
Bienvenu, J. et al., T-bet and Eomes instruct the development of two
distinct natural killer cell lineages in the liver and in the bonemarrow.
J. Exp. Med. 2014. 211: 563–577.
1345 Klose, C. S., Flach, M., Mohle, L., Rogell, L., Hoyler, T., Ebert, K., Fabi-
unke, C. et al., Differentiation of type 1 ILCs from a common progenitor
to all helper-like innate lymphoid cell lineages. Cell 2014. 157: 340–356.
1346 Sojka, D. K., Plougastel-Douglas, B., Yang, L., Pak-Wittel, M. A., Arty-
omov, M. N., Ivanova, Y., Zhong, C. et al., Tissue-resident natural
killer (NK) cells are cell lineages distinct from thymic and conventional
splenic NK cells. Elife 2014. 3: e01659.
1347 Walker, J. A. and McKenzie, A. N., Development and function of group
2 innate lymphoid cells. Curr. Opin. Immunol. 2013. 25: 148–155.
1348 Montaldo, E., Juelke, K. and Romagnani, C., Group 3 innate lymphoid
cells (ILC3s): origin, differentiation, and plasticity in humans andmice.
Eur. J. Immunol. 2015. 45: 2171–2182.
1349 Spits, H. and Cupedo, T., Innate lymphoid cells: emerging insights in
development, lineage relationships, and function. Annu. Rev. Immunol.
2012. 30: 647–675.
1350 Paclik, D., Stehle, C., Lahmann, A.,Hutloff, A. and Romagnani, C., ICOS
regulates the pool of group 2 innate lymphoid cells under homeostatic
and inflammatory conditions in mice. Eur. J. Immunol. 2015. 45: 2766–
2772.
1351 Ryon, J. J., Isolation of mononuclear cells from tonsillar tissue. Curr.
Protoc. Immunol. 2001. Chapter 7: Unit 7 8.
1352 Gasteiger, G., Fan, X., Dikiy, S., Lee, S. Y. and Rudensky, A. Y., Tis-
sue residency of innate lymphoid cells in lymphoid and nonlymphoid
organs. Science 2015. 350: 981–985.
1353 Hoyler, T., Klose, C. S., Souabni, A., Turqueti-Neves, A., Pfeifer, D.,
Rawlins, E. L., Voehringer, D. et al., The transcription factor GATA-3
controls cell fate and maintenance of type 2 innate lymphoid cells.
Immunity 2012. 37: 634–648.
1354 Fuchs, A., Vermi, W., Lee, J. S., Lonardi, S., Gilfillan, S., Newberry, R.
D., Cella, M. et al., Intraepithelial type 1 innate lymphoid cells are a
unique subset of IL-12- and IL-15-responsive IFN-gamma-producing
cells. Immunity 2013. 38: 769–781.
1355 Robinette, M. L., Fuchs, A., Cortez, V. S., Lee, J. S.,Wang, Y., Durum, S.
K., Gilfillan, S. et al., Transcriptional programs define molecular char-
acteristics of innate lymphoid cell classes and subsets. Nat. Immunol.
2015. 16: 306–317.
1356 Serafini, N., Klein Wolterink, R. G., Satoh-Takayama, N., Xu, W.,
Vosshenrich, C. A., Hendriks, R. W. and Di Santo, J. P., Gata3 drives
development of RORgammat+ group 3 innate lymphoid cells. J. Exp.
Med. 2014. 211: 199–208.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1946 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
1357 Moro, K., Yamada, T., Tanabe, M., Takeuchi, T., Ikawa, T., Kawamoto,
H., Furusawa, J. et al., Innate production of T(H)2 cytokines by adi-
pose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010.
463: 540–544.
1358 Neill, D. R., Wong, S. H., Bellosi, A., Flynn, R. J., Daly, M., Langford, T.
K., Bucks, C. et al., Nuocytes represent a new innate effector leukocyte
that mediates type-2 immunity. Nature 2010. 464: 1367–1370.
1359 Sawa, S., Cherrier, M., Lochner, M., Satoh-Takayama, N., Fehling, H. J.,
Langa, F. et al., Lineage relationship analysis of RORgammat+ innate
lymphoid cells. Science 2010. 330: 665–669.
1360 Rankin, L. C., Groom, J. R., Chopin, M., Herold, M. J., Walker, J. A.,
Mielke, L. A. et al., The transcription factor T-bet is essential for the
development of NKp46+ innate lymphocytes via the Notch pathway.
Nat. Immunol. 2013. 14: 389–395.
1361 Klose, C. S.,Kiss, E. A., Schwierzeck, V., Ebert, K.,Hoyler, T., d’Hargues,
Y., Goppert, N. et al., A T-bet gradient controls the fate and function of
CCR6-RORgammat+ innate lymphoid cells. Nature 2013. 494: 261–265.
1362 Vonarbourg, C., Mortha, A., Bui, V. L., Hernandez, P. P., Kiss, E. A.,
Hoyler, T., Flach, M. et al., Regulated expression of nuclear recep-
tor RORgammat confers distinct functional fates to NK cell receptor-
expressing RORgammat(+) innate lymphocytes. Immunity 2010. 33:
736–751.
1363 Cella, M., Fuchs, A., Vermi, W., Facchetti, F., Otero, K., Lennerz, J. K.
M., Doherty, J. M. et al., A human natural killer cell subset provides an
innate source of IL-22 formucosal immunity.Nature 2009. 457: 722–725.
1364 Mjosberg, J. M., Trifari, S., Crellin, N. K., Peters, C. P., van Drunen, C.
M., Piet, B., Fokkens, W. J. et al., Human IL-25- and IL-33-responsive
type 2 innate lymphoid cells are defined by expression of CRTH2 and
CD161. Nat. Immunol. 2011. 12: 1055–1062.
1365 Bernink, J. H., Peters, C. P., Munneke, M., te Velde, A. A., Meijer, S. L.,
Weijer, K., Hreggvidsdottir, H. S. et al., Human type 1 innate lymphoid
cells accumulate in inflamed mucosal tissues. Nat. Immunol. 2013. 14:
221–229.
1366 Hazenberg, M. D. and Spits, H., Human innate lymphoid cells. Blood
2014. 124: 700–709.
1367 Cupedo, T., Crellin, N. K., Papazian, N., Rombouts, E. J., Weijer, K.,
Grogan, J. L., Fibbe, W. E. et al., Human fetal lymphoid tissue-inducer
cells are interleukin 17-producing precursors to RORC+ CD127+ natu-
ral killer-like cells. Nat. Immunol. 2009. 10: 66–74.
1368 Marquardt, N., Beziat, V., Nystrom, S., Hengst, J., Ivarsson, M. A.,
Kekalainen, E., Johansson, H. et al., Cutting edge: identification and
characterization of human intrahepatic CD49a+ NK cells. J. Immunol.
2015. 194: 2467–2471.
1369 Vacca, P., Montaldo, E., Croxatto, D., Loiacono, F., Canegallo, F., Ven-
turini, P. L.,Moretta, L. et al., Identification of diverse innate lymphoid
cells in human decidua. Mucosal Immunol. 2015. 8: 254–264.
1370 Montaldo, E., Vacca, P., Chiossone, L., Croxatto, D., Loiacono, F., Mar-
tini, S., Ferrero, S. et al., Unique eomes(+) NK cell subsets are present
in uterus and decidua during early pregnancy. Front. Immunol. 2015. 6:
646.
1371 Teunissen, M. B., Munneke, J. M., Bernink, J. H., Spuls, P. I., Res, P.
C., Te Velde, A., Cheuk, S. et al., Composition of innate lymphoid cell
subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin
and blood of psoriasis patients. J. Invest. Dermatol. 2014. 134: 2351–2360.
1372 Lim, A. I., Li, Y., Lopez-Lastra, S., Stadhouders, R., Paul, F., Casrouge,
A., Serafini, N. et al., Systemic human ILC precursors provide a sub-
strate for tissue ILC differentiation. Cell 2017. 168: 1086–1100 e1010.
1373 Wojno, E. D.,Monticelli, L. A., Tran, S. V., Alenghat, T., Osborne, L. C.,
Thome, J. J.,Willis, C. et al., The prostaglandinD(2) receptor CRTH2 reg-
ulates accumulation of group 2 innate lymphoid cells in the inflamed
lung. Mucosal Immunol. 2015. 8: 1313–1323.
1374 Kim, S., Iizuka, K., Kang, H. S., Dokun, A., French, A. R., Greco, S. and
Yokoyama, W. M., In vivo developmental stages in murine natural
killer cell maturation. Nat. Immunol. 2002. 3: 523–528.
1375 Hayakawa, Y. and Smyth, M. J., CD27 dissects mature NK cells into
two subsets with distinct responsiveness and migratory capacity. J.
Immunol. 2006. 176: 1517–1524.
1376 Chiossone, L., Chaix, J., Fuseri, N., Roth, C., Vivier, E. and Walzer, T.,
Maturation of mouse NK cells is a 4-stage developmental program.
Blood 2009. 113: 5488–5496.
1377 Bjorkstrom, N. K., Riese, P., Heuts, F., Andersson, S., Fauriat, C., Ivars-
son, M. A., Bjorklund, A. T. et al., Expression patterns of NKG2A, KIR,
and CD57 define a process of CD56dim NK-cell differentiation uncou-
pled from NK-cell education. Blood 2010. 116: 3853–3864.
1378 Lopez-Verges, S.,Milush, J. M., Pandey, S., York, V. A., Arakawa-Hoyt,
J., Pircher, H., Norris, P. J. et al., CD57 defines a functionally distinct
population of mature NK cells in the human CD56dimCD16+ NK-cell
subset. Blood 2010. 116: 3865–3874.
1379 Juelke, K., Killig, M., Luetke-Eversloh, M., Parente, E., Gruen, J.,
Morandi, B., Ferlazzo, G. et al., CD62L expression identifies a unique
subset of polyfunctional CD56dim NK cells. Blood 2010. 116: 1299–1307.
1380 Sanos, S. L., Bui, V. L.,Mortha, A.,Oberle, K.,Heners, C., Johner, C. and
Diefenbach, A., ROR gamma t and commensal microflora are required
for the differentiation of mucosal interleukin 22-producing NKp46(+)
cells. Nat. Immunol. 2009. 10: 83–91.
1381 Satoh-Takayama, N., Vosshenrich, C. A. J., Lesjean-Pottier, S., Sawa,
S., Lochner, M., Rattis, F., Mention, J. J. et al., Microbial flora drives
interleukin 22 production in intestinal NKp46(+) cells that provide
innate mucosal immune defense. Immunity 2008. 29: 958–970.
1382 Luci, C., Reynders, A., Ivanov, I. I., Cognet, C., Chiche, L., Chasson, L.,
Hardwigsen, J. et al., Influence of the transcription factor ROR gamma
t on the development of NKp46(+) cell populations in gut and skin.
Nat. Immunol. 2009. 10: 75–82.
1383 Fort, M. M., Cheung, J., Yen, D., Li, J., Zurawski, S. M., Lo, S.,Menon, S.
et al., IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies
in vivo. Immunity 2001. 15: 985–995.
1384 Price, A. E., Liang, H. E., Sullivan, B. M., Reinhardt, R. L., Eisley, C.
J., Erle, D. J. and Locksley, R. M., Systemically dispersed innate IL-13-
expressing cells in type 2 immunity. Proc. Natl. Acad. Sci. USA 2010. 107:
11489–11494.
1385 Walzer, T., Blery, M., Chaix, J., Fuseri, N., Chasson, L., Robbins, S. H.,
Jaeger, S. et al., Identification, activation, and selective in vivo ablation
of mouse NK cells via NKp46. Proc. Natl. Acad. Sci. USA 2007. 104: 3384–
3389.
1386 Carlyle, J. R., Mesci, A., Ljutic, B., Belanger, S., Tai, L. H., Rousselle, E.,
Troke, A. D. et al., Molecular and genetic basis for strain-dependent
NK1.1 alloreactivity ofmouseNK cells. J. Immunol. 2006. 176: 7511–7524.
1387 Del Zotto, G., Marcenaro, E., Vacca, P., Sivori, S., Pende, D., Della
Chiesa, M., Moretta, F. et al., Markers and function of human NK cells
in normal and pathological conditions. Cytom. B Clin. Cytom. 2017. 92:
100–114.
1388 Crinier, A., Milpied, P., Escaliere, B., Piperoglou, C., Galluso, J., Bal-
samo, A., Spinelli, L. et al., High-dimensional single-cell analysis
identifies organ-specific signatures and conserved nk cell subsets in
humans and mice. Immunity 2018.49: 971–986 e975.
1389 Weizman, O. E., Adams, N. M., Schuster, I. S., Krishna, C., Pritykin, Y.,
Lau, C., Degli-Esposti, M. A. et al., ILC1 confer early host protection at
initial sites of viral infection. Cell 2017.171: 795–808 e712.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1947
1390 Huntington, N. D., Tabarias, H., Fairfax, K., Brady, J., Hayakawa, Y.,
Degli-Esposti, M. A., Smyth, M. J. et al., NK cell maturation and periph-
eral homeostasis is associated with KLRG1 up-regulation. J. Immunol.
2007. 178: 4764–4770.
1391 Sciume, G., Hirahara, K., Takahashi, H., Laurence, A., Villarino, A. V.,
Singleton, K. L., Spencer, S. P. et al., Distinct requirements for T-bet in
gut innate lymphoid cells. J. Exp. Med. 2012. 209: 2331–2338.
1392 Quatrini, L.,Wieduwild, E., Escaliere, B., Filtjens, J.,Chasson, L., Laprie,
C., Vivier, E. et al., Endogenous glucocorticoids control host resistance
to viral infection through the tissue-specific regulation of PD-1 expres-
sion on NK cells. Nat. Immunol. 2018. 19: 954–962.
1393 Herberman, R. B., Nunn, M. E., Holden, H. T. and Lavrin, D. H., Natural
cytotoxic reactivity of mouse lymphoid cells against syngeneic and
allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer
1975. 16: 230–239.
1394 Herberman, R. B., Nunn, M. E. and Lavrin, D. H., Natural cytotoxic
reactivity of mouse lymphoid cells against syngeneic acid allogeneic
tumors. I. Distribution of reactivity and specificity. Int. J. Cancer 1975.
16: 216–229.
1395 Ljunggren, H. G. and Karre, K., In search of the ‘missing self’: MHC
molecules and NK cell recognition. Immunol. Today 1990. 11: 237–244.
1396 Moretta, A., Bottino, C., Mingari, M. C., Biassoni, R. and Moretta, L.,
What is a natural killer cell? Nat. Immunol. 2002. 3: 6–8.
1397 Vivier, E., Tomasello, E., Baratin, M., Walzer, T. and Ugolini, S., Func-
tions of natural killer cells. Nat. Immunol. 2008. 9: 503–510.
1398 Lopez-Botet, M., Perez-Villar, J. J., Carretero, M., Rodriguez, A.,Melero,
I., Bellon, T., Llano, M. et al., Structure and function of the CD94 C-
type lectin receptor complex involved in recognition of HLA class I
molecules. Immunol. Rev. 1997. 155: 165–174.
1399 Braud, V.M.,Allan, D. S.,O’Callaghan, C. A., Soderstrom, K.,D’Andrea,
A., Ogg, G. S., Lazetic, S. et al., HLA-E binds to natural killer cell recep-
tors CD94/NKG2A, B and C. Nature 1998. 391: 795–799.
1400 Moretta, A., Bottino, C., Vitale, M., Pende, D., Biassoni, R., Mingari,
M. C. and Moretta, L., Receptors for HLA class-I molecules in human
natural killer cells. Annu. Rev. Immunol. 1996. 14: 619–648.
1401 Parham, P., MHC class I molecules and KIRs in human history, health
and survival. Nat. Rev. Immunol. 2005. 5: 201–214.
1402 Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M.
C., Biassoni, R. et al., Activating receptors and coreceptors involved in
human natural killer cell-mediated cytolysis.Annu. Rev. Immunol. 2001.
19: 197–223.
1403 Vivier, E., Raulet, D. H.,Moretta, A.,Caligiuri, M. A., Zitvogel, L., Lanier,
L. L.,Yokoyama,W. M. et al., Innate or adaptive immunity? The exam-
ple of natural killer cells. Science 2011. 331: 44–49.
1404 Raulet, D. H., Roles of the NKG2D immunoreceptor and its ligands.Nat.
Rev. Immunol. 2003. 3: 781–790.
1405 Moretta, A., Sivori, S., Vitale, M., Pende, D., Morelli, L., Augugliaro,
R., Bottino, C. et al., Existence of both inhibitory (p58) and activatory
(p50) receptors for HLA-C molecules in human natural killer cells. J.
Exp. Med. 1995. 182: 875–884.
1406 Wagtmann, N., Biassoni, R., Cantoni, C., Verdiani, S., Malnati, M. S.,
Vitale, M., Bottino, C. et al., Molecular clones of the p58NK cell receptor
reveal immunoglobulin-related molecules with diversity in both the
extra- and intracellular domains. Immunity 1995. 2: 439–449.
1407 Sivori, S., Cantoni, C., Parolini, S.,Marcenaro, E., Conte, R.,Moretta, L.
andMoretta, A., IL-21 induces both rapidmaturation of human CD34+
cell precursors towards NK cells and acquisition of surface killer Ig-like
receptors. Eur. J. Immunol. 2003. 33: 3439–3447.
1408 Freud, A. G. and Caligiuri, M. A., Human natural killer cell develop-
ment. Immunol. Rev. 2006. 214: 56–72.
1409 Hu, P. F., Hultin, L. E., Hultin, P., Hausner, M. A., Hirji, K., Jewett, A.,
Bonavida, B. et al., Natural killer cell immunodeficiency in HIV disease
is manifest by profoundly decreased numbers of CD16+CD56+ cells
and expansion of a population of CD16dimCD56- cells with low lytic
activity. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995. 10: 331–340.
1410 Mavilio, D., Lombardo, G., Benjamin, J., Kim, D., Follman, D., Marce-
naro, E., O’Shea, M. A. et al., Characterization of CD56-/CD16+ natural
killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-
infected viremic individuals. Proc. Natl. Acad. Sci. U. S. A. 2005. 102:
2886–2891.
1411 Della Chiesa, M., Falco, M., Podesta, M., Locatelli, F.,Moretta, L., Fras-
soni, F. and Moretta, A., Phenotypic and functional heterogeneity of
human NK cells developing after umbilical cord blood transplantation:
a role for human cytomegalovirus? Blood 2012. 119: 399–410.
1412 Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive,
D., Moretta, L. et al., Identification of a subset of human natural killer
cells expressing high levels of programmed death 1: a phenotypic and
functional characterization. J. Allergy Clin. Immunol. 2017.139: 335–346
e333.
1413 Caligiuri, M. A., Zmuidzinas, A., Manley, T. J., Levine, H., Smith, K. A.
and Ritz, J., Functional consequences of interleukin 2 receptor expres-
sion on resting human lymphocytes. Identification of a novel natural
killer cell subset with high affinity receptors. J. Exp. Med. 1990. 171:
1509–1526.
1414 Carson, W. E., Fehniger, T. A. and Caligiuri, M. A., CD56bright natural
killer cell subsets: characterization of distinct functional responses to
interleukin-2 and the c-kit ligand. Eur. J. Immunol. 1997. 27: 354–360.
1415 Frey, M., Packianathan, N. B., Fehniger, T. A., Ross, M. E., Wang, W.
C., Stewart, C. C., Caligiuri, M. A. et al., Differential expression and
function of L-selectin on CD56bright and CD56dim natural killer cell
subsets. J. Immunol. 1998. 161: 400–408.
1416 Campbell, J. J.,Qin, S.,Unutmaz, D., Soler, D.,Murphy, K. E.,Hodge, M.
R.,Wu, L. et al., Unique subpopulations of CD56+NK andNK-T periph-
eral blood lymphocytes identified by chemokine receptor expression
repertoire. J. Immunol. 2001. 166: 6477–6482.
1417 Robertson, M. J., Role of chemokines in the biology of natural killer
cells. J. Leukoc. Biol. 2002. 71: 173–183.
1418 Lima, M., Leander, M., Santos, M., Santos, A. H., Lau, C.,Queiros, M. L.,
Goncalves, M. et al., Chemokine receptor expression on normal blood
CD56(+) NK-cells elucidates cell partners that comigrate during the
innate and adaptive immune responses and identifies a transitional
NK-cell population. J. Immunol. Res. 2015. 2015: 839684.
1419 De Maria, A., Bozzano, F., Cantoni, C. and Moretta, L., Revisit-
ing human natural killer cell subset function revealed cytolytic
CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma
on activation. Proc. Natl. Acad. Sci. USA 2011. 108: 728–732.
1420 Fauriat, C., Long, E. O., Ljunggren, H. G. and Bryceson, Y. T., Regulation
of human NK-cell cytokine and chemokine production by target cell
recognition. Blood 2010. 115: 2167–2176.
1421 Guma, M., Angulo, A., Vilches, C., Gomez-Lozano, N., Malats, N. and
Lopez-Botet, M., Imprint of human cytomegalovirus infection on the
NK cell receptor repertoire. Blood 2004. 104: 3664–3671.
1422 Malmberg, K. J., Beziat, V. and Ljunggren, H. G., Spotlight on NKG2C
and the human NK-cell response to CMV infection. Eur. J. Immunol.
2012. 42: 3141–3145.
1423 Muccio, L., Bertaina, A., Falco, M., Pende, D., Meazza, R., Lopez-Botet,
M., Moretta, L. et al., Analysis of memory-like natural killer cells in
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1948 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
human cytomegalovirus-infected children undergoing alphabeta+T
and B cell-depleted hematopoietic stem cell transplantation for hema-
tological malignancies. Haematologica 2016. 101: 371–381.
1424 Sivori, S., Falco, M.,Marcenaro, E., Parolini, S., Biassoni, R., Bottino, C.,
Moretta, L. et al., Early expression of triggering receptors and regula-
tory role of 2B4 in human natural killer cell precursors undergoing in
vitro differentiation. Proc. Natl. Acad. Sci. USA 2002. 99: 4526–4531.
1425 Vacca, P., Pietra, G., Falco, M., Romeo, E., Bottino, C., Bellora, F., Pre-
fumo, F. et al., Analysis of natural killer cells isolated from human
decidua: Evidence that 2B4 (CD244) functions as an inhibitory receptor
and blocks NK-cell function. Blood 2006. 108: 4078–4085.
1426 Vacca, P., Vitale, C., Montaldo, E., Conte, R., Cantoni, C., Fulcheri, E.,
Darretta, V. et al., CD34+ hematopoietic precursors are present in
human decidua and differentiate into natural killer cells upon interac-
tion with stromal cells. Proc. Natl. Acad. Sci. USA 2011. 108: 2402–2407.
1427 Hanna, J., Goldman-Wohl, D., Hamani, Y., Avraham, I., Greenfield,
C., Natanson-Yaron, S., Prus, D. et al., Decidual NK cells regulate key
developmental processes at the human fetal-maternal interface. Nat.
Med. 2006. 12: 1065–1074.
1428 Fehniger, T. A., Cooper, M. A., Nuovo, G. J., Cella, M., Facchetti, F.,
Colonna, M. and Caligiuri, M. A., CD56bright natural killer cells are
present in human lymph nodes and are activated by T cell-derived IL-
2: a potential new link between adaptive and innate immunity. Blood
2003. 101: 3052–3057.
1429 Ferlazzo, G., Thomas, D., Lin, S. L., Goodman, K., Morandi, B., Muller,
W. A., Moretta, A. et al., The abundant NK cells in human secondary
lymphoid tissues require activation to express killer cell Ig-like recep-
tors and become cytolytic. J. Immunol. 2004. 172: 1455–1462.
1430 Merad, M., Sathe, P., Helft, J., Miller, J. and Mortha, A., The dendritic
cell lineage: ontogeny and function of dendritic cells and their subsets
in the steady state and the inflamed setting. Annu. Rev. Immunol. 2013.
31: 563–604.
1431 Ginhoux, F. and Guilliams, M., Tissue-resident macrophage ontogeny
and homeostasis. Immunity 2016. 44: 439–449.
1432 Heidkamp, G. F. et al., Functional specialization of Dendritic cell sub-
sets. Encyclopedia of Cell Biology, (Elsevier) 2016. 588–604.
1433 Dress, R. J., Wong, A. Y. and Ginhoux, F., Homeostatic control of den-
dritic cell numbers and differentiation. Immunol. Cell Biol. 2018. 96: 463–
476.
1434 Hoeffel, G. and Ginhoux, F., Fetal monocytes and the origins of tissue-
resident macrophages. Cell. Immunol. 2018. 330: 5–15.
1435 Collin, M. and Ginhoux, F., Human dendritic cells. Semin. Cell Dev. Biol.
2019. 86: 1–2.
1436 Schlitzer, A., Sivakamasundari, V.,Chen, J., Sumatoh, H. R., Schreuder,
J., Lum, J., Malleret, B. et al., Identification of cDC1- and cDC2-
committed DC progenitors reveals early lineage priming at the com-
mon DC progenitor stage in the bone marrow. Nat. Immunol. 2015. 16:
718–728.
1437 Guilliams, M., Dutertre, C. A., Scott, C. L., McGovern, N., Sichien, D.,
Chakarov, S., Van Gassen, S. et al., Unsupervised high-dimensional
analysis aligns dendritic cells across tissues and species. Immunity
2016. 45: 669–684.;
1438 Dress, R. J., Dutertre, C. A., Giladi, A., Schlitzer, A., Low, I., Shadan,
N. B., Tay, A. et al., Plasmacytoid dendritic cells develop from Ly6D+
lymphoid progenitors distinct from the myeloid lineage. Nat. Immunol.
2019. 20: 852–864.
1439 Rodrigues, P. F., Alberti-Servera, L., Eremin, A., Grajales-Reyes, G. E.,
Ivanek, R. and Tussiwand, R., Distinct progenitor lineages contribute
to the heterogeneity of plasmacytoid dendritic cells. Nat. Immunol.
2018. 19: 711–722.
1440 Herman, J. S., Sagar and Grun, D., FateID infers cell fate bias in mul-
tipotent progenitors from single-cell RNA-seq data. Nat. Methods 2018.
15: 379–386.
1441 Hoeffel, G., Wang, Y., Greter, M., See, P., Teo, P., Malleret, B., Leboeuf,
M. et al., Adult Langerhans cells derive predominantly from embryonic
fetal liver monocytes with a minor contribution of yolk sac-derived
macrophages. J. Exp. Med. 2012. 209: 1167–1181.
1442 Ginhoux, F., Tacke, F., Angeli, V., Bogunovic, M., Loubeau, M., Dai, X.
M., Stanley, E. R. et al., Langerhans cells arise frommonocytes in vivo.
Nat. Immunol. 2006. 7: 265–273.
1443 Doebel, T., Voisin, B. and Nagao, K., Langerhans Cells - The
Macrophage in Dendritic Cell Clothing. Trends Immunol. 2017. 38: 817–
828.
1444 Ginhoux, F. and Jung, S., Monocytes andmacrophages: developmental
pathways and tissue homeostasis.Nat. Rev. Immunol. 2014. 14: 392–404.
1445 Geissmann, F., Jung, S. and Littman, D. R., Blood monocytes consist
of two principal subsets with distinct migratory properties. Immunity
2003. 19: 71–82.
1446 Tamoutounour, S., Henri, S., Lelouard, H., de Bovis, B., de Haar, C.,
van der Woude, C. J., Woltman, A. M. et al., CD64 distinguishes
macrophages from dendritic cells in the gut and reveals the Th1-
inducing role of mesenteric lymph node macrophages during colitis.
Eur. J. Immunol. 2012. 42: 3150–3166.
1447 Bain, C. C., Scott, C. L., Uronen-Hansson, H., Gudjonsson, S., Jans-
son, O., Grip, O., Guilliams, M. et al., Resident and pro-inflammatory
macrophages in the colon represent alternative context-dependent
fates of the same Ly6Chi monocyte precursors. Mucosal Immunol 2013.
6: 498–510.
1448 Heidkamp, G. F., Sander, J., Lehmann, C. H. K., Heger, L., Eissing, N.,
Heger, L., Baranska, A. et al., Human lymphoid organ dendritic cell
identity is predominantly dictated by ontogeny, not tissue microenvi-
ronment. Sci. Immunol. 2016. 1: pii: eaai7677.
1449 Alca´ntara-Herna´ndez, M., Leylek, R., Wagar, L. E., Engleman, E. G.,
Keler, T., Marinkovich, M. P., Davis, M. M. et al., High-Dimensional
Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual
Variation and Tissue Specialization. Immunity. 2017. 47: 1037–1050.e6.
1450 See, P., Dutertre, C. A., Chen, J., Gunther, P., McGovern, N., Irac, S. E.,
Gunawan, M. et al., Mapping the human DC lineage through the inte-
gration of high-dimensional techniques. Science 2017. 356: eaag3009.
1451 Ziegler-Heitbrock, L., Ancuta, P., Crowe, S., Dalod, M., Grau, V., Hart,
D. N., Leenen, P. J. et al., Nomenclature of monocytes and dendritic
cells in blood. Blood 2010. 116: e74–80.
1452 Briseno, C. G., Haldar, M., Kretzer, N. M.,Wu, X., Theisen, D. J., Kc, W.,
Durai, V. et al., Distinct transcriptional programs control cross-priming
in classical and monocyte-derived dendritic cells. Cell Rep 2016. 15:
2462–2474.
1453 Fujiyama, S., Nakahashi-Oda, C., Abe, F., Wang, Y., Sato, K. and
Shibuya, A., Identification and isolation of splenic tissue-resident
macrophage sub-populations by flow cytometry. Int. Immunol. 2019.
31: 51–56.
1454 Crozat, K., Guiton, R., Contreras, V., Feuillet, V., Dutertre, C. A., Ven-
tre, E., Vu Manh, T. P. et al., The XC chemokine receptor 1 is a con-
served selective marker of mammalian cells homologous to mouse
CD8alpha+ dendritic cells. J. Exp. Med. 2010. 207: 1283–1292.
1455 Gurka, S., Hartung, E., Becker, M. and Kroczek, R. A., Mouse conven-
tional dendritic cells can be universally classified based on the mutu-
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1949
ally exclusive expression of XCR1 and SIRPalpha. Front Immunol 2015.
6: 35.
1456 Misharin, A. V.,Morales-Nebreda, L.,Mutlu, G. M., Budinger, G. R. and
Perlman, H., Flow cytometric analysis of macrophages and dendritic
cell subsets in the mouse lung. Am. J. Respir. Cell Mol. Biol. 2013. 49:
503–510.
1457 Chakarov, S., Lim, H. Y., Tan, L., Lim, S. Y., See, P., Lum, J., Zhang,
X. M. et al., Two distinct interstitial macrophage populations coexist
across tissues in specific subtissular niches. Science 2019. 363.
1458 Schlitzer, A., McGovern, N., Teo, P., Zelante, T., Atarashi, K., Low, D.,
Ho, A. W. et al., IRF4 transcription factor-dependent CD11b+ dendritic
cells in human and mouse control mucosal IL-17 cytokine responses.
Immunity 2013. 38: 970–983.
1459 Shaw, T. N., Houston, S. A., Wemyss, K., Bridgeman, H. M., Bar-
bera, T. A., Zangerle-Murray, T., Strangward, P. et al., Tissue-resident
macrophages in the intestine are long lived and defined by Tim-4 and
CD4 expression. J. Exp. Med. 2018. 215: 1507–1518.
1460 Takenaka, S., Safroneeva, E., Xing, Z. and Gauldie, J., Dendritic cells
derived frommurine colonic mucosa have unique functional and phe-
notypic characteristics. J. Immunol. 2007. 178: 7984–7993.
1461 Johansson-Lindbom, B., Svensson, M., Pabst, O., Palmqvist, C., Mar-
quez, G., Forster, R. and Agace, W. W., Functional specialization of
gut CD103+ dendritic cells in the regulation of tissue-selective T cell
homing. J. Exp. Med. 2005. 202: 1063–1073.
1462 Harusato, A., Geem, D. and Denning, T. L., Macrophage isolation from
the mouse small and large intestine.Methods Mol. Biol. 2016. 1422: 171–
180.
1463 Gross, M., Salame, T. M. and Jung, S., Guardians of the gut—murine
intestinal macrophages and dendritic cells. Front Immunol 2015. 6: 254.
1464 Helft, J. and Merad, M., Isolation of cutaneous dendritic cells. Methods
Mol. Biol. 2010. 595: 231–233.
1465 Benck, C. J., Martinov, T., Fife, B. T. and Chatterjea, D., Isolation of
infiltrating leukocytes from mouse skin using enzymatic digest and
gradient separation. J Vis Exp 2016: e53638.
1466 Forni, M. F., RamosMaia Lobba, A., Pereira Ferreira, A. H. and Sogayar,
M. C., Simultaneous isolation of three different stem cell populations
from murine skin. PLoS One 2015. 10: e0140143.
1467 Merad, M., Ginhoux, F. and Collin, M., Origin, homeostasis and func-
tion of Langerhans cells and other langerin-expressing dendritic cells.
Nat. Rev. Immunol. 2008. 8: 935–947.
1468 Stutte, S., Jux, B., Esser, C. and Forster, I., CD24a expression levels
discriminate Langerhans cells from dermal dendritic cells in murine
skin and lymph nodes. J. Invest. Dermatol. 2008. 128: 1470–1475.
1469 Malissen, B., Tamoutounour, S. and Henri, S., The origins and func-
tions of dendritic cells andmacrophages in the skin. Nat. Rev. Immunol.
2014. 14: 417–428.
1470 Becht, E.,McInnes, L.,Healy, J.,Dutertre, C. A.,Kwok, I.W. H.,Ng, L. G.,
Ginhoux, F. et al., Dimensionality reduction for visualizing single-cell
data using UMAP. Nat. Biotechnol. 2019. 37: 38–44.
1471 McInnes, L., Healy, J., Saul, N. and Großberger, L., UMAP: uniform
manifold approximation and projection. J. Open Source Softw. 2018. 3:
861.
1472 Ester, M., Kriegel, H. P., Sander, J. and Xu, X., A density-based algo-
rithm for discovering clusters in large spatial databases with noise. In
KDD’96 Proceedings of the Second International Conference on Knowl-
edge Discovery and Data Mining. Portland, OR, 1996, pp. 226–231.
1473 Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir el, A.
D., Tadmor, M. D., Litvin, O. et al., Data-driven phenotypic dissection
of AML reveals progenitor-like cells that correlate with prognosis. Cell
2015. 162: 184–197.
1474 Villani, A. C., Satija, R., Reynolds, G., Sarkizova, S., Shekhar, K.,
Fletcher, J., Griesbeck, M. et al., Single-cell RNA-seq reveals new types
of human blood dendritic cells, monocytes, and progenitors. Science
2017. 356: eaaah4573.
1475 Dutertre, C.-A., Becht, E., Irac, S. E., Khalilnezhad, A., Narang, V.,
Khalilnezhad, S., Ng, P. Y. et al., Single-cell analysis of human
mononuclear phagocytes reveals subset-defining markers and iden-
tifies circulating inflammatory dendritic cells. Immunity 2019. 51: 573–
589.e8.
1476 Casanova-Acebes, M., Pitaval, C., Weiss, L. A., Nombela-Arrieta, C.,
Chevre, R., N, A. G.,Kunisaki, Y.,Zhang, D. et al., Rhythmicmodulation
of the hematopoietic niche through neutrophil clearance. Cell 2013.
153: 1025–1035.
1477 Maueroder, C., Mahajan, A., Paulus, S., Gosswein, S., Hahn, J., Kien-
hofer, D., Biermann, M. H. et al., Menage-a-Trois: the ratio of bicar-
bonate to CO2 and the pH regulate the capacity of neutrophils to form
NETs. Front. Immunol. 2016. 7: 583.
1478 Evrard, M., Kwok, I. W. H., Chong, S. Z., Teng, K. W. W., Becht, E.,
Chen, J., Sieow, J. L. et al., Developmental analysis of bone marrow
neutrophils reveals populations specialized in expansion, trafficking,
and effector functions. Immunity 2018. 48: 364–379 e368.
1479 Kim, M. H., Yang, D., Kim, M., Kim, S. Y., Kim, D. and Kang, S. J., A
late-lineagemurine neutrophil precursor population exhibits dynamic
changes during demand-adapted granulopoiesis. Sci. Rep. 2017. 7:
39804.
1480 Zhu, Y. P., Padgett, L., Dinh, H. Q.,Marcovecchio, P., Blatchley, A.,Wu,
R., Ehinger, E. et al., Identification of an early unipotent neutrophil pro-
genitor with pro-tumoral activity in mouse and human bone marrow.
Cell Rep. 2018. 24: 2329–2341 e2328.
1481 Geering, B., Stoeckle, C., Conus, S. and Simon, H. U., Living and dying
for inflammation: neutrophils, eosinophils, basophils. Trends Immunol.
2013. 34: 398–409.
1482 Borregaard, N., Neutrophils, frommarrow to microbes. Immunity 2010.
33: 657–670.
1483 Ley, K., Hoffman, H. M., Kubes, P., Cassatella, M. A., Zychlinsky, A.,
Hedrick, C. C. and Catz, S. D., Neutrophils: new insights and open
questions. Sci. Immunol. 2018. 3.
1484 Ng, L. G., Ostuni, R. and Hidalgo, A., Heterogeneity of neutrophils. Nat.
Rev. Immunol. 2019. 19: 255–265.
1485 Terstappen, L. W., Safford, M. and Loken, M. R., Flow cytometric anal-
ysis of human bonemarrow. III. Neutrophil maturation. Leukemia 1990.
4: 657–663.
1486 Satake, S.,Hirai, H.,Hayashi, Y., Shime, N., Tamura, A., Yao, H., Yosh-
ioka, S. et al., C/EBPbeta is involved in the amplification of early gran-
ulocyte precursors during candidemia-induced “emergency” granu-
lopoiesis. J. Immunol. 2012. 189: 4546–4555.
1487 Theilgaard-Monch, K., Jacobsen, L. C., Borup, R., Rasmussen, T., Bjer-
regaard, M. D., Nielsen, F. C., Cowland, J. B. et al., The transcriptional
programof terminal granulocytic differentiation. Blood 2005. 105: 1785–
1796.
1488 Garley, M. and Jablonska, E., Heterogeneity among neutrophils. Arch.
Immunol. Ther. Exp. 2018. 66: 21–30.
1489 Scapini, P., Marini, O., Tecchio, C. and Cassatella, M. A., Human neu-
trophils in the saga of cellular heterogeneity: insights and open ques-
tions. Immunol. Rev. 2016. 273: 48–60.
1490 Coffelt, S. B., Kersten, K., Doornebal, C. W., Weiden, J., Vrijland, K.,
Hau, C. S., Verstegen, N. J. M. et al., IL-17-producing gammadelta
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1950 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
T cells and neutrophils conspire to promote breast cancer metasta-
sis. Nature 2015. 522: 345–348.
1491 Engblom, C., Pfirschke, C., Zilionis, R., Da Silva Martins, J., Bos, S.
A., Courties, G., Rickelt, S. et al., Osteoblasts remotely supply lung
tumors with cancer-promoting SiglecF(high) neutrophils. Science 2017.
358: eaal5081.
1492 Youn, J. I., Collazo, M., Shalova, I. N., Biswas, S. K. and Gabrilovich,
D. I., Characterization of the nature of granulocytic myeloid-derived
suppressor cells in tumor-bearingmice. J. Leukoc. Biol. 2012. 91: 167–181.
1493 McAlpine, C. S., Kiss, M. G., Rattik, S., He, S., Vassalli, A., Valet, C.,
Anzai, A. et al., Sleep modulates haematopoiesis and protects against
atherosclerosis. Nature 2019. 566: 383–387.
1494 Grassi, L., Pourfarzad, F., Ullrich, S., Merkel, A., Were, F., Carrillo-de-
Santa-Pau, E., Yi, G. et al., Dynamics of transcription regulation in
human bone marrow myeloid differentiation to mature blood neu-
trophils. Cell Rep. 2018. 24: 2784–2794.
1495 Friedenstein, A. J., Chailakhjan, R. K. and Lalykina, K. S., The develop-
ment of fibroblast colonies in monolayer cultures of guinea-pig bone
marrow and spleen cells. Cell Tissue Kinet. 1970. 3: 393–403.
1496 Friedenstein, A. J., Chailakhyan, R. K., Latsinik, N. V., Panasyuk, A. F.
and Keiliss-Borok, I. V., Stromal cells responsible for transferring the
microenvironment of the hemopoietic tissues. Cloning in vitro and
retransplantation in vivo. Transplantation 1974. 17: 331–340.
1497 Frenette, P. S., Pinho, S., Lucas, D. and Scheiermann, C., Mesenchy-
mal stem cell: keystone of the hematopoietic stem cell niche and a
stepping-stone for regenerative medicine. Annu. Rev. Immunol. 2013.
31: 285–316.
1498 Pinho, S. and Frenette, P. S., Haematopoietic stem cell activity and
interactions with the niche. Nat. Rev. Mol. Cell Biol. 2019.
1499 Chan, C. K., Chen, C. C., Luppen, C. A., Kim, J. B., DeBoer, A. T.,
Wei, K., Helms, J. A. et al., Endochondral ossification is required for
haematopoietic stem-cell niche formation. Nature 2009. 457: 490–494.
1500 Mendez-Ferrer, S., Michurina, T. V., Ferraro, F., Mazloom, A. R.,
Macarthur, B. D., Lira, S. A., Scadden, D. T. et al., Mesenchymal and
haematopoietic stem cells form a unique bone marrow niche. Nature
2010. 466: 829–834.
1501 Kunisaki, Y., Bruns, I., Scheiermann, C., Ahmed, J., Pinho, S., Zhang,
D., Mizoguchi, T. et al., Arteriolar niches maintain haematopoietic
stem cell quiescence. Nature 2013. 502: 637–643.
1502 Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G. and Morrison, S. J.,
Leptin-receptor-expressing mesenchymal stromal cells represent the
main source of bone formed by adult bone marrow. Cell Stem Cell 2014.
15: 154–168.
1503 Omatsu, Y., Sugiyama, T., Kohara, H., Kondoh, G., Fujii, N., Kohno,
K. and Nagasawa, T., The essential functions of adipo-osteogenic pro-
genitors as the hematopoietic stem and progenitor cell niche. Immunity
2010. 33: 387–399.
1504 Greenbaum, A., Hsu, Y. M., Day, R. B., Schuettpelz, L. G., Christopher,
M. J., Borgerding, J. N.,Nagasawa, T. et al., CXCL12 in early mesenchy-
mal progenitors is required for haematopoietic stem-cellmaintenance.
Nature 2013. 495: 227–230.
1505 Mizoguchi, T., Pinho, S., Ahmed, J., Kunisaki, Y., Hanoun, M.,Mendel-
son, A., Ono, N. et al., Osterix marks distinct waves of primitive and
definitive stromal progenitors during bone marrow development. Dev.
Cell 2014. 29: 340–349.
1506 Chan, C. K., Seo, E. Y., Chen, J. Y., Lo, D.,McArdle, A., Sinha, R., Tevlin,
R. et al., Identification and specification of the mouse skeletal stem
cell. Cell 2015. 160: 285–298.
1507 Marecic, O., Tevlin, R., McArdle, A., Seo, E. Y., Wearda, T., Duldulao,
C., Walmsley, G. G. et al., Identification and characterization of an
injury-induced skeletal progenitor. Proc Natl Acad Sci USA 2015. 112:
9920–9925.
1508 Debnath, S., Yallowitz, A. R., McCormick, J., Lalani, S., Zhang, T., Xu,
R., Li, N. et al., Discovery of a periosteal stem cell mediating intramem-
branous bone formation. Nature 2018. 562: 133–139.
1509 Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini,
F., Krause, D., Deans, R. et al., Minimal criteria for defining multipo-
tent mesenchymal stromal cells. The International Society for Cellular
Therapy position statement. Cytotherapy 2006. 8: 315–317.
1510 Suire, C., Brouard, N., Hirschi, K. and Simmons, P. J., Isolation of the
stromal-vascular fraction of mouse bone marrow markedly enhances
the yield of clonogenic stromal progenitors. Blood 2012. 119: e86–95.
1511 Pinho, S., Lacombe, J., Hanoun, M., Mizoguchi, T., Bruns, I., Kunisaki,
Y. and Frenette, P. S., PDGFRalpha and CD51 mark human nestin+
sphere-forming mesenchymal stem cells capable of hematopoietic
progenitor cell expansion. J. Exp. Med. 2013. 210: 1351–1367.
1512 Morikawa, S., Mabuchi, Y., Kubota, Y., Nagai, Y., Niibe, K., Hiratsu,
E., Suzuki, S. et al., Prospective identification, isolation, and systemic
transplantation of multipotent mesenchymal stem cells in murine
bone marrow. J. Exp. Med. 2009. 206: 2483–2496.
1513 Houlihan, D. D.,Mabuchi, Y.,Morikawa, S.,Niibe, K.,Araki, D., Suzuki,
S., Okano, H. et al., Isolation of mouse mesenchymal stem cells on the
basis of expression of Sca-1 and PDGFR-alpha.Nat. Protoc. 2012. 7: 2103–
2111.
1514 Worthley, D. L., Churchill, M., Compton, J. T., Tailor, Y., Rao, M., Si,
Y., Levin, D. et al., Gremlin 1 identifies a skeletal stem cell with bone,
cartilage, and reticular stromal potential. Cell 2015. 160: 269–284.
1515 Boulais, P. E., Mizoguchi, T., Zimmerman, S., Nakahara, F., Vivie, J.,
Mar, J. C., van Oudenaarden, A. et al., Themajority of CD45(-) Ter119(-)
CD31(-) bone marrow cell fraction is of hematopoietic origin and con-
tains erythroid and lymphoid progenitors. Immunity 2018. 49: 627–639,
e626.
1516 Morrison, S. J., Uchida, N. and Weissman, I. L., The biology of
hematopoietic stem cells. Annu. Rev. Cell. Dev. Biol. 1995. 11: 35–71.
1517 Spangrude, G. J., Brooks, D. M. and Tumas, D. B., Long-term repopula-
tion of irradiatedmicewith limiting numbers of purifiedhematopoietic
stem cells: in vivo expansion of stem cell phenotype but not function.
Blood 1995. 85(4): 1006–1016.
1518 Cheshier, S. H., Morrison, S. J., Liao, X. and Weissman, I. L., In
vivo proliferation and cell cycle kinetics of long-term self-renewing
hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 1999. 96(6): 3120–
3125.
1519 Calvi, L. M., Adams, G. B., Weibrecht, K. W., Weber, J. M., Olson, D.
P., Knight, M. C., Martin, R. P. et al., Osteoblastic cells regulate the
haematopoietic stem cell niche. Nature 2003. 425(6960): 841–846.
1520 Arai, F., Hirao, A., Ohmura, M., Sato, H.,Matsuoka, S., Takubo, K., Ito,
K. et al., Tie2/angiopoietin-1 signaling regulates hematopoietic stem
cell quiescence in the bone marrow niche. Cell 2004. 118(2): 149–161.
1521 Zhang, J., Niu, C., Ye, L., Huang, H., He, X., Tong, W. G., Ross, J. et al.,
Identification of the haematopoietic stem cell niche and control of the
niche size. Nature 2003. 425(6960): 836–841.
1522 Hofer, T., Busch, K., Klapproth, K. and Rodewald, H. R., Fate mapping
and quantitation of hematopoiesis in vivo. Annu. Rev. Immunol. 2016.
34: 449–478.
1523 Carrelha, J., Meng, Y., Kettyle, L. M., Luis, T. C., Norfo, R., Alcolea, V.,
Boukarabila, H. et al., Hierarchically related lineage-restricted fates of
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1951
multipotent haematopoietic stem cells. Nature 2018. 554(7690): 106–
111.
1524 Haas, S.,Hansson, J.,Klimmeck, D., Loeffler, D.,Velten, L.,Uckelmann,
H., Wurzer, S. et al., Inflammation-induced emergency megakary-
opoiesis driven by hematopoietic stem cell-like megakaryocyte pro-
genitors. Cell Stem Cell 2015. 17(4): 422–434.
1525 Medvinsky, A., Rybtsov, S. and Taoudi, S., Embryonic origin of the
adult hematopoietic system: advances and questions. Development
2011. 138(6): 1017–1031.
1526 Kajikhina, K.,Melchers, F. and Tsuneto, M., Chemokine polyreactivity
of IL7Ralpha+CSF-1R+ lympho-myeloid progenitors in the developing
fetal liver. Sci. Rep. 2015. 5: 12817.
1527 Mikkola, H. K. and Orkin, S. H., The journey of developing hematopoi-
etic stem cells. Development 2006. 133(19): 3733–3744.
1528 Majeti, R., Park, C. Y., Weissman, I. L., Identification of a hierarchy of
multipotent hematopoietic progenitors in human cord blood. Cell Stem
Cell 2007. 1(6): 635–645.
1529 Notta, F., Zandi, S., Takayama, N., Dobson, S., Gan, O. I., Wilson, G.,
Kaufmann, K. B. et al., Distinct routes of lineage development reshape
the human blood hierarchy across ontogeny. Science 2016. 351(6269):
aab2116.
1530 Cosgun, K. N., Rahmig, S., Mende, N., Reinke, S., Hauber, I., Schafer,
C., Petzold, A. et al., Kit regulates HSC engraftment across the human-
mouse species barrier. Cell Stem Cell 2014. 15(2): 227–238.
1531 Kiel, M. J., Yilmaz, O. H., Iwashita, T., Yilmaz, O. H., Terhorst, C. and
Morrison, S. J., SLAM family receptors distinguish hematopoietic stem
and progenitor cells and reveal endothelial niches for stem cells. Cell
2005. 121(7): 1109–1121.
1532 Papathanasiou, P., Attema, J. L., Karsunky, H., Xu, J., Smale, S. T. and
Weissman, I. L., Evaluation of the long-term reconstituting subset of
hematopoietic stem cells with CD150. Stem Cells 2009. 27(10): 2498–
2508.
1533 Yilmaz, O. H., Kiel, M. J. and Morrison, S. J., SLAM family markers are
conserved among hematopoietic stem cells from old and reconstituted
mice and markedly increase their purity. Blood 2006. 107(3): 924–930.
1534 Pei, W., Feyerabend, T. B., Rossler, J., Wang, X., Postrach, D., Busch,
K., Rode, I. et al., Polylox barcoding reveals haematopoietic stem cell
fates realized in vivo. Nature 2017. 548(7668): 456–460.
1535 Busch, K., Klapproth, K., Barile, M., Flossdorf, M., Holland-Letz, T.,
Schlenner, S. M., Reth, M. et al., Fundamental properties of unper-
turbed haematopoiesis from stem cells in vivo. Nature 2015. 518(7540):
542–546.
1536 Gomez Perdiguero, E., Klapproth, K., Schulz, C., Busch, K., Azzoni,
E., Crozet, L., Garner, H. et al., Tissue-resident macrophages origi-
nate from yolk-sac-derived erythro-myeloid progenitors. Nature 2015.
518(7540): 547–551.
1537 Tornack, J., Reece, S. T., Bauer, W. M., Vogelzang, A., Bandermann,
S., Zedler, U., Stingl, G. et al., Human and Mouse Hematopoietic Stem
Cells Are a Depot for Dormant Mycobacterium tuberculosis. PLoS One
2017. 12(1): e0169119.
1538 Spangrude, G. J., Heimfeld, S. and Weissman, I. L., Purification and
characterization of mouse hematopoietic stem cells. Science 1988.
241(4861): 58–62.
1539 Ikuta, K. and Weissman, I. L., Evidence that hematopoietic stem cells
express mouse c-kit but do not depend on steel factor for their gener-
ation. Proc. Natl. Acad. Sci. USA 1992. 89(4): 1502–1506.
1540 Morrison, S. J. andWeissman, I. L., The long-term repopulating subset
of hematopoietic stem cells is deterministic and isolatable by pheno-
type. Immunity 1994. 1(8): 661–673.
1541 Okada, S., Nakauchi, H., Nagayoshi, K., Nishikawa, S., Miura, Y. and
Suda, T., In vivo and in vitro stem cell function of c-kit- and Sca-1-
positive murine hematopoietic cells. Blood 1992. 80: 3044–3050.
1542 Balazs, A. B., Fabian, A. J., Esmon, C. T. and Mulligan, R. C., Endothe-
lial protein C receptor (CD201) explicitly identifies hematopoietic stem
cells in murine bone marrow. Blood 2006. 107: 2317–2321.
1543 Osawa, M., Hanada, K., Hamada, H. and Nakauchi, H., Long-term
lymphohematopoietic reconstitution by a single CD34-low/negative
hematopoietic stem cell. Science 1996. 273: 242–245.
1544 Tornack, J., Kawano, Y., Garbi, N., Hammerling, G. J.,Melchers, F. and
Tsuneto, M., Flt3 ligand-eGFP-reporter expression characterizes func-
tionally distinct subpopulations of CD150(+) long-term repopulating
murine hematopoietic stem cells. Eur. J. Immunol. 2017. 47: 1477–1487.
1545 Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A. M., Sampath, J.,
Morris, J. J., Lagutina, I. et al., The ABC transporter Bcrp1/ABCG2 is
expressed in a wide variety of stem cells and is a molecular determi-
nant of the side-population phenotype. Nat. Med. 2001. 7: 1028–1034.
1546 Ergen, A. V., Jeong,M., Lin, K. K.,Challen, G. A.,Goodell, M. A., Isolation
and characterization of mouse side population cells. Methods Mol. Biol.
2013. 946: 151–162.
1547 Lu, R., Neff, N. F., Quake, S. R. and Weissman, I. L., Tracking single
hematopoietic stem cells in vivo using high-throughput sequencing
in conjunction with viral genetic barcoding. Nat. Biotechnol. 2011. 29:
928–933.
1548 Bystrykh, L. V., de Haan, G. and Verovskaya, E., Barcoded vector
libraries and retroviral or lentiviral barcoding of hematopoietic stem
cells. Methods Mol. Biol. 2014. 1185: 345–360.
1549 Kawano, Y., Petkau, G., Stehle, C., Durek, P., Heinz, G. A., Tanimoto,
K., Karasuyama, H. et al., Stable lines and clones of long-term pro-
liferating normal, genetically unmodified murine common lymphoid
progenitors. Blood 2018. 131(18): 2026–2035.
1550 Knapp, D. J., Hammond, C. A., Miller, P. H., Rabu, G. M., Beer, P. A.,
Ricicova, M., Lecault, V. et al., Dissociation of survival, proliferation,
and state control in human hematopoietic stem cells. Stem Cell Rep.
2017. 8(1): 152–162.
1551 Yamamoto, R., Morita, Y., Ooehara, J., Hamanaka, S., Onodera, M.,
Rudolph, K. L., Ema, H. et al., Clonal analysis unveils self-renewing
lineage-restricted progenitors generated directly from hematopoietic
stem cells. Cell 2013. 154(5): 1112–1126.
1552 Uchida, N. and Weissman, I. L., Searching for hematopoietic stem
cells: evidence that Thy-1.1lo Lin- Sca-1+ cells are the only stem cells
in C57BL/Ka-Thy-1.1 bone marrow. J. Exp. Med. 1992. 175(1): 175–184.
1553 Murray, L., Chen, B., Galy, A., Chen, S., Tushinski, R., Uchida, N.,
Negrin, R. et al., Enrichment of human hematopoietic stem cell activ-
ity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral
blood. Blood 1995. 85(2): 368–378.
1554 Civin, C. I., Strauss, L. C., Brovall, C., Fackler, M. J., Schwartz, J. F. and
Shaper, J. H., Antigenic analysis of hematopoiesis. III. A hematopoi-
etic progenitor cell surface antigen defined by a monoclonal antibody
raised against KG-1a cells. J. Immunol. 1984. 133(1): 157–165.
1555 Goodell, M. A., Rosenzweig, M.,Kim, H.,Marks, D. F.,DeMaria, M., Par-
adis, G., Grupp, S. A. et al., Dye efflux studies suggest that hematopoi-
etic stem cells expressing low or undetectable levels of CD34 antigen
exist in multiple species. Nat. Med. 1997. 3(12): 1337–1345.
1556 Kang, Y., Chao, N. J., Aversa, F., Unmanipulated or CD34 selected hap-
lotype mismatched transplants. Curr. Opin. Hematol. 2008. 15(6): 561–
567.
1557 Wang, J., Kimura, T., Asada, R., Harada, S., Yokota, S., Kawamoto,
Y., Fujimura, Y. et al., SCID-repopulating cell activity of human cord
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1952 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
blood-derived CD34- cells assured by intra-bone marrow injection.
Blood 2003. 101(8): 2924–2931.
1558 Bhatia, M., Bonnet, D., Murdoch, B., Gan, O. I. and Dick, J. E., A newly
discovered class of humanhematopoietic cellswith SCID-repopulating
activity. Nat. Med. 1998. 4(9): 1038–1045.
1559 Danet, G. H., Luongo, J. L., Butler, G., Lu, M. M., Tenner, A. J., Simon, M.
C. and Bonnet, D. A., C1qRp defines a new human stem cell population
with hematopoietic and hepatic potential. Proc. Natl. Acad. Sci. USA
2002. 99(16): 10441–10445.
1560 Herbein, G., Sovalat, H., Wunder, E., Baerenzung, M., Bachorz, J.,
Lewandowski, H., Schweitzer, C. et al., Isolation and identification of
two CD34+ cell subpopulations from normal human peripheral blood.
Stem Cells 1994. 12: 187–197.
1561 Bhatia, M., Wang, J. C., Kapp, U., Bonnet, D. and Dick, J. E., Purifica-
tion of primitive human hematopoietic cells capable of repopulating
immune-deficient mice. Proc. Natl. Acad. Sci. USA 1997. 94(10): 5320–
5325.
1562 Notta, F., Doulatov, S., Laurenti, E., Poeppl, A., Jurisica, I. and Dick,
J. E., Isolation of single human hematopoietic stem cells capable of
long-term multilineage engraftment. Science 2011. 333(6039): 218–221.
1563 Fares, I.,Chagraoui, J., Lehnertz, B.,MacRae, T.,Mayotte, N.,Tomellini,
E., Aubert, L. et al., EPCR expression marks UM171-expanded CD34(+)
cord blood stem cells. Blood 2017. 129(25): 3344–3351.
1564 Iwasaki, H., Arai, F., Kubota, Y.,Dahl, M., Suda, T., Endothelial protein
C receptor-expressing hematopoietic stem cells reside in the perisinu-
soidal niche in fetal liver. Blood 2010. 116(4): 544–553.
1565 Galuzzi, L., Vacchelli, E., Bravo-San Pedro, J. M., Buque´, A., Senovilla,
L., Baracco, E. E., Bloy, N. et al., Classification of current anticancer
immunotherapies. Oncotarget 2015. 5(24): 12472–12508.
1566 Hanahan, D. andWeinberg, R. A., Hallmarks of cancer – thenext gener-
ation. Cell 2011. 144: 646–674. https://doi.org/10.1016/j.cell.2011.02.013
1567 Lansdorp, P. M., Sutherland, H. J. and Eaves, C. J., Selective expression
of CD45 isoforms on functional subpopulations of CD34+ hemopoi-
etic cells from human bone marrow. J. Exp. Med. 1990. 172: 363–366.
https://doi.org/363-3660022-1007/90/07/0363/04
1568 van Dongen, J. J. M., Lhermitte, L., Bo¨ttcher, S., Almeida, J., van
der Velden, J. V. H., Flores-Montero, J., Rawstron, A. et al., on
behalf of the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708).
EuroFlow antibody panels for standardized n-dimensional flow cyto-
metric immunophenotyping of normal, reactive and malignant leuko-
cytes. Leukemia 2012. 26: 1908–1975.
1569 Streitz, M., Miloud, T., Kapinsky, M., Reed, M. R., Magari, R., Geissler,
E. K., Hutchinson, J. A. et al., Standardization of whole blood immune
phenotype monitoring for clinical trials: panels and methods from the
ONE study. Transplant Res. 2013. 2(1): 17.
1570 Alix-Panabie`res, C. and Pantel, K., Challenges in circulat-
ing tumour cell research. Nat. Rev. Cancer 2014. 14: 623–631.
https://doi.org/10.1038/nrc3820
1571 Lopresti, A., Malergue, F., Bertucci, F., Liberatoscioli, M. L., Garnier,
S., DaCosta, Q., Finetti, P. et al., Sensitive and easy screening for cir-
culating tumor cells by flow cytometry. JCI Insight. 2019. 5: 128180.
https://doi.org/10.1172/jci.insight.128180
1572 Schumacher, T. and Schreiber, R. D., Neoantigens in cancer
immunotherapy. Science 2015. 348(6230): 69–74.
1573 Grizzi, F., Mirandola, L., Qehajaj, D., Cobos, E., Figueroa, J. A. and
Chiriva-Internati, M., Cancer-testis antigens and immunotherapy in
the light of cancer complexity. Int. Rev. Immunol. 2015. 34: 143–153.
https://doi.org/10.3109/08830185.2015.1018418
1574 Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M. and
van Hall, T., The urgent need to recover MHC class I in cancers
for effective immunotherapy. Curr. Opin. Immunol. 2016. 39: 44–51.
https://doi.org/10.1016/j.coi.2015.12.007
1575 Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W. and Jung, H., Regula-
tion of ligands for the NKG2D activating receptor. Annu. Rev. Immunol.
2013. 31: 413–441.
1576 Sers, C., Kuner, R., Fak, C. S., Lund, P., Sueltmann, H., Braun, M.,
Buness, A. et al., Down-regulation of HLA Class I and NKG2D ligands
through a concerted action of MAPK and DNA methyltransferases in
colorectal cancer cells. Int. J. Cancer 2009. 125(7): 1626–1639.
1577 Luo, Z., Wu, R. R., Lv, L., Li, P., Zhang, L. Y., Hao, Q. L. and Li, W.,
Prognostic value of CD44 expression in non-small cell lung cancer: a
systematic review. Int. J. Clin. Exp. Pathol. 2014. 7(7): 3632–3646.
1578 Paulis, Y. W., Huijbers, E. J., van der Schaft, D. W., Soetekouw, P. M.,
Pauwels, P., Tjan-Heijnen, V. C. and Griffioen, A. W., CD44 enhances
tumor aggressiveness by promoting tumor cell plasticity. Oncotarget
2015. 6(23): 19634–19646.
1579 http://www.cancerresearchuk.org/about-cancer/what-is-cancer/how-
cancer-starts/types-of-cancer#carcinomas
1580 Weng, Y. R., Cui, Y. and Fang, J. Y., Biological functions of cytokeratin
18 in cancer. Mol. Cancer Res. 2012. 10(4); 485–493.
1581 Appert-Collin, A., Hubert, P., Cre´mel, G. and Bennasroune, A., Role of
ErbB receptors in cancer cell migration and invasion. Front. Pharmacol.
2015. https://doi.org/10.3389/fphar.2015.00283
1582 http://www.cancer.org/cancer/breastcancer/detailedguide/breast-
cancer-breast-cancer-types
1583 Park, J. W., Lee, J. K., Phillips, J. W., Huang, P., Cheng, D., Huang, J.
and Witte, O. N., Prostate epithelial cell of origin determines cancer
differentiation state in an organoid transformation assay. Proc. Natl.
Acad. Sci. USA 2016. 113: 4482–4487.
1584 http://screening.iarc.fr/colpochap.php?chap=2
1585 https://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb2/bb2-
chap1.pdf
1586 http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-
cancer-what-is-bladder-cancer
1587 Hruban, R. H. and Fukushima, N., Pancreatic adenocarcinoma: update
on the surgical pathology of carcinomas of ductal origin and PanINs.
Modern Pathol. 2007. 20: 61–70.
1588 DuBois, S. G., Epling, C. L., Teague, J., Matthay, K. K. and Sin-
clair, E., Flow cytometric detection of ewing sarcoma cells in periph-
eral blood and bone marrow. Pediatr. Blood Cancer 2010. 54(1): 13–18.
https://doi.org/10.1002/pbc.22245
1589 Avey, D., Brewers, B. and Zhu, F., Recent advances in the study of
Kaposi’s sarcoma-associated herpesvirus replication and athogenesis.
Virol Sin. 2015. 30(2): 130-145. https://doi.org/10.1007/s12250-015-3595-
2
1590 Deel, M. D., Li, J. J., Crose, L. E. and Linardic, C. M., A Review:molecular
aberrations within hippo signaling in bone and soft-tissue sarcomas.
Front Oncol. 2015. 5: 190. https://doi.org/10.3389/fonc.2015.00190
1591 Sullivan, R. J., The role of mitogen-activated protein targeting in
melanoma beyond BRAFV600. Curr. Opin. Oncol. 2016. 28(2): 185–191.
1592 Sucker, A.,Zhao, F.,Real, B.,Heeke, C.,Bielefeld, N.,Maßen, S.,Horn, S.
et al., Genetic evolution of T cell resistance in the course of melanoma
progression. Clin. Canc. Res. 2014. 20(24): 6593–6604.
1593 Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri,
L., Capanni, M. et al., NCRs and DNAM-1 mediate NK cell recognition
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1953
and lysis of human andmousemelanoma cell lines in vitro and in vivo.
J. Clin. Invest. 2009. 119(5): 1251–1263. https://doi.org/10.1172/JCI36022
1594 Binder, D. C., Davis, A. A. and Wainwright, D. A., Immunotherapy for
cancer in the central nervous system: Current and future directions.
Oncoimmunology 2015. 5(2): e1082027.
1595 Razavi, S. M., Lee, K. E., Jin, B. E., Aujla, P. S., Gholamin, S. and Li, G.,
Immune Evasion Strategies of Glioblastoma. Frnt. Surg. 2016. 3: 11.
1596 Seifert, M., Garbe, M., Friedrich, B.,Mittelbronn, M. and Klink, B., Com-
parative transcriptomics reveals similarities and differences between
astrocytoma grades. BMC Cancer 2015. 15: 952.
1597 Dranoff, G., Experimental mouse tumour models: what can be learnt
about human cancer immunology? Nat. Rev. Immunol. 2012. 12: 61–66.
https://doi.org/10.1038/nri3129
1598 Morton, J. J., Bird, G., Fefaeli, Y. and Jimeno, A., Humanized mouse
xenograft models: narrowing the tumor-microenvironment gap. Canc.
Res. 2016. 76: 6153–6158.
1599 Huntington, N. D., Xu, Y., Puthalakath, H., Light, A., Willis, S. N.,
Strasser, A. et al., CD45 links the B cell receptor with cell survival
and is required for the persistence of germinal centers. Nat. Immunol.
2006. 7(2): 190–198.
1600 Oracki, S. A.,Walker, J. A., Hibbs, M. L., Corcoran, L. M. and Tarlinton,
D.M., Plasma cell development and survival. Immunol. Rev. 2010. 237(1):
140–159.
1601 Brynjolfsson, S. F., Persson Berg, L., Olsen Ekerhult, T., Rimkute, I.,
Wick, M. J., Martensson, I. L. et al., Long-lived plasma cells in mice
and men. Front. Immunol. 2018. 9: 2673.
1602 Steensma, D. P., Gertz, M. A., Greipp, P. R., Kyle, R. A., Lacy, M. Q.,
Lust, J. A. et al., A high bone marrow plasma cell labeling index in
stable plateau-phase multiple myeloma is a marker for early disease
progression and death. Blood 2001. 97(8): 2522–2523.
1603 Bakkus, M. H.,Heirman, C.,Van Riet, I.,Van Camp, B. and Thielemans,
K., Evidence that multiple myeloma Ig heavy chain VDJ genes contain
somatic mutations but show no intraclonal variation. Blood 1992. 80(9):
2326–2335.
1604 Kosmas, C., Stamatopoulos, K., Stavroyianni, N., Zoi, K., Belessi, C.,
Viniou, N. et al., Origin anddiversification of the clonogenic cell inmul-
tiple myeloma: lessons from the immunoglobulin repertoire. Leukemia
2000. 14(10): 1718–1726.
1605 Pfeifer, S., Perez-Andres, M., Ludwig, H., Sahota, S. S. and Zojer,
N., Evaluating the clonal hierarchy in light-chain multiple myeloma:
implications against themyeloma stem cell hypothesis. Leukemia 2011.
25(7): 1213–1216.
1606 Hansmann, L.,Han, A., Penter, L., Liedtke, M. and Davis, M. M., Clonal
expansion and interrelatedness of distinct B-lineage compartments in
multiple myeloma bone marrow. Cancer Immunol. Res. 2017. 5: 744–754.
1607 Hideshima, T., Nakamura, N., Chauhan, D. and Anderson, K. C., Bio-
logic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple
myeloma. Oncogene 2001. 20(42): 5991–6000.
1608 de Haart, S. J., van de Donk, N.W.,Minnema, M. C.,Huang, J. H.,Aarts-
Riemens, T.,Bovenschen, N. et al., Accessory cells of themicroenviron-
ment protect multiple myeloma from T-cell cytotoxicity through cell
adhesion-mediated immune resistance. Clin. Cancer Res. 2013. 19(20):
5591–5601.
1609 Hideshima, T., Bergsagel, P. L., Kuehl, W. M. and Anderson, K. C.,
Advances in biology of multiple myeloma: clinical applications. Blood
2004. 104: 607–618.
1610 Mitsiades, C. S., Mitsiades, N., Munshi, N. C. and Anderson, K. C.,
Focus on multiple myeloma. Cancer Cell 2004. 6(5): 439–444.
1611 Mitsiades, C. S., Mitsiades, N. S., Richardson, P. G., Munshi, N. C. and
Anderson, K. C., Multiple myeloma: a prototypic disease model for
the characterization and therapeutic targeting of interactions between
tumor cells and their local microenvironment. J. Cell. Biochem. 2007.
101(4): 950–968.
1612 Bianchi, G. andMunshi, N. C., Pathogenesis beyond the cancer clone(s)
in multiple myeloma. Blood 2015. 125(20): 3049–3058.
1613 Keats, J. J., Chesi, M., Egan, J. B., Garbitt, V. M., Palmer, S. E., Braggio,
E. et al., Clonal competition with alternating dominance in multiple
myeloma. Blood 2012. 120(5): 1067–1076.
1614 Lohr, J. G., Kim, S., Gould, J., Knoechel, B., Drier, Y., Cotton, M. J. et al.,
Genetic interrogation of circulating multiple myeloma cells at single-
cell resolution. Sci. Transl. Med. 2016. 8(363): 363ra147.
1615 Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M.
S., Auclair, D. et al., Widespread genetic heterogeneity in multiple
myeloma: implications for targeted therapy. Cancer Cell 2014. 25(1): 91–
101.
1616 Paino, T., Paiva, B., Sayagues, J. M.,Mota, I., Carvalheiro, T., Corchete,
L. A. et al., Phenotypic identification of subclones inmultiplemyeloma
with different chemoresistant, cytogenetic and clonogenic potential.
Leukemia 2015. 29(5): 1186–1194.
1617 Arroz, M., Came, N., Lin, P., Chen, W., Yuan, C., Lagoo, A. et al., Con-
sensus guidelines on plasma cell myeloma minimal residual disease
analysis and reporting. Cytom. B Clin. Cytom. 2016. 90(1): 31–39.
1618 Flores-Montero, J., de Tute, R., Paiva, B., Perez, J. J., Bottcher, S.,Wind,
H. et al., Immunophenotype of normal vs. myeloma plasma cells:
Toward antibody panel specifications for MRD detection in multiple
myeloma. Cytom. B Clin. Cytom. 2016. 90(1): 61–72.
1619 Jelinek, T. and Hajek, R., Monoclonal antibodies—a new era in the
treatment of multiple myeloma. Blood Rev. 2016. 30(2): 101–110.
1620 Paiva, B., Puig, N., Cedena, M. T., de Jong, B. G., Ruiz, Y., Rapado, I.
et al., Differentiation stage of myeloma plasma cells: biological and
clinical significance. Leukemia 2017. 31(2): 382–392.
1621 Lisenko, K., Schonland, S., Hegenbart, U., Wallenwein, K., Braun, U.,
Mai, E. K. et al., Potential therapeutic targets in plasma cell disorders:
a flow cytometry study. Cytom. B Clin. Cytom. 2017. 92(2): 145–152.
1622 Berliner, N., Ault, K. A., Martin, P. and Weinberg, D. S., Detection of
clonal excess in lymphoproliferative disease by kappa/lambda analy-
sis: correlation with immunoglobulin gene DNA rearrangement. Blood
1986. 67(1): 80–85.
1623 Smock, K. J., Perkins, S. L. and Bahler, D. W., Quantitation of plasma
cells in bone marrow aspirates by flow cytometric analysis compared
with morphologic assessment. Arch. Pathol. Lab. Med. 2007. 131(6): 951–
955.
1624 Lokhorst, H. M., Laubach, J. and Nahi, H., Dose-dependent efficacy of
daratumumab (DARA) as monotherapy in patients with relapsed or
refractory multiple myeloma (RR MM). J Clin. Oncol. 2014. 32: abstract
8513.
1625 Lammerts van Bueren, J., Jakobs, D. and Kaldenhoven, N., Direct in
vitro comparison of daratumumab with surrogate analogs of CD38
antibodies MOR03087, SAR650984 and Ab79. In: 56th ASH Annual Meet-
ing & Exposition: Oral and Poster Abstracts, 2014.
1626 Oberle, A., Brandt, A., Alawi, M., Langebrake, C., Janjetovic, S.,
Wolschke, C. et al., Long-term CD38 saturation by daratumumab
interferes with diagnostic myeloma cell detection. Haematologica 2017.
102(9): e368–e370.
1627 Perincheri, S., Torres, R., Tormey, C. A., Smith, B. R., Rinder, H. M. and
Siddon, A. J., Daratumumab interferes with flow cytometric evaluation
of multiple myeloma. 2016. 128(22): 5630–5630.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1954 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
1628 Malaer, J. D. and Mathew, P. A., CS1 (SLAMF7, CD319) is an effective
immunotherapeutic target for multiple myeloma. Am. J. Cancer Res.
2017. 7(8): 1637–1641.
1629 Tellier, J., Shi, W., Minnich, M., Liao, Y., Crawford, S., Smyth, G. K.
et al., Blimp-1 controls plasma cell function through the regulation
of immunoglobulin secretion and the unfolded protein response. Nat.
Immunol. 2016. 17(3): 323–330.
1630 Rawstron, A. C.,Orfao, A., Beksac, M., Bezdickova, L., Brooimans, R. A.,
Bumbea, H. et al., Report of the European Myeloma Network on multi-
parametric flow cytometry inmultiplemyeloma and related disorders.
Haematologica 2008. 93(3): 431–438.
1631 Paiva, B., Garcia-Sanz, R. and San Miguel, J. F., Multiple myelomamin-
imal residual disease. Cancer Treat. Res. 2016. 169: 103–122.
1632 Paiva, B., van Dongen, J. J. and Orfao, A., New criteria for response
assessment: role of minimal residual disease in multiple myeloma.
Blood 2015. 125(20): 3059–3068.
1633 Flores-Montero, J., Sanoja-Flores, L., Paiva, B., Puig, N., Garcia-
Sanchez, O., Bottcher, S. et al., Next Generation Flow for highly sensi-
tive and standardized detection of minimal residual disease in multi-
ple myeloma. Leukemia 2017. 31(10): 2094–2103.
1634 Roschewski, M., Stetler-Stevenson, M., Yuan, C., Mailankody, S.,
Korde, N. and Landgren, O., Minimal residual disease: what are the
minimum requirements? J. Clin. Oncol. 2014. 32(5): 475–476.
1635 Cahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christo-
pherson, K. S.,Xing, Y. et al., A TranscriptomeDatabase for Astrocytes,
Neurons, and Oligodendrocytes: A New Resource for Understanding
Brain Development and Function. J. Neurosci. 2008. 28: 264–278.
1636 Hawrylycz, M. J., Lein, E. S., Guillozet-Bongaarts, A. L., Shen, E. H.,
Ng, L., Miller, J. A., Van De Lagemaat, L. N. et al., An anatomically
comprehensive atlas of the adult human brain transcriptome. Nature
2012. 489: 391.
1637 Mink, J. W., Blumenschine, R. J. and Adams, D. B., Ratio of central
nervous system to body metabolism in vertebrates: its constancy and
functional basis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 1981. 241:
R203–R212.
1638 Lake, B. B., Ai, R., Kaeser, G. E., Salathia, N. S., Yung, Y. C., Liu, R.,
Wildberg, A. et al., Neuronal subtypes and diversity revealed by single-
nucleus RNA sequencing of the human brain. Science 2016. 352: 1586–
1590.
1639 Bradl, M. and Lassmann, H., Oligodendrocytes: biology and pathology.
Acta Neuropathol. 2010. 119: 37–53.
1640 Sofroniew, M. V. and Vinters, H. V., Astrocytes: biology and pathology.
Acta Neuropathol. 2010. 119: 7–35.
1641 Bergstro¨m, T. and Forsberg-Nilsson, K., Neural stem cells: brain build-
ing blocks and beyond. Ups. J. Med. Sci. 2012. 117: 132–142.
1642 Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S.,
Mehler, M. F. et al., Fate mapping analysis reveals that adult microglia
derive from primitive macrophages. Science 2010. 330: 841–845.
1643 Goldmann, T.,Wieghofer, P., Jorda˜o, M. J. C., Prutek, F.,Hagemeyer, N.,
Frenzel, K.,Amann, L. et al., Origin, fate and dynamics ofmacrophages
at central nervous system interfaces. Nat. Immunol. 2016. 17: 797–805.
1644 Kantzer, C. G., Boutin, C.,Herzig, I. D.,Wittwer, C., Reiß, S.,Tiveron, M.
C., Drewes, J. et al., Anti-ACSA-2 defines a novel monoclonal antibody
for prospective isolation of living neonatal and adult astrocytes. Glia
2017. 65: 990–1004.
1645 Batiuk, M. Y.,De Vin, F.,Duque, S. I., Li, C., Saito, T., Saido, T., Fiers, M.
et al., An immunoaffinity-based method for isolating ultrapure adult
astrocytes based on ATP1B2 targeting by the ACSA-2 antibody. J. Biol.
Chem. 2017. 292: 8874–8891.
1646 Lin, C.-C. J., Yu, K., Hatcher, A., Huang, T.-W., Lee, H. K., Carlson, J.,
Weston, M. C. et al., Identification of diverse astrocyte populations and
their malignant analogs. Nat. Neurosci. 2017. 20: 396.
1647 Tsai, H.-H., Li, H., Fuentealba, L. C.,Molofsky, A. V., Taveira-Marques,
R.,Zhuang, H.,Tenney, A. et al., Regional astrocyte allocation regulates
CNS synaptogenesis and repair. Science 2012. 337: 358–362.
1648 Guttenplan, K. A. and Liddelow, S. A., Astrocytes and microglia: mod-
els and tools. J. Exp. Med. 2018. 216: 71–83.
1649 Zhuo, L., Sun, B., Zhang, C. L., Fine, A., Chiu, S. Y. and Messing, A.,
Live astrocytes visualized by green fluorescent protein in transgenic
mice. Dev. Biol. 1997. 187: 36–42.
1650 Nolte, C., Matyash, M., Pivneva, T., Schipke, C. G., Ohlemeyer, C.,
Hanisch, U.-K., Kirchhoff, F. et al., GFAP promoter-controlled EGFP-
expressing transgenicmice: a tool to visualize astrocytes and astroglio-
sis in living brain tissue. Glia 2001. 33: 72–86.
1651 Kuzmanovic, M., Dudley, V. J. and Sarthy, V. P., GFAP promoter drives
Muller cell-specific expression in transgenic mice. Invest. Ophthalmol.
Vis. Sci. 2003. 44: 3606–3613.
1652 Cho, W., Hagemann, T. L., Johnson, D. A., Johnson, J. A. and Messing,
A., Dual transgenic reporter mice as a tool for monitoring expression
of glial fibrillary acidic protein. J. Neurochem. 2009. 110: 343–351.
1653 Regan, M. R., Huang, Y. H., Kim, Y. S., Dykes-Hoberg, M. I., Jin, L.,
Watkins, A. M., Bergles, D. E. et al., Variations in promoter activity
reveal a differential expression and physiology of glutamate trans-
porters by glia in the developing and mature CNS. J. Neurosci. 2007. 27:
6607–6619.
1654 Bardehle, S., Kruger, M., Buggenthin, F., Schwausch, J., Ninkovic, J.,
Clevers, H., Snippert, H. J. et al., Live imaging of astrocyte responses to
acute injury reveals selective juxtavascular proliferation.Nat. Neurosci.
2013. 16: 580–586.
1655 Yang, Y., Vidensky, S., Jin, L., Jie, C., Lorenzini, I., Frankl, M. and Roth-
stein, J. D., Molecular comparison of GLT1+ and ALDH1L1+ astrocytes
in vivo in astroglial reporter mice. Glia 2011. 59: 200–207.
1656 Gong, S., Zheng, C., Doughty, M. L., Losos, K., Didkovsky, N., Scham-
bra, U. B., Nowak, N. J. et al., A gene expression atlas of the cen-
tral nervous system based on bacterial artificial chromosomes. Nature
2003. 425: 917–925.
1657 Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W.,
Sher, A. and Littman, D. R., Analysis of fractalkine receptor CX(3)CR1
function by targeted deletion and green fluorescent protein reporter
gene insertion. Mol. Cell Biol. 2000. 20: 4106–4114.
1658 Yona, S., Kim, K. W., Wolf, Y., Mildner, A., Varol, D., Breker, M.,
Strauss-Ayali, D. et al., Fate mapping reveals origins and dynamics
of monocytes and tissue macrophages under homeostasis. Immunity
2013. 38: 79–91.
1659 Buttgereit, A., Lelios, I., Yu, X., Vrohlings, M., Krakoski, N. R., Gautier,
E. L.,Nishinakamura, R. et al., Sall1 is a transcriptional regulator defin-
ing microglia identity and function. Nat. Immunol. 2016. 17: 1397–1406.
1660 Hirasawa, T., Ohsawa, K., Imai, Y., Ondo, Y., Akazawa, C., Uchino,
S. and Kohsaka, S., Visualization of microglia in living tissues using
Iba1-EGFP transgenic mice. J. Neurosci. Res. 2005. 81: 357–362.
1661 Sasmono, R. T., Oceandy, D., Pollard, J. W., Tong, W., Pavli, P.,
Wainwright, B. J., Ostrowski, M. C. et al., A macrophage colony-
stimulating factor receptor-green fluorescent protein transgene is
expressed throughout the mononuclear phagocyte system of the
mouse. Blood 2003. 101: 1155–1163.
1662 Dziennis, S., Van Etten, R. A., Pahl, H. L., Morris, D. L., Rothstein, T.
L., Blosch, C. M., Perlmutter, R. M. et al., The CD11b promoter directs
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1955
high-level expression of reporter genes in macrophages in transgenic
mice. Blood 1995. 85: 319–329.
1663 Yang, J., Hills, D., Taylor, E., Pfeffer, K., Ure, J. and Medvinsky, A.,
Transgenic tools for analysis of the haematopoietic system: knock-in
CD45 reporter and deletor mice. J. Immunol. Methods 2008. 337: 81–87.
1664 Pillai, M. M.,Hayes, B. and Torok-Storb, B., Inducible transgenes under
the control of the hCD68 promoter identifiesmousemacrophages with
a distribution that differs from the F4/80 - and CSF-1R-expressing pop-
ulations. Exp. Hematol. 2009. 37: 1387–1392.
1665 Iqbal, A. J., Mcneill, E., Kapellos, T. S., Regan-Komito, D., Norman, S.,
Burd, S., Smart, N. et al., Human CD68 promoter GFP transgenic mice
allow analysis ofmonocyte tomacrophage differentiation in vivo. Blood
2014. 124: e33–e44.
1666 Ha¨gglund, M., Borgius, L., Dougherty, K. J. and Kiehn, O., Activation of
groups of excitatory neurons in the mammalian spinal cord or hind-
brain evokes locomotion. Nat. Neurosci. 2010. 13: 246–252.
1667 Blanco-Centurion, C., Bendell, E., Zou, B., Sun, Y., Shiromani, P. J. and
Liu, M., VGAT and VGLUT2 expression in MCH and orexin neurons in
double transgenic reporter mice. IBRO Rep. 2018. 4: 44–49.
1668 Daigle, T. L., Madisen, L., Hage, T. A., Valley, M. T., Knoblich, U.,
Larsen, R. S., Takeno, M. M. et al., A suite of transgenic driver and
reporter mouse lines with enhanced brain-cell-type targeting and
functionality. Cell 2018. 174: 465–480.e422.
1669 Martin, D., Xu, J., Porretta, C. and Nichols, C. D., Neurocytometry: flow
cytometric sorting of specific neuronal populations from human and
rodent brain. ACS Chem. Neurosci. 2017. 8: 356–367.
1670 Evrony, G. D., Cai, X., Lee, E., Hills, L. B., Elhosary, P. C., Lehmann,
H. S., Parker, J. J. et al., Single-neuron sequencing analysis of L1 retro-
transposition and somaticmutation in the human brain. Cell 2012. 151:
483–496.
1671 Cai, X., Evrony, G. D., Lehmann, H. S., Elhosary, P. C., Mehta, B. K.,
Poduri, A. and Walsh, C. A., Single-cell, genome-wide sequencing
identifies clonal somatic copy-number variation in the human brain.
Cell Rep. 2014. 8: 1280–1289.
1672 Girdhar, K., Hoffman, G. E., Jiang, Y., Brown, L., Kundakovic, M.,
Hauberg, M. E., Francoeur, N. J. et al., Cell-specific histone modifi-
cation maps in the human frontal lobe link schizophrenia risk to the
neuronal epigenome. Nat. Neurosci. 2018. 21: 1126–1136.
1673 Matevossian, A. and Akbarian, S., Neuronal nuclei isolation from
human postmortem brain tissue. J. Vis. Exp. 2008. 1: 914.
1674 McCarthy, K. D. and De Vellis, J., Preparation of separate astroglial and
oligodendroglial cell cultures from rat cerebral tissue. J. Cell. Biol. 1980.
85: 890–902.
1675 Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T.,
Richardson,W. D. and Raff, M. C., Cell death and control of cell survival
in the oligodendrocyte lineage. Cell 1992. 70: 31–46.
1676 Seiwa, C., Kojima-Aikawa, K., Matsumoto, I. and Asou, H., CNS
myelinogenesis in vitro: myelin basic protein deficient shiverer oligo-
dendrocytes. J. Neurosci. Res. 2002. 69: 305–317.
1677 Yang, Z., Watanabe, M. and Nishiyama, A., Optimization of oligo-
dendrocyte progenitor cell culture method for enhanced survival. J.
Neurosci. Meth. 2005. 149: 50–56.
1678 Robinson, A. P., Rodgers, J. M., Goings, G. E. and Miller, S. D., Char-
acterization of oligodendroglial populations in mouse demyelinating
disease using flow cytometry: clues for MS pathogenesis. PLoS ONE
2014. 9: e107649.
1679 Zhang, Y., Sloan, S. A., Clarke, L. E., Caneda, C., Plaza, C. A., Blu-
menthal, P. D., Vogel, H. et al., Purification and Characterization of
Progenitor and Mature Human Astrocytes Reveals Transcriptional and
Functional Differences with Mouse. Neuron 2016. 89: 37–53.
1680 Deng, Y., Kim, B., He, X., Kim, S., Lu, C., Wang, H., Cho, S. G. et al.,
Direct visualization of membrane architecture of myelinating cells in
transgenic mice expressing membrane-anchored EGFP. Genesis 2014.
52: 341–349.
1681 Hughes, E. G., Kang, S. H., Fukaya, M. and Bergles, D. E., Oligodendro-
cyte progenitors balance growth with self-repulsion to achieve home-
ostasis in the adult brain. Nat. Neurosci. 2013. 16: 668–676.
1682 Sedgwick, J. D., Schwender, S., Imrich, H., Do¨rries, R., Butcher, G. W.
and Ter Meulen, V., Isolation and direct characterization of resident
microglial cells from the normal and inflamed central nervous system.
Proc. Natl. Acad. Sci. USA 1991. 88: 7438–7442.
1683 Bennett, M. L., Bennett, F. C., Liddelow, S. A., Ajami, B., Zamanian,
J. L., Fernhoff, N. B., Mulinyawe, S. B. et al., New tools for studying
microglia in the mouse and human CNS. Proc. Natl. Acad. Sci. USA 2016.
113: E1738–E1746.
1684 Korin, B., Ben-Shaanan, T. L., Schiller, M., Dubovik, T., Azulay-Debby,
H., Boshnak, N. T., Koren, T. et al., High-dimensional, single-cell char-
acterization of the brain’s immune compartment. Nat. Neurosci. 2017.
20: 1300–1309.
1685 Mrdjen, D., Hartmann, F. J. and Becher, B., High dimensional cytom-
etry of central nervous system leukocytes during neuroinflammation.
Methods Mol. Biol. 2017. 1559: 321–332.
1686 Ajami, B., Samusik, N.,Wieghofer, P., Ho, P. P., Crotti, A., Bjornson, Z.,
Prinz, M. et al., Single-cell mass cytometry reveals distinct populations
of brain myeloid cells in mouse neuroinflammation and neurodegen-
eration models. Nat. Neurosci. 2018. 21: 541–551.
1687 Mrdjen, D., Pavlovic, A.,Hartmann, F. J., Schreiner, B.,Utz, S. G., Leung,
B. P., Lelios, I. et al., High-dimensional single-cell mapping of cen-
tral nervous system immune cells reveals distinct myeloid subsets in
health, aging, and disease. Immunity 2018. 48: 599.
1688 Bo¨ttcher, C., Schlickeiser, S., Sneeboer, M. a. M., Kunkel, D., Knop, A.,
Paza, E., Fidzinski, P. et al., Human microglia regional heterogeneity
and phenotypes determined by multiplexed single-cell mass cytome-
try. Nat. Neurosci. 2019. 22: 78–90.
1689 Ecker, J. R., Geschwind, D. H., Kriegstein, A. R., Ngai, J., Osten, P.,
Polioudakis, D., Regev, A. et al., The BRAIN Initiative Cell Census Con-
sortium: lessons learned toward generating a comprehensive brain cell
atlas. Neuron 2017. 96: 542–557.
1690 Tham, C. S., Lin, F. F., Rao, T. S., Yu, N. and Webb, M., Microglial
activation state and lysophospholipid acid receptor expression. Int. J.
Dev. Neurosci. 2003. 21: 431–443.
1691 Pfenninger, C. V., Roschupkina, T., Hertwig, F., Kottwitz, D., Englund,
E., Bengzon, J., Jacobsen, S. E. et al., CD133 is not present on neurogenic
astrocytes in the adult subventricular zone, but on embryonic neural
stem cells, ependymal cells, and glioblastoma cells. Cancer Res. 2007.
67: 5727–5736.
1692 Moussaud, S. and Draheim, H. J., A new method to isolate microglia
from adult mice and culture them for an extended period of time. J.
Neurosci. Methods 2010. 187: 243–253.
1693 Foo, L. C., Allen, N. J., Bushong, E. A., Ventura, P. B., Chung, W.-S.,
Zhou, L., Cahoy, J. D. et al., Development of a Method for the Purifica-
tion and Culture of Rodent Astrocytes. Neuron 2011. 71: 799–811.
1694 Horst, A. K., Neumann, K., Diehl, L. and Tiegs, G., Modulation of liver
tolerance by conventional and nonconventional antigen-presenting
cells and regulatory immune cells. Cell. Mol. Immunol. 2016. 13: 277–
292.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1956 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
1695 Jenne, C. N. and Kubes, P., Immune surveillance by the liver. Nat.
Immunol. 2013. 14: 996–1006.
1696 Thomson, A. W. and Knolle, P. A., Antigen-presenting cell function in
the tolerogenic liver environment.Nat. Rev. Immunol. 2010. 10: 753–766.
1697 Crispe, I. N., Immune tolerance in liver disease. Hepatology 2014. 60:
2109–2117.
1698 Racanelli, V. and Rehermann, B., The liver as an immunological organ.
Hepatology. 2006. 43: S54–62.
1699 Blom, K. G., Qazi, M. R., Matos, J. B., Nelson, B. D., DePierre, J. W. and
Abedi-Valugerdi, M., Isolation of murine intrahepatic immune cells
employing a modified procedure for mechanical disruption and func-
tional characterization of the B, T and natural killer T cells obtained.
Clin. Exp. Immunol. 2009. 155: 320–329.
1700 Gao, B., Radaeva, S. and Park, O., Liver natural killer and natural killer
T cells: immunobiology and emerging roles in liver diseases. J. Leukoc.
Biol. 2009. 86: 513–528.
1701 Niemeyer, M.,Darmoise, A.,Mollenkopf, H. J.,Hahnke, K.,Hurwitz, R.,
Besra, G. S., Schaible, U. E. et al., Natural killer T-cell characterization
through gene expression profiling: an account of versatility bridging
T helper type 1 (Th1), Th2 and Th17 immune responses. Immunology
2008. 123: 45–56.
1702 Pang, D. J., Neves, J. F., Sumaria, N. and Pennington, D. J., Under-
standing the complexity of γδ T-cell subsets in mouse and human.
Immunology 2012. 136: 283–290.
1703 Golubovskaya, V. and Wu, L., Different subsets of T cells, memory,
effector functions, and CAR-T immunotherapy. Cancers 2016. 8(3): E36.
1704 Davies, L. C., Jenkins, S. J.,Allen, J. E. and Taylor, P. R., Tissue-resident
macrophages. Nat. Immunol. 2013. 14: 986–995.
1705 Gordon, S. and Plu¨ddemann, A., Tissue macrophages: Heterogeneity
and functions. BMC. Biol. 2017. 15: 53.
1706 Gordon, S. and Taylor, P. R., Monocyte andmacrophage heterogeneity.
Nat. Rev. Immunol. 2005. 5: 953–964.
1707 Shortman, K. and Liu, Y. J., Mouse and human dendritic cell subtypes.
Nat. Rev. Immunol. 2002. 2: 151–161.
1708 Meurens, F., Summerfield, A., Nauwynck, H., Saif, L. and Gerdts, V.,
The pig: a model for human infectious diseases. Trends Microbiol. 2012.
20: 50–57.
1709 Piriou-Guzylack, L. and Salmon, H., Membranemarkers of the immune
cells in swine: an update. Vet. Res. 2008. 39: 54.
1710 Dawson, H. D. and Lunney, J. K., Porcine cluster of differentiation (CD)
markers 2018 update. Res. Vet. Sci. 2018. 118: 199–246.
1711 Saalmu¨ller, A., Reddehase, M. J., Bu¨hring, H.-J., Jonjic´, S. and Koszi-
nowski, U. H., Simultaneous expression of CD4 and CD8 antigens
by a substantial proportion of resting porcine T lymphocytes. Eur. J.
Immunol. 1987. 17(9): 1297–1301.
1712 Saalmu¨ller, A., Weiland, F. and Reddehase, M. J., Resting porcine
T lymphocytes expressing class II major histocompatibility antigen.
Immunobiology 1991. 183: 102–114.
1713 Reutner, K., Leitner, J., Mullebner, A., Ladinig, A., Essler, S. E., Duvi-
gneau, J. C.,Ritzmann,M. et al., CD27 expressiondiscriminates porcine
T helper cells with functionally distinct properties. Vet. Res. 2013. 44(1):
18.
1714 Mair, K. H., Essler, S. E., Patzl, M., Storset, A. K., Saalmu¨ller, A. and
Gerner, W., NKp46 expression discriminates porcine NK cells with dif-
ferent functional properties. Eur. J. Immunol. 2012. 42(5): 1261–1271.
1715 A´lvarez, B., Escalona, Z., Uenishi, H., Toki, D., Revilla, C., Yuste, M.,
Go´mez del Moral, M. et al., Molecular and functional characterization
of porcine Siglec-3/CD33 and analysis of its expression in blood and
tissues. Dev. Comp. Immunol. 2015. 51(2): 238–250.
1716 Summerfield, A., Guzylack-Piriou, L., Schaub, A., Carrasco, C. P.,
Taˆche, V., Charley, B. and McCullough, K. C., Porcine peripheral
blood dendritic cells and natural interferon-producing cells. Immunol-
ogy 2003. 110(4): 440–449.
1717 Escalona, Z., A´lvarez, B., Uenishi, H., Toki, D., Yuste, M., Revilla, C.,
Go´mez del Moral, M. et al., Molecular characterization of porcine
Siglec-10 and analysis of its expression in blood and tissues.Dev. Comp.
Immunol. 2015. 48(1): 116–123. https://doi.org/10.1016/j.dci.2014.09.011
1718 Sedlak, C., Patzl, M., Saalmu¨ller, A. and Gerner, W., IL-12 and
IL-18 induce interferon-γ production and de novo CD2 expression
in porcine δ T cells. Dev. Comp. Immunol. 2014b. 47(1): 115–122.
https://doi.org/10.1016/j.dci.2014.07.007
1719 Yang, H. and Parkhouse, R. M., Phenotypic classification of porcine
lymphocyte subpopulations in blood and lymphoid tissues. Immunol-
ogy 1996. 89(1): 76–83.
1720 Saalmu¨ller, A.,Hirt, W. and Reddehase, M. J., Porcine γ/δ T lymphocyte
subsets differing in their propensity to home to lymphoid tissue. Eur.
J. Immunol. 1990. 20(10): 2343–2346.
1721 Sinkora, M., Sˇinkorova´, J. and Holtmeier, W., Development of γδ thy-
mocyte subsets during prenatal and postnatal ontogeny. Immunology
2005. 115(4): 544–555.
1722 Wen, K., Bui, T., Li, G., Liu, F., Li, Y., Kocher, J. and Yuan, L., Char-
acterization of immune modulating functions of γδ T cell subsets in
a gnotobiotic pig model of human rotavirus infection. Comp. Immunol.
Microbiol. Infect. Dis. 2012. 35(4): 289–301.
1723 Lee, J., Choi, K., Olin, M. R., Cho, S.-N. and Molitor, T. W., δ T cells
in immunity induced by Mycobacterium bovis Bacillus Calmette-Gue´rin
vaccination. Infect. Immun. 2004. 72(3): 1504–1511.
1724 Sedlak, C., Patzl, M., Saalmu¨ller, A. and Gerner, W., CD2 and CD8α
define porcine γδ T cells with distinct cytokine production profiles.
Dev. Comp. Immunol. 2014. 45: 97–106.
1725 Yang, H. and Parkhouse, R. M., Differential expression of CD8 epi-
topes amongst porcine CD8-positive functional lymphocyte subsets.
Immunology 1997. 92(1): 45–52.
1726 Olin, M. R.,Choi, K. H., Lee, J. andMolitor, T.W., δ T-lymphocyte cyto-
toxic activity against Mycobacterium bovis analyzed by flow cytometry.
J. Immunol. Methods 2005. 297: 1–11.
1727 Rodrı´guez-Go´mez, I. M., Talker, S. C., Ka¨ser, T., Stadler, M., Reiter,
L., Ladinig, A., Milburn, J. V. et al., Expression of T-Bet, eomeso-
dermin, and GATA-3 correlates with distinct phenotypes and func-
tional properties in porcine γδ T cells. Front. Immunol. 2019. 10.
https://doi.org/10.3389/fimmu.2019.00396
1728 Summerfield, A.,Rziha, H.-J. andSaalmu¨ller, A., Functional characteri-
zation of porcine CD4+CD8+extrathymic T lymphocytes. Cell. Immunol.
1996. 168(2): 291–296. https://doi.org/10.1006/cimm.1996.0078
1729 Rodrı´guez-Go´mez, I. M.,Talker, S. C.,Ka¨ser, T.,Stadler,M.,Hammer, S.
E., Saalmu¨ller, A. and Gerner, W., Expression of T-bet, eomesodermin
andGATA-3 in porcine αβT cells.Dev. Comp. Immunol. 2016. 60: 115–126.
1730 Talker, S. C., Ka¨ser, T., Reutner, K., Sedlak, C., Mair, K. H., Koinig,
H., Graage, R. et al., Phenotypic maturation of porcine NK- and T-cell
subsets. Dev. Comp. Immunol. 2013. 40(1): 51–68.
1731 Ka¨ser, T., Gerner, W., Hammer, S. E., Patzl, M. and Saalmu¨ller,
A., Detection of Foxp3 protein expression in porcine T lym-
phocytes. Vet. Immunol. Immunopathol. 2008. 125(1–2): 92–101.
https://doi.org/10.1016/j.vetimm.2008.05.007
1732 Ebner, F., Rausch, S., Scharek-Tedin, L., Pieper, R., Burwinkel, M., Zen-
tek, J. and Hartmann, S., A novel lineage transcription factor based
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1957
analysis reveals differences in T helper cell subpopulation develop-
ment in infected and intrauterine growth restricted (IUGR) piglets.Dev.
Comp. Immunol. 2014. 46: 333–340.
1733 Gerner, W., Denyer, M. S., Takamatsu, H.-H., Wileman, T. E.,
Wiesmu¨ller, K.-H., Pfaff, E. and Saalmu¨ller, A., Identification of novel
foot-and-mouth disease virus specific T-cell epitopes in c/c and d/d
haplotype miniature swine. Virus Res. 2006. 121(2): 223–228.
1734 Ebner, F., Schwiertz, P., Steinfelder, S., Pieper, R., Zentek,
J., Schu¨tze, N., Baums, C. G. et al., Pathogen-reactive T
helper cell analysis in the pig. Front. Immunol. 2017. 8: 565.
https://doi.org/10.3389/fimmu.2017.00565
1735 Stepanova, K. and Sinkora, M., Porcine γδ T lymphocytes can be cat-
egorized into two functionally and developmentally distinct subsets
according to expression of CD2 and level of TCR. J. Immunol. 2013.
190(5): 2111–2120. https://doi.org/10.4049/jimmunol.1202890
1736 Gerner, W., Talker, S. C., Koinig, H. C., Sedlak, C., Mair, K. H. and
Saalmu¨ller, A., Phenotypic and functional differentiation of porcine
Aβ T cells: current knowledge and available tools. Mol. Immunol. 2015.
66(1): 3–13. https://doi.org/10.1016/j.molimm.2014.10.025
1737 Holzer, B., Morgan, S. B., Matsuoka, Y., Edmans, M., Salguero, F. J.,
Everett, H., Brookes, S. M. et al., Comparison of heterosubtypic protec-
tion in ferrets and pigs induced by a single-cycle influenza vaccine. J.
Immunol. 2018. 200: 4068–4077.
1738 Hayashi, Y., Okutani, M., Ogawa, S., Tsukahara, T. and Inoue, R., Gen-
eration of anti-porcine CD69 monoclonal antibodies and their useful-
ness to evaluate early activation of cellular immunity by flow cytomet-
ric analysis. Anim. Sci. J. 2018. 89: 825–832.
1739 Yang, W. C., Schultz, R. D. and Spano, J. S., Isolation and characteri-
zation of porcine natural killer (NK) cells. Vet. Immunol. Immunopathol.
1987. 14(4): 345–356.
1740 Denyer, M. S.,Wileman, T. E., Stirling, C. M., Zuber, B. and Takamatsu,
H. H., Perforin expression can define CD8 positive lymphocyte subsets
in pigs allowing phenotypic and functional analysis of natural killer,
cytotoxic T, natural killer T and MHC un-restricted cytotoxic T-cells.
Vet. Immunol. Immunopathol. 2006. 110: 279–292.
1741 Walzer, T., Jaeger, S., Chaix, J. and Vivier, E., Natural Killer Cells: From
CD3(-)NKp46(+) to post-genomics meta-analyses. Curr. Opin. Immunol.
2007. 19(3): 365–372.
1742 Mair, K. H., Mu¨llebner, A., Essler, S. E., Duvigneau, J. C., Storset, A.
K., Saalmu¨ller, A. and Gerner, W., Porcine CD8αdim/-NKp46high NK
cells are in a highly activated state. Vet. Res. 2013. 44 (March): 13.
https://doi.org/10.1186/1297-9716-44-13
1743 Forberg, H., Hauge, A. G., Valheim, M., Garcon, F., Nunez, A., Gerner,
W.,Mair, K. H. et al., Early responses of natural killer cells in pigs exper-
imentally infected with 2009 pandemic H1N1 influenza A virus. PLoS
One 2014. 9(6): e100619. https://doi.org/10.1371/journal.pone.0100619
1744 Jones, M., Cordell, J. L., Beyers, A. D., Tse, A. G. and Mason, D. Y.,
Detection of T and B cells in many animal species using cross-reactive
anti-peptide antibodies. J. Immunol. 1993. 150: 5429–5435.
1745 Reutner, K., Leitner, J., Essler, S. E., Witter, K., Patzl, M., Steinberger,
P., Saalmu¨ller, A. et al., Porcine CD27: identification, expression and
functional aspects in lymphocyte subsets in swine.Dev. Comp. Immunol.
2012. 38(2): 321–331.
1746 Sinkora, M., Stepanova, K. and Sinkorova, J., Different Anti-CD21 anti-
bodies can be used to discriminate developmentally and functionally
different subsets of B lymphocytes in circulation of pigs. Dev. Comp.
Immunol. 2013. 39(4): 409–418.
1747 Kandasamy, S., Chattha, K. S., Vlasova, A. N., Rajashekara, G.
and Saif, L. J., Lactobacilli and Bifidobacteria enhance mucosal
B cell responses and differentially modulate systemic antibody
responses to an oral human rotavirus vaccine in a neonatal
gnotobiotic pig disease model. Gut Microbes 2014. 5(5): 639–651.
https://doi.org/10.4161/19490976.2014.969972
1748 Braun, R. O., Python, S. and Summerfield, A., Porcine B cell subset
responses to toll-like receptor ligands. Front. Immunol. 2017. 8: 1044.
https://doi.org/10.3389/fimmu.2017.01044
1749 Summerfield, A., Auray, G. and Ricklin, M., Comparative dendritic cell
biology of veterinary mammals. Annu. Rev. Anim. Biosci. 2015. 3: 533–
557.
1750 Vu Manh, T.-P., Elhmouzi-Younes, J., Urien, C., Ruscanu, S., Jouneau,
L., Bourge, M., Moroldo, M. et al., Defining mononuclear phagocyte
subset homology across several distant warm-blooded vertebrates
through comparative transcriptomics. Front. Immunol. 2015. 6: 299.
1751 Soldevila, F., Edwards, J. C.,Graham, S. P., Stevens, L. M., Crudgington,
B., Crooke, H. R.,Werling, D. et al., Characterization of themyeloid cell
populations’ resident in the porcine palatine tonsil. Front. Immunol.
2018. 9: 1800.
1752 Auray, G., Keller, I., Python, S., Gerber, M., Bruggmann, R., Ruggli, N.
and Summerfield, A., Characterization and transcriptomic analysis of
porcine blood conventional and plasmacytoid dendritic cells reveals
striking species-specific differences. J. Immunol. 2016. 197(12): 4791–
4806.
1753 Maisonnasse, P., Bouguyon, E., Piton, G., Ezquerra, A., Urien, C.,
Deloizy, C., Bourge, M. et al., The respiratory DC/macrophage
network at steady-state and upon influenza infection in the
swine biomedical model. Mucosal Immunol. 2016a. 9(4): 835–849.
https://doi.org/10.1038/mi.2015.105
1754 Chun, T., Wang, K., Zuckermann, F. A. and Rex Gaskins, H., Molecu-
lar cloning and characterization of a novel CD1 gene from the pig. J.
Immunol. 1999. 162(11): 6562–6571.
1755 Nestle, F. O., Zheng, X. G., Thompson, C. B., Turka, L. A. and Nickoloff,
B. J., Characterization of dermal dendritic cells obtained from normal
human skin reveals phenotypic and functionally distinctive subsets. J.
Immunol. 1993. 151(11): 6535–6545.
1756 Dutertre, C.-A., Wang, L.-F. and Ginhoux, F., Aligning bona fide den-
dritic cell populations across species. Cell. Immunol. 2014. 291(1): 3–10.
https://doi.org/10.1016/j.cellimm.2014.08.006
1757 Chamorro, S., Revilla, C., Alvarez, B., Alonso, F., Ezquerra, A. and
Domı´nguez, J., Phenotypic and functional heterogeneity of porcine
blood monocytes and its relation with maturation. Immunology 2005.
114(1): 63–71.
1758 Ondrackova, P., Nechvatalova, K., Kucerova, Z., Leva, L., Dominguez,
J. and Faldyna, M., Porcine mononuclear phagocyte subpopulations
in the lung, blood and bone marrow: dynamics during inflammation
induced by actinobacillus pleuropneumoniae. Vet. Res. 2010. 41: 64.
1759 Fairbairn, L., Kapetanovic, R., Beraldi, D., Sester, D. P., Tuggle,
C. K., Archibald, A. L. and Hume, D. A., Comparative analysis of
monocyte subsets in the pig. J. Immunol. 2013. 190(12): 6389–6396.
https://doi.org/10.4049/jimmunol.1300365
1760 Ondrackova, P., Leva, L., Kucerova, Z., Vicenova, M., Mensikova, M.
and Faldyna, M., Distribution of porcine monocytes in different lym-
phoid tissues and the lungs during experimental actinobacillus pleu-
ropneumoniae infection and the role of chemokines. Vet. Res. 2013. 44:
98.
1761 Moreno, S.,Alvarez, B., Poderoso, T., Revilla, C.Ezquerra, A.,Alonso, F.
and Dominguez, J., Porcine monocyte subsets differ in the expression
of CCR2 and in their responsiveness to CCL2. Vet Res. 2010. 41: 76.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1958 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
1762 Ezquerra, A., Revilla, C., Alvarez, B., Pe´rez, C., Alonso, F.
and Domı´nguez, J., Porcine myelomonocytic markers and
cell populations. Dev. Comp. Immunol. 2009. 33(3): 284–298.
https://doi.org/10.1016/j.dci.2008.06.002
1763 Ferna´ndez-Caballero, T., A´lvarez, B., Revilla, C., Zaldı´var-Lo´pez, S.,
Alonso, F., Garrido, J. J., Ezquerra, A´. et al., Phenotypic and functional
characterization of porcine bonemarrowmonocyte subsets.Dev. Comp.
Immunol. 2018. 81: 95–104. https://doi.org/10.1016/j.dci.2017.11.012
1764 Talker, S. C., Baumann, A., Tuba Barut, G., Keller, I., Bruggmann, R.
and Summerfield, A., Precise delineation and transcriptional charac-
terization of bovine blood dendritic-cell and monocyte subsets. Front.
Immunol. 2018. 9: 2505.
1765 Sinkora, M. and Sinkorova, J., B cell lymphogenesis in swine is located
in the bone marrow. J. Immunol. 2014. 193(10): 5023–5032.
1766 Maisonnasse, P., Bordet, E., Bouguyon, E. and Bertho, N., Bron-
cho alveolar dendritic cells and macrophages are highly similar
to their interstitial counterparts. PLoS One 2016b. 11(12): e0167315.
https://doi.org/10.1371/journal.pone.0167315
1767 Bordet, E., Maisonnasse, P., Renson, P., Bouguyon, E., Crisci, E., Tiret,
M.,Descamps, D. et al., Porcine alveolarmacrophage-like cells are pro-
inflammatory pulmonary intravascular macrophages that produce
large titers of porcine reproductive and respiratory syndrome virus.
Sci. Rep. 2018. 8(1): 10172. https://doi.org/10.1038/s41598-018-28234-y
1768 Guilliams, M.,Ginhoux, F., Jakubzick, C.,Naik, S. H.,Onai, N., Schraml,
B. U., Segura, E. et al., Dendritic cells, monocytes and macrophages: a
unified nomenclature based on ontogeny. Nat. Rev. Immunol. 2014. 14:
571–578.
1769 Bharat, A., Bhorade, S. M., Morales-Nebreda, L., McQuattie-
Pimentel, A. C., Soberanes, S., Ridge, K., DeCamp, M. M. et al.,
Flow cytometry reveals similarities between lung macrophages in
humans and mice. Am. J. Respir Cell Mol Biol 2016. 54(1): 147–149.
https://doi.org/10.1165/rcmb.2015-0147LE
1770 Cai, Y., Sugimoto, C., Arainga, M., Alvarez, X., Didier, E. S. and
Kuroda, M. J., In vivo characterization of alveolar and interstitial lung
macrophages in rhesus macaques: implications for understanding
lung disease in humans. J. Immunol. (Baltimore, Md.: 1950) 2014. 192(6):
2821–2829. https://doi.org/10.4049/jimmunol.1302269
1771 Yu, Y.-R. A.,Hotten, D. F.,Malakhau, Y.,Volker, E.,Ghio, A. J.,Noble, P.
W., Kraft, M. et al., Flow cytometric analysis of myeloid cells in human
blood, bronchoalveolar lavage, and lung tissues. Am. J. Respir. Cell Mol.
Biol. 2016. 54(1): 13–24.
1772 Marquet, F., Vu Manh, T.-P., Maisonnasse, P., Elhmouzi-Younes, J.,
Urien, C., Bouguyon, E., Jouneau, L. et al., Pig skin includes dendritic
cell subsets transcriptomically related to human CD1a and CD14 den-
dritic cells presenting different migrating behaviors and T cell activa-
tion capacities. J. Immunol. 2014. 193(12): 5883–5893.
1773 Parra-Sa´nchez, H., Puebla-Clark, L., Rese´ndiz, M., Valenzuela, O. and
Herna´ndez, J., Characterization and expression of DEC205 in the CDC1
and CDC2 subsets of porcine dendritic cells from spleen, tonsil, and
submaxillary and mesenteric lymph nodes. Mol. Immunol. 2018. 96: 1–
7.
1774 Saalmu¨ller, A., Pauly, T., Lunney, J. K., Boyd, P., Aasted, B., Sachs,
D. H., Arn, S. et al., Overview of the second international workshop
to define swine cluster of differentiation (CD) antigens. Vet. Immunol.
Immunopathol. 1998. 60(3–4): 207–228.
1775 Leitner, J., Reutner, K., Essler, S. E., Popow, I., Gerner, W., Stein-
berger, P. and Saalmu¨ller, A., Porcine SWC1 Is CD52—final determina-
tion by the use of a retroviral CDNA expression library. Vet. Immunol.
Immunopathol. 2012. 146(1): 27–34.
1776 Pe´rez, C., Revilla, C., Alvarez, B., Chamorro, S., Correa, C., Domenech,
N., Alonso, F. et al., Phenotypic and functional characterization of
porcine granulocyte developmental stages using two new markers.
Dev. Comp. Immunol. 2007. 31(3): 296–306.
1777 Saalmu¨ller, A. and Aasted, B., Summary of the animal homologue
section of HLDA8. Vet. Immunol. Immunopathol. 2007. 119: 2–13.
1778 Saalmu¨ller, A., Lunney, J. K., Daubenberger, C., Davis, W., Fischer, U.,
Go¨bel, T. W. and Griebel, P. et al., Summary of the animal homologue
section of HLDA8. Cell. Immunol. 2005. 236: 51–58.
1779 Cobaleda, C., Schebesta, A., Delogu, A. and Busslinger, M., Pax5: the
guardian of B cell identity and function. Nat. Immunol. 2007. 8: 463–470.
1780 Brodie, T., Brenna, E. and Sallusto, F., OMIP-018: chemokine receptor
expression on human T helper cells. Cytometry A 2013. 83: 530–532.
1781 Shaffer, A. L.,Lin, K.-I.,Kuo, T. C.,Yu, X.,Hurt, E.M.,Rosenwald, A. and
Giltnane, J. M. et al., Blimp-1 orchestrates plasma cell differentiation
by extinguishing the mature B cell gene expression program. Immunity
2002. 17: 51–62.
1782 Bekeredjian-Ding, I. and Jego, G., Toll-like receptors—sentries in the
B-cell response. Immunology 2009. 128: 311–323.
1783 Calame, K., Activation-dependent induction of Blimp-1. Curr. Opin.
Immunol. 2008. 20: 259–264.
1784 Gerner, W., Ka¨ser, T. and Saalmu¨ller, A., Porcine T lymphocytes and
NK cells - an update. Dev. Comp. Immunol. 2009. 33: 310–320.
1785 Saalmu¨ller, A.,Werner, T. and Fachinger, V., T-helper cells from naive
to committed. Vet. Immunol. Immunopathol. 2002. 87: 137–145.
1786 Bolzer, K., Ka¨ser, T., Saalmu¨ller, A. and Hammer, S. E., Molecular
characterisation of porcine Forkhead-box p3 (Foxp3). Vet. Immunol.
Immunopathol. 2009. 132: 275–281.
1787 Rocchi, M. S., Wattegedera, S. R., Frew, D., Entrican, G., Huntley, J. F.
and McNeilly, T. N., Identification of CD4+CD25high Foxp3+ T cells in
ovine peripheral blood. Vet. Immunol. Immunopathol. 2011. 144: 172–177.
1788 Ka¨ser, T., Mair, K. H., Hammer, S. E., Gerner, W. and Saalmu¨ller, A.,
Natural and inducible Tregs in swine: helios expression and functional
properties. Dev. Comp. Immunol. 2015. 49: 323–331.
1789 Kwong, L. S., Thom, M., Sopp, P., Rocchi, M., Wattegedera, S., Entri-
can, G. and Hope, J. C., Production and characterization of two
monoclonal antibodies to bovine tumour necrosis factor alpha (TNF-
alpha) and their cross-reactivity with ovine TNF-alpha. Vet. Immunol.
Immunopathol. 2010. 135: 320–324.
1790 Wattegedera, S. R., Corripio-Miyar, Y., Pang, Y., Frew, D., McNeilly,
T. N., Palarea-Albaladejo, J. and McInnes, C. J. et al., Enhancing the
toolbox to study IL-17A in cattle and sheep. Vet. Res. 2017. 48: 20.
1791 Pedersen, L. G., Castelruiz, Y., Jacobsen, S. and Aasted, B., Identifi-
cation of monoclonal antibodies that cross-react with cytokines from
different animal species.Vet. Immunol. Immunopathol. 2002. 88: 111–122.
1792 Franzoni, G., Kurkure, N. V., Edgar, D. S., Everett, H. E., Gerner, W.,
Bodman-Smith, K. B.,Crooke, H. R. et al., Assessment of the phenotype
and functionality of porcine CD8T cell responses following vaccination
with live attenuated classical swine fever virus (CSFV) and virulent
CSFV challenge. Clin. Vaccine Immunol. 2013. 20: 1604–1616.
1793 Takamatsu, H. H., Denyer, M. S., Stirling, C., Cox, S., Aggarwal, N.,
Dash, P., Wileman, T. E. et al., Porcine γδ T cells: possible roles on the
innate and adaptive immune responses following virus infection. Vet.
Immunol. Immunopathol. 2006. 112: 49–61.
1794 Saeys, Y., Gassen, S. V. and Lambrecht, B. N., Computational flow
cytometry: helping to make sense of high-dimensional immunology
data. Nat. Rev. Immunol. 2016. 16: 449–462.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1959
1795 Aghaeepour, N., Finak, G., The FlowCAP Consortium, The DREAM
Consortium, Hoos, H., Mosmann, T. R., Brinkman, R. et al., Critical
assessment of automated flow cytometry data analysis techniques.
Nat. Methods 2013. 10: 228–238.
1796 Bashashati, A. and Brinkman, R. R., A survey of flow cytometry data
analysis methods. Adv. Bioinformatics 2009. 2009: 584603
1797 O’Neill, K., Aghaeepour, N., Spidlen, J. and Brinkman, R. R., Flow
cytometry bioinformatics. PLoS Comput. Biol. 2013. 9: e1003365.
1798 Aghaeepour, N., Chattopadhyay, P. K., Ganesan, A., O’Neill, K., Zare,
H., Jalali, A.,Hoos, H. et al., Early immunologic correlates of HIV protec-
tion can be identified from computational analysis of complex multi-
variate T-cell flow cytometry assays. Bioinformatics 2012. 28: 1009–1016.
1799 Aghaeepour, N., Nikolic, R., Hoos, H. H., and Brinkman, R. R. Rapid
cell population identification in flow cytometry data. Cytometry Part A
2011. 79A: 6–13.
1800 Finak, G., Bashashati, A., Brinkman, R. and Gottardo, R., Merging mix-
ture components for cell population identification in flow cytometry.
Adv. Bioinformatics 2009, 247646.
1801 Mosmann, T. R., Naim, I., Rebhahn, J., Rebhahn, J., Datta, S., Cave-
naugh, J. S., Weaver, J. M. and Sharma, G., SWIFT-scalable clustering
for automated identification of rare cell populations in large, high-
dimensional flow cytometry datasets, Part 2: Biological evaluation.
Cytometry A 2014. 85: 422–433.
1802 Finak, G., Langweiler, M., Jaimes, M.,Malek, M., Taghiyar, J., Korin, Y.,
Raddassi, K. et al., Standardizing flow cytometry immunophenotyping
analysis from the human immunophenotyping consortium. Sci. Rep.
2016. 6: 20686.
1803 Qian, Y.,Wei, C., Eun-Hyung Lee, F., Campbell, J.,Halliley, J., Lee, J. A.,
Cai, J. et al., Elucidation of seventeen human peripheral blood B-cell
subsets and quantification of the tetanus response using a density-
based method for the automated identification of cell populations in
multidimensional flow cytometry data. Cytometry B Clin. Cytom. 2010.
78(Suppl 1): S69–S82.
1804 Qiu, P., Simonds, E. F., Bendall, S. C., Gibbs, K. D., Bruggner, R. V.,
Linderman, M. D., Sachs, K. et al., Extracting a cellular hierarchy from
high-dimensional cytometry data with SPADE.Nat. Biotechnol. 2011. 29:
886–891.
1805 Naim, I., Datta, S., Cavenaugh, J. S., Mosmann, T. R. and Sharma,
G., SWIFT-scalable clustering for automated identification of rare cell
populations in large, high-dimensional flow cytometry datasets, Part
1: Algorithm design, Cytometry A 2014. 85: 408–421.
1806 Leipold, M. D. and Maecker, H. T., Mass cytometry: protocol for daily
tuning and running cell samples on a CyTOF mass cytometer. J. Vis.
Exp. 2012. e4398.
1807 Fletez-Brant, K., Spidlen, J., Brinkman, R. R., Roederer, M. and Chat-
topadhyay, P. K., flowClean: Automated identification and removal of
fluorescence anomalies in flow cytometry data. Cytometry A 2016. 89:
461–471.
1808 Finak, G., Perez, J. M.,Weng, A. and Gottardo, R., Optimizing transfor-
mations for automated, high throughput analysis of flow cytometry
data. BMC Bioinformatics. 2010. 11: 546.
1809 Finak, G., Perez, J. M. andGottardo, R., flowTrans: Parameter Optimiza-
tion for Flow Cytometry Data Transformation. R package version 1.24.0.
2010.
1810 Hahne, F., Khodabakhshi, A. H., Bashashati, A.,Wong, C. J., Gascoyne,
R. D., Weng, A. P., Seyfert-Margolis, V. et al., Per-channel basis nor-
malization methods for flow cytometry data. Cytometry A 2010. 77:
121–131.
1811 Finak, G., Jiang,W.,Krouse, K.,Wei, C., Sanz, I., Phippard, D.,Asare, A.
et al., High–throughput flow cytometry data normalization for clinical
trials. Cytometry A 2014. 85: 277–286
1812 Mair, F., Gate to the future: computational analysis of immunopheno-
typing data. Cytometry A 2019. 95: 147–149.
1813 Aghaeepour, N., Chattopadhyay, P., Chikina, M., Dhaene, T., Van
Gassen, S., Kursa, M., Lambrecht, B. N. et al., A benchmark for eval-
uation of algorithms for identification of cellular correlates of clinical
outcomes. Cytometry 2016. 89: 16–21.
1814 Weber, L. M. and Robinson, M. D., Comparison of clustering meth-
ods for high-dimensional single-cell flow and mass cytometry data.
Cytometry A 2016. 89: 1084–1096.
1815 Li, H., Shaham, U., Stanton, K. P., Yao, Y., Montgomery, R. R. and
Kluger, Y., Gatingmass cytometry data by deep learning. Bioinformatics
2017. 33: 3423–3430.
1816 Ko, B. S., Wang, Y. F., Li, J. L., Li, C. C., Weng, P. F., Hsu, S. C., Hou,
H. A. et al., Clinically validated machine learning algorithm for detect-
ing residual diseases with multicolor flow cytometry analysis in acute
myeloid leukemia and myelodysplastic syndrome. EBioMedicine 2018.
37: 91–100.
1817 Azad, A., Rajwa, B. and Pothen, A., Immunophenotype discovery, hier-
archical organization, and template-based classification of flowcytom-
etry samples. Front. Oncol. 2016. 6: 188.
1818 Finak, G., Frelinger, J., Jiang, W.,Newell, E. W., Ramey, J.,Davis, M. M.,
Kalams, S. A. et al., OpenCyto: An open source infrastructure for scal-
able, robust, reproducible, and automated, end-to-end flow cytometry
data analysis. PLoS Comput. Biol. 2014. 10: e1003806.
1819 Malek, M., Taghiyar, M. J., Chong, L., Finak, G., Gottardo, R. and
Brinkman, R. R., flowDensity: Reproducing manual gating of flow
cytometry data by automated density-based cell population identi-
fication. Bioinformatics 2015. 31: 606–607.
1820 Lux, M., Brinkman, R. R., Chauve, C., Laing, A., Lorenc, A., Abeler-
Do¨rner, L.,Hammer, B. et al., flowLearn: fast and precise identification
and quality checking of cell populations in flow cytometry. Bioinformat-
ics 2018. 1: 9.
1821 Kalina, T., Flores-Montero, J., Lecrevisse, Q., Pedreira, C. E., van der
Velden, V. H., Novakova, M., Mejstrikova, E., Hrusak, O. et al., Quality
assessment program for Euro Flow protocols: Summary results of four-
year (2010–2013) quality assurance rounds. Cytometry A 2015. 87(2):
145–156.
1822 Aghaeepour, N., FlowMeans: non-parametric flow cytometry data gat-
ing. R package version. 2010. 1(0).
1823 Aghaeepour, N. and Simonds, E. F., GateFinder: projection-based gat-
ing strategy optimization for polychromatic and mass flow cytometry
data. Bioinformatics 2018. 34: 4131–4133.
1824 Amir, E.-A. D.,Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H.,
Bendall, S. C., Shenfeld, D. K. et al., viSNE enables visualization of high
dimensional single-cell data and reveals phenotypic heterogeneity of
leukemia. Nat. Biotechnol. 2013. 31: 545–552.
1825 Samani, F. S.,Moore, J. K.,Khosravani, P. and Ebrahimi, M., Features of
free software packages in flow cytometry: a comparison between four
non-commercial software sources. Cytotechnology. 2014. 66(4): 555–559.
1826 Chen, T. J. and Kotecha, N., Cytobank: providing an analytics platform
for community cytometry data analysis and collaboration. Curr. Top.
Microbiol. Immunol. 2014. 377: 127–157.
1827 Roederer, M., Nozzi, J. L. and Nason, M. C., SPICE: Exploration and
analysis of post-cytometric complex multivariate datasets. Cytometry
A. 2011. 79: 167–174.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1960 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
1828 Spidlen, J., Barsky, A., Breuer, K., Carr, P., Nazaire, M. D., Hill, B. A.,
Qian, Y. et al., GenePattern flow cytometry suite. Source Code Biol. Med.
2013. 8: 14.
1829 Brinkman, R. R., Aghaeepour, N., Finak, G., Gottardo, R.,Mosmann, T.
and Scheuermann, R. H., Automated analysis of flow cytometry data
comes of age. Cytometry A 2016. 89: 16–21.
1830 Benjamini, Y. and Hochberg, Y., Controlling the False Discovery Rate
- a Practical and Powerful Approach to Multiple Testing. Journal of the
Royal Statistical Society Series B-Methodological 1995. 57: 289–300.
1831 Almudevar, A., Multiple hypothesis testing: a methodological
overview. Methods Mol. Biol. 2013. 972: 37–55.
1832 Rebhahn, J. A., Roumanes, D. R., Qi, Y., Khan, A., Thakar, J., Rosen-
berg, A., Lee, F. E. et al., Competitive SWIFT cluster templates enhance
detection of aging changes. Cytometry A 2016. 89: 59–70.
1833 Maaten, L. V. D. and Hinton, G., Visualizing data using t-SNE. J. Mach.
Learn. Res. 2008. 9: 2579–2605.
1834 Aghaeepour, N., Jalali, A., O’Neill, K., Chattopadhyay, P. K., Roederer,
M., Hoos, H. H. and Brinkman, R. R., RchyOptimyx: Cellular hierarchy
optimization for flow cytometry. Cytometry A 2012. 81: 1022–1030.
1835 O’Neill, K., Jalali, A., Aghaeepour, N., Hoos, H. and Brinkman, R. R.,
Enhanced flowType/RchyOptimyx: a bioconductor pipeline for discov-
ery in high-dimensional cytometry data. Bioinformatics 2014. 30: 1329–
1330.
1836 Tong, D. L., Ball, G. R. and Pockley, A. G., gEM/GANN: a multivariate
computational strategy for auto-characterizing relationships between
cellular and clinical phenotypes and predicting disease progression
time using high-dimensional flow cytometry data. Cytometry 2015. 87:
616–623.
1837 Gassen, S. V.,Vens, C.,Dhaene, T., Lambrecht, B. N. and Saeys, Y., Flo-
ReMi: flow density survival regression using minimal feature redun-
dancy. Cytometry A 2015. 89: 22–29.
1838 Mair, F.,Hartmann, F. J.,Mrdjen, D., Tosevski, V., Krieg, C. and Becher,
B., The end of gating? An introduction to automated analysis of high
dimensional cytometry data. Eur. J. Immunol. 2016. 46: 34–43.
1839 LeCun, Y., Bengio, Y. and Hinton, G., Deep learning. Nature 2015. 521:
436–444.
1840 Rosenblatt, F., The Perceptron: a probabilistic model for information
storage and organization in the brain. Psychol. Rev. 1958. 65: 386–408.
1841 Szegedy, C., Liu, W., Jia, Y., Sermanet, P., Reed, S. E., Anguelov, D.,
Erhan, D. et al., Going deeper with convolutions. 2015 IEEE Conference
on Computer Vision and Pattern Recognition (CVPR), Boston, MA, 2015,
pp. 1–9.
1842 Gupta, P. J. Harrison,Wieslander, H., Pielawski, N., Kartasalo, K., Par-
tel, G., Solorzano, L., Suveer, A. et al., Deep learning in image cytome-
try: a review. Cytometry A 2019. 95: 366–380.
1843 Eulenberg, P., Koehler, N., Blasi, T., Filby, A., Carpenter, A. E., Rees,
P., Theis, F. J. et al., Reconstructing cell cycle and disease progression
using deep learning. Nat. Commun. 2017. 8: 463.
1844 Behrmann, J., Etmann, C., Boskamp, T., Casadonte, R., Kriegsmann, J.
and Maass, P., Deep learning for tumor classification in imaging mass
spectrometry. Bioinformatics 2017. 1: 1–10.
1845 Arvaniti, E. and Claassen, M., Sensitive detection of rare disease-
associated cell subsets via representation learning.Nat. Commun. 2017.
8: 14825
1846 Li, H., Shaham, U., Stanton, K. P., Yao, Y., Montgomery, R. R., Kluger,
Y. et al., Gating mass cytometry data by deep learning. Bioinformatics
2017. 33: 3423–3430.
1847 Ornatsky, O. I., Kinach, R., Bandura, D. R., Lou, X., Tanner, S. D.,
Baranov, V. I., Nitz, M. and Winnik, M. A., Development of analyti-
cal methods for multiplex bio-assay with inductively coupled plasma
mass spectrometry. J. Anal. At. Spectrom. 2008. 23: 463–469.
1848 Jolliffe, I. T., Principal component analysis, Springer Science & Business
Media, Berlin, Germany 2002.
1849 Bendall, S. C., Simonds, E. F., Qiu, P., Amir el, A. D., Krutzik, P. O.,
Finck, R., Bruggner, R. V. et al., Single-cell mass cytometry of differ-
ential immune and drug responses across a human hematopoietic
continuum. Science 2011. 332: 687–696.
1850 Newell, E. W., Sigal, N., Bendall, S. C., Nolan, G. P. and Davis, M. M.,
Cytometry by time-of-flight shows combinatorial cytokine expression
and virus-specific cell niches within a continuum of CD8+ T cell phe-
notypes. Immunity 2012. 36: 142–152.
1851 Kotecha, N., Krutzik, P. O. and Irish, J. M., Web-based analysis and
publication of flow cytometry experiments. Curr. Protoc. Cytom. 2010.
Chapter 10, Unit10.17.
1852 Ho¨llt, T. et al., Cytosplore: interactive immune cell phenotyping for
large single-cell datasets. Comput. Graphics Forum 2016. 35: 171–180.
1853 Chen, H. et al., Cytofkit: a bioconductor package for an integratedmass
cytometry data analysis pipeline. PLoS Comput. Biol. 2016. 12: e1005112.
1854 Kobak, D. and Berens, P., The art of using t-SNE for single-cell tran-
scriptomics. bioRxiv. 2018. Available at: https://doi.org/10.1101/453449
1855 Wattenberg, M., Vie´gas, F. and Johnson, I., How to use t-SNE effec-
tively. Distill 2016. 1(10). https://doi.org/10.23915/distill.00002
1856 Belkina, A. C. et al., Automated optimal parameters for T-distributed
stochastic neighbor embedding improve visualization and allow anal-
ysis of large datasets. bioRxiv. 2018.
1857 Linderman, G. C., Rachh, M., Hoskins, J. G., Steinerberger,
S. and Kluger, Y., Efficient Algorithms for t-distributed
stochastic neighborhood embedding. arXiv. 2017. Available at:
https://arxiv.org/abs/1712.09005
1858 van der Maaten, L. J. P., Accelerating t-SNE using tree-based algo-
rithms. J. Mach. Learn. Res. 2014. (15): 3221–3245.
1859 Pezzotti, N., Lelieveldt, B. P. F., Van Der Maaten, L., Hollt, T., Eise-
mann, E., Vilanova, A. et al., Approximated and user steerable tSNE
for progressive visual analytics. IEEE Trans. Vis. Comput. Graph. 2017.
23: 1739–1752.
1860 Linderman, G. C., Rachh, M., Hoskins, J. G., Steinerberger, S. and
Kluger, Y., Fast interpolation-based t-SNE for improved visualization
of single-cell RNA-seq data. Nat. Methods 2019. 16(3): 243–245.
1861 Pezzotti, N., Ho¨ll, T., Lelieveldt, T., Eisemann, E. and Vilanova, A.,
Hierarchical stochastic neighbor embedding. Comput. Graphics Forum
2016. 35: 21–30.
1862 van Unen, V.,Ho¨llt, T., Pezzotti, N., Li, N., Reinders, M. J. T., Eisemann,
E., Koning, F. et al., Visual analysis of mass cytometry data by hier-
archical stochastic neighbour embedding reveals rare cell types. Nat.
Commun. 2017. 8: 1740.
1863 Linderman, G. C. and Steinerberger, S., Clustering with t-SNE, prov-
ably. arXiv. 2017. Available at: https://arxiv.org/abs/1706.02582
1864 Shekhar, K. et al., Automatic classification of cellular expression by
nonlinear stochastic embedding (ACCENSE). Proc. Natl. Acad. Sci. USA
2014. 111: 202–207.
1865 Murphy, R. F., Automated identification of subpopulations in flowcyto-
metric list mode data using cluster analysis. Cytometry. 1985. 6: 302–
309.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1961
1866 Diggins, K. E., Gandelman, J. S., Roe, C. E. and Irish, J. M., Generat-
ing quantitative cell identity labels with marker enrichment modeling
(MEM). Curr. Protoc. Cytom. 2018. 83: 10.21.1–10.21.28.
1867 Schadt, E. E., Lamb, J., Yang, X., Zhu, J., Edwards, S., Guhathakurta, D.,
Sieberts, S. K. et al., An integrative genomics approach to infer causal
associations between gene expression and disease. Nat. Genet. 2005.
37: 710–717.
1868 Emilsson, V., Thorleifsson, G., Zhang, B., Leonardson, A. S., Zink, F.,
Zhu, J., Carlson, S. et al., Genetics of gene expression and its effect on
disease. Nature 2008. 452: 423–428.
1869 Stegle, O.,Teichmann, S. A. andMarioni, J. C., Computational and ana-
lytical challenges in single-cell transcriptomics. Nat. Rev. Genet. 2015;
16: 133–145.
1870 Bantscheff, M., Schirle, M., Sweetman, G., Rick, J. and Kuster, B.,
Quantitative mass spectrometry in proteomics: a critical review. Anal.
Bioanal. Chem. 2007. 389: 1017–1031.
1871 Weston, A. D. and Hood, L., Systems biology, proteomics, and the
future of health care: toward predictive, preventative, and personal-
ized medicine. J. Proteome Res. 2004. 3: 179–196.
1872 Aghaeepour, N., Lehallier, B., Baca, Q., Ganio, E. A., Wong, R. J.,
Ghaemi, M. S., Culos, A. et al., A proteomic clock of human pregnancy.
Am. J. Obstet. Gynecol. 2018. 218: 347.e1–347.e14.
1873 Patterson, A. D., Maurhofer, O., Beyoglu, D., Lanz, C., Krausz, K. W.,
Pabst, T., Gonzalez, F. J. et al., Aberrant lipid metabolism in hepatocel-
lular carcinoma revealed by plasma metabolomics and lipid profiling.
Cancer Res. 2011. 71: 6590–6600.
1874 Zhao, Y., Fu, L., Li, R., Wang, L. N., Yang, Y., Liu, N. N., Zhang, C. M.
et al., Metabolic profiles characterizing different phenotypes of poly-
cystic ovary syndrome: plasmametabolomics analysis. BMCMed. 2012.
10: 153.
1875 Chen, X., Liu, L., Palacios, G., Gao, J., Zhang, N., Li, G., Lu, J. et al.,
Plasmametabolomics reveals biomarkers of the atherosclerosis. J. Sep.
Sci. 2010. 33: 2776–2783.
1876 Psychogios, N., Hau, D. D., Peng, J., Guo, A. C.,Mandal, R., Bouatra, S.,
Sinelnikov, I. et al., The human serum metabolome. PLoS One 2011. 6:
e16957.
1877 Bathe, O. F. et al., Feasibility of identifying pancreatic cancer based
on serum metabolomics. Cancer Epidemiol. Biomarkers Prev. 2011. 20:
140–147.
1878 Zhang, A., Sun, H. and Wang, X., Serum metabolomics as a novel
diagnostic approach for disease: a systematic review. Anal. Bioanal.
Chem. 2012. 404: 1239–1245.
1879 Bouatra, S., Aziat, F., Mandal, R., Guo, A. C., Wilson, M. R., Knox, C.,
Bjorndahl, T. C. et al., The human urine metabolome. PLoS One 2013.
8: e73076.
1880 Kim, Y., Koo, I., Jung, B. H., Chung, B. C. and Lee, D., Multivariate
classification of urinemetabolome profiles for breast cancer diagnosis.
BMC Bioinformatics 2010. 11: S4.
1881 Dethlefsen, L., McFall-Ngai, M. and Relman, D. A., An ecological and
evolutionary perspective on human-microbe mutualism and disease.
Nature 2007. 449: 811–818.
1882 Woodward, L. J.,Anderson, P. J.,Austin, N. C.,Howard, K. and Inder, T.
E., Neonatal MRI to predict neurodevelopmental outcomes in preterm
infants. N. Engl. J. Med. 2006. 355: 685–694.
1883 Giesen, C., Wang, H. A., Schapiro, D., Zivanovic, N., Jacobs, A., Hat-
tendorf, B., Schuffler, P. J. et al., Highly multiplexed imaging of tumor
tissues with subcellular resolution by mass cytometry. Nat. Methods
2014. 11: 417–422.
1884 Halilaj, E., Hastie, T. J., Gold, G. E. and Delp, S. L., Physical activity is
associated with changes in knee cartilage microstructure. Osteoarthr.
Cartil. 2018. 26: 770–774.
1885 Jensen, P. B., Jensen, L. J. and Brunak, S., Mining electronic health
records: towards better research applications and clinical care. Nat.
Rev. Genet. 2012. 13: 395–405.
1886 Marbach, D., Costello, J. C., Ku¨ffner, R., Vega, N. M., Prill, R. J., Cama-
cho, D. M., Allison, K. R. et al., Wisdom of crowds for robust gene
network inference. Nat. Methods 2012. 9: 796–804.
1887 Elhalawani, H. et al., Machine Learning Applications in Head and
Neck Radiation Oncology: Lessons From Open-Source Radiomics Chal-
lenges. Front. Oncol. 2018. 8: 294.
1888 Ritchie, M. D., Holzinger, E. R., Li, R., Pendergrass, S. A. and Kim, D.,
Methods of integrating data to uncover genotype-phenotype interac-
tions. Nat. Rev. Genet. 2015. 16: 85–97.
1889 Feinberg, A. P., Epigenomics reveals a functional genome anatomy and
a new approach to common disease. Nat. Biotechnol. 2010. 28: 1049–
1052.
1890 Huang, S., Chaudhary, K. and Garmire, L. X., More Is Better: Recent
Progress in Multi-Omics Data Integration Methods. Front. Genet. 2017.
8: 84.
1891 Bersanelli, M. et al., Methods for the integration of multi-omics data:
mathematical aspects. BMC Bioinformatics 2016. 17(Suppl 2): 15.
1892 Li, Y.,Wu, F-X. and Ngom, A., A review onmachine learning principles
for multi-view biological data integration. Brief. Bioinformatics 2018. 19:
325–340.
1893 Tini, G., Marchetti, L., Priami, C. and Scott-Boyer, M-P., Multi-omics
integration-a comparison of unsupervised clustering methodologies.
Brief. Bioinformatics 2017. bbx167
1894 Shen, R., Olshen, A. B. and Ladanyi, M., Integrative clustering of mul-
tiple genomic data types using a joint latent variablemodel with appli-
cation to breast and lung cancer subtype analysis. Bioinformatics 2009.
25: 2906–2912.
1895 Lock, E. F., Hoadley, K. A., Marron, J. S. and Nobel, A. B., Joint and
individual variation explained (jive) for integrated analysis of multiple
data types. Ann. Appl. Stat. 2013. 7: 523–542.
1896 Wang, B. et al., Similarity network fusion for aggregating data types
on a genomic scale. Nat. Methods 2014. 11: 333–337.
1897 Nassar, H. and Gleich, D. F., in Proceedings of the 2017 SIAM interna-
tional conference on data mining, In N. Chawla, W. Wang, (Eds) Society
for Industrial and Applied Mathematics, Philadelphia, PA, 2017. pp.
615–623.
1898 Lock, E. F.,Dunson, D. B., Bayesian consensus clustering. Bioinformatics
2013. 29: 2610–2616.
1899 Lin, D., Zhang, J., Li, J., Calhoun, V. D., Deng, H. W. and Wang, Y. P.,
Group sparse canonical correlation analysis for genomic data integra-
tion. BMC Bioinformatics 2013. 14: 245.
1900 Holzinger, E. R., Dudek, S. M., Frase, A. T., Pendergrass, S. A. and
Ritchie, M. D., ATHENA: the analysis tool for heritable and environ-
mental network associations. Bioinformatics 2014. 30: 698–705.
1901 Ghaemi, M. S. et al., Multiomics modeling of the immunome, tran-
scriptome, microbiome, proteome and metabolome adaptations dur-
ing human pregnancy. Bioinformatics 2019. 35: 95–103.
1902 Singh, A. et al., DIABLO: an integrative approach for identifying
key molecular drivers from multi-omic assays. Bioinformatics 2019.
https://doi.org/10.1093/bioinformatics/bty1054
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1962 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
1903 He, L., Yang, Z., Zhao, Z., Lin, H. and Li, Y., Extracting drug-drug inter-
action from the biomedical literature using a stacked generalization-
based approach. PLoS One 2013. 8: e65814.
1904 Bendall, S. C., Davis, K. L., Amir, E.-A. D., Tadmor, M. D., Simonds,
E. F., Chen, T. J., Shenfeld, D. K. et al., Single-cell trajectory detec-
tion uncovers progression and regulatory coordination in human B
cell development. Cell 2014. 157: 714–725.
1905 Saelens, W., Cannoodt, R., Todorov, H. and Saeys, Y., A comparison
of single-cell trajectory inference methods. Nat. Biotechnol. 2019. 37:
547–554.
1906 Treutlein, B., Lee, Q. Y., Camp, J. G., Mall, M., Koh, W., Shariati, S. A.
M., Sim, S. et al., Dissecting direct reprogramming from fibroblast to
neuron using single-cell RNA-seq. Nature 2016. 534: 391–395.
1907 Cannoodt, R., Saelens, W. and Saeys, Y., Computational methods for
trajectory inference from single cell transcriptomics. Eur. J. Immunol.
2016. 46: 2496–2506.
1908 Rebhahn, J. A.,Deng, N., Sharma, G., Livingstone, A. M.,Huang, S. and
Mosmann, T. R., An animated landscape representation of CD4+ T-cell
differentiation, variability, and plasticity: insights into the behavior of
populations versus cells. Eur. J. Immunol. 2014. 44: 2216–2229.
1909 Dean, P. N. and Jett, J. J., Mathematical analysis of DNA distributions
derived from flow microfluorometry. J. Cell. Biol. 1974. 60: 523–527.
1910 Gray, J. W., Cell cycle analysis from computer synthesis of deoxyri-
bonucleic acid histograms. J. Histochem. Cytochem. 1974. 22: 642–650.
1911 Watson, J. V., The application of age distribution theory in the analysis
of cytofluorimetric DNA-histogram data. Cell Tissue Kinet. 1977. 10: 157–
169.
1912 Watson, J. V., Chambers, S. H. and Smith, P. J., A pragmatic approach
to the analysis of DNA histograms with a definable G1 peak. Cytometry
1987. 8: 1–8.
1913 Rosenblatt, J. I., Hokanson, J. A., McLaughlin, S. R. and Leary, J. F.,
Theoretical basis for sampling statistics useful for detecting and iso-
lating rare cells using flow cytometry and cell sorting. Cytometry 1997.
27: 233–238.
1914 Poisson, S. D., Recherches sur la probabilite´ des jugements en matie`re crim-
inelle et en matie`re civile: pre´ce´de´es des re`gles ge´ne´rales du calcul des proba-
bilite´s. Bachelier, Paris, France, 1837.
1915 Gosset, W. S., The probable error of a mean. Biometrica 1908. 6: 1–25.
1916 Fisher, R. A., Statistical methods for research workers. Oliver & Boyd, Edin-
burgh, U.K., 1925.
1917 Watson, J. V., Flow cytometry data analysis: basic concepts and statistics,
Cambridge University Press, Cambridge, UK, 2005.
1918 Fisher, R. A. and Yates, F., Statistical tables for biological, medical and
agricultural research. Oliver and Boyd, Edinburgh, UK, 1963. p. 86.
1919 Snedecor, G. W., Statistical methods 4th ed., Iowa State College Press,
Ames, Iowa, 1946.
1920 Wilcoxon, F., Individual comparisons by ranking methods. Biometrics
Bull. 1945. 1: 80–83.
1921 Mann, H. B. andWhitney, D. R., On a test ofwhether one of two random
variables is stochastically larger than the other. Ann. Math. Stat. 1947.
18: 50–60.
1922 Siegel, S. and Castello´n, N. J., Non-parametric statistics for the behavioral
sciences, 2nd ed., McGraw-Hill, New York, NY, 1988, Chapter 6.
1923 Young, I. T., Proof without prejudice: use of the Kolmogorov–Smirnov
test for the analysis of histograms from flow systems and other
sources. J. Histochem. Cytochem. 1977. 25: 935–941.
1924 Kendall, M. G., Rank and product-moment correlation. Biometrika 1949.
36: 177–193.
1925 Watson, J. V., Proof without prejudice revisited: Immunofluorescence
histogram analysis using cumulative frequency subtraction plus ratio
analysis of means. Cytometry 2001. 43: 55–68.
1926 Bocsi, J., Melzer, S., Da¨hnert, I. and Ta´rnok, A., OMIP-023: 10-color, 13
antibody panel for in-depth phenotyping of human peripheral blood
leukocytes. Cytometry A 2014. 85: 781–784.
1927 Melzer, S., Zachariae, S., Bocsi, J., Engel, C., Lo¨ffler, M. and Ta´rnok,
A., Reference intervals for leukocyte subsets in adults: Results from
a population-based study using 10-color flow cytometry. Cytometry B
Clin. Cytom. 2015. 88: 270–281.
1928 Nettey, L., Giles, A. J. and Chattopadhyay, P. K., OMIP-050: a 28-
color/30-parameter fluorescence flow cytometry panel to enumerate
and characterize cells expressing a wide array of immune checkpoint
molecules. Cytometry A 2018. 93:1094–1096.
1929 Mazza, E. M. C., Brummelman, J., Alvisi, G., Roberto, A., De Paoli,
F., Zanon, V, Colombo, F., Roederer, M. et al., Background fluores-
cence and spreading error are major contributors of variability in
high-dimensional flow cytometry data visualization by t-distributed
stochastic neighboring embedding. Cytometry A 2018. 93:785–792.
1930 Diggins, K. E., Ferrell, P. B. and Irish, J. M., Methods for discovery and
characterization of cell subsets in high dimensional mass cytometry
data. Methods 2015. 82: 55–63.
1931 Pierzchalski, A., Robitzki, A., Mittag, A., Emmrich, F., Sack, U.,
O’Connor, J. E., Bocsi, J. et al., Cytomics and nanobioengineering.
Cytometry B Clin. Cytom. 2008. 74:416–426.
1932 Van Gassen, S., Callebaut, B., Van Helden, M. J., Lambrecht, B.
N., Demeester, P., Dhaene, T. and Saeys, Y., FlowSOM: using self-
organizing maps for visualization and interpretation of cytometry
data. Cytometry A 2015. 87: 636–645.
1933 Elhmouzi-Younes, J., Palgen, J. L., Tchitchek, N., Delandre, S., Namet,
I., Bodinham, C. L., Pizzoferro, K. et al., In depth comparative pheno-
typing of blood innate myeloid leukocytes from healthy humans and
macaques using mass cytometry. Cytometry A 2017. 91:969–982.
1934 Loeffler, M., Engel, C., Ahnert, P., Alfermann, D., Arelin, K., Baber, R.,
Beutner, F. et al., The LIFE-Adult-Study: objectives and design of a
population-based cohort study with 10000 deeply phenotyped adults
in Germany. BMC Public Health 2015. 15: 691.
1935 Moher, D., Glasziou, P., Chalmers, I., Nasser, M., Bossuyt, P. M., Kore-
vaar, D. A., Graham, I. D. et al., Increasing value and reducing waste
in biomedical research: who’s listening? Lancet 2015. 387: 1573–1586.
1936 Taylor, C. F., Field, D., Sansone, S. A.,Aerts, J.,Apweiler, R.,Ashburner,
M., Ball, C. A. et al., Promoting coherentminimum reporting guidelines
for biological and biomedical investigations: the MIBBI project. Nat.
Biotechnol. 2008. 26: 889–896.
1937 Nies, K. P. H., Kraaijvanger, R., Lindelauf, K. H. K., Drent, R. J. M. R.,
Rutten, R. M. J., Ramaekers, F. C. S. and Leers, M. P. G., Determina-
tion of the proliferative fractions in differentiating hematopoietic cell
lineages of normal bone marrow. Cytometry A. 2018. 93:1097–1105.
1938 Parks, D. R., Moore, W. A., Brinkman, R. R., Chen, Y., Condello, D., El
Khettabi, F., Nolan, J. P. et al., Methodology for evaluating and com-
paring flow cytometers: a multisite study of 23 instruments. Cytometry
A 2018. 93:1087–1091.
1939 Jaracz-Ros, A., He´mon, P., Krzysiek, R., Bachelerie, F., Schlecht-Louf,
G. and Gary-Gouy, H., OMIP-048 MC: quantification of calcium sensors
and channels expression in lymphocyte subsets by mass cytometry.
Cytometry A 2018. 93:681–684.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1963
1940 Leavesley, S. andTa´rnok, A., Tycho Brahe’sway to precision.Cytometry
A. 2018. 93:977–979.
1941 Spidlen, J., Breuer, K. and Brinkman, R., Preparing a Minimum Infor-
mation about a Flow Cytometry Experiment (MIFlowCyt) compli-
ant manuscript using the International Society for Advancement of
Cytometry (ISAC) FCS file repository (FlowRepository.org). Curr. Protoc.
Cytom. 2012. Chapter 10: Unit 10.18.
1942 Holzwarth, K., Ko¨hler, R., Philipsen, L., Tokoyoda, K., Ladyhina, V.,
Wa¨hlby, C., Niesner, R. A. et al., Multiplexed fluorescence microscopy
reveals heterogeneity among stromal cells inmouse bonemarrow sec-
tions. Cytometry A 2018. 93:876–888.
1943 Roederer, M. and Ta´rnok, A., OMIPs–Orchestrating multiplexity in
polychromatic science. Cytometry A 2010. 77: 811–812.
1944 Finak, G., Jiang,W. and Gottardo, R., CytoML for cross-platform cytom-
etry data sharing. Cytometry A 2018. 93: 1189–1196
1945 O’Neill, K. and Brinkman, R. R., Publishing code is essential for repro-
ducible flow cytometry bioinformatics. Cytometry A 2016. 89: 10–11.
1946 Thomson Reuters. Collaborative Science - Solving the Issues of
Discovery, Attribution and Measurement in Data Sharing. 2012.
http://wokinfo.com/products_tools/multidisciplinary/dci/collaborative_
science_essay.pdf
1947 Piwowar, H. A. and Chapman, W. W., A review of jour-
nal policies for sharing research data. Proceedings ELPUB 2008
Conference on Electronic Publishing, 2008, http://elpub.scix.net/
data/works/att/001_elpub2008.content.pdf
1948 Fecher, B., Friesike, S. and Hebing, M., What drives academic data
sharing? PLoS One 2015. 10: e0118053.
1949 Nicol, A., Caruso, J. and Archambault, E´., Open Data Access
Policies and Strategies in the European Research Area and
Beyond. Science-Metrix, Inc. Produced for the European Com-
mission DG Research & Innovation, 2013, http://www.science-
metrix.com/pdf/SM_EC_OA_Data.pdf
1950 National Institute of Health. NIH Data Sharing Policy.
http://grants.nih.gov/grants/policy/data_sharing/
1951 PLOS. PLOS’ New Data Policy: Public Access to Data.
http://blogs.plos.org/everyone/2014/02/24/plos-new-data-policy-
public-access-data-2/
1952 Spidlen, J., Breuer, K., Rosenberg, C., Kotecha, N. and Brinkman, R.
R., FlowRepository: a resource of annotated flow cytometry datasets
associated with peer-reviewed publications. Cytometry A 2012. 81: 727–
731.
1953 Kong, Y. M.,Dahlke, C.,Xiang, Q.,Qian, Y.,Karp, D. and Scheuermann,
R. H., Toward an ontology-based framework for clinical research
databases. J. Biomed. Inform. 2011. 44: 48–58.
1954 Bhattacharya, S.,Andorf, S.,Gomes, L.,Dunn, P., Schaefer, H., Pontius,
J., Berger, P. et al., ImmPort: disseminating data to the public for the
future of immunology. Immunol. Res. 2014. 58: 234–239.
1955 Brusic, V., Gottardo, R., Kleinstein, S. H., Davis, M. M.; HIPC steering
committee, Computational resources for high-dimensional immune
analysis from the Human Immunology Project Consortium. Nat.
Biotechnol. 2014. 32(2): 146–148.
1956 U.S. Department of Health & Human Services. Summary of
the HIPAA Privacy Rule. http://www.hhs.gov/sites/default/files/
privacysummary.pdf
1957 Vasilevsky, N. A., Minnier, J., Haendel, M. A. and Champieux, R. E.,
Reproducible and reusable research: are journal data sharing policies
meeting the mark? Peer J. 2017. 5: e3208.
1958 Kay, D. B., Cambier, J. L. and Wheeless, L. L., Jr., Imaging in flow. J.
Histochem. Cytochem. 1979. 27: 329–334.
1959 George, T. C., Basiji, D. A., Hall, B. E., Lynch, D. H., Ortyn, W. E., Perry,
D. J., Seo, M. J. et al., Distinguishing modes of cell death using the
ImageStreammultispectral imaging flow cytometer. Cytometry A 2004.
59: 237–245.
1960 Pozarowski, P., Holden, E. and Darzynkiewicz, Z., Laser scanning
cytometry: principles and applications-an update. Methods Mol. Biol.
2013. 931: 187–212.
1961 Stavrakis, S., Holzner, G., Choo, J. and deMello, A., High-throughput
microfluidic imaging flow cytometry. Curr. Opin. Biotechnol. 2019. 55:
36–43.
1962 Nitta, N., Sugimura, T., Isozaki, A.,Mikami, H., Hiraki, K., Sakuma, S.,
Iino, T. et al., Intelligent image-activated cell sorting. Cell 2018. 175:
266–276.
1963 Hritzo, M. K., Courneya, J. P. and Golding, A., Imaging flow cytometry:
a method for examining dynamic native FOXO1 localization in human
lymphocytes. J. Immunol. Methods 2018. 454: 59–70.
1964 Maguire, O., Collins, C., O’Loughlin, K., Miecznikowski, J. and Min-
derman, H., Quantifying nuclear p65 as a parameter for NF-kappaB
activation: Correlation between ImageStream cytometry, microscopy,
and Western blot. Cytometry A 2011. 79: 461–469.
1965 Maguire, O., Tornatore, K. M.,O’Loughlin, K. L., Venuto, R. C. andMin-
derman, H., Nuclear translocation of nuclear factor of activated T cells
(NFAT) as a quantitative pharmacodynamic parameter for tacrolimus.
Cytometry A 2013. 83: 1096–1104.
1966 Stone, R. C., Feng, D., Deng, J., Singh, S., Yang, L., Fitzgerald-Bocarsly,
P., Eloranta, M. L. et al., Interferon regulatory factor 5 activation in
monocytes of systemic lupus erythematosus patients is triggered by
circulating autoantigens independent of type I interferons. Arthritis
Rheum. 2012. 64: 788–798.
1967 Trifonova, R. T. and Barteneva, N. S., Quantitation of IRF3 nuclear
translocation in heterogeneous cellular populations from cervical tis-
sue using imaging flow cytometry. Methods Mol. Biol. 2018. 1745: 125–
153.
1968 Volk, A., Li, J., Xin, J., You, D., Zhang, J., Liu, X., Xiao, Y. et al.,
Co-inhibition of NF-kappaB and JNK is synergistic in TNF-expressing
human AML. J. Exp. Med. 2014. 211: 1093–1108.
1969 Wan, C. K., Andraski, A. B., Spolski, R., Li, P., Kazemian, M., Oh, J.,
Samsel, L. et al., Opposing roles of STAT1 and STAT3 in IL-21 function
in CD4+ T cells. Proc. Natl. Acad. Sci. USA 2015. 112: 9394–9399.
1970 Haridas, V., Ranjbar, S., Vorobjev, I. A., Goldfeld, A. E. and Barteneva,
N. S., Imaging flowcytometry analysis of intracellular pathogens.Meth-
ods 2017. 112: 91–104.
1971 Pugsley, H. R., Quantifying autophagy: Measuring LC3 puncta and
autolysosome formation in cells using multispectral imaging flow
cytometry. Methods 2017. 112: 147–156.
1972 Lannigan, J. and Erdbruegger, U., Imaging flow cytometry for the char-
acterization of extracellular vesicles. Methods 2017. 112: 55–67.
1973 Shenoy, G. N., Loyall, J.,Maguire, O., Iyer, V.,Kelleher, R. J., Jr.,Minder-
man, H., Wallace, P. K. et al., Exosomes associated with human ovar-
ian tumors harbor a reversible checkpoint of T-cell responses. Cancer
Immunol. Res. 2018. 6: 236–247.
1974 Ploppa, A., George, T. C., Unertl, K. E., Nohe, B. and Durieux, M.
E., ImageStream cytometry extends the analysis of phagocytosis and
oxidative burst. Scand J. Clin. Lab. Invest. 2011. 71: 362–369.
1975 Henery, S., George, T., Hall, B., Basiji, D., Ortyn, W. and Morrissey, P.,
Quantitative image based apoptotic index measurement using multi-
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1964 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
spectral imaging flow cytometry: a comparison with standard photo-
metric methods. Apoptosis 2008. 13: 1054–1063.
1976 Poh, S. E. P., Png, E. and Tong, L., Quantitative image analysis of cel-
lular morphology using Amnis R© ImageStreamX Mark II imaging flow
cytometer: a comparison against conventionalmethods. Single Cell Biol.
2015. 4: s1.
1977 Balta, E., Stopp, J., Castelletti, L., Kirchgessner, H., Samstag, Y. and
Wabnitz, G. H., Qualitative and quantitative analysis of PMN/T-cell
interactions by InFlow and super-resolutionmicroscopy.Methods 2017.
112: 25–38.
1978 Mace, T. A., Zhong, L., Kilpatrick, C., Zynda, E., Lee, C. T., Capitano,
M., Minderman, H. et al., Differentiation of CD8+ T cells into effector
cells is enhanced by physiological range hyperthermia. J. Leukoc. Biol.
2011. 90: 951–962.
1979 Maguire, O., Wallace, P. K. and Minderman, H., Fluorescent in situ
hybridization in suspension by imaging flow cytometry. Methods Mol.
Biol. 2016. 1389: 111–126.
1980 Blasi, T.,Hennig, H., Summers, H. D.,Theis, F. J.,Cerveira, J., Patterson,
J. O.,Davies, D. et al., Label-free cell cycle analysis for high-throughput
imaging flow cytometry. Nat. Commun. 2016. 7: 10256.
1981 Ortyn,W. E., Perry, D. J.,Venkatachalam, V., Liang, L.,Hall, B. E., Frost,
K. and Basiji, D. A., Extended depth of field imaging for high speed cell
analysis. Cytometry A 2007. 71: 215–231.
1982 Ortyn, W. E.,Hall, B. E., George, T. C., Frost, K., Basiji, D. A., Perry, D. J.,
Zimmerman, C. A. et al., Sensitivity measurement and compensation
in spectral imaging. Cytometry A 2006. 69: 852–862.
1983 Chester, C. and Maecker, H. T., Algorithmic tools for mining high-
dimensional cytometry data. J. Immunol. 2015. 195: 773–779.
1984 Krutzik, P. O. and Nolan, G. P., Fluorescent cell barcoding in flow
cytometry allows high-throughput drug screening and signaling pro-
filing. Nat. Methods 2006. 3: 361–368.
1985 Bodenmiller, B., Zunder, E. R., Finck, R., Chen, T. J., Savig, E. S., Brug-
gner, R. V., Simonds, E. F. et al., Multiplexed mass cytometry profiling
of cellular states perturbed by small-molecule regulators. Nat. Biotech-
nol. 2012. 30: 858–867.
1986 Behbehani, G. K., Thom, C., Zunder, E. R., Finck, R., Gaudilliere, B.,
Fragiadakis, G. K., Fantl, W. J. et al., Transient partial permeabiliza-
tion with saponin enables cellular barcoding prior to surface marker
staining. Cytometry A 2014. 85: 1011-1019.
1987 Mei, H. E., Leipold, M. D. and Maecker, H. T., Platinum-conjugated
antibodies for application in mass cytometry. Cytometry A 2016. 89:
292–300.
1988 Mei, H. E., Leipold, M. D., Schulz, A. R., Chester, C. and Maecker, H.
T., Barcoding of live human peripheral blood mononuclear cells for
multiplexed mass cytometry. J. Immunol. 2015. 194: 2022–2031.
1989 Lai, L., Ong, R., Li, J. and Albani, S., A CD45-based barcoding approach
to multiplex mass-cytometry (CyTOF). Cytometry A 2015. 87: 369–
374.
1990 Akkaya, B.,Miozzo, P., Holstein, A. H., Shevach, E. M., Pierce, S. K. and
Akkaya, M., A simple, versatile antibody-based barcoding method for
flow cytometry. J. Immunol. 2016.
1991 Nassar, A. F., Wisnewski, A. V. and Raddassi, K., Automation of sam-
ple preparation for mass cytometry barcoding in support of clinical
research: protocol optimization. Anal. Bioanal. Chem. 2017. 409: 2363–
2372.
1992 Zunder, E. R., Finck, R.,Behbehani, G. K.,Amir el, A. D.,Krishnaswamy,
S., Gonzalez, V. D., Lorang, C. G. et al., Palladium-based mass tag cell
barcoding with a doublet-filtering scheme and single-cell deconvolu-
tion algorithm. Nat. Protoc. 2015. 10: 316–333.
1993 Catena, R., Ozcan, A., Zivanovic, N. and Bodenmiller, B., Enhanced
multiplexing in mass cytometry using osmium and ruthenium tetrox-
ide species. Cytometry A 2016. 89: 491–497.
1994 Chevrier, S., Crowell, H. L., Zanotelli, V. R. T., Engler, S., Robinson, M.
D. and Bodenmiller, B., Compensation of signal spillover in suspension
and imaging mass cytometry. Cell Syst. 2018. 6: 612–620.e615.
1995 Fread, K. I., Strickland, W. D., Nolan, G. P. and Zunder, E. R., An
updated debarcoding tool for mass cytometry with cell type-specific
and cell sample-specific stringency adjustment. Pac. Symp. Biocomput.
2017. 22: 588–598.
1996 Zivanovic, N., Jacobs, A. and Bodenmiller, B., A practical guide to mul-
tiplexed mass cytometry. Curr. Top. Microbiol. Immunol. 2013.
1997 Hartmann, F. J., Simonds, E. F. and Bendall, S. C., A universal live cell
barcoding-platform for multiplexed human single cell analysis. Sci.
Rep. 2018. 8: 10770.
1998 Yamanaka, Y. J., Szeto, G. L., Gierahn, T. M., Forcier, T. L., Benedict,
K. F., Brefo, M. S., Lauffenburger, D. A. et al., Cellular barcodes for
efficiently profiling single-cell secretory responses by microengraving.
Anal. Chem. 2012. 84: 10531–10536.
1999 Schulz, A. R. and Mei, H. E., Surface barcoding of live PBMC for multi-
plexed mass cytometry. Methods Mol. Biol. 2019. 1989: 93–108.
2000 Simard, C., Cloutier, M. and Neron, S., Rapid determination of IL-6
specific activity by flow cytometry. J. Immunol. Methods 2014. 415: 63–
65.
2001 Simard, C., Cloutier, M. and Neron, S., Feasibility study: phosphospe-
cific flow cytometry enabling rapid functional analysis of bonemarrow
samples from patients withmultiplemyeloma. Cytometry B Clin. Cytom.
2014. 86: 139–144.
2002 Krutzik, P. O., Clutter, M. R., Trejo, A. and Nolan, G. P., Fluorescent
cell barcoding for multiplex flow cytometry. Curr. Protoc. Cytom. 2011.
Chapter 6: Unit 6 31.
2003 Krutzik, P. O., Crane, J. M., Clutter, M. R. and Nolan, G. P., High-content
single-cell drug screening with phosphospecific flow cytometry. Nat.
Chem. Biol. 2008. 4: 132–142.
2004 Frischbutter, S., Schultheis, K., Patzel, M., Radbruch, A. and Baum-
grass, R., Evaluation of calcineurin/NFAT inhibitor selectivity in pri-
mary human Th cells using bar-coding and phospho-flow cytometry.
Cytometry A 2012. 81: 1005–1011.
2005 Bernardo, S. M., Allen, C. P.,Waller, A., Young, S. M., Oprea, T., Sklar,
L. A. and Lee, S. A., An automated high-throughput cell-based mul-
tiplexed flow cytometry assay to identify novel compounds to target
Candida albicans virulence-related proteins. PLoS One 2014. 9: e110354.
2006 Spurgeon, B. E., Aburima, A., Oberprieler, N. G., Tasken, K. and
Naseem, K. M., Multiplexed phosphospecific flow cytometry enables
large-scale signaling profiling and drug screening in blood platelets. J.
Thromb. Haemost. 2014. 12: 1733–1743.
2007 Clark, M. A., Goheen, M. M., Spidale, N. A., Kasthuri, R. S., Fulford,
A. and Cerami, C., RBC barcoding allows for the study of erythrocyte
population dynamics and P. falciparum merozoite invasion. PLoS One
2014. 9: e101041.
2008 Becher, B., Schlitzer, A., Chen, J., Mair, F., Sumatoh, H. R., Teng, K. W.
et al., High-dimensional analysis of the murine myeloid cell system.
Nat. Immunol. 2014. 15: 1181–1189.
2009 McCarthy, R. L., Mak, D. H., Burks, J. K. and Barton, M. C., Rapid
monoisotopic cisplatin based barcoding for multiplexed mass cytom-
etry. Sci. Rep. 2017. 7: 3779.
2010 Schulz, A. R. and Mei, H. E., Cell-surface barcoding of live PBMC for
multiplexed mass cytometry. In McGuire, H. and Ashhurst, T. (Eds.)
Methods in molecular biology. Springer Nature, Basingstoke, UK 2019.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1965
2011 Willis, L. M., Park, H.,Watson, M. W. L.,Majonis, D.,Watson, J. L. and
Nitz, M., Tellurium-based mass cytometry barcode for live and fixed
cells. Cytometry A 2018. 93: 685–694.
2012 Wu, X.,DeGottardi, Q.,Wu, I. C.,Wu, L., Yu, J., Kwok, W. W. and Chiu,
D. T., Ratiometric Barcoding for Mass Cytometry. Anal. Chem. 2018. 90:
10688–10694.
2013 Meng, H., Warden, A., Zhang, L., Zhang, T., Li, Y., Tan, Z., Wang,
B. et al., A mass-ratiometry-based CD45 barcoding method for mass
cytometry detection. SLAS Technol. 2019. 2472630319834057.
2014 Irish, J. M., Myklebust, J. H., Alizadeh, A. A., Houot, R., Sharman, J. P.,
Czerwinski, D. K., Nolan, G. P. et al., B-cell signaling networks reveal a
negative prognostic human lymphoma cell subset that emerges during
tumor progression. Proc. Natl. Acad. Sci. USA 2010. 107: 12747–12754.
2015 Gaudillie`re, B., Fragiadakis, G. K., Bruggner, R. V., Nicolau, M., Finck,
R., Tingle, M., Silva, J. et al., Clinical recovery from surgery correlates
with single-cell immune signatures. Sci. Transl. Med. 2014. 6: 255ra131.
2016 Bandura, D. R., Baranov, V. I., Ornatsky, O. I., Antonov, A., Kinach, R.,
Lou, X., Pavlov, S. et al., Mass cytometry: technique for real time single
cell multitarget immunoassay based on inductively coupled plasma
time-of-flight mass spectrometry. Anal. Chem. 2009. 81: 6813–6822.
2017 Bendall, S. C., Nolan, G. P., Roederer, M. and Chattopadhyay, P. K., A
deep profiler’s guide to cytometry. Trends Immunol. 2012. 33: 323–332.
2018 Tanner, S. D., Baranov, V. I.,Ornatsky, O. I., Bandura, D. R. and George,
T. C., An introduction to mass cytometry: fundamentals and applica-
tions. Cancer Immunol. Immunother. 2013. 62: 955–965.
2019 Wong, M. T., Ong, D. E., Lim, F. S., Teng, K. W., McGovern, N.,
Narayanan, S., Ho, W. Q. et al., A high-dimensional atlas of human
T cell diversity reveals tissue-specific trafficking and cytokine signa-
tures. Immunity 2016. 45: 442–456.
2020 Zunder, E. R., Lujan, E., Goltsev, Y., Wernig, M. and Nolan, G. P., A
continuous molecular roadmap to iPSC reprogramming through pro-
gression analysis of single-cell mass cytometry. Cell Stem Cell 2015. 16:
323–337.
2021 Nair, N., Mei, H. E., Chen, S. Y., Hale, M., Nolan, G. P., Maecker, H. T.,
Genovese, M. et al., Mass cytometry as a platform for the discovery
of cellular biomarkers to guide effective rheumatic disease therapy.
Arthritis Res. Ther. 2015. 17: 127.
2022 Mingueneau, M., Boudaoud, S., Haskett, S., Reynolds, T. L., Noc-
turne, G., Norton, E., Zhang, X. et al., Cytometry by time-of-flight
immunophenotyping identifies a blood Sjogren’s signature correlat-
ing with disease activity and glandular inflammation. J. Allergy Clin.
Immunol. 2016. 137: 1809–1821 e1812.
2023 Olin, A., Henckel, E., Chen, Y., Lakshmikanth, T., Pou, C., Mikes, J.,
Gustafsson, A. et al., Stereotypic immune systemdevelopment in new-
born children. Cell 2018. 174: 1277–1292.
2024 Brodin, P., Jojic, V., Gao, T., Bhattacharya, S., Angel, C. J., Furman, D.,
Shen-Orr, S. et al., Variation in the human immune system is largely
driven by non-heritable influences. Cell 2015. 160: 37–47.
2025 Pejoski, D., Tchitchek, N., Rodriguez Pozo, A., Elhmouzi-Younes, J.,
Yousfi-Bogniaho, R., Rogez-Kreuz, C., Clayette, P. et al., Identification
of vaccine-altered circulating b cell phenotypes using mass cytometry
and a two-step clustering analysis. J. Immunol. 2016. 196: 4814–4831.
2026 Leipold, M. D., Ornatsky, O., Baranov, V., Whitfield, C. and Nitz, M.,
Development of mass cytometrymethods for bacterial discrimination.
Anal. Biochem. 2011. 419: 1–8.
2027 Guo, Y., Baumgart, S., Stark, H. J., Harms, H. and Muller, S., Mass
cytometry for detection of silver at the bacterial single cell level. Front
Microbiol. 2017. 8: 1326.
2028 Yang, Y. S., Atukorale, P. U., Moynihan, K. D., Bekdemir, A., Rakhra,
K., Tang, L., Stellacci, F. et al., High-throughput quantitation of inor-
ganic nanoparticle biodistribution at the single-cell level using mass
cytometry. Nat. Commun. 2017. 8: 14069.
2029 Abdelrahman, A. I., Ornatsky, O., Bandura, D., Baranov, V., Kinach,
R., Dai, S., Thickett, S. C. et al., Metal-containing polystyrene beads as
standards for mass cytometry. J. Anal. At Spectrom. 2010. 25: 260–268.
2030 Galli, E., Friebel, E., Ingelfinger, F., Unger, S., Nunez, N. G. and Becher,
B., The end of omics? High dimensional single cell analysis in precision
medicine. Eur. J. Immunol. 2019. 49: 212–220.
2031 Kimball, A. K., Oko, L. M., Bullock, B. L., Nemenoff, R. A., van Dyk, L.
F. and Clambey, E. T., A beginner’s guide to analyzing and visualizing
mass cytometry data. J. Immunol. 2018. 200: 3–22.
2032 Cosma, A., A time to amaze, a time to settle down, and a time to
discover. Cytometry A 2015. 87: 795–796.
2033 Chang, Q., Ornatsky, O. I., Siddiqui, I., Loboda, A., Baranov, V. I. and
Hedley, D. W., Imagingmass cytometry. Cytometry A 2017. 91: 160–169.
2034 Zhao, Y., Uduman, M., Siu, J. H. Y., Tull, T. J., Sanderson, J. D., Wu,
Y. B., Zhou, J. Q. et al., Spatiotemporal segregation of humanmarginal
zone and memory B cell populations in lymphoid tissue. Nat. Commun.
2018. 9: 3857.
2035 Keren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S.,
Yang, S. R. et al., A structured tumor-immune microenvironment in
triple negative breast cancer revealed by multiplexed ion beam imag-
ing. Cell 2018. 174: 1373–1387 e1319.
2036 Tricot, S.,Meyrand, M., Sammicheli, C., Elhmouzi-Younes, J.,Corneau,
A., Bertholet, S., Malissen, M., Le Grand, R. et al., Evaluating the effi-
ciency of isotope transmission for improved panel design and a com-
parison of the detection sensitivities of mass cytometer instruments.
Cytometry A 2015. 87: 357–368.
2037 Rahman, A. H., Tordesillas, L. and Berin, M. C., Heparin reduces non-
specific eosinophil staining artifacts in mass cytometry experiments.
Cytometry A 2016. 89: 601–607.
2038 Schulz, A. R., Stanislawiak, S., Baumgart, S., Grutzkau, A. and Mei,
H. E., Silver nanoparticles for the detection of cell surface antigens in
mass cytometry. Cytometry A 2017. 91: 25–33.
2039 Lin, W., Hou, Y., Lu, Y., Abdelrahman, A. I., Cao, P., Zhao, G., Tong,
L. et al., A high-sensitivity lanthanide nanoparticle reporter for mass
cytometry: tests on microgels as a proxy for cells. Langmuir 2014. 30:
3142–3153.
2040 Tong, L., Lu, E., Pichaandi, J., Zhao, G. and Winnik, M. A., Synthesis
of uniform NaLnF4 (Ln: Sm to Ho) nanoparticles for mass cytometry. J.
Phys. Chem. C 2016. 120: 6269–6280.
2041 Baumgart, S., Schulz, A. R., Peddinghaus, A., Stanislawiak, S., Gillert,
S., Hirseland, H., Krauthauser, S. et al., Dual-labelled antibodies for
flow and mass cytometry: a new tool for cross-platform comparison
and enrichment of target cells for mass cytometry. Eur. J. Immunol.
2017.
2042 Finck, R., Simonds, E. F., Jager, A., Krishnaswamy, S., Sachs, K., Fantl,
W., Pe’er, D. et al., Normalization of mass cytometry data with bead
standards. Cytometry A 2013. 83: 483–494.
2043 Schulz, A. R., Baumgart, S., Schulze, J., Urbicht, M., Grutzkau, A. and
Mei, H. E., Stabilizing antibody cocktails for mass cytometry. Cytometry
A 2019.
2044 Kadic, E.,Moniz, R. J.,Huo, Y., Chi, A. and Kariv, I., Effect of cryopreser-
vation on delineation of immune cell subpopulations in tumor speci-
mens as determinated by multiparametric single cell mass cytometry
analysis. BMC Immunol. 2017. 18: 6.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1966 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
2045 Kleinsteuber, K., Corleis, B., Rashidi, N., Nchinda, N., Lisanti, A., Cho,
J. L., Medoff, B. D. et al., Standardization and quality control for high-
dimensional mass cytometry studies of human samples. Cytometry A
2016. 89: 903–913.
2046 Leipold, M. D.,Obermoser, G., Fenwick, C., Kleinstuber, K., Rashidi, N.,
McNevin, J. P., Nau, A. N. et al., Comparison of CyTOF assays across
sites: Results of a six-center pilot study. J. Immunol. Methods 2018. 453:
37–43.
2047 Sumatoh, H. R.,Teng, K.W.,Cheng, Y. andNewell, E.W., Optimization
of mass cytometry sample cryopreservation after staining. Cytometry
A 2017. 91: 48–61.
2048 Nicholas, K. J., Greenplate, A. R., Flaherty, D. K.,Matlock, B. K., Juan, J.
S., Smith, R. M., Irish, J. M. et al., Multiparameter analysis of stimulated
human peripheral bloodmononuclear cells: a comparison ofmass and
fluorescence cytometry. Cytometry A 2016. 89: 271–280.
2049 Baumgart, S., Peddinghaus, A., Schulte-Wrede, U., Mei, H. E. and
Grutzkau, A., OMIP-034: comprehensive immune phenotyping of
human peripheral leukocytes by mass cytometry for monitoring
immunomodulatory therapies. Cytometry A 2017. 91: 34–38.
2050 Behbehani, G. K., Bendall, S. C., Clutter, M. R., Fantl, W. J. et al., Single-
cell mass cytometry adapted tomeasurements of the cell cycle. Cytom-
etry A 2012. 81: 552–566.
2051 Frei, A. P., Bava, F. A., Zunder, E. R., Hsieh, E. W., Chen, S. Y., Nolan,
G. P. and Gherardini, P. F., Highly multiplexed simultaneous detection
of RNAs and proteins in single cells. Nat. Methods 2016. 13: 269–275.
2052 Mavropoulos, A., Allo, B., He, M., Park, E., Majonis, D. and Ornatsky,
O., Simultaneous detection of protein and mRNA in Jurkat and KG-1a
cells by mass cytometry. Cytometry A 2017. 91: 1200–1208.
2053 Cheung, P., Vallania, F., Warsinske, H. C., Donato, M., Schaffert, S.,
Chang, S. E., Dvorak, M. et al., Single-cell chromatin modification pro-
filing reveals increased epigenetic variations with aging. Cell 2018. 173:
1385–1397 e1314.
2054 Lumba, M. A., Willis, L. M., Santra, S., Rana, R., Schito, L., Rey, S.,
Wouters, B. G. et al., A beta-galactosidase probe for the detection of
cellular senescence by mass cytometry. Org. Biomol. Chem. 2017. 15:
6388–6392.
2055 Edgar, L. J., Vellanki, R. N., Halupa, A., Hedley, D., Wouters, B. G. and
Nitz, M., Identification of hypoxic cells using an organotellurium tag
compatible with mass cytometry. Angew Chem. Int. Ed. Engl. 2014. 53:
11473–11477.
2056 Stern, A. D., Rahman, A. H. and Birtwistle, M. R., Cell size assays for
mass cytometry. Cytometry A 2017. 91: 14–24.
2057 Rapsomaniki, M. A., Lun, X. K., Woerner, S., Laumanns, M., Boden-
miller, B. and Martinez, M. R., CellCycleTRACER accounts for cell cycle
and volume in mass cytometry data. Nat. Commun. 2018. 9: 632.
2058 Budzinski, L., Schulz, A. R., Baumgart, S., Burns, T.,Rose, T.,Hirseland,
H. andMei, H. E., Osmium-labeledmicrospheres for bead-based assays
in mass cytometry. J. Immunol. 2019. 202: 3103–3112.
2059 Bringeland, G. H., Bader, L., Blaser, N., Budzinski, L., Schulz, A. R.,Mei,
H. E., Myhr, K. M. et al., Optimization of receptor occupancy assays
in mass cytometry: standardization across channels with QSC beads.
Cytometry A 2019. 95: 314–322.
2060 Ornatsky, O. I., Lou, X., Nitz, M., Schafer, S., Sheldrick, W. S., Baranov,
V. I., Bandura, D. R. et al., Study of cell antigens and intracellular DNA
by identification of element-containing labels and metallointercala-
tors using inductively coupled plasmamass spectrometry. Anal. Chem.
2008. 80: 2539–2547.
2061 Blair, T. A., Michelson, A. D. and Frelinger, A. L., 3rd, Mass cytometry
reveals distinct platelet subtypes in healthy subjects and novel alter-
ations in surface glycoproteins in Glanzmann thrombasthenia. Sci. Rep.
2018. 8: 10300.
2062 Lee, B. H. and Rahman, A. H., Acquisition, Processing, and Quality
Control of Mass Cytometry Data. Methods Mol. Biol. 2019. 1989: 13–31.
2063 Fienberg, H. G., Simonds, E. F., Fantl, W. J., Nolan, G. P. and Boden-
miller, B., A platinum-based covalent viability reagent for single-cell
mass cytometry. Cytometry A 2012. 81: 467–475.
2064 Leipold, M. D. and Maecker, H. T., Phenotyping of live human PBMC
using CyTOFTM mass cytometry. bio-protocol 2015. 5: e1382.
2065 Han, G., Spitzer, M. H., Bendall, S. C., Fantl, W. J. and Nolan, G.
P., Metal-isotope-tagged monoclonal antibodies for high-dimensional
mass cytometry. Nat. Protoc. 2018. 13: 2121–2148.
2066 Han, G., Chen, S. Y., Gonzalez, V. D., Zunder, E. R., Fantl, W. J.
and Nolan, G. P., Atomic mass tag of bismuth-209 for increasing the
immunoassay multiplexing capacity of mass cytometry. Cytometry A
2017. 91: 1150–1163.
2067 Horowitz, A., Strauss-Albee, D. M., Leipold, M., Kubo, J., Nemat-
Gorgani, N., Dogan, O. C., Dekker, C. L. et al., Genetic and environ-
mental determinants of human NK cell diversity revealed by mass
cytometry. Sci. Transl. Med. 2013. 5: 208ra145.
2068 Leipold, M. D., Newell, E. W. and Maecker, H. T., Multiparameter phe-
notyping of human PBMCs using mass cytometry. Methods Mol. Biol.
2015. 1343: 81–95.
2069 Olsen, L. R., Leipold, M. D., Pedersen, C. B. and Maecker, H. T., The
anatomy of single cell mass cytometry data. Cytometry A 2018.
2070 Robinson, J. P., Patsekin, V., Holdman, C., Ragheb, K., Sturgis, J., Fatig,
R., Avramova, L. V. et al., High-throughput secondary screening at the
single-cell level. J. Lab. Automat. 2012. 18: 85–98.
2071 Robinson, J. P.,Durack, G. and Kelley, S., An innovation in flow cytom-
etry data collection & analysis producing a correlated multiple sample
analysis in a single file. Cytometry 1991. 12: 82–90.
2072 Newell, E., Bendall, S., Hong, D., Lewis, D., Nolan, G. and Davis, M.,
Surveying the influenza-specific cytotoxic T cell response in humans
and mice using mass-cytometry (CyTOF) and combinatorial tetramer
staining. Clin. Immunol. 2010. 135: S104–S104.
2073 Rajwa, B., Venkatapathi, M., Ragheb, K., Banada, P. P., Hirleman, E.
D., Lary, T. and Robinson, J. P. Automated classification of bacterial
particles in flow by multiangle scatter measurement and a support
vector machine classifier. Cytometry Part A 2008. 73A: 369–379.
2074 Costa, E. S., Pedreira, C. E., Barrena, S., Lecrevisse, Q., Flores, J., Qui-
jano, S., Almeida, J. et al., Automated pattern-guided principal com-
ponent analysis vs expert-based immunophenotypic classification of
B-cell chronic lymphoproliferative disorders: A step forward in the
standardization of clinical immunophenotyping. Leukemia 2010. 24:
1927–1933.
2075 Dundar, M., Akova, F., Yerebakan, H. Z. and Rajwa, B., A non-
parametric Bayesian model for joint cell clustering and cluster match-
ing: identification of anomalous sample phenotypes with random
effects. BMC Bioinformatics 2014. 15: 314.
2076 Bagwell, C. B., Hunsberger, B. C., Herbert, D. J., Munson, M. E., Hill,
B. L., Bray, C. M. and Preffer, F. I., Probability state modeling theory.
Cytometry A 2015. 87: 646–660.
2077 Robinson, J. P., Rajwa, B., Patsekin, V. and Davisson, V. J., Computa-
tional analysis of high throughput flow cytometry data. Expert Opin.
Drug Deliv. 2012. 7: 679–693.
2078 Fulton, R. J., McDade, R. L., Smith, P. L., Kienker, L. J. and Kettman,
J. R. Advanced multiplexed analysis with the FlowMetrix system. Clin.
Chem. 1997. 43: 1749–1756.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1967
2079 Robinson, J. P., Patsekin, V., Gregori, G., Rajwa, B. and Jones, J., Multi-
spectral flow cytometry: next generation tools for automated classifi-
cation. Microsc. Microanal. 2005. 11: 2–3.
2080 Mair, F. and Prlic, M., OMIP-044: 28-color immunophenotyping of the
human dendritic cell compartment. Cytometry A. 2018. 106: 255.
2081 Nolan, J. P. and Condello, D., Spectral flow cytometry. Curr. Protoc.
Cytom. 2013. Chapter 1:Unit1.27–1.27.13.
2082 Bagwell, C. B. and Adams, E. G., Fluorescence spectral overlap com-
pensation for any number of flow cytometry parameters. Ann. N. Y.
Acad. Sci. 1993. 677: 167–184.
2083 Roederer, M., Compensation is not dependent on signal intensity or
on number of parameters. Cytometry. 2001. 46: 357–359.
2084 Perfetto, S. P., Chattopadhyay, P. K. and Roederer, M., Seventeen-
colour flow cytometry: unravelling the immune system. Nat. Rev.
Immunol. 2004. 4: 648–655.
2085 Mahnke, Y. D., Brodie, T. M., Sallusto, F., Roederer, M., Lugli, E., The
who’s who of T-cell differentiation: human memory T-cell subsets.
Eur. J. Immunol. 2013. 43: 2797–2809.
2086 Herzenberg, L. A., Tung, J.,Moore, W. A., Herzenberg, L. A. and Parks,
D. R., Interpreting flow cytometry data: a guide for the perplexed. Nat.
Immunol. 2006. 7: 681–685.
2087 Gerner, M. Y., Kastenmu¨ller, W., Ifrim, I., Kabat, J. and Germain, R.
N., Histo-cytometry: a method for highly multiplex quantitative tis-
sue imaging analysis applied to dendritic cell subset microanatomy in
lymph nodes. Immunity. 2012. 37: 364–376.
2088 Ashhurst, T. M., Smith, A. L. and King, N. J. C., High-dimensional fluores-
cence cytometry. JohnWiley & Sons, Inc., Hoboken, NJ 2017. 5.8.1–5.8.38.
2089 Picelli, S., Faridani, O. R., Bjo¨rklund, A. K., Winberg, G., Sagasser, S.
and Sandberg, R., Full-length RNA-seq from single cells using Smart-
seq2. Nat. Protoc. 2014. 9: 171–181.
2090 Lafzi, A.,Moutinho, C., Picelli, S. and Heyn, H., Tutorial: guidelines for
the experimental design of single-cell RNA sequencing studies. Nat.
Protoc. 2018. 13: 2742–2757.
2091 Macosko, E. Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman,
M., Tirosh, I. et al., Highly parallel genome-wide expression profiling
of individual cells using nanoliter droplets. Cell. 2015. 161: 1202–1214.
2092 Klein, A. M., Mazutis, L., Akartuna, I., Tallapragada, N., Veres, A., Li,
V., Peshkin, L. et al., Droplet barcoding for single-cell transcriptomics
applied to embryonic stem cells. Cell. 2015. 161: 1187–1201.
2093 Valihrach, L., Androvic, P. and Kubista, M., Platforms for single-cell
collection and analysis. Int. J. Mol. Sci. 2018. 19: 807.
2094 Cao, J., Packer, J. S., Ramani, V., Cusanovich, D. A., Huynh, C., Daza,
R., Qiu, X. et al., Comprehensive single-cell transcriptional profiling of
a multicellular organism. Science. 2017. 357: 661–667.
2095 Bucevicˇius, J., Lukinavicˇius, G. and Gerasimaite˙, R., The use of Hoechst
dyes for DNA staining and beyond. Chemosensors. 2018. 6: 18.
2096 Smith, P. J., Blunt, N., Wiltshire, M., Hoy, T., Teesdale-Spittle, P.,
Craven, M. R., Watson, J. V. et al., Characteristics of a novel deep
red/infrared fluorescent cell-permeant DNA probe, DRAQ5, in intact
human cells analyzed by flow cytometry, confocal and multiphoton
microscopy. Cytometry. 2000. 40: 280–291.
2097 Wlodkowic, D., Skommer, J. and Darzynkiewicz, Z., Flow cytometry-
based apoptosis detection. Methods Mol. Biol. 2009. 559: 19–32.
2098 Belloc, F., Belaud-Rotureau, M. A., Lavignolle, V., Bascans, E., Braz-
Pereira, E., Durrieu, F. and Lacombe, F., Flow cytometry detection of
caspase 3 activation in preapoptotic leukemic cells. Cytometry. 2000.
40: 151–160.
2099 Shapiro, H. M., Practical flow cytometry. Wiley-Liss, Hoboken, NJ 2003.
2100 Riddell, A., Gardner, R., Perez-Gonzalez, A., Lopes, T. and Martinez, L.,
Rmax: a systematic approach to evaluate instrument sort performance
using center stream catch. Methods. 2015. 82: 64–73.
2101 Ziegenhain, C., Vieth, B., Parekh, S., Reinius, B., Guillaumet-Adkins,
A., Smets, M., Leonhardt, H. et al., Comparative analysis of single-cell
RNA sequencing methods. Mol. Cell. 2017. 65: 631–643.
2102 Semrau, S., Goldmann, J. E., Soumillon, M.,Mikkelsen, T. S., Jaenisch,
R. and van Oudenaarden, A., Dynamics of lineage commitment
revealed by single-cell transcriptomics of differentiating embryonic
stem cells. Nat. Commun. 2017. 8: 243.
2103 Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S.
M., Wakimoto, H., Cahill, D. P. et al., Single-cell RNA-seq highlights
intratumoral heterogeneity in primary glioblastoma. Science. 2014. 344:
1396–1401.
2104 Lopez, R., Regier, J., Cole, M. B., Jordan, M. I. and Yosef, N., Deep gener-
ative modeling for single-cell transcriptomics. Nat. Methods. 2018. 15:
1053–1058.
2105 Bacher, R. and Kendziorski, C., Design and computational analysis of
single-cell RNA-sequencing experiments. Genome Biol. 2016. 17: 63.
2106 Vallejos, C. A.,Marioni, J. C. and Richardson, S., BASiCS: Bayesian anal-
ysis of single-cell sequencing data PLoS Comput. Biol. 2015. 11: e1004333.
2107 Anders, S. and Huber, W., Differential expression analysis for
sequence count data. Genome Biol. 2010. 11: R106.
2108 Robinson, M. D. and Oshlack, A., A scaling normalization method for
differential expression analysis of RNA-seq data. Genome Biol. 2010. 11:
R25.
2109 Bullard, J. H., Purdom, E., Hansen, K. D. and Dudoit, S., Evaluation
of statistical methods for normalization and differential expression in
mRNA-Seq experiments. BMC Bioinformatics. 2010. 11: 94.
2110 Bacher, R., Chu, L-F, Leng, N., Gasch, A. P., Thomson, J. A., Stewart,
R. M., Newton, M. et al., SCnorm: robust normalization of single-cell
RNA-seq data. Nat. Methods. 2017. 14: 584–586.
2111 Lun, A. T. L., Bach, K. andMarioni, J. C., Pooling across cells to normal-
ize single-cell RNA sequencing data with many zero counts. Genome
Biol. 2016. 17: 75.
2112 Butler, A.,Hoffman, P., Smibert, P., Papalexi, E. and Satija, R., Integrat-
ing single-cell transcriptomic data across different conditions, tech-
nologies, and species. Nat. Biotechnol. 2018. 36: 411–420.
2113 Abdi, H. and Williams, L. J., Principal component analysis. Wiley Inter-
discip. Rev. Comput. Stat. 2010. 2: 433–459.
2114 Sta˚hlberg, A. and Bengtsson, M., Single-cell gene expression profiling
using reverse transcription quantitative real-time PCR. Methods. 2010.
50: 282–288.
2115 Sta˚hlberg, A., Bengtsson, M., Hemberg, M. and Semb, H., Quantitative
transcription factor analysis of undifferentiated single human embry-
onic stem cells. Clin. Chem. 2009. 55: 2162–2170.
2116 Kiselev, V. Y., Kirschner, K., Schaub, M. T., Andrews, T., Yiu, A., Chan-
dra, T., Natarajan, K. N. et al., SC3: consensus clustering of single-cell
RNA-seq data. Nat. Methods. 2017. 14: 483–486.
2117 Soneson, C. and Robinson, M. D., Bias, robustness and scalability in
single-cell differential expression analysis. Nat. Methods. 2018. 15: 255–
261.
2118 Koch, C. and Muller, S., Personalized microbiome dynamics—
cytometric fingerprints for routine diagnostics. Mol. Aspects Med. 2018.
59: 123–134.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1968 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
2119 Muller, S., Modes of cytometric bacterial DNA pattern: a tool for pur-
suing growth. Cell Prolif. 2007. 40: 621–639.
2120 Delgado-Baquerizo, M., Oliverio, A. M., Brewer, T. E., Benavent-
Gonzalez, A., Eldridge, D. J., Bardgett, R. D., Maestre, F. T. et al., A
global atlas of the dominant bacteria found in soil. Science 2018. 359:
320–325.
2121 Koch, C., Harnisch, F., Schroder, U. and Muller, S., Cytometric fin-
gerprints: evaluation of new tools for analyzing microbial community
dynamics. Front Microbiol. 2014. 5: 273.
2122 Zimmermann, J., Hubschmann, T., Schattenberg, F., Schumann, J.,
Durek, P., Riedel, R., Friedrich, M. et al., High-resolution microbiota
flow cytometry reveals dynamic colitis-associated changes in fecal
bacterial composition. Eur. J. Immunol. 2016. 46: 1300–1303.
2123 Vandeputte, D., Kathagen, G., D’Hoe, K., Vieira-Silva, S., Valles-
Colomer, M., Sabino, J.,Wang, J. et al., Quantitativemicrobiome profil-
ing links gut community variation to microbial load. Nature 2017. 551:
507–511.
2124 Muller, S. and Nebe-von-Caron, G., Functional single-cell analyses:
flow cytometry and cell sorting of microbial populations and commu-
nities. FEMS Microbiol. Rev. 2010. 34: 554–587.
2125 Lambrecht, J., Schattenberg, F., Harms, H. and Mueller, S., Character-
izing microbiome dynamics—flow cytometry based workflows from
pure cultures to natural communities. J. Vis. Exp. 2018.
2126 Gunther, S., Hubschmann, T., Rudolf, M., Eschenhagen, M., Roske,
I., Harms, H. and Muller, S., Fixation procedures for flow cytometric
analysis of environmental bacteria. J. Microbiol. Methods 2008. 75: 127–
134.
2127 Shi, L., Gunther, S., Hubschmann, T., Wick, L. Y., Harms, H. and
Muller, S., Limits of propidium iodide as a cell viability indicator for
environmental bacteria. Cytometry A 2007. 71: 592–598.
2128 Props, R., Rubbens, P., Besmer, M., Buysschaert, B., Sigrist, J., Weilen-
mann, H., Waegeman, W. et al., Detection of microbial disturbances
in a drinking water microbial community through continuous acqui-
sition and advanced analysis of flow cytometry data. Water Res. 2018.
145: 73–82.
2129 Stepanauskas, R., Fergusson, E. A., Brown, J., Poulton, N. J., Tupper,
B., Labonte, J. M., Becraft, E. D. et al., Improved genome recovery and
integrated cell-size analyses of individual uncultured microbial cells
and viral particles. Nat. Commun. 2017. 8: 84.
2130 Jahn, M., Seifert, J., von Bergen, M., Schmid, A., Buhler, B. and Muller,
S., Subpopulation-proteomics in prokaryotic populations. Curr. Opin.
Biotechnol. 2013. 24: 79–87.
2131 Liu, Z., Cichocki, N., Hubschmann, T., Suring, C., Ofiteru, I. D., Sloan,
W. T., Grimm, V. et al., Neutral mechanisms and niche differentiation
in steady-state insular microbial communities revealed by single cell
analysis. Environ. Microbiol. 2019. 21: 164–181.
2132 Koch, C., Gunther, S., Desta, A. F., Hubschmann, T. and Muller,
S., Cytometric fingerprinting for analyzing microbial intracommunity
structure variation and identifying subcommunity function. Nat. Pro-
toc. 2013. 8: 190–202.
2133 Rogers, W. T. and Holyst, H. A., FlowFP: A Bioconductor Package for
Fingerprinting Flow Cytometric Data. Adv. Bioinformatics 2009. 193947.
2134 De Roy, K., Clement, L., Thas, O., Wang, Y. and Boon, N., Flow cytom-
etry for fast microbial community fingerprinting. Water Res. 2012. 46:
907–919.
2135 Koch, C., Fetzer, I., Harms, H. and Muller, S., CHIC-an automated
approach for the detection of dynamic variations in complexmicrobial
communities. Cytometry A 2013. 83: 561–567.
2136 Schroder, K. and Tschopp, J., The inflammosomes. Cell 2010. 140: 821–
832.
2137 Aachoui, Y., Sagulenko, V., Miao, E. A. and Stacey, K. J., Inflam-
masomemediated pyroptotic and apoptotic cell death, and defense
against infection. Curr. Opin. Microbiol. 2013. 16: 319–326.
2138 Miao, E. A., Rajan, J. V. and Aderem, A., Caspase-1-induced pyroptotic
cell death. Immunol. Rev. 2011. 243: 206–214.
2139 Jin, C. and Flavell, R.A., MolecularmechanismofNLRP3 inflammasome
activation. J. Clin. Immunol. 2010. 30: 628–631.
2140 Lamkanfi, M., Emerging inflammasome effectormechanisms.Nat. Rev.
Immunol. 2011. 11: 213–220.
2141 Vajjhala, P. R., Lu, A., Brown, D. L., Pang, S. W., Sagulenko, V., Sester,
D. P., Cridland, S. O. et al., The inflammasome adaptor ASC induces
procaspase-8 death effector domain filaments. J. Biol. Chem. 2015. 4;290:
29217–29230.
2142 Man, S. M., Tourlomousis, P., Hopkins, L., Monie, T. P., Fitzgerald,
K. A. and Bryant, C. E., Salmonella infection induces recruitment of
Caspase-8 to the inflammasome to modulate IL-1beta production. J.
Immunol. 2013. 191: 5239–5246.
2143 Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N.
and Tschopp, J., NALP3 forms an IL-1beta-processing inflammasome
with increased activity in Muckle-Wells autoinflammatory disorder.
Immunity 2004. 20: 319–325.
2144 Martinon, F., Agostini, L., Meylan, E. and Tschopp, J., Identification
of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin
inflammasome. Curr. Biol. 2004. 14: 1929–1934.
2145 Sagulenko, V., Thygesen, S. J., Sester, D. P., Idris, A., Cridland, J. A.,
Vajjhala, P. R., Roberts, T. L., Schroder, K., Vince, J. E., Hill, J. M. Silke, J.
and Stacey K. J., AIM2 and NLRP3 inflammasomes activate both apop-
totic and pyroptotic death pathways via ASC. Cell Death Differ. 2013. 20:
1149–1160.
2146 Masumoto, J., Taniguchi, S., Ayukawa, K., Sarvotham, H., Kishino, T.,
Niikawa, N., Hidaka, E. et al., ASC, a novel 22-kDa protein, aggregates
during apoptosis of human promyelocytic leukemia HL-60 cells. J. Biol.
Chem. 1999. 274: 33835–33838.
2147 Franklin, B. S.,Bossaller, L.,DeNardo, D.,Ratter, J. M., Stutz, A., Engels,
G., Brenker, C. et al., The adaptor ASC has extracellular and ‘prionoid’
activities that propagate inflammation.Nat. Immunol. 2014. 15: 727–737.
2148 Baroja-Mazo, A., Martı´n-Sa´nchez, F., Gomez, A. I., Martı´nez, C. M.,
Amores-Iniesta, J., Compan, V., Barbera`-Cremades, M. et al., The
NLRP3 inflammasome is released as a particulate danger signal that
amplifies the inflammatory response. Nat. Immunol. 2014. 15: 738–748.
2149 Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R.,
Tejera, D., Vieira-Saecker, A. et al., Microglia-derived ASC specks
cross-seed amyloid-β in Alzheimer’s disease. Nature 2017. 552: 355–
361.
2150 Pollard, K. M. and Kono, D. H., Requirements for innate immune path-
ways in environmentally induced autoimmunity. BMC Med. 2013. 11:
100.
2151 Master, S. L., Specific inflammasomes in complex diseases. Clin.
Immunol. 2013. 143: 223–228.
2152 Rubartelli, A., Redox control of NLRP3 inflammasome activation in
health and disease. J. Leukoc. Biol. 2012. 92: 951–958.
2153 Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S.,
Vieira-Saecker, A., Griep, A. et al., NLRP3 is activated in Alzheimer’s
disease and contributes to pathology in APP/PS1 mice. Nature 2013.
493: 674–678.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1969
2154 Saresella, M., La Rosa, F., Piancone, F., Zoppis, M., Marventano, I.,
Calabrese, E., Rainone, V., Nemni, R. et al., The NLRP3 and NLRP1
inflammasomes are activated inAlzheimer’s disease.Mol. Neurodegener
2016. 11(1): 23.
2155 Saresella, M., Piancone, F., Marventano, I., Zoppis, M., Hernis, A.,
Zanette, M., Trabattoni, D. et al., Multiple Inflammasome Complexes
are Activated in Autistic SpectrumDisorders. Brain Behav. Immun. 2016.
57: 125–133.
2156 Piancone, F., Saresella, M., Marventano, I., La Rosa, F., Santangelo,
M. A., Caputo, D., Mendozzi, L., Rovaris, M. et al., Monosodium urate
crystals activate the inflammasome in primary progressive multiple
sclerosis. Front. Immunol. 2018. 9: 983.
2157 Bandera, A.,Masetti, M., Fabbiani, M., Biasin, M.,Muscatello, A., Squil-
lace, N., Clerici, M. et al., The NLRP3 Inflammasome is Upregulated in
HIV-Infected ART-treated Individuals with Defective Immune Recov-
ery. Front. Immunol. 2018. 9: 214.
2158 Nagar, A., DeMarco, R. A. and Harton, J. A., Inflammasome and
caspase-1 activity characterization and evaluation: An imaging flow
cytometer-based detection and assessment of inflammasome specks
and caspase-1 activation. J. Immunol. 2019. 202: 1003–1015.
2159 Hooijberg, J. H. Broxterman H. J., Kool M., Assaraf Y. G., Peters G. J.,
Noordhuis P. and Scheper R. J., Antifolate resistance mediated by the
multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999. 59:
2532–2535.
2160 Zeng, H. et al., Transport of methotrexate (MTX) and folates by mul-
tidrug resistance protein (MRP) 3 andMRP1: effect of polyglutamylation
on MTX transport. Cancer Res. 2001. 61: 7225–7232.
2161 Volk, E. L., Farley, K. M.,Wu, Y., Li, F., Robey, R. W. and Schneider, E.,
Overexpression of wild-type breast cancer resistance proteinmediates
methotrexate resistance. Cancer Res. 2002. 62: 5035–5040.
2162 Sarkadi, B. et al., Human multidrug resistance ABCB and ABCG trans-
porters: participation in a chemoimmunity defense system. Physiol Rev.
2006. 86: 1179–1236.
2163 Lee, N. H., Pharmacogenetics of drugmetabolizing enzymes and trans-
porters: effects on pharmacokinetics and pharmacodynamics of anti-
cancer agents. Anticancer Agents Med. Chem. 2010. 10: 583–592.
2164 Porcelli, L., Lemos, C., Peters, G. J., Paradiso, A. and Azzariti, A., Intra-
cellular trafficking of MDR transporters and relevance of SNPs. Curr.
Top. Med. Chem. 2009. 9: 197–208.
2165 Damiani, D. et al., The prognostic value of P-glycoprotein (ABCB) and
breast cancer resistance protein (ABCG2) in adults with de novo acute
myeloid leukemia with normal karyotype. Haematologica 2006. 91: 825–
828.
2166 Georges, E., Tsuruo, T. and Ling, V., Topology of P-glycoprotein as
determined by epitope mapping of MRK-16 monoclonal antibody. J.
Biol. Chem. 1993. 268: 1792–1798.
2167 Vasudevan, S., Tsuruo, T. and Rose, D. R., Mode of binding of anti-
P-glycoprotein antibody MRK-16 to its antigen. A crystallographic and
molecular modeling study. J. Biol. Chem. 1998. 273: 25413–25419.
2168 Telbisz, A., Hegedu¨s, C., O¨zvegy-Laczka, C., Goda, K., Va´rady, G.,
Taka´ts, Z., Szabo´, E. et al., Antibody binding shift assay for rapid
screening of drug interactionswith the humanABCG2multidrug trans-
porter. Eur. J. Pharm. Sci. 2012. 45: 101–109.
2169 Toldi, G. et al., Peripheral lymphocyte multidrug resistance activity
as a predictive tool of biological therapeutic response in rheumatoid
arthritis. J. Rheumatol. 2019. 46: 572–578.
2170 Micsik, T. et al., MDR-1 and MRP-1 activity in peripheral blood leuko-
cytes of rheumatoid arthritis patients. Diagn. Pathol. 2015. 10: 216.
2171 Homolya, L., Hollo´, Z., Germann, U. A., Pastan, I., Gottesman, M. M.,
Sarkadi, B. Fluorescent cellular indicators are extruded by the mul-
tidrug resistance protein. J. Biol. Chem. 1993. 268: 21493–21496.
2172 Cortada, C. M. et al., Lymphocyte P-glycoprotein variability in healthy
individuals. Medicina 2009. 69: 619–624.
2173 Szere´my, P., Tauberne´ Jakab, K., Bara´th, S., Apjok, A., Filkor, K.,
Hollo´, Z., Ma´rki-Zay, J., Kappelmayer, J., Sipka, S., Krajcsi, P.,
Toldi, G. Determination of reference values of MDR-ABC trans-
porter activities in CD3+ lymphocytes of healthy volunteers using
a flow cytometry based method. Cytometry B Clin. Cytom. 2018
https://doi.org/10.1002/cyto.b.21729. [Epub ahead of print].
2174 Yu, L., Sa, S., Wang, L., Dulmage, K., Bhagwat, N., Yee, S. S., Sen,
M. et al., An integrated enrichment system to facilitate isolation and
molecular characterization of single cancer cells from whole blood.
Cytometry A 2018. 93: 1226–1233.
2175 Hayashi, T., Shibata, N., Okumura, R., Kudome, T., Nishimura, O.,
Tarui, H. and Agata, K., Single-cell gene profiling of planarian stem
cells using fluorescent activated cell sorting and its “index sorting"
function for stem cell research. Dev. Growth Differ. 2010. 52: 131–144.
2176 Schulte, R.,Wilson, N. K., Prick, J. C., Cossetti, C.,Maj, M. K., Gottgens,
B. and Kent, D. G., Index sorting resolves heterogeneous murine
hematopoietic stem cell populations. Exp. Hematol. 2015. 43: 803–811.
2177 Wilson, N. K., Kent, D. G., Buettner, F., Shehata, M., Macaulay, I. C.,
Calero-Nieto, F. J., Sanchez Castillo, M. et al., Combined single-cell
functional and gene expression analysis resolves heterogeneity within
stem cell populations. Cell Stem Cell 2015. 16: 712–724.
2178 Busse, C. E., Czogiel, I., Braun, P., Arndt, P. F. and Wardemann,
H., Single-cell based high-throughput sequencing of full-length
immunoglobulin heavy and light chain genes. Eur. J. Immunol. 2014.
44: 597–603.
2179 Gee, M. H., Han, A., Lofgren, S. M., Beausang, J. F., Mendoza, J. L.,
Birnbaum,M. E.,Bethune,M. T. et al., Antigen identification for orphan
T cell receptors expressed on tumor-infiltrating lymphocytes.Cell 2018.
172: 549–563.
2180 Penter, L., Dietze, K., Bullinger, L., Westermann, J., Rahn, H. P. and
Hansmann, L., FACS single cell index sorting is highly reliable and
determines immune phenotypes of clonally expanded T cells. Eur. J.
Immunol. 2018. 48: 1248–1250.
2181 Penter, L., Dietze, K., Ritter, J., Lammoglia-Cobo, M. F., Garmshausen,
J., Aigner, F., Bullinger, L. et al., Localization-associated immune phe-
notypes of clonally expanded tumor-infiltrating T cells and distribu-
tion of their target antigens in rectal cancer. Oncoimmunology 2019. 8:
e1586409.
2182 Higdon, L. E., Cain, C. J., Colden, M. A. and Maltzman, J. S. Optimiza-
tion of single-cell plate sorting for high throughput sequencing appli-
cations. J. Immunol. Methods 2019. 466: 17–23.
2183 Kleeberger, C. A., Lyles, R. H., Margolick, J. B., Rinaldo, C. R., Phair, J.
P. and Giorgi, J. V., Viability and recovery of peripheral blood mononu-
clear cells cryopreserved for up to 12 years in a multicenter study. Clin.
Diagn. Lab. Immunol. 1999. 6: 14–19.
2184 Ruitenberg, J. J., Mulder, C. B., Maino, V. C., Landay, A. L. and
Ghanekar, S. A., VACUTAINER CPT and Ficoll density gradient sep-
aration perform equivalently in maintaining the quality and function
of PBMC from HIV seropositive blood samples. BMC Immunol. 2006. 7:
11.
2185 Grievink, H. W., Luisman, T., Kluft, C.,Moerland, M. andMalone, K. E.,
Comparison of three isolation techniques for human peripheral blood
mononuclear cells: cell recovery and viability, population composition,
and cell functionality. Biopreserv. Biobank. 2016. 14: 410–415.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1970 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
2186 Disis, M. L., dela Rosa, C., Goodell, V., Kuan, L-Y, Chang, JCC, Kuus-
Reichel, K., Clay, T. M. et al., Maximizing the retention of antigen spe-
cific lymphocyte function after cryopreservation. J. Immunol. Methods
2006. 308: 13–18.
2187 Weinberg, A., Song, L-Y,Wilkening, C., Sevin, A., Blais, B., Louzao, R.,
Stein, D. et al., Optimization and limitations of use of cryopreserved
peripheral blood mononuclear cells for functional and phenotypic T-
cell characterization. Clin. Vaccine Immunol. 2009. 16: 1176–1186.
2188 Bull, M., Lee, D., Stucky, J., Chiu, Y-L, Rubin, A., Horton, H. and McEl-
rath, M. J., Defining blood processing parameters for optimal detection
of cryopreserved antigen-specific responses for HIV vaccine trials. J.
Immunol. Methods. 2007. 322: 57–69.
2189 Scheiermann, C., Kunisaki, Y. and Frenette, P. S., Circadian control of
the immune system. Nat. Rev. Immunol. 2013. 13: 190–198.
2190 Tompa, A., Nilsson-Bowers, A. and Faresjo¨, M., Subsets of CD4+,
CD8+, and CD25hi lymphocytes are in general not influenced by isola-
tion and long-term cryopreservation. J. Immunol. 2018. 201: 1799–1809.
2191 Seale, A. C., de Jong, B. C., Zaidi, I., Duvall, M., Whittle, H., Rowland-
Jones, S. and Jaye, A., Effects of cryopreservation on CD4+ CD25+
T cells of HIV-1 infected individuals. J. Clin. Lab. Anal. 2008. 22: 153–158.
2192 Assumpcio´Romeu, M., Mestre, M., Gonza´lez, L., Valls, A., Verdaguer,
J., Corominas, M., Bas, J. et al., Lymphocyte immunophenotyping by
flow cytometry in normal adults. J. Immunol. Methods 1992. 154: 7–10.
2193 Lemieux, J., Jobin, C., Simard, C. and Ne´ron, S., A global look into
human T cell subsets before and after cryopreservation using multi-
parametric flow cytometry and two-dimensional visualization analy-
sis. J. Immunol. Methods 2016. 434: 73–82.
2194 Wang, L., Hu¨ckelhoven, A., Hong, J., Jin, N.,Mani, J., Chen, B., Schmitt,
M. et al., Standardization of cryopreserved peripheral blood mononu-
clear cells through a resting process for clinical immunomonitoring—
development of an algorithm. Cytometry A. 2016. 89: 246–258.
2195 Holland, M., Cunningham, R., Seymour, L., Kleinsteuber, K., Cunning-
ham, A., Patel, T., Manos, M. et al., Separation, banking, and quality
control of peripheral blood mononuclear cells from whole blood of
melanoma patients. Cell Tissue Bank. 2018. 19: 783–790.
2196 De Boer, F., Dra¨ger, A. M., Van der Wall, E., Pinedo, H. M. and Schu-
urhuis, G. J., Changes in L-selectin expression on CD34-positive cells
upon cryopreservation of peripheral blood stem cell transplants. Bone
Marrow Transplant. 1998. 22: 1103–1110.
2197 Campbell, D. E., Tustin, N. B., Riedel, E., Tustin, R., Taylor, J., Murray,
J. and Douglas, S. D., Cryopreservation decreases receptor PD-1 and
ligand PD-L1 coinhibitory expression on peripheral bloodmononuclear
cell-derived T cells and monocytes. Clin. Vaccine Immunol. 2009. 16:
1648–1653.
2198 Zhang, W.,Nilles, T. L., Johnson, J. R. and Margolick, J. B., The effect of
cellular isolation and cryopreservation on the expression of markers
identifying subsets of regulatory T cells. J. Immunol. Methods. 2016. 431:
31–37.
2199 Posevitz-Fejfa´r, A., Posevitz, V., Gross, C. C., Bhatia, U., Kurth, F.,
Schu¨tte, V., Bar-Or, A. et al., Effects of blood transportation on human
peripheral mononuclear cell yield, phenotype and function: implica-
tions for immune cell biobanking. PLoS One. 2014. 9: e115920.
2200 Nemes, E.,Kagina, B.M. N., Smit, E.,Africa, H., Steyn,M.,Hanekom,W.
A. and Scriba, T. J., Differential leukocyte counting and immunophe-
notyping in cryopreserved ex vivo whole blood. Cytometry A. 2015. 87:
157–165.
2201 Maecker, H. T., McCoy, J. P., FOCIS Human Immunophenotyping Con-
sortium, Amos, M., Elliott, J., Gaigalas, A., Wang, L. et al., A model for
harmonizing flow cytometry in clinical trials. Nat. Immunol. 2010. 11:
975–978.
2202 Burel, J. G.,Qian, Y., Lindestam Arlehamn, C.,Weiskopf, D., Zapardiel-
Gonzalo, J., Taplitz, R., Gilman, R. H. et al., An integrated workflow to
assess technical and biological variability of cell population frequen-
cies in human peripheral blood by flow cytometry. J. Immunol. 2017.
198: 1748–1758.
2203 Bernemann, I., Kersting, M., Prokein, J., Hummel, M., Klopp, N. and
Illig, T., [Centralized biobanks: a basis for medical research]. Bundes-
gesundheitsblatt. Gesundheitsforschung. Gesundheitsschutz. 2016. 59: 336–
343.
2204 Labarga, A., Beloqui, I. and Martin, A. G., Information Management.
Methods Mol. Biol. 2017. 1590: 29–39.
2205 Bendou, H., Sizani, L., Reid, T., Swanepoel, C.,Ademuyiwa, T.,Merino-
Martinez, R.,Meuller, H. et al., Baobab laboratory informationmanage-
ment system: development of an open-source laboratory information
management system for biobanking. Biopreserv. Biobank. 2017. 15: 116–
120.
2206 Mate, S., Kadioglu, D., Majeed, R. W., Sto¨hr, M. R., Folz, M., Vorm-
stein, P., Storf, H. et al., Proof-of-concept integration of heterogeneous
biobank IT infrastructures into a hybrid biobanking network. Stud.
Health Technol. Inform. 2017. 243: 100–104.
2207 Consuegra, I., Rodrı´guez-Aierbe, C., Santiuste, I., Bosch, A., Martı´nez-
Marı´n, R., Fortuto, M. A.,Dı´az, T. et al., Isolationmethods of peripheral
blood mononuclear cells in spanish biobanks: an overview. Biopreserv.
Biobank. 2017. 15: 305–309.
2208 Aziz, N., Margolick, J. B., Detels, R., Rinaldo, C. R., Phair, J., Jamieson,
B. D. and Butch, A. W., Value of a quality assessment program in
optimizing cryopreservation of peripheral blood mononuclear cells in
a multicenter study. Clin. Vaccine Immunol. 2013. 20: 590–595.
2209 Ramos, T. V., Mathew, A. J., Thompson, M. L. and Ehrhardt, R. O.,
Standardized cryopreservation of human primary cells. Curr. Protoc.
Cell Biol. 2014. 64: A.3I.1-8.
2210 Xiao, D., Ling, K. H. J., Custodio, J., Majeed, S. R. and Tarnowski, T.,
Quantitation of intracellular triphosphate metabolites of antiretrovi-
ral agents in peripheral blood mononuclear cells (PBMCs) and corre-
sponding cell count determinations: review of current methods and
challenges. Expert Opin. Drug Metab. Toxicol. 2018. 14: 781–802.
2211 Becher, F., Pruvost, A. G., Schlemmer, D. D., Cre´minon, C. A., Goujard,
C. M., Delfraissy, J. F., Benech, H. C. et al., Significant levels of intra-
cellular stavudine triphosphate are found in HIV-infected zidovudine-
treated patients. AIDS. 2003. 17: 555–561.
2212 Corkum, C. P., Ings, D. P., Burgess, C., Karwowska, S., Kroll, W. and
Michalak, T. I., Immune cell subsets and their gene expression pro-
files from human PBMC isolated by Vacutainer Cell Preparation Tube
(CPTTM) and standard density gradient. BMC Immunol. 2015. 16: 48.
2213 Angel, S., von Briesen, H., Oh, Y.-J., Baller, M. K., Zimmermann, H.
and Germann, A., Toward optimal cryopreservation and storage for
achievement of high cell recovery and maintenance of cell viability
and T cell functionality. Biopreserv. Biobank. 2016. 14: 539–547.
2214 Angelo, M., Bendall, S. C., Finck, R.,Hale, M. B.,Hitzman, C., Borowsky,
A. D., Levenson, R. M. et al., Multiplexed ion beam imaging of human
breast tumors. Nat. Med. 2014. 20: 436–442.
2215 Smets, T., Stevenaert, F., Adams, H. and Vanhoof, G., Deep profiling
of the immune system of multiple myeloma patients using cytometry
by time-of-flight (CyTOF). Methods Mol. Biol. 2018. 1792: 47–54.
2216 Edwards, B. S. and Sklar, L. A., Flow cytometry: impact on early drug
discovery. J. Biomol. Screen 2015. 20: 689–707.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1971
2217 Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. and Prunotto, M., Opportu-
nities and challenges in phenotypic drug discovery: an industry per-
spective. Nat. Rev. Drug Discov. 2017. 16: 531–543.
2218 Vignali, D. A., Multiplexed particle-based flow cytometric assays. J.
Immunol. Methods 2000. 243: 243–255.
2219 Joslin, J., Gilligan, J., Anderson, P., Garcia, C., Sharif, O., Hampton, J.,
Cohen, S. et al., A Fully automated high-throughput flow cytometry
screening system enabling phenotypic drug discovery. SLAS Discov.
2018. 23: 697–707.
2220 Bredemeyer, A. L., Edwards, B. S., Haynes, M. K.,Morales, A. J.,Wang,
Y., Ursu, O.,Waller, A. et al., High-throughput screening approach for
identifying compounds that inhibit nonhomologous end joining. SLAS
Discov. 2018. 23: 624–633.
2221 Buranda, T., Gineste, C., Wu, Y., Bondu, V., Perez, D., Lake, K. R.,
Edwards, B. S. et al., A high-throughput flow cytometry screen identi-
fies molecules that inhibit hantavirus cell entry. SLAS Discov. 2018. 23:
634–645.
2222 Wang, Y., Yoshihara, T., King, S., Le, T., Leroy, P., Zhao, X., Chan,
C. K. et al., Automated high-throughput flow cytometry for high-
content screening in antibody development. SLAS Discov. 2018. 23: 656–
666.
2223 Martinez, E. M., Klebanoff, S. D., Secrest, S., Romain, G., Haile, S. T.,
Emtage, P. C. R. and Gilbert, A. E., High-throughput flow cytometric
method for the simultaneous measurement of CAR-T cell characteri-
zation and cytotoxicity against solid tumor cell lines. SLAS Discov. 2018.
23: 603–612.
2224 Kaur, M. and Esau, L., Two-step protocol for preparing adherent
cells for high-throughput flow cytometry. Biotechniques 2015. 59: 119–
126.
2225 Chan, B. M., Badh, A., Berry, K. A., Grauer, S. A. and King, C. T., Flow
cytometry-based epitope binning using competitive binding profiles
for the characterization of monoclonal antibodies against cellular and
soluble protein targets. SLAS Discov. 2018. 23: 613–623.
2226 Virginia Litwin, P. M., Flow cytometry in drug discovery and development.
Wiley, Hoboken, NJ 2011.
2227 Goni-de-Cerio, F., Mariani, V., Cohen, D., Madi, L., Thevenot, J.,
Oliveira, H., Uboldi, C. et al., Biocompatibility study of two diblock
copolymeric nanoparticles for biomedical applications by in vitro tox-
icity testing. J. Nanopart. Res. 2013. 15: 1–17.
2228 Buenz, E. J., Limburg, P. J. and Howe, C. L., A high-throughput 3-
parameter flow cytometry-based cell death assay. Cytometry A 2007.
71: 170–173.
2229 Boitano, A. E.,Wang, J., Romeo, R., Bouchez, L. C., Parker, A. E., Sutton,
S. E., Walker, J. R. et al., Aryl hydrocarbon receptor antagonists pro-
mote the expansion of human hematopoietic stem cells. Science 2010.
329: 1345–1348.
2230 Zhao, Z.,Henowitz, L. and Zweifach, A., Amultiplexed assay thatmon-
itors effects of multiple compound treatment times reveals candidate
immune-enhancing compounds. SLAS Discov. 2018. 23: 646–655.
2231 Ding, M.,Kaspersson, K.,Murray, D. and Bardelle, C., High-throughput
flow cytometry for drug discovery: principles, applications, and case
studies. Drug Discov. Today 2017. 22: 1844–1850.
2232 Javarappa, K. K.,Tsallos, D. andHeckman, C. A., Amultiplexed screen-
ing assay to evaluate chemotherapy-induced myelosuppression using
healthy peripheral blood and bone marrow. SLAS Discov. 2018. 23: 687–
696.
2233 Nolan, J. P. andMandy, F., Multiplexed andmicroparticle-based analy-
ses: quantitative tools for the large-scale analysis of biological systems.
Cytometry A 2006. 69: 318–325.
2234 Moeller, T., Brown, C., Muchow, M. and Yee, B., Transcript regulation
of 18ADME genes by prototypical inducers in humanhepatocytes.Drug
Metab. Rev. 2012. 44: 79–80.
2235 Liu, Z. and O’Rourke, J., Expediting antibody discovery with a cell and
bead multiplexed competition assay. SLAS Discov. 2018. 23: 667–675.
2236 Young, S. M., Bologa, C., Prossnitz, E. R., Oprea, T. I., Sklar, L. A. and
Edwards, B. S., High-throughput screening with HyperCyt flow cytom-
etry to detect small molecule formylpeptide receptor ligands. J. Biomol.
Screen 2005. 10: 374–382.
2237 Lahl, K., Loddenkemper, C., Drouin, C., Freyer, J., Arnason, J., Eberl,
G., Hamann, A. et al., Selective depletion of Foxp3+ regulatory T cells
induces a scurfy-like disease. J. Exp. Med. 2007. 204: 57–63.
2238 Zhang, J. H., Chung, T. D. and Oldenburg, K. R., A simple statistical
parameter for use in evaluation and validation of high throughput
screening assays. J. Biomol. Screen 1999. 4: 67–73.
2239 Moore, J. and Roederer, M., The flow cytometry shared resource labora-
tory: best practices to assure a high-quality, cost-effective partnership
with biomedical research laboratories. Cytometry A 2009. 75: 643–649.
2240 Meder, D. et al., Institutional core facilities: prerequisite for break-
throughs in the life sciences: core facilities play an increasingly impor-
tant role in biomedical research by providing scientists access to
sophisticated technology and expertise. EMBO Rep. 2016. 17: 1088–1093.
2241 Barsky, L. W. et al., International Society for Advancement of Cytom-
etry (ISAC) flow cytometry shared resource laboratory (SRL) best prac-
tices. Cytometry A 2016. 89: 1017–1030.
2242 Ferrando-May, E. et al., Advanced light microscopy core facilities: Bal-
ancing service, science and career.Microsc. Res. Tech. 2016. 79: 463–479.
2243 Brown, C. M., Careers in core facility management. Cold Spring Harb.
Perspect. Biol. 2018. 10(8).
2244 Davies, D., Filby, A. and Lannigan, J., Shared Resource Laboratory (SRL)
Communications—a new journal type. Cytometry A 2018.
2245 Box, A. C., Park, J.,Semerad, C. L.,Konnesky, J. andHaug, J. S., Cost acc-
ounting method for cytometry facilities. Cytometry A 2012. 81: 439–444.
2246 Petrunkina, A.M., Algorithmandmetrics for a standardized evaluation
of cell sorting service delivery. Cytometry A 2013. 83: 602–607.
2247 Lennartz, K., Lu, M., Flasshove, M.,Moritz, T. and Kirstein, U., Improv-
ing the biosafety of cell sorting by adaptation of a cell sorting system
to a biosafety cabinet. Cytometry A 2005. 66: 119–127.
2248 Mische, S. and Wilkerson, A., Disaster and Contingency Planning for
Scientific Shared Resource Cores. J. Biomol. Tech. 2016. 27: 4–17.
2249 Antal-Szalma´s, P., Nagy, B. Jr, Debreceni, I. B. and Kappelmayer, J.,
Measurement of soluble biomarkers by flow cytometry. EJIFCC 2013.
23: 135–142.
2250 Commenges, D., Alkhassim, C., Gottardo, R., Hejblum, B. and
Thiebaut, R., cytometree: a binary tree algorithm for automatic gat-
ing in cytometry analysis. bioRxiv. 2018 1:335554.
2251 de Jager, W., te Velthuis, H., Prakken, B. J., Kuis, W. and Rijkers, G.
T., Simultaneous detection of 15 human cytokines in a single sam-
ple of stimulated peripheral blood mononuclear cells. Clin. Diagn. Lab.
Immunol. 2003. 10: 133–139.
2252 DiGiuseppe, J. A., Cardinali, J. L., Rezuke, W. N. and Pe’er, D., Pheno-
Graph and viSNE facilitate the identification of abnormal T-cell popu-
lations in routine clinical flow cytometric data. Cytometry B Clin. Cytom.
2018. 94: 744–757.
2253 Gomaa, A. and Boye, J., Simultaneous detection of multi-allergens in
an incurred food matrix using ELISA, multiplex flow cytometry and
liquid chromatography mass spectrometry (LC–MS). Food Chem. 2015.
175: 585–592.
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1972 Andrea Cossarizza et al. Eur. J. Immunol. 2019. 49: 1457–1973
2254 http://www.cancer.net/cancer-types/sarcoma-soft-tissue/overview
2255 Maggi, L., Cimaz, R., Capone, M., Santarlasci, V., Rossi, M. C., Maz-
zoni, A., Montaini, G. et al., Immunosuppressive activity of abatacept
on circulating T helper lymphocytes from juvenile idiopathic arthritis
patients. Int. Arch. Allergy Immunol. 2016. 171: 45–53.
2256 Mauero¨der, C.,Chaurio, R. A.,Dumych, T., Podolska, M., Lootsik, M. D.,
Culemann, S., Friedrich, R. P. et al., A blast without power—cell death
induced by the tuberculosis-necrotizing toxin fails to elicit adequate
immune responses. Cell Death Differ. 2016. 23: 1016–1025.
2257 Munoz, L. E.,Maueroder, C., Chaurio, R., Berens, C.,Herrmann, M. and
Janko, C., Colourful death: six-parameter classification of cell death by
flow cytometry–dead cells tell tales. Autoimmunity 2013. 46: 336–341.
2258 Salvioli, S., Ardizzoni, A., Franceschi, C. and Cossarizza, A., JC-1, but
not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess
AW changes in intact cells: implications for studies on mitochondrial
functionality during apoptosis. FEBS Lett. 1997. 411: 77–82.
Abbreviations: 7AAD: 7-aminoactinomycin D · ab: antibody · ADC:
analog-to-digital conversion · ADCC: antibody dependent cellular cyto-
toxicity · AHR: aryl hydrocarbon receptor · AM: acetoxymethyl · AMPK:
5AMP-activated protein kinase · ANX-V: annexin-V · AO: acridine
orange · APC: allophycocyanin · APD: avalanche photodiodes · APS:
ammonium peroxodisulfate · ASCs: antibody-secreting cells · ATCC:
American type tissue collection ·ATGs: autophagy related genes ·AxA5:
fluorophore-conjugated annexin A5 · BafA: bafilomycin A1 · BAFF: Bcell
activating factor · BCL6: B-cell lymphoma 6 · BD: Becton Dickinson ·
bDNA: branched DNA technology · BDS: bright detail similarity · BF:
brightfield · BFA: brefeldin A · BISC: Bioinformatics Integration Sup-
port Contract · BM: bone marrow · BP: band pass · BrdU: 5-bromo-2-
deoxyuridine · BSA: bovine serum albumin · BV: brilliant violet · CCCP:
carbonyl cyanide 3-chloro phenyl hydrazine · CCDs: charge-coupled
devices · CLL: chronic lymphocytic leukemia · cDCs: classical DCs ·
CDR: complementarity determining regions · CEA: carcinoembryonal ·
CECs: circulating endothelial cells · CFSE: carboxyfluorescein succin-
imidyl ester · CFU-F: colony-forming units-fibroblasts · CIMT: cancer
immunotherapy consortium · CIP: CIMT immunoguiding program · CK:
cytokeratin 18 · CM: central memory · cMOP: common monocyte pre-
cursors · CMV: cytomegalovirus · CS&T: cytometer setup and tracking
· CSF: cerebrospinal fluid · CT: cancer-testis · CTCs: circulating tumor
cells · CTL: cytolytic cells · CV: coefficient of variation · CW: continu-
ous wave · Cy: cyanine · CyTOF: Cytometry by Time-Of-Flight · DAIT:
Division of Allergy, Immunology, and Transplantation · DAMP: danger-
associated molecular patterns · DAPI: 4,6-diamidine-2-phenylindole ·
DCF: 2,7-dichlorofluorescein · DCFDA: 2-7-dichlorodihydrofluorescein
diacetate ·DCs: dendritic cells ·DCV: dyecycle violet ·DHR: dihydrorho-
damine · DIOC6: 3,3-dihexyloxacarbocyanine iodide · DLD: determin-
istic lateral displacement · DLP: dichroic longpass · DMSO: dimethyl
sulfoxide · DNase: deoxyribonuclease · DNR: dynamic detection range
· DPBS: Dulbecco’s phosphate buffered saline · DPEC: double posi-
tive effector cells · E:T: effector-to-target cell · ECI 2015: European
Congress of Immunology ECI 2015 · EdU: 5-ethynyl-2-deoxyuridine ·
EGFR: epidermal growth factor receptor · EM: effector memory cells
· ENOBs: effective number of bits · ERK pathway: extracellular-signal
regulated kinase pathway · ESCCA: European Society for Clinical Cell
Analysis · FACS: fluorescence activated cell sorting · FBS: fetal bovine
serum · Fc: fragment of immunoglobulins · FCCP: carbonyl cyanide-
4- (trifluoromethoxy)phenylhydrazone · FCM: flow cytometry · FCS:
fetal calf serum · FCS: flow cytometry standard · FDA: fluorescein-
diacetate · FGFR: fibroblast growth factor receptor · FISH: fluorescent
in situ hybridization · FITC: fluorescein isothiocyanate · FL1-10: fluo-
rescence channels · FLIMs: fluorescent life time measurements · FMK:
fluoromethyl ketone · FMO: fluorescenceminus one · FOCIS: Federation
of Clinical Immunology Societies · FOXP3: forkhead box P3 · FSC: for-
ward scatter · GATA3: GATA binding protein-3 · GFP: green fluorescent
protein · GUIs: graphical user interfaces · GZMB: granzyme B · HBSS:
Hank’s balanced saline solution · HCC: hepatocellular carcinoma · HCS:
hematopoietic progenitor cells · HHV8: human herpesvirus 8 · HIPAA:
Health Insurance Portability and Accountability Act · HIPC: Human
Immunology Project Consortium ·HIV: Human immunodeficiency virus
· HLA: human leukocyte antigen · HSC: hematopoietic stem cell · HTS:
high throughput system · IBD: inflammatory bowel disease · ICCS: Inter-
national Clinical Cytometry Society · ICPC TOF-MS: inductively-coupled
plasma time of flight mass spectrometry · IdU: Iodo-2-deoxyuridine
· IFN: interferon · Ig: immunoglobulin · IL: interleukin · ILCs: innate
lymphoid cells · ImmPort: immunology database and analysis portal ·
iono: ionomycin · IRF4: interferon regulatory factor 4 · ISAC: Interna-
tional Society for Analytical Cytology · ISR: internal store release · ITAM:
immune-receptor tyrosinebased activating motifs · ITIM: immune-
receptor tyrosine-based inhibition motif · KIRs: killer Ig-like receptors ·
KLH: keyhole limpet hemocyanin · KLRG1: killer cell lectin-like receptor
G1 · K-S: Kolmogorov-Smirnov statistic · L/D: live dead · LCA: leuko-
cyte common antigen · Lin: lineage markers · Lin−: lineage-negative
· lncRNA: long non-coding RNA · LmP: lamina propria · LP: long pass
· LPS: lipopolysaccharide · LRR: leucine-rich repeat · LRR-CT: LRR C-
terminal capping · LRR-NT: LRR N-terminal · LTi: lymphoid tissue-
inducer cells · mAb: monoclonal antibody · MAP kinase: membrane
activated protein kinase · MARS-seq: massive parallel single-cell RNA-
seq ·mBCs: memory B cells ·MCs: mononuclear cells ·MdFI: median flu-
orescence intensity ·MDP: monocyte/macrophage-DC precursors ·MFI:
mean fluorescence intensity · MHC: major histocompatibility complex
· MIBBI: minimum information for biological and biomedical investi-
gations · MIBI: multiplexed ion beam imaging · MIFloCyt: minimum
information about a flow cytometry experiment · mitoPY: mitochon-
dria peroxy yellow-1 · MitoSOX: mitochondrial superoxide indicator ·
MMM: metal-minusmany · MN: monensin · MoDC: monocyte-derived
DC · MPEC: memoryprecursor effector cells · mRNA: messenger RNA ·
MSPCs: mesenchymal stem and progenitor cells · mt: mitochondrial ·
mtmP: mitochondrial membrane potential · mTOR: mammalian target
of rapamycin complex 1 · NAO: nonyl acridine orange · NIAID: National
Institute of Allergy and Infectious Diseases · NIH: National Institutes
of Health · NIR: near infrared · NK: natural killer · NLOs: non-lymphoid
organs · NSCLC: non-small cell lung cancer · NYSTEM Program: New
York State Department of Health Program · OH: hydroxyl radicals ·
OMIP: optimizedmulticolor immunofluorescence panels ·OVA: ovalbu-
min · OxPhos: oxidative phosphorylation · PI3K: Phosphatidylinositol-
4,5- bisphosphate 3-kinase · PAMPs: pathogen-associated molecular
patterns · PB: peripheral blood · PBMC: peripheral blood mononuclear
cells · PBPC: peripheral blood progenitor cell · PBS: phosphate buffered
saline · PD-1: programmed cell death protein 1 · PDGFR: platelet-derived
growth factor receptor · PEA: phosphatidylethanolamine · PE: phycoery-
thrin · PerCP: peridinin-chlorophyll · PI: propidium iodide · PMA: phor-
bol 12-myristate 13-acetate · PMT: photomultiplier tube · PP: phagocyto-
sis product · PS: phosphatidylserine · PVP: polyvinylpyrrolidone · PY(G):
pyronin Y(G) · RAR: retinoic acid receptor · RCC: renal cell carcinoma
· Rho123: rhodamine-123 · RNase: ribonuclease · ROR-γt: retinoic acid
receptor-related orphan receptor gamma t · RORγtfm: RORγt fate map-
ping · ROS: reactive oxygen species · RPMI 1640: Roswell Park Memo-
rial Institute 1640 · RT: room temperature · SAPK/JNK pathway: stress-
activated protein kinase/c-jun n-terminal kinase · SAW: surface acous-
tic waves · SB: staining buffer · SD: standard deviation · SE: standard
error · SEB: Staphylococcus enterotoxin B · SERS: surface enhanced
Raman scattering · SI: small intestinal · SIP: sample injection port ·
SLE: systemic lupus erythematosus · SLEC: short-lived effector cells
· SLOs: secondary lymphoid organs · SMO: signal-minus-one · SNRs:
signal-tonoise ratios · SOCE: store-operated Ca2+ entry · SOV: spillover
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2019. 49: 1457–1973 References 1973
value · SP: short pass · SPADE: Spanning-tree progression analysis of
densitynormalized data · β2m: beta-2-microglobulin · SSC: side scatter
· SSM: spillover-spreading matrix · TAA: tumor-associates antigens ·
Tcon: conventional T cells · TCR: T cell receptor · TCRtg: TCR-transgenic
· TdT: terminal deoxynucleotidyltransferase · Th cells: T helper cells
· TIA: transimpedance · TM: memory T lymphocytes · TMRE: tetram-
ethylrhodamine ·TNF: tumor necrosis factor ·TOF: time-of-flight ·Treg:
regulatory T cells ·TRAIL: TNF-related apoptosis-inducing ligand ·TSLP:
thymic stromal lymphopoietin · t-SNE: t-distributed stochastic neigh-
bor embedding · TUNEL: TdT-mediated dUTP nick end labelling · VA:
voltage · ULK1: Serine/threonine-protein kinase ULK1 · UV: ultraviolet
· Var: variance · VLR: variable lymphocyte receptor · Vps34: vacuolar
protein sorting34 · WDM: wavelength division multiplexer
Full correspondence: Prof. Andrea Cossarizza and Dr. Hyun-Dong Chang
e-mail: andrea.cossarizza@unimore.it; chang@drfz.de
C© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
